<SEC-DOCUMENT>0001193125-19-096700.txt : 20190403
<SEC-HEADER>0001193125-19-096700.hdr.sgml : 20190403
<ACCEPTANCE-DATETIME>20190403170006
ACCESSION NUMBER:		0001193125-19-096700
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		125
CONFORMED PERIOD OF REPORT:	20181231
FILED AS OF DATE:		20190403
DATE AS OF CHANGE:		20190403

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Merus N.V.
		CENTRAL INDEX KEY:			0001651311
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37773
		FILM NUMBER:		19729815

	BUSINESS ADDRESS:	
		STREET 1:		YALELAAN 62
		CITY:			3584 CM UTRECHT
		STATE:			P7
		ZIP:			3584 CM
		BUSINESS PHONE:		31 030 253 8800

	MAIL ADDRESS:	
		STREET 1:		YALELAAN 62
		CITY:			3584 CM UTRECHT
		STATE:			P7
		ZIP:			3584 CM

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Merus B.V.
		DATE OF NAME CHANGE:	20150819
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>d696632d20f.htm
<DESCRIPTION>20-F
<TEXT>
<HTML><HEAD>
<TITLE>20-F</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">20-F</FONT> </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><B>REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P></TD></TR></TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B></B>&#9746;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P></TD></TR></TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>For the fiscal year ended December&nbsp;31, 2018 </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><B>SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date of event requiring this shell company report
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Commission file number <FONT STYLE="white-space:nowrap">001-37773</FONT> </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>MERUS N.V. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of
Registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s name into English) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>The Netherlands </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Jurisdiction of incorporation or organization) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Yalelaan 62 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>3584 CM
Utrecht </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>The Netherlands </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ton Logtenberg </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>President,
Chief Executive Officer and Principal Financial Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Merus N.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Yalelaan 62 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>3584 CM
Utrecht </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>The Netherlands </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: +31 30 253 8800 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, Telephone, <FONT STYLE="white-space:nowrap">E-mail</FONT> and/or Facsimile number and Address of Company Contact Person) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered or to be registered pursuant to Section&nbsp;12(b) of the Act. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name of each exchange on which
registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Common shares, nominal value &#128;0.09 per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered or to be registered pursuant to Section&nbsp;12(g) of the Act. None </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities for which there is a reporting obligation pursuant to Section&nbsp;15(d) of the Act. None </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Indicate the number of outstanding shares of each of the issuer&#146;s classes of capital or common stock as of the close of the period covered
by the annual report. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Common shares, nominal value &#128;0.09&nbsp;per share: 23,358,977 as of December&nbsp;31, 2018 </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act.&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&#9746;&nbsp;&nbsp;No </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this report is an annual or transition report, indicate
by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934.&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&#9746;&nbsp;&nbsp;No </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of
1934 during the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to
such filing requirements for the past 90 days&nbsp;&nbsp;&nbsp;&nbsp;&#9746;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;No </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check
mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> (&#167;232.405 of this chapter) during the preceding 12
months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;&#9746;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;No </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT>
filer, or an emerging growth company. See definition of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Large accelerated filer&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Accelerated filer&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-accelerated
filer&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Emerging&nbsp;growth&nbsp;company&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to
use the extended transition period for complying with any new or revised financial accounting standards&#134; provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">&#134; The term &#147;new or revised financial accounting standard&#148; refers to any update issued by the Financial Accounting Standards Board to its
Accounting Standards Codification after April&nbsp;5, 2012. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark which basis of accounting the registrant has used to prepare the
financial statements included in this filing: </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="6%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">U.S.&nbsp;GAAP&nbsp;&nbsp;&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7.50em; font-size:8pt; font-family:Times New Roman">International Financial Reporting Standards as issued</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:7.50em; font-size:8pt; font-family:Times New Roman">by the International Accounting Standards Board&nbsp;&nbsp;&#9746;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Other&nbsp;&nbsp;&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If &#147;Other&#148; has been checked in response to the previous question, indicate by check mark which financial statement
item the registrant has elected to follow.&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;Item&nbsp;17&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;Item&nbsp;18 </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If
this is an Annual Report, indicate by check mark whether the registrant is a shell company (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&#9746;&nbsp;&nbsp;No </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<A NAME="toc"></A>ABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc696632_1">PART&nbsp;I</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;1</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_2">Identity of Directors, Senior Management and Advisers.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_3">Offer Statistics and Expected Timetable.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;3</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_4">Key Information.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>A.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_5">Selected Financial Data.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">3</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>B.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_6">Capitalization and Indebtedness.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">4</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>C.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_7">Reasons for the Offer and Use of Proceeds.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">4</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>D.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_8">Risk Factors.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">4</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;4</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_9">Information on the Company.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>A.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_10">History and Development of the Company</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">52</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>B.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_11">Business Overview</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">53</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>C.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_12">Organizational Structure.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">93</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>D.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_13">Property, Plant and Equipment.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">93</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>E.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_14">Unresolved Staff Comments.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">93</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_15">Operating and Financial Review and Prospects.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>A.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_16">Operating Results</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">93</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>B.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_17">Liquidity and Capital Resources</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">116</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>C.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_18">Research and Development, Patent and Licenses, etc.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">119</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>D.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_19">Trend Information.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">120</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>E.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_20"><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">120</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>F.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_21">Tabular Disclosure of Contractual Obligations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">120</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>G.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_22">Safe Harbor.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">120</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;6</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_23">Directors, Senior Management and Employees.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>A.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_24">Directors and Senior Management.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">121</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>B.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_25">Compensation.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">124</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>C.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_26">Board Practices.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">131</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>D.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_27">Employees.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">133</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>E.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_28">Share Ownership.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">133</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_29">Major Shareholders and Related Party Transactions.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>A.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_30">Major Shareholders.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">133</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>B.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_31">Related Party Transactions.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">136</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>C.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_32">Interests of Experts and Counsel.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">138</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_33">Financial Information</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>A.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_34">Consolidated Statements and Other Financial Information.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">138</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>B.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_35">Significant Changes.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">139</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_36">The Offer and Listing.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>A.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_37">Offer and Listing Details.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">139</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>B.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_38">Plan of Distribution.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">140</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>C.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_39">Markets.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">140</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>D.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_40">Selling Shareholders.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">140</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>E.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_41">Dilution.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">140</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>F.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_42">Expenses of the Issue.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">140</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;10</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_43">Additional Information.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>A.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_44">Share Capital.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">140</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>B.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_45">Memorandum and Articles of Association.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">140</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>C.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_46">Material Contracts.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">156</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>D.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_47">Exchange Controls.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">157</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>E.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_48">Taxation.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">157</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>F.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_49">Dividends and Paying Agents.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">167</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>G.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_50">Statement by Experts.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">167</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>H.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_51">Documents on Display.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">167</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>I.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_52">Subsidiary Information.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">167</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;11</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_53">Quantitative and Qualitative Disclosures About Market Risk.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;12</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_54">Description of Securities Other than Equity Securities.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>A.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_55">Debt Securities.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">167</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>B.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_56">Warrants and Rights.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">167</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>C.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_57">Other Securities.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">168</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>D.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc696632_58">American Depositary Shares.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">168</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>P<A HREF="#toc696632_59">ART&nbsp;II</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_60">Defaults, Dividend Arrearages and Delinquencies.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_61">Material Modifications to the Rights of Security Holders and Use of Proceeds.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_63">Controls and Procedures.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16A.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_64">Audit Committees Financial Expert.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16B.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_65">Code of Ethics.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16C.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_66">Principal Accountant Fees and Services.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_67">Exemptions from the Listing Standards for Audit Committees.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16E.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_68">Purchases of Equity Securities by the Issuer and Affiliated Purchasers.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16F.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_69">Change in Registrant&#146;s Certifying Accountant.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16G.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_70">Corporate Governance.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16H.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_71">Mine Safety Disclosure.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc696632_72">PART&nbsp;III</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_73">Financial Statements.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;18</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_74">Financial Statements.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;19</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><A HREF="#toc696632_75">Exhibits.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Annual Report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> or the Annual Report, to &#147;Merus,&#148; the
&#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Merus N.V. and its consolidated subsidiary. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRESENTATION OF FINANCIAL AND OTHER DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We report under International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or the IASB.
None of the financial statements presented in this Annual Report were prepared in accordance with generally accepted accounting principles in the United States. We present our financial statements in euros and in accordance with IFRS as issued by
the IASB. We have made rounding adjustments to some of the figures included in this Annual Report. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them. All references
in this Annual Report to &#147;$,&#148; &#147;US$,&#148; &#147;U.S.$,&#148; &#147;U.S. dollars,&#148; &#147;dollars&#148; and &#147;USD&#148; mean U.S. dollars and all references to &#147;&#128;&#148; mean euros, unless otherwise noted. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Annual Report contains statements that constitute forward-looking statements. All statements other than statements of historical facts
contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success,
plans and objectives of management for future operations and future results of anticipated products, are forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995 and other federal securities laws. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify
forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;contemplate,&#148;
&#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. The forward-looking statements in this Annual Report are only predictions. We
have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking
statements speak only as of the date of this Annual Report and are subject to a number of risks, uncertainties and assumptions described under the sections in this Annual Report titled &#147;Risk Factors&#148; and &#147;Operating and Financial
Review and Prospects&#148; and elsewhere in this Annual Report. These forward-looking statements are subject to numerous risks, including, without limitation, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our operations as a clinical-stage company with a limited operating history and a history of operating losses;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainty about the initiation, timing, progress and results of clinical trials of our bispecific antibody
candidates, including regarding when results of such trials will be made public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations related to payments and clinical development under our collaboration agreement with Incyte
Corporation, or Incyte; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our clinical development plans for <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT
STYLE="white-space:nowrap">MCLA-117,</FONT> <FONT STYLE="white-space:nowrap">MCLA-158</FONT> , and <FONT STYLE="white-space:nowrap">MCLA-145;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">research and/or development of preclinical programs being <FONT STYLE="white-space:nowrap">co-developed</FONT>
with Incyte, Simcere, Betta Pharmaceuticals Co. Ltd, or Betta, and for other bispecific antibody candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals for any of our bispecific antibody candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish sales, marketing and distribution capabilities for any of our bispecific antibody
candidates for which we may obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain manufacturing arrangements for our bispecific antibody candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
bispecific antibody candidates and related technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to defend against any claims by third parties that we are infringing upon their intellectual property
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenues, capital requirements and our need for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our bispecific antibody candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government laws and regulations on our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risk factors discussed in this Annual Report. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Annual Report contains market data and industry forecasts that were obtained from industry publications. These data involve a number of
assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified any third-party information. While we believe the market position, market opportunity and market size information
included in this Annual Report is generally reliable, such information is inherently imprecise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc696632_1"></A>PART I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_2"></A>Item&nbsp;1 Identity of Directors, Senior Management and Advisers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_3"></A>Item&nbsp;2 Offer
Statistics and Expected Timetable. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_4">
</A>Item&nbsp;3 Key Information. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_5"></A>A. Selected Financial Data. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following selected consolidated financial data should be read in conjunction with &#147;Operating and Financial Review and Prospects,&#148;
our consolidated financial statements and related notes, and other financial information included in this Annual Report. We have derived the consolidated statement of profit or loss and comprehensive loss data for the years ended December&nbsp;31,
2018, 2017 and 2016 and the consolidated statement of financial position data as of December&nbsp;31, 2018 and 2017 from our audited financial statements included elsewhere in this Annual Report. We have derived the consolidated statement of profit
or loss and comprehensive loss data for the years ended December&nbsp;31, 2015 and 2014 and the consolidated statement of financial position data as of December&nbsp;31, 2016, 2015 and 2014 from our audited consolidated financial statements that are
not included in this Annual Report. Our historical results are not necessarily indicative of the results that should be expected in the future. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Restated**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016<BR>Restated**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015<BR>Restated**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014<BR>Restated**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(</B><B><I>euros</I></B><B></B><B><I></I></B><B></B><B><I>&nbsp;in</I></B><B></B><B><I></I></B><B></B><B><I>&nbsp;thousands,</I></B><B></B><B><I></I></B><B></B><B><I>&nbsp;except
share</I></B><B></B><B><I></I></B><B></B><B><I>&nbsp;and</I></B><B></B><B><I></I></B><B></B><B><I>&nbsp;per</I></B><B></B><B><I></I></B><B></B><B><I>&nbsp;share</I></B><B></B><B><I></I></B><B></B><B><I>&nbsp;data</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Profit or Loss and Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">31,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">21,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,181</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,847</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Result before taxation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Result after taxation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic (and diluted) loss per&nbsp;share*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.09</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,286,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,196,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,236,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,871,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,829,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the periods included in these financial statements, share options and restricted stock units were excluded
from the diluted loss per share calculation as we were in a loss position in each period presented above. As a result, basic and diluted loss per share is equal. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Revenue for the years ended December&nbsp;31, 2017, 2016, 2015 and 2014 have been restated due to the impact of
the retrospective effects of the adoption of IFRS&nbsp;15, an accounting standard related to revenue recognition. Revenue for the year ended December&nbsp;31, 2017 has been restated to reflect additional revenue
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of &#128;8.3&nbsp;million, or &#128;0.43&nbsp;per share, primarily related to the amortization of the upfront license payment received from Incyte. Revenue for the year ended December&nbsp;31,
2016 has been restated to reflect a reduction in revenue of &#128;0.2&nbsp;million, or &#128;0.01&nbsp;per share, related to lower amortization of the upfront license payment received from ONO. Revenue for the year ended December&nbsp;31, 2015 has
been restated to reflect a reduction in revenue of &#128;0.1&nbsp;million, or &#128;0.01&nbsp;per share, related to lower amortization of the <FONT STYLE="white-space:nowrap">up-front</FONT> license payment received from ONO. Revenue for the year
ended December&nbsp;31, 2014 has been restated to reflect additional revenue of &#128;0.7&nbsp;million, or &#128;0.24 per share, related to higher amortization of the <FONT STYLE="white-space:nowrap">up-front</FONT> license payment received from
ONO. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Financial Position Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">143,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">149,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">56,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">32,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(175,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(106,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,783</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,887</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Total liabilities, accumulated loss and total equity have been restated for the impact of the retrospective
effects of the adoption of IFRS&nbsp;15, an accounting standard related to revenue recognition. The result of the restatement was a decrease to total liabilities and accumulated loss and an increase to total equity of &#128;8.7&nbsp;million,
&#128;0.4&nbsp;million, &#128;0.6&nbsp;million and &#128;0.7&nbsp;million as of December&nbsp;31, 2017, 2016, 2015 and 2014, respectively. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_6"></A>B. Capitalization and Indebtedness. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_7"></A>C. Reasons for the
Offer and Use of Proceeds. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_8">
</A>D. Risk Factors. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should carefully consider the risks and uncertainties described below and the other information in this
Annual Report. Our business, financial condition or results of operations could be materially and adversely affected if any of these risks occur. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business and Industry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are a clinical-stage company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable
future and may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage immuno-oncology company with a limited operating
history. We have incurred net losses of &#128;24.2&nbsp;million, &#128;64.7&nbsp;million, and &#128;47.4&nbsp;million for the years ended December&nbsp;31, 2018, 2017 and 2016, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, we had an accumulated loss of &#128;175.1&nbsp;million. Our losses have resulted principally from expenses
incurred in research and development of our bispecific antibody candidates and from management and administrative costs and other expenses that we have incurred while building our business infrastructure. We expect to continue to incur significant
operating losses for the foreseeable future as we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continue our research and development efforts and seek to obtain regulatory approval and commercialization of our bispecific antibody candidates. We anticipate that our expenses will increase
substantially as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct our ongoing Phase 2 clinical trial of <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> our most advanced
bispecific antibody candidate, for the treatment of metastatic breast cancer in combination with other therapies and our ongoing, single agent, Phase 1/2 clinical trial for the treatment of gastric and
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct our ongoing Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">MCLA-117,</FONT> our second most
advanced bispecific antibody candidate, for the treatment of acute myeloid leukemia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct our ongoing Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">MCLA-158</FONT> for the treatment
of solid tumors with an initial focus on colorectal cancer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commence clinical trials for <FONT STYLE="white-space:nowrap">MCLA-145</FONT> for the treatment of solid tumors,
which is being <FONT STYLE="white-space:nowrap">co-developed</FONT> with Incyte Corporation, or Incyte; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue the research and development of our other bispecific antibody candidates, including the development of <FONT
STYLE="white-space:nowrap">MCLA-129</FONT> in collaboration with Betta Pharmaceuticals Co. Ltd.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand the clinical programs to explore new potential combination therapies or indications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to enhance our technology platform, which generates our pipeline of product candidates, and discover and
develop additional antibody candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals for any antibody candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially establish a sales, marketing and distribution infrastructure and
<FONT STYLE="white-space:nowrap">scale-up</FONT> manufacturing capabilities to commercialize any products for which we may obtain regulatory approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">secure, maintain and/or obtain freedom to operate for our technologies and products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add clinical, scientific, operational, financial, information technology and management information systems and
personnel, including personnel to support our product development and potential future commercialization efforts and to support our operation as a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience any delays or encounter any issues with any of the above, including but not limited to failed studies,
complex results, manufacturing challenges, safety issues or other regulatory challenges. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have financed our
operations primarily through public offerings and private placements of our common shares and our collaboration and license agreement with Incyte. We have devoted a significant portion of our financial resources and efforts to developing our
full-length human bispecific antibody therapeutics, which we refer to as Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, our technology platform, identifying potential bispecific antibody candidates, conducting <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies of a variety of candidates, conducting our clinical trials of <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT STYLE="white-space:nowrap">MCLA-117</FONT> and <FONT
STYLE="white-space:nowrap">MCLA-158,</FONT> and preparing to commence clinical study of <FONT STYLE="white-space:nowrap">MCLA-145.</FONT> We are in the early stages of development of our bispecific antibody candidates, and we have not completed
development of any Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or any other drugs or biologics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To become and
remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> testing and clinical trials of our bispecific antibody candidates, discovering and developing additional antibody candidates, obtaining regulatory approval for any bispecific antibody candidates that
successfully complete clinical trials, establishing manufacturing and marketing capabilities and ultimately selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may
never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with pharmaceutical product and
biological development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the U.S. Food and Drug Administration, or the FDA, or the European
Medicines Agency, or EMA, or other regulatory authorities to perform studies in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of any of our bispecific antibody candidates,
our expenses could increase and commercial revenue could be further delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we do generate product royalties or product sales,
we may never achieve or sustain profitability on a quarterly or annual basis. Our failure to sustain profitability would depress the market price of our common shares and could impair our ability to raise capital, expand our business, diversify our
product offerings or continue our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will need additional funding in order to complete development of our bispecific
antibody candidates and commercialize our products, if approved. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our ongoing clinical trials of <FONT
STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT STYLE="white-space:nowrap">MCLA-117,</FONT> and <FONT STYLE="white-space:nowrap">MCLA-158</FONT> and commence the clinical study of <FONT STYLE="white-space:nowrap">MCLA-145</FONT> and continue to
research, develop and conduct <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies of our other antibody candidates. In addition, if we obtain regulatory approval for any of our bispecific antibody candidates, we expect to incur significant
commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, we continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial
additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future
commercialization efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we expect that our existing cash, cash equivalents and investments as of
December&nbsp;31, 2018 will be sufficient to fund our operations into the second quarter of 2021. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our
future capital requirements will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost, progress and results of our ongoing clinical trials of <FONT STYLE="white-space:nowrap">MCLA-128</FONT>
and the Phase 1 clinical trials of <FONT STYLE="white-space:nowrap">MCLA-117</FONT> and <FONT STYLE="white-space:nowrap">MCLA-158;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of our collaboration with Incyte to develop bispecific antibodies candidates, including the expected
commencement of a clinical trial for <FONT STYLE="white-space:nowrap">MCLA-145;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing clinical supplies of our bispecific antibody candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development,
laboratory testing and clinical trials for our other antibody candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of any of our antibody candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and
distribution, for any of our antibody candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our
intellectual property rights and defending any intellectual property-related claims, including any potential future claims by third parties that we are infringing upon their intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of securing, maintaining and/or obtaining freedom to operate for our technologies and
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sales of our bispecific antibody candidates for which we receive
marketing approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or invest in businesses, products and technologies, including our collaboration
with Incyte and any other licensing or collaboration arrangements for any of our bispecific antibody candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We depend heavily on the success of our bispecific antibody candidates, and we cannot give any assurance that any of our bispecific
antibody candidates will receive regulatory approval, which is necessary before they can be commercialized. If we, Incyte, or any other strategic partners we may enter into collaboration agreements with for the development and commercialization of
our bispecific antibody candidates, are unable to commercialize our bispecific antibody candidates, or experience significant delays in doing so, our business, financial condition and results of operations will be materially adversely affected.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have invested a significant portion of our efforts and financial resources in the development of bispecific antibody candidates
using our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform. Our ability to generate royalty and product revenues, which we do not expect will occur for at least the next several years, if ever, will depend
heavily on the successful development and eventual commercialization of these bispecific antibody candidates, which may never occur. We currently generate no revenues from sales of any products, and we may never be able to develop or commercialize a
marketable product. Each of our bispecific antibody candidates will require additional clinical development, management of clinical, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and manufacturing activities, regulatory approval in multiple
jurisdictions, obtaining manufacturing supply, including commercial manufacturing supply, building of a commercial organization, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not
permitted to market or promote any of our bispecific antibody candidates before we receive regulatory approval from the FDA, the EMA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our
bispecific antibody candidates. The success of our bispecific antibody candidates will depend on several factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for bispecific antibody candidates which we may license to others, such as to Incyte, the successful efforts of
those parties in completing clinical trials of, receipt of regulatory approval for and commercialization of such bispecific antibody candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for the bispecific antibody candidates to which we retain rights, completion of
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials of, receipt of marketing approvals for, establishment of commercial manufacturing supplies of and successful commercialization of such bispecific antibody candidates;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for all of our bispecific antibody candidates, if and when approved, acceptance of our bispecific antibody
candidates by patients, the medical community and third-party payors, effectively competing with other therapies, a continued acceptable safety profile following approval and qualifying for, maintaining, enforcing and defending our intellectual
property rights and claims. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our collaborators, as applicable, do not achieve one or more of these factors in a
timely manner or at all, we could experience significant delays or an inability to successfully commercialize our bispecific antibody candidates, which would materially adversely affect our business, financial condition and results of operations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not previously submitted a Biologics License Application, or BLA, to the FDA, a Marketing Authorisation Application, or MAA, to
the EMA, or similar regulatory approval filings to comparable foreign authorities, for any bispecific antibody candidate, and we cannot be certain that any of our bispecific antibody candidates will be successful in clinical trials or receive
regulatory approval. Further, our bispecific antibody candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our bispecific antibody candidates, we may not be able
to continue our operations. Even if we successfully obtain regulatory approvals to market one or more of our bispecific antibody candidates, our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patient subsets that we
are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to seek regulatory approval to commercialize our bispecific antibody candidates both in the United States and the EU, and potentially
in additional foreign countries. While the scope of regulatory approval is similar in other countries, to obtain separate regulatory approval in many other countries we must comply with the numerous and varying regulatory requirements of such
countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our bispecific antibody candidates, and we cannot predict success in these jurisdictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform is an unproven, novel approach to the
production of molecules for therapeutic intervention. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not received regulatory approval for a therapeutic based on a
full-length human bispecific IgG approach. We cannot be certain that our approach will lead to the development of approvable or marketable products. In addition, our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> may have
different effectiveness rates in various indications and in different geographical areas. Finally, the FDA, the EMA or other regulatory agencies may lack experience in evaluating the safety and efficacy of products based on Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> therapeutics, which could result in a longer than expected regulatory review process, increase our expected development costs and delay or prevent commercialization of our bispecific antibody
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform relies on third parties for
biological materials. Some biological materials have not always met our expectations or requirements, and any disruption in the supply of these biological materials could materially adversely affect our business. Although we have control processes
and screening procedures, biological materials are susceptible to damage and contamination and may contain active pathogens. Improper storage of these materials, by us or any third-party suppliers, may require us to destroy some of our biological
raw materials or product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Failure to successfully validate, develop and obtain regulatory approval for companion
diagnostics could harm our development strategy. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek to identify patient subsets within a disease category that may derive
selective and meaningful benefit from the bispecific antibody candidates we are developing. Through collaborations, we may develop companion diagnostics to help us to more accurately identify patients within a particular subset, both during our
clinical trials and in connection with the commercialization of our bispecific antibody candidates. Companion diagnostics are subject to regulation by the FDA, the EU legislative bodies, and comparable foreign regulatory authorities as companion
diagnostic medical devices and typically require separate regulatory approval prior to commercialization. If needed, we intend to develop companion diagnostics in collaboration with third parties and are dependent on the scientific insights and
sustained cooperation and effort of any third-party collaborators in developing and obtaining approval for companion diagnostics. We and our collaborators may encounter difficulties in developing and obtaining approval for any companion diagnostics,
including issues relating to selectivity/specificity, analytical validation, reproducibility or clinical validation. Any delay or failure by us or our collaborators to develop or obtain regulatory approval of companion diagnostics could delay or
prevent approval of our bispecific antibody candidates. In addition, our collaborators may encounter production difficulties that could constrain the supply of the companion diagnostics, and both they and we may have difficulties gaining acceptance
of the use of the companion diagnostics in the clinical community. If such companion diagnostics fail to gain market acceptance, it would have an adverse effect on our ability to derive revenues from sales of our products. In addition, the
diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic that we anticipate using in connection with development and commercialization of our bispecific antibody candidates or our
relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative companion diagnostic test for use in connection with the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development and commercialization of our bispecific antibody candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization
of our bispecific antibody candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our limited operating history may make it difficult for you to evaluate the success of our
business to date and to assess our future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception in 2003, we have devoted a significant portion of our
resources to developing <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT STYLE="white-space:nowrap">MCLA-117,</FONT> <FONT STYLE="white-space:nowrap">MCLA-158,</FONT> <FONT STYLE="white-space:nowrap">MCLA-145</FONT> and our other antibody
candidates, building our intellectual property portfolio, developing our clinical manufacturing supply chain, planning our business, raising capital and providing general and administrative support for these operations. While we have ongoing
clinical trials for <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT STYLE="white-space:nowrap">MCLA-117</FONT> and <FONT STYLE="white-space:nowrap">MCLA-158,</FONT> and expect to commence a clinical trial for
<FONT STYLE="white-space:nowrap">MCLA-145</FONT> in the first half of 2019, we have not completed any clinical trials for any bispecific antibody candidate. We have not yet demonstrated our ability to successfully complete any Phase 2 clinical trial
or any Phase&nbsp;3 or other pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product
commercialization. Additionally, we expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Consequently,
any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our holders, restrict our operations or require us to relinquish rights to our
technologies or bispecific antibody candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenues, we
expect to finance our cash needs through equity or debt financings and upfront and milestone payments, if any, received under our collaboration with Incyte and any other future licenses or collaborations, together with our existing cash and cash
equivalents. In order to accomplish our business objectives and further develop our product pipeline, we will, however, need to seek additional funds. If we raise additional capital through the sale of equity or convertible debt securities, your
ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common shares. In addition, the possibility of such issuance may cause the market
price of our common shares to decline. Debt financing, if available, may result in increased fixed payment obligations and involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures, declaring dividends, or acquiring, selling or licensing intellectual property rights, which could adversely impact our ability to conduct our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third
parties, we may have to relinquish valuable rights to our intellectual property, technologies, future revenue streams or bispecific antibody candidates or grant licenses on terms that may not be favorable to us. We could also be required to seek
funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable. Any of these occurrences may have a material adverse effect on our business, operating results and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize our bispecific antibody candidates. In addition, we cannot guarantee that
future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or
development programs or the commercialization of any of our bispecific antibody candidates, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business,
financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our business may become subject to economic, political, regulatory and other risks
associated with international operations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company based in the Netherlands, our business is subject to risks associated with
conducting business internationally. Many of our suppliers and collaborative and clinical trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability, in particular, in <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> economies and markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing regulatory requirements for drug approvals in <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing jurisdictions could present different issues for securing, maintaining and/or obtaining freedom to
operate in such jurisdictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in compliance with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws and regulations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulations and customs, tariffs and trade barriers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> currency exchange rates of the euro and currency
controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in a specific country&#146;s or region&#146;s political or economic environment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> governments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing reimbursement regimes and price controls in certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative consequences from changes in tax laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with international privacy regulations, including the General Data Protection Regulation, or the GDPR,
that went into effect in 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative consequences from Brexit, and its potential impact on supply-chain and our personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties associated with staffing and managing international operations, including differing labor relations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including
war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exchange rate
fluctuations or abandonment of the euro currency may materially affect our results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to
the international scope of our operations, fluctuations in exchange rates, particularly between the euro and the U.S. dollar, may adversely affect us. Although we are based in the Netherlands, we source research and development, manufacturing,
consulting and other services from several countries. Further, potential future revenue may be derived from abroad, particularly from the United States. Additionally, our funding has mainly come from investors and collaborators mainly in the United
States. As a result, our business and share price may be affected by fluctuations in foreign exchange rates between the euro and these other currencies, which may also have a significant impact on our reported results of operations and cash flows
from period to period. Currently, we do not have any exchange rate hedging arrangements in place. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the possible abandonment of the euro by one or more members of the EU could
materially affect our business in the future. Despite measures taken by the EU to provide funding to certain EU member states in financial difficulties and by a number of European countries to stabilize their economies and reduce their debt burdens,
it is possible that the euro could be abandoned in the future as a currency by countries that have adopted its use. This could lead to the <FONT STYLE="white-space:nowrap">re-introduction</FONT> of individual currencies in one or more EU member
states, or in more extreme circumstances, the dissolution of the EU. The effects on our business of a potential dissolution of the EU, the exit of one or more EU member states from the EU or the abandonment of the euro as a currency, are impossible
to predict with certainty, and any such events could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Risks from improper conduct by our employees, agents, contractors, or collaborators could adversely affect our reputation, business,
prospects, operating results, and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot ensure that our compliance controls, policies, and procedures
will in every instance protect us from acts committed by our employees, agents, contractors, or collaborators that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, health care,
employment, foreign corrupt practices, trade restrictions and sanctions, environmental, competition, and patient privacy and other privacy laws and regulations. Such improper actions could subject us to civil or criminal investigations, and monetary
and injunctive penalties, and could adversely impact our ability to conduct business, operating results, and reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject
to a number of anti-corruption laws, including the Foreign Corrupt Practices Act, or FCPA, in the United States, the Bribery Act in the United Kingdom and the anti-corruption provisions of the Dutch Criminal Code in the Netherlands. Our failure to
comply with anti-corruption laws applicable to us could result in penalties, which could harm our reputation and harm our business, financial condition, results of operations, cash flows or prospects. The FCPA generally prohibits companies and their
intermediaries from making improper payments to foreign officials for the purpose of improperly or corruptly obtaining or keeping business, obtaining preferential treatment and/or other undue benefits or advantages. The FCPA also requires public
companies to maintain accurate books and records and devise a system of sufficient internal accounting controls. We regularly review and update our policies and procedures and internal controls designed to provide reasonable assurance that we, our
employees, distributors and other intermediaries comply with the anti-corruption laws to which we are subject. However, there are inherent limitations to the effectiveness of any policies, procedures and internal controls, including the possibility
of human error and the circumvention or overriding of the policies, procedures and internal controls. There can be no assurance that such policies or procedures or internal controls will work effectively at all times or protect us against liability
under these or other laws for actions taken by our employees, distributors and other intermediaries with respect to our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC
and Department of Justice continue to view FCPA enforcement activities as a high priority. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and
regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, requirements to obtain export licenses,
cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could materially damage our reputation, our brand, our international operations,
our ability to attract and retain employees, and our business, prospects, operating results, and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Development
and Clinical Testing of Our Bispecific Antibody Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>All of our bispecific antibody candidates are in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> or early-stage clinical development. Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of our bispecific antibody
candidates, particularly <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT STYLE="white-space:nowrap">MCLA-117</FONT> or <FONT STYLE="white-space:nowrap">MCLA-158,</FONT> and the commencement of our clinical trial for <FONT
STYLE="white-space:nowrap">MCLA-145,</FONT> which we are developing with Incyte, are prolonged or </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>
delayed, we or any collaborators may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our bispecific antibody candidates on a timely basis or at all.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain the requisite regulatory approvals to market and sell any of our bispecific antibody candidates, we or any collaborator
for such candidates must demonstrate through extensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials that our products are safe and effective in humans. Clinical testing is expensive and can take many years to
complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and early-stage clinical trials of our bispecific
antibody candidates may not be predictive of the results of later-stage clinical trials. Bispecific antibody candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety
profiles, notwithstanding promising results in earlier trials. Our future clinical trial results may not be successful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have
not completed any clinical trials required for the approval of any of our bispecific antibody candidates. Although we are conducting ongoing clinical trials for <FONT STYLE="white-space:nowrap">MCLA-128,</FONT>
<FONT STYLE="white-space:nowrap">MCLA-117</FONT> and <FONT STYLE="white-space:nowrap">MCLA-158,</FONT> plan to commence a clinical trial for <FONT STYLE="white-space:nowrap">MCLA-145</FONT> in the first half of 2019, and are conducting <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies for other bispecific antibody candidates, we may experience delays in our ongoing clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned,
enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed, suspended, or terminated for a variety of reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in or failure to reach agreement on acceptable terms with prospective contract research organizations, or
CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in establishing the appropriate dosage levels in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in or failure to recruit suitable patients to participate in a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the difficulty in certain countries in identifying the <FONT STYLE="white-space:nowrap">sub-populations</FONT>
that we are trying to treat in a particular trial, which may delay enrollment and reduce the power of a clinical trial to detect statistically significant results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lower than anticipated retention rates of patients in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to have patients complete a trial or return for post-treatment
<FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding new clinical trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safety or tolerability concerns could cause us or our collaborators or Health Authorities, as applicable, to
suspend or terminate a trial if we or our collaborators or Health Authorities, find that the participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in or failure to obtain regulatory approval to commence a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in or failure to obtain institutional review board, or IRB, approval at each site; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party research contractors failing to comply with regulatory requirements or applicable law, or to meet
their contractual obligations to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements, policies and guidelines; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing sufficient quantities of bispecific antibody candidate for use in clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the quality or stability of a bispecific antibody candidate falling below acceptable standards;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the treatment landscape for our target indications that may make our bispecific antibody candidates no
longer relevant; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third party actions claiming infringement by our bispecific antibody candidates in clinical trials outside of the
United States and obtaining injunctions interfering with our progress; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including
war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could encounter delays if
a clinical trial is suspended or terminated by us, by the IRBs or Ethics Committees of the institutions in which such trials are being conducted, by the Data Review Committee or Data Safety Monitoring Board for such trial or by the FDA, the
Competent Authorities of the EEA Member States (the 28 EU Member States plus Iceland, Liechtenstein and Norway) or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including
failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EEA Competent Authorities or other regulatory authorities resulting in
the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the
clinical trial. If we experience delays in the completion of, or termination of, any clinical trial of our bispecific antibody candidates, the commercial prospects of our bispecific antibody candidates will be harmed, and our ability to generate
product revenues from any of these bispecific antibody candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our bispecific antibody candidate development and approval process and
jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to
commercialize our bispecific antibody candidates and impair our ability to commercialize our bispecific antibody candidates and may harm our business and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause,
or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our bispecific antibody candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials must be conducted in accordance with the FDA, the EU and other applicable regulatory authorities&#146; legal requirements,
regulations or guidelines, and are subject to oversight by these governmental agencies and Ethics Committees or IRBs at the medical institutions where the clinical trials are conducted. In addition, clinical trials must be conducted with supplies of
our bispecific antibody candidates produced under current good manufacturing practice, or cGMP, requirements and other regulations. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials
and while we have agreements governing their committed activities, we have limited influence over their actual performance. We depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with good
clinical practice, or GCP, requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the study to GCP standards or are delayed for a significant time in the execution of trials,
including achieving full enrollment, we may be affected by increased costs, program delays or both, which may harm our business. In addition, clinical trials that are conducted in countries outside the EU and the United States may subject us to
further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of <FONT STYLE="white-space:nowrap">non-EU</FONT> and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> CROs, as well as expose
us to risks associated with clinical investigators who are unknown to the FDA or the EMA, and different standards of diagnosis, screening and medical care. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our bispecific antibody candidates may have serious adverse, undesirable or
unacceptable side effects which may delay or prevent marketing approval. If such side effects are identified during the development of our bispecific antibody candidates or following approval, if any, we may need to abandon our development of such
bispecific antibody candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval, if any. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undesirable side effects that may be caused by our bispecific antibody candidates could cause us or regulatory authorities to interrupt, delay
or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA or other comparable foreign authorities. In February 2015, we commenced a Phase 1/2 clinical trial in Europe of
our most advanced bispecific antibody candidate, <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> for the treatment of various solid tumors. Additionally, in January 2018 we commenced a Phase&nbsp;2 clinical trial in Europe and the United States
exploring <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> in combination with other agents, in patients with metastatic breast cancer. To date, patients treated with <FONT STYLE="white-space:nowrap">MCLA-128</FONT> have experienced adverse
reactions that may be related to the treatment, including infusion-related reactions, diarrhea, vomiting, fatigue, skin rash, sore mouth and shortness of breath. In May 2016, we commenced a Phase 1 clinical trial in Europe of our bispecific antibody
<FONT STYLE="white-space:nowrap">MCLA-117.</FONT> To date, patients treated with <FONT STYLE="white-space:nowrap">MCLA-117</FONT> have experienced adverse reactions that may be related to the treatment, most commonly infusion-related reactions. In
May 2018 we commenced a Phase 1 clinical trial in Europe of our bispecific antibody <FONT STYLE="white-space:nowrap">MCLA-158</FONT> in patients with solid tumors with an initial focus on colorectal cancer. To date, patients treated with <FONT
STYLE="white-space:nowrap">MCLA-158</FONT> have experienced adverse reactions that may be related to the treatment, most commonly infusion-related reactions. Results of our trials could reveal a high and unacceptable severity and prevalence of these
or other side effects. In such an event, our trials could be suspended or terminated and the FDA, the EMA, EEA Competent Authorities, or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our
bispecific antibody candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of
these occurrences may harm our business, financial condition and prospects significantly. Additionally, if any of our bispecific antibody candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects
caused by such products, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw approvals of such products and require us to take our approved product off
the market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or
field alerts to physicians and pharmacies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution
to patients, or that we implement a risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the product outweigh its risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the dose or the way the product is administered, conduct additional clinical trials
or change the labeling of the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to limitations on how we may promote the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of the product may decrease significantly; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to litigation or product liability claims; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of
the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Adverse events in the field of oncology could damage public perception of our
bispecific antibody candidates and negatively affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commercial success of our products will depend in part on
public acceptance of the use of cancer immunotherapies. Adverse events in clinical trials of our bispecific antibody candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse
events in the field of oncology that may occur in the future, could result in a decrease in demand for any products that we may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future adverse events in immuno-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter
labeling requirements and potential regulatory delays in the testing or approvals of our products. Any increased scrutiny could delay or increase the costs of obtaining regulatory approval for our bispecific antibody candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We depend on enrollment of patients in our clinical trials for our bispecific antibody candidates. If we are unable to enroll patients
in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patient candidates. For the <FONT
STYLE="white-space:nowrap">MCLA-128</FONT> Phase 2 clinical trial, we plan to enroll approximately 120 patients with metastatic breast cancer in the United States and Europe. In the Phase 1 clinical trial of
<FONT STYLE="white-space:nowrap">MCLA-117,</FONT> we plan to enroll approximately 50 adult patients with AML. In the Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">MCLA-158,</FONT> we plan to enroll approximately 120 adult patients with
colorectal cancer and possibly other solid tumors. In the planned Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> we plan to enroll approximately 118 adult patients with solid tumors. These trials and other trials we
conduct may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical
trials will likely compete with other clinical trials for antibody candidates that are in the same therapeutic areas as our bispecific antibody candidates, and this competition will reduce the number and types of patients available to us, because
some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to
conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment depends on many factors, including the size and nature of the patient population, eligibility criteria for the trial, the
proximity of patients to clinical sites, the design of the clinical protocol, the availability of competing clinical trials, the availability of new drugs approved for the indication the clinical trial is investigating, and clinicians&#146; and
patients&#146; perceptions as to the potential advantages of the drug being studied in relation to other available therapies. These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and
cost-effective manner. Delays in the completion of any clinical trial of our bispecific antibody candidates will increase our costs, slow down our bispecific antibody candidate development and approval process, delay or potentially jeopardize our
ability to commence product sales and generate revenue and harm our reputation and ability to obtain financing. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately
lead to the denial of regulatory approval of our bispecific antibody candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may become exposed to costly and damaging
liability claims, either when testing our bispecific antibody candidates in the clinic or at the commercial stage; and our product liability insurance may not cover all damages from such claims. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing,
marketing and use of pharmaceutical products. Currently, we have no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products that have been approved for commercial sale; however, the current and future use of bispecific antibody candidates by us and our corporate collaborators in clinical trials, and the sale
of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies, our corporate collaborators or others selling such products. Any
claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our bispecific antibody candidates or any prospects for commercialization of our bispecific antibody
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a
drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our bispecific antibody candidates were to cause adverse side effects during clinical trials or after approval of the bispecific antibody candidate, we may be
exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our bispecific antibody candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we maintain adequate product liability insurance for our bispecific antibody candidates, it is possible that our liabilities could
exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for any of our bispecific antibody candidates. However, we may not be able to maintain insurance
coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of
insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of
the events described above occur, this could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the FDA, the EMA and comparable foreign authorities are lengthy, time consuming and inherently
unpredictable, and if we are ultimately unable to obtain regulatory approval for our bispecific antibody candidates, our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The time required to obtain approval by the FDA, the EMA and comparable foreign authorities is unpredictable but typically takes many years
following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to
gain approval may change during the course of a bispecific antibody candidate&#146;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any bispecific antibody candidate and it is possible that none
of our existing bispecific antibody candidates or any bispecific antibody candidates we may seek to develop in the future will ever obtain regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bispecific antibody candidates could fail to receive regulatory approval for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, the EMA or comparable foreign regulatory authorities may disagree with the design or implementation of
our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA, the EMA or comparable foreign regulatory
authorities that a bispecific antibody candidate is safe and effective for its proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that a bispecific antibody candidate&#146;s clinical and other benefits outweigh
its safety risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, the EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our bispecific antibody candidates may not be sufficient to support
the submission of a BLA or other submission or to obtain regulatory approval in the United&nbsp;States, the EU or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, the EMA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or
facilities of third-party manufacturers with which we contract for clinical and commercial supplies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, the EMA or comparable foreign regulatory authorities may fail to approve the companion diagnostics we
contemplate developing with collaborators; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA, the EMA or comparable foreign regulatory authorities may
significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This lengthy approval process
as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market any of our bispecific antibody candidates, which would significantly harm our business, results of operations and
prospects. The FDA, the EMA and other regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our bispecific antibody candidates. Even if we believe
the data collected from clinical trials of our bispecific antibody candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA or any other regulatory authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if we were to obtain approval, regulatory authorities may approve any of our bispecific antibody candidates for fewer or
more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a bispecific antibody candidate with
a label that does not include the labeling claims necessary or desirable for the successful commercialization of that bispecific antibody candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our bispecific
antibody candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if our bispecific antibody candidates obtain regulatory approval, we will be subject to ongoing
obligations and continued regulatory review, which may result in significant additional expense. Additionally, our bispecific antibody candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be
subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
the FDA, the EMA or a comparable foreign regulatory authority approves any of our bispecific antibody candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and
recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with
cGMPs and GCPs for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to commercialize such products. In addition, any regulatory approvals that we receive for our bispecific
antibody candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4
clinical trials, and surveillance to monitor the safety and efficacy of the bispecific antibody candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If there are changes in the
application of legislation or regulatory policies, or if problems are discovered with a product or our manufacture of a product, or if we or one of our distributors, licensees or <FONT STYLE="white-space:nowrap">co-marketers</FONT> fails to comply
with regulatory requirements, the regulators could take various actions. These include imposing fines on us, imposing restrictions on the product or its manufacture and requiring us to recall or remove the product from the market. The regulators
could also suspend or withdraw our marketing authorizations, requiring us to conduct additional clinical trials, change our product labeling or submit additional applications for marketing authorization. If any of these events occurs, our ability to
sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to use and expand our technology platform to
build a pipeline of antibody candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key element of our strategy is to use and expand our Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform to build a pipeline of antibody candidates and progress these antibody candidates through clinical development for the treatment of a variety of different types of diseases.
Although our research and development efforts to date have resulted in a pipeline of bispecific antibody candidates directed at various cancers, we may not be able to develop bispecific antibody candidates that are safe and effective. Even if we are
successful in continuing to build our pipeline, the potential antibody candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate
that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize antibody candidates, we will face difficulty in obtaining product
revenues in future periods, which could result in significant harm to our financial position and adversely affect our share price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain marketing approval of any of our bispecific antibody candidates in a major pharmaceutical market such as the United
States or the EU, we may never obtain approval or commercialize our products in other major markets, which would limit our ability to realize their full market potential. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any products in a country or territory, we must establish and comply with numerous and varying regulatory requirements of
such countries or territories regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval
will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking regulatory approvals in all major markets could result in
significant delays, difficulties and costs for us and may require additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from
country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure
to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We currently do not have any bispecific antibody candidates approved for sale in any jurisdiction, whether in
the Netherlands, the United States or any other international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain
and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products will be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Due to our limited resources and access to capital, we must, and have in the past decided to, prioritize development of certain
bispecific antibody candidates over other potential candidates. These decisions may prove to have been wrong and may adversely affect our revenues. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited resources and access to capital to fund our operations, we must decide which antibody candidates to pursue and the
amount of resources to allocate to each. Our decisions concerning the allocation of research, collaboration, management and financial resources toward particular compounds, bispecific antibody candidates or therapeutic areas may not lead to the
development of viable commercial products and may divert resources away from better opportunities. Similarly, our decisions to delay, terminate or collaborate with third parties in respect of certain product development programs may also prove not
to be optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the market potential of our bispecific antibody candidates or misread trends in the biopharmaceutical industry, in particular for our lead
bispecific antibody candidates, our business, financial condition and results of operations could be materially adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Because we are subject to environmental, health and safety laws and regulations, we
may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities which may adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations, including our research, development, testing and manufacturing activities, are subject to numerous environmental, health and
safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of, and the maintenance of a registry for, hazardous materials and biological materials, such as chemical
solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be
subject to fines or other sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As with other companies engaged in activities similar to ours, we face a risk of environmental
liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be
required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, our production and development efforts may be interrupted or delayed and our financial condition and results of
operations may be materially adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, principal investigators, CROs,
consultants, vendors and collaborators may engage in misconduct or other improper activities, including noncompliance with applicable law, regulatory standards and requirements, which could have a material adverse effect on our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants, vendors and
collaborators may engage in fraudulent conduct or other illegal activities. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate: (i)&nbsp;the regulations of the FDA, the
EMA and other regulatory authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii)&nbsp;manufacturing standards; (iii)&nbsp;federal and state data privacy, security, fraud and
abuse and other healthcare laws and regulations in the United States and abroad; or (iv)&nbsp;laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in
the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing,
discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of
clinical trials or creating fraudulent data in our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to
identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental
investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If
any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant
civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs, individual imprisonment, other sanctions, contractual
damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our research and development activities could be affected or delayed as a result of
possible restrictions on animal testing. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain laws and regulations require us to test our bispecific antibody candidates on
animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing
activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be
interrupted, delayed or become more expensive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval of Our Bispecific Antibody Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our
bispecific antibody candidates and may affect the prices we may set. The successful commercialization of our bispecific antibody candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate
coverage and reimbursement levels and pricing policies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the EU, and other foreign jurisdictions, there have
been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a
number of initiatives at the United States federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March&nbsp;2010, the Patient Protection and Affordable Care Act, as amended by the Health
Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changes the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the
pharmaceutical and biotechnology industries include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, <FONT STYLE="white-space:nowrap">non-deductible</FONT> fee on any entity that manufactures or imports
certain branded prescription drugs and biologic agents, which is apportioned among these entities according to their market share in certain government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s
outpatient drugs to be covered under Medicare Part D; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to
23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated
for drugs that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extension of a manufacturer&#146;s Medicaid rebate liability to covered drugs dispensed to individuals who are
enrolled in Medicaid managed care organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment of a Center for Medicare Innovation at the Centers for Medicare&nbsp;&amp; Medicaid Services, or
CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the current presidential administration and U.S. Congress may continue to
seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA. There have also been judicial challenges to certain aspects of the ACA. For example, on December&nbsp;14, 2018, a U.S. District Court Judge in the Northern
District of Texas, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. While the
current presidential administration and the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, have both stated that the ruling will have no immediate effect, it is unclear how this decision and subsequent appeals, if any, will impact the
law. We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget
Control Act of 2011 resulted in aggregate reductions of Medicare payments to providers of 2%&nbsp;per fiscal year. These reductions went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute will remain in
effect through 2027 unless additional Congressional action is taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers,
including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions
in Medicare and other health care funding, which could have a material adverse effect on our customers and accordingly, our financial operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies, including payment for companion diagnostics, may be subject to changes in healthcare legislation and
regulatory initiatives. For example, CMS began bundling the Medicare payments for certain laboratory tests ordered while a patient received services in a hospital outpatient setting and, beginning in 2018, CMS began paying for clinical laboratory
services based on a weighted average of reported prices that private payors, Medicare Advantage plans, and Medicaid Managed Care plans pay for laboratory services. In addition, recently there has been heightened governmental scrutiny over the manner
in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed to, among other things, bring more transparency to product pricing, review the
relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, the 21st Century Cures Act, or Cures Act, changed the reimbursement methodology for infusion
drugs and biologics furnished through durable medical equipment in an attempt to remedy over- and underpayment of certain products. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could
limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our bispecific antibody candidates or additional pricing pressures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to
control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to
encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In
addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.
This could reduce the ultimate demand for our products or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our current or any
future products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating
costs. The delivery of healthcare in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
EU,&nbsp;including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy.
National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in
most EU&nbsp;member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market
products, this could prevent or delay marketing approval of our bispecific antibody candidates, restrict or regulate post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval. In
international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict how the policies of changing political administrations could impact, impose significant burdens on, or otherwise materially
delay, FDA&#146;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications.&nbsp;For example, certain policies of the
current presidential administration may impact our business and industry. Namely, the current presidential administration has taken several executive actions, including the issuance if a number of Executive Orders. It is difficult to predict how
these requirements will be implemented, and the extent to which they will impact the FDA&#146;s ability to exercise its regulatory authority.&nbsp;If these executive actions impose constraints on FDA&#146;s ability to engage in oversight and
implementation activities in the normal course, our business may be negatively impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, policies of the individual government
agencies, including the FDA or similar regulatory authorities, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, in December 2016, the Cures
Act was signed into law and, among other things, is intended to modernize the regulation of drugs and biologics and spur innovation. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new
requirements or policies, or if we or our collaborators are not able to maintain regulatory compliance, our bispecific antibody candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability,
which would adversely affect our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes in funding for the&nbsp;FDA&nbsp;and other government agencies could hinder
their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the&nbsp;FDA&nbsp;to review and approve or clear new products can be affected by a variety of factors, including government
budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition,
government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the&nbsp;FDA&nbsp;and other agencies may also slow the time necessary for new drugs, biologics and medical devices to be
reviewed and/or approved or cleared by necessary government agencies, which would adversely affect our business.&nbsp;For example, over the last several years, including for 35 days beginning on December&nbsp;22, 2018, the U.S. government has shut
down several times and certain regulatory agencies, such as the&nbsp;FDA, have had to furlough critical&nbsp;FDA&nbsp;employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the
FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be
subject to healthcare laws, regulation and enforcement; our failure to comply with these laws could harm our results of operations and financial conditions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we do not currently have any products on the market, if we obtain FDA approval for any of our bispecific antibody candidates and begin
commercializing those products in the United States, our operations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be directly, or indirectly through our customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S.
federal Anti-Kickback Statute. Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. These laws may impact, among other things, our proposed
sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers, physicians and other parties through which we market, sell and distribute our products for which we obtain
marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business. Finally, we may be subject to additional healthcare, statutory
and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. The laws that may affect our ability to operate include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly
and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual
for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does
not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act, which,
among other things, impose criminal and civil penalties, including through civil whistleblower or <I>qui tam</I> actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the U.S. federal
government, claims for payment or approval that are false or fraudulent , knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to
avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a
false or fraudulent claim for purposes of the False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal
and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making
any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute
or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH,
and its implementing regulations, and as amended again by the Final HIPAA Omnibus Rule, Modifications to the HIPAA Privacy, Security, Enforcement and Breach Notification Rules Under HITECH and the Genetic Information Nondiscrimination Act; Other
Modifications to the HIPAA Rules, published in January 2013, which imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health
information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or
disclosure of individually identifiable health information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Food, Drug and Cosmetic Act, or FDCA, which prohibits, among other things, the adulteration or
misbranding of drugs, biologics and medical devices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal legislation commonly referred to as Physician Payments Sunshine Act, enacted as part of the ACA,
and its implementing regulations, which requires certain manufacturers of drugs, devices, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to report annually to the CMS information related to certain
payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and
their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to
our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require
pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare
providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, and that requires the tracking and reporting of gifts and other remuneration
and items of value provided to healthcare professionals and entities; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not
preempted by HIPAA, thus complicating compliance efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">European and other foreign law equivalents of each of the laws, including reporting requirements detailing
interactions with and payments to healthcare providers and data privacy and security requirements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that our
internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do
not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or
any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as
Medicare and Medicaid, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits, reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement, and the
curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or
administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations. Further, defending
against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We face potential liability related to the privacy of health information we obtain from clinical trials sponsored by us or our
collaborators, from research institutions and our collaborators, and directly from individuals. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most health care providers,
including research institutions from which we or our collaborators obtain patient health information, are subject to privacy and security regulations promulgated under the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as
amended by the Health Information Technology for Economic and Clinical Health Act. Any person may be prosecuted under HIPAA&#146;s criminal provisions either directly or under
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">aiding-and-abetting</FONT></FONT> or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly
receive individually identifiable health information from a HIPAA-covered health care provider or research institution that has not satisfied HIPAA&#146;s requirements for disclosure of individually identifiable health information. In addition, we
may maintain sensitive personally identifiable information, including health information, that we receive throughout </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we
may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our and our collaborators&#146; clinical trial programs and research collaborations outside the U.S. may implicate international data
protection laws, including, in Europe, the General Data Protection Regulation, or the GDPR and local laws further implementing or supplementing the GDPR. The GDPR implements more stringent operational requirements for processors and controllers of
personal data including requirements for such companies to be able to ensure and be able to demonstrate compliance with the GDPR. If our or our collaborators&#146; privacy or data security measures fail to comply with the GDPR requirements, we may
be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20&nbsp;million Euros or up to 4% of the total worldwide annual turnover of the preceding financial
year, whichever is higher. In addition to statutory enforcement, a <FONT STYLE="white-space:nowrap">non-compliance</FONT> can lead to compensation claims by affected individuals, negative publicity and a potential loss of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to EU laws on personal data export, as we may transfer personal data from the EU to other jurisdictions which are not
considered by the European Commission to offer &#147;adequate&#148; protection of personal data. Such transfers need to be legitimized by a valid transfer mechanism under the GDPR. There is currently ongoing litigation challenging the commonly used
transfer mechanism, the EU model clauses. In addition, the U.S. Privacy Shield is under review by the European Commission. As such, it is uncertain whether the Privacy Shield framework and/or model clauses will be invalidated in the near future.
Further, the United Kingdom&#146;s decision to leave the EU has created uncertainty with regard to the status of the UK as an &#147;adequate country&#148; for the purposes of data transfers outside the European Economic Area. In particular, it is
unclear how data transfers to and from the UK will be regulated. These changes could require us to make operational changes and could increase costs and may lead to governmental enforcement actions, litigation, fines and penalties or adverse
publicity that could have an adverse effect on our business. See &#147;Business&#151;Privacy and Data Protection Laws in Europe.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are likely to be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws both inside and outside the United States. Claims that we have violated individuals&#146; privacy
rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or any collaborators fail to comply with applicable federal, state, or local regulatory requirements, we could be subject to a range of
regulatory actions that could affect our or any collaborators&#146; ability to seek to commercialize our clinical candidates. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote
substantial resources that could otherwise be used in other aspects of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization of Our
Bispecific Antibody Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We operate in highly competitive and rapidly changing industries, which may result in others
discovering, developing or commercializing competing products before or more successfully than we do. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical and
pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to discover, develop and obtain marketing approval for new and innovative products on a
cost-effective basis and to market them successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and
biopharmaceutical companies, academic institutions, government agencies and other private and public research institutions in Europe, the United States and other jurisdictions. These organizations may have significantly greater resources
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
than we do and conduct similar research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and marketing of products that compete with our
bispecific antibody candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the proliferation of new drugs and therapies into oncology, we expect to face increasingly intense
competition as new technologies become available. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Any bispecific antibody candidates that we successfully develop and commercialize will compete
with existing therapies and new therapies that may become available in the future. The highly competitive nature of and rapid technological changes in the biotechnology and pharmaceutical industries could render our bispecific antibody candidates or
our technology obsolete, less competitive or uneconomical. Our competitors may, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have significantly greater financial, manufacturing, marketing, drug development, technical and human resources
than we do; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop and commercialize products that are safer, more effective, less expensive, more convenient or easier to
administer, or have fewer or less severe side effects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain quicker regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish superior proprietary positions covering our products and technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implement more effective approaches to sales and marketing; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">form more advantageous strategic alliances. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these factors occur, our business, financial condition and results of operations could be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, existing and future collaborators may decide to market and sell products that compete with the bispecific antibody candidates
that we have agreed to license to them. While we have agreements governing their committed activities, we have limited influence over their actual performance, and any competition by our collaborators could also have a material adverse effect on our
future business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Smaller and other early stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and
patient registration for clinical trials, retaining manufacturers to produce clinical trial materials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to obtain orphan drug designation or obtain or maintain orphan drug exclusivity for our products, our competitors may sell
products to treat the same conditions and our revenue will be reduced. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may designate a product
as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable
expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the EMA&#146;s Committee for Orphan Medicinal Products, or COMP, grants orphan drug designation to promote the development of products
that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU. Additionally, designation is granted for products intended for the
diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in
developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, orphan drug designation entitles a party to financial incentives such
as opportunities for grant funding towards clinical trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan
designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a
showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity. In the EU, orphan drug designation entitles a party to financial incentives such as reduction of fees
or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is
sufficiently profitable not to justify maintenance of market exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to seek orphan drug designation from the FDA and the
EMA for our assets in clinical development, including <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT STYLE="white-space:nowrap">MCLA-117</FONT> and other clinical assets, where supported by data in the appropriate indications that meet the
criteria for orphan status. Even if we are able to obtain orphan designation in the United States and/or the EU, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with
developing pharmaceutical products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the
request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for
a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan drug is approved, the FDA or the EMA can
subsequently approve the same drug with the same active moiety for the same condition if the FDA or the EMA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither
shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we intend to seek orphan drug designation, when appropriate, we may not receive such
designation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The successful commercialization of our bispecific antibody candidates will depend in part on the extent to which
governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain adequate coverage and reimbursement for our bispecific antibody candidates, if approved, could limit
our ability to market those products and decrease our ability to generate revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The availability and adequacy of coverage and
reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford products such as our bispecific antibody candidates, assuming
approval. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize and attract
additional collaborators to invest in the development of our bispecific antibody candidates. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT
STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the EU or elsewhere will be available for any product that we may develop, and any
reimbursement that may become available may be decreased or eliminated in the future. Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage
and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our bispecific antibody candidate and other therapies as substitutable and only
offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our bispecific antibody candidate, pricing of existing drugs may limit the amount we will be able to charge
for our bispecific antibody candidate. These payors may deny or revoke the reimbursement status of a given drug product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our
bispecific antibody candidates and may not be able to obtain a satisfactory financial return on products that we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is
significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an
important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and
reimbursement policies for drugs and biologics. Some third-party payors may require <FONT STYLE="white-space:nowrap">pre-approval</FONT> of coverage for new or innovative devices or drug therapies before they will reimburse health care providers who
use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our bispecific antibody candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining reimbursement status is time-consuming and costly. No uniform policy for coverage and reimbursement for drug
products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly
process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.
Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, international operations are generally subject to extensive governmental price controls and other market
regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of our bispecific antibody candidates. In many countries, the
prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign
price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our bispecific antibody candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced
compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, increasing
efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they
may not cover or provide adequate payment for our bispecific antibody candidates. We expect to experience pricing pressures in connection with the sale of any of our bispecific antibody candidates due to the trend toward managed healthcare, the
increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very
intense. As a result, increasingly high barriers are being erected to the entry of new products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our products may not gain market
acceptance, in which case we may not be able to generate product revenues, which will materially adversely affect our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the FDA, the EMA or any other regulatory authority approves the marketing of any bispecific antibody candidates that we develop on our
own or with a collaborator, physicians, healthcare providers, patients or the medical community may not accept or use them. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenues or any
profits from operations. The degree of market acceptance of any of our bispecific antibody candidates will depend on a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and clinical profile of competing products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to provide acceptable evidence of safety and efficacy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relative convenience and ease of administration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effectiveness; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient diagnostics and screening infrastructure in each market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability of adequate coverage, reimbursement and adequate payment from health maintenance organizations and
other insurers, both public and private; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other potential advantages over alternative treatment methods. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our bispecific antibody candidates fail to gain market acceptance, this will have a material adverse impact on our ability to generate
revenues to provide a satisfactory, or any, return on our investments. Even if some products achieve market acceptance, the market may prove not to be large enough to allow us to generate significant revenues. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We currently have no marketing, sales or distribution infrastructure. If we are unable to develop sales, marketing and distribution
capabilities on our own or through collaborations, or if we fail to achieve adequate pricing and/or reimbursement we will not be successful in commercializing our bispecific antibody candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no marketing, sales and distribution capabilities because all of our bispecific antibody candidates are still in clinical or <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development. If any of our bispecific antibody candidates are approved, we intend either to establish a sales and marketing organization with technical expertise and supporting distribution capabilities
to commercialize our bispecific antibody candidates, or to outsource this function to a third party. Either of these options would be expensive and time consuming. These costs may be incurred in advance of any approval of our bispecific antibody
candidates. In addition, we may not be able to hire a sales force that is sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal sales, marketing and
distribution capabilities would adversely impact the commercialization of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that we enter into collaboration
agreements with respect to marketing, sales or distribution, our product revenue may be lower than if we directly marketed or sold any approved products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these
third-party collaborators, which may not be successful and are generally not within our control. If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products.
If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have never commercialized a bispecific antibody candidate before and may lack the necessary expertise, personnel and resources to
successfully commercialize our products on our own or together with suitable collaborators. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never commercialized a
bispecific antibody candidate, and we currently have no sales force, marketing or distribution capabilities. To achieve commercial success for the bispecific antibody candidates, which we may license to others, we will rely on the assistance and
guidance of those collaborators. For bispecific antibody candidates for which we retain commercialization rights, we will have to develop our own sales, marketing and supply organization or outsource these activities to a third party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that may affect our ability to commercialize our bispecific antibody candidates on
our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our bispecific antibody candidates and other unforeseen costs
associated with creating an independent sales and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of our bispecific antibody candidates. We may not be able to
build an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our bispecific antibody candidates, we may not generate revenues
from them or be able to reach or sustain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our bispecific antibody candidates for which we intend to seek approval as
biologic products may face competition sooner than anticipated. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Care Act, signed into law on
March&nbsp;23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT
STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first approved
by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of
exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#146;s own <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data and data
from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and
meaning are subject to uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that any of our bispecific antibody candidates approved as a biological product under a
BLA should qualify for the <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise. Other aspects of the BPCIA, some of which
may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to
traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jurisdictions in addition to the United States have established abbreviated pathways for regulatory approval of biological products that are
biosimilar to earlier approved reference products. For example, the EU has had an established regulatory pathway for biosimilars since 2005. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increased likelihood of biosimilar competition has increased the risk of loss of innovators&#146; market exclusivity. Due to this risk,
and uncertainties regarding patent protection, if our clinical candidates are approved for marketing, it is not possible to predict the length of market exclusivity for any particular product with certainty based solely on the expiration of the
relevant patent(s) or the current forms of regulatory exclusivity. It is also not possible to predict changes in United States regulatory law that might reduce biological product regulatory exclusivity. The loss of market exclusivity for a product
would likely materially and negatively affect revenues and we may not generate adequate or sufficient revenues from them or be able to reach or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct our <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials. If these third parties do not successfully carry out </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>
their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our bispecific antibody candidates and our business could be
substantially harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relied upon and plan to continue to rely upon third parties, including independent clinical
investigators and third-party CROs, to conduct our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials and to monitor and manage data for our ongoing <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical
programs. We rely on these parties for execution of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each
of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party
contractors and CROs are required to comply with good clinical practice, or GCP, requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the EEA, and comparable foreign regulatory
authorities for all of our products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable
GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We
cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced
under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of
resources, including time, which they devote to our bispecific antibody candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our bispecific antibody candidates, or if their
performance is substandard, it may delay or compromise the prospects for approval and commercialization of any bispecific antibody candidates that we develop. In addition, the use of third-party service providers may require us to disclose our
proprietary information to these parties, which could increase the risk that this information will be misappropriated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CROs have the
right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the
subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to
do so on commercially reasonable terms. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is
compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully
commercialize our bispecific antibody candidates. As a result, our results of operations and the commercial prospects for our bispecific antibody candidates would be harmed, our costs could increase and our ability to generate revenues could be
delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a
natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or
take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not
have a material adverse impact on our business, financial condition and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The collaboration and license agreement, or the
Collaboration Agreement, with Incyte Corporation, or Incyte, is important to our business. If suitable bispecific antibody candidates are not identified for further </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>
development and commercialization activities under the Collaboration Agreement, or if we or Incyte fail to adequately perform under the Collaboration Agreement, or if we or Incyte terminate the
Collaboration Agreement, the development and commercialization of our bispecific antibody candidates would be delayed or terminated and our business would be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Collaboration Agreement may be terminated: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in its entirety or on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis by Incyte for convenience; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in its entirety or on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis by either party due to a material breach of the Collaboration Agreement, or any one or more programs under the Collaboration Agreement, as
applicable; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis
(but not in its entirety), by either party if the other party challenges the terminating party&#146;s patents for such program, and such challenge is not withdrawn within 30 days. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Collaboration Agreement is terminated with respect to one or more programs, all rights in the terminated programs revert to us, subject
to payment to Incyte of a reverse royalty of between 0% and 4% on sales of future products, depending on the stage of development as of the date of termination, if we elect to pursue development and commercialization of bispecific antibody products
arising from the terminated programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Termination of the Collaboration Agreement could cause significant delays in our product candidate
development and commercialization efforts, which could prevent us from commercializing our bispecific antibody candidates without first expanding our internal capabilities or entering into another agreement with a third party. Any suitable
alternative collaboration or license agreement would take considerable time to negotiate and could also be on less favorable terms to us. In addition, under the Collaboration Agreement, Incyte agreed to conduct certain clinical development
activities. If the Collaboration Agreement were to be terminated, and whether or not we identify another suitable collaborator, we may need to seek additional financing to support the research and development of any terminated product candidates so
that we may continue development activities, or we may be forced to discontinue development of terminated product candidates, each of which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Collaboration Agreement, with the exception of <FONT STYLE="white-space:nowrap">MCLA-145</FONT> where we retain full US rights, we
are dependent upon Incyte to successfully develop and commercialize bispecific antibody candidates that are identified for further development under the Collaboration Agreement. With the exception of those programs where we retain certain <FONT
STYLE="white-space:nowrap">co-development</FONT> rights, we have limited ability to influence or control Incyte&#146;s development and commercialization activities or the resources it allocates to development of bispecific antibody product
candidates identified under the Collaboration Agreement. Our interests and Incyte&#146;s interests may differ or conflict from time to time, or we may disagree with Incyte&#146;s level of effort or resource allocation. Incyte may internally
prioritize programs under development within the collaboration differently than we would, or it may not allocate sufficient resources to effectively or optimally develop or commercialize bispecific antibody candidates arising from such programs. If
these events were to occur, our ability to receive revenue from the commercialization of products arising from such programs would be reduced, and our business would be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to enter into new strategic relationships our business, financial condition, commercialization prospects and results of
operations may be materially adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development programs and the potential commercialization of our
bispecific antibody candidates will require substantial additional cash to fund expenses. Therefore, for some of our bispecific antibody candidates, we may decide to enter into new collaborations with pharmaceutical or biopharmaceutical companies
for the development and potential commercialization of those bispecific antibody candidates. For instance, we have license and collaboration agreements with ONO, Incyte, Simcere Pharmaceutical Group and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Betta Pharmaceuticals Co. Ltd. which we have licensed the development and commercialization of certain of our bispecific antibody candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to negotiate and document.
We may also be restricted under existing and future collaboration agreements from entering into agreements on certain terms with other potential collaborators. We may not be able to negotiate collaborations on acceptable terms, or at all. If that
were to occur, we may have to curtail the development of a particular bispecific antibody candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope
of our sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own,
we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring our bispecific antibody candidates to market and generate product revenue. If
we do&nbsp;enter into a new collaboration agreement, we could be subject to the following risks, each of which may materially harm our business, commercialization prospects and financial condition: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to control the amount and timing of resources that the collaborator devotes to the product
development program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the collaborator may experience financial difficulties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to relinquish important rights such as marketing, distribution and intellectual property
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator could move forward with a competing product developed either independently or in collaboration
with third parties, including our competitors; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business combinations or significant changes in a collaborator&#146;s business strategy may adversely affect our
willingness to complete our obligations under any arrangement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We currently rely on third-party suppliers and
other third parties for production of our bispecific antibody candidates and our dependence on these third parties may impair the advancement of our research and development programs and the development of our bispecific antibody candidates.
Moreover, we intend to rely on third parties to produce commercial supplies of any approved bispecific antibody candidate and our commercialization of any of our bispecific antibody candidates could be stopped, delayed or made less profitable if
those third parties fail to obtain approval of the FDA or comparable regulatory authorities, fail to provide us with sufficient quantities of bispecific antibody product or fail to do so at acceptable quality levels or prices or fail to otherwise
complete their duties in compliance with their obligations to us or other parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on and expect to continue to rely on
third-party contract manufacturing organizations, or CMOs, for the supply of current good manufacturing practice-grade, or cGMP-grade, clinical trial materials and commercial quantities of our bispecific antibody candidates and products, if
approved. Reliance on third-party providers may expose us to more risk than if we were to manufacture bispecific antibody candidates ourselves. The facilities used by our contract manufacturers to manufacture our bispecific antibody candidates must
be approved by the FDA pursuant to inspections that will be conducted after we submit our BLA to the FDA. We have limited control over the manufacturing process of, and beyond contractual terms, we are completely dependent on our CMOs for compliance
with cGMP for the manufacture of our bispecific antibody candidates. If our CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to
secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a
comparable foreign regulatory authority does not approve these facilities for the manufacture of our bispecific antibody candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which
would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significantly impact our ability to develop, obtain regulatory approval for or market our bispecific antibody candidates, if approved. In addition, any failure to achieve and maintain compliance
with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our bispecific antibody candidates or that obtained approvals could be revoked, which would adversely affect our business and
reputation. Furthermore, third-party providers may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement because of their own financial difficulties or business
priorities, at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate replacement or another acceptable solution in time, our clinical trials could be delayed or our commercial activities could be harmed. In
addition, the fact that we are dependent on our collaborators, our CMOs and other third parties for the manufacture, filling, storage and distribution of our bispecific antibody candidates means that we are subject to the risk that the products may
have manufacturing defects that we have limited ability to prevent or control. The sale of products containing such defects could adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Growth in the costs and expenses of components or raw materials may also adversely influence our business, financial condition and results of
operations. Supply sources could be interrupted from time to time and, if interrupted, there is no guarantee that supplies could be resumed (whether in part or in whole) within a reasonable timeframe and at an acceptable cost or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on our CMOs to purchase from third-party suppliers the materials necessary to produce our bispecific antibody candidates for our
clinical trials, and will rely on our existing and future collaborators to purchase from third-party suppliers the materials necessary to develop and produce our bispecific antibody candidates for future clinical trials. There are a limited number
of suppliers for raw materials that we use to manufacture our drugs and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our bispecific antibody candidates
for our clinical trials, and if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers or manufacturers paid by our collaborators. Moreover, we
currently do not have any agreements for the commercial production of these raw materials. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a bispecific antibody candidate to complete the clinical
trial or have secured resupply capacity, any significant delay in the supply of a bispecific antibody candidate, or the raw material components thereof, for a planned or an ongoing clinical trial due to the need to replace a third-party manufacturer
could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our bispecific antibody candidates. If our manufacturers, collaborators or we are unable to purchase these raw materials after
regulatory approval has been obtained for our bispecific antibody candidates, the commercial launch of our bispecific antibody candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues
from the sale of our bispecific antibody candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on our manufacturers and other subcontractors to comply with and respect the
proprietary rights of others in conducting their contractual obligations for us. If our manufacturers or other subcontractors fail to acquire the proper licenses or otherwise infringe third party proprietary rights in the course of completing their
contractual obligations to us, we may have to find alternative manufacturers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for or market our bispecific
antibody candidates, if approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property and Information Technology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We rely on patents and other intellectual property rights to protect our technology, including bispecific antibody candidates and our
Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform, the enforcement, defense and maintenance of which may be challenging and costly. Failure to enforce or protect these rights adequately could harm our ability to
compete and impair our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on obtaining and maintaining patents and other forms of
intellectual property rights for our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform, our bispecific antibody and antibody candidates, products, their format and methods used to produce, screen, manufacture
and purify those antibody and antibody candidates, the methods for treating patients using those candidates, among other aspects of our technology or on <FONT STYLE="white-space:nowrap">licensing-in</FONT> such rights. Failure to protect or to
obtain, maintain or extend adequate patent and other intellectual property rights could materially adversely affect our ability to develop and market our products and bispecific antibody candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive and time-consuming, and we and our current or future licensors, licensees or collaborators may not
be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our licensors, licensees or collaborators will fail to identify patentable aspects of
inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Further, the issuance, scope, validity, enforceability and commercial value of our and our current or future
licensors&#146;, licensees&#146; or collaborators&#146; patent rights are highly uncertain. Our and our licensors&#146; pending and future patent applications may not result in patents being issued which protect our technology or products, in whole
or in part, or which effectively prevent others from commercializing competitive technologies and products. The patent examination process may require us or our licensors, licensees or collaborators to narrow the scope of the claims of our or our
licensors&#146;, licensees&#146; or collaborators&#146; pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot assure you that all of the potentially relevant prior art relating to our
patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our
Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform, bispecific antibody candidates, and other technologies, third parties may initiate opposition, interference,
<FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, interpartes review, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such
patents, which may result in the patent claims being narrowed or invalidated. Our and our licensors&#146;, licensees&#146; or collaborators&#146; patent applications cannot be enforced against third parties practicing the technology claimed in such
applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because patent applications are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we
or our licensors were the first to file any patent application related to our technology, including a bispecific antibody candidate. Furthermore, if third parties have filed such patent applications on or before March&nbsp;15, 2013, an interference
proceeding can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such applications after March&nbsp;15, 2013, a
derivation proceeding can be initiated by such third parties to determine whether our invention was derived from theirs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Issued
patents covering one or more of our products or the Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform could be found invalid or unenforceable if challenged in court. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To protect our competitive position, we may from time to time need to resort to litigation to enforce or defend any patents or other
intellectual property rights owned by or licensed to us, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties. As enforcement of intellectual property rights is difficult, unpredictable
and expensive, we may fail in enforcing our rights&#151;in which case our competitors may be permitted to use our technology without being enjoined, required to pay us any license fees, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or compensate us for lost profits. In addition, litigation involving our patents carries the risk that one or more of our patents will be held invalid (in whole or in part, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">claim-by-claim</FONT></FONT> basis) or held unenforceable. Such an adverse court ruling could allow third parties to commercialize our product candidates or methods, or our Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform, and then compete directly with us, without payment to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
we were to initiate legal proceedings against a third party to enforce a patent covering our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform, one of our products or methods, the defendant could counterclaim
that our patent is invalid and/or unenforceable. In patent litigation in the United States or in certain jurisdictions in Europe, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge
could be an alleged failure to meet any of several statutory requirements, for example, lack of utility, novelty, obviousness, <FONT STYLE="white-space:nowrap">non-enablement</FONT> or lack of written description or as constituting unpatentable
subject matter. Grounds for an unenforceability assertion could be an allegation that someone substantively involved in prosecution of the patent withheld <FONT STYLE="white-space:nowrap">but-for</FONT> material information from the U.S. Patent and
Trademark Office or Patent Office, or engaged in affirmatively egregious misconduct, during prosecution, with a specific intent to deceive the Patent Office. The outcome following legal assertions of invalidity and unenforceability during patent
litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a
legal assertion of invalidity and/or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our technologies, products, methods or certain aspects of our Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform. Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights also will not protect our technology if
competitors design around our protected technology without infringing our patents or other intellectual property rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights of third parties could adversely affect our ability to commercialize our bispecific antibody candidates,
such that we could be required to litigate or obtain licenses from third parties in order to develop or market our bispecific antibody candidates. Such litigation or licenses could be costly or not available on commercially reasonable terms.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our
technology, methods or product candidates or elements thereof, our manufacture or uses relevant to our development plans, our bispecific antibody candidates, or other attributes of our bispecific antibody candidates or our Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform. In such cases, we may not be in a position to develop or commercialize products or bispecific antibody candidates unless we successfully pursue litigation to nullify or
invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. In addition, we are aware of issued patents and/or
pending patent applications held by third parties that may be alleged as covering some of our bispecific antibody candidates. We believe that if such patents or patent applications (if issued as currently pending) were asserted against us, we would
have counterclaims and defenses against such claims, including <FONT STYLE="white-space:nowrap">non-infringement,</FONT> the affirmative defense of safe harbor designed to protect activity undertaken to obtain federal regulatory approval of a drug,
including under 35 U.S.C. &#167; 271(e) and similar foreign exceptions to infringement, patent invalidity and/or unenforceability. However, if such counterclaims and defenses were not successful and such patents were successfully asserted against us
such that they are found to be valid and enforceable, and infringed by our bispecific antibody candidates, unless we obtain a license to such patents, which may not be available on commercially reasonable terms or at all, we could be prevented from
continuing to develop or commercialize our products. We could also be required to pay substantial damages. Similarly, the targets of our bispecific antibody candidates have also been the subject of research by many companies, which have filed patent
applications or have patents related to such targets and their uses. There can be no assurance any such patents will not be asserted against us or that we will not need to seek licenses from such third parties. We may not be able to secure such
licenses on acceptable terms, if at all, and any such litigation would be costly and time-consuming. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is also possible that we failed to identify relevant patents or applications. For
example, U.S. applications filed before November&nbsp;29, 2000 and certain U.S. applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and
elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our products or platform
technology could have been filed by others without our knowledge. Furthermore, we operate in a highly competitive field, and given our limited resources, it is unreasonable to monitor all patent applications purporting to claim broad coverage in the
areas in which we are active. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our methods, product candidates or the
use of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third party intellectual property right holders, including our competitors, may actively bring
infringement claims against us. The granting of orphan drug status in respect of any of our bispecific antibody candidates does not guarantee our freedom to operate and is separate from our risk of possible infringement of third parties&#146;
intellectual property rights. We may not be able to successfully settle or otherwise resolve such potential infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage or
continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail in any such dispute, in addition to being forced to pay damages, we or our licensees may be temporarily or permanently prohibited
from commercializing any of our bispecific antibody candidates that are held to be infringing. We might, if possible, also be forced to redesign bispecific antibody candidates so that we no longer infringe the third-party intellectual property
rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if the breadth or strength of protection provided by our or our present or future licensors&#146;, collaborators&#146; or
partners&#146; patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future bispecific antibody candidates. Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to compete may be adversely affected if we are unsuccessful in defending against any claims by competitors or others that we
are infringing upon their intellectual property rights. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The various markets in which we plan to operate are subject to frequent
and extensive litigation regarding patents and other intellectual property rights.&nbsp;In addition, many companies in intellectual property-dependent industries, including those producing therapeutics to treat and potentially cure cancer, have
employed intellectual property litigation as a means to gain an advantage over their competitors. As a result, we may be required to defend against claims of intellectual property infringement that may be asserted by our competitors against us and,
if the outcome of any such litigation is adverse to us, it may affect our ability to compete effectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our involvement in litigation,
and in any interferences, opposition, pre and post-grant administrative proceedings or other intellectual property proceedings inside and outside of the United States may divert management from focusing on business operations, could cause us to
spend significant amounts of money and may have no guarantee of success. Any potential intellectual property litigation also could force us to do one or more of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stop selling, incorporating, manufacturing or using our products in the United States and/or other jurisdictions
that are covered by the subject intellectual property; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain from a third party asserting its intellectual property rights, a license to sell or use the relevant
technology, which license may not be available on reasonable terms, or at all, or may be <FONT STYLE="white-space:nowrap">non-exclusive</FONT> thereby giving our competitors access to the same technologies licensed to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redesign those technologies, products or processes that use any allegedly infringing or misappropriated
technology, which may result in significant cost or delay to us, or which redesign could be technically infeasible; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay damages, including the possibility of treble damages in a patent case if a court finds us to have willfully
infringed certain intellectual property rights. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are aware that significant number of patents and patent applications
may exist relating to aspects of therapeutic antibody technologies filed by, and issued to, third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that we
will ultimately prevail if any of this third-party intellectual property is asserted against us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property litigation
could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if resolved in
our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there
could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, this could have a substantial adverse effect on the price
of our common shares. Such litigation or proceedings and the legal costs associated with them, could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or
other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources.
Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or maintaining necessary rights to our bispecific antibody candidates through acquisitions and <FONT
STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have rights to the intellectual property, including patent
applications relating to our bispecific antibody candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, <FONT
STYLE="white-space:nowrap">in-license,</FONT> maintain or use these proprietary rights. In addition, our bispecific antibody candidates may require specific formulations to work effectively and efficiently and the rights to these formulations may be
held by others. We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for our
bispecific antibody candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual
property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, we sometimes collaborate with U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> academic institutions to accelerate our <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in
technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the
intellectual property rights to other parties, potentially blocking our ability to pursue elements of the technology at issue in such collaborations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive us to be a competitor may be unwilling to assign or
license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain a license to third-party
intellectual property rights necessary for the development of a bispecific antibody candidate or program, we may have to abandon development of that bispecific antibody candidate or program and our business and financial condition could suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of
interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our registered or unregistered trademarks, trade names or service marks may
be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks, trade names, and service marks, which we need to build name recognition by
potential collaborators, partners or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks, trade names and service marks then we may not be able to compete effectively and
our business may be adversely affected. If other entities use trademarks, trade names or service marks similar to ours in different jurisdictions, or have senior rights to ours, it could interfere with our use of our current trademarks, trade names
or service marks throughout the world. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain protection under the Hatch-Waxman Amendments and similar <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> legislation for extending the term of patents covering each of our bispecific antibody candidates, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our bispecific
antibody candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including biosimilar or generic medications. Given the amount of time required for the development, testing
and regulatory review of new bispecific antibody candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with
sufficient rights to exclude others from commercializing products similar or identical to ours, causing our revenue from applicable products to be reduced, possibly materially, and potentially harming our ability to recover our investment in such
product or obtain a reasonable return on that investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and conditions of FDA marketing approval of
our bispecific antibody candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar
legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review
process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension
could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our
competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We enjoy only limited geographical protection with respect to certain patents and may face difficulties in certain jurisdictions, which
may diminish the value of intellectual property rights&nbsp;in those jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally file our first patent application
(<I>i.e.</I>, priority filing) at the EPO or the United States Patent and Trademark Office. International applications under the Patent Cooperation Treaty, or PCT, are usually filed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
within 12 months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in additional jurisdictions where we believe our bispecific antibody
candidates may be marketed. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before
grant. Finally, the grant proceeding of each national/regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by
others.&nbsp;It is also quite common that depending on the country, the scope of patent protection may vary for the same bispecific antibody candidate and/or technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may use our and our existing or future licensors&#146;, collaborators&#146; or partners&#146; technologies in jurisdictions where
we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our existing or future licensors, collaborators or partners have patent protection, but
enforcement is not as strong as that in the United States. These products may compete with our bispecific antibody candidates, and our and our existing or future licensors&#146;, collaborators&#146; or partners&#146; patents or other intellectual
property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of some jurisdictions do not protect
intellectual property rights to the same extent as the laws in the United States and the EU, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter
difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition
from others in those jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some countries have compulsory licensing laws under which a patent owner may be compelled to grant
licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the
value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business and results of operations may be
adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights
have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make compounds that are the same as or similar to our bispecific antibody candidates but
that are not covered by the claims of the patents that we own or have exclusively licensed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of third parties may have an adverse effect on our business. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or any future strategic partners might not have been the first to conceive or reduce to
practice the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or any future strategic partners might not have been the first to file patent applications
covering certain of our inventions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending patent applications will not lead to issued patents. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may
be held invalid or unenforceable, as a result of legal challenges by our competitors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in our major commercial markets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties performing manufacturing or testing for us using our products or technologies could use the
intellectual property of others without obtaining a proper license. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional technologies that are patentable. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect
our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property,
particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time-consuming and inherently
uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2011, the America Invents Act, or the AIA, was enacted in the United States, resulting in significant changes to
the U.S. patent system. An important change introduced by the AIA was a transition to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system for deciding which party should be granted a
patent when two or more patent applications are filed by different parties claiming the same invention, which went into effect on March&nbsp;16, 2013. Therefore, a third party that now files a patent application in the USPTO before we do could be
awarded a patent covering an invention of ours even if we created the invention before it was created by the third party. While we are cognizant of the time from invention to filing of a patent application, circumstances could prevent us from
promptly filing patent applications for our inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among some of the other changes introduced by the AIA were changes that limit
where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&nbsp;16, 2013. Because of a lower
burden of proof in USPTO proceedings compared to the burden of proof in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim
invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have
been invalidated if first challenged by the third party as a defendant in a district court action. The AIA and its continued implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, and the
patent applications of our existing and future collaborators or licensors and the enforcement or defense of our issued patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending
on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents
that we might obtain in the future. Similarly, there is complexity and uncertainty related to European patent laws.&nbsp;For example, the European Patent Convention was amended in April 2010&nbsp;to limit the time permitted for filing divisional
applications. In addition, the EP patent system is relatively stringent in the type of amendments that are allowed during prosecution. These limitations and requirements could adversely affect our ability to obtain new patents in the future that may
be important for our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Confidentiality agreements with employees, contractors, agents, consultants, collaborators and
others may not adequately prevent disclosure of trade secrets and protect other proprietary information. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We consider proprietary
trade secrets and/or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> and unpatented <FONT STYLE="white-space:nowrap">know-how</FONT> to be important to our business. We may rely on trade secrets and/or confidential <FONT
STYLE="white-space:nowrap">know-how</FONT> to protect our technology, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
especially where patent protection is believed to be of limited value. However, trade secrets and/or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> are difficult to maintain as
confidential. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our
employees, consultants, contractors, collaborators and advisors to enter into confidentiality agreements with us. However, current or former employees, consultants, contractors, collaborators and advisers may unintentionally or willfully disclose
our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information or we may be unaware of such disclosure to enforce our confidentiality
agreements. Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> is expensive, time consuming and unpredictable. The enforceability of confidentiality
agreements may vary from jurisdiction to jurisdiction. Furthermore, if a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to
compete with us, which could harm our competitive position. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to obtain or maintain trade secrets and/or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> trade protection could
adversely affect our competitive position. Moreover, our competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent
protection, our competitors could limit our use of our trade secrets and/or confidential <FONT STYLE="white-space:nowrap">know-how.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under certain circumstances and to guarantee our freedom to operate, we may also decide to publish some
<FONT STYLE="white-space:nowrap">know-how</FONT> to prevent others from obtaining patent rights covering such <FONT STYLE="white-space:nowrap">know-how.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or
claiming ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our employees, including our senior management,
were previously employed at universities or at other biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT
STYLE="white-space:nowrap">non-competition</FONT> agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of
others in their work for us, we may be subject to claims that we or these employees have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#146;s
former employer. Litigation may be necessary to defend against these claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail in prosecuting or defending any such claims, in
addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third
party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and
distract management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document
submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over
the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there
are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT>
events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly
legalize and submit formal documents. If we or our existing or future licensors or collaborators fail to maintain the patents and patent applications covering our bispecific antibody candidates, our competitors might be able to enter the market,
which would have an adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Use of social media could give rise to liability, breaches of data security, or
reputational harm. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our employees use social media to communicate internally and externally. While we have policies and
procedures in place governing employee use of social media, there is risk that the use of social media by us or our employees to communicate about our products or business may give rise to liability, lead to the loss of trade secrets or other
intellectual property, or result in public exposure of personal information of our employees, clinical trial patients, customers, and others. Furthermore, negative posts or comments about us or our products in social media could seriously damage our
reputation, brand image, and goodwill. Any of these events could have a material adverse effect on our business, prospects, operating results, and financial condition and could adversely affect the price of our Common Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our computer systems, or those used by our CROs or other contractors or consultants, may fail or suffer security breaches, which could
adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our computer systems and data and those of our
current or future CROs or other contractors and consultants are vulnerable to compromise or damage from computer hacking, malicious software, fraudulent activity, employee misconduct, human error, telecommunication and electrical failures, natural
disasters, or other cybersecurity attacks or accidents. Future acquisitions could expose us to additional cybersecurity risks and vulnerabilities from any newly acquired information technology infrastructure. Cybersecurity attacks are constantly
increasing in sophistication and are made by groups and individuals with a wide range of motives (including industrial espionage) and expertise, including by organized criminal groups, &#147;hacktivists,&#148; nation states, and others. As a company
with an increasingly global presence, our systems are subject to frequent attacks, which are becoming more commonplace in the industry, including attempted hacking, phishing attempts, such as cyber-related threats involving spoofed or manipulated
electronic communications, which increasingly represent considerable risk. Due to the nature of some of these attacks, there is a risk that an attack may remain undetected for a period of time. While we continue to make investments to improve the
protection of data and information technology, including in the hiring of information technology personnel, and improvements to IT infrastructure and controls, there can be no assurance that our efforts will prevent service interruptions or security
breaches. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any cybersecurity incident could adversely affect our business, by leading to, for example, the loss of trade secrets or other
intellectual property, demands for ransom or other forms of blackmail, or the unauthorized disclosure of personal or other sensitive information of our employees, clinical trial patients, customers, and others. Although to our knowledge we have not
experienced any material cybersecurity incident to date, if such an event were to occur, it could seriously harm our development programs and our business operations. We could be subject to regulatory actions taken by governmental authorities,
litigation under laws that protect the privacy of personal information, or other forms of legal proceedings, which could result in significant liabilities or penalties. Further, a cybersecurity incident may disrupt our business or damage our
reputation, which could have a material adverse effect on our business, prospects, operating results, share price and shareholder value, and financial condition.&nbsp;We could also incur substantial remediation costs, including the costs of
investigating the incident, repairing or replacing damaged systems, restoring normal business operations, implementing increased cybersecurity protections, and paying increased insurance premiums. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our future growth and ability to compete depends on retaining our key personnel and recruiting additional qualified personnel.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends upon the continued contributions of our key management, scientific and technical personnel, many of whom have
been instrumental for us and have substantial experience with our therapies and related technologies. These key management individuals include the members of our board of directors. For example, our founder and President, Chief Executive Officer and
Principal Financial Officer, Ton Logtenberg, holds a Ph.D. in medical biology, was a professor in the Department of Immunology at Utrecht University and <FONT STYLE="white-space:nowrap">co-founded</FONT> the Dutch biotechnology company, Crucell N.V.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loss of key managers and senior scientists could delay our research and development activities. In addition, the competition for
qualified personnel in the biopharmaceutical and pharmaceutical field is intense, and our future success depends upon our ability to attract, retain and motivate highly-skilled scientific, technical and managerial employees. We face competition for
personnel from other companies, universities, public and private research institutions and other organizations. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement business strategy, which
could have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our development, regulatory and sales and marketing
capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect
to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs and sales and marketing. To manage our anticipated future growth, we must continue to
implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team
in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may
divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Common Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common shares may be volatile and may fluctuate due to factors beyond our control. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The share price of publicly traded emerging biopharmaceutical and drug discovery and development companies has been highly volatile and is
likely to remain highly volatile in the future. The market price of our common shares may fluctuate significantly due to a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">positive or negative results of testing and clinical trials by us, strategic partners or competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in entering into strategic relationships with respect to development and/or commercialization of our
bispecific antibody candidates or entry into strategic relationships on terms that are not deemed to be favorable to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">technological innovations or commercial product introductions by us or competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in government regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments concerning proprietary rights, including patents and litigation matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">public concern relating to the commercial value or safety of any of our bispecific antibody candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financing or other corporate transactions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports or comments by securities or industry analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general market conditions in the pharmaceutical industry or in the economy as a whole; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events and factors, many of which are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other market and industry factors may cause the market price and demand for our securities to fluctuate substantially, regardless of
our actual operating performance, which may limit or prevent investors from readily selling their common shares and may otherwise negatively affect the liquidity of our common shares. In addition, the stock market in general, and biopharmaceutical
companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will continue to incur increased costs as a result of operating as a public company with limited liability (naamloze vennootschap),
and our management team will be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, and particularly after we no longer qualify as an emerging growth company, we will continue to incur significant legal,
accounting and other expenses related to our operation as a public company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Market, or Nasdaq, and other
applicable securities rules and regulations impose various requirements on <FONT STYLE="white-space:nowrap">non-U.S.</FONT> reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and
corporate governance practices. Our Board of Directors and other personnel will need to continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have and will continue to increase our
legal and financial compliance costs and will make some activities more time-consuming and costly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These rules and regulations are often
subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing
uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404, we are required to furnish a report by our management on
our internal control over financial reporting with our Annual Report on Form <FONT STYLE="white-space:nowrap">20-F.</FONT> While we remain an emerging growth company, we will not be required to include an attestation report on internal control over
financial reporting issued by our independent registered public accounting firm. To maintain compliance with Section&nbsp;404, we engage in a process to document and evaluate our internal control over financial reporting, which is both costly and
challenging. In this regard, we continue to dedicate internal resources and have engaged outside consultants and adopted a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve
control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk
that we will not be able to maintain effective internal control over financial reporting as required by Section&nbsp;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss
of confidence in the reliability of our financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have previously identified material weaknesses in our internal
control over financial reporting and any future material weaknesses could, if not remediated, result in material misstatements in our financial statements and cause shareholders to lose confidence in our financial and other public reporting, which
would harm our business and the trading price of our common shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public reporting company, our management is required to
report annually on the effectiveness of our internal control over financial reporting pursuant to Section 404. In connection with this reporting obligation, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
evaluate our procedures with respect to our internal control over financial reporting including documenting and testing our controls. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In its review of our internal control over financial reporting in connection with the annual audit for 2017, management identified a material
weakness associated with a lack of adequate <FONT STYLE="white-space:nowrap">cut-off</FONT> procedures to ensure the timely recognition, measurement and classification of operating expenses and recording of certain
<FONT STYLE="white-space:nowrap">period-end</FONT> accruals. Specifically, we did not design and maintain effective internal control over the assessment of the accounting for significant contractual arrangements related to our clinical research and
manufacturing agreements and the classification of operating expenses. Management also concluded that two material weaknesses identified for the year ended December 31, 2016 were unremediated as of December 31, 2017. Specifically, we had
insufficient accounting resources to fulfill IFRS and SEC reporting requirements and an absence of comprehensive IFRS accounting policies and financial reporting procedures. To remediate these material weaknesses, we (i)&nbsp;redesigned specific
processes and controls associated with review of contractual agreements, including to assure proper clinical research and manufacturing expense cut-off, including a quarterly identification and review of significant agreements with our management
team to ensure that the relevant accounting implications are identified and considered, (ii)&nbsp;redesigned our controls over proper classification and recognition of operating expenses, including the related balance sheet accounts,
(iii)&nbsp;hired several new, experienced personnel in our financial reporting organization and engaged several experienced consultants to further assist our financial reporting organization, (iv)&nbsp;enhanced our documentation of IFRS accounting
policies and SEC financial reporting procedures and (v)&nbsp;increased the oversight and review procedures related to our financial close and reporting processes. As of December&nbsp;31, 2018, our management concluded that these material weaknesses
had been remediated and that our internal control over financial reporting was effective as of December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If other
undetected material weaknesses in our internal controls exist, it could result in material misstatements in our financial statements requiring us to restate previously issued financial statements. In addition, material weaknesses, and any resulting
restatements, could cause investors to lose confidence in our reported financial information, and could subject us to regulatory scrutiny and to litigation from shareholders, which could have a material adverse effect on our business and the price
of our common shares. Furthermore, the correction of any such material weaknesses could require additional remedial measures including additional personnel, which could be costly and time-consuming. If we do not maintain adequate financial and
management personnel, processes and controls, we may not be able to manage our business effectively or accurately report our financial performance on a timely basis, which could cause a decline in our common share price and adversely affect our
results of operations and financial condition. Failure to comply with the Sarbanes-Oxley Act of 2002 could potentially subject us to sanctions or investigations by the SEC, Nasdaq or other regulatory authorities, which would require additional
financial and management resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Members of our senior management, members of our board of directors, and certain shareholders
affiliated with members of our board of directors may be able to exercise significant control over us, and the interests of our other shareholders may conflict with the interests of our existing shareholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, members of our senior management, our board of directors and shareholders affiliated with members of our board of
directors, in the aggregate, beneficially owned approximately 19% of our common shares. Depending on the level of attendance at our general meetings of shareholders, these shareholders may be in a position to determine the outcome of decisions taken
at any such general meeting. Any shareholder or group of shareholders controlling more than 50% of the share capital present and voting at our general meetings of shareholders may control any shareholder resolution requiring a simple majority,
including the appointment of board members, certain decisions relating to our capital structure, the approval of certain significant corporate transactions and amendments to our articles of association. Among other consequences, this concentration
of ownership may have the effect of delaying or preventing a change in control and might therefore negatively affect the market price of our common shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Future sales, or the possibility of future sales, of a substantial number of our
common shares could adversely affect the price of the shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into a registration rights agreement pursuant to
which we agreed, under certain circumstances, to file a registration statement to register the resale of the shares held by certain of our existing shareholders, as well as to cooperate in certain public offerings of such shares. In addition, we
have registered and intend to continue to register all common shares that we may issue under our equity compensation plans. Once registered, these common shares can be freely sold in the public market upon issuance, subject to volume limitations
applicable to affiliates who hold such shares. In addition, in connection with entering into the Collaboration Agreement, we entered into a Share Subscription Agreement with Incyte, pursuant to which we issued and sold to Incyte 3,200,000 of our
common shares. Incyte&#146;s ability to sell these common shares is subject to certain limitations, including limitations on the volume of shares that may be sold during a given time period. In addition, in connection with entering into a settlement
agreement with Regeneron Pharmaceuticals, we entered into a Share Subscription Agreement with Regeneron, pursuant to which we issued and sold to Regeneron 600,000 of our common shares. Regeneron&#146;s ability to sell these common shares is subject
to certain limitations, including limitations on the volume of shares that may be sold during a given time period. However, future sales of a substantial number of our common shares, or the perception that such sales will occur, could cause a
decline in the market price of our common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Provisions of our articles of association or Dutch corporate law might deter
acquisition bids for us that might be considered favorable and prevent or frustrate any attempt to replace or remove the then board of directors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of our articles of association may make it more difficult for a third party to acquire control of us or effect a change in our board
of directors. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the authorization of a class of preferred shares that may be issued to a friendly party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility to appoint our board members for staggered terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a provision that our board members may only be removed by the general meeting of shareholders by a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> majority of votes cast representing more than 50% of our outstanding share capital (unless the removal was proposed by the board of directors); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a requirement that certain matters, including an amendment of our articles of association, may only be brought to
our shareholders for a vote upon a proposal by our board of directors. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our anti-takeover provision may prevent a
beneficial change of control. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We adopted an anti-takeover measure pursuant to which our board of directors may, without
shareholder approval, issue (or grant the right to acquire) preferred shares. Pursuant to a call option agreement entered into with an independent special purpose foundation, we may issue an amount of preferred shares up to 100% of our issued
capital held by third parties immediately prior to the issuance of such preferred shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred shares will be issued to the
foundation for their nominal value, of which only 25% will be due upon issuance. The voting rights of our shares are based on nominal value and as we expect our shares to continue to trade substantially in excess of nominal value, preferred shares
issued at nominal value can obtain significant voting power for a substantially reduced price and thus be used as a defensive measure. These preferred shares will have both a liquidation and dividend preference over our common shares and will accrue
cash dividends at a fixed rate. Subject to the foundation exercising its call option under the call option agreement, the board may issue these preferred shares to protect us from influences that do not serve our best interests and threaten to
undermine our continuity, independence and identity. These influences may include a third-party acquiring a significant percentage of our common shares, the announcement of a public offer for our common shares, other concentration of control over
our common shares or any other form of pressure on us to alter our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
strategic policies. The foundation&#146;s articles of association provide that it will act to serve the best interests of us, our associated business and all parties connected to us, by opposing
any influences that conflict with these interests and threaten to undermine our continuity, independence and identity. This foundation is structured to operate independently of us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not expect to pay cash dividends for the foreseeable future, any returns on an investment in our common shares will likely
depend entirely upon any future appreciation in the price of our common shares, which is uncertain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not paid any cash
dividends since our incorporation. Even if future operations lead to significant levels of distributable profits, we currently intend that any earnings will be reinvested in our business and that cash dividends will not be paid until we have an
established revenue stream to support continuing cash dividends. Payment of any future dividends to shareholders will in addition effectively be at the discretion of the general meeting, upon proposal of the board of directors, after taking into
account various factors including our business prospects, cash requirements, financial performance and new product development. In addition, payment of future cash dividends may be made only if our shareholders&#146; equity exceeds the sum of our <FONT
STYLE="white-space:nowrap">paid-in</FONT> and <FONT STYLE="white-space:nowrap">called-up</FONT> share capital plus the reserves required to be maintained by Dutch law or by our articles of association. Accordingly, investors cannot rely on cash
dividend income from our common shares and any returns on an investment in our common shares will likely depend entirely upon any future appreciation in the price of our common shares. In addition, the low trading volume of our common shares may
adversely affect the trading price of our common shares, and our shareholders may not be able to sell their common shares for a price higher than the price they paid for our common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Holders of our common shares outside the Netherlands may not be able to exercise preemptive rights. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of an increase in our share capital, holders of our common shares are generally entitled under Dutch law to full preemptive
rights, unless these rights are excluded either by a resolution of the general meeting of shareholders, or by a resolution of the board (if the board has been designated by the general meeting of shareholders for this purpose). Certain holders of
our common shares outside the Netherlands, in particular U.S. holders of our common shares, may not be able to exercise preemptive rights unless a registration statement under the Securities Act is declared effective with respect to our common
shares issuable upon exercise of such rights or an exemption from the registration requirements is available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The rights of our
shareholders may be different from the rights of shareholders in companies governed by the laws of U.S. jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
Dutch public company with limited liability (<I>naamloze vennootschap</I>). Our corporate affairs are governed by our articles of association and by the laws governing companies incorporated in the Netherlands. The rights of shareholders and the
responsibilities of members of our board may be different from the rights and obligations of shareholders in companies governed by the laws of U.S. jurisdictions. In the performance of its duties, our board is required by Dutch law to consider the
interests of our company, its shareholders, its employees and other stakeholders, in all cases with due observation of the principles of reasonableness and fairness. It is possible that some of these parties will have interests that are different
from, or in addition to, the interests of our shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are not obligated to and do not comply with all the best practice
provisions of the Dutch Corporate Governance Code. This may affect the rights of our shareholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the Dutch
Corporate Governance Code, or the DCGC. The DCGC contains both principles and best practice provisions for board of directors, shareholders and general meetings of shareholders, financial reporting, auditors, disclosure, compliance and enforcement
standards. The DCGC applies to all Dutch companies listed on a government-recognized stock exchange, whether in the Netherlands or elsewhere, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including Nasdaq. The principles and best practice provisions apply to our board (in relation to role and composition, conflicts of interest and independence requirements, board committees and
remuneration), shareholders and the general meeting of shareholders (for example, regarding anti-takeover protection and our obligations to provide information to our shareholders) and financial reporting (such as external auditor and internal audit
requirements). We do not comply with all the best practice provisions of the DCGC. As a result, the rights of our shareholders may be affected and our shareholders may not have the same level of protection as a shareholder in another Dutch public
company with limited liability (<I>naamloze vennootschap</I>) listed in the Netherlands that fully complies with the DCGC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Claims
of U.S. civil liabilities may not be enforceable against us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of the Netherlands. Most of our
assets are located outside the United States. The United States and the Netherlands currently do not have a treaty providing for the reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters.
With respect to choice of court agreements in civil or commercial matters, we note that the Hague Convention on Choice of Court Agreements entered into force for the Netherlands, but has not entered into force for the United States. Consequently, a
final judgment for payment given by a court in the United&nbsp;States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the Netherlands. In order to obtain a judgment which is
enforceable in the Netherlands, the party in whose favor a final and conclusive judgment of the U.S. court has been rendered will be required to file its claim with a court of competent jurisdiction in the Netherlands. Such party may submit to the
Dutch court the final judgment rendered by the U.S. court. If and to the extent that the Dutch court finds that the jurisdiction of the U.S. court has been based on grounds which are internationally acceptable and that proper legal procedures have
been observed, the court of the Netherlands will, in principle, give binding effect to the judgment of the U.S. court, unless such judgment contravenes principles of public policy of the Netherlands or is irreconcilable with a judgement of a Dutch
court or foreign court that is acknowledged in the Netherlands. Dutch courts may deny the recognition and enforcement of punitive damages or other awards. Moreover, a Dutch court may reduce the amount of damages granted by a U.S. court and recognize
damages only to the extent that they are necessary to compensate actual losses or damages. Enforcement and recognition of judgments of U.S. courts in the Netherlands are solely governed by the provisions of the Dutch Code of Civil Procedure
(<I>Wetboek van Burgerlijke Rechtsvordering</I>). As a result of the above, it may not be possible for investors to effect service of process within the United States upon us or members of our board or certain experts named herein who are residents
of the Netherlands or countries other than the United States or to enforce any judgments against the same obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are a foreign private issuer and, as a result, we will not be subject to U.S. proxy rules and will be subject to Exchange Act
reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
report under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange
Act, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (i)&nbsp;the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect
of a security registered under the Exchange Act; (ii)&nbsp;the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short
period of time; and (iii)&nbsp;the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> containing unaudited financial and other specified information, or current
reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K,</FONT> upon the occurrence of specified significant events. In addition, foreign private issuers are not required to file their annual report on Form
<FONT STYLE="white-space:nowrap">20-F</FONT> until 120 days after the end of each fiscal year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT>
within 75 days after the end of each fiscal year. Foreign private issuers are also exempt from the Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information. As a result of the above, our shareholders may not have the same protections afforded to shareholders of companies that are not foreign private issuers. However, we are subject to
Dutch laws and regulations with regard to such matters and voluntarily furnish quarterly unaudited financial information to the SEC on Form <FONT STYLE="white-space:nowrap">6-K.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>As a foreign private issuer and as permitted by the listing requirements of Nasdaq, we rely on certain home country governance practices
rather than the corporate governance requirements of Nasdaq. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as a foreign private issuer. As a result, in accordance
with the listing requirements of Nasdaq, we rely on home country governance requirements and certain exemptions thereunder rather than relying on the corporate governance requirements of Nasdaq. In accordance with Dutch law and generally accepted
business practices, our articles of association do not provide quorum requirements generally applicable to general meetings of shareholders. To this extent, our practice varies from the requirement of Nasdaq Listing Rule&nbsp;5620(c), which requires
an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than <FONT STYLE="white-space:nowrap">one-third</FONT> of the outstanding voting stock. Although we must provide shareholders with an agenda
and other relevant documents for the general meeting of shareholders, Dutch law does not have a regulatory regime for the solicitation of proxies and the solicitation of proxies is not a generally accepted business practice in the Netherlands, thus
our practice will vary from the requirement of Nasdaq Listing Rule&nbsp;5620(b). In addition, we have opted out of certain Dutch shareholder approval requirements for the issuance of securities in connection with certain events such as the
acquisition of stock or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change of control of us and certain private placements. To this extent, our practice varies from the
requirements of Nasdaq Rule 5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with such events. Accordingly, our shareholders may not have the same protections afforded to
shareholders of companies that are subject to these Nasdaq requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may lose our foreign private issuer status which would
then require us to comply with the Exchange Act&#146;s domestic reporting regime and cause us to incur significant legal, accounting and other expenses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a foreign private issuer and therefore we are not required to comply with all of the periodic disclosure and current reporting
requirements of the Exchange Act applicable to U.S. domestic issuers. If we no longer qualify as a foreign private issuer as of end of the second quarter of a fiscal year, we would be required to comply with all of the periodic disclosure and
current reporting requirements of the Exchange Act applicable to U.S. domestic issuers as of the start of the following fiscal year. In order to maintain our current status as a foreign private issuer, (a)&nbsp;50% or more of our common shares must
be either directly or indirectly held of record by <FONT STYLE="white-space:nowrap">non-residents</FONT> of the United States or (b)(i)&nbsp;a majority of our executive officers or directors may not be United States citizens or residents,
(ii)&nbsp;more than 50&nbsp;percent of our assets cannot be located in the United States and (iii)&nbsp;our business must be administered principally outside the United States. If we lost this status, we would be required to comply with the Exchange
Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices in
accordance with various SEC and Nasdaq rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the
cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some activities highly time consuming and costly. We also
expect that if we were required to comply with the rules and regulations applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept
reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company,&#148; and we cannot be certain if the reduced
reporting requirements applicable to &#147;emerging growth companies&#148; will make our common shares less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act. For as long as we continue to be an &#147;emerging growth
company,&#148; we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies,&#148; including not being required to comply with the auditor
attestation requirements of Section&nbsp;404, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As an &#147;emerging
growth company,&#148; we are not required to report selected financial data for periods prior to the earliest audited financial statements presented in the registration statement for the initial public offering of our common shares. As a result, we
only have to present selected financial data for periods starting with the year ended December&nbsp;31, 2014. Public companies that are not emerging growth companies must present selected financial data for a five-year period. We may take advantage
of these exemptions until we are no longer an &#147;emerging growth company.&#148; We could be an &#147;emerging growth company&#148; for up to five years, although circumstances could cause us to lose that status earlier, including if the aggregate
market value of our common shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the end of our second fiscal quarter, in which case we would no longer be an &#147;emerging growth company&#148; as of
the fiscal <FONT STYLE="white-space:nowrap">year-end.</FONT> We cannot predict if investors will find our common shares less attractive because we may rely on these exemptions. If some investors find our common shares less attractive as a result,
there may be a less active trading market for our common shares and the price of our common shares may be more volatile. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If
securities or industry analysts publish inaccurate or unfavorable research about our business, the price of our common shares and our trading volume could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common shares depends in part on the research and reports that securities or industry analysts publish about us or
our business. If one or more of the analysts who cover us downgrade our common shares or publish inaccurate or unfavorable research about our business, the price of our common shares would likely decline. If one or more of these analysts cease
coverage of us or fail to publish reports on us regularly, demand for our common shares could decrease, which might cause the price of our common shares and trading volume to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be classified as a passive foreign investment company for U.S. federal income tax purposes, which could result in adverse U.S.
federal income tax consequences to U.S. investors in the common shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the current and anticipated value of our assets,
including goodwill, and the composition of our income, assets and operations, we do not believe we were a &#147;passive foreign investment company,&#148; or PFIC, for our taxable year ended December&nbsp;31, 2018. A
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> company will be considered a PFIC for any taxable year if (i)&nbsp;at least 75% of its gross income is passive income (including interest income), or (ii)&nbsp;at least 50% of the value of its assets
(based on an average of the quarterly values of the assets during a taxable year) is attributable to assets that produce or are held for the production of passive income. The value of our assets generally is determined by reference to the market
price of our common shares, which may fluctuate considerably. In addition, the composition of our income and assets is affected by how, and how quickly, we spend the cash we raise. It is possible the Internal Revenue Service could disagree with our
position that we were not a PFIC in 2018. If we were to be treated as a PFIC for any taxable year during which a U.S. Holder (as defined in the section of this Annual Report entitled &#147;Item 10.E Taxation&#148;) holds a common share, certain
adverse U.S. federal income tax consequences could apply to such U.S. Holder. See &#147;Item 10.E Taxation.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If a United States person is treated as owning at least 10% of our common shares, such
holder may be subject to adverse U.S. federal income tax consequences. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. Holder is treated as owning (directly, indirectly
or constructively) at least 10% of the value or voting power of our common shares, such U.S. Holder may be treated as a &#147;United States shareholder&#148; with respect to each &#147;controlled foreign corporation&#148; in our group (if any). If
our group includes one or more U.S. subsidiaries, certain of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries could be treated as controlled foreign corporations (regardless of whether we are treated as a controlled foreign
corporation). A United States shareholder of a controlled foreign corporation may be required to report annually and include in its U.S. taxable income its pro rata share of &#147;Subpart F income,&#148; &#147;global intangible <FONT
STYLE="white-space:nowrap">low-taxed</FONT> income&#148; and investments in U.S. property by controlled foreign corporations, regardless of whether we make any distributions. An individual that is a United States shareholder with respect to a
controlled foreign corporation generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation. Failure to comply with these reporting obligations may
subject a United States shareholder to significant monetary penalties and may prevent the statute of limitations from starting with respect to such United States shareholder&#146;s U.S. federal income tax return for the year for which reporting was
due. We cannot provide any assurances that we will assist investors in determining whether any of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries is treated as a controlled foreign corporation or whether such investor is treated as
a United States shareholder with respect to any of such controlled foreign corporations. Further, we cannot provide any assurances that we will furnish to any United States shareholders information that may be necessary to comply with the
aforementioned reporting and tax payment obligations. U.S. Holders should consult their tax advisors regarding the potential application of these rules to their investment in our common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive tax reform legislation could adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2017, the U.S. government enacted comprehensive tax legislation that includes significant changes to the taxation of
business entities, known as the Tax Cuts and Jobs Act, or TCJA. These changes include, among others, a permanent reduction to the corporate income tax rate, limiting interest deductions and the use of net operating losses, adopting elements of a
territorial tax system and introducing certain anti-base erosion provisions. We continue to examine the impact the TCJA may have on our business. The effect of the TCJA on our business, whether adverse or favorable, is uncertain, and may not become
evident for some period of time. U.S. Holders should consult their legal and tax advisors regarding the TCJA and the potential tax consequences of investing in our common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_9"></A>Item&nbsp;4 Information on the Company. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_10"></A>A. History and Development of the Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated as Merus B.V. under the laws of the Netherlands on June&nbsp;16, 2003. Our principal executive offices are located at
Yalelaan 62, 3584 CM Utrecht, The Netherlands. Our telephone number at the Utrecht address is +31 30 253 8800. Our website address is<I> www.merus.nl</I>. Information contained on, or that can be accessed through, our website does not constitute a
part of this Annual Report. We have included our website address in this Annual Report solely as an inactive textual reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our agent
for service of process in the United States is Merus US Inc., whose address is One Broadway, Cambridge, Massachusetts, United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
SEC maintains an Internet site that contains reports, proxy information statements and other information regarding issuers that file electronically with the SEC (<U>http://www.sec.gov</U>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our capital expenditures primarily consist of laboratory equipment and leasehold improvements. For the years ended December&nbsp;31, 2018,
2017, and 2016, the amount of cash paid for our principal capital expenditures was &#128;1.6&nbsp;million, &#128;0.7&nbsp;million and &#128;0.5&nbsp;million, respectively. Our current capital expenditures are distributed
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
between the United States and Europe with most of our capital expenditures made in the Netherlands. We expect to finance our current capital expenditures from the cash flows from operating
activities, public offerings and private placements and our collaboration and license agreements. We expect our capital expenditures to increase in absolute terms in the near term as we continue to advance our research and development programs and
grow our operations. For more information on our capital expenditures, see the section of this Annual Report titled &#147;Item 5.B.&#151;Liquidity and Capital Resources&#151;Capital Expenditures.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>B. Business Overview<A NAME="toc696632_11"></A> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics. Our pipeline of full-length human
bispecific antibody candidates, which we refer to as Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, are generated from our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform, which is able
to generate a diverse array of antibody-heavy chains against virtually any target, paired with a common light chain. Two heavy chains paired with a common light chain can be combined to produce novel bispecific antibodies that bind a diverse array
of targets and display differentiated biology. By binding to two different targets, Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can provide a variety of mechanisms of action. For example, Merus Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can be designed to simultaneously block receptors that drive tumor cell growth and survival and to mobilize the patient&#146;s immune response by engaging
<FONT STYLE="white-space:nowrap">T-cells</FONT> and/or activating various killer cells to eradicate tumors. In our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, our bispecific antibody candidates killed tumor cells, a result that we
believe supports their potential development for the treatment of cancer. In February 2015, we commenced a Phase 1/2 clinical trial of our most advanced bispecific antibody candidate, <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> for the
treatment of HER2-expressing solid tumors. In January 2018, we dosed the first patient in a Phase 2, open-label, multi-center international clinical trial to evaluate <FONT STYLE="white-space:nowrap">MCLA-128</FONT> in two metastatic breast cancer,
or MBC, populations including HER2-positive MBC patients and hormone receptor <FONT STYLE="white-space:nowrap">positive/HER2-low</FONT> MBC patients. <FONT STYLE="white-space:nowrap">MCLA-128</FONT> is a full-length IgG bispecific antibody candidate
with enhanced antibody-dependent cell-mediated cytotoxicity, or ADCC, targeting HER2 and HER3 receptors. <FONT STYLE="white-space:nowrap">MCLA-128</FONT> is designed to block the HER3 signaling pathway by employing a DOCK&nbsp;&amp; BLOCK<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> mechanism. <FONT STYLE="white-space:nowrap">MCLA-128</FONT> is designed to &#147;dock&#148; onto a specific region of the HER2 receptor to
orientate <FONT STYLE="white-space:nowrap">MCLA-128&#146;s</FONT> HER3 binding arm to &#147;block&#148; HER2:HER3 heterodimerization. Oncogenic signaling through the HER3 pathway, even in the presence of high heregulin concentrations, may thus be
blocked. The Phase 2 clinical trial is designed to observe the activity of this HER2/HER3-targeted candidate in combination with current standards of care in areas of unmet need. The trial is ongoing and is enrolling patients at sites in the United
States and Europe. We plan to provide an update on the Phase 2 clinical trial in the second half of 2019. Concurrently, our Phase 1/2 clinical trial evaluating single agent activity for <FONT STYLE="white-space:nowrap">MCLA-128</FONT> in gastric
cancer and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, or NSCLC, is ongoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We reported interim data from the
gastric cancer patient cohort in the single-agent trial of <FONT STYLE="white-space:nowrap">MCLA-128</FONT> at the European Society for Medical Oncology Congress, or ESMO, in October 2018. As of February&nbsp;15, 2018, the data showed a clinical
benefit rate of 24% (6 of 25 patients), and that <FONT STYLE="white-space:nowrap">MCLA-128</FONT> was well tolerated with mainly grade 1/2 adverse events observed in patients treated with <FONT STYLE="white-space:nowrap">MCLA-128</FONT> across all
indications explored. Single agent antitumor activity was seen in heavily pretreated gastric/gastro-oesophageal junction, or GC/GEJ, cancer patients progressing on anti-HER2 therapy. Notably, the unique mechanism of action of <FONT
STYLE="white-space:nowrap">MCLA-128</FONT> was published in the May 2018 edition of the scientific journal<I> Cancer Cell</I> titled, &#147;Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via
HER2-Guided Ligand Blockade.&#148; PB4188, the research candidate described in the paper, was identified after screening a panel of hundreds of bispecific antibodies binding to the HER2/HER3 target pair in relevant functional assays. Using a
structure function approach, we showed that PB4188 employs a unique mechanism designed to inhibit the growth of tumors by docking to HER2 and blocking ligand interaction with HER3, thereby preventing stabilization of the HER2:HER3 heterodimer and
sustained signaling. The activity of PB4188 was unaffected by increasing concentrations of HRG, the ligand for HER3 which mirrors the autocrine or paracrine signaling environment of the tumor, in contrast to monoclonal antibodies against the same
targets, tested as single agents or in combination. These <I>in vitro</I> findings were also observed in four independent and pathophysiologically relevant xenograft models, which showed dose dependency and correlation with relevant pharmacodynamic
factors. This unbiased functional screening led to the identification of development candidate <FONT STYLE="white-space:nowrap">MCLA-128.</FONT> We </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
believe these results reinforce the potential of our functional screening process that allows for the discovery of unique biology driven by the bispecific antibody format. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2016, we commenced a <FONT STYLE="white-space:nowrap">single-arm,</FONT> open-label, global Phase 1 clinical trial of our second
bispecific antibody candidate, <FONT STYLE="white-space:nowrap">MCLA-117,</FONT> for the treatment of acute myeloid leukemia, or AML, and we announced the filing of the Investigational New Drug application, or IND, in the United States for <FONT
STYLE="white-space:nowrap">MCLA-117</FONT> in 2018 and the subsequent authorization to proceed with clinical studies by the U.S. Food and Drug Administration, or the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AML generally has a poor prognosis and limited progress has been made in disease outcomes despite a growing AML patient population. Clinical
and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies suggest that treatment-resistant leukemic stem cells are a potential cause of disease relapse. <FONT STYLE="white-space:nowrap">MCLA-117</FONT> is designed to bind to CD3, a
cell-surface molecule present on all <FONT STYLE="white-space:nowrap">T-cells,</FONT> and to CLEC12A, a cell surface molecule present on approximately 90 to 95% of AML tumor cells and stem cells in newly diagnosed and relapsed patients. <FONT
STYLE="white-space:nowrap">MCLA-117</FONT> is designed to recruit and activate <FONT STYLE="white-space:nowrap">T-cells</FONT> to kill AML tumor cells and stem cells. In our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, <FONT
STYLE="white-space:nowrap">MCLA-117</FONT> killed tumor cells in blood samples of AML patients. If the results of this clinical trial are favorable, we plan to seek orphan drug designation for <FONT STYLE="white-space:nowrap">MCLA-117</FONT> for the
treatment of AML from the FDA and the European Medicines Agency, or EMA. We are continuing our dose escalation of the Phase 1 clinical trial for <FONT STYLE="white-space:nowrap">MCLA-117.</FONT> We plan to provide an update on our <FONT
STYLE="white-space:nowrap">MCLA-117</FONT> program upon announcement of the maximum tolerated dose for <FONT STYLE="white-space:nowrap">MCLA-117</FONT> and anticipate data readouts for the Phase 1 clinical trial in the second half of 2019. We also
intend to evaluate <FONT STYLE="white-space:nowrap">MCLA-117</FONT> for the treatment of myelodysplastic syndrome, or MDS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to
<FONT STYLE="white-space:nowrap">MCLA-128</FONT> and <FONT STYLE="white-space:nowrap">MCLA-117,</FONT> we are also developing <FONT STYLE="white-space:nowrap">MCLA-158,</FONT> a bispecific antibody candidate that is designed to bind to cancer stem
cells expressing leucine-rich repeat-containing G protein-coupled receptor 5, or Lgr5, and epidermal growth factor receptors, or EGFR, for the potential treatment of solid tumors with an initial focus on metastatic colorectal cancer, and the first
Clinical Trials Application, or CTA, to the EMA was approved to initiate a Phase 1 clinical trial in Europe in January 2018. We also filed an IND for <FONT STYLE="white-space:nowrap">MCLA-158</FONT> with the FDA in the first quarter of 2018, which
received authorization to proceed from the FDA in April 2018. In May 2018, we commenced an open-label, multicenter Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">MCLA-158</FONT> and expect emerging data by the end of 2019. <FONT
STYLE="white-space:nowrap">MCLA-158</FONT> is designed to kill cancer stem cells using two different mechanisms of action. The first mechanism of action involves blocking growth and survival pathways in tumor stem cells. The second mechanism of
action involves the recruitment and enhancement of immune effector cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also planning to commence a clinical trial for <FONT
STYLE="white-space:nowrap">MCLA-145,</FONT> which is being developed in collaboration with Incyte Corporation and is designed to bind to <FONT STYLE="white-space:nowrap">PD-L1</FONT> and CD137. <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> the
first drug candidate <FONT STYLE="white-space:nowrap">co-developed</FONT> under our global research collaboration with Incyte. Developed through an unbiased functional screening of multiple immunomodulatory target combinations, <FONT
STYLE="white-space:nowrap">MCLA-145</FONT> is a Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> <FONT STYLE="white-space:nowrap">T-cell</FONT> agonist that binds with high affinity and specificity to human <FONT
STYLE="white-space:nowrap">PD-L1</FONT> and CD137 in preclinical models. The unique immunostimulatory profile of <FONT STYLE="white-space:nowrap">MCLA-145</FONT> derives from the ability to potently activate immune effector cells in the context of
the tumor microenvironment while simultaneously blocking inhibitory signals in the same immune cell population. In December 2018, we filed an IND for <FONT STYLE="white-space:nowrap">MCLA-145</FONT> with the FDA and in January 2019, we received
authorization to proceed from the FDA. We have full rights to develop and commercialize <FONT STYLE="white-space:nowrap">MCLA-145</FONT> in the United States and Incyte is responsible for its development and commercialization outside the U.S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also developing <FONT STYLE="white-space:nowrap">MCLA-129,</FONT> which is being developed pursuant to collaboration and license
agreement with Betta Pharmaceuticals Co. Ltd. or Betta Pharmaceuticals. Under the terms of the agreement, Betta Pharmaceuticals has agreed to be responsible for clinical development and commercialization of
<FONT STYLE="white-space:nowrap">MCLA-129</FONT> in China. As a key strategic component of the collaboration, Betta will retain a contract manufacturing organization with experience in filing Initial New Drug (IND) applications with U.S. and
European regulatory authorities in order to produce clinical trial materials for the Chinese market and rest of world. Betta will facilitate regulatory filings and early stage clinical trial materials supply for potential use by us for development
of <FONT STYLE="white-space:nowrap">MCLA-129</FONT> outside of China. <FONT STYLE="white-space:nowrap">MCLA-129</FONT> is a Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> binding to EGFR and cMET for the treatment of solid
tumors. EGFR is an important oncogenic driver in many cancers; the upregulation of <FONT STYLE="white-space:nowrap">c-MET</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
signaling has been associated with resistance to EGFR inhibition. <FONT STYLE="white-space:nowrap">MCLA-129</FONT> has two distinct mechanisms of action. First, our DOCK&nbsp;&amp; BLOCK<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> mechanism of action blocks the signaling of EGFR as well as <FONT STYLE="white-space:nowrap">c-MET,</FONT> with the potential to inhibit tumor growth and survival. Second, <FONT
STYLE="white-space:nowrap">MCLA-129</FONT> utilizes ADCC-enhancement technology designed for greater cell-killing potential. Because the DOCK&nbsp;&amp; BLOCK and ADCC mechanism of action is based on the
<FONT STYLE="white-space:nowrap">co-expression</FONT> of EGFR and <FONT STYLE="white-space:nowrap">c-MET,</FONT> we expect it to have less toxicity compared to agents targeting EGFR alone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have several other antibody candidates in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development that bind to other target
combinations. Each of our antibody candidates in our preclinical and clinical pipeline are designed to bind to targets believed to be useful in the treatment of cancer with an intention to establish efficacy and obtain information for submission to
the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform employs an array of patented
technologies and techniques to generate bispecific human antibodies. We utilize our patented MeMo<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> mouse harboring a common light chain in
its germline to produce an array of antibodies with diverse heavy chains that are capable of binding virtually any antigen target. Based on the power of the common light chain, and using Merus&#146; patented dimerization technology, Merus can take
these diverse panels of heavy chains and efficiently generate large and diverse libraries of bispecific antibodies. We also employ our patented Spleen to Screen<SUP STYLE="font-size:85%; vertical-align:top"> &#153;</SUP> technology to efficiently
screen panels of common light chain antibodies, designed to allow us to rapidly identify and generate Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> therapeutic candidates
with differentiated modes of action. The Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology also includes use of patented host cells to produce these multispecific
antibodies efficiently. The Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> format retains the IgG format of conventional mAbs and is designed to preserve the format&#146;s
key features, including stability, long half-life and low immunogenicity, when developing our bispecific antibody candidates. We leverage industry-standard manufacturing processes and infrastructure to efficiently produce Biclonics<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to become a leading immuno-oncology company developing innovative bispecific antibodies to treat and potentially cure various types
of cancer. Our business strategy comprises the following components: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Successfully develop our most advanced bispecific antibody candidate,
<FONT STYLE="white-space:nowrap">MCLA-128,</FONT> for the treatment of solid tumors.</I></B> We are developing <FONT STYLE="white-space:nowrap">MCLA-128</FONT> for the treatment of patients with HER2-expressing and other solid tumors, including
breast, gastric and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer. We commenced a Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">MCLA-128</FONT> in Europe in February 2015. In the dose escalation phase of the
trial, the recommended dose of <FONT STYLE="white-space:nowrap">MCLA-128</FONT> was established. Preliminary efficacy data suggests consistent antitumor activity in heavily pretreated metastatic breast cancer patients progressing on HER2 therapies.
In January 2018, we commenced a combination Phase 2 clinical trial in the United States for <FONT STYLE="white-space:nowrap">MCLA-128</FONT> and we plan to provide an update on the Phase 2 clinical trial in the second half of 2019. Concurrently, our
Phase 1/2 clinical trial evaluating single agent activity for <FONT STYLE="white-space:nowrap">MCLA-128</FONT> in gastric cancer and NSCLC is ongoing. We reported data from the gastric cancer patient cohort in the single-agent trial of <FONT
STYLE="white-space:nowrap">MCLA-128</FONT> at ESMO in October 2018. The data showed a clinical benefit rate of 24% (6 of 25 patients), with <FONT STYLE="white-space:nowrap">MCLA-128</FONT> being well tolerated with mainly grade 1/2 adverse events in
patients treated with <FONT STYLE="white-space:nowrap">MCLA-128</FONT> across all indications explored to date. Promising single agent antitumor activity was seen in heavily pretreated GC/GEJ cancer patients progressing on anti-HER2 therapy. We
believe that if <FONT STYLE="white-space:nowrap">MCLA-128</FONT> is successfully developed and obtains regulatory approval, it has the potential to address disease-specific challenges that are not currently being met by existing therapies.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Successfully develop our second most advanced bispecific antibody candidate,
<FONT STYLE="white-space:nowrap">MCLA-117,</FONT> for the treatment of AML.</I></B><B> </B>We are developing <FONT STYLE="white-space:nowrap">MCLA-117</FONT> for the treatment of patients with AML. We commenced a Phase 1 clinical trial of <FONT
STYLE="white-space:nowrap">MCLA-117</FONT> in Europe in May 2016 for the treatment of patients with AML to assess its safety, tolerability and anti-tumor activity and filed an IND in the United States in January 2018, for which we obtained
authorization to proceed from the FDA in February 2018. We </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
are continuing our dose escalation of the Phase 1 clinical trial for <FONT STYLE="white-space:nowrap">MCLA-117.</FONT> We plan to provide an update on our
<FONT STYLE="white-space:nowrap">MCLA-117</FONT> program upon announcement of the maximum tolerated dose for <FONT STYLE="white-space:nowrap">MCLA-117</FONT> and anticipate data readouts for the Phase 1 clinical trial in the second half of 2019. If
the results of this clinical trial are favorable, we plan to seek orphan drug designation from the FDA and the EMA for <FONT STYLE="white-space:nowrap">MCLA-117</FONT> for the treatment of AML. We believe that if
<FONT STYLE="white-space:nowrap">MCLA-117</FONT> is successfully developed and obtains regulatory approval, it has the potential to transform the treatment of AML. We also intend to evaluate <FONT STYLE="white-space:nowrap">MCLA-117</FONT> for the
treatment of MDS. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Successfully develop our third bispecific antibody candidate,
<FONT STYLE="white-space:nowrap">MCLA-158,</FONT> for the treatment of metastatic colorectal cancer and other solid tumors</I></B><B>.</B> We are developing <FONT STYLE="white-space:nowrap">MCLA-158</FONT> for the treatment of solid tumors with an
initial focus on the treatment of metastatic colorectal cancer. <FONT STYLE="white-space:nowrap">MCLA-158</FONT> has received approval of a CTA in several European countries for the potential treatment of metastatic colorectal cancer, including
patients with the <FONT STYLE="white-space:nowrap">RAS-mutation,</FONT> which represent a substantial unmet need. We also filed an IND for <FONT STYLE="white-space:nowrap">MCLA-158</FONT> with the FDA in the first quarter of 2018, which received
authorization to proceed from the FDA in April 2018. In May 2018, we commenced an open-label, multicenter Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">MCLA-158.</FONT> Emerging data for our Phase 1 trial is expected at the end of 2019.
<FONT STYLE="white-space:nowrap">MCLA-158</FONT> is an investigational, ADCC-enhanced Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> designed to bind to cancer stem cells
expressing Lgr5 and EGFR. We believe that if <FONT STYLE="white-space:nowrap">MCLA-158</FONT> is successfully developed and obtains regulatory approval, it has the potential to address and transform the treatment of metastatic colorectal cancer and
other solid tumors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Successfully develop our fourth bispecific antibody candidate,
<FONT STYLE="white-space:nowrap">MCLA-145,</FONT> for the treatment of solid tumors</I></B><B>.</B> We plan to commence a clinical trial for <FONT STYLE="white-space:nowrap">MCLA-145</FONT> for the treatment of solid tumors in the first half of
2019. We filed an IND for <FONT STYLE="white-space:nowrap">MCLA-145</FONT> with the FDA in December 2018, which received authorization to proceed from the FDA in January 2019. <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> which is being
developed in collaboration with Incyte Corporation and is designed to bind to <FONT STYLE="white-space:nowrap">PD-L1</FONT> and CD137, was developed through an unbiased functional screening of multiple immunomodulatory target combinations and is a
Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> <FONT STYLE="white-space:nowrap">T-cell</FONT> agonist that has been observed to bind with high affinity and specificity to human <FONT STYLE="white-space:nowrap">PD-L1</FONT> and
CD137 in preclinical models. We believe that the unique immunostimulatory profile of <FONT STYLE="white-space:nowrap">MCLA-145</FONT> derives from its ability to potently activate immune effector cells in the context of the tumor microenvironment
while simultaneously blocking inhibitory signals in the same immune cell population. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Accelerate the internal discovery and development of additional immunotherapeutic antibody
candidates</I></B><B>.</B>&nbsp;We believe we are well positioned to expand our pipeline of Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the treatment of other forms of
cancer. Our platform employs our proprietary common light chain transgenic MeMo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the production of diverse human heavy chains that can be paired to generate bispecific antibodies, coupled
with our Spleen to Screen<SUP STYLE="font-size:85%; vertical-align:top"> TM</SUP> technology that is designed to allow us to rapidly identify and generate Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> therapeutic candidates
with differentiated modes of action that have the potential to kill tumor cells with high potency. We are conducting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies of an array of candidates for our internal proprietary pipeline as well
as in collaboration with Incyte. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Seek strategic collaborative relationships</I></B><B>.</B>&nbsp;We intend to continue to seek strategic
collaborations to facilitate the capital-efficient development of our Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform and to identify potential target
combinations in immuno-oncology and other therapeutic areas. We have entered into collaborations with Incyte, ONO Pharmaceutical Co., Ltd., Simcere Pharmaceutical Group, and Betta Pharmaceuticals to develop bispecific antibody candidates based on
our Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform and plan to work with other collaborators to validate and expand the use of our Biclonics<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform and the development of bispecific antibody candidates. We believe these collaborations could potentially provide significant funding
to advance our bispecific antibody candidate pipeline while allowing us to benefit from the development expertise of our collaborators. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use our technology platform to develop Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the
treatment of various types of cancer. The following table summarizes our bispecific antibody candidate pipeline: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g696632g64b25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview of Existing Immunotherapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite a number of advances in the past decade, a significant unmet need in cancer still exists. While targeted antibody therapeutics have
been successful in treating some cancers, the therapeutic effects of almost all such therapies are transient. Cancer cells are able to adapt to escape recognition and elimination by the immune system, thereby contributing to tumor growth and
progression. Acquired resistance to cancer therapies remains a significant clinical problem with patients frequently relapsing and the tumors metastasizing to other organs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immunotherapy is a new class of cancer treatment that works to harness the intrinsic powers of the immune system to fight tumor cells. There
are a number of immunotherapies that engage various aspects of the immune system, for example: (1)&nbsp;monoclonal antibodies with enhanced ADCC, (2)&nbsp;bispecific <FONT STYLE="white-space:nowrap">T-cell</FONT> engaging molecules,
(3)&nbsp;immunomodulatory monoclonal antibodies and <FONT STYLE="white-space:nowrap">(4)&nbsp;CAR-T</FONT> and TCR therapies. While these therapies vary in mechanism of action, they rely on specific components of the innate or adaptive immune system
to kill tumor cells or counteract signals produced by cancer cells that suppress immune responses. The potential of immunotherapeutic approaches is best demonstrated by the long durable remissions, exceeding 10 years, observed after checkpoint
inhibitor treatment in a subset of patients with advanced melanoma. More recent evidence from clinical trials suggests that a growing list of cancers will respond to checkpoint inhibitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Monoclonal Antibodies with Enhanced ADCC.</I></B>&nbsp;Monoclonal antibodies bind to a single target expressed by tumor cells and have
been modified to more efficiently attract immune effector cells, such as NK cells and macrophages, to effectively kill tumor cells. Several mAbs with enhanced ADCC for the treatment of solid and leukemic tumors have yielded promising results in
clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By binding to a single target, mAbs with enhanced ADCC depend on the varying levels of expression of that target on the
tumor and normal tissues to leverage the advantage of enhanced tumor cell-killing while minimizing toxicity. Ideal targets for antibodies would be solely expressed by the diseased cell and not by normal cells. Unfortunately, many of these targets
are also expressed by healthy tissues. By binding to a single target, mAbs with enhanced ADCC potentially can induce autoimmune toxicity, <FONT STYLE="white-space:nowrap">so-called</FONT> <FONT STYLE="white-space:nowrap">&#147;on-target,</FONT> <FONT
STYLE="white-space:nowrap">off-tumor&#148;</FONT> toxicity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Bispecific <FONT STYLE="white-space:nowrap">T-Cell</FONT> Engaging
Molecules.</I></B><B><I></I></B>&nbsp;Bispecific <FONT STYLE="white-space:nowrap">T-cell</FONT> engaging molecules enhance a patient&#146;s immune response to tumors by <FONT STYLE="white-space:nowrap">re-targeting</FONT> <FONT
STYLE="white-space:nowrap">T-cells</FONT> to tumor cells. These molecules have been developed for a variety of both hematological and solid tumors and are currently in clinical trials. We are aware of a bispecific
<FONT STYLE="white-space:nowrap">T-cell</FONT> engaging molecule therapeutic that has received regulatory approval for the treatment of acute lymphoblastic leukemia as well as additional bispecific <FONT STYLE="white-space:nowrap">T-cell</FONT>
engaging molecules that are currently in clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most <FONT STYLE="white-space:nowrap">T-cell</FONT> engaging molecules in
development are currently based on antibody fragments connected by a flexible linker and, unlike Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, do not utilize the advantages of the full-length IgG format. These molecules may
have shorter half-lives than conventional mAbs, which could require continuous infusion of the molecule or could pose manufacturing and immunogenicity challenges. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Immunomodulatory mAbs.</I></B><B><I></I></B>&nbsp;Immunotherapeutic strategies have been shown in clinical trials to increase the
ability of the immune system to recognize and eradicate tumor cells. Among these treatment strategies, immunomodulatory mAbs that enhance the function of <FONT STYLE="white-space:nowrap">T-cells</FONT> have achieved noteworthy results for multiple
types of cancers. Immunomodulatory mAbs that bind to molecules involved in <FONT STYLE="white-space:nowrap">T-cell</FONT> inhibition are called checkpoint inhibitors because they block normally negative regulators of
<FONT STYLE="white-space:nowrap">T-cell</FONT> immunity. These checkpoint inhibitors target molecules such as the cytotoxic <FONT STYLE="white-space:nowrap">T-lymphocyte</FONT> antigen 4, or <FONT STYLE="white-space:nowrap">CTLA-4,</FONT> and <FONT
STYLE="white-space:nowrap">PD-1.</FONT> Additionally, immunomodulatory mAbs that bind to <FONT STYLE="white-space:nowrap">co-stimulatory</FONT> molecules involved in <FONT STYLE="white-space:nowrap">T-cell</FONT> activation, such as the tumor
necrosis factor receptors OX40 and CD137, have shown tumor cell-killing activity in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> animal models of cancer and are currently being evaluated in early-stage clinical trials. Combinations of
immunomodulatory mAbs have been observed to enhance the anti-cancer response in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and in clinical trials of patients with various tumor types, but have also been observed to result in more
pronounced toxicities. We believe that Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> have the potential to capture the benefits of combinations of immunomodulatory mAbs,
combined with more specific targeting to tumor-specific <FONT STYLE="white-space:nowrap">T-cells</FONT> and tumor cells, thereby potentially diminishing the toxic side effects and providing a cost-effective <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">two-in-one</FONT></FONT> therapeutic for the treatment of cancer patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">CAR-T</FONT> and TCR Therapies.</I></B><B><I></I></B><FONT STYLE="white-space:nowrap">&nbsp;T-cells</FONT> recognize diseased cells by receptors engaging with antigens that are present on cancer cells. <FONT
STYLE="white-space:nowrap">CAR-T</FONT> therapy entails genetically engineering <FONT STYLE="white-space:nowrap">T-cells</FONT> to express synthetic chimeric antigen receptors, or CARs, that direct T-cells to antigens on the surface of cancer cells.
The <FONT STYLE="white-space:nowrap">T-cell</FONT> receptor, or TCR, modifies <FONT STYLE="white-space:nowrap">T-cells</FONT> to express high-affinity tumor specific TCRs that recognize intra-cellular antigens present on the surface of target cells.
In clinical trials, <FONT STYLE="white-space:nowrap">CAR-T</FONT> and TCR therapies have been observed to have anti-tumor activity in a narrow spectrum of hematologic cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe a key limitation of <FONT STYLE="white-space:nowrap">CAR-T</FONT> and TCR therapies is the need to retrieve <FONT
STYLE="white-space:nowrap">non-compromised</FONT> immune effector cells from a cancer patient, which requires a complex and costly individualized process to develop the therapy. These challenges limit their potential and use in a variety of
indications, including the treatment of solid tumors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To address patient populations not responding to single-antibody based drugs, there
is an increased focus on synergistically combining immunotherapeutics in the scientific community and from biopharmaceutical companies. Opportunities to create innovative antibody-based therapeutics lie in several technology advances, including
bispecific antibodies that bind to multiple targets, <FONT STYLE="white-space:nowrap">Fc-optimization,</FONT> which enhances the body&#146;s immune system to mediate the killing of cancer cells, and antibody drug conjugates, or ADCs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background on Antibodies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
conventional antibody is a <FONT STYLE="white-space:nowrap">Y-shaped</FONT> molecule that consists of two identical heavy chains and two identical light chains, as shown in the figure below. These four chains pair to form two variable regions that
bind to antigens, or targets, and a constant region, which includes a region known as the Fc, that binds to receptors present on effector cells in the immune system. In conventional mAbs, the variable regions are identical and bind to the same
targets.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g696632g97x19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In bispecific antibodies, the variable regions can be modified to bind to two different targets. To achieve
this in the full-length IgG format, two different heavy chains and two identical light chains, also referred to as the common light chain, are combined. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In both conventional mAbs and IgG bispecific antibodies, the Fc region can bind to Fc receptors present on effector cells. This binding
results in the recruitment and activation of immune effector cells and amplifies the immune system&#146;s response to antigens bound by the variable region of the antibody. This process is called ADCC. The Fc region can be modified to enhance ADCC
so as to generate a more potent immune response against a particular target. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
Platform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a pipeline of Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> generated from our patented
technology platform. Our platform enables the rapid identification of immunotherapeutics with the potential to produce tumor cell-killing activity and/or to modulate the tumor microenvironment to promote more effective anti-tumor immune responses,
and allows for the flexible and rapid generation of Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> against virtually any particular target pair. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By binding to two different targets, Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can be designed to block receptors
that drive tumor cell growth and survival and to mobilize the patient&#146;s immune response by activating various killer cells to eradicate tumors. We believe our Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform allows us to approach cancer treatment through multiple modes of action: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Blocking combinations of growth factor receptors that drive tumor cell growth and relapse while
simultaneously recruiting immune effector cells through enhanced ADCC</I></B>.&nbsp;Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> may be generated for various combinations
of growth factor receptors that play a role in tumors with different molecular profiles, while a modification in the Fc region of the Biclonics<SUP STYLE="font-size:85%; vertical-align:top">
</SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> facilitates the enhanced recruitment of immune effector cells, such as NK cells and macrophages, to directly kill tumor cells through ADCC. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Activating <FONT STYLE="white-space:nowrap">T-cells</FONT> to kill tumor cells by binding to CD3 expressed
on <FONT STYLE="white-space:nowrap">T-cells</FONT> and a tumor-associated target</I></B><B>.</B> CD3 is a cell-surface molecule present on all <FONT STYLE="white-space:nowrap">T-cells.</FONT> We create Biclonics<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> that are designed to simultaneously bind to CD3 and a tumor-associated target, which allows for
<FONT STYLE="white-space:nowrap">T-cell</FONT> recruitment and engagement to selectively kill tumor cells. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Blocking two checkpoint inhibitory pathways for more efficient
<FONT STYLE="white-space:nowrap">T-cell</FONT> activation.</I></B><B><I></I></B>&nbsp;Cancer cells are able to block the tumor-killing function of <FONT STYLE="white-space:nowrap">T-cells</FONT> through the expression of inhibitory molecules.
Scientific research has shown that combinations of mAbs are more potent than single mAbs when used against these inhibitory molecules to unblock and revive this mechanism of <FONT STYLE="white-space:nowrap">T-cells</FONT> which kills tumor
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
cell targets. Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can be designed to prevent the blocking of <FONT
STYLE="white-space:nowrap">T-cells</FONT> by cancer cells while retaining the advantages of specific targeting in the tumor environment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Achieving a DOCK</I></B><B><I></I></B><B><I>&nbsp;&amp; BLOCK</I></B><B><I><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP></I></B><B><I> mechanism of action to favorably impact <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">hard-to-target</FONT></FONT> receptors that may drive tumor growth or
escape.</I></B> Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are designed to be capable of binding a tumor associated target prevalent on cancer cells, which then permits the other arm of the Biclonics<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> to be proximate to bind and block lesser expressed targets that have ligand or enzymatic functions that may tend to drive tumor growth or
escape. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Blocking a checkpoint inhibitory pathway while simultaneously providing a
<FONT STYLE="white-space:nowrap">co-stimulatory</FONT> signal for more efficient activation of <FONT STYLE="white-space:nowrap">T-cells</FONT></I></B><B>.</B> In addition to being blocked by inhibitory molecules, tumor specific <FONT
STYLE="white-space:nowrap">T-cells</FONT> may simultaneously require an activation signal to engage in tumor cell-killing. Biclonics can be designed to concurrently alleviate the blocking of <FONT STYLE="white-space:nowrap">T-cells</FONT> and
deliver the signals required to activate the killing potential of <FONT STYLE="white-space:nowrap">T-cells.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Simultaneously targeting a growth factor receptor expressed by tumor cells and an immunomodulatory molecule
involved in blocking tumor-specific <FONT STYLE="white-space:nowrap">T-cells.</FONT></I></B> Growth factor receptors like epidermal growth factor receptors, or EGFR, and HER2 are expressed on many tumors. Biclonics can be designed to target such
growth factor receptors while delivering an activation signal or <FONT STYLE="white-space:nowrap">de-blocking</FONT> signal to <FONT STYLE="white-space:nowrap">T-cells.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our process to select lead Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for clinical development takes approximately 12
months and is illustrated below. We use our patented MeMo<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Spleen to Screen<SUP STYLE="font-size:85%; vertical-align:top"> TM</SUP>
human antibody generation and Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> production technologies to rapidly build large collections of Biclonics<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> directed against particular target pairs. We then test these collections in cell-based functional assays to identify Biclonics<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> that have differentiated modes of action. We select the most potent or efficacious Biclonics<SUP STYLE="font-size:85%; vertical-align:top">
</SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and evaluate them in multiple<I> in vitro</I> and<I> in vivo</I> assays to identify lead candidates for clinical development. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Selection of Lead Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g696632g42u11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform includes the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Human antibody generation.</I></B>&nbsp;Our platform for generating human antibodies employs our patented
transgenic mice, which we refer to as MeMo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, which harbors a common light chain in its germline. MeMo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> harnesses the power of the<I> in
vivo</I> immune system to yield human antibodies with the potential for high potency, specificity, solubility and low immunogenicity. Upon immunization, MeMo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is capable of generating large
and diverse panels of heavy chains that all pair with the same common light chain. These heavy chains are then used to generate large and diverse panels of Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, human
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
bispecific, antibodies capable of binding two different targets of virtually any combination. Using this technology, we produce large and diverse panels of high-affinity antibodies against a
broad variety of targets. We believe this approach enhances the discovery and development of high-quality human antibodies that, through the common light chain, generates sequences that are ready to be converted into the Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> format. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>The full-length Immunoglobulin G format.</I></B><B><I></I></B>&nbsp;The Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> format is designed to retain several of the favorable attributes of conventional human IgG mAbs, including their stability and predictability during manufacturing as well as their long half-life
and low immunogenicity during treatment of patients. Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> consist of two different heavy chains that need to stably form, or
heterodimerize, inside a manufacturing cell line. Using our patented dimerization technology, we employ amino acids with opposite charges in each of these heavy chains to efficiently drive this process. The use of a single, or common, light chain in
our human Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> antibodies is designed to have the heavy chains pair with the correct, common light chain to efficiently form
functional antigen binding regions. The combination of these approaches prevents the need for additional, more artificial techniques, such as the use of linkers or chemical reactions, to force the pairing of different parts of the bispecific
antibody. The resulting Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are bispecific heterodimeric IgG antibodies that closely mimic IgG antibodies that are produced
naturally by the immune system. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> format also permits us to make
modifications to the Fc region of the IgG antibody in order to enhance or limit effector functions associated with this part of the molecule. This strategy has been successfully executed with conventional therapeutic mAbs. In order to enhance
efficacy and promote immunotherapeutic activity, we can use genetically altered cell lines used in production to generate Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> that
are enhanced for ADCC, resulting in the improved ability to recruit NK cells and macrophages. This ADCC enhancement has been made to our most advanced bispecific antibody candidate, <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> and other of our
antibody candidates, <FONT STYLE="white-space:nowrap">MCLA-158</FONT> and <FONT STYLE="white-space:nowrap">MCLA-129.</FONT> In order to improve safety and tolerability, we can modify our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">
</SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> to prevent the excessive release of signaling proteins called cytokines, which can overstimulate the immune system. This process is called
<FONT STYLE="white-space:nowrap">Fc-silencing</FONT> as it blocks the ability of our Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> to bind to certain protein receptors on
cells, known as Fc receptors, which are associated with cytokine release. We utilize Fc silencing in the design of our bispecific antibody candidate, <FONT STYLE="white-space:nowrap">MCLA-117.</FONT> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>High-throughput functional screening.</I></B><B><I></I></B>&nbsp;We employ our Spleen to Screen<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> technology to rapidly screen panels of target-specific common light chain antibodies. Subsequently, DNA constructs are generated and introduced into mammalian cells that encode panels of
target-specific human antibodies. The common light chain format and modified Fc region of the IgG antibody ensure the secretion of virtually pure Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> into the cell culture medium. The medium of thousands of cell cultures is harvested and individually used in cell- and tissue-based functional assays to permit the identification of Biclonics<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> with differentiated modes of action. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, the chart below shows the results of a <FONT STYLE="white-space:nowrap">pre-clinical</FONT> study in which hundreds of different
Biclonics targeting HER2 and HER3 were functionally screened against tumor cell samples, with and without heregulin present. Of the antibody candidates depicted in the chart, 40 exhibited superior inhibition of cell growth compared to trastuzumab, a
drug commonly prescribed for the treatment of breast cancer, and were selected in the process leading to identification of <FONT STYLE="white-space:nowrap">MCLA-128.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g696632g23o72.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Benefits of Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform provides the following benefits: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Rapid generation of human IgG antibodies having diversity at the heavy chain targeting an array of
antigens, that are ready to be paired to produce our Biclonics</I></B><B><I></I></B><B><I><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></I></B><B><I>, bispecific antibodies.</I></B> Use of our patented MeMo<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Spleen to Screen<SUP STYLE="font-size:85%; vertical-align:top"> TM</SUP>, heterodimerization and Fc modification technologies, permits us to rapidly generate a large amount of diverse bispecific
antibodies capable of targeting an array of antigen combinations. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Biclonics</I></B><B><I><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></I></B><B><I></I></B><B><I>&nbsp;are stable, bispecific,
full-length human IgG antibodies with no linkers or fusion proteins.</I></B><B><I></I></B>&nbsp;Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> retain the IgG format of antibodies that are produced naturally by the immune system.
Additionally, in contrast to many other bispecific antibody formats, Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> do not require linkers to force the correct pairing of heavy and light chains or exploit fusion proteins to add
functionality to the molecule. These qualities minimize time-consuming engineering efforts and allow us to create Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> with predictable behavior during
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Biclonics</I></B><B><I><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></I></B><B><I> preserve
the stability, behavior and adaptability of normal IgG antibodies.</I></B>&nbsp;Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;are based on the robust and commonly used IgG format to yield the favorable<I> in
vivo</I>&nbsp;qualities associated with conventional mAbs, such as stability, long half-life and low immunogenicity. As a result, our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> format provides attractive options for dosage
schedules and methods of administration, rendering them compatible with multiple modes of action for the efficient killing of tumor cells. Further, the IgG format allows us to apply previously established technologies to further optimize our
Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for therapeutic use. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Biclonics</I></B><B><I><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></I></B><B><I> can be
reliably manufactured with high yields.</I></B>&nbsp;Because our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> retain the IgG format of antibodies, our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are
manufactured using the large-scale industry-standard processes that are also used for the production of conventional mAbs, and the yields of Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> we obtain are comparable to those of
normal IgG antibodies. In stable cell lines, we are able to obtain over 90% of bispecific antibody formation using these processes and the <FONT STYLE="white-space:nowrap">IgG-based</FONT> purification process results in up to greater than 98%
purity for our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our Biclonics</I></B><B><I><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></I></B><B><I>
technology platform allows for functional evaluation of Biclonics</I></B><B><I><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></I></B><B><I></I></B><B><I>&nbsp;in the relevant therapeutic format leading to the discovery of therapeutic
candidates with differentiated properties.</I></B> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform enables rapid functional screening of large collections of bispecific antibodies which allows us to
identify lead candidates with multiple mechanisms of action that have the potential to effectively kill tumor cells with high potency. This is an important step in the identification of lead bispecific antibody candidates with functionalities that
compare favorably against other forms of immunotherapeutics, such as conventional mAbs as well as their combinations. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Bispecific
Antibody Candidate Portfolio </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We commenced a Phase 2, open-label, multi-center, international clinical trial of our most advanced
bispecific antibody candidate, <FONT STYLE="white-space:nowrap">MCLA-128</FONT> for the treatment of patients with MBC in January 2018 and plan to provide an update in the second half of 2019. Concurrently, our Phase 1/2 study of <FONT
STYLE="white-space:nowrap">MCLA-128</FONT> in gastric and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancers is ongoing. Additionally, we commenced a Phase&nbsp;1, <FONT STYLE="white-space:nowrap">single-arm,</FONT> open-label
clinical trial of our second bispecific antibody candidate, <FONT STYLE="white-space:nowrap">MCLA-117,</FONT> for the treatment of patients with AML in May 2016, and announced the filing of an IND in the United States for <FONT
STYLE="white-space:nowrap">MCLA-117</FONT> in January 2018, which subsequently received authorization from the FDA. Dose escalation in the Phase 1 trial is ongoing. We plan to provide an update on our <FONT STYLE="white-space:nowrap">MCLA-117</FONT>
program upon announcement of the maximum tolerated dose for <FONT STYLE="white-space:nowrap">MCLA-117</FONT> and anticipate data readouts for the Phase 1 clinical trial in the second half of 2019. In May 2018, we commenced a Phase&nbsp;1,
open-label, multicenter clinical trial of <FONT STYLE="white-space:nowrap">MCLA-158,</FONT> for the treatment of solid tumors with an initial focus on metastatic colorectal cancer, for which we have received CTA approvals in several European
countries. We filed an IND with FDA in the first quarter of 2018, which received authorization to proceed from the FDA in April 2018, and have expanded the trial to the United States. Emerging data for our Phase 1 trial is expected at the end of
2019. In addition, we expect to commence a Phase I clinical trial for <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> which is designed to bind to <FONT STYLE="white-space:nowrap">PD-L1</FONT> and CD137 and is part of our collaboration with
Incyte, in the first half of 2019, for the treatment of solid tumors. In addition, we have several other antibody candidates in preclinical development as part of our collaboration with Incyte, among other preclinical candidates in various stages of
development, which we are developing with Simcere and Betta for which we have full <FONT STYLE="white-space:nowrap">ex-China</FONT> rights, and that are part of Merus&#146; wholly-owned internal proprietary pipeline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">MCLA-128</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">MCLA-128</FONT> is an ADCC-enhanced Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> that
is designed to bind HER2 to block the HER3 signaling pathway. HER3-mediated inherent and acquired resistance to HER2-targeted therapies has been implicated in various solid tumors, including breast, gastric and
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer tumor cells. The scientific rationale for targeting HER2, or human epidermal growth factor receptor 2, and HER3, or human epidermal growth factor receptor 3, is that HER2 is
amplified in many solid tumors and is associated with poor prognosis and the activation of HER3 causes cancer cells to be or to become resistant to treatment. On the surface of tumor cells, HER2 preferably pairs, or dimerizes, with HER3, and the
resulting pair drives malignant progression of HER2-expressing cancer cells. Heregulin, which is the ligand for HER3, causes cancer cells to grow and become resistant to treatment with HER2-targeted therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have designed <FONT STYLE="white-space:nowrap">MCLA-128</FONT> to overcome the inherent and acquired resistance of tumor cells using two
different mechanisms. The first mechanism blocks growth and survival pathways to stop tumor expansion, while preventing tumor cells from escaping through activation of the HER3/heregulin pathway. The second mechanism, enhanced ADCC, involves the
recruitment and enhancement of immune effector cells, such as NK cells and macrophages, to directly kill the tumor through a modification of the Fc region. This dual mechanism of action is illustrated in the graphic below. <FONT
STYLE="white-space:nowrap">MCLA-128</FONT> is designed to block the HER3 signaling pathway by employing a DOCK&nbsp;&amp; BLOCK<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
mechanism. <FONT STYLE="white-space:nowrap">MCLA-128</FONT> is designed to &#147;dock&#148; onto a specific region of the HER2 receptor to orientate <FONT STYLE="white-space:nowrap">MCLA-128&#146;s</FONT> HER3 binding arm to &#147;block&#148;
HER2:HER3 heterodimerization. Oncogenic signaling through the HER3 pathway, even in the presence of high heregulin concentrations, may thus be blocked. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><FONT STYLE="white-space:nowrap">MCLA-128</FONT> Mechanism of Action </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g696632g51n81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Pre-Clinical</FONT> Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies of HER2-expressing tumor cell lines, we measured the impact of <FONT
STYLE="white-space:nowrap">MCLA-128</FONT> on heregulin-driven growth and cellular changes, characterized by a metastatic phenotype. In these studies, we observed that both growth and metastatic characteristics were poorly blocked by therapeutic
mAbs targeting HER2 and HER3, while the application of <FONT STYLE="white-space:nowrap">MCLA-128</FONT> resulted in the inhibition of heregulin induced changes in cultures of cancer cells. <FONT STYLE="white-space:nowrap">MCLA-128</FONT> also
blocked activation of two key signaling pathways for the growth and survival of tumor cells more effectively than the combination of the currently approved therapeutic HER2 mAbs, Herceptin (trastuzumab) and Perjeta (pertuzumab). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in the chart below, the administration of <FONT STYLE="white-space:nowrap">MCLA-128</FONT> reduced heregulin-driven tumor growth at
significantly lower concentrations than mAbs targeting HER2 or HER3 and the combination of Herceptin and Perjeta. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g696632g97j68.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">MCLA-128</FONT> also blocked phosphorylation and activation
of key proteins in the signaling pathways for the cell growth and survival of cancer cell lines, a result that was not observed with the combination of HER2 mAbs, Herceptin and Perjeta. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also studied the ADCC activity of <FONT STYLE="white-space:nowrap">MCLA-128</FONT> in cell lines expressing different types of Fc
receptors. As shown in the two charts below, because <FONT STYLE="white-space:nowrap">MCLA-128</FONT> is ADCC enhanced, it was able to bind and activate Fc receptors required for the recruitment of immune killer cells regardless of the receptor
affinity of the patient. Studies have estimated that more than 50% of the patient population carry Fc receptors that are of low affinity and are poorly activated by therapeutic antibodies such as Herceptin. We have observed in our <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies that <FONT STYLE="white-space:nowrap">MCLA-128</FONT> was also more potent than Herceptin in activating immune killer cells carrying low affinity Fc receptors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Fc Receptor Activation by <FONT STYLE="white-space:nowrap">MCLA-128</FONT> (Fc&atilde;R Subtype) </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g696632g78q41.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g696632g41l33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, we also compared the ability of <FONT
STYLE="white-space:nowrap">MCLA-128</FONT> to inhibit the<I> in vivo</I> growth of cell lines such as <FONT STYLE="white-space:nowrap">JIMT-1,</FONT> which is an aggressive breast cancer line resistant to HER2-targeted therapies. In these studies,
we administered four doses of MCLA-128 at 2.5 mg/kg. The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">MCLA-128-treated</FONT></FONT> mice experienced as high as a 58% reduction of their tumor size during the <FONT
STYLE="white-space:nowrap">21-day</FONT> treatment period, compared to a less than 11% reduction after administration of a combination of Herceptin and Perjeta. Regrowth of the tumor was observed after treatment was halted on day 21. This result is
illustrated in the chart below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g696632g05g03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Analysis of tumors taken from mice at day 21 showed that HER3 signaling was effectively blocked when
treated with <FONT STYLE="white-space:nowrap">MCLA-128</FONT> whereas no effect was observed with the combination of Herceptin and Perjeta. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> studies have been conducted to evaluate whether tumor
suppression can be sustained by continuing treatment over the <FONT STYLE="white-space:nowrap">60-day</FONT> observation period. The result was that tumor suppression was not sustained. However, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a higher percentage (60%)&nbsp;of mice treated with <FONT STYLE="white-space:nowrap">MCLA-128</FONT> survived beyond 60 days than mice receiving either the vehicle or the combination of Herceptin
and Perjeta. This result is illustrated in the chart below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g696632g19c23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Development of <FONT STYLE="white-space:nowrap">MCLA-128</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2015, we commenced an open-label Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">MCLA-128</FONT> in Europe for the
treatment of HER2-expressing solid tumors. The first part of the trial, the dose escalation phase, is complete. In Part 1 of this trial, <FONT STYLE="white-space:nowrap">MCLA-128</FONT> was well-tolerated up to the highest tested dose of 900 mg and
we observed early positive efficacy results. No dose limiting toxicities were observed. The cumulative safety and available pharmacokinetic, or PK, data, along with the aid of a PK simulation study, were used to support a recommended dose for a
Phase 2 clinical trial of 750 mg, administered over 120 minutes, which we are using in Part 2 of this trial. The Part 2 is ongoing, and is designed to further study the safety, tolerability and clinical efficacy of
<FONT STYLE="white-space:nowrap">MCLA-128</FONT> in patients with solid tumors that are relapsed or refractory to available standard treatment or for whom no curative therapy is available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For this Phase 1/2 trial, we have implemented an exploratory biomarker investigation using tumor tissue and blood samples from patients. The
biomarkers we are evaluating include heregulin expression, HER2 and HER3 receptor expression and PI3K/AKT pathway activation status, which refers to an intracellular pathway regulating processes such as cell survival, cell proliferation and cell
growth. We believe this approach, in conjunction with genetic profiling, will allow for the validation of biomarker assays and will provide guidance for enrolling additional patients based on relevant biomarkers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverse events observed have included infusion related reactions, which were mild or moderate in severity and well managed with premedication
or symptomatic medication. No severe GI events or symptomatic cardiac events have been reported. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 2 portion of the study is
ongoing and designed to explore selected metastatic indications including breast, gastric and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancers. In May 2017, we announced the results of our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 study of <FONT STYLE="white-space:nowrap">MCLA-128</FONT> in solid tumors, including final Phase 1 data and preliminary activity in patients with HER2-positive MBC from the Phase 2
portion of the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the ongoing study, a cohort of 11 HER2-positive MBC patients has been treated with single agent <FONT
STYLE="white-space:nowrap">MCLA-128</FONT> (9 patients at RP2D and two patients at 480 mg q3 weeks from part 1). These MBC patients were all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
heavily pretreated, having received a median of 6 prior lines of metastatic therapy, all having <FONT STYLE="white-space:nowrap">2-5</FONT> prior HER2 inhibitor therapies, and some of the
patients with outright disease progression to the last line of therapy. One MBC patient achieved a confirmed partial response (&gt;8+ months) and 7 had stable disease (including 4 sustained stabilizations lasting greater than 5 months). The clinical
benefit rate (complete and partial responses plus stable disease lasting at least 12 weeks) among the cohort of MBC patients was 64% or 7 of 11 patients. We believe the antitumor activity reported as single agent and extensive preclinical evidence
support further development of <FONT STYLE="white-space:nowrap">MCLA-128</FONT> in combination in MBC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2018, we commenced a
Phase 2, open-label, multi-center international clinical trial to evaluate <FONT STYLE="white-space:nowrap">MCLA-128</FONT> in two MBC populations including HER2-positive MBC patients and hormone receptor
<FONT STYLE="white-space:nowrap">positive/HER2-low</FONT> MBC patients. The <FONT STYLE="white-space:nowrap">MCLA-128</FONT> Phase 2 clinical trial is ongoing and expected to enroll approximately 120 patients in total across the United States and
Europe. The first cohort, HER2-positive MBC patients who are progressing on anti-HER2 therapies including trastuzumab, pertuzumab and <FONT STYLE="white-space:nowrap">TDM-1,</FONT> will receive <FONT STYLE="white-space:nowrap">MCLA-128</FONT> in
combination with trastuzumab and chemotherapy. The second cohort, MBC patients with confirmed hormone receptor positive status and <FONT STYLE="white-space:nowrap">HER2-low</FONT> (immuno-histo-chemistry (IHC) HER2 1+ or 2+ and fluorescent <FONT
STYLE="white-space:nowrap">in-situ</FONT> hybridization (FISH) negative for HER2 amplification) who are progressing on hormone therapies and CDK4/6 inhibitors, will receive <FONT STYLE="white-space:nowrap">MCLA-128</FONT> in combination with
endocrine therapy. The primary endpoint for both cohorts is the clinical benefit rate at 24 weeks. We plan to provide an update on the Phase&nbsp;2 clinical trial in the second half of 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We reported data from the gastric cancer patient cohort in the single-agent trial of <FONT STYLE="white-space:nowrap">MCLA-128</FONT> at ESMO
in October 2018. As of February&nbsp;15, 2018, a clinical benefit rate of 24% (6 of 25 patients) was observed, and <FONT STYLE="white-space:nowrap">MCLA-128</FONT> was well tolerated with mainly grade 1/2 adverse events in patients treated with <FONT
STYLE="white-space:nowrap">MCLA-128</FONT> across all indications explored. Single agent antitumor activity, including one patient with a durable complete response of 5.8&nbsp;months, was seen in heavily pretreated GC/GEJ cancer patients progressing
on one to three anti-HER2 therapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">MCLA-117</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">MCLA-117</FONT> for AML </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">MCLA-117</FONT> is a Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;that is designed
to bind to CD3, a cell-surface molecule present on all <FONT STYLE="white-space:nowrap">T-cells,</FONT> and to CLEC12A, a cell surface molecule present on AML tumor cells and stem cells. CLEC12A is not found on normal blood stem cells nor on cells
that give rise to red blood cells and platelets nor is it present on other <FONT STYLE="white-space:nowrap">non-hematopoietic</FONT> cells in the body. This is in contrast to the expression patterns of CD123 and CD33, which are present on normal
blood stem cells, and in the case of CD33, also the cells that give rise to red blood cells and platelets. Both CD123 and CD33 are being explored by others as targets for AML therapy. We believe that the expression pattern of CLEC12A makes it an
attractive and differentiated molecule for targeted therapy in cancer patients. Moreover, CLEC12A is expressed on approximately 90 to 95% of newly diagnosed and relapsed cases of AML, and we believe that many patients with AML could potentially
benefit from treatment with <FONT STYLE="white-space:nowrap">MCLA-117.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By binding to CD3 and CLEC12A, <FONT
STYLE="white-space:nowrap">MCLA-117</FONT> is designed to recruit and activate <FONT STYLE="white-space:nowrap">T-cells</FONT> to kill CLEC12A-expressing AML tumor cells and stem cells. AML tumor stem cells are thought to be resistant to current
chemotherapeutic treatment regimens, and the inability to eliminate these cells with conventional therapies is thought to significantly contribute to disease relapse in AML patients. We believe that elimination of this leukemic stem cell population
by treatment with <FONT STYLE="white-space:nowrap">MCLA-117</FONT> may prevent recurrence of the tumor. The mechanism of action of <FONT STYLE="white-space:nowrap">MCLA-117</FONT> is illustrated in the graphic below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><FONT STYLE="white-space:nowrap">MCLA-117</FONT> Mechanism of Action </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g696632g28d86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unlike some other bispecific antibody formats, the full-length IgG format of
<FONT STYLE="white-space:nowrap">MCLA-117</FONT> and its associated longer half-life is designed to keep it from having to be administered through continuous infusion using infusion pumps. In addition, through
<FONT STYLE="white-space:nowrap">Fc-silencing,</FONT> <FONT STYLE="white-space:nowrap">MCLA-117</FONT> is designed to avoid binding to Fc receptors present on macrophages and other blood cells that could result in toxicity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that <FONT STYLE="white-space:nowrap">MCLA-117</FONT> could be developed as induction therapy, as consolidation therapy to treat
minimal residual disease and as rescue therapy for patients with relapsed or refractory AML. We intend to explore its use both as a single agent and in combination with commonly used chemotherapy agents and other treatment regimens of AML. We expect
the safety profile of <FONT STYLE="white-space:nowrap">MCLA-117</FONT> to be favorable based on the restricted expression of CLEC12A in human tissues which is anticipated to result in manageable neutropenia. We also expect infusion related reactions
based on the observed level of cytokine release upon <FONT STYLE="white-space:nowrap">co-culture</FONT> with blood cells, which can be mitigated by gradual dose increments and by providing <FONT STYLE="white-space:nowrap">co-medication</FONT> when
required. As CLEC12A is not expressed on megakaryocyte and erythroid progenitor cells, we expect the application of <FONT STYLE="white-space:nowrap">MCLA-117</FONT> would not result in a decrease of platelet counts or red blood cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, <FONT STYLE="white-space:nowrap">MCLA-117</FONT> specifically targeted
and killed AML tumor cells mediated by a high affinity of the Biclonics for CLEC12A and a relatively low affinity for CD3. In these studies, <FONT STYLE="white-space:nowrap">MCLA-117</FONT> recruited <FONT STYLE="white-space:nowrap">T-cells</FONT>
to selectively kill tumor cells in blood samples of AML patients containing an unfavorable ratio of <FONT STYLE="white-space:nowrap">T-cells</FONT> to AML tumor cells. We observed that 1,000 ng/ml of <FONT STYLE="white-space:nowrap">MCLA-117</FONT>
was sufficient to induce the elimination of tumor cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in the figure below, treatment of an AML patient&#146;s blood samples
with <FONT STYLE="white-space:nowrap">MCLA-117</FONT> resulted in the efficient killing of AML tumor cells in our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies. An unmanipulated primary blood sample containing both CLEC12A positive
patient tumor cells and <FONT STYLE="white-space:nowrap">T-cells</FONT> was cultured for 10 days with either a dosage of 1,000 ng/ml of <FONT STYLE="white-space:nowrap">MCLA-117</FONT> or a dosage of a control Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> that did not bind to CLEC12A but retained CD3 binding activity. On day 10, the percentage of AML tumor cells in the culture dish dosed with <FONT STYLE="white-space:nowrap">MCLA-117</FONT> had
decreased from 93% to 1% while the proportion of <FONT STYLE="white-space:nowrap">T-cells</FONT> had increased from 5% to 95%, indicating that CD3 positive <FONT STYLE="white-space:nowrap">T-cells</FONT> had been activated to proliferate, engage and
kill the AML tumor cells by <FONT STYLE="white-space:nowrap">MCLA-117.</FONT> In contrast, the percentage of AML tumor cells in the culture dish dosed with a control Biclonics had slightly decreased from 93% to 81% while the proportion of <FONT
STYLE="white-space:nowrap">T-cells</FONT> had only increased from 5% to 16%, indicating that binding to CLEC12A by <FONT STYLE="white-space:nowrap">MCLA-117</FONT> was required to result in the efficient killing of AML tumor cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g696632g79t36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We commenced a Phase 1, <FONT STYLE="white-space:nowrap">single-arm,</FONT> open-label clinical trial in
Europe of <FONT STYLE="white-space:nowrap">MCLA-117</FONT> in May 2016 for the treatment of patients with AML to assess its safety, tolerability and anti-tumor activity. The first phase of the trial is designed as a dose escalation study, followed
by a second safety dose expansion phase. The study is designed to enroll adult patients with all AML subtypes. Patients with relapsed or refractory disease and newly diagnosed, untreated AML patients who are older than 65 years and are usually not
eligible as candidates for intensive or conventional approved treatments would all be eligible for enrollment in the trial. The trial is ongoing and we expect to enroll approximately 50 patients in this trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary endpoint of the Phase 1 trial is the assessment of the safety and tolerability of <FONT STYLE="white-space:nowrap">MCLA-117</FONT>
in order to determine the maximum tolerated dose and frequency of administration. Secondary endpoints include pharmacokinetic measures, anti-tumor response and clinical benefit. To date, patients treated with
<FONT STYLE="white-space:nowrap">MCLA-117</FONT> have experienced adverse reactions that may be related to the treatment, most commonly infusion-related reactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January of 2018, we submitted an IND to the FDA for <FONT STYLE="white-space:nowrap">MCLA-117</FONT> for the potential treatment of AML,
which was authorized to proceed by the FDA in February 2018, and have expanded the trial to the United States. We are continuing our dose escalation of the Phase 1 clinical trial for <FONT STYLE="white-space:nowrap">MCLA-117.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the results of the clinical trial are favorable, we plan to seek orphan drug designation from the FDA and the EMA for <FONT
STYLE="white-space:nowrap">MCLA-117</FONT> in the United States and in Europe, respectively, for the treatment of AML. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">MCLA-117</FONT> for MDS </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also intend to evaluate <FONT STYLE="white-space:nowrap">MCLA-117</FONT> for the treatment of MDS. MDS is a disease that occurs when the
blood-forming cells in the bone marrow lose the ability to develop normally. Patients with MDS have lower numbers of one or more types of cells in the blood such as red blood cells and platelets and are at higher risk to develop AML. Similar to AML,
we believe that the expression pattern of CLEC12A makes it an attractive and differentiated molecule for targeted therapy in patients with MDS. CLEC12A is expressed in approximately 89% of patients with MDS, and we believe that many patients with
MDS could potentially benefit from treatment with <FONT STYLE="white-space:nowrap">MCLA-117.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">MCLA-158</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">MCLA-158</FONT> is an investigational ADCC-enhanced Biclonics that is designed to bind to Lgr5 and
EGFR-expressing cancer stem cells for the treatment of solid tumors, including colorectal cancer. Cancer stem cells are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a subpopulation of long-lived and chemo-resistant cells that contribute to the growth and metastatic potential of a tumor. Cancer stem cells have the capacity to divide and give rise to new
cancer stem cells via a process called self-renewal, the capacity to differentiate or change into the other cells that form the bulk of the tumor and an ability to withstand chemotherapy and radiation exposure. We believe these features make cancer
stem cells an attractive therapeutic target to overcome the inherent and acquired resistance of tumors to conventional therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
2012, colorectal cancer was the third most common cancer worldwide. Patients with metastatic disease have a mean survival time of less than two&nbsp;years. Approximately 90% of all colorectal cancers display mutational activation of the Wnt pathway.
The Wnt pathway is critical for the maintenance of stem cells and has been linked to cancer. Lgr5 is an amplifying receptor of the Wnt pathway, is over-expressed in approximately 70% of advanced colorectal cancers and is correlated with lymph node
metastases. Lgr5 expression is higher in metastatic tumors and associated with tumor-initiating cells or cancer stem cells. Lgr5 positive cells are highly mitotically active and are expected to be particularly dependent on growth and survival
factors that activate EGFR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have designed <FONT STYLE="white-space:nowrap">MCLA-158</FONT> to target cancer stem cells expressing Lgr5
and EGFR using two different mechanisms of action. The first mechanism of action blocks growth and survival pathways in cancer stem cells. The second mechanism of action, enhanced ADCC, involves the recruitment and enhancement of immune effector
cells to directly kill cancer stem cells that persist in solid tumors, such as colorectal cancer, and cause relapse and metastasis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, we used our proprietary technology combined with high content imaging to identify <FONT STYLE="white-space:nowrap">MCLA-158</FONT> after screening hundreds of&nbsp;bispecific
antibodies for activity in more than 20 patient-derived colorectal cancer organoids. Organoids are cell cultures based on cancer cells from patients that mimic the physiology of tumor growth and depend on the presence of cancer stem cells for their
maintenance. In our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, <FONT STYLE="white-space:nowrap">MCLA-158</FONT> was significantly more potent than an EGFR-targeting mAb, cetuximab, in inhibiting the growth of patient-derived
colorectal cancer organoids. In our <FONT STYLE="white-space:nowrap">ex-vivo</FONT> organoid studies, <FONT STYLE="white-space:nowrap">MCLA-158</FONT> selectively blocked the ability of colorectal cancer organoids to regrow after serial passaging,
suggesting that <FONT STYLE="white-space:nowrap">MCLA-158</FONT> has the potential to eliminate stem cells <I>in vitro</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies <FONT STYLE="white-space:nowrap">MCLA-158</FONT> has been observed to be selectively more active in human tumor-derived organoids than in organoids derived from normal human colon. The activity
of <FONT STYLE="white-space:nowrap">MCLA-158</FONT> on the tumor organoid size was more than 100 times greater than on the normal colon organoids. In contrast, the activity of cetuximab was similar to the activity of
<FONT STYLE="white-space:nowrap">MCLA-158</FONT> on normal colon organoids and 20 to 100 times less than the activity of <FONT STYLE="white-space:nowrap">MCLA-158</FONT> on tumor organoids. We observed this result on three additional normal colon
organoids and four tumor organoids, three of which were derived from metastatic lesions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies to date and the expression pattern of Lgr5 and EGFR and their known roles in tumor progression, we believe that <FONT STYLE="white-space:nowrap">MCLA-158</FONT> has the potential to
improve the survival outcome of patients with metastatic colorectal cancer, <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, ovarian cancer and potentially other solid tumors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have received approval of CTAs in several European countries for <FONT STYLE="white-space:nowrap">MCLA-158</FONT> for the potential
treatment of metastatic colorectal cancer, including patients with the <FONT STYLE="white-space:nowrap">RAS-mutation,</FONT> which represent a substantial unmet need. The first CTA was approved to initiate a Phase 1 clinical trial in Europe in
January 2018. We filed an IND for <FONT STYLE="white-space:nowrap">MCLA-158</FONT> with the FDA in the first quarter of 2018, which received authorization to proceed from the FDA in April 2018. In May 2018, we commenced an open-label, multicenter
Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">MCLA-158</FONT> in patients with solid tumors with an initial focus on metastatic colorectal cancer and expect emerging data by the end of 2019. The Phase 1 trial consists of two parts: dose
escalation and dose expansion. The dose escalation part is intended to determine the appropriate dose of <FONT STYLE="white-space:nowrap">MCLA-158.</FONT> The dose expansion part is intended to evaluate the safety and tolerability of the defined
dose of <FONT STYLE="white-space:nowrap">MCLA-158</FONT> in patients with solid tumors. The trial is also designed to evaluate preliminary antitumor activity of single-agent <FONT STYLE="white-space:nowrap">MCLA-158.</FONT> We expect to enroll
approximately 120&nbsp;adult patients with colorectal cancer and possibly other solid tumors in this trial. Recruitment in the trial is ongoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Bispecific Antibody Candidates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">MCLA-145</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">MCLA-145</FONT> is an investigational
Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;that is designed to bind to <FONT STYLE="white-space:nowrap">PD-L1</FONT> and CD137. We received authorization to proceed under the IND for
<FONT STYLE="white-space:nowrap">MCLA-145</FONT> from the FDA in January 2019 and expect to initiate a Phase 1 clinical trial in the first half of 2019. <FONT STYLE="white-space:nowrap">MCLA-145</FONT> is designed to enhance the activation of tumor
specific tumor infiltrating lymphocytes. <FONT STYLE="white-space:nowrap">MCLA-145</FONT> is the first drug candidate <FONT STYLE="white-space:nowrap">co-developed</FONT> under our global research and collaboration with Incyte Corporation. We have
full rights to develop and commercialize <FONT STYLE="white-space:nowrap">MCLA-145</FONT> in the United States and Incyte is responsible for its development and commercialization outside the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">MCLA-129</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">MCLA-129</FONT> is a Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, designed to bind
EGFR and cMET, for the treatment of solid tumors. EGFR is an important oncogenic driver in many cancers. The upregulation of <FONT STYLE="white-space:nowrap">c-MET</FONT> signaling has been associated with resistance to EGFR inhibition. <FONT
STYLE="white-space:nowrap">MCLA-129</FONT> has two distinct mechanisms of action. First, our DOCK&nbsp;&amp; BLOCK<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> mechanism of action blocks the signaling of EGFR as well as <FONT
STYLE="white-space:nowrap">c-MET,</FONT> with the potential to inhibit tumor growth and survival. Second, <FONT STYLE="white-space:nowrap">MCLA-129</FONT> utilizes ADCC-enhancement technology designed for greater cell-killing potential. Because the
DOCK&nbsp;&amp; BLOCK and ADCC mechanism of action is based on the <FONT STYLE="white-space:nowrap">co-expression</FONT> of EGFR and <FONT STYLE="white-space:nowrap">c-MET,</FONT> we expect it to have less toxicity compared to agents targeting EGFR
alone. <FONT STYLE="white-space:nowrap">MCLA-129</FONT> is being developed pursuant to collaboration and license agreement with Betta Pharmaceuticals. Under the terms of the agreement, Betta Pharmaceuticals has agreed to be responsible for clinical
development and commercialization of <FONT STYLE="white-space:nowrap">MCLA-129</FONT> in China. As a key strategic component of the collaboration, Betta will retain a contract manufacturing organization with experience in filing IND applications
with U.S. regulatory authorities and CTAs with European regulatory authorities in order to produce clinical trial materials for the Chinese market and rest of world. Betta will facilitate regulatory filings and early stage clinical trial materials
supply for potential use by us for development of <FONT STYLE="white-space:nowrap">MCLA-129</FONT> outside of China. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Pre-Clinical</FONT> Discovery Programs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to further leverage our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform to identify multiple
additional antibody candidates and advance them to clinical development. Each of these antibody candidates are designed to bind to targets believed to be useful in the treatment of cancer with an intention to establish efficacy and obtain
information for submission to the FDA. Our current focus is on a number of immunotherapeutic targets and pathways that have demonstrated promising tumor killing ability in early-stage clinical trials and scientific literature. Using our platform, we
will continue to evaluate new targets and combinations to identify potential candidates with the highest immunotherapeutic potential and select those candidates to be advanced into clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our
business strategy, we intend to continue to seek research collaborations in order to derive further value from our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform and more fully exploit its potential. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incyte Corporation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
entered into a collaboration and license agreement, or the Collaboration Agreement, with Incyte Corporation, or Incyte. Under the terms of the Collaboration Agreement, we and Incyte have agreed to collaborate with respect to the research, discovery
and development of bispecific antibodies utilizing our proprietary bispecific technology platform. The collaboration encompasses up to 11 independent programs, including some of our current preclinical immuno-oncology discovery programs. For one of
the current preclinical programs, concerning <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> we retain the exclusive right to develop and commercialize products and product candidates in the United States, while Incyte has the exclusive right to
develop and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialize products and product candidates arising from such program outside the United States. For <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> we and Incyte will conduct and share
equally the costs of mutually agreed global development activities and will be solely responsible for independent development activities in our respective territories. We have the option to <FONT STYLE="white-space:nowrap">co-fund</FONT> development
of products arising from one specified program, and subject to certain conditions, to a second specified program, in each case exchange for a share of profits in the United States, as well as the right to participate in a specified proportion of
detailing activities in the United States for one of such programs. If we exercise our <FONT STYLE="white-space:nowrap">co-funding</FONT> option for a program, we would be responsible for funding 35% of the associated future global development costs
and, for certain of such programs, would be responsible for reimbursing Incyte for certain development costs incurred prior to the option exercise. All products as to which we have exercised our option to
<FONT STYLE="white-space:nowrap">co-fund</FONT> development would be subject to joint development plans and overseen by a joint development committee, with Incyte having final determination as to such plans in cases of dispute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each program other than <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> where we have not elected to
<FONT STYLE="white-space:nowrap">co-fund</FONT> development or where we do not have such a <FONT STYLE="white-space:nowrap">co-funding</FONT> option, Incyte is solely responsible for all costs of global development and commercialization activities.
We retain the rights to our bispecific technology platform as well as clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> candidates and future programs emerging from our platform that are outside the scope of the Collaboration
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2017, upon the Collaboration Agreement becoming effective, Incyte made an upfront
<FONT STYLE="white-space:nowrap">non-refundable</FONT> payment to us of $120&nbsp;million for the rights granted under the Collaboration Agreement. For each program as to which we do not have commercialization or
<FONT STYLE="white-space:nowrap">co-development</FONT> rights, we are eligible to receive up to $100&nbsp;million in future contingent development and regulatory milestones and up to $250&nbsp;million in commercialization milestones, as well as
tiered royalties ranging from 6% to 10% of global net sales. For each program as to which we have exercised our option to <FONT STYLE="white-space:nowrap">co-fund</FONT> development, we are eligible to receive a 50% share of profits (or sustain 50%
of any losses) in the United States and tiered royalties ranging from 6% to 10% of net sales of products outside of the United States. If we opt to cease <FONT STYLE="white-space:nowrap">co-funding</FONT> a program as to which we exercised our <FONT
STYLE="white-space:nowrap">co-development</FONT> option, then we will no longer receive a share of profits in the United States but will be eligible to receive the same milestones from the <FONT STYLE="white-space:nowrap">co-funding</FONT>
termination date and the same tiered royalties described above with respect to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-co-developed</FONT></FONT> programs and, depending on the stage at which we choose to cease <FONT
STYLE="white-space:nowrap">co-funding</FONT> development costs, additional royalties ranging up to 4% of net sales in the United States. For <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> for which we retain all commercial rights in the United
States, we and Incyte are each eligible to receive tiered royalties on net sales in the other&#146;s territory at rates ranging from 6% to 10%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Collaboration Agreement will continue on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis until neither party has any royalty payment obligations with respect to such program or, if earlier, the termination of the Collaboration
Agreement or any program in accordance with the terms of the Collaboration Agreement. The Collaboration Agreement may be terminated in its entirety, or on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis, by Incyte for convenience. The Collaboration Agreement may also be terminated by either party under certain other circumstances, including
material breach, or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis for patent challenge of patents under the applicable program, in each case as set forth in the Collaboration Agreement.
If the Collaboration Agreement is terminated in its entirety or with respect to one or more programs, all rights in the terminated programs revert to us, subject to payment to Incyte of a reverse royalty of up to 4% on sales of future products, if
we elect to pursue development and commercialization of products arising from the terminated programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the
Collaboration Agreement, we entered into a Share Subscription Agreement with Incyte, pursuant to which, in January 2017, we issued and sold to Incyte 3,200,000 common shares for an aggregate purchase price of $80.0&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ONO Pharmaceutical </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014,
we entered into a strategic research and license agreement with ONO, under which we granted ONO an exclusive, worldwide, royalty-bearing license to research, test, make, use and market a limited </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
set of bispecific antibody candidates, if approved, based on our Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
technology platform, directed to two undisclosed targets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ONO paid us a <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront
fee of &#128;1.0&nbsp;million, and we are eligible to receive up to an aggregate of &#128;57.0&nbsp;million in milestone payments upon achievement of specified research and clinical development milestones. To date, we have achieved four of the
specified <FONT STYLE="white-space:nowrap">pre-clinical</FONT> milestones under this research and license agreement and have received an aggregate of &#128;2.7&nbsp;million in milestone payments. For products commercialized under this agreement, if
any, we are also eligible to receive a <FONT STYLE="white-space:nowrap">mid-single</FONT> digit royalty on net sales. For a designated period, which may include limited time periods following termination of this agreement, in certain circumstances
we and our affiliates are prohibited from researching, developing or commercializing bispecific antibodies against the undisclosed target combination that are the subject of this agreement. ONO also provides funding for our research and development
activities under an agreed-upon plan. This research and license agreement will expire after all milestone payments have been received and all related patent rights have expired, unless terminated earlier. ONO has the right to terminate this
agreement at any time for any reason, with or without cause. The licenses granted to ONO may convert to royalty-free, fully-paid, perpetual licenses if ONO terminates the agreement for uncured material breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;14, 2018, we entered into a second contract research and license agreement with ONO. Pursuant to an exclusive option granted to
ONO in the prior agreement executed in April 2014, ONO exercised its option to enter into the March 2018 agreement. We granted ONO an exclusive, worldwide, royalty-bearing license, with the right to sublicense, research, test, make, use and market
bispecific antibody candidates based on our Biclonics<B><SUP STYLE="font-size:85%; vertical-align:top"> </SUP></B><B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B> technology platform against two undisclosed targets directed to a
particular undisclosed target combination. ONO identifies and selects the licensed bispecific antibodies for which it is responsible for conducting further <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical development activities for
such licensed bispecific antibodies and pharmaceutical products containing such antibodies, including manufacture and process development. ONO controls and has exclusive rights over the worldwide commercialization of any approved products, including
worldwide supply, and is solely responsible for all costs and expenses related to commercialization. ONO has agreed to fund our research and development activities and be responsible for the payment of all costs and expenses for its own research and
development activities, which are set out in a mutually agreed upon research plan. We retain all rights to use and commercialize any antibodies that are generated under the collaborative research program, excluding the up to five lead and/or
selected antibodies against the targets ONO is pursuing, provided that the use and commercialization is not with respect to the particular target combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ONO has agreed to pay an upfront <FONT STYLE="white-space:nowrap">non-refundable</FONT> payment of &#128;700,000 for the rights granted and we
are also eligible to receive an aggregate of &#128;57.0&nbsp;million in milestone payments upon achievement of specified research and clinical development milestones. For products commercialized under the License Agreement, if any, the Company is
eligible to receive a <FONT STYLE="white-space:nowrap">mid-single</FONT> digit royalty on net sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a designated period, which may
include limited time periods following termination of this agreement, in certain circumstances we are prohibited from researching, developing or commercializing bispecific antibodies against the undisclosed target combination that are the subject of
this agreement. ONO also provides funding for our research and development activities under an agreed-upon plan. This research and license agreement will expire after all milestone payments have been received and all related patent rights have
expired, unless terminated earlier. ONO has the right to terminate this agreement at any time for any reason, with or without cause. The licenses granted to ONO may convert to royalty-free, fully-paid, perpetual licenses if ONO terminates the
agreement for uncured material breach. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Simcere Pharmaceutical Group </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2018, we entered into an agreement with Simcere Pharmaceutical Group, or Simcere, granting Simcere an exclusive license to
develop and commercialize in China three bispecific antibodies to be produced by Merus utilizing our proprietary Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology
platform in the area of immuno-oncology. We retain all rights outside of China. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to lead research and discovery activities while Simcere has agreed to be
responsible for the <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, clinical development, regulatory filings and commercialization of these product candidates in China. We received an upfront payment, and are eligible to receive
milestone payments contingent upon Simcere achieving certain specified development and commercial goals. To date, we have achieved one undisclosed milestone payment under this agreement. We are eligible to receive tiered royalty payments on sales of
any products resulting from the collaboration in China from Simcere. Simcere is eligible to receive tiered royalty payments on sales outside of China from us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Betta Pharmaceuticals Co. Ltd. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;10, 2018, we entered into a collaboration and license agreement with Betta Pharmaceuticals Co. Ltd., or Betta, where we granted Betta an exclusive license to develop and commercialize in China
<FONT STYLE="white-space:nowrap">MCLA-129,</FONT> a Merus proprietary Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> produced by our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform. We
retain all rights outside of China. Under the terms of the agreement, Betta will retain a contract manufacturing organization with experience in filing IND applications with U.S. authorities and CTAs with European regulatory authorities in order to
produce clinical trial materials for the Chinese market and the rest of the world. As a key strategic component of the collaboration, Betta will be responsible for IND enabling studies and manufacturing of clinical trial materials in China, which we
intend to use to assist regulatory filing and early stage clinical development in the rest of the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to a <FONT
STYLE="white-space:nowrap">non-refundable</FONT> upfront payment, we and Betta will share equally the cost of the transfer of the manufacturing technology to a contract manufacturing organization. We are also eligible to receive milestone payments
contingent upon Betta achieving certain specified development and commercial goals as well as tiered royalty payments of net sales of any products resulting from the collaboration in China. Betta is eligible to receive milestone payments contingent
upon us achieving certain specified development and commercial goals, and is eligible to receive tiered royalty payments of net sales outside of China. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform relies on third parties for biological materials. We rely on and expect to continue to rely on third-party contract manufacturing organizations, or CMOs, for the supply of
current good manufacturing practice-grade, or cGMP-grade, clinical trial materials and commercial quantities of our bispecific antibody candidates and products, if approved. We currently do not have any agreements for the commercial production of
bispecific product candidates, but we have contracted several biopharmaceutical CMOs for the clinical manufacturing of <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT STYLE="white-space:nowrap">MCLA-117,</FONT>
<FONT STYLE="white-space:nowrap">MCLA-158</FONT> and <FONT STYLE="white-space:nowrap">MCLA-145.</FONT> We believe that the standardized Biclonics<SUP STYLE="font-size:85%; vertical-align:top">
</SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> manufacturing process can be transferred to additional CMOs and potential future <FONT STYLE="white-space:nowrap">co-development</FONT> or
<FONT STYLE="white-space:nowrap">co-commercialization</FONT> collaborations or partnerships for the production of clinical and commercial supplies of our Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in the ordinary course of business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and Marketing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not yet defined our sales, marketing or product distribution strategy for <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT
STYLE="white-space:nowrap">MCLA-117,</FONT> <FONT STYLE="white-space:nowrap">MCLA-158</FONT> or any of our other bispecific antibody candidates because our bispecific antibody candidates are still in
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> or early-stage clinical development. Our commercial strategy may include the use of strategic partners, distributors, a contract sales force, or the establishment of our own commercial and
specialty sales force. We plan to further evaluate these alternatives as we approach approval for one of our bispecific antibody candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We compete directly with
companies that focus on immuno-oncology and companies dedicating their resources to cancer therapies. We also face competition from academic research institutions, governmental </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agencies and other various public and private research institutions. With the proliferation of new drugs and therapies into oncology, we expect to face increasingly intense competition as new
technologies become available. Any bispecific antibody candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than
we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be
significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining top qualified scientific and management personnel and establishing
clinical trial sites and patient registration for clinical trials, manufacturer&#146;s production capacity, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of all of our therapeutic bispecific antibody candidates, if approved, are likely to be
their efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic competition and the availability of reimbursement from government and other third-party
payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer,
more effective, less expensive, more convenient or easier to administer, or have fewer or less severe effects than any products that we may develop. Our competitors also may obtain FDA, EMA or other regulatory approval for their products more
rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if our bispecific antibody candidates achieve marketing approval, they may be
priced at a significant premium over competitive products if any have been approved by then. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to currently marketed therapies,
there are also a number of products in late-stage clinical development to treat cancer, including other bispecific antibodies or similar molecules. Our closest competitors in this area include Affimed N.V., Zymeworks Inc., Genmab A/S, MacroGenics,
Inc., Merrimack Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. and Xencor, Inc. The bispecific antibody candidates in development by competitors may provide efficacy, safety, dosing convenience and other benefits that are not provided by
currently marketed therapies. As a result, they may provide significant competition for any of our bispecific antibody candidates for which we obtain marketing approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to
protect and enhance the proprietary technologies, inventions, and improvements that we believe are important to our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties.
Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions,
improvements, platforms and antibody candidates that are important to the development and implementation of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
March&nbsp;7, 2018: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our patent portfolio related to our bispecific antibody candidate
<FONT STYLE="white-space:nowrap">MCLA-128</FONT> consists of one PCT application, filed on February&nbsp;27, 2015 which entered national phases in the United States, Europe and 17&nbsp;other foreign countries with an expected expiry not earlier than
February&nbsp;27, 2035. Claims are directed to the <FONT STYLE="white-space:nowrap">MCLA-128</FONT> composition of matter and methods of using <FONT STYLE="white-space:nowrap">MCLA-128</FONT> to treat subjects having or at risk of having an <FONT
STYLE="white-space:nowrap">ErbB-2</FONT> and/or ErbB3 positive tumor. In addition, our portfolio includes four PCT patent application covering further methods of using <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> including in combination
therapies, to treat patients, three of which were filed on April&nbsp;3, 2018, and one filed on May&nbsp;17, 2018. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our patent portfolio related to our bispecific antibody candidate
<FONT STYLE="white-space:nowrap">MCLA-117</FONT> consists of a first PCT application, filed on September&nbsp;27, 2013, which entered national phases in the United States, Europe and 14&nbsp;foreign countries with an expected expiry not earlier than
September&nbsp;27, 2033. There is currently one pending US application, one issued EP patent and a pending EP divisional application, 14&nbsp;pending foreign applications, and five issued patents in several foreign jurisdictions. In addition, we
filed a second PCT application related to <FONT STYLE="white-space:nowrap">MCLA-117</FONT> on July&nbsp;8, 2016, which has entered national phases in the United States, Europe and 13 foreign countries with an expected expiry not earlier than July,
2036. There is currently one issued U.S. patent and two pending U.S. applications, one issued and one pending EP applications, and 13 pending foreign applications. Claims are related to the <FONT STYLE="white-space:nowrap">MCLA-117</FONT>
composition of matter and methods of using <FONT STYLE="white-space:nowrap">MCLA-117</FONT> in the treatment or prevention of MDS, chronic myelogenous leukemia, or CML, or AML. In addition, our portfolio includes one PCT patent application covering
methods of using <FONT STYLE="white-space:nowrap">MCLA-117,</FONT> including in combination therapies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our patent portfolio related to our bispecific antibody candidate
<FONT STYLE="white-space:nowrap">MCLA-158</FONT> consists of one PCT filed on October&nbsp;21, 2016, which entered or will enter national/regional phases in the United States, Europe and 14 other foreign countries with an expiry no earlier than
October&nbsp;21, 2036. Claims are directed to the <FONT STYLE="white-space:nowrap">MCLA-158</FONT> composition of matter and methods of using <FONT STYLE="white-space:nowrap">MCLA-158</FONT> in the treatment or prevention of various solid tumors.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our patent portfolio related our bispecific antibody candidate <FONT STYLE="white-space:nowrap">MCLA-145</FONT>
consists of one PCT filed on September&nbsp;22, 2017, which entered or will enter national/regional phases in the United States, Europe and 18 other foreign countries with an expiry no earlier than September 2037. Claims are directed to the <FONT
STYLE="white-space:nowrap">MCLA-145</FONT> composition of matter and methods of using <FONT STYLE="white-space:nowrap">MCLA-145</FONT> in the treatment or prevention of various solid tumors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our patent portfolio related our bispecific antibody candidate <FONT STYLE="white-space:nowrap">MCLA-129</FONT>
consists of one PCT filed on August&nbsp;9, 2018, with an expiry no earlier than August 2038. Claims are directed to the <FONT STYLE="white-space:nowrap">MCLA-129</FONT> composition of matter and methods of using
<FONT STYLE="white-space:nowrap">MCLA-129</FONT> in the treatment or prevention of various solid tumors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our patent portfolio related to our MeMo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> mouse consists
of three issued U.S. patents, eight pending U.S. applications, one issued European patent that has been validated in many countries, and five pending European applications, 12 issued foreign patents and 10 pending foreign applications, all with an
expected expiry not earlier than June&nbsp;29, 2029. Claims are directed to a common light chain animal and methods of producing antibodies by exposing the animal to an antigen. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our patent portfolio related to our Spleen to Screen<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>
technology consists of two issued U.S. patents, one pending U.S. application, one issued European Patent, one pending European application and two issued foreign patents, with three foreign pending applications, all with an expected expiry not
earlier than September&nbsp;26, 2032. For a discussion concerning opposition proceedings against this patent family see Item 8 &#147;Legal Proceedings&#148; and Note 21 to our Consolidated Financial Statements included in this Annual Report.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our patent portfolio related to recombinant production of mixtures of antibodies, and includes claims directed to
host cells generating multi-specific antibodies consists of five issued U.S. patents, and four pending U.S. applications, two issued European patents, 15 issued foreign patents, and four pending foreign applications, all with an expected expiry not
earlier than July, 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to continue to expand our intellectual property estate by filing patent applications
directed to dosage forms, methods of treatment and additional compositions created or identified from our Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform,
improvements to our Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform and ongoing development of our antibody candidates. Specifically, we seek patent
protection in the United States and internationally for novel compositions of matter directed to aspects of the molecules, basic structures and processes for manufacturing these molecules and the use of these molecules in a variety of therapies.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio is intended to cover, but is not limited to, the composition of matter
of our bispecific antibody candidates, their methods of use, the Biclonics<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform used to generate them, related
technologies and/or other aspects of the inventions that are important to our business, including our MeMo<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> mouse, Spleen to Screen<SUP
STYLE="font-size:85%; vertical-align:top"> TM</SUP> technology, and recombinant host cells capable of producing our antibody candidates, methods of purification, and heterodimerization, among other proprietary technology. We also rely on trademarks,
trade secrets and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely on <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and
<FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop, strengthen, and maintain our proprietary positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
success will depend on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> related to our business, defend and enforce our
patents, maintain our licenses to use intellectual property owned by third parties, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third parties. For
important factors related to our proprietary technology, inventions, improvements, platforms and bispecific antibody candidates, please see the section entitled &#147;Risk Factors&#151;Risks Related to Intellectual Property and Information
Technology.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to extensive regulation. We expect our bispecific antibody candidates to be regulated as biologics. Biological products are
subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, and the Public Health Service Act, or PHS Act, and other federal, state, local and foreign statutes and regulations. Both the FD&amp;C Act and the PHS Act and
their corresponding regulations govern, among other things, the testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological
products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Biological Products Development Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process required by the FDA before a biologic may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of extensive nonclinical, sometimes referred to as
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> laboratory tests, and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> animal trials and applicable requirements for the humane use of laboratory animals and formulation studies in accordance
with applicable regulations, including good laboratory practices, or GLPs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials according to the FDA&#146;s regulations,
commonly referred to as good clinical practice, or GCP, regulations and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product
for its intended use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety, purity, and
potency from results of nonclinical testing and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological
product is produced to assess compliance with current Good Manufacturing Practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the biological product&#146;s identity, strength, quality and
purity; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the BLA;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval, or licensure, of the BLA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing any biological bispecific antibody candidate in humans, the bispecific antibody candidate enters the <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> testing stage. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> tests, also referred to as nonclinical trials, generally include laboratory evaluations of product chemistry, toxicity and
formulation, as well as animal studies to assess the potential safety and activity of the bispecific antibody candidate. The conduct of the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> tests must comply with federal regulations and
requirements including GLPs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical trial sponsor must submit the results of the
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the clinical trial on a clinical hold within that <FONT
STYLE="white-space:nowrap">30-day</FONT> time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological bispecific antibody
candidate at any time before or during clinical trials due to safety concerns or <FONT STYLE="white-space:nowrap">non-compliance.</FONT> If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under
terms authorized by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the biological bispecific antibody candidate to healthy
volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#146;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of
the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur.
Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#146;s regulations comprising the GCP requirements, including the
requirement that all research subjects provide informed consent. Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be
conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated
benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1. The biological bispecific antibody candidate is initially introduced into healthy human subjects and
tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2. The biological bispecific antibody candidate is evaluated in a limited patient population to identify
possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an
expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These
clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety <FONT STYLE="white-space:nowrap">follow-up.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During all phases of clinical development, regulatory agencies require extensive monitoring
and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the
FDA and the investigators for serious and unexpected adverse events, any findings from other trials, tests in laboratory animals or<I> in vitro</I> testing that suggest a significant risk for human subjects, or any clinically important increase in
the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for
reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s initial receipt of the information. The FDA or the sponsor or its data safety
monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a
clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the biological bispecific antibody candidate has been associated with unexpected serious harm to patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.
Sponsors of clinical trials of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov.
Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the
results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal trials and must also develop additional information about the
physical characteristics of the biological bispecific antibody candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of
adventitious agents with use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing
quality batches of the bispecific antibody candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must
be selected and tested and stability studies must be conducted to demonstrate that the biological bispecific antibody candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Review and Approval Processes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion of clinical trials of a biological bispecific antibody candidate, FDA approval of a BLA must be obtained before commercial
marketing of the biological product. The BLA must include results of product development, laboratory and animal trials, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. In
addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological bispecific antibody candidate for the claimed indications in all relevant pediatric
subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. A sponsor who is planning to submit a marketing application for a drug or biological product that includes a new
active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan, or PSP, within sixty days after an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological product for an
indication for which orphan designation has been granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must
be accompanied by a user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as
orphan drugs, unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within 60 days following
submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time
of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is
accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure and potent, and whether the
product is being manufactured in accordance with cGMP requirements to assure and preserve the product&#146;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products
that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under
what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk
Evaluation and Mitigation Strategy, or REMS, is necessary to assure the safe use of the biological bispecific antibody candidate. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the
BLA without a REMS, if required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The
FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally,
before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory
criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than the applicant interprets the same data. If the FDA decides not to approve the BLA in its present
form, the FDA will issue a complete response letter that usually describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example,
requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the
applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a
product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may
require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a REMS, or otherwise limit the
scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase IV clinical trials, designed to further assess a biological product&#146;s safety and effectiveness, and testing and surveillance
programs to monitor the safety of approved products that have been commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the performance goals agreed to by the FDA
under the PDUFA is to review 90% of standard BLAs in 10 months from the filing date and 90% of priority BLAs in six months from the filing date, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates for
standard and priority BLAs and its review goals are subject to change from time to time. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the BLA sponsor otherwise provides additional
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000 individuals in
the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and marketing the drug for this type of disease or condition will be recovered from sales in the
United States. Orphan product designation must be requested before submitting a BLA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan
product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United
States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. In addition, if a product
receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for
a period of seven&nbsp;years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer with orphan exclusivity is unable to assure sufficient quantities of the
approved orphan designated product. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the
orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same biological product as defined by the FDA or if our bispecific antibody
candidate is determined to be contained within the competitor&#146;s product for the same indication or disease. If a drug or biological product designated as an orphan product receives marketing approval for an indication broader than what is
designated, it may not be entitled to orphan product exclusivity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new biological products that meet certain
criteria. Specifically, new biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or
condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new biologic may request that the FDA designate the biologic as a Fast Track product at any time
during the clinical development of the product. Unique to a Fast Track product, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule
for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the
application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA
programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it is intended to treat a serious disease or condition and has the potential to provide safe and
effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the
evaluation of an application for a new biological product designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Biological products studied for their safety and
effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval, which means that they may be approved on the basis of adequate and
well-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical
endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of
approval, the FDA may require that a sponsor of a biological product subject to accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval
<FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast Track designation, priority review and accelerated approval do not change the
standards for approval but may expedite the development or approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the provisions of the Food and Drug
Administration Safety and Innovation Act, or FDASIA, enacted in 2012, the FDA established a Breakthrough Therapy Designation which is intended to expedite the development and review of products that treat serious or life-threatening diseases or
conditions. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug
may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the features of Fast Track
designation, as well as more intensive FDA interaction and guidance. The Breakthrough Therapy Designation is a distinct status from both accelerated approval and priority review, but these can also be granted to the same bispecific antibody
candidate if the relevant criteria are met. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. All
requests for breakthrough therapy designation will be reviewed within 60 days of receipt, and FDA will either grant or deny the request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fast Track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval
but may expedite the development or approval process. Even if we receive one of these designations for our bispecific antibody candidates, the FDA may later decide that our bispecific antibody candidates no longer meet the conditions for
qualification. In addition, these designations may not provide us with a material commercial advantage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Maintaining substantial compliance with applicable federal, state, and local statutes and regulations requires the expenditure of
substantial time and financial resources. Rigorous and extensive FDA regulation of biological products continues after approval, particularly with respect to cGMP requirements. We will rely, and expect to continue to rely, on third parties for the
production of clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance
and maintenance of records and documentation. Other post-approval requirements applicable to biological products include record-keeping requirements, reporting of adverse effects, and reporting updated safety and efficacy information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also must comply with the FDA&#146;s advertising and promotion requirements, such as those related to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#146;s approved labeling (known as
<FONT STYLE="white-space:nowrap">&#147;off-label</FONT> use&#148;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with
the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at
any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to
approve pending applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biological product manufacturers and other entities involved in the manufacture and distribution of approved biological products are required
to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other laws. Accordingly, manufacturers must
continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and
other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Patent Term Restoration and Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of the FDA approval of the use of our bispecific antibody candidates, some of our U.S.
patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of
up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s
approval date. The patent term restoration period is generally <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the
approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved biological product is eligible for the extension and the
application for the extension must be submitted prior to the expiration of the patent and within a <FONT STYLE="white-space:nowrap">60-day</FONT> period from the date the product is first approved for commercial marketing. The U.S. PTO, in
consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for one of our currently owned patents to add patent life beyond its current
expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA; however, there can be no assurance that any such extension will be granted to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Biosimilars and Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological products that are
biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. The FDA has issued several guidance documents outlining an approach to review and approve biosimilars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in
terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that
it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched
after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structures of
biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. For example, in January 2017 the FDA
issued draft guidance outlining considerations for sponsors seeking to demonstrate interchangeability with a reference biologic. However, to date the FDA has not approved a BLA for an interchangeable biological product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA
until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was
first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the
sponsor&#146;s own <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity
periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#147;interchangeable&#148; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy
law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six
months to existing exclusivity periods and patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of
a pediatric trial in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BPCIA is complex and continues to be interpreted and implemented by the FDA. Certain aspects of the BPCIA, some of which may impact the
BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and meaning of the BPCIA remain subject to significant uncertainty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>FDA Regulation of Companion Diagnostics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our bispecific antibody candidates may require use of an<I> in vitro</I> diagnostic to identify appropriate patient populations
for our products. These diagnostics, often referred to as companion diagnostics, are regulated as medical devices. In the United States, the FD&amp;C Act and its implementing regulations, and other federal and state statutes and regulations govern,
among other things, medical device design and development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and
promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA
marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA approval. We expect that any companion diagnostic developed for our bispecific antibody candidates will
utilize the PMA pathway. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If use of a companion diagnostic is essential to safe and effective use of a drug or biologic product, then the
FDA generally will require approval or clearance of the diagnostic contemporaneously with the approval of the therapeutic product. On August&nbsp;6, 2014, the FDA issued a final guidance document addressing the development and approval process for
&#147;<I> In Vitro</I> Companion Diagnostic Devices.&#148; According to the guidance, for novel candidates such as our bispecific antibody candidates, a companion diagnostic device and its corresponding drug or biologic candidate should be approved
or cleared contemporaneously by the FDA for the use indicated in the therapeutic product labeling. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be
considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be
considered a significant risk device under the FDA&#146;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a
diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations.
The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. In July 2016, the FDA issued a draft guidance document intended to further assist sponsors of
therapeutic products and sponsors of<I> in vitro</I> companion diagnostic devices on issues related to <FONT STYLE="white-space:nowrap">co-development</FONT> of these products, and in December 2018, the FDA issued
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a draft guidance describing considerations for the development and labeling of in vitro companion diagnostic devices to support the indicated uses of multiple drug or biological oncology
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA generally requires companion diagnostics intended to select the patients who will respond to cancer treatment to obtain
approval of a PMA for that diagnostic contemporaneously with approval of the therapeutic. The review of these<I> in vitro</I> companion diagnostics in conjunction with the review of a cancer therapeutic involves coordination of review by the
FDA&#146;s Center for Biologics Evaluation and Research and by the FDA&#146;s Center for Devices and Radiological Health. The PMA process, including the gathering of clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data and the
submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#146;s safety and effectiveness and
information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. In addition, PMAs for certain devices must generally include the results
from extensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a
diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results when the same sample is tested multiple times by multiple users at multiple laboratories. As part of the PMA review, the FDA will typically inspect the
manufacturer&#146;s facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval
letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA, such as changes in labeling, or specific additional information, such as submission of final labeling,
in order to secure final approval of the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA
can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA&#146;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not
approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary,
in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval
requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable
determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for
the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#146;s manufacturing processes and those of its suppliers are
required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility
records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Government Regulation Outside of the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other
things, clinical trials and any commercial sales and distribution of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries
prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior
to the commencement of human clinical trials. In the European Union, for example, a CTA must be submitted to each country&#146;s national health authority and an independent ethics committee, much like the FDA and the IRB, respectively. Once the CTA
is approved in accordance with a country&#146;s requirements, clinical trial development may proceed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The requirements and process
governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical
principles that have their origin in the Declaration of Helsinki. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain regulatory approval of an investigational biological product
under European Union regulatory systems, we must submit a marketing authorization application. The application used to file the BLA in the United States is similar to that required in the European Union, with the exception of, among other things,
country-specific document requirements. The European Union also provides opportunities for market exclusivity. For example, in the European Union, upon receiving marketing authorization, new chemical entities generally receive eight years of data
exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#146;s data to assess a generic application. During the additional <FONT
STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a generic marketing authorization can be submitted, and the innovator&#146;s data may be referenced, but no generic product can be marketed until the expiration of the market
exclusivity. However, there is no guarantee that a product will be considered by the European Union&#146;s regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity. Products receiving orphan designation
in the European Union can receive ten years of market exclusivity; during this period, no marketing authorization application may be accepted and no marketing authorization may be granted for a similar medicinal product for the same indication. An
orphan product can also obtain an additional two years of market exclusivity in the European Union for pediatric studies. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan
indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The criteria for designating an &#147;orphan medicinal product&#148; in the European Union are similar in principle to those
in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1)&nbsp;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition;
(2)&nbsp;either (a)&nbsp;such condition affects no more than five in 10,000 persons in the European Union when the application is made, or (b)&nbsp;the product, without the benefits derived from orphan status, would not generate sufficient return in
the European Union to justify investment; and (3)&nbsp;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the European Union, or if such a method exists, the product will be of
significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing
authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan drug designation must be submitted before the application for marketing authorization. The applicant will receive a fee
reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan drug designation does not convey any
advantage in, or shorten the duration of, the regulatory review and approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">10-year</FONT>
market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the second applicant can establish that its product, although similar, is safer, more effective or otherwise
clinically superior; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicant consents to a second orphan medicinal product application; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicant cannot supply enough orphan medicinal product. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the
conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical
principles that have their origin in the Declaration of Helsinki. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements,
we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to FDA restrictions on marketing of pharmaceutical and biological products, other U.S. federal and state healthcare regulatory laws
restrict business practices in the biopharmaceutical industry, which include, but are not limited to, state and federal anti-kickback, false claims, data privacy and security, and physician payment and drug pricing transparency laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying,
soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any item or service
reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to
arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities
from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not meet the
requirements of a statutory or regulatory exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback
Statute. Instead, the legality of the arrangement will be evaluated on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a cumulative review of all its facts and circumstances. Several
courts have interpreted the statute&#146;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the intent standard under the Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity
does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal
Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. The majority of states also have anti-kickback laws, which establish similar prohibitions and in some cases may apply to items or
services reimbursed by any third-party payor, including commercial insurers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal false claims and civil monetary penalties laws,
including the civil False Claims Act, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false, fictitious or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fraudulent claim for payment to, or approval by, the federal government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim
to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. A claim includes &#147;any request or demand&#148; for money or property presented to the
U.S. government. Actions under the civil False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the civil False Claims Act can result in very significant
monetary penalties and treble damages. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would
bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#146; marketing of products for unapproved (<I> e.g.</I> ,
<FONT STYLE="white-space:nowrap">off-label)</FONT> uses. In addition, the civil monetary penalties statute imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that
the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. Many states also have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid
and other state programs, or, in several states, apply regardless of the payor. Given the significant size of actual and potential settlements, it is expected that the government authorities will continue to devote substantial resources to
investigating healthcare providers&#146; and manufacturers&#146; compliance with applicable fraud and abuse laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Health
Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit
program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying,
concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute,
the ACA broadened the reach of certain criminal healthcare fraud statutes created under HIPAA by amending the intent requirement such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in
order to have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there has been a recent trend of increased federal and state regulation of payments
made to physicians and certain other healthcare providers. The ACA imposed, among other things, new annual reporting requirements through the Physician Payments Sunshine Act for covered manufacturers for certain payments and &#147;transfers of
value&#148; provided to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all
payments, transfers of value and ownership or investment interests may result in civil monetary penalties of up to an aggregate of $150,000 per year and up to an aggregate of $1&nbsp;million per year for &#147;knowing failures.&#148; Covered
manufacturers must submit reports by the 90th&nbsp;day of each subsequent calendar year. In addition, certain states require implementation of compliance programs and compliance with the pharmaceutical industry&#146;s voluntary compliance guidelines
and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices, and/or tracking and reporting of pricing and marketing information as well as gifts, compensation and other remuneration or items
of value provided to physicians and other healthcare professionals and entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also be subject to data privacy and security
regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, impose
specified requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities and their business associates. Among other things, HITECH made HIPAA&#146;s security standards
directly applicable to &#147;business associates,&#148; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf
of a covered entity. HITECH also increased the civil and criminal penalties that may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts
to enforce the federal HIPAA laws and seek attorney&#146;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ
from each other in significant ways and may not have the same requirements, thus complicating compliance efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are
found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement,
contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, reporting obligations and oversight if we
become subject to a corporate integrity agreement or other agreement, and individual imprisonment, any of which could adversely affect our ability to operate our business and our financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that any of our bispecific antibody candidates, once approved, are sold in a foreign country, we may be subject to similar
foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or other
transfers of value to healthcare professionals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Privacy and Data Protection Laws in Europe </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to European laws relating to our and our suppliers&#146;, collaborators&#146; and subcontractors&#146; (where they act as
processors) collection, control, processing and other use of personal data (i.e., any data relating to an identifiable living individual, whether that individual can be identified directly or indirectly). We are subject to the supervision of local
data protection authorities in those jurisdictions where we are established, and where we process personal data in the context of the activities of that establishment (e.g., undertaking clinical trials). We and our suppliers, collaborators and
subcontractors process personal data including in relation to our employees, employees of customers, clinical trial patients, healthcare professionals and employees of suppliers including health and medical information. The data privacy regime in
the EU includes the General Data Protection Regulation, or GDPR, and national laws and regulations implementing or supplementing it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
GDPR requires that personal data is only collected for specified, explicit and legal purposes as set out in the GDPR or local laws, and the data may then only be processed in a manner compatible with those purposes. The personal data collected and
processed must be adequate, relevant and not excessive in relation to the purposes for which it is collected and processed, it must be held securely, not transferred outside of the European Economic Area, or EEA unless certain steps are taken to
ensure an adequate level of protection, and must not be retained for longer than necessary for the purposes for which it was collected. In addition, the GDPR requires companies processing personal data to take certain organizational steps to ensure
that they have adequate records, policies, security, training and governance frameworks in place to ensure, and to be able to demonstrate, protection. For example, the GDPR requires us to make more detailed disclosures to data subjects, requires
disclosure of the legal basis on which we can process personal data, makes it harder for us to obtain valid consent for processing, requires the appointment of a data protection officer where sensitive personal data (i.e., health data) is processed
on a large scale, introduces mandatory data breach notification throughout the EU and imposes additional obligations on us when we are contracting with certain service providers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, to the extent a company processes, controls or otherwise uses &#147;special category&#148; personal data (including
patients&#146; health or medical information, genetic information and biometric information), more stringent rules apply, further limiting the circumstances and the manner in which a company is legally permitted to process that data. The GDPR
provides a broad right for EU member states to create supplemental national laws which may result in divergence across Europe making it harder to maintain a consistent operating model or standard operating procedures. Such laws, for example, may
relate to the processing of health, genetic and biometric data, which could further limit our ability to use and share such data or could cause our costs to increase, and harm our business and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to EU laws on personal data export, as we may transfer personal data
from the EU to other jurisdictions which are not considered by the European Commission to offer &#147;adequate&#148; protection of personal data. Such transfers need to be legitimized by a valid transfer mechanism under the GDPR. There is currently
ongoing litigation challenging the commonly used transfer mechanism, the EU model clauses. In addition, the U.S. Privacy Shield is under review by the European Commission. As such, it is uncertain whether the Privacy Shield framework and/or model
clauses will be invalidated in the near future. Further, the United Kingdom&#146;s decision to leave the EU has created uncertainty with regard to the status of the UK as an &#147;adequate country&#148; for the purposes of data transfers outside the
European Economic Area. In particular, it is unclear how data transfers to and from the UK will be regulated. These changes could require us to make operational changes, including finding alternative bases for the compliant transfer of personal data
from the EEA to the United States, and increased costs and may lead to governmental enforcement actions, litigation, fines and penalties or adverse publicity that could have an adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are costs and administrative burdens associated with compliance with the GDPR and the resultant changes in the EU and EEA member
states&#146; national laws. Any failure or perceived failure to comply with global privacy laws carries with it the risk of significant penalties and sanctions of up to &#128;20&nbsp;million or 4% of global turnover. These laws or new
interpretations, enactments or supplementary forms of these laws, could create liability for us, could impose additional operational requirements on our business, could affect the manner in which we use and transmit patient information and could
increase our cost of doing business. Claims of violations of privacy rights or contractual breaches, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Coverage and Reimbursement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological products for which we obtain
regulatory approval. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of
the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Sales of any products for which we receive regulatory
approval for commercial sale will therefore depend, in part, on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities, managed care plans, private health insurers and other
organizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the process for determining whether a third-party payor will provide coverage for a pharmaceutical
or biological product typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to
specific products on an approved list, also known as a formulary, which might not include all of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products for a particular indication. A decision by a third-party payor not to cover our
bispecific antibody candidates could reduce physician utilization of our products once approved and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a third-party payor&#146;s decision to provide
coverage for a pharmaceutical or biological product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an
appropriate return on our investment in product development. Additionally, coverage and reimbursement for new products can differ significantly from payor to payor. One third-party payor&#146;s decision to cover a particular medical product or
service does not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide
scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
European Union, governments influence the price of products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. To
obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. Other member states allow
companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription products, has become very intense. As a result, increasingly high barriers are
being erected to the entry of new products. In addition, in some countries, cross border imports from <FONT STYLE="white-space:nowrap">low-priced</FONT> markets exert a commercial pressure on pricing within a country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of pharmaceutical or
biological products have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of pharmaceutical or
biological products, medical devices and medical services, in addition to questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our
products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Healthcare Reform
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors
have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products. For example, in March 2010, the ACA was enacted, which, among other things, increased the minimum Medicaid rebates owed by most
manufacturers under the Medicaid Drug Rebate Program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;
extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans; imposed mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers&#146; outpatient
drugs coverage under Medicare Part D; subjected drug manufacturers to new annual fees based on pharmaceutical companies&#146; share of sales to federal healthcare programs; and created a new Patient Centered Outcomes Research Institute to oversee,
identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. The current presidential administration and U.S. Congress will likely continue to seek to modify, repeal, or otherwise invalidate
all, or certain provisions of, the ACA. There have also been judicial challenges to certain aspects of the ACA. For example, on December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, ruled that the individual mandate
is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. While the Trump Administration and the Centers for
Medicare&nbsp;&amp; Medicaid Services, or CMS, have both stated that the ruling will have no immediate effect, it is unclear how this decision, subsequent appeals, if any, will impact the law. The ultimate content, timing or effect of any healthcare
reform legislation on the U.S. healthcare industry is unclear. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that other healthcare reform measures that may be adopted in the
future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria and lower reimbursement, new payment methodologies and additional downward pressure on the price that we receive for any approved
product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. Moreover, recently there has been heightened governmental scrutiny over the manner in which
manufacturers set prices for their marketed products, which have resulted in several recent Congressional inquiries and proposed and enacted legislation designed to, among other things, bring more transparency to product pricing, review the
relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical and biological products. Individual states in the United States have also become increasingly active in
passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. The implementation of cost containment measures or other healthcare
reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, on
August&nbsp;2, 2011, the Budget Control Act of 2011 was enacted, which, among other things, included aggregate reductions of Medicare payments to providers of 2%&nbsp;per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to
subsequent legislative amendments to the statute will stay in effect through 2027 unless additional Congressional action is taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, further
reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts
that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_12"></A>C. Organizational Structure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have one wholly-owned subsidiary, Merus US, Inc., which is incorporated in the United States in the State of Delaware. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_13"></A>D. Property, Plant and Equipment. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We lease approximately 12,320 square meters of office and laboratory space in Utrecht, the Netherlands. This facility serves as our corporate
headquarters and central laboratory facility. The leases for this space expire on October&nbsp;31, 2021. We have also entered into a lease for 7,583 square feet of additional office space in Cambridge, Massachusetts, which commenced on April&nbsp;1,
2019 and has a term of seven years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Environmental Issues </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For information on environmental issues that may affect our utilization of our Dutch facility, please see the section of this Annual Report
titled &#147;Item&nbsp;3.D. Risk Factors&#151;Risks Related to Our Business and Industry&#151;<I></I><I>&#147;</I><I>Because we are subject to environmental, health and safety laws and regulations, we may become exposed to liability and substantial
expenses in connection with environmental compliance or remediation activities which may adversely affect our business and financial condition</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_14"></A>Item&nbsp;4A. Unresolved Staff Comments. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_15"></A>Item&nbsp;5
Operating and Financial Review and Prospects. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_16"></A>A. Operating Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
immuno-oncology company developing innovative bispecific antibody therapeutics. Our pipeline of full-length human bispecific antibody candidates, which we refer to as Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, are generated
from our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform, which is able to generate a diverse array of antibody-heavy chains against virtually any target, paired with a common light chain. Two heavy chains
paired with a common light chain can be combined to produce novel bispecific antibodies that bind a diverse array of targets and display differentiated biology. By binding to two different targets, Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can provide a variety of mechanisms of action. For example, Merus Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can be designed to simultaneously block receptors that drive
tumor cell </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
growth and survival and to mobilize the patient&#146;s immune response by engaging <FONT STYLE="white-space:nowrap">T-cells</FONT> and/or activating various killer cells to eradicate tumors. In
our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, our bispecific antibody candidates killed tumor cells, a result that we believe supports their potential development for the treatment of cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2015, we commenced a Phase 1/2 clinical trial of our most advanced bispecific antibody candidate,
<FONT STYLE="white-space:nowrap">MCLA-128,</FONT> for the treatment of HER2-expressing solid tumors. In January 2018, we dosed the first patient in a Phase 2, open-label, multi-center international clinical trial to evaluate <FONT
STYLE="white-space:nowrap">MCLA-128</FONT> in two metastatic breast cancer, or MBC, populations including HER2-positive MBC patients and hormone receptor <FONT STYLE="white-space:nowrap">positive/HER2-low</FONT> MBC patients. <FONT
STYLE="white-space:nowrap">MCLA-128</FONT> is a full-length IgG bispecific antibody candidate with enhanced antibody-dependent cell-mediated cytotoxicity, or ADCC, targeting HER2 and HER3 receptors. <FONT STYLE="white-space:nowrap">MCLA-128</FONT>
is designed to block the HER3 signaling pathway by employing a DOCK&nbsp;&amp; BLOCK<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> mechanism.
<FONT STYLE="white-space:nowrap">MCLA-128</FONT> is designed to &#147;dock&#148; onto a specific region of the HER2 receptor to orientate <FONT STYLE="white-space:nowrap">MCLA-128&#146;s</FONT> HER3 binding arm to &#147;block&#148; HER2:HER3
heterodimerization. Oncogenic signaling through the HER3 pathway, even in the presence of high heregulin concentrations, may thus be blocked. The Phase 2 clinical trial is designed to observe the activity of this HER2/HER3-targeted candidate in
combination with current standards of care in areas of unmet need. The trial is ongoing and is enrolling patients at sites in the United States and Europe. We plan to provide an update on the Phase 2 clinical trial in the second half of 2019.
Concurrently, our Phase 1/2 clinical trial evaluating single agent activity for <FONT STYLE="white-space:nowrap">MCLA-128</FONT> in gastric cancer and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, or NSCLC, is ongoing. We
reported data from the gastric cancer patient cohort in the single-agent trial of <FONT STYLE="white-space:nowrap">MCLA-128</FONT> at the European Society for Medical Oncology Congress in October 2018. As of February&nbsp;15, 2018, the data showed a
clinical benefit rate of 24% (6 of 25 patients), and that <FONT STYLE="white-space:nowrap">MCLA-128</FONT> was well tolerated with mainly grade 1/2 adverse events observed in patients treated with <FONT STYLE="white-space:nowrap">MCLA-128</FONT>
across all indications explored. Single agent antitumor activity was seen in heavily pretreated gastric/gastro-oesophageal junction, or GC/GEJ, cancer patients progressing on anti-HER2 therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2016, we commenced a Phase 1, <FONT STYLE="white-space:nowrap">single-arm,</FONT> open-label, global clinical trial of our second
bispecific antibody candidate, <FONT STYLE="white-space:nowrap">MCLA-117,</FONT> for the treatment of acute myeloid leukemia, or AML, and we announced the filing of the Investigational New Drug application, or IND, in the United States, or the U.S.,
for <FONT STYLE="white-space:nowrap">MCLA-117</FONT> in 2018 and the subsequent authorization to proceed with clinical studies by the Food and Drug Administration, or the FDA. AML generally has a poor prognosis and limited progress has been made in
disease outcomes despite a growing AML patient population. Clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies suggest that treatment-resistant leukemic stem cells are a potential cause of disease relapse. <FONT
STYLE="white-space:nowrap">MCLA-117</FONT> designed to bind to CD3, a cell-surface molecule present on all <FONT STYLE="white-space:nowrap">T-cells,</FONT> and to CLEC12A, a cell surface molecule present on approximately 90 to 95% of AML tumor cells
and stem cells in newly diagnosed and relapsed patients. <FONT STYLE="white-space:nowrap">MCLA-117</FONT> is designed to recruit and activate <FONT STYLE="white-space:nowrap">T-cells</FONT> to kill AML tumor cells and stem cells. In our <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies, <FONT STYLE="white-space:nowrap">MCLA-117</FONT> killed tumor cells in blood samples of AML patients. We plan to seek orphan drug designation for
<FONT STYLE="white-space:nowrap">MCLA-117</FONT> for the treatment of AML from the FDA and the European Medicines Agency, or the EMA. We are continuing our dose escalation of the Phase 1 clinical trial for
<FONT STYLE="white-space:nowrap">MCLA-117.</FONT> We plan to provide an update on our <FONT STYLE="white-space:nowrap">MCLA-117</FONT> program upon announcement of the maximum tolerated dose for <FONT STYLE="white-space:nowrap">MCLA-117</FONT> and
anticipate data readouts for the Phase 1 clinical trial in the second half of 2019. We also intend to evaluate <FONT STYLE="white-space:nowrap">MCLA-117</FONT> for the treatment of myelodysplastic syndrome. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to <FONT STYLE="white-space:nowrap">MCLA-128</FONT> and <FONT STYLE="white-space:nowrap">MCLA-117,</FONT> we are also developing <FONT
STYLE="white-space:nowrap">MCLA-158,</FONT> a bispecific antibody candidate that is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5, or Lgr5, and epidermal growth factor receptors, or
EGFR, for the potential treatment of solid tumors with an initial focus on metastatic colorectal cancer, and the first Clinical Trials Application to the EMA was approved to initiate a Phase 1 clinical trial in Europe in January 2018. We also filed
an IND for <FONT STYLE="white-space:nowrap">MCLA-158</FONT> with the FDA in the first quarter of 2018, which received authorization to proceed from the FDA in April 2018. In May 2018, we commenced a Phase 1, open-label, multicenter clinical trial of
<FONT STYLE="white-space:nowrap">MCLA-158</FONT> and expect emerging data by the end of 2019. <FONT STYLE="white-space:nowrap">MCLA-158</FONT> is designed to kill cancer stem cells using two different mechanisms of action. The first mechanism of
action involves blocking growth and survival pathways in tumor stem cells. The second mechanism of action involves the recruitment and enhancement of immune effector cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also planning to commence a clinical trial for
<FONT STYLE="white-space:nowrap">MCLA-145,</FONT> which is being developed in collaboration with Incyte Corporation, or Incyte, and is designed to bind to <FONT STYLE="white-space:nowrap">PD-L1</FONT> and CD137. In December 2018, we filed an IND for
<FONT STYLE="white-space:nowrap">MCLA-145</FONT> with the FDA and in January 2019, we received authorization to proceed from the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
also have several other antibody candidates in preclinical development that bind to other target combinations. Each of our antibody candidates in our preclinical and clinical pipeline are designed to bind to targets believed to be useful in the
treatment of cancer with an intention to establish efficacy and obtain information for submission to the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception in June
2003, our initial operations were focused on organizing and staffing our company, business planning, raising capital, and establishing our proprietary Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform technology,
bispecific antibody candidates, and our intellectual property portfolio. In more recent periods, we have devoted a significant portion of our financial resources and efforts to continued development of our Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform, identifying potential bispecific antibody candidates and conducting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and initiating and conducting our clinical
trials of <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT STYLE="white-space:nowrap">MCLA-117</FONT> and <FONT STYLE="white-space:nowrap">MCLA-158,</FONT> and planning to initiate a clinical trial for
<FONT STYLE="white-space:nowrap">MCLA-145.</FONT> We do not currently have any approved products and have never generated any revenue from product sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have financed our operations primarily through (i)&nbsp;the initial public offering of our common shares, (ii)&nbsp;a public placement of
equity securities with Incyte (iii)&nbsp;upfront and milestone payments received from Incyte, ONO Pharmaceutical Co., Ltd., or Ono, and Simcere Pharmaceutical Group, or Simcere, (iv)&nbsp;a private placement of common shares on February&nbsp;15,
2018, and (v)&nbsp;a public placement of equity securities with Regeneron Pharmaceuticals Inc. or Regeneron. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;6, 2016, the
general meeting of our shareholders resolved to approve and effect a capital reorganization, based on a reverse share split. The effect of the reverse share split was a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-1.8</FONT></FONT> reverse share split of the outstanding common and preferred shares held by our shareholders. This reverse share split became effective on May&nbsp;6, 2016. All
share, <FONT STYLE="white-space:nowrap">per-share</FONT> and related information presented in the financial statements and corresponding disclosure notes have been retrospectively adjusted, where applicable, to reflect the impact of the reverse
share split. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2016, we completed the initial public offering of our common shares, or the IPO, and issued 6,139,926 common shares,
including 639,926 common shares issued upon the partial exercise of the underwriters of their option to purchase additional shares, for net proceeds to us, after deducting underwriting discounts and commissions and offering expenses, of
$53.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, we issued and sold an aggregate of 3,099,997 of our common shares to certain new and existing
investors for aggregate gross proceeds of approximately $55.8&nbsp;million, or &#128;44.8&nbsp;million, at a purchase price of $18.0 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2016, we entered into a collaboration and license agreement with Incyte, or the Incyte collaboration and license agreement. Under
the terms of the Incyte collaboration and license agreement, we and Incyte agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing our proprietary bispecific technology platform. The
collaboration encompasses up to 11 independent programs, including two of our current preclinical immuno-oncology discovery programs. In January 2017, upon the Incyte collaboration and license agreement becoming effective, Incyte made an upfront <FONT
STYLE="white-space:nowrap">non-refundable</FONT> payment to us of $120.0&nbsp;million, or &#128;112.0&nbsp;million. For more on the Incyte collaboration and license agreement, see &#147;Collaboration Agreements&#148; below. In connection with the
Incyte collaboration and license agreement, we entered into a Share Subscription Agreement, pursuant to which, in January 2017, we issued and sold to Incyte 3,200,000 common shares for an aggregate purchase price of $80.0&nbsp;million, or
&#128;74.7&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2018, we issued and sold an aggregate of 600,000 shares to Regeneron Pharmaceuticals, Inc., or
Regeneron, in connection with our settlement of certain litigation and administrative opposition proceedings </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with Regeneron for aggregate gross proceeds of $15.0&nbsp;million, or &#128;13.1&nbsp;million. Accordingly, we recorded the common shares issued at the fair value of the underlying securities on
the date of issuance. The difference between the total proceeds received of $15.0&nbsp;million, or &#128;13.1&nbsp;million, and the aggregate value of common shares issued of $6.9&nbsp;million, or &#128;6.0&nbsp;million, was recorded as a gain on
litigation settlement of $8.1&nbsp;million, or &#128;7.1&nbsp;million, during the year-ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2018, we held cash and cash equivalents of &#128;143.7&nbsp;million and investments of &#128;61.8&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
a clinical-stage company and have not generated any revenue from product sales. We expect to incur significant expenses and operating losses for the foreseeable future as we advance our bispecific antibody candidates from discovery through <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development and into clinical trials, and seek regulatory approval and pursue commercialization of any approved bispecific antibody candidate. In addition, if we obtain regulatory approval for any of
our bispecific antibody candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. We expect to incur expenses in connection with the
<FONT STYLE="white-space:nowrap">in-license</FONT> or acquisition of additional bispecific antibody candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that we
will require additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity or debt
financings or other sources, which may include collaborations and business development opportunities with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and
when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenue to achieve profitability, and we may never do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we expect that our existing cash, cash equivalents and investments as of December&nbsp;31, 2018 will be
sufficient to fund our operations into the second quarter of 2021. For this assessment we have taken into consideration our existing cash and cash equivalents of &#128;143.7&nbsp;million and investments of &#128;61.8&nbsp;million as of
December&nbsp;31, 2018. See &#147;Item 5.B&#151;Liquidity and Capital Resources.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration and Other Revenue Generating Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our business strategy, we intend to continue to seek strategic collaborations to facilitate the capital-efficient development of our
Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform and to identify potential target combinations in immuno-oncology and other therapeutic areas. We believe that these collaborations could potentially provide
significant funding to advance our antibody candidate pipeline while allowing us to benefit from the development expertise of our collaborators. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incyte Corporation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
entered into the Incyte collaboration and license agreement with Incyte. Under the terms of the Incyte collaboration and license agreement, we and Incyte have agreed to collaborate with respect to the research, discovery and development of
bispecific antibodies utilizing our proprietary bispecific technology platform. The collaboration encompasses up to 11 independent programs, including some of our current preclinical immuno-oncology discovery programs. For one of the current
preclinical programs concerning <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> we retain the exclusive right to develop and commercialize products and product candidates in the U.S., while Incyte has the exclusive right to develop and
commercialize products and product candidates arising from such program outside the U.S. For <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> we and Incyte will conduct and share equally the costs of mutually agreed global development activities
and will be solely responsible for independent development activities in our respective territories. We have the option to <FONT STYLE="white-space:nowrap">co-fund</FONT> development of products arising from one specified program, and subject to
certain conditions, to a second specified program, in each case exchange for a share of profits in the U.S., as well as the right to participate in a specified proportion of detailing activities in the U.S. for one of such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
programs. If we exercise our <FONT STYLE="white-space:nowrap">co-funding</FONT> option for a program, we would be responsible for funding 35% of the associated future global development costs
and, for certain of such programs, would be responsible for reimbursing Incyte for certain development costs incurred prior to the option exercise. All products as to which we have exercised our option to
<FONT STYLE="white-space:nowrap">co-fund</FONT> development would be subject to joint development plans and overseen by a joint development committee, with Incyte having final determination as to such plans in cases of dispute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each program other than <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> where we have not elected to
<FONT STYLE="white-space:nowrap">co-fund</FONT> development or where we do not have such a <FONT STYLE="white-space:nowrap">co-funding</FONT> option, Incyte is solely responsible for all costs of global development and commercialization activities.
We retain the rights to our technology platform as well as clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> candidates and future programs emerging from our platform that are outside the scope of the Incyte collaboration and license
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2017, upon the Collaboration Agreement becoming effective, Incyte made an upfront
<FONT STYLE="white-space:nowrap">non-refundable</FONT> payment to us of $120.0&nbsp;million, or &#128;112.0&nbsp;million, for the rights granted under the Collaboration Agreement. For each program as to which we do not have commercialization or <FONT
STYLE="white-space:nowrap">co-development</FONT> rights, we are eligible to receive up to $100.0&nbsp;million in future contingent development and regulatory milestones and up to $250.0&nbsp;million in commercialization milestones, as well as tiered
royalties ranging from 6% to 10% of global net sales. For each program as to which we have exercised our option to <FONT STYLE="white-space:nowrap">co-fund</FONT> development, we are eligible to receive a 50% share of profits (or sustain 50% of any
losses) in the U.S. and tiered royalties ranging from 6% to 10% of net sales of products outside of the U.S. If we opt to cease <FONT STYLE="white-space:nowrap">co-funding</FONT> a program as to which we exercised our
<FONT STYLE="white-space:nowrap">co-development</FONT> option, then we will no longer receive a share of profits in the U.S. but will be eligible to receive the same milestones from the <FONT STYLE="white-space:nowrap">co-funding</FONT> termination
date and the same tiered royalties described above with respect to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-co-developed</FONT></FONT> programs and, depending on the stage at which we choose to cease <FONT
STYLE="white-space:nowrap">co-funding</FONT> development costs, additional royalties ranging up to 4% of net sales in the U.S.. For <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> for which we retain all commercial rights in the U.S., we and
Incyte are each eligible to receive tiered royalties on net sales in the other&#146;s territory at rates ranging from 6% to 10%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Incyte collaboration and license agreement will continue on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis until neither party has any royalty payment obligations with respect to such
program or, if earlier, the termination of the Incyte collaboration and license agreement or any program in accordance with the terms of the Incyte collaboration and license agreement. The Incyte collaboration and license agreement may be terminated
in its entirety, or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis, by Incyte for convenience. The Incyte collaboration and license agreement may also be terminated by either party under
certain other circumstances, including material breach, or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis for patent challenge of patents under the applicable program, in each case as
set forth in the Incyte collaboration and license agreement. If the Incyte collaboration and license agreement is terminated in its entirety or with respect to one or more programs, all rights in the terminated programs revert to us, subject to
payment to Incyte of a reverse royalty of up to 4% on sales of future products, if we elect to pursue development and commercialization of products arising from the terminated programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Incyte collaboration and license agreement, we entered into a Share Subscription Agreement with Incyte, pursuant to
which, in January 2017, we issued and sold to Incyte 3,200,000 common shares for an aggregate purchase price of $80.0&nbsp;million, or &#128;74.7&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with International Financial Reporting Standards, or IFRS, 15, <I>Revenue from Contracts with Customers</I>, or IFRS 15, and the
prior revenue guidance, we combined the Incyte collaboration and license agreement and Share Subscription Agreement and accounted for them as a single contract based on the following criteria: (i)&nbsp;they were entered into at the same time with
the same customer; (ii)&nbsp;the arrangements&#146; mutual existence is acknowledged in the separate agreements; and (iii)&nbsp;they were negotiated as a package with a single commercial objective. As a result, our fixed consideration pursuant to
the arrangement with Incyte is $152.6&nbsp;million, consisting of the $120.0&nbsp;million, or &#128;112.0&nbsp;million, <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront fee from the Incyte collaboration and license agreement and
$32.6&nbsp;million, or &#128;31.4&nbsp;million, in consideration from the issuance and sale of common shares pursuant to the Share Subscription Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ONO Pharmaceutical </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, we entered into a strategic research and license agreement with ONO, under which we granted ONO an exclusive, worldwide,
royalty-bearing license to research, test, make, use and market bispecific antibody candidates based on our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform with undisclosed targets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ONO paid us a <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront fee of &#128;1.0&nbsp;million. We are eligible to receive up to
an aggregate of &#128;57.0&nbsp;million in milestone payments upon achievement of specified research and clinical development milestones. To date, we have achieved four of the specified <FONT STYLE="white-space:nowrap">pre-clinical</FONT> milestones
under this research and license agreement and have received an aggregate of &#128;2.7&nbsp;million in milestone payments. For products commercialized under this agreement, if any, we are also eligible to receive a
<FONT STYLE="white-space:nowrap">mid-single</FONT> digit royalty on net sales. For a designated period, which may include limited time periods following termination of this agreement, in certain circumstances we and our affiliates are prohibited
from researching, developing or commercializing bispecific antibodies against the undisclosed target combinations that are the subject of this agreement. This research and license agreement will expire after all milestone payments have been received
and all related patent rights have expired, unless terminated earlier. ONO also provides funding for our research and development activities under an agreed-upon plan. ONO has the right to terminate this agreement at any time for any reason, with or
without cause. The licenses granted to ONO may convert to royalty-free, fully-paid, perpetual licenses if ONO terminates the agreement for uncured material breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2016, we entered into a separate agreement to provide chemistry, manufacturing and controls, or CMC, services to ONO. In
consideration of the performance of the CMC services, ONO agreed to pay fees of &#128;1.4&nbsp;million for full-time equivalent reimbursement and an aggregate of &#128;3.0&nbsp;million of milestone payments for the delivery of a master cell bank,
delivery of toxicology drug product, and delivery of GMP drug product. During 2018, we achieved all three of the milestones and received an aggregate of &#128;3.0&nbsp;million in milestone payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;14, 2018, we entered into a second contract research and license agreement with ONO. Pursuant to an exclusive option granted to
ONO in a prior agreement executed in April 2014, ONO exercised its option to enter into the March 2018 agreement. We granted ONO an exclusive, worldwide, royalty-bearing license, with the right to sublicense, research, test, make, use and market
bispecific antibody candidates based on our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform against two undisclosed targets directed to a particular undisclosed target combination. ONO identifies and selects
the licensed bispecific antibodies for which it is responsible for conducting further <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical development activities for such licensed bispecific antibodies and pharmaceutical products
containing such antibodies, including manufacture and process development. ONO controls and has exclusive rights over the worldwide commercialization of any approved products, including worldwide supply, and is solely responsible for all costs and
expenses related to commercialization. ONO has agreed to fund our research and development activities and be responsible for the payment of all costs and expenses for its own research and development activities, which are set out in a mutually
agreed upon research plan. We retain all rights to use and commercialize any antibodies that are generated under the collaborative research program, excluding the up to five lead and/or selected antibodies against the targets ONO is pursuing,
provided that the use and commercialization is not with respect to the particular target combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ONO has agreed to pay an upfront <FONT
STYLE="white-space:nowrap">non-refundable</FONT> payment of &#128;700,000 for the rights granted and we are also eligible to receive an aggregate of &#128;57.0&nbsp;million in milestone payments upon achievement of specified research and clinical
development milestones. For products commercialized under the License Agreement, if any, the Company is eligible to receive a <FONT STYLE="white-space:nowrap">mid-single</FONT> digit royalty on net sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a designated period, which may include limited time periods following termination of this agreement, in certain circumstances we are
prohibited from researching, developing or commercializing bispecific antibodies against the undisclosed target combination that are the subject of this agreement. ONO also provides funding for our research and development activities under an
agreed-upon plan. This research and license agreement will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expire after all milestone payments have been received and all related patent rights have expired, unless terminated earlier. ONO has the right to terminate this agreement at any time for any
reason, with or without cause. The licenses granted to ONO may convert to royalty-free, fully-paid, perpetual licenses if ONO terminates the agreement for uncured material breach. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Simcere Pharmaceutical Group </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;8, 2018, we entered into an agreement with Simcere granting Simcere an exclusive license to develop and commercialize in China three bispecific antibodies to be produced by us utilizing our proprietary Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform in the area of immuno-oncology. We will retain all rights outside of China. Under the terms of the agreement, we have agreed to lead research and discovery activities, while
Simcere has agreed to be responsible for the <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, clinical development, regulatory filings and commercialization of these product candidates in China. As a key strategic component of the
collaboration, Simcere will be responsible for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and manufacturing of clinical trial materials in China, which we intend to use to assist regulatory filing and early stage clinical
development in the rest of the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We received an upfront, <FONT STYLE="white-space:nowrap">non-refundable</FONT> payment of
$2.75&nbsp;million, or &#128;2.3&nbsp;million, relating to three separate research programs. We are eligible to receive up to an aggregate of $52.2&nbsp;million, or &#128;45.6&nbsp;million, in milestone payments contingent upon Simcere achieving
certain specified development and commercial goals. To date, we have achieved one milestone under this agreement and have received an aggregate of $0.8&nbsp;million, or &#128;0.6&nbsp;million, in milestone payments. We will be eligible to receive
tiered royalty payments on sales of any products resulting from the collaboration in China from Simcere. Simcere will be eligible to receive tiered royalty payments on sales outside of China from us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Betta Pharmaceuticals Co. Ltd. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;10, 2018, we entered into a collaboration and license agreement with Betta Pharmaceuticals Co. Ltd., or Betta, where we granted Betta an exclusive license to develop and commercialize in China
<FONT STYLE="white-space:nowrap">MCLA-129,</FONT> a proprietary Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> produced by our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform. We retain
all rights outside of China. Under the terms of the agreement, Betta has agreed to retain a contract manufacturing organization with experience in filing IND applications with U.S. regulatory authorities and CTAs with European regulatory authorities
in order to produce clinical trial materials for the Chinese market and rest of the world. As a key strategic component of the collaboration, Betta will be responsible for IND enabling studies and manufacturing of clinical trial materials in China,
which we intend to use to assist regulatory filing and early stage clinical development in the rest of the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to a <FONT
STYLE="white-space:nowrap">non-refundable</FONT> upfront payment of $1.0&nbsp;million, or &#128;0.9&nbsp;million, we and Betta will share equally the cost of the transfer of the manufacturing technology to a contract manufacturing organization. We
are also eligible to receive an aggregate of $12.0&nbsp;million, or &#128;10.5&nbsp;million in milestone payments contingent upon Betta achieving certain specified development and commercial goals. We are also eligible to receive from Betta tiered
royalty payments of net sales of any products resulting from the collaboration in China. Betta is eligible to receive from us an aggregate of $12.0&nbsp;million, or &#128;10.5&nbsp;million, in milestone payments contingent upon us achieving certain
specified development and commercial goals, and is eligible to receive tiered royalty payments of net sales outside of China. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Operations
Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date,
our revenue has consisted principally of the amortization of <FONT STYLE="white-space:nowrap">up-front</FONT> payments and milestones as well as cost reimbursements in support of our license and collaboration agreements and revenue from several
government grants, primarily with respect to research and development activities related to the use of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology in various indication areas. We have no products approved for sale. We do not expect to receive any revenue from any
bispecific antibody candidates that we develop, including <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT STYLE="white-space:nowrap">MCLA-117</FONT> and <FONT STYLE="white-space:nowrap">MCLA-158</FONT> which we intend to commence development
including <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> and our preclinical bispecific antibody candidates until we obtain regulatory approval and commercialize such products, or until we potentially enter into collaborative agreements with
third parties for the development and commercialization of such candidates. Our ability to generate revenue for each product candidate for which we receive regulatory approval will depend on numerous factors, including competition, commercial
manufacturing capability and market acceptance of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have derived the majority of our revenue to date from research,
collaboration and license agreements with Incyte, ONO, Simcere and Betta. These agreements contain multiple promised goods and services, including license rights to certain of our product candidates and research and development services. The terms
of these arrangements typically include payment of one or more of the following: <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront fees; reimbursement of research and development costs; development, regulatory, and commercial milestone
payments; and royalties on net sales of licensed products, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective January&nbsp;1, 2018, we adopted IFRS 15 using the
retrospective method, with the effect of initially applying this standard recognized at the beginning of the earliest period presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had two open contracts on the adoption date and have assessed these contracts under the new revenue standard. In addition, we elected to
apply the practical expedient to not apply this guidance to contracts that were completed before the beginning of the earliest period presented, or January&nbsp;1, 2016, and the practical expedients for contract modifications (assessing the
contracts in combination with any modifications before January&nbsp;1, 2016). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adoption of IFRS 15 impacted the amortization of our
upfront license payments under the collaboration and license agreement entered into with Incyte on December&nbsp;20, 2016 and under the research and license agreement entered into with ONO on April&nbsp;8, 2014. We previously recognized revenue from
upfront license payments on a straight-line basis over the contractual term or the period of continuing managerial involvement, which was previously estimated to be 21 years for the Incyte collaboration and license agreement and 4.5 years for the
ONO research and license agreement. Upon adoption of IFRS 15, we assessed the goods and services promised under the Incyte collaboration and license agreement and identified only one performance obligation to which the transaction price was
allocated &#150; a license to our proprietary technology combined with the joint steering committee, or JSC, services during the research term. The transfer of the license and the JSC participation represented one combined performance obligation
since they were not deemed distinct. As a result, under IFRS 15, revenue from upfront license payments under the Incyte collaboration and license agreement will be recognized as we satisfy the combined performance obligation, or over the nine-year
research term, which is a period during which we have a present enforceable obligation to provide JSC services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the
adoption of IFRS 15, our prior years&#146; consolidated financial statements have been restated. We adopted the new standard using the retrospective method. The impact of adopting IFRS 15 resulted in a decrease of approximately
&#128;8.7&nbsp;million to deferred revenue with an offset to accumulated deficit, effective January&nbsp;1, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under IFRS 15, revenue
from contracts with customers, including contracts from Incyte, Simcere, Ono and Betta, is recognized when our customer obtains control of the promised goods or services, in an amount that reflects the consideration that we had determined to expect
to receive in exchange for those goods or services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Up-front</FONT> License Payments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement,
we recognize revenue allocated to the license when the license is transferred to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
customer and the customer is able to use and benefit from the license. For licenses that are not distinct and bundled with other performance obligations, we utilize judgment to assess the nature
of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the
combined performance obligation. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Revenue attributable to the amortization of upfront license payments
relates to the contracts with Incyte, Ono, Simcere and Betta. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Milestones </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the inception of each arrangement that includes <FONT STYLE="white-space:nowrap">pre-commercial</FONT> milestone payments, we evaluate
whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant cumulative revenue reversal would not occur,
the associated milestone value is included in the transaction price. Milestone payments that are not within our control, such as regulatory approvals, are not considered probable of being achieved until the uncertainty related to the milestone is
resolved. The transaction price is then allocated to each performance obligation on a relative selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. Any such adjustments affect
revenue in the period of adjustment. At the end of each subsequent reporting period, we reevaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall
transaction price. Revenue attributable to milestones or the amortization of milestones relates to the contracts with Ono and Simcere. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and
Development Cost Reimbursement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development cost reimbursement revenue, which is typically related to reimbursements from
collaborators for our performance of research and development services under the respective agreements, is recognized on the basis of labor hours valued at a contractually agreed rate. Research and development cost reimbursement revenue also
includes reimbursements for related <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses and third-party costs. Research and development cost reimbursement revenue is recognized in the same period as
the costs for which they are intended to compensate. We typically act as the principal under such arrangements and, therefore, record these reimbursements on a gross basis. Revenue attributable to research and development cost reimbursement relates
to the contracts with Incyte and Ono. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Government Grants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also receive certain government and regional grants, which support our research efforts in defined projects, and include contributions
towards the research and development cost. When there is reasonable assurance that the Company will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, government grants
are recognized as revenue on a gross basis on a systematic basis over the periods in which the Company recognizes expenses for the related costs for which the grants are intended to compensate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs consist principally of the costs associated with our research and development activities, conducting preclinical
studies and clinical trials and activities related to our regulatory filings. Our research and development expenses consist of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">salaries for research and development staff and related expenses, including share-based compensation expenses;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with contract research organizations, or CROs, contract manufacturing
organizations, and consultants that conduct and support clinical trials and preclinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to develop product candidates, including raw materials and supplies, product testing, and facility related
expenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with obtaining and maintaining patents and other intellectual property; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amortization and depreciation of tangible and intangible fixed assets used to develop our product candidates.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense research and development costs when we incur them. We record costs for certain development activities, such
as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information our vendors provide to us. We expense the manufacturing costs of our
internally-developed product candidates that are used in clinical trials as they are incurred, as research and development expense. We do not allocate employee-related costs, depreciation, rental and other indirect costs to specific research and
development programs because these costs are deployed across multiple programs under research and development and, as such, are separately classified as unallocated research and development expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses are expected to increase as we advance the clinical development of
<FONT STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT STYLE="white-space:nowrap">MCLA-117</FONT> and <FONT STYLE="white-space:nowrap">MCLA-158</FONT> and, in collaboration with Incyte, <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> and further
advance the research and development of our preclinical bispecific antibody candidates and other earlier stage products. In January 2019, the FDA accepted our IND application for <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> our most advanced
drug candidate in our collaboration and license agreement with Incyte. The successful development of our bispecific antibody candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing and estimated costs of the
efforts that will be necessary to complete the development of, or the period, if any, in which material net cash inflows may commence from, any of our bispecific antibody candidates. This is due to numerous risks and uncertainties associated with
developing drugs, including the uncertainty of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, rate of progress and expense of our research and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials and early-stage results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and timing of regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expense of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to market, commercialize and achieve market acceptance for
<FONT STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT STYLE="white-space:nowrap">MCLA-117,</FONT> <FONT STYLE="white-space:nowrap">MCLA-158</FONT> and <FONT STYLE="white-space:nowrap">MCLA-145</FONT> or any other bispecific antibody candidate that
we may develop in the future. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the development of any
of our antibody candidates would significantly change the costs, timing and viability associated with the development of that antibody candidate. For example, if the FDA, the EMA or other regulatory authority were to require us to conduct
preclinical and clinical studies beyond those which we currently anticipate will be required for the completion of clinical development or if we experience significant delays in enrollment in any clinical trials, we could be required to expend
significant additional financial resources and time on the completion of our clinical development programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development
activities are central to our business model. We expect research and development costs to increase significantly for the foreseeable future as our development programs progress, as we continue to support the clinical trials of our bispecific
antibody candidates as treatments for various cancers and as we move these candidates into additional clinical trials. There are numerous factors associated with the successful </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialization of any of our bispecific antibody candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time
based on our stage of development. Additionally, future commercial and regulatory factors beyond our control may impact our clinical development programs and plans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management and Administration Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management and administration costs consist principally of salaries and related expenses for employees other than research and development
staff, including employees in finance, legal, human resources, investor relations and business development functions. These costs include all salary, salary-related expenses and share-based compensation expenses. We expect that our management and
administration costs will increase in the future as our business expands and we increase our headcount to support the expected growth in our operating activities and public company requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other expenses
consist principally of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">professional fees for auditing and tax services and consulting expenses not related to research and development
activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">professional fees for legal services, including litigation costs, not related to the protection and maintenance
of our intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost of facilities, communication and office expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">board of director fees and corresponding share-based compensation expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information technology services and cybersecurity enhancements, investigations or remediations; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amortization and depreciation of tangible and intangible fixed assets not related to research and development
activities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our other expenses will increase in the future as we expand our operating activities and we
continue to incur additional costs associated with operating as a public company. We expect other expenses to increase in future periods to support our research and development efforts, including the continuation of the clinical trials of our
bispecific antibody candidates as treatments for various cancers and the initiation of clinical trials for potential new antibody candidates. These cost increases will likely be due to increased headcount, expanded infrastructure and increased costs
for insurance. Public company-related expense increases will include costs of additional legal fees, accounting, tax and audit fees, consulting fees, director and officer liability insurance premiums and costs related to investor relations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other
income consists of a gain recorded in connection with our settlement of certain litigation with Regeneron. On December&nbsp;20, 2018, we signed a global settlement and cross-license agreement with Regeneron, where the parties have agreed to end all
pending litigation and administrative, opposition proceedings pertaining to our and Regeneron&#146;s respective antibody generation technologies. Regeneron also purchased 600,000 of our common shares at a price of $25.0 per share for total aggregate
proceeds of $15.0&nbsp;million, or &#128;13.1&nbsp;million. Accordingly, we recorded the common shares issued at the fair value of the underlying securities on the date of issuance. The difference between the total proceeds received of
$15.0&nbsp;million, or &#128;13.1&nbsp;million, and the aggregate value of common shares issued of $6.9&nbsp;million, or &#128;6.0&nbsp;million, was recorded as a gain on litigation settlement of $8.1&nbsp;million, or &#128;7.1&nbsp;million, during
the year-ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finance income consists of interest earned on our cash and cash equivalents held on account,
accretion of investment earnings and net foreign exchange gains on our U.S. dollar denominated cash, cash equivalents and investments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finance expenses consist of net foreign exchange losses on our U.S. dollar denominated cash,
cash equivalents and investments, interest and related expenses for the settlement of our forward contract for the Share Subscription Agreement with Incyte and interest accrued on our formerly outstanding indebtedness and financing costs associated
with our registration statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of Years Ended December&nbsp;31, 2018 and 2017 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The below table summarizes our results of operations for the years ended December&nbsp;31, 2018 and 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">31,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">21,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">9,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-24</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,847</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-151</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Result after taxation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-62</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,450</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>See Note 4 to our consolidated financial statements found at the end of this annual report for details
regarding the restatement as a result of a change in accounting policy.</I></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><A HREF="#tx696632_70">Revenue</A> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total revenue increased by &#128;9.5&nbsp;million to &#128;31.4&nbsp;million for the year ended December&nbsp;31, 2018, from
&#128;21.9&nbsp;million for the year ended December&nbsp;31, 2017. The increase in total revenue is primarily attributable to the amortization of upfront license payments and milestone payments and an increase in R&amp;D cost reimbursement revenue.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenues are generated entirely in the Netherlands. In the following table, revenue is disaggregated by primary source of revenue as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upfront payment amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">17,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D cost reimbursement and milestone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from contracts with customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from grants on research projects</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-84</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">31,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">21,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">9,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>See Note 4 to our consolidated financial statements found at the end of this annual report for details
regarding the restatement as a result of a change in accounting policy </I></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upfront payment amortization increased by &#128;2.8&nbsp;million to &#128;17.7&nbsp;million
for the year ended December&nbsp;31, 2018, from &#128;14.9&nbsp;million for the year ended December&nbsp;31, 2017. For the year ended December&nbsp;31, 2018, we recognized amortization of &#128;15.9&nbsp;million on upfront payments related to the
Incyte collaboration and license agreement, amortization of &#128;1.2&nbsp;million on upfront payments related to the second ONO research and license agreement, &#128;0.5&nbsp;million on upfront payments related to the Simcere collaboration and
license agreement and less than &#128;0.1&nbsp;million on the upfront payment related to the Betta collaboration and license agreement. For the year ended December&nbsp;31, 2017, we recognized &#128;14.9&nbsp;million of amortization of the upfront
payment related to the Incyte collaboration and license agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">R&amp;D cost reimbursement and milestone revenue for the year ended
December&nbsp;31, 2018, was &#128;13.6&nbsp;million and consisted of cost reimbursements, milestone payment amortization and research milestones achieved in support of our research and license agreements with Incyte, ONO and Simcere. During the year
ended December, 2018, we recognized &#128;8.8&nbsp;million of cost reimbursements in support of our research and license agreements with Incyte and &#128;0.4&nbsp;million of cost reimbursements in support of our research and license agreements with
ONO. We recognized an aggregate of &#128;4.0&nbsp;million in research milestones under our ONO agreements for the year ended December&nbsp;31, 2018 and &#128;0.4&nbsp;million in research milestone payment amortization under our Simcere agreements
for the year ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">R&amp;D cost reimbursement and milestone revenue for the year ended December&nbsp;31, 2017 was
&#128;5.8&nbsp;million and consisted of cost reimbursements in support of our research and license agreements with Incyte and ONO. We did not recognize any research milestones during 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2018, we recognized &#128;0.2&nbsp;million in grant income compared to &#128;1.2&nbsp;million in grant income for the year ended
December&nbsp;31, 2017. On June&nbsp;12, 2017, the European Commission approved for reimbursement the final installment of the <FONT STYLE="white-space:nowrap">FP-7</FONT> grant for &#128;0.7&nbsp;million. Revenue for this final installment was
recorded in income from grants on research projects during the year ended December&nbsp;31, 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">46,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">34,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">12,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs increased &#128;12.6&nbsp;million, or 37%, to &#128;46.7&nbsp;million for the
year ended December&nbsp;31, 2018, from &#128;34.1&nbsp;million for the year ended December&nbsp;31, 2017. The increase was primarily due to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;10.1&nbsp;million increase in spending for our <FONT STYLE="white-space:nowrap">MCLA-128</FONT> program in
support of our ongoing clinical trials as well as higher costs in our preclinical and discovery programs associated with development, manufacturing and production design activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;4.1&nbsp;million increase in for our <FONT STYLE="white-space:nowrap">MCLA-145</FONT> program associated
with manufacturing and production activities to support the planned initiation of our Phase I clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;4.4&nbsp;million decrease in expenses associated with manufacturing activities for <FONT
STYLE="white-space:nowrap">MCLA-158</FONT> and <FONT STYLE="white-space:nowrap">MCLA-117,</FONT> partially offset by an increase in ongoing clinical costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Increase of &#128;1.1&nbsp;million for conducting research and development, preclinical, manufacturing and
production design in connection with various preclinical and discovery programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;1.6&nbsp;million increase in employee salary and related benefits attributable to the hiring of more
development personnel and an increase of &#128;0.7&nbsp;million of subsidies under the Wet Bevordering Speur- &amp; Ontwikkelingswerk Act, or WBSO Act, partially offset by a &#128;0.5&nbsp;million decrease in share-based compensation expenses; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;1.3&nbsp;million increase in costs related to other research and development expenses not allocated to
projects, including depreciation of lab equipment and increased lab supplies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses may
vary substantially from period to period based on the timing of our research and development activities, including due to timing of initiation of clinical trials and enrollment of patients in clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management and Administration Costs </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">13,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-24</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management and administration costs decreased &#128;3.3&nbsp;million, or 24%, during the year ended
December&nbsp;31, 2018 as compared to the year ended December&nbsp;31, 2017. The decrease was primarily attributable to lower share-based compensation expenses of &#128;4.2&nbsp;million, partially offset by an increase in headcount in finance, legal
and business development functions to support the expansion of our operations, which resulted in an increase in salary and related expenses of &#128;0.9&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Expenses </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">13,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">9,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other expenses increased &#128;3.8&nbsp;million, or 40%, during the year ended December&nbsp;31, 2018 as
compared to the year ended December&nbsp;31, 2017. The increase was due to an increase in consulting, accounting and professional fees of &#128;2.3&nbsp;million in support of maintaining a public company status, an increase in facilities expenses of
&#128;1.3&nbsp;million in support of higher headcount, an increase in legal expenses of &#128;0.4&nbsp;million related to the litigation and opposition costs related to certain litigation with Regeneron, which was settled in December 2018, partially
offset by a decrease in travel expenses of &#128;0.2&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and similar related income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net gain on foreign exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">6,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">605</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-98</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss on foreign exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative financial instrument expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-151</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finance income increased &#128;6.7&nbsp;million, or 605%, during the year ended
December&nbsp;31, 2018 as compared to the year ended December&nbsp;31, 2017. This increase was due to foreign exchange gains on our U.S. dollar denominated cash, cash equivalents and investments of approximately &#128;6.0&nbsp;million due to a
weakening U.S. dollar relative to the euro during 2018. As of December&nbsp;31, 2018, we held approximately $49.3&nbsp;million and $70.8&nbsp;million in U.S. dollar denominated cash and cash equivalent accounts and investment accounts, respectively,
subject to the fluctuation in foreign currency between the euro and U.S. dollar. Interest income primarily results from interest earned on cash held on account and accretion of investment earnings. Our current year increase in cash, cash equivalents
and investments was due primarily to $55.8&nbsp;million of funds received as part of the private placement of common shares during the first quarter of 2018 as well as $15.0&nbsp;million of funds received as part of the Regeneron Share Subscription
Agreement during the fourth quarter of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income for the year ended December&nbsp;31, 2018 included a gain of
&#128;7.1&nbsp;million related to our settlement of certain litigation with Regeneron. On December&nbsp;20, 2018, we signed a global settlement and cross-license agreement with Regeneron, where the parties have agreed to end all pending litigation
and opposition proceedings pertaining to our and Regeneron&#146;s respective antibody generation technologies. Regeneron also purchased 600,000 of our common shares at a price of $25.0 per share. Accordingly, we recorded the common shares issued at
the fair value of the underlying securities on the date of issuance. The difference between the total proceeds received of $15.0&nbsp;million, or &#128;13.1&nbsp;million, and the aggregate value of common shares issued of $6.9&nbsp;million, or
&#128;6.0&nbsp;million, was recorded as a gain on litigation settlement of $8.1&nbsp;million, or &#128;7.1&nbsp;million, during the year-ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finance costs for the year ended December&nbsp;31, 2017 included an amount of &#128;10.7&nbsp;million related to the effective settlement, on
January&nbsp;23, 2017, of the forward contract related to the Share Subscription Agreement with Incyte. During the year ended December&nbsp;31, 2017, we also expensed &#128;0.2&nbsp;million of prepaid share issuance costs related to a potential
future issuance of shares under the Company&#146;s <FONT STYLE="white-space:nowrap">F-3</FONT> Registration Statement when the future issuance was no longer consider probable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We experienced increased losses on our U.S. dollar denominated cash, cash equivalents and investments of approximately &#128;19.1&nbsp;million
during 2017. As of December&nbsp;31, 2017, we held approximately $98.0&nbsp;million and $49.4&nbsp;million in U.S. dollar denominated cash and cash equivalent accounts and investment accounts, respectively, subject to the fluctuation in foreign
currency between the euro and U.S. dollar. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Tax Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax expenses were &#128;0.4&nbsp;million and &#128;0.2&nbsp;million for the years ended December&nbsp;31, 2018 and 2017, respectively.
Current-year income tax expense was attributable to our U.S. operating subsidiary, which was established in February 2016 to provide general management services and strategic advisory services to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of Years Ended December&nbsp;31, 2017 and 2016 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The below table summarizes our results of operations for the years ended December&nbsp;31, 2017 and 2016. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">21,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">19,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">773</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Result after taxation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,013</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">17,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>See Note 4 to our consolidated financial statements found at the end of this annual report for details
regarding the restatement as a result of a change in accounting policy </I></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total revenue increased by &#128;19.4&nbsp;million to &#128;21.9&nbsp;million for the year ended December&nbsp;31, 2017, from
&#128;2.5&nbsp;million for the year ended December&nbsp;31, 2016. The increase in total revenue is primarily attributable to the amortization of upfront license payments and milestone payments and an increase in R&amp;D cost reimbursement revenue.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenues are generated entirely in the Netherlands. In the following table, revenue is disaggregated by primary source of revenue as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upfront payment amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,564</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D cost reimbursement and milestone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">422</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from contracts with customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,745</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from grants on research projects</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-14</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">21,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">19,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">773</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>See Note 4 to our consolidated financial statements found at the end of this annual report for details
regarding the restatement as a result of a change in accounting policy </I></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upfront payment amortization increased by
&#128;14.9&nbsp;million to &#128;14.9&nbsp;million for the year ended December&nbsp;31, 2017, from &#128;14,000 for the year ended December&nbsp;31, 2016. For the year ended December&nbsp;31, 2017, we recognized &#128;14.9&nbsp;million of
amortization of the upfront payment related to the Incyte collaboration and license agreement. For the year ended December&nbsp;31, 2016, we recognized approximately &#128;14,000 of amortization of the upfront payment related to the ONO research and
license agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">R&amp;D cost reimbursement and milestone revenue for the year ended December&nbsp;31, 2017
was &#128;5.8&nbsp;million and consisted of cost reimbursements in support of our research and license agreements with Incyte and ONO. We did not recognize any research milestones during 2017. During 2016, we recognized one research milestone
reached under our agreement with ONO, which amounted to &#128;0.7&nbsp;million. Additionally, we recognized revenue of &#128;0.4&nbsp;million from an agreement that was signed with ONO on March&nbsp;7, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2017, we had two active grants consisting of cash allowances for specific research and development projects. For the years ended
December&nbsp;31, 2017 and 2016, we recognized &#128;1.2&nbsp;million and &#128;1.4&nbsp;million in grant income, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and
Development Costs </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">34,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">18,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">15,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs increased &#128;15.7&nbsp;million, or 85%, to &#128;34.1&nbsp;million for the
year ended December&nbsp;31, 2017, from &#128;18.4&nbsp;million for the year ended December&nbsp;31, 2016. The increase was primarily due to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;9.1&nbsp;million increase in spending in connection with our preclinical and discovery programs in support
of ongoing development activities for <FONT STYLE="white-space:nowrap">MCLA-158</FONT> (&#128;3.5 million) and <FONT STYLE="white-space:nowrap">MCLA-145</FONT> (&#128;3.2 million), as well as higher costs incurred for conducting research and
development, preclinical, manufacturing and production design in connection with various preclinical and discovery programs (&#128;2.4 million); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;2.0&nbsp;million and &#128;0.4&nbsp;million increase in spending for our
<FONT STYLE="white-space:nowrap">MCLA-128</FONT> and <FONT STYLE="white-space:nowrap">MCLA-117</FONT> programs, respectively, in support of our ongoing clinical trials expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;2.6&nbsp;million increase in employee salary and related benefits and &#128;2.5&nbsp;million increase in
share-based compensation expenses, partially offset by the receipt of an additional &#128;1.8&nbsp;million in subsidies under the WBSO Act, all of which were attributable to the hiring of more development personnel during the year ended
December&nbsp;31, 2017; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;0.7&nbsp;million increase related to higher spending on intellectual property and license costs for legal
and professional services. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses may vary substantially from period to period based on
the timing of our research and development activities, including due to timing of initiation of clinical trials and enrollment of patients in clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management and Administration Costs </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">13,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">9,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management and administration costs increased &#128;9.4&nbsp;million, or 222%, during the year ended
December&nbsp;31, 2017 as compared to the year ended December&nbsp;31, 2016. The increase was primarily attributable to the increase in headcount in finance, legal and business development functions to support the expansion of our operations, which
included increases in salary and related expenses of &#128;2.5&nbsp;million and share-based compensation expenses of &#128;6.9&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Expenses </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">9,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other expenses increased &#128;1.7&nbsp;million, or 22%, during the year ended December&nbsp;31, 2017 as
compared to the year ended December&nbsp;31, 2016. The increase was due to an increase in consulting, accounting and professional fees of &#128;1.7&nbsp;million in support of maintaining a public company status and an increase in facilities expenses
of &#128;0.4&nbsp;million in support of higher headcount, which were partially offset by a decrease in litigation costs of &#128;0.4&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and similar related income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,164</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,164</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss on foreign exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,655</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative financial instrument expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-44</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income primarily results from interest earned on cash held on account and accretion of investment
earnings. The increase in cash, cash equivalents and investments for the year ended December&nbsp;31, 2017 was due primarily to the $200.0&nbsp;million of funds received as part of the Incyte Agreements during the first quarter of 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finance expense increased &#128;10.7&nbsp;million, or 54%, during the year ended December&nbsp;31, 2017 as compared to the year ended
December&nbsp;31, 2016. This increase was due to an increase in foreign exchange expense of &#128;19.0&nbsp;million, partially offset by an &#128;8.5&nbsp;million decrease in derivative financial instrument expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We experienced increased losses on our U.S. dollar denominated cash, cash equivalents and investments of approximately &#128;19.1&nbsp;million
during 2017. As of December&nbsp;31, 2017, we held approximately $98.0&nbsp;million and $49.4&nbsp;million in U.S. dollar denominated cash and cash equivalent accounts and investment accounts, respectively, subject to the fluctuation in foreign
currency between the euro and U.S. dollar. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;20, 2016, we entered into the share subscription agreement with Incyte and
recognized a freestanding forward contract (derivative asset) of $32.6&nbsp;million, or &#128;31.4&nbsp;million, in our statement of financial position. The interest expense and similar expenses for the year ended December&nbsp;31, 2017 include an
amount of &#128;10.7&nbsp;million related to the effective settlement of the forward contract on January&nbsp;23, 2017, the date the shares were issued and the date through which the related expense was incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2017, we expensed &#128;0.2&nbsp;million of prepaid share issuance costs related to a potential future issuance of shares under our <FONT
STYLE="white-space:nowrap">F-3</FONT> Registration Statement when the future issuance was no longer consider probable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Tax Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax expenses were &#128;0.2&nbsp;million and zero for the years ended December&nbsp;31, 2017 and 2016, respectively. Current-year income
tax expense was attributable to our U.S. operating subsidiary, which was established in February 2016 to provide general management services and strategic advisory services to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operating and financial review is based on our consolidated financial statements, which we have prepared in accordance with IFRS as issued
by the International Accounting Standards Board, or the IASB. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent
assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. These estimates and assumptions are monitored and analyzed by us for changes in facts and circumstances, and
material changes in these estimates could occur in the future. We base our estimates on our historical experience, trends in the industry and various other factors that are believed to be reasonable under the circumstances. Actual results may differ
from these estimates under different assumptions or conditions. There have been no material adjustments to prior period estimates for any of the periods included in this Annual Report on Form <FONT STYLE="white-space:nowrap">20-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our significant accounting policies are more fully described in the notes to our financial statements appearing elsewhere in this Annual
Report on Form <FONT STYLE="white-space:nowrap">20-F.</FONT> We believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective
January&nbsp;1, 2018, we adopted IFRS 15. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have derived the majority of our revenue to date from research, collaboration and license agreements with Incyte, ONO, Simcere and Betta.
These agreements contain multiple promised goods and services, including license rights to certain of our product candidates and research and development services. The terms of these arrangements typically include payment of one or more of the
following: <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront fees; reimbursement of research and development costs; development, regulatory, and commercial milestone payments; and royalties on net sales of licensed products, if any.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the new revenue standard, we recognize revenue when our customer obtains control of promised goods or services, in an amount that
reflects the consideration that we expect to receive in exchange for those goods or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue following the
five-step model prescribed under IFRS 15: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Identification of the contract with the customer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Identification of the performance obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Determination of the transaction price, including the constraint on variable consideration;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Allocation of the transaction price to the performance obligations in the contract; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Recognition of revenue when (or as) the Company satisfies each performance obligation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to account for contracts with customers, such as agreements with Incyte, ONO, Simcere and Betta, we identify the promised goods or
services in the contract and evaluate whether such promised goods or services </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
represent performance obligations. We account for those components as separate performance obligations when the following criteria are met: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the customer can benefit from the good or service either on its own or together with other resources that are
readily available to the customer, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our promise to transfer the good or service to the customer is separately identifiable from other promises in the
contract. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This evaluation requires subjective determinations and requires us to make judgments about the promised goods
and services and whether such goods and services are separable from the other aspects of the contractual relationship. In determining the performance obligations, we evaluate certain criteria, including whether the promised good or service is
capable of being distinct and whether such good or service is distinct within the context of the contract, based on consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the
research, manufacturing and commercialization capabilities of the partner, the availability of research and manufacturing expertise in the general marketplace, and the level of integration, interrelation, and interdependence among the promises to
transfer goods or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction price is allocated among the performance obligations using the relative selling price method,
and the applicable revenue recognition criteria are applied to each of the separate performance obligations. At contract inception, we determine the standalone selling price for each performance obligation identified in the contract. If an
observable price of the promised good or service sold separately is not readily available, we utilize assumptions that require judgment to estimate the standalone selling price, which may include development timelines, probabilities of technical and
regulatory success, reimbursement rates for personnel costs, forecasted revenues, potential limitations to the selling price of the product, expected technological life of the product, and discount rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the license to the intellectual property is determined to be distinct from the other performance obligations identified in the arrangement,
we recognize revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined
performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the combined
performance obligation. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. When we recognize revenue allocated to the license at a point in time, we may
experience significant fluctuations in our revenue from quarter to quarter and year to year depending on the timing of transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
the inception of each arrangement that includes <FONT STYLE="white-space:nowrap">pre-commercial</FONT> milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the
transaction price using the most likely amount method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our
control, such as regulatory approvals, are not considered probable of being achieved until the uncertainty related to the milestone is resolved. The transaction price is then allocated to each performance obligation on a relative selling price
basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we reevaluate the probability of achievement of such development milestones and any
related constraint, and if necessary, adjust its estimate of the overall transaction price. Any such adjustments may significantly affect our revenue in the period of adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed
to be the predominant item to which the royalties relate, we recognize revenue at the later of: (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance obligation to which some or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also receive certain government and regional grants, which support our research efforts in defined projects, and include contributions
towards the cost of research and development. When there is reasonable assurance that we will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, government grants are
recognized as revenue on a gross basis in the profit or loss account on a systematic basis over the periods in which the entity recognizes expenses for the related costs for which the grants are intended to compensate. In the case of grants related
to assets, the received grant will be deducted from the carrying amount of the asset. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incur research and development expenses related to our clinical and preclinical drug development programs, which include: (i)&nbsp;payroll
and related costs (including share-based payment expenses) associated with research and development personnel; (ii)&nbsp;costs related to clinical trials and preclinical testing of our technologies under development; (iii)&nbsp;costs to develop
product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses; (iv)&nbsp;expenses for research services provided by universities and contract laboratories; and (v)&nbsp;other research and
development expenses. Research and development expenses are recognized in our consolidated statement of profit or loss and comprehensive loss as incurred and have typically no alternative future uses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses are capitalized if, and only if, all of the following have been demonstrated: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the technical feasibility of completing the intangible asset so that it will be available for use or sale;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the intention to complete the intangible asset and use or sell it; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to use or sell the intangible asset; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how the intangible asset will generate probable future economic benefits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of adequate technical, financial and other resources to complete the development and to use or
sell the intangible asset; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to measure reliably the expenditure attributable to the intangible asset during its development.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing its consolidated financial statements, we are required to estimate certain of our
research and development expenses, including estimates of third-party contract costs relating to preclinical studies and clinical trial activities and related contract manufacturing expenses. This process involves reviewing open contracts and
purchase orders, communicating with research and development personnel to identify services that have been performed for us and estimating the level of service performed and the associated cost incurred for the service when we have not yet been
invoiced or otherwise notified of the actual cost. The most significant estimates relate to expenses incurred under agreements with contract research organizations and contract manufacturing organizations that conduct research and development,
preclinical and clinical activities on our behalf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of our service providers invoice monthly in arrears for services
performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the
accuracy of our estimates with the service providers to gauge the reasonableness of our estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Differences between actual and
estimated expenses recorded have not been material and are adjusted for in the period in which they become known. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain stock ownership programs that entitle key management personnel, staff, directors and consultants providing similar services to
purchase or receive our common shares. Under these programs, holders of vested options are entitled to purchase our common shares at the exercise price determined at the date of grant while holders of vested restricted stock units, or RSUs, are
entitled to the right to receive our common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Share-based compensation is recognized as an expense in our consolidated financial
statements based on the grant date fair value over the vesting period in accordance with each separate vesting tranche of the award granted, taking into consideration actual and expected forfeitures at each reporting date and at the respective
vesting dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The options vest in installments over a four-year period from the grant date: 25% of the options vest on the first
anniversary of the vesting commencement date, and the remaining 75% of the options vest in 36 monthly installments. The RSUs vest in installments over a four-year period from the grant date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the RSUs is based on the market value of our common shares on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of share options is calculated using the Hull&nbsp;&amp; White option pricing model, which considers the terms and conditions
attached to the grants made and is reflective of expected exercise behavior. Prior to our IPO, the estimated fair value of each share option granted was determined utilizing the Black-Scholes option pricing model. Both models use of subjective
assumptions, including expected volatility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the lack of a public market for the trading of our common stock prior to our IPO and a
lack of historical and implied volatility data, we have based our estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. We selected companies with comparable characteristics to us,
including enterprise value, risk profiles, position within the industry and with historical share price information sufficient to meet the expected term of the share-based awards. We will continue to apply this process until a sufficient amount of
historical information regarding the volatility of our own stock price becomes available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Valuation of Our Common Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since we were not listed on a national securities exchange until May&nbsp;19, 2016, there was no published share price information available
until May&nbsp;19, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the initial public offering of our common shares, the fair value of our common shares was determined by
our then management board and supervisory board, and took into account our most recently available valuation of common shares performed by an independent valuation firm and our assessment of additional objective and subjective factors we believed
were relevant and which may have changed from the date of the most recent valuation through the date of the grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our then management
board and supervisory board considered numerous objective and subjective factors to determine their best estimate of the fair value of our common shares as of each grant date, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achievement of enterprise milestones, including entering into collaboration and licensing agreements, as well as
funding milestones; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">contemporaneous third-party valuations of our common shares for our most recent share issuances;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need for future financing to fund operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices at which we sold our preferred shares and the rights and preferences of our preferred shares and our
preferred shares relative to our common shares; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a discrete liquidity event, such as a sale of our company or an initial public
offering given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external market and economic conditions impacting our industry sector; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of an active public market for our common shares and our preferred shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the fair values of our common shares as of each grant date, three generally accepted approaches were considered: income
approach, market approach and cost approach. In addition, the guidance prescribed by the American Institute of Certified Public Accounts, or AICPA, <I>Audit and Accounting Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as
Compensation</I> has been considered. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to income taxes in the Netherlands and the U.S. Judgment is required in determining the use of net operating loss carry-forwards
and taxation of upfront and milestone payments for income tax purposes. There are many transactions and calculations for which the ultimate tax determination is uncertain. Where the final tax outcome of these matters is different from the amounts
that were initially recorded, such differences will impact the current and deferred income tax assets and liabilities in the period in which such determination is made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal and state income taxes were paid in the U.S. because of our U.S. subsidiary; however, no tax charge or income was recognized in our
Dutch entity during the reporting period since we are in a loss-making position and have a history of losses. We have tax loss carry-forwards of &#128;75.9&nbsp;million, &#128;149.2&nbsp;million, and &#128;101.1&nbsp;million as of December&nbsp;31,
2018, 2017 and 2016, respectively. As a result of Dutch income tax law, tax loss carry-forwards are subject to a time limitation of nine years from the year these tax losses were incurred. Legislation has been enacted that decreases the
carry-forwards time limitation of tax losses incurred after December&nbsp;31, 2018 from 9 years to 6 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred income tax assets
are recognized for tax losses and other temporary differences to the extent that the realization of the related tax benefit through future taxable profits is probable. We recognize deferred tax assets arising from unused tax losses, unused tax
credits and temporary differences only to the extent that there are sufficient taxable temporary differences or if there is convincing other evidence that sufficient taxable profit will be available against which the unused tax losses, unused tax
credits and temporary differences can be utilized. Our judgement is that sufficient convincing other evidence is not available and therefore, a deferred tax asset is not recognized. We agreed with the Dutch tax authorities in November 2018 that the
$120.0&nbsp;million upfront license fee received from Incyte Corporation will be fully recognized in 2017 for Dutch corporate income tax purposes. As a result, $120.0&nbsp;million of our tax losses were fully recognized in 2017. This results in a
temporary difference of &#128;114.6&nbsp;million between the book carrying amount and the Dutch tax basis of zero of the deferred revenue as of December&nbsp;31, 2018. This temporary difference also includes other similar license fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to promote innovative technology development activities and investments in new technologies, a corporate income tax incentive has
been introduced in Dutch tax law called the &#147;Innovation Box.&#148; Based on the Innovations Box ruling, we would owe on the first 75% of qualifying profits under the Dutch jurisdiction effectively 7% for Dutch income taxes. The remaining profit
would be taxed at the headline Dutch statutory tax rate. The headline Dutch statutory tax rate is 25% for fiscal years 2018 and 2019. Legislation has been enacted amending the headline Dutch statutory tax rate to 22.55% for fiscal year 2020 and
20.5% for fiscal year 2021 and onwards. Taxable profits will only qualify for the Innovations Box once the tax losses carried forward are completely utilized. The agreement with the Dutch tax authorities was originally signed for the fiscal years
beginning in 2011 through 2015 and was subsequently extended up to and including fiscal year 2019. Since we are loss-making, no Dutch income tax is recognized in profit or loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the adoption of IFRS 9, <I>Financial Instruments</I> on January&nbsp;1, 2018, we classify and account for our investments at amortized
cost using the effective interest rate method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the adoption of the new guidance, our investments were classified and accounted
for as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">held-to-maturity</FONT></FONT> under IAS 39 and were initially measured at fair value. Subsequent to initial recognition, they were measured at amortized cost using the
effective interest rate method. Investments were classified as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">held-to-maturity</FONT></FONT> and carried at amortized cost as we had the positive intent and ability to hold them
until maturity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial adoption of IFRS&nbsp;9 had no impact on previously reported amounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income from these securities is included in finance income. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a discussion of
recently adopted or issued accounting pronouncements please refer to Item 18, Financial Statements, within this Annual Report on Form <FONT STYLE="white-space:nowrap">20-F.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_17"></A>B. Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Funds </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our
inception in 2003, we have devoted substantially all of our resources to developing our platform technology, bispecific antibody candidates, building our intellectual property portfolio, developing our supply chain, business planning, raising
capital and providing for general and administrative support for these operations. We do not currently have any approved products and have never generated any revenue from product sales. We have principally financed our operations through
(i)&nbsp;the initial public offering of our common shares, (ii)&nbsp;a public placement of equity securities with Incyte, (iii)&nbsp;an upfront and milestone payments received from Incyte, Ono and Simcere (iv)&nbsp;a private placement of common
shares on February&nbsp;15, 2018, and (v)&nbsp;a placement of equity securities with Regeneron in December 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;24, 2016, we
closed an initial public offering of 5,500,000 of our common shares and, on May&nbsp;26, 2016, of an additional 639,926 of our common shares, at a price to the public of $10.0 per share. We received net proceeds, after deducting underwriting
discounts and commissions and offering expenses, of $53.3&nbsp;million. On May&nbsp;19, 2016, our common shares were listed on the Nasdaq and all of our preferred shares converted into common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2016, we entered into the Incyte collaboration and license agreement, and the Share Subscription Agreement, with Incyte. In
January 2017, we received an upfront payment of $120.0&nbsp;million (&#128;110.2&nbsp;million)&nbsp;from Incyte pursuant to the Incyte collaboration and license agreement and $80.0&nbsp;million (&#128;74.7&nbsp;million)&nbsp;upon the issuance and
sale by us of 3.2&nbsp;million common shares to Incyte pursuant to the Share Subscription Agreement, for total cash proceeds to us of $200.0&nbsp;million (&#128;184.4&nbsp;million). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2018, we entered into a purchase agreement with the purchasers named therein (the &#147;Investors&#148;). Pursuant to the
purchase agreement, we agreed to sell an aggregate of 3,099,997 of our common shares, nominal value &#128;0.09&nbsp;per share, to the Investors for aggregate gross proceeds of approximately $55.8&nbsp;million (&#128;44.8&nbsp;million), at a purchase
price equal to $18.00 per share. The closing of the private placement occurred on February&nbsp;15, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;20, 2018, we
issued and sold an aggregate of 600,000&nbsp;shares to Regeneron in connection with our settlement of certain litigations and administrative, opposition proceedings with Regeneron for aggregate gross proceeds of $15.0&nbsp;million
(&#128;13.1&nbsp;million). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, we had cash and cash equivalents of &#128;143.7&nbsp;million
and investments of &#128;61.8&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below summarizes our cash flows for each of the periods presented. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017&nbsp;Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016&nbsp;Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>euros</I></B><B></B><B><I></I></B><B></B><B><I>&nbsp;in</I></B><B></B><B><I></I></B><B></B><B><I>&nbsp;thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase/(decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,326</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">107,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">24,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>See Note 4 to our consolidated financial statements found at the end of this annual report for details
regarding the restatement as a result of a change in accounting policy</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2018, we used &#128;40.5&nbsp;million
of cash in operating activities, as compared to the use of &#128;37.4&nbsp;million in cash during 2017, an increase in the use of cash of &#128;3.1&nbsp;million. This increase in net cash used in operating activities was primarily the result of
changes in working capital of &#128;6.3&nbsp;million, an increase in taxes paid of &#128;0.6&nbsp;million, partially offset by the decrease in net loss adjusted for <FONT STYLE="white-space:nowrap">non-cash</FONT> items of &#128;3.8&nbsp;million.
Our <FONT STYLE="white-space:nowrap">non-operating</FONT> and <FONT STYLE="white-space:nowrap">non-cash</FONT> charges during the year ended December&nbsp;31, 2018 primarily consisted of unrealized foreign exchange results of &#128;5.6&nbsp;million
and share option expenses of &#128;7.9&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2017, we used &#128;37.4&nbsp;million of cash in operating activities, as
compared to the use of &#128;25.7&nbsp;million in cash during 2016, an increase in the use of cash of &#128;11.7&nbsp;million. This increase in net cash used in operating activities was the result of the increase in net loss adjusted for <FONT
STYLE="white-space:nowrap">non-cash</FONT> items of &#128;1.9&nbsp;million and changes in working capital of &#128;9.8&nbsp;million. Our <FONT STYLE="white-space:nowrap">non-operating</FONT> and <FONT STYLE="white-space:nowrap">non-cash</FONT>
charges during the year ended December&nbsp;31, 2017 primarily consisted of unrealized foreign exchange results of &#128;15.8&nbsp;million, share option expenses of &#128;12.8&nbsp;million and the change in fair value of the derivative financial
instrument of &#128;10.7&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the years ended December&nbsp;31, 2018, 2017 and 2016
was &#128;19.4&nbsp;million, &#128;41.6&nbsp;million and &#128;0.4&nbsp;million, respectively. The decrease in net cash used in investing activities of &#128;22.2&nbsp;million for the year ended December&nbsp;31, 2018 related primarily to the
maturity of our short-term investments of &#128;58.9&nbsp;million and higher interest received of &#128;0.3&nbsp;million, partially offset by a &#128;34.1&nbsp;million increase in investments purchased, a &#128;2.1&nbsp;million increase in purchases
of intellectual property and a &#128;0.8&nbsp;million increase in purchases of property, plant and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in net cash
used in investing activities of &#128;41.2&nbsp;million for the year ended December&nbsp;31, 2017 primarily related to a &#128;41.8&nbsp;million increase in investments purchased and a &#128;0.2 million&nbsp;increase in purchases of property, plant
and equipment, partially offset by higher interest received of &#128;0.8&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities in 2018
was &#128;51.6&nbsp;million, which was primarily related to proceeds received from our private placement offering that closed in February 2018 and proceeds received from Regeneron Pharmaceuticals in the fourth quarter of 2018. Net cash provided by
financing activities in 2017 was &#128;186.2&nbsp;million, which was primarily related to the receipt of &#128;186.7&nbsp;million from the Incyte Agreements, partially offset by the full repayment of the loan from Rabobank of
&#128;0.5&nbsp;million.&nbsp;Net cash provided by financing activities in 2016 was &#128;50.2&nbsp;million, which was primarily related to proceeds from our IPO in May of 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating and Capital Expenditure Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not achieved profitability since our inception and, as of December&nbsp;31, 2018, we had an accumulated loss of
&#128;175.1&nbsp;million. We expect to continue to incur significant operating losses for the foreseeable future as we continue our research and development efforts and seek to obtain regulatory approval and commercialization of our bispecific
antibody candidates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase substantially in connection with our ongoing development activities related to <FONT
STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT STYLE="white-space:nowrap">MCLA-117,</FONT> <FONT STYLE="white-space:nowrap">MCLA-158,</FONT> the planned commencement of a Phase&nbsp;1 clinical trial for
<FONT STYLE="white-space:nowrap">MCLA-145,</FONT> and continued research and development of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> programs. In addition, we expect to continue to incur additional costs associated with operating as
a public company. We anticipate that our expenses will increase substantially if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct the clinical trials for <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> our most advanced bispecific
antibody candidate in Phase 2 for metastatic breast cancer populations and Phase 1/2 in other solid tumors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct the Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">MCLA-117,</FONT> our second most advanced
bispecific antibody candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct the Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">MCLA-158,</FONT> our third most advanced
bispecific antibody candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate the Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">MCLA-145;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue the research and development of our other antibody candidates in preclinical development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to enhance our technology platform, which generates our pipeline of Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and discover and develop additional antibody candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals for any bispecific antibody candidates that successfully completes clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially establish a sales, marketing and distribution infrastructure and
<FONT STYLE="white-space:nowrap">scale-up</FONT> manufacturing capabilities to commercialize any products for which we may obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio, including litigation costs associated with
defending against alleged patent infringement claims or enforcing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add clinical, scientific, operational, financial and management information systems and personnel, including
personnel to support our product development and potential future commercialization efforts and to support our operation as a public company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience any delays or encounter any issues any of the above, including but not limited to failed studies,
complex results, safety issues or other regulatory challenges. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we expect that our existing cash,
cash equivalents and investments as of December&nbsp;31, 2018 will be sufficient to fund our operations into the second quarter of 2021. For this assessment, we have taken into consideration our existing cash and cash equivalents of
&#128;143.7&nbsp;million, which include the $55.8&nbsp;million, or &#128;44.8&nbsp;million, in proceeds received from our private placement offering that closed in February 2018, $15.0&nbsp;million, or &#128;13.1&nbsp;million, in proceeds received
from Regeneron&#146;s purchase of 600,000 of our common shares in connection with our settlement of certain litigations and administrative, opposition proceedings and investments of &#128;61.8&nbsp;million as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our opinion, our working capital is sufficient for our present requirements. However, we have based this estimate on assumptions that may
prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development of <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT
STYLE="white-space:nowrap">MCLA-117,</FONT> <FONT STYLE="white-space:nowrap">MCLA-158,</FONT> <FONT STYLE="white-space:nowrap">MCLA-145</FONT> and our preclinical programs and because the extent to which we may enter into collaborations with third
parties for development of these bispecific antibody candidates is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses associated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with completing the research and development of our bispecific antibody candidates. Our future capital requirements for <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT
STYLE="white-space:nowrap">MCLA-117,</FONT> <FONT STYLE="white-space:nowrap">MCLA-158,</FONT> <FONT STYLE="white-space:nowrap">MCLA-145</FONT> or our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> programs will depend on many factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress, timing and completion of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> testing and clinical
trials for our current or any future bispecific antibody candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of potential new antibody candidates we identify and decide to develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in growing our organization to the size needed to allow for the research, development and
potential commercialization of our current or any future bispecific antibody candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in filing patent applications and maintaining and enforcing patents or defending against
claims or infringements raised by third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the time and costs involved in obtaining regulatory approval for our bispecific antibody candidates and any
delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to any of these bispecific antibody candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any licensing or milestone fees we might have to pay during future development of our current or any future
bispecific antibody candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selling and marketing activities undertaken in connection with the anticipated commercialization of our current
or any future bispecific antibody candidates and costs involved in the creation of an effective sales and marketing organization; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of revenues, if any, we may derive either directly or in the form of royalty payments from future
sales of our bispecific antibody candidates, if approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying potential bispecific antibody candidates and
conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product
sales. In addition, our bispecific antibody candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if
ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adequate additional funds may
not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include
liquidation or other preferences that adversely affect your rights as a shareholder. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take
specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute your ownership interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to
relinquish valuable rights to our technologies, future revenue streams, research programs or bispecific antibody candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt
financings when needed, we may be required to delay, limit, reduce or terminate our product development programs or any future commercialization efforts or grant rights to develop and market bispecific antibody candidates that we would otherwise
prefer to develop and market ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_18"></A>C. Research and Development, Patent and Licenses, etc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of our research and development activities, see &#147;Item 4.B.&#151;Business Overview&#148; and
&#147;Item&nbsp;5.A.&#151;Operating Results.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_19"></A>D. Trend Information. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as disclosed elsewhere in this Annual Report, we are not aware of any trends, uncertainties, demands, commitments or events that are
reasonably likely to have a material adverse effect on our net revenues, income from continuing operations, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of
future operating results or financial conditions. For more information, see &#147;Item 4.B.&#151;Business Overview,&#148; &#147;Item 5.A.&#151;Operating Results,&#148; and &#147;Item 5.B.&#151;Liquidity and Capital Resources.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_20"></A>E. <FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the periods presented, we did not and do not currently have any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements,
as defined in the rules and regulations of the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_21"></A>F. Tabular Disclosure of Contractual Obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Minimum future payments of our contractual obligations as of December&nbsp;31, 2018 are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&lt;&nbsp;1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">1-3&nbsp;years</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">3-5&nbsp;years</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&gt;&nbsp;5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts in the table reflect payments due for our office and laboratory facilities in Utrecht, Netherlands.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2019, we entered into a lease agreement for approximately 7,583 square feet of office space in Cambridge,
Massachusetts. The lease has a term of seven years and expires on April&nbsp;1, 2026. The lease provides for escalating rent each year, with total cash payments of approximately $4.9&nbsp;million, or &#128;4.2&nbsp;million, payable over the lease
term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, we had several ongoing clinical and nonclinical contracts for our various pipeline programs. We enter
into contracts in the normal course of business with contract research organizations and clinical sites for the conduct of clinical trials, professional consultants for expert advice and other vendors for clinical supply manufacturing or other
services. These contracts are not included in the table above as generally they are cancellable, with notice, at our option and do not have significant cancellation penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_22"></A>G. Safe Harbor. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No disclosure required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_23"></A>Item&nbsp;6 Directors, Senior Management and Employees. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_24"></A>A. Directors and Senior Management. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information about our senior management and board of directors, including their ages as of the date of this Annual
Report: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="64%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Position</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Senior Management</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lex Bakker, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Development Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John de Kruif</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Technology Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Hui Liu, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Business Officer and Head of Merus U.S.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ton Logtenberg, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Principal Financial Officer and President of Merus US, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Peter B. Silverman</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">General Counsel, and Chief Intellectual Property Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">L.&nbsp;Andres&nbsp;Sirulnik,&nbsp;M.D.,&nbsp;Ph.D.&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mark Throsby, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Scientific Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Board of Directors</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ton Logtenberg, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Principal Financial Officer (Executive Director)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Russell G. Greig, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board <FONT STYLE="white-space:nowrap">(Non-Executive</FONT> Director)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mark Iwicki</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Member <FONT STYLE="white-space:nowrap">(Non-Executive</FONT> Director)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Len Kanavy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Member <FONT STYLE="white-space:nowrap">(Non-Executive</FONT> Director)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John de Koning, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Member <FONT STYLE="white-space:nowrap">(Non-Executive</FONT> Director)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Anand Mehra, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Member <FONT STYLE="white-space:nowrap">(Non-Executive</FONT> Director)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Gregory Perry</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice Chairman of the Board <FONT STYLE="white-space:nowrap">(Non-Executive</FONT> Director)</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Senior Management </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Alexander (&#147;Lex&#148;) Berthold Hendrik Bakker, Ph.D</I></B><B>.</B> has served as our Chief Development Officer since October 2010.
His responsibilities include strategic scientific leadership, management of preclinical and clinical development and manufacturing, business development support, external collaboration and partnership management. Prior to joining Merus,
Dr.&nbsp;Bakker directed preclinical and clinical development at Crucell N.V., a biotechnology company. Mr.&nbsp;Bakker holds a Ph.D. in Tumor Immunology from the University of Nijmegen and was a postdoctoral fellow at the DNAX Research Institute.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>John de Kruif, Ph.D.</I></B> has served as our Chief Technology Officer since January 2013 and previously served as our Chief
Scientific Officer from April 2007 to January 2013. His responsibilities include management of antibody discovery, antibody platform technology development, antibody engineering, external collaborations, partnerships management and operational
activities. Before joining Merus, from October 2000 to October 2006, he served as a director of antibody discovery for Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology. Dr.&nbsp;de Kruif holds a PhD in
Antibody Engineering from Utrecht University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Hui Liu, Ph.D.</I></B> has served as our Chief Business Officer since December 2015
and Head of Merus U.S. since October 2018. His responsibilities include all aspects of business development, including <FONT STYLE="white-space:nowrap">in-</FONT> and <FONT STYLE="white-space:nowrap">out-</FONT> licensing, acquisitions and alliance
management, and expansion of Merus in the U.S. Prior to joining Merus, Dr.&nbsp;Liu served as Vice President and Global Head, Business Development&nbsp;&amp; Licensing, Oncology at Novartis AG, a pharmaceutical company, from 2013 to 2015, and as
Vice President and Global Head, Business Development&nbsp;&amp; Licensing, Vaccines&nbsp;&amp; Diagnostics, from 2009 to 2012. Prior to Novartis, Dr.&nbsp;Liu held various management positions at Pfizer, Inc., a pharmaceutical company, from 2004 to
2009 and at Pfizer, Inc. and its predecessor company Warner-Lambert from 1997 to 2001. From 2001 to 2004, Dr.&nbsp;Liu was an investment banker at Goldman Sachs and Citigroup. Dr.&nbsp;Liu holds a Ph.D. in molecular biology and an M.B.A. in finance
from the University of Michigan and a B.S. in biology from Peking University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ton Logtenberg, Ph.D.</I></B> has served as our President&nbsp;&amp; Chief Executive
Officer and an executive board member since co-founding our company in June 2003, and has served as our Principal Financial Officer since January 2019. Dr.&nbsp;Logtenberg also serves as President of our subsidiary, Merus US, Inc. Prior to joining
Merus, Dr.&nbsp;Logtenberg <FONT STYLE="white-space:nowrap">co-founded</FONT> Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology, and served as its executive vice president and chief scientific officer
from July 2000 until November 2003. Dr.&nbsp;Logtenberg has served as a member of the board of directors of the Jenner Foundation since 2008 and a member of the board of directors of Utrecht Science Park since November 2014, and a member of the
supervisory board of the HUB Foundation since August 2018. Dr.&nbsp;Logtenberg holds a Ph.D. in medical biology from Utrecht University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Peter B. Silverman, J.D.</I></B> has served as our General Counsel since February 2018 and our Chief Intellectual Property Officer and
Head of US Legal since February 2017. His responsibilities include all aspects of the company&#146;s legal and intellectual property matters. Prior to joining Merus, Mr.&nbsp;Silverman was a Partner at Kirkland&nbsp;&amp; Ellis LLP, where he
represented numerous life sciences companies concerning an array of legal matters and technologies.&nbsp;Mr.&nbsp;Silverman also served as judicial law clerk to U.S. District Court Judge Anne E. Thompson of the District of New Jersey.&nbsp;He holds
a J.D. from Fordham University School of Law, graduating magna cum laude and Order of the Coif. He is admitted to practice law in New York. Mr.&nbsp;Silverman also holds a B.A. in biology from the University of Rochester. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Andres Sirulnik, M.D., Ph.D.</I></B> has served as our Chief Medical Officer since October 2016. His responsibilities include clinical
strategy and development. Prior to joining Merus, Dr.&nbsp;Sirulnik was at Novartis Pharmaceuticals from 2008 to 2016, most recently serving as Vice President &#150; Senior Global Clinical Program Head and Research Physician in Oncology Clinical
Development. From 2003 to 2008, Dr.&nbsp;Sirulnik was an attending physician in the leukemia program at Dana Farber Cancer Institute and Instructor in Medicine at Harvard Medical School where he focused his research and clinical work in rare
hematologic malignancies. Dr.&nbsp;Sirulnik received his medical degree from the University of Buenos Aires, Argentina, and his Ph.D. in medicine and molecular biology at the University of Cambridge, England. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mark Throsby, Ph.D.</I></B> has served as our Chief Scientific Officer since January 2013 and previously served as our Chief Operating
Officer from October 2008 to January 2013. His responsibilities include strategic scientific leadership, management of discovery, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> research and translational research, business development support,
external collaborations and partnerships management. Before joining Merus, from October 2000 to October 2008, he served as a senior scientist and then as director of antibody discovery for Crucell N.V., a biotechnology company specializing in
vaccines and biopharmaceutical technology. Dr.&nbsp;Throsby holds a Ph.D. in neuro-immunology from Monash University. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ton Logtenberg, Ph.D.</I></B> has served as an executive director of our company since founding our company in June 2003. See
&#147;&#151;Senior Management.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Russell G. Greig</I></B>,<B><I> Ph.D.</I></B> has served as the Chairman of our board of
directors and been a <FONT STYLE="white-space:nowrap">non-executive</FONT> member of our board of directors since July 2018. Dr.&nbsp;Greig worked at GlaxoSmithKline for three decades, most recently as President of SR One, GlaxoSmithKline&#146;s
corporate venture group. Prior to joining SR One, he served as President of GlaxoSmithKline&#146;s Pharmaceuticals International from 2003 to 2008 as well as on the GlaxoSmithKline corporate executive team. Currently, Dr.&nbsp;Greig serves as
Chairman of: AM&nbsp;Pharma and MedEye Solutions in the Netherlands, eTheRNA in Belgium and Sanifit in Spain. He was previously Chairman of Ablynx in Belgium (acquired by Sanofi, France), Isconova in Sweden (acquired by Novavax, United States),
Novagali in France (acquired by Santen, Japan), Syntaxin in the United Kingdom (acquired by Ipsen, France) and Bionor in Norway, as well as board member of TiGenix in Belgium (acquired by Takeda, Japan), Oryzon in Spain and Onxeo Pharma (previously
BioAlliance Pharma) in France, and a venture partner at Kurma Life Sciences (Paris, France). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mark Iwicki</I></B> has been a <FONT
STYLE="white-space:nowrap">non-executive</FONT> member of our board of directors since June 2015. From June 2015 until July 2018, Mr.&nbsp;Iwicki served as the Chairman of our board of directors. Mr.&nbsp;Iwicki is the chief executive officer and
chairman of the board of directors of Kala Pharmaceuticals, Inc. and serves as a member of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
boards of directors of Aimmune Therapeutics, Inc., Nimbus Therapeutics, Oxeia Biopharmaceuticals and Akero Therapeutics, Inc. In addition, Mr.&nbsp;Iwicki has served on the board of the Wellesley
Youth Hockey Association. Mr.&nbsp;Iwicki served as president and chief executive officer and a member of the board of directors of Civitas Therapeutics, Inc. from January 2014 until its acquisition by Acorda Therapeutics, Inc. in October 2014. From
December 2012 to January 2014, Mr.&nbsp;Iwicki served as president and chief executive officer and director at Blend Therapeutics, Inc. From 2007 to June 2012, Mr.&nbsp;Iwicki was president and chief executive officer and director of Sunovion
Pharmaceuticals, Inc., formerly Sepracor, Inc. Mr.&nbsp;Iwicki holds an M.B.A. from Loyola University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Len Kanavy</I></B> has been
a <FONT STYLE="white-space:nowrap">non-executive</FONT> member of our board of directors since July 2018. Mr.&nbsp;Kanavy most recently served as Senior Vice President, Commercial Business Operations at Genentech where he was responsible for
strategic decisions of the U.S. commercial business including product launches, valuation of business development opportunities, clinical development plan options and pricing. He was a Board Member of the Genentech Access to Care Foundation. Prior
to joining Genentech, Mr.&nbsp;Kanavy was Vice President, Commercial Operations at Novartis Pharmaceuticals, where he led teams in business analytics, strategy, and product launches. He currently serves on the board of privately held KMK Consulting.
Mr.&nbsp;Kanavy holds a B.S. in Business Administration and an MBA with a specialization in Finance from the University of Scranton. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>John de Koning, Ph.D.</I></B> was nominated to serve on our board of directors by Co&ouml;peratief LSP&nbsp;IV&nbsp;U.A., one of our
shareholders, and has been a <FONT STYLE="white-space:nowrap">non-executive</FONT> member of our board of directors since&nbsp;January&nbsp;2010. Dr.&nbsp;De&nbsp;Koning has been a partner at LSP (Life Sciences Partners) since January 2006.
Dr.&nbsp;De Koning currently serves on the boards of the private companies GTX medical, eTheRNA and Aelin Therapeutics. Previously, he served on the supervisory boards of BMEYE (acquired by Edwards Lifesciences), Prosensa (acquired by BioMarin) and
Skyline Diagnostics, and as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director on the boards of argenx, Pronota (acquired by MyCartis) and Innovative Biosensors Inc. Dr.&nbsp;De Koning holds an M.Sc. in medical biology from Utrecht
University and a Ph.D. in oncology from the Erasmus University Rotterdam. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Anand Mehra, M.D.</I></B> was nominated to serve on our
board of directors by Sofinnova Venture Partners IX, L.P., one of our shareholders, and has been a <FONT STYLE="white-space:nowrap">non-executive</FONT> member of our board of directors since August 2015. Dr.&nbsp;Mehra has been with Sofinnova
Investments (f.k.a. Sofinnova Ventures) since 2007, most recently holding the position of a general partner where he focuses on working with entrepreneurs to build drug development companies. He has led the firm&#146;s investments in Vicept
Therapeutics (acquired by Allergan), Aerie Pharmaceuticals, Inc., Aclaris Therapeutics, Inc., and Prothena Corporation PLC. He currently serves as a member of the boards of directors of Spark Therapeutics, Inc. and Aclaris Therapeutics, Inc., as
well as on the boards of several private companies. Dr.&nbsp;Mehra holds his M.D. from Columbia University&#146;s College of Physicians and Surgeons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gregory D. Perry</I></B> has been a <FONT STYLE="white-space:nowrap">non-executive</FONT> member of our board of directors since May
2016 and Vice Chairman of our board of directors since August 2018. Mr.&nbsp;Perry is the Chief Financial Officer at Finch Therapeutics Group and serves as a member of the Board of Directors of Kala Pharmaceuticals. Mr.&nbsp;Perry served as Chief
Financial and Administrative Officer of Novelion Therapeutics Inc. or Novelion, a public company, from November 2016 to December 2017. Prior to this, Mr.&nbsp;Perry was Chief Financial Officer of Aegerion Pharmaceuticals Inc., a public company, from
July 2015 until its merger with Novelion in November 2016. Prior to that, he served as Chief Financial and Business Officer of Eleven Biotherapeutics, Inc., a public company, from January 2014 to June 2015. Before joining Eleven Biotherapeutics,
Mr.&nbsp;Perry served as the Interim Chief Financial Officer of InVivo Therapeutics, a public company, from September 2013 to December 2013, and prior to that he served as the Senior Vice President and Chief Financial Officer of ImmunoGen, Inc., a
public company, from 2009 until he was promoted in 2011 to Executive Vice President and Chief Financial Officer, a role he held until 2013. Before that, he was the Chief Financial Officer of Elixir Pharmaceuticals. Mr.&nbsp;Perry previously was
Senior Vice President and Chief Financial Officer of Transkaryotic Therapies. He has also held various financial leadership roles within PerkinElmer Inc., Domantis Ltd., Honeywell and General Electric. Since February 2018, Mr.&nbsp;Perry has served
on the Board of Directors of Kala Pharmaceuticals, including as Chair of its Audit Committee. From December 2011 to February 2016, Mr.&nbsp;Perry served on the Board of Directors of Ocata </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Therapeutics (a public biotechnology company), including as Chair of its Audit Committee and a member of its Compensation Committee, until it was acquired by Astellas Pharma Inc. Mr.&nbsp;Perry
received a B.A. in Economics and Political Science from Amherst College. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of the members of our board of directors or senior management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_25"></A>B. Compensation. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Senior
Management Remuneration </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the approximate remuneration paid during our 2018 fiscal year to our current
senior management. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Name and Principal Position(1)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity</B><br><B>Awards(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other</B><br><B>Compensation(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lex B.H. Bakker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">274,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">70,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">198,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">22,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">565,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President, Chief Development Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John de Kruif</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">245,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">62,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">207,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">16,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">531,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President, Chief Technology Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hui Liu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">305,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">83,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">404,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">21,509</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">814,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, Chief Business Officer and Head of Merus U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">445,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">155,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,218,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">31,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,852,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer and Principal Financial Officer and President of Merus
US</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter B. Silverman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">274,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">53,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">207,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">16,365</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">552,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, General Counsel and Chief IP Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">L. Andres Sirulnik</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">340,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">124,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">425,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">19,838</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">909,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, Chief Medical Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Throsby</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">314,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">88,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">453,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">16,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">873,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, Chief Scientific Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">John Crowley, our former Chief Financial Officer, resigned from employment with the company in January 2019.
The total amount of compensation paid, and benefits in kind granted, by us to Mr.&nbsp;Crowley for our 2018 fiscal year was &#128;802,536. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts shown reflect bonuses awarded for achievement of performance goals in our 2018 fiscal year. Amount
shown for Mr.&nbsp;Sirulnik also includes a retention payment of &#128;42,405 paid to him during 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts shown represent the grant date fair value of option awards granted in 2018. Option awards are measured
using the Hull&nbsp;&amp; White option pricing model. For a description of the assumptions used in valuing these awards, see Note 12 to our financial statements included elsewhere in this Annual Report. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts shown represent pension, retirement or other similar contributions made by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a brief description of the compensation plans and arrangements in which our senior management participate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Base Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We pay our senior management a base salary to compensate them for the satisfactory performance of services rendered to our company. Base salary
is intended to provide a fixed component of compensation reflecting the senior management&#146;s level of responsibility and performance. Our senior management&#146;s base salaries for 2018 are set forth in the table above entitled &#147;Senior
Management Remuneration.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Short-Term Incentive Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a short-term incentive plan pursuant to which we may grant our employees, including our senior management, incentive cash bonuses
based upon corporate and/or individual performance. We generally pay annual cash bonuses based upon the achievement of set financial targets, <FONT STYLE="white-space:nowrap">non-financial</FONT> and personal goals and company milestones for the
period. Achievement of the targets is measured following <FONT STYLE="white-space:nowrap">year-end</FONT> and the actual bonus amounts paid to our senior management, including our executive officers, are determined by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The corporate objectives set for 2018 pursuant to our short-term incentive plan accounted for 70% of the senior management&#146;s bonus
opportunity and were generally related to clinical developments, intellectual property, business developments and preclinical pipeline development. Individual objectives are established annually for each member of the senior management and, in 2018,
accounted for 30% of the senior management&#146;s bonus opportunity. The actual bonus amounts paid to our senior management for 2018 are set forth in the table above entitled &#147;Senior Management Remuneration&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Long-Term Incentive Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain the
2016 Plan under which we may grant cash and equity-based incentive awards to eligible service providers, including our board members, in order to attract, retain and motivate the persons who make important contributions to our company. The plan
administrator has the authority to take all actions and make all determinations under the 2016 Plan, to interpret the 2016 Plan and award agreements and to adopt, amend and repeal rules for the administration of the 2016 Plan as it deems advisable.
The plan administrator also has the authority to determine which eligible service providers receive awards, grant awards and set the terms and conditions of all awards under the 2016 Plan, including any vesting and vesting acceleration provisions,
subject to the conditions and limitations in the 2016 Plan. The 2016 Plan provides for the grant of stock options, stock appreciation rights, restricted stock, dividend equivalents, restricted stock units, and other stock or cash based awards. In
connection with any <FONT STYLE="white-space:nowrap">spin-off,</FONT> change in control, or change in any applicable laws or accounting principles, the plan administrator has broad discretion to take action under the 2016 Plan to prevent the
dilution or enlargement of intended benefits, facilitate the transaction or event or give effect to the change in applicable laws or accounting principles. The plan administrator may generally amend or terminate the 2016 Plan at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the options and RSUs that we granted to our senior management
in 2018 under the 2016 Plan: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Name(1)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B><br><B>Subject to</B><br><B>Option</B><br><B>(#)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise</B><br><B>Price&nbsp;Per</B><br><B>Share&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Restricted</B><br><B>Share</B><br><B>Units (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lex Bakker, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John de Kruif</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hui Liu, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/4/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/4/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Silverman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">L. Andres Sirulnik, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Throsby, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Crowley was granted an option to purchase 43,000 shares of our common stock on February&nbsp;21, 2018
on the same terms as the options granted to other members of our senior management. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The options and RSUs vest as to 25% of the shares on the first anniversary of the grant date and as to the
remaining 75% of the shares in equal monthly installments for the 36 calendar months thereafter. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pension Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We offer some of our senior management the opportunity to participate in a post-retirement plan in order to provide competitive post-retirement
benefits. For 2018, we contributed a total of &#128;0.1 million&nbsp;to provide pension, retirement or similar benefits to our senior management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Lex B.H.
Bakker, Chief Development Officer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2010, we entered into an employment agreement with Mr.&nbsp;Bakker pursuant to which he
serves as our Chief Development Officer. The agreement is for an unspecified term and may be terminated at the end of a calendar month by either Mr.&nbsp;Bakker or the company, subject to the applicable statutory notice periods. Pursuant to the
employment agreement, Mr.&nbsp;Bakker is entitled to a base salary, an annual vacation allowance of 8% of his gross salary, participation in a pension scheme, reimbursement for certain commuting expenses and, in the event if his disability, certain
continued payments of his base salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement contains restrictive covenants which restrict Mr.&nbsp;Bakker&#146;s ability to
compete with the company for a period of 12 months following termination. Mr.&nbsp;Bakker is subject to a penalty of &#128;10,000 for each violation of this covenant and an additional fine of &#128;1,000 for each day the violation continues.
Mr.&nbsp;Bakker is also prohibited from performing work for another employer or client during the course of his employment with us and is subject to a per violation fine of &#128;5,000 and per day fine of &#128;1,000 for as long as the violation
continues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement also contains covenants regarding Mr.&nbsp;Bakker&#146;s protection of our confidential information for a period
of 5 years following his termination, violation of which subjects him to penalties of &#128;50,000 for each violation and &#128;1,000 for each day the violation continues, and regarding ownership of our intellectual property. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>John de Kruif, Chief Technology Officer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2007, we entered into an employment agreement with Dr.&nbsp;de Kruif for an unspecified term, which agreement may be terminated at the
end of a calendar month by either Dr.&nbsp;de Kruif or the company subject to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable statutory notice periods. Pursuant to the employment agreement, Dr.&nbsp;de Kruif is entitled to a base salary, an annual vacation allowance equal to 8% of his gross salary,
participation in a pension scheme and, in the event if his disability, certain continued payments of his base salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement
contains restrictive covenants which restrict Dr.&nbsp;de Kruif&#146;s ability to compete with us for a period of 12 months following termination. Dr.&nbsp;de Kruif is subject to a penalty of &#128;10,000 for each violation of this covenant and an
additional fine of &#128;1,000 for each day the violation continues. Dr.&nbsp;de Kruif is also prohibited from performing work for another employer or client during the course of his employment with us and is subject to a per violation fine of
&#128;5,000 and per day fine of &#128;1,000 for as long as the violation continues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement also contains covenants regarding
Dr.&nbsp;de Kruif&#146;s protection of our confidential information for a period of five years following termination of his employment, violation of which subjects him to penalties of &#128;50,000 for each violation and &#128;1,000 for each day the
violation continues. Dr.&nbsp;de Kruif has also entered into a separate agreement with us regarding ownership of our intellectual property. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Hui Liu, Chief Business Officer and Head of Merus U.S. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;1, 2015, we and Merus US entered into an employment agreement with Hui Liu, which was amended and restated on March&nbsp;2,
2016, pursuant to which Mr.&nbsp;Liu serves as Executive Vice President and Chief Business Officer of us and Merus US. The employment agreement provides for an annual base salary and the opportunity to earn an annual cash incentive award based on
performance with a target value equal to 35% of Mr.&nbsp;Liu&#146;s annual base salary. If Mr.&nbsp;Liu&#146;s employment is terminated by Merus US without cause or due to Mr.&nbsp;Liu&#146;s resignation for good reason, then subject to his
executing a general release of claims and continuing compliance with the Company&#146;s proprietary information agreement, Mr.&nbsp;Liu will be entitled to receive (i)&nbsp;base salary continuation payments for 6 months and (ii)&nbsp;potential
accelerated vesting of any portion of his initial option award that is unvested as of the date of his termination. If Mr.&nbsp;Liu&#146;s employment is terminated without cause or due to Mr.&nbsp;Liu&#146;s resignation for good reason within 12
months following a change in control of us, then subject to his executing a general release of claims and continuing compliance with the proprietary information agreement, Mr.&nbsp;Liu will be entitled to receive (i)&nbsp;a lump sum payment equal to
six months of his base salary and 50% of his target annual bonus; (ii)&nbsp;direct payment of or reimbursement for continued medical, dental or vision coverage pursuant to COBRA for up to nine months, and (iii)&nbsp;accelerated vesting of any
portion of his initial option award that is unvested as of his date of termination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ton Logtenberg, President, Chief Executive
Officer and Principal Financial Officer and Executive Director and President of Merus US </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an employment
agreement, as amended from time to time, with Ton Logtenberg pursuant to which Dr.&nbsp;Logtenberg serves as our President, Chief Executive Officer and Principal Financial Officer. The agreement is for an unspecified&nbsp;term and may be terminated
by either Dr.&nbsp;Logtenberg or the company subject to the applicable statutory notice periods; provided that, the agreement will automatically terminate without notice at the end of the month in which Dr.&nbsp;Logtenberg reaches the age at which
he is entitled to pension under Dutch law. Pursuant to the employment agreement, Dr.&nbsp;Logtenberg is entitled to an annual base salary and may earn an annual cash incentive award based on performance with a target value equal to 50% of his annual
base salary. Dr.&nbsp;Logtenberg is also entitled to certain other benefits, including health and disability benefits, reimbursement for commuting expenses and participation in the company&#146;s pension plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Dr.&nbsp;Logtenberg&#146;s employment is terminated by the company without cause or due to Dr.&nbsp;Logtenberg&#146;s resignation for good
reason, then subject to his executing a general release of claims and continued compliance with the company&#146;s proprietary information agreement, Dr.&nbsp;Logtenberg will be entitled to receive (i)&nbsp;base salary continuation payments for 6
months and (ii)&nbsp;potential accelerated vesting of any portion of his option awards that are unvested as of the date of his termination. If Dr.&nbsp;Logtenberg&#146;s employment is terminated without cause or due to Dr.&nbsp;Logtenberg&#146;s
resignation for good reason within 12 months following a change in control, then subject to his executing a general release of claims and continued compliance with the proprietary information agreement,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Dr.&nbsp;Logtenberg will be entitled to receive (i)&nbsp;a lump sum payment equal to six months of his base salary and 50% of his target annual bonus and (ii)&nbsp;accelerated vesting of any
portion of his unvested equity awards, except that performance based equity awards will only vest subject to the attainment of the applicable performance goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement contains restrictive covenants which restrict Dr.&nbsp;Logtenberg&#146;s ability to compete with us for a period of 24 months
following his termination of employment or solicit our employees for a period of 12&nbsp;months following termination. In the event Dr.&nbsp;Logtenberg violates these restrictive covenants, he will be subject to a penalty of &#128;25,000 for each
violation and an additional penalty of &#128;1,000 for each day the violation continues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement also contains covenants regarding
protection of our confidential information, violation of which subjects Dr.&nbsp;Logtenberg to the same penalties as described above, and ownership of intellectual property. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Peter B. Silverman, General Counsel and Chief Intellectual Property Officer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2017, we and Merus US entered into an employment agreement with Peter B. Silverman.&nbsp;The employment agreement provides for an
annual base salary and the opportunity to earn an annual cash incentive award based on performance with a target value equal to 30% of Mr.&nbsp;Silverman&#146;s annual base salary. If Mr.&nbsp;Silverman&#146;s employment is terminated by Merus US
without cause or due to Mr.&nbsp;Silverman&#146;s resignation for good reason, then subject to his executing a general release of claims and continuing compliance with our proprietary information agreement, Mr.&nbsp;Silverman will be entitled to
receive (i)&nbsp;an amount in cash equal to the sum of 0.5 times his annual base salary and (ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rata</FONT> portion of his target annual bonus for the calendar year in which the date of termination
occurs, which shall be paid in the form of salary continuation in regular installments over the <FONT STYLE="white-space:nowrap">six-month</FONT> period following his termination in accordance with the Company&#146;s customary payroll
practices.&nbsp;On February&nbsp;21, 2018, Mr.&nbsp;Silverman was appointed Executive Vice President and General Counsel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>L. Andres
Sirulnik, Chief Medical Officer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;1, 2016, we and Merus US entered into an employment agreement with L. Andres
Sirulnik. Pursuant to the employment agreement, Mr.&nbsp;Sirulnik serves as Executive Vice President and Chief Medical Officer of us and Merus US. The employment agreement provides for an annual base salary and the opportunity to earn an annual cash
incentive award based on performance with a target value equal to 40% of Mr.&nbsp;Sirulnik&#146;s annual base salary. In addition, the Company agreed to pay Mr.&nbsp;Sirulnik an amount equal to $50,000, within thirty (30)&nbsp;days following each of
November&nbsp;8, 2017 and November&nbsp;8, 2018, subject to Mr.&nbsp;Sirulnik&#146;s continued employment with the Company through each such date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mark Throsby, Chief Science Officer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2008, we entered into an employment agreement with Mr.&nbsp;Throsby for an unspecified term, which agreement may be terminated at the
end of a calendar month by either Mr.&nbsp;Throsby or the company subject to the applicable statutory notice periods. Pursuant to the employment agreement, Mr.&nbsp;Throsby is entitled to a base salary, an annual vacation allowance equal to 8% of
his gross salary, participation in a pension scheme and, in the event if his disability, certain continued payments of his base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement contains restrictive covenants which restrict Mr.&nbsp;Throsby&#146;s ability to compete with the company for a period of 12
months following termination. Mr.&nbsp;Throsby is subject to a penalty of &#128;10,000 for each violation of this covenant and an additional fine of &#128;1,000 for each day the violation continues. Mr.&nbsp;Throsby is also prohibited from
performing work for another employer or client during the course of his employment with us and is subject to a per violation fine of &#128;5,000 and per day fine of &#128;1,000 for as long as the violation continues. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement also contains covenants regarding Mr.&nbsp;Throsby&#146;s protection of our
confidential information for a period of 5 years following his termination, violation of which subjects him to penalties of &#128;50,000 for each violation and &#128;1,000 for each day the violation continues. Mr.&nbsp;Throsby has also entered into
a separate agreement with us regarding ownership of our intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation of Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the remuneration paid during our 2018 fiscal year to members of our board of directors. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;earned</B><br><B>or paid in</B><br><B>Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Awards(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg, Ph.D.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell Greig, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">38,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">122,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">160,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wolfgang Berthold, Ph.D.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">19,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">129,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">148,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lionel Carnot(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">20,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">20,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John de Koning, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">40,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">59,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">100,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Iwicki</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">55,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">59,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">114,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Len Kanavy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">32,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">52,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">85,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anand Mehra, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">39,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">59,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">99,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory Perry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">45,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">59,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">104,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Logtenberg did not receive any additional compensation for his service on our board during 2018.
Amounts paid to Dr.&nbsp;Logtenberg for his service as an executive officer are set forth in the section &#147;Senior Management Remuneration&#148; above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount shown represents the grant date fair value of option awards granted in 2018 measured using the
Hull&nbsp;&amp; White option pricing model. For a description of the assumptions used in valuing these awards, see note 12 to our financial statements included elsewhere in this Annual Report. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Berthold resigned from our board of directors on June&nbsp;28, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Carnot resigned from our board of directors on July&nbsp;20, 2018. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Remuneration of Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Dutch law does not require that we establish a remuneration program for our members of our board of directors, we have established a <FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Director Compensation Program. Under this program, remuneration for the members of our board of directors consists of cash and initial and annual equity awards. For 2018, each board member was entitled
to receive an annual retainer of $36,050. The chairman of the board was entitled to an additional annual retainer of $50,000 and the chairman of the audit committee, compensation committee and nomination and corporate governance committee were each
entitled to an additional annual retainer of $15,450, $13,000 and $13,000, respectively. A board member serving as a member of a committee other than the chairman was entitled to receive an additional annual retainer of $7,725 for service on the
audit committee, $5,150 for service on the compensation committee, and $3,863 for service on the nomination and corporate governance committee. Retainers under the program are payable in arrears in four equal quarterly installments within
15&nbsp;days following the end of each calendar quarter, provided, that the amount of each payment will be prorated for any portion of a quarter that a board member is not serving on our board. The remuneration program further provides for an
automatic increase of the annual retainers on the first day of each calendar year by an amount equal to 3% of the value of such annual retainer in effect as of the immediately preceding calendar year. The amounts described above for 2018 give effect
to this annual increase. The board of directors may appoint observers to the board of directors, pending their formal appointment as a board member, in which case, unless the board of directors decides otherwise, the date service as an observer
commences shall be considered the effective date of commencing service as a board member for purposes of the remuneration program for the board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each board member who is initially appointed to our board is eligible to receive an option
to purchase the number of common shares of our company having an aggregate grant date fair value of $206,000 on the date of grant, with respect to initial awards granted in 2018. Unless otherwise determined by the board of directors, options to
purchase common shares granted to an observer while serving, or upon commencing service, as an observer shall be considered an initial award described in the previous sentence. In addition, if a board member has served on the board (as a <FONT
STYLE="white-space:nowrap">non-executive</FONT> director or as an observer) for at least six months and continues to serve as a board member following any annual general meeting of shareholders held following his or her initial appointment as a
board member, such board member is eligible to receive, on the date of each such annual meeting or as soon as practical thereafter, an option to purchase the number of common shares of our company having an aggregate grant date fair value of
$103,000 on the date of grant, with respect to annual awards granted in 2018. Options granted to our board members under the program have an exercise price equal to the fair market value of our common shares on the date of grant and expire not later
than ten years after the date of grant. The options granted as initial awards vest as to 33% of the shares subject to the award on the first anniversary of the date of grant and in 24 substantially equal monthly installments thereafter. The options
granted annually to board members vest in 12 substantially equal monthly installments following the date of grant. In each case, vesting is subject to continued service as a board member or an observer through each such vesting date. In addition,
all unvested options vest in full upon the occurrence of a change in control. The grant date fair value of each initial award and annual award is, subject to approval by our board of directors, increased on the first day of each calendar year by an
amount equal to 3% of the grant date fair value in effect as of the immediately preceding calendar year, provided, that in no event shall the number of shares awarded pursuant to an initial award exceed 17,000 common shares and an annual award
exceed 8,500 common shares, in each case, subject to adjustment as provided in the 2016 Plan. Our board of directors approved such 3% increase on September&nbsp;18, 2018, with effect from January&nbsp;1, 2018, and the amounts described above for
2018 give effect to this annual increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each board member is entitled to be reimbursed for reasonable travel and other expenses
incurred in connection with attending meetings of the board and any committee of the board on which he or she serves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Board of
Directors 2018 Fiscal Year Equity Awards </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During fiscal 2018, members of our board of directors were granted options to purchase common
shares under the 2016 Plan as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B><br><B>Subject to</B><br><B>Option</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise</B><br><B>Price&nbsp;Per</B><br><B>Share ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg, Ph.D.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell Greig, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/20/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,966</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/20/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wolfgang Berthold, Ph.D.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/28/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/28/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lionel Carnot (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Iwicki</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/20/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,983</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/20/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Len Kanavy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,669</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/5/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John de Koning, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/20/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,983</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/20/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anand Mehra, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/20/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,983</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/20/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory Perry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/20/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,983</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/20/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Information on the options granted to Dr.&nbsp;Logtenberg during 2018 is set forth in the section &#147;Senior
Management Remuneration&#148; above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The options vest as to 33% of the shares subject to the award on the first anniversary of the date of grant and
in 24 substantially equal monthly installments thereafter, subject to accelerated vesting upon the occurrence of a change in control. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Berthold resigned from our board of directors on June&nbsp;28, 2018. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The options vest in 24 substantially equal monthly installments following the date of grant, subject to
accelerate vesting upon the occurrence of a change in control. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Carnot resigned from our board of directors on July&nbsp;20, 2018 and was not granted any options
during fiscal 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The options vest in 12 substantially equal monthly installments following the date of grant, subject to
accelerate vesting upon the occurrence of a change in control. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_26"></A>C. Board Practices. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;29, 2017, upon approval by our shareholders, our corporate governance structure changed from a
<FONT STYLE="white-space:nowrap">two-tier</FONT> model with a management board under the supervision of a supervisory board to a <FONT STYLE="white-space:nowrap">one-tier</FONT> model with a unitary board of directors. Our board of directors is
comprised of seven members. Each board member is elected for a term of up to four years. A board member may be <FONT STYLE="white-space:nowrap">re-appointed</FONT> for up to two subsequent terms. Board members must retire periodically in accordance
with a rotation plan. Our board members do not have a retirement age requirement under our Articles of Association. Our board members are elected, or <FONT STYLE="white-space:nowrap">re-appointed</FONT> as the case may be, by our general meeting of
shareholders in accordance with the Articles of Association to serve until their successors are duly elected and qualified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
expiration of the current terms of the members of our Board of Directors and the period each member has served in that term are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Current</B><br><B>Term&nbsp;Began</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Current</B><br><B>Term&nbsp;Expires</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Iwicki</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell G. Greig</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Len Kanavy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John de Koning, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anand Mehra, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory Perry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ton Logtenberg does not have a fixed expiration date for his current term of office. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no arrangements or understanding between us and any of the members of our board of directors providing for benefits upon termination of their
service. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has established an Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee, which
operate pursuant to written charters adopted by our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee, which consists of Gregory Perry, Anand Mehra and John de Koning, assists our board of directors in overseeing our
accounting and financial reporting processes and the audits of our financial statements. Mr.&nbsp;Perry serves as Chairman of the committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending the appointment of the independent auditor to the general meeting of shareholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the appointment, compensation, retention and oversight of any accounting firm engaged for the purpose of
preparing or issuing an audit report or performing other audit services; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> the audit services and
<FONT STYLE="white-space:nowrap">non-audit</FONT> services to be provided by our independent auditor before the auditor is engaged to render such services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating the independent auditor&#146;s qualifications, performance and independence, and presenting its
conclusions to the board on at least an annual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with the board and the independent auditor our financial statements and our financial
reporting process; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving or ratifying any related person transaction (as defined in our related person transaction policy) in
accordance with our related person transaction policy. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee is also charged with overseeing the
responsibilities of the Board of Directors with respect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s funding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the application of information and communication technology by the Company, including risks relating to
cybersecurity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the operation of the Company&#146;s Code of Business Conduct and Ethics and its other internal policies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s tax policy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing the effectiveness of the design and operation of the internal controls with the Board of
Directors, including any identified material failings in the internal controls; and ii. any material changes made to, and any material improvements planned for, the internal controls. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee meets as often as one or more members of the audit committee deem necessary, but in any event, meets at least four times
per year. The audit committee meets at least once per year with our independent accountant, without our management being present. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation
Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee, which consists of Mark Iwicki, Len Kanavy and Gregory Perry, assists our board of directors
in determining management compensation. Mr.&nbsp;Iwicki serves as Chairman of the committee. The compensation committee prepares a proposal for the board concerning the compensation of each member of our management to be proposed for adoption by the
general meeting of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee&#146;s responsibilities include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, reviewing and proposing policies relevant to management compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating each member of management&#146;s performance in light of such policies and reporting to the board;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analyzing the possible outcomes of the variable remuneration components and how they may affect the remuneration
of management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending any equity long-term incentive component of each member of management&#146;s compensation in line
with the remuneration policy and reviewing our management compensation and benefits policies generally; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing risks arising from our compensation policies and practices. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">N<B><I>omination and Corporate Governance Committee</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nomination and corporate governance committee, which consists of Russell Greig, Mark Iwicki and John de Koning, assists our board of
directors in identifying individuals qualified to become members of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
board and part of our management consistent with criteria established by our board and in developing our corporate governance principles. Mr.&nbsp;Greig serves as Chairman of the nomination and
corporate governance committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nomination and corporate governance committee&#146;s responsibilities include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">drawing up selection criteria and appointment procedures for board members and management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating the size and composition of our board and management and making a proposal for a
composition profile of the board at least annually; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending nominees for election to our board and its corresponding committees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assessing the functioning of individual members of the board and management and reporting the results of such
assessment to the board; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to the board our rules governing the board, reviewing and reassessing the adequacy of
such rules governing the board and recommending any proposed changes to the board. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a foreign private issuer. As
a result, in accordance with the rules of the Nasdaq Stock Market LLC, we comply with Dutch governance requirements and certain exemptions thereunder rather than complying with Nasdaq corporate governance standards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_27"></A>D. Employees. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, we had 98 employees, 50 of whom hold M.D. or Ph.D. degrees. Seventy-seven of our employees work in research and
development and 21 work in management and administrative areas. All of our employees are located in the Netherlands except for 17 employees located in the United States. None of our employees is subject to a collective bargaining agreement or
represented by a trade or labor union. We have established a workers&#146; council for our employees, effective as of January&nbsp;
1, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_28"></A>E. Share Ownership. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For information regarding the share ownership of members of our board of directors and senior management and arrangements involving our
employees in our share capital, see &#147;Item 6.B.&#151;Compensation&#148; and &#147;Item 7.A.&#151;Major Shareholders and Related Party Transactions.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_29"></A>Item&nbsp;7 Major Shareholders and Related Party Transactions. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_30"></A>A. Major Shareholders. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information relating to the beneficial ownership of our common shares as of December&nbsp;31, 2018 by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person known to us who beneficially owns 5% or more of our outstanding common shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each member of our board of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each member of our senior management. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of common shares beneficially owned by each entity, person, director or senior manager is determined in accordance with the rules
of the U.S. Securities and Exchange Commission, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the entity or individual has sole
or shared voting power or investment power as well as any shares that the entity or individual has the right to acquire within 60 days following December&nbsp;31, 2018 through the exercise of any option, warrant or other right. Except as otherwise
indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all common shares held by that person, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Common shares that a person has the right to acquire within 60 days following
December&nbsp;31, 2018 are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person. As of
December&nbsp;31, 2018, we had 23,358,977 common shares outstanding. Unless otherwise indicated below, the address for each beneficial owner listed is c/o Merus N.V., at Yalelaan 62, 3584 CM Utrecht, The Netherlands. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;beneficially&nbsp;owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of beneficial owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% or greater shareholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BVF<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,514,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Incyte Corporation<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bay City Capital Co&ouml;peratief
U.A.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,113,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sofinnova Venture Partners IX,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,961,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aquilo Capital Management, LLC<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,480,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cooperatief LSP IV UA<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,225,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baker Brothers Life Sciences L.P.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,160,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Senior management and Board of Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">762,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hui Liu, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">L. Andres Sirulnik<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Throsby, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lex B.H. Bakker, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter B. Silverman<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John de Kruif<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell G. Greig, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Iwicki<SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Len Kanavy<SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John de Koning, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(17)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anand Mehra<SUP STYLE="font-size:85%; vertical-align:top">(4) (18)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,985,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory Perry<SUP STYLE="font-size:85%; vertical-align:top">(19)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates beneficial ownership of less than 1% of the total outstanding common shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 2,179,666 shares held directly by Biotechnology Value Fund, L.P. (&#147;BVF&#148;), (b)
1,659,586 shares held directly by Biotechnology Value Fund II, L.P. (&#147;BVF2&#148;), (c) 315,275 shares held by Biotechnology Value Trading Fund OS LP (&#147;Trading Fund OS&#148;) (d) 100,751 shares held directly by Investment 10, L.L.C.
(&#147;Investment 10&#148;), and (e) 259,635 shares held directly by MSI BVF SPV LLC (&#147;MSI&#148;). BVF Partners OS Ltd. (&#147;Partners OS&#148;), as the general partner of Trading Fund OS, may be deemed to beneficially own the shares held by
Trading Fund OS. BVF Partners L.P. (&#147;Partners&#148;), as the general partner of BVF and BVF2, the investment manager of Trading Fund OS, Investment 10, and MSI and the sole member of Partners OS, may be deemed to beneficially own the shares
beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, Investment 10, and MSI. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the shares beneficially owned by Partners Investment 10, and MSI. Mark N.
Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the shares beneficially owned by BVF Inc. The beneficial ownership information is based on a Schedule 13G/A filed with the SEC on February&nbsp;14, 2019 and
information known to us. The address for each of these entities is 44 Montgomery Street, 40th Floor, San Francisco, CA 94104. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 3,200,000 common shares held directly by Incyte Corporation (&#147;Incyte&#148;).
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 2,062,025 common shares held directly by Bay City Capital Fund V, L.P. (&#147;Fund V&#148;),
(b) 39,295 common shares held by Bay City Capital Fund V <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Fund, L.P. (&#147;Fund <FONT STYLE="white-space:nowrap">V-SBS&#148;)</FONT> are the two sole investors of COOP. Bay City Capital
Management V LLC (&#147;BCCM V&#148;) is the general partner of Fund V and Fund <FONT STYLE="white-space:nowrap">V-SBS,</FONT> and (c) 12,254 common shares held directly by Bay City Capital LLC (&#147;BCC&#148;). BCC is the adviser and manager of
BCCM V. BCCM V and BCC represent Fund V and Fund <FONT STYLE="white-space:nowrap">V-SBS,</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
respectively. Thus, BCCM V and BCC share voting and investment power over the shares held by each of Fund V and Fund <FONT STYLE="white-space:nowrap">V-SBS.</FONT> Lionel Carnot is a member of
BCCM V and is employed as a managing director of BCC together with Fred Craves, Carl Goldfischer, Dayton Misfeldt and Rob Hopfner. As such, each of these individuals may be deemed to share voting and investment power over these entities, and they
disclaim beneficial ownership of all shares except to the extent of any pecuniary interest therein. Beneficial ownership information is based on a Schedule 13D filed with the SEC on November&nbsp;28, 2018. The mailing address for BCC, Fund V, Fund <FONT
STYLE="white-space:nowrap">V-SBS</FONT> and BCCM V is De Boelelaan 7, 1083 HJ Amsterdam, Netherlands. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,961,039 common shares held directly by Sofinnova Venture Partners IX, L.P. (&#147;Sofinnova
VP&#148;). Sofinnova Management IX, L.L.C. (&#147;Sofinnova Management&#148;) is the general partner of Sofinnova VP and Anand Mehra, Michael Powell and James Healy are the managing members of Sofinnova Management. Sofinnova Management, Anand Mehra
(a member of our board), Michael Powell and James Healy may be deemed to have shared voting and dispositive power over the shares owned by Sofinnova VP. Such entities and individuals disclaim beneficial ownership over all shares except to the extent
of any pecuniary interest therein. Beneficial ownership information is based on information known to us and a Schedule 13D filed with the SEC on September&nbsp;27, 2017. The address for Sofinnova VP and Sofinnova Management is 3000 Sand Hill Road,
Building 4, Suite 250, Menlo Park, California 94025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 1,194,112 common shares held directly by Aquilo Capital, L.P. (&#147;Aquilo&#148;) and
(b)&nbsp;286,743&nbsp;common shares held directly by Aquilo Capital II, L.P. (&#147;Aquilo II&#148;). Aquilo Capital Management LLC (&#147;Aquilo Management&#148;) is the general partner of Aquilo and Aquilo II and Marc Schneidman is the managing
member of Aquilo Management. Aquilo Management and Mr.&nbsp;Schneidman may be deemed to be beneficial owners of the shares held by Aquilo and Aquilo II, and Aquilo and Aquilo II may be deemed to beneficially own the shares held by the other entity.
The beneficial ownership information presented is based on a Schedule 13G/A filed with the SEC on February&nbsp;14, 2019 and information known to us. The address for Aquilo and Aquilo II is One Letterman Drive, Suite D4900, San Francisco,
California, 94129. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,225,661 common shares held directly by Co&ouml;peratief LSP IV U.A. (&#147;LSP&#148;). LSP IV
Management BV (&#147;LSP Management&#148;) is the sole director of LSP. The managing directors of LSP Management are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. As such, LSP Management, Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may be
deemed to beneficially own and share voting power over these shares. LSP Management, Martijn Kleijwegt, Rene Kuijten and Joachim Rothe disclaim beneficial ownership of the shares. John de Koning, a member of our board, is employed as a partner at
LSP. Mr.&nbsp;de Koning has no beneficial ownership of these shares, but he has a pecuniary interest in these shares pursuant to his employment at LSP. Beneficial ownership information is based on a Schedule 13D/A filed with the SEC on June&nbsp;3,
2016. LSP&#146;s mailing address is c/o LSP, Johannes Vermeerplein 9, 1071 DV Amsterdam, Netherlands. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 1,054,257 common shares held directly by Baker Brothers Life Sciences, L.P. (&#147;Life
Sciences&#148;) and (b) 105,757 common shares held directly by 667, L.P. (&#147;667&#148;, and together with Life Sciences, the &#147;Baker Funds&#148;). Baker Bros. Advisors LP (&#147;Advisors&#148;) is the Investment Adviser for the Baker Funds
and has sole voting and investment power with respect to the shares held by the Baker Funds. Baker Bros. Advisors (GP) LLC is the sole general partner of Advisors. Baker Bros. Advisors (GP) LLC, Julian C. Baker and Felix J. Baker as principals of
the Baker Bros. Advisors (GP) LLC, and Advisors disclaim beneficial ownership of all shares. Beneficial ownership information is based on a Schedule 13G filed with the SEC on February&nbsp;14, 2017. The address for each of these entities is 667
Madison Avenue, 21st Floor, New York, NY 10065. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a)&nbsp;160,814 common shares held by BioPhrase, B.V. (&#147;BioPhrase&#148;),
Dr.&nbsp;Logtenberg&#146;s personal holding company, (b)&nbsp;129,647 common shares held by Dr.&nbsp;Logtenberg, (c) 464,068 options to purchase common shares held by Dr.&nbsp;Logtenberg, including options that vest within 60 days following
December&nbsp;31, 2018 and (d) 7,734 restricted stock units (&#147;RSUs&#148;) held by Dr.&nbsp;Logtenberg, including RSUs that vest within 60 days following December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a)&nbsp;40,490 common shares, (b)&nbsp;136,317 options to purchase common shares including options
that vest within 60 days following December&nbsp;31, 2018 and (c) 1,746 restricted stock units (&#147;RSUs&#148;), including RSUs that vest within 60 days following December&nbsp;31, 2018. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase common shares, including options that vest within 60 days following
December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 11,038 common shares, (b) 152,589 options to purchase common shares including options that vest
within 60 days following December&nbsp;31, 2018 and (c) 2,124 restricted stock units (&#147;RSUs&#148;), including RSUs that vest within 60 days following December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a)&nbsp;9,010 common shares, (b)&nbsp;39,776 options to purchase common shares including options
that vest within 60 days following December&nbsp;31, 2018 and (c) 324 restricted stock units (&#147;RSUs&#148;), including RSUs that vest within 60 days following December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase common shares, including options that vest within 60&nbsp;days following
December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 1,811 common shares, (b)&nbsp;35,396 options to purchase common shares including options that
vest within 60 days following December&nbsp;31, 2018 and (c)&nbsp;237 restricted stock units (&#147;RSUs&#148;), including RSUs that vest within 60 days following December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase common shares, including options that vest within 60&nbsp;days following
December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase common shares, including options that vest within 60&nbsp;days following
December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase common shares, including options that vest within 60&nbsp;days following
December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 1,961,039 shares held by Sofinnova Venture Partners IX LP prior to this offering and (b) 24,132
options to purchase common shares, including options that vest within 60&nbsp;days following December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(19)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase common shares, including options that vest within 60&nbsp;days following
December&nbsp;31, 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To our knowledge, other than as provided in the table above, our other filings with the SEC and
this Annual Report on Form&nbsp;20-F, there has been no significant change in the percentage ownership held by any major shareholder since January&nbsp;1, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_31"></A>B. Related Party Transactions. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of related party transactions we have entered into since January&nbsp;1, 2016 or currently in effect with any
member of our board of directors or our executive officers and the holders of 5% or more of our common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights Agreement with Incyte </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Incyte collaboration and license agreement, we entered into a Share Subscription Agreement, or the Subscription
Agreement, with Incyte pursuant to which we agreed to register the common shares held by Incyte by June&nbsp;1, 2017. We also agreed to use our reasonable best efforts to keep the registration statement effective until the earlier of (a)&nbsp;all of
the common shares held by Incyte having been sold pursuant to an effective registration statement or in compliance with Rule 144 promulgated under the Securities Act of 1933, as amended, or the Securities Act, (b)&nbsp;at such time when the common
shares held by Incyte could, in the opinion of counsel satisfactory to us, be sold by Incyte in a single transaction under the terms of the Subscription Agreement and the volume and manner of sale limitations under Rule 144 of the Securities Act,
and (c)&nbsp;at such time as the registration statement registering the common shares has been effective for 42 months following the <FONT STYLE="white-space:nowrap">lock-up</FONT> period of the common shares as specified in the Subscription
Agreement. On June&nbsp;1, 2017, we filed a registration statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-218432)</FONT> with the U.S. Securities and Exchange Commission registering
the common shares held by Incyte, which was amended on June&nbsp;14, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights Agreement with Certain Investors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into a registration rights agreement, or the Registration Rights Agreement, with certain of our shareholders, pursuant to which
such shareholders are entitled to the following rights with respect to the registration of their common shares for public resale under the Securities Act. The registration of common shares as a result of the following rights being exercised would
enable their holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the
holders of, at least, 30% of the registrable securities then outstanding request that we effect a registration with respect to all or part of their registrable securities, we may be required to register all or part of the registrable securities then
outstanding. We are obligated to effect at most two registrations in response to these demand registration rights. If the holders requesting registration intend to distribute their shares by means of an underwriting, the managing underwriter of such
offering has the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration
Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we propose to register any of our common shares under the Securities Act, subject to certain exceptions, the holders of
registrable securities are entitled to notice of the registration and to include their registrable securities in the registration. If our proposed registration involves an underwriting, the managing underwriter of such offering has the right to
limit the number of shares to be underwritten for reasons related to the marketing of the shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT>
Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the holders of our registrable securities then outstanding request that we effect a registration of some or all
of their registrable securities and we are entitled under the Securities Act to register our common shares on a registration statement on Form <FONT STYLE="white-space:nowrap">F-3,</FONT> we are obligated to effect such registration. We are not
obligated to effect a registration pursuant to these <FONT STYLE="white-space:nowrap">F-3</FONT> registration rights if (i)&nbsp;the expected aggregate net proceeds from the sale of the registrable securities for which registration is requested is
equal to or less than $1.0&nbsp;million or (ii)&nbsp;if, within a given <FONT STYLE="white-space:nowrap">12-month</FONT> period, we have already effected two registrations on Form <FONT STYLE="white-space:nowrap">F-3</FONT> for the holders of
registrable securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ordinarily, other than underwriting discounts and commissions, we are required to pay all expenses incurred by us related to any registration
effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling
security holders and blue sky fees and expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination of Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration rights terminate upon the earlier of May&nbsp;24, 2020, or, with respect to the registration rights of an individual holder,
when the holder can sell all of such holder&#146;s registrable securities in a three-month period without restriction under Rule 144 under the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a
description of our agreements with our executive officers, see &#147;Item 6.B.&#151;Compensation.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into agreements with our board of directors and our senior management to indemnify them against expenses and liabilities to the
fullest extent permitted by law. These agreements provide, subject to certain exceptions, for indemnification for related expenses including, among other expenses, attorneys&#146; fees, judgments, penalties, fines and settlement amounts incurred by
any of these individuals in any action or proceeding. In addition to such indemnification, we provide our board of directors and senior management with directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_32"></A>C. Interests of Experts and Counsel. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_33"></A>Item&nbsp;8 Financial Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_34"></A>A. Consolidated Statements and Other Financial Information. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
consolidated financial statements are appended at the end of this Annual Report, starting at page <FONT STYLE="white-space:nowrap">F-1,</FONT> and are incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;11,
2014, Regeneron Pharmaceuticals, Inc., or Regeneron, filed a complaint in the United States District Court for the Southern District of New York alleging that we were infringing one or more claims in Regeneron&#146;s U.S. Patent No.&nbsp;8,502,018,
entitled &#147;Methods of Modifying Eukaryotic Cells&#148;, or the &#145;018 patent. In 2015, the trial court entered judgments finding that we do not infringe the claims of the &#145;018 patent, that the patent is invalid, and that the patent was
procured through inequitable conduct and is unenforceable. On July&nbsp;27, 2017 the U.S. Court of Appeals for the Federal Circuit affirmed the trial court&#146;s conclusion that Regeneron engaged in inequitable conduct before the United States
Patent and Trademark Office while prosecuting the &#145;018 patent and affirmed that the &#145;018 patent is unenforceable. On December&nbsp;26, 2017, the Federal Circuit denied Regeneron&#146;s petition for rehearing and rehearing en banc seeking a
review of that decision and on October&nbsp;1, 2018, the Supreme Court of the United States denied Regeneron&#146;s petition for certiorari, rendering the case finally resolved in our favor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;26, 2018, the trial court granted our motion for attorneys&#146; fees, expert fees, and costs associated with our defense of the
above litigation, and ordered the parties to address the amount of the award. We provided a detailed explanation of our attorneys&#146; fees, expert fees, and costs of such award, which Regeneron responded to seeking a reduction of the amount. The
matter was fully briefed as of May&nbsp;18, 2018, and the court issued an Order on June&nbsp;25, 2018, which published on July&nbsp;10, 2018, granting our motion for $8,332,453.46 in attorneys&#146; fees, $465,390.34 in expert fees, and
$1,717,100.69 in litigation expenses and costs, along with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-judgment interest. Regeneron appealed the decision awarding attorneys&#146; fees to us to the Federal Circuit, filing its opening brief
on November&nbsp;7, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;11, 2014, Regeneron served a writ in the Netherlands alleging that we were infringing one or more
claims in their European patent EP&nbsp;1&nbsp;360&nbsp;287&nbsp;B1. We had opposed that patent in June 2014. On September&nbsp;17, 2014, Regeneron&#146;s patent EP 1 360 287 B1 was revoked in its entirety by the European Opposition Division of the
European Patent Office, or the EPO. In Europe, an appeal hearing occurred in October and November 2015 at the Technical Board of Appeal for the EPO at which time the patent was reinstated to Regeneron with amended claims. On October&nbsp;2, 2017, we
filed an appeal with the Technical Board of Appeal for the EPO to address whether the patent having claims amended during the course of opposition complies with Art. 84 EPC, Art. 123(2) EPC and Rule 80 EPC. On May&nbsp;25, 2018, at Regeneron&#146;s
request, a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hearing before the Technical Board of Appeals for the EPO was scheduled for September&nbsp;13, 2018, to address whether the description of EP 1 360 287 B1 patent having claims amended during the
course of opposition complies with Art. 84 EPC, Art. 123(2) EPC and Rule 80 EPC. The Technical Board of Appeals provided preliminary views on the matter on August&nbsp;23, 2018, after which our appeal filed on October&nbsp;2, 2017 was withdrawn on
September&nbsp;5, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regeneron also previously raised opposition proceedings against certain of our patents in jurisdictions including
Europe, Japan and Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;20, 2018, we signed a global settlement and cross-license agreement with Regeneron, where
the parties have agreed to end all pending litigation and opposition proceedings pertaining to certain of our and Regeneron&#146;s respective antibody generation technologies. Regeneron also purchased 600,000 of our common shares at a price of $25
per share for total aggregate proceeds to us of $15.0&nbsp;million. The cross-license and stock purchase were made in conjunction with the agreement to withdraw Regeneron&#146;s appeal of the fee award, and agreement to dismissal of all claims to
approximately $10.5&nbsp;million for the reimbursement of attorneys&#146; fees and other expenses, plus interest, awarded to Merus by the trial court. Under the terms of the settlement, Regeneron has withdrawn its appeal of the decision awarding
attorneys&#146; fees to us as a result of the U.S. District Court litigation described above. In addition, Regeneron has dismissed its stayed case in the Netherlands asserting the EP&nbsp;1&nbsp;360&nbsp;287 B1 patent, and both parties have
withdrawn all pending oppositions against one another pending as December&nbsp;20, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2018, Regeneron and an unnamed
third party filed notices of opposition against our EP 2604625 patent entitled &#147;Generation of Binding Molecules,&#148; in the EPO. The notices asserted, as applicable, added subject matter, lack of novelty, lack of inventive step, and
insufficiency. Regeneron has withdrawn its opposition pursuant to the December&nbsp;20, 2018 settlement. On August&nbsp;20, 2018, we timely responded to these submissions, with proceedings to be ongoing pursuant to the filing of the unnamed third
party. An opposition hearing is currently scheduled for June 2019. As this opposition proceeding continues, we cannot assure you that we will ultimately prevail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may be involved in various other claims and legal proceedings relating to claims arising out of our operations. We are
not currently a party to any other material legal proceedings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend Distribution Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never paid or declared any cash dividends on our common shares, and we do not anticipate paying any cash dividends on our common shares
in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Under Dutch law, a Dutch public company with limited liability (<I>naamloze vennootschap</I>) may only
pay dividends if the shareholders&#146; equity (<I>eigen vermogen</I>) exceeds the sum of the <FONT STYLE="white-space:nowrap">paid-up</FONT> and <FONT STYLE="white-space:nowrap">called-up</FONT> share capital plus the reserves required to be
maintained by Dutch law or our Articles of Association. Subject to such restrictions, any future determination to pay dividends will be at the discretion of our general meeting upon the proposal of our board of directors. Any future approval will
depend upon the board&#146;s review of a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our board deems relevant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_35"></A>B. Significant Changes. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_36"></A>Item&nbsp;9
The Offer and Listing. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_37"></A>A. Offer and Listing Details. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common shares are listed on The Nasdaq Global Market under the symbol &#147;MRUS&#148;. Our common shares are not listed on any other
market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_38"></A>B. Plan of Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_39"></A>C. Markets. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common shares are listed on The Nasdaq Global Market under the symbol &#147;MRUS.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_40"></A>D. Selling Shareholders. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_41"></A>E. Dilution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_42"></A>F. Expenses of the Issue. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_43"></A>Item&nbsp;10. Additional Information. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_44"></A>A. Share Capital. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_45"></A>B. Memorandum and Articles of Association. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated on
June&nbsp;16, 2003 as a private company with limited liability (<I>besloten vennootschap met beperkte aansprakelijkheid</I>) under Dutch law. In connection with the initial public offering of our common shares, we converted into a Dutch public
company with limited liability (<I>naamloze vennootschap</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registered with the Dutch Trade Register (<I>handelsregister</I>)
under number 30189136. Our corporate seat is in Utrecht, the Netherlands, and our registered office is Yalelaan 62, 3584 CM Utrecht, the Netherlands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is a summary of relevant information concerning material provisions of our articles of association and applicable Dutch law.
This summary does not constitute legal advice regarding those matters and should not be regarded as such. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Articles of Association
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general meeting of shareholders can only resolve to amend the articles of association at the proposal of the board of
directors. A resolution by the general meeting of shareholders to amend the articles of association requires a simple majority of the votes cast. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Company&#146;s Shareholders&#146; Register </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must keep our shareholders&#146; register accurate and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date.</FONT></FONT> The board of directors keeps our shareholders&#146; register and records names and addresses of all holders of registered shares, showing the date on which
the shares were acquired, the date of the acknowledgement of the transfer by or notification of the transfer to us as well as the amount paid on each share. The register also includes the names and addresses of those with a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
right to use and enjoyment in common shares belonging to another person (<I>vruchtgebruik</I>) or a pledge in respect of registered shares, as well as any other particulars which must be recorded
in our shareholders&#146; register pursuant to Dutch law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Objectives </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate objectives are: (1)&nbsp;to develop products and services in the area of biotechnology, (2)&nbsp;to finance group companies or
other parties, (3)&nbsp;to borrow, to lend to raise funds, including the issue of bonds, promissory notes or other financial instruments or evidence of indebtedness, as well as to enter into agreements in connection with the aforementioned,
(4)&nbsp;to supply advice and to render services to group companies and other parties, (5)&nbsp;to render guarantees, to bind us, to provide security, to warrant performance in any other way and to assume liability, whether jointly and severally or
otherwise, in respect of obligations of group companies or other parties, (6)&nbsp;to incorporate, to participate in any way whatsoever in, to manage, to supervise and to hold any other interest in other entities, companies, partnerships and
businesses, (7)&nbsp;to obtain, alienate, encumber, manage and exploit registered property and items of property in general, (8)&nbsp;to trade in currencies, securities and items of property in general, (9)&nbsp;to develop and trade in patent,
trademarks, licenses, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property rights, and (10)&nbsp;to perform any and all activity of an industrial, financial or commercial nature and to do anything which in the broadest
sense is connected with or may be conducive to the above-mentioned objects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitation on Liability and Indemnification Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Dutch law, directors may be held liable by us or by third parties for damages in the event of improper or negligent performance of their
duties, including as a result of infringement of our articles of association or of certain provisions of the Dutch Civil Code. In certain circumstances, they may also incur additional specific civil and criminal liabilities. Directors and certain
other officers are insured under an insurance policy taken out by us against damages resulting from their conduct when acting in the capacities as such directors or officers. In addition, our articles of association provide for indemnification of
our current and former directors (and such other of our current or former officer or employee as designated by our board of directors), including reimbursement for reasonable legal fees and damages or fines based on acts or failures to act in their
duties. No indemnification shall be given to an indemnified officer (1)&nbsp;if a competent court or arbitral tribunal has established, without possibility for appeal, that the acts or omissions of such indemnified officer that led to the financial
losses, damages, expenses, suit, claim, action or legal proceedings resulted from either an improper performance of his or her duties as an officer of the company or an unlawful or illegal act, (2)&nbsp;to the extent that his or her financial
losses, damages and expenses are covered by insurance and the insurer has settled, or has provided reimbursement for, these financial losses, damages and expenses (or has irrevocably undertaken to do so) and (3)&nbsp;in relation to proceedings
brought by such indemnified officer against us, except for proceedings brought to enforce indemnification to which he or she is entitled pursuant to our articles of association or an agreement between such indemnified officer and us which has been
approved by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, indemnification under our articles of association will generally not be available in
instances of willful misconduct (<I>opzet</I>), intentionally reckless (<I>bewust roekeloos</I>) or seriously culpable (<I>ernstig verwijtbaar</I>) conduct unless Dutch law provides otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholders&#146; Meetings and Consents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General Meeting </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General meetings of
shareholders are held in Utrecht, Amsterdam, Rotterdam, The Hague or in the municipality of Haarlemmermeer (Schiphol Airport), all of which are in the Netherlands. The annual general meeting of shareholders must be held within six months of the end
of each financial year. Additional extraordinary general meetings of shareholders may also be held, whenever considered appropriate by the board of directors. An additional extraordinary general meeting of shareholders must also be held within three
months </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
after our board of directors has considered it to be likely that our shareholders&#146; equity has decreased to an amount equal to or lower than half of our paid up and called up capital, in
order to discuss the measures to be taken if so required. If our board of directors has failed to ensure the annual general meeting of shareholders or the mandatory extraordinary general meeting of shareholders is held, each shareholder or others
with meeting rights under Dutch law may be authorized by the competent Dutch court in preliminary relief proceedings to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant
to Dutch law, one or more shareholders or others with meeting rights under Dutch law, who jointly represent at least <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the issued capital may request us to convene a general meeting, setting out in
detail the matters to be discussed. If our board of directors has not taken the steps necessary to ensure that such meeting can be held within six weeks after the request, the requesting party/parties may, on their application, be authorized by the
competent Dutch court in preliminary relief proceedings to convene a general meeting of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General meetings of shareholders
can be convened by a notice to be published in a Dutch daily newspaper with national circulation, which shall include an agenda stating the items to be voted and/or discussed and any other particulars required under Dutch law. The agenda shall
include such items as have been included therein by the board of directors. The agenda shall also include such items requested by one or more shareholders or others with meeting rights under Dutch law, representing at least 3% of the issued share
capital. Requests must be made in writing and received by us at least 60 days before the day of the meeting. No resolutions shall be adopted on items other than those which have been included in the agenda, unless by a unanimous vote of all
shareholders and others with voting rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the Dutch Corporate Governance Code, or DCGC, shareholders are expected to
exercise the right of requesting the convening of a general meeting of shareholders or of putting an item on the agenda only after consulting the board of directors in that respect. If one or more shareholders intend to request that an item be put
on the agenda that may result in a change in our strategy (e.g., the removal of directors), the board of directors should be given the opportunity to invoke a reasonable response time of up to 180 days after the board of directors is informed of the
intentions of the shareholder(s). The board of directors should use this period for further deliberation, constructive consultation (in any event with the shareholder(s) who have made the request) and the exploration of alternatives. At the end of
the response period, the board of directors should report its actions to the general meeting of shareholders. The response time may be invoked only once for any given general meeting of shareholders and may not be invoked for an agenda item in
respect of which the response period has been invoked previously or for a general meeting of shareholders if a shareholder holds at least 75% of our issued share capital as a consequence of a successful public offer (irrespective of whether the
offer was friendly or hostile). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general meeting is presided over by the chairman of the board of directors. If no chairman has been
elected or if he or she is not present at the meeting, the general meeting shall be presided over by the chief executive officer. If no chief executive officer has been elected or if he or she is not present at the meeting, the general meeting shall
be presided over by another director present at the meeting. If no director is present at the meeting, the general meeting shall be presided over by any other person appointed by the general meeting. In each case, the person who should chair the
general meeting pursuant to the rules described above may appoint another person to chair the general meeting instead. Directors may always attend a general meeting of shareholders. In these meetings, they have an advisory vote. The chairman of the
meeting may decide at his or her discretion to admit other persons to the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shareholders and others with meeting rights under
Dutch law are authorized to attend the general meeting of shareholders, to address the meeting and, in so far as they have such right, to vote. For this purpose, those who have voting rights and/or meeting rights under Dutch law on the record date
for a general meeting of shareholders (i.e., the 28th day prior to the meeting) and are recorded as such in a register designated by the board of directors shall be considered to have those rights, irrespective of whoever is entitled to the shares
at the time of the general meeting of shareholders. The board of directors is free to determine, when convening a general meeting of shareholders, whether to apply a record date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Quorum and Voting Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each common share and each preferred share carries the right to cast one vote at the general meeting of shareholders. This right can be
exercised in person or by proxy. No vote may be cast at a general meeting of shareholders in respect of a share belonging to us or any of our subsidiaries or in respect of a share for which we or any of our subsidiaries holds the depository
receipts. Persons with a right to the use and enjoyment of our shares held by another person and pledgees of shares belonging to us or our subsidiaries are not precluded from exercising their voting rights if the right to use and enjoyment or pledge
was created before the relevant share belonged to us or one of our subsidiaries. We and our subsidiaries may not vote shares in respect of which we or any of our subsidiaries hold(s) a right of use and enjoyment or a pledge. Shares which cannot be
voted pursuant to these rules will not be taken into account for the purpose of determining the number of votes cast, or the amount of the share capital that is represented, at a general meeting of shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Dutch law and generally accepted business practices, our articles of association do not provide quorum requirements
generally applicable to general meetings of shareholders. Quorum requirements will only apply pursuant to Dutch law in case of a limited number of situations. Decisions of the general meeting of shareholders are taken by a simple majority of votes
cast, except where Dutch law or our articles of association provide for a qualified majority or unanimity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Election of Directors </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our articles
of association, the directors are appointed by the general meeting of shareholders upon nomination by our board of directors. However, the general meeting of shareholders may at all times overrule the binding nomination by a resolution adopted by at
least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes cast, provided such majority represents more than half of the issued share capital. If the general meeting of shareholders overrules the binding nomination, the board
of directors shall make a new nomination. If the nomination comprises one candidate for a vacancy, a resolution concerning the nomination shall result in the appointment of the candidate, unless the nomination is overruled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At a general meeting of shareholders, a resolution to appoint a director can only be passed in respect of candidates whose names are stated
for that purpose in the agenda of that general meeting of shareholders or in the explanatory notes thereto. Upon the appointment of a person as a director, the general meeting of shareholders shall determine whether that person is appointed as
executive director or as <FONT STYLE="white-space:nowrap">non-executive</FONT> director. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Duties and Liabilities of Directors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Dutch law, the board of directors as a collective is responsible for our management, strategy, policy and operations. The executive
directors manage our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business and operations and implement our strategy. The <FONT STYLE="white-space:nowrap">non-executive</FONT> directors focus on the
supervision on the policy and functioning of the performance of the duties of all directors and our general state of affairs. Each director has a statutory duty to act in the corporate interest of the company and its business. Under Dutch law, the
corporate interest extends to the interests of all corporate stakeholders, such as shareholders, creditors, employees, customers and suppliers. The duty to act in the corporate interest of the company also applies in the event of a proposed sale or <FONT
STYLE="white-space:nowrap">break-up</FONT> of the company, provided that the circumstances generally dictate how such duty is to be applied and how the respective interests of various groups of stakeholders should be weighed. Any resolution of the
board of directors regarding a material change in our identity or character requires approval of the general meeting of shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends and
Other Distributions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amount Available for Distribution </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a Dutch public company with limited liability (<I>naamloze vennootschap</I>), we may only make distributions to the extent that our
shareholders&#146; equity exceeds the sum of the <FONT STYLE="white-space:nowrap">paid-in</FONT> and <FONT STYLE="white-space:nowrap">called-up</FONT> share capital plus the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reserves as required to be maintained by Dutch law. Under our articles of association, a dividend is first paid out of the profit, if available for distribution, with respect to any preferred
shares. After that, the board of directors shall determine which part of the remaining profit shall be added to our reserves. After reservation by the board of directors of any profit, the remaining profit will be at the disposal of the general
meeting of shareholders for distribution on our common shares. However, a distribution to the holders of common shares can only be resolved upon by the general meeting upon a proposal of the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may only make a distribution of dividends after the adoption of our annual accounts demonstrating that such distribution is legally
permitted. The board of directors is permitted, subject to certain requirements, to declare interim dividends (or other interim distributions) without the approval of the general meeting of shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general meeting of shareholders, subject to certain requirements and a proposal to that effect made by the board of directors, may decide
to make distributions from our distributable reserves. The board of directors, however, may resolve to charge amounts to be paid up on shares against our reserves, irrespective of whether those shares are issued to existing shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends and other distributions shall be payable on such date and, if it concerns a distribution in cash, in such currency as determined by
the board of directors. If it concerns a distribution in the form of assets, the board of directors shall determine the value attributed to such distribution for purposes of recording the distribution in our accounts with due observance of
applicable law (including the applicable accounting principles). Claims to dividends and other distributions not paid within five years from the date that such dividends or distributions became payable, will lapse and any such amounts will be
considered to have been forfeited to us (<I>verjaring</I>). For the purpose of calculating the amount or allocation of any distribution, shares held by us in our own capital shall not be taken into account. No distribution shall be made to us in
respect of shares held by us in our own capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not anticipate paying any cash dividends for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Squeeze out Procedures </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Dutch law,
a shareholder who, alone or together with one or more group companies, for his/their own account contribute(s) at least 95% of our issued share capital may initiate proceedings against our minority shareholders jointly for the transfer of their
shares to the claimant. The proceedings are held before the Enterprise Chamber of the Amsterdam court of Appeal, or Enterprise Chamber. The Enterprise Chamber may grant the claim for squeeze out in relation to all minority shareholders and will
determine the price to be paid for the shares, if necessary after appointment of one or three experts who will offer an opinion to the Enterprise Chamber on the value to be paid for the shares of the minority shareholders. Once the order to transfer
becomes final before the Enterprise Chamber, the shareholder acquiring the shares shall give written notice of the date and place of payment and the price to the holders of the shares to be acquired whose addresses are known to such shareholder.
Unless the addresses of all of them are known to the acquiring shareholder, such shareholder is required to publish the same in a Dutch daily newspaper with a national circulation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Protective measures </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Dutch
law, various protective measures are possible and permissible within the boundaries set by Dutch law and Dutch case law. Our governance arrangements include several provisions that may have the effect of making a takeover of our company more
difficult or less attractive. In this respect, our general meeting of shareholders has granted the right to the Protective Foundation to acquire preferred shares pursuant to a call option agreement entered into on May&nbsp;6, 2016, or the call
option agreement. This call option is continuous in nature and can be exercised repeatedly on multiple occasions. If the Protective Foundation exercises the call option pursuant to the call option agreement, an amount of preferred shares up to 100%
of our issued capital held by third parties immediately prior to the issuance of such preferred shares will be issued to the Protective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Foundation. These preferred shares will be issued to the Protective Foundation under the obligation to pay up to 25% of their nominal value upon issuance. In order for the Protective Foundation
to finance the issue price in relation to the preferred shares, the Protective Foundation intends to enter into a finance arrangement with a bank. As an alternative to securing financing with a bank, subject to applicable restrictions under Dutch
law, the call option agreement provides that the Protective Foundation may request us (1)&nbsp;to provide, or cause our subsidiaries to provide, sufficient funding to the Protective Foundation to enable it to satisfy the payment obligation (or part
thereof) in cash and/or (2)&nbsp;to charge an amount equal to the payment obligation (or part thereof) against our profits and/or reserves in satisfaction of such payment obligation. The Protective Foundation&#146;s articles of association provide
that it will promote and protect the best interests of us, our associated business and our stakeholders and opposing influences that conflict with these interests and threaten our strategy, continuity, independence and/or identity. These influences
may include a third party acquiring a significant percentage of our common shares, the announcement of an unsolicited public offer for our common shares, other concentration of control over our common shares or any other form of undue pressure on us
to alter our strategic policies. The Protective Foundation is structured to operate independently of us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As indicated above, if the
Protective Foundation would exercise its call option, the preferred shares to be issued pursuant thereto shall be issued against the obligation to pay up to 25% of their nominal value. The voting rights of our shares are based on nominal value and,
as we expect our common shares to trade substantially in excess of nominal value, preferred shares issued at 25% of their nominal value can carry significant voting power for a substantially reduced price compared to the price of our common shares
and thus can be used as a defensive measure. These preferred shares will have both a liquidation and dividend preference over our common shares and will accrue cash dividends at a <FONT STYLE="white-space:nowrap">pre-determined</FONT> rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Protective Foundation would be expected to require us to cancel its preferred shares once the perceived threat to the company and its
stakeholders has been removed or sufficiently mitigated or neutralized. However, subject to the same limitations described above, the Protective Foundation would continue to have the right to exercise the call option in the future in response to a
new threat to the interests of us, our business and our stakeholders from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our articles of association contain
certain provisions which might have the effect of delaying or preventing a change in control or otherwise discouraging a potential acquirer from attempting to obtain control of us. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements that certain shareholder matters, including the amendment of our articles of association may only be
voted on by the general meeting of shareholders at the proposal of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a provision that our directors may only be removed by the general meeting of shareholders by a <FONT
STYLE="white-space:nowrap">two-</FONT> thirds majority of votes cast, provided such majority represents more than half of our issued share capital if such removal is not proposed by our board of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our directors being appointed on the basis of a binding nomination by our board of directors, which can only be
overruled by the general meeting of shareholders by a resolution adopted by at least a <FONT STYLE="white-space:nowrap">two-</FONT> thirds majority of the votes cast, provided such majority represents more than half of the issued share capital (in
which case the board of directors shall make a new nomination). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, we may implement staggered terms of up to four
years for our directors, as a result of which only approximately <FONT STYLE="white-space:nowrap">one-fourth</FONT> of our directors will be subject to election in any one year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Dutch Corporate Law and Our Articles of Association and U.S. Corporate Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following comparison between Dutch corporation law, which applies to us, and Delaware corporation law, the law under which many publicly
listed corporations in the United States are incorporated, discusses additional matters not otherwise described in this prospectus. Although we believe this summary is materially accurate, the summary is subject to Dutch law, including Book 2 of the
Dutch Civil Code, and Delaware corporation law, including the Delaware General Corporation Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Governance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Duties of Directors </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The
Netherlands</I>. We have a <FONT STYLE="white-space:nowrap">one-tier</FONT> board structure consisting of one or more executive directors and one or more <FONT STYLE="white-space:nowrap">non-executive</FONT> directors. Under Dutch law, the board of
directors as a collective is responsible for the management and the strategy, policy and operations of the company. See &#147;&#151;Board of Directors&#151;Duties and Liabilities of Directors.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. The board of directors bears the ultimate responsibility for managing the business and affairs of a corporation. In
discharging this function, directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its stockholders. Delaware courts have decided that the directors of a Delaware corporation are required to exercise
informed business judgment in the performance of their duties. Informed business judgment means that the directors have informed themselves of all material information reasonably available to them. Delaware courts have also imposed a heightened
standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation. In addition, under Delaware law, when the board of directors of a Delaware corporation approves
the sale or <FONT STYLE="white-space:nowrap">break-up</FONT> of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Terms </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Netherlands.
</I>The DCGC provides the following best practice recommendations on the terms for directors&#146; service: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Executive directors should be appointed for a maximum period of four years, without limiting the number of
consecutive terms executive directors may serve. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Non-executive</FONT> directors should be appointed for two consecutive periods
of no more than four years. Thereafter, <FONT STYLE="white-space:nowrap">non-executive</FONT> directors may be reappointed for a maximum of two consecutive periods of no more than two years, provided that any reappointment after an eight-year term
of office should be disclosed and explained in the company&#146;s annual board report. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive director currently
has an employment agreement with us for an indefinite period of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general meeting of shareholders shall at all times be entitled
to suspend or remove a director. Under our articles of association, the general meeting of shareholders may only adopt a resolution to suspend or remove such director by at least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the
votes cast, provided such majority represents more than half of the issued share capital, unless the resolution is passed at the proposal of the board of directors, in which case a simple majority of the votes cast is sufficient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware. </I>The Delaware General Corporation Law generally provides for a <FONT STYLE="white-space:nowrap">one-year</FONT> term for
directors, but permits directorships to be divided into up to three classes with up to three-year terms, with the years for each class expiring in different years, if permitted by the certificate of incorporation, an initial bylaw or a bylaw adopted
by the stockholders. A director elected to serve a term on a &#147;classified&#148; board may not be removed by stockholders without cause. There is no limit in the number of terms a director may serve. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Vacancies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Netherlands.
</I>Under Dutch law, directors are appointed and reappointed by the general meeting of shareholders. Under our articles of association, directors are appointed by the general meeting of shareholders upon the binding nomination by our board of
directors. However, the general meeting of shareholders may at all times overrule the binding nomination by a resolution adopted by at least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes cast, provided such majority
represents more than half of the issued share capital. If the general meeting of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shareholders overrules the binding nomination, the board of directors shall make a new nomination. If the nomination comprises one candidate for a vacancy, a resolution concerning the nomination
shall result in the appointment of the candidate, unless the nomination is overruled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our articles of association, a resolution of
the general meeting of shareholders to appoint a director can only be passed in respect of candidates whose names are stated for that purpose in the agenda of that general meeting of shareholders or in the explanatory notes thereto. Upon the
appointment of a person as a director, the general meeting of shareholders shall determine whether that person is appointed as executive director or as <FONT STYLE="white-space:nowrap">non-</FONT> executive director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. The Delaware General Corporation Law provides that vacancies and newly created directorships may be filled by a majority of
the directors then in office (even though less than a quorum) unless (i)&nbsp;otherwise provided in the certificate of incorporation or bylaws of the corporation or (ii)&nbsp;the certificate of incorporation directs that a particular class of stock
is to elect such director, in which case any other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Conflict-of-Interest</FONT></FONT> Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Netherlands</I>. Under Dutch law and our articles of association, our directors shall not take part in any discussion or decision-making
that involves a subject or transaction in relation to which he or she has a conflict of interest with us. Our articles of association provide that if as a result thereof no resolution of the board of directors can be adopted, the resolution can
nonetheless be adopted by the board of directors as if none of the directors had a conflict of interest. In that case, each director is entitled to participate in the discussion and decision-making process and to cast a vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DCGC provides the following best practice recommendations in relation to conflicts of interests: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a director should report any potential conflict of interest in a transaction that is of material significance to
the company and/or to such director to the other directors without delay, providing all relevant information in relation to the conflict; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the board of directors should then decide, outside the presence of the director concerned, whether there is a
conflict of interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transactions in which there is a conflict of interest with a director should be agreed on arms&#146; length
terms; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decision to enter into such a transaction in which there is a conflict of interest with a director that is of
material significance to the company and/or to such director shall require the approval of the board of directors, and such transactions should be disclosed in the company&#146;s annual board report. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. The Delaware General Corporation Law generally permits transactions involving a Delaware corporation and an interested
director of that corporation if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the material facts as to the director&#146;s relationship or interest are disclosed and a majority of
disinterested directors consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the material facts are disclosed as to the director&#146;s relationship or interest and a majority of shares
entitled to vote thereon consent; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the transaction is fair to the corporation at the time it is authorized by the board of directors, a committee of
the board of directors or the stockholders. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proxy Voting by Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Netherlands. </I>An absent director may issue a proxy for a specific board meeting but only to another director in writing (including in
electronic form). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware. </I>A director of a Delaware corporation may not issue a proxy representing the
director&#146;s voting rights as a director. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholder Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Netherlands. </I>In
accordance with Dutch law and our articles of association, each issued common share confers the right to cast one vote at the general meeting of shareholders. No vote may be cast at a general meeting of shareholders in respect of a share belonging
to us or any of our subsidiaries or in respect of a share for which we or any of our subsidiaries holds the depository receipts. Persons with a right to the use and enjoyment of our shares held by another person and pledgees of shares belonging to
us or our subsidiaries are not precluded from exercising their voting rights if the right to use and enjoyment or pledge was created before the relevant share belonged to us or one of our subsidiaries. We and our subsidiaries may not vote shares in
respect of which we or any of our subsidiaries hold(s) a right of use and enjoyment or a pledge. Shares which cannot be voted pursuant to these rules will not be taken into account for the purpose of determining the number of votes cast, or the
amount of the share capital that is represented, at a general meeting of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each general meeting of shareholders, the
board of directors may apply a record date in order to establish which shareholders are entitled to attend and vote at the general meeting of shareholders. The record date and the manner in which shareholders can register and exercise their rights
will be set out in the notice of the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware. </I>Under the Delaware General Corporation Law, each stockholder is entitled
to one vote per share of stock, unless the certificate of incorporation provides otherwise. In addition, the certificate of incorporation may provide for cumulative voting at all elections of directors of the corporation, or at elections held under
specified circumstances. Either the certificate of incorporation or the bylaws may specify the number of shares and/or the amount of other securities that must be represented at a meeting in order to constitute a quorum, but in no event will a
quorum consist of less than one third of the shares entitled to vote at a meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders as of the record date for the meeting are
entitled to vote at the meeting, and the board of directors may fix a record date that is no more than 60 nor less than 10 days before the date of the meeting, and if no record date is set then the record date is the close of business on the day
next preceding the day on which notice is given, or if notice is waived then the record date is the close of business on the day next preceding the day on which the meeting is held. The determination of the stockholders of record entitled to notice
or to vote at a meeting of stockholders shall apply to any adjournment of the meeting, but the board of directors may fix a new record date for the adjourned meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shareholder Proposals </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The
Netherlands. </I>Pursuant to our articles of association, extraordinary general meetings of shareholders will be held whenever required under Dutch law or whenever our board of directors deems such to be appropriate or necessary. Pursuant to Dutch
law, one or more shareholders or others with meeting rights under Dutch law representing at least <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the issued share capital may request us to convene a general meeting, setting out in detail the
matters to be discussed. If our board of directors has not taken the steps necessary to ensure that such meeting can be held within six weeks after the request, the requesting party/parties may, on their application, be authorized by the competent
Dutch court in preliminary relief proceedings to convene a general meeting of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, under our articles of association, the
agenda for a general meeting of shareholders shall include such items requested by one or more shareholders, and others with meeting rights under Dutch law, representing at least 3% of the issued share capital. Requests must be made in writing and
received by us at least 60 days before </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the day of the meeting. In accordance with the DCGC, shareholders are expected to exercise the right of requesting the convening of a general meeting of shareholders or of putting an item on the
agenda only after consulting the board of directors in that respect. If one or more shareholders intend to request that an item be put on the agenda that may result in a change in our strategy (e.g., the removal of directors), the board of directors
should be given the opportunity to invoke a reasonable response time of up to 180 days after the board of directors is informed of the intentions of the shareholder(s). The board of directors should use this period for further deliberation,
constructive consultation (in any event with the shareholder(s) who have made the request) and the exploration of alternatives. At the end of the response period, the board of directors should report its actions to the general meeting of
shareholders. The response time may be invoked only once for any given general meeting of shareholders and may not be invoked for an agenda item in respect of which the response period has been invoked previously or for a general meeting of
shareholders if a shareholder holds at least 75% of our issued share capital as a consequence of a successful public offer (irrespective of whether the offer was friendly or hostile). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware. </I>Delaware law does not specifically grant stockholders the right to bring business before an annual or special meeting.
However, if a Delaware corporation is subject to the SEC&#146;s proxy rules, a stockholder who owns at least $2,000 in market value, or 1% of the corporation&#146;s securities entitled to vote, may propose a matter for a vote at an annual or special
meeting in accordance with those rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Action by Written Consent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Netherlands. </I>Our articles of association do not allow shareholders&#146; resolutions to be adopted in writing without holding a
meeting of shareholders. However, holders of preferred shares may pass resolutions in writing instead of at a meeting by a unanimous vote of all shareholders concerned. These votes may be cast electronically. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware. </I>Although permitted by Delaware law, publicly listed companies do not typically permit stockholders of a corporation to take
action by written consent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Appraisal Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Netherlands. </I>The concept of appraisal rights is not known as such under Dutch law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, pursuant to Dutch law a shareholder who, alone or together with one or more group companies, for his/ their own account contribute(s)
at least 95% of our issued share capital may initiate proceedings against our minority shareholders jointly for the transfer of their shares to the claimant. See &#147;&#151;Shareholder Vote on Certain Reorganizations&#151;The Netherlands.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, Dutch law provides that, to the extent that the acquiring company in a cross-border merger is organized under the laws of
another Member State of the European Economic Area, a shareholder of a Dutch disappearing company who has voted against the cross-border merger may file a claim with the Dutch company for compensation. Such compensation is to be determined by one or
more independent experts. The shares of such shareholder that are subject to such claim will cease to exist as of the moment of entry into effect of the cross-border merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. The Delaware General Corporation Law provides for stockholder appraisal rights, or the right to demand payment in cash of the
judicially determined fair value of the stockholder&#146;s shares, in connection with certain mergers and consolidations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shareholder Suits </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Netherlands. </I>In the event a third party is liable to a Dutch company, only the company itself can bring a civil action against that
party. The individual shareholders do not have the right to bring an action on behalf of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the company. If individual shareholders bring an action for damages against such a third party in their name, a court will under normal circumstances dismiss such a claim. Only in the event that
the cause for the liability of a third party to the company also constitutes a tortious act directly against a shareholder could that shareholder have an individual right of action against such third party in its own name. The Dutch Civil Code
provides for the possibility to initiate actions collectively. A foundation or an association whose objective is to protect the rights of a group of persons having similar interests can institute a collective action. The collective action itself
under the current state of law cannot result in an order for payment of monetary damages but may only result in a declaratory judgment (verklaring voor recht). In order to obtain compensation for damages, the foundation or association and the
defendant may reach&#151;often on the basis of such declaratory judgment&#151;a settlement. A Dutch court may declare the settlement agreement binding upon all the injured parties with an <FONT STYLE="white-space:nowrap">opt-out</FONT> choice for an
individual injured party. An individual injured party may also itself institute a civil claim for damages. A bill is currently pending before Dutch Parliament which, if enacted into law in its present form, would remove the restrictions on seeking
monetary damages on a collective basis while at the same time imposing additional requirements on collective action organizations as well as certain enhanced admissability thresholds for collective actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware. </I>Under the Delaware General Corporation Law, a stockholder may bring a derivative action on behalf of the corporation to
enforce the rights of the corporation. An individual also may commence a class action suit on behalf of himself and other similarly situated stockholders where the requirements for maintaining a class action under Delaware law have been met. A
person may institute and maintain such a suit only if that person was a stockholder at the time of the transaction which is the subject of the suit. In addition, under Delaware case law, the plaintiff normally must be a stockholder at the time of
the transaction that is the subject of the suit and throughout the duration of the derivative suit. Delaware law also requires that the derivative plaintiff make a demand on the directors of the corporation to assert the corporate claim before the
suit may be prosecuted by the derivative plaintiff in court, unless such a demand would be futile. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Repurchase of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Netherlands. </I>Under Dutch law, a limited liability company may not subscribe for newly issued shares in its own capital. A limited
liability company may, however, subject to certain restrictions of Dutch law and its articles of association, acquire shares in its own capital. We may acquire fully paid shares in our own capital at any time for no valuable consideration.
Furthermore, subject to certain provisions of Dutch law and our articles of association, we may repurchase fully paid shares in our own capital for valuable consideration to the extent that (i)&nbsp;such repurchase would not cause our
shareholders&#146; equity to fall below an amount equal to the sum of the <FONT STYLE="white-space:nowrap">paid-up</FONT> and <FONT STYLE="white-space:nowrap">called-up</FONT> part of the issued share capital and the reserves we are required to
maintain pursuant to applicable law and (ii)&nbsp;we would not as a result of such repurchase hold more than 50% of our own issued share capital, including shares held by our subsidiaries and shares in respect of which a pledge has been created in
our favor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than shares acquired for no valuable consideration, common shares may only be acquired following a resolution of our
board of directors, acting pursuant to an authorization for the repurchase of shares granted by the general meeting of shareholders. An authorization by the general meeting of shareholders for the repurchase of shares can be granted for a maximum
period of 18 months. Such authorization must specify the number and class of shares that may be acquired, the manner in which these shares may be acquired and the price range within which the shares may be acquired. At our annual general meeting of
shareholders held on July&nbsp;20, 2018, our board of directors was authorized, for a period of 18 months following the date of such meeting, to cause the repurchase of shares (or depository receipts for shares) by us of up to 10% of our issued
share capital (determined as at the close of business on the date of that meeting), for a price per share not exceeding 110% of the average closing price of our common shares on Nasdaq for the five trading days prior to the date the acquisition is
agreed upon by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No authorization of the general meeting of shareholders is required if common shares are
acquired by us with the intention of transferring such common shares to our employees (including employees of our group companies) under an applicable employee share purchase plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. Under the Delaware General Corporation Law, a corporation may purchase or redeem its own shares unless the capital of the
corporation is impaired or the purchase or redemption would cause an impairment of the capital of the corporation. A Delaware corporation may, however, purchase or redeem out of capital any of its preferred shares or, if no preferred shares are
outstanding, any of its own shares if such shares will be retired upon acquisition and the capital of the corporation will be reduced in accordance with specified limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Protective Measures </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The
Netherlands. </I>Under Dutch law, various protective measures are possible and permissible within the boundaries set by Dutch law and Dutch case law. Our governance arrangements include several provisions that may have the effect of making a
takeover of our company more difficult or less attractive, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the authorization of a class of preferred shares that can be issued to the Protective Foundation upon the
exercise by the Protective Foundation of its call option, in such a manner as to dilute the voting interest of any potential acquirer or activist; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility to appoint our board members for staggered terms, as a result of which only approximately <FONT
STYLE="white-space:nowrap">one-fourth</FONT> of our directors may be subject to election in any one year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a provision that our directors may only be removed by the general meeting of shareholders by a <FONT
STYLE="white-space:nowrap">two-</FONT> thirds majority of votes cast, provided such majority represents more than half of our issued share capital, if such removal is not proposed by our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our directors being appointed on the basis of a binding nomination by our board of directors, which can only be
overruled by the general meeting of shareholders by a resolution adopted by at least a <FONT STYLE="white-space:nowrap">two-</FONT> thirds majority of the votes cast, provided such majority represents more than half of the issued share capital (in
which case the board of directors shall make a new nomination); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements that certain shareholder matters, including an amendment of our articles of association, may only be
voted on by the general meeting of shareholders at the proposal of our board of directors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware. </I>In addition
to other aspects of Delaware law governing fiduciary duties of directors during a potential takeover, the Delaware General Corporation Law also contains a business combination statute that protects Delaware companies from hostile takeovers and from
actions following the takeover by prohibiting some transactions once an acquirer has gained a significant holding in the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the Delaware General Corporation Law prohibits &#147;business combinations,&#148; including mergers, sales and leases of
assets, issuances of securities and similar transactions by a corporation or a subsidiary with an interested stockholder that beneficially owns 15% or more of a corporation&#146;s voting stock, within three years after the person becomes an
interested stockholder, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the transaction that will cause the person to become an interested stockholder is approved by the board of
directors of the target prior to the transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after the completion of the transaction in which the person becomes an interested stockholder, the interested
stockholder holds at least 85% of the voting stock of the corporation not including shares owned by persons who are directors and officers of interested stockholders and shares owned by specified employee benefit plans; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after the person becomes an interested stockholder, the business combination is approved by the board of
directors of the corporation and holders of at least 66.67% of the outstanding voting stock, excluding shares held by the interested stockholder. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Delaware corporation may elect not to be governed by Section&nbsp;203 by a provision
contained in the original certificate of incorporation of the corporation or an amendment to the original certificate of incorporation or to the bylaws of the company, which amendment must be approved by a majority of the shares entitled to vote and
may not be further amended by the board of directors of the corporation. Such an amendment is not effective until twelve months following its adoption. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inspection of Books and Records </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Netherlands. </I>The board of directors should provide the general meeting of shareholders with all information requested by the general
meeting of shareholders, unless this would be contrary to an overriding interest of ours. If the board of directors invokes an overriding interest, it must give its reasons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware. </I>Under the Delaware General Corporation Law, any stockholder may inspect for any proper purpose certain of the
corporation&#146;s books and records during the corporation&#146;s usual hours of business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Removal of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Netherlands. </I>The general meeting of shareholders shall at all times be entitled to suspend or remove a director. Under our articles
of association, the general meeting of shareholders may only adopt a resolution to suspend or remove such a director by at least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes cast, provided such majority represents more
than half of the issued share capital, unless the resolution is passed at the proposal of the board of directors, in which latter case a simple majority of the votes cast is sufficient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware. </I>Under the Delaware General Corporation Law, any director or the entire board of directors may be removed, with or without
cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (i)&nbsp;unless the certificate of incorporation provides otherwise, in the case of a corporation whose board is classified, stockholders may
effect such removal only for cause, or (ii)&nbsp;in the case of a corporation having cumulative voting, if less than the entire board is to be removed, no director may be removed without cause if the votes cast against his removal would be
sufficient to elect him if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he is a part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preemptive Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The
Netherlands. </I>Under Dutch law and our articles of association, in the event of an issuance of common shares, each holder of common shares will have a pro rata preemptive right in proportion to the aggregate nominal value of the common shares held
by such holder (with the exception of common shares to be issued to our employees or employees of our group companies, common shares issued against a contribution other than in cash, or common shares issued to a party exercising a previously
acquired right to subscribe for such common shares). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our articles of association, the preemptive rights in respect of newly issued
common shares may be restricted or excluded by a resolution of the general meeting of shareholders at the proposal of the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors may restrict or exclude the preemptive rights in respect of newly issued common shares if it has been designated as the
authorized body to do so by the general meeting of shareholders. Such designation can be granted for a period not exceeding five years. A resolution of the general meeting of shareholders to restrict or exclude the preemptive rights or to designate
the board of directors as the authorized body to do so requires a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes cast, if less than one half of our issued share capital is represented at the meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our annual general meeting of shareholders held on July&nbsp;20, 2018, our board of
directors was authorized for a period of five years from the date of such meeting to limit or exclude preemptive rights in connection with the issue of common shares or the granting of rights to subscribe for common shares pursuant to the use of the
authorization also granted at such annual general meeting of shareholders to the board of directors to issue common shares and grant rights to subscribe for common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our articles of association, no preemptive rights apply in respect of preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. Under the Delaware General Corporation Law, stockholders have no preemptive rights to subscribe for additional issues of
stock or to any security convertible into such stock unless, and to the extent that, such rights are expressly provided for in the certificate of incorporation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Netherlands.
</I>Dutch law provides that dividends may be distributed after adoption of the annual accounts by the general meeting of shareholders from which it appears that such dividend distribution is allowed. Moreover, dividends, interim dividends (or other
interim distributions) and distributions from distributable reserves may only be made to the extent that shareholders&#146; equity exceeds the amount of the <FONT STYLE="white-space:nowrap">paid-up</FONT> and
<FONT STYLE="white-space:nowrap">called-up</FONT> part of the issued share capital and the reserves that must be maintained under Dutch law or the company&#146;s articles of association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our articles of association, a dividend is first paid out of the profit, if available for distribution, with respect to any preferred
shares. After that, the board of directors shall determine which part of the remaining profit shall be added to our reserves. After reservation by the board of directors of any profit, the remaining profit will be at the disposal of the general
meeting of shareholders for distribution on our common shares. However, a distribution to the holders of common shares can only be resolved upon by the general meeting at the proposal of the board of directors. We may only make a distribution of
dividends after the adoption of our annual accounts demonstrating that such distribution is legally permitted. The board of directors is permitted, subject to certain requirements, to declare interim dividends (or other interim distributions)
without the approval of the general meeting of shareholders. The general meeting of shareholders, subject to certain requirements and a proposal to that effect made by the board of directors, may decide to make distributions from our distributable
reserves. The board of directors, however, may resolve to charge amounts to be paid up on shares against our reserves, irrespective of whether those shares are issued to existing shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends and other distributions shall be payable on such date and, if it concerns a distribution in cash, in such currency as determined by
the board of directors. If it concerns a distribution in the form of assets, the board of directors shall determine the value attributed to such distribution for purposes of recording the distribution in our accounts with due observance of
applicable law (including the applicable accounting principles). Claims to dividends and other distribution not paid within five years from the date that such dividends or distributions became payable, will lapse and any such amounts will be
considered to have been forfeited to us (<I>verjaring</I>).For the purpose of calculating the amount or allocation of any distribution, shares held by us in our own capital shall not be taken into account. No distribution shall be made to us in
respect of shares held by us in our own capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware. </I>Under the Delaware General Corporation Law, a Delaware corporation may
pay dividends out of its surplus (the excess of net assets over capital), or in case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year (provided that the amount of the
capital of the corporation is not less than the aggregate amount of the capital represented by the issued and outstanding stock of all classes having a preference upon the distribution of assets). In determining the amount of surplus of a Delaware
corporation, the assets of the corporation, including stock of subsidiaries owned by the corporation, must be valued at their fair market value as determined by the board of directors, without regard to their historical book value. Dividends may be
paid in the form of common shares, property or cash. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholder Vote on Certain Reorganizations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Netherlands. </I>Under Dutch law, the general meeting of shareholders must approve resolutions of the board of directors relating to a
material change in the identity or the character of the company or the business of the company, which includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a transfer of the business or virtually the entire business to a third party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the entry into or termination of a long-term cooperation of the company or a subsidiary with another legal entity
or company or as a fully liable partner in a limited partnership or general partnership, if such cooperation or termination is of <FONT STYLE="white-space:nowrap">far-reaching</FONT> significance for the company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the acquisition or divestment by the company or a subsidiary of a participating interest in the capital of a
company having a value of at least <FONT STYLE="white-space:nowrap">one-third</FONT> of the amount of the company&#146;s assets according to its statement of financial position and explanatory notes or, if the company prepares a consolidated
statement of financial position, according to its consolidated statement of financial position and explanatory notes in the last adopted annual accounts of the company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Dutch law, a shareholder who, alone or together with one or more group companies, for his/their own account contribute(s) at least 95%
of a company&#146;s issued share capital may initiate proceedings against the company&#146;s minority shareholders jointly for the transfer of their shares to the claimant. The proceedings are held before the Enterprise Chamber, which may grant the
claim for squeeze out in relation to all minority shareholders and will determine the price to be paid for the shares, if necessary after appointment of one or three experts who will offer an opinion to the Enterprise Chamber on the value to be paid
for the shares of the minority shareholders. Once the order to transfer becomes final before the Enterprise Chamber, the shareholder acquiring the shares shall give written notice of the date and place of payment and the price to the holders of the
shares to be acquired whose addresses are known to such shareholder. Unless the addresses of all of them are known to the acquiring shareholder, such shareholder is required to publish the same in a Dutch daily newspaper with a national circulation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>. Under the Delaware General Corporation Law, the vote of a majority of the outstanding shares of capital stock entitled
to vote thereon generally is necessary to approve a merger or consolidation or the sale of all or substantially all of the assets of a corporation. The Delaware General Corporation Law permits a corporation to include in its certificate of
incorporation a provision requiring for any corporate action the vote of a larger portion of the stock or of any class or series of stock than would otherwise be required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Delaware General Corporation Law, no vote of the stockholders of a surviving corporation to a merger is needed, however, unless
required by the certificate of incorporation, if (i)&nbsp;the agreement of merger does not amend in any respect the certificate of incorporation of the surviving corporation, (ii)&nbsp;the shares of stock of the surviving corporation are not changed
in the merger and (iii)&nbsp;the number of shares of common stock of the surviving corporation into which any other shares, securities or obligations to be issued in the merger may be converted does not exceed 20% of the surviving corporation&#146;s
common stock outstanding immediately prior to the effective date of the merger. In addition, stockholders may not be entitled to vote in certain mergers with other corporations that own 90% or more of the outstanding shares of each class of stock of
such corporation, but the stockholders will be entitled to appraisal rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Remuneration of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Netherlands. </I>Under Dutch law, we must adopt a remuneration policy for our directors. Such remuneration policy, and changes thereto,
shall be adopted by the general meeting of shareholders at the proposal of the board of directors. The board of directors determines the remuneration of the directors in accordance with the remuneration policy. Our executive directors may not
participate in the discussions or decision-making regarding the remuneration of executive directors. A proposal by the board of directors with respect to remuneration schemes in the form of shares or rights to shares is submitted by the board of
directors to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
general meeting for its approval. This proposal must set out at least the maximum number of shares or rights to shares to be granted to the directors and the criteria for granting or amendment.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our shareholders approved our Supervisory Board Member Compensation Program at a general meeting on May&nbsp;6, 2016. Our shareholders
have approved certain amendments to such program, and the program has been renamed the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director Compensation Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware. </I>Under the Delaware General Corporation Law, the stockholders do not generally have the right to approve the compensation
policy for directors or the senior management of the corporation, although certain aspects of executive compensation may be subject to stockholder vote due to the provisions of U.S. federal securities and tax law, as well as exchange requirements.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dutch Corporate Governance Code </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DCGC contains both principles and best practice provisions for boards of directors, shareholders and general meetings of shareholders,
financial reporting, auditors, disclosure, compliance and enforcement standards. A copy of the DCGC can be found on <I>www.mccg.nl</I>. As a listed Dutch company incorporated under Dutch law, we are subject to the DCGC and are required to disclose
in our annual report, filed in the Netherlands, whether we comply with the provisions of the DCGC. If we do not comply with the provisions of the DCGC (for example, because of a conflicting Nasdaq requirement or otherwise), we must list the reasons
for any deviation from the DCGC in our annual report. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We acknowledge the importance of good corporate governance. However, at this stage,
we do not comply with all the provisions of the DCGC, to a large extent because such provisions conflict with or are inconsistent with the corporate governance rules of Nasdaq and U.S. securities laws that apply to us, or because such provisions do
not reflect best practices of global companies listed on Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussions below summarize the most important differences between
our governance structure and the principles and best practices of the DCGC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Risk management and internal audit function (best practice provisions 1.2.2, 1.3.1 and 1.3.2)</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not established an internal audit department. Our board of directors is of the opinion that adequate
alternative measures have been taken in the form of the company&#146;s risk management and control systems and that it is presently not necessary to establish an internal audit function. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Remuneration (best practice provisions 3.1.2, 3.2.3, 3.3.2 and 3.3.3)</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The options granted under the 2010 Plan vest in instalments over a four-year period from the grant date. Twenty- five percent of the options
vest on the first anniversary of the vesting commencement date, and the remaining 75% of the options vest in 36 monthly instalments for each full month of continuous service provided by the option holder thereafter, such that 100% of the options
shall become vested on the fourth anniversary of the vesting commencement date. The options granted are exercisable once vested. Options will lapse on the eighth anniversary of the date of grant. The options granted under the 2016 Plan will be
subject to vesting in accordance with the applicable award agreement and will be exercisable upon vesting. The term of options granted under the 2016 Plan may not be longer than ten years. We do not intend to comply with all of the requirements
under best practice provisions 3.1.2, 3.2.3, 3.3.2 and 3.3.3 of the DCGC as we believe it is in the best interest of the company to attract and retain highly skilled management board members on conditions based on market practice, as we believe
these are. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with market practice in the United States, the primary trading jurisdiction of our common shares, and in order to
further support our ability to attract and retain the right highly qualified candidates for a position on our board of directors, options awarded to our directors as part of their remuneration are subject to time-based
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vesting. The 2016 Plan under which shares may be granted (including to the executive directors) provides for the retention of shares for the time period specified in the applicable award
agreement. We believe that shares held by the members of our board of directors should be retained for a certain period; however, such period may be shorter than five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with market practice in the United States, our <FONT STYLE="white-space:nowrap">non-executive</FONT> directors receive rights to
acquire common shares in our capital as part of their remuneration and may also receive other equity-based remuneration. We believe that such remuneration structure is appropriate due to our listing on Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under circumstances, the severance payment to which our President&nbsp;&amp; Chief Executive Officer might become entitled could exceed the
maximum recommended by the DCGC. This deviation from the DCGC is justified as it is consistent with market practice in the United States. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Majority requirements for dismissal and setting-aside binding nominations (best practice
provision&nbsp;4.3.3)</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors are appointed by our general meeting of shareholders upon the binding
nomination by our board of directors. Our general meeting of shareholders may only overrule the binding nomination by a resolution passed by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of votes cast, provided such majority
represents more than half of our issued share capital. In addition, except if proposed by our board of directors, our directors may be suspended or dismissed by our general meeting of shareholders at any time by a resolution passed by a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> majority of votes cast, provided such majority represents more than half of the Company&#146;s issued share capital. The possibility to convene a new general meeting of shareholders as referred to in
Section&nbsp;2:120(3) of the Dutch Civil Code in respect of these matters has been excluded in our articles of association. We believe that these provisions support the continuity of the company and its business and that those provisions, therefore,
are in the best interests of our shareholders and our other stakeholders. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Attendance of board candidates at the general meeting of shareholders (best practice provision 4.1.8)</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to conflicting appointments, Mr.&nbsp;Kanavy and Mr.&nbsp;Greig could not be present at our annual general meeting
of shareholders held on July&nbsp;
20, 2018, where they were formally appointed as <FONT STYLE="white-space:nowrap">non-executive</FONT> directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_46"></A>C. Material
Contracts. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into the following material contracts since the period beginning two years prior to the date of this Annual
Report. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Underwriting Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
entered into an underwriting agreement with Citigroup Global Markets, Inc. and Jefferies LLC, as representatives of the underwriters, on May&nbsp;18, 2016, for the initial public offering of our common shares. We have agreed to indemnify the
underwriters against certain liabilities, including liabilities under the Securities Act, and to contribute to payments the underwriters may be required to make in respect of such liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License and Collaboration Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have entered into license and collaboration agreements with Incyte Corporation, ONO Pharmaceuticals, Inc. Simcere Pharmaceutical Group, and Betta Pharmaceuticals Co. Ltd. Information on these agreements may be found in this Annual Report under
&#147;Item 4&#151;Information on the Company&#151;Collaboration Agreements&#148; and is incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with our executive officers. Information on these agreements may be found in this Annual
Report under &#147;Item 6&#151;Directors, Senior Management and Employees&#151;Compensation&#148; and is incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with members of our board of directors and our executive officers. Information on the
indemnification agreements may be found in this Annual Report under &#147;Item 7&#151;Major Shareholders and Related Party Transactions&#151;Indemnification Agreements&#148; and is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
entered into registration rights agreements with Incyte under the Share Subscription Agreement and with certain of our shareholders under a Registration Rights Agreement. Information on the registration rights agreements may be found in this Annual
Report under &#147;Item 7&#151;Major Shareholders and Related Party Transactions&#151;Registration Rights&#148; and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into a stock purchase agreement and registration rights agreement concerning, wherein we received aggregate gross proceeds of
approximately $55.8&nbsp;million from a private placement offering closed on February&nbsp;15, 2018 (see Note 1). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;1, 2016, we entered into a lease agreement with Stichting Incubator Utrecht for approximately 11,125 square feet of office and
laboratory space in Utrecht, the Netherlands. The lease has a term of five years and expires on October&nbsp;31, 2021. The agreed rental price is &#128;0.4&nbsp;million per year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2018, we entered into a separate lease agreement with Stichting Incubator Utrecht and leased additional space to expense our
office and laboratory space in Utrecht, the Netherlands. The lease has a team of three years and six months and expires on October&nbsp;31, 2021. The agreed rental price is &#128;0.6&nbsp;million per year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2019, we entered in a lease agreement for approximately 7,583 square feet of office space in Cambridge, Massachusetts. The lease has
a term of seven years and expires on April&nbsp;1, 2026. The lease provides for escalating rent each year, with total cash payments of approximately $4.9&nbsp;million, or &#128;4.2&nbsp;million, payable over the lease term. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_47"></A>D. Exchange Controls. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the existing laws of the Netherlands, there are no exchange controls applicable to the import or export of capital, including the
availability of cash and cash equivalents for use by us or to the transfer to persons outside of the Netherlands of dividends or other distributions with respect to, or of the proceeds from the sale of, shares of a Dutch company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_48"></A>E. Taxation. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material
Dutch Tax Considerations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following paragraphs summarize a number of material Dutch tax considerations relating to the purchase,
ownership and disposition of our common shares during 2018. The following is intended as general information only, and is in no way a comprehensive or complete description of all aspects of Dutch tax law that may be relevant for a holder of common
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective shareholders should consult their tax advisor regarding the tax consequences of any purchase, ownership or disposal
of common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary is based on the Dutch tax law as applied and interpreted by Dutch tax courts, and as published
and effective on the date hereof, without prejudice to any amendments introduced at a later date and implemented with or without retroactive effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purpose of this paragraph, &#147;Dutch Taxes&#148; shall mean taxes of whatever
nature levied by or on behalf of the Netherlands or any of its subdivisions or taxing authorities. The Netherlands means the part of the Kingdom of the Netherlands located in Europe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where in this Dutch taxation paragraph reference is made to &#147;Shareholder,&#148; that concept includes, but is not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an owner of one or more common shares who has both an economic interest in those common shares, as well as the
title to those common shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a person who, or an entity that, holds the entire economic interest in one or more common shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a person who, or an entity that, holds an interest in an entity, that is transparent for Dutch tax purposes,
such as a partnership or a mutual fund, the assets of which comprise of one or more common shares, within the meaning of items (1)&nbsp;or (2) above: or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a person who is deemed to hold an interest in common shares, as referred to under items&nbsp;(1) through (3),
pursuant to the attribution rules of article 2.14a, of the Dutch Income Tax Act 2001 (<I>Wet inkomstenbelasting 2001</I>, or ITA), with respect to property that has been segregated, for instance in a trust or a foundation. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Taxes on Income and Capital Gains </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section provides an overview of general Dutch tax consequences that may be relevant for Shareholders, but does not describe the possible
Dutch tax considerations or consequences that may be relevant to a Shareholder who is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual for whom the income or capital gains derived from the common shares is attributable to employment
activities including deemed employment activities performed by such holders or certain individuals related to such holders (as defined in the ITA) or statutory directors (<I>bestuurders</I>) or supervisory directors (<I>commissarissen</I>) of a
company resident in the Netherlands, the income from which is taxable in the Netherlands; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an entity that is not subject to Dutch corporate income tax or is in full or in part exempt from Dutch corporate
income tax (such as pension funds), as well as entities that are exempt from Dutch corporate income tax, as well as entities that are exempt from Dutch corporate income tax in their country of residence, such country of residence being another state
of the European Union, Norway, Liechtenstein, Iceland or any other state with which the Netherlands have agreed to exchange information in line with international standards; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investment institution (<I>beleggingsinstelling</I>) as defined in article 6a (<I>vrijgestelde
beleggingsinstelling)</I> or 28 (<I>fiscale beleggingsinstelling) </I>of the Dutch 1969 Corporate income tax act (<I>Wet op de vennootschapsbelasting 1969</I>, or CITA); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an entity entitled to the participation exemption regime (<I>deelnemingsvrijstelling</I>) with respect to the
common shares as defined in article 13, CITA. A participation generally exists in case of a shareholding of at least 5% of the company&#146;s <FONT STYLE="white-space:nowrap">paid-in</FONT> share capital. A holder may also have a participation if
such holder does not have a 5% shareholding but a related entity (statutorily defined term) has a participation or if the company in which the shares are held is a related entity (statutorily defined term); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a holder of a lucrative interest (<I>lucratief belang</I> as defined in article 3.92b ITA), as we assume no
employees of the company purchased the common shares issued in our initial public offering; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a holder of a substantial interest <I>(aanmerkelijk belang</I> as defined in chapter 4 ITA), which is generally
the case when the Shareholder, alone, or where such shareholder is an individual, together with his or her partner (statutorily defined term), directly or indirectly, holds or is deemed to hold (a)&nbsp;an interest of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
at least 5% in either the capital or the voting rights of any class of shares in the Company, (b)&nbsp;rights or options to obtain such interest or (c)&nbsp;certain profit sharing rights in the
Company. A deemed substantial interest may arise if part of a substantial interest in a company has been disposed of, or is deemed to have been disposed of, on a <FONT STYLE="white-space:nowrap">non-recognition</FONT> basis. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dutch Residents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The description of certain Dutch tax consequences in this paragraph is only intended for Shareholders that are either individuals who are
resident or deemed to be resident in the Netherlands for Dutch income tax purposes, (&#147;Dutch Individuals&#148;), or entities that are subject to the CITA and are resident or deemed to be resident in the Netherlands for corporate income tax
purposes, (&#147;Dutch Corporate Entities&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dutch resident individuals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dutch Individuals that derive or are deemed to derive any benefits from common shares (including any capital gains realized on the disposal of
such common shares) which benefits are attributable to an enterprise from which the Dutch Individual derives profits, whether as an entrepreneur (<I>ondernemer</I>) or pursuant to a <FONT STYLE="white-space:nowrap">co-entitlement</FONT> to the net
value of an enterprise (<I>medegerechtigd tot het vermogen)</I>, other than as a shareholder, are generally subject to Dutch income tax on those benefits at progressive rates with a maximum of 51.95%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dutch Individuals that derive or are deemed to derive any benefits from common shares, including any gains realized on the disposal of such
common shares, that constitute benefits from miscellaneous activities (<I>resultaat uit overige werkzaamheden</I>), are generally subject to Dutch income tax at progressive rates on such benefits with a maximum of 51.95%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dutch Individuals may, among other things, derive, or be deemed to derive, benefits from common shares that are taxable as benefits from
miscellaneous activities in case the investment activities go beyond the activities of an active portfolio investor (<I>normaal actief vermogensbeheer)</I>, due to, for instance, the use of insider knowledge (<I>voorkennis</I>) or comparable forms
of special knowledge. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dutch Individuals, whose common shares are not attributable to an enterprise, and whose common shares do not
qualify as generating income from miscellaneous activities will not be subject to Dutch income tax on the actual income (including capital gains) derived from the common shares. Instead, those Dutch Individuals will be taxed at a flat rate of 30% on
the deemed income from savings and investments (<I>sparen en beleggen</I>). This amount of deemed income depends on the total net value of all savings and investments of a taxpayer that are subject to the tax regime applicable to savings and
investments in excess of the statutory defined exempt net asset amount (<I>heffingsvrij </I>vermogen) of &#128;30,000 (or &#128;60,000 in case of fiscal partnership). The total net value in excess of the exempt net asset amount and up to and
including &#128;70,800 (in excess of the exempt net asset amount) will be deemed to yield a return of 2.02%. A deemed return of 4.33% applies to the range between the total net value in excess of the sum of the defined exempt net asset amount and
&#128;70,800 up to and including &#128;978,000 in excess of the defined exempt net asset amount. Insofar the total net value in excess of the defined exempt net asset amount exceeds &#128;978,000, a deemed yield return of 5.38% applies. The yield
basis would normally consist of the fair market value of the common shares generally to be determined at the beginning of the relevant year. Based on Dutch legislation, the deemed return on savings and investments will be amended annually. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dutch resident entities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dutch Corporate Entities are subject to corporate income tax on income, including capital gains, derived from the common shares. The first
&#128;200,000 profits are taxable at a rate of 20%, while any profits in excess of &#128;200,000 are taxable at a rate of 25%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Dutch</FONT> residents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Dutch</FONT> resident individuals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Shareholder that is an individual and not a resident or deemed resident of the Netherlands,
<FONT STYLE="white-space:nowrap">(&#147;Non-Resident</FONT> Individuals&#148;), for Dutch tax purposes, will not be subject to any Dutch taxes on income (other than the dividend withholding tax described below) or capital gains in respect of
dividends distributed by the Company or in respect of any gains realized on the disposal of common shares unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Individual derives profits from an enterprise, or
pursuant to a <FONT STYLE="white-space:nowrap">co-entitlement</FONT> to the net value of such enterprise, other than as a holder of securities, which enterprise either is managed in the Netherlands or carried out, in whole or in part, through a
permanent establishment or a permanent representative which is taxable in the Netherlands and the common shares are attributable to such enterprise; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-Resident</FONT> Individual derives benefits or is deemed to derive
benefits from common shares that are taxable as benefits from miscellaneous activities in the Netherlands. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If either of
the conditions above apply, income or capital gains in respect of dividends distributed by the Company or in respect of any gain realized on the disposal of common shares will in general be subject to Dutch income tax at the progressive rates with a
maximum of 51.95%, on the understanding that such benefits derived as benefits from miscellaneous activities will only be taxable in the Netherlands if such activities are performed or deemed to be performed in the Netherlands. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Dutch</FONT> resident entities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Shareholder, other than an individual, that is not a resident or deemed resident of the Netherlands for Dutch tax purposes, will not be
subject to any Dutch taxes on income or capital gains (other than the dividend withholding tax described below) in respect of dividends distributed by the Company or in respect of any gain realized on the disposal of common shares, unless that
Shareholder derives profits from an enterprise, or pursuant to a <FONT STYLE="white-space:nowrap">co-entitlement</FONT> to the net value of such enterprise other than as a holder of securities, which enterprise either is managed in the Netherlands
or carried out, in whole or in part, through a permanent establishment or a permanent representative which is taxable in the Netherlands and the common shares are attributable to such enterprise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the condition above applies, income and capital gains derived from the common shares will, in general, be subject to regular Dutch
corporate income tax. The first &#128;200,000 profits are taxable at a rate of 20%, while any profits in excess of &#128;200,000 are taxable at a rate of 25%. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividend withholding tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends payments, or Dividend Payments, made by the Company are generally subject to 15% Dutch dividend withholding tax. The Company is
responsible for withholding the Dutch dividend withholding tax, while the tax is ultimately for the account of the Shareholder. The term &#145;Dividend Payments&#146; includes, but is not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distributions in cash or in kind, as well as deemed or constructive distributions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liquidation proceeds, proceeds of redemption of common shares or, generally, considerations in excess of the
average <FONT STYLE="white-space:nowrap">paid-in</FONT> capital recognized for Dutch dividend withholding tax purposes, paid upon the repurchase of common shares by the company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the nominal value of common shares issued to a holder of common shares or an increase of the nominal value of
common shares, to the extent that it does not appear that a contribution, recognized for Dutch dividend withholding tax purposes, has been made or will be made; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partial repayment of <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, recognized for Dutch dividend
withholding tax purposes, if and to the extent that there are Net Profits (<I>zuivere winst</I>), unless </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the general meeting of the shareholders has resolved in advance to make such repayment; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the nominal value of the common shares concerned has been reduced by a corresponding amount by way of an
amendment of the Company&#146;s articles of association in advance of such a repayment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term Net Profits includes
anticipated profits that have yet to be realized but that are reasonably certain and determinable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a Shareholder is a resident for
Dutch tax purposes of a country other than the Netherlands, and is considered to be a resident of Aruba or St. Martin under the provisions of the Tax Convention for the Kingdom of the Netherlands (<I>Belastingregeling voor het Koninkrijk</I>), a
resident of Curacao under the provisions of the Tax Convention between the Netherlands and Curacauo or is considered to be a resident of a country other than the Netherlands under the provisions of the double taxation convention between that country
of residence and the Netherlands, that Shareholder may be eligible for a full or partial exemption from, or refund of Dutch dividend withholding tax, depending on the terms of the applicable double taxation convention. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, subject to certain conditions and based on the implementation of the EU Parent Subsidiary Directive (Directive 90/435/EEG, as
amended) in Dutch legislation, an exemption from Dutch dividend withholding tax may exist for Dividend Payments to certain qualifying entities that are resident in another EU Member State or in a State of the EEA, if that entity holds at least 5% of
the share capital of the Company. Further, an exemption from Dutch dividend withholding tax may exist for Dividend Payments to certain qualifying entities that are resident of a State with which the Netherlands has concluded a convention for the
avoidance of double taxation that covers dividend distributions, if that entity hold at least 5% of the share capital of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
qualifying <FONT STYLE="white-space:nowrap">tax-exempt</FONT> entity that is a resident of a Member State of the EU, or that is a resident of a State of the EEA, may be eligible for a refund of withheld Dutch dividend withholding taxes, if the
entity would not have been subject to Dutch corporate income tax had it been a tax resident of the Netherlands </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Qualifying investors (such
as pension funds, sovereign wealth funds and exempt government bodies) from outside the EU and the EEA <FONT STYLE="white-space:nowrap">(so-called</FONT> third countries) may be eligible for a refund of Dutch dividend withholding tax. The refund
only applies to portfolio investments when the following conditions are cumulatively met: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Shareholder is resident in a designated country with which the Netherlands has concluded adequate
arrangements for the exchange of information; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Shareholder is not subject to any profits tax or is exempt from any profits tax in the country of its
residence and would not have been subject to Dutch corporate income tax, if the Shareholder had been resident in the Netherlands. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dutch Individuals and Dutch Corporate Entities can generally credit Dutch dividend withholding tax against their personal income tax
respectively corporate income tax liability. The same generally applies to Shareholders that are neither resident nor deemed resident of the Netherlands if the common shares are attributable to a Dutch permanent establishment of such a <FONT
STYLE="white-space:nowrap">non-resident</FONT> Shareholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to legislation introduced to counteract the practice of dividend
stripping, a reduction, exemption, credit or refund of Dutch dividend withholding tax is interalia denied if the recipient of the Dividend Payment does not qualify as the beneficial owner (<I>uiteindelijk gerechtigde</I>) of that Dividend Payment.
The <FONT STYLE="white-space:nowrap">anti-dividend</FONT> stripping legislation generally targets situations in which shareholders retain their economic interest in common shares but reduce the withholding tax due on the Dividend Payment by entering
into a transaction with another party with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(mainly) that intent. The Dutch Ministry of Finance takes the position that the definition of beneficial ownership introduced by this legislation will also be applied in the context of a double
taxation convention. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gift tax and inheritance tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dutch Residents </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gift or
inheritance taxes will arise in the Netherlands with respect to a transfer of the common shares by way of a gift by, or, on the death of, a holder of common shares who is resident or deemed to be resident in the Netherlands at the time of the gift
or his/her death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Netherlands gift tax will arise in case of a gift of the common shares under a condition precedent (<I>opschortende
voorwaarde</I>) by an individual who at the date of the gift was resident or deemed to be resident, but at the date of the fulfillment of the condition was neither resident nor deemed to be resident in the Netherlands, unless such individual
deceases within 180 days after the date of the fulfillment of the condition, while being resident or deemed to be resident in the Netherlands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Netherlands gift and inheritance taxes, amongst others, a person that holds the Dutch nationality will be deemed to be
resident in the Netherlands if that person has been resident in the Netherlands at any time during the ten years preceding the date of the gift&#151;in case of a gift under a condition precedent, the date of the fulfillment of the condition&#151;or
the date of the death of this person. Additionally, for purposes of Dutch gift tax, a person not holding the Dutch nationality will be deemed to be resident in the Netherlands if that person has been resident in the Netherlands at any time during
the 12 months preceding the date of the gift or <FONT STYLE="white-space:nowrap">-</FONT> in case of a gift under a condition precedent <FONT STYLE="white-space:nowrap">-</FONT> the date of the fulfillment of the condition. Applicable tax treaties
may override the tax implications of deemed residency. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Dutch</FONT> Residents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Dutch gift or inheritance tax will arise on the transfer of common shares by way of a gift by, or on the death of, a holder of common shares
who is neither resident nor deemed to be resident in the Netherlands, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in case of a gift of the common shares under a condition precedent (<I>opschortende voorwaarde</I>) by an
individual who at the date of the gift was neither resident nor deemed to be resident in the Netherlands, such individual is resident or deemed to be resident in the Netherlands at the date of the fulfillment of the condition; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in case of a gift of the common shares by an individual who at the date of the gift or, in case of a gift under a
condition precedent, at the date of the fulfillment of the condition was neither resident nor deemed to be resident in the Netherlands, such individual is deceased within 180 days after the date of the gift or the fulfillment of the condition, while
being resident or deemed to be resident in the Netherlands. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, Dutch inheritance tax will arise in case of a
gift under a condition precedent by an individual who, at the date of the gift, was neither resident nor deemed resident of the Netherlands, but at the date of his or her death was resident or deemed to be resident in the Netherlands, and the
condition was fulfilled after the date of his or her death. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Value added tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Dutch value added tax will be due in the Netherlands in respect of payments made in consideration for the issue of common shares, or in
respect of the transfer of common shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Dutch registration tax, customs duty, stamp duty, real estate transfer tax or any other similar documentary tax or duty will be due in the
Netherlands in respect of or in connection with the mere issue, transfer or delivery of the common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Residency </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Shareholder will not become, and will not be deemed to be, resident in the Netherlands merely by virtue of holding a common share or by
virtue of the execution, performance and/or delivery of any relevant documents related thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax Considerations for
U.S. Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of the material U.S. federal income tax consequences to the U.S. Holders described below
of owning and disposing of our common shares. It is not a comprehensive description of all tax considerations that may be relevant to a particular person&#146;s decision to acquire securities. This discussion applies only to a U.S. Holder that holds
our common shares as a capital asset for tax purposes (generally, property held for investment). In addition, it does not describe all of the tax consequences that may be relevant in light of a U.S. Holder&#146;s particular circumstances, including
state and local tax consequences, estate tax consequences, alternative minimum tax consequences, the potential application of the provisions of United States Internal Revenue Code of 1986, as amended, or the Code, known as the Medicare contribution
tax, and tax consequences applicable to U.S. Holders subject to special rules, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers or traders in securities who use a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of tax accounting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and certain former citizens or long-term residents of the U.S.; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common shares as part of a hedging transaction, &#147;straddle,&#148; wash sale, conversion
transaction or integrated transaction or persons entering into a constructive sale with respect to our common shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons whose &#147;functional currency&#148; for U.S. federal income tax purposes is not the U.S. dollar;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax exempt entities, including &#147;individual retirement accounts&#148; and &#147;Roth IRAs&#148;, or
government organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">S corporations or entities classified as partnerships for U.S. federal income tax purposes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies or real estate investment trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquired our common shares pursuant to the exercise of an employee stock option or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to the our
common shares being taken into account in an applicable financial statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own or are deemed to own ten percent or more of our shares by vote or value; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common shares in connection with a trade or business conducted outside the United States.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity that is classified as a partnership for U.S. federal income tax purposes holds our common shares, the U.S.
federal income tax treatment of a partner will generally depend on the status of the partner and the activities of the partnership. Partnerships holding our common shares and partners in such partnerships are encouraged to consult their tax advisers
as to the particular U.S. federal income tax consequences of holding and disposing of our common shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion is based on the Code, administrative pronouncements, judicial decisions,
final, temporary and proposed Treasury Regulations, and the income tax treaty between the Netherlands and the United States (the &#147;Treaty&#148;) all as of the date hereof, changes to any of which may affect the tax consequences described
herein&#151;possibly with retroactive effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#147;U.S. Holder&#148; is a holder who, for U.S. federal income tax purposes, is a
beneficial owner of our common shares who is eligible for the benefits of the Treaty and is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a citizen or individual resident of the U.S.; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the
United States, any state therein or the District of Columbia; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. Holders are encouraged to consult their tax advisers concerning the U.S. federal, state, local and foreign tax
consequences of owning and disposing of our common shares in their particular circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under &#147;Passive Foreign Investment Company Rules,&#148; distributions paid on our common shares, other than
certain<I> pro rata</I> distributions of our common shares, will generally be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Because we do not
calculate our earnings and profits under U.S. federal income tax principles, we expect that distributions generally will be reported to U.S. Holders as dividends. Subject to applicable limitations, dividends paid to certain <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders may be taxable at preferential rates applicable to &#147;qualified dividend income.&#148; However, the qualified dividend income treatment may not apply if we are treated as a PFIC with
respect to the U.S. Holder. The amount of a dividend will include any amounts withheld by us in respect of Dutch income taxes. The amount of the dividend will be treated as foreign-source dividend income to U.S. Holders and will not be eligible for
the dividends-received deduction generally available to U.S. corporations under the Code. Dividends will be included in a U.S. Holder&#146;s income on the date of the U.S. Holder&#146;s receipt of the dividend. The amount of any dividend income paid
in foreign currency will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is
converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted
into U.S. dollars after the date of receipt. Such gain or loss would generally be treated as U.S.-source ordinary income or loss. The amount of any distribution of property other than cash (and other than certain <I>pro rata</I> distributions of our
common shares or rights to acquire our common shares) will be the fair market value of such property on the date of distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject
to applicable limitations, some of which vary depending upon the U.S. Holder&#146;s particular circumstances, Dutch income taxes withheld from dividends on our common shares at a rate not exceeding the rate provided by the Treaty will be creditable
against the U.S. Holder&#146;s U.S. federal income tax liability. The rules governing foreign tax credits are complex and U.S. Holders should consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances.
In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including any Dutch income tax, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct
foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale or Other Taxable
Disposition of Our Common Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under &#147;Passive Foreign Investment Company Rules,&#148; gain
or loss realized on the sale or other taxable disposition of our common shares will be capital gain or loss, and will be long-term </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital gain or loss if the U.S. Holder held our common shares for more than one year. The amount of the gain or loss will equal the difference between the U.S. Holder&#146;s tax basis in the
common shares disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. This gain or loss will generally be U.S.-source gain or loss for foreign tax credit purposes. The deductibility of capital losses is
subject to limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the consideration received by a U.S. Holder is not paid in U.S. dollars, the amount realized will be the U.S.
dollar value of the payment received determined by reference to the spot rate of exchange on the date of the sale or other disposition. However, if our common shares are treated as traded on an &#147;established securities market&#148; and the U.S.
Holder is either a cash basis taxpayer or an accrual basis taxpayer that has made a special election (which must be applied consistently from year to year and cannot be changed without the consent of the Internal Revenue Service, or IRS), such
holder will determine the U.S. dollar value of the amount realized in a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> dollar currency by translating the amount received at the spot rate of exchange on the settlement date of the sale. If a U.S.
Holder is an accrual basis taxpayer that is not eligible to or does not elect to determine the amount realized using the spot rate on the settlement date, such holder will recognize foreign currency gain or loss to the extent of any difference
between the U.S. dollar amount realized on the date of sale or disposition and the U.S. dollar value of the currency received at the spot rate on the settlement date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company Rules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the value of our assets, including goodwill, and the composition of our income, assets and operations during the year ended
December&nbsp;31, 2018, we do not believe we were a PFIC for our taxable year ended December&nbsp;31, 2018. However, the application of the PFIC rules is subject to uncertainty in several respects, and we cannot assure holders of our common shares
that the IRS will not take a contrary position. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation will be classified as a PFIC for any taxable year in which, after applying certain look-through rules, either: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least 75% of its gross income is passive income; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least 50% of its gross assets (determined on the basis of a quarterly average) is attributable to assets that
produce passive income or are held for the production of passive income. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be treated as owning our proportionate
share of the assets and earning our proportionate share of the income of any other corporation in which we own, directly or indirectly, 25% or more (by value) of the equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A separate determination must be made after the close of each taxable year as to whether we are a PFIC for that year. As a result, our PFIC
status may change. In particular, the total value of our assets for purposes of the asset test generally will be calculated using the market price of our common shares, which may fluctuate considerably. Fluctuations in the market price of our common
shares may result in our being a PFIC for any taxable year. In addition, the composition of our income and assets is affected by how, and how quickly, we spend the cash we raise in any offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are classified as a PFIC in any year with respect to which a U.S. Holder owns our common shares, we will continue to be treated as a
PFIC with respect to such U.S. Holder in all succeeding years during which the U.S. Holder owns such common shares, regardless of whether we continue to meet the tests described above unless (1)&nbsp;we cease to be a PFIC and&nbsp;the U.S. Holder
has made a &#147;deemed sale&#148; election under the PFIC rules, or (2)&nbsp;the U.S. Holder makes a QEF Election (defined below) with respect to taxable years in which we are a PFIC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are a PFIC for any taxable year, U.S. Holders will be subject to special tax rules with respect to any &#147;excess distribution&#148;
that they receive and any gain they realize from a sale or other disposition (including a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pledge) of our common shares. Distributions U.S. Holders of our common shares receive in a taxable year that are greater than 125% of the average annual distributions they received during the
shorter of the three preceding taxable years or their holding period for the common shares will be treated as an excess distribution. Under these special tax rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the excess distribution or gain will be allocated ratably over their holding period for the common shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to the current taxable year, and any taxable year prior to the first taxable year in which
we became a PFIC, will be treated as ordinary income; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to each other year will be subject to the highest tax rate in effect for that year and the
interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax liability for amounts allocated to years prior to the year of disposition or &#147;excess distribution&#148; cannot be offset by any
net operating losses for such years, and gains (but not losses) realized on the sale of the common shares cannot be treated as capital, even if U.S. Holders hold the common shares as capital assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain elections may be available that would result in alternative treatments. U.S. Holders can avoid the interest charge on excess
distributions or gain relating to our common shares by making a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election with respect to our common shares, provided that our common shares are
&#147;marketable.&#148; Our common shares will be marketable if they are &#147;regularly traded&#148; on certain U.S. stock exchanges or on a foreign stock exchange that meets certain conditions. The adverse consequences of owning stock in a PFIC
could also be mitigated if a U.S. Holder makes a valid &#147;qualified electing fund&#148; election, or QEF election, which, among other things, would require a U.S. Holder to include currently in income its <I>pro rata</I> share of the PFIC&#146;s
net capital gain and ordinary earnings, based on earnings and profits as determined for U.S. federal income tax purposes. Unless otherwise provided by the U.S. Treasury, each U.S. shareholder of a PFIC is required to file an annual report containing
such information as the U.S. Treasury may require. A U.S. Holder&#146;s failure to file the annual report will cause the statute of limitations for such U.S. Holder&#146;s U.S. federal income tax return to remain open with regard to the items
required to be included in such report until three years after the U.S. Holder files the annual report, and, unless such failure is due to reasonable cause and not willful neglect, the statute of limitations for the U.S. Holder&#146;s entire U.S.
federal income tax return will remain open during such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are or become a PFIC, U.S. Holders should consult their tax advisors
regarding any reporting requirements that may apply to them. U.S. Holders are urged to consult their tax advisors regarding the application of the PFIC rules to the ownership and disposition of our common shares and the potential availability of a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> or QEF election. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup
Withholding </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related
financial intermediaries generally are subject to information reporting, and may be subject to backup withholding, unless (i)&nbsp;the U.S. Holder is a corporation or other exempt recipient or (ii)&nbsp;in the case of backup withholding, the U.S.
Holder provides a correct taxpayer identification number and certifies that it is not subject to backup withholding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding
is not an additional tax. The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit against the holder&#146;s U.S. federal income tax liability and may entitle it to a refund, provided that the required
information is timely furnished to the IRS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information with Respect to Foreign Financial Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders who are individuals (and, under proposed regulations, certain entities) may be required to report information relating to
our common shares, subject to certain exceptions (including an exception for our common shares held in accounts maintained by certain U.S. financial institutions). U.S. Holders should consult their tax advisers regarding their reporting obligations
with respect to their ownership and disposition of our common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>F. Dividends and Paying Agents.<A NAME="toc696632_49"></A> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_50"></A>G. Statement by Experts. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_51"></A>H. Documents on Display. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a corporate website at<I> www.merus.nl</I>. We make available free of charge on our website our Reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;6-K</FONT> and our Annual Reports on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> as soon as reasonably practicable after we electronically file such material with, or furnish it to, the U.S. Securities and
Exchange Commission, or the SEC. Information contained on, or that can be accessed through, our website does not constitute a part of this Annual Report. We have included our website address in this Annual Report solely as an inactive textual
reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also review a copy of this Annual Report, including exhibits and any schedule filed herewith, and obtain copies of
such materials at prescribed rates, at the SEC&#146;s Public Reference Room in Room 1580, 100&nbsp;F&nbsp;Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330.</FONT></FONT></FONT> The SEC maintains a website (<I>www.sec.gov</I>) that contains reports, proxy and information statements and other
information regarding registrants that file electronically, such as us, with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">References made in this Annual Report to any
contract or other document of Merus N.V. are not necessarily complete and you should refer to the exhibits attached or incorporated by reference into this Annual Report for copies of the actual contract or document. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_52"></A>I. Subsidiary Information. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="toc696632_53"></A>Item&nbsp;11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Quantitative and Qualitative Disclosures About Market Risk. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements are appended at the end of this Annual Report, starting at page
<FONT STYLE="white-space:nowrap">F-1,</FONT> and are incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="toc696632_54"></A>Item&nbsp;12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Description of Securities Other than Equity Securities. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_55"></A>A. Debt Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_56"></A>B. Warrants and Rights. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_57"></A>C. Other Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc696632_58"></A>D. American Depositary Shares. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc696632_59"></A>PART II </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="toc696632_60"></A>Item&nbsp;13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Defaults, Dividend Arrearages and Delinquencies. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="toc696632_61"></A>Item&nbsp;14</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Material Modifications to the Rights of Security Holders and Use of Proceeds. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="toc696632_63"></A>Item&nbsp;15</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Controls and Procedures. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Effectiveness of Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and
operated, can provide only reasonable assurance of achieving the desired control objectives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Evaluation of Disclosure Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management, under the supervision and with the participation of our chief executive and principal financial officer, evaluated the
effectiveness of the design and operation of our disclosure controls and procedures (as defined in <FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15(e)</FONT> and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act, as amended)
as of December&nbsp;31, 2018. Based on that evaluation, our chief executive and principal financial officer concluded that, as of December&nbsp;31, 2018, our disclosure controls and procedures were effective at the reasonable assurance level. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management&#146;s Annual Report on Internal Control over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management, including our chief executive and principal financial officer, is responsible for establishing and maintaining adequate
internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management assessed the
effectiveness of our internal control over financial reporting as of December&nbsp;31, 2018. This assessment was performed under the direction and supervision of our chief executive and principal financial officer, and based on criteria set forth in
&#147;Internal Control&#151;Integrated Framework (2013)&#148; issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on this assessment, our management concluded that, as of December&nbsp;31, 2018, our internal control over financial reporting was
effective. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attestation Report of Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Annual Report does not include an attestation report of our independent registered public accounting firm due to an exemption established
by the JOBS Act for emerging growth companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Remediation of Material Weaknesses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A material weakness is a control deficiency or a combination of control deficiencies in internal control over financial reporting, such that
there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As reported in our Annual Report on Form 20-F for the year ended December 31, 2017, we
identified three material weaknesses as of December 31, 2017, two of which were unremediated material weaknesses identified for the year ended December 31, 2016. In our review of our internal control over financial reporting for the year ended
December 31, 2017, management identified a material weakness associated with a lack of adequate cut-off procedures to ensure the timely recognition, measurement and classification of operating expenses and recording of certain period-end accruals.
Specifically, we did not design and maintain effective internal control over the assessment of the accounting for significant contractual arrangements related to our clinical research and manufacturing agreements and the classification of operating
expenses. In our review of our internal control over financial reporting in connection with the annual audit for the year ended December&nbsp;31, 2016, management identified two material weaknesses related to insufficient accounting resources
required to fulfill IFRS and SEC reporting requirements and the absence of comprehensive IFRS accounting policies and financial reporting procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, we implemented a remediation plan for the material weaknesses identified above and, among other
things, (i)&nbsp;redesigned specific processes and controls associated with review of contractual agreements, including to assure proper clinical research and manufacturing agreements expense cut-off, including a quarterly identification and review
of significant agreements with the management team to ensure that the relevant accounting implications are identified and considered, (ii)&nbsp;redesigned our controls over proper classification and recognition of operating expenses, including the
related balance sheet accounts, (iii)&nbsp;hired several new, experienced personnel in our financial reporting organization and engaged several experienced consultants to further assist our financial reporting organization, (iv)&nbsp;enhanced our
IFRS accounting policies and procedures and (v)&nbsp;increased the oversight and review procedures related to our financial close and reporting processes. Management has completed the testing and evaluation of the design and operating effectiveness
of these controls and concluded that, as of December 31, 2018, we had remediated the previously reported material weaknesses in internal control over financial reporting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in Internal Control over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as described in this Item 15, there was no change in our internal control over financial reporting (as defined in Rule <FONT
STYLE="white-space:nowrap">13a-15(f)</FONT> under the Exchange Act) identified in connection with the evaluation of our internal control over financial reporting during the year ended December&nbsp;31, 2018 that has materially affected, or is
reasonably likely to materially affect, our internal control over financial reporting. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Ite<A NAME="toc696632_64"></A>m&nbsp;16A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Audit Committees Financial Expert. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has determined that Gregory Perry is an audit committee financial expert as defined by the rules of the U.S. Securities
and Exchange Commission and has the requisite financial sophistication under the applicable rules and regulations of Nasdaq. Mr.&nbsp;Perry is independent as such term is defined in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the
Securities Exchange Act of 1934, as amended, and under the listing standards of Nasdaq. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;16<A NAME="toc696632_65"></A>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Code of Ethics. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have adopted a Code of Business Conduct and Ethics, or the Code of Conduct, that is applicable to all of our employees, management, including our principal executive officer, principal financial officer and principal accounting officer, board of
directors, consultants, and others temporarily assigned to perform work or services for us. The Code of Conduct is available on our website at<I> https://ir.merus.nl/static-files/4dfe52fa-e01e-4a32-8ffe-99a55877a236</I>. We intend to satisfy the
disclosure requirement under Item&nbsp;16B(e) of Form <FONT STYLE="white-space:nowrap">20-F</FONT> regarding amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics, as well as Nasdaq&#146;s requirement to disclose
waivers with respect to directors and executive officers, by posting such information on our website at the address and location specified above. Our board of directors is responsible for administering the Code of Conduct. The board of directors is
allowed to amend, alter or terminate the Code of Conduct. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="toc696632_66"></A>Item&nbsp;16C.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Principal Accountant Fees and Services. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the fees of KPMG Accountants N.V., our independent registered public accounting firm, billed to us for each of
the last two fiscal years for audit and other services: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Fee Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,023,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,234,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-Related Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Other Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,063,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,244,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Fees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Audit fees consist of fees billed for the audit of our annual consolidated financial statements, the review of the interim consolidated
financial statements, and related services that are normally provided in connection with registration statements, including the registration statement for our initial public offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit-Related Fees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Audit related fees
relate to an assurance engagement related to a specific research grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Fees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tax fees consist of fees for professional services, including tax consulting and compliance. We did not incur any tax fees in 2018 or 2017.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>All Other Fees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All other fees
consist of fees for accounting research tools. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee <FONT STYLE="white-space:nowrap">Pre-Approval</FONT> Policy and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the charter of the Audit Committee, the Audit Committee <FONT STYLE="white-space:nowrap">pre-approves</FONT> audit and <FONT
STYLE="white-space:nowrap">non-audit</FONT> services before engaging our independent auditor to provide those services, unless the independent auditor is engaged under a <FONT STYLE="white-space:nowrap">pre-approval</FONT> policy established by the
Audit Committee or if the services to be provided by the independent auditor fall within the available exceptions under the rules of the U.S. Securities and Exchange Commission. The Audit Committee delegated its authority to <FONT
STYLE="white-space:nowrap">pre-approve</FONT> services to the Chairman of the Audit Committee on September&nbsp;19, 2017, and the designee must present any such approvals to the full Audit Committee at the next Audit Committee meeting. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Ite<A NAME="toc696632_67"></A>m&nbsp;16D.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exemptions from the Listing Standards for Audit Committees. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="toc696632_68"></A>Item&nbsp;16E.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Purchases of Equity Securities by the Issuer and Affiliated Purchasers. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="toc696632_69"></A>Item&nbsp;16F.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Change in Registrant&#146;s Certifying Accountant. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been no change in our independent accountant during our two most recent fiscal years. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="toc696632_70"></A>Item&nbsp;16G.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Corporate Governance. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a foreign private issuer. As a result, in accordance with the rules of the Nasdaq Stock Market LLC, we comply with Dutch governance
requirements and certain exemptions thereunder rather than complying with Nasdaq corporate governance standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a
summary of the Nasdaq listing rules with which we do not comply: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nasdaq Listing Rule 5620(c): In accordance with Dutch law and generally accepted business practices, our Articles
of Association do not provide quorum requirements generally applicable to general meetings of shareholders in the United States. To this extent, our practice varies from the requirement of Nasdaq Listing Rule 5620(c), which requires an issuer to
provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than <FONT STYLE="white-space:nowrap">one-third</FONT> of the outstanding voting stock. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nasdaq Listing Rule 5620(b): Although we must provide shareholders with an agenda and other relevant documents
for the general meeting of shareholders, Dutch law does not have a regulatory regime for the solicitation of proxies and the solicitation of proxies is not a generally accepted business practice in the Netherlands, thus our practice varies from the
requirement of Nasdaq Listing Rule 5620(b). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nasdaq Listing Rule 5605(d) and (e): As permitted by the listing requirements of Nasdaq, we have also opted out
of the requirements of Nasdaq Listing Rule 5605(d), which requires an issuer to have a compensation committee that consists entirely of independent directors, and Nasdaq Listing Rule&nbsp;5605(e), which requires an issuer to have independent
director oversight of director nominations. Although we have chosen not to comply with Nasdaq Rule 5605(d) regarding the independence of our compensation committee, all of the current members of our compensation committee meet the heightened
independence requirements under this rule. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nasdaq Listing Rule 5635: We have opted out of shareholder approval requirements for the issuance of securities
in connection with certain events such as the acquisition of stock or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change of control of us and certain private placements. To this
extent, our practice varies from the requirements of Nasdaq Listing Rule 5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with such events. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="toc696632_71"></A>Item&nbsp;16H.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Mine Safety Disclosure. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc696632_72"></A>PART III </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="toc696632_73"></A>Item&nbsp;17</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See our financial statements beginning on page <FONT STYLE="white-space:nowrap">F-1.</FONT> </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;18</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements.<A NAME="toc696632_74"></A> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See our financial statements beginning on page <FONT STYLE="white-space:nowrap">F-1.</FONT> </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="toc696632_75"></A>Item&nbsp;19</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits. </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporated by Reference to</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Filings Indicated</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>File No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed/</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Furnished</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex11.htm">Articles of Association (English translation)</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">20-F</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312516606452/d326237dex41.htm">Registration Rights Agreement, dated May&nbsp;24, 2016, by and among the Registrant and the shareholders party thereto</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">6-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-37773</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">5/27/16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex41.htm">Merus N.V. 2010 Employee Option Plan, as amended</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">20-F</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex42.htm">Merus N.V. 2016 Incentive Award Plan and forms of award agreements thereunder, as amended </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">20-F</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518359219/d569434dex103.htm"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director Compensation Program</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">333-229044</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">12/27/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.4#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312516582683/d29248dex104.htm">Form of Board of Directors Indemnification Agreement</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1/A</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-207490</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">5/9/16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.5#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312515346981/d29248dex105.htm">Employment Contract between the Registrant and Ton Logtenberg, dated January&nbsp;21, 2010.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-207490</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10/19/15</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.7#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex47.htm">Employment Agreement, dated December 16, 2015, by and among Merus US, Inc., the Registrant and Hui Liu, as amended on March&nbsp;2, 2016
</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">20-F</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.7</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.8#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex48.htm">Employment Agreement, dated November&nbsp;1, 2016, by and among Merus US, Inc., the Registrant and L. Andres Sirulnik </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">20-F</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.9#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex49.htm">English language translation of Employment Agreement, dated as of July&nbsp;
19, 2008, by and between the Registrant and Mark Throsby, as amended on March&nbsp;10, 2010 </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">20-F</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.10#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex410.htm">English language translation of Employment Agreement, dated as of August&nbsp;5, 2010, by and between the Registrant and Alexander
Bakker</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">20-F</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.10</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporated by Reference to</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Filings Indicated</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>File No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed/</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Furnished</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.11#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex411.htm">English language translation of Employment Agreement, dated as of April&nbsp;
2, 2007, by and between the Registrant and John de Kruif, as amended on March&nbsp;10, 2010 </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">20-F</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.11</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.12#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex412.htm">Employment Agreement, dated as of December 24, 2016, by and between the Registrant and Peter Silverman, as amended February&nbsp;1,
2017</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">20-F</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312515346981/d29248dex108.htm">English language translation of Loan Agreement between the Registrant and Co&ouml;peratieve Rabobank Utrechtse Heuvelrug U.A., dated December&nbsp;29,
 2005.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-207490</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.8</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10/19/15</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312516434605/d29248dex109.htm">English language translation of letter amendment, dated October&nbsp;
21, 2015, to Loan Agreement between the Registrant and Co&ouml;peratieve Rabobank Utrechtse Heuvelrug U.A.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1/A</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-207490</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.9</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">1/21/16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.14.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312516582683/d29248dex1091.htm">English language translation of letter amendment, dated March&nbsp;
15, 2016, to Loan Agreement between the Registrant and Co&ouml;peratieve Rabobank Utrechtse Heuvelrug U.A.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1/A</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-207490</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.9.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">5/9/16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.14.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312516582683/d29248dex1092.htm">English language translation of letter amendment, dated March&nbsp;
15, 2016, to Loan Agreement between the Registrant and Co&ouml;peratieve Rabobank Utrechtse Heuvelrug U.A.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1/A</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-207490</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.9.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">5/9/16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312516582683/d29248dex1012.htm">English language translation of Lease Agreement between the Registrant and Stichting Incubator Utrecht, dated April&nbsp;22,
2016.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1/A</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-207490</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">5/9/16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.15.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex4151.htm">English language translation of Amendment to Lease Agreement, dated as of November&nbsp;
1, 2016 by and between the Registrant and Stichting Incubator Utrecht </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">20-F</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.15.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.15.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518245788/d592967dex993.htm">English language translation of the Lease, dated May 1, 2018, by and between the Registrant and Stichting Incubator Utrecht</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">6-K</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">99.3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">8/10/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.16&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312517148152/d355766dex412.htm">Collaboration and License Agreement, dated December&nbsp;20, 2016, by and between the Registrant and Incyte Corporation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">20-F</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-37773</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/28/17</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.17&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312517148152/d355766dex413.htm">Share Subscription Agreement, dated December&nbsp;20, 2016, by and between the Registrant and Incyte Corporation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">20-F</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">001-37773</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.13</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/28/17</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporated by Reference to</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Filings Indicated</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>File No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed/</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Furnished</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.18&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312515346981/d29248dex109.htm">Contract Research and License Agreement and Addendum between the Registrant and ONO Pharmaceutical Co., Ltd., dated April&nbsp;8,
2014.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-207490</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.9</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10/19/15</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.19&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex419.htm">Contract Research and License Agreement by and between the Registrant and Ono Pharmaceuticals Co., Ltd., dated March&nbsp;14,
2018</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">20-F</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.19</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518047493/d539820dex991.htm">Securities Purchase Agreement, dated February&nbsp;
13, 2018, by an among the registrant and the Investors identified on Exhibit A attached thereto</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">6-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">0001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">99.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2/15/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518047493/d539820dex992.htm">Registration Rights Agreement, dated February&nbsp;
13, 2018, by and among the registrant and the Investors identified on Exhibit A attached thereto</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">6-K</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">0001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">99.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2/15/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;8.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312516535709/d29248dex211.htm">List of Subsidiaries</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1/A</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">333-207490</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">21.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/8/16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>12.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d696632dex121.htm">Rule <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">13a-14(a)/15d-14(a)</FONT></FONT> Certification of Chief Executive Officer </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>13.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d696632dex131.htm">Section&nbsp;1350 Certification of Chief Executive Officer </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">*&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>15.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d696632dex151.htm">Consent of KPMG Accountants N.V. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Calculation Linkbase Document.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Label Linkbase Document.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Presentation Linkbase Document.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Furnished herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment granted as to portions of the exhibit. Confidential materials omitted and filed
separately with the Securities and Exchange Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Index to Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Financial Statements as of December&nbsp;31, 2018, 2017 and 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin696632_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin696632_2">Consolidated Statement of Financial Position as of December&nbsp;
31, 2018 and 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin696632_3">Consolidated Statement of Profit or Loss and Comprehensive Loss for the Years
 Ended December&nbsp;31, 2018, 2017 and 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin696632_4">Consolidated Statement of Changes in Equity for the Years Ended December&nbsp;31,
 2018, 2017 and 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin696632_5">Consolidated Statement of Cash Flows for the Years Ended December&nbsp;
31, 2018, 2017 and 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin696632_6">Notes to the Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin696632_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Shareholders and Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merus N.V.: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Opinion on the Consolidated Financial Statements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
audited the accompanying consolidated statements of financial position of Merus N.V. and subsidiary (together, &#145;the Company&#146;) as of December 31, 2018 and 2017, the related consolidated statements of profit or loss and comprehensive loss,
changes in equity, and cash flows for each of the years in the three year period ended December 31, 2018, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present
fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the years in the three year period ended December 31, 2018, in conformity with
International Financial Reporting Standards as issued by the International Accounting Standards Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in Accounting Principle </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 4 to the consolidated financial statements, the Company adopted IFRS 15 Revenue from Contracts with Customers as of January 1, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis for Opinion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial
statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control
over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control
over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement
of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our
audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KPMG Accountants N.V. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2009. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amstelveen, the Netherlands </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 3, 2019 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Merus N.V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin696632_2"></A>Consolidated Statements of Financial Position </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,<BR>2017<BR>Restated*</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,420</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,945</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,075</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>22,885</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,032</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,855</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>143,747</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>195,634</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>218,519</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued and <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,102</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>264,854</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(175,085</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>91,871</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>97,675</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,819</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes and social security liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>256</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,934</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities and accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,964</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28,973</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>126,648</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity and liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>218,519</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note&nbsp;4 for details regarding the restatement as a result of a change in accounting policy.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Merus N.V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin696632_3"></A>Consolidated Statement of Profit or Loss and Comprehensive Loss </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="4" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(</B><B><I>euros in thousands, except per</I></B><B></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>share data</I></B><B>)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31,448</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(46,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,395</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(13,160</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(70,295</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating result</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(38,847</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,843</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,095</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other income (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,934</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Result before taxation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(23,913</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(356</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Result after taxation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(24,269</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange differences from translation of foreign operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other comprehensive income for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(24,235</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic (and diluted) loss per share**</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1.09</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results and comprehensive losses for the years presented are fully attributable to the owners of the Company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note 4 for details regarding the restatement as a result of a change in accounting policy.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the periods included in these financial statements, share options and restricted stock units were excluded
from the diluted loss per share calculation as the Company was in a loss position in each period presented above. As a result, basic and diluted loss per share are equal. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Merus N.V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin696632_4"></A>Consolidated Statement of Changes in Shareholders&#146; Equity </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common</B><br><B>share</B><br><B>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B><br><B>Pref.</B><br><B>share</B><br><B>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B><br><B>Pref.</B><br><B>share</B><br><B>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;C</B><br><B>Pref.</B><br><B>share</B><br><B>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common</B><br><B>share</B><br><B>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B><br><B>Pref.</B><br><B>share</B><br><B>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B><br><B>Pref.</B><br><B>share</B><br><B>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;C</B><br><B>Pref.</B><br><B>share</B><br><B>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>loss</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>shareholders&#146;</B><br><B>equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="38" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at January&nbsp;1, 2016*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>351</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>373</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,564</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,334</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>38,906</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,105</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(63,382</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28,302</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of adoption of accounting standard</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Restated balance at January&nbsp;1, 2016*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>351</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>373</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,564</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,334</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>38,906</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,105</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(62,783</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28,901</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restated result after taxation for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(47,437</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(47,429</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transactions with owners of the Company:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of shares (net)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>51,151</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPO expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,509</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,509</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of preference shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(351</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,906</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity settled shared-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,307</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total contributions by and distributions to owners of the Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,418</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(351</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(373</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>138,314</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,334</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(38,906</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(49,105</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,307</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>52,949</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Restated balance at December&nbsp;31, 2016*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,448</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>139,878</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(106,905</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34,421</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Restated balance at January&nbsp;1, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,448</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>139,878</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(106,905</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34,421</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restated result after taxation for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(64,774</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>89</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(64,685</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common</B><br><B>share</B><br><B>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B><br><B>Pref.</B><br><B>share</B><br><B>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B><br><B>Pref.</B><br><B>share</B><br><B>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;C</B><br><B>Pref.</B><br><B>share</B><br><B>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common</B><br><B>share</B><br><B>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B><br><B>Pref.</B><br><B>share</B><br><B>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B><br><B>Pref.</B><br><B>share</B><br><B>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;C</B><br><B>Pref.</B><br><B>share</B><br><B>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>loss</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>shareholders&#146;</B><br><B>equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="38" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transactions with owners of the Company:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of shares (net)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>74,041</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity settled shared-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,815</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total contributions by and distributions to owners of the Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>301</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>73,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,815</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>86,856</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="4" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Restated balance at December&nbsp;31, 2017*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,749</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>213,618</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(158,775</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>56,592</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="4" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at January&nbsp;1, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,749</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>213,618</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(158,775</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>56,592</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Result after taxation for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(24,269</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(24,235</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transactions with owners of the Company:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of shares (net)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>51,589</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity settled shared-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,925</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total contributions by and distributions to owners of the Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>353</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>51,236</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,925</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>59,514</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,102</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>264,854</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(175,085</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>91,871</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note&nbsp;4 for details regarding the restatement as a result of a change in accounting policy.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Merus N.V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin696632_5"></A>Consolidated Statement of Cash Flows </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="4" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Result after taxation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(24,269</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments for:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value derivative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8, 16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized foreign exchange results</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,553</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,&nbsp;6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>638</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payment expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,925</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net finance (income) expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,181</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(22,440</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,247</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,351</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in working capital:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,576</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(946</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>618</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities and accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(663</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(13,877</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,933</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax and social security liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(39,871</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(624</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(40,499</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(75,930</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from investment maturities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>58,912</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,125</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,552</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,&nbsp;16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,279</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(19,416</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuing shares, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50,713</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from stock option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>876</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid share issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from collaboration and license agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(486</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>51,589</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,326</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effects of exchange rate changes on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,395</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>149,678</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents, end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>143,747</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT>
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in accrued capital expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note&nbsp;4 for details regarding the restatement as a result of a change in accounting policy.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin696632_6"></A>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General Information </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nature of Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merus N.V. is a clinical-stage
immuno-oncology company developing innovative bispecific antibody therapeutics, headquartered in Utrecht, the Netherlands. Merus US, Inc. is a wholly-owned subsidiary of Merus N.V. located at One Broadway, Cambridge, Massachusetts, United States
(&#147;U.S.&#148;). These consolidated financial statements as at and for year ended December&nbsp;31, 2018 comprise Merus N.V. and Merus US, Inc. (collectively, the &#147;Company&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merus N.V. was incorporated in the Netherlands, with its statutory seat in Utrecht. In connection with becoming a listed company on the Nasdaq Global Market
(&#147;Nasdaq&#148;), on May&nbsp;19, 2016, Merus N.V.&#146;s legal structure under Dutch law was changed from a private company with limited liability (in Dutch: <I>besloten vennootschap met beperkte aansprakelijkheid</I>) to a public company with
limited liability (in Dutch: naamloze vennootschap) and Merus N.V.&#146;s name changed from &#147;Merus B.V.&#148; to &#147;Merus N.V.&#148; The address of the Company&#146;s registered office is Yalelaan 62, 3584 CM Utrecht, The Netherlands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since inception, the Company has generated an accumulated loss of &#128;175.1&nbsp;million as of December&nbsp;31, 2018. The Company expects to continue to
incur significant expenses and operating losses for the foreseeable future as its bispecific antibody candidates advance through discovery, preclinical development and clinical trials and as it seeks regulatory approval and pursues commercialization
of any approved bispecific antibody candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, the Company may need additional financing to support its continuing operations. Until the
Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through public equity offerings, debt financings, or other sources, which may include collaborations with third parties and business
development opportunities. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The Company&#146;s inability to raise capital as and when needed would have a negative impact on its financial condition and
ability to pursue its business strategy. The Company will need to generate significant revenues to achieve profitability and may never do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on
the Company&#146;s current operating plan, Merus expects that its existing cash and cash equivalents of &#128;143.7&nbsp;million and investments of &#128;61.8&nbsp;million as of December&nbsp;31, 2018 will be sufficient to fund its operations into
the second quarter of 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reverse Share Split </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
May&nbsp;6, 2016, the general meeting of the Company&#146;s shareholders resolved to approve and effect a capital reorganization, based on a reverse share split. The effect of the reverse share split was a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-for-1.8</FONT></FONT> reverse share split of the outstanding common and preferred shares held by the Company&#146;s shareholders. This reverse share split became effective on May&nbsp;6, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Initial Public Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;24, 2016, the
Company closed the initial public offering of 5,500,000 of its common shares and, on May&nbsp;26, 2016, of an additional 639,926 of its common shares, at a price to the public of $10.0 per share (the &#147;IPO&#148;). Net proceeds to the Company
after deducting underwriting discounts and commissions and offering expenses were $53.3&nbsp;million. On May&nbsp;19, 2016, the Company&#146;s common shares were listed on the Nasdaq and all of the Company&#146;s preferred shares converted into
common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Follow-on</FONT> Public Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;1, 2017, the Company filed with the U.S. Securities and Exchange Commission a registration statement on Form
<FONT STYLE="white-space:nowrap">F-3</FONT> (Registration Number <FONT STYLE="white-space:nowrap">333-218432)</FONT> (the <FONT STYLE="white-space:nowrap">&#147;F-3</FONT> Registration Statement&#148;), under which it registered up
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to $250.0&nbsp;million of its securities and 3,200,000 shares sold to Incyte Corporation (&#147;Incyte&#148;). The <FONT STYLE="white-space:nowrap">F-3</FONT> Registration Statement became
effective on June&nbsp;16, 2017. On June&nbsp;1, 2017, the Company also entered into a sales agreement with Cowen and Company, LLC (&#147;Cowen&#148;), under which the Company may issue and sell from time to time up to $50.0&nbsp;million of its
common shares registered under the <FONT STYLE="white-space:nowrap">F-3</FONT> Registration Statement through Cowen as its sales agent. Sales of common shares, if any, will be made at market prices by any method that is deemed to be an &#147;at the
market&#148; offering. The aggregate compensation payable to Cowen as sales agent equals 3.0% of the gross sales price of the shares sold through it pursuant to the sales agreement. No sales have been made by the Company under the sales agreement.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement of Common Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
February&nbsp;13, 2018, the Company entered into a Securities Purchase Agreement (the &#147;Purchase Agreement&#148;) with the purchasers named therein (the &#147;Investors&#148;). Pursuant to the Purchase Agreement, the Company agreed to sell an
aggregate of 3,099,997 of its common shares, nominal value &#128;0.09 per share, to the Investors at a purchase price equal to $18.0 per share (the &#147;Private Placement&#148;). The Purchase Agreement contained customary representations and
warranties from the Company and the Investors and customary closing conditions. On February&nbsp;15, 2018, the Company completed the sale under the Private Placement and received aggregate gross proceeds of approximately $55.8&nbsp;million, or
&#128;44.8&nbsp;million. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Basis of Presentation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (&#147;IFRS&#148;) as issued by the
International Accounting Standards Board (&#147;IASB&#148;). Certain amounts were reclassified in the prior period financial statements to conform to the current period presentation. These changes in classification do not materially affect the
previously reported consolidated financial statements for any period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements have been prepared under the historical cost convention
unless otherwise stated in the below accounting policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial statements have been authorized for issuance on April 3, 2019.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Functional and Presentation Currency </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Items recorded
in each of the Company&#146;s entities are measured using the currency of the primary economic environment in which the entity operates (the &#147;functional currency&#148;). The consolidated financial statements are presented in euros, which is
Merus N.V.&#146;s functional currency. The functional currency of Merus US, Inc. is the U.S. dollar.&nbsp;All amounts are rounded to the nearest thousand euros, except where otherwise indicated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Segment Reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company operates in one reportable
segment, which comprises the discovery and development of innovative bispecific therapeutics. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates, Judgements and Assumptions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the application of the Company&#146;s accounting policies, management is required to make judgments, estimates and assumptions that affect the reported
amounts of assets, liabilities, income and expenses that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results
may differ from these estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized
prospectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following are the critical judgments and assumptions that management has made in the process of applying
the Company&#146;s accounting policies and that have the most significant effect on the amounts recognized in the consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Settled Share-Based Payments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share options
granted to employees, consultants and directors are measured at the grant date fair value of the equity instruments granted. The grant date fair value is determined through the use of an option-pricing model considering the following variables: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exercise price of the option; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the expected life of the option; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the current value of the underlying shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the expected volatility of the share price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the dividends expected on the shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the risk-free interest rate for the life of the option. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Company&#146;s IPO, the estimated fair value of each share option granted was determined utilizing the Black-Scholes option pricing model.
Subsequent to the IPO, the Company&#146;s judgment was that the Hull&nbsp;&amp; White option pricing model is the most appropriate method for determining the fair value of its share options since it considers the terms and conditions attached to the
grants made and is reflective of expected exercise behavior. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the Company was not listed on a national securities exchange until May&nbsp;19, 2016,
there was no published share price information available until May&nbsp;19, 2016. Consequently, the Company estimated the fair value of its common shares and the expected volatility for the period up to May&nbsp;19, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company&#146;s shares have not been publicly traded for a sufficient amount of time, the expected volatility is set by considering the historic share
price volatility of a set of peer companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For <FONT STYLE="white-space:nowrap">pre-IPO</FONT> valuations, the continuous yield on euro government
bonds with a term to maturity comparable to the expected life of the share options, as published by the European Central Bank, was applied. For <FONT STYLE="white-space:nowrap">post-IPO</FONT> valuations, the continuous yield on U.S. Treasury Bills
with a term to maturity comparable to the expected life of the share options, as published by the U.S. Department of Treasury, is applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The result of
the share option valuations and the related compensation expense that is recognized for the respective vesting periods during which services are received, is dependent on the model and input parameters used. Even though management considers the fair
values reasonable and defensible based on the methodologies applied and the information available, others might derive a different fair value for the Company&#146;s share options. These assumptions and estimates are further discussed in Note 12 to
the consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Capitalization of Development Costs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The criteria for capitalization of development costs have been considered by management and determined not to have been met through December&nbsp;31, 2018.
Therefore, all development expenditures relating to internally generated intangible assets in the year ended December&nbsp;31, 2018 were expensed as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income Taxes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The criteria for the recognition of unused
tax losses and deductible temporary differences are disclosed in Note 3. As of December&nbsp;31, 2018, deferred tax assets have not been recognized in respect of tax losses and deductible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
temporary differences as the Company has no history of generating taxable profits. Therefore, at the balance sheet date, there is no convincing evidence that sufficient taxable profit will be
available against which the tax losses and deductible temporary differences can be utilized. The amount of the unrecognized tax losses and deductible temporary differences is disclosed in Note 7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merus US, Inc., which is incorporated in the U.S. in the State of Delaware, is subject to statutory U.S. Federal corporate income taxes and state income taxes
for Massachusetts. Current year income tax expense was attributable entirely to Merus US, Inc. which provides general management services and strategic advisory services to the Company. Corporate income tax expenses were &#128;0.4&nbsp;million,
&#128;0.2&nbsp;million and &#128;0.0&nbsp;million for the years ended December&nbsp;31, 2018, 2017 and 2016, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Company&#146;s research, collaboration and license agreements with ONO Pharmaceutical Co., Ltd. (&#147;ONO&#148;), Incyte, Jiangsu
Simcere Pharmaceutical Co. Ltd. (&#147;Simcere&#148;) and Betta Pharmaceuticals Co. Ltd. (&#147;Betta&#148;), the Company has received or will receive upfront&nbsp;nonrefundable&nbsp;payments and milestones for certain rights granted under the
respective agreements. The applicable period over which to recognize these upfront or milestone payments requires significant judgment and was impacted by the adoption of IFRS 15. See Note 4 and Note 11. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accrual of R&amp;D expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and Development
(&#147;R&amp;D&#148;) expenses are recognized in the consolidated statement of profit or loss and comprehensive loss as incurred and have no alternative future uses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the process of preparing its consolidated financial statements, the Company is required to estimate certain of its R&amp;D expenses, including
estimates of third-party contract costs relating to preclinical studies and clinical trial activities and related contract manufacturing expenses. This process involves reviewing open contracts and purchase orders, communicating with R&amp;D
personnel to identify services that have been performed for the Company and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual
cost. See Note 14. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The majority of the Company&#146;s service providers invoice monthly in arrears for services performed or when contractual milestones
are met. The Company makes estimates of its R&amp;D expenses as of each reporting date in its consolidated financial statements based on facts and circumstances known to it at that time. The Company periodically confirms the accuracy of its
estimates with the service providers to gauge the reasonableness of its estimates. Differences between actual and estimated expenses recorded have not been material and are adjusted for in the period in which they become known. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Significant Accounting Policies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accounting policies set out below have been consistently applied to all periods presented in the consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income and expenses are accounted for on an accrual basis. Profit is only included when realized at the statement of financial position date. Losses
originating before the end of the financial year are taken into account if they have become known before preparation of the financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of consolidation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(i) Subsidiaries </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsidiaries are entities controlled by the Company, consisting of Merus N.V.&#146;s wholly owned subsidiary Merus US, Inc. The Company controls an entity when
it is exposed to, or has rights to, variable returns from its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial
statements from the date on which control commences until the date on which control ceases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(ii) Loss of control </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When the Company loses control over a subsidiary, it derecognizes the assets and liabilities of the subsidiary, and any
<FONT STYLE="white-space:nowrap">non-controlling</FONT> interests and other components of equity. Any resulting gain or loss is recognized in profit or loss. Any interest retained in the former subsidiary is measured at fair value when control is
lost. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(iii) Transactions eliminated on consolidation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intercompany balances and transactions, and any unrealized income and expenses arising from intercompany transactions, are eliminated in consolidation.
Unrealized gains arising from transactions with equity-accounted investees are eliminated against the investment to the extent of the Company&#146;s interest in the investee. Unrealized losses are eliminated in the same way as unrealized gains, but
only to the extent that there is no evidence of impairment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Currency Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign currency transactions are translated using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the
settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at the exchange rate at the reporting date are generally recognized in the statement of profit or loss and comprehensive
loss as a component of finance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results and financial position of foreign operations that have a functional currency different from the
presentation currency are translated into the presentation currency as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that
balance sheet; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">income and expenses for each statement of profit or loss and comprehensive income or loss are translated at
average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the exchange rates at the dates of the
transactions); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all resulting exchange differences are recognized in other comprehensive income. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Property, Plant and Equipment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property, plant and
equipment are measured at cost less accumulated depreciation and accumulated impairment losses (if any). Cost includes expenditures that are directly attributable to the acquisition of the items. Depreciation of property, plant and equipment is
recognized in the consolidated statement of profit and loss and comprehensive loss on a straight-line basis over estimated useful lives of generally five years, taking residual value into account. If significant parts of an item of property, plant
and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent
expenditures are capitalized only when the expenditure will increase the future economic benefit of the asset. All other expenditures are expensed in the consolidated statement of profit or loss and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation rates are based on the following estimated economic useful lives of the tangible fixed assets concerned: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Plant and
equipment&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 years </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leasehold improvements &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shorter of useful life or term of lease
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Other fixed
assets:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 years </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intangible Assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets are identifiable <FONT
STYLE="white-space:nowrap">non-monetary</FONT> assets without physical substance. An asset is a resource that is controlled by the enterprise as a result of past events (for example, purchase or self-creation) and from which future economic benefits
(inflows of cash or other assets) are expected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The useful lives of intangible assets are assessed to be finite and amortized over the useful economic
life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. Amortization begins when the asset is available for use. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Patents </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents acquired separately by the Company are
reported at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized in the consolidated statement of profit and loss and comprehensive loss on a straight-line basis over the shorter of the estimated economic
or legal lives. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimates being accounted for on a prospective basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>R&amp;D </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company incurs R&amp;D expenses related to
its clinical trials and preclinical drug development programs. Development expenses are defined as expenses incurred to achieve technical and commercial feasibility. Expenditures on research activities are recognized as an expense in the period in
which it is incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development is capitalized if, and only if, all of the following have been demonstrated: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the technical feasibility of completing the intangible asset so that it will be available for use or sale;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the intention to complete the intangible asset and use or sell it; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="#fin696632_84">the ability to use or sell the intangible asset;</A> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how the intangible asset will generate probable future economic benefits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of adequate technical, financial and other resources to complete the development and to use or
sell the intangible asset; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to measure reliably the expenditure. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Instruments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company classifies <FONT
STYLE="white-space:nowrap">non-derivative</FONT> financial assets as either financial assets at fair value through profit or loss, financial assets at amortized cost or financial assets at fair value through other comprehensive income or loss. The
Company classifies <FONT STYLE="white-space:nowrap">non-derivative</FONT> financial liabilities into either financial liabilities at fair value through profit or loss or the other financial liabilities category. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Derivative</FONT> Financial Assets and Financial Liabilities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company initially recognizes receivables and investments at fair value on the date when they are originated. Subsequent to initial recognition, they are
measured at amortized cost using the effective interest rate method. All other financial assets and financial liabilities are initially recognized on the trade date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset
expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains substantially all of
the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in such derecognized financial assets that is created or retained by the Company is recognized as a separate asset or liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company initially recognizes <FONT STYLE="white-space:nowrap">non-derivate</FONT> financial liabilities at fair value less any directly attributable
transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
derecognizes a financial liability when its contractual obligations are settled or cancelled, or expire. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and financial liabilities are
offset and the net amount presented in the statement of financial position when, and only when, the Company has a legal right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability
simultaneously. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investments are
classified and accounted for at amortized cost and initially measured at fair value. Subsequent to initial recognition, they are measured at amortized cost using the effective interest rate method. Investments are classified as amortized cost as the
Company has the positive intent and ability to hold them until maturity. Interest income from these securities is included in finance income. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Receivables </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These assets are initially recognized at
fair value plus any directly attributable transaction costs, if any. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Derivative Financial Assets and Liabilities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derivative financial instruments are initially recognized at fair value on the date on which a derivative contract is entered into and are subsequently
remeasured at fair value with net changes in fair value presented as finance expenses (negative net changes in fair value) or finance income (positive net changes in fair value) in the consolidated statement of profit or loss and comprehensive loss.
Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. Derivatives embedded in host contracts are accounted for as separate derivatives and recorded at fair value if
their economic characteristics and risks are not closely related to those of the host contracts and the host contracts are not held for trading or designated at fair value through profit or loss. These embedded derivatives are measured at fair value
with changes in fair value recognized in profit or loss. Reassessment only occurs if there is either a change in the terms of the contract that significantly modifies the cash flows that would otherwise be required or a reclassification of a
financial asset out of the fair value through profit or loss category. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash and Cash Equivalents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of presentation in the statement of cash flows as well as the statement of financial position, cash and cash equivalents include deposits held
with financial institutions with original maturities of less than three months from the date of acquisition. Cash and cash equivalents include &#128;49.1&nbsp;million of investments with a three month or less maturity, callable on demand. The
carrying values of cash equivalents approximate fair value due to their short-term maturities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Treatment of equity issuance costs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs related to the issuance of new shares have been accounted for as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Incremental costs, if any, that are directly attributable to issuing new shares are included as prepaid expenses
and are deducted from equity on the date the Company closes its new share transactions (net of any income tax benefit). Such as, for example, the date of the closing of its IPO, <FONT STYLE="white-space:nowrap">follow-on</FONT> public offerings or
the share subscription agreements with Incyte or Regeneron Pharmaceuticals Inc. (&#147;Regeneron&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Incremental costs directly associated with a probable, successful future offering of equity instruments are also
deferred and deducted from equity when the new shares are issued; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Costs that relate to listing on Nasdaq, or other new share transaction costs that are otherwise not incremental
and directly attributable to issuing new shares, are recorded as an expense in the consolidated statement of profit or loss and comprehensive loss; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Costs that relate to both share issuance and listing are allocated between those functions on a rational and
consistent basis. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
provision is recognized if the following applies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the company has a legal or constructive obligation, arising from a past event; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount can be estimated reliably; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is probable that an outflow of resources embodying economic benefits will be required to settle the
obligation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If all or part of the payments that are necessary to settle a provision are virtually certain to be fully or partially
compensated by a third party upon settlement of the provision, then the compensation amount is presented separately as an asset. Provisions are determined by discounting the expected future cash flows at a
<FONT STYLE="white-space:nowrap">pre-tax</FONT> rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as finance cost. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impairment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financial Assets Measured at Amortized
Cost </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At each reporting date, the Company considers evidence of impairment for these assets at both an individual asset and a collective level. All
individually significant assets are individually assessed for impairment. Those found not to be impaired are then collectively assessed for any impairment that has been incurred but not yet individually identified. Assets that are not individually
significant are collectively assessed for impairment. Collective assessment is carried out by grouping together assets with similar risk characteristics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To assess impairment for its financial assets, the Company uses the general expected credit loss model over the next twelve months of the expected life of its
financial assets. Under this model, the Company calculates the allowance for credit losses by considering on a discounted basis, the cash shortfalls it would incur in various default scenarios for prescribed future periods and multiplying the
shortfalls by the probability of each scenario occurring. The allowance on the financial asset is the sum of these probability-weighted outcomes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the
Company&#146;s investments, the Company applies the low credit risk simplification as it does not believe there to be any credit risk related to these assets given the credit quality ratings required by the Company&#146;s investment policy. At every
reporting date, the Company evaluates whether a particular debt instrument is considered to have low credit risk using all supportable information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Impairment losses are recognized in the consolidated statement of profit or loss and comprehensive loss and
is the amount required to adjust the loss allowance at the reporting date to the amount that is required to be recognized based on the aforementioned policy. If the amount of impairment loss subsequently decreases and the decrease can be related
objectively to an event occurring after the impairment was recognized, then the previously recognized impairment loss is reversed through profit or loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Financial</FONT> Assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At each reporting date, the Company reviews the carrying amounts of its <FONT STYLE="white-space:nowrap">non-financial</FONT> assets to determine whether there
is any indication of impairment. If any such indication exists, then the asset&#146;s recoverable amount is estimated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For impairment testing, assets are
grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or cash generating units (&#147;CGU&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The recoverable amount of an asset or CGU is the greater of its value in use and its fair value less costs to sell. Value in use is based on the estimated
future cash flows, discounted to their present value using a <FONT STYLE="white-space:nowrap">pre-tax</FONT> discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An impairment loss is recognized if the carrying amount of an asset or CGU exceeds its recoverable amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Impairment losses are recognized in profit or loss. They are allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to
reduce the carrying amounts of the other assets in the CGU on a pro rata basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An impairment loss is reversed only to the extent that the asset&#146;s
carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been&nbsp;recognized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue Recognition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective January&nbsp;1, 2018, the
Company adopted IFRS 15, <I>Revenue from Contracts with Customers</I> (&#147;IFRS 15&#148;). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance,
collaboration arrangements and financial instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the contracts within the scope of IFRS 15&nbsp;may contain multiple promised goods and
services, which often include license rights to certain of the Company&#146;s product candidates and R&amp;D activities. Payments under such agreements include: (i)&nbsp;upfront nonrefundable license fees; (ii)&nbsp;payments for R&amp;D services
performed by the Company, including reimbursement for certain external costs; (iii)&nbsp;payments based upon the achievement of certain development, regulatory and commercial milestones; and (iv)&nbsp;royalties on net product sales, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under IFRS 15, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration
that the Company expects to receive in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed under IFRS 15: (i) identification of the contract(s) with the customer; (ii)&nbsp;identification of
the performance obligations; (iii)&nbsp;determination of the transaction price, including the constraint on variable consideration; (iv)&nbsp;allocation of the transaction price to the performance obligations in the contract; and
(v)&nbsp;recognition of revenue when (or as) the Company satisfies each performance obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to account for contracts with customers, the
Company identifies the promised goods or services in the contract and evaluates whether such promised goods or services represent performance obligations. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company accounts for those components as separate performance obligations when the following criteria are met: (i)&nbsp;the customer can benefit from the good or service either on its own or
together with other resources that are readily available to the customer, and (ii)&nbsp;the Company&#146;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. This evaluation
requires subjective determinations and requires the Company to make judgments about the promised goods and services and whether such goods and services are separable from the other aspects of the contractual relationship. In determining the
performance obligations, the Company evaluates certain criteria, including whether the promised good or service is capable of being distinct and whether such good or service is distinct within the context of the contract, based on consideration of
the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research, manufacturing and commercialization capabilities of the partner; the availability of research and manufacturing expertise in
the general marketplace; and the level of integration, interrelation, and interdependence among the promises to transfer goods or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
transaction price is allocated among the performance obligations using the relative selling price method and the applicable revenue recognition criteria are applied to each of the separate performance obligations. At contract inception, the Company
determines the standalone selling price for each performance obligation identified in the contract. If an observable price of the promised good or service sold separately is not readily available, the Company utilizes assumptions that require
judgment to estimate the standalone selling price, which may include development timelines, probabilities of technical and regulatory success, reimbursement rates for personnel costs, forecasted revenues, potential limitations to the selling price
of the product, expected technological life of the product and discount rates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Up-front</FONT> License Payments
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the license to the Company&#146;s intellectual property is determined to be distinct from the other performance obligations identified in the
arrangement, the Company recognizes revenue allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are not distinct and bundled with other performance
obligations, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of
measuring progress for purposes of recognizing revenue from the combined performance obligation. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue
recognition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Milestones </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the inception of each
arrangement that includes <FONT STYLE="white-space:nowrap">pre-commercial</FONT> milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction
price using the most likely amount method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the
Company&#146;s control, such as regulatory approvals, are not considered probable of being achieved until the uncertainty related to the milestone is resolved. The transaction price is then allocated to each performance obligation on a relative
selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. Any such adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which
affects revenue in the period of adjustment. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of
the overall transaction price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Royalties </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
arrangements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, the Company
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recognizes revenue at the later of: (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance obligation to which some or all of the royalty has been allocated has been satisfied
(or partially satisfied). To date, the Company has not recognized any royalty revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>R&amp;D Cost Reimbursement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">R&amp;D cost reimbursement revenue, which is typically related to reimbursements from customers for the Company&#146;s performance of R&amp;D services under
the respective agreements, is recognized on the basis of labor hours valued at a contractually agreed rate. R&amp;D cost reimbursement revenue also includes reimbursements for related
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses and third-party costs. R&amp;D cost reimbursement revenue is recognized in the same period as the costs for which they are intended to compensate.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company typically acts as the principal under such arrangements and, therefore, records these reimbursements on a gross basis. The impact of the new
revenue standard IFRS 15 was also assessed for the instances under the ONO research and license agreement (defined below) where the Company acts as an agent. The Company concluded that no control was obtained for these pass-through arrangements to
reimburse costs under the ONO research and license agreement and as such the costs were netted in R&amp;D instead of being recognised as expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Costs of Obtaining a Contract with a Customer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company capitalizes the incremental costs of obtaining a contract with a customer if it expects to recover those costs. To date, the Company has not capitalized any incremental costs for obtaining a contract. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Government Grants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company receives certain
government and regional grants, which support its research efforts in defined projects, and include contributions towards the R&amp;D cost. When there is reasonable assurance that the Company will comply with the conditions attached to a received
grant, and when there is reasonable assurance that the grant will be received, government grants are recognized as revenue on a gross basis in the consolidated statement of profit or loss and comprehensive loss on a systematic basis over the periods
in which the Company recognizes expenses for the related costs for which the grants are intended to compensate. In the case of grants related to assets, the received grant will be deducted from the carrying amount of the asset. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WBSO </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The WBSO (<I>afdrachtvermindering speur- en
ontwikkelingswerk</I>) is a Dutch fiscal facility that provides subsidies to companies, knowledge centers and self-employed people who perform R&amp;D activities (as defined in the WBSO Act). Under this act, a contribution is paid towards the labor
costs of employees directly involved in R&amp;D and other related expenditures. The contribution is in the form of a reduction of payroll taxes. Subsidies relating to labor costs are deferred and recognized in the consolidated statement of profit or
loss and comprehensive loss as negative labor costs over the period necessary to match them with the labor costs that they are intended to compensate (see Note 15). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Short-term Employee Benefits
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the
Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share-Based Payment Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The grant-date fair value of equity-settled share-based payment awards granted to employees including grants of employee options, restricted share units, and
modifications to existing instruments, is recognized as an expense, net of an estimated forfeiture rate, with a corresponding increase in equity (accumulated loss), over the vesting period of the awards. Service conditions and <FONT
STYLE="white-space:nowrap">non-market</FONT> related conditions are not taken into account in determining the fair value. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and <FONT
STYLE="white-space:nowrap">non-market</FONT> performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service and
<FONT STYLE="white-space:nowrap">non-market</FONT> performance conditions at the vesting date. For any share-based payment awards with market conditions or <FONT STYLE="white-space:nowrap">non-vesting</FONT> conditions, the grant-date fair value of
the share-based payment is measured to reflect such conditions and there is no <FONT STYLE="white-space:nowrap">true-up</FONT> for differences between expected and actual outcomes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Employment Benefit Plans </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
contributes to a post-employment benefit plan that entitles executive officers and other staff members to retire at the age of 67 and receive annual payments based upon the average salary earned during the service period. The Company has insured the
liabilities from the post-employment benefit plan with an insurance company and has no other obligation than to pay the annual insurance premiums to the insurance company. The annual pension payments are conditional; the Company will have no further
obligation (legal or constructive) to pay further amounts if the insurance fund has insufficient assets to pay all employee benefits relating to current and prior service. Based on its characteristics, the Company&#146;s post-employment benefit plan
is classified as a defined contribution plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obligations for contributions to defined contribution plans are expensed as the related service is
provided. Prepaid contributions are recognized as an asset. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Leases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Determining whether an Arrangement Contains a Lease </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At
inception of an arrangement, the Company determines whether such an arrangement is or contains a lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At inception or on reassessment of the
arrangement, the Company separates payments and other consideration required by such an arrangement into those for the lease and those for other elements on the basis of their relative fair values. If the Company concludes for a finance lease that
it is impracticable to separate the payments reliably, then an asset and a liability are recognized at an amount equal to the fair value of the underlying asset. Subsequently, the liability is reduced as payments are made and an imputed finance cost
on the liability is recognized using the Company&#146;s incremental borrowing rate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Leased Assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets held by the Company under leases that transfer to the Company substantially all of the risks and rewards of ownership are classified as finance leases.
The leased assets are measured initially at an amount equal to the lower of their fair value and the present value of the minimum lease payments. Subsequent to initial recognition, the assets are accounted for in accordance with the accounting
policy applicable to that asset. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets held under other leases are classified as operating leases and are not recognized in the Company&#146;s statement
of financial position. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Lease Payments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments made
under operating leases are recognized in the consolidated statement of profit or loss and comprehensive loss on a straight-line basis over the term of the lease. Lease incentives received are recognized as an integral part of the total lease
expense, over the term of the lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minimum lease payments made under finance leases are apportioned between the finance expense and the
reduction of the outstanding liability. The finance expense is allocated to each period during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the&nbsp;liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Finance Income and Finance Expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
finance income and finance expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interest and related income; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interest expense and changes in fair value of the forward contract (derivative); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financing costs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the foreign currency gain or loss on financial assets and financial liabilities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest income or expense is recognized using the effective interest method. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income Tax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income tax expense comprises current and
deferred tax. It is recognized in the consolidated statement of profit or loss and comprehensive loss except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive income or loss.
Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at
the reporting date. Current tax also includes any tax arising from dividends. Current tax assets and liabilities are offset only if certain criteria are met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the
amounts used for taxation purposes. Deferred tax is not recognized for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business
combination and that affects neither accounting nor taxable profit or loss; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">temporary differences related to investments in subsidiaries, associates and joint arrangements to the extent
that the group is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">taxable temporary differences arising on the initial recognition of goodwill. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax assets are recognized for unused tax losses, unused tax credits and deductible temporary differences to the extent that it is probable that
future taxable profits will be available against which they can be used. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized; such
reductions are reversed when the probability of future taxable profits improves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unrecognized deferred tax assets are reassessed at each reporting date
and recognized to the extent that it has become probable that future taxable profits will be available against which they can be utilized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax
is measured at the tax rates that are expected to be applied to temporary differences when they reverse, using tax rates enacted or substantively enacted at the reporting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Company expects, at the reporting date, to
recover or settle the carrying amount of its assets and liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax assets and liabilities are offset only if certain criteria are met. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recently Issued or Adopted International Financial Reporting Standards </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Newly Adopted International Financial Reporting Standards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>IFRS 15, Revenue from Contracts with Customers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
May 2014, the IASB issued IFRS 15, which supersedes existing revenue recognition guidance. Prior to the adoption of IFRS 15, revenue was recognized to the extent that it was probable that the economic benefits would flow to the Company and the
revenue could be reliably measured. The standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. To achieve that core principle, an entity must
identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when (or as) the
entity satisfies the performance obligation. IFRS 15 was effective for annual and interim reporting periods beginning on or after January&nbsp;1, 2018 and should be applied retrospectively to each prior reporting period presented or retrospectively
with the cumulative effect of initially applying this update recognized at the date of initial application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company adopted the new standard
effective January&nbsp;1, 2018, using the retrospective method, with the effect of initially applying this standard recognized at the beginning of the earliest period presented. The Company had two open contracts on the adoption date and has
assessed these contracts under the new revenue standard. In addition, the Company elected to apply the practical expedient to not apply this guidance to contracts that were completed before the beginning of the earliest period presented, or
January&nbsp;1, 2016, and the practical expedients for contract modifications (assessing the contracts in combination with any modifications before January&nbsp;1, 2016). Under the practical expedient, the Company excluded certain option and
exclusivity agreements that expired in 2015 and 2014, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The adoption of IFRS 15 impacted the amortization of the Company&#146;s upfront
license payments under the collaboration and license agreement entered into with Incyte on December&nbsp;20, 2016 (the &#147;Incyte collaboration and license agreement&#148;) and under the research and license agreement entered into with ONO on
April&nbsp;8, 2014 (the &#147;ONO research and license agreement&#148;). The Company previously recognized revenue from upfront license payments on a straight-line basis over the contractual term or the period of continuing managerial involvement,
which was previously estimated to be 21 years for the Incyte collaboration and license agreement and 4.5 years for the ONO research and license agreement. Upon adoption of IFRS 15, the Company assessed the goods and services promised under the
Incyte collaboration and license agreement and identified only one performance obligation to which the transaction price was allocated&#151;a license to the Company&#146;s proprietary technology combined with the joint steering committee
(&#147;JSC&#148;) services during the research term. The transfer of the license and the JSC participation represented one combined performance obligation since they were not deemed distinct. As a result, under IFRS 15, revenue from upfront license
payments under the Incyte collaboration and license agreement will be recognized as the Company satisfies the combined performance obligation, or over the nine-year research term, which is a period during which the Company has a present enforceable
obligation to provide JSC services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the adoption of IFRS 15, prior year financial statements have been restated. The impact of adopting
IFRS 15 resulted in a decrease of approximately &#128;8.7&nbsp;million to deferred revenue with an offset to accumulated deficit, effective January&nbsp;1, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following financial statement line items have been shown to reflect the adjustments recognized for each
individual line item in the Company&#146;s respective consolidated financial statements for the period noted: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Consolidated Statement of Profit or Loss
and Comprehensive Loss </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,&nbsp;2017<BR>(As originally<BR>presented)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS&nbsp;15<BR>Adoption</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,&nbsp;2017<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,617</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,&nbsp;2016<BR>(As originally<BR>presented)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS&nbsp;15<BR>Adoption</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,&nbsp;2016<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Consolidated Statement of Financial Position </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2017<BR>(As originally<BR>presented)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS 15<BR>Adoption</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2017<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2016<BR>(As originally<BR>presented)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS 15<BR>Adoption</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2016<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(106,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Consolidated Statement of Cash Flows </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2017<BR>(As originally<BR>presented)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS 15<BR>Adoption</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2017<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Result after taxation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73,089</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in working capital:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,315</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,933</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2016<BR>(As originally<BR>presented)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS 15<BR>Adoption</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2016<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Result after taxation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in working capital:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>IFRS 9 Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IFRS 9, <I>Financial Instruments</I> (&#147;IFRS 9&#148;) replaces the provisions of IAS 39 that relate to the recognition, classification and measurement of
financial assets and financial liabilities; derecognition of financial instruments; impairment of financial assets and hedge accounting. IFRS 9 also significantly amends other standards dealing with financial instruments such as IFRS 7, <I>Financial
Instruments: Disclosures</I>. The Company assessed the classification and measurement of the financial instruments it held at the date of initial application of IFRS 9, or January&nbsp;1, 2018, and has classified its financial instruments into the
appropriate IFRS 9 categories. There were no changes to the carrying value of the Company&#146;s financial instruments resulting from this reclassification and, accordingly, there was no impact to the Company&#146;s opening accumulated deficit at
January&nbsp;1, 2018, as a result of the adoption of IFRS&nbsp;9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IFRS 9 replaces the &#145;incurred loss&#146; model in IAS 39 with an &#145;expected
credit loss&#146; (&#147;ECL&#148;) model. The new impairment model applies to financial assets measured at amortized cost, contract assets and debt investments at fair value recorded through other comprehensive loss, but not to investments in
equity instruments. Under IFRS&nbsp;9, credit losses are recognized earlier than under IAS 39. Under IFRS 9, loss allowances are measured on either <FONT STYLE="white-space:nowrap">12-month</FONT> ECLs, which result from possible default events
within the 12 months after the reporting date, or lifetime ECLs, which result from all possible default events over the expected life of a financial </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial assets recorded at
amortized cost consist of cash and cash equivalents, investments and trade and other receivables. These financial assets are considered to have a low credit risk and, as such, there was no impact to the Company&#146;s opening accumulated deficit as
a result of the change in impairment methodology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Newly Issued International Financial Reporting Standards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>IFRS 16 Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2016, the IASB issued
IFRS 16, <I>Leases</I>. IFRS&nbsp;16 established a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> model that requires all lessees to recognize a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability in their statement of financial position that arise from leases with a term that is greater than twelve months. The standard is effective for periods beginning on or
after January&nbsp;1, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company adopted IFRS 16 on January&nbsp;1, 2019, using a modified retrospective transition approach applied to leases
existing as of, or entered into after, January&nbsp;1, 2019. The Company elected the practical expedients available under the transition guidance including, but not limited to, the recognition exemption for short-term and <FONT
STYLE="white-space:nowrap">low-value</FONT> leases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has reviewed its existing lease contracts and the impact of the new leasing standard on its
consolidated statement of profit or loss and comprehensive loss, financial position and related disclosures. Although the Company is in the process of evaluating the full impact of IFRS 16 on its consolidated financial statements, it expects to
recognize a lease liability and related <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset of approximately &#128;3.0&nbsp;million in its consolidated statement of financial position for its real
estate leases existing as of January&nbsp;1, 2019. This amount does not include the Cambridge, Massachusetts office lease, which was executed in March 2019 (see Note&nbsp;22). The Company is still evaluating the impact of its <FONT
STYLE="white-space:nowrap">non-real</FONT> estate leases, but it is not expected to be material to the Company&#146;s financial statements. The Company&#146;s consolidated statement of profit or loss and comprehensive loss will reflect additional
depreciation expense due to the <FONT STYLE="white-space:nowrap">right-of</FONT> use assets, an increase in finance costs for effective interest expense on its lease liabilities and a decrease in rent expense. The Company also expects to expand its
disclosures regarding the amounts, timing and uncertainties of cash flows related to its lease portfolio. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>IFRIC 23 Uncertainty over Income Tax
Treatments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IFRIC 23 <I>Uncertainty over Income Tax Treatments </I>(&#147;IFRIC 23&#148;) clarifies how the recognition and measurement
requirements of IAS 12, <I>Income taxes</I>, are applied where there is uncertainty over income tax treatments. An uncertain tax treatment is any tax treatment applied by an entity where there is uncertainty over whether that treatment will be
accepted by the tax authority.&nbsp;Under IFRIC 23, the key test is whether it&#146;s probable that the tax authority will accept the company&#146;s chosen tax treatment allowing for the assumption that the tax authorities will have full knowledge
of all relevant information in assessing a proposed tax treatment. IFRIC 23 applies for annual periods beginning on or after January&nbsp;1, 2019, with early adoption permitted. The Company does not expect IFRIC 23 will have a material impact on the
Company&#146;s financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Property, Plant and Equipment </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Movements in property, plant and equipment, net were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Plant and</B><br><B>equipment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other&nbsp;fixed</B><br><B>assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as at January&nbsp;1, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Changes in book value</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals (Cost)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals (Accumulated depreciation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as at December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(506</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Changes in book value</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals (Cost)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals (Accumulated depreciation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,052</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><A HREF="#fin696632_86">6.</A></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><A HREF="#fin696632_86">Intangible Assets</A> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The intangible assets, net are related to acquired intellectual property rights were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(euros&nbsp;in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as at January&nbsp;1</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>860</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(548</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(486</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>312</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,225</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(92</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book value as at December&nbsp;31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as at December&nbsp;31</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,085</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(640</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, the Company acquired or licensed certain intellectual property and, under the
terms of the related agreements, paid &#128;2.2&nbsp;million in fees. The transactions were accounted for as an asset acquisition. As a result, the Company capitalized &#128;2.2&nbsp;million as intangible assets in its consolidated statements of
financial position. The Company amortizes the cost of the acquired or licensed intellectual property over its estimated economic life based on the remaining legal life of the related patents from the date of acquisition or license. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Taxation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax assets have not been recognized in respect of tax losses and deductible temporary differences, because the Company has no history of generating
taxable profits and at the balance sheet date, there is no convincing evidence that sufficient taxable profit will be available against which the tax losses can be utilized. As of December&nbsp;31, 2018, the tax losses carried forward amounted to
&#128;75.9&nbsp;million as compared to &#128;140.5&nbsp;million at December&nbsp;31, 2017 (as restated for the adoption of IFRS 15. See Note 4 for details). The deductible temporary difference, which completely relates to deferred revenue, amounted
to &#128;114.6&nbsp;million at December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2018, the Dutch tax authorities confirmed that the $120.0&nbsp;million upfront license
fee received from Incyte can be fully recognized in 2017 for Dutch corporate income tax purposes, which resulted in a significant reduction of the Company&#146;s tax loss carry-forwards. The treatment of upfront license fees received is consistently
applied by the Company for Dutch corporate income tax purposes. There will be no impact on the Company&#146;s consolidated statements of financial position or consolidated statement of profit or loss and comprehensive loss as no deferred tax asset
was recognized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to promote innovative technology development activities and investments in new technologies, a corporate income tax incentive
has been introduced in Dutch tax law called the Innovations Box. Based on the Innovations Box ruling, the Company would owe on the first 75% of qualifying profits under the Dutch jurisdiction effectively 7% for Dutch income taxes. The remaining
profit would be taxed at the headline Dutch statutory tax rate of 25%. The headline Dutch statutory tax rate is 25% for fiscal years 2018 and 2019. Legislation has been enacted amending the headline Dutch statutory tax rate to 22.55% for fiscal year
2020 and 20.5% for fiscal year 2021. Taxable profits will only qualify for the Innovations Box once the tax losses carried forward are completely utilized. The agreement with the tax authorities was originally signed for the tax years beginning in
2011 through 2015 and was subsequently extended up to and including year 2019. Since the Company is loss-making, no Dutch income tax is recognized in the consolidated statement of profit or loss and comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merus US, Inc., which is incorporated in the U.S. in the State of Delaware, is subject to statutory U.S.
Federal corporate income taxes and state income taxes for Massachusetts at a blended rate of 28% and 40% for the years ended December&nbsp;31, 2018 and 2017, respectively. Current year income tax expense was attributable entirely to Merus US, Inc.
which was established on February&nbsp;17, 2016 and provided general management services and strategic advisory services to the Company. Corporate income tax expenses were &#128;0.4&nbsp;million and &#128;0.2&nbsp;million for the years ended
December&nbsp;31, 2018 and 2017, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Investments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2018, the Company adopted IFRS 9 and classifies and accounts for its investments at amortized cost. The Company&#146;s investments as of
December&nbsp;31, 2017 were classified and accounted for as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">held-to-maturity</FONT></FONT> under IAS 39. The initial adoption of IFRS 9 had no impact on previously reported amounts
(See Note 4). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s investments include investments in commercial paper, debt securities issued by several public corporations and the U.S.
Treasury. Current investments include investments with a maturity date of greater than three months at the date of settlement. Investments with a maturity of 12 months or more from the original investment date are classified <FONT
STYLE="white-space:nowrap">as&nbsp;non-current.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investments as of December&nbsp;31, 2018 and 2017 consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B><I>(euros in thousands)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>22,208</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,733</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate fixed income bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,185</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,729</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,855</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate fixed income bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,945</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,945</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61,800</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company first began its investment program during the fourth quarter of 2017. During the years ended December&nbsp;31,
2018 and 2017, the Company purchased investments totaling &#128;75.9&nbsp;million and &#128;41.8&nbsp;million, respectively, which are held and denominated in U.S. dollars. During the years ended December&nbsp;31, 2018 and 2017, the Company received
proceeds of &#128;58.9&nbsp;million and &#128;0, respectively, relating to investment maturities. As a result of the fluctuation in foreign currency between the euro and U.S. dollar, the Company recorded foreign currency exchange net gains of
&#128;3.2&nbsp;million as a component of finance income for the year ended December&nbsp;31, 2018. For the year ended December&nbsp;31, 2017, the Company recorded foreign currency exchange net losses of &#128;0.8&nbsp;million as a component of
finance expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Trade and Other Receivables </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All trade and other receivables are short-term and due within 1 year. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B><I>(euros&nbsp;in&nbsp;thousands)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,690</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unbilled receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>236</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAT receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>891</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,783</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid pension costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>213</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>219</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,032</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade and unbilled receivables relate primarily to invoicing for cost reimbursements relating to the Incyte collaboration and
license agreement, ONO research and license agreement and Simcere research and license agreement. VAT receivable relates to a value added tax receivable from the Dutch tax authorities based on the tax application for the fourth quarter of 2018. The
Company is evaluating if the benefits of claiming foreign VAT are favorable compared to the related costs and expects to finalize the assessment and conclude in the course of 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses consist of expenses that were paid but are related to activities taking place in subsequent periods and prepaid taxes. The increase in
prepaid expenses at December&nbsp;31, 2018 relates primarily to advance payments made to contract research and contract manufacturing organizations in support of the Company&#146;s preclinical, clinical trial, and contract manufacturing activities.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Liabilities and Accruals </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All amounts are short-term and payable within 1 year. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B><I>(euros&nbsp;in&nbsp;thousands)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>167</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>560</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued bonus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,523</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,409</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IP legal fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>212</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidy advance received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>42</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,051</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,964</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued R&amp;D costs relate to third-party contract costs for preclinical studies and clinical trial activities and related
contract manufacturing expenses. The decrease in R&amp;D costs is due to the timing of invoices received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued bonuses relate to employee bonuses for
the financial year 2018, which were paid out in February 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsidy advances received relate to active grants where the Company has received cash in
excess of allowances, which is required to be repaid or recognized as grant revenue when the relevant reimbursable costs are incurred as services are performed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Deferred Revenue </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred revenue consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B><I>(euros&nbsp;in&nbsp;thousands)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,934</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>97,675</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>114,609</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>See Note 4 for details regarding the restatement as a result of a change in accounting policy.</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of the total deferred revenue balance at December&nbsp;31, 2018, &#128;112.6&nbsp;million related to the Incyte collaboration and
license agreement and a share subscription agreement (the &#147;Incyte share subscription agreement&#148;) entered into by the Company with Incyte on December&nbsp;20, 2016 (together, the &#147;Incyte Agreements&#148;) and &#128;2.1
million&nbsp;related to the collaboration and license agreement entered into by the Company with Simcere on January&nbsp;8, 2018 (the &#147;Simcere collaboration and license agreement&#148;). The total deferred revenue balance at December&nbsp;31,
2017, related solely to the Incyte Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Incyte collaboration and license agreement, Incyte agreed to pay the Company a
$120.0&nbsp;million, or <FONT STYLE="white-space:nowrap">&#128;112.0&nbsp;million,&nbsp;non-refundable&nbsp;upfront</FONT> payment, and under the Incyte share subscription agreement, Incyte agreed to purchase 3.2&nbsp;million common shares at a
price per share of $25.0, for an aggregate purchase price of $80.0&nbsp;million. In January 2017, the Company completed the sale of its common shares under the Incyte share subscription agreement and received the $80.0&nbsp;million in aggregate
purchase price. In February 2017, the Company received the $120.0&nbsp;million, or &#128;112.0&nbsp;million, <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment and recorded it as deferred revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company combined the Incyte collaboration and license agreement and Incyte share subscription agreement and accounted for them as a single contract based
on the following criteria: (i)&nbsp;they were entered into at the same time with the same customer; (ii)&nbsp;the arrangements&#146; mutual existence is acknowledged in the separate agreements; and (iii)&nbsp;they were negotiated as a package with a
single commercial objective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Incyte share subscription agreement was denominated in a foreign currency (U.S. dollars) other than the
Company&#146;s functional currency (euro), the Company determined that the freestanding forward contract to sell its own shares at a future date, to which the Company became committed on December&nbsp;20, 2016, did not qualify as equity and thus a
freestanding forward contract (derivative asset) was recognized in the Company&#146;s consolidated statement of financial position. The difference between the purchase price of $25.0 per common share in the Incyte share subscription agreement and
the market price of the Company&#146;s common shares on December&nbsp;20, 2016 was considered to be part of the consideration received under the Incyte Agreements. As a result, on December&nbsp;20, 2016, the Company recorded a liability (deferred
revenue) of $32.6&nbsp;million, or &#128;31.4&nbsp;million, in its consolidated statement of financial position for the same amount as the fair value of the freestanding forward contract (derivative asset). The deferred revenue liability is not
remeasured subsequent to the initial recognition and is accounted for in the same manner as the <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s fixed consideration under the Incyte Agreements is $152.6&nbsp;million, consisting of the $120.0&nbsp;million, or &#128;112.0&nbsp;million,
<FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment from the Incyte collaboration and license agreement and $32.6&nbsp;million, or &#128;31.4&nbsp;million, in consideration from the issuance and sale of common shares pursuant to
the Incyte share subscription agreement. The transaction price was allocated to a single combined performance obligation that includes a license to the Company&#146;s technology combined with the JSC services during the research term. Revenue from
upfront license payments under the Incyte collaboration and license </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement will be recognized as the Company satisfies the combined performance obligation, or over the nine-year research term, which is a period during which the Company has present enforceable
obligation to provide JSC services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Simcere collaboration and license agreement, the Company agreed to grant Simcere an exclusive license to
develop and commercialize in China three bispecific antibodies to be produced by Merus utilizing the Company&#146;s Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;technology platform in the area of immuno-oncology. The
Company will retain all rights outside of China. As part of the agreement, the Company has agreed to lead research and discovery activities, while Simcere has agreed to be responsible for the Investigational New Drug (&#147;IND&#148;) enabling
studies, clinical development, regulatory filings and commercialization of these product candidates in China. The Company received an upfront, <FONT STYLE="white-space:nowrap">non-refundable</FONT> payment of $2.75&nbsp;million, or
&#128;2.3&nbsp;million, relating to three separate research programs. Each research program was determined to be a separate performance obligation and consideration was allocated to each separate obligation. In addition, the Company received a
payment of $0.8&nbsp;million, or &#128;0.6&nbsp;million, relating to one of the programs, which was also recorded as deferred revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
amortizes the upfront and milestone payment to revenue over time based on the estimated duration of each research program. As of December&nbsp;31, 2018, the first and second research programs had commenced. For the year ended December&nbsp;31, 2018,
the Company recognized revenue of &#128;0.9&nbsp;million, relating to these two programs for the amortization of upfront and milestone payments. The remaining research program had not commenced as of December&nbsp;31,&nbsp;2018. Accordingly, no
revenue has been recognized related to the remaining research program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;14, 2018, the Company entered into a second contract research and
license agreement with ONO (the &#147;second ONO research and license agreement&#148;). Pursuant to an exclusive option granted to ONO in the ONO research and license agreement, ONO exercised its option to enter into the second ONO research and
license agreement. The Company granted ONO an exclusive, worldwide, royalty-bearing license, with the right to sublicense, research, test, make, use and market bispecific antibody candidates based on the Company&#146;s Biclonics<B><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B><B><SUP STYLE="font-size:85%; vertical-align:top"> </SUP></B>technology platform against two undisclosed targets directed to a particular undisclosed target combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, ONO identifies and selects the licensed bispecific antibodies for which it is responsible for conducting <FONT
STYLE="white-space:nowrap">further&nbsp;non-clinical&nbsp;and</FONT> clinical development activities for such licensed bispecific antibodies and pharmaceutical products containing such antibodies, including manufacture and process development.
Additionally, ONO controls and has exclusive rights over the worldwide commercialization of any approved products, including worldwide supply, and is solely responsible for all costs and expenses related to commercialization. ONO has also agreed to
fund the Company&#146;s R&amp;D activities and be responsible for the payment of all costs and expenses for its own R&amp;D activities, which are set out in a mutually agreed upon research plan. The Company retains all rights to use and
commercialize any antibodies that are generated under the collaborative research program, excluding the up to five lead and/or selected antibodies against the targets ONO is pursuing, provided that the use and commercialization is not with respect
to the particular target combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ONO agreed to pay the Company an <FONT STYLE="white-space:nowrap">upfront,&nbsp;non-refundable&nbsp;payment</FONT>
of &#128;0.7&nbsp;million, &#128;0.3&nbsp;million intended to compensate the Company for research services already completed upon entering into the agreement, and &#128;0.2&nbsp;million to be paid to the Company over time for full time equivalent
funding. The Company identified a single performance obligation of providing research services to ONO, which were fully completed in 2018, and recognized all deferred payments received of approximately &#128;1.2&nbsp;million as revenue during the
year ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;10, 2018, the Company entered into a collaboration and license agreement with Betta (the &#147;Betta
collaboration and license agreement&#148;), where the Company granted Betta an exclusive license to develop and commercialize in China <FONT STYLE="white-space:nowrap">MCLA-129,</FONT> a proprietary Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> produced by its Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The Company retains all rights outside of China. Under the terms of the Betta collaboration and license agreement, Betta has agreed to retain a contract manufacturing organization with experience
in filing IND applications with U.S. regulatory authorities and CTAs with European regulatory authorities in order to produce clinical trial materials for the Chinese market and rest of the world. As a key strategic component of the collaboration,
Betta will be responsible for IND enabling studies and manufacturing of clinical trial materials in China, which the Company intends to use to assist regulatory filing and early stage clinical development in the rest of the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to a <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment of $1.0&nbsp;million, or &#128;0.9&nbsp;million, Betta and the Company
will share equally the cost of the transfer of the manufacturing technology to a contract manufacturing organization. The Company is also eligible to receive an aggregate of $12.0&nbsp;million, or &#128;10.5&nbsp;million, in milestone payments
contingent upon Betta achieving certain specified development and commercial goals as well as tiered royalty payments of net sales of any products resulting from the collaboration in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company identified a single combined performance obligation, which includes a license to <FONT STYLE="white-space:nowrap">MCLA-129</FONT> and other
promised goods and services, and will recognize revenue over time based on the estimated duration of the <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. For the year ended December&nbsp;31, 2018, the Company recognized revenue of less
than &#128;0.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Betta is eligible to receive from the Company an aggregate of $12.0&nbsp;million, or &#128;10.5&nbsp;million, in milestone
payments contingent upon the Company achieving certain specified development and commercial goals, and is eligible to receive tiered royalty payments of net sales outside of China. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Shareholders&#146; Equity </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reverse Share Split </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;6, 2016, the general
meeting of the Company&#146;s shareholders resolved to approve and effect a capital reorganization, based on a reverse share split. The effect of the reverse share split was a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-1.8</FONT></FONT> reverse share split of the outstanding common and preferred shares held by the Company&#146;s shareholders. This reverse share split became effective on
May&nbsp;6, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Initial Public Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
May&nbsp;24, 2016, the Company closed the initial public offering of 5,500,000 of its common shares and, on May&nbsp;26, 2016, of an additional 639,926 of its common shares, at a price to the public of $10.0 per share. Net proceeds to the Company
after deducting underwriting discounts and commissions and offering expenses were $53.3&nbsp;million. On May&nbsp;19, 2016, the Company&#146;s common shares were listed on the Nasdaq and all of the Company&#146;s preferred shares converted into
common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Subscription Agreement with Incyte </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with the Incyte collaboration and license agreement discussed above under Note 11, the Company entered into the Incyte share subscription agreement
on December&nbsp;20, 2016. On January&nbsp;23, 2017, under the terms of the Incyte share subscription agreement, the Company issued 3,200,000 of its common shares to Incyte at the agreed price per share of $25.0, for an aggregate purchase price of
$80.0&nbsp;million, or &#128;74.7&nbsp;million. The Company received proceeds of &#128;74.4&nbsp;million, net of issuance costs of &#128;0.2&nbsp;million. A &#128;1.1&nbsp;million discount on the subscription share price, combined with a
&#128;0.4&nbsp;million foreign currency translation accompanying the issuance of these shares, increased share capital by &#128;0.3&nbsp;million and share premium by &#128;73.4&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement of Common Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;13,
2018, the Company entered into the Purchase Agreement. Pursuant to the Purchase Agreement, the Company agreed to sell an aggregate of 3,099,997 of its common shares to the Investors at a purchase price
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equal to $18.0 per share. The Purchase Agreement contains customary representations and warranties from the Company and the Investors and customary closing conditions. On February&nbsp;15, 2018,
the Company completed the sale under the Private Placement and received gross proceeds of approximately $55.8&nbsp;million, or &#128;44.8&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Subscription Agreement with Regeneron </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
December&nbsp;20, 2018, the Company entered into a share subscription agreement with Regeneron (the &#147;Regeneron Subscription Agreement&#148;). See Note 21 for details. Pursuant to the Regeneron Subscription Agreement, the Company agreed to sell
an aggregate of 600,000 of its common shares to Regeneron at a purchase price equal to $25.0 per share. The Regeneron Subscription Agreement contains customary representations and warranties from the Company and Regeneron and customary closing
conditions. On December&nbsp;21, 2018, the Company completed the sale under the Regeneron Subscription Agreement and received gross proceeds of $15.0&nbsp;million, or &#128;13.1&nbsp;million. Accordingly, the Company recorded the common shares
issued at the fair value of the underlying securities on the date of issuance. The difference between the total proceeds received of $15.0&nbsp;million, or &#128;13.1&nbsp;million, and the aggregate value of common shares issued of
$6.9&nbsp;million, or &#128;6.0&nbsp;million, was recorded as a gain on litigation settlement of $8.1&nbsp;million, or &#128;7.1&nbsp;million, during the year-ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issued and <FONT STYLE="white-space:nowrap">Paid-in</FONT> Share Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All issued shares have been fully paid in cash. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common
Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2018, 2017 and 2016, a total of 23,358,977, 19,429,848, and 16,085,851 common shares, respectively, were issued and
fully paid in cash. The following is a tabular reconciliation of common shares outstanding for the years ended December&nbsp;31, 2018 and 2017, respectively. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Shares outstanding at January&nbsp;1,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,429,848</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,085,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued for cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,699,997</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of common share options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>135,888</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of RSUs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>93,244</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares outstanding at December&nbsp;31,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,358,977</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,429,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share Premium Reserve </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The share premium reserve relates to amounts contributed by shareholders at the issue of shares in excess of the par value of the shares issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All share premium can be considered as free share premium as referred to in the Netherlands Income tax act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share-Based Payment Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2010, the Company
established the Merus B.V. 2010 Employee Option Plan (the &#147;2010 Plan&#148;) that entitled key management personnel, staff and consultants providing similar services to purchase shares in the Company. Under the 2010 Plan, holders of vested
options were entitled to purchase depositary receipts for common shares at the exercise price determined at the date of grant. Upon exercise of the option, common shares were issued to a foundation established to facilitate administration of
share-based compensation awards and pool the voting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interests of the underlying shares, and depositary receipts were issued by the foundation to the individual holders. In connection with the IPO, the 2010 Plan was amended to cancel the depositary
receipts and allow individual holders to directly hold the common shares obtained upon exercise of their options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Options granted under the 2010 Plan are
exercisable once vested. The options granted under the 2010 Plan vest in installments over a four-year period from the grant date. Twenty-five percent of the options vest on the first anniversary of the vesting commencement date, and the remaining
seventy-five percent of the options vest in 36 monthly installments for each full month of continuous service provided by the option holder thereafter, such that 100% of the options become vested on the fourth anniversary of the vesting commencement
date. Options lapse on the eighth anniversary of the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the IPO, participants that voluntarily left the Company, except for members
of the former Supervisory Board, were required to offer to the foundation the depositary receipts acquired from exercising options against payment of the exercise price or the lower fair market value of the underlying shares. This obligation for a
participant to offer depositary receipts to the foundation upon resignation within four years from exercising the options was treated as a <FONT STYLE="white-space:nowrap">non-market</FONT> vesting condition. In connection with the IPO, the
foundation was dissolved and the common shares underlying depositary receipts distributed. In addition, the 2010 Option Plan was amended such that a participant is no longer required to offer depositary receipts to the foundation upon resignation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reduction of the vesting period has been accounted for, taking into consideration the modified vesting conditions, to reflect the best estimate
available of the options that are expected to vest. At the modification date in 2016, the cumulative expense for the options has been <FONT STYLE="white-space:nowrap">trued-up</FONT> to reflect the reduced vesting period. This amendment of a <FONT
STYLE="white-space:nowrap">non-market</FONT> vesting (service) condition did not impact the fair value of the options granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the
IPO, the Company established the 2016 Incentive Award Plan (the &#147;2016 Plan&#148;). Following the IPO, the Company is no longer making grants under the 2010 Plan; however, the terms of the 2010 Plan will continue to govern grants made under the
2010 Plan. All new incentive award grants since the IPO are being made under the 2016 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Options granted under the 2016 Plan are exercisable once
vested. The options granted under the 2016 Plan vest in installments over a four-year period from the grant date. Twenty-five percent of the options vest on the first anniversary of the vesting commencement date, and the remaining seventy-five
percent of the options vest in 36 monthly installments for each full month of continuous service provided by the option holder thereafter, such that 100% of the options shall become vested on the fourth anniversary of the vesting commencement date.
Options will lapse on the tenth anniversary of the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RSUs granted under the 2016 Plan also vest in installments over a four-year period
from the grant date. Each RSU represents the right to receive one common share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also established the Supervisory Board Compensation Program,
which was subsequently replaced by the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director Compensation Program to reflect the change in governance structure of the Company (see Note 1). As part of this program, <FONT
STYLE="white-space:nowrap">non-executive</FONT> directors are entitled to cash compensation as well as equity compensation. The equity compensation consists of an initial option grant as well as annual awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial awards granted under the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Compensation Program vest in installments over a three-year period.
Thirty-three percent of the options vest on the first anniversary of the vesting commencement date, and the remaining sixty seven percent of the options in 24 substantially equal monthly installments thereafter, such that the award shall be fully
vested on the third anniversary of the vesting commencement date. Each subsequent award shall vest and become exercisable in 12 substantially equal monthly installments following the vesting commencement date, such that the subsequent award shall be
fully vested on the first anniversary of the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based payment expenses are recognized as from the IPO date for each subsequent award that a <FONT
STYLE="white-space:nowrap">non-executive</FONT> director is entitled to over their remaining term. Since subsequent awards are not subject to shareholder approval, the grant date is established and expenses are based on grant date fair value. The
grant date fair value is not updated in each future reporting period and therefore the estimated fair value is not revised and expense recognized is based on the actual grant date fair value of the awards granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the &#147;evergreen&#148; provisions of the 2016 Plan, the number of common shares authorized for issuance under the plan automatically increased
by 934,359 common shares to 1,469,785 common shares effective January&nbsp;1, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Measurement of Fair Value of the Equity-Settled Share-Based
Payment Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the share options granted to the employee and the Board of Directors has been measured using a binomial option
pricing model. Service and <FONT STYLE="white-space:nowrap">non-market</FONT> performance conditions attached to the transactions were not taken into account in measuring fair value. Key management personnel include the Company&#146;s executive
management and the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The inputs used in the measurement of the fair values and the related fair values at the grant dates for the
options granted during the respective years were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="11" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Key</B><br><B>Management</B><br><B>Personnel</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other</B><br><B>Employees</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Key</B><br><B>Management</B><br><B>Personnel</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other</B><br><B>Employees</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Key</B><br><B>Management</B><br><B>Personnel</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other</B><br><B>Employees</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&#128;6.82&nbsp;&#150;&nbsp;&#128;12.27</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&#128;7.74&nbsp;&#150;&nbsp;&#128;13.32</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;9.04&nbsp;&#150;&nbsp;&#128;16.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;8.94&nbsp;&#150;&nbsp;&#128;18.02</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;9.97&nbsp;&#150;&nbsp;&#128;11.03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;5.74&nbsp;&#150;&nbsp;&#128;5.79</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&#128;13.01&nbsp;&#150;&nbsp;&#128;19.90</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&#128;12.29&nbsp;&#150;&nbsp;&#128;21.02</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;17.08&nbsp;&#150;&nbsp;&#128;24.54</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;13.71&nbsp;&#150;&nbsp;&#128;27.47</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;15.24&nbsp;&#150;&nbsp;&#128;16.85</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;8.46&nbsp;&#150;&nbsp;&#128;8.87</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&#128;13.01&nbsp;&#150;&nbsp;&#128;19.90</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&#128;12.29&nbsp;&#150;&nbsp;&#128;21.02</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;17.08&nbsp;&#150;&nbsp;&#128;24.54</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;13.71&nbsp;&#150;&nbsp;&#128;27.47</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;15.24&nbsp;&#150;&nbsp;&#128;16.85</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#128;8.46&nbsp;&#150;&nbsp;&#128;8.87</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Expected volatility (weighted-average)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>94.71%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>92.16%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">95.05%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">94.88%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">95.30%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">97.15%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Expected life</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10 years</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10 years</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10 years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10 years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8&nbsp;&#150;&nbsp;10 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>0%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>0%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>2.79%&nbsp;&#150;&nbsp;3.20%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>2.83%&nbsp;&#150;&nbsp;3.10%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.29%&nbsp;&#150;&nbsp;2.51%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.24%&nbsp;&#150;&nbsp;2.62%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.84%&nbsp;&#150;&nbsp;1.86%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.10%&nbsp;&#150;&nbsp;1.87%</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reconciliation of outstanding share options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of share options and the weighted average exercise prices of share options granted were as follows for the respective years: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13.99</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,213,985</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,394,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">953,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14.48</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(38,874</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,164</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,351</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(31,629</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6.80</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(135,888</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(136,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14.96</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>625,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,014,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">496,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14.62</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,633,039</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,213,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,394,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December&nbsp;31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,275,669</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">418,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The options outstanding at December&nbsp;31, 2018 had an exercise price in the range of &#128;1.93 to
&#128;27.47 (2017: &#128;1.93 to &#128;27.47; 2016: &#128;1.93 to &#128;16.85) and a weighted-average remaining contractual life of 7.0 years (2017: 8.25 years; 2016: 6.68 years). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average share price at the date of exercise for share options exercised in 2018 was &#128;17.03. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of share options outstanding, by group of employees, was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Group of employees entitled</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Key management personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,148,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,777,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,302,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">484,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">436,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,633,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,213,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,394,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2017, the Company granted RSUs to Key Management Personnel. The following table summarizes the Company&#146;s
RSU&#146;s activity: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>average</B><br><B>grant&nbsp;date<BR>fair value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>average<BR>grant&nbsp;date<BR>fair value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">20.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20.03</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(12,219</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20.03</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(93,244</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20.03</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7,331</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20.03</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>214,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at December&nbsp;31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20.03</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>101,302</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20.03</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>194,546</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Revenue </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is recognized at the amount to which the Company expects to be entitled for the transfer of promised goods or services to customers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disaggregation of Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
revenues are generated entirely in the Netherlands. In the following table, revenue is disaggregated by primary source of revenue as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B><I>(euros in thousands)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upfront payment amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17,686</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D cost reimbursement and milestone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from contracts with customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31,252</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from grants on research projects</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>196</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31,448</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>See Note 4 for details regarding the restatement as a result of a change in accounting policy.</I>
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2018, the Company recognized amortization of &#128;15.9&nbsp;million on
upfront payments related to the Incyte collaboration and license agreement, amortization of &#128;1.2&nbsp;million on upfront payments related to the second ONO research and license agreement, &#128;0.5&nbsp;million on upfront payments related to
the Simcere collaboration and license agreement and less than &#128;0.1&nbsp;million on the upfront payment related to the Betta collaboration and license agreement. For the year ended December&nbsp;31, 2017, the Company recognized
&#128;14.9&nbsp;million of amortization of the upfront payment related to the Incyte collaboration and license agreement. For the year ended December&nbsp;31, 2016, the Company recognized approximately &#128;14,000 of amortization of the <FONT
STYLE="white-space:nowrap">up-front</FONT> payment related to the ONO research and license agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">R&amp;D cost reimbursement and milestone revenue
for the year ended December&nbsp;31, 2018, was &#128;13.6&nbsp;million and consisted of cost reimbursements, milestone payment amortization and research milestones achieved in support of the Company&#146;s research and license agreements with
Incyte, ONO and Simcere. During the year ended December, 2018, the Company recognized &#128;8.8&nbsp;million of cost reimbursements in support of the Company&#146;s research and license agreements with Incyte and &#128;0.4&nbsp;million of cost
reimbursements in support of the Company&#146;s research and license agreements with ONO. The Company recognized an aggregate of &#128;4.0&nbsp;million in research milestones under its ONO agreements and &#128;0.4&nbsp;million in research milestone
payment amortization under its Simcere agreements for the year ended December&nbsp;31, 2018. The Company did not recognize any revenue relating to research milestones under its Betta collaboration and license agreement for the year ended
December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">R&amp;D cost reimbursement and milestone revenue for the year ended December&nbsp;31, 2017 was &#128;5.8&nbsp;million and
consisted of cost reimbursements in support of the Company&#146;s agreements with Incyte and ONO. The Company did not recognize any research milestones during 2017. During 2016, the Company recognized one research milestone reached under the ONO
agreement, which amounted to &#128;0.7&nbsp;million. Additionally, the Company recorded revenue of &#128;0.4&nbsp;million from an agreement that was signed with ONO on March&nbsp;7, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has been awarded grants consisting of cash allowances for specific R&amp;D projects. The unconditional receipt of the grant allowances is
dependent on the final review of the reporting provided by the Company at the end of the contract term. For the years ended December&nbsp;31, 2018, 2017, and 2016, the Company recognized &#128;0.2&nbsp;million, &#128;1.2&nbsp;million, and
&#128;1.4&nbsp;million in grant income, respectively. As of August 2018, all grants awarded were completed. On June&nbsp;12, 2017, the European Commission approved for reimbursement the final installment of the
<FONT STYLE="white-space:nowrap">FP-7</FONT> grant and the Company subsequently recognized the remaining &#128;0.7&nbsp;million to grant revenue. On October&nbsp;16, 2017, the Company received notification from the European Commission requesting the
Company to revise its final report and indicated that the remaining &#128;0.4&nbsp;million of funds were to remain with the Company and distributed to the other beneficiaries to the program. In November 2017, the Company remitted
&#128;0.2&nbsp;million to the other beneficiaries and recognized an additional &#128;0.2&nbsp;million of grant revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contract Balances
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A trade receivable is recorded when the Company satisfies a performance obligation by transferring a promised good or service and has earned the
unconditional right to consideration from its customer. Trade receivables relate to invoicing for cost reimbursements, upfront payments and research milestones achieved in support of the Company&#146;s research and license agreements with Incyte,
ONO, Simcere and Betta. Payment terms relating to receivables with Incyte, ONO and Simcere are 30 days and payment terms relating to receivables with Betta are 60 days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A contract asset is recorded when the Company satisfies a performance obligation by transferring a promised good or service and has earned the right to
consideration from its customer. These assets represent a conditional right to consideration. Contract assets relate to unbilled amounts for cost reimbursements and research milestones achieved in support of the Company&#146;s research and license
agreements with Incyte and ONO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A contract liability is recorded when consideration is received, or such consideration is unconditionally due, from a
customer prior to transferring goods or services under the terms of the contract. Contract liabilities are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recognized as revenue as control of the products or services is transferred to the customer and all revenue recognition criteria have been met. Contract liabilities relate to upfront payments
received related to the Incyte collaboration and license agreement, ONO research and license agreement and the Simcere research and license agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents changes in the Company&#146;s trade receivables, contract assets and contract liabilities during the year ended December&nbsp;31,
2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deductions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade&nbsp;receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,855</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total trade&nbsp;receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,855</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unbilled receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,014</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,014</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents changes in the Company&#146;s trade receivables, contract assets and contract liabilities during
the year ended December&nbsp;31, 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deductions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade&nbsp;receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total trade&nbsp;receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unbilled receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120,530</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120,530</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,933</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,933</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the adoption of IFRS 15, total deferred revenue was reduced by &#128;8.7&nbsp;million as of December&nbsp;31,
2017. See Note 4 for details. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2018, deductions from deferred revenue are comprised of revenue recognized that was
included in deferred revenue at the beginning of the period totaling &#128;15.9&nbsp;million and revenue recognized that was not included in deferred revenue at the beginning of the period totaling &#128;2.1&nbsp;million. For the year ended
December&nbsp;31, 2017, deductions from deferred revenue are comprised of revenue recognized that was included in deferred revenue at the beginning of the period totaling &#128;3.2&nbsp;million and revenue recognized that was not included in
deferred revenue at the beginning of the period totaling &#128;11.7&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><A HREF="#fin696632_87">14.</A></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><A HREF="#fin696632_87">Total Operating Expenses</A> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents a breakdown of operating expenses: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manufacturing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,914</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IP and license costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,852</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,036</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other R&amp;D costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total R&amp;D costs</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Management and administration costs</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,395</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,425</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,735</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total other expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,160</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>70,295</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">R&amp;D costs primarily include: (i)&nbsp;payroll and related costs (including share-based payment expenses) associated with
R&amp;D personnel; (ii)&nbsp;costs related to clinical trials and preclinical testing of the Company&#146;s technologies under development; (iii)&nbsp;costs to develop product candidates, including raw materials and supplies, product testing,
depreciation, and facility related expenses; (iv)&nbsp;expenses for research services provided by universities and contract laboratories; (v)&nbsp;costs associated with obtaining and maintaining patents and other intellectual property; and
(vi)&nbsp;other R&amp;D expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other R&amp;D costs consist mainly of laboratory supplies and depreciation expense related to R&amp;D activities, which
cannot be specifically allocated to a research project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents a breakdown of other R&amp;D costs: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discovery and preclinical costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,506</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,169</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other R&amp;D costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,263</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other R&amp;D costs</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management and administrative costs consist of salaries and related expenses for employees in finance, legal, human resources,
investor relations and business development functions. These costs include all salary, salary related expenses and share-based compensation expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other operating expenses consist primarily of expenses related to professional fees for consulting, audit, and tax services of &#128;6.3&nbsp;million (2017:
&#128;4.0&nbsp;million, 2016: &#128;1.7 million), which support the finance function in maintaining and establishing public company status and general legal, insurance and facility related expenses amounting to &#128;4.2&nbsp;million (2017:
&#128;3.2&nbsp;million, 2016: &#128;3.9&nbsp;million). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating expenses presented by nature are outlined below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract manufacturing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,914</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other external and outsourced costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,459</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee costs&nbsp;and related benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,284</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>638</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>70,295</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The other external and outsourced costs consist mainly of preclinical costs of &#128;5.5&nbsp;million (2017:
&#128;2.5&nbsp;million, 2016: &#128;5.2 million), clinical costs of &#128;9.2&nbsp;million (2017: &#128;5.9&nbsp;million, 2016: &#128;3.4 million) and IP costs of &#128;3.3&nbsp;million (2017: &#128;2.9&nbsp;million, 2016: &#128;2.7 million). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Employee Benefits </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of the employee benefits are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and wages</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,783</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WBSO subsidy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,257</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Social security premiums</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>919</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Health insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>330</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pension costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>749</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,925</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other personnel expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,835</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total employee benefits expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,284</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based compensation expense recognized as employee benefit expenses during the years ended December&nbsp;31, 2018, 2017
and 2016 was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B><I>(euros in thousands)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,710</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,742</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>473</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,925</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsidies earned under the WBSO relating to eligible R&amp;D costs are deferred and recognized in the Company&#146;s income
statement as a reduction to labor costs over the period labor costs are expected to be incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s headcount at&nbsp;December 31, 2018
was approximately 98&nbsp;full-time equivalents and consisted of 81 employees in the Netherlands and&nbsp;17 employees in the U.S. A total of 21&nbsp;employees who are devoted to activities other than R&amp;D and overall management of the Company
were included under management and administration costs for the year ended December&nbsp;31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s headcount at&nbsp;December 31, 2017 was approximately 83&nbsp;full-time equivalents and
consisted of 70 employees in the Netherlands and&nbsp;13 employees in the U.S. A total of 21&nbsp;employees who are devoted to activities other than R&amp;D and overall management of the Company were included under management and administration
costs for the year ended December&nbsp;31, 2017. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Income (Expense) </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents a breakdown of other income (expense): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and similar related income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,809</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net gain on foreign exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,034</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>7,843</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>1,112</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>88</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,095</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss on foreign exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative financial instrument expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,934</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest income primarily results from interest earned on cash held on account and accretion of investment earnings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company presents foreign currency gains and losses on a net basis as either finance income or finance expense depending on whether foreign currency
movements are in a net gain or net loss position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income consists of a gain recorded in connection with the Regeneron Subscription Agreement. See
Note 12 and Note 21 for details. Pursuant to the Regeneron Subscription Agreement, the Company agreed to sell an aggregate of 600,000 of its common shares to Regeneron at a purchase price equal to $25.0 per share. On December&nbsp;21, 2018, the
Company completed the sale under the Regeneron Subscription Agreement and received gross proceeds of $15.0&nbsp;million, or &#128;13.1&nbsp;million. Accordingly, the Company recorded the common shares issued at the fair value of the underlying
securities on the date of issuance. The difference between the total proceeds received of $15.0&nbsp;million, or &#128;13.1&nbsp;million, and the aggregate value of common shares issued of $6.9&nbsp;million, or &#128;6.0&nbsp;million, was recorded
as a gain on litigation settlement of $8.1&nbsp;million, or &#128;7.1&nbsp;million, during the year-ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;20,
2016, the Company entered into the share subscription agreement with Incyte and recognized a freestanding forward contract (derivative asset) of $32.6&nbsp;million, or &#128;31.4&nbsp;million, in its statement of financial position. In accordance
with IAS 39, the finance costs for the year ended December&nbsp;31, 2017 and 2016, include an amount of &#128;10.7&nbsp;million and &#128;19.2&nbsp;million, respectively, related to a fair value remeasurement of the forward contract through
December&nbsp;31, 2016 and through January&nbsp;23, 2017, the date the shares were issued to Incyte. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Loss per share </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company calculates basic net income (loss) per share attributable to equity holders of the Company and diluted net loss per share attributable to equity
holders of the Company by dividing the net income (loss) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attributable to equity holders of the Company by the weighted average number of common shares outstanding during the period. Diluted net income per share attributable to common stockholders is
computed by dividing net income attributable to equity holders of the Company by the diluted number of shares outstanding during the period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except where
the result would be antidilutive to net income, diluted net income per share attributable to equity holders of the Company is computed assuming the exercise of share options and the vesting of RSUs (using the treasury stock method), as well as their
related income tax effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to equity holders of the Company was calculated as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(e</B><B><I>uros in thousands, except per share data</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to equity holders of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(24,235</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>22,286,720</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,196,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,236,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1.09</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note 4 for details regarding the restatement as a result of a change in accounting policy
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2018, 2017 and 2016, share options and unvested RSUs were excluded from the calculation of net
loss per attributable to equity holders of the Company due to their antidilutive effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company did not declare dividends for any of the years
presented in these financial statements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Instruments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 4, the Company&#146;s initial adoption of IFRS 9 had no impact on previously reported amounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Risk Management </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is exposed to a
variety of financial risks: credit risk, liquidity risk and market risk. The Company&#146;s overall risk management program seeks to minimize potential adverse effects of these financial risk factors on the Company&#146;s financial performance.
Management is primarily responsible for the overall risk management approach and for the approval of risk strategies and principles of the Company. The Company&#146;s Audit Committee oversees these risk management activities. The Company&#146;s
management reviews and approves policies for managing each of these risks which are summarized below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Credit Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and
arises principally from the Company&#146;s receivables from its collaborators and investments in debt securities and financial institutions. The Company&#146;s principal financial assets are held to maturity investments, trade receivables, unbilled
receivables and cash and cash equivalents that are derived primarily from financing activities and, to a lesser extent, from its operations. The main purpose of these financial assets is to support the Company&#146;s operations which consist
primarily of research and development, preclinical and clinical development and related manufacturing in support of the Company&#146;s preclinical and clinical development programs for <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT
STYLE="white-space:nowrap">MCLA-117,</FONT> <FONT STYLE="white-space:nowrap">MCLA-158</FONT> and <FONT STYLE="white-space:nowrap">MCLA-145.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying amount of financial assets represents the maximum credit exposure. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and unbilled receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,926</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61,800</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>143,747</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>208,473</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents include deposits and investments held with financial institutions with original maturities of less
than three months. Investments include commercial paper, securities issued by several public corporations and the U.S. Treasury with a maturity date of greater than three months at the date of settlement. Cash and cash equivalents are held at banks
and financial institutions with credit ratings varying between A and AA, while investments are in highly rated vehicles with identical credit ratings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aging of trade and unbilled receivables was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(</B><B><I>euros&nbsp;in&nbsp;thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neither past due nor impaired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,926</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Past due</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,926</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no allowance for impairment relating to trade and unbilled receivables, investments and cash and cash equivalents.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Liquidity risk is the risk that the
Company will not be able to meet its financial obligations as they become due. The Company&#146;s core objective is to maintain a balance between continuity of funding and flexibility through the monitoring of cash flows at varying levels to ensure
that it has sufficient cash on demand to meet expected operational expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following are the remaining contractual maturities of financial
liabilities as at December&nbsp;31, 2018 and 2017. The amounts are gross and undiscounted. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying</B><br><B>amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&lt; 12</B><br><B>months</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;-&nbsp;2</B><br><B>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2&nbsp;-&nbsp;5</B><br><B>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&gt;&nbsp;5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities and accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying</B><br><B>amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&lt; 12</B><br><B>months</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;-&nbsp;2</B><br><B>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2&nbsp;-&nbsp;5</B><br><B>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&gt; 5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities and accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market risk is the risk that changes in market prices&#151;such as foreign exchange rates and interest rates&#151;will affect the Company&#146;s income or the
value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return. The Company&#146;s market risk relates to foreign
exchange and to a lesser extent, interest risks. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign currency risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign exchange risk arises from future commercial transactions and recognized assets and liabilities in foreign currencies. With respect to monetary assets
and liabilities denominated in foreign currencies, the Company&#146;s primary currency exposure is impacted by monetary assets and liabilities denominated in U.S. dollars. Changes in sensitivity rates reflect various changes in the economy
year-over-year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a sensitivity analysis for a change in the primary currency exposure for the Company relating to monetary
assets and liabilities denominated in U.S. dollars as of December&nbsp;31, 2018. The analysis shows the impact that a change in the exchange rate at that date would have on the Company&#146;s total comprehensive loss: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Financial Statement Line Item Exposure</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Effect&nbsp;on&nbsp;profit</B><br><B>before&nbsp;tax&nbsp;if&nbsp;USD</B><br><B>strengthens 5%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Effect&nbsp;on&nbsp;profit</B><br><B>before&nbsp;tax&nbsp;if&nbsp;USD</B><br><B>weakens 5%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes and social security liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables, other liabilities and accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>103,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,150</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,150</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing exchange rate per the European Central Bank utilized above for converting the U.S. dollar to euro at
December&nbsp;31, 2018 was 0.8734. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exposure to interest rate risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interest rate profile of the Company&#146;s interest-bearing financial instruments is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(</B><B><I>euros in thousands</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fixed-rate instruments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61,800</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Variable rate instruments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>143,747</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted average remaining days to maturity for the Company&#146;s investment portfolio is 135 days as of
December&nbsp;31, 2018. Due to the short remaining hold period for the Company&#146;s investments and resulting limited impact of changes in interest rates on the Company, no sensitivity data is provided. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting Classifications and Fair Values </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
classifications of the Company&#146;s financial assets and financial liabilities, all of which are not measure at fair value, are disclosed in the tables above. The fair value of the financial assets and financial liabilities not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
measured at fair value is not disclosed, as the carrying amount of the financial assets and financial liabilities is a reasonable approximation of the fair value. Accordingly, information on the
fair value hierarchy is omitted. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Board Compensation and Key Management Personnel </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;29, 2017, the Company changed its governance structure from a <FONT STYLE="white-space:nowrap">two-tier</FONT> model consisting of a Management
Board acting under the supervision of a separate Supervisory Board to a <FONT STYLE="white-space:nowrap">one-tier</FONT> board model with a unitary Board of Directors consisting of an executive director and
<FONT STYLE="white-space:nowrap">non-executive</FONT> directors. In the <FONT STYLE="white-space:nowrap">one-tier</FONT> board model, the Board of Directors as a collective (i.e., the executive director and the
<FONT STYLE="white-space:nowrap">non-executive</FONT> directors) are charged with both the management and monitoring functions of the Company&#146;s general course of affairs inclusive of the Company&#146;s overall business strategy and financial
policies. The executive director manages the day <FONT STYLE="white-space:nowrap">to-day</FONT> business and operations of the Company and implements the Company&#146;s strategy. The <FONT STYLE="white-space:nowrap">non-executive</FONT> directors
focus on the supervision of policy and the performance of the duties of all directors, as well as the Company&#146;s general state of affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to
May&nbsp;29, 2017, the Company&#146;s Management Board was in charge of managing the Company and consisted of Ton Logtenberg, Chief Executive Officer (&#147;CEO&#148;) and Shelly Margetson, the former Chief Operating Officer (&#147;COO&#148;).
Ms.&nbsp;Margetson resigned as a statutory director of the Company effective as of May&nbsp;24, 2017 and ended her employment with the Company effective as of August&nbsp;1, 2017. The Supervisory Board was responsible for the supervision of the
Management Board and the general course of affairs of the Company. Subsequent to May&nbsp;29, 2017, the members of the Supervisory Board are now <FONT STYLE="white-space:nowrap">non-executive</FONT> directors, while Mr.&nbsp;Logtenberg remains as
the lone executive director on the unitary Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to Board of Directors, the Company employs certain key management personnel
responsible for executing the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business and operations of the Company. Key management personnel are those persons having authority and responsibility for
planning, directing and controlling the activities of the Company. The Company includes the following employees in this classification: Alexander Berthold Hendrik Bakker, Ph.D., Chief Development Officer, John de Kruif, Chief Technology Officer, Hui
Liu, Ph.D., Chief Business Officer and Head of Merus U.S., Peter Silverman, General Counsel and Chief Intellectual Property Officer, L. Andres Sirulnik, M.D., Ph.D., Chief Medical Officer (&#147;CMO&#148;), and Mark Throsby, Ph.D., Chief Scientific
Officer. On January&nbsp;2, 2019, Mr.&nbsp;Crowley resigned as the Executive Vice President and CFO to pursue other opportunities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Directors
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2018, 2017 and 2016, the following amounts were charged to the consolidated statement of profit or loss and comprehensive loss for the remuneration
of the statutory directors: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross&nbsp;salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pension</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(</B><B><I>in euros</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg, President, CEO and Principal Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">445,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,696,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,330,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,675,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,497,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">369,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">907,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,441,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shelley Margetson(*), Former COO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(**)&nbsp;420,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">451,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">892,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">453,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(*)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Resigned as a statutory director of the Company effective as of May&nbsp;24, 2017. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(**)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Gross salary includes severance payments totaling &#128;257,260. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, Mr.&nbsp;Logtenberg was granted 129,000 share options. As of
December&nbsp;31, 2018, 2017 and 2016, Mr.&nbsp;Logtenberg held 758,925, 661,629 and 376,912 share options, respectively, with a weighted average exercise price of &#128;17.07, &#128;14.20, &#128;2.98, respectively. As of December&nbsp;31, 2018 and
2017, Mr.&nbsp;Logtenberg held 64,450 and 123,745 unvested RSUs, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon Ms.&nbsp;Margetson&#146;s separation date, she was entitled to an
accelerated vesting of any unvested share options and RSUs held that would have vested during the <FONT STYLE="white-space:nowrap">12-month</FONT> period following her separation date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Management Personnel </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The remainder of the key
management personnel has received the following remuneration: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Remuneration</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(</B><B><I>in euros</I></B><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term employment benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,705,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,808,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,139,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-employment benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,688,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,171,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,195,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,435,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,088,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,354,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of the key management personnel have long-term benefits in the form of life and long-term disability insurance policies,
which have been affected in their name as well as severance conditions in case of termination without cause or leave for a good reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of key
management personnel, or their related parties, hold positions in other companies that result in them having control or significant influence over these companies. These companies did not enter into transactions with the Company during the year.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;27, 2016, the Company appointed Andres Sirulnik as its CMO. A total 219,890 share options were granted to Dr.&nbsp;Sirulnik with an
exercise price of &#128;16.85&nbsp;per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;15, 2017, the Company appointed Peter Silverman as its Senior Vice President, Legal. A
total 50,000 share options were granted to Mr.&nbsp;Silverman with an exercise price of &#128;24.54&nbsp;per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;1, 2016, the Company
appointed John Crowley as its CFO. A total of 183,241 share options were granted to Mr.&nbsp;Crowley with an exercise price of &#128;15.24&nbsp;per share. On January&nbsp;2, 2019, Mr.&nbsp;Crowley resigned as the Executive Vice President and CFO. In
connection with his departure, Mr.&nbsp;Crowley entered into a separation and release agreement with the Company, pursuant to which Mr.&nbsp;Crowley will be entitled to receive a severance payment equal to 6 months of his annual salary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2016, the Company established the Supervisory Board Remuneration Program, which was subsequently replaced by the
<FONT STYLE="white-space:nowrap">Non-Executive</FONT> Compensation Program to reflect the change in governance structure of the Company. As part of this program, <FONT STYLE="white-space:nowrap">non-executive</FONT> directors are entitled to cash
compensation as well as equity compensation. The equity compensation consists of an initial option grant as well as subsequent annual share-based awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following amounts were charged to the consolidated statement of profit or loss and comprehensive loss
for the remuneration of the members of the Board: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash</B><br><B>compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash</B><br><B>compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash</B><br><B>compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B><I>(in euros)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B><I>(in euros)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B><I>(in euros)</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Russell Greig</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Mark Iwicki</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Len Kanavy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Wolfgang Berthold</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Lionel Carnot*</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">John de Koning</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Anand Mehra</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Gregory Perry</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>292,231</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>506,550</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>798,781</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>252,703</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>573,875</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>826,578</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>176,620</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>520,322</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>696,942</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(*)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">former board member </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at December&nbsp;31, members of the Board held the following number of options: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December, 31 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell Greig</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">19.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Iwicki</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">6.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Len Kanavy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">16.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wolfgang Berthold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">15.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lionel Carnot*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">11.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John de Koning</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">11.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anand Mehra</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">11.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory Perry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">11.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gabriele Dallmann*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">11.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">9.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(*)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">former board member </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Related party disclosures </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2018, 2017 and 2016, certain Key Management Personnel and other senior management received regular salaries, bonuses and
contributions to post-employment schemes as well as <FONT STYLE="white-space:nowrap">non-cash</FONT> compensation as disclosed in Note 19. Additionally, members of the Board of Directors received compensation for their services in the form of cash
compensation as well as <FONT STYLE="white-space:nowrap">non-cash</FONT> compensation, as disclosed in Note 19. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;24, 2017, the Company entered
into a settlement agreement with Shelley Margetson, the Company&#146;s former Chief Operating Officer pursuant to which Ms.&nbsp;Margetson resigned as a statutory director of the Company effective as of May&nbsp;24, 2017 and ended her employment
with the Company effective as of August&nbsp;1, 2017. As part of the terms of the settlement agreement, Ms.&nbsp;Margetson is entitled to a severance payment equal to 12 months of her annual base salary, 50% of which was paid in a lump sum in August
2017 and the remaining 50% is being paid in the form of salary continuation over the <FONT STYLE="white-space:nowrap">six-month</FONT> period following August&nbsp;1, 2017. In addition, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Ms.&nbsp;Margetson was entitled to an accelerated vesting of any unvested Company options and restricted stock units held by Ms.&nbsp;Margetson that would have vested during the <FONT
STYLE="white-space:nowrap">12-month</FONT> period following her separation date. As of December&nbsp;31, 2018 and 2017, the Company had an accrual of &#128;0 and less than &#128;0.1&nbsp;million, respectively, related to this agreement included in
accrued personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;2, 2019, John Crowley resigned as the Executive Vice President and Chief Financial Officer of the &#147;Company. In
connection with his departure, Mr.&nbsp;Crowley entered into a Separation and Release Agreement with the Company, pursuant to which Mr.&nbsp;Crowley is entitled to receive a severance payment equal to 6 months of his annual salary. The transaction
will be recorded in the Company&#146;s consolidated financial statements during the three months ending March&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As disclosed in Note 11 and
Note 13, the Company entered into the Incyte collaboration and license agreement and the Incyte share subscription agreement in which the terms and transactional amounts incurred between Incyte and the Company are more fully described. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March 31, 2019, the following shareholders currently hold a position in the Board of Directors and have filed a form
<FONT STYLE="white-space:nowrap">13-D</FONT> to reflect ownership in the Company of greater than 5%: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Co&ouml;peratief LSP IV U.A. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sofinnova Venture Partners IX, L.P. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, Ton Logtenberg, the Company&#146;s President, CEO and Principal Financial Officer and Executive Director, is the sole the Director and owner of
Biophrase BV (&#147;Biophrase&#148;). As of March&nbsp;31, 2019, Biophrase is a less than 1% shareholder. There were no transactions between the Company and Biophrase BV in 2018. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commitments and contingencies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lease Commitments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company leases its corporate
headquarters under an agreement, which expires in the fourth quarter of 2021. If the lease is not terminated by Merus N.V., it will be automatically renewed for a period of two years. The agreed rental price is &#128;0.4&nbsp;million per year. On
May&nbsp;1, 2018, the Company leased additional space to expand its corporate headquarters under a separate agreement. Under the terms of the new agreement, the term began on May&nbsp;1, 2018 and expires in the fourth quarter of 2021. The agreed
upon rental price is &#128;0.6&nbsp;million per year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For leases that contain fixed increases in the minimum annual lease payment during the original
term of the lease, the Company recognizes rental expense on a straight-line basis over the lease term and records the difference between rent expense and the amount currently payable as deferred rent, as a component of other liabilities and
accruals. For the years ended December&nbsp;31, 2018, 2017 and 2016 the Company recognized &#128;1.3&nbsp;million, &#128;0.6&nbsp;million and &#128;0.3&nbsp;million, respectively, for rent and service charges related to the leased office space. In
addition, the Company has provided deposits totaling &#128;0.3&nbsp;million and &#128;0.1&nbsp;million included in other assets as of December&nbsp;31, 2018, and December&nbsp;31, 2017, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future minimum lease payments under these leases as of December&nbsp;31, 2018 are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less than one year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Between one and five years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">More than five years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is contractually obligated to return leased space in good order, repair and condition excluding
ordinary wear and tear upon termination of the lease agreement. The Company&#146;s asset retirement obligations were not significant as of December&nbsp;31, 2018 and 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s contractual obligations associated with <FONT STYLE="white-space:nowrap">non-real</FONT> estate leases were not significant as of
December&nbsp;31, 2018 and 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2019, the Company entered in a lease agreement for approximately 7,583 square feet of office space in
Cambridge, Massachusetts. Refer to Note 22 for further details. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Commitments Related to the Collaboration and License Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Incyte collaboration and license agreement, the Company and Incyte have agreed to collaborate with respect to the research, discovery and development
of bispecific antibodies utilizing the Company&#146;s proprietary bispecific technology platform. The collaboration encompasses up to 11 independent programs, including some of the Company&#146;s current preclinical immuno-oncology discovery
programs. For one of the current programs, concerning <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> the Company retains the exclusive right to develop and commercialize products and product candidates in the U.S., while Incyte has the exclusive
right to develop and commercialize products and product candidates arising from such program outside the U.S. For <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> the Company and Incyte will conduct and share equally the costs of mutually agreed
global development activities and will be solely responsible for independent development activities in the respective territories. The actual amounts that the Company may pay to Incyte or that Incyte may pay to the Company will depend on numerous
factors outside of the Company&#146;s control, including the success of certain clinical development efforts with respect to <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> the content and timing of decisions made by the regulators, the
reimbursement and competitive landscape around <FONT STYLE="white-space:nowrap">MCLA-145</FONT> and other factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company has
commitments to make potential future milestone payments to third parties under certain of its license arrangements. These milestones primarily relate to the initiation and results of clinical trials, obtaining regulatory approval in various
jurisdictions and the future commercial success of development programs, the outcome and timing of which are difficult to predict and subject to significant uncertainty. In addition to the milestones discussed above, the Company is obligated to pay
royalties on future sales, which are contingent on generating levels of sales of future products that have not been achieved and may never be achieved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Funding Commitments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31,
2018, the Company had several ongoing clinical and nonclinical studies for its various pipeline programs. The Company enters into contracts in the normal course of business with contract research organizations and clinical sites for the conduct of
clinical trials, professional consultants for expert advice and other vendors for clinical supply manufacturing or other services. These contracts are generally cancellable, with notice, at the Company&#146;s option and do not have significant
cancellation penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2018, the Company entered into certain contracts to purchase property, plant and equipment in 2019 for
&#128;0.6&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Guarantees </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#146;s request in such capacity. The maximum potential amount of future payments the Company could be
required to make is unlimited; however, the Company has directors&#146; and officers&#146; insurance coverage that is intended to limit its exposure and enable it to recover a portion of any future amounts paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into certain agreements with other parties in the ordinary course of business that
contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords, clinical sites and customers. Under these provisions, the Company may indemnifies and holds harmless the
indemnified party for losses suffered or incurred by the indemnified party as a result of the Company&#146;s activities, such as gross negligence, willful misconduct or at times, other activities. These indemnification provisions may survive
termination of the underlying agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions may be unlimited. However, to date the Company has not incurred material costs to
defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal. Accordingly, the Company did not have any liabilities recorded for these obligations as of
December&nbsp;31, 2018 and 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;11, 2014, Regeneron Pharmaceuticals, Inc. (&#147;Regeneron&#148;) filed a complaint in the U.S. District Court for the Southern District of New
York, alleging that the Company was infringing one or more claims in Regeneron&#146;s U.S. Patent No.&nbsp;8,502,018, entitled &#147;Methods of Modifying Eukaryotic Cells.&#148; In 2015, the trial court entered judgments finding that the Company
does not infringe the claims of the Patent No.&nbsp;8,502,018, that the patent is invalid, and that the patent was procured through inequitable conduct and is unenforceable. On July&nbsp;27, 2017 the U.S. Court of Appeals for the Federal Circuit
affirmed the trial court&#146;s conclusion that Regeneron engaged in inequitable conduct before the U.S. Patent and Trademark Office while prosecuting the Patent No.&nbsp;8,502,018 and affirmed that the Patent No.&nbsp;8,502,018 is unenforceable. On
December&nbsp;26, 2017, the Federal Circuit denied Regeneron&#146;s petition for rehearing and rehearing en banc seeking a review of that decision and on October&nbsp;1, 2018, the Supreme Court of the U.S. denied Regeneron&#146;s petition for
certiorari, rendering the case finally resolved in the Company&#146;s favor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;26, 2018, the trial court granted the Company&#146;s motion
for attorneys&#146; fees, expert fees, and costs associated with the Company&#146;s defense of the above litigation, and ordered the parties to address the amount of the award. The Company provided a detailed explanation of its attorneys&#146; fees,
expert fees, and costs of such award, which Regeneron responded to, seeking a reduction of the amount. The matter was fully briefed as of May&nbsp;18, 2018, and the court issued an Order on June&nbsp;25, 2018, which published on July&nbsp;10, 2018,
granting the Company&#146;s motion for $8,332,453.46 in attorneys&#146; fees, $465,390.34 in expert fees, and $1,717,100.69 in litigation expenses and costs, along with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-judgment interest.
Regeneron appealed the decision awarding attorneys&#146; fees to the Company to the Federal Circuit, filing its opening brief on November&nbsp;7, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;11, 2014, Regeneron served a writ in the Netherlands alleging that the Company was infringing one or more claims in their European patent EP 1
360 287 B1. The Company had opposed that patent in June 2014. On September&nbsp;17, 2014, Regeneron&#146;s patent EP 1 360 287 B1 was revoked in its entirety by the European Opposition Division of the European Patent Office (the &#147;EPO&#148;). In
Europe, an appeal hearing occurred in October and November 2015 at the Technical Board of Appeal for the EPO at which time the patent was reinstated to Regeneron with amended claims. On October&nbsp;2, 2017, the Company filed an appeal with the
Technical Board of Appeal for the EPO to address whether the patent having claims amended during the course of opposition complies with Art. 84 EPC, Art. 123(2) EPC and Rule 80 EPC. On May&nbsp;25, 2018, at Regeneron&#146;s request, a hearing before
the Technical Board of Appeals for the EPO was scheduled for September&nbsp;13, 2018, to address whether the description of EP 1 360 287 B1 patent having claims amended during the course of opposition complies with Art. 84 EPC, Art. 123(2) EPC and
Rule 80 EPC. The Technical Board of Appeals provided preliminary views on the matter on August&nbsp;23, 2018, after which the Company&#146;s appeal filed on October&nbsp;2, 2017 was withdrawn on September&nbsp;5, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The costs incurred in the above litigation and opposition were &#128;1.4&nbsp;million, &#128;1.0&nbsp;million and &#128;1.5&nbsp;million for the years ended
December&nbsp;31, 2018, 2017 and 2016, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regeneron also previously raised opposition proceedings against certain of the Company&#146;s patents in
jurisdictions including Europe, Japan and Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;20, 2018, the Company signed a global settlement and cross-license agreement with
Regeneron, where the parties have agreed to end all pending litigation and opposition proceedings pertaining to the Company&#146;s and Regeneron&#146;s respective antibody generation technologies. Regeneron also purchased 600,000 of the
Company&#146;s common shares at a price of $25 per share for total aggregate proceeds of $15.0&nbsp;million. The cross-license and stock purchase were made in conjunction with the agreement to withdraw Regeneron&#146;s appeal of the fee award, and
agreement to dismissal of all claims to approximately $10.5&nbsp;million for the reimbursement of attorneys&#146; fees and other expenses, plus interest, awarded to Merus by the trial court. Under the terms of the settlement, Regeneron has withdrawn
its appeal of the decision awarding attorneys&#146; fees to the Company as a result of the U.S. District Court litigation described above. In addition, Regeneron has dismissed its stayed case in the Netherlands asserting the EP 1 360 287 B1 patent,
and both parties have withdrawn all pending oppositions as of December&nbsp;20, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2018, an unnamed third party and Regeneron filed
notices of opposition against the Company&#146;s EP 2604625 patent, entitled &#147;Generation of Binding Molecules,&#148; in the EPO. The notices asserted, as applicable, added subject matter, lack of novelty, lack of inventive step, and
insufficiency. Regeneron will no longer be pursuing this opposition pursuant to December&nbsp;20, 2018 settlement. On August&nbsp;20, 2018, the Company timely responded to these submissions, with proceedings to be ongoing with respect to the unnamed
third party. An opposition hearing is scheduled for June 2019. As this opposition proceeding continues, the Company cannot be certain that the Company will ultimately prevail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, the Company may be involved in various other claims and legal proceedings relating to claims arising out of the Company&#146;s operations.
The Company is not currently a party to any other material legal proceedings. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Subsequent events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2019, the Company entered in a lease agreement for approximately 7,583 square feet of office space in Cambridge, Massachusetts. The lease has a term
of seven years and expires on April&nbsp;1, 2026. The lease provides for escalating rent each year, with total cash payments of approximately $4.9&nbsp;million, or &#128;4.2&nbsp;million, payable over the lease term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registrant hereby certifies that it meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">20-F</FONT> and that
it has duly caused and authorized the undersigned to sign this annual report on its behalf. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MERUS N.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ton Logtenberg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ton Logtenberg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer and Principal Financial Officer</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: April 3, 2019 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>2
<FILENAME>d696632dex121.htm
<DESCRIPTION>EX-12.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-12.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 12.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, Ton
Logtenberg, certify that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this annual report on Form
<FONT STYLE="white-space:nowrap">20-F</FONT> of Merus N.V.; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT
STYLE="white-space:nowrap">15d-15(f))</FONT> for the company and have: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &nbsp;&nbsp;&nbsp;&nbsp;Designed such
disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to me by
others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over
financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted
accounting principles; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the company&#146;s disclosure controls
and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the company&#146;s internal control over financial reporting
that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#146;s internal control over financial reporting; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the
company&#146;s auditors and the audit committee of the company&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the company&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a
significant role in the company&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date:&nbsp;&nbsp;&nbsp;&nbsp;April 3, 2019 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ton Logtenberg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Principal Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(Principal Executive Officer)</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>3
<FILENAME>d696632dex131.htm
<DESCRIPTION>EX-13.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-13.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 13.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Ton Logtenberg, President, Chief Executive Officer and Principal Financial Officer of Merus N.V. (the &#147;Company&#148;), hereby certify, pursuant to 18
U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;The Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of the Company for the period ended
December&nbsp;31, 2018 (the &#147;Report&#148;) fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 3, 2019 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ton Logtenberg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">President, Chief Executive Officer and Principal Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">(Principal Executive Officer)</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>4
<FILENAME>d696632dex151.htm
<DESCRIPTION>EX-15.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-15.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 15.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merus N.V.: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in the registration statement (No. <FONT STYLE="white-space:nowrap">333-211497)</FONT> on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> and in the registration statement (No. <FONT STYLE="white-space:nowrap">333-218432)</FONT> on Form <FONT STYLE="white-space:nowrap">F-3</FONT> of Merus N.V. of our report dated April&nbsp;3, 2019, with respect
to the consolidated statements of financial position of Merus N.V. as of December&nbsp;31, 2018 and 2017, the related consolidated statements of profit or loss and comprehensive loss, changes in equity, and cash flows for each of the years in the
three-year period ended December&nbsp;31, 2018, and the related notes, which report appears in the December&nbsp;31, 2018 annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> of Merus N.V. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our report refers to the adoption of International Financial Reporting Standard 15 Revenue from Contracts with Customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KPMG Accountants N.V. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amstelveen, The Netherlands </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;3, 2019 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>mrus-20181231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN Xcelerate Instance Document - https://www.dfinsolutions.com/ -->
<!-- Version:  6.23.6 -->
<!-- Round: 6 -->
<!-- Creation date: 2019-04-03T15:11:08Z -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2018-03-16/ifrs-full" xmlns:mrus="http://www.merus.nl/20181231" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="mrus-20181231.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <ifrs-full:NumberOfSharesIssued contextRef="eol_PE977595--1820-F0010_STD_0_20160524_0_3475672x3509221" unitRef="shares" decimals="INF" id="id_14264487_DE14600A-A898-4898-8EA3-E990C33B9A49_3001_0">5500000</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesIssued contextRef="eol_PE977595--1820-F0010_STD_0_20160526_0_3475672x3486453" unitRef="shares" decimals="INF" id="id_14264487_DE14600A-A898-4898-8EA3-E990C33B9A49_2002_1">639926</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:ParValuePerShare contextRef="eol_PE977595--1820-F0010_STD_0_20160526_0_3475672x3509221" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_14264487_DE14600A-A898-4898-8EA3-E990C33B9A49_3002_2">10.0</ifrs-full:ParValuePerShare>
  <ifrs-full:DeferredIncome contextRef="eol_PE977595--1820-F0010_STD_0_20161220_0_3423078x3554473" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_5717A6D9-8CF6-4E96-9AF5-87277DE2D685_2002_1">31400000</ifrs-full:DeferredIncome>
  <ifrs-full:DeferredIncome contextRef="eol_PE977595--1820-F0010_STD_0_20161220_0_3423078x3554473" unitRef="iso4217_USD" decimals="-5" id="id_14264487_5717A6D9-8CF6-4E96-9AF5-87277DE2D685_2001_1">32600000</ifrs-full:DeferredIncome>
  <ifrs-full:DerivativeFinancialAssets contextRef="eol_PE977595--1820-F0010_STD_0_20161220_0_3423078x3554473" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_E8DDF043-0AF2-4DF5-A23A-6F346A173C3A_2002_0">31400000</ifrs-full:DerivativeFinancialAssets>
  <ifrs-full:DerivativeFinancialAssets contextRef="eol_PE977595--1820-F0010_STD_0_20161220_0_3423078x3554473" unitRef="iso4217_USD" decimals="-5" id="id_14264487_E8DDF043-0AF2-4DF5-A23A-6F346A173C3A_2001_0">32600000</ifrs-full:DerivativeFinancialAssets>
  <ifrs-full:ParValuePerShare contextRef="eol_PE977595--1820-F0010_STD_0_20180213_0_3416740x3507527" unitRef="iso4217_EUR_per_shares" decimals="INF" id="id_14264487_22EF4E11-B2C0-4D9C-87FD-65374785A5D8_2001_1">0.09</ifrs-full:ParValuePerShare>
  <mrus:LitigationSettlementsGrantedForAttorneysFees contextRef="eol_PE977595--1820-F0010_STD_0_20180326_0" unitRef="iso4217_USD" decimals="2" id="id_14264487_CB6D0BA3-426B-4E20-BFF9-98F2E243A097_1001_0">8332453.46</mrus:LitigationSettlementsGrantedForAttorneysFees>
  <mrus:LitigationSettlementsGrantedForExpertFees contextRef="eol_PE977595--1820-F0010_STD_0_20180326_0" unitRef="iso4217_USD" decimals="2" id="id_14264487_CB6D0BA3-426B-4E20-BFF9-98F2E243A097_1001_1">465390.34</mrus:LitigationSettlementsGrantedForExpertFees>
  <mrus:LitigationSettlementsGrantedForLitigationExpensesAndCosts contextRef="eol_PE977595--1820-F0010_STD_0_20180326_0" unitRef="iso4217_USD" decimals="2" id="id_14264487_CB6D0BA3-426B-4E20-BFF9-98F2E243A097_1001_2">1717100.69</mrus:LitigationSettlementsGrantedForLitigationExpensesAndCosts>
  <mrus:PercentageOfOwnershipInterestByShareholders contextRef="eol_PE977595--1820-F0010_STD_0_20190331_0_3416740x3486460_3422662x3416700" unitRef="pure" decimals="INF" id="id_14264487_6DD26928-0AA7-46D7-BCCA-145D402AA8C8_1001_1">0.05</mrus:PercentageOfOwnershipInterestByShareholders>
  <mrus:PercentageOfOwnershipInterestByShareholders contextRef="eol_PE977595--1820-F0010_STD_0_20190331_0_3416740x3486462_3422662x3416700" unitRef="pure" decimals="INF" id="id_14264487_6DD26928-0AA7-46D7-BCCA-145D402AA8C8_2001_2">0.05</mrus:PercentageOfOwnershipInterestByShareholders>
  <ifrs-full:NumberOfSharesIssued contextRef="eol_PE977595--1820-F0010_STD_0_20170601_0_3416740x3486468" unitRef="shares" decimals="INF" id="id_14264487_A8CE59B9-656D-41BA-97D0-521963ED5B08_1001_1">3200000</ifrs-full:NumberOfSharesIssued>
  <mrus:SecuritiesPledgedAsCollateralForRegistration contextRef="eol_PE977595--1820-F0010_STD_0_20170601_0_3416740x3486468" unitRef="iso4217_USD" decimals="-5" id="id_14264487_A8CE59B9-656D-41BA-97D0-521963ED5B08_1001_0">250000000</mrus:SecuritiesPledgedAsCollateralForRegistration>
  <mrus:NumberOfSharesIssuable contextRef="eol_PE977595--1820-F0010_STD_0_20170601_0_3416740x3513899" unitRef="shares" decimals="-5" id="id_14264487_A8CE59B9-656D-41BA-97D0-521963ED5B08_2001_2">50000000</mrus:NumberOfSharesIssuable>
  <mrus:PercentageOfAggregateCompensationPayable contextRef="eol_PE977595--1820-F0010_STD_0_20170601_0_3416740x3513899" unitRef="pure" decimals="3" id="id_14264487_A8CE59B9-656D-41BA-97D0-521963ED5B08_2001_3">0.030</mrus:PercentageOfAggregateCompensationPayable>
  <ifrs-full:CashAndCashEquivalents contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2002_38">32851000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1010_3">28901000</ifrs-full:Equity>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_14264487_2D9E1ED7-9102-4197-AE9A-6039F1DD098B_2001_0">953689</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_2001_0">5.35</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495214_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1001_3">30000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495214_3417632x3421013_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3001_1">30000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495215_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1002_3">21000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495215_3417632x3421013_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3002_1">21000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495216_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1003_3">351000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495216_3417632x3421013_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3003_1">351000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495217_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1004_3">373000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495217_3417632x3421013_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3004_1">373000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495218_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1006_3">1334000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495218_3417632x3422849_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3006_1">1334000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495219_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1007_3">38906000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495219_3417632x3422849_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3007_1">38906000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495220_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1008_3">49105000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495220_3417632x3422849_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3008_1">49105000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495221_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1005_3">1564000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495221_3417632x3422849_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3005_1">1564000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1009_3">-62783000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417632x3422911_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_2009_2">599000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3417632x3422911_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3009_1">-63382000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_2010_2">599000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20151231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3010_1">28302000</ifrs-full:Equity>
  <ifrs-full:CashAndCashEquivalents contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1003_38">56917000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_3A4B2BC1-1D1D-438F-8861-501136348433_3_2">3492000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
  <ifrs-full:DeferredIncomeClassifiedAsNoncurrent contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_3A4B2BC1-1D1D-438F-8861-501136348433_3_1">27934000</ifrs-full:DeferredIncomeClassifiedAsNoncurrent>
  <ifrs-full:ContractLiabilities contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_42350E10-239D-4AF2-8266-66F681BDEDBD_1002_1">31426000</ifrs-full:ContractLiabilities>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_7010_13">34421000</ifrs-full:Equity>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_14264487_8B4407D4-240E-47E7-BFCD-310CE2DB413C_1003_2">1394844</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_81C606C9-877F-4A25-8240-D20899DA93A2_4001_3">374000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_14264487_2D9E1ED7-9102-4197-AE9A-6039F1DD098B_1003_6">418453</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:RetainedEarnings contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_3A4B2BC1-1D1D-438F-8861-501136348433_3_0">-106905000</ifrs-full:RetainedEarnings>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_1003_3">648000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:TradeReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B9006E8A-8CC3-4797-AB24-FDAA49648F60_1002_1">205000</ifrs-full:TradeReceivables>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_1003_6">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_1003_0">8.69</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3416740x3421023" unitRef="shares" decimals="INF" id="id_14264487_8B4407D4-240E-47E7-BFCD-310CE2DB413C_2003_0">1302417</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3416740x3514206" unitRef="shares" decimals="INF" id="id_14264487_8B4407D4-240E-47E7-BFCD-310CE2DB413C_3003_1">92427</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3416904x3416753" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_81C606C9-877F-4A25-8240-D20899DA93A2_5001_2">-486000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3416904x3416976" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_2003_2">-1387000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3416904x3416976_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_2002_2">-1166000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3416904x3416976_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_2001_2">-221000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3416904x3420576" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_81C606C9-877F-4A25-8240-D20899DA93A2_6001_1">860000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3416904x3420576" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_3003_1">2035000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3416904x3420576_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_3002_1">1386000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3416904x3420576_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_3001_1">649000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:ContractLiabilities contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3416963x3508994" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_42350E10-239D-4AF2-8266-66F681BDEDBD_1001_1">31426000</ifrs-full:ContractLiabilities>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_1002_3">220000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_1001_3">428000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:TradeReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3417430x3424016" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B9006E8A-8CC3-4797-AB24-FDAA49648F60_1001_1">205000</ifrs-full:TradeReceivables>
  <ifrs-full:NumberOfSharesIssuedAndFullyPaid contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3417439x3422519" unitRef="shares" decimals="0" id="id_14264487_CCFFE51C-AC42-429F-A080-997279263246_1003_0">16085851</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
  <ifrs-full:NumberOfSharesOutstanding contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3417439x3422519" unitRef="shares" decimals="0" id="id_14264487_1929F029-CC6A-4563-801E-C284057C67AE_3001_0">16085851</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3417439x3495214_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_7001_13">1448000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3417439x3495221_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_7005_13">139878000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_7009_13">-106905000</ifrs-full:Equity>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3422662x3416700" unitRef="iso4217_EUR" decimals="INF" id="id_14264487_D2C11233-6864-41A5-86A7-1FC6F9FA0B51_1003_1">16.85</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3422662x3423353" unitRef="iso4217_EUR" decimals="INF" id="id_14264487_D2C11233-6864-41A5-86A7-1FC6F9FA0B51_2003_0">1.93</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_3A4B2BC1-1D1D-438F-8861-501136348433_2_2">1882000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
  <ifrs-full:DeferredIncomeClassifiedAsNoncurrent contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_3A4B2BC1-1D1D-438F-8861-501136348433_2_1">-2272000</ifrs-full:DeferredIncomeClassifiedAsNoncurrent>
  <ifrs-full:RetainedEarnings contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_3A4B2BC1-1D1D-438F-8861-501136348433_2_0">390000</ifrs-full:RetainedEarnings>
  <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_3A4B2BC1-1D1D-438F-8861-501136348433_1_2">1610000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
  <ifrs-full:DeferredIncomeClassifiedAsNoncurrent contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_3A4B2BC1-1D1D-438F-8861-501136348433_1_1">30206000</ifrs-full:DeferredIncomeClassifiedAsNoncurrent>
  <ifrs-full:RetainedEarnings contextRef="eol_PE977595--1820-F0010_STD_0_20161231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_3A4B2BC1-1D1D-438F-8861-501136348433_1_0">-107295000</ifrs-full:RetainedEarnings>
  <ifrs-full:ParValuePerShare contextRef="eol_PE977595--1820-F0010_STD_0_20170123_0_3416740x3486468" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_14264487_9F2AB8E1-719D-46E7-9990-5A0CA58BD01F_2001_1">25.0</ifrs-full:ParValuePerShare>
  <ifrs-full:NumberOfSharesIssued contextRef="eol_PE977595--1820-F0010_STD_0_20170123_0_3416740x3486468" unitRef="shares" decimals="INF" id="id_14264487_9F2AB8E1-719D-46E7-9990-5A0CA58BD01F_2001_0">3200000</ifrs-full:NumberOfSharesIssued>
  <mrus:PrepaidShareIssueRelatedCost contextRef="eol_PE977595--1820-F0010_STD_0_20170123_0_3416740x3486468" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_9F2AB8E1-719D-46E7-9990-5A0CA58BD01F_2002_4">200000</mrus:PrepaidShareIssueRelatedCost>
  <ifrs-full:CashAndCashEquivalents contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1002_39">149678000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:Assets contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_11">196803000</ifrs-full:Assets>
  <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_2_7">8627000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
  <ifrs-full:CurrentLiabilities contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_24">27660000</ifrs-full:CurrentLiabilities>
  <ifrs-full:DeferredIncome contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_830EAA38-871F-48F4-AC96-336FAB76AFAE_2_2">128486000</ifrs-full:DeferredIncome>
  <ifrs-full:CurrentAdvances contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_2_5">224000</ifrs-full:CurrentAdvances>
  <ifrs-full:CurrentInterestReceivable contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_2_5">170000</ifrs-full:CurrentInterestReceivable>
  <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_3_2">15935000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
  <ifrs-full:DeferredIncomeClassifiedAsNoncurrent contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_3_1">112551000</ifrs-full:DeferredIncomeClassifiedAsNoncurrent>
  <ifrs-full:ContractLiabilities contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CE40E457-E3B7-4108-99F6-618E5B763DA0_1002_1">128486000</ifrs-full:ContractLiabilities>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_2_4">34043000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:CurrentTradeReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_2_0">1594000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:ContractAssets contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_AAEECD3A-A490-47A4-A19C-88AEF875DFF6_1002_1">710000</ifrs-full:ContractAssets>
  <ifrs-full:CurrentAssets contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_10">188134000</ifrs-full:CurrentAssets>
  <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_21">243000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
  <ifrs-full:CurrentValueAddedTaxReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_2_2">582000</ifrs-full:CurrentValueAddedTaxReceivables>
  <ifrs-full:EquityAndLiabilities contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_26">196803000</ifrs-full:EquityAndLiabilities>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_9010_22">56592000</ifrs-full:Equity>
  <ifrs-full:HeldtomaturityInvestments contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_2_7">41103000</ifrs-full:HeldtomaturityInvestments>
  <ifrs-full:IssuedCapital contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_13">1749000</ifrs-full:IssuedCapital>
  <ifrs-full:MaximumExposureToCreditRisk contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E741B6AE-592A-40A0-8D63-16EEA58E4B0A_1002_3">193064000</ifrs-full:MaximumExposureToCreditRisk>
  <ifrs-full:NoncurrentAssets contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_5">8669000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="shares" decimals="INF" id="id_14264487_8B4407D4-240E-47E7-BFCD-310CE2DB413C_1002_2">2213985</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:OtherNoncurrentAssets contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_4">129000</ifrs-full:OtherNoncurrentAssets>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_2">312000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_81C606C9-877F-4A25-8240-D20899DA93A2_1002_3">312000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:Liabilities contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_25">140211000</ifrs-full:Liabilities>
  <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_FCFE9C90-4643-4F48-A321-D31AFFD8A5D0_1002_2">9031000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
  <ifrs-full:NumberOfEmployees contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="Employees" decimals="INF" id="id_14264487_040DB130-D21C-4D66-94C6-E06204813C70_1001_0">83</ifrs-full:NumberOfEmployees>
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="shares" decimals="INF" id="id_14264487_931C8F45-65AF-4273-8D38-1B87506DC76D_1002_0">194546</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="shares" decimals="INF" id="id_14264487_2D9E1ED7-9102-4197-AE9A-6039F1DD098B_1002_6">687070</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:NoncurrentHeldtomaturityInvestments contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_2_6">7060000</ifrs-full:NoncurrentHeldtomaturityInvestments>
  <ifrs-full:OtherCurrentReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_2_6">92000</ifrs-full:OtherCurrentReceivables>
  <ifrs-full:RetainedEarnings contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_3_0">-158775000</ifrs-full:RetainedEarnings>
  <ifrs-full:TradeAndOtherCurrentReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_2_7">4413000</ifrs-full:TradeAndOtherCurrentReceivables>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_7003_12">1168000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_20">2855000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
  <ifrs-full:TradeReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F8B7FC2B-1154-4601-887C-8DB3A5477E34_1003_1">1594000</ifrs-full:TradeReceivables>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_1C9A2645-8CE2-43DE-B4D4-CB5AD26735C7_1002_0">20.03</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:SharePremium contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_14">213618000</ifrs-full:SharePremium>
  <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_2_2">1545000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_1002_6">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_FCFE9C90-4643-4F48-A321-D31AFFD8A5D0_1002_0">2855000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_1002_0">13.99</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <mrus:OtherAccruals contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_2_6">535000</mrus:OtherAccruals>
  <mrus:SecurityDeposits contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_FC788C4F-FFA1-4B14-AED5-CE0544122BE9_1002_1">100000</mrus:SecurityDeposits>
  <mrus:CurrentPrepaidPensionCosts contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_2_4">838000</mrus:CurrentPrepaidPensionCosts>
  <mrus:CurrentPrepaidGeneralExpenses contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_2_3">427000</mrus:CurrentPrepaidGeneralExpenses>
  <mrus:AccruedPersonnel contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_2_1">446000</mrus:AccruedPersonnel>
  <mrus:AccruedResearchAndDevelopmentStudies contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_2_3">5272000</mrus:AccruedResearchAndDevelopmentStudies>
  <mrus:AccruedIntellectualPropertyLegalFee contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_2_4">509000</mrus:AccruedIntellectualPropertyLegalFee>
  <mrus:AccruedAuditorsFee contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_2_0">96000</mrus:AccruedAuditorsFee>
  <mrus:CurrentUnbilledReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_2_1">710000</mrus:CurrentUnbilledReceivables>
  <mrus:TradeAndUnbilledReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E741B6AE-592A-40A0-8D63-16EEA58E4B0A_1002_0">2283000</mrus:TradeAndUnbilledReceivables>
  <mrus:OtherLiabilitiesAndAccrualsUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_FCFE9C90-4643-4F48-A321-D31AFFD8A5D0_1002_1">6176000</mrus:OtherLiabilitiesAndAccrualsUndiscountedCashFlows>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3416740x3421023" unitRef="shares" decimals="INF" id="id_14264487_8B4407D4-240E-47E7-BFCD-310CE2DB413C_2002_0">1777437</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3416740x3514206" unitRef="shares" decimals="INF" id="id_14264487_8B4407D4-240E-47E7-BFCD-310CE2DB413C_3002_1">436548</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3416753" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_81C606C9-877F-4A25-8240-D20899DA93A2_2002_2">-548000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3416976" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_8003_11">-506000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3416976_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_8002_11">-150000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3416976_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_8001_11">-356000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3420576" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_81C606C9-877F-4A25-8240-D20899DA93A2_3002_1">860000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3420576" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_9003_10">1674000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3420576_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_9002_10">413000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3420576_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_9001_10">1261000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3509593" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_FCFE9C90-4643-4F48-A321-D31AFFD8A5D0_1001_2">9031000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
  <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3509593" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_FCFE9C90-4643-4F48-A321-D31AFFD8A5D0_1001_0">2855000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
  <mrus:OtherLiabilitiesAndAccrualsUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3509593" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_FCFE9C90-4643-4F48-A321-D31AFFD8A5D0_1001_1">6176000</mrus:OtherLiabilitiesAndAccrualsUndiscountedCashFlows>
  <ifrs-full:ContractLiabilities contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3416963x3508994" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CE40E457-E3B7-4108-99F6-618E5B763DA0_1001_1">128486000</ifrs-full:ContractLiabilities>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_7002_12">263000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_7001_12">905000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:TradeReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3417430x3424016" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F8B7FC2B-1154-4601-887C-8DB3A5477E34_1002_1">1594000</ifrs-full:TradeReceivables>
  <ifrs-full:ContractAssets contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3417430x3496068" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_AAEECD3A-A490-47A4-A19C-88AEF875DFF6_1001_1">710000</ifrs-full:ContractAssets>
  <ifrs-full:NumberOfSharesIssuedAndFullyPaid contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3417439x3422519" unitRef="shares" decimals="0" id="id_14264487_CCFFE51C-AC42-429F-A080-997279263246_1002_0">19429848</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
  <ifrs-full:NumberOfSharesOutstanding contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3417439x3422519" unitRef="shares" decimals="0" id="id_14264487_1929F029-CC6A-4563-801E-C284057C67AE_2002_0">19429848</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3417439x3495214_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_9001_22">1749000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3417439x3495221_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_9005_22">213618000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_9009_22">-158775000</ifrs-full:Equity>
  <mrus:TradeAndUnbilledReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3420436x3420078" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F9F8E184-773A-4DEB-80FD-A77848677137_2002_0">2283000</mrus:TradeAndUnbilledReceivables>
  <ifrs-full:NumberOfEmployees contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3420782x3421581" unitRef="Employees" decimals="INF" id="id_14264487_040DB130-D21C-4D66-94C6-E06204813C70_2001_1">70</ifrs-full:NumberOfEmployees>
  <ifrs-full:NumberOfEmployees contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3420782x3424474" unitRef="Employees" decimals="INF" id="id_14264487_040DB130-D21C-4D66-94C6-E06204813C70_3001_2">13</ifrs-full:NumberOfEmployees>
  <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3421968x3422054" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_FCFE9C90-4643-4F48-A321-D31AFFD8A5D0_1003_2">9031000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
  <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3421968x3422054" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_FCFE9C90-4643-4F48-A321-D31AFFD8A5D0_1003_0">2855000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
  <mrus:OtherLiabilitiesAndAccrualsUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3421968x3422054" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_FCFE9C90-4643-4F48-A321-D31AFFD8A5D0_1003_1">6176000</mrus:OtherLiabilitiesAndAccrualsUndiscountedCashFlows>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3422662x3416700" unitRef="iso4217_EUR" decimals="INF" id="id_14264487_D2C11233-6864-41A5-86A7-1FC6F9FA0B51_1002_1">27.47</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3422662x3423353" unitRef="iso4217_EUR" decimals="INF" id="id_14264487_D2C11233-6864-41A5-86A7-1FC6F9FA0B51_2002_0">1.93</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_2_2">8939000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
  <ifrs-full:DeferredIncomeClassifiedAsNoncurrent contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_2_1">-17644000</ifrs-full:DeferredIncomeClassifiedAsNoncurrent>
  <ifrs-full:RetainedEarnings contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_2_0">8705000</ifrs-full:RetainedEarnings>
  <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_1_2">6996000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
  <ifrs-full:DeferredIncomeClassifiedAsNoncurrent contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_1_1">130195000</ifrs-full:DeferredIncomeClassifiedAsNoncurrent>
  <ifrs-full:RetainedEarnings contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_1_0">-167480000</ifrs-full:RetainedEarnings>
  <ifrs-full:DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3423034x3424053" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_1A0AFD4D-25EA-483F-9334-20D49FC44D03_2002_1">140500000</ifrs-full:DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3424453x3479596" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_1002_0">15527000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3424453x3514284" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_2002_2">7886000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:NoncurrentHeldtomaturityInvestments contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3424453x3514284" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_2002_5">7060000</ifrs-full:NoncurrentHeldtomaturityInvestments>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3424453x3530660" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_3002_3">1453000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3424453x3535979" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_4002_1">9177000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:CashAndCashEquivalents contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3424455x3420520" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_A6434540-658C-40A1-AF84-DD56B574512B_2002_1">149678000</ifrs-full:CashAndCashEquivalents>
  <mrus:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3424457x3514207" unitRef="shares" decimals="INF" id="id_14264487_4156BFB9-915C-4DB7-9B0F-B98B28CE93CC_1001_0">934359</mrus:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <ifrs-full:NumberOfEmployees contextRef="eol_PE977595--1820-F0010_STD_0_20171231_0_3475752x3514214" unitRef="Employees" decimals="INF" id="id_14264487_040DB130-D21C-4D66-94C6-E06204813C70_4001_3">21</ifrs-full:NumberOfEmployees>
  <mrus:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE977595--1820-F0010_STD_0_20180101_0_3424457x3514207" unitRef="shares" decimals="INF" id="id_14264487_4156BFB9-915C-4DB7-9B0F-B98B28CE93CC_1002_0">1469785</mrus:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <ifrs-full:CashAndCashEquivalents contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1001_39">143747000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:ActuarialAssumptionOfRetirementAge contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="Y" decimals="0" id="id_14264487_197EB3AC-71D2-4CF4-940D-01A935843873_1001_0">67</ifrs-full:ActuarialAssumptionOfRetirementAge>
  <ifrs-full:Assets contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_1_11">218519000</ifrs-full:Assets>
  <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_AF9A1C6C-F4E3-4546-B1C0-602A83B5B5BA_1001_0">175100000</ifrs-full:AccumulatedOtherComprehensiveIncome>
  <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_1_7">7964000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
  <ifrs-full:CurrentLiabilities contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_1_24">28973000</ifrs-full:CurrentLiabilities>
  <ifrs-full:DeferredIncome contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_830EAA38-871F-48F4-AC96-336FAB76AFAE_1_2">114609000</ifrs-full:DeferredIncome>
  <ifrs-full:DeferredTaxAssets contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="INF" id="id_14264487_1A0AFD4D-25EA-483F-9334-20D49FC44D03_1001_0">0</ifrs-full:DeferredTaxAssets>
  <ifrs-full:CurrentAdvances contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_1_5">42000</ifrs-full:CurrentAdvances>
  <ifrs-full:CurrentInterestReceivable contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_1_5">213000</ifrs-full:CurrentInterestReceivable>
  <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_830EAA38-871F-48F4-AC96-336FAB76AFAE_1_0">16934000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
  <ifrs-full:DeferredIncomeClassifiedAsNoncurrent contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_830EAA38-871F-48F4-AC96-336FAB76AFAE_1_1">97675000</ifrs-full:DeferredIncomeClassifiedAsNoncurrent>
  <ifrs-full:ContractLiabilities contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CE40E457-E3B7-4108-99F6-618E5B763DA0_3002_4">114609000</ifrs-full:ContractLiabilities>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_1_4">44855000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:CurrentTradeReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_1_0">2690000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:ContractAssets contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_AAEECD3A-A490-47A4-A19C-88AEF875DFF6_3002_4">236000</ifrs-full:ContractAssets>
  <ifrs-full:CurrentAssets contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_1_10">195634000</ifrs-full:CurrentAssets>
  <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_1_21">256000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
  <ifrs-full:CurrentValueAddedTaxReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_1_2">891000</ifrs-full:CurrentValueAddedTaxReceivables>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="shares" decimals="INF" id="id_14264487_1469EA42-F951-4C73-B189-5B232EFF4ADE_2_11">23358977</dei:EntityCommonStockSharesOutstanding>
  <ifrs-full:EquityAndLiabilities contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_1_26">218519000</ifrs-full:EquityAndLiabilities>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_11010_31">91871000</ifrs-full:Equity>
  <ifrs-full:HeldtomaturityInvestments contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_D7A5AE51-E79D-4E7A-A619-327BB3C0C880_1001_1">61800000</ifrs-full:HeldtomaturityInvestments>
  <ifrs-full:IssuedCapital contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_1_13">2102000</ifrs-full:IssuedCapital>
  <ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_5FE5154E-FDDC-47FC-8BFE-AF818273D434_1001_3">4685000</ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease>
  <ifrs-full:MaximumExposureToCreditRisk contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E741B6AE-592A-40A0-8D63-16EEA58E4B0A_1001_3">208473000</ifrs-full:MaximumExposureToCreditRisk>
  <ifrs-full:NoncurrentAssets contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_1_5">22885000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="shares" decimals="INF" id="id_14264487_8B4407D4-240E-47E7-BFCD-310CE2DB413C_1001_2">2633039</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:OtherNoncurrentAssets contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_1_4">1075000</ifrs-full:OtherNoncurrentAssets>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_1_2">2445000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_81C606C9-877F-4A25-8240-D20899DA93A2_1001_9">2445000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:Liabilities contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_1_25">126648000</ifrs-full:Liabilities>
  <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_91DE91DD-088D-41D2-B6C3-78569E25799D_1002_2">11783000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
  <ifrs-full:NumberOfEmployees contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="Employees" decimals="INF" id="id_14264487_EC0E7D4F-FD16-4CAE-9EF0-7F3D0C753108_1001_0">98</ifrs-full:NumberOfEmployees>
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="shares" decimals="INF" id="id_14264487_931C8F45-65AF-4273-8D38-1B87506DC76D_1001_5">101302</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="shares" decimals="INF" id="id_14264487_2D9E1ED7-9102-4197-AE9A-6039F1DD098B_1001_6">1275669</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:NoncurrentHeldtomaturityInvestments contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_1_6">16945000</ifrs-full:NoncurrentHeldtomaturityInvestments>
  <ifrs-full:OtherCurrentReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_1_6">219000</ifrs-full:OtherCurrentReceivables>
  <ifrs-full:RetainedEarnings contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_1_15">-175085000</ifrs-full:RetainedEarnings>
  <ifrs-full:TradeAndOtherCurrentReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_1_7">7032000</ifrs-full:TradeAndOtherCurrentReceivables>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_13003_21">2420000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_A9DA9ED8-6776-4AD2-BBD0-F9A9ED7ECCD4_1001_1">49100000</ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents>
  <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_1_20">3819000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
  <ifrs-full:TradeReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F8B7FC2B-1154-4601-887C-8DB3A5477E34_3003_4">2690000</ifrs-full:TradeReceivables>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_1C9A2645-8CE2-43DE-B4D4-CB5AD26735C7_1001_5">20.03</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:SharePremium contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_1_14">264854000</ifrs-full:SharePremium>
  <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_1_2">1523000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_1001_6">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_91DE91DD-088D-41D2-B6C3-78569E25799D_1002_0">3819000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_1001_5">14.62</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <mrus:OtherAccruals contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_1_6">1051000</mrus:OtherAccruals>
  <mrus:SecurityDeposits contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_FC788C4F-FFA1-4B14-AED5-CE0544122BE9_1001_1">300000</mrus:SecurityDeposits>
  <mrus:CurrentPrepaidGeneralExpenses contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_1_3">2783000</mrus:CurrentPrepaidGeneralExpenses>
  <mrus:DividendDeclared contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="INF" id="id_14264487_ED3C3B07-8038-44EA-96E5-DB2D5E09D949_1001_0">0</mrus:DividendDeclared>
  <mrus:AccruedPersonnel contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_1_1">560000</mrus:AccruedPersonnel>
  <mrus:AccruedResearchAndDevelopmentStudies contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_1_3">4409000</mrus:AccruedResearchAndDevelopmentStudies>
  <mrus:AccruedIntellectualPropertyLegalFee contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_1_4">212000</mrus:AccruedIntellectualPropertyLegalFee>
  <mrus:AccruedAuditorsFee contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_1_0">167000</mrus:AccruedAuditorsFee>
  <mrus:CurrentUnbilledReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_1_1">236000</mrus:CurrentUnbilledReceivables>
  <mrus:TradeAndUnbilledReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E741B6AE-592A-40A0-8D63-16EEA58E4B0A_1001_0">2926000</mrus:TradeAndUnbilledReceivables>
  <mrus:OtherLiabilitiesAndAccrualsUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_91DE91DD-088D-41D2-B6C3-78569E25799D_1002_1">7964000</mrus:OtherLiabilitiesAndAccrualsUndiscountedCashFlows>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416740x3421023" unitRef="shares" decimals="INF" id="id_14264487_8B4407D4-240E-47E7-BFCD-310CE2DB413C_2001_0">2148744</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfSharesIssued contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416740x3486468" unitRef="shares" decimals="-5" id="id_14264487_4B358E3D-4B35-4BAE-BB5B-FA25DF71D69A_2001_1">3200000</ifrs-full:NumberOfSharesIssued>
  <mrus:NonRefundableUpfrontPaymentsReceivable contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416740x3486468" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_4B358E3D-4B35-4BAE-BB5B-FA25DF71D69A_2002_0">112000000</mrus:NonRefundableUpfrontPaymentsReceivable>
  <mrus:NonRefundableUpfrontPaymentsReceivable contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416740x3486468" unitRef="iso4217_USD" decimals="-5" id="id_14264487_4B358E3D-4B35-4BAE-BB5B-FA25DF71D69A_2001_0">120000000</mrus:NonRefundableUpfrontPaymentsReceivable>
  <mrus:PercentageOfOwnershipInterestByShareholders contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416740x3493439_3422662x3423353" unitRef="pure" decimals="INF" id="id_14264487_48552587-7C3F-4A21-82B3-8467366362B6_1001_0">0.01</mrus:PercentageOfOwnershipInterestByShareholders>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416740x3514206" unitRef="shares" decimals="INF" id="id_14264487_8B4407D4-240E-47E7-BFCD-310CE2DB413C_3001_1">484295</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3416753" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_81C606C9-877F-4A25-8240-D20899DA93A2_2001_8">-640000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3416976" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_15003_20">-1052000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3416976_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_15002_20">-248000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3416976_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_15001_20">-804000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3420576" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_81C606C9-877F-4A25-8240-D20899DA93A2_3001_7">3085000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3420576" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_16003_19">3472000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3420576_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_16002_19">713000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3420576_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_16001_19">2759000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3509593" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_91DE91DD-088D-41D2-B6C3-78569E25799D_1001_2">11783000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
  <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3509593" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_91DE91DD-088D-41D2-B6C3-78569E25799D_1001_0">3819000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
  <mrus:OtherLiabilitiesAndAccrualsUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3509593" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_91DE91DD-088D-41D2-B6C3-78569E25799D_1001_1">7964000</mrus:OtherLiabilitiesAndAccrualsUndiscountedCashFlows>
  <ifrs-full:ContractLiabilities contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3416963x3508994" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CE40E457-E3B7-4108-99F6-618E5B763DA0_3001_4">114609000</ifrs-full:ContractLiabilities>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_13002_21">465000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_13001_21">1955000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:TradeReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3417430x3424016" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F8B7FC2B-1154-4601-887C-8DB3A5477E34_3002_4">2690000</ifrs-full:TradeReceivables>
  <ifrs-full:ContractAssets contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3417430x3496068" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_AAEECD3A-A490-47A4-A19C-88AEF875DFF6_3001_4">236000</ifrs-full:ContractAssets>
  <ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3417436x3416901" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_A4628AF6-2B5B-43D5-BA7F-C43F755CEEE8_2001_1">2200000</ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights>
  <ifrs-full:NumberOfSharesIssuedAndFullyPaid contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3417439x3422519" unitRef="shares" decimals="0" id="id_14264487_CCFFE51C-AC42-429F-A080-997279263246_1001_0">23358977</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
  <ifrs-full:NumberOfSharesOutstanding contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3417439x3422519" unitRef="shares" decimals="0" id="id_14264487_1929F029-CC6A-4563-801E-C284057C67AE_2001_4">23358977</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3417439x3495214_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_11001_31">2102000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3417439x3495221_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_11005_31">264854000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_11009_31">-175085000</ifrs-full:Equity>
  <mrus:TradeAndUnbilledReceivables contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3420436x3420078" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F9F8E184-773A-4DEB-80FD-A77848677137_2001_0">2926000</mrus:TradeAndUnbilledReceivables>
  <ifrs-full:NumberOfEmployees contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3420782x3421581" unitRef="Employees" decimals="INF" id="id_14264487_EC0E7D4F-FD16-4CAE-9EF0-7F3D0C753108_2001_1">81</ifrs-full:NumberOfEmployees>
  <ifrs-full:NumberOfEmployees contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3420782x3424474" unitRef="Employees" decimals="INF" id="id_14264487_EC0E7D4F-FD16-4CAE-9EF0-7F3D0C753108_3001_2">17</ifrs-full:NumberOfEmployees>
  <ifrs-full:LeaseLiabilities contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3421584x3553416" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_D8220720-C25E-46AF-BECE-3E3B18AB604C_1001_0">3000000</ifrs-full:LeaseLiabilities>
  <ifrs-full:RightofuseAssets contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3421584x3553416" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_D8220720-C25E-46AF-BECE-3E3B18AB604C_1001_1">3000000</ifrs-full:RightofuseAssets>
  <ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3421968x3421286" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_5FE5154E-FDDC-47FC-8BFE-AF818273D434_2001_1">3106000</ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease>
  <ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3421968x3422054" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_5FE5154E-FDDC-47FC-8BFE-AF818273D434_4001_0">1579000</ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease>
  <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3421968x3422054" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_91DE91DD-088D-41D2-B6C3-78569E25799D_1003_2">11783000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
  <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3421968x3422054" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_91DE91DD-088D-41D2-B6C3-78569E25799D_1003_0">3819000</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
  <mrus:OtherLiabilitiesAndAccrualsUndiscountedCashFlows contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3421968x3422054" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_91DE91DD-088D-41D2-B6C3-78569E25799D_1003_1">7964000</mrus:OtherLiabilitiesAndAccrualsUndiscountedCashFlows>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3422662x3416700" unitRef="iso4217_EUR" decimals="INF" id="id_14264487_D2C11233-6864-41A5-86A7-1FC6F9FA0B51_1001_1">27.47</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3422662x3423353" unitRef="iso4217_EUR" decimals="INF" id="id_14264487_D2C11233-6864-41A5-86A7-1FC6F9FA0B51_2001_0">1.93</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <mrus:AggregateValueOfCommonSharesIssued contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3422992x3481669" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_AAAAD971-75A8-48E3-AFE3-701B68558EB4_2002_1">6000000</mrus:AggregateValueOfCommonSharesIssued>
  <mrus:AggregateValueOfCommonSharesIssued contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3422992x3481669" unitRef="iso4217_USD" decimals="-5" id="id_14264487_AAAAD971-75A8-48E3-AFE3-701B68558EB4_2001_1">6900000</mrus:AggregateValueOfCommonSharesIssued>
  <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3423034x3424053" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_1A0AFD4D-25EA-483F-9334-20D49FC44D03_2001_2">114600000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
  <ifrs-full:DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3423034x3424053" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_1A0AFD4D-25EA-483F-9334-20D49FC44D03_2001_1">75900000</ifrs-full:DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates>
  <ifrs-full:DeferredIncome contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3423078x3486516" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_0EC39A5A-77C8-4672-882B-19A491247187_1001_0">112600000</ifrs-full:DeferredIncome>
  <ifrs-full:DeferredIncome contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3423078x3496111" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_0EC39A5A-77C8-4672-882B-19A491247187_2001_1">2100000</ifrs-full:DeferredIncome>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3424453x3479596" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_1001_0">22208000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3424453x3514284" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_2001_2">14185000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:NoncurrentHeldtomaturityInvestments contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3424453x3514284" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_2001_5">16945000</ifrs-full:NoncurrentHeldtomaturityInvestments>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3424453x3530660" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_3001_3">1729000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3424453x3535979" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_4001_1">6733000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:CashAndCashEquivalents contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3424455x3420520" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_A6434540-658C-40A1-AF84-DD56B574512B_2001_1">143747000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:NumberOfEmployees contextRef="eol_PE977595--1820-F0010_STD_0_20181231_0_3475752x3514214" unitRef="Employees" decimals="INF" id="id_14264487_EC0E7D4F-FD16-4CAE-9EF0-7F3D0C753108_4001_3">21</ifrs-full:NumberOfEmployees>
  <mrus:ReverseStockSplitConversionRatio contextRef="eol_PE977595--1820-F0010_STD_1_20160506_0" unitRef="pure" decimals="4" id="id_14264487_0EABEEBA-6CCD-47C2-A7C3-C39EE5C26171_1_0">0.5556</mrus:ReverseStockSplitConversionRatio>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--1820-F0010_STD_1_20160526_0_3475672x3509221" unitRef="iso4217_USD" decimals="-5" id="id_14264487_DE14600A-A898-4898-8EA3-E990C33B9A49_1002_3">53300000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_1_20161101_0_3416740x3504974" unitRef="shares" decimals="INF" id="id_14264487_257A0B2A-4CF7-4E16-82B8-541812D963B6_1001_0">183241</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <mrus:ExercisePricePerShare contextRef="eol_PE977595--1820-F0010_STD_1_20161101_0_3416740x3504974" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_257A0B2A-4CF7-4E16-82B8-541812D963B6_1001_1">15.24</mrus:ExercisePricePerShare>
  <mrus:PurchasePricePerCommonShare contextRef="eol_PE977595--1820-F0010_STD_1_20161220_0_3423078x3554473" unitRef="iso4217_USD_per_shares" decimals="1" id="id_14264487_5717A6D9-8CF6-4E96-9AF5-87277DE2D685_1001_0">25.0</mrus:PurchasePricePerCommonShare>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_1_20170215_0_3416740x3494322" unitRef="shares" decimals="INF" id="id_14264487_011ED72E-7B59-4E39-880C-233B77E10622_1001_0">50000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <mrus:ExercisePricePerShare contextRef="eol_PE977595--1820-F0010_STD_1_20170215_0_3416740x3494322" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_011ED72E-7B59-4E39-880C-233B77E10622_1001_1">24.54</mrus:ExercisePricePerShare>
  <mrus:UpfrontPayment contextRef="eol_PE977595--1820-F0010_STD_1_20170228_0_3416740x3486468" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_4B358E3D-4B35-4BAE-BB5B-FA25DF71D69A_1004_5">112000000</mrus:UpfrontPayment>
  <mrus:UpfrontPayment contextRef="eol_PE977595--1820-F0010_STD_1_20170228_0_3416740x3486468" unitRef="iso4217_USD" decimals="-5" id="id_14264487_4B358E3D-4B35-4BAE-BB5B-FA25DF71D69A_1003_5">120000000</mrus:UpfrontPayment>
  <mrus:PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod contextRef="eol_PE977595--1820-F0010_STD_1_20170524_0" unitRef="pure" decimals="2" id="id_14264487_6D337156-1BC6-480C-B1FD-A0D3CF47E73D_1_1">0.50</mrus:PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod>
  <mrus:PercentageOfSeverancePaymentPaid contextRef="eol_PE977595--1820-F0010_STD_1_20170524_0" unitRef="pure" decimals="2" id="id_14264487_6D337156-1BC6-480C-B1FD-A0D3CF47E73D_1_0">0.50</mrus:PercentageOfSeverancePaymentPaid>
  <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued contextRef="eol_PE977595--1820-F0010_STD_1_20180213_0_3416740x3507527" unitRef="shares" decimals="INF" id="id_14264487_22EF4E11-B2C0-4D9C-87FD-65374785A5D8_1001_0">3099997</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_1_20180213_0_3416740x3507527" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_14264487_22EF4E11-B2C0-4D9C-87FD-65374785A5D8_1001_3">18.0</mrus:SharePurchasedPricePerShare>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--1820-F0010_STD_1_20180215_0_3416740x3507527" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_22EF4E11-B2C0-4D9C-87FD-65374785A5D8_1002_2">44800000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--1820-F0010_STD_1_20180215_0_3416740x3507527" unitRef="iso4217_USD" decimals="-5" id="id_14264487_22EF4E11-B2C0-4D9C-87FD-65374785A5D8_1003_2">55800000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:RentalExpense contextRef="eol_PE977595--1820-F0010_STD_1_20180501_0_3423078x3556805" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_7A094031-E6E3-47BE-839A-959147BB3DA8_2_0">600000</ifrs-full:RentalExpense>
  <mrus:LeasesExpirationPeriod contextRef="eol_PE977595--1820-F0010_STD_1_20180501_0_3423078x3556805" id="id_14264487_7A094031-E6E3-47BE-839A-959147BB3DA8_2_2">Fourth quarter of 2021</mrus:LeasesExpirationPeriod>
  <mrus:UpfrontPayment contextRef="eol_PE977595--1820-F0010_STD_1_20181210_0_3423078x3554523" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_D46E5EE9-3102-4C5B-B9D1-DB500A3EA5DB_2_0">900000</mrus:UpfrontPayment>
  <mrus:UpfrontPayment contextRef="eol_PE977595--1820-F0010_STD_1_20181210_0_3423078x3554523" unitRef="iso4217_USD" decimals="-5" id="id_14264487_D46E5EE9-3102-4C5B-B9D1-DB500A3EA5DB_1_0">1000000</mrus:UpfrontPayment>
  <mrus:MilestonePaymentReceived contextRef="eol_PE977595--1820-F0010_STD_1_20181210_0_3423078x3554523" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_D46E5EE9-3102-4C5B-B9D1-DB500A3EA5DB_2_1">10500000</mrus:MilestonePaymentReceived>
  <mrus:MilestonePaymentReceived contextRef="eol_PE977595--1820-F0010_STD_1_20181210_0_3423078x3554523" unitRef="iso4217_USD" decimals="-5" id="id_14264487_D46E5EE9-3102-4C5B-B9D1-DB500A3EA5DB_1_1">12000000</mrus:MilestonePaymentReceived>
  <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued contextRef="eol_PE977595--1820-F0010_STD_1_20181220_0_3422992x3481669" unitRef="shares" decimals="0" id="id_14264487_A1C3D0CD-8AA4-41F5-813D-0DFFAB3EC93D_1001_0">600000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_1_20181220_0_3422992x3481669" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_14264487_A1C3D0CD-8AA4-41F5-813D-0DFFAB3EC93D_1001_2">25.0</mrus:SharePurchasedPricePerShare>
  <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued contextRef="eol_PE977595--1820-F0010_STD_1_20181220_0_3423078x3556559" unitRef="shares" decimals="0" id="id_14264487_51A53C91-676D-4C2B-9214-DA792C26DFD3_2001_0">600000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="eol_PE977595--1820-F0010_STD_1_20181220_0_3423078x3556559" unitRef="iso4217_USD" decimals="-5" id="id_14264487_51A53C91-676D-4C2B-9214-DA792C26DFD3_1001_2">15000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <mrus:ReimbursementOfExpenses contextRef="eol_PE977595--1820-F0010_STD_1_20181220_0_3423078x3556559" unitRef="iso4217_USD" decimals="-5" id="id_14264487_51A53C91-676D-4C2B-9214-DA792C26DFD3_1001_3">10500000</mrus:ReimbursementOfExpenses>
  <mrus:PurchasePricePerCommonShare contextRef="eol_PE977595--1820-F0010_STD_1_20181220_0_3423078x3556559" unitRef="iso4217_USD_per_shares" decimals="0" id="id_14264487_51A53C91-676D-4C2B-9214-DA792C26DFD3_1001_1">25</mrus:PurchasePricePerCommonShare>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--1820-F0010_STD_1_20181221_0_3422992x3481669" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_A1C3D0CD-8AA4-41F5-813D-0DFFAB3EC93D_1003_1">13100000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--1820-F0010_STD_1_20181221_0_3422992x3481669" unitRef="iso4217_USD" decimals="-5" id="id_14264487_A1C3D0CD-8AA4-41F5-813D-0DFFAB3EC93D_1002_1">15000000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="eol_PE977595--1820-F0010_STD_1_20181221_0_3423078x3556559" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_C185FA8A-3451-4D6E-A9AC-1F643887C52D_1004_2">13100000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="eol_PE977595--1820-F0010_STD_1_20181221_0_3423078x3556559" unitRef="iso4217_USD" decimals="-5" id="id_14264487_C185FA8A-3451-4D6E-A9AC-1F643887C52D_1003_2">15000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <mrus:EstimatedContractualTerm contextRef="eol_PE977595--1820-F0010_STD_1_20140408_0_3423078x3513897" id="id_14264487_9E267809-F4C7-4AE1-81C4-1C37E984DAF4_3002_1">P4Y6M</mrus:EstimatedContractualTerm>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_1_20160307_0_3416740x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_233C3E75-4A9F-4193-A65A-F863C872BE9F_1003_2">400000</ifrs-full:Revenue>
  <mrus:GrantIncome contextRef="eol_PE977595--1820-F0010_STD_1_20170612_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_8A2BDAFB-590D-4532-ADCE-1B626C35DDF9_4_0">700000</mrus:GrantIncome>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_1_20161027_0_3416740x3498640" unitRef="shares" decimals="INF" id="id_14264487_CA08B5D2-9A0E-45F1-AB82-4A24A8A2DD09_1001_0">219890</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <mrus:ExercisePricePerShare contextRef="eol_PE977595--1820-F0010_STD_1_20161027_0_3416740x3498640" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_CA08B5D2-9A0E-45F1-AB82-4A24A8A2DD09_1001_1">16.85</mrus:ExercisePricePerShare>
  <mrus:ReimbursementOfGrant contextRef="eol_PE977595--1820-F0010_STD_1_20171016_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_8A2BDAFB-590D-4532-ADCE-1B626C35DDF9_5_1">400000</mrus:ReimbursementOfGrant>
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="eol_PE977595--1820-F0010_STD_1_20170123_0_3416740x3486468" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_9F2AB8E1-719D-46E7-9990-5A0CA58BD01F_1002_6">400000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--1820-F0010_STD_1_20170123_0_3416740x3486468" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_9F2AB8E1-719D-46E7-9990-5A0CA58BD01F_1002_2">74700000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--1820-F0010_STD_1_20170123_0_3416740x3486468" unitRef="iso4217_USD" decimals="-5" id="id_14264487_9F2AB8E1-719D-46E7-9990-5A0CA58BD01F_1001_2">80000000</ifrs-full:ProceedsFromIssuingShares>
  <mrus:IncreaseDecreaseInCapital contextRef="eol_PE977595--1820-F0010_STD_1_20170123_0_3416740x3486468" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_9F2AB8E1-719D-46E7-9990-5A0CA58BD01F_1002_7">300000</mrus:IncreaseDecreaseInCapital>
  <mrus:ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements contextRef="eol_PE977595--1820-F0010_STD_1_20170123_0_3416740x3486468" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_9F2AB8E1-719D-46E7-9990-5A0CA58BD01F_1002_5">1100000</mrus:ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements>
  <mrus:IncreaseDecreaseInSharePremium contextRef="eol_PE977595--1820-F0010_STD_1_20170123_0_3416740x3486468" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_9F2AB8E1-719D-46E7-9990-5A0CA58BD01F_1002_8">73400000</mrus:IncreaseDecreaseInSharePremium>
  <mrus:NetProceedsFromIssuingShares contextRef="eol_PE977595--1820-F0010_STD_1_20170123_0_3416740x3486468" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_9F2AB8E1-719D-46E7-9990-5A0CA58BD01F_1002_3">74400000</mrus:NetProceedsFromIssuingShares>
  <mrus:GrantIncome contextRef="eol_PE977595--1820-F0010_STD_30_20171130_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_8A2BDAFB-590D-4532-ADCE-1B626C35DDF9_6_0">200000</mrus:GrantIncome>
  <mrus:AmountRemittedToOtherBeneficiaries contextRef="eol_PE977595--1820-F0010_STD_30_20171130_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_8A2BDAFB-590D-4532-ADCE-1B626C35DDF9_6_2">200000</mrus:AmountRemittedToOtherBeneficiaries>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--1820-F0010_STD_31_20170131_0_3416740x3486468" unitRef="iso4217_USD" decimals="-5" id="id_14264487_4B358E3D-4B35-4BAE-BB5B-FA25DF71D69A_1005_4">80000000</ifrs-full:ProceedsFromIssuingShares>
  <mrus:SquareFeetOfOfficeSpaceUnderLeaseAgreement contextRef="eol_PE977595--1820-F0010_STD_31_20190331_0_3417666x3556647_3421584x3537338" unitRef="sqft" decimals="0" id="id_14264487_E36D5C08-BB17-49A8-A5DF-F22006E13056_1001_0">7583</mrus:SquareFeetOfOfficeSpaceUnderLeaseAgreement>
  <ifrs-full:RentalExpense contextRef="eol_PE977595--1820-F0010_STD_31_20190331_0_3421584x3537338" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_83799621-4603-430F-8F0E-9D8614F97015_1001_3">4200000</ifrs-full:RentalExpense>
  <ifrs-full:RentalExpense contextRef="eol_PE977595--1820-F0010_STD_31_20190331_0_3421584x3537338" unitRef="iso4217_USD" decimals="-5" id="id_14264487_83799621-4603-430F-8F0E-9D8614F97015_1002_3">4900000</ifrs-full:RentalExpense>
  <mrus:LeaseTermExpirationDate contextRef="eol_PE977595--1820-F0010_STD_31_20190331_0_3421584x3537338" id="id_14264487_83799621-4603-430F-8F0E-9D8614F97015_1001_2">2026-04-01</mrus:LeaseTermExpirationDate>
  <mrus:OperatingLeaseTermOfLeaseAgreement contextRef="eol_PE977595--1820-F0010_STD_31_20190331_0_3421584x3537338" id="id_14264487_83799621-4603-430F-8F0E-9D8614F97015_1001_1">P7Y</mrus:OperatingLeaseTermOfLeaseAgreement>
  <mrus:SquareFeetOfOfficeSpaceUnderLeaseAgreement contextRef="eol_PE977595--1820-F0010_STD_31_20190331_0_3421584x3537338" unitRef="sqft" decimals="0" id="id_14264487_83799621-4603-430F-8F0E-9D8614F97015_1001_0">7583</mrus:SquareFeetOfOfficeSpaceUnderLeaseAgreement>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_10003_5">776000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_3">-10667000</ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_14">-14933000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_12">505000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_3_3">-3.37</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_26">-41625000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInOperations contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_16">-37341000</ifrs-full:CashFlowsFromUsedInOperations>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_10">-1837000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_7">1040000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_4">15767000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_35">186222000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_19">-37413000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:ChangesInPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_10003_9">520000</ifrs-full:ChangesInPropertyPlantAndEquipment>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_11">-20000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_5">318000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_6">12815000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_8">-26247000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_81C606C9-877F-4A25-8240-D20899DA93A2_2_5">62000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10010_17">-64685000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_68078692-077B-4C21-8EB2-80F32AD7B4E5_2_3">318000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_10003_6">256000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:FinanceCosts contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_2_7">30335000</ifrs-full:FinanceCosts>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_2_5">12815000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_37">-14423000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:FinanceIncome contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_2_2">1112000</ifrs-full:FinanceIncome>
  <ifrs-full:EmployeeBenefitsExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_68078692-077B-4C21-8EB2-80F32AD7B4E5_2_2">20999000</ifrs-full:EmployeeBenefitsExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_5">13697000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_18">43000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10010_20">12815000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_36">107184000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_2_11">249000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_2_0">2808998</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_2_5">8088647</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_2_2">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_2_1">108416</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_25">929000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="shares" decimals="INF" id="id_14264487_931C8F45-65AF-4273-8D38-1B87506DC76D_2_3">7331</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="shares" decimals="INF" id="id_14264487_931C8F45-65AF-4273-8D38-1B87506DC76D_2_1">12219</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="shares" decimals="INF" id="id_14264487_2D9E1ED7-9102-4197-AE9A-6039F1DD098B_2_2">762</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="shares" decimals="INF" id="id_14264487_2D9E1ED7-9102-4197-AE9A-6039F1DD098B_2_1">58164</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_17">29000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:IssueOfEquity contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10010_19">74041000</ifrs-full:IssueOfEquity>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_2_4">5171233</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_2_3">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="shares" decimals="INF" id="id_14264487_2D9E1ED7-9102-4197-AE9A-6039F1DD098B_2_4">1014733</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:OperatingExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_9">57217000</ifrs-full:OperatingExpense>
  <ifrs-full:OtherComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10010_16">89000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherShorttermEmployeeBenefits contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_2_6">656000</ifrs-full:OtherShorttermEmployeeBenefits>
  <ifrs-full:ProfitLossBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_2_10">-64525000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_3_1">-35302000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="shares" decimals="INF" id="id_14264487_931C8F45-65AF-4273-8D38-1B87506DC76D_2_2">0</ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="shares" decimals="INF" id="id_14264487_2D9E1ED7-9102-4197-AE9A-6039F1DD098B_2_3">136666</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_28">74738000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:NetForeignExchangeLoss contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_2_5">19449000</ifrs-full:NetForeignExchangeLoss>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="shares" decimals="INF" id="id_14264487_931C8F45-65AF-4273-8D38-1B87506DC76D_2_4">214096</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_2_14">89000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherExpenseByNature contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_8">9395000</ifrs-full:OtherExpenseByNature>
  <ifrs-full:OtherFinanceIncomeCost contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_2_9">-29223000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:PaymentsForDebtIssueCosts contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_29">190000</ifrs-full:PaymentsForDebtIssueCosts>
  <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_21">41830000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_24">724000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_4">34125000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_2_4">21915000</ifrs-full:Revenue>
  <ifrs-full:SocialSecurityContributions contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_2_2">621000</ifrs-full:SocialSecurityContributions>
  <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_7A795159-273A-478A-93E2-AF01494DDF99_2_1">0</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
  <ifrs-full:ProfessionalFeesExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_9DFE7ABA-C7C0-4A1F-8BE9-A71C01DAA2EB_2_0">4000000</ifrs-full:ProfessionalFeesExpense>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10010_15">-64774000</ifrs-full:ProfitLoss>
  <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_33">486000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_1C9A2645-8CE2-43DE-B4D4-CB5AD26735C7_2_2">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_2_7">20999000</ifrs-full:ShorttermEmployeeBenefitsExpense>
  <ifrs-full:WagesAndSalaries contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_2_0">9556000</ifrs-full:WagesAndSalaries>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_1C9A2645-8CE2-43DE-B4D4-CB5AD26735C7_2_1">20.03</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_2_3">2.24</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_1C9A2645-8CE2-43DE-B4D4-CB5AD26735C7_2_4">20.03</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_2_4">19.88</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:TradingIncomeExpenseOnDerivativeFinancialInstruments contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_2_6">-10696000</ifrs-full:TradingIncomeExpenseOnDerivativeFinancialInstruments>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_1C9A2645-8CE2-43DE-B4D4-CB5AD26735C7_2_3">20.03</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_2_2">8.67</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_2_1">17.27</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_2010_3">193866</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:GeneralLegalInsuranceAndFacilityRelatedExpenses contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_9DFE7ABA-C7C0-4A1F-8BE9-A71C01DAA2EB_2_1">3200000</mrus:GeneralLegalInsuranceAndFacilityRelatedExpenses>
  <mrus:OtherIncomeExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_2_8">-29223000</mrus:OtherIncomeExpense>
  <mrus:ProceedsFromCollaborationAgreement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_32">111993000</mrus:ProceedsFromCollaborationAgreement>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10010_21">86856000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <mrus:RevenueRecognizedIncludedInDeferredRevenue contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_87B93F59-C6CE-4FD8-A145-4B0FD3DF97A7_2_0">3200000</mrus:RevenueRecognizedIncludedInDeferredRevenue>
  <mrus:RevenueRecognizedNotIncludedInDeferredRevenue contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_87B93F59-C6CE-4FD8-A145-4B0FD3DF97A7_2_1">11700000</mrus:RevenueRecognizedNotIncludedInDeferredRevenue>
  <mrus:DeductionsInContractAssets contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_2A09F546-20FB-44EF-8399-02D50D5088AC_4002_3">120530000</mrus:DeductionsInContractAssets>
  <mrus:AdditionsInContractLiabilities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_42350E10-239D-4AF2-8266-66F681BDEDBD_4002_2">111993000</mrus:AdditionsInContractLiabilities>
  <mrus:DeductionsInContractLiabilities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_42350E10-239D-4AF2-8266-66F681BDEDBD_4002_3">14933000</mrus:DeductionsInContractLiabilities>
  <mrus:AdditionsInContractAssets contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_2A09F546-20FB-44EF-8399-02D50D5088AC_4002_2">121240000</mrus:AdditionsInContractAssets>
  <mrus:ClinicalCosts contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E5A85DC4-90A0-4CA4-A801-47E373A70955_2_1">5919000</mrus:ClinicalCosts>
  <mrus:OtherResearchAndDevelopmentExpenseOther contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E5A85DC4-90A0-4CA4-A801-47E373A70955_2_2">3635000</mrus:OtherResearchAndDevelopmentExpenseOther>
  <mrus:DiscoveryAndPreclinicalCosts contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E5A85DC4-90A0-4CA4-A801-47E373A70955_2_0">2473000</mrus:DiscoveryAndPreclinicalCosts>
  <mrus:PreclinicalCosts contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_EE8874EB-D696-4FCF-9D1F-4A232AF85BF5_2_0">2500000</mrus:PreclinicalCosts>
  <mrus:IntellectualPropertyCosts contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_EE8874EB-D696-4FCF-9D1F-4A232AF85BF5_2_2">2900000</mrus:IntellectualPropertyCosts>
  <mrus:AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_13">4977000</mrus:AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals>
  <mrus:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_15">214000</mrus:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities>
  <mrus:ChangesInRestrictedCash contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_34">167000</mrus:ChangesInRestrictedCash>
  <mrus:GrantIncome contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_8A2BDAFB-590D-4532-ADCE-1B626C35DDF9_2_0">1200000</mrus:GrantIncome>
  <mrus:PensionCosts contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_2_4">652000</mrus:PensionCosts>
  <mrus:HealthInsurance contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_2_3">222000</mrus:HealthInsurance>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_2003_9">826578</mrus:RemunerationForFormerEmployees>
  <mrus:StockAwardExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B5A6BE7B-5975-44A4-A2A1-EED190DB18B0_2_3">12815000</mrus:StockAwardExpense>
  <mrus:WBSOSubsidy contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_2_1">3523000</mrus:WBSOSubsidy>
  <mrus:OtherOperatingExpenses contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_7">8356000</mrus:OtherOperatingExpenses>
  <mrus:LitigationCosts contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_6">1039000</mrus:LitigationCosts>
  <mrus:ManufacturingCost contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_0">13567000</mrus:ManufacturingCost>
  <mrus:PersonnelRelatedResearchAndDevelopmentExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_2">6673000</mrus:PersonnelRelatedResearchAndDevelopmentExpense>
  <mrus:OtherResearchAndDevelopmentExpenses contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_3">12027000</mrus:OtherResearchAndDevelopmentExpenses>
  <mrus:RentAndServiceChargesExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_FC788C4F-FFA1-4B14-AED5-CE0544122BE9_2_0">600000</mrus:RentAndServiceChargesExpense>
  <mrus:InterestAndRelatedIncome contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_2_0">1112000</mrus:InterestAndRelatedIncome>
  <mrus:OtherExternalAndOutsourcedCosts contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_68078692-077B-4C21-8EB2-80F32AD7B4E5_2_1">22333000</mrus:OtherExternalAndOutsourcedCosts>
  <mrus:ContractManufacturingExpenses contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_68078692-077B-4C21-8EB2-80F32AD7B4E5_2_0">13567000</mrus:ContractManufacturingExpenses>
  <mrus:ChangesInAccruedCapitalExpenditures contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_41">52000</mrus:ChangesInAccruedCapitalExpenditures>
  <mrus:InterestAndOtherExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_2_4">190000</mrus:InterestAndOtherExpense>
  <mrus:AccrualsToEmployeeSeveranceIndemnities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_6D337156-1BC6-480C-B1FD-A0D3CF47E73D_3_2">0</mrus:AccrualsToEmployeeSeveranceIndemnities>
  <mrus:WeightedAverageNumberOfShares contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="shares" decimals="INF" id="id_14264487_780AD06D-9847-4BE0-8664-B9F729C217F8_2_3">19196440</mrus:WeightedAverageNumberOfShares>
  <mrus:SharebasedCompensationWeightedAverageRemainingContractualLife contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" id="id_14264487_D2C11233-6864-41A5-86A7-1FC6F9FA0B51_2_2">P8Y3M</mrus:SharebasedCompensationWeightedAverageRemainingContractualLife>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_2010_4">9.61</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:IPAndLicenseCosts contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_1">1858000</mrus:IPAndLicenseCosts>
  <mrus:AdditionsToTradeReceivables contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B9006E8A-8CC3-4797-AB24-FDAA49648F60_4002_2">122781000</mrus:AdditionsToTradeReceivables>
  <mrus:DeductionsInTradeReceivables contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B9006E8A-8CC3-4797-AB24-FDAA49648F60_4002_3">121392000</mrus:DeductionsInTradeReceivables>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3421023" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_9_3">0.9505</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3421023" unitRef="Y" decimals="0" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_9_4">10</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3421023" unitRef="pure" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_9_5">0.00</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3421023_3422662x3416700" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_7_6">0.0229</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <mrus:EmployeeOptionExercisedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3421023_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_7_2">17.08</mrus:EmployeeOptionExercisedPricePerShare>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3421023_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_7_1">17.08</mrus:SharePurchasedPricePerShare>
  <mrus:FairValueAssumptionsGrantDateSharePrice contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3421023_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_7_0">9.04</mrus:FairValueAssumptionsGrantDateSharePrice>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3421023_3422662x3423353" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_8_6">0.0251</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <mrus:EmployeeOptionExercisedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3421023_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_8_2">24.54</mrus:EmployeeOptionExercisedPricePerShare>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3421023_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_8_1">24.54</mrus:SharePurchasedPricePerShare>
  <mrus:FairValueAssumptionsGrantDateSharePrice contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3421023_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_8_0">16.10</mrus:FairValueAssumptionsGrantDateSharePrice>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492745" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_2004_3">24040</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492745" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_3003_4">128474</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492745" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_2004_4">8.90</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492745_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_3001_4">37530</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492745_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_3002_4">90944</mrus:RemunerationForFormerEmployees>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492855" unitRef="iso4217_EUR" decimals="0" id="id_14264487_C20DC179-4953-4AB9-A638-2D3C441CEE34_1005_0">5497845</ifrs-full:DirectorsRemunerationExpense>
  <mrus:NumberOfOptionsHeldByTheChiefExecutiveOfficers contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492855" unitRef="shares" decimals="INF" id="id_14264487_980A9597-926B-4320-9757-88517FDA697F_1002_0">661629</mrus:NumberOfOptionsHeldByTheChiefExecutiveOfficers>
  <mrus:NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492855" unitRef="pure" decimals="INF" id="id_14264487_980A9597-926B-4320-9757-88517FDA697F_1002_2">123745</mrus:NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers>
  <mrus:AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492855" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_980A9597-926B-4320-9757-88517FDA697F_1002_1">14.20</mrus:AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492855_3416904x3498764" unitRef="iso4217_EUR" decimals="0" id="id_14264487_C20DC179-4953-4AB9-A638-2D3C441CEE34_1002_0">337945</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492855_3416904x3505512" unitRef="iso4217_EUR" decimals="0" id="id_14264487_C20DC179-4953-4AB9-A638-2D3C441CEE34_1001_0">432782</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492855_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_C20DC179-4953-4AB9-A638-2D3C441CEE34_1004_0">4675590</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492855_3416904x3556606" unitRef="iso4217_EUR" decimals="0" id="id_14264487_C20DC179-4953-4AB9-A638-2D3C441CEE34_1003_0">51528</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3496102" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_1002_2">20720000</ifrs-full:Revenue>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3498639" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_2007_3">22650</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3498639" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_4003_7">123298</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3498639" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_2007_4">11.80</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3498639_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_4001_7">39615</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3498639_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_4002_7">83683</mrus:RemunerationForFormerEmployees>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3504768" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_2005_3">22650</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3504768" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_5003_5">97315</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3504768" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_2005_4">11.80</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3504768_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_5001_5">35445</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3504768_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_5002_5">61870</mrus:RemunerationForFormerEmployees>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3504975" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_2006_3">22650</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3504975" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_6003_6">152186</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3504975" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_2006_4">11.80</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3504975_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_6001_6">38573</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3504975_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_6002_6">113613</mrus:RemunerationForFormerEmployees>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3505029" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_2002_3">79226</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3505029" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_7003_2">180436</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3505029" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_2002_4">7.32</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3505029_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_7001_2">59840</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3505029_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_7002_2">120596</mrus:RemunerationForFormerEmployees>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3505535" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_2008_3">22650</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3505535" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_8003_8">144869</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3505535" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_2008_4">11.80</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3505535_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_8001_8">41700</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3505535_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_8002_8">103169</mrus:RemunerationForFormerEmployees>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3509602" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_2002_3">1195000</ifrs-full:Revenue>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3514206" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_12_3">0.9488</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3514206" unitRef="Y" decimals="0" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_12_4">10</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3514206" unitRef="pure" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_12_5">0.00</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3514206_3422662x3416700" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_10_6">0.0224</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <mrus:EmployeeOptionExercisedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3514206_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_10_2">13.71</mrus:EmployeeOptionExercisedPricePerShare>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3514206_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_10_1">13.71</mrus:SharePurchasedPricePerShare>
  <mrus:FairValueAssumptionsGrantDateSharePrice contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3514206_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_10_0">8.94</mrus:FairValueAssumptionsGrantDateSharePrice>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3514206_3422662x3423353" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_11_6">0.0262</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <mrus:EmployeeOptionExercisedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3514206_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_11_2">27.47</mrus:EmployeeOptionExercisedPricePerShare>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3514206_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_11_1">27.47</mrus:SharePurchasedPricePerShare>
  <mrus:FairValueAssumptionsGrantDateSharePrice contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3514206_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_11_0">18.02</mrus:FairValueAssumptionsGrantDateSharePrice>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3514219" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_3002_0">14933000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3554539" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_4002_1">5787000</ifrs-full:Revenue>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3556605" unitRef="iso4217_EUR" decimals="0" id="id_14264487_C20DC179-4953-4AB9-A638-2D3C441CEE34_2005_1">892129</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3556605_3416904x3505512" unitRef="iso4217_EUR" decimals="0" id="id_14264487_C20DC179-4953-4AB9-A638-2D3C441CEE34_2001_1">420782</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3556605_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_C20DC179-4953-4AB9-A638-2D3C441CEE34_2004_1">451752</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3556605_3416904x3556606" unitRef="iso4217_EUR" decimals="0" id="id_14264487_C20DC179-4953-4AB9-A638-2D3C441CEE34_2003_1">19595</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416904x3416976" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_11003_8">-1137000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416904x3416976_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_11002_8">-1086000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416904x3416976_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_11001_8">-51000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416904x3420576" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_12003_7">1137000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416904x3420576_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_12002_7">1086000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416904x3420576_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_12001_7">51000</ifrs-full:DisposalsPropertyPlantAndEquipment>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_2001_9">252703</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_A9709B03-C298-400E-9F1B-9560D83BBBFF_2002_9">573875</mrus:RemunerationForFormerEmployees>
  <mrus:AdditionsInContractLiabilities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416963x3508994" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_42350E10-239D-4AF2-8266-66F681BDEDBD_4001_2">111993000</mrus:AdditionsInContractLiabilities>
  <mrus:DeductionsInContractLiabilities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3416963x3508994" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_42350E10-239D-4AF2-8266-66F681BDEDBD_4001_3">14933000</mrus:DeductionsInContractLiabilities>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_10002_5">113000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:ChangesInPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_10002_9">43000</ifrs-full:ChangesInPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_10002_6">70000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_10001_5">663000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:ChangesInPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_10001_9">477000</ifrs-full:ChangesInPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_10001_6">186000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <mrus:AdditionsToTradeReceivables contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417430x3424016" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B9006E8A-8CC3-4797-AB24-FDAA49648F60_4001_2">122781000</mrus:AdditionsToTradeReceivables>
  <mrus:DeductionsInTradeReceivables contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417430x3424016" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B9006E8A-8CC3-4797-AB24-FDAA49648F60_4001_3">121392000</mrus:DeductionsInTradeReceivables>
  <mrus:DeductionsInContractAssets contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417430x3496068" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_2A09F546-20FB-44EF-8399-02D50D5088AC_4001_3">120530000</mrus:DeductionsInContractAssets>
  <mrus:AdditionsInContractAssets contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417430x3496068" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_2A09F546-20FB-44EF-8399-02D50D5088AC_4001_2">121240000</mrus:AdditionsInContractAssets>
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417439x3422519" unitRef="pure" decimals="INF" id="id_14264487_1929F029-CC6A-4563-801E-C284057C67AE_1002_3">7331</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417439x3422519" unitRef="pure" decimals="INF" id="id_14264487_1929F029-CC6A-4563-801E-C284057C67AE_1002_2">136666</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <mrus:NumberOfSharesIssuedForCash contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417439x3422519" unitRef="shares" decimals="0" id="id_14264487_1929F029-CC6A-4563-801E-C284057C67AE_1002_1">3200000</mrus:NumberOfSharesIssuedForCash>
  <ifrs-full:IssueOfEquity contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417439x3495214_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10001_19">301000</ifrs-full:IssueOfEquity>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417439x3495214_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10001_21">301000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:IssueOfEquity contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417439x3495221_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10005_19">73740000</ifrs-full:IssueOfEquity>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417439x3495221_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10005_21">73740000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10009_17">-64685000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10009_20">12815000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:OtherComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10009_16">89000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10009_15">-64774000</ifrs-full:ProfitLoss>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10009_21">12815000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:FinanceCosts contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3419692x3495181_3423078x3554473" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_E8DDF043-0AF2-4DF5-A23A-6F346A173C3A_1003_1">10700000</ifrs-full:FinanceCosts>
  <ifrs-full:ApplicableTaxRate contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3420782x3424474" unitRef="pure" decimals="2" id="id_14264487_DA49123C-D250-44E7-A84C-86E772EF376D_1002_1">0.40</ifrs-full:ApplicableTaxRate>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3420782x3424474" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_85B2D5A1-471B-46DD-A6CA-B847B937A892_1002_0">200000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <mrus:AccrualsToEmployeeSeveranceIndemnities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3422662x3423353" unitRef="iso4217_EUR" decimals="INF" id="id_14264487_6D337156-1BC6-480C-B1FD-A0D3CF47E73D_5_2">100000</mrus:AccrualsToEmployeeSeveranceIndemnities>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F50D74E8-62F9-46D7-A94F-EA8F8024910F_2_2">-8315000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3420637" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_2_3">0.43</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_2_2">8315000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_2_1">8315000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_2_0">8315000</ifrs-full:Revenue>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F50D74E8-62F9-46D7-A94F-EA8F8024910F_2_0">8315000</ifrs-full:ProfitLoss>
  <mrus:IncreaseDecreaseInDeferredRevenue1 contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_AA0EA26B-1B7F-40ED-AB59-567BE811A133_1001_0">-8700000</mrus:IncreaseDecreaseInDeferredRevenue1>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F50D74E8-62F9-46D7-A94F-EA8F8024910F_1_2">-6618000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3422609" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_1_3">-3.80</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_1_2">-73000000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_1_1">-43617000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_1_0">13600000</ifrs-full:Revenue>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F50D74E8-62F9-46D7-A94F-EA8F8024910F_1_0">-73089000</ifrs-full:ProfitLoss>
  <mrus:IncreaseDecreaseInDeferredRevenue1 contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3508886" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_18E54147-DA5E-4033-A7A7-73CF9F03E66B_1001_0">-8700000</mrus:IncreaseDecreaseInDeferredRevenue1>
  <mrus:UpfrontPaymentAmortization contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3423078x3486516" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_D763C17C-A9C7-4FD1-B76B-1230E71ADC74_1002_500000">14900000</mrus:UpfrontPaymentAmortization>
  <mrus:StockAwardExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3475752x3481637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B5A6BE7B-5975-44A4-A2A1-EED190DB18B0_1002_0">3245000</mrus:StockAwardExpense>
  <mrus:StockAwardExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3475752x3491841" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B5A6BE7B-5975-44A4-A2A1-EED190DB18B0_2002_2">628000</mrus:StockAwardExpense>
  <mrus:StockAwardExpense contextRef="eol_PE977595--1820-F0010_STD_365_20171231_0_3475752x3514214" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B5A6BE7B-5975-44A4-A2A1-EED190DB18B0_3002_1">8942000</mrus:StockAwardExpense>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_17003_14">1798000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_14">-13877000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_12">618000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_780AD06D-9847-4BE0-8664-B9F729C217F8_1_4">-1.09</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_26">-19416000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInOperations contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_16">-39871000</ifrs-full:CashFlowsFromUsedInOperations>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_81C606C9-877F-4A25-8240-D20899DA93A2_1_4">2225000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_10">-2576000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_7">1181000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_4">-5553000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
  <dei:AmendmentFlag contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_0ACBD4B0-59C1-4C36-A416-82A2904A2337_1_1">false</dei:AmendmentFlag>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_35">51589000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_19">-40499000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:ChangesInPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_17003_18">1252000</ifrs-full:ChangesInPropertyPlantAndEquipment>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_11">-946000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_5">638000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_6">7925000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_8">-22440000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_81C606C9-877F-4A25-8240-D20899DA93A2_1_5">92000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_13010_26">-24235000</ifrs-full:ComprehensiveIncome>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_1469EA42-F951-4C73-B189-5B232EFF4ADE_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_4119128A-2D7B-4A70-8412-BD2D0B9B7BB1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Financial Instruments&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company classifies &lt;font style="WHITE-SPACE: nowrap"&gt;non-derivative&lt;/font&gt; financial assets as
 either financial assets at fair value through profit or loss,
 financial assets at amortized cost or financial assets at fair
 value through other comprehensive income or loss. The Company
 classifies &lt;font style="WHITE-SPACE: nowrap"&gt;non-derivative&lt;/font&gt;
 financial liabilities into either financial liabilities at fair
 value through profit or loss or the other financial liabilities
 category.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Non-Derivative&lt;/font&gt;
 Financial Assets and Financial Liabilities&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company initially recognizes receivables and investments at
 fair value on the date when they are originated. Subsequent to
 initial recognition, they are measured at amortized cost using the
 effective interest rate method. All other financial assets and
 financial liabilities are initially recognized on the trade
 date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The Company derecognizes a financial asset when the contractual
 rights to the cash flows from the asset expire, or it transfers the
 rights to receive the contractual cash flows in a transaction in
 which substantially all the risks and rewards of ownership of the
 financial asset are transferred, or it neither transfers nor
 retains substantially all of the risks and rewards of ownership and
 does not retain control over the transferred asset. Any interest in
 such derecognized financial assets that is created or retained by
 the Company is recognized as a separate asset or liability.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company initially recognizes &lt;font style="WHITE-SPACE: nowrap"&gt;non-derivate&lt;/font&gt; financial liabilities at
 fair value less any directly attributable transaction costs.
 Subsequent to initial recognition, these liabilities are measured
 at amortized cost using the effective interest method.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company derecognizes a financial liability when its contractual
 obligations are settled or cancelled, or expire.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Financial assets and financial liabilities are offset and the net
 amount presented in the statement of financial position when, and
 only when, the Company has a legal right to offset the amounts and
 intends either to settle them on a net basis or to realize the
 asset and settle the liability simultaneously.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Receivables&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 These assets are initially recognized at fair value plus any
 directly attributable transaction costs, if any.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Derivative Financial Assets and Liabilities&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Derivative financial instruments are initially recognized at fair
 value on the date on which a derivative contract is entered into
 and are subsequently remeasured at fair value with net changes in
 fair value presented as finance expenses (negative net changes in
 fair value) or finance income (positive net changes in fair value)
 in the consolidated statement of profit or loss and comprehensive
 loss. Derivatives are carried as financial assets when the fair
 value is positive and as financial liabilities when the fair value
 is negative. Derivatives embedded in host contracts are accounted
 for as separate derivatives and recorded at fair value if their
 economic characteristics and risks are not closely related to those
 of the host contracts and the host contracts are not held for
 trading or designated at fair value through profit or loss. These
 embedded derivatives are measured at fair value with changes in
 fair value recognized in profit or loss. Reassessment only occurs
 if there is either a change in the terms of the contract that
 significantly modifies the cash flows that would otherwise be
 required or a reclassification of a financial asset out of the fair
 value through profit or loss category.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_476EE5E0-A473-48EB-A2B4-944F627F2A4A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Provisions&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 A provision is recognized if the following applies:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the company has a legal or constructive obligation,
 arising from a past event;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the amount can be estimated reliably; and&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;it is probable that an outflow of resources embodying
 economic benefits will be required to settle the obligation.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 If all or part of the payments that are necessary to settle a
 provision are virtually certain to be fully or partially
 compensated by a third party upon settlement of the provision, then
 the compensation amount is presented separately as an asset.
 Provisions are determined by discounting the expected future cash
 flows at a &lt;font style="WHITE-SPACE: nowrap"&gt;pre-tax&lt;/font&gt; rate
 that reflects current market assessments of the time value of money
 and the risks specific to the liability. The unwinding of the
 discount is recognized as finance cost.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_68078692-077B-4C21-8EB2-80F32AD7B4E5_1_3">638000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_17003_15">546000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_4521D880-8395-4F56-9F8D-D98DCE0D93F3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Income Tax&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Income tax expense comprises current and deferred tax. It is
 recognized in the consolidated statement of profit or loss and
 comprehensive loss except to the extent that it relates to a
 business combination, or items recognized directly in equity or in
 other comprehensive income or loss. Current tax comprises the
 expected tax payable or receivable on the taxable income or loss
 for the year and any adjustment to tax payable or receivable in
 respect of previous years. It is measured using tax rates enacted
 or substantively enacted at the reporting date. Current tax also
 includes any tax arising from dividends. Current tax assets and
 liabilities are offset only if certain criteria are met.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Deferred tax is recognized in respect of temporary differences
 between the carrying amounts of assets and liabilities for
 financial reporting purposes and the amounts used for taxation
 purposes. Deferred tax is not recognized for:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;temporary differences on the initial recognition of
 assets or liabilities in a transaction that is not a business
 combination and that affects neither accounting nor taxable profit
 or loss;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;temporary differences related to investments in
 subsidiaries, associates and joint arrangements to the extent that
 the group is able to control the timing of the reversal of the
 temporary differences and it is probable that they will not reverse
 in the foreseeable future; and&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;taxable temporary differences arising on the initial
 recognition of goodwill.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Deferred tax assets are recognized for unused tax losses, unused
 tax credits and deductible temporary differences to the extent that
 it is probable that future taxable profits will be available
 against which they can be used. Deferred tax assets are reviewed at
 each reporting date and are reduced to the extent that it is no
 longer probable that the related tax benefit will be realized; such
 reductions are reversed when the probability of future taxable
 profits improves.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Unrecognized deferred tax assets are reassessed at each reporting
 date and recognized to the extent that it has become probable that
 future taxable profits will be available against which they can be
 utilized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Deferred tax is measured at the tax rates that are expected to be
 applied to temporary differences when they reverse, using tax rates
 enacted or substantively enacted at the reporting date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The measurement of deferred tax reflects the tax consequences that
 would follow from the manner in which the Company expects, at the
 reporting date, to recover or settle the carrying amount of its
 assets and liabilities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Deferred tax assets and liabilities are offset only if certain
 criteria are met.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_41A7B8B5-78A9-4F0A-A75D-28F7D3664884_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Foreign Currency Transactions&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Foreign currency transactions are translated using the exchange
 rates at the dates of the transactions. Foreign exchange gains and
 losses resulting from the settlement of such transactions and from
 the translation of monetary assets and liabilities denominated in
 foreign currencies at the exchange rate at the reporting date are
 generally recognized in the statement of profit or loss and
 comprehensive loss as a component of finance costs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The results and financial position of foreign operations that have
 a functional currency different from the presentation currency are
 translated into the presentation currency as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;assets and liabilities for each balance sheet
 presented are translated at the closing rate at the date of that
 balance sheet;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;income and expenses for each statement of profit or
 loss and comprehensive income or loss are translated at average
 exchange rates (unless this is not a reasonable approximation of
 the cumulative effect of the rates prevailing on the transaction
 dates, in which case income and expenses are translated at the
 exchange rates at the dates of the transactions); and&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;all resulting exchange differences are recognized in
 other comprehensive income.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_CF2ED05C-8E22-4AD8-8085-8E01529B8ACA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Impairment&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Financial Assets Measured at Amortized Cost&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 At each reporting date, the Company considers evidence of
 impairment for these assets at both an individual asset and a
 collective level. All individually significant assets are
 individually assessed for impairment. Those found not to be
 impaired are then collectively assessed for any impairment that has
 been incurred but not yet individually identified. Assets that are
 not individually significant are collectively assessed for
 impairment. Collective assessment is carried out by grouping
 together assets with similar risk characteristics.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 To assess impairment for its financial assets, the Company uses the
 general expected credit loss model over the next twelve months of
 the expected life of its financial assets. Under this model, the
 Company calculates the allowance for credit losses by considering
 on a discounted basis, the cash shortfalls it would incur in
 various default scenarios for prescribed future periods and
 multiplying the shortfalls by the probability of each scenario
 occurring. The allowance on the financial asset is the sum of these
 probability-weighted outcomes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 For the Company&amp;#x2019;s investments, the Company applies the low
 credit risk simplification as it does not believe there to be any
 credit risk related to these assets given the credit quality
 ratings required by the Company&amp;#x2019;s investment policy. At every
 reporting date, the Company evaluates whether a particular debt
 instrument is considered to have low credit risk using all
 supportable information.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Impairment losses are recognized in the consolidated statement of
 profit or loss and comprehensive loss and is the amount required to
 adjust the loss allowance at the reporting date to the amount that
 is required to be recognized based on the aforementioned policy. If
 the amount of impairment loss subsequently decreases and the
 decrease can be related objectively to an event occurring after the
 impairment was recognized, then the previously recognized
 impairment loss is reversed through profit or loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Non-Financial&lt;/font&gt;
 Assets&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 At each reporting date, the Company reviews the carrying amounts of
 its &lt;font style="WHITE-SPACE: nowrap"&gt;non-financial&lt;/font&gt; assets
 to determine whether there is any indication of impairment. If any
 such indication exists, then the asset&amp;#x2019;s recoverable amount
 is estimated.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 For impairment testing, assets are grouped together into the
 smallest group of assets that generates cash inflows from
 continuing use that are largely independent of the cash inflows of
 other assets or cash generating units (&amp;#x201C;CGU&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The recoverable amount of an asset or CGU is the greater of its
 value in use and its fair value less costs to sell. Value in use is
 based on the estimated future cash flows, discounted to their
 present value using a &lt;font style="WHITE-SPACE: nowrap"&gt;pre-tax&lt;/font&gt; discount rate that reflects
 current market assessments of the time value of money and the risks
 specific to the asset or CGU.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 An impairment loss is recognized if the carrying amount of an asset
 or CGU exceeds its recoverable amount.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Impairment losses are recognized in profit or loss. They are
 allocated first to reduce the carrying amount of any goodwill
 allocated to the CGU, and then to reduce the carrying amounts of
 the other assets in the CGU on a pro rata basis.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 An impairment loss is reversed only to the extent that the
 asset&amp;#x2019;s carrying amount does not exceed the carrying amount
 that would have been determined, net of depreciation or
 amortization, if no impairment loss had been&amp;#xA0;recognized.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_28C39493-3F4F-49B7-AF9D-01A17F8A0A07_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Intangible Assets&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Intangible assets are identifiable &lt;font style="WHITE-SPACE: nowrap"&gt;non-monetary&lt;/font&gt; assets without physical
 substance. An asset is a resource that is controlled by the
 enterprise as a result of past events (for example, purchase or
 self-creation) and from which future economic benefits (inflows of
 cash or other assets) are expected.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The useful lives of intangible assets are assessed to be finite and
 amortized over the useful economic life and assessed for impairment
 whenever there is an indication that the intangible asset may be
 impaired. Amortization begins when the asset is available for
 use.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Patents&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Patents acquired separately by the Company are reported at cost
 less accumulated amortization and accumulated impairment losses.
 Amortization is recognized in the consolidated statement of profit
 and loss and comprehensive loss on a straight-line basis over the
 shorter of the estimated economic or legal lives. The estimated
 useful life and amortization method are reviewed at the end of each
 reporting period, with the effect of any changes in estimates being
 accounted for on a prospective basis.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;R&amp;amp;D&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company incurs R&amp;amp;D expenses related to its clinical trials
 and preclinical drug development programs. Development expenses are
 defined as expenses incurred to achieve technical and commercial
 feasibility. Expenditures on research activities are recognized as
 an expense in the period in which it is incurred.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Development is capitalized if, and only if, all of the following
 have been demonstrated:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the technical feasibility of completing the intangible
 asset so that it will be available for use or sale;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the intention to complete the intangible asset and use
 or sell it;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the ability to use or sell the intangible asset;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;how the intangible asset will generate probable future
 economic benefits;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the availability of adequate technical, financial and
 other resources to complete the development and to use or sell the
 intangible asset; and&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the ability to measure reliably the expenditure.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_2E77211B-D3B7-4C4B-B51B-3758A4193D00_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Effective January&amp;#xA0;1, 2018, the Company adopted IFRS 15,
 &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; (&amp;#x201C;IFRS
 15&amp;#x201D;). This standard applies to all contracts with customers,
 except for contracts that are within the scope of other standards,
 such as leases, insurance, collaboration arrangements and financial
 instruments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The terms of the contracts within the scope of IFRS 15&amp;#xA0;may
 contain multiple promised goods and services, which often include
 license rights to certain of the Company&amp;#x2019;s product candidates
 and R&amp;amp;D activities. Payments under such agreements include:
 (i)&amp;#xA0;upfront nonrefundable license fees; (ii)&amp;#xA0;payments for
 R&amp;amp;D services performed by the Company, including reimbursement
 for certain external costs; (iii)&amp;#xA0;payments based upon the
 achievement of certain development, regulatory and commercial
 milestones; and (iv)&amp;#xA0;royalties on net product sales, if
 any.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Under IFRS 15, the Company recognizes revenue when its customer
 obtains control of promised goods or services, in an amount that
 reflects the consideration that the Company expects to receive in
 exchange for those goods or services. The Company recognizes
 revenue following the five-step model prescribed under IFRS 15: (i)
 identification of the contract(s) with the customer;
 (ii)&amp;#xA0;identification of the performance obligations;
 (iii)&amp;#xA0;determination of the transaction price, including the
 constraint on variable consideration; (iv)&amp;#xA0;allocation of the
 transaction price to the performance obligations in the contract;
 and (v)&amp;#xA0;recognition of revenue when (or as) the Company
 satisfies each performance obligation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In order to account for contracts with customers, the Company
 identifies the promised goods or services in the contract and
 evaluates whether such promised goods or services represent
 performance obligations. The Company accounts for those components
 as separate performance obligations when the following criteria are
 met: (i)&amp;#xA0;the customer can benefit from the good or service
 either on its own or together with other resources that are readily
 available to the customer, and (ii)&amp;#xA0;the Company&amp;#x2019;s
 promise to transfer the good or service to the customer is
 separately identifiable from other promises in the contract. This
 evaluation requires subjective determinations and requires the
 Company to make judgments about the promised goods and services and
 whether such goods and services are separable from the other
 aspects of the contractual relationship. In determining the
 performance obligations, the Company evaluates certain criteria,
 including whether the promised good or service is capable of being
 distinct and whether such good or service is distinct within the
 context of the contract, based on consideration of the relevant
 facts and circumstances for each arrangement. Factors considered in
 this determination include the research, manufacturing and
 commercialization capabilities of the partner; the availability of
 research and manufacturing expertise in the general marketplace;
 and the level of integration, interrelation, and interdependence
 among the promises to transfer goods or services.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The transaction price is allocated among the performance
 obligations using the relative selling price method and the
 applicable revenue recognition criteria are applied to each of the
 separate performance obligations. At contract inception, the
 Company determines the standalone selling price for each
 performance obligation identified in the contract. If an observable
 price of the promised good or service sold separately is not
 readily available, the Company utilizes assumptions that require
 judgment to estimate the standalone selling price, which may
 include development timelines, probabilities of technical and
 regulatory success, reimbursement rates for personnel costs,
 forecasted revenues, potential limitations to the selling price of
 the product, expected technological life of the product and
 discount rates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Up-front&lt;/font&gt; License
 Payments&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 If the license to the Company&amp;#x2019;s intellectual property is
 determined to be distinct from the other performance obligations
 identified in the arrangement, the Company recognizes revenue
 allocated to the license when the license is transferred to the
 customer and the customer is able to use and benefit from the
 license. For licenses that are not distinct and bundled with other
 performance obligations, the Company utilizes judgment to assess
 the nature of the combined performance obligation to determine
 whether the combined performance obligation is satisfied over time
 or at a point in time and, if over time, the appropriate method of
 measuring progress for purposes of recognizing revenue from the
 combined performance obligation. The Company evaluates the measure
 of progress each reporting period and, if necessary, adjusts the
 measure of performance and related revenue recognition.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Milestones&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 At the inception of each arrangement that includes &lt;font style="WHITE-SPACE: nowrap"&gt;pre-commercial&lt;/font&gt; milestone payments, the
 Company evaluates whether the milestones are considered probable of
 being reached and estimates the amount to be included in the
 transaction price using the most likely amount method. If it is
 probable that a significant cumulative revenue reversal would not
 occur, the associated milestone value is included in the
 transaction price. Milestone payments that are not within the
 Company&amp;#x2019;s control, such as regulatory approvals, are not
 considered probable of being achieved until the uncertainty related
 to the milestone is resolved. The transaction price is then
 allocated to each performance obligation on a relative selling
 price basis, for which the Company recognizes revenue as or when
 the performance obligations under the contract are satisfied. Any
 such adjustments are recorded on a cumulative &lt;font style="WHITE-SPACE: nowrap"&gt;catch-up&lt;/font&gt; basis, which affects revenue
 in the period of adjustment. At the end of each subsequent
 reporting period, the Company reevaluates the probability of
 achievement of such development milestones and any related
 constraint, and if necessary, adjusts its estimate of the overall
 transaction price.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Royalties&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 For arrangements that include sales-based royalties, including
 milestone payments based on the level of sales, and where the
 license is deemed to be the predominant item to which the royalties
 relate, the Company recognizes revenue at the later of:
 (i)&amp;#xA0;when the related sales occur, or (ii)&amp;#xA0;when the
 performance obligation to which some or all of the royalty has been
 allocated has been satisfied (or partially satisfied). To date, the
 Company has not recognized any royalty revenue.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;R&amp;amp;D Cost Reimbursement&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 R&amp;amp;D cost reimbursement revenue, which is typically related to
 reimbursements from customers for the Company&amp;#x2019;s performance
 of R&amp;amp;D services under the respective agreements, is recognized
 on the basis of labor hours valued at a contractually agreed rate.
 R&amp;amp;D cost reimbursement revenue also includes reimbursements for
 related &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;out-of-pocket&lt;/font&gt;&lt;/font&gt; expenses and
 third-party costs. R&amp;amp;D cost reimbursement revenue is recognized
 in the same period as the costs for which they are intended to
 compensate.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company typically acts as the principal under such arrangements
 and, therefore, records these reimbursements on a gross basis. The
 impact of the new revenue standard IFRS 15 was also assessed for
 the instances under the ONO research and license agreement (defined
 below) where the Company acts as an agent. The Company concluded
 that no control was obtained for these pass-through arrangements to
 reimburse costs under the ONO research and license agreement and as
 such the costs were netted in R&amp;amp;D instead of being recognised
 as expense.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Costs of Obtaining a Contract with a Customer&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company capitalizes the incremental costs of obtaining a
 contract with a customer if it expects to recover those costs. To
 date, the Company has not capitalized any incremental costs for
 obtaining a contract.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Government Grants&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company receives certain government and regional grants, which
 support its research efforts in defined projects, and include
 contributions towards the R&amp;amp;D cost. When there is reasonable
 assurance that the Company will comply with the conditions attached
 to a received grant, and when there is reasonable assurance that
 the grant will be received, government grants are recognized as
 revenue on a gross basis in the consolidated statement of profit or
 loss and comprehensive loss on a systematic basis over the periods
 in which the Company recognizes expenses for the related costs for
 which the grants are intended to compensate. In the case of grants
 related to assets, the received grant will be deducted from the
 carrying amount of the asset.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;WBSO&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The WBSO (&lt;i&gt;afdrachtvermindering speur- en ontwikkelingswerk&lt;/i&gt;)
 is a Dutch fiscal facility that provides subsidies to companies,
 knowledge centers and self-employed people who perform R&amp;amp;D
 activities (as defined in the WBSO Act). Under this act, a
 contribution is paid towards the labor costs of employees directly
 involved in R&amp;amp;D and other related expenditures. The
 contribution is in the form of a reduction of payroll taxes.
 Subsidies relating to labor costs are deferred and recognized in
 the consolidated statement of profit or loss and comprehensive loss
 as negative labor costs over the period necessary to match them
 with the labor costs that they are intended to compensate (see Note
 15).&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
  <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_509F68FC-49FB-450A-A484-FEA818E6043E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Employee Benefits&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Short-term Employee Benefits&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Short-term employee benefits are expensed as the related service is
 provided. A liability is recognized for the amount expected to be
 paid if the Company has a present legal or constructive obligation
 to pay this amount as a result of past service provided by the
 employee and the obligation can be estimated reliably.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;i&gt;Share-Based Payment Transactions&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The grant-date fair value of equity-settled share-based payment
 awards granted to employees including grants of employee options,
 restricted share units, and modifications to existing instruments,
 is recognized as an expense, net of an estimated forfeiture rate,
 with a corresponding increase in equity (accumulated loss), over
 the vesting period of the awards. Service conditions and
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-market&lt;/font&gt; related
 conditions are not taken into account in determining the fair
 value. The amount recognized as an expense is adjusted to reflect
 the number of awards for which the related service and &lt;font style="WHITE-SPACE: nowrap"&gt;non-market&lt;/font&gt; performance conditions are
 expected to be met, such that the amount ultimately recognized is
 based on the number of awards that meet the related service and
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-market&lt;/font&gt; performance
 conditions at the vesting date. For any share-based payment awards
 with market conditions or &lt;font style="WHITE-SPACE: nowrap"&gt;non-vesting&lt;/font&gt; conditions, the grant-date
 fair value of the share-based payment is measured to reflect such
 conditions and there is no &lt;font style="WHITE-SPACE: nowrap"&gt;true-up&lt;/font&gt; for differences between
 expected and actual outcomes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Post-Employment Benefit Plans&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company contributes to a post-employment benefit plan that
 entitles executive officers and other staff members to retire at
 the age of 67 and receive annual payments based upon the average
 salary earned during the service period. The Company has insured
 the liabilities from the post-employment benefit plan with an
 insurance company and has no other obligation than to pay the
 annual insurance premiums to the insurance company. The annual
 pension payments are conditional; the Company will have no further
 obligation (legal or constructive) to pay further amounts if the
 insurance fund has insufficient assets to pay all employee benefits
 relating to current and prior service. Based on its
 characteristics, the Company&amp;#x2019;s post-employment benefit plan
 is classified as a defined contribution plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Obligations for contributions to defined contribution plans are
 expensed as the related service is provided. Prepaid contributions
 are recognized as an asset.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_F8274428-09E5-4D94-9A90-9758FAC3BAB6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Determining whether an Arrangement Contains a Lease&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 At inception of an arrangement, the Company determines whether such
 an arrangement is or contains a lease.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 At inception or on reassessment of the arrangement, the Company
 separates payments and other consideration required by such an
 arrangement into those for the lease and those for other elements
 on the basis of their relative fair values. If the Company
 concludes for a finance lease that it is impracticable to separate
 the payments reliably, then an asset and a liability are recognized
 at an amount equal to the fair value of the underlying asset.
 Subsequently, the liability is reduced as payments are made and an
 imputed finance cost on the liability is recognized using the
 Company&amp;#x2019;s incremental borrowing rate.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Leased Assets&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Assets held by the Company under leases that transfer to the
 Company substantially all of the risks and rewards of ownership are
 classified as finance leases. The leased assets are measured
 initially at an amount equal to the lower of their fair value and
 the present value of the minimum lease payments. Subsequent to
 initial recognition, the assets are accounted for in accordance
 with the accounting policy applicable to that asset.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Assets held under other leases are classified as operating leases
 and are not recognized in the Company&amp;#x2019;s statement of
 financial position.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Lease Payments&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Payments made under operating leases are recognized in the
 consolidated statement of profit or loss and comprehensive loss on
 a straight-line basis over the term of the lease. Lease incentives
 received are recognized as an integral part of the total lease
 expense, over the term of the lease.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Minimum lease payments made under finance leases are apportioned
 between the finance expense and the reduction of the outstanding
 liability. The finance expense is allocated to each period during
 the lease term so as to produce a constant periodic rate of
 interest on the remaining balance of the&amp;#xA0;liability.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_7130BDAB-84C1-4557-800E-5D8BD7853B7E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Property, Plant and Equipment&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Property, plant and equipment are measured at cost less accumulated
 depreciation and accumulated impairment losses (if any). Cost
 includes expenditures that are directly attributable to the
 acquisition of the items. Depreciation of property, plant and
 equipment is recognized in the consolidated statement of profit and
 loss and comprehensive loss on a straight-line basis over estimated
 useful lives of generally five years, taking residual value into
 account. If significant parts of an item of property, plant and
 equipment have different useful lives, they are accounted for as
 separate items (major components) of property, plant and
 equipment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Subsequent expenditures are capitalized only when the expenditure
 will increase the future economic benefit of the asset. All other
 expenditures are expensed in the consolidated statement of profit
 or loss and comprehensive loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Depreciation rates are based on the following estimated economic
 useful lives of the tangible fixed assets concerned:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Plant and
 equipment&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;5
 years&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Leasehold improvements
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Shorter of useful
 life or term of lease&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Other fixed
 assets:&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;5
 years&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
  <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_FEDB8B80-8DB9-451F-930C-FE7F45D4F68F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The following is a tabular reconciliation of common shares
 outstanding for the years ended December&amp;#xA0;31, 2018 and 2017,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Common Shares outstanding at January&amp;#xA0;1,&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;19,429,848&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,085,851&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Issued for cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,699,997&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,200,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise of common share options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;135,888&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;136,666&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vesting of RSUs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;93,244&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,331&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Common shares outstanding at December&amp;#xA0;31,&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;23,358,977&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,429,848&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
  <ifrs-full:DisclosureOfDeferredIncomeExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_3CC94DD6-9083-46BF-9760-DCF987377F1B_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Deferred Revenue&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Deferred revenue consisted of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;br /&gt;
 Restated*&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;&lt;i&gt;(euros&amp;#xA0;in&amp;#xA0;thousands)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&amp;#x2014;current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;16,934&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,935&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;97,675&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;112,551&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;114,609&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;*&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;&lt;i&gt;See Note 4 for details regarding the restatement as
 a result of a change in accounting policy.&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Of the total deferred revenue balance at December&amp;#xA0;31, 2018,
 &amp;#x20AC;112.6&amp;#xA0;million related to the Incyte collaboration and
 license agreement and a share subscription agreement (the
 &amp;#x201C;Incyte share subscription agreement&amp;#x201D;) entered into by
 the Company with Incyte on December&amp;#xA0;20, 2016 (together, the
 &amp;#x201C;Incyte Agreements&amp;#x201D;) and &amp;#x20AC;2.1
 million&amp;#xA0;related to the collaboration and license agreement
 entered into by the Company with Simcere on January&amp;#xA0;8, 2018
 (the &amp;#x201C;Simcere collaboration and license agreement&amp;#x201D;).
 The total deferred revenue balance at December&amp;#xA0;31, 2017,
 related solely to the Incyte Agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Under the Incyte collaboration and license agreement, Incyte agreed
 to pay the Company a $120.0&amp;#xA0;million,
 or&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&amp;#x20AC;112.0&amp;#xA0;million,&amp;#xA0;non-refundable&amp;#xA0;upfront&lt;/font&gt;&amp;#xA0;payment,
 and under the Incyte share subscription agreement, Incyte agreed to
 purchase 3.2&amp;#xA0;million common shares at a price per share of
 $25.0, for an aggregate purchase price of $80.0&amp;#xA0;million. In
 January 2017, the Company completed the sale of its common shares
 under the Incyte share subscription agreement and received the
 $80.0&amp;#xA0;million in aggregate purchase price. In February 2017,
 the Company received the $120.0&amp;#xA0;million, or
 &amp;#x20AC;112.0&amp;#xA0;million,&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable&lt;/font&gt;&amp;#xA0;upfront
 payment and recorded it as deferred revenue.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company combined the Incyte collaboration and license agreement
 and Incyte share subscription agreement and accounted for them as a
 single contract based on the following criteria: (i)&amp;#xA0;they were
 entered into at the same time with the same customer; (ii)&amp;#xA0;the
 arrangements&amp;#x2019; mutual existence is acknowledged in the
 separate agreements; and (iii)&amp;#xA0;they were negotiated as a
 package with a single commercial objective.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As the Incyte share subscription agreement was denominated in a
 foreign currency (U.S. dollars) other than the Company&amp;#x2019;s
 functional currency (euro), the Company determined that the
 freestanding forward contract to sell its own shares at a future
 date, to which the Company became committed on December&amp;#xA0;20,
 2016, did not qualify as equity and thus a freestanding forward
 contract (derivative asset) was recognized in the Company&amp;#x2019;s
 consolidated statement of financial position. The difference
 between the purchase price of $25.0 per common share in the Incyte
 share subscription agreement and the market price of the
 Company&amp;#x2019;s common shares on December&amp;#xA0;20, 2016 was
 considered to be part of the consideration received under the
 Incyte Agreements. As a result, on December&amp;#xA0;20, 2016, the
 Company recorded a liability (deferred revenue) of
 $32.6&amp;#xA0;million, or &amp;#x20AC;31.4&amp;#xA0;million, in its
 consolidated statement of financial position for the same amount as
 the fair value of the freestanding forward contract (derivative
 asset). The deferred revenue liability is not remeasured subsequent
 to the initial recognition and is accounted for in the same manner
 as the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable&lt;/font&gt;&amp;#xA0;upfront
 payment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company&amp;#x2019;s fixed consideration under the Incyte Agreements
 is $152.6&amp;#xA0;million, consisting of the $120.0&amp;#xA0;million, or
 &amp;#x20AC;112.0&amp;#xA0;million,&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable&lt;/font&gt;&amp;#xA0;upfront
 payment from the Incyte collaboration and license agreement and
 $32.6&amp;#xA0;million, or &amp;#x20AC;31.4&amp;#xA0;million, in consideration
 from the issuance and sale of common shares pursuant to the Incyte
 share subscription agreement. The transaction price was allocated
 to a single combined performance obligation that includes a license
 to the Company&amp;#x2019;s technology combined with the JSC services
 during the research term. Revenue from upfront license payments
 under the Incyte collaboration and license agreement will be
 recognized as the Company satisfies the combined performance
 obligation, or over the nine-year research term, which is a period
 during which the Company has present enforceable obligation to
 provide JSC services.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Under the Simcere collaboration and license agreement, the Company
 agreed to grant Simcere an exclusive license to develop and
 commercialize in China three bispecific antibodies to be produced
 by Merus utilizing the Company&amp;#x2019;s Biclonics&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;technology
 platform in the area of immuno-oncology. The Company will retain
 all rights outside of China. As part of the agreement, the Company
 has agreed to lead research and discovery activities, while Simcere
 has agreed to be responsible for the Investigational New Drug
 (&amp;#x201C;IND&amp;#x201D;) enabling studies, clinical development,
 regulatory filings and commercialization of these product
 candidates in China. The Company received an
 upfront,&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable&lt;/font&gt;&amp;#xA0;payment
 of $2.75&amp;#xA0;million, or &amp;#x20AC;2.3&amp;#xA0;million, relating to
 three separate research programs. Each research program was
 determined to be a separate performance obligation and
 consideration was allocated to each separate obligation. In
 addition, the Company received a payment of $0.8&amp;#xA0;million, or
 &amp;#x20AC;0.6&amp;#xA0;million, relating to one of the programs, which was
 also recorded as deferred revenue.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company amortizes the upfront and milestone payment to revenue
 over time based on the estimated duration of each research program.
 As of December&amp;#xA0;31, 2018, the first and second research
 programs had commenced. For the year ended December&amp;#xA0;31, 2018,
 the Company recognized revenue of &amp;#x20AC;0.9&amp;#xA0;million, relating
 to these two programs for the amortization of upfront and milestone
 payments. The remaining research program had not commenced as of
 December&amp;#xA0;31,&amp;#xA0;2018. Accordingly, no revenue has been
 recognized related to the remaining research program.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On March&amp;#xA0;14, 2018, the Company entered into a second contract
 research and license agreement with ONO (the &amp;#x201C;second ONO
 research and license agreement&amp;#x201D;). Pursuant to an exclusive
 option granted to ONO in the ONO research and license agreement,
 ONO exercised its option to enter into the second ONO research and
 license agreement. The Company granted ONO an exclusive, worldwide,
 royalty-bearing license, with the right to sublicense, research,
 test, make, use and market bispecific antibody candidates based on
 the Company&amp;#x2019;s Biclonics&lt;b&gt;&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/b&gt;&lt;b&gt;&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xA0;&lt;/sup&gt;&lt;/b&gt;technology
 platform against two undisclosed targets directed to a particular
 undisclosed target combination.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Under the terms of the agreement, ONO identifies and selects the
 licensed bispecific antibodies for which it is responsible for
 conducting&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;further&amp;#xA0;non-clinical&amp;#xA0;and&lt;/font&gt;&amp;#xA0;clinical
 development activities for such licensed bispecific antibodies and
 pharmaceutical products containing such antibodies, including
 manufacture and process development. Additionally, ONO controls and
 has exclusive rights over the worldwide commercialization of any
 approved products, including worldwide supply, and is solely
 responsible for all costs and expenses related to
 commercialization. ONO has also agreed to fund the Company&amp;#x2019;s
 R&amp;amp;D activities and be responsible for the payment of all costs
 and expenses for its own R&amp;amp;D activities, which are set out in a
 mutually agreed upon research plan. The Company retains all rights
 to use and commercialize any antibodies that are generated under
 the collaborative research program, excluding the up to five lead
 and/or selected antibodies against the targets ONO is pursuing,
 provided that the use and commercialization is not with respect to
 the particular target combination.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 ONO agreed to pay the Company an&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;upfront,&amp;#xA0;non-refundable&amp;#xA0;payment&lt;/font&gt;&amp;#xA0;of
 &amp;#x20AC;0.7&amp;#xA0;million, &amp;#x20AC;0.3&amp;#xA0;million intended to
 compensate the Company for research services already completed upon
 entering into the agreement, and &amp;#x20AC;0.2&amp;#xA0;million to be paid
 to the Company over time for full time equivalent funding. The
 Company identified a single performance obligation of providing
 research services to ONO, which were fully completed in 2018, and
 recognized all deferred payments received of approximately
 &amp;#x20AC;1.2&amp;#xA0;million as revenue during the year ended
 December&amp;#xA0;31, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On December&amp;#xA0;10, 2018, the Company entered into a collaboration
 and license agreement with Betta (the &amp;#x201C;Betta collaboration
 and license agreement&amp;#x201D;), where the Company granted Betta an
 exclusive license to develop and commercialize in
 China&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;MCLA-129,&lt;/font&gt;&amp;#xA0;a
 proprietary Biclonics&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;produced
 by its Biclonics&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;technology
 platform. The Company retains all rights outside of China. Under
 the terms of the Betta collaboration and license agreement, Betta
 has agreed to retain a contract manufacturing organization with
 experience in filing IND applications with U.S. regulatory
 authorities and CTAs with European regulatory authorities in order
 to produce clinical trial materials for the Chinese market and rest
 of the world. As a key strategic component of the collaboration,
 Betta will be responsible for IND enabling studies and
 manufacturing of clinical trial materials in China, which the
 Company intends to use to assist regulatory filing and early stage
 clinical development in the rest of the world.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In addition to a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable&lt;/font&gt;&amp;#xA0;upfront
 payment of $1.0&amp;#xA0;million, or &amp;#x20AC;0.9&amp;#xA0;million, Betta and
 the Company will share equally the cost of the transfer of the
 manufacturing technology to a contract manufacturing organization.
 The Company is also eligible to receive an aggregate of
 $12.0&amp;#xA0;million, or &amp;#x20AC;10.5&amp;#xA0;million, in milestone
 payments contingent upon Betta achieving certain specified
 development and commercial goals as well as tiered royalty payments
 of net sales of any products resulting from the collaboration in
 China.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company identified a single combined performance obligation,
 which includes a license to&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;MCLA-129&lt;/font&gt;&amp;#xA0;and other
 promised goods and services, and will recognize revenue over time
 based on the estimated duration of
 the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;IND-enabling&lt;/font&gt;&amp;#xA0;studies.
 For the year ended December&amp;#xA0;31, 2018, the Company recognized
 revenue of less than &amp;#x20AC;0.1&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Betta is eligible to receive from the Company an aggregate of
 $12.0&amp;#xA0;million, or &amp;#x20AC;10.5&amp;#xA0;million, in milestone
 payments contingent upon the Company achieving certain specified
 development and commercial goals, and is eligible to receive tiered
 royalty payments of net sales outside of China.&amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p&gt;&amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</ifrs-full:DisclosureOfDeferredIncomeExplanatory>
  <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_D1551B5A-235C-4749-BC00-1960603C2E02_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Movements in property, plant and equipment, net were as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Plant and&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;equipment&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Other&amp;#xA0;fixed&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as at January&amp;#xA0;1, 2017&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;649&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,386&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,035&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(221&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,166&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,387&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Book value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;428&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;648&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Changes in book value&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Additions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;663&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;113&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;776&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(186&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(256&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Disposals (Cost)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(51&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,086&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,137&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Disposals (Accumulated depreciation)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,086&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,137&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;477&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;43&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;520&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as at December&amp;#xA0;31, 2017&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;413&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,674&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(356&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(150&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(506&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Book value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;905&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;263&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,168&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Changes in book value&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Additions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,498&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;300&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,798&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(448&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(98&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(546&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Disposals (Cost)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Disposals (Accumulated depreciation)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,050&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;202&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,252&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as at December&amp;#xA0;31, 2018&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,759&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;713&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,472&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(804&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(248&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,052&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Book value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,955&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;465&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,420&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
  <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_E1B97525-C2C6-4F7F-A30F-A81647FA23A9_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr style="page-break-inside:avoid"&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;15.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;" align="left"&gt;&lt;b&gt;Employee Benefits&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Details of the employee benefits are as follows:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Salaries and wages&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;10,783&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,556&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,166&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 WBSO subsidy&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(4,257&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,523&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,721&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Social security premiums&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;919&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;621&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;382&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Health insurance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;330&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;222&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Pension costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;749&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;652&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;507&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Share-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,925&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,815&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,307&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Other personnel expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,835&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;656&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;442&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total employee benefits expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;18,284&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,999&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,110&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Share-based compensation expense recognized as employee benefit
 expenses during the years ended December&amp;#xA0;31, 2018, 2017 and
 2016 was as follows:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;&lt;i&gt;(euros in
 thousands)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 R&amp;amp;D costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,710&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,245&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;703&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Management and administration costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,742&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,942&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,037&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Other expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;473&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;628&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;567&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,925&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,815&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,307&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Subsidies earned under the WBSO relating to eligible R&amp;amp;D costs
 are deferred and recognized in the Company&amp;#x2019;s income statement
 as a reduction to labor costs over the period labor costs are
 expected to be incurred.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company&amp;#x2019;s headcount at&amp;#xA0;December 31, 2018 was
 approximately 98&amp;#xA0;full-time equivalents and consisted of 81
 employees in the Netherlands and&amp;#xA0;17 employees in the U.S. A
 total of 21&amp;#xA0;employees who are devoted to activities other than
 R&amp;amp;D and overall management of the Company were included under
 management and administration costs for the year ended
 December&amp;#xA0;31, 2018.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company&amp;#x2019;s headcount at&amp;#xA0;December 31, 2017 was
 approximately 83&amp;#xA0;full-time equivalents and consisted of 70
 employees in the Netherlands and&amp;#xA0;13 employees in the U.S. A
 total of 21&amp;#xA0;employees who are devoted to activities other than
 R&amp;amp;D and overall management of the Company were included under
 management and administration costs for the year ended
 December&amp;#xA0;31, 2017.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
  <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_36D4E160-D415-485E-988B-69DEA64A2CF1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;General Information&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;Nature of Business&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Merus N.V. is a clinical-stage immuno-oncology company developing
 innovative bispecific antibody therapeutics, headquartered in
 Utrecht, the Netherlands. Merus US, Inc. is a wholly-owned
 subsidiary of Merus N.V. located at One Broadway, Cambridge,
 Massachusetts, United States (&amp;#x201C;U.S.&amp;#x201D;). These
 consolidated financial statements as at and for year ended
 December&amp;#xA0;31, 2018 comprise Merus N.V. and Merus US, Inc.
 (collectively, the &amp;#x201C;Company&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Merus N.V. was incorporated in the Netherlands, with its statutory
 seat in Utrecht. In connection with becoming a listed company on
 the Nasdaq Global Market (&amp;#x201C;Nasdaq&amp;#x201D;), on May&amp;#xA0;19,
 2016, Merus N.V.&amp;#x2019;s legal structure under Dutch law was
 changed from a private company with limited liability (in Dutch:
 &lt;i&gt;besloten vennootschap met beperkte aansprakelijkheid&lt;/i&gt;) to a
 public company with limited liability (in Dutch: naamloze
 vennootschap) and Merus N.V.&amp;#x2019;s name changed from &amp;#x201C;Merus
 B.V.&amp;#x201D; to &amp;#x201C;Merus N.V.&amp;#x201D; The address of the
 Company&amp;#x2019;s registered office is Yalelaan 62, 3584 CM Utrecht,
 The Netherlands.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Since inception, the Company has generated an accumulated loss of
 &amp;#x20AC;175.1&amp;#xA0;million as of December&amp;#xA0;31, 2018. The Company
 expects to continue to incur significant expenses and operating
 losses for the foreseeable future as its bispecific antibody
 candidates advance through discovery, preclinical development and
 clinical trials and as it seeks regulatory approval and pursues
 commercialization of any approved bispecific antibody
 candidate.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As a result, the Company may need additional financing to support
 its continuing operations. Until the Company can generate
 significant revenue from product sales, if ever, the Company
 expects to finance its operations through public equity offerings,
 debt financings, or other sources, which may include collaborations
 with third parties and business development opportunities. Adequate
 additional financing may not be available to the Company on
 acceptable terms, or at all. The Company&amp;#x2019;s inability to raise
 capital as and when needed would have a negative impact on its
 financial condition and ability to pursue its business strategy.
 The Company will need to generate significant revenues to achieve
 profitability and may never do so.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Based on the Company&amp;#x2019;s current operating plan, Merus expects
 that its existing cash and cash equivalents of
 &amp;#x20AC;143.7&amp;#xA0;million and investments of
 &amp;#x20AC;61.8&amp;#xA0;million as of December&amp;#xA0;31, 2018 will be
 sufficient to fund its operations into the second quarter of
 2021.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Reverse Share Split&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On May&amp;#xA0;6, 2016, the general meeting of the Company&amp;#x2019;s
 shareholders resolved to approve and effect a capital
 reorganization, based on a reverse share split. The effect of the
 reverse share split was a &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1-for-1.8&lt;/font&gt;&lt;/font&gt; reverse share split
 of the outstanding common and preferred shares held by the
 Company&amp;#x2019;s shareholders. This reverse share split became
 effective on May&amp;#xA0;6, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Initial Public Offering&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On May&amp;#xA0;24, 2016, the Company closed the initial public
 offering of 5,500,000 of its common shares and, on May&amp;#xA0;26,
 2016, of an additional 639,926 of its common shares, at a price to
 the public of $10.0 per share (the &amp;#x201C;IPO&amp;#x201D;). Net proceeds
 to the Company after deducting underwriting discounts and
 commissions and offering expenses were $53.3&amp;#xA0;million. On
 May&amp;#xA0;19, 2016, the Company&amp;#x2019;s common shares were listed on
 the Nasdaq and all of the Company&amp;#x2019;s preferred shares
 converted into common shares.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Follow-on&lt;/font&gt; Public
 Offering&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On June&amp;#xA0;1, 2017, the Company filed with the U.S. Securities
 and Exchange Commission a registration statement on Form
 &lt;font style="WHITE-SPACE: nowrap"&gt;F-3&lt;/font&gt; (Registration Number
 &lt;font style="WHITE-SPACE: nowrap"&gt;333-218432)&lt;/font&gt; (the
 &lt;font style="WHITE-SPACE: nowrap"&gt;&amp;#x201C;F-3&lt;/font&gt; Registration
 Statement&amp;#x201D;), under which it registered up to
 $250.0&amp;#xA0;million of its securities and 3,200,000 shares sold to
 Incyte Corporation (&amp;#x201C;Incyte&amp;#x201D;). The &lt;font style="WHITE-SPACE: nowrap"&gt;F-3&lt;/font&gt; Registration Statement became
 effective on June&amp;#xA0;16, 2017. On June&amp;#xA0;1, 2017, the Company
 also entered into a sales agreement with Cowen and Company, LLC
 (&amp;#x201C;Cowen&amp;#x201D;), under which the Company may issue and sell
 from time to time up to $50.0&amp;#xA0;million of its common shares
 registered under the &lt;font style="WHITE-SPACE: nowrap"&gt;F-3&lt;/font&gt;
 Registration Statement through Cowen as its sales agent. Sales of
 common shares, if any, will be made at market prices by any method
 that is deemed to be an &amp;#x201C;at the market&amp;#x201D; offering. The
 aggregate compensation payable to Cowen as sales agent equals 3.0%
 of the gross sales price of the shares sold through it pursuant to
 the sales agreement. No sales have been made by the Company under
 the sales agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Private Placement of Common Shares&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On February&amp;#xA0;13, 2018, the Company entered into a Securities
 Purchase Agreement (the &amp;#x201C;Purchase Agreement&amp;#x201D;) with the
 purchasers named therein (the &amp;#x201C;Investors&amp;#x201D;). Pursuant to
 the Purchase Agreement, the Company agreed to sell an aggregate of
 3,099,997 of its common shares, nominal value &amp;#x20AC;0.09 per
 share, to the Investors at a purchase price equal to $18.0 per
 share (the &amp;#x201C;Private Placement&amp;#x201D;). The Purchase Agreement
 contained customary representations and warranties from the Company
 and the Investors and customary closing conditions. On
 February&amp;#xA0;15, 2018, the Company completed the sale under the
 Private Placement and received aggregate gross proceeds of
 approximately $55.8&amp;#xA0;million, or &amp;#x20AC;44.8&amp;#xA0;million.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
  <ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_4C0D010E-D0DD-45C6-81FE-D82DAC83E712_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr style="page-break-inside:avoid"&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;" align="left"&gt;&lt;b&gt;Investments&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On January&amp;#xA0;1, 2018, the Company adopted IFRS 9 and classifies
 and accounts for its investments at amortized cost. The
 Company&amp;#x2019;s investments as of December&amp;#xA0;31, 2017 were
 classified and accounted for as &lt;font style="white-space:nowrap"&gt;&lt;font style="white-space:nowrap"&gt;held-to-maturity&lt;/font&gt;&lt;/font&gt; under IAS 39.
 The initial adoption of IFRS 9 had no impact on previously reported
 amounts (See Note 4).&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company&amp;#x2019;s investments include investments in commercial
 paper, debt securities issued by several public corporations and
 the U.S. Treasury. Current investments include investments with a
 maturity date of greater than three months at the date of
 settlement. Investments with a maturity of 12 months or more from
 the original investment date are classified &lt;font style="white-space:nowrap"&gt;as&amp;#xA0;non-current.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Investments as of December&amp;#xA0;31, 2018 and 2017 consisted of the
 following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;i&gt;(euros in
 thousands)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;22,208&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,527&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 U.S. Treasury securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6,733&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,177&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Corporate fixed income bonds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;14,185&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,886&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Agency bonds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,729&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,453&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Current investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;44,855&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,043&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Corporate fixed income bonds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;16,945&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,060&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;font style="white-space:nowrap"&gt;Non-current&lt;/font&gt; investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;16,945&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,060&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;61,800&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,103&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company first began its investment program during the fourth
 quarter of 2017. During the years ended December&amp;#xA0;31, 2018 and
 2017, the Company purchased investments totaling
 &amp;#x20AC;75.9&amp;#xA0;million and &amp;#x20AC;41.8&amp;#xA0;million,
 respectively, which are held and denominated in U.S. dollars.
 During the years ended December&amp;#xA0;31, 2018 and 2017, the Company
 received proceeds of &amp;#x20AC;58.9&amp;#xA0;million and &amp;#x20AC;0,
 respectively, relating to investment maturities. As a result of the
 fluctuation in foreign currency between the euro and U.S. dollar,
 the Company recorded foreign currency exchange net gains of
 &amp;#x20AC;3.2&amp;#xA0;million as a component of finance income for the
 year ended December&amp;#xA0;31, 2018. For the year ended
 December&amp;#xA0;31, 2017, the Company recorded foreign currency
 exchange net losses of &amp;#x20AC;0.8&amp;#xA0;million as a component of
 finance expense.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory>
  <ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_C68F55C4-9EE3-4E20-A1AA-A8CD9D5C155C_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Other Liabilities and Accruals&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 All amounts are short-term and payable within 1 year.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;&lt;i&gt;(euros&amp;#xA0;in&amp;#xA0;thousands)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Audit fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;167&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Personnel-related&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;560&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;446&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued bonus&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,523&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,545&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 R&amp;amp;D costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,409&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,272&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 IP legal fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;212&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;509&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Subsidy advance received&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;42&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;224&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other accruals&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,051&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;535&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,964&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,627&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Accrued R&amp;amp;D costs relate to third-party contract costs for
 preclinical studies and clinical trial activities and related
 contract manufacturing expenses. The decrease in R&amp;amp;D costs is
 due to the timing of invoices received.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Accrued bonuses relate to employee bonuses for the financial year
 2018, which were paid out in February 2019.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Subsidy advances received relate to active grants where the Company
 has received cash in excess of allowances, which is required to be
 repaid or recognized as grant revenue when the relevant
 reimbursable costs are incurred as services are performed.&lt;/p&gt;


 &lt;/div&gt;</ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory>
  <ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_B43D1BAF-2C01-4EC2-8E2A-FA50350324F6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Recently Issued or Adopted International Financial
 Reporting Standards&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;Newly Adopted International Financial Reporting
 Standards&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;IFRS 15, Revenue from Contracts with Customers&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In May 2014, the IASB issued IFRS 15, which supersedes existing
 revenue recognition guidance. Prior to the adoption of IFRS 15,
 revenue was recognized to the extent that it was probable that the
 economic benefits would flow to the Company and the revenue could
 be reliably measured. The standard requires an entity to recognize
 the amount of revenue to which it expects to be entitled for the
 transfer of promised goods or services to customers. To achieve
 that core principle, an entity must identify the contract(s) with a
 customer, identify the performance obligations in the contract,
 determine the transaction price, allocate the transaction price to
 the performance obligations in the contract, and recognize revenue
 when (or as) the entity satisfies the performance obligation. IFRS
 15 was effective for annual and interim reporting periods beginning
 on or after January&amp;#xA0;1, 2018 and should be applied
 retrospectively to each prior reporting period presented or
 retrospectively with the cumulative effect of initially applying
 this update recognized at the date of initial application.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company adopted the new standard effective January&amp;#xA0;1,
 2018, using the retrospective method, with the effect of initially
 applying this standard recognized at the beginning of the earliest
 period presented. The Company had two open contracts on the
 adoption date and has assessed these contracts under the new
 revenue standard. In addition, the Company elected to apply the
 practical expedient to not apply this guidance to contracts that
 were completed before the beginning of the earliest period
 presented, or January&amp;#xA0;1, 2016, and the practical expedients
 for contract modifications (assessing the contracts in combination
 with any modifications before January&amp;#xA0;1, 2016). Under the
 practical expedient, the Company excluded certain option and
 exclusivity agreements that expired in 2015 and 2014,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The adoption of IFRS 15 impacted the amortization of the
 Company&amp;#x2019;s upfront license payments under the collaboration
 and license agreement entered into with Incyte on December&amp;#xA0;20,
 2016 (the &amp;#x201C;Incyte collaboration and license agreement&amp;#x201D;)
 and under the research and license agreement entered into with ONO
 on April&amp;#xA0;8, 2014 (the &amp;#x201C;ONO research and license
 agreement&amp;#x201D;). The Company previously recognized revenue from
 upfront license payments on a straight-line basis over the
 contractual term or the period of continuing managerial
 involvement, which was previously estimated to be 21 years for the
 Incyte collaboration and license agreement and 4.5 years for the
 ONO research and license agreement. Upon adoption of IFRS 15, the
 Company assessed the goods and services promised under the Incyte
 collaboration and license agreement and identified only one
 performance obligation to which the transaction price was
 allocated&amp;#x2014;a license to the Company&amp;#x2019;s proprietary
 technology combined with the joint steering committee
 (&amp;#x201C;JSC&amp;#x201D;) services during the research term. The transfer
 of the license and the JSC participation represented one combined
 performance obligation since they were not deemed distinct. As a
 result, under IFRS 15, revenue from upfront license payments under
 the Incyte collaboration and license agreement will be recognized
 as the Company satisfies the combined performance obligation, or
 over the nine-year research term, which is a period during which
 the Company has a present enforceable obligation to provide JSC
 services.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As a result of the adoption of IFRS 15, prior year financial
 statements have been restated. The impact of adopting IFRS 15
 resulted in a decrease of approximately &amp;#x20AC;8.7&amp;#xA0;million to
 deferred revenue with an offset to accumulated deficit, effective
 January&amp;#xA0;1, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The following financial statement line items have been shown to
 reflect the adjustments recognized for each individual line item in
 the Company&amp;#x2019;s respective consolidated financial statements
 for the period noted:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Consolidated Statement of Profit or Loss and Comprehensive
 Loss&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="50%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;br /&gt;
 (As originally&lt;br /&gt;
 presented)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS&amp;#xA0;15&lt;br /&gt;
 Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,600&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,915&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Operating result&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,617&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(35,302&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total comprehensive loss for the period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(73,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(64,685&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Loss per share&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.43&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="48%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;br /&gt;
 (As originally&lt;br /&gt;
 presented)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS&amp;#xA0;15&lt;br /&gt;
 Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,719&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(209&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,510&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Operating result&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(27,672&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(209&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(27,881&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total comprehensive loss for the period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(47,220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(209&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(47,429&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Loss per share&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.57&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.01&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.58&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Consolidated Statement of Financial Position&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;br /&gt;
 (As originally&lt;br /&gt;
 presented)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS 15&lt;br /&gt;
 Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(167,480&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,705&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(158,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue, &lt;font style="WHITE-SPACE: nowrap"&gt;non-current&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;130,195&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,644&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;112,551&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,996&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,939&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,935&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="48%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;br /&gt;
 (As originally&lt;br /&gt;
 presented)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS 15&lt;br /&gt;
 Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(107,295&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;390&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(106,905&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue, &lt;font style="WHITE-SPACE: nowrap"&gt;non-current&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,206&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,272&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,610&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,882&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,492&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;i&gt;Consolidated Statement of Cash Flows&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="50%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;br /&gt;
 (As originally&lt;br /&gt;
 presented)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS 15&lt;br /&gt;
 Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Result after taxation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(73,089&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(64,774&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Changes in working capital:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,618&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14,933&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;br /&gt;
 (As originally&lt;br /&gt;
 presented)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS 15&lt;br /&gt;
 Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Result after taxation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(47,228&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(209&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(47,437&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Changes in working capital:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(223&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;209&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;IFRS 9 Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 IFRS 9, &lt;i&gt;Financial Instruments&lt;/i&gt; (&amp;#x201C;IFRS 9&amp;#x201D;)
 replaces the provisions of IAS 39 that relate to the recognition,
 classification and measurement of financial assets and financial
 liabilities; derecognition of financial instruments; impairment of
 financial assets and hedge accounting. IFRS 9 also significantly
 amends other standards dealing with financial instruments such as
 IFRS 7, &lt;i&gt;Financial Instruments: Disclosures&lt;/i&gt;. The Company
 assessed the classification and measurement of the financial
 instruments it held at the date of initial application of IFRS 9,
 or January&amp;#xA0;1, 2018, and has classified its financial
 instruments into the appropriate IFRS 9 categories. There were no
 changes to the carrying value of the Company&amp;#x2019;s financial
 instruments resulting from this reclassification and, accordingly,
 there was no impact to the Company&amp;#x2019;s opening accumulated
 deficit at January&amp;#xA0;1, 2018, as a result of the adoption of
 IFRS&amp;#xA0;9.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 IFRS 9 replaces the &amp;#x2018;incurred loss&amp;#x2019; model in IAS 39
 with an &amp;#x2018;expected credit loss&amp;#x2019; (&amp;#x201C;ECL&amp;#x201D;)
 model. The new impairment model applies to financial assets
 measured at amortized cost, contract assets and debt investments at
 fair value recorded through other comprehensive loss, but not to
 investments in equity instruments. Under IFRS&amp;#xA0;9, credit losses
 are recognized earlier than under IAS 39. Under IFRS 9, loss
 allowances are measured on either &lt;font style="WHITE-SPACE: nowrap"&gt;12-month&lt;/font&gt; ECLs, which result from
 possible default events within the 12 months after the reporting
 date, or lifetime ECLs, which result from all possible default
 events over the expected life of a financial&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 instrument.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company&amp;#x2019;s financial assets recorded at amortized cost
 consist of cash and cash equivalents, investments and trade and
 other receivables. These financial assets are considered to have a
 low credit risk and, as such, there was no impact to the
 Company&amp;#x2019;s opening accumulated deficit as a result of the
 change in impairment methodology.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Newly Issued International Financial Reporting Standards&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;IFRS 16 Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In January 2016, the IASB issued IFRS 16, &lt;i&gt;Leases&lt;/i&gt;.
 IFRS&amp;#xA0;16 established a &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;right-of-use&lt;/font&gt;&lt;/font&gt; model that
 requires all lessees to recognize a &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;right-of-use&lt;/font&gt;&lt;/font&gt; asset and a lease
 liability in their statement of financial position that arise from
 leases with a term that is greater than twelve months. The standard
 is effective for periods beginning on or after January&amp;#xA0;1,
 2019.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company adopted IFRS 16 on January&amp;#xA0;1, 2019, using a
 modified retrospective transition approach applied to leases
 existing as of, or entered into after, January&amp;#xA0;1, 2019. The
 Company elected the practical expedients available under the
 transition guidance including, but not limited to, the recognition
 exemption for short-term and &lt;font style="WHITE-SPACE: nowrap"&gt;low-value&lt;/font&gt; leases.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The Company has reviewed its existing lease contracts and the
 impact of the new leasing standard on its consolidated statement of
 profit or loss and comprehensive loss, financial position and
 related disclosures. Although the Company is in the process of
 evaluating the full impact of IFRS 16 on its consolidated financial
 statements, it expects to recognize a lease liability and related
 &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;right-of-use&lt;/font&gt;&lt;/font&gt; asset of
 approximately &amp;#x20AC;3.0&amp;#xA0;million in its consolidated statement
 of financial position for its real estate leases existing as of
 January&amp;#xA0;1, 2019. This amount does not include the Cambridge,
 Massachusetts office lease, which was executed in March 2019 (see
 Note&amp;#xA0;22). The Company is still evaluating the impact of its
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-real&lt;/font&gt; estate leases,
 but it is not expected to be material to the Company&amp;#x2019;s
 financial statements. The Company&amp;#x2019;s consolidated statement of
 profit or loss and comprehensive loss will reflect additional
 depreciation expense due to the &lt;font style="WHITE-SPACE: nowrap"&gt;right-of&lt;/font&gt; use assets, an increase in
 finance costs for effective interest expense on its lease
 liabilities and a decrease in rent expense. The Company also
 expects to expand its disclosures regarding the amounts, timing and
 uncertainties of cash flows related to its lease portfolio.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;IFRIC 23 Uncertainty over Income Tax Treatments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 IFRIC 23 &lt;i&gt;Uncertainty over Income Tax Treatments&lt;/i&gt;
 (&amp;#x201C;IFRIC 23&amp;#x201D;) clarifies how the recognition and
 measurement requirements of IAS 12, &lt;i&gt;Income taxes&lt;/i&gt;, are
 applied where there is uncertainty over income tax treatments. An
 uncertain tax treatment is any tax treatment applied by an entity
 where there is uncertainty over whether that treatment will be
 accepted by the tax authority.&amp;#xA0;Under IFRIC 23, the key test is
 whether it&amp;#x2019;s probable that the tax authority will accept the
 company&amp;#x2019;s chosen tax treatment allowing for the assumption
 that the tax authorities will have full knowledge of all relevant
 information in assessing a proposed tax treatment. IFRIC 23 applies
 for annual periods beginning on or after January&amp;#xA0;1, 2019, with
 early adoption permitted. The Company does not expect IFRIC 23 will
 have a material impact on the Company&amp;#x2019;s financial
 statements.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory>
  <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_C8423623-4195-4503-8FDB-6C681ADAA18F_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;17.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Loss per share&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company calculates basic net income (loss) per share
 attributable to equity holders of the Company and diluted net loss
 per share attributable to equity holders of the Company by dividing
 the net income (loss) attributable to equity holders of the Company
 by the weighted average number of common shares outstanding during
 the period. Diluted net income per share attributable to common
 stockholders is computed by dividing net income attributable to
 equity holders of the Company by the diluted number of shares
 outstanding during the period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Except where the result would be antidilutive to net income,
 diluted net income per share attributable to equity holders of the
 Company is computed assuming the exercise of share options and the
 vesting of RSUs (using the treasury stock method), as well as their
 related income tax effects.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Basic and diluted net loss per share attributable to equity holders
 of the Company was calculated as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="57%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;br /&gt;
 Restated*&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;br /&gt;
 Restated*&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(e&lt;/b&gt;&lt;b&gt;&lt;i&gt;uros
 in thousands, except per share data&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Numerator:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss attributable to equity holders of the Company&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(24,235&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(64,685&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(47,429&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Denominator:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average shares outstanding&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;22,286,720&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,196,440&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,236,649&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Loss per share&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(1.09&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.58&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;*&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;See Note 4 for details regarding the restatement as a
 result of a change in accounting policy&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 During the years ended December&amp;#xA0;31, 2018, 2017 and 2016, share
 options and unvested RSUs were excluded from the calculation of net
 loss per attributable to equity holders of the Company due to their
 antidilutive effect.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company did not declare dividends for any of the years
 presented in these financial statements.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
  <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_6858B6D9-6297-4B1C-BF19-3EA51A8C2ABA_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Taxation&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Deferred tax assets have not been recognized in respect of tax
 losses and deductible temporary differences, because the Company
 has no history of generating taxable profits and at the balance
 sheet date, there is no convincing evidence that sufficient taxable
 profit will be available against which the tax losses can be
 utilized. As of December&amp;#xA0;31, 2018, the tax losses carried
 forward amounted to &amp;#x20AC;75.9&amp;#xA0;million as compared to
 &amp;#x20AC;140.5&amp;#xA0;million at December&amp;#xA0;31, 2017 (as restated
 for the adoption of IFRS 15. See Note 4 for details). The
 deductible temporary difference, which completely relates to
 deferred revenue, amounted to &amp;#x20AC;114.6&amp;#xA0;million at
 December&amp;#xA0;31, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In November 2018, the Dutch tax authorities confirmed that the
 $120.0&amp;#xA0;million upfront license fee received from Incyte can be
 fully recognized in 2017 for Dutch corporate income tax purposes,
 which resulted in a significant reduction of the Company&amp;#x2019;s
 tax loss carry-forwards. The treatment of upfront license fees
 received is consistently applied by the Company for Dutch corporate
 income tax purposes. There will be no impact on the Company&amp;#x2019;s
 consolidated statements of financial position or consolidated
 statement of profit or loss and comprehensive loss as no deferred
 tax asset was recognized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In order to promote innovative technology development activities
 and investments in new technologies, a corporate income tax
 incentive has been introduced in Dutch tax law called the
 Innovations Box. Based on the Innovations Box ruling, the Company
 would owe on the first 75% of qualifying profits under the Dutch
 jurisdiction effectively 7% for Dutch income taxes. The remaining
 profit would be taxed at the headline Dutch statutory tax rate of
 25%. The headline Dutch statutory tax rate is 25% for fiscal years
 2018 and 2019. Legislation has been enacted amending the headline
 Dutch statutory tax rate to 22.55% for fiscal year 2020 and 20.5%
 for fiscal year 2021. Taxable profits will only qualify for the
 Innovations Box once the tax losses carried forward are completely
 utilized. The agreement with the tax authorities was originally
 signed for the tax years beginning in 2011 through 2015 and was
 subsequently extended up to and including year 2019. Since the
 Company is loss-making, no Dutch income tax is recognized in the
 consolidated statement of profit or loss and comprehensive
 loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Merus US, Inc., which is incorporated in the U.S. in the State of
 Delaware, is subject to statutory U.S. Federal corporate income
 taxes and state income taxes for Massachusetts at a blended rate of
 28% and 40% for the years ended December&amp;#xA0;31, 2018 and 2017,
 respectively. Current year income tax expense was attributable
 entirely to Merus US, Inc. which was established on
 February&amp;#xA0;17, 2016 and provided general management services and
 strategic advisory services to the Company. Corporate income tax
 expenses were &amp;#x20AC;0.4&amp;#xA0;million and &amp;#x20AC;0.2&amp;#xA0;million
 for the years ended December&amp;#xA0;31, 2018 and 2017,
 respectively.&lt;/p&gt;


 &lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
  <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_5EBEB77D-4A57-4706-80E1-12FE0ECEEB4E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The inputs used in the measurement of the fair values and the
 related fair values at the grant dates for the options granted
 during the respective years were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="29%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="11" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;Key&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Management&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Personnel&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;All Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Employees&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;Key&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Management&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Personnel&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;All Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Employees&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;Key&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Management&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Personnel&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;All Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Employees&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;&amp;#x20AC;6.82&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;12.27&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;&amp;#x20AC;7.74&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;13.32&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;9.04&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;16.10&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;8.94&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;18.02&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;9.97&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;11.03&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;5.74&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;5.79&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Share price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;&amp;#x20AC;13.01&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;19.90&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;&amp;#x20AC;12.29&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;21.02&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;17.08&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;24.54&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;13.71&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;27.47&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;15.24&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;16.85&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;8.46&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;8.87&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;&amp;#x20AC;13.01&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;19.90&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;&amp;#x20AC;12.29&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;21.02&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;17.08&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;24.54&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;13.71&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;27.47&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;15.24&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;16.85&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;8.46&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;8.87&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility (weighted-average)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;94.71%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;92.16%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;95.05%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;94.88%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;95.30%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;97.15%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected life&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;10 years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;10 years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;10 years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;10&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;10 years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;8&amp;#xA0;&amp;#x2013;&amp;#xA0;10
 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividends&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;0%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;0%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;2.79%&amp;#xA0;&amp;#x2013;&amp;#xA0;3.20%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;2.83%&amp;#xA0;&amp;#x2013;&amp;#xA0;3.10%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 2.29%&amp;#xA0;&amp;#x2013;&amp;#xA0;2.51%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 2.24%&amp;#xA0;&amp;#x2013;&amp;#xA0;2.62%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 1.84%&amp;#xA0;&amp;#x2013;&amp;#xA0;1.86%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 0.10%&amp;#xA0;&amp;#x2013;&amp;#xA0;1.87%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
  <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_7E9F4561-9F62-496D-9FCF-6B4F81D9DB9C_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 These consolidated financial statements have been prepared in
 accordance with International Financial Reporting Standards
 (&amp;#x201C;IFRS&amp;#x201D;) as issued by the International Accounting
 Standards Board (&amp;#x201C;IASB&amp;#x201D;). Certain amounts were
 reclassified in the prior period financial statements to conform to
 the current period presentation. These changes in classification do
 not materially affect the previously reported consolidated
 financial statements for any period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The financial statements have been prepared under the historical
 cost convention unless otherwise stated in the below accounting
 policies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 These consolidated financial statements have been authorized for
 issuance on April 3, 2019.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Functional and Presentation Currency&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Items recorded in each of the Company&amp;#x2019;s entities are measured
 using the currency of the primary economic environment in which the
 entity operates (the &amp;#x201C;functional currency&amp;#x201D;). The
 consolidated financial statements are presented in euros, which is
 Merus N.V.&amp;#x2019;s functional currency. The functional currency of
 Merus US, Inc. is the U.S. dollar.&amp;#xA0;All amounts are rounded to
 the nearest thousand euros, except where otherwise indicated.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Segment Reporting&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company operates in one reportable segment, which comprises the
 discovery and development of innovative bispecific
 therapeutics.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Use of Estimates, Judgements and Assumptions&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In the application of the Company&amp;#x2019;s accounting policies,
 management is required to make judgments, estimates and assumptions
 that affect the reported amounts of assets, liabilities, income and
 expenses that are not readily apparent from other sources. The
 estimates and associated assumptions are based on historical
 experience and other factors that are considered to be relevant.
 Actual results may differ from these estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Estimates and underlying assumptions are reviewed on an ongoing
 basis. Revisions to accounting estimates are recognized
 prospectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The following are the critical judgments and assumptions that
 management has made in the process of applying the Company&amp;#x2019;s
 accounting policies and that have the most significant effect on
 the amounts recognized in the consolidated financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Equity Settled Share-Based Payments&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Share options granted to employees, consultants and directors are
 measured at the grant date fair value of the equity instruments
 granted. The grant date fair value is determined through the use of
 an option-pricing model considering the following variables:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(a)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;the exercise price of the option;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(b)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;the expected life of the option;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(c)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;the current value of the underlying shares;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(d)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;the expected volatility of the share price;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(e)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;the dividends expected on the shares; and&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(f)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;the risk-free interest rate for the life of the
 option.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Prior to the Company&amp;#x2019;s IPO, the estimated fair value of each
 share option granted was determined utilizing the Black-Scholes
 option pricing model. Subsequent to the IPO, the Company&amp;#x2019;s
 judgment was that the Hull&amp;#xA0;&amp;amp; White option pricing model is
 the most appropriate method for determining the fair value of its
 share options since it considers the terms and conditions attached
 to the grants made and is reflective of expected exercise
 behavior.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Since the Company was not listed on a national securities exchange
 until May&amp;#xA0;19, 2016, there was no published share price
 information available until May&amp;#xA0;19, 2016. Consequently, the
 Company estimated the fair value of its common shares and the
 expected volatility for the period up to May&amp;#xA0;19, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As the Company&amp;#x2019;s shares have not been publicly traded for a
 sufficient amount of time, the expected volatility is set by
 considering the historic share price volatility of a set of peer
 companies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 For&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;pre-IPO&lt;/font&gt;&amp;#xA0;valuations,
 the continuous yield on euro government bonds with a term to
 maturity comparable to the expected life of the share options, as
 published by the European Central Bank, was applied.
 For&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;post-IPO&lt;/font&gt;&amp;#xA0;valuations,
 the continuous yield on U.S. Treasury Bills with a term to maturity
 comparable to the expected life of the share options, as published
 by the U.S. Department of Treasury, is applied.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The result of the share option valuations and the related
 compensation expense that is recognized for the respective vesting
 periods during which services are received, is dependent on the
 model and input parameters used. Even though management considers
 the fair values reasonable and defensible based on the
 methodologies applied and the information available, others might
 derive a different fair value for the Company&amp;#x2019;s share
 options. These assumptions and estimates are further discussed in
 Note 12 to the consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Capitalization of Development Costs&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The criteria for capitalization of development costs have been
 considered by management and determined not to have been met
 through December&amp;#xA0;31, 2018. Therefore, all development
 expenditures relating to internally generated intangible assets in
 the year ended December&amp;#xA0;31, 2018 were expensed as
 incurred.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The criteria for the recognition of unused tax losses and
 deductible temporary differences are disclosed in Note 3. As of
 December&amp;#xA0;31, 2018, deferred tax assets have not been
 recognized in respect of tax losses and deductible temporary
 differences as the Company has no history of generating taxable
 profits. Therefore, at the balance sheet date, there is no
 convincing evidence that sufficient taxable profit will be
 available against which the tax losses and deductible temporary
 differences can be utilized. The amount of the unrecognized tax
 losses and deductible temporary differences is disclosed in Note
 7.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Merus US, Inc., which is incorporated in the U.S. in the State of
 Delaware, is subject to statutory U.S. Federal corporate income
 taxes and state income taxes for Massachusetts. Current year income
 tax expense was attributable entirely to Merus US, Inc. which
 provides general management services and strategic advisory
 services to the Company. Corporate income tax expenses were
 &amp;#x20AC;0.4&amp;#xA0;million, &amp;#x20AC;0.2&amp;#xA0;million and
 &amp;#x20AC;0.0&amp;#xA0;million for the years ended December&amp;#xA0;31, 2018,
 2017 and 2016, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Pursuant to the Company&amp;#x2019;s research, collaboration and license
 agreements with ONO Pharmaceutical Co., Ltd. (&amp;#x201C;ONO&amp;#x201D;),
 Incyte, Jiangsu Simcere Pharmaceutical Co. Ltd.
 (&amp;#x201C;Simcere&amp;#x201D;) and Betta Pharmaceuticals Co. Ltd.
 (&amp;#x201C;Betta&amp;#x201D;), the Company has received or will receive
 upfront&amp;#xA0;nonrefundable&amp;#xA0;payments and milestones for certain
 rights granted under the respective agreements. The applicable
 period over which to recognize these upfront or milestone payments
 requires significant judgment and was impacted by the adoption of
 IFRS 15. See Note 4 and Note 11.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Accrual of R&amp;amp;D expenses&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Research and Development (&amp;#x201C;R&amp;amp;D&amp;#x201D;) expenses are
 recognized in the consolidated statement of profit or loss and
 comprehensive loss as incurred and have no alternative future
 uses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As part of the process of preparing its consolidated financial
 statements, the Company is required to estimate certain of its
 R&amp;amp;D expenses, including estimates of third-party contract costs
 relating to preclinical studies and clinical trial activities and
 related contract manufacturing expenses. This process involves
 reviewing open contracts and purchase orders, communicating with
 R&amp;amp;D personnel to identify services that have been performed for
 the Company and estimating the level of service performed and the
 associated cost incurred for the service when the Company has not
 yet been invoiced or otherwise notified of the actual cost. See
 Note 14.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The majority of the Company&amp;#x2019;s service providers invoice
 monthly in arrears for services performed or when contractual
 milestones are met. The Company makes estimates of its R&amp;amp;D
 expenses as of each reporting date in its consolidated financial
 statements based on facts and circumstances known to it at that
 time. The Company periodically confirms the accuracy of its
 estimates with the service providers to gauge the reasonableness of
 its estimates. Differences between actual and estimated expenses
 recorded have not been material and are adjusted for in the period
 in which they become known.&lt;/p&gt;


 &lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
  <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_FC3C06D0-2249-4EAA-BB0C-9CD71EBEB749_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;22.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Subsequent events&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On February&amp;#xA0;15, 2019, the Company entered in a lease agreement
 for approximately 7,583 square feet of office space in Cambridge,
 Massachusetts. The lease has a term of seven years and expires on
 April&amp;#xA0;1, 2026. The lease provides for escalating rent each
 year, with total cash payments of approximately $4.9&amp;#xA0;million,
 or &amp;#x20AC;4.2&amp;#xA0;million, payable over the lease term.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
  <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_71E8FF7A-A493-4F66-B08E-8A69462846F4_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;18.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Financial Instruments&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 As discussed in Note 4, the Company&amp;#x2019;s initial adoption of
 IFRS 9 had no impact on previously reported amounts.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Financial Risk Management&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company is exposed to a variety of financial risks: credit
 risk, liquidity risk and market risk. The Company&amp;#x2019;s overall
 risk management program seeks to minimize potential adverse effects
 of these financial risk factors on the Company&amp;#x2019;s financial
 performance. Management is primarily responsible for the overall
 risk management approach and for the approval of risk strategies
 and principles of the Company. The Company&amp;#x2019;s Audit Committee
 oversees these risk management activities. The Company&amp;#x2019;s
 management reviews and approves policies for managing each of these
 risks which are summarized below.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Credit Risk&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Credit risk is the risk of financial loss to the Company if a
 customer or counterparty to a financial instrument fails to meet
 its contractual obligations and arises principally from the
 Company&amp;#x2019;s receivables from its collaborators and investments
 in debt securities and financial institutions. The Company&amp;#x2019;s
 principal financial assets are held to maturity investments, trade
 receivables, unbilled receivables and cash and cash equivalents
 that are derived primarily from financing activities and, to a
 lesser extent, from its operations. The main purpose of these
 financial assets is to support the Company&amp;#x2019;s operations which
 consist primarily of research and development, preclinical and
 clinical development and related manufacturing in support of the
 Company&amp;#x2019;s preclinical and clinical development programs for
 &lt;font style="WHITE-SPACE: nowrap"&gt;MCLA-128,&lt;/font&gt; &lt;font style="WHITE-SPACE: nowrap"&gt;MCLA-117,&lt;/font&gt; &lt;font style="WHITE-SPACE: nowrap"&gt;MCLA-158&lt;/font&gt; and &lt;font style="WHITE-SPACE: nowrap"&gt;MCLA-145.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The carrying amount of financial assets represents the maximum
 credit exposure.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade and unbilled receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,926&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;61,800&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;143,747&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;149,678&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;208,473&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;193,064&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Cash and cash equivalents include deposits and investments held
 with financial institutions with original maturities of less than
 three months. Investments include commercial paper, securities
 issued by several public corporations and the U.S. Treasury with a
 maturity date of greater than three months at the date of
 settlement. Cash and cash equivalents are held at banks and
 financial institutions with credit ratings varying between A and
 AA, while investments are in highly rated vehicles with identical
 credit ratings.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The aging of trade and unbilled receivables was as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros&amp;#xA0;in&amp;#xA0;thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Neither past due nor impaired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,926&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Past due&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,926&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 There is no allowance for impairment relating to trade and unbilled
 receivables, investments and cash and cash equivalents.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Liquidity Risk&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Liquidity risk is the risk that the Company will not be able to
 meet its financial obligations as they become due. The
 Company&amp;#x2019;s core objective is to maintain a balance between
 continuity of funding and flexibility through the monitoring of
 cash flows at varying levels to ensure that it has sufficient cash
 on demand to meet expected operational expenses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following are the remaining contractual maturities of financial
 liabilities as at December&amp;#xA0;31, 2018 and 2017. The amounts are
 gross and undiscounted.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="22" align="center"&gt;&lt;b&gt;December&amp;#xA0;31, 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;amount&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;&amp;lt; 12&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;months&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;1&amp;#xA0;-&amp;#xA0;2&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2&amp;#xA0;-&amp;#xA0;5&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;&amp;gt;&amp;#xA0;5&amp;#xA0;years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="22" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade payables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,819&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,819&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,819&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other liabilities and accruals&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,964&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,964&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,964&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,783&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,783&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,783&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="22" align="center"&gt;&lt;b&gt;December&amp;#xA0;31, 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;amount&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;&amp;lt; 12&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;months&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;1&amp;#xA0;-&amp;#xA0;2&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2&amp;#xA0;-&amp;#xA0;5&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;&amp;gt; 5&amp;#xA0;years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="22" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade payables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,855&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,855&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,855&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other liabilities and accruals&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,176&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,176&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,176&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,031&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,031&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,031&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Market Risk&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Market risk is the risk that changes in market prices&amp;#x2014;such as
 foreign exchange rates and interest rates&amp;#x2014;will affect the
 Company&amp;#x2019;s income or the value of its holdings of financial
 instruments. The objective of market risk management is to manage
 and control market risk exposures within acceptable parameters,
 while optimizing the return. The Company&amp;#x2019;s market risk
 relates to foreign exchange and to a lesser extent, interest
 risks.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Foreign currency risk&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Foreign exchange risk arises from future commercial transactions
 and recognized assets and liabilities in foreign currencies. With
 respect to monetary assets and liabilities denominated in foreign
 currencies, the Company&amp;#x2019;s primary currency exposure is
 impacted by monetary assets and liabilities denominated in U.S.
 dollars. Changes in sensitivity rates reflect various changes in
 the economy year-over-year.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table provides a sensitivity analysis for a change in
 the primary currency exposure for the Company relating to monetary
 assets and liabilities denominated in U.S. dollars as of
 December&amp;#xA0;31, 2018. The analysis shows the impact that a change
 in the exchange rate at that date would have on the Company&amp;#x2019;s
 total comprehensive loss:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="52%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 &lt;b&gt;Financial Statement Line Item Exposure&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Balance&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Effect&amp;#xA0;on&amp;#xA0;profit&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;before&amp;#xA0;tax&amp;#xA0;if&amp;#xA0;USD&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;strengthens 5%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Effect&amp;#xA0;on&amp;#xA0;profit&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;before&amp;#xA0;tax&amp;#xA0;if&amp;#xA0;USD&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;weakens 5%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;43,074&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,154&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,154&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61,800&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,090&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,090&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade and other receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,886&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;144&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(144&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Taxes and social security liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(88&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade payables, other liabilities and accruals&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,795&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(240&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;240&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;103,000&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;5,150&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(5,150&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The closing exchange rate per the European Central Bank utilized
 above for converting the U.S. dollar to euro at December&amp;#xA0;31,
 2018 was 0.8734.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Exposure to interest rate risk&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The interest rate profile of the Company&amp;#x2019;s interest-bearing
 financial instruments is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Fixed-rate instruments&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;61,800&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Variable rate instruments&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;143,747&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;149,678&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The weighted average remaining days to maturity for the
 Company&amp;#x2019;s investment portfolio is 135 days as of
 December&amp;#xA0;31, 2018. Due to the short remaining hold period for
 the Company&amp;#x2019;s investments and resulting limited impact of
 changes in interest rates on the Company, no sensitivity data is
 provided.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Accounting Classifications and Fair Values&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The classifications of the Company&amp;#x2019;s financial assets and
 financial liabilities, all of which are not measure at fair value,
 are disclosed in the tables above. The fair value of the financial
 assets and financial liabilities not measured at fair value is not
 disclosed, as the carrying amount of the financial assets and
 financial liabilities is a reasonable approximation of the fair
 value. Accordingly, information on the fair value hierarchy is
 omitted.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
  <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_00B66CE8-BD88-41A0-B32B-997F6A796763_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The number of share options and the weighted average exercise
 prices of share options granted were as follows for the respective
 years:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(&amp;#x20AC;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(&amp;#x20AC;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(&amp;#x20AC;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at January&amp;#xA0;1&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;13.99&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,213,985&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.69&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,394,844&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;953,689&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited during the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;14.48&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(38,874&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(58,164&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.07&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,351&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expired during the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;11.00&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(31,629&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(762&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,454&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised during the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6.80&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(135,888&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(136,666&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(18,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted during the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;14.96&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;625,445&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19.88&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,014,733&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.74&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;496,243&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;14.62&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,633,039&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13.99&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,213,985&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.69&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,394,844&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercisable at December&amp;#xA0;31&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,275,669&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;687,070&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;418,453&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
  <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_5D867849-7304-472C-9842-827F6D12E584_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Property, Plant and Equipment&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Movements in property, plant and equipment, net were as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Plant and&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;equipment&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Other&amp;#xA0;fixed&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as at January&amp;#xA0;1, 2017&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;649&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,386&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,035&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(221&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,166&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,387&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Book value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;428&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;648&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Changes in book value&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Additions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;663&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;113&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;776&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(186&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(256&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Disposals (Cost)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(51&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,086&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,137&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Disposals (Accumulated depreciation)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,086&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,137&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;477&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;43&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;520&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as at December&amp;#xA0;31, 2017&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;413&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,674&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(356&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(150&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(506&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Book value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;905&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;263&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,168&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Changes in book value&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Additions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,498&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;300&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,798&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(448&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(98&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(546&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Disposals (Cost)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Disposals (Accumulated depreciation)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,050&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;202&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,252&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as at December&amp;#xA0;31, 2018&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,759&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;713&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,472&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(804&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(248&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,052&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Book value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,955&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;465&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,420&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
  <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_1B48DC12-96ED-442A-BBD7-106ED1A93E98_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The intangible assets, net are related to acquired intellectual
 property rights were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(euros&amp;#xA0;in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as at January&amp;#xA0;1&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Historical cost&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;860&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;860&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(548&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Book value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;312&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;374&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Additions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,225&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amortization for the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(92&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(62&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Book value as at December&amp;#xA0;31&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,445&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;312&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as at December&amp;#xA0;31&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Historical cost&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,085&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;860&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(640&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(548&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Book value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,445&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;312&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
  <ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_1376E4CD-011A-4049-9412-C34801FA996C_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Future minimum lease payments under these leases as of
 December&amp;#xA0;31, 2018 are as follows:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Less than one year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,579&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Between one and five years&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,106&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 More than five years&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,685&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory>
  <ifrs-full:DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_0C6EDF6A-6C5F-40F7-B56A-177E06F3D958_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The aging of trade and unbilled receivables was as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros&amp;#xA0;in&amp;#xA0;thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Neither past due nor impaired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,926&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Past due&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,926&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory>
  <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_2248839E-E95D-4C7E-8C31-7699D51A3DCE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Intangible Assets&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The intangible assets, net are related to acquired intellectual
 property rights were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(euros&amp;#xA0;in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as at January&amp;#xA0;1&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Historical cost&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;860&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;860&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(548&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Book value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;312&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;374&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Additions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,225&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amortization for the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(92&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(62&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Book value as at December&amp;#xA0;31&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,445&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;312&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as at December&amp;#xA0;31&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Historical cost&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,085&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;860&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(640&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(548&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Book value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,445&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;312&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 During the year ended December&amp;#xA0;31, 2018, the Company acquired
 or licensed certain intellectual property and, under the terms of
 the related agreements, paid &amp;#x20AC;2.2&amp;#xA0;million in fees. The
 transactions were accounted for as an asset acquisition. As a
 result, the Company capitalized &amp;#x20AC;2.2&amp;#xA0;million as
 intangible assets in its consolidated statements of financial
 position. The Company amortizes the cost of the acquired or
 licensed intellectual property over its estimated economic life
 based on the remaining legal life of the related patents from the
 date of acquisition or license.&lt;/p&gt;


 &lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
  <ifrs-full:DisclosureOfRevenueExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_5D8B0335-A94B-4808-9510-2A7B281A15AB_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;13.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Revenue&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Revenue is recognized at the amount to which the Company expects to
 be entitled for the transfer of promised goods or services to
 customers.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Disaggregation of Revenue&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company&amp;#x2019;s revenues are generated entirely in the
 Netherlands. In the following table, revenue is disaggregated by
 primary source of revenue as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;br /&gt;
 Restated*&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;br /&gt;
 Restated*&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;&lt;i&gt;(euros in
 thousands)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Upfront payment amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;17,686&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,933&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 R&amp;amp;D cost reimbursement and milestone&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;13,566&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,787&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,109&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Revenue from contracts with customers&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;31,252&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,720&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,123&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Income from grants on research projects&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;196&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,195&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,387&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;31,448&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,915&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,510&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;*&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;i&gt;See Note 4 for details regarding the restatement as
 a result of a change in accounting policy.&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 For the year ended December&amp;#xA0;31, 2018, the Company recognized
 amortization of &amp;#x20AC;15.9&amp;#xA0;million on upfront payments
 related to the Incyte collaboration and license agreement,
 amortization of &amp;#x20AC;1.2&amp;#xA0;million on upfront payments related
 to the second ONO research and license agreement,
 &amp;#x20AC;0.5&amp;#xA0;million on upfront payments related to the Simcere
 collaboration and license agreement and less than
 &amp;#x20AC;0.1&amp;#xA0;million on the upfront payment related to the Betta
 collaboration and license agreement. For the year ended
 December&amp;#xA0;31, 2017, the Company recognized
 &amp;#x20AC;14.9&amp;#xA0;million of amortization of the upfront payment
 related to the Incyte collaboration and license agreement. For the
 year ended December&amp;#xA0;31, 2016, the Company recognized
 approximately &amp;#x20AC;14,000 of amortization of the &lt;font style="WHITE-SPACE: nowrap"&gt;up-front&lt;/font&gt; payment related to the ONO
 research and license agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 R&amp;amp;D cost reimbursement and milestone revenue for the year ended
 December&amp;#xA0;31, 2018, was &amp;#x20AC;13.6&amp;#xA0;million and consisted
 of cost reimbursements, milestone payment amortization and research
 milestones achieved in support of the Company&amp;#x2019;s research and
 license agreements with Incyte, ONO and Simcere. During the year
 ended December, 2018, the Company recognized
 &amp;#x20AC;8.8&amp;#xA0;million of cost reimbursements in support of the
 Company&amp;#x2019;s research and license agreements with Incyte and
 &amp;#x20AC;0.4&amp;#xA0;million of cost reimbursements in support of the
 Company&amp;#x2019;s research and license agreements with ONO. The
 Company recognized an aggregate of &amp;#x20AC;4.0&amp;#xA0;million in
 research milestones under its ONO agreements and
 &amp;#x20AC;0.4&amp;#xA0;million in research milestone payment amortization
 under its Simcere agreements for the year ended December&amp;#xA0;31,
 2018. The Company did not recognize any revenue relating to
 research milestones under its Betta collaboration and license
 agreement for the year ended December&amp;#xA0;31, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 R&amp;amp;D cost reimbursement and milestone revenue for the year ended
 December&amp;#xA0;31, 2017 was &amp;#x20AC;5.8&amp;#xA0;million and consisted of
 cost reimbursements in support of the Company&amp;#x2019;s agreements
 with Incyte and ONO. The Company did not recognize any research
 milestones during 2017. During 2016, the Company recognized one
 research milestone reached under the ONO agreement, which amounted
 to &amp;#x20AC;0.7&amp;#xA0;million. Additionally, the Company recorded
 revenue of &amp;#x20AC;0.4&amp;#xA0;million from an agreement that was
 signed with ONO on March&amp;#xA0;7, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company has been awarded grants consisting of cash allowances
 for specific R&amp;amp;D projects. The unconditional receipt of the
 grant allowances is dependent on the final review of the reporting
 provided by the Company at the end of the contract term. For the
 years ended December&amp;#xA0;31, 2018, 2017, and 2016, the Company
 recognized &amp;#x20AC;0.2&amp;#xA0;million, &amp;#x20AC;1.2&amp;#xA0;million, and
 &amp;#x20AC;1.4&amp;#xA0;million in grant income, respectively. As of August
 2018, all grants awarded were completed. On June&amp;#xA0;12, 2017, the
 European Commission approved for reimbursement the final
 installment of the &lt;font style="WHITE-SPACE: nowrap"&gt;FP-7&lt;/font&gt;
 grant and the Company subsequently recognized the remaining
 &amp;#x20AC;0.7&amp;#xA0;million to grant revenue. On October&amp;#xA0;16, 2017,
 the Company received notification from the European Commission
 requesting the Company to revise its final report and indicated
 that the remaining &amp;#x20AC;0.4&amp;#xA0;million of funds were to remain
 with the Company and distributed to the other beneficiaries to the
 program. In November 2017, the Company remitted
 &amp;#x20AC;0.2&amp;#xA0;million to the other beneficiaries and recognized
 an additional &amp;#x20AC;0.2&amp;#xA0;million of grant revenue.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Contract Balances&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 A trade receivable is recorded when the Company satisfies a
 performance obligation by transferring a promised good or service
 and has earned the unconditional right to consideration from its
 customer. Trade receivables relate to invoicing for cost
 reimbursements, upfront payments and research milestones achieved
 in support of the Company&amp;#x2019;s research and license agreements
 with Incyte, ONO, Simcere and Betta. Payment terms relating to
 receivables with Incyte, ONO and Simcere are 30 days and payment
 terms relating to receivables with Betta are 60 days.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 A contract asset is recorded when the Company satisfies a
 performance obligation by transferring a promised good or service
 and has earned the right to consideration from its customer. These
 assets represent a conditional right to consideration. Contract
 assets relate to unbilled amounts for cost reimbursements and
 research milestones achieved in support of the Company&amp;#x2019;s
 research and license agreements with Incyte and ONO.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 A contract liability is recorded when consideration is received, or
 such consideration is unconditionally due, from a customer prior to
 transferring goods or services under the terms of the contract.
 Contract liabilities are recognized as revenue as control of the
 products or services is transferred to the customer and all revenue
 recognition criteria have been met. Contract liabilities relate to
 upfront payments received related to the Incyte collaboration and
 license agreement, ONO research and license agreement and the
 Simcere research and license agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table presents changes in the Company&amp;#x2019;s trade
 receivables, contract assets and contract liabilities during the
 year ended December&amp;#xA0;31, 2018:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="50%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Additions&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Deductions&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade&amp;#xA0;receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,594&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,951&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(18,855&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,690&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total trade&amp;#xA0;receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,594&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,951&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(18,855&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,690&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contract assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unbilled receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,045&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;236&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total contract assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,045&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;236&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contract liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,137&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(18,014&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;114,609&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total contract liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,137&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(18,014&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;114,609&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table presents changes in the Company&amp;#x2019;s trade
 receivables, contract assets and contract liabilities during the
 year ended December&amp;#xA0;31, 2017:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2016&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Additions&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Deductions&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade&amp;#xA0;receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122,781&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(121,392&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,594&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total trade&amp;#xA0;receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122,781&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(121,392&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,594&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contract assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unbilled receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121,240&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(120,530&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total contract assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121,240&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(120,530&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contract liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,426&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;111,993&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14,933&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total contract liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,426&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;111,993&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14,933&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As a result of the adoption of IFRS 15, total deferred revenue was
 reduced by &amp;#x20AC;8.7&amp;#xA0;million as of December&amp;#xA0;31, 2017.
 See Note 4 for details.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 For the year ended December&amp;#xA0;31, 2018, deductions from deferred
 revenue are comprised of revenue recognized that was included in
 deferred revenue at the beginning of the period totaling
 &amp;#x20AC;15.9&amp;#xA0;million and revenue recognized that was not
 included in deferred revenue at the beginning of the period
 totaling &amp;#x20AC;2.1&amp;#xA0;million. For the year ended
 December&amp;#xA0;31, 2017, deductions from deferred revenue are
 comprised of revenue recognized that was included in deferred
 revenue at the beginning of the period totaling
 &amp;#x20AC;3.2&amp;#xA0;million and revenue recognized that was not
 included in deferred revenue at the beginning of the period
 totaling &amp;#x20AC;11.7&amp;#xA0;million.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfRevenueExplanatory>
  <dei:DocumentPeriodEndDate contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_0ACBD4B0-59C1-4C36-A416-82A2904A2337_1_2">2018-12-31</dei:DocumentPeriodEndDate>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_1469EA42-F951-4C73-B189-5B232EFF4ADE_1_5">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_1469EA42-F951-4C73-B189-5B232EFF4ADE_1_9">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_1469EA42-F951-4C73-B189-5B232EFF4ADE_1_10">false</dei:EntityExTransitionPeriod>
  <dei:EntityFilerCategory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_1469EA42-F951-4C73-B189-5B232EFF4ADE_1_7">Accelerated Filer</dei:EntityFilerCategory>
  <ifrs-full:FinanceCosts contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_1_7">4000</ifrs-full:FinanceCosts>
  <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_8AA7F4F0-9E37-4554-9FA9-1D1EF1FFE65C_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Shareholders&amp;#x2019; Equity&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;Reverse Share Split&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On May&amp;#xA0;6, 2016, the general meeting of the Company&amp;#x2019;s
 shareholders resolved to approve and effect a capital
 reorganization, based on a reverse share split. The effect of the
 reverse share split was a &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1-for-1.8&lt;/font&gt;&lt;/font&gt; reverse share split
 of the outstanding common and preferred shares held by the
 Company&amp;#x2019;s shareholders. This reverse share split became
 effective on May&amp;#xA0;6, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Initial Public Offering&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On May&amp;#xA0;24, 2016, the Company closed the initial public
 offering of 5,500,000 of its common shares and, on May&amp;#xA0;26,
 2016, of an additional 639,926 of its common shares, at a price to
 the public of $10.0 per share. Net proceeds to the Company after
 deducting underwriting discounts and commissions and offering
 expenses were $53.3&amp;#xA0;million. On May&amp;#xA0;19, 2016, the
 Company&amp;#x2019;s common shares were listed on the Nasdaq and all of
 the Company&amp;#x2019;s preferred shares converted into common
 shares.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Share Subscription Agreement with Incyte&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Concurrent with the Incyte collaboration and license agreement
 discussed above under Note 11, the Company entered into the Incyte
 share subscription agreement on December&amp;#xA0;20, 2016. On
 January&amp;#xA0;23, 2017, under the terms of the Incyte share
 subscription agreement, the Company issued 3,200,000 of its common
 shares to Incyte at the agreed price per share of $25.0, for an
 aggregate purchase price of $80.0&amp;#xA0;million, or
 &amp;#x20AC;74.7&amp;#xA0;million. The Company received proceeds of
 &amp;#x20AC;74.4&amp;#xA0;million, net of issuance costs of
 &amp;#x20AC;0.2&amp;#xA0;million. A &amp;#x20AC;1.1&amp;#xA0;million discount on the
 subscription share price, combined with a &amp;#x20AC;0.4&amp;#xA0;million
 foreign currency translation accompanying the issuance of these
 shares, increased share capital by &amp;#x20AC;0.3&amp;#xA0;million and
 share premium by &amp;#x20AC;73.4&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Private Placement of Common Shares&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On February&amp;#xA0;13, 2018, the Company entered into the Purchase
 Agreement. Pursuant to the Purchase Agreement, the Company agreed
 to sell an aggregate of 3,099,997 of its common shares to the
 Investors at a purchase price equal to $18.0 per share. The
 Purchase Agreement contains customary representations and
 warranties from the Company and the Investors and customary closing
 conditions. On February&amp;#xA0;15, 2018, the Company completed the
 sale under the Private Placement and received gross proceeds of
 approximately $55.8&amp;#xA0;million, or &amp;#x20AC;44.8&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Share Subscription Agreement with Regeneron&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On December&amp;#xA0;20, 2018, the Company entered into a share
 subscription agreement with Regeneron (the &amp;#x201C;Regeneron
 Subscription Agreement&amp;#x201D;). See Note 21 for details. Pursuant
 to the Regeneron Subscription Agreement, the Company agreed to sell
 an aggregate of 600,000 of its common shares to Regeneron at a
 purchase price equal to $25.0 per share. The Regeneron Subscription
 Agreement contains customary representations and warranties from
 the Company and Regeneron and customary closing conditions. On
 December&amp;#xA0;21, 2018, the Company completed the sale under the
 Regeneron Subscription Agreement and received gross proceeds of
 $15.0&amp;#xA0;million, or &amp;#x20AC;13.1&amp;#xA0;million. Accordingly, the
 Company recorded the common shares issued at the fair value of the
 underlying securities on the date of issuance. The difference
 between the total proceeds received of $15.0&amp;#xA0;million, or
 &amp;#x20AC;13.1&amp;#xA0;million, and the aggregate value of common shares
 issued of $6.9&amp;#xA0;million, or &amp;#x20AC;6.0&amp;#xA0;million, was
 recorded as a gain on litigation settlement of $8.1&amp;#xA0;million,
 or &amp;#x20AC;7.1&amp;#xA0;million, during the year-ended December&amp;#xA0;31,
 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Issued and &lt;font style="WHITE-SPACE: nowrap"&gt;Paid-in&lt;/font&gt;
 Share Capital&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 All issued shares have been fully paid in cash.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Common Shares&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 At December&amp;#xA0;31, 2018, 2017 and 2016, a total of 23,358,977,
 19,429,848, and 16,085,851 common shares, respectively, were issued
 and fully paid in cash. The following is a tabular reconciliation
 of common shares outstanding for the years ended December&amp;#xA0;31,
 2018 and 2017, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Common Shares outstanding at January&amp;#xA0;1,&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;19,429,848&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,085,851&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Issued for cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,699,997&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,200,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise of common share options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;135,888&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;136,666&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vesting of RSUs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;93,244&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,331&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Common shares outstanding at December&amp;#xA0;31,&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;23,358,977&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,429,848&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Share Premium Reserve&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The share premium reserve relates to amounts contributed by
 shareholders at the issue of shares in excess of the par value of
 the shares issued.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 All share premium can be considered as free share premium as
 referred to in the Netherlands Income tax act.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Share-Based Payment Arrangements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In 2010, the Company established the Merus B.V. 2010 Employee
 Option Plan (the &amp;#x201C;2010 Plan&amp;#x201D;) that entitled key
 management personnel, staff and consultants providing similar
 services to purchase shares in the Company. Under the 2010 Plan,
 holders of vested options were entitled to purchase depositary
 receipts for common shares at the exercise price determined at the
 date of grant. Upon exercise of the option, common shares were
 issued to a foundation established to facilitate administration of
 share-based compensation awards and pool the voting interests of
 the underlying shares, and depositary receipts were issued by the
 foundation to the individual holders. In connection with the IPO,
 the 2010 Plan was amended to cancel the depositary receipts and
 allow individual holders to directly hold the common shares
 obtained upon exercise of their options.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Options granted under the 2010 Plan are exercisable once vested.
 The options granted under the 2010 Plan vest in installments over a
 four-year period from the grant date. Twenty-five percent of the
 options vest on the first anniversary of the vesting commencement
 date, and the remaining seventy-five percent of the options vest in
 36 monthly installments for each full month of continuous service
 provided by the option holder thereafter, such that 100% of the
 options become vested on the fourth anniversary of the vesting
 commencement date. Options lapse on the eighth anniversary of the
 date of grant.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Prior to the IPO, participants that voluntarily left the Company,
 except for members of the former Supervisory Board, were required
 to offer to the foundation the depositary receipts acquired from
 exercising options against payment of the exercise price or the
 lower fair market value of the underlying shares. This obligation
 for a participant to offer depositary receipts to the foundation
 upon resignation within four years from exercising the options was
 treated as a &lt;font style="WHITE-SPACE: nowrap"&gt;non-market&lt;/font&gt;
 vesting condition. In connection with the IPO, the foundation was
 dissolved and the common shares underlying depositary receipts
 distributed. In addition, the 2010 Option Plan was amended such
 that a participant is no longer required to offer depositary
 receipts to the foundation upon resignation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The reduction of the vesting period has been accounted for, taking
 into consideration the modified vesting conditions, to reflect the
 best estimate available of the options that are expected to vest.
 At the modification date in 2016, the cumulative expense for the
 options has been &lt;font style="WHITE-SPACE: nowrap"&gt;trued-up&lt;/font&gt;
 to reflect the reduced vesting period. This amendment of a
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-market&lt;/font&gt; vesting
 (service) condition did not impact the fair value of the options
 granted.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In connection with the IPO, the Company established the 2016
 Incentive Award Plan (the &amp;#x201C;2016 Plan&amp;#x201D;). Following the
 IPO, the Company is no longer making grants under the 2010 Plan;
 however, the terms of the 2010 Plan will continue to govern grants
 made under the 2010 Plan. All new incentive award grants since the
 IPO are being made under the 2016 Plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Options granted under the 2016 Plan are exercisable once vested.
 The options granted under the 2016 Plan vest in installments over a
 four-year period from the grant date. Twenty-five percent of the
 options vest on the first anniversary of the vesting commencement
 date, and the remaining seventy-five percent of the options vest in
 36 monthly installments for each full month of continuous service
 provided by the option holder thereafter, such that 100% of the
 options shall become vested on the fourth anniversary of the
 vesting commencement date. Options will lapse on the tenth
 anniversary of the date of grant.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The RSUs granted under the 2016 Plan also vest in installments over
 a four-year period from the grant date. Each RSU represents the
 right to receive one common share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company also established the Supervisory Board Compensation
 Program, which was subsequently replaced by the &lt;font style="WHITE-SPACE: nowrap"&gt;Non-Executive&lt;/font&gt; Director Compensation
 Program to reflect the change in governance structure of the
 Company (see Note 1). As part of this program, &lt;font style="WHITE-SPACE: nowrap"&gt;non-executive&lt;/font&gt; directors are entitled
 to cash compensation as well as equity compensation. The equity
 compensation consists of an initial option grant as well as annual
 awards.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The initial awards granted under the &lt;font style="WHITE-SPACE: nowrap"&gt;Non-Executive&lt;/font&gt; Compensation Program
 vest in installments over a three-year period. Thirty-three percent
 of the options vest on the first anniversary of the vesting
 commencement date, and the remaining sixty seven percent of the
 options in 24 substantially equal monthly installments thereafter,
 such that the award shall be fully vested on the third anniversary
 of the vesting commencement date. Each subsequent award shall vest
 and become exercisable in 12 substantially equal monthly
 installments following the vesting commencement date, such that the
 subsequent award shall be fully vested on the first anniversary of
 the date of grant.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Share-based payment expenses are recognized as from the IPO date
 for each subsequent award that a &lt;font style="WHITE-SPACE: nowrap"&gt;non-executive&lt;/font&gt; director is entitled to
 over their remaining term. Since subsequent awards are not subject
 to shareholder approval, the grant date is established and expenses
 are based on grant date fair value. The grant date fair value is
 not updated in each future reporting period and therefore the
 estimated fair value is not revised and expense recognized is based
 on the actual grant date fair value of the awards granted.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Pursuant to the &amp;#x201C;evergreen&amp;#x201D; provisions of the 2016
 Plan, the number of common shares authorized for issuance under the
 plan automatically increased by 934,359 common shares to 1,469,785
 common shares effective January&amp;#xA0;1, 2019.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Measurement of Fair Value of the Equity-Settled Share-Based
 Payment Arrangements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The fair value of the share options granted to the employee and the
 Board of Directors has been measured using a binomial option
 pricing model. Service and &lt;font style="WHITE-SPACE: nowrap"&gt;non-market&lt;/font&gt; performance conditions
 attached to the transactions were not taken into account in
 measuring fair value. Key management personnel include the
 Company&amp;#x2019;s executive management and the Board of
 Directors.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The inputs used in the measurement of the fair values and the
 related fair values at the grant dates for the options granted
 during the respective years were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="29%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="11" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;Key&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Management&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Personnel&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;All Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Employees&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;Key&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Management&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Personnel&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;All Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Employees&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;Key&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Management&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Personnel&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;All Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Employees&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;&amp;#x20AC;6.82&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;12.27&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;&amp;#x20AC;7.74&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;13.32&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;9.04&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;16.10&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;8.94&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;18.02&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;9.97&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;11.03&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;5.74&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;5.79&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Share price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;&amp;#x20AC;13.01&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;19.90&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;&amp;#x20AC;12.29&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;21.02&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;17.08&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;24.54&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;13.71&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;27.47&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;15.24&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;16.85&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;8.46&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;8.87&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;&amp;#x20AC;13.01&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;19.90&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;&amp;#x20AC;12.29&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;21.02&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;17.08&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;24.54&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;13.71&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;27.47&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;15.24&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;16.85&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &amp;#x20AC;8.46&amp;#xA0;&amp;#x2013;&amp;#xA0;&amp;#x20AC;8.87&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility (weighted-average)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;94.71%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;92.16%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;95.05%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;94.88%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;95.30%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;97.15%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected life&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;10 years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;10 years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;10 years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;10&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;10 years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;8&amp;#xA0;&amp;#x2013;&amp;#xA0;10
 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividends&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;0%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;0%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;2.79%&amp;#xA0;&amp;#x2013;&amp;#xA0;3.20%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;2.83%&amp;#xA0;&amp;#x2013;&amp;#xA0;3.10%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 2.29%&amp;#xA0;&amp;#x2013;&amp;#xA0;2.51%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 2.24%&amp;#xA0;&amp;#x2013;&amp;#xA0;2.62%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 1.84%&amp;#xA0;&amp;#x2013;&amp;#xA0;1.86%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 0.10%&amp;#xA0;&amp;#x2013;&amp;#xA0;1.87%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Reconciliation of outstanding share options&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The number of share options and the weighted average exercise
 prices of share options granted were as follows for the respective
 years:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(&amp;#x20AC;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(&amp;#x20AC;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(&amp;#x20AC;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at January&amp;#xA0;1&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;13.99&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,213,985&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.69&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,394,844&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;953,689&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited during the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;14.48&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(38,874&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(58,164&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.07&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,351&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expired during the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;11.00&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(31,629&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(762&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,454&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised during the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6.80&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(135,888&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(136,666&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(18,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted during the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;14.96&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;625,445&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19.88&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,014,733&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.74&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;496,243&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;14.62&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,633,039&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13.99&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,213,985&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.69&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,394,844&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercisable at December&amp;#xA0;31&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,275,669&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;687,070&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;418,453&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The options outstanding at December&amp;#xA0;31, 2018 had an exercise
 price in the range of &amp;#x20AC;1.93 to &amp;#x20AC;27.47 (2017:
 &amp;#x20AC;1.93 to &amp;#x20AC;27.47; 2016: &amp;#x20AC;1.93 to &amp;#x20AC;16.85) and
 a weighted-average remaining contractual life of 7.0 years (2017:
 8.25 years; 2016: 6.68 years).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The weighted-average share price at the date of exercise for share
 options exercised in 2018 was &amp;#x20AC;17.03.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The number of share options outstanding, by group of employees, was
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 &lt;b&gt;Group of employees entitled&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Key management personnel&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,148,744&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,777,437&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,302,417&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 All other employees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;484,295&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;436,548&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92,427&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,633,039&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,213,985&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,394,844&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 During 2017, the Company granted RSUs to Key Management Personnel.
 The following table summarizes the Company&amp;#x2019;s RSU&amp;#x2019;s
 activity:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;grant&amp;#xA0;date&lt;br /&gt;
 fair value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;br /&gt;
 average&lt;br /&gt;
 grant&amp;#xA0;date&lt;br /&gt;
 fair value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested at January&amp;#xA0;1&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;194,546&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#x20AC;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited during the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#x20AC;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(12,219&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expired during the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vested during the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#x20AC;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(93,244&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#x20AC;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(7,331&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted during the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#x20AC;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;214,096&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested at December&amp;#xA0;31&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#x20AC;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;101,302&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#x20AC;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;194,546&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
  <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_B720143B-4994-4616-8865-DB1D2DCD545A_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The accounting policies set out below have been consistently
 applied to all periods presented in the consolidated financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Income and expenses are accounted for on an accrual basis. Profit
 is only included when realized at the statement of financial
 position date. Losses originating before the end of the financial
 year are taken into account if they have become known before
 preparation of the financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Basis of consolidation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;(i) Subsidiaries&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Subsidiaries are entities controlled by the Company, consisting of
 Merus N.V.&amp;#x2019;s wholly owned subsidiary Merus US, Inc. The
 Company controls an entity when it is exposed to, or has rights to,
 variable returns from its involvement with the entity and has the
 ability to affect those returns through its power over the entity.
 The financial statements of subsidiaries are included in the
 consolidated financial statements from the date on which control
 commences until the date on which control ceases.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;(ii) Loss of control&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 When the Company loses control over a subsidiary, it derecognizes
 the assets and liabilities of the subsidiary, and any &lt;font style="WHITE-SPACE: nowrap"&gt;non-controlling&lt;/font&gt; interests and other
 components of equity. Any resulting gain or loss is recognized in
 profit or loss. Any interest retained in the former subsidiary is
 measured at fair value when control is lost.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;(iii) Transactions eliminated on consolidation&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Intercompany balances and transactions, and any unrealized income
 and expenses arising from intercompany transactions, are eliminated
 in consolidation. Unrealized gains arising from transactions with
 equity-accounted investees are eliminated against the investment to
 the extent of the Company&amp;#x2019;s interest in the investee.
 Unrealized losses are eliminated in the same way as unrealized
 gains, but only to the extent that there is no evidence of
 impairment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Foreign Currency Transactions&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Foreign currency transactions are translated using the exchange
 rates at the dates of the transactions. Foreign exchange gains and
 losses resulting from the settlement of such transactions and from
 the translation of monetary assets and liabilities denominated in
 foreign currencies at the exchange rate at the reporting date are
 generally recognized in the statement of profit or loss and
 comprehensive loss as a component of finance costs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The results and financial position of foreign operations that have
 a functional currency different from the presentation currency are
 translated into the presentation currency as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;assets and liabilities for each balance sheet
 presented are translated at the closing rate at the date of that
 balance sheet;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;income and expenses for each statement of profit or
 loss and comprehensive income or loss are translated at average
 exchange rates (unless this is not a reasonable approximation of
 the cumulative effect of the rates prevailing on the transaction
 dates, in which case income and expenses are translated at the
 exchange rates at the dates of the transactions); and&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;all resulting exchange differences are recognized in
 other comprehensive income.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Property, Plant and Equipment&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Property, plant and equipment are measured at cost less accumulated
 depreciation and accumulated impairment losses (if any). Cost
 includes expenditures that are directly attributable to the
 acquisition of the items. Depreciation of property, plant and
 equipment is recognized in the consolidated statement of profit and
 loss and comprehensive loss on a straight-line basis over estimated
 useful lives of generally five years, taking residual value into
 account. If significant parts of an item of property, plant and
 equipment have different useful lives, they are accounted for as
 separate items (major components) of property, plant and
 equipment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Subsequent expenditures are capitalized only when the expenditure
 will increase the future economic benefit of the asset. All other
 expenditures are expensed in the consolidated statement of profit
 or loss and comprehensive loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Depreciation rates are based on the following estimated economic
 useful lives of the tangible fixed assets concerned:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Plant and
 equipment&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;5
 years&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Leasehold improvements
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Shorter of useful
 life or term of lease&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Other fixed
 assets:&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;5
 years&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Intangible Assets&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Intangible assets are identifiable &lt;font style="WHITE-SPACE: nowrap"&gt;non-monetary&lt;/font&gt; assets without physical
 substance. An asset is a resource that is controlled by the
 enterprise as a result of past events (for example, purchase or
 self-creation) and from which future economic benefits (inflows of
 cash or other assets) are expected.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The useful lives of intangible assets are assessed to be finite and
 amortized over the useful economic life and assessed for impairment
 whenever there is an indication that the intangible asset may be
 impaired. Amortization begins when the asset is available for
 use.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Patents&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Patents acquired separately by the Company are reported at cost
 less accumulated amortization and accumulated impairment losses.
 Amortization is recognized in the consolidated statement of profit
 and loss and comprehensive loss on a straight-line basis over the
 shorter of the estimated economic or legal lives. The estimated
 useful life and amortization method are reviewed at the end of each
 reporting period, with the effect of any changes in estimates being
 accounted for on a prospective basis.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;R&amp;amp;D&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company incurs R&amp;amp;D expenses related to its clinical trials
 and preclinical drug development programs. Development expenses are
 defined as expenses incurred to achieve technical and commercial
 feasibility. Expenditures on research activities are recognized as
 an expense in the period in which it is incurred.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Development is capitalized if, and only if, all of the following
 have been demonstrated:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the technical feasibility of completing the intangible
 asset so that it will be available for use or sale;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the intention to complete the intangible asset and use
 or sell it;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the ability to use or sell the intangible asset;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;how the intangible asset will generate probable future
 economic benefits;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the availability of adequate technical, financial and
 other resources to complete the development and to use or sell the
 intangible asset; and&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the ability to measure reliably the expenditure.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Financial Instruments&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company classifies &lt;font style="WHITE-SPACE: nowrap"&gt;non-derivative&lt;/font&gt; financial assets as
 either financial assets at fair value through profit or loss,
 financial assets at amortized cost or financial assets at fair
 value through other comprehensive income or loss. The Company
 classifies &lt;font style="WHITE-SPACE: nowrap"&gt;non-derivative&lt;/font&gt;
 financial liabilities into either financial liabilities at fair
 value through profit or loss or the other financial liabilities
 category.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Non-Derivative&lt;/font&gt;
 Financial Assets and Financial Liabilities&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company initially recognizes receivables and investments at
 fair value on the date when they are originated. Subsequent to
 initial recognition, they are measured at amortized cost using the
 effective interest rate method. All other financial assets and
 financial liabilities are initially recognized on the trade
 date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The Company derecognizes a financial asset when the contractual
 rights to the cash flows from the asset expire, or it transfers the
 rights to receive the contractual cash flows in a transaction in
 which substantially all the risks and rewards of ownership of the
 financial asset are transferred, or it neither transfers nor
 retains substantially all of the risks and rewards of ownership and
 does not retain control over the transferred asset. Any interest in
 such derecognized financial assets that is created or retained by
 the Company is recognized as a separate asset or liability.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company initially recognizes &lt;font style="WHITE-SPACE: nowrap"&gt;non-derivate&lt;/font&gt; financial liabilities at
 fair value less any directly attributable transaction costs.
 Subsequent to initial recognition, these liabilities are measured
 at amortized cost using the effective interest method.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company derecognizes a financial liability when its contractual
 obligations are settled or cancelled, or expire.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Financial assets and financial liabilities are offset and the net
 amount presented in the statement of financial position when, and
 only when, the Company has a legal right to offset the amounts and
 intends either to settle them on a net basis or to realize the
 asset and settle the liability simultaneously.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Investments&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Investments are classified and accounted for at amortized cost and
 initially measured at fair value. Subsequent to initial
 recognition, they are measured at amortized cost using the
 effective interest rate method. Investments are classified as
 amortized cost as the Company has the positive intent and ability
 to hold them until maturity. Interest income from these securities
 is included in finance income.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Receivables&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 These assets are initially recognized at fair value plus any
 directly attributable transaction costs, if any.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Derivative Financial Assets and Liabilities&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Derivative financial instruments are initially recognized at fair
 value on the date on which a derivative contract is entered into
 and are subsequently remeasured at fair value with net changes in
 fair value presented as finance expenses (negative net changes in
 fair value) or finance income (positive net changes in fair value)
 in the consolidated statement of profit or loss and comprehensive
 loss. Derivatives are carried as financial assets when the fair
 value is positive and as financial liabilities when the fair value
 is negative. Derivatives embedded in host contracts are accounted
 for as separate derivatives and recorded at fair value if their
 economic characteristics and risks are not closely related to those
 of the host contracts and the host contracts are not held for
 trading or designated at fair value through profit or loss. These
 embedded derivatives are measured at fair value with changes in
 fair value recognized in profit or loss. Reassessment only occurs
 if there is either a change in the terms of the contract that
 significantly modifies the cash flows that would otherwise be
 required or a reclassification of a financial asset out of the fair
 value through profit or loss category.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 For the purpose of presentation in the statement of cash flows as
 well as the statement of financial position, cash and cash
 equivalents include deposits held with financial institutions with
 original maturities of less than three months from the date of
 acquisition. Cash and cash equivalents include
 &amp;#x20AC;49.1&amp;#xA0;million of investments with a three month or less
 maturity, callable on demand. The carrying values of cash
 equivalents approximate fair value due to their short-term
 maturities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Treatment of equity issuance costs&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Costs related to the issuance of new shares have been accounted for
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Incremental costs, if any, that are directly
 attributable to issuing new shares are included as prepaid expenses
 and are deducted from equity on the date the Company closes its new
 share transactions (net of any income tax benefit). Such as, for
 example, the date of the closing of its IPO, &lt;font style="WHITE-SPACE: nowrap"&gt;follow-on&lt;/font&gt; public offerings or the
 share subscription agreements with Incyte or Regeneron
 Pharmaceuticals Inc. (&amp;#x201C;Regeneron&amp;#x201D;);&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Incremental costs directly associated with a probable,
 successful future offering of equity instruments are also deferred
 and deducted from equity when the new shares are issued;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Costs that relate to listing on Nasdaq, or other new
 share transaction costs that are otherwise not incremental and
 directly attributable to issuing new shares, are recorded as an
 expense in the consolidated statement of profit or loss and
 comprehensive loss; and&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Costs that relate to both share issuance and listing
 are allocated between those functions on a rational and consistent
 basis.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Provisions&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 A provision is recognized if the following applies:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the company has a legal or constructive obligation,
 arising from a past event;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the amount can be estimated reliably; and&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;it is probable that an outflow of resources embodying
 economic benefits will be required to settle the obligation.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 If all or part of the payments that are necessary to settle a
 provision are virtually certain to be fully or partially
 compensated by a third party upon settlement of the provision, then
 the compensation amount is presented separately as an asset.
 Provisions are determined by discounting the expected future cash
 flows at a &lt;font style="WHITE-SPACE: nowrap"&gt;pre-tax&lt;/font&gt; rate
 that reflects current market assessments of the time value of money
 and the risks specific to the liability. The unwinding of the
 discount is recognized as finance cost.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Impairment&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Financial Assets Measured at Amortized Cost&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 At each reporting date, the Company considers evidence of
 impairment for these assets at both an individual asset and a
 collective level. All individually significant assets are
 individually assessed for impairment. Those found not to be
 impaired are then collectively assessed for any impairment that has
 been incurred but not yet individually identified. Assets that are
 not individually significant are collectively assessed for
 impairment. Collective assessment is carried out by grouping
 together assets with similar risk characteristics.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 To assess impairment for its financial assets, the Company uses the
 general expected credit loss model over the next twelve months of
 the expected life of its financial assets. Under this model, the
 Company calculates the allowance for credit losses by considering
 on a discounted basis, the cash shortfalls it would incur in
 various default scenarios for prescribed future periods and
 multiplying the shortfalls by the probability of each scenario
 occurring. The allowance on the financial asset is the sum of these
 probability-weighted outcomes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 For the Company&amp;#x2019;s investments, the Company applies the low
 credit risk simplification as it does not believe there to be any
 credit risk related to these assets given the credit quality
 ratings required by the Company&amp;#x2019;s investment policy. At every
 reporting date, the Company evaluates whether a particular debt
 instrument is considered to have low credit risk using all
 supportable information.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Impairment losses are recognized in the consolidated statement of
 profit or loss and comprehensive loss and is the amount required to
 adjust the loss allowance at the reporting date to the amount that
 is required to be recognized based on the aforementioned policy. If
 the amount of impairment loss subsequently decreases and the
 decrease can be related objectively to an event occurring after the
 impairment was recognized, then the previously recognized
 impairment loss is reversed through profit or loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Non-Financial&lt;/font&gt;
 Assets&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 At each reporting date, the Company reviews the carrying amounts of
 its &lt;font style="WHITE-SPACE: nowrap"&gt;non-financial&lt;/font&gt; assets
 to determine whether there is any indication of impairment. If any
 such indication exists, then the asset&amp;#x2019;s recoverable amount
 is estimated.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 For impairment testing, assets are grouped together into the
 smallest group of assets that generates cash inflows from
 continuing use that are largely independent of the cash inflows of
 other assets or cash generating units (&amp;#x201C;CGU&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The recoverable amount of an asset or CGU is the greater of its
 value in use and its fair value less costs to sell. Value in use is
 based on the estimated future cash flows, discounted to their
 present value using a &lt;font style="WHITE-SPACE: nowrap"&gt;pre-tax&lt;/font&gt; discount rate that reflects
 current market assessments of the time value of money and the risks
 specific to the asset or CGU.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 An impairment loss is recognized if the carrying amount of an asset
 or CGU exceeds its recoverable amount.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Impairment losses are recognized in profit or loss. They are
 allocated first to reduce the carrying amount of any goodwill
 allocated to the CGU, and then to reduce the carrying amounts of
 the other assets in the CGU on a pro rata basis.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 An impairment loss is reversed only to the extent that the
 asset&amp;#x2019;s carrying amount does not exceed the carrying amount
 that would have been determined, net of depreciation or
 amortization, if no impairment loss had been&amp;#xA0;recognized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Effective January&amp;#xA0;1, 2018, the Company adopted IFRS 15,
 &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; (&amp;#x201C;IFRS
 15&amp;#x201D;). This standard applies to all contracts with customers,
 except for contracts that are within the scope of other standards,
 such as leases, insurance, collaboration arrangements and financial
 instruments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The terms of the contracts within the scope of IFRS 15&amp;#xA0;may
 contain multiple promised goods and services, which often include
 license rights to certain of the Company&amp;#x2019;s product candidates
 and R&amp;amp;D activities. Payments under such agreements include:
 (i)&amp;#xA0;upfront nonrefundable license fees; (ii)&amp;#xA0;payments for
 R&amp;amp;D services performed by the Company, including reimbursement
 for certain external costs; (iii)&amp;#xA0;payments based upon the
 achievement of certain development, regulatory and commercial
 milestones; and (iv)&amp;#xA0;royalties on net product sales, if
 any.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Under IFRS 15, the Company recognizes revenue when its customer
 obtains control of promised goods or services, in an amount that
 reflects the consideration that the Company expects to receive in
 exchange for those goods or services. The Company recognizes
 revenue following the five-step model prescribed under IFRS 15: (i)
 identification of the contract(s) with the customer;
 (ii)&amp;#xA0;identification of the performance obligations;
 (iii)&amp;#xA0;determination of the transaction price, including the
 constraint on variable consideration; (iv)&amp;#xA0;allocation of the
 transaction price to the performance obligations in the contract;
 and (v)&amp;#xA0;recognition of revenue when (or as) the Company
 satisfies each performance obligation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In order to account for contracts with customers, the Company
 identifies the promised goods or services in the contract and
 evaluates whether such promised goods or services represent
 performance obligations. The Company accounts for those components
 as separate performance obligations when the following criteria are
 met: (i)&amp;#xA0;the customer can benefit from the good or service
 either on its own or together with other resources that are readily
 available to the customer, and (ii)&amp;#xA0;the Company&amp;#x2019;s
 promise to transfer the good or service to the customer is
 separately identifiable from other promises in the contract. This
 evaluation requires subjective determinations and requires the
 Company to make judgments about the promised goods and services and
 whether such goods and services are separable from the other
 aspects of the contractual relationship. In determining the
 performance obligations, the Company evaluates certain criteria,
 including whether the promised good or service is capable of being
 distinct and whether such good or service is distinct within the
 context of the contract, based on consideration of the relevant
 facts and circumstances for each arrangement. Factors considered in
 this determination include the research, manufacturing and
 commercialization capabilities of the partner; the availability of
 research and manufacturing expertise in the general marketplace;
 and the level of integration, interrelation, and interdependence
 among the promises to transfer goods or services.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The transaction price is allocated among the performance
 obligations using the relative selling price method and the
 applicable revenue recognition criteria are applied to each of the
 separate performance obligations. At contract inception, the
 Company determines the standalone selling price for each
 performance obligation identified in the contract. If an observable
 price of the promised good or service sold separately is not
 readily available, the Company utilizes assumptions that require
 judgment to estimate the standalone selling price, which may
 include development timelines, probabilities of technical and
 regulatory success, reimbursement rates for personnel costs,
 forecasted revenues, potential limitations to the selling price of
 the product, expected technological life of the product and
 discount rates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Up-front&lt;/font&gt; License
 Payments&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 If the license to the Company&amp;#x2019;s intellectual property is
 determined to be distinct from the other performance obligations
 identified in the arrangement, the Company recognizes revenue
 allocated to the license when the license is transferred to the
 customer and the customer is able to use and benefit from the
 license. For licenses that are not distinct and bundled with other
 performance obligations, the Company utilizes judgment to assess
 the nature of the combined performance obligation to determine
 whether the combined performance obligation is satisfied over time
 or at a point in time and, if over time, the appropriate method of
 measuring progress for purposes of recognizing revenue from the
 combined performance obligation. The Company evaluates the measure
 of progress each reporting period and, if necessary, adjusts the
 measure of performance and related revenue recognition.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Milestones&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 At the inception of each arrangement that includes &lt;font style="WHITE-SPACE: nowrap"&gt;pre-commercial&lt;/font&gt; milestone payments, the
 Company evaluates whether the milestones are considered probable of
 being reached and estimates the amount to be included in the
 transaction price using the most likely amount method. If it is
 probable that a significant cumulative revenue reversal would not
 occur, the associated milestone value is included in the
 transaction price. Milestone payments that are not within the
 Company&amp;#x2019;s control, such as regulatory approvals, are not
 considered probable of being achieved until the uncertainty related
 to the milestone is resolved. The transaction price is then
 allocated to each performance obligation on a relative selling
 price basis, for which the Company recognizes revenue as or when
 the performance obligations under the contract are satisfied. Any
 such adjustments are recorded on a cumulative &lt;font style="WHITE-SPACE: nowrap"&gt;catch-up&lt;/font&gt; basis, which affects revenue
 in the period of adjustment. At the end of each subsequent
 reporting period, the Company reevaluates the probability of
 achievement of such development milestones and any related
 constraint, and if necessary, adjusts its estimate of the overall
 transaction price.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Royalties&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 For arrangements that include sales-based royalties, including
 milestone payments based on the level of sales, and where the
 license is deemed to be the predominant item to which the royalties
 relate, the Company recognizes revenue at the later of:
 (i)&amp;#xA0;when the related sales occur, or (ii)&amp;#xA0;when the
 performance obligation to which some or all of the royalty has been
 allocated has been satisfied (or partially satisfied). To date, the
 Company has not recognized any royalty revenue.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;R&amp;amp;D Cost Reimbursement&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 R&amp;amp;D cost reimbursement revenue, which is typically related to
 reimbursements from customers for the Company&amp;#x2019;s performance
 of R&amp;amp;D services under the respective agreements, is recognized
 on the basis of labor hours valued at a contractually agreed rate.
 R&amp;amp;D cost reimbursement revenue also includes reimbursements for
 related &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;out-of-pocket&lt;/font&gt;&lt;/font&gt; expenses and
 third-party costs. R&amp;amp;D cost reimbursement revenue is recognized
 in the same period as the costs for which they are intended to
 compensate.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company typically acts as the principal under such arrangements
 and, therefore, records these reimbursements on a gross basis. The
 impact of the new revenue standard IFRS 15 was also assessed for
 the instances under the ONO research and license agreement (defined
 below) where the Company acts as an agent. The Company concluded
 that no control was obtained for these pass-through arrangements to
 reimburse costs under the ONO research and license agreement and as
 such the costs were netted in R&amp;amp;D instead of being recognised
 as expense.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Costs of Obtaining a Contract with a Customer&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company capitalizes the incremental costs of obtaining a
 contract with a customer if it expects to recover those costs. To
 date, the Company has not capitalized any incremental costs for
 obtaining a contract.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Government Grants&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company receives certain government and regional grants, which
 support its research efforts in defined projects, and include
 contributions towards the R&amp;amp;D cost. When there is reasonable
 assurance that the Company will comply with the conditions attached
 to a received grant, and when there is reasonable assurance that
 the grant will be received, government grants are recognized as
 revenue on a gross basis in the consolidated statement of profit or
 loss and comprehensive loss on a systematic basis over the periods
 in which the Company recognizes expenses for the related costs for
 which the grants are intended to compensate. In the case of grants
 related to assets, the received grant will be deducted from the
 carrying amount of the asset.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;WBSO&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The WBSO (&lt;i&gt;afdrachtvermindering speur- en ontwikkelingswerk&lt;/i&gt;)
 is a Dutch fiscal facility that provides subsidies to companies,
 knowledge centers and self-employed people who perform R&amp;amp;D
 activities (as defined in the WBSO Act). Under this act, a
 contribution is paid towards the labor costs of employees directly
 involved in R&amp;amp;D and other related expenditures. The
 contribution is in the form of a reduction of payroll taxes.
 Subsidies relating to labor costs are deferred and recognized in
 the consolidated statement of profit or loss and comprehensive loss
 as negative labor costs over the period necessary to match them
 with the labor costs that they are intended to compensate (see Note
 15).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Employee Benefits&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Short-term Employee Benefits&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Short-term employee benefits are expensed as the related service is
 provided. A liability is recognized for the amount expected to be
 paid if the Company has a present legal or constructive obligation
 to pay this amount as a result of past service provided by the
 employee and the obligation can be estimated reliably.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;i&gt;Share-Based Payment Transactions&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The grant-date fair value of equity-settled share-based payment
 awards granted to employees including grants of employee options,
 restricted share units, and modifications to existing instruments,
 is recognized as an expense, net of an estimated forfeiture rate,
 with a corresponding increase in equity (accumulated loss), over
 the vesting period of the awards. Service conditions and
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-market&lt;/font&gt; related
 conditions are not taken into account in determining the fair
 value. The amount recognized as an expense is adjusted to reflect
 the number of awards for which the related service and &lt;font style="WHITE-SPACE: nowrap"&gt;non-market&lt;/font&gt; performance conditions are
 expected to be met, such that the amount ultimately recognized is
 based on the number of awards that meet the related service and
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-market&lt;/font&gt; performance
 conditions at the vesting date. For any share-based payment awards
 with market conditions or &lt;font style="WHITE-SPACE: nowrap"&gt;non-vesting&lt;/font&gt; conditions, the grant-date
 fair value of the share-based payment is measured to reflect such
 conditions and there is no &lt;font style="WHITE-SPACE: nowrap"&gt;true-up&lt;/font&gt; for differences between
 expected and actual outcomes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Post-Employment Benefit Plans&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company contributes to a post-employment benefit plan that
 entitles executive officers and other staff members to retire at
 the age of 67 and receive annual payments based upon the average
 salary earned during the service period. The Company has insured
 the liabilities from the post-employment benefit plan with an
 insurance company and has no other obligation than to pay the
 annual insurance premiums to the insurance company. The annual
 pension payments are conditional; the Company will have no further
 obligation (legal or constructive) to pay further amounts if the
 insurance fund has insufficient assets to pay all employee benefits
 relating to current and prior service. Based on its
 characteristics, the Company&amp;#x2019;s post-employment benefit plan
 is classified as a defined contribution plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Obligations for contributions to defined contribution plans are
 expensed as the related service is provided. Prepaid contributions
 are recognized as an asset.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Determining whether an Arrangement Contains a Lease&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 At inception of an arrangement, the Company determines whether such
 an arrangement is or contains a lease.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 At inception or on reassessment of the arrangement, the Company
 separates payments and other consideration required by such an
 arrangement into those for the lease and those for other elements
 on the basis of their relative fair values. If the Company
 concludes for a finance lease that it is impracticable to separate
 the payments reliably, then an asset and a liability are recognized
 at an amount equal to the fair value of the underlying asset.
 Subsequently, the liability is reduced as payments are made and an
 imputed finance cost on the liability is recognized using the
 Company&amp;#x2019;s incremental borrowing rate.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Leased Assets&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Assets held by the Company under leases that transfer to the
 Company substantially all of the risks and rewards of ownership are
 classified as finance leases. The leased assets are measured
 initially at an amount equal to the lower of their fair value and
 the present value of the minimum lease payments. Subsequent to
 initial recognition, the assets are accounted for in accordance
 with the accounting policy applicable to that asset.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Assets held under other leases are classified as operating leases
 and are not recognized in the Company&amp;#x2019;s statement of
 financial position.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Lease Payments&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Payments made under operating leases are recognized in the
 consolidated statement of profit or loss and comprehensive loss on
 a straight-line basis over the term of the lease. Lease incentives
 received are recognized as an integral part of the total lease
 expense, over the term of the lease.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Minimum lease payments made under finance leases are apportioned
 between the finance expense and the reduction of the outstanding
 liability. The finance expense is allocated to each period during
 the lease term so as to produce a constant periodic rate of
 interest on the remaining balance of the&amp;#xA0;liability.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Finance Income and Finance Expenses&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company&amp;#x2019;s finance income and finance expenses
 include:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;interest and related income;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;interest expense and changes in fair value of the
 forward contract (derivative);&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;financing costs; and&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the foreign currency gain or loss on financial assets
 and financial liabilities.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Interest income or expense is recognized using the effective
 interest method.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Income Tax&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Income tax expense comprises current and deferred tax. It is
 recognized in the consolidated statement of profit or loss and
 comprehensive loss except to the extent that it relates to a
 business combination, or items recognized directly in equity or in
 other comprehensive income or loss. Current tax comprises the
 expected tax payable or receivable on the taxable income or loss
 for the year and any adjustment to tax payable or receivable in
 respect of previous years. It is measured using tax rates enacted
 or substantively enacted at the reporting date. Current tax also
 includes any tax arising from dividends. Current tax assets and
 liabilities are offset only if certain criteria are met.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Deferred tax is recognized in respect of temporary differences
 between the carrying amounts of assets and liabilities for
 financial reporting purposes and the amounts used for taxation
 purposes. Deferred tax is not recognized for:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;temporary differences on the initial recognition of
 assets or liabilities in a transaction that is not a business
 combination and that affects neither accounting nor taxable profit
 or loss;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;temporary differences related to investments in
 subsidiaries, associates and joint arrangements to the extent that
 the group is able to control the timing of the reversal of the
 temporary differences and it is probable that they will not reverse
 in the foreseeable future; and&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;taxable temporary differences arising on the initial
 recognition of goodwill.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Deferred tax assets are recognized for unused tax losses, unused
 tax credits and deductible temporary differences to the extent that
 it is probable that future taxable profits will be available
 against which they can be used. Deferred tax assets are reviewed at
 each reporting date and are reduced to the extent that it is no
 longer probable that the related tax benefit will be realized; such
 reductions are reversed when the probability of future taxable
 profits improves.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Unrecognized deferred tax assets are reassessed at each reporting
 date and recognized to the extent that it has become probable that
 future taxable profits will be available against which they can be
 utilized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Deferred tax is measured at the tax rates that are expected to be
 applied to temporary differences when they reverse, using tax rates
 enacted or substantively enacted at the reporting date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The measurement of deferred tax reflects the tax consequences that
 would follow from the manner in which the Company expects, at the
 reporting date, to recover or settle the carrying amount of its
 assets and liabilities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Deferred tax assets and liabilities are offset only if certain
 criteria are met.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_1_5">7925000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_BE8BFC1B-135E-407C-B695-A31037E88FA7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The number of share options outstanding, by group of employees, was
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 &lt;b&gt;Group of employees entitled&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Key management personnel&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,148,744&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,777,437&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,302,417&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 All other employees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;484,295&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;436,548&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92,427&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,633,039&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,213,985&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,394,844&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory>
  <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_13058E1B-F276-4909-8EB0-4638F31D72BE_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Trade and Other Receivables&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 All trade and other receivables are short-term and due within 1
 year.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;&lt;i&gt;(euros&amp;#xA0;in&amp;#xA0;thousands)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,690&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,594&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unbilled receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;236&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 VAT receivable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;891&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,783&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;427&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid pension costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;838&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Interest receivable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;213&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;219&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,032&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,413&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Trade and unbilled receivables relate primarily to invoicing for
 cost reimbursements relating to the Incyte collaboration and
 license agreement, ONO research and license agreement and Simcere
 research and license agreement. VAT receivable relates to a value
 added tax receivable from the Dutch tax authorities based on the
 tax application for the fourth quarter of 2018. The Company is
 evaluating if the benefits of claiming foreign VAT are favorable
 compared to the related costs and expects to finalize the
 assessment and conclude in the course of 2019.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Prepaid expenses consist of expenses that were paid but are related
 to activities taking place in subsequent periods and prepaid taxes.
 The increase in prepaid expenses at December&amp;#xA0;31, 2018 relates
 primarily to advance payments made to contract research and
 contract manufacturing organizations in support of the
 Company&amp;#x2019;s preclinical, clinical trial, and contract
 manufacturing activities.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_37">2395000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <dei:EntityRegistrantName contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_1469EA42-F951-4C73-B189-5B232EFF4ADE_1_1">Merus N.V.</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_1469EA42-F951-4C73-B189-5B232EFF4ADE_1_8">false</dei:EntityShellCompany>
  <dei:EntityVoluntaryFilers contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_1469EA42-F951-4C73-B189-5B232EFF4ADE_1_6">No</dei:EntityVoluntaryFilers>
  <ifrs-full:FinanceIncome contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_1_2">7843000</ifrs-full:FinanceIncome>
  <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_29E631A8-7302-4D6F-8F8A-BE59E8718FBF_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;20.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Related party disclosures&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 For the years ended December&amp;#xA0;31, 2018, 2017 and 2016, certain
 Key Management Personnel and other senior management received
 regular salaries, bonuses and contributions to post-employment
 schemes as well as&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-cash&lt;/font&gt;&amp;#xA0;compensation
 as disclosed in Note 19. Additionally, members of the Board of
 Directors received compensation for their services in the form of
 cash compensation as well as&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-cash&lt;/font&gt;&amp;#xA0;compensation,
 as disclosed in Note 19.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On May&amp;#xA0;24, 2017, the Company entered into a settlement
 agreement with Shelley Margetson, the Company&amp;#x2019;s former Chief
 Operating Officer pursuant to which Ms.&amp;#xA0;Margetson resigned as
 a statutory director of the Company effective as of May&amp;#xA0;24,
 2017 and ended her employment with the Company effective as of
 August&amp;#xA0;1, 2017. As part of the terms of the settlement
 agreement, Ms.&amp;#xA0;Margetson is entitled to a severance payment
 equal to 12 months of her annual base salary, 50% of which was paid
 in a lump sum in August 2017 and the remaining 50% is being paid in
 the form of salary continuation over
 the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;period
 following August&amp;#xA0;1, 2017. In addition, Ms.&amp;#xA0;Margetson was
 entitled to an accelerated vesting of any unvested Company options
 and restricted stock units held by Ms.&amp;#xA0;Margetson that would
 have vested during the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;12-month&lt;/font&gt;&amp;#xA0;period
 following her separation date. As of December&amp;#xA0;31, 2018 and
 2017, the Company had an accrual of &amp;#x20AC;0 and less than
 &amp;#x20AC;0.1&amp;#xA0;million, respectively, related to this agreement
 included in accrued personnel.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On January&amp;#xA0;2, 2019, John Crowley resigned as the Executive
 Vice President and Chief Financial Officer of the &amp;#x201C;Company.
 In connection with his departure, Mr.&amp;#xA0;Crowley entered into a
 Separation and Release Agreement with the Company, pursuant to
 which Mr.&amp;#xA0;Crowley is entitled to receive a severance payment
 equal to 6 months of his annual salary. The transaction will be
 recorded in the Company&amp;#x2019;s consolidated financial statements
 during the three months ending March&amp;#xA0;31, 2019.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As disclosed in Note 11 and Note 13, the Company entered into the
 Incyte collaboration and license agreement and the Incyte share
 subscription agreement in which the terms and transactional amounts
 incurred between Incyte and the Company are more fully
 described.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As of March 31, 2019, the following shareholders currently hold a
 position in the Board of Directors and have filed a
 form&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;13-D&lt;/font&gt;&amp;#xA0;to reflect
 ownership in the Company of greater than 5%:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;Co&amp;#xF6;peratief LSP IV U.A.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;Sofinnova Venture Partners IX, L.P.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Additionally, Ton Logtenberg, the Company&amp;#x2019;s President, CEO
 and Principal Financial Officer and Executive Director, is the sole
 the Director and owner of Biophrase BV (&amp;#x201C;Biophrase&amp;#x201D;).
 As of March&amp;#xA0;31, 2019, Biophrase is a less than 1% shareholder.
 There were no transactions between the Company and Biophrase BV in
 2018.&lt;/p&gt;


 &lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
  <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_4FDD6754-7C59-4823-B0B9-75C29EC53578_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table presents changes in the Company&amp;#x2019;s trade
 receivables, contract assets and contract liabilities during the
 year ended December&amp;#xA0;31, 2018:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="50%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Additions&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Deductions&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade&amp;#xA0;receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,594&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,951&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(18,855&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,690&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total trade&amp;#xA0;receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,594&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,951&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(18,855&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,690&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contract assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unbilled receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,045&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;236&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total contract assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,045&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,519&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;236&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contract liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,137&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(18,014&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;114,609&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total contract liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,137&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(18,014&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;114,609&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table presents changes in the Company&amp;#x2019;s trade
 receivables, contract assets and contract liabilities during the
 year ended December&amp;#xA0;31, 2017:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2016&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Additions&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Deductions&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade&amp;#xA0;receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122,781&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(121,392&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,594&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total trade&amp;#xA0;receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122,781&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(121,392&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,594&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contract assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unbilled receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121,240&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(120,530&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total contract assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121,240&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(120,530&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contract liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,426&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;111,993&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14,933&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total contract liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,426&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;111,993&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14,933&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_0ACBD4B0-59C1-4C36-A416-82A2904A2337_1_4">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_0ACBD4B0-59C1-4C36-A416-82A2904A2337_1_3">2018</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_0ACBD4B0-59C1-4C36-A416-82A2904A2337_1_0">20-F</dei:DocumentType>
  <ifrs-full:EmployeeBenefitsExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_68078692-077B-4C21-8EB2-80F32AD7B4E5_1_2">18284000</ifrs-full:EmployeeBenefitsExpense>
  <dei:EntityCentralIndexKey contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_1469EA42-F951-4C73-B189-5B232EFF4ADE_1_2">0001651311</dei:EntityCentralIndexKey>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_1469EA42-F951-4C73-B189-5B232EFF4ADE_1_4">No</dei:EntityWellKnownSeasonedIssuer>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_1_5">10395000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_18">624000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_13010_29">7925000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_36">-8326000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_1_11">356000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_1_0">2705438</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_1_5">6435298</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_1_2">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_1_1">40882</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_25">1279000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="shares" decimals="INF" id="id_14264487_931C8F45-65AF-4273-8D38-1B87506DC76D_1_3">93244</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="shares" decimals="INF" id="id_14264487_2D9E1ED7-9102-4197-AE9A-6039F1DD098B_1_2">31629</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="shares" decimals="INF" id="id_14264487_2D9E1ED7-9102-4197-AE9A-6039F1DD098B_1_1">38874</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:OtherFinanceIncome contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_1_8">7095000</ifrs-full:OtherFinanceIncome>
  <ifrs-full:OtherIncome contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_1_3">7095000</ifrs-full:OtherIncome>
  <ifrs-full:ProceedsFromExerciseOfOptions contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_30">876000</ifrs-full:ProceedsFromExerciseOfOptions>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_17">4000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:IssueOfEquity contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_13010_28">51589000</ifrs-full:IssueOfEquity>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_1_4">3688978</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_1_3">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
  <ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_A5145860-2B25-4EC2-88BD-9CC5AB18F132_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following are the remaining contractual maturities of financial
 liabilities as at December&amp;#xA0;31, 2018 and 2017. The amounts are
 gross and undiscounted.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="22" align="center"&gt;&lt;b&gt;December&amp;#xA0;31, 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;amount&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;&amp;lt; 12&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;months&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;1&amp;#xA0;-&amp;#xA0;2&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2&amp;#xA0;-&amp;#xA0;5&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;&amp;gt;&amp;#xA0;5&amp;#xA0;years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="22" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade payables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,819&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,819&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,819&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other liabilities and accruals&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,964&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,964&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,964&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,783&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,783&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,783&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="22" align="center"&gt;&lt;b&gt;December&amp;#xA0;31, 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;amount&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;&amp;lt; 12&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;months&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;1&amp;#xA0;-&amp;#xA0;2&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2&amp;#xA0;-&amp;#xA0;5&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;&amp;gt; 5&amp;#xA0;years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="22" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade payables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,855&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,855&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,855&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other liabilities and accruals&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,176&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,176&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,176&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,031&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,031&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,031&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="shares" decimals="INF" id="id_14264487_2D9E1ED7-9102-4197-AE9A-6039F1DD098B_1_4">625445</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:OperatingExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_1_9">70295000</ifrs-full:OperatingExpense>
  <ifrs-full:OtherComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_13010_25">34000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherShorttermEmployeeBenefits contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_1_6">1835000</ifrs-full:OtherShorttermEmployeeBenefits>
  <ifrs-full:ProfitLossBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_1_10">-23913000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_1_5">-38847000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="shares" decimals="INF" id="id_14264487_931C8F45-65AF-4273-8D38-1B87506DC76D_1_2">0</ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="shares" decimals="INF" id="id_14264487_2D9E1ED7-9102-4197-AE9A-6039F1DD098B_1_3">135888</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_28">50713000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:NetForeignExchangeGain contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_1_1">6034000</ifrs-full:NetForeignExchangeGain>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_1_14">34000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherExpenseByNature contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_1_8">13160000</ifrs-full:OtherExpenseByNature>
  <ifrs-full:OtherFinanceIncomeCost contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_1_9">14934000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_21">75930000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_24">1552000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_1_4">46740000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_1_4">31448000</ifrs-full:Revenue>
  <ifrs-full:SocialSecurityContributions contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_1_2">919000</ifrs-full:SocialSecurityContributions>
  <dei:TradingSymbol contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_1469EA42-F951-4C73-B189-5B232EFF4ADE_1_0">MRUS</dei:TradingSymbol>
  <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_22">58912000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
  <ifrs-full:ProfessionalFeesExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_9DFE7ABA-C7C0-4A1F-8BE9-A71C01DAA2EB_1_0">6300000</ifrs-full:ProfessionalFeesExpense>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_13010_24">-24269000</ifrs-full:ProfitLoss>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_23">2125000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_D22D6C68-C304-48A2-8DF1-6CAB4211BBCE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table provides a sensitivity analysis for a change in
 the primary currency exposure for the Company relating to monetary
 assets and liabilities denominated in U.S. dollars as of
 December&amp;#xA0;31, 2018. The analysis shows the impact that a change
 in the exchange rate at that date would have on the Company&amp;#x2019;s
 total comprehensive loss:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="52%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 &lt;b&gt;Financial Statement Line Item Exposure&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Balance&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Effect&amp;#xA0;on&amp;#xA0;profit&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;before&amp;#xA0;tax&amp;#xA0;if&amp;#xA0;USD&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;strengthens 5%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Effect&amp;#xA0;on&amp;#xA0;profit&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;before&amp;#xA0;tax&amp;#xA0;if&amp;#xA0;USD&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;weakens 5%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;43,074&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,154&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,154&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61,800&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,090&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,090&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade and other receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,886&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;144&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(144&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Taxes and social security liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(88&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade payables, other liabilities and accruals&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,795&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(240&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;240&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;103,000&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;5,150&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(5,150&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_1C9A2645-8CE2-43DE-B4D4-CB5AD26735C7_1_2">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_1_7">18284000</ifrs-full:ShorttermEmployeeBenefitsExpense>
  <ifrs-full:WagesAndSalaries contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_1_0">10783000</ifrs-full:WagesAndSalaries>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_1_3">6.80</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageSharePrice contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="INF" id="id_14264487_1EFAC40F-3150-4D3D-9A4D-5CCC2C4FF2FD_1_0">17.03</ifrs-full:WeightedAverageSharePrice>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_1_4">14.96</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_3CC3A1EC-9957-465E-9F1D-68D3E162F5CA_1_0">Five years</ifrs-full:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_1C9A2645-8CE2-43DE-B4D4-CB5AD26735C7_1_3">20.03</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_1_2">11.00</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_1_1">14.48</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_3010_1">235432</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:GeneralLegalInsuranceAndFacilityRelatedExpenses contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_9DFE7ABA-C7C0-4A1F-8BE9-A71C01DAA2EB_1_1">4200000</mrus:GeneralLegalInsuranceAndFacilityRelatedExpenses>
  <mrus:OtherIncomeExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_1_8">14934000</mrus:OtherIncomeExpense>
  <mrus:AllowanceForImpairment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="INF" id="id_14264487_978880C2-15CC-4993-8E82-0253FB990457_1_0">0</mrus:AllowanceForImpairment>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_13010_30">59514000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <mrus:RevenueRecognizedIncludedInDeferredRevenue contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_87B93F59-C6CE-4FD8-A145-4B0FD3DF97A7_1_0">15900000</mrus:RevenueRecognizedIncludedInDeferredRevenue>
  <mrus:RevenueRecognizedNotIncludedInDeferredRevenue contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_87B93F59-C6CE-4FD8-A145-4B0FD3DF97A7_1_1">2100000</mrus:RevenueRecognizedNotIncludedInDeferredRevenue>
  <mrus:DeductionsInContractAssets contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_AAEECD3A-A490-47A4-A19C-88AEF875DFF6_4002_3">1519000</mrus:DeductionsInContractAssets>
  <mrus:AdditionsInContractLiabilities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CE40E457-E3B7-4108-99F6-618E5B763DA0_4002_2">4137000</mrus:AdditionsInContractLiabilities>
  <mrus:DeductionsInContractLiabilities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CE40E457-E3B7-4108-99F6-618E5B763DA0_4002_3">18014000</mrus:DeductionsInContractLiabilities>
  <mrus:AdditionsInContractAssets contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_AAEECD3A-A490-47A4-A19C-88AEF875DFF6_4002_2">1045000</mrus:AdditionsInContractAssets>
  <mrus:ClinicalCosts contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E5A85DC4-90A0-4CA4-A801-47E373A70955_1_1">9169000</mrus:ClinicalCosts>
  <mrus:OtherResearchAndDevelopmentExpenseOther contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E5A85DC4-90A0-4CA4-A801-47E373A70955_1_2">4263000</mrus:OtherResearchAndDevelopmentExpenseOther>
  <mrus:DiscoveryAndPreclinicalCosts contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E5A85DC4-90A0-4CA4-A801-47E373A70955_1_0">5506000</mrus:DiscoveryAndPreclinicalCosts>
  <mrus:PreclinicalCosts contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_EE8874EB-D696-4FCF-9D1F-4A232AF85BF5_1_0">5500000</mrus:PreclinicalCosts>
  <mrus:IntellectualPropertyCosts contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_EE8874EB-D696-4FCF-9D1F-4A232AF85BF5_1_2">3300000</mrus:IntellectualPropertyCosts>
  <mrus:AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_13">-663000</mrus:AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals>
  <mrus:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_15">13000</mrus:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities>
  <mrus:GrantIncome contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_8A2BDAFB-590D-4532-ADCE-1B626C35DDF9_1_0">200000</mrus:GrantIncome>
  <mrus:PensionCosts contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_1_4">749000</mrus:PensionCosts>
  <mrus:HealthInsurance contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_1_3">330000</mrus:HealthInsurance>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_2003_9">798781</mrus:RemunerationForFormerEmployees>
  <mrus:StockAwardExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B5A6BE7B-5975-44A4-A2A1-EED190DB18B0_1_3">7925000</mrus:StockAwardExpense>
  <mrus:WBSOSubsidy contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_1_1">4257000</mrus:WBSOSubsidy>
  <mrus:OtherOperatingExpenses contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_1_7">11735000</mrus:OtherOperatingExpenses>
  <mrus:LitigationCosts contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_1_6">1425000</mrus:LitigationCosts>
  <mrus:ManufacturingCost contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_1_0">18914000</mrus:ManufacturingCost>
  <mrus:PersonnelRelatedResearchAndDevelopmentExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_1_2">7036000</mrus:PersonnelRelatedResearchAndDevelopmentExpense>
  <mrus:OtherResearchAndDevelopmentExpenses contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_1_3">18938000</mrus:OtherResearchAndDevelopmentExpenses>
  <mrus:RentAndServiceChargesExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_FC788C4F-FFA1-4B14-AED5-CE0544122BE9_1_0">1300000</mrus:RentAndServiceChargesExpense>
  <mrus:InterestAndRelatedIncome contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_1_0">1809000</mrus:InterestAndRelatedIncome>
  <mrus:OtherExternalAndOutsourcedCosts contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_68078692-077B-4C21-8EB2-80F32AD7B4E5_1_1">32459000</mrus:OtherExternalAndOutsourcedCosts>
  <mrus:ContractManufacturingExpenses contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_68078692-077B-4C21-8EB2-80F32AD7B4E5_1_0">18914000</mrus:ContractManufacturingExpenses>
  <mrus:ChangesInAccruedCapitalExpenditures contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1_41">346000</mrus:ChangesInAccruedCapitalExpenditures>
  <mrus:InterestAndOtherExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_1_4">4000</mrus:InterestAndOtherExpense>
  <mrus:AccrualsToEmployeeSeveranceIndemnities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_6D337156-1BC6-480C-B1FD-A0D3CF47E73D_2_2">0</mrus:AccrualsToEmployeeSeveranceIndemnities>
  <mrus:WeightedAverageNumberOfShares contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="shares" decimals="INF" id="id_14264487_780AD06D-9847-4BE0-8664-B9F729C217F8_1_3">22286720</mrus:WeightedAverageNumberOfShares>
  <mrus:PeriodOfOptionToExerciseTreatedAsNonVestingConditions contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_5FEAEE92-4A73-4390-A32F-30CBC2DAF6F3_1_2">Within four years</mrus:PeriodOfOptionToExerciseTreatedAsNonVestingConditions>
  <mrus:DescriptionOfDepositoryReceiptsBasedExercisePrice contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_5FEAEE92-4A73-4390-A32F-30CBC2DAF6F3_1_0">Prior to the IPO, participants that voluntarily left the Company, except for  members of the former Supervisory Board, were required to offer to the foundation the depositary receipts acquired from exercising options against  payment of the exercise price or the lower fair market value of the underlying shares.</mrus:DescriptionOfDepositoryReceiptsBasedExercisePrice>
  <mrus:DescriptionOfNonVestingCondition contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_5FEAEE92-4A73-4390-A32F-30CBC2DAF6F3_1_1">This obligation for a participant to offer depositary receipts to the foundation upon resignation within four years from exercising the options was treated as a non-marketvesting condition.</mrus:DescriptionOfNonVestingCondition>
  <mrus:NumberOfReportableSegments1 contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="Segment" decimals="INF" id="id_14264487_75AE757C-96BB-4183-A4FD-1A2B9F1D2E15_1_0">1</mrus:NumberOfReportableSegments1>
  <mrus:SharebasedCompensationWeightedAverageRemainingContractualLife contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_D2C11233-6864-41A5-86A7-1FC6F9FA0B51_1_2">P7Y</mrus:SharebasedCompensationWeightedAverageRemainingContractualLife>
  <mrus:CashAndCashEquivalentsMaximumMaturityPeriod contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_A9DA9ED8-6776-4AD2-BBD0-F9A9ED7ECCD4_1_0">P3M</mrus:CashAndCashEquivalentsMaximumMaturityPeriod>
  <mrus:DisclosureOfHeldToMaturityInvestmentExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_F18DBFB4-C31A-4BB2-8751-7D440AD89DEF_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Investments as of December&amp;#xA0;31, 2018 and 2017 consisted of the
 following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;i&gt;(euros in
 thousands)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;22,208&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,527&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 U.S. Treasury securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6,733&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,177&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Corporate fixed income bonds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;14,185&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,886&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Agency bonds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,729&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,453&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Current investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;44,855&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,043&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Corporate fixed income bonds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;16,945&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,060&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;font style="white-space:nowrap"&gt;Non-current&lt;/font&gt; investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;16,945&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,060&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;61,800&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,103&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfHeldToMaturityInvestmentExplanatory>
  <mrus:DisclosureOfOperatingExpensesExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_8D3A9BAC-4D09-4F4A-8BAF-8E09A84841B4_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;14.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Total Operating Expenses&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The following table presents a breakdown of operating expenses:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Manufacturing costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;18,914&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,567&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,162&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 IP and license costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,852&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,858&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,167&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Personnel related R&amp;amp;D&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,036&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,673&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,285&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other R&amp;amp;D costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;18,938&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,027&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;i&gt;Total R&amp;amp;D costs&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;46,740&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,125&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,424&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;i&gt;Management and administration costs&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;10,395&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,258&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Litigation costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,425&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,039&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,490&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other operating expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;11,735&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,356&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,219&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;i&gt;Total other expenses&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;13,160&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,395&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,709&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Total operating expenses&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;70,295&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,217&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,391&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 R&amp;amp;D costs primarily include: (i)&amp;#xA0;payroll and related costs
 (including share-based payment expenses) associated with R&amp;amp;D
 personnel; (ii)&amp;#xA0;costs related to clinical trials and
 preclinical testing of the Company&amp;#x2019;s technologies under
 development; (iii)&amp;#xA0;costs to develop product candidates,
 including raw materials and supplies, product testing,
 depreciation, and facility related expenses; (iv)&amp;#xA0;expenses for
 research services provided by universities and contract
 laboratories; (v)&amp;#xA0;costs associated with obtaining and
 maintaining patents and other intellectual property; and
 (vi)&amp;#xA0;other R&amp;amp;D expenses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Other R&amp;amp;D costs consist mainly of laboratory supplies and
 depreciation expense related to R&amp;amp;D activities, which cannot be
 specifically allocated to a research project.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table presents a breakdown of other R&amp;amp;D
 costs:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Discovery and preclinical costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;5,506&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,473&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,185&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Clinical costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;9,169&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,919&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,409&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other R&amp;amp;D costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,263&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,635&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,216&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Total other R&amp;amp;D costs&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;18,938&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,027&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Management and administrative costs consist of salaries and related
 expenses for employees in finance, legal, human resources, investor
 relations and business development functions. These costs include
 all salary, salary related expenses and share-based compensation
 expenses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Other operating expenses consist primarily of expenses related to
 professional fees for consulting, audit, and tax services of
 &amp;#x20AC;6.3&amp;#xA0;million (2017: &amp;#x20AC;4.0&amp;#xA0;million, 2016:
 &amp;#x20AC;1.7 million), which support the finance function in
 maintaining and establishing public company status and general
 legal, insurance and facility related expenses amounting to
 &amp;#x20AC;4.2&amp;#xA0;million (2017: &amp;#x20AC;3.2&amp;#xA0;million, 2016:
 &amp;#x20AC;3.9&amp;#xA0;million).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Operating expenses presented by nature are outlined below:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contract manufacturing&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;18,914&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,567&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,162&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other external and outsourced costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;32,459&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,333&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,885&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Employee costs&amp;#xA0;and related benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;18,284&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,999&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,110&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;638&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;318&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;234&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total operating expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;70,295&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,217&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,391&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The other external and outsourced costs consist mainly of
 preclinical costs of &amp;#x20AC;5.5&amp;#xA0;million (2017:
 &amp;#x20AC;2.5&amp;#xA0;million, 2016: &amp;#x20AC;5.2 million), clinical costs
 of &amp;#x20AC;9.2&amp;#xA0;million (2017: &amp;#x20AC;5.9&amp;#xA0;million, 2016:
 &amp;#x20AC;3.4 million) and IP costs of &amp;#x20AC;3.3&amp;#xA0;million (2017:
 &amp;#x20AC;2.9&amp;#xA0;million, 2016: &amp;#x20AC;2.7 million).&lt;/p&gt;
 &lt;/div&gt;</mrus:DisclosureOfOperatingExpensesExplanatory>
  <mrus:DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_943885EC-A152-4097-9792-79A3D705B7A3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The following table presents a breakdown of other income
 (expense):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Finance income&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Interest income and similar related income&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,809&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,112&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;88&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net gain on foreign exchange&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6,034&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="right"&gt;&lt;b&gt;7,843&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="right"&gt;&lt;b&gt;1,112&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="right"&gt;&lt;b&gt;88&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other income&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,095&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Finance costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Interest and other expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(4&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(190&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss on foreign exchange&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19,449&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(409&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Derivative financial instrument expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,696&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19,235&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(4&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(30,335&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19,644&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total other income (expense)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;14,934&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(29,223&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19,556&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory>
  <mrus:DisclosureOfOperatingExpensesByNatureExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_D4045712-0813-4385-A752-AF8B3EA4F2F4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Operating expenses presented by nature are outlined below:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contract manufacturing&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;18,914&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,567&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,162&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other external and outsourced costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;32,459&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,333&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,885&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Employee costs&amp;#xA0;and related benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;18,284&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,999&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,110&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;638&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;318&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;234&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total operating expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;70,295&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,217&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,391&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfOperatingExpensesByNatureExplanatory>
  <mrus:DisclosureOfCommitmentsAndContingenciesExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_9567D859-C2A6-4B6A-B2EA-EE8320165574_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;21.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Commitments and contingencies&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Lease Commitments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company leases its corporate headquarters under an agreement,
 which expires in the fourth quarter of 2021. If the lease is not
 terminated by Merus N.V., it will be automatically renewed for a
 period of two years. The agreed rental price is
 &amp;#x20AC;0.4&amp;#xA0;million per year. On May&amp;#xA0;1, 2018, the Company
 leased additional space to expand its corporate headquarters under
 a separate agreement. Under the terms of the new agreement, the
 term began on May&amp;#xA0;1, 2018 and expires in the fourth quarter of
 2021. The agreed upon rental price is &amp;#x20AC;0.6&amp;#xA0;million per
 year.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 For leases that contain fixed increases in the minimum annual lease
 payment during the original term of the lease, the Company
 recognizes rental expense on a straight-line basis over the lease
 term and records the difference between rent expense and the amount
 currently payable as deferred rent, as a component of other
 liabilities and accruals. For the years ended December&amp;#xA0;31,
 2018, 2017 and 2016 the Company recognized &amp;#x20AC;1.3&amp;#xA0;million,
 &amp;#x20AC;0.6&amp;#xA0;million and &amp;#x20AC;0.3&amp;#xA0;million, respectively,
 for rent and service charges related to the leased office space. In
 addition, the Company has provided deposits totaling
 &amp;#x20AC;0.3&amp;#xA0;million and &amp;#x20AC;0.1&amp;#xA0;million included in
 other assets as of December&amp;#xA0;31, 2018, and December&amp;#xA0;31,
 2017, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Future minimum lease payments under these leases as of
 December&amp;#xA0;31, 2018 are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Less than one year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,579&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Between one and five years&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,106&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 More than five years&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,685&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The Company is contractually obligated to return leased space in
 good order, repair and condition excluding ordinary wear and tear
 upon termination of the lease agreement. The Company&amp;#x2019;s asset
 retirement obligations were not significant as of December&amp;#xA0;31,
 2018 and 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company&amp;#x2019;s contractual obligations associated with
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-real&lt;/font&gt; estate leases
 were not significant as of December&amp;#xA0;31, 2018 and 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In March 2019, the Company entered in a lease agreement for
 approximately 7,583 square feet of office space in Cambridge,
 Massachusetts. Refer to Note 22 for further details.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Commitments Related to the Collaboration and License
 Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Under the Incyte collaboration and license agreement, the Company
 and Incyte have agreed to collaborate with respect to the research,
 discovery and development of bispecific antibodies utilizing the
 Company&amp;#x2019;s proprietary bispecific technology platform. The
 collaboration encompasses up to 11 independent programs, including
 some of the Company&amp;#x2019;s current preclinical immuno-oncology
 discovery programs. For one of the current programs, concerning
 &lt;font style="WHITE-SPACE: nowrap"&gt;MCLA-145,&lt;/font&gt; the Company
 retains the exclusive right to develop and commercialize products
 and product candidates in the U.S., while Incyte has the exclusive
 right to develop and commercialize products and product candidates
 arising from such program outside the U.S. For &lt;font style="WHITE-SPACE: nowrap"&gt;MCLA-145,&lt;/font&gt; the Company and Incyte will
 conduct and share equally the costs of mutually agreed global
 development activities and will be solely responsible for
 independent development activities in the respective territories.
 The actual amounts that the Company may pay to Incyte or that
 Incyte may pay to the Company will depend on numerous factors
 outside of the Company&amp;#x2019;s control, including the success of
 certain clinical development efforts with respect to &lt;font style="WHITE-SPACE: nowrap"&gt;MCLA-145,&lt;/font&gt; the content and timing of
 decisions made by the regulators, the reimbursement and competitive
 landscape around &lt;font style="WHITE-SPACE: nowrap"&gt;MCLA-145&lt;/font&gt;
 and other factors.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In addition, the Company has commitments to make potential future
 milestone payments to third parties under certain of its license
 arrangements. These milestones primarily relate to the initiation
 and results of clinical trials, obtaining regulatory approval in
 various jurisdictions and the future commercial success of
 development programs, the outcome and timing of which are difficult
 to predict and subject to significant uncertainty. In addition to
 the milestones discussed above, the Company is obligated to pay
 royalties on future sales, which are contingent on generating
 levels of sales of future products that have not been achieved and
 may never be achieved.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Other Funding Commitments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 As of December&amp;#xA0;31, 2018, the Company had several ongoing
 clinical and nonclinical studies for its various pipeline programs.
 The Company enters into contracts in the normal course of business
 with contract research organizations and clinical sites for the
 conduct of clinical trials, professional consultants for expert
 advice and other vendors for clinical supply manufacturing or other
 services. These contracts are generally cancellable, with notice,
 at the Company&amp;#x2019;s option and do not have significant
 cancellation penalties.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 During 2018, the Company entered into certain contracts to purchase
 property, plant and equipment in 2019 for
 &amp;#x20AC;0.6&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Guarantees&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company indemnifies its officers and directors for certain
 events or occurrences while the officer or director is, or was,
 serving at the Company&amp;#x2019;s request in such capacity. The
 maximum potential amount of future payments the Company could be
 required to make is unlimited; however, the Company has
 directors&amp;#x2019; and officers&amp;#x2019; insurance coverage that is
 intended to limit its exposure and enable it to recover a portion
 of any future amounts paid.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The Company enters into certain agreements with other parties in
 the ordinary course of business that contain indemnification
 provisions. These typically include agreements with directors and
 officers, business partners, contractors, landlords, clinical sites
 and customers. Under these provisions, the Company may indemnifies
 and holds harmless the indemnified party for losses suffered or
 incurred by the indemnified party as a result of the
 Company&amp;#x2019;s activities, such as gross negligence, willful
 misconduct or at times, other activities. These indemnification
 provisions may survive termination of the underlying agreements.
 The maximum potential amount of future payments the Company could
 be required to make under these indemnification provisions may be
 unlimited. However, to date the Company has not incurred material
 costs to defend lawsuits or settle claims related to these
 indemnification provisions. As a result, the estimated fair value
 of these obligations is minimal. Accordingly, the Company did not
 have any liabilities recorded for these obligations as of
 December&amp;#xA0;31, 2018 and 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On March&amp;#xA0;11, 2014, Regeneron Pharmaceuticals, Inc.
 (&amp;#x201C;Regeneron&amp;#x201D;) filed a complaint in the U.S. District
 Court for the Southern District of New York, alleging that the
 Company was infringing one or more claims in Regeneron&amp;#x2019;s U.S.
 Patent No.&amp;#xA0;8,502,018, entitled &amp;#x201C;Methods of Modifying
 Eukaryotic Cells.&amp;#x201D; In 2015, the trial court entered judgments
 finding that the Company does not infringe the claims of the Patent
 No.&amp;#xA0;8,502,018, that the patent is invalid, and that the patent
 was procured through inequitable conduct and is unenforceable. On
 July&amp;#xA0;27, 2017 the U.S. Court of Appeals for the Federal
 Circuit affirmed the trial court&amp;#x2019;s conclusion that Regeneron
 engaged in inequitable conduct before the U.S. Patent and Trademark
 Office while prosecuting the Patent No.&amp;#xA0;8,502,018 and affirmed
 that the Patent No.&amp;#xA0;8,502,018 is unenforceable. On
 December&amp;#xA0;26, 2017, the Federal Circuit denied
 Regeneron&amp;#x2019;s petition for rehearing and rehearing en banc
 seeking a review of that decision and on October&amp;#xA0;1, 2018, the
 Supreme Court of the U.S. denied Regeneron&amp;#x2019;s petition for
 certiorari, rendering the case finally resolved in the
 Company&amp;#x2019;s favor.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On March&amp;#xA0;26, 2018, the trial court granted the Company&amp;#x2019;s
 motion for attorneys&amp;#x2019; fees, expert fees, and costs associated
 with the Company&amp;#x2019;s defense of the above litigation, and
 ordered the parties to address the amount of the award. The Company
 provided a detailed explanation of its attorneys&amp;#x2019; fees,
 expert fees, and costs of such award, which Regeneron responded to,
 seeking a reduction of the amount. The matter was fully briefed as
 of May&amp;#xA0;18, 2018, and the court issued an Order on
 June&amp;#xA0;25, 2018, which published on July&amp;#xA0;10, 2018, granting
 the Company&amp;#x2019;s motion for $8,332,453.46 in attorneys&amp;#x2019;
 fees, $465,390.34 in expert fees, and $1,717,100.69 in litigation
 expenses and costs, along with &lt;font style="WHITE-SPACE: nowrap"&gt;pre-&lt;/font&gt; and post-judgment interest.
 Regeneron appealed the decision awarding attorneys&amp;#x2019; fees to
 the Company to the Federal Circuit, filing its opening brief on
 November&amp;#xA0;7, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On March&amp;#xA0;11, 2014, Regeneron served a writ in the Netherlands
 alleging that the Company was infringing one or more claims in
 their European patent EP 1 360 287 B1. The Company had opposed that
 patent in June 2014. On September&amp;#xA0;17, 2014, Regeneron&amp;#x2019;s
 patent EP 1 360 287 B1 was revoked in its entirety by the European
 Opposition Division of the European Patent Office (the
 &amp;#x201C;EPO&amp;#x201D;). In Europe, an appeal hearing occurred in
 October and November 2015 at the Technical Board of Appeal for the
 EPO at which time the patent was reinstated to Regeneron with
 amended claims. On October&amp;#xA0;2, 2017, the Company filed an
 appeal with the Technical Board of Appeal for the EPO to address
 whether the patent having claims amended during the course of
 opposition complies with Art. 84 EPC, Art. 123(2) EPC and Rule 80
 EPC. On May&amp;#xA0;25, 2018, at Regeneron&amp;#x2019;s request, a hearing
 before the Technical Board of Appeals for the EPO was scheduled for
 September&amp;#xA0;13, 2018, to address whether the description of EP 1
 360 287 B1 patent having claims amended during the course of
 opposition complies with Art. 84 EPC, Art. 123(2) EPC and Rule 80
 EPC. The Technical Board of Appeals provided preliminary views on
 the matter on August&amp;#xA0;23, 2018, after which the Company&amp;#x2019;s
 appeal filed on October&amp;#xA0;2, 2017 was withdrawn on
 September&amp;#xA0;5, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The costs incurred in the above litigation and opposition were
 &amp;#x20AC;1.4&amp;#xA0;million, &amp;#x20AC;1.0&amp;#xA0;million and
 &amp;#x20AC;1.5&amp;#xA0;million for the years ended December&amp;#xA0;31, 2018,
 2017 and 2016, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Regeneron also previously raised opposition proceedings against
 certain of the Company&amp;#x2019;s patents in jurisdictions including
 Europe, Japan and Australia.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On December&amp;#xA0;20, 2018, the Company signed a global settlement
 and cross-license agreement with Regeneron, where the parties have
 agreed to end all pending litigation and opposition proceedings
 pertaining to the Company&amp;#x2019;s and Regeneron&amp;#x2019;s respective
 antibody generation technologies. Regeneron also purchased 600,000
 of the Company&amp;#x2019;s common shares at a price of $25 per share
 for total aggregate proceeds of $15.0&amp;#xA0;million. The
 cross-license and stock purchase were made in conjunction with the
 agreement to withdraw Regeneron&amp;#x2019;s appeal of the fee award,
 and agreement to dismissal of all claims to approximately
 $10.5&amp;#xA0;million for the reimbursement of attorneys&amp;#x2019; fees
 and other expenses, plus interest, awarded to Merus by the trial
 court. Under the terms of the settlement, Regeneron has withdrawn
 its appeal of the decision awarding attorneys&amp;#x2019; fees to the
 Company as a result of the U.S. District Court litigation described
 above. In addition, Regeneron has dismissed its stayed case in the
 Netherlands asserting the EP 1 360 287 B1 patent, and both parties
 have withdrawn all pending oppositions as of December&amp;#xA0;20,
 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On April&amp;#xA0;5, 2018, an unnamed third party and Regeneron filed
 notices of opposition against the Company&amp;#x2019;s EP 2604625
 patent, entitled &amp;#x201C;Generation of Binding Molecules,&amp;#x201D; in
 the EPO. The notices asserted, as applicable, added subject matter,
 lack of novelty, lack of inventive step, and insufficiency.
 Regeneron will no longer be pursuing this opposition pursuant to
 December&amp;#xA0;20, 2018 settlement. On August&amp;#xA0;20, 2018, the
 Company timely responded to these submissions, with proceedings to
 be ongoing with respect to the unnamed third party. An opposition
 hearing is scheduled for June 2019. As this opposition proceeding
 continues, the Company cannot be certain that the Company will
 ultimately prevail.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 From time to time, the Company may be involved in various other
 claims and legal proceedings relating to claims arising out of the
 Company&amp;#x2019;s operations. The Company is not currently a party to
 any other material legal proceedings.&lt;/p&gt;
 &lt;/div&gt;</mrus:DisclosureOfCommitmentsAndContingenciesExplanatory>
  <mrus:DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_06452D58-19FB-4A05-BF1A-56D9AF466D88_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Share-based compensation expense recognized as employee benefit
 expenses during the years ended December&amp;#xA0;31, 2018, 2017 and
 2016 was as follows:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;&lt;i&gt;(euros in
 thousands)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 R&amp;amp;D costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,710&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,245&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;703&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Management and administration costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,742&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,942&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,037&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Other expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;473&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;628&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;567&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,925&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,815&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,307&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory>
  <mrus:DisclosureOfDetailedInformationOfRelatedPartyExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_9B33D25A-5B2D-4F67-BB6A-FFC328E69905_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The remainder of the key management personnel has received the
 following remuneration:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 &lt;b&gt;Remuneration&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;in
 euros&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Short-term employment benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,705,438&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,808,998&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,139,763&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Post-employment benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;40,882&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;108,416&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,720&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other long-term benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Termination benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Share-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,688,978&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,171,233&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,195,876&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,435,298&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,088,647&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,354,359&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfDetailedInformationOfRelatedPartyExplanatory>
  <mrus:DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_90BFD9C4-0EB6-4C44-A417-3FFD56981F57_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 For the purpose of presentation in the statement of cash flows as
 well as the statement of financial position, cash and cash
 equivalents include deposits held with financial institutions with
 original maturities of less than three months from the date of
 acquisition. Cash and cash equivalents include
 &amp;#x20AC;49.1&amp;#xA0;million of investments with a three month or less
 maturity, callable on demand. The carrying values of cash
 equivalents approximate fair value due to their short-term
 maturities.&lt;/p&gt;
 &lt;/div&gt;</mrus:DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory>
  <mrus:DisclosureOfTradeAndOtherCurrentReceivableExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_FD4E897B-224E-4149-B26F-BA4FDCFA1EE0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 All trade and other receivables are short-term and due within 1
 year.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;&lt;i&gt;(euros&amp;#xA0;in&amp;#xA0;thousands)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,690&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,594&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unbilled receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;236&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 VAT receivable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;891&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,783&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;427&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid pension costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;838&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Interest receivable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;213&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;219&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,032&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,413&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfTradeAndOtherCurrentReceivableExplanatory>
  <mrus:DisclosureChargedToTheProfitAndLossStatementExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_130B5411-45D3-4928-8B9D-E1BDA6BA3DEA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In 2018, 2017 and 2016, the following amounts were charged to the
 consolidated statement of profit or loss and comprehensive loss for
 the remuneration of the statutory directors:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 &lt;b&gt;Name&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&amp;#xA0;salary&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Bonus&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Pension&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Option&amp;#xA0;cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="18" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;in
 euros&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Ton Logtenberg, President, CEO and Principal Financial Officer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;445,606&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;155,962&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,881&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,696,918&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,330,367&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;432,782&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;337,945&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,528&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,675,590&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,497,845&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;369,204&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;147,820&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,717&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;907,236&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,441,977&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Shelley Margetson(*), Former COO&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(**)&amp;#xA0;420,782&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,595&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;451,752&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;892,129&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;198,987&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;84,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,152&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;164,547&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;453,686&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(*)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Resigned as a statutory director of the Company
 effective as of May&amp;#xA0;24, 2017.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(**)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Gross salary includes severance payments totaling
 &amp;#x20AC;257,260.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</mrus:DisclosureChargedToTheProfitAndLossStatementExplanatory>
  <mrus:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_48752424-6ABD-41AC-B258-08E3958451D0_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Details of the employee benefits are as follows:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Salaries and wages&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;10,783&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,556&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,166&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 WBSO subsidy&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(4,257&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,523&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,721&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Social security premiums&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;919&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;621&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;382&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Health insurance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;330&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;222&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Pension costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;749&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;652&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;507&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Share-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,925&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,815&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,307&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Other personnel expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,835&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;656&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;442&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total employee benefits expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;18,284&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,999&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,110&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory>
  <mrus:DisclosureOfInformationAboutRevenueExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_864F83CF-1B12-4A63-8A27-144EA5030320_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company&amp;#x2019;s revenues are generated entirely in the
 Netherlands. In the following table, revenue is disaggregated by
 primary source of revenue as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;br /&gt;
 Restated*&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;br /&gt;
 Restated*&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;&lt;i&gt;(euros in
 thousands)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Upfront payment amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;17,686&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,933&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 R&amp;amp;D cost reimbursement and milestone&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;13,566&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,787&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,109&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Revenue from contracts with customers&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;31,252&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,720&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,123&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Income from grants on research projects&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;196&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,195&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,387&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;31,448&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,915&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,510&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;*&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;i&gt;See Note 4 for details regarding the restatement as
 a result of a change in accounting policy.&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfInformationAboutRevenueExplanatory>
  <mrus:DisclosureOfOtherIncomeExpenseExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_337F3227-9C9F-4544-B157-7108E289B3BD_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;16.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Other Income (Expense)&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The following table presents a breakdown of other income
 (expense):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Finance income&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Interest income and similar related income&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,809&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,112&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;88&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net gain on foreign exchange&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6,034&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="right"&gt;&lt;b&gt;7,843&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="right"&gt;&lt;b&gt;1,112&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="right"&gt;&lt;b&gt;88&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other income&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,095&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Finance costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Interest and other expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(4&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(190&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss on foreign exchange&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19,449&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(409&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Derivative financial instrument expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,696&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19,235&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(4&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(30,335&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19,644&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total other income (expense)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;14,934&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(29,223&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19,556&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Interest income primarily results from interest earned on cash held
 on account and accretion of investment earnings.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company presents foreign currency gains and losses on a net
 basis as either finance income or finance expense depending on
 whether foreign currency movements are in a net gain or net loss
 position.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Other income consists of a gain recorded in connection with the
 Regeneron Subscription Agreement. See Note 12 and Note 21 for
 details. Pursuant to the Regeneron Subscription Agreement, the
 Company agreed to sell an aggregate of 600,000 of its common shares
 to Regeneron at a purchase price equal to $25.0 per share. On
 December&amp;#xA0;21, 2018, the Company completed the sale under the
 Regeneron Subscription Agreement and received gross proceeds of
 $15.0&amp;#xA0;million, or &amp;#x20AC;13.1&amp;#xA0;million. Accordingly, the
 Company recorded the common shares issued at the fair value of the
 underlying securities on the date of issuance. The difference
 between the total proceeds received of $15.0&amp;#xA0;million, or
 &amp;#x20AC;13.1&amp;#xA0;million, and the aggregate value of common shares
 issued of $6.9&amp;#xA0;million, or &amp;#x20AC;6.0&amp;#xA0;million, was
 recorded as a gain on litigation settlement of $8.1&amp;#xA0;million,
 or &amp;#x20AC;7.1&amp;#xA0;million, during the year-ended December&amp;#xA0;31,
 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On December&amp;#xA0;20, 2016, the Company entered into the share
 subscription agreement with Incyte and recognized a freestanding
 forward contract (derivative asset) of $32.6&amp;#xA0;million, or
 &amp;#x20AC;31.4&amp;#xA0;million, in its statement of financial position.
 In accordance with IAS 39, the finance costs for the year ended
 December&amp;#xA0;31, 2017 and 2016, include an amount of
 &amp;#x20AC;10.7&amp;#xA0;million and &amp;#x20AC;19.2&amp;#xA0;million,
 respectively, related to a fair value remeasurement of the forward
 contract through December&amp;#xA0;31, 2016 and through
 January&amp;#xA0;23, 2017, the date the shares were issued to
 Incyte.&lt;/p&gt;
 &lt;/div&gt;</mrus:DisclosureOfOtherIncomeExpenseExplanatory>
  <mrus:DisclosureOfInterestBearingFinancialInstrumentsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_79BDF54B-92E2-440F-A289-DDF6A80CB1B9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The interest rate profile of the Company&amp;#x2019;s interest-bearing
 financial instruments is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Fixed-rate instruments&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;61,800&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Variable rate instruments&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;143,747&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;149,678&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfInterestBearingFinancialInstrumentsExplanatory>
  <mrus:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_0957FC6A-184C-4DBE-9F08-1EF928AFFCFF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 During 2017, the Company granted RSUs to Key Management Personnel.
 The following table summarizes the Company&amp;#x2019;s RSU&amp;#x2019;s
 activity:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;grant&amp;#xA0;date&lt;br /&gt;
 fair value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;br /&gt;
 average&lt;br /&gt;
 grant&amp;#xA0;date&lt;br /&gt;
 fair value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested at January&amp;#xA0;1&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;194,546&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#x20AC;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited during the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#x20AC;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(12,219&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expired during the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vested during the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#x20AC;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(93,244&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#x20AC;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(7,331&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted during the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#x20AC;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;214,096&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested at December&amp;#xA0;31&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#x20AC;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;101,302&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#x20AC;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;194,546&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory>
  <mrus:DisclosureOfDeferredRevenueExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_E375EBA3-E460-4513-9D26-9266CE72BB89_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Deferred revenue consisted of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;br /&gt;
 Restated*&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;&lt;i&gt;(euros&amp;#xA0;in&amp;#xA0;thousands)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&amp;#x2014;current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;16,934&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,935&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;97,675&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;112,551&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;114,609&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;*&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;i&gt;See Note 4 for details regarding the restatement as
 a result of a change in accounting policy.&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfDeferredRevenueExplanatory>
  <mrus:DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_BD1ACA5D-0A80-4691-B7D6-0F979FC8B3C7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table presents a breakdown of other R&amp;amp;D
 costs:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Discovery and preclinical costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;5,506&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,473&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,185&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Clinical costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;9,169&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,919&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,409&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other R&amp;amp;D costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,263&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,635&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,216&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Total other R&amp;amp;D costs&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;18,938&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,027&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory>
  <mrus:DescriptionOfAccountingPolicyForInvestmentsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_70523A6D-F0C2-43B9-8F94-BB18026DBB62_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Investments&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Investments are classified and accounted for at amortized cost and
 initially measured at fair value. Subsequent to initial
 recognition, they are measured at amortized cost using the
 effective interest rate method. Investments are classified as
 amortized cost as the Company has the positive intent and ability
 to hold them until maturity. Interest income from these securities
 is included in finance income.&lt;/p&gt;
 &lt;/div&gt;</mrus:DescriptionOfAccountingPolicyForInvestmentsExplanatory>
  <mrus:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_AFA1259C-52B1-426A-A2DE-8CB9E06EE48C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Basis of consolidation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;(i) Subsidiaries&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Subsidiaries are entities controlled by the Company, consisting of
 Merus N.V.&amp;#x2019;s wholly owned subsidiary Merus US, Inc. The
 Company controls an entity when it is exposed to, or has rights to,
 variable returns from its involvement with the entity and has the
 ability to affect those returns through its power over the entity.
 The financial statements of subsidiaries are included in the
 consolidated financial statements from the date on which control
 commences until the date on which control ceases.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;(ii) Loss of control&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 When the Company loses control over a subsidiary, it derecognizes
 the assets and liabilities of the subsidiary, and any &lt;font style="WHITE-SPACE: nowrap"&gt;non-controlling&lt;/font&gt; interests and other
 components of equity. Any resulting gain or loss is recognized in
 profit or loss. Any interest retained in the former subsidiary is
 measured at fair value when control is lost.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;(iii) Transactions eliminated on consolidation&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Intercompany balances and transactions, and any unrealized income
 and expenses arising from intercompany transactions, are eliminated
 in consolidation. Unrealized gains arising from transactions with
 equity-accounted investees are eliminated against the investment to
 the extent of the Company&amp;#x2019;s interest in the investee.
 Unrealized losses are eliminated in the same way as unrealized
 gains, but only to the extent that there is no evidence of
 impairment.&lt;/p&gt;
 &lt;/div&gt;</mrus:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory>
  <mrus:DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_8ADD8AA7-72FF-4A6F-A204-7D8F89499910_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The following financial statement line items have been shown to
 reflect the adjustments recognized for each individual line item in
 the Company&amp;#x2019;s respective consolidated financial statements
 for the period noted:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Consolidated Statement of Profit or Loss and Comprehensive
 Loss&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="50%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;br /&gt;
 (As originally&lt;br /&gt;
 presented)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS&amp;#xA0;15&lt;br /&gt;
 Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,600&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,915&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Operating result&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,617&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(35,302&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total comprehensive loss for the period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(73,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(64,685&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Loss per share&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.43&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="48%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;br /&gt;
 (As originally&lt;br /&gt;
 presented)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS&amp;#xA0;15&lt;br /&gt;
 Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,719&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(209&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,510&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Operating result&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(27,672&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(209&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(27,881&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total comprehensive loss for the period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(47,220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(209&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(47,429&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Loss per share&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.57&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.01&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.58&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Consolidated Statement of Financial Position&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;br /&gt;
 (As originally&lt;br /&gt;
 presented)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS 15&lt;br /&gt;
 Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(167,480&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,705&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(158,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue, &lt;font style="WHITE-SPACE: nowrap"&gt;non-current&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;130,195&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,644&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;112,551&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,996&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,939&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,935&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="48%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;br /&gt;
 (As originally&lt;br /&gt;
 presented)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS 15&lt;br /&gt;
 Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(107,295&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;390&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(106,905&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue, &lt;font style="WHITE-SPACE: nowrap"&gt;non-current&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,206&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,272&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,934&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,610&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,882&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,492&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;i&gt;Consolidated Statement of Cash Flows&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="50%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;br /&gt;
 (As originally&lt;br /&gt;
 presented)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS 15&lt;br /&gt;
 Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Result after taxation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(73,089&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(64,774&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Changes in working capital:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,618&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14,933&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;br /&gt;
 (As originally&lt;br /&gt;
 presented)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS 15&lt;br /&gt;
 Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Result after taxation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(47,228&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(209&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(47,437&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Changes in working capital:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(223&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;209&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory>
  <mrus:DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_A92C28B3-9867-454D-8526-C5C35B711F5C_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;19.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Board Compensation and Key Management
 Personnel&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On May&amp;#xA0;29, 2017, the Company changed its governance structure
 from a &lt;font style="WHITE-SPACE: nowrap"&gt;two-tier&lt;/font&gt; model
 consisting of a Management Board acting under the supervision of a
 separate Supervisory Board to a &lt;font style="WHITE-SPACE: nowrap"&gt;one-tier&lt;/font&gt; board model with a unitary
 Board of Directors consisting of an executive director and
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-executive&lt;/font&gt; directors.
 In the &lt;font style="WHITE-SPACE: nowrap"&gt;one-tier&lt;/font&gt; board
 model, the Board of Directors as a collective (i.e., the executive
 director and the &lt;font style="WHITE-SPACE: nowrap"&gt;non-executive&lt;/font&gt; directors) are charged
 with both the management and monitoring functions of the
 Company&amp;#x2019;s general course of affairs inclusive of the
 Company&amp;#x2019;s overall business strategy and financial policies.
 The executive director manages the day &lt;font style="WHITE-SPACE: nowrap"&gt;to-day&lt;/font&gt; business and operations of the
 Company and implements the Company&amp;#x2019;s strategy. The
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-executive&lt;/font&gt; directors
 focus on the supervision of policy and the performance of the
 duties of all directors, as well as the Company&amp;#x2019;s general
 state of affairs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Prior to May&amp;#xA0;29, 2017, the Company&amp;#x2019;s Management Board
 was in charge of managing the Company and consisted of Ton
 Logtenberg, Chief Executive Officer (&amp;#x201C;CEO&amp;#x201D;) and Shelly
 Margetson, the former Chief Operating Officer (&amp;#x201C;COO&amp;#x201D;).
 Ms.&amp;#xA0;Margetson resigned as a statutory director of the Company
 effective as of May&amp;#xA0;24, 2017 and ended her employment with the
 Company effective as of August&amp;#xA0;1, 2017. The Supervisory Board
 was responsible for the supervision of the Management Board and the
 general course of affairs of the Company. Subsequent to
 May&amp;#xA0;29, 2017, the members of the Supervisory Board are now
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-executive&lt;/font&gt; directors,
 while Mr.&amp;#xA0;Logtenberg remains as the lone executive director on
 the unitary Board of Directors.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In addition to Board of Directors, the Company employs certain key
 management personnel responsible for executing the &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;day-to-day&lt;/font&gt;&lt;/font&gt; business and
 operations of the Company. Key management personnel are those
 persons having authority and responsibility for planning, directing
 and controlling the activities of the Company. The Company includes
 the following employees in this classification: Alexander Berthold
 Hendrik Bakker, Ph.D., Chief Development Officer, John de Kruif,
 Chief Technology Officer, Hui Liu, Ph.D., Chief Business Officer
 and Head of Merus U.S., Peter Silverman, General Counsel and Chief
 Intellectual Property Officer, L. Andres Sirulnik, M.D., Ph.D.,
 Chief Medical Officer (&amp;#x201C;CMO&amp;#x201D;), and Mark Throsby, Ph.D.,
 Chief Scientific Officer. On January&amp;#xA0;2, 2019, Mr.&amp;#xA0;Crowley
 resigned as the Executive Vice President and CFO to pursue other
 opportunities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Executive Directors&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In 2018, 2017 and 2016, the following amounts were charged to the
 consolidated statement of profit or loss and comprehensive loss for
 the remuneration of the statutory directors:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 &lt;b&gt;Name&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&amp;#xA0;salary&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Bonus&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Pension&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Option&amp;#xA0;cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="18" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;in
 euros&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Ton Logtenberg, President, CEO and Principal Financial Officer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;445,606&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;155,962&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,881&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,696,918&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,330,367&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;432,782&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;337,945&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,528&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,675,590&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,497,845&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;369,204&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;147,820&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,717&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;907,236&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,441,977&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Shelley Margetson(*), Former COO&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(**)&amp;#xA0;420,782&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,595&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;451,752&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;892,129&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;198,987&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;84,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,152&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;164,547&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;453,686&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(*)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Resigned as a statutory director of the Company
 effective as of May&amp;#xA0;24, 2017.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(**)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Gross salary includes severance payments totaling
 &amp;#x20AC;257,260.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 During the year ended December&amp;#xA0;31, 2018, Mr.&amp;#xA0;Logtenberg
 was granted 129,000 share options. As of December&amp;#xA0;31, 2018,
 2017 and 2016, Mr.&amp;#xA0;Logtenberg held 758,925, 661,629 and
 376,912 share options, respectively, with a weighted average
 exercise price of &amp;#x20AC;17.07, &amp;#x20AC;14.20, &amp;#x20AC;2.98,
 respectively. As of December&amp;#xA0;31, 2018 and 2017,
 Mr.&amp;#xA0;Logtenberg held 64,450 and 123,745 unvested RSUs,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Upon Ms.&amp;#xA0;Margetson&amp;#x2019;s separation date, she was entitled
 to an accelerated vesting of any unvested share options and RSUs
 held that would have vested during the &lt;font style="WHITE-SPACE: nowrap"&gt;12-month&lt;/font&gt; period following her
 separation date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Key Management Personnel&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The remainder of the key management personnel has received the
 following remuneration:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 &lt;b&gt;Remuneration&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;in
 euros&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Short-term employment benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,705,438&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,808,998&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,139,763&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Post-employment benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;40,882&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;108,416&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,720&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other long-term benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Termination benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Share-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,688,978&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,171,233&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,195,876&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,435,298&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,088,647&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,354,359&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Some of the key management personnel have long-term benefits in the
 form of life and long-term disability insurance policies, which
 have been affected in their name as well as severance conditions in
 case of termination without cause or leave for a good reason.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 A number of key management personnel, or their related parties,
 hold positions in other companies that result in them having
 control or significant influence over these companies. These
 companies did not enter into transactions with the Company during
 the year.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On October&amp;#xA0;27, 2016, the Company appointed Andres Sirulnik as
 its CMO. A total 219,890 share options were granted to
 Dr.&amp;#xA0;Sirulnik with an exercise price of &amp;#x20AC;16.85&amp;#xA0;per
 share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On February&amp;#xA0;15, 2017, the Company appointed Peter Silverman as
 its Senior Vice President, Legal. A total 50,000 share options were
 granted to Mr.&amp;#xA0;Silverman with an exercise price of
 &amp;#x20AC;24.54&amp;#xA0;per share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On November&amp;#xA0;1, 2016, the Company appointed John Crowley as its
 CFO. A total of 183,241 share options were granted to
 Mr.&amp;#xA0;Crowley with an exercise price of &amp;#x20AC;15.24&amp;#xA0;per
 share. On January&amp;#xA0;2, 2019, Mr.&amp;#xA0;Crowley resigned as the
 Executive Vice President and CFO. In connection with his departure,
 Mr.&amp;#xA0;Crowley entered into a separation and release agreement
 with the Company, pursuant to which Mr.&amp;#xA0;Crowley will be
 entitled to receive a severance payment equal to 6 months of his
 annual salary.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Non-Executive&lt;/font&gt;
 Directors&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In May 2016, the Company established the Supervisory Board
 Remuneration Program, which was subsequently replaced by the
 &lt;font style="WHITE-SPACE: nowrap"&gt;Non-Executive&lt;/font&gt; Compensation
 Program to reflect the change in governance structure of the
 Company. As part of this program, &lt;font style="WHITE-SPACE: nowrap"&gt;non-executive&lt;/font&gt; directors are entitled
 to cash compensation as well as equity compensation. The equity
 compensation consists of an initial option grant as well as
 subsequent annual share-based awards.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The following amounts were charged to the consolidated statement of
 profit or loss and comprehensive loss for the remuneration of the
 members of the Board:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="28%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31, 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31, 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31, 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 &lt;b&gt;Name&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Cash&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;compensation&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Option&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Cash&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;compensation&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Option&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Cash&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;compensation&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Option&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;&lt;i&gt;(in
 euros)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;&lt;i&gt;(in
 euros)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;&lt;i&gt;(in
 euros)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Russell Greig&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79,333&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;117,936&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Mark Iwicki&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;55,066&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;68,666&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123,732&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;59,840&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;120,596&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,436&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;50,394&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;183,367&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;233,761&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Len Kanavy&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,859&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;152,485&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;185,344&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Wolfgang Berthold&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;65,776&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;85,091&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;37,530&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,944&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,474&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;50,928&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,778&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Lionel Carnot*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,401&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,401&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,445&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61,870&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,852&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;66,959&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;91,811&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 John de Koning&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;40,768&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,044&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;91,812&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,573&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;113,613&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;152,186&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,230&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;37,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;63,230&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Anand Mehra&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,863&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,449&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74,312&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,615&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;83,683&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123,298&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,938&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;84,703&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;111,641&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Gregory Perry&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,356&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,797&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100,153&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,700&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;103,169&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;144,869&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,356&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,365&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;125,721&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;292,231&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;506,550&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;798,781&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;252,703&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;573,875&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;826,578&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;176,620&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;520,322&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;696,942&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(*)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;former board member&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As at December&amp;#xA0;31, members of the Board held the following
 number of options:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="50%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31, 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31, 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December, 31 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 &lt;b&gt;Name&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Russell Greig&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,966&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Mark Iwicki&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;84,209&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.07&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79,226&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.32&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,576&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.57&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Len Kanavy&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,818&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16.33&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Wolfgang Berthold&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36,540&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.22&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,040&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.90&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,724&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.02&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Lionel Carnot*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.87&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 John de Koning&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.34&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.87&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Anand Mehra&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.34&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.87&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Gregory Perry&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.34&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.87&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Gabriele Dallmann*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,828&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;235,432&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;193,866&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.61&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;185,128&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.21&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(*)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;former board member&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory>
  <mrus:DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_48B62F01-EAB5-4DEB-B95C-5A1F1BE60456_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Finance Income and Finance Expenses&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company&amp;#x2019;s finance income and finance expenses
 include:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;interest and related income;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;interest expense and changes in fair value of the
 forward contract (derivative);&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;financing costs; and&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the foreign currency gain or loss on financial assets
 and financial liabilities.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Interest income or expense is recognized using the effective
 interest method.&lt;/p&gt;
 &lt;/div&gt;</mrus:DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory>
  <mrus:DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_E6F028F2-0B2B-4ADE-8A1A-49729908AA1F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 All amounts are short-term and payable within 1 year.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;&lt;i&gt;(euros&amp;#xA0;in&amp;#xA0;thousands)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Audit fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;167&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Personnel-related&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;560&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;446&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued bonus&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,523&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,545&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 R&amp;amp;D costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,409&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,272&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 IP legal fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;212&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;509&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Subsidy advance received&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;42&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;224&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other accruals&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,051&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;535&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,964&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,627&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock>
  <mrus:DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_72553186-122E-42FC-AAAB-0C8630C536B4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The following table presents a breakdown of operating expenses:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Manufacturing costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;18,914&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,567&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,162&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 IP and license costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,852&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,858&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,167&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Personnel related R&amp;amp;D&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,036&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,673&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,285&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other R&amp;amp;D costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;18,938&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,027&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;i&gt;Total R&amp;amp;D costs&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;46,740&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,125&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,424&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;i&gt;Management and administration costs&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;10,395&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,258&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Litigation costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,425&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,039&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,490&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other operating expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;11,735&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,356&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,219&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;i&gt;Total other expenses&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;13,160&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,395&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,709&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Total operating expenses&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;70,295&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,217&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,391&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory>
  <mrus:DisclosureOfDetailsOfEarningsPerShareExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_A4E32943-8373-4CF7-B483-B42C48C4643C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Basic and diluted net loss per share attributable to equity holders
 of the Company was calculated as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="57%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;br /&gt;
 Restated*&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;br /&gt;
 Restated*&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(e&lt;/b&gt;&lt;b&gt;&lt;i&gt;uros
 in thousands, except per share data&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Numerator:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss attributable to equity holders of the Company&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(24,235&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(64,685&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(47,429&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Denominator:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average shares outstanding&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;22,286,720&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,196,440&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,236,649&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Loss per share&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(1.09&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.58&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;*&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;See Note 4 for details regarding the restatement as a
 result of a change in accounting policy&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfDetailsOfEarningsPerShareExplanatory>
  <mrus:DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_66981609-AAD1-4298-9174-373C3A757D03_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The following amounts were charged to the consolidated statement of
 profit or loss and comprehensive loss for the remuneration of the
 members of the Board:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="28%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31, 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31, 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;December&amp;#xA0;31, 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 &lt;b&gt;Name&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Cash&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;compensation&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Option&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Cash&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;compensation&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Option&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Cash&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;compensation&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Option&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;&lt;i&gt;(in
 euros)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;&lt;i&gt;(in
 euros)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;&lt;i&gt;(in
 euros)&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Russell Greig&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79,333&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;117,936&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Mark Iwicki&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;55,066&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;68,666&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123,732&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;59,840&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;120,596&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,436&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;50,394&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;183,367&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;233,761&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Len Kanavy&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,859&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;152,485&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;185,344&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Wolfgang Berthold&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;65,776&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;85,091&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;37,530&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,944&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,474&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;50,928&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,778&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Lionel Carnot*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,401&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,401&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,445&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61,870&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,852&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;66,959&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;91,811&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 John de Koning&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;40,768&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,044&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;91,812&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,573&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;113,613&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;152,186&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,230&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;37,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;63,230&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Anand Mehra&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,863&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,449&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74,312&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,615&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;83,683&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123,298&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,938&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;84,703&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;111,641&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Gregory Perry&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,356&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,797&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100,153&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,700&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;103,169&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;144,869&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,356&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,365&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;125,721&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;292,231&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;506,550&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;798,781&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;252,703&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;573,875&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;826,578&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;176,620&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;520,322&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;696,942&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(*)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;former board member&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory>
  <mrus:DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_3E0D0C56-76F8-46B9-BAA0-70D9DAE44CB3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As at December&amp;#xA0;31, members of the Board held the following
 number of options:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="50%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31, 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31, 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December, 31 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 &lt;b&gt;Name&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Russell Greig&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,966&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Mark Iwicki&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;84,209&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.07&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79,226&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.32&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,576&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.57&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Len Kanavy&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,818&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16.33&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Wolfgang Berthold&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36,540&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.22&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,040&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.90&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,724&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.02&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Lionel Carnot*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.87&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 John de Koning&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.34&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.87&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Anand Mehra&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.34&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.87&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Gregory Perry&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.34&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.87&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Gabriele Dallmann*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,828&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;235,432&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;193,866&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.61&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;185,128&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#x20AC;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.21&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(*)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;former board member&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_3010_2">11.52</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:IPAndLicenseCosts contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_1_1">1852000</mrus:IPAndLicenseCosts>
  <mrus:DisclosureOfMaximumExposureToCreditRiskExplanatory contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_3472A5F5-4459-4132-8296-56C69BF9DD7B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The carrying amount of financial assets represents the maximum
 credit exposure.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(&lt;/b&gt;&lt;b&gt;&lt;i&gt;euros
 in thousands&lt;/i&gt;&lt;/b&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade and unbilled receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,926&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;61,800&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;143,747&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;149,678&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;208,473&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;193,064&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfMaximumExposureToCreditRiskExplanatory>
  <mrus:AdditionsToTradeReceivables contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F8B7FC2B-1154-4601-887C-8DB3A5477E34_4003_2">19951000</mrus:AdditionsToTradeReceivables>
  <mrus:DeductionsInTradeReceivables contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F8B7FC2B-1154-4601-887C-8DB3A5477E34_4003_3">18855000</mrus:DeductionsInTradeReceivables>
  <mrus:WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0" id="id_14264487_687F3B2D-E064-48B0-9F34-FAA1EC646149_1_0">P135D</mrus:WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3421023" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_3_3">0.9471</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3421023" unitRef="Y" decimals="0" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_3_4">10</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3421023" unitRef="pure" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_3_5">0.00</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3421023_3422662x3416700" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_1_6">0.0279</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <mrus:EmployeeOptionExercisedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3421023_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_1_2">13.01</mrus:EmployeeOptionExercisedPricePerShare>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3421023_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_1_1">13.01</mrus:SharePurchasedPricePerShare>
  <mrus:FairValueAssumptionsGrantDateSharePrice contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3421023_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_1_0">6.82</mrus:FairValueAssumptionsGrantDateSharePrice>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3421023_3422662x3423353" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_2_6">0.0320</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <mrus:EmployeeOptionExercisedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3421023_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_2_2">19.90</mrus:EmployeeOptionExercisedPricePerShare>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3421023_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_2_1">19.90</mrus:SharePurchasedPricePerShare>
  <mrus:FairValueAssumptionsGrantDateSharePrice contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3421023_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_2_0">12.27</mrus:FairValueAssumptionsGrantDateSharePrice>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3486468" unitRef="iso4217_USD_per_shares" decimals="1" id="id_14264487_4B358E3D-4B35-4BAE-BB5B-FA25DF71D69A_1001_2">25.0</mrus:SharePurchasedPricePerShare>
  <mrus:MilestoneRevenuesAndCostsReimbursements contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3486516" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_EDC8EC1D-7D66-4C8E-9D44-F5E2140FD0D3_1001_1">8800000</mrus:MilestoneRevenuesAndCostsReimbursements>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492745" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_3004_1">36540</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492745" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_3003_4">85091</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492745" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_3004_2">15.22</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492745_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_3001_4">19315</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492745_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_3002_4">65776</mrus:RemunerationForFormerEmployees>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492855" unitRef="iso4217_EUR" decimals="0" id="id_14264487_716AE753-5133-4CCC-9580-51A3D0738536_1005_0">3330367</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492855" unitRef="pure" decimals="INF" id="id_14264487_04F0C648-1908-4CA2-BAD5-3AD778B35B9D_1001_0">129000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <mrus:NumberOfOptionsHeldByTheChiefExecutiveOfficers contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492855" unitRef="shares" decimals="INF" id="id_14264487_980A9597-926B-4320-9757-88517FDA697F_1001_0">758925</mrus:NumberOfOptionsHeldByTheChiefExecutiveOfficers>
  <mrus:NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492855" unitRef="pure" decimals="INF" id="id_14264487_980A9597-926B-4320-9757-88517FDA697F_1001_2">64450</mrus:NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers>
  <mrus:AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492855" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_980A9597-926B-4320-9757-88517FDA697F_1001_1">17.07</mrus:AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492855_3416904x3498764" unitRef="iso4217_EUR" decimals="0" id="id_14264487_716AE753-5133-4CCC-9580-51A3D0738536_1002_0">155962</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492855_3416904x3505512" unitRef="iso4217_EUR" decimals="0" id="id_14264487_716AE753-5133-4CCC-9580-51A3D0738536_1001_0">445606</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492855_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_716AE753-5133-4CCC-9580-51A3D0738536_1004_0">2696918</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492855_3416904x3556606" unitRef="iso4217_EUR" decimals="0" id="id_14264487_716AE753-5133-4CCC-9580-51A3D0738536_1003_0">31881</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:LicenceFeeIncome contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3496066_3475724x3503788" unitRef="iso4217_USD" decimals="-5" id="id_14264487_D564E8D7-FFCA-40B0-9C75-982956D77767_1001_0">120000000</ifrs-full:LicenceFeeIncome>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3496102" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_1001_2">31252000</ifrs-full:Revenue>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3498639" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_3007_1">27633</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3498639" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_4003_7">74312</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3498639" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_3007_2">14.34</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3498639_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_4001_7">39863</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3498639_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_4002_7">34449</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3504768" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_5003_5">20401</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3504768_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_5001_5">20401</mrus:RemunerationForFormerEmployees>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3504975" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_3006_1">27633</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3504975" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_6003_6">91812</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3504975" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_3006_2">14.34</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3504975_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_6001_6">40768</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3504975_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_6002_6">51044</mrus:RemunerationForFormerEmployees>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3505029" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_3002_1">84209</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3505029" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_7003_2">123732</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3505029" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_3002_2">10.07</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3505029_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_7001_2">55066</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3505029_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_7002_2">68666</mrus:RemunerationForFormerEmployees>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3505535" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_3008_1">27633</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3505535" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_8003_8">100153</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3505535" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_3008_2">14.34</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3505535_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_8001_8">45356</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3505535_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_8002_8">54797</mrus:RemunerationForFormerEmployees>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3509602" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_2001_3">196000</ifrs-full:Revenue>
  <mrus:MilestoneRevenues contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_EDC8EC1D-7D66-4C8E-9D44-F5E2140FD0D3_2001_3">4000000</mrus:MilestoneRevenues>
  <mrus:MilestoneRevenuesAndCostsReimbursements contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_EDC8EC1D-7D66-4C8E-9D44-F5E2140FD0D3_2001_2">400000</mrus:MilestoneRevenuesAndCostsReimbursements>
  <mrus:TermsOfPaymentOfTradeReceivables contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3513897" id="id_14264487_88F08561-0748-4E4A-BDC6-853B7E726B8B_1001_0">30 days</mrus:TermsOfPaymentOfTradeReceivables>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3514206" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_6_3">0.9216</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3514206" unitRef="Y" decimals="0" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_6_4">10</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3514206" unitRef="pure" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_6_5">0.00</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3514206_3422662x3416700" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_4_6">0.0283</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <mrus:EmployeeOptionExercisedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3514206_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_4_2">12.29</mrus:EmployeeOptionExercisedPricePerShare>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3514206_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_4_1">12.29</mrus:SharePurchasedPricePerShare>
  <mrus:FairValueAssumptionsGrantDateSharePrice contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3514206_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_4_0">7.74</mrus:FairValueAssumptionsGrantDateSharePrice>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3514206_3422662x3423353" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_5_6">0.0310</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <mrus:EmployeeOptionExercisedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3514206_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_5_2">21.02</mrus:EmployeeOptionExercisedPricePerShare>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3514206_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_5_1">21.02</mrus:SharePurchasedPricePerShare>
  <mrus:FairValueAssumptionsGrantDateSharePrice contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3514206_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_5_0">13.32</mrus:FairValueAssumptionsGrantDateSharePrice>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3514219" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_3001_0">17686000</ifrs-full:Revenue>
  <mrus:TermsOfPaymentOfTradeReceivables contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3554523" id="id_14264487_88F08561-0748-4E4A-BDC6-853B7E726B8B_2001_2">60 days</mrus:TermsOfPaymentOfTradeReceivables>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3554539" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_4001_1">13566000</ifrs-full:Revenue>
  <mrus:MilestoneRevenues contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3554542" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_EDC8EC1D-7D66-4C8E-9D44-F5E2140FD0D3_4001_4">400000</mrus:MilestoneRevenues>
  <mrus:TermsOfPaymentOfTradeReceivables contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3554542" id="id_14264487_88F08561-0748-4E4A-BDC6-853B7E726B8B_3001_1">30 days</mrus:TermsOfPaymentOfTradeReceivables>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3556563" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_3001_1">9966</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3556563" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_9003_1">117936</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3556563" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_3001_2">19.97</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3556563_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_9001_1">38603</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3556563_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_9002_1">79333</mrus:RemunerationForFormerEmployees>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3556564" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_3003_1">21818</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3556564" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_10003_3">185344</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3556564" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_3003_2">16.33</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3556564_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_10001_3">32859</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3556564_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_10002_3">152485</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_2001_9">292231</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_12423E5F-9460-462F-9702-497D5964FF3F_2002_9">506550</mrus:RemunerationForFormerEmployees>
  <mrus:AdditionsInContractLiabilities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416963x3508994" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CE40E457-E3B7-4108-99F6-618E5B763DA0_4001_2">4137000</mrus:AdditionsInContractLiabilities>
  <mrus:DeductionsInContractLiabilities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3416963x3508994" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CE40E457-E3B7-4108-99F6-618E5B763DA0_4001_3">18014000</mrus:DeductionsInContractLiabilities>
  <ifrs-full:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417395x3421037" id="id_14264487_8287671B-D300-4385-B1C4-03FDA3977CED_1001_1">Shorter of useful life or term of lease</ifrs-full:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_17002_14">300000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:ChangesInPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_17002_18">202000</ifrs-full:ChangesInPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417395x3421738" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_17002_15">98000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417395x3421738" id="id_14264487_8287671B-D300-4385-B1C4-03FDA3977CED_2001_2">5 years</ifrs-full:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_17001_14">1498000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:ChangesInPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_17001_18">1050000</ifrs-full:ChangesInPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417395x3509419" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_17001_15">448000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417395x3509419" id="id_14264487_8287671B-D300-4385-B1C4-03FDA3977CED_3001_0">5 years</ifrs-full:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment>
  <mrus:AdditionsToTradeReceivables contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417430x3424016" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F8B7FC2B-1154-4601-887C-8DB3A5477E34_4002_2">19951000</mrus:AdditionsToTradeReceivables>
  <mrus:DeductionsInTradeReceivables contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417430x3424016" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F8B7FC2B-1154-4601-887C-8DB3A5477E34_4002_3">18855000</mrus:DeductionsInTradeReceivables>
  <mrus:DeductionsInContractAssets contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417430x3496068" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_AAEECD3A-A490-47A4-A19C-88AEF875DFF6_4001_3">1519000</mrus:DeductionsInContractAssets>
  <mrus:AdditionsInContractAssets contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417430x3496068" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_AAEECD3A-A490-47A4-A19C-88AEF875DFF6_4001_2">1045000</mrus:AdditionsInContractAssets>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417430x3508720" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_A4628AF6-2B5B-43D5-BA7F-C43F755CEEE8_1001_0">2200000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3422077_3418104x3423397_3424455x3514296_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_2004_2">6000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3422077_3418104x3423397_3424455x3514297_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_3004_3">-6000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3422077_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_1004_1">123000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3476336_3418104x3423397_3424455x3514296_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_2003_2">144000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3476336_3418104x3423397_3424455x3514297_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_3003_3">-144000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3476336_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_1003_1">2886000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3479569_3418104x3423397_3424455x3514296_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_2002_2">3090000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3479569_3418104x3423397_3424455x3514297_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_3002_3">-3090000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3479569_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_1002_1">61800000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3499174_3418104x3423397_3424455x3514296_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_2001_2">2154000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3499174_3418104x3423397_3424455x3514297_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_3001_3">-2154000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3499174_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_1001_1">43074000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3529562_3418104x3423397_3424455x3514296_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_2006_2">-240000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3529562_3418104x3423397_3424455x3514297_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_3006_3">240000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3529562_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_1006_1">-4795000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3558218_3418104x3423397_3424455x3514296_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_2005_2">-4000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3558218_3418104x3423397_3424455x3514297_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_3005_3">4000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3558218_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_1005_1">-88000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417439x3422519" unitRef="pure" decimals="INF" id="id_14264487_1929F029-CC6A-4563-801E-C284057C67AE_1001_3">93244</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417439x3422519" unitRef="pure" decimals="INF" id="id_14264487_1929F029-CC6A-4563-801E-C284057C67AE_1001_2">135888</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <mrus:NumberOfSharesIssuedForCash contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417439x3422519" unitRef="shares" decimals="0" id="id_14264487_1929F029-CC6A-4563-801E-C284057C67AE_1001_1">3699997</mrus:NumberOfSharesIssuedForCash>
  <ifrs-full:IssueOfEquity contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417439x3495214_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_13001_28">353000</ifrs-full:IssueOfEquity>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417439x3495214_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_13001_30">353000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:IssueOfEquity contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417439x3495221_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_13005_28">51236000</ifrs-full:IssueOfEquity>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417439x3495221_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_13005_30">51236000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_13009_26">-24235000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_13009_29">7925000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:OtherComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_13009_25">34000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_13009_24">-24269000</ifrs-full:ProfitLoss>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_13009_30">7925000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3418104x3423397_3424455x3514296_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_2007_2">5150000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3418104x3423397_3424455x3514297_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_3007_3">-5150000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <ifrs-full:ApplicableTaxRate contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3420782x3421581" unitRef="pure" decimals="2" id="id_14264487_37400F7E-9445-4377-9EC0-7D3F96FCD696_1001_2">0.25</ifrs-full:ApplicableTaxRate>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3420782x3421581" unitRef="iso4217_EUR" decimals="INF" id="id_14264487_37400F7E-9445-4377-9EC0-7D3F96FCD696_1001_6">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <mrus:AverageQualifyingProfitsEffectiveTaxRate contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3420782x3421581" unitRef="pure" decimals="2" id="id_14264487_37400F7E-9445-4377-9EC0-7D3F96FCD696_1001_0">0.75</mrus:AverageQualifyingProfitsEffectiveTaxRate>
  <mrus:InnovationsBoxRate contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3420782x3421581" unitRef="pure" decimals="2" id="id_14264487_37400F7E-9445-4377-9EC0-7D3F96FCD696_1001_1">0.07</mrus:InnovationsBoxRate>
  <ifrs-full:ApplicableTaxRate contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3420782x3421581_3421968x3421288" unitRef="pure" decimals="4" id="id_14264487_37400F7E-9445-4377-9EC0-7D3F96FCD696_2001_4">0.2255</ifrs-full:ApplicableTaxRate>
  <ifrs-full:ApplicableTaxRate contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3420782x3421581_3421968x3421294" unitRef="pure" decimals="3" id="id_14264487_37400F7E-9445-4377-9EC0-7D3F96FCD696_3001_5">0.205</ifrs-full:ApplicableTaxRate>
  <ifrs-full:ApplicableTaxRate contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3420782x3421581_3421968x3422054" unitRef="pure" decimals="2" id="id_14264487_37400F7E-9445-4377-9EC0-7D3F96FCD696_4001_3">0.25</ifrs-full:ApplicableTaxRate>
  <ifrs-full:ApplicableTaxRate contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3420782x3424474" unitRef="pure" decimals="2" id="id_14264487_DA49123C-D250-44E7-A84C-86E772EF376D_1001_1">0.28</ifrs-full:ApplicableTaxRate>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3420782x3424474" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_85B2D5A1-471B-46DD-A6CA-B847B937A892_1001_0">400000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <mrus:RevenueRecognized contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3422158x3496110" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_2055A2B1-4D82-4EA2-9180-615850DA64FD_1001_0">900000</mrus:RevenueRecognized>
  <mrus:RevenueRecognized contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3422662x3416700" unitRef="iso4217_EUR" decimals="INF" id="id_14264487_F392E82F-89D5-4670-A7DF-94A12918916C_1_0">100000</mrus:RevenueRecognized>
  <mrus:AccrualsToEmployeeSeveranceIndemnities contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3422662x3423353" unitRef="iso4217_EUR" decimals="INF" id="id_14264487_6D337156-1BC6-480C-B1FD-A0D3CF47E73D_4_2">100000</mrus:AccrualsToEmployeeSeveranceIndemnities>
  <ifrs-full:GainsOnLitigationSettlements contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3422992x3481669" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_AAAAD971-75A8-48E3-AFE3-701B68558EB4_1002_2">7100000</ifrs-full:GainsOnLitigationSettlements>
  <ifrs-full:GainsOnLitigationSettlements contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3422992x3481669" unitRef="iso4217_USD" decimals="-5" id="id_14264487_AAAAD971-75A8-48E3-AFE3-701B68558EB4_1001_2">8100000</ifrs-full:GainsOnLitigationSettlements>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3422992x3481669" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_AAAAD971-75A8-48E3-AFE3-701B68558EB4_1002_0">13100000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3422992x3481669" unitRef="iso4217_USD" decimals="-5" id="id_14264487_AAAAD971-75A8-48E3-AFE3-701B68558EB4_1001_0">15000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <mrus:UpfrontPayment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423034x3508994_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_96404FCF-6B6C-48C3-ACAD-42DF33AD071F_1001_0">700000</mrus:UpfrontPayment>
  <ifrs-full:ConsiderationPaidReceived contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3486516" unitRef="iso4217_USD" decimals="-5" id="id_14264487_819F8602-3757-405B-80DE-DB81A3AAC184_1002_0">152600000</ifrs-full:ConsiderationPaidReceived>
  <mrus:UpfrontPayment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3486516" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_819F8602-3757-405B-80DE-DB81A3AAC184_1001_1">112000000</mrus:UpfrontPayment>
  <mrus:UpfrontPayment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3486516" unitRef="iso4217_USD" decimals="-5" id="id_14264487_819F8602-3757-405B-80DE-DB81A3AAC184_1002_1">120000000</mrus:UpfrontPayment>
  <mrus:UpfrontPaymentAmortization contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3486516" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_D763C17C-A9C7-4FD1-B76B-1230E71ADC74_1001_400000">15900000</mrus:UpfrontPaymentAmortization>
  <mrus:EstimatedContractualTerm contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3486516" id="id_14264487_9E267809-F4C7-4AE1-81C4-1C37E984DAF4_1001_0">P21Y</mrus:EstimatedContractualTerm>
  <mrus:EstimatedContractualTerm contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3496065" id="id_14264487_9E267809-F4C7-4AE1-81C4-1C37E984DAF4_2001_2">P9Y</mrus:EstimatedContractualTerm>
  <mrus:UpfrontPayment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3496111" unitRef="iso4217_EUR" decimals="-4" id="id_14264487_3EB5DF39-3E6A-4905-8873-7B4238EC3CD1_1001_0">2300000</mrus:UpfrontPayment>
  <mrus:UpfrontPayment contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3496111" unitRef="iso4217_USD" decimals="-4" id="id_14264487_3EB5DF39-3E6A-4905-8873-7B4238EC3CD1_1002_0">2750000</mrus:UpfrontPayment>
  <mrus:MilestonePaymentReceived contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3496111" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_3EB5DF39-3E6A-4905-8873-7B4238EC3CD1_1001_1">600000</mrus:MilestonePaymentReceived>
  <mrus:MilestonePaymentReceived contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3496111" unitRef="iso4217_USD" decimals="-5" id="id_14264487_3EB5DF39-3E6A-4905-8873-7B4238EC3CD1_1002_1">800000</mrus:MilestonePaymentReceived>
  <mrus:UpfrontPaymentAmortization contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3496111" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_D763C17C-A9C7-4FD1-B76B-1230E71ADC74_2001_400002">500000</mrus:UpfrontPaymentAmortization>
  <mrus:RevenueRemainingPerformanceObligations contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_96404FCF-6B6C-48C3-ACAD-42DF33AD071F_2001_1">1200000</mrus:RevenueRemainingPerformanceObligations>
  <mrus:AmountPaidForFullTimeEquivalentFunding contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_96404FCF-6B6C-48C3-ACAD-42DF33AD071F_2001_2">200000</mrus:AmountPaidForFullTimeEquivalentFunding>
  <mrus:AmountPaidToCompensateForResearchServices contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_96404FCF-6B6C-48C3-ACAD-42DF33AD071F_2001_3">300000</mrus:AmountPaidToCompensateForResearchServices>
  <mrus:UpfrontPaymentAmortization contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_D763C17C-A9C7-4FD1-B76B-1230E71ADC74_3001_400001">1200000</mrus:UpfrontPaymentAmortization>
  <ifrs-full:ConsiderationPaidReceived contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3554473" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_819F8602-3757-405B-80DE-DB81A3AAC184_2001_2">31400000</ifrs-full:ConsiderationPaidReceived>
  <ifrs-full:ConsiderationPaidReceived contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3554473" unitRef="iso4217_USD" decimals="-5" id="id_14264487_819F8602-3757-405B-80DE-DB81A3AAC184_2002_2">32600000</ifrs-full:ConsiderationPaidReceived>
  <mrus:MilestonePaymentReceived contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3554523" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_6151CF77-E4F9-4E2F-BFE9-C22370370C42_1002_0">10500000</mrus:MilestonePaymentReceived>
  <mrus:MilestonePaymentReceived contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3554523" unitRef="iso4217_USD" decimals="-5" id="id_14264487_6151CF77-E4F9-4E2F-BFE9-C22370370C42_1001_0">12000000</mrus:MilestonePaymentReceived>
  <mrus:UpfrontPaymentAmortization contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3554523" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_D763C17C-A9C7-4FD1-B76B-1230E71ADC74_4001_400003">100000</mrus:UpfrontPaymentAmortization>
  <ifrs-full:GainsOnLitigationSettlements contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3556559" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_C185FA8A-3451-4D6E-A9AC-1F643887C52D_1002_4">7100000</ifrs-full:GainsOnLitigationSettlements>
  <ifrs-full:GainsOnLitigationSettlements contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3556559" unitRef="iso4217_USD" decimals="-5" id="id_14264487_C185FA8A-3451-4D6E-A9AC-1F643887C52D_1001_4">8100000</ifrs-full:GainsOnLitigationSettlements>
  <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3556559" unitRef="shares" decimals="0" id="id_14264487_C185FA8A-3451-4D6E-A9AC-1F643887C52D_1001_0">600000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3556559" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_C185FA8A-3451-4D6E-A9AC-1F643887C52D_1002_2">13100000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3556559" unitRef="iso4217_USD" decimals="-5" id="id_14264487_C185FA8A-3451-4D6E-A9AC-1F643887C52D_1001_2">15000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <mrus:PurchasePricePerCommonShare contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3556559" unitRef="iso4217_USD_per_shares" decimals="1" id="id_14264487_C185FA8A-3451-4D6E-A9AC-1F643887C52D_1001_1">25.0</mrus:PurchasePricePerCommonShare>
  <mrus:ValueOfCommonSharesIssued contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3556559" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_C185FA8A-3451-4D6E-A9AC-1F643887C52D_1002_3">6000000</mrus:ValueOfCommonSharesIssued>
  <mrus:ValueOfCommonSharesIssued contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3556559" unitRef="iso4217_USD" decimals="-5" id="id_14264487_C185FA8A-3451-4D6E-A9AC-1F643887C52D_1001_3">6900000</mrus:ValueOfCommonSharesIssued>
  <ifrs-full:RentalExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3556804" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_7A094031-E6E3-47BE-839A-959147BB3DA8_1_0">400000</ifrs-full:RentalExpense>
  <mrus:LeasesExpirationPeriod contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3556804" id="id_14264487_7A094031-E6E3-47BE-839A-959147BB3DA8_1_2">Fourth quarter of 2021</mrus:LeasesExpirationPeriod>
  <mrus:OperatingLeaseTermOfLeaseAgreement contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3556804" id="id_14264487_7A094031-E6E3-47BE-839A-959147BB3DA8_1_1">P2Y</mrus:OperatingLeaseTermOfLeaseAgreement>
  <mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424456x3417893" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_F686CF32-CDD4-4AEE-B152-845CFA3EE215_1007_1">103000000</mrus:ForeignExchangeSensitivityEffectOnProfitBeforeTax>
  <mrus:PeriodOfRemainingOptionsVestingPeriod contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514087" id="id_14264487_9FC23CA0-F922-474B-BB3E-89175F52C6B9_1001_4">36 monthly installments</mrus:PeriodOfRemainingOptionsVestingPeriod>
  <mrus:DescriptionOfOptionLapse contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514087" id="id_14264487_9FC23CA0-F922-474B-BB3E-89175F52C6B9_1001_6">Options lapse on the eighth anniversary of the date of grant.</mrus:DescriptionOfOptionLapse>
  <mrus:DescriptionOfOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514087" id="id_14264487_9FC23CA0-F922-474B-BB3E-89175F52C6B9_1001_0">Options granted under the 2010 Plan are exercisable once vested.</mrus:DescriptionOfOptionsGranted>
  <mrus:DescriptionOfDepositoryReceiptsBasedExercisePrice contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514087" id="id_14264487_5FEAEE92-4A73-4390-A32F-30CBC2DAF6F3_1001_3">The 2010 Option Plan was amended such that a participant is no longer required to offer depositary receipts to the foundation  upon resignation.</mrus:DescriptionOfDepositoryReceiptsBasedExercisePrice>
  <mrus:SharebasedCompensationAwardVestingPeriod contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514087" id="id_14264487_9FC23CA0-F922-474B-BB3E-89175F52C6B9_1001_1">P4Y</mrus:SharebasedCompensationAwardVestingPeriod>
  <mrus:PercentageOfRemainingVestingOptions contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514087" unitRef="pure" decimals="2" id="id_14264487_9FC23CA0-F922-474B-BB3E-89175F52C6B9_1001_3">0.75</mrus:PercentageOfRemainingVestingOptions>
  <mrus:PercentageOfInitialVestingOptions contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514087" unitRef="pure" decimals="2" id="id_14264487_9FC23CA0-F922-474B-BB3E-89175F52C6B9_1001_2">0.25</mrus:PercentageOfInitialVestingOptions>
  <mrus:PercentageOfVestingOptions contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514087" unitRef="pure" decimals="INF" id="id_14264487_9FC23CA0-F922-474B-BB3E-89175F52C6B9_1001_5">1.00</mrus:PercentageOfVestingOptions>
  <mrus:PeriodOfRemainingOptionsVestingPeriod contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514207" id="id_14264487_CD4FCBF4-ADB1-4380-A6D9-00C8A265A294_1001_4">36 monthly installments</mrus:PeriodOfRemainingOptionsVestingPeriod>
  <mrus:DescriptionOfOptionLapse contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514207" id="id_14264487_CD4FCBF4-ADB1-4380-A6D9-00C8A265A294_1001_6">Options will lapse on the tenth anniversary of the date of grant.</mrus:DescriptionOfOptionLapse>
  <mrus:DescriptionOfOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514207" id="id_14264487_CD4FCBF4-ADB1-4380-A6D9-00C8A265A294_1001_0">Options granted under the 2016 Plan are exercisable once vested.</mrus:DescriptionOfOptionsGranted>
  <mrus:NumberOfCommonShareEntitledToReceive contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514207" unitRef="shares" decimals="INF" id="id_14264487_C758E8E3-9664-4A3E-A091-CF1C39CFD6E2_1001_1">1</mrus:NumberOfCommonShareEntitledToReceive>
  <mrus:SharebasedCompensationAwardVestingPeriod contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514207" id="id_14264487_CD4FCBF4-ADB1-4380-A6D9-00C8A265A294_1001_1">P4Y</mrus:SharebasedCompensationAwardVestingPeriod>
  <mrus:NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514207" id="id_14264487_C758E8E3-9664-4A3E-A091-CF1C39CFD6E2_1001_0">P4Y</mrus:NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod>
  <mrus:PercentageOfRemainingVestingOptions contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514207" unitRef="pure" decimals="2" id="id_14264487_CD4FCBF4-ADB1-4380-A6D9-00C8A265A294_1001_3">0.75</mrus:PercentageOfRemainingVestingOptions>
  <mrus:PercentageOfInitialVestingOptions contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514207" unitRef="pure" decimals="2" id="id_14264487_CD4FCBF4-ADB1-4380-A6D9-00C8A265A294_1001_2">0.25</mrus:PercentageOfInitialVestingOptions>
  <mrus:PercentageOfVestingOptions contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514207" unitRef="pure" decimals="INF" id="id_14264487_CD4FCBF4-ADB1-4380-A6D9-00C8A265A294_1001_5">1.00</mrus:PercentageOfVestingOptions>
  <mrus:PeriodOfVestingInstallmentsOfInitialVestingAwards contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514208" id="id_14264487_469818B3-0292-4D58-BD1C-525036290B95_1001_0">Three-year period</mrus:PeriodOfVestingInstallmentsOfInitialVestingAwards>
  <mrus:PeriodOfRemainingOptionsVestingPeriod contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514208" id="id_14264487_469818B3-0292-4D58-BD1C-525036290B95_1001_3">24 substantially equal monthly  installments</mrus:PeriodOfRemainingOptionsVestingPeriod>
  <mrus:DescriptionOfGrantAward contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514208" id="id_14264487_469818B3-0292-4D58-BD1C-525036290B95_1001_5">Following  the vesting commencement date, such that the subsequent award shall be fully  vested on the first anniversary of the date of grant.</mrus:DescriptionOfGrantAward>
  <mrus:PeriodOfAwardsWillBeVestedAndExercised contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514208" id="id_14264487_469818B3-0292-4D58-BD1C-525036290B95_1001_4">12 substantially equal monthly installments</mrus:PeriodOfAwardsWillBeVestedAndExercised>
  <mrus:PercentageOfRemainingVestingOptions contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514208" unitRef="pure" decimals="2" id="id_14264487_469818B3-0292-4D58-BD1C-525036290B95_1001_2">0.67</mrus:PercentageOfRemainingVestingOptions>
  <mrus:PercentageOfInitialVestingOptions contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514208" unitRef="pure" decimals="2" id="id_14264487_469818B3-0292-4D58-BD1C-525036290B95_1001_1">0.33</mrus:PercentageOfInitialVestingOptions>
  <mrus:StockAwardExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3475752x3481637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B5A6BE7B-5975-44A4-A2A1-EED190DB18B0_1001_0">2710000</mrus:StockAwardExpense>
  <ifrs-full:NetForeignExchangeGain contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3475752x3486700" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_7A795159-273A-478A-93E2-AF01494DDF99_1001_2">3200000</ifrs-full:NetForeignExchangeGain>
  <mrus:StockAwardExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3475752x3491841" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B5A6BE7B-5975-44A4-A2A1-EED190DB18B0_2001_2">473000</mrus:StockAwardExpense>
  <mrus:StockAwardExpense contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3475752x3514214" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B5A6BE7B-5975-44A4-A2A1-EED190DB18B0_3001_1">4742000</mrus:StockAwardExpense>
  <ifrs-full:WagesAndSalaries contextRef="eol_PE977595--1820-F0010_STD_365_20181231_0_3475782x3513422" unitRef="iso4217_EUR" decimals="0" id="id_14264487_5C457EE7-2D3E-45AE-8928-A18F08C2B5CA_1001_0">257260</ifrs-full:WagesAndSalaries>
  <mrus:PaymentOfPropertyPlantAndEquipment contextRef="eol_PE977595--1820-F0010_STD_365_20191231_0_3421584x3558220" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_1CD22F52-D1FE-4903-B58D-223D812F5EB3_1001_0">600000</mrus:PaymentOfPropertyPlantAndEquipment>
  <ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_3">-19213000</ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_14">-14000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_12">-121000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_3_3">-3.58</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_26">-408000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInOperations contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_16">-25678000</ifrs-full:CashFlowsFromUsedInOperations>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_10">-1256000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_7">33000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_4">365000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_35">50201000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_19">-25733000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_11">-109000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_5">234000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_6">3307000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_8">-24351000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8010_6">-47429000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:DepreciationAndAmortisationExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_68078692-077B-4C21-8EB2-80F32AD7B4E5_3_3">234000</ifrs-full:DepreciationAndAmortisationExpense>
  <ifrs-full:FinanceCosts contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_3_7">19644000</ifrs-full:FinanceCosts>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_3_5">3307000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_37">6000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:FinanceIncome contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_3_2">88000</ifrs-full:FinanceIncome>
  <ifrs-full:EmployeeBenefitsExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_68078692-077B-4C21-8EB2-80F32AD7B4E5_3_2">8110000</ifrs-full:EmployeeBenefitsExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_5">4258000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8010_11">3307000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_36">24060000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_3_0">1139763</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_3_5">2354359</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_3_2">0</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_3_1">18720</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
  <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_25">88000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
  <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_14264487_2D9E1ED7-9102-4197-AE9A-6039F1DD098B_3_2">5454</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_14264487_2D9E1ED7-9102-4197-AE9A-6039F1DD098B_3_1">31351</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_17">55000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:IssueOfEquity contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8010_8">51151000</ifrs-full:IssueOfEquity>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_3_4">1195876</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_AAD93268-ACB2-42DD-A02B-843214FA779E_3_3">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_14264487_2D9E1ED7-9102-4197-AE9A-6039F1DD098B_3_4">496243</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:OperatingExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_9">30391000</ifrs-full:OperatingExpense>
  <ifrs-full:OtherComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8010_5">8000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherShorttermEmployeeBenefits contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_3_6">442000</ifrs-full:OtherShorttermEmployeeBenefits>
  <ifrs-full:ProfitLossBeforeTax contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_3_10">-47437000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_3_1">-27881000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_14264487_2D9E1ED7-9102-4197-AE9A-6039F1DD098B_3_3">18283</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_28">50547000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:NetForeignExchangeLoss contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_3_5">409000</ifrs-full:NetForeignExchangeLoss>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_3_14">8000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherExpenseByNature contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_8">7709000</ifrs-full:OtherExpenseByNature>
  <ifrs-full:OtherFinanceIncomeCost contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_3_9">-19556000</ifrs-full:OtherFinanceIncomeCost>
  <ifrs-full:PaymentsForShareIssueCosts contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_31">230000</ifrs-full:PaymentsForShareIssueCosts>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_24">496000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_4">18424000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_3_4">2510000</ifrs-full:Revenue>
  <ifrs-full:SocialSecurityContributions contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_3_2">382000</ifrs-full:SocialSecurityContributions>
  <ifrs-full:ProfessionalFeesExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_9DFE7ABA-C7C0-4A1F-8BE9-A71C01DAA2EB_3_0">1700000</ifrs-full:ProfessionalFeesExpense>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8010_4">-47437000</ifrs-full:ProfitLoss>
  <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_33">167000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_3_7">8110000</ifrs-full:ShorttermEmployeeBenefitsExpense>
  <ifrs-full:WagesAndSalaries contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_3_0">5166000</ifrs-full:WagesAndSalaries>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_3_3">1.93</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_3_4">14.74</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:TradingIncomeExpenseOnDerivativeFinancialInstruments contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_3_6">-19235000</ifrs-full:TradingIncomeExpenseOnDerivativeFinancialInstruments>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_3_2">11.95</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="2" id="id_14264487_9D3D32B2-D86B-4AD0-AE86-0397920CA8D3_3_1">6.07</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_1010_5">185128</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:GeneralLegalInsuranceAndFacilityRelatedExpenses contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_9DFE7ABA-C7C0-4A1F-8BE9-A71C01DAA2EB_3_1">3900000</mrus:GeneralLegalInsuranceAndFacilityRelatedExpenses>
  <mrus:OtherIncomeExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_3_8">-19556000</mrus:OtherIncomeExpense>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8010_12">52949000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <mrus:ClinicalCosts contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E5A85DC4-90A0-4CA4-A801-47E373A70955_3_1">3409000</mrus:ClinicalCosts>
  <mrus:OtherResearchAndDevelopmentExpenseOther contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E5A85DC4-90A0-4CA4-A801-47E373A70955_3_2">2216000</mrus:OtherResearchAndDevelopmentExpenseOther>
  <mrus:DiscoveryAndPreclinicalCosts contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_E5A85DC4-90A0-4CA4-A801-47E373A70955_3_0">5185000</mrus:DiscoveryAndPreclinicalCosts>
  <mrus:PreclinicalCosts contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_EE8874EB-D696-4FCF-9D1F-4A232AF85BF5_3_0">5200000</mrus:PreclinicalCosts>
  <mrus:IntellectualPropertyCosts contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_EE8874EB-D696-4FCF-9D1F-4A232AF85BF5_3_2">2700000</mrus:IntellectualPropertyCosts>
  <mrus:AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_13">286000</mrus:AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals>
  <mrus:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_15">-113000</mrus:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities>
  <mrus:ChangesInRestrictedCash contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_34">51000</mrus:ChangesInRestrictedCash>
  <mrus:GrantIncome contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_8A2BDAFB-590D-4532-ADCE-1B626C35DDF9_3_0">1400000</mrus:GrantIncome>
  <mrus:PensionCosts contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_3_4">507000</mrus:PensionCosts>
  <mrus:HealthInsurance contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_3_3">27000</mrus:HealthInsurance>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_2003_9">696942</mrus:RemunerationForFormerEmployees>
  <mrus:StockAwardExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B5A6BE7B-5975-44A4-A2A1-EED190DB18B0_3_3">3307000</mrus:StockAwardExpense>
  <mrus:WBSOSubsidy contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_CC5AE96A-1FAC-40A2-ACCA-22DAF5D5BEEB_3_1">1721000</mrus:WBSOSubsidy>
  <mrus:OtherOperatingExpenses contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_7">6219000</mrus:OtherOperatingExpenses>
  <mrus:LitigationCosts contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_6">1490000</mrus:LitigationCosts>
  <mrus:ManufacturingCost contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_0">3162000</mrus:ManufacturingCost>
  <mrus:PersonnelRelatedResearchAndDevelopmentExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_2">3285000</mrus:PersonnelRelatedResearchAndDevelopmentExpense>
  <mrus:OtherResearchAndDevelopmentExpenses contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_3">10810000</mrus:OtherResearchAndDevelopmentExpenses>
  <mrus:RentAndServiceChargesExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_FC788C4F-FFA1-4B14-AED5-CE0544122BE9_3_0">300000</mrus:RentAndServiceChargesExpense>
  <mrus:InterestAndRelatedIncome contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_3_0">88000</mrus:InterestAndRelatedIncome>
  <mrus:OtherExternalAndOutsourcedCosts contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_68078692-077B-4C21-8EB2-80F32AD7B4E5_3_1">18885000</mrus:OtherExternalAndOutsourcedCosts>
  <mrus:ContractManufacturingExpenses contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_68078692-077B-4C21-8EB2-80F32AD7B4E5_3_0">3162000</mrus:ContractManufacturingExpenses>
  <mrus:InitialPublicOfferingCosts contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8010_9">1509000</mrus:InitialPublicOfferingCosts>
  <mrus:WeightedAverageNumberOfShares contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_14264487_780AD06D-9847-4BE0-8664-B9F729C217F8_3_3">13236649</mrus:WeightedAverageNumberOfShares>
  <mrus:SharebasedCompensationWeightedAverageRemainingContractualLife contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" id="id_14264487_D2C11233-6864-41A5-86A7-1FC6F9FA0B51_3_2">P6Y8M5D</mrus:SharebasedCompensationWeightedAverageRemainingContractualLife>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_1010_6">7.21</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:IPAndLicenseCosts contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_1">1167000</mrus:IPAndLicenseCosts>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3421023" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_15_3">0.9530</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3421023" unitRef="Y" decimals="0" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_15_4">10</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3421023" unitRef="pure" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_15_5">0.00</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3421023_3422662x3416700" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_13_6">0.0184</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <mrus:EmployeeOptionExercisedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3421023_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_13_2">15.24</mrus:EmployeeOptionExercisedPricePerShare>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3421023_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_13_1">15.24</mrus:SharePurchasedPricePerShare>
  <mrus:FairValueAssumptionsGrantDateSharePrice contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3421023_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_13_0">9.97</mrus:FairValueAssumptionsGrantDateSharePrice>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3421023_3422662x3423353" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_14_6">0.0186</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <mrus:EmployeeOptionExercisedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3421023_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_14_2">16.85</mrus:EmployeeOptionExercisedPricePerShare>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3421023_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_14_1">16.85</mrus:SharePurchasedPricePerShare>
  <mrus:FairValueAssumptionsGrantDateSharePrice contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3421023_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_14_0">11.03</mrus:FairValueAssumptionsGrantDateSharePrice>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492745" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_1004_5">26724</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492745" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_3003_4">70778</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492745" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_1004_6">3.02</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492745_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_3001_4">19850</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492745_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_3002_4">50928</mrus:RemunerationForFormerEmployees>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492855" unitRef="iso4217_EUR" decimals="0" id="id_14264487_F4E4A95D-F632-4181-9DAA-09B1A0D7788A_1005_0">1441977</ifrs-full:DirectorsRemunerationExpense>
  <mrus:NumberOfOptionsHeldByTheChiefExecutiveOfficers contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492855" unitRef="shares" decimals="INF" id="id_14264487_980A9597-926B-4320-9757-88517FDA697F_1003_0">376912</mrus:NumberOfOptionsHeldByTheChiefExecutiveOfficers>
  <mrus:AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492855" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_980A9597-926B-4320-9757-88517FDA697F_1003_1">2.98</mrus:AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492855_3416904x3498764" unitRef="iso4217_EUR" decimals="0" id="id_14264487_F4E4A95D-F632-4181-9DAA-09B1A0D7788A_1002_0">147820</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492855_3416904x3505512" unitRef="iso4217_EUR" decimals="0" id="id_14264487_F4E4A95D-F632-4181-9DAA-09B1A0D7788A_1001_0">369204</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492855_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_F4E4A95D-F632-4181-9DAA-09B1A0D7788A_1004_0">907236</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492855_3416904x3556606" unitRef="iso4217_EUR" decimals="0" id="id_14264487_F4E4A95D-F632-4181-9DAA-09B1A0D7788A_1003_0">17717</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3496102" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_1003_2">1123000</ifrs-full:Revenue>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3498639" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_1007_5">17000</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3498639" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_4003_7">111641</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3498639" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_1007_6">8.87</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3498639_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_4001_7">26938</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3498639_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_4002_7">84703</mrus:RemunerationForFormerEmployees>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3504768" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_1005_5">17000</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3504768" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_5003_5">91811</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3504768" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_1005_6">8.87</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3504768_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_5001_5">24852</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3504768_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_5002_5">66959</mrus:RemunerationForFormerEmployees>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3504975" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_1006_5">17000</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3504975" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_6003_6">63230</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3504975" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_1006_6">8.87</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3504975_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_6001_6">26230</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3504975_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_6002_6">37000</mrus:RemunerationForFormerEmployees>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505029" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_1002_5">73576</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505029" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_7003_2">233761</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505029" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_1002_6">6.57</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505029_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_7001_2">50394</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505029_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_7002_2">183367</mrus:RemunerationForFormerEmployees>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505387" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_1009_5">16828</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505387" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_1009_6">3.24</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505535" unitRef="shares" decimals="INF" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_1008_5">17000</mrus:NumberOfOptionsHeldByTheMembersOfSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505535" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_8003_8">125721</mrus:RemunerationForFormerEmployees>
  <mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505535" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_08282A27-EA17-4BF4-A6BC-EBD7554D11FD_1008_6">8.87</mrus:WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505535_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_8001_8">28356</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505535_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_8002_8">97365</mrus:RemunerationForFormerEmployees>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3509602" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_2003_3">1387000</ifrs-full:Revenue>
  <mrus:MilestoneRevenues contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_233C3E75-4A9F-4193-A65A-F863C872BE9F_1002_1">700000</mrus:MilestoneRevenues>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514206" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_18_3">0.9715</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514206" unitRef="pure" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_18_5">0.00</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514206_3422662x3416700" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_16_6">0.0010</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514206_3422662x3416700" unitRef="Y" decimals="0" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_16_4">8</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <mrus:EmployeeOptionExercisedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514206_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_16_2">8.46</mrus:EmployeeOptionExercisedPricePerShare>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514206_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_16_1">8.46</mrus:SharePurchasedPricePerShare>
  <mrus:FairValueAssumptionsGrantDateSharePrice contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514206_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_16_0">5.74</mrus:FairValueAssumptionsGrantDateSharePrice>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514206_3422662x3423353" unitRef="pure" decimals="4" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_17_6">0.0187</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514206_3422662x3423353" unitRef="Y" decimals="0" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_17_4">10</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <mrus:EmployeeOptionExercisedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514206_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_17_2">8.87</mrus:EmployeeOptionExercisedPricePerShare>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514206_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_17_1">8.87</mrus:SharePurchasedPricePerShare>
  <mrus:FairValueAssumptionsGrantDateSharePrice contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514206_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_48060DFA-8EEA-460E-8F31-FA44EA7452D5_17_0">5.79</mrus:FairValueAssumptionsGrantDateSharePrice>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514219" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_3003_0">14000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3554539" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_4003_1">1109000</ifrs-full:Revenue>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3556605" unitRef="iso4217_EUR" decimals="0" id="id_14264487_F4E4A95D-F632-4181-9DAA-09B1A0D7788A_2005_1">453686</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3556605_3416904x3498764" unitRef="iso4217_EUR" decimals="0" id="id_14264487_F4E4A95D-F632-4181-9DAA-09B1A0D7788A_2002_1">84000</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3556605_3416904x3505512" unitRef="iso4217_EUR" decimals="0" id="id_14264487_F4E4A95D-F632-4181-9DAA-09B1A0D7788A_2001_1">198987</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3556605_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_F4E4A95D-F632-4181-9DAA-09B1A0D7788A_2004_1">164547</ifrs-full:DirectorsRemunerationExpense>
  <ifrs-full:DirectorsRemunerationExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3556605_3416904x3556606" unitRef="iso4217_EUR" decimals="0" id="id_14264487_F4E4A95D-F632-4181-9DAA-09B1A0D7788A_2003_1">6152</ifrs-full:DirectorsRemunerationExpense>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416904x3499176" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_2001_9">176620</mrus:RemunerationForFormerEmployees>
  <mrus:RemunerationForFormerEmployees contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3416904x3506232" unitRef="iso4217_EUR" decimals="0" id="id_14264487_8C22909E-F921-45D5-A7B6-DF03F668489F_2002_9">520322</mrus:RemunerationForFormerEmployees>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495214_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8001_10">745000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <ifrs-full:IssueOfEquity contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495214_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8001_8">673000</ifrs-full:IssueOfEquity>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495214_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8001_12">1418000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495215_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8002_10">-21000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495215_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8002_12">-21000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495216_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8003_10">-351000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495216_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8003_12">-351000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495217_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8004_10">-373000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495217_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8004_12">-373000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495218_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8006_10">-1334000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495218_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8006_12">-1334000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495219_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8007_10">-38906000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495219_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8007_12">-38906000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495220_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8008_10">-49105000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495220_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8008_12">-49105000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495221_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8005_10">89345000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <ifrs-full:IssueOfEquity contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495221_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8005_8">50478000</ifrs-full:IssueOfEquity>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495221_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8005_12">138314000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <mrus:InitialPublicOfferingCosts contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495221_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8005_9">1509000</mrus:InitialPublicOfferingCosts>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8009_6">-47429000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8009_11">3307000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:OtherComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8009_5">8000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8009_4">-47437000</ifrs-full:ProfitLoss>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8009_12">3307000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:FinanceCosts contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3419692x3495181_3423078x3554473" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_E8DDF043-0AF2-4DF5-A23A-6F346A173C3A_1004_1">19200000</ifrs-full:FinanceCosts>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3420782x3424474" unitRef="iso4217_EUR" decimals="-5" id="id_14264487_85B2D5A1-471B-46DD-A6CA-B847B937A892_1003_0">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_EA2CD452-7A2C-4005-B5A3-555913775E83_2_2">209000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3422913x3420637" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_2_3">-0.01</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_2_2">-209000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_2_1">-209000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_2_0">-209000</ifrs-full:Revenue>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_EA2CD452-7A2C-4005-B5A3-555913775E83_2_0">-209000</ifrs-full:ProfitLoss>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_EA2CD452-7A2C-4005-B5A3-555913775E83_1_2">-223000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3422913x3422609" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_1_3">-3.57</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_1_2">-47220000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_1_1">-27672000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:Revenue contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_1_0">2719000</ifrs-full:Revenue>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_EA2CD452-7A2C-4005-B5A3-555913775E83_1_0">-47228000</ifrs-full:ProfitLoss>
  <mrus:UpfrontPaymentAmortization contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3423078x3513897" unitRef="iso4217_EUR" decimals="-2" id="id_14264487_D763C17C-A9C7-4FD1-B76B-1230E71ADC74_3003_600001">14000000</mrus:UpfrontPaymentAmortization>
  <mrus:StockAwardExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3475752x3481637" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B5A6BE7B-5975-44A4-A2A1-EED190DB18B0_1003_0">703000</mrus:StockAwardExpense>
  <mrus:StockAwardExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3475752x3491841" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B5A6BE7B-5975-44A4-A2A1-EED190DB18B0_2003_2">567000</mrus:StockAwardExpense>
  <mrus:StockAwardExpense contextRef="eol_PE977595--1820-F0010_STD_366_20161231_0_3475752x3514214" unitRef="iso4217_EUR" decimals="-3" id="id_14264487_B5A6BE7B-5975-44A4-A2A1-EED190DB18B0_3003_1">2037000</mrus:StockAwardExpense>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3475752x3514214">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ManagementAndAdministrationCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3475752x3491841">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:OtherExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3475752x3481637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3423078x3513897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:OnoResearchAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3422913x3420637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3420782x3424474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3419692x3495181_3423078x3554473">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:EffectOfOverlayApproachReclassificationAxis">mrus:IAS39Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:IncyteShareSubscriptionAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3417632x3422911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495221_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:CommonSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495220_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassCPreferenceSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495219_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassBPreferenceSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495218_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassAPreferenceSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495217_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassCPreferenceShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495216_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassBPreferenceShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495215_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassAPreferenceShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3417439x3495214_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:CommonShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3556605_3416904x3556606">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:PensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:ShelleyMargetsonFormerCOOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3556605_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:ShelleyMargetsonFormerCOOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3556605_3416904x3505512">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:GrossSalaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:ShelleyMargetsonFormerCOOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3556605_3416904x3498764">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:BonusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:ShelleyMargetsonFormerCOOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3556605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:ShelleyMargetsonFormerCOOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3554539">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:ResearchAndDevelopmentCostReimbursementAndMilestoneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514219">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:UpfrontPaymentAmortizationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514206_3422662x3423353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AllOtherEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514206_3422662x3416700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AllOtherEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3514206">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AllOtherEmployeesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3513897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:OnoResearchAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3509602">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505535_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:GregoryPerryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505535_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:GregoryPerryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505535">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:GregoryPerryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505387">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:GabrieleDallmannMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505029_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:MarkIwickiMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505029_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:MarkIwickiMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3505029">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:MarkIwickiMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3504975_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:JohnDeKoningMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3504975_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:JohnDeKoningMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3504975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:JohnDeKoningMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3504768_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:LionelCarnotMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3504768_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:LionelCarnotMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3504768">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:LionelCarnotMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3498639_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AnandMehraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3498639_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AnandMehraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3498639">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AnandMehraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3496102">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:RevenueFromContractsWithCustomersMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492855_3416904x3556606">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:PensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:TonLogtenbergCEOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492855_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:TonLogtenbergCEOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492855_3416904x3505512">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:GrossSalaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:TonLogtenbergCEOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492855_3416904x3498764">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:BonusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:TonLogtenbergCEOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:TonLogtenbergCEOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492745_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:WolfgangBertholdMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492745_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:WolfgangBertholdMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3492745">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:WolfgangBertholdMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3421023_3422662x3423353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3421023_3422662x3416700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0_3416740x3421023">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_366_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20191231_0_3421584x3558220">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">mrus:OtherFundingCommitmentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3475782x3513422">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:EmployeeBenefitSchemeAxis">mrus:SeveranceCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3475752x3514214">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ManagementAndAdministrationCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3475752x3491841">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:OtherExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3475752x3486700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:NetFinanceIncomeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3475752x3481637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514208">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">mrus:NonexecutiveCompensationProgramMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">mrus:TwoThousandSixteenOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3424457x3514087">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">mrus:TwoThousandTenOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3556804">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:LeasesAgreementForCorporateHeadquartersMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3556559">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:RegeneronSubscriptionAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3554523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:BettaPharmaceuticalsCoLtdMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3554473">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:IncyteShareSubscriptionAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3513897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:OnoResearchAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3496111">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3496065">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:IncyteProprietaryTechnologyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3423078x3486516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:IncyteCollaborationAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3423034x3508994_3423078x3513897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:OnoResearchAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3422992x3481669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">mrus:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3422662x3423353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3422662x3416700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3422158x3496110">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3420782x3424474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3420782x3421581_3421968x3422054">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3420782x3421581_3421968x3421294">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3420782x3421581_3421968x3421288">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3420782x3421581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3418104x3423397_3424455x3514297_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">mrus:FivePercentageDecreaseInFunctionalRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3418104x3423397_3424455x3514296_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">mrus:FivePercentageIncreaseInFunctionalRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417632x3422911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417439x3495221_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:CommonSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417439x3495214_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:CommonShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417439x3422519">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3558218_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">mrus:TaxesAndSocialSecurityLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3558218_3418104x3423397_3424455x3514297_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">mrus:TaxesAndSocialSecurityLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">mrus:FivePercentageDecreaseInFunctionalRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3558218_3418104x3423397_3424455x3514296_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">mrus:TaxesAndSocialSecurityLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">mrus:FivePercentageIncreaseInFunctionalRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3529562_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">mrus:TradePayablesOtherLiabilitiesAndAccrualsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3529562_3418104x3423397_3424455x3514297_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">mrus:TradePayablesOtherLiabilitiesAndAccrualsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">mrus:FivePercentageDecreaseInFunctionalRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3529562_3418104x3423397_3424455x3514296_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">mrus:TradePayablesOtherLiabilitiesAndAccrualsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">mrus:FivePercentageIncreaseInFunctionalRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3499174_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">mrus:CashAndCashEquivalents1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3499174_3418104x3423397_3424455x3514297_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">mrus:CashAndCashEquivalents1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">mrus:FivePercentageDecreaseInFunctionalRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3499174_3418104x3423397_3424455x3514296_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">mrus:CashAndCashEquivalents1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">mrus:FivePercentageIncreaseInFunctionalRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3479569_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">mrus:InvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3479569_3418104x3423397_3424455x3514297_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">mrus:InvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">mrus:FivePercentageDecreaseInFunctionalRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3479569_3418104x3423397_3424455x3514296_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">mrus:InvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">mrus:FivePercentageIncreaseInFunctionalRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3476336_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">mrus:TradeAndOtherReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3476336_3418104x3423397_3424455x3514297_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">mrus:TradeAndOtherReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">mrus:FivePercentageDecreaseInFunctionalRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3476336_3418104x3423397_3424455x3514296_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">mrus:TradeAndOtherReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">mrus:FivePercentageIncreaseInFunctionalRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3422077_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3422077_3418104x3423397_3424455x3514297_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">mrus:FivePercentageDecreaseInFunctionalRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417434x3422077_3418104x3423397_3424455x3514296_3424456x3417893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">mrus:FivePercentageIncreaseInFunctionalRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417430x3508720">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">mrus:PatentsAndIntellectualPropertyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417430x3496068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417430x3424016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417395x3509419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">mrus:PlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417395x3421738">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3417395x3421037">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416963x3508994">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3556564_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:LenKanavyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3556564_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:LenKanavyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3556564">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:LenKanavyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3556563_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:RussellGreigMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3556563_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:RussellGreigMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3556563">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:RussellGreigMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3554542">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:SimcerePharmaceuticalCoLtdMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3554539">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:ResearchAndDevelopmentCostReimbursementAndMilestoneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3554523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:BettaPharmaceuticalsCoLtdMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3514219">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:UpfrontPaymentAmortizationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3514206_3422662x3423353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AllOtherEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3514206_3422662x3416700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AllOtherEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3514206">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AllOtherEmployeesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3513897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:OnoResearchAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3509602">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3505535_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:GregoryPerryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3505535_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:GregoryPerryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3505535">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:GregoryPerryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3505029_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:MarkIwickiMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3505029_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:MarkIwickiMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3505029">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:MarkIwickiMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3504975_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:JohnDeKoningMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3504975_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:JohnDeKoningMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3504975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:JohnDeKoningMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3504768_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:LionelCarnotMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3504768">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:LionelCarnotMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3498639_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AnandMehraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3498639_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AnandMehraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3498639">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AnandMehraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3496102">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:RevenueFromContractsWithCustomersMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3496066_3475724x3503788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeTaxAuthority1Axis">mrus:DutchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492855_3416904x3556606">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:PensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:TonLogtenbergCEOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492855_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:TonLogtenbergCEOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492855_3416904x3505512">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:GrossSalaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:TonLogtenbergCEOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492855_3416904x3498764">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:BonusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:TonLogtenbergCEOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:TonLogtenbergCEOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492745_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:WolfgangBertholdMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492745_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:WolfgangBertholdMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3492745">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:WolfgangBertholdMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3486516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteCollaborationAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3486468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3421023_3422662x3423353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3421023_3422662x3416700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0_3416740x3421023">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20181231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3475752x3514214">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ManagementAndAdministrationCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3475752x3491841">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:OtherExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3475752x3481637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3423078x3486516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:IncyteCollaborationAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3508886">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">mrus:IFRS15RevenueFromContractsWithCustomersMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3422913x3420637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3422662x3423353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3420782x3424474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3419692x3495181_3423078x3554473">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:EffectOfOverlayApproachReclassificationAxis">mrus:IAS39Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:IncyteShareSubscriptionAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3417632x3422911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3417439x3495221_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:CommonSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3417439x3495214_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:CommonShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3417439x3422519">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3417430x3496068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3417430x3424016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3417395x3509419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">mrus:PlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3417395x3421738">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416963x3508994">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416904x3420576_3417395x3509419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">mrus:PlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416904x3420576_3417395x3421738">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416904x3420576">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416904x3416976_3417395x3509419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">mrus:PlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416904x3416976_3417395x3421738">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416904x3416976">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3556605_3416904x3556606">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:PensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:ShelleyMargetsonFormerCOOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3556605_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:ShelleyMargetsonFormerCOOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3556605_3416904x3505512">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:GrossSalaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:ShelleyMargetsonFormerCOOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3556605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:ShelleyMargetsonFormerCOOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3554539">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:ResearchAndDevelopmentCostReimbursementAndMilestoneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3514219">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:UpfrontPaymentAmortizationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3514206_3422662x3423353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AllOtherEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3514206_3422662x3416700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AllOtherEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3514206">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AllOtherEmployeesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3509602">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3505535_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:GregoryPerryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3505535_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:GregoryPerryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3505535">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:GregoryPerryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3505029_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:MarkIwickiMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3505029_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:MarkIwickiMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3505029">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:MarkIwickiMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3504975_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:JohnDeKoningMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3504975_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:JohnDeKoningMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3504975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:JohnDeKoningMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3504768_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:LionelCarnotMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3504768_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:LionelCarnotMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3504768">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:LionelCarnotMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3498639_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AnandMehraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3498639_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AnandMehraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3498639">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AnandMehraMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3496102">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:RevenueFromContractsWithCustomersMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492855_3416904x3556606">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:PensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:TonLogtenbergCEOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492855_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:TonLogtenbergCEOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492855_3416904x3505512">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:GrossSalaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:TonLogtenbergCEOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492855_3416904x3498764">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:BonusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:TonLogtenbergCEOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:TonLogtenbergCEOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492745_3416904x3506232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:OptionCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:WolfgangBertholdMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492745_3416904x3499176">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CashCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:WolfgangBertholdMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3492745">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:WolfgangBertholdMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3421023_3422662x3423353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3421023_3422662x3416700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0_3416740x3421023">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_365_20171231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_31_20190331_0_3421584x3537338">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">mrus:NonAdjustingEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2019-03-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_31_20190331_0_3417666x3556647_3421584x3537338">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">mrus:MitCambridgeRealEstateLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">mrus:NonAdjustingEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2019-03-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_31_20170131_0_3416740x3486468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_30_20171130_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2017-11-01</startDate>
      <endDate>2017-11-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20170123_0_3416740x3486468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-23</startDate>
      <endDate>2017-01-23</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20171016_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2017-10-16</startDate>
      <endDate>2017-10-16</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20161027_0_3416740x3498640">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AndresSirulnikChiefMedicalOfficerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-10-27</startDate>
      <endDate>2016-10-27</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20170612_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2017-06-12</startDate>
      <endDate>2017-06-12</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20160307_0_3416740x3513897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:OnoResearchAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-03-07</startDate>
      <endDate>2016-03-07</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20140408_0_3423078x3513897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:OnoResearchAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-08</startDate>
      <endDate>2014-04-08</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20181221_0_3423078x3556559">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:RegeneronSubscriptionAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-12-21</startDate>
      <endDate>2018-12-21</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20181221_0_3422992x3481669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">mrus:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-12-21</startDate>
      <endDate>2018-12-21</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20181220_0_3423078x3556559">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:RegeneronSubscriptionAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-12-20</startDate>
      <endDate>2018-12-20</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20181220_0_3422992x3481669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">mrus:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-12-20</startDate>
      <endDate>2018-12-20</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20181210_0_3423078x3554523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:BettaPharmaceuticalsCoLtdMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-12-10</startDate>
      <endDate>2018-12-10</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20180501_0_3423078x3556805">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-05-01</startDate>
      <endDate>2018-05-01</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20180215_0_3416740x3507527">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:InvestorsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-02-15</startDate>
      <endDate>2018-02-15</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20180213_0_3416740x3507527">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:InvestorsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-02-13</startDate>
      <endDate>2018-02-13</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20170524_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2017-05-24</startDate>
      <endDate>2017-05-24</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20170228_0_3416740x3486468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-02-28</startDate>
      <endDate>2017-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20170215_0_3416740x3494322">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:PeterSilvermanSeniorVicePresidentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-02-15</startDate>
      <endDate>2017-02-15</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20161220_0_3423078x3554473">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:IncyteShareSubscriptionAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-12-20</startDate>
      <endDate>2016-12-20</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20161101_0_3416740x3504974">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:JohnCrowleyChiefFinancialOfficerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-11-01</startDate>
      <endDate>2016-11-01</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20160526_0_3475672x3509221">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:SubsidiarySaleOfStock1Axis">mrus:InitialPublicOfferingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-05-26</startDate>
      <endDate>2016-05-26</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_1_20160506_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2016-05-06</startDate>
      <endDate>2016-05-06</endDate>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3475752x3514214">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ManagementAndAdministrationCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3424455x3420520">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3424453x3535979">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">mrus:USTreasurySecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3424453x3530660">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">mrus:AgencyBondMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3424453x3514284">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">mrus:CorporateFixedIncomeBondsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3424453x3479596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">mrus:CommercialPaper1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3423078x3496111">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3423078x3486516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:IncyteCollaborationAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3423034x3424053">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3422992x3481669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">mrus:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3422662x3423353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3422662x3416700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3421968x3422054">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3421968x3421286">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3421584x3553416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">mrus:AdoptionOfIFRS16Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3420782x3424474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3420782x3421581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3420436x3420078">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ifrs-full:FinancialAssetsNeitherPastDueNorImpairedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3417632x3422911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3417439x3495221_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:CommonSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3417439x3495214_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:CommonShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3417439x3422519">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3417436x3416901">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CapitalisedDevelopmentExpenditureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3417430x3496068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3417430x3424016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3417395x3509419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">mrus:PlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3417395x3421738">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3416963x3508994">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3509593">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CarryingAmountAndValueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3420576_3417395x3509419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">mrus:PlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3420576_3417395x3421738">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3420576">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3416976_3417395x3509419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">mrus:PlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3416976_3417395x3421738">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3416976">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3416904x3416753">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3416740x3514206">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AllOtherEmployeesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3416740x3493439_3422662x3423353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:BiophraseBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3416740x3486468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0_3416740x3421023">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20181231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20180101_0_3424457x3514207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">mrus:TwoThousandSixteenOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-01-01</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3475752x3514214">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ManagementAndAdministrationCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3424457x3514207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">mrus:TwoThousandSixteenOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3424455x3420520">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3424453x3535979">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">mrus:USTreasurySecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3424453x3530660">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">mrus:AgencyBondMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3424453x3514284">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">mrus:CorporateFixedIncomeBondsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3424453x3479596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">mrus:CommercialPaper1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3423034x3424053">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3422913x3420637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3422662x3423353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3422662x3416700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3421968x3422054">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3420782x3424474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3420782x3421581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3420436x3420078">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ifrs-full:FinancialAssetsNeitherPastDueNorImpairedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3417632x3422911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3417439x3495221_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:CommonSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3417439x3495214_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:CommonShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3417439x3422519">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3417430x3496068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3417430x3424016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3417395x3509419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">mrus:PlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3417395x3421738">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3416963x3508994">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3509593">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">mrus:CarryingAmountAndValueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3420576_3417395x3509419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">mrus:PlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3420576_3417395x3421738">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3420576">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3416976_3417395x3509419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">mrus:PlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3416976_3417395x3421738">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3416976">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3416904x3416753">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3416740x3514206">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AllOtherEmployeesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0_3416740x3421023">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20171231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20170123_0_3416740x3486468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-01-23</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3422913x3420637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3422662x3423353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3422662x3416700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3417632x3422911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3417439x3495221_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:CommonSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3417439x3495214_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:CommonShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3417439x3422519">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3417430x3424016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3417395x3509419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">mrus:PlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3417395x3421738">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3416963x3508994">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3416904x3420576_3417395x3509419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">mrus:PlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3416904x3420576_3417395x3421738">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3416904x3420576">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3416904x3416976_3417395x3509419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">mrus:PlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3416904x3416976_3417395x3421738">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3416904x3416976">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3416904x3416753">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3416740x3514206">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AllOtherEmployeesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0_3416740x3421023">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3422913x3420637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417632x3422911_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417632x3422911_3422913x3420637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417632x3422911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495221_3417632x3422849_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:CommonSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495221_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:CommonSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495220_3417632x3422849_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassCPreferenceSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495220_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassCPreferenceSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495219_3417632x3422849_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassBPreferenceSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495219_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassBPreferenceSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495218_3417632x3422849_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassAPreferenceSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495218_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassAPreferenceSharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495217_3417632x3421013_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassCPreferenceShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495217_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassCPreferenceShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495216_3417632x3421013_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassBPreferenceShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495216_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassBPreferenceShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495215_3417632x3421013_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassAPreferenceShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495215_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:ClassAPreferenceShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495214_3417632x3421013_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:CommonShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0_3417439x3495214_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:CommonShareCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20170601_0_3416740x3513899">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:CowenAndCoLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-06-01</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20170601_0_3416740x3486468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-06-01</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20190331_0_3416740x3486462_3422662x3416700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:SofinnovaVenturePartnersNineLimitedPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20190331_0_3416740x3486460_3422662x3416700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:CooperatiefLspFourUitgeslotenAansprakelijkheidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20180326_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <instant>2018-03-26</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20180213_0_3416740x3507527">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:InvestorsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-02-13</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20161220_0_3423078x3554473">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:IncyteShareSubscriptionAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-20</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20160526_0_3475672x3509221">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:SubsidiarySaleOfStock1Axis">mrus:InitialPublicOfferingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-05-26</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20160526_0_3475672x3486453">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:SubsidiarySaleOfStock1Axis">mrus:OverAllotmentOption1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-05-26</instant>
    </period>
  </context>
  <context id="eol_PE977595--1820-F0010_STD_0_20160524_0_3475672x3509221">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:SubsidiarySaleOfStock1Axis">mrus:InitialPublicOfferingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-05-24</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_EUR">
    <measure>iso4217:EUR</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_EUR_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:EUR</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="Employees">
    <measure>mrus:Employees</measure>
  </unit>
  <unit id="Y">
    <measure>utr:Y</measure>
  </unit>
  <unit id="sqft">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="Segment">
    <measure>mrus:Segment</measure>
  </unit>
  <xbrll:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1001_3" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1001_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10010_15" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10010_15" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10010_16" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10010_16" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10010_17" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10010_17" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1002_3" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1002_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1003_3" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1003_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1004_3" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1004_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1005_3" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1005_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1006_3" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1006_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1007_3" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1007_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1008_3" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1008_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1009_3" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1009_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1010_3" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1010_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3001_1" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3001_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3002_1" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3002_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3003_1" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3003_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3004_1" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3004_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3005_1" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3005_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3006_1" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3006_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3007_1" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3007_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3008_1" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3008_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3009_1" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3009_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3010_1" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3010_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_7001_13" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_7001_13" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_7005_13" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_7005_13" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_7009_13" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_7009_13" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_7010_13" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_7010_13" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8010_4" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8010_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8010_5" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8010_5" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8010_6" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8010_6" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_9001_22" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_9001_22" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_9005_22" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_9005_22" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_9009_22" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_9009_22" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_9010_22" xlink:label="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_9010_22" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_2_7" xlink:label="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_2_7" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_3_1" xlink:label="id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_3_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_3_3" xlink:label="id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_3_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_10" xlink:label="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_10" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_11" xlink:label="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_11" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_13" xlink:label="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_13" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_14" xlink:label="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_14" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_2" xlink:label="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_2" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_20" xlink:label="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_20" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_21" xlink:label="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_21" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_24" xlink:label="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_24" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_25" xlink:label="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_25" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_26" xlink:label="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_26" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_4" xlink:label="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_5" xlink:label="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_5" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_2_2" xlink:label="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_2_2" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_2_7" xlink:label="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_2_7" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_3_2" xlink:label="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_3_2" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_3_7" xlink:label="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_3_7" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_780AD06D-9847-4BE0-8664-B9F729C217F8_1_4" xlink:label="id_14264487_780AD06D-9847-4BE0-8664-B9F729C217F8_1_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_2_4" xlink:label="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_2_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_3_4" xlink:label="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_3_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_3_0" xlink:label="id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_3_0" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_3_1" xlink:label="id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_3_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_3_2" xlink:label="id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_3_2" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_2_10" xlink:label="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_2_10" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_2_11" xlink:label="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_2_11" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_2_14" xlink:label="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_2_14" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_2_9" xlink:label="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_2_9" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_3_10" xlink:label="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_3_10" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_3_14" xlink:label="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_3_14" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_3_9" xlink:label="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_3_9" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_4" xlink:label="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_5" xlink:label="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_5" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_8" xlink:label="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_8" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_9" xlink:label="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_9" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_4" xlink:label="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_5" xlink:label="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_5" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_8" xlink:label="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_8" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_9" xlink:label="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_9" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1002_39" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1002_39" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1003_38" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1003_38" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_10" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_10" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_11" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_11" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_12" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_12" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_13" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_13" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_14" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_14" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_15" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_15" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_16" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_16" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_17" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_17" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_18" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_18" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_19" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_19" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_21" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_21" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_24" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_24" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_25" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_25" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_26" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_26" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_28" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_28" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_29" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_29" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_3" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_32" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_32" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_33" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_33" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_34" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_34" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_35" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_35" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_36" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_36" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_37" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_37" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_4" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_41" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_41" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_5" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_5" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_6" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_6" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_7" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_7" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_8" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_8" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2002_38" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2002_38" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_10" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_10" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_11" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_11" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_12" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_12" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_13" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_13" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_14" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_14" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_15" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_15" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_16" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_16" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_17" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_17" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_19" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_19" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_24" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_24" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_25" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_25" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_26" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_26" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_28" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_28" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_3" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_31" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_31" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_33" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_33" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_34" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_34" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_35" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_35" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_36" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_36" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_37" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_37" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_4" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_5" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_5" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_6" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_6" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_7" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_7" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_8" xlink:label="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_8" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_2_7" xlink:label="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_2_7" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_7003_12" xlink:label="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_7003_12" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_2_4" xlink:label="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_2_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_2_6" xlink:label="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_2_6" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_3_1" xlink:label="id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_3_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_3_3" xlink:label="id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_3_3" xlink:type="locator"/>
    <xbrll:footnote xlink:label="footnote_1049748027" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</xbrll:footnote>
    <xbrll:footnote xlink:label="footnote_1049748032" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">For the periods included in these financial statements, share options and restricted stock units were excluded from the diluted loss per share calculation as the Company was in a loss position in each period presented above. As a result, basic and diluted loss per share are equal.</xbrll:footnote>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1001_3" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10010_15" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10010_16" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_10010_17" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1002_3" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1003_3" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1004_3" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1005_3" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1006_3" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1007_3" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1008_3" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1009_3" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_1010_3" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3001_1" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3002_1" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3003_1" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3004_1" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3005_1" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3006_1" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3007_1" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3008_1" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3009_1" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_3010_1" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_7001_13" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_7005_13" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_7009_13" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_7010_13" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8010_4" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8010_5" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_8010_6" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_9001_22" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_9005_22" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_9009_22" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_077E9E5C-D769-4FD6-B28B-46F9F2074388_9010_22" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_08BE5DC8-CCA2-49D8-8A5A-F7A9345ADD2A_2_7" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_3_1" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_3_3" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_0C6864B6-2986-4D8A-9BDA-02000C63ACC8_3_3" xlink:to="footnote_1049748032" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_10" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_11" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_13" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_14" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_2" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_20" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_21" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_24" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_25" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_26" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_4" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_55C782F4-C4AF-4ACF-9303-61D491EECC5D_2_5" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_2_2" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_2_7" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_3_2" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_67B1961F-09F5-4FD4-B78D-7244CA79B199_3_7" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_780AD06D-9847-4BE0-8664-B9F729C217F8_1_4" xlink:to="footnote_1049748032" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_2_4" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_8605ABA9-41BC-470E-B97F-FCFFA9A44D45_3_4" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_3_0" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_3_1" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_925BD7CC-01B9-4427-A5C5-2FED480FDA7A_3_2" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_2_10" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_2_11" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_2_14" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_2_9" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_3_10" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_3_14" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_9D3910C0-6AB7-47CD-92BC-F70157A02320_3_9" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_4" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_5" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_8" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_2_9" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_4" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_5" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_8" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_ADBCB07D-C42B-4287-961B-2D2D692317E6_3_9" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1002_39" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_1003_38" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_10" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_11" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_12" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_13" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_14" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_15" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_16" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_17" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_18" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_19" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_21" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_24" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_25" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_26" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_28" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_29" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_3" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_32" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_33" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_34" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_35" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_36" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_37" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_4" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_41" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_5" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_6" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_7" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2_8" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_2002_38" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_10" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_11" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_12" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_13" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_14" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_15" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_16" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_17" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_19" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_24" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_25" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_26" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_28" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_3" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_31" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_33" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_34" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_35" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_36" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_37" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_4" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_5" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_6" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_7" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_BCB60DA8-4D93-43E3-A678-0A5B60BE2201_3_8" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_C8C4FB8A-2DC8-4484-B951-54E7A0CDCB92_2_7" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_C8F4DE19-A73D-43B4-A3EE-24C27C5514A5_7003_12" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_2_4" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_E7AFC1AA-25CD-4320-97D8-92B73CBB8D4A_2_6" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_3_1" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_3_3" xlink:to="footnote_1049748027" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_14264487_EEED2BE3-7ABD-4AFD-A8D2-45A2D714793C_3_3" xlink:to="footnote_1049748032" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
  </xbrll:footnoteLink>
</xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>mrus-20181231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN Xcelerate Taxonomy Schema - https://www.dfinsolutions.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 6 -->
<!-- Creation date: 2019-04-03T15:11:08Z -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:srt-types="http://fasb.org/srt-types/2018-01-31"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:mrus="http://www.merus.nl/20181231"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2018-03-16/ifrs-full"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  targetNamespace="http://www.merus.nl/20181231"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000" id="ias_1_2018-03-16_role-210000">
        <link:definition>103 - Statement - Consolidated Statement of Financial Position</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000" id="ias_1_2018-03-16_role-320000">
        <link:definition>104 - Statement - Consolidated Statement of Profit or Loss and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/StatementOfChangesInEquity-610000" id="ias_1_2018-03-16_role-610000">
        <link:definition>105 - Statement - Consolidated Statement of Changes in Shareholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000" id="ias_7_2018-03-16_role-520000">
        <link:definition>106 - Statement - Consolidated Statement of Cash flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
        <link:definition>107 - Disclosure - General Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
        <link:definition>108 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
        <link:definition>109 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory">
        <link:definition>110 - Disclosure - Recently Issued or Adopted International Financial Reporting Standards</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatory">
        <link:definition>111 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatory">
        <link:definition>112 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIncomeTaxExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfIncomeTaxExplanatory">
        <link:definition>113 - Disclosure - Taxation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory">
        <link:definition>114 - Disclosure - Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory">
        <link:definition>115 - Disclosure - Trade and Other Receivables</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory">
        <link:definition>116 - Disclosure - Other Liabilities and Accruals</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory">
        <link:definition>117 - Disclosure - Deferred Revenue</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory">
        <link:definition>118 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfRevenueExplanatory">
        <link:definition>119 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory">
        <link:definition>120 - Disclosure - Total Operating Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory">
        <link:definition>121 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatory">
        <link:definition>122 - Disclosure - Other Income (Expense)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatory">
        <link:definition>123 - Disclosure - Loss per share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatory">
        <link:definition>124 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory">
        <link:definition>125 - Disclosure - Board Compensation and Key Management Personnel</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRelatedPartyExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfRelatedPartyExplanatory">
        <link:definition>126 - Disclosure - Related party disclosures</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatory">
        <link:definition>127 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory">
        <link:definition>128 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies" id="Role_NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies">
        <link:definition>129 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables">
        <link:definition>130 - Disclosure - Recently Issued or Adopted International Financial Reporting Standards (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatoryTables">
        <link:definition>131 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatoryTables">
        <link:definition>132 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables">
        <link:definition>133 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables">
        <link:definition>134 - Disclosure - Trade and Other Receivables (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables">
        <link:definition>135 - Disclosure - Other Liabilities and Accruals (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables">
        <link:definition>136 - Disclosure - Deferred Revenue (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables">
        <link:definition>137 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables">
        <link:definition>138 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables">
        <link:definition>139 - Disclosure - Total Operating Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables">
        <link:definition>140 - Disclosure - Employee Benefits (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatoryTables">
        <link:definition>141 - Disclosure - Other Income (Expense) (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatoryTables">
        <link:definition>142 - Disclosure - Loss per share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatoryTables">
        <link:definition>143 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatoryTables">
        <link:definition>144 - Disclosure - Board Compensation and Key Management Personnel (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatoryTables">
        <link:definition>145 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureGeneralInformationAdditionalInformation" id="DisclosureGeneralInformationAdditionalInformation">
        <link:definition>146 - Disclosure - General Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation" id="DisclosureBasisOfPresentationAdditionalInformation">
        <link:definition>147 - Disclosure - Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation" id="DisclosureSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>148 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation" id="DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation">
        <link:definition>149 - Disclosure - Recently Issued International Financial Reporting Standards - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss" id="DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss">
        <link:definition>150 - Disclosure - Recently Issued International Financial Reporting Standards - Consolidated Statements of Profit or Loss and Comprehensive Loss (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfFinancialPositions" id="DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfFinancialPositions">
        <link:definition>151 - Disclosure - Recently Issued International Financial Reporting Standards - Consolidated Statements of Financial Positions (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfCashFlows" id="DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfCashFlows">
        <link:definition>152 - Disclosure - Recently Issued International Financial Reporting Standards - Consolidated Statements of Cash Flows (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfChangesInPropertyPlantAndEquipment" id="DisclosurePropertyPlantAndEquipmentScheduleOfChangesInPropertyPlantAndEquipment">
        <link:definition>153 - Disclosure - Property, Plant and Equipment - Schedule of Changes in Property, Plant and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureIntangibleAssetsSummaryOfMovementsOfIntellectualPropertyRight" id="DisclosureIntangibleAssetsSummaryOfMovementsOfIntellectualPropertyRight">
        <link:definition>154 - Disclosure - Intangible Assets - Summary of Movements of Intellectual Property Right (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation" id="DisclosureIntangibleAssetsAdditionalInformation">
        <link:definition>155 - Disclosure - Intangible Assets - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureTaxationAdditionalInformation" id="DisclosureTaxationAdditionalInformation">
        <link:definition>156 - Disclosure - Taxation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments" id="DisclosureInvestmentsSummaryOfInvestments">
        <link:definition>157 - Disclosure - Investments - Summary of Investments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsAdditionalInformation" id="DisclosureInvestmentsAdditionalInformation">
        <link:definition>158 - Disclosure - Investments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year" id="DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year">
        <link:definition>159 - Disclosure - Trade and Other Receivables - Summary of Trade and Other Receivables Due Within 1 Year (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureOtherLiabilitiesAndAccrualsSummaryOfShorttermAndPayableWithin1Year" id="DisclosureOtherLiabilitiesAndAccrualsSummaryOfShorttermAndPayableWithin1Year">
        <link:definition>160 - Disclosure - Other Liabilities and Accruals - Summary of Short-term and Payable Within 1 Year (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenue" id="DisclosureDeferredRevenueSummaryOfDeferredRevenue">
        <link:definition>161 - Disclosure - Deferred Revenue - Summary of Deferred Revenue (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation" id="DisclosureDeferredRevenueAdditionalInformation">
        <link:definition>162 - Disclosure - Deferred Revenue - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationEquity" id="DisclosureShareholdersEquityAdditionalInformationEquity">
        <link:definition>163 - Disclosure - Shareholders' Equity - Additional Information - Equity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfCommonSharesOutstanding" id="DisclosureShareholdersEquitySummaryOfReconciliationOfCommonSharesOutstanding">
        <link:definition>164 - Disclosure - Shareholders' Equity - Summary of Reconciliation of Common Shares Outstanding (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationShareBasedPaymentArrangements" id="DisclosureShareholdersEquityAdditionalInformationShareBasedPaymentArrangements">
        <link:definition>165 - Disclosure - Shareholders' Equity - Additional Information - Share Based Payment Arrangements (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates" id="DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates">
        <link:definition>166 - Disclosure - Shareholders' Equity - Summary of Inputs Used in the Measurement of the Fair Values and the Related Fair Values at the Grant Dates (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions" id="DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions">
        <link:definition>167 - Disclosure - Shareholders' Equity - Summary of Reconciliation of Outstanding Share Options (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding" id="DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding">
        <link:definition>168 - Disclosure - Shareholders' Equity - Summary of Number of Share Options Outstanding (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs" id="DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs">
        <link:definition>169 - Disclosure - Shareholders' Equity - Summary of Reconciliation of RSU's (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueSummaryOfRevenue" id="DisclosureRevenueSummaryOfRevenue">
        <link:definition>170 - Disclosure - Revenue - Summary of Revenue (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueAdditionalInformation" id="DisclosureRevenueAdditionalInformation">
        <link:definition>171 - Disclosure - Revenue - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory" id="DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory">
        <link:definition>172 - Disclosure - Revenue - Disclosure Of Changes In Trade Receivables Contract Assets And Contract Liabilities Explanatory (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses" id="DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses">
        <link:definition>173 - Disclosure - Total Operating Expenses - Summary of Total Operating Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts" id="DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts">
        <link:definition>174 - Disclosure - Total Operating Expenses - Breakdown of Other Research and Development Costs (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesAdditionalInformation" id="DisclosureTotalOperatingExpensesAdditionalInformation">
        <link:definition>175 - Disclosure - Total Operating Expenses - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesOperatingExpensesByNature" id="DisclosureTotalOperatingExpensesOperatingExpensesByNature">
        <link:definition>176 - Disclosure - Total Operating Expenses - Operating Expenses by Nature (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits" id="DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits">
        <link:definition>177 - Disclosure - Employee Benefits - Disclosure of Detailed Information About Employee Benefits (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses" id="DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses">
        <link:definition>178 - Disclosure - Employee Benefits - Schedule of Share-based Compensation Expenses Recognized as Employee Benefit Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation" id="DisclosureEmployeeBenefitsAdditionalInformation">
        <link:definition>179 - Disclosure - Employee Benefits - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureOtherIncomeExpenseSummaryOfOtherIncomeExpense" id="DisclosureOtherIncomeExpenseSummaryOfOtherIncomeExpense">
        <link:definition>180 - Disclosure - Other Income (Expense) - Summary of Other Income (Expense) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureOtherIncomeExpenseAdditionalInformation" id="DisclosureOtherIncomeExpenseAdditionalInformation">
        <link:definition>181 - Disclosure - Other Income (Expense) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShare" id="DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShare">
        <link:definition>182 - Disclosure - Loss per Share - Summary of Basic and Diluted Loss per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureLossPerShareAdditionalInformation" id="DisclosureLossPerShareAdditionalInformation">
        <link:definition>183 - Disclosure - Loss per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfMaximumCreditExposure" id="DisclosureFinancialInstrumentSummaryOfMaximumCreditExposure">
        <link:definition>184 - Disclosure - Financial Instrument - Summary of Maximum Credit Exposure (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfAgingOfTradeAndUnbilledReceivables" id="DisclosureFinancialInstrumentSummaryOfAgingOfTradeAndUnbilledReceivables">
        <link:definition>185 - Disclosure - Financial Instrument - Summary of Aging of Trade and Unbilled Receivables (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentAdditionalInformation" id="DisclosureFinancialInstrumentAdditionalInformation">
        <link:definition>186 - Disclosure - Financial Instrument - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfMaturityAnalysisForNonderivativeFinancialLiabilities" id="DisclosureFinancialInstrumentsSummaryOfMaturityAnalysisForNonderivativeFinancialLiabilities">
        <link:definition>187 - Disclosure - Financial Instruments - Summary of Maturity Analysis For Nonderivative Financial Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfSensitivityAnalysisForChangeInPrimaryCurrencyExposure" id="DisclosureFinancialInstrumentsSummaryOfSensitivityAnalysisForChangeInPrimaryCurrencyExposure">
        <link:definition>188 - Disclosure - Financial Instruments - Summary of Sensitivity Analysis for Change in Primary Currency Exposure (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfInterestBearingFinancialInstruments" id="DisclosureFinancialInstrumentSummaryOfInterestBearingFinancialInstruments">
        <link:definition>189 - Disclosure - Financial Instrument - Summary of Interest Bearing Financial Instruments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatement" id="DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatement">
        <link:definition>190 - Disclosure - Board Compensation and Key Management Personnel - Summary on Charge to the Profit and Loss Statement (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatementParenthetical" id="DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatementParenthetical">
        <link:definition>191 - Disclosure - Board Compensation and Key Management Personnel - Summary on Charge to the Profit and Loss Statement (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelAdditionalInformation" id="DisclosureBoardCompensationAndKeyManagementPersonnelAdditionalInformation">
        <link:definition>192 - Disclosure - Board Compensation and Key Management Personnel - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfRelatedParty" id="DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfRelatedParty">
        <link:definition>193 - Disclosure - Board Compensation and Key Management Personnel - Summary of Related Party (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfConsolidatedStatementOfProfitAndLossForTheRemunerationOfTheFormerMembersOfTheSupervisoryBoard" id="DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfConsolidatedStatementOfProfitAndLossForTheRemunerationOfTheFormerMembersOfTheSupervisoryBoard">
        <link:definition>194 - Disclosure - Board Compensation and Key Management Personnel - Summary of Consolidated Statement of Profit and Loss for the Remuneration of the (Former) Members of the Supervisory Board (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard" id="DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard">
        <link:definition>195 - Disclosure - Board Compensation and Key Management Personnel - Summary of Average Exercise Price Per Share Held by the Members of the Supervisory Board (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureRelatedPartyDisclosuresAdditionalInformation" id="DisclosureRelatedPartyDisclosuresAdditionalInformation">
        <link:definition>196 - Disclosure - Related Party Disclosures - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation">
        <link:definition>197 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderLease" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderLease">
        <link:definition>198 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Lease (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation" id="DisclosureSubsequentEventsAdditionalInformation">
        <link:definition>199 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="mrus-20181231_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="mrus-20181231_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="mrus-20181231_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="mrus-20181231_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://fasb.org/srt-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <import namespace="http://xbrl.ifrs.org/taxonomy/2018-03-16/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="https://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <element name="AccrualsToEmployeeSeveranceIndemnities" id="mrus_AccrualsToEmployeeSeveranceIndemnities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedAuditorsFee" id="mrus_AccruedAuditorsFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedIntellectualPropertyLegalFee" id="mrus_AccruedIntellectualPropertyLegalFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedPersonnel" id="mrus_AccruedPersonnel" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedResearchAndDevelopmentStudies" id="mrus_AccruedResearchAndDevelopmentStudies" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionsInContractAssets" id="mrus_AdditionsInContractAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionsInContractLiabilities" id="mrus_AdditionsInContractLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionsToTradeReceivables" id="mrus_AdditionsToTradeReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals" id="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" id="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdoptionOfIFRS16Member" id="mrus_AdoptionOfIFRS16Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AgencyBondMember" id="mrus_AgencyBondMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AggregateValueOfCommonSharesIssued" id="mrus_AggregateValueOfCommonSharesIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AllOtherEmployeesMember" id="mrus_AllOtherEmployeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AllowanceForImpairment" id="mrus_AllowanceForImpairment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmountPaidForFullTimeEquivalentFunding" id="mrus_AmountPaidForFullTimeEquivalentFunding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmountPaidToCompensateForResearchServices" id="mrus_AmountPaidToCompensateForResearchServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmountRemittedToOtherBeneficiaries" id="mrus_AmountRemittedToOtherBeneficiaries" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AnandMehraMember" id="mrus_AnandMehraMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AndresSirulnikChiefMedicalOfficerMember" id="mrus_AndresSirulnikChiefMedicalOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers" id="mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AverageQualifyingProfitsEffectiveTaxRate" id="mrus_AverageQualifyingProfitsEffectiveTaxRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BettaPharmaceuticalsCoLtdMember" id="mrus_BettaPharmaceuticalsCoLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BiophraseBVMember" id="mrus_BiophraseBVMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BonusMember" id="mrus_BonusMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CarryingAmountAndValueMember" id="mrus_CarryingAmountAndValueMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashAndCashEquivalents1Member" id="mrus_CashAndCashEquivalents1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashAndCashEquivalentsMaximumMaturityPeriod" id="mrus_CashAndCashEquivalentsMaximumMaturityPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashCompensationMember" id="mrus_CashCompensationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChangeInWorkingCapitalAbstract" id="mrus_ChangeInWorkingCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChangesInAccruedCapitalExpenditures" id="mrus_ChangesInAccruedCapitalExpenditures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements" id="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChangesInRestrictedCash" id="mrus_ChangesInRestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassAPreferenceShareCapitalMember" id="mrus_ClassAPreferenceShareCapitalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassAPreferenceSharePremiumMember" id="mrus_ClassAPreferenceSharePremiumMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassBPreferenceShareCapitalMember" id="mrus_ClassBPreferenceShareCapitalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassBPreferenceSharePremiumMember" id="mrus_ClassBPreferenceSharePremiumMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassCPreferenceShareCapitalMember" id="mrus_ClassCPreferenceShareCapitalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassCPreferenceSharePremiumMember" id="mrus_ClassCPreferenceSharePremiumMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClinicalCosts" id="mrus_ClinicalCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommercialPaper1Member" id="mrus_CommercialPaper1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonShareCapitalMember" id="mrus_CommonShareCapitalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonSharePremiumMember" id="mrus_CommonSharePremiumMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContractManufacturingExpenses" id="mrus_ContractManufacturingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CooperatiefLspFourUitgeslotenAansprakelijkheidMember" id="mrus_CooperatiefLspFourUitgeslotenAansprakelijkheidMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CorporateFixedIncomeBondsMember" id="mrus_CorporateFixedIncomeBondsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CowenAndCoLlcMember" id="mrus_CowenAndCoLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CurrentPrepaidGeneralExpenses" id="mrus_CurrentPrepaidGeneralExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CurrentPrepaidPensionCosts" id="mrus_CurrentPrepaidPensionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CurrentUnbilledReceivables" id="mrus_CurrentUnbilledReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeductionsInContractAssets" id="mrus_DeductionsInContractAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeductionsInContractLiabilities" id="mrus_DeductionsInContractLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeductionsInTradeReceivables" id="mrus_DeductionsInTradeReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredRevenueMember" id="mrus_DeferredRevenueMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract" id="mrus_DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" id="mrus_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" id="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory" id="mrus_DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfAccountingPolicyForInvestmentsExplanatory" id="mrus_DescriptionOfAccountingPolicyForInvestmentsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfDepositoryReceiptsBasedExercisePrice" id="mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfGrantAward" id="mrus_DescriptionOfGrantAward" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfNonVestingCondition" id="mrus_DescriptionOfNonVestingCondition" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfOptionLapse" id="mrus_DescriptionOfOptionLapse" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfOptionsGranted" id="mrus_DescriptionOfOptionsGranted" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureChargedToTheProfitAndLossStatementAbstract" id="mrus_DisclosureChargedToTheProfitAndLossStatementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureChargedToTheProfitAndLossStatementExplanatory" id="mrus_DisclosureChargedToTheProfitAndLossStatementExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureChargedToTheProfitAndLossStatementLineItems" id="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureChargedToTheProfitAndLossStatementTable" id="mrus_DisclosureChargedToTheProfitAndLossStatementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DisclosureOfAccrualsAndOtherPayablesAbstract" id="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock" id="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory" id="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory" id="mrus_DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract" id="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" id="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" id="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DisclosureOfCommitmentsAndContingenciesAbstract" id="mrus_DisclosureOfCommitmentsAndContingenciesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfCommitmentsAndContingenciesExplanatory" id="mrus_DisclosureOfCommitmentsAndContingenciesExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfCommitmentsAndContingenciesLineItems" id="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfCommitmentsAndContingenciesTable" id="mrus_DisclosureOfCommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DisclosureOfDeferredIncomeAbstract" id="mrus_DisclosureOfDeferredIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfDeferredIncomeLineItems" id="mrus_DisclosureOfDeferredIncomeLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfDeferredIncomeTable" id="mrus_DisclosureOfDeferredIncomeTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DisclosureOfDeferredRevenueExplanatory" id="mrus_DisclosureOfDeferredRevenueExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" id="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory" id="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory" id="mrus_DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" id="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfDetailedInformationOfRelatedPartyExplanatory" id="mrus_DisclosureOfDetailedInformationOfRelatedPartyExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory" id="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory" id="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfDetailsOfEarningsPerShareExplanatory" id="mrus_DisclosureOfDetailsOfEarningsPerShareExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfEmployeeBenefitsAbstract" id="mrus_DisclosureOfEmployeeBenefitsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfEmployeeBenefitsLineItems" id="mrus_DisclosureOfEmployeeBenefitsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfEmployeeBenefitsTable" id="mrus_DisclosureOfEmployeeBenefitsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DisclosureOfEventsAfterReportingPeriodLineItems" id="mrus_DisclosureOfEventsAfterReportingPeriodLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfEventsAfterReportingPeriodTable" id="mrus_DisclosureOfEventsAfterReportingPeriodTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DisclosureoffinancialinformationAbstract" id="mrus_DisclosureoffinancialinformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfGeneralInformationAbstract" id="mrus_DisclosureOfGeneralInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfGeneralInformationLineItems" id="mrus_DisclosureOfGeneralInformationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfGeneralInformationTable" id="mrus_DisclosureOfGeneralInformationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DisclosureOfHeldToMaturityInvestmentExplanatory" id="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfInformationAboutRevenueExplanatory" id="mrus_DisclosureOfInformationAboutRevenueExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfInterestBearingFinancialInstrumentsAbstract" id="mrus_DisclosureOfInterestBearingFinancialInstrumentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfInterestBearingFinancialInstrumentsExplanatory" id="mrus_DisclosureOfInterestBearingFinancialInstrumentsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfInterestBearingFinancialInstrumentsLineItems" id="mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfInterestBearingFinancialInstrumentsTable" id="mrus_DisclosureOfInterestBearingFinancialInstrumentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DisclosureOfMaximumExposureToCreditRiskExplanatory" id="mrus_DisclosureOfMaximumExposureToCreditRiskExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory" id="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfOperatingExpensesAbstract" id="mrus_DisclosureOfOperatingExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfOperatingExpensesByNatureExplanatory" id="mrus_DisclosureOfOperatingExpensesByNatureExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfOperatingExpensesExplanatory" id="mrus_DisclosureOfOperatingExpensesExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardAbstract" id="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory" id="mrus_DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" id="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" id="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DisclosureOfOtherIncomeExpenseExplanatory" id="mrus_DisclosureOfOtherIncomeExpenseExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfRecentlyIssuedIfrsAbstract" id="mrus_DisclosureOfRecentlyIssuedIfrsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfRelatedPartyAbstract" id="mrus_DisclosureOfRelatedPartyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfShareOfEquityInvestmentLineItems" id="mrus_DisclosureOfShareOfEquityInvestmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfSignificantAccountingPoliciesAbstract" id="mrus_DisclosureOfSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfSignificantAccountingPoliciesLineItems" id="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfSignificantAccountingPoliciesTable" id="mrus_DisclosureOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory" id="mrus_DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfTradeAndOtherCurrentReceivableExplanatory" id="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DiscoveryAndPreclinicalCosts" id="mrus_DiscoveryAndPreclinicalCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DividendDeclared" id="mrus_DividendDeclared" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="mrus_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DutchMember" id="mrus_DutchMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeBenefitSchemeAxis" id="mrus_EmployeeBenefitSchemeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="EmployeeBenefitSchemeDomain" id="mrus_EmployeeBenefitSchemeDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeOptionExercisedPricePerShare" id="mrus_EmployeeOptionExercisedPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EstimatedContractualTerm" id="mrus_EstimatedContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExercisePricePerShare" id="mrus_ExercisePricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueAssumptionsGrantDateSharePrice" id="mrus_FairValueAssumptionsGrantDateSharePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FivePercentageDecreaseInFunctionalRateMember" id="mrus_FivePercentageDecreaseInFunctionalRateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FivePercentageIncreaseInFunctionalRateMember" id="mrus_FivePercentageIncreaseInFunctionalRateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FixedRateOfInstrumentsAbstract" id="mrus_FixedRateOfInstrumentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ForeignExchangeSensitivityEffectOnProfitBeforeTax" id="mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GabrieleDallmannMember" id="mrus_GabrieleDallmannMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GeneralLegalInsuranceAndFacilityRelatedExpenses" id="mrus_GeneralLegalInsuranceAndFacilityRelatedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GrantIncome" id="mrus_GrantIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GregoryPerryMember" id="mrus_GregoryPerryMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GrossSalaryMember" id="mrus_GrossSalaryMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="HealthInsurance" id="mrus_HealthInsurance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IAS39Member" id="mrus_IAS39Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IFRS15RevenueFromContractsWithCustomersMember" id="mrus_IFRS15RevenueFromContractsWithCustomersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeMember" id="mrus_IncomeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeStatementLineItemLocationAxis" id="mrus_IncomeStatementLineItemLocationAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="IncomeStatementLineItemLocationMember" id="mrus_IncomeStatementLineItemLocationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxAuthority1Axis" id="mrus_IncomeTaxAuthority1Axis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="IncomeTaxAuthority1Domain" id="mrus_IncomeTaxAuthority1Domain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInCapital" id="mrus_IncreaseDecreaseInCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInDeferredRevenue1" id="mrus_IncreaseDecreaseInDeferredRevenue1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInSharePremium" id="mrus_IncreaseDecreaseInSharePremium" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseThroughContributionsByAndDistributionsToOwnersEquity" id="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncyteCollaborationAgreementMember" id="mrus_IncyteCollaborationAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncyteCorporationMember" id="mrus_IncyteCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncyteMember" id="mrus_IncyteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncyteProprietaryTechnologyMember" id="mrus_IncyteProprietaryTechnologyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncyteShareSubscriptionAgreementMember" id="mrus_IncyteShareSubscriptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InitialPublicOfferingCosts" id="mrus_InitialPublicOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InitialPublicOfferingMember" id="mrus_InitialPublicOfferingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InnovationsBoxRate" id="mrus_InnovationsBoxRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IntellectualPropertyCosts" id="mrus_IntellectualPropertyCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InterestAndOtherExpense" id="mrus_InterestAndOtherExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InterestAndRelatedIncome" id="mrus_InterestAndRelatedIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InvestmentMember" id="mrus_InvestmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InvestorsMember" id="mrus_InvestorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IPAndLicenseCosts" id="mrus_IPAndLicenseCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="JohnCrowleyChiefFinancialOfficerMember" id="mrus_JohnCrowleyChiefFinancialOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="JohnDeKoningMember" id="mrus_JohnDeKoningMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeasesAgreementForCorporateHeadquartersMember" id="mrus_LeasesAgreementForCorporateHeadquartersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeasesExpirationPeriod" id="mrus_LeasesExpirationPeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeaseTermExpirationDate" id="mrus_LeaseTermExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LenKanavyMember" id="mrus_LenKanavyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LionelCarnotMember" id="mrus_LionelCarnotMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LitigationCosts" id="mrus_LitigationCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LitigationSettlementsGrantedForAttorneysFees" id="mrus_LitigationSettlementsGrantedForAttorneysFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LitigationSettlementsGrantedForExpertFees" id="mrus_LitigationSettlementsGrantedForExpertFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LitigationSettlementsGrantedForLitigationExpensesAndCosts" id="mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ManagementAndAdministrationCostsMember" id="mrus_ManagementAndAdministrationCostsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ManufacturingCost" id="mrus_ManufacturingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MarkIwickiMember" id="mrus_MarkIwickiMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestonePaymentReceived" id="mrus_MilestonePaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneRevenues" id="mrus_MilestoneRevenues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneRevenuesAndCostsReimbursements" id="mrus_MilestoneRevenuesAndCostsReimbursements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MitCambridgeRealEstateLlcMember" id="mrus_MitCambridgeRealEstateLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetFinanceIncomeExpenseMember" id="mrus_NetFinanceIncomeExpenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetInterestIncomeAndExpenseTable" id="mrus_NetInterestIncomeAndExpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="NetProceedsFromIssuingShares" id="mrus_NetProceedsFromIssuingShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember" id="mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonAdjustingEventMember" id="mrus_NonAdjustingEventMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonCurrentAssetsFinanceLiabilitiesAbstract" id="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonexecutiveCompensationProgramMember" id="mrus_NonexecutiveCompensationProgramMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonRefundableUpfrontPaymentsReceivable" id="mrus_NonRefundableUpfrontPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfCommonShareEntitledToReceive" id="mrus_NumberOfCommonShareEntitledToReceive" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod" id="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfOptionsHeldByTheChiefExecutiveOfficers" id="mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfOptionsHeldByTheMembersOfSupervisoryBoard" id="mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers" id="mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfReportableSegments1" id="mrus_NumberOfReportableSegments1" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfSharesIssuable" id="mrus_NumberOfSharesIssuable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfSharesIssuedForCash" id="mrus_NumberOfSharesIssuedForCash" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumeratorComputationOfBasicAndDilutedEarningsPerShareAbstract" id="mrus_NumeratorComputationOfBasicAndDilutedEarningsPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OnoResearchAndLicenseAgreementMember" id="mrus_OnoResearchAndLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingExpensesFromRailroadAndRelatedBusinessAbstract" id="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLeaseTermOfLeaseAgreement" id="mrus_OperatingLeaseTermOfLeaseAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OptionCostMember" id="mrus_OptionCostMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherAccruals" id="mrus_OtherAccruals" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherExpensesMember" id="mrus_OtherExpensesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherExternalAndOutsourcedCosts" id="mrus_OtherExternalAndOutsourcedCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherFundingCommitmentsMember" id="mrus_OtherFundingCommitmentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherIncomeExpense" id="mrus_OtherIncomeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherLiabilitiesAndAccrualsUndiscountedCashFlows" id="mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherOperatingExpenses" id="mrus_OtherOperatingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherResearchAndDevelopmentExpenseOther" id="mrus_OtherResearchAndDevelopmentExpenseOther" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherResearchAndDevelopmentExpenses" id="mrus_OtherResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OverAllotmentOption1Member" id="mrus_OverAllotmentOption1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PatentsAndIntellectualPropertyMember" id="mrus_PatentsAndIntellectualPropertyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentOfPropertyPlantAndEquipment" id="mrus_PaymentOfPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PensionCosts" id="mrus_PensionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PensionMember" id="mrus_PensionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfAggregateCompensationPayable" id="mrus_PercentageOfAggregateCompensationPayable" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfInitialVestingOptions" id="mrus_PercentageOfInitialVestingOptions" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfOwnershipInterestByShareholders" id="mrus_PercentageOfOwnershipInterestByShareholders" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfRemainingVestingOptions" id="mrus_PercentageOfRemainingVestingOptions" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod" id="mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfSeverancePaymentPaid" id="mrus_PercentageOfSeverancePaymentPaid" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfVestingOptions" id="mrus_PercentageOfVestingOptions" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodOfAwardsWillBeVestedAndExercised" id="mrus_PeriodOfAwardsWillBeVestedAndExercised" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodOfOptionToExerciseTreatedAsNonVestingConditions" id="mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodOfRemainingOptionsVestingPeriod" id="mrus_PeriodOfRemainingOptionsVestingPeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodOfVestingInstallmentsOfInitialVestingAwards" id="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PersonnelRelatedResearchAndDevelopmentExpense" id="mrus_PersonnelRelatedResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeterSilvermanSeniorVicePresidentMember" id="mrus_PeterSilvermanSeniorVicePresidentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PlantAndEquipmentMember" id="mrus_PlantAndEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreclinicalCosts" id="mrus_PreclinicalCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrepaidShareIssueRelatedCost" id="mrus_PrepaidShareIssueRelatedCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromCollaborationAgreement" id="mrus_ProceedsFromCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PurchasePricePerCommonShare" id="mrus_PurchasePricePerCommonShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RegeneronPharmaceuticalsIncMember" id="mrus_RegeneronPharmaceuticalsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RegeneronSubscriptionAgreementMember" id="mrus_RegeneronSubscriptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReimbursementOfExpenses" id="mrus_ReimbursementOfExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReimbursementOfGrant" id="mrus_ReimbursementOfGrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RemunerationForFormerEmployees" id="mrus_RemunerationForFormerEmployees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RentalExpensesOnRealEstateAbstract" id="mrus_RentalExpensesOnRealEstateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RentAndServiceChargesExpense" id="mrus_RentAndServiceChargesExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAndDevelopmentCostReimbursementAndMilestoneMember" id="mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAndDevelopmentCostsMember" id="mrus_ResearchAndDevelopmentCostsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueFromContractsWithCustomersMember" id="mrus_RevenueFromContractsWithCustomersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueLineItems" id="mrus_RevenueLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueRecognized" id="mrus_RevenueRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueRecognizedIncludedInDeferredRevenue" id="mrus_RevenueRecognizedIncludedInDeferredRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueRecognizedNotIncludedInDeferredRevenue" id="mrus_RevenueRecognizedNotIncludedInDeferredRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueRemainingPerformanceObligations" id="mrus_RevenueRemainingPerformanceObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueTable" id="mrus_RevenueTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ReverseStockSplitConversionRatio" id="mrus_ReverseStockSplitConversionRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RussellGreigMember" id="mrus_RussellGreigMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SecuritiesPledgedAsCollateralForRegistration" id="mrus_SecuritiesPledgedAsCollateralForRegistration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SecurityDeposits" id="mrus_SecurityDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeveranceCostsMember" id="mrus_SeveranceCostsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized" id="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharebasedCompensationAwardVestingPeriod" id="mrus_SharebasedCompensationAwardVestingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharebasedCompensationWeightedAverageRemainingContractualLife" id="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharePurchasedPricePerShare" id="mrus_SharePurchasedPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShelleyMargetsonFormerCOOMember" id="mrus_ShelleyMargetsonFormerCOOMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SimcereCollaborationAndLicenseAgreementMember" id="mrus_SimcereCollaborationAndLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SimcerePharmaceuticalCoLtdMember" id="mrus_SimcerePharmaceuticalCoLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SofinnovaVenturePartnersNineLimitedPartnershipMember" id="mrus_SofinnovaVenturePartnersNineLimitedPartnershipMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SquareFeetOfOfficeSpaceUnderLeaseAgreement" id="mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement" type="num:areaItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockAwardExpense" id="mrus_StockAwardExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SubsequentsEventsAbstract" id="mrus_SubsequentsEventsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SubsidiarySaleOfStock1Axis" id="mrus_SubsidiarySaleOfStock1Axis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="SubsidiarySaleOfStockDomain" id="mrus_SubsidiarySaleOfStockDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SupplementalDisclosureOfCashFlowInformationAbstract" id="mrus_SupplementalDisclosureOfCashFlowInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TaxesAndSocialSecurityLiabilitiesMember" id="mrus_TaxesAndSocialSecurityLiabilitiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TermsOfPaymentOfTradeReceivables" id="mrus_TermsOfPaymentOfTradeReceivables" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TextBlockAbstract" id="mrus_TextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TonLogtenbergCEOMember" id="mrus_TonLogtenbergCEOMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TradeAndOtherReceivableMember" id="mrus_TradeAndOtherReceivableMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TradeAndUnbilledReceivables" id="mrus_TradeAndUnbilledReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TradePayablesOtherLiabilitiesAndAccrualsMember" id="mrus_TradePayablesOtherLiabilitiesAndAccrualsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TransactionsWithOwnersAbstract" id="mrus_TransactionsWithOwnersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandSixteenOptionPlanMember" id="mrus_TwoThousandSixteenOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandTenOptionPlanMember" id="mrus_TwoThousandTenOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UnbilledReceivablesMember" id="mrus_UnbilledReceivablesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontAndMilestonePaymentsMember" id="mrus_UpfrontAndMilestonePaymentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontPayment" id="mrus_UpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontPaymentAmortization" id="mrus_UpfrontPaymentAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontPaymentAmortizationMember" id="mrus_UpfrontPaymentAmortizationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="USTreasurySecuritiesMember" id="mrus_USTreasurySecuritiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ValueOfCommonSharesIssued" id="mrus_ValueOfCommonSharesIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WBSOSubsidy" id="mrus_WBSOSubsidy" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard" id="mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageNumberOfShares" id="mrus_WeightedAverageNumberOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio" id="mrus_WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WolfgangBertholdMember" id="mrus_WolfgangBertholdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>mrus-20181231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN Xcelerate Taxonomy Calculation Linkbase - https://www.dfinsolutions.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 6 -->
<!-- Creation date: 2019-04-03T15:11:08Z -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DocumentandEntityInformation" roleURI="http://www.merus.nl/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#ias_1_2018-03-16_role-210000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#ias_1_2018-03-16_role-320000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#ias_1_2018-03-16_role-610000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfChangesInEquity-610000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#ias_7_2018-03-16_role-520000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureGeneralInformationAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureGeneralInformationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBasisOfPresentationAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfFinancialPositions" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfFinancialPositions"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfCashFlows" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosurePropertyPlantAndEquipmentScheduleOfChangesInPropertyPlantAndEquipment" roleURI="http://www.merus.nl/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfChangesInPropertyPlantAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureIntangibleAssetsSummaryOfMovementsOfIntellectualPropertyRight" roleURI="http://www.merus.nl/taxonomy/role/DisclosureIntangibleAssetsSummaryOfMovementsOfIntellectualPropertyRight"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureIntangibleAssetsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTaxationAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTaxationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureInvestmentsSummaryOfInvestments" roleURI="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureInvestmentsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureOtherLiabilitiesAndAccrualsSummaryOfShorttermAndPayableWithin1Year" roleURI="http://www.merus.nl/taxonomy/role/DisclosureOtherLiabilitiesAndAccrualsSummaryOfShorttermAndPayableWithin1Year"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureDeferredRevenueSummaryOfDeferredRevenue" roleURI="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureDeferredRevenueAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquityAdditionalInformationEquity" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationEquity"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquitySummaryOfReconciliationOfCommonSharesOutstanding" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfCommonSharesOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquityAdditionalInformationShareBasedPaymentArrangements" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationShareBasedPaymentArrangements"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRevenueSummaryOfRevenue" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueSummaryOfRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRevenueAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTotalOperatingExpensesAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTotalOperatingExpensesOperatingExpensesByNature" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesOperatingExpensesByNature"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureEmployeeBenefitsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureOtherIncomeExpenseSummaryOfOtherIncomeExpense" roleURI="http://www.merus.nl/taxonomy/role/DisclosureOtherIncomeExpenseSummaryOfOtherIncomeExpense"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureOtherIncomeExpenseAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureOtherIncomeExpenseAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShare" roleURI="http://www.merus.nl/taxonomy/role/DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureLossPerShareAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureLossPerShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentSummaryOfMaximumCreditExposure" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfMaximumCreditExposure"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentSummaryOfAgingOfTradeAndUnbilledReceivables" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfAgingOfTradeAndUnbilledReceivables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentsSummaryOfMaturityAnalysisForNonderivativeFinancialLiabilities" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfMaturityAnalysisForNonderivativeFinancialLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentsSummaryOfSensitivityAnalysisForChangeInPrimaryCurrencyExposure" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfSensitivityAnalysisForChangeInPrimaryCurrencyExposure"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentSummaryOfInterestBearingFinancialInstruments" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfInterestBearingFinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatement" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatement"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatementParenthetical" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatementParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfRelatedParty" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfConsolidatedStatementOfProfitAndLossForTheRemunerationOfTheFormerMembersOfTheSupervisoryBoard" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfConsolidatedStatementOfProfitAndLossForTheRemunerationOfTheFormerMembersOfTheSupervisoryBoard"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRelatedPartyDisclosuresAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRelatedPartyDisclosuresAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderLease" roleURI="http://www.merus.nl/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderLease"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfIncomeTaxExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIncomeTaxExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfRevenueExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfRelatedPartyExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRelatedPartyExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentHeldtomaturityInvestments" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentHeldtomaturityInvestments" xlink:label="ifrs-full_NoncurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentHeldtomaturityInvestments" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_DeferredIncomeClassifiedAsCurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_IssuedCapital" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_SharePremium" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_RetainedEarnings" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Liabilities" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_DeferredIncomeClassifiedAsNoncurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_CurrentLiabilities" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentHeldtomaturityInvestments" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherExpenseByNature" xlink:label="ifrs-full_OtherExpenseByNature"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherFinanceIncome" xlink:label="ifrs-full_OtherFinanceIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="ifrs-full_OtherFinanceIncomeCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_OtherExpenseByNature" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherFinanceIncomeCost" xlink:to="ifrs-full_FinanceIncome" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherFinanceIncomeCost" xlink:to="ifrs-full_FinanceCosts" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherFinanceIncomeCost" xlink:to="ifrs-full_OtherFinanceIncome" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="1.1200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_OtherFinanceIncomeCost" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_Revenue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_OperatingExpense" order="1.0500" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfChangesInEquity-610000">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" xlink:label="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InitialPublicOfferingCosts" xlink:label="mrus_InitialPublicOfferingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" xlink:to="ifrs-full_IssueOfEquity" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" xlink:to="mrus_InitialPublicOfferingCosts" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="1.0800" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ChangesInRestrictedCash" xlink:label="mrus_ChangesInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PaymentsForDebtIssueCosts" xlink:label="ifrs-full_PaymentsForDebtIssueCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ProceedsFromCollaborationAgreement" xlink:label="mrus_ProceedsFromCollaborationAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsForDebtIssueCosts" order="1.2500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsForShareIssueCosts" order="1.2700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="mrus_ProceedsFromCollaborationAgreement" order="1.2800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="1.2900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="mrus_ChangesInRestrictedCash" order="1.3000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1.1800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="1.2000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="1.2100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperations" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities" order="1.1500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" order="1.1600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_ProfitLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="1.3100" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureGeneralInformationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfFinancialPositions">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfCashFlows">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfChangesInPropertyPlantAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:label="ifrs-full_ChangesInPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" order="1.0600" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureIntangibleAssetsSummaryOfMovementsOfIntellectualPropertyRight">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTaxationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentHeldtomaturityInvestments" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_HeldtomaturityInvestments" xlink:label="ifrs-full_HeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentHeldtomaturityInvestments" xlink:label="ifrs-full_NoncurrentHeldtomaturityInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_HeldtomaturityInvestments" xlink:to="ifrs-full_CurrentHeldtomaturityInvestments" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_HeldtomaturityInvestments" xlink:to="ifrs-full_NoncurrentHeldtomaturityInvestments" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentInterestReceivable" xlink:label="ifrs-full_CurrentInterestReceivable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CurrentPrepaidGeneralExpenses" xlink:label="mrus_CurrentPrepaidGeneralExpenses"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CurrentPrepaidPensionCosts" xlink:label="mrus_CurrentPrepaidPensionCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CurrentUnbilledReceivables" xlink:label="mrus_CurrentUnbilledReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_CurrentTradeReceivables" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="mrus_CurrentUnbilledReceivables" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="mrus_CurrentPrepaidGeneralExpenses" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="mrus_CurrentPrepaidPensionCosts" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_CurrentInterestReceivable" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables" order="1.0700" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureOtherLiabilitiesAndAccrualsSummaryOfShorttermAndPayableWithin1Year">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AccruedAuditorsFee" xlink:label="mrus_AccruedAuditorsFee"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AccruedIntellectualPropertyLegalFee" xlink:label="mrus_AccruedIntellectualPropertyLegalFee"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AccruedPersonnel" xlink:label="mrus_AccruedPersonnel"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AccruedResearchAndDevelopmentStudies" xlink:label="mrus_AccruedResearchAndDevelopmentStudies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAdvances" xlink:label="ifrs-full_CurrentAdvances"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherAccruals" xlink:label="mrus_OtherAccruals"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="mrus_AccruedAuditorsFee" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="mrus_AccruedPersonnel" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="mrus_AccruedResearchAndDevelopmentStudies" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="mrus_AccruedIntellectualPropertyLegalFee" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAdvances" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="mrus_OtherAccruals" order="1.0700" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenue">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncome" xlink:label="ifrs-full_DeferredIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_DeferredIncome" xlink:to="ifrs-full_DeferredIncomeClassifiedAsCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_DeferredIncome" xlink:to="ifrs-full_DeferredIncomeClassifiedAsNoncurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationEquity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfCommonSharesOutstanding">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationShareBasedPaymentArrangements">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueSummaryOfRevenue">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IPAndLicenseCosts" xlink:label="mrus_IPAndLicenseCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LitigationCosts" xlink:label="mrus_LitigationCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ManufacturingCost" xlink:label="mrus_ManufacturingCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherExpenseByNature" xlink:label="ifrs-full_OtherExpenseByNature"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherOperatingExpenses" xlink:label="mrus_OtherOperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherResearchAndDevelopmentExpenses" xlink:label="mrus_OtherResearchAndDevelopmentExpenses"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PersonnelRelatedResearchAndDevelopmentExpense" xlink:label="mrus_PersonnelRelatedResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="mrus_LitigationCosts" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="mrus_OtherOperatingExpenses" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="mrus_ManufacturingCost" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="mrus_IPAndLicenseCosts" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="mrus_PersonnelRelatedResearchAndDevelopmentExpense" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="mrus_OtherResearchAndDevelopmentExpenses" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClinicalCosts" xlink:label="mrus_ClinicalCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DiscoveryAndPreclinicalCosts" xlink:label="mrus_DiscoveryAndPreclinicalCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherResearchAndDevelopmentExpenseOther" xlink:label="mrus_OtherResearchAndDevelopmentExpenseOther"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherResearchAndDevelopmentExpenses" xlink:label="mrus_OtherResearchAndDevelopmentExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrus_OtherResearchAndDevelopmentExpenses" xlink:to="mrus_DiscoveryAndPreclinicalCosts" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrus_OtherResearchAndDevelopmentExpenses" xlink:to="mrus_ClinicalCosts" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrus_OtherResearchAndDevelopmentExpenses" xlink:to="mrus_OtherResearchAndDevelopmentExpenseOther" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesOperatingExpensesByNature">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ContractManufacturingExpenses" xlink:label="mrus_ContractManufacturingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherExternalAndOutsourcedCosts" xlink:label="mrus_OtherExternalAndOutsourcedCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense" xlink:to="mrus_ContractManufacturingExpenses" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense" xlink:to="mrus_OtherExternalAndOutsourcedCosts" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_HealthInsurance" xlink:label="mrus_HealthInsurance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherShorttermEmployeeBenefits" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PensionCosts" xlink:label="mrus_PensionCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SocialSecurityContributions" xlink:label="ifrs-full_SocialSecurityContributions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_WBSOSubsidy" xlink:label="mrus_WBSOSubsidy"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_WagesAndSalaries" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="mrus_WBSOSubsidy" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_SocialSecurityContributions" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="mrus_HealthInsurance" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="mrus_PensionCosts" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_OtherShorttermEmployeeBenefits" order="1.0700" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureOtherIncomeExpenseSummaryOfOtherIncomeExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InterestAndOtherExpense" xlink:label="mrus_InterestAndOtherExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InterestAndRelatedIncome" xlink:label="mrus_InterestAndRelatedIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="ifrs-full_NetForeignExchangeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradingIncomeExpenseOnDerivativeFinancialInstruments" xlink:label="ifrs-full_TradingIncomeExpenseOnDerivativeFinancialInstruments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="mrus_InterestAndOtherExpense" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_NetForeignExchangeLoss" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_TradingIncomeExpenseOnDerivativeFinancialInstruments" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome" xlink:to="mrus_InterestAndRelatedIncome" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_NetForeignExchangeGain" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureOtherIncomeExpenseAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShare">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureLossPerShareAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfMaximumCreditExposure">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_HeldtomaturityInvestments" xlink:label="ifrs-full_HeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="ifrs-full_MaximumExposureToCreditRisk"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TradeAndUnbilledReceivables" xlink:label="mrus_TradeAndUnbilledReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_MaximumExposureToCreditRisk" xlink:to="mrus_TradeAndUnbilledReceivables" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_MaximumExposureToCreditRisk" xlink:to="ifrs-full_HeldtomaturityInvestments" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_MaximumExposureToCreditRisk" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfAgingOfTradeAndUnbilledReceivables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfMaturityAnalysisForNonderivativeFinancialLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows" xlink:label="mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfSensitivityAnalysisForChangeInPrimaryCurrencyExposure">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfInterestBearingFinancialInstruments">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatement">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatementParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfRelatedParty">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="1.0500" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfConsolidatedStatementOfProfitAndLossForTheRemunerationOfTheFormerMembersOfTheSupervisoryBoard">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRelatedPartyDisclosuresAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderLease">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIncomeTaxExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRelatedPartyExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>mrus-20181231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN Xcelerate Taxonomy Definition Linkbase - https://www.dfinsolutions.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 6 -->
<!-- Creation date: 2019-04-03T15:11:08Z -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DocumentandEntityInformation" roleURI="http://www.merus.nl/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#ias_1_2018-03-16_role-210000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#ias_1_2018-03-16_role-320000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#ias_1_2018-03-16_role-610000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfChangesInEquity-610000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#ias_7_2018-03-16_role-520000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureGeneralInformationAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureGeneralInformationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBasisOfPresentationAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfFinancialPositions" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfFinancialPositions"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfCashFlows" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosurePropertyPlantAndEquipmentScheduleOfChangesInPropertyPlantAndEquipment" roleURI="http://www.merus.nl/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfChangesInPropertyPlantAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureIntangibleAssetsSummaryOfMovementsOfIntellectualPropertyRight" roleURI="http://www.merus.nl/taxonomy/role/DisclosureIntangibleAssetsSummaryOfMovementsOfIntellectualPropertyRight"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureIntangibleAssetsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTaxationAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTaxationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureInvestmentsSummaryOfInvestments" roleURI="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureInvestmentsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureOtherLiabilitiesAndAccrualsSummaryOfShorttermAndPayableWithin1Year" roleURI="http://www.merus.nl/taxonomy/role/DisclosureOtherLiabilitiesAndAccrualsSummaryOfShorttermAndPayableWithin1Year"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureDeferredRevenueSummaryOfDeferredRevenue" roleURI="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureDeferredRevenueAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquityAdditionalInformationEquity" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationEquity"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquitySummaryOfReconciliationOfCommonSharesOutstanding" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfCommonSharesOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquityAdditionalInformationShareBasedPaymentArrangements" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationShareBasedPaymentArrangements"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRevenueSummaryOfRevenue" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueSummaryOfRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRevenueAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTotalOperatingExpensesAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTotalOperatingExpensesOperatingExpensesByNature" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesOperatingExpensesByNature"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureEmployeeBenefitsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureOtherIncomeExpenseSummaryOfOtherIncomeExpense" roleURI="http://www.merus.nl/taxonomy/role/DisclosureOtherIncomeExpenseSummaryOfOtherIncomeExpense"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureOtherIncomeExpenseAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureOtherIncomeExpenseAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShare" roleURI="http://www.merus.nl/taxonomy/role/DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureLossPerShareAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureLossPerShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentSummaryOfMaximumCreditExposure" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfMaximumCreditExposure"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentSummaryOfAgingOfTradeAndUnbilledReceivables" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfAgingOfTradeAndUnbilledReceivables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentsSummaryOfMaturityAnalysisForNonderivativeFinancialLiabilities" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfMaturityAnalysisForNonderivativeFinancialLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentsSummaryOfSensitivityAnalysisForChangeInPrimaryCurrencyExposure" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfSensitivityAnalysisForChangeInPrimaryCurrencyExposure"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentSummaryOfInterestBearingFinancialInstruments" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfInterestBearingFinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatement" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatement"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatementParenthetical" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatementParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfRelatedParty" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfConsolidatedStatementOfProfitAndLossForTheRemunerationOfTheFormerMembersOfTheSupervisoryBoard" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfConsolidatedStatementOfProfitAndLossForTheRemunerationOfTheFormerMembersOfTheSupervisoryBoard"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRelatedPartyDisclosuresAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRelatedPartyDisclosuresAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderLease" roleURI="http://www.merus.nl/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderLease"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfIncomeTaxExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIncomeTaxExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfRevenueExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfRelatedPartyExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRelatedPartyExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfChangesInEquity-610000">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassAPreferenceShareCapitalMember" xlink:label="mrus_ClassAPreferenceShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassAPreferenceSharePremiumMember" xlink:label="mrus_ClassAPreferenceSharePremiumMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassBPreferenceShareCapitalMember" xlink:label="mrus_ClassBPreferenceShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassBPreferenceSharePremiumMember" xlink:label="mrus_ClassBPreferenceSharePremiumMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassCPreferenceShareCapitalMember" xlink:label="mrus_ClassCPreferenceShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassCPreferenceSharePremiumMember" xlink:label="mrus_ClassCPreferenceSharePremiumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CommonShareCapitalMember" xlink:label="mrus_CommonShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CommonSharePremiumMember" xlink:label="mrus_CommonSharePremiumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" xlink:label="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InitialPublicOfferingCosts" xlink:label="mrus_InitialPublicOfferingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TransactionsWithOwnersAbstract" xlink:label="mrus_TransactionsWithOwnersAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_CommonShareCapitalMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_ClassAPreferenceShareCapitalMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_ClassBPreferenceShareCapitalMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_ClassCPreferenceShareCapitalMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_CommonSharePremiumMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_ClassAPreferenceSharePremiumMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_ClassBPreferenceSharePremiumMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_ClassCPreferenceSharePremiumMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_SharePremiumMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="mrus_TransactionsWithOwnersAbstract" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="ifrs-full_IssueOfEquity" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="mrus_InitialPublicOfferingCosts" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" order="1.2300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureGeneralInformationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CowenAndCoLlcMember" xlink:label="mrus_CowenAndCoLlcMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfGeneralInformationLineItems" xlink:label="mrus_DisclosureOfGeneralInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfGeneralInformationTable" xlink:label="mrus_DisclosureOfGeneralInformationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_HeldtomaturityInvestments" xlink:label="ifrs-full_HeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteCorporationMember" xlink:label="mrus_IncyteCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InitialPublicOfferingMember" xlink:label="mrus_InitialPublicOfferingMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InvestorsMember" xlink:label="mrus_InvestorsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfSharesIssuable" xlink:label="mrus_NumberOfSharesIssuable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OverAllotmentOption1Member" xlink:label="mrus_OverAllotmentOption1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfAggregateCompensationPayable" xlink:label="mrus_PercentageOfAggregateCompensationPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ReverseStockSplitConversionRatio" xlink:label="mrus_ReverseStockSplitConversionRatio"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SecuritiesPledgedAsCollateralForRegistration" xlink:label="mrus_SecuritiesPledgedAsCollateralForRegistration"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SubsidiarySaleOfStock1Axis" xlink:label="mrus_SubsidiarySaleOfStock1Axis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SubsidiarySaleOfStockDomain" xlink:label="mrus_SubsidiarySaleOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SubsidiarySaleOfStockDomain" xlink:label="mrus_SubsidiarySaleOfStockDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="mrus_DisclosureOfGeneralInformationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="ifrs-full_HeldtomaturityInvestments" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="mrus_ReverseStockSplitConversionRatio" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="mrus_SecuritiesPledgedAsCollateralForRegistration" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="mrus_NumberOfSharesIssuable" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="mrus_PercentageOfAggregateCompensationPayable" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="mrus_SharePurchasedPricePerShare" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfGeneralInformationTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfGeneralInformationTable" xlink:to="mrus_SubsidiarySaleOfStock1Axis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_InvestorsMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncyteCorporationMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_CowenAndCoLlcMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="mrus_SubsidiarySaleOfStock1Axis" xlink:to="mrus_SubsidiarySaleOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="mrus_SubsidiarySaleOfStock1Axis" xlink:to="mrus_SubsidiarySaleOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_SubsidiarySaleOfStockDomain" xlink:to="mrus_InitialPublicOfferingMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_SubsidiarySaleOfStockDomain" xlink:to="mrus_OverAllotmentOption1Member" order="1.1500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfSignificantAccountingPoliciesTable" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfReportableSegments1" xlink:label="mrus_NumberOfReportableSegments1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:to="mrus_DisclosureOfSignificantAccountingPoliciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:to="mrus_NumberOfReportableSegments1" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ActuarialAssumptionOfRetirementAge" xlink:label="ifrs-full_ActuarialAssumptionOfRetirementAge"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CashAndCashEquivalentsMaximumMaturityPeriod" xlink:label="mrus_CashAndCashEquivalentsMaximumMaturityPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfSignificantAccountingPoliciesTable" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="ifrs-full_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PlantAndEquipmentMember" xlink:label="mrus_PlantAndEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:label="ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:to="mrus_DisclosureOfSignificantAccountingPoliciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:to="mrus_CashAndCashEquivalentsMaximumMaturityPeriod" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_ActuarialAssumptionOfRetirementAge" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="mrus_PlantAndEquipmentMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="1.0700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdoptionOfIFRS16Member" xlink:label="mrus_AdoptionOfIFRS16Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_EstimatedContractualTerm" xlink:label="mrus_EstimatedContractualTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncreaseDecreaseInDeferredRevenue1" xlink:label="mrus_IncreaseDecreaseInDeferredRevenue1"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteCollaborationAgreementMember" xlink:label="mrus_IncyteCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteProprietaryTechnologyMember" xlink:label="mrus_IncyteProprietaryTechnologyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OnoResearchAndLicenseAgreementMember" xlink:label="mrus_OnoResearchAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="mrus_EstimatedContractualTerm" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="mrus_IncreaseDecreaseInDeferredRevenue1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_LeaseLiabilities" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_RightofuseAssets" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_TypesOfContractsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="mrus_AdoptionOfIFRS16Member" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteCollaborationAgreementMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_OnoResearchAndLicenseAgreementMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteProprietaryTechnologyMember" order="1.0900" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_Revenue" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfFinancialPositions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedBalanceSheetStatementTable" xlink:label="srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="ifrs-full_RetainedEarnings" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="ifrs-full_DeferredIncomeClassifiedAsNoncurrent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="ifrs-full_DeferredIncomeClassifiedAsCurrent" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ChangeInWorkingCapitalAbstract" xlink:label="mrus_ChangeInWorkingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedCashFlowStatementTable" xlink:label="srt_CondensedCashFlowStatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="srt_CondensedCashFlowStatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="ifrs-full_ProfitLoss" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="mrus_ChangeInWorkingCapitalAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfChangesInPropertyPlantAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:label="ifrs-full_ChangesInPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PlantAndEquipmentMember" xlink:label="mrus_PlantAndEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_ChangesInPropertyPlantAndEquipment" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="mrus_PlantAndEquipmentMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" order="1.0900" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureIntangibleAssetsSummaryOfMovementsOfIntellectualPropertyRight">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CapitalisedDevelopmentExpenditureMember" xlink:label="ifrs-full_CapitalisedDevelopmentExpenditureMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights" xlink:label="ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PatentsAndIntellectualPropertyMember" xlink:label="mrus_PatentsAndIntellectualPropertyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="mrus_PatentsAndIntellectualPropertyMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="ifrs-full_CapitalisedDevelopmentExpenditureMember" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTaxationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AverageQualifyingProfitsEffectiveTaxRate" xlink:label="mrus_AverageQualifyingProfitsEffectiveTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates" xlink:label="ifrs-full_DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DutchMember" xlink:label="mrus_DutchMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeTaxAuthority1Axis" xlink:label="mrus_IncomeTaxAuthority1Axis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeTaxAuthority1Domain" xlink:label="mrus_IncomeTaxAuthority1Domain"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeTaxAuthority1Domain" xlink:label="mrus_IncomeTaxAuthority1Domain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteMember" xlink:label="mrus_IncyteMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InnovationsBoxRate" xlink:label="mrus_InnovationsBoxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LicenceFeeIncome" xlink:label="ifrs-full_LicenceFeeIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_NL" xlink:label="country_NL"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="ifrs-full_UnusedTaxLossesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeferredTaxAssets" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_LicenceFeeIncome" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="mrus_AverageQualifyingProfitsEffectiveTaxRate" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="mrus_InnovationsBoxRate" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_ApplicableTaxRate" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_MaturityAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="mrus_IncomeTaxAuthority1Axis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncyteMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_NL" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="mrus_IncomeTaxAuthority1Axis" xlink:to="mrus_IncomeTaxAuthority1Domain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="mrus_IncomeTaxAuthority1Axis" xlink:to="mrus_IncomeTaxAuthority1Domain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_IncomeTaxAuthority1Domain" xlink:to="mrus_DutchMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_UnusedTaxLossesMember" order="1.0900" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AgencyBondMember" xlink:label="mrus_AgencyBondMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CommercialPaper1Member" xlink:label="mrus_CommercialPaper1Member"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CorporateFixedIncomeBondsMember" xlink:label="mrus_CorporateFixedIncomeBondsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentHeldtomaturityInvestments" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinancialAssetsTypeMember" xlink:label="ifrs-full_FinancialAssetsTypeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinancialAssetsTypeMember" xlink:label="ifrs-full_FinancialAssetsTypeMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_HeldtomaturityInvestments" xlink:label="ifrs-full_HeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentHeldtomaturityInvestments" xlink:label="ifrs-full_NoncurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfFinancialAssetsAxis" xlink:label="ifrs-full_TypesOfFinancialAssetsAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_USTreasurySecuritiesMember" xlink:label="mrus_USTreasurySecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialAssetsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_CurrentHeldtomaturityInvestments" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NoncurrentHeldtomaturityInvestments" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_HeldtomaturityInvestments" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="ifrs-full_TypesOfFinancialAssetsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="mrus_CommercialPaper1Member" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="mrus_USTreasurySecuritiesMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="mrus_CorporateFixedIncomeBondsMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="mrus_AgencyBondMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsTypeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsTypeMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeStatementLineItemLocationAxis" xlink:label="mrus_IncomeStatementLineItemLocationAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeStatementLineItemLocationMember" xlink:label="mrus_IncomeStatementLineItemLocationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NetFinanceIncomeExpenseMember" xlink:label="mrus_NetFinanceIncomeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialAssetsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NetForeignExchangeGain" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="mrus_IncomeStatementLineItemLocationAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="mrus_IncomeStatementLineItemLocationAxis" xlink:to="mrus_IncomeStatementLineItemLocationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_NetFinanceIncomeExpenseMember" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureOtherLiabilitiesAndAccrualsSummaryOfShorttermAndPayableWithin1Year">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenue">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AmountPaidForFullTimeEquivalentFunding" xlink:label="mrus_AmountPaidForFullTimeEquivalentFunding"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AmountPaidToCompensateForResearchServices" xlink:label="mrus_AmountPaidToCompensateForResearchServices"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_BettaPharmaceuticalsCoLtdMember" xlink:label="mrus_BettaPharmaceuticalsCoLtdMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="ifrs-full_ConsiderationPaidReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncome" xlink:label="ifrs-full_DeferredIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DeferredRevenueMember" xlink:label="mrus_DeferredRevenueMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDeferredIncomeLineItems" xlink:label="mrus_DisclosureOfDeferredIncomeLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDeferredIncomeTable" xlink:label="mrus_DisclosureOfDeferredIncomeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteCollaborationAgreementMember" xlink:label="mrus_IncyteCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteCorporationMember" xlink:label="mrus_IncyteCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteShareSubscriptionAgreementMember" xlink:label="mrus_IncyteShareSubscriptionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MilestonePaymentReceived" xlink:label="mrus_MilestonePaymentReceived"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NonRefundableUpfrontPaymentsReceivable" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OnoResearchAndLicenseAgreementMember" xlink:label="mrus_OnoResearchAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PurchasePricePerCommonShare" xlink:label="mrus_PurchasePricePerCommonShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueRecognized" xlink:label="mrus_RevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueRemainingPerformanceObligations" xlink:label="mrus_RevenueRemainingPerformanceObligations"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SimcereCollaborationAndLicenseAgreementMember" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_UpfrontAndMilestonePaymentsMember" xlink:label="mrus_UpfrontAndMilestonePaymentsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_UpfrontPayment" xlink:label="mrus_UpfrontPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_DisclosureOfDeferredIncomeTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="ifrs-full_DeferredIncome" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_NonRefundableUpfrontPaymentsReceivable" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_SharePurchasedPricePerShare" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_UpfrontPayment" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_PurchasePricePerCommonShare" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="ifrs-full_ConsiderationPaidReceived" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_MilestonePaymentReceived" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_RevenueRecognized" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_RevenueRemainingPerformanceObligations" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_AmountPaidForFullTimeEquivalentFunding" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_AmountPaidToCompensateForResearchServices" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="ifrs-full_TypesOfContractsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="srt_ProductOrServiceAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="ifrs-full_RangeAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncyteCorporationMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrus_UpfrontAndMilestonePaymentsMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="mrus_DeferredRevenueMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteCollaborationAgreementMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_SimcereCollaborationAndLicenseAgreementMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_OnoResearchAndLicenseAgreementMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteShareSubscriptionAgreementMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_BettaPharmaceuticalsCoLtdMember" order="1.2200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationEquity">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AggregateValueOfCommonSharesIssued" xlink:label="mrus_AggregateValueOfCommonSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements" xlink:label="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="ifrs-full_EntitysTotalForAssociatesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="ifrs-full_EntitysTotalForAssociatesMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GainsOnLitigationSettlements" xlink:label="ifrs-full_GainsOnLitigationSettlements"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncreaseDecreaseInCapital" xlink:label="mrus_IncreaseDecreaseInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncreaseDecreaseInSharePremium" xlink:label="mrus_IncreaseDecreaseInSharePremium"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteCorporationMember" xlink:label="mrus_IncyteCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InitialPublicOfferingMember" xlink:label="mrus_InitialPublicOfferingMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InvestorsMember" xlink:label="mrus_InvestorsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NetProceedsFromIssuingShares" xlink:label="mrus_NetProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OverAllotmentOption1Member" xlink:label="mrus_OverAllotmentOption1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PrepaidShareIssueRelatedCost" xlink:label="mrus_PrepaidShareIssueRelatedCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RegeneronPharmaceuticalsIncMember" xlink:label="mrus_RegeneronPharmaceuticalsIncMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ReverseStockSplitConversionRatio" xlink:label="mrus_ReverseStockSplitConversionRatio"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SubsidiarySaleOfStock1Axis" xlink:label="mrus_SubsidiarySaleOfStock1Axis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SubsidiarySaleOfStockDomain" xlink:label="mrus_SubsidiarySaleOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ReverseStockSplitConversionRatio" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_NetProceedsFromIssuingShares" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PrepaidShareIssueRelatedCost" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_IncreaseDecreaseInCapital" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_IncreaseDecreaseInSharePremium" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharePurchasedPricePerShare" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_AggregateValueOfCommonSharesIssued" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_GainsOnLitigationSettlements" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="mrus_SubsidiarySaleOfStock1Axis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForAssociatesMember" xlink:to="mrus_RegeneronPharmaceuticalsIncMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncyteCorporationMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_InvestorsMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_EntitysTotalForAssociatesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_EntitysTotalForAssociatesMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="mrus_SubsidiarySaleOfStock1Axis" xlink:to="mrus_SubsidiarySaleOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_SubsidiarySaleOfStockDomain" xlink:to="mrus_InitialPublicOfferingMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_SubsidiarySaleOfStockDomain" xlink:to="mrus_OverAllotmentOption1Member" order="1.2100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfCommonSharesOutstanding">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfSharesIssuedForCash" xlink:label="mrus_NumberOfSharesIssuedForCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="mrus_NumberOfSharesIssuedForCash" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationShareBasedPaymentArrangements">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice" xlink:label="mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfGrantAward" xlink:label="mrus_DescriptionOfGrantAward"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfNonVestingCondition" xlink:label="mrus_DescriptionOfNonVestingCondition"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfOptionLapse" xlink:label="mrus_DescriptionOfOptionLapse"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfOptionsGranted" xlink:label="mrus_DescriptionOfOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NonexecutiveCompensationProgramMember" xlink:label="mrus_NonexecutiveCompensationProgramMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfCommonShareEntitledToReceive" xlink:label="mrus_NumberOfCommonShareEntitledToReceive"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod" xlink:label="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfInitialVestingOptions" xlink:label="mrus_PercentageOfInitialVestingOptions"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfRemainingVestingOptions" xlink:label="mrus_PercentageOfRemainingVestingOptions"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfVestingOptions" xlink:label="mrus_PercentageOfVestingOptions"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PeriodOfAwardsWillBeVestedAndExercised" xlink:label="mrus_PeriodOfAwardsWillBeVestedAndExercised"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions" xlink:label="mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PeriodOfRemainingOptionsVestingPeriod" xlink:label="mrus_PeriodOfRemainingOptionsVestingPeriod"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards" xlink:label="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SharebasedCompensationAwardVestingPeriod" xlink:label="mrus_SharebasedCompensationAwardVestingPeriod"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SharebasedCompensationWeightedAverageRemainingContractualLife" xlink:label="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TwoThousandSixteenOptionPlanMember" xlink:label="mrus_TwoThousandSixteenOptionPlanMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TwoThousandTenOptionPlanMember" xlink:label="mrus_TwoThousandTenOptionPlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageSharePrice" xlink:label="ifrs-full_WeightedAverageSharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_DescriptionOfOptionsGranted" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharebasedCompensationAwardVestingPeriod" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PercentageOfInitialVestingOptions" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PercentageOfRemainingVestingOptions" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PeriodOfRemainingOptionsVestingPeriod" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PercentageOfVestingOptions" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_DescriptionOfOptionLapse" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_DescriptionOfNonVestingCondition" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_NumberOfCommonShareEntitledToReceive" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PeriodOfAwardsWillBeVestedAndExercised" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_DescriptionOfGrantAward" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="mrus_TwoThousandTenOptionPlanMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="mrus_TwoThousandSixteenOptionPlanMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="mrus_NonexecutiveCompensationProgramMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AllOtherEmployeesMember" xlink:label="mrus_AllOtherEmployeesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_EmployeeOptionExercisedPricePerShare" xlink:label="mrus_EmployeeOptionExercisedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_FairValueAssumptionsGrantDateSharePrice" xlink:label="mrus_FairValueAssumptionsGrantDateSharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_FairValueAssumptionsGrantDateSharePrice" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharePurchasedPricePerShare" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_EmployeeOptionExercisedPricePerShare" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_AllOtherEmployeesMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AllOtherEmployeesMember" xlink:label="mrus_AllOtherEmployeesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_AllOtherEmployeesMember" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueSummaryOfRevenue">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeMember" xlink:label="mrus_IncomeMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember" xlink:label="mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueFromContractsWithCustomersMember" xlink:label="mrus_RevenueFromContractsWithCustomersMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueLineItems" xlink:label="mrus_RevenueLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueTable" xlink:label="mrus_RevenueTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_UpfrontPaymentAmortizationMember" xlink:label="mrus_UpfrontPaymentAmortizationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_UpfrontPaymentAmortizationMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_RevenueFromContractsWithCustomersMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncomeMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_RevenueTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="ifrs-full_Revenue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_RevenueTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AmountRemittedToOtherBeneficiaries" xlink:label="mrus_AmountRemittedToOtherBeneficiaries"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_BettaPharmaceuticalsCoLtdMember" xlink:label="mrus_BettaPharmaceuticalsCoLtdMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_GrantIncome" xlink:label="mrus_GrantIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IFRS15RevenueFromContractsWithCustomersMember" xlink:label="mrus_IFRS15RevenueFromContractsWithCustomersMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncreaseDecreaseInDeferredRevenue1" xlink:label="mrus_IncreaseDecreaseInDeferredRevenue1"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteCollaborationAgreementMember" xlink:label="mrus_IncyteCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MilestoneRevenues" xlink:label="mrus_MilestoneRevenues"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MilestoneRevenuesAndCostsReimbursements" xlink:label="mrus_MilestoneRevenuesAndCostsReimbursements"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OnoResearchAndLicenseAgreementMember" xlink:label="mrus_OnoResearchAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ReimbursementOfGrant" xlink:label="mrus_ReimbursementOfGrant"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember" xlink:label="mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueLineItems" xlink:label="mrus_RevenueLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueRecognizedIncludedInDeferredRevenue" xlink:label="mrus_RevenueRecognizedIncludedInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueRecognizedNotIncludedInDeferredRevenue" xlink:label="mrus_RevenueRecognizedNotIncludedInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueTable" xlink:label="mrus_RevenueTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SimcereCollaborationAndLicenseAgreementMember" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SimcerePharmaceuticalCoLtdMember" xlink:label="mrus_SimcerePharmaceuticalCoLtdMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TermsOfPaymentOfTradeReceivables" xlink:label="mrus_TermsOfPaymentOfTradeReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_UpfrontPaymentAmortization" xlink:label="mrus_UpfrontPaymentAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_OnoResearchAndLicenseAgreementMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_SimcerePharmaceuticalCoLtdMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_BettaPharmaceuticalsCoLtdMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncyteCollaborationAgreementMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="mrus_IFRS15RevenueFromContractsWithCustomersMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_RevenueTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_UpfrontPaymentAmortization" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="ifrs-full_Revenue" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_MilestoneRevenuesAndCostsReimbursements" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_MilestoneRevenues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_GrantIncome" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_ReimbursementOfGrant" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_AmountRemittedToOtherBeneficiaries" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_TermsOfPaymentOfTradeReceivables" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_IncreaseDecreaseInDeferredRevenue1" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_RevenueRecognizedIncludedInDeferredRevenue" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_RevenueRecognizedNotIncludedInDeferredRevenue" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_RevenueTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_RevenueTable" xlink:to="ifrs-full_TypesOfContractsAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_RevenueTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteCollaborationAgreementMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_OnoResearchAndLicenseAgreementMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_SimcereCollaborationAndLicenseAgreementMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_BettaPharmaceuticalsCoLtdMember" order="1.1900" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdditionsInContractAssets" xlink:label="mrus_AdditionsInContractAssets"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdditionsInContractLiabilities" xlink:label="mrus_AdditionsInContractLiabilities"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdditionsToTradeReceivables" xlink:label="mrus_AdditionsToTradeReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ContractAssets" xlink:label="ifrs-full_ContractAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DeductionsInContractAssets" xlink:label="mrus_DeductionsInContractAssets"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DeductionsInContractLiabilities" xlink:label="mrus_DeductionsInContractLiabilities"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DeductionsInTradeReceivables" xlink:label="mrus_DeductionsInTradeReceivables"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DeferredRevenueMember" xlink:label="mrus_DeferredRevenueMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeReceivablesMember" xlink:label="ifrs-full_TradeReceivablesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_UnbilledReceivablesMember" xlink:label="mrus_UnbilledReceivablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_TradeReceivablesMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="mrus_UnbilledReceivablesMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_TradeReceivables" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_AdditionsToTradeReceivables" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_DeductionsInTradeReceivables" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_ContractAssets" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_AdditionsInContractAssets" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_DeductionsInContractAssets" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_ContractLiabilities" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_AdditionsInContractLiabilities" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_DeductionsInContractLiabilities" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="mrus_DeferredRevenueMember" order="1.0100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesOperatingExpensesByNature">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfEmployeeBenefitsTable" xlink:label="mrus_DisclosureOfEmployeeBenefitsTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfShareOfEquityInvestmentLineItems" xlink:label="mrus_DisclosureOfShareOfEquityInvestmentLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeStatementLineItemLocationAxis" xlink:label="mrus_IncomeStatementLineItemLocationAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeStatementLineItemLocationMember" xlink:label="mrus_IncomeStatementLineItemLocationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ManagementAndAdministrationCostsMember" xlink:label="mrus_ManagementAndAdministrationCostsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherExpensesMember" xlink:label="mrus_OtherExpensesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ResearchAndDevelopmentCostsMember" xlink:label="mrus_ResearchAndDevelopmentCostsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_StockAwardExpense" xlink:label="mrus_StockAwardExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="mrus_IncomeStatementLineItemLocationAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfShareOfEquityInvestmentLineItems" xlink:to="mrus_DisclosureOfEmployeeBenefitsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfShareOfEquityInvestmentLineItems" xlink:to="mrus_StockAwardExpense" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="mrus_IncomeStatementLineItemLocationAxis" xlink:to="mrus_IncomeStatementLineItemLocationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_ResearchAndDevelopmentCostsMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_ManagementAndAdministrationCostsMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_OtherExpensesMember" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfEmployeeBenefitsLineItems" xlink:label="mrus_DisclosureOfEmployeeBenefitsLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfEmployeeBenefitsTable" xlink:label="mrus_DisclosureOfEmployeeBenefitsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeStatementLineItemLocationAxis" xlink:label="mrus_IncomeStatementLineItemLocationAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeStatementLineItemLocationMember" xlink:label="mrus_IncomeStatementLineItemLocationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeStatementLineItemLocationMember" xlink:label="mrus_IncomeStatementLineItemLocationMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ManagementAndAdministrationCostsMember" xlink:label="mrus_ManagementAndAdministrationCostsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_NL" xlink:label="country_NL"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfEmployees" xlink:label="ifrs-full_NumberOfEmployees"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfEmployeeBenefitsLineItems" xlink:to="mrus_DisclosureOfEmployeeBenefitsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfEmployeeBenefitsLineItems" xlink:to="ifrs-full_NumberOfEmployees" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="mrus_IncomeStatementLineItemLocationAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_NL" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="mrus_IncomeStatementLineItemLocationAxis" xlink:to="mrus_IncomeStatementLineItemLocationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="mrus_IncomeStatementLineItemLocationAxis" xlink:to="mrus_IncomeStatementLineItemLocationMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_ManagementAndAdministrationCostsMember" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureOtherIncomeExpenseSummaryOfOtherIncomeExpense">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureOtherIncomeExpenseAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DerivativeFinancialAssets" xlink:label="ifrs-full_DerivativeFinancialAssets"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:label="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EffectOfOverlayApproachReclassificationAxis" xlink:label="ifrs-full_EffectOfOverlayApproachReclassificationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GainsOnLitigationSettlements" xlink:label="ifrs-full_GainsOnLitigationSettlements"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IAS39Member" xlink:label="mrus_IAS39Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InAccordanceWithIFRS9Member" xlink:label="ifrs-full_InAccordanceWithIFRS9Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InAccordanceWithIFRS9Member" xlink:label="ifrs-full_InAccordanceWithIFRS9Member_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteShareSubscriptionAgreementMember" xlink:label="mrus_IncyteShareSubscriptionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NetInterestIncomeAndExpenseTable" xlink:label="mrus_NetInterestIncomeAndExpenseTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PurchasePricePerCommonShare" xlink:label="mrus_PurchasePricePerCommonShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RegeneronSubscriptionAgreementMember" xlink:label="mrus_RegeneronSubscriptionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ValueOfCommonSharesIssued" xlink:label="mrus_ValueOfCommonSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:to="mrus_NetInterestIncomeAndExpenseTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:to="mrus_PurchasePricePerCommonShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:to="mrus_ValueOfCommonSharesIssued" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:to="ifrs-full_GainsOnLitigationSettlements" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:to="ifrs-full_DerivativeFinancialAssets" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:to="ifrs-full_FinanceCosts" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_EffectOfOverlayApproachReclassificationAxis" xlink:to="ifrs-full_InAccordanceWithIFRS9Member" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_EffectOfOverlayApproachReclassificationAxis" xlink:to="ifrs-full_InAccordanceWithIFRS9Member_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InAccordanceWithIFRS9Member" xlink:to="mrus_IAS39Member" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_NetInterestIncomeAndExpenseTable" xlink:to="ifrs-full_EffectOfOverlayApproachReclassificationAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_NetInterestIncomeAndExpenseTable" xlink:to="ifrs-full_TypesOfContractsAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteShareSubscriptionAgreementMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_RegeneronSubscriptionAgreementMember" order="1.1000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShare">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureLossPerShareAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfMaximumCreditExposure">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfAgingOfTradeAndUnbilledReceivables">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:label="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:label="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember" xlink:label="ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember" xlink:label="ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinancialAssetsNeitherPastDueNorImpairedMember" xlink:label="ifrs-full_FinancialAssetsNeitherPastDueNorImpairedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ImpairmentOfFinancialAssetsAxis" xlink:label="ifrs-full_ImpairmentOfFinancialAssetsAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TradeAndUnbilledReceivables" xlink:label="mrus_TradeAndUnbilledReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:to="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:to="mrus_TradeAndUnbilledReceivables" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:to="ifrs-full_ImpairmentOfFinancialAssetsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember" xlink:to="ifrs-full_FinancialAssetsNeitherPastDueNorImpairedMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ImpairmentOfFinancialAssetsAxis" xlink:to="ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ImpairmentOfFinancialAssetsAxis" xlink:to="ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfMaturityAnalysisForNonderivativeFinancialLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CarryingAmountAndValueMember" xlink:label="mrus_CarryingAmountAndValueMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows" xlink:label="mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="mrus_CarryingAmountAndValueMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_MaturityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfSensitivityAnalysisForChangeInPrimaryCurrencyExposure">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CashAndCashEquivalents1Member" xlink:label="mrus_CashAndCashEquivalents1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_FivePercentageDecreaseInFunctionalRateMember" xlink:label="mrus_FivePercentageDecreaseInFunctionalRateMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_FivePercentageIncreaseInFunctionalRateMember" xlink:label="mrus_FivePercentageIncreaseInFunctionalRateMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax" xlink:label="mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InvestmentMember" xlink:label="mrus_InvestmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherAssetsMember" xlink:label="ifrs-full_OtherAssetsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TaxesAndSocialSecurityLiabilitiesMember" xlink:label="mrus_TaxesAndSocialSecurityLiabilitiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TradeAndOtherReceivableMember" xlink:label="mrus_TradeAndOtherReceivableMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TradePayablesOtherLiabilitiesAndAccrualsMember" xlink:label="mrus_TradePayablesOtherLiabilitiesAndAccrualsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_USD" xlink:label="currency_USD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="srt_CurrencyAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="mrus_CashAndCashEquivalents1Member" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="mrus_InvestmentMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="mrus_TradeAndOtherReceivableMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="ifrs-full_OtherAssetsMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="mrus_TaxesAndSocialSecurityLiabilitiesMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="mrus_TradePayablesOtherLiabilitiesAndAccrualsMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="mrus_FivePercentageIncreaseInFunctionalRateMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="mrus_FivePercentageDecreaseInFunctionalRateMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_InterestRateTypesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_InterestRateTypesMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CurrencyRiskMember" order="1.0700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfInterestBearingFinancialInstruments">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfInterestBearingFinancialInstrumentsTable" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="ifrs-full_FloatingInterestRateMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_HeldtomaturityInvestments" xlink:label="ifrs-full_HeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems" xlink:to="mrus_DisclosureOfInterestBearingFinancialInstrumentsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems" xlink:to="ifrs-full_HeldtomaturityInvestments" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfInterestBearingFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="ifrs-full_FloatingInterestRateMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_InterestRateTypesMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatement">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_BonusMember" xlink:label="mrus_BonusMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DirectorsRemunerationExpense" xlink:label="ifrs-full_DirectorsRemunerationExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_GrossSalaryMember" xlink:label="mrus_GrossSalaryMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OptionCostMember" xlink:label="mrus_OptionCostMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PensionMember" xlink:label="mrus_PensionMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ShelleyMargetsonFormerCOOMember" xlink:label="mrus_ShelleyMargetsonFormerCOOMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TonLogtenbergCEOMember" xlink:label="mrus_TonLogtenbergCEOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="mrus_GrossSalaryMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="mrus_BonusMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="mrus_PensionMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="mrus_OptionCostMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="mrus_DisclosureChargedToTheProfitAndLossStatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="ifrs-full_DirectorsRemunerationExpense" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_TonLogtenbergCEOMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_ShelleyMargetsonFormerCOOMember" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatementParenthetical">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_EmployeeBenefitSchemeAxis" xlink:label="mrus_EmployeeBenefitSchemeAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_EmployeeBenefitSchemeDomain" xlink:label="mrus_EmployeeBenefitSchemeDomain"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_EmployeeBenefitSchemeDomain" xlink:label="mrus_EmployeeBenefitSchemeDomain_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SeveranceCostsMember" xlink:label="mrus_SeveranceCostsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="mrus_DisclosureChargedToTheProfitAndLossStatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="ifrs-full_WagesAndSalaries" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:to="mrus_EmployeeBenefitSchemeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="mrus_EmployeeBenefitSchemeAxis" xlink:to="mrus_EmployeeBenefitSchemeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="mrus_EmployeeBenefitSchemeAxis" xlink:to="mrus_EmployeeBenefitSchemeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_EmployeeBenefitSchemeDomain" xlink:to="mrus_SeveranceCostsMember" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AndresSirulnikChiefMedicalOfficerMember" xlink:label="mrus_AndresSirulnikChiefMedicalOfficerMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers" xlink:label="mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ExercisePricePerShare" xlink:label="mrus_ExercisePricePerShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_JohnCrowleyChiefFinancialOfficerMember" xlink:label="mrus_JohnCrowleyChiefFinancialOfficerMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers" xlink:label="mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers" xlink:label="mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PeterSilvermanSeniorVicePresidentMember" xlink:label="mrus_PeterSilvermanSeniorVicePresidentMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TonLogtenbergCEOMember" xlink:label="mrus_TonLogtenbergCEOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="mrus_DisclosureChargedToTheProfitAndLossStatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="mrus_ExercisePricePerShare" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_TonLogtenbergCEOMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_AndresSirulnikChiefMedicalOfficerMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_JohnCrowleyChiefFinancialOfficerMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_PeterSilvermanSeniorVicePresidentMember" order="1.0900" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfRelatedParty">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfConsolidatedStatementOfProfitAndLossForTheRemunerationOfTheFormerMembersOfTheSupervisoryBoard">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AnandMehraMember" xlink:label="mrus_AnandMehraMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CashCompensationMember" xlink:label="mrus_CashCompensationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_GregoryPerryMember" xlink:label="mrus_GregoryPerryMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_JohnDeKoningMember" xlink:label="mrus_JohnDeKoningMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LenKanavyMember" xlink:label="mrus_LenKanavyMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LionelCarnotMember" xlink:label="mrus_LionelCarnotMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MarkIwickiMember" xlink:label="mrus_MarkIwickiMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OptionCostMember" xlink:label="mrus_OptionCostMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RemunerationForFormerEmployees" xlink:label="mrus_RemunerationForFormerEmployees"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RussellGreigMember" xlink:label="mrus_RussellGreigMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_WolfgangBertholdMember" xlink:label="mrus_WolfgangBertholdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="mrus_CashCompensationMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="mrus_OptionCostMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" xlink:to="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" xlink:to="mrus_RemunerationForFormerEmployees" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_RussellGreigMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_MarkIwickiMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_LenKanavyMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_WolfgangBertholdMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_LionelCarnotMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_JohnDeKoningMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_AnandMehraMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_GregoryPerryMember" order="1.0800" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AnandMehraMember" xlink:label="mrus_AnandMehraMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_GabrieleDallmannMember" xlink:label="mrus_GabrieleDallmannMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_GregoryPerryMember" xlink:label="mrus_GregoryPerryMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_JohnDeKoningMember" xlink:label="mrus_JohnDeKoningMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LenKanavyMember" xlink:label="mrus_LenKanavyMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LionelCarnotMember" xlink:label="mrus_LionelCarnotMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MarkIwickiMember" xlink:label="mrus_MarkIwickiMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard" xlink:label="mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RussellGreigMember" xlink:label="mrus_RussellGreigMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard" xlink:label="mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_WolfgangBertholdMember" xlink:label="mrus_WolfgangBertholdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" xlink:to="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" xlink:to="mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" xlink:to="mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_RussellGreigMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_MarkIwickiMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_LenKanavyMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_WolfgangBertholdMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_LionelCarnotMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_JohnDeKoningMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_AnandMehraMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_GregoryPerryMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_GabrieleDallmannMember" order="1.0900" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRelatedPartyDisclosuresAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AccrualsToEmployeeSeveranceIndemnities" xlink:label="mrus_AccrualsToEmployeeSeveranceIndemnities"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_BiophraseBVMember" xlink:label="mrus_BiophraseBVMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CooperatiefLspFourUitgeslotenAansprakelijkheidMember" xlink:label="mrus_CooperatiefLspFourUitgeslotenAansprakelijkheidMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfOwnershipInterestByShareholders" xlink:label="mrus_PercentageOfOwnershipInterestByShareholders"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod" xlink:label="mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfSeverancePaymentPaid" xlink:label="mrus_PercentageOfSeverancePaymentPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SofinnovaVenturePartnersNineLimitedPartnershipMember" xlink:label="mrus_SofinnovaVenturePartnersNineLimitedPartnershipMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="mrus_PercentageOfSeverancePaymentPaid" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="mrus_AccrualsToEmployeeSeveranceIndemnities" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="mrus_PercentageOfOwnershipInterestByShareholders" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_CooperatiefLspFourUitgeslotenAansprakelijkheidMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_SofinnovaVenturePartnersNineLimitedPartnershipMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_BiophraseBVMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1.0600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfCommitmentsAndContingenciesTable" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LeasesAgreementForCorporateHeadquartersMember" xlink:label="mrus_LeasesAgreementForCorporateHeadquartersMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LeasesExpirationPeriod" xlink:label="mrus_LeasesExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LitigationCosts" xlink:label="mrus_LitigationCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LitigationSettlementsGrantedForAttorneysFees" xlink:label="mrus_LitigationSettlementsGrantedForAttorneysFees"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LitigationSettlementsGrantedForExpertFees" xlink:label="mrus_LitigationSettlementsGrantedForExpertFees"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts" xlink:label="mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MitCambridgeRealEstateLlcMember" xlink:label="mrus_MitCambridgeRealEstateLlcMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember" xlink:label="mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NonAdjustingEventMember" xlink:label="mrus_NonAdjustingEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OperatingLeaseTermOfLeaseAgreement" xlink:label="mrus_OperatingLeaseTermOfLeaseAgreement"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherFundingCommitmentsMember" xlink:label="mrus_OtherFundingCommitmentsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PaymentOfPropertyPlantAndEquipment" xlink:label="mrus_PaymentOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PurchasePricePerCommonShare" xlink:label="mrus_PurchasePricePerCommonShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RegeneronSubscriptionAgreementMember" xlink:label="mrus_RegeneronSubscriptionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ReimbursementOfExpenses" xlink:label="mrus_ReimbursementOfExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RentalExpense" xlink:label="ifrs-full_RentalExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RentAndServiceChargesExpense" xlink:label="mrus_RentAndServiceChargesExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SecurityDeposits" xlink:label="mrus_SecurityDeposits"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement" xlink:label="mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="mrus_MitCambridgeRealEstateLlcMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_DisclosureOfCommitmentsAndContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="ifrs-full_RentalExpense" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_OperatingLeaseTermOfLeaseAgreement" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_LeasesExpirationPeriod" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_RentAndServiceChargesExpense" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_SecurityDeposits" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_PaymentOfPropertyPlantAndEquipment" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_LitigationSettlementsGrantedForAttorneysFees" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_LitigationSettlementsGrantedForExpertFees" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_LitigationCosts" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_PurchasePricePerCommonShare" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_ReimbursementOfExpenses" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesTable" xlink:to="ifrs-full_TypesOfContractsAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesTable" xlink:to="ifrs-full_CounterpartiesAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="mrus_OtherFundingCommitmentsMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="mrus_NonAdjustingEventMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_LeasesAgreementForCorporateHeadquartersMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_RegeneronSubscriptionAgreementMember" order="1.2100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderLease">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease" xlink:label="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems" xlink:to="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems" xlink:to="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable" xlink:to="ifrs-full_MaturityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:label="mrus_DisclosureOfEventsAfterReportingPeriodLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfEventsAfterReportingPeriodTable" xlink:label="mrus_DisclosureOfEventsAfterReportingPeriodTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LeaseTermExpirationDate" xlink:label="mrus_LeaseTermExpirationDate"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NonAdjustingEventMember" xlink:label="mrus_NonAdjustingEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OperatingLeaseTermOfLeaseAgreement" xlink:label="mrus_OperatingLeaseTermOfLeaseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RentalExpense" xlink:label="ifrs-full_RentalExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement" xlink:label="mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="mrus_DisclosureOfEventsAfterReportingPeriodTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="mrus_OperatingLeaseTermOfLeaseAgreement" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="mrus_LeaseTermExpirationDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_RentalExpense" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfEventsAfterReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="mrus_NonAdjustingEventMember" order="1.0500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIncomeTaxExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRelatedPartyExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>mrus-20181231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN Xcelerate Taxonomy Labels Linkbase - https://www.dfinsolutions.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 6 -->
<!-- Creation date: 2019-04-03T15:11:08Z -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AccrualsToEmployeeSeveranceIndemnities" xlink:label="mrus_AccrualsToEmployeeSeveranceIndemnities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AccrualsToEmployeeSeveranceIndemnities_lbl" xml:lang="en-US" id="id_14264487_3465637_3_1">Accruals To Employee Severance Indemnities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AccrualsToEmployeeSeveranceIndemnities_lbl" xml:lang="en-US" id="id_14264487_3465637_1_1">Accruals To Employee Severance Indemnities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AccrualsToEmployeeSeveranceIndemnities_lbl" xml:lang="en-US" id="id_14264487_3465637_2_1">Accrued severance payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AccrualsToEmployeeSeveranceIndemnities" xlink:to="mrus_AccrualsToEmployeeSeveranceIndemnities_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AccruedAuditorsFee" xlink:label="mrus_AccruedAuditorsFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AccruedAuditorsFee_lbl" xml:lang="en-US" id="id_14264487_3463404_3_1">accrued auditors fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AccruedAuditorsFee_lbl" xml:lang="en-US" id="id_14264487_3463404_1_1">accrued auditors fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AccruedAuditorsFee_lbl" xml:lang="en-US" id="id_14264487_3463404_2_1">Audit fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AccruedAuditorsFee" xlink:to="mrus_AccruedAuditorsFee_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AccruedIntellectualPropertyLegalFee" xlink:label="mrus_AccruedIntellectualPropertyLegalFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AccruedIntellectualPropertyLegalFee_lbl" xml:lang="en-US" id="id_14264487_3463218_3_1">Accrued intellectual property legal fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AccruedIntellectualPropertyLegalFee_lbl" xml:lang="en-US" id="id_14264487_3463218_1_1">Accrued intellectual property legal fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AccruedIntellectualPropertyLegalFee_lbl" xml:lang="en-US" id="id_14264487_3463218_2_1">IP legal fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AccruedIntellectualPropertyLegalFee" xlink:to="mrus_AccruedIntellectualPropertyLegalFee_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AccruedPersonnel" xlink:label="mrus_AccruedPersonnel"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AccruedPersonnel_lbl" xml:lang="en-US" id="id_14264487_3463216_3_1">Accrued personnel.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AccruedPersonnel_lbl" xml:lang="en-US" id="id_14264487_3463216_1_1">Accrued personnel</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AccruedPersonnel_lbl" xml:lang="en-US" id="id_14264487_3463216_2_1">Personnel-related</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AccruedPersonnel" xlink:to="mrus_AccruedPersonnel_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AccruedResearchAndDevelopmentStudies" xlink:label="mrus_AccruedResearchAndDevelopmentStudies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AccruedResearchAndDevelopmentStudies_lbl" xml:lang="en-US" id="id_14264487_3463217_3_1">Accrued research and development studies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AccruedResearchAndDevelopmentStudies_lbl" xml:lang="en-US" id="id_14264487_3463217_1_1">Accrued research and development studies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AccruedResearchAndDevelopmentStudies_lbl" xml:lang="en-US" id="id_14264487_3463217_2_1">R&amp;D costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AccruedResearchAndDevelopmentStudies" xlink:to="mrus_AccruedResearchAndDevelopmentStudies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl" xml:lang="en-US" id="id_14264487_3416753_1_1">Accumulated depreciation, amortisation and impairment [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl" xml:lang="en-US" id="id_14264487_3416753_2_1">Accumulated amortization [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl" xml:lang="en-US" id="id_14264487_3416976_1_1">Accumulated depreciation and amortisation [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl" xml:lang="en-US" id="id_14264487_3416976_2_1">Accumulated depreciation and amortisation [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xml:lang="en-US" id="id_14264487_3417200_1_1">Accumulated other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xml:lang="en-US" id="id_14264487_3417200_2_1">Accumulated loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ActuarialAssumptionOfRetirementAge" xlink:label="ifrs-full_ActuarialAssumptionOfRetirementAge"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ActuarialAssumptionOfRetirementAge_lbl" xml:lang="en-US" id="id_14264487_3416763_1_1">Actuarial assumption of retirement age</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ActuarialAssumptionOfRetirementAge_lbl" xml:lang="en-US" id="id_14264487_3416763_2_1">Retirement age</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ActuarialAssumptionOfRetirementAge" xlink:to="ifrs-full_ActuarialAssumptionOfRetirementAge_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdditionsInContractAssets" xlink:label="mrus_AdditionsInContractAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AdditionsInContractAssets_lbl" xml:lang="en-US" id="id_14264487_3448902_3_1">Additions in contract assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AdditionsInContractAssets_lbl" xml:lang="en-US" id="id_14264487_3448902_1_1">Additions in contract assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AdditionsInContractAssets_lbl" xml:lang="en-US" id="id_14264487_3448902_2_1">Contract assets, additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AdditionsInContractAssets" xlink:to="mrus_AdditionsInContractAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdditionsInContractLiabilities" xlink:label="mrus_AdditionsInContractLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AdditionsInContractLiabilities_lbl" xml:lang="en-US" id="id_14264487_3448900_3_1">Additions in contract liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AdditionsInContractLiabilities_lbl" xml:lang="en-US" id="id_14264487_3448900_1_1">Additions in contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AdditionsInContractLiabilities_lbl" xml:lang="en-US" id="id_14264487_3448900_2_1">Contract liabilities, additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AdditionsInContractLiabilities" xlink:to="mrus_AdditionsInContractLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" id="id_14264487_3416773_1_1">Additions other than through business combinations, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" id="id_14264487_3416773_2_1">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3416549_1_1">Additions other than through business combinations, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3416549_2_1">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdditionsToTradeReceivables" xlink:label="mrus_AdditionsToTradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AdditionsToTradeReceivables_lbl" xml:lang="en-US" id="id_14264487_3554546_3_1">Additions to trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AdditionsToTradeReceivables_lbl" xml:lang="en-US" id="id_14264487_3554546_1_1">Additions to trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AdditionsToTradeReceivables_lbl" xml:lang="en-US" id="id_14264487_3554546_2_1">Trade receivables, additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AdditionsToTradeReceivables" xlink:to="mrus_AdditionsToTradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US" id="id_14264487_3417003_1_1">Adjustments for decrease (increase) in other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US" id="id_14264487_3417003_2_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US" id="id_14264487_3416776_1_1">Adjustments for decrease (increase) in trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US" id="id_14264487_3416776_2_1">Trade and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US" id="id_14264487_3417004_1_1">Adjustments for depreciation and amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US" id="id_14264487_3417004_2_1">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US" id="id_14264487_3416779_1_1">Adjustments for finance income (cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US" id="id_14264487_3416779_14_1">Net finance (income) expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_lbl" xml:lang="en-US" id="id_14264487_3416563_1_1">Adjustments for gains (losses) on change in fair value of derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_lbl" xml:lang="en-US" id="id_14264487_3416563_14_1">Change in fair value derivative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_lbl" xml:lang="en-US" id="id_14264487_3416567_1_1">Adjustments for increase (decrease) in deferred income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_lbl" xml:lang="en-US" id="id_14264487_3416567_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals_lbl" xml:lang="en-US" id="id_14264487_3449780_3_1">Adjustments for increase (decrease) in other liabilities and accurals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals_lbl" xml:lang="en-US" id="id_14264487_3449780_1_1">Adjustments for increase (decrease) in other liabilities and accurals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals_lbl" xml:lang="en-US" id="id_14264487_3449780_2_1">Other liabilities and accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals" xlink:to="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities_lbl" xml:lang="en-US" id="id_14264487_3449781_3_1">Adjustments for increase (decrease) in Tax and social security liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities_lbl" xml:lang="en-US" id="id_14264487_3449781_1_1">Adjustments for increase (decrease) in Tax and social security liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities_lbl" xml:lang="en-US" id="id_14264487_3449781_2_1">Tax and social security liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" xlink:to="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US" id="id_14264487_3416571_1_1">Adjustments for increase (decrease) in trade and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US" id="id_14264487_3416571_2_1">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" id="id_14264487_3417013_1_1">Adjustments to reconcile profit (loss) [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" id="id_14264487_3417013_2_1">Adjustments for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" id="id_14264487_3417014_1_1">Adjustments for share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" id="id_14264487_3417014_2_1">Share-based payment expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xml:lang="en-US" id="id_14264487_3416786_1_1">Adjustments for unrealised foreign exchange losses (gains)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xml:lang="en-US" id="id_14264487_3416786_2_1">Unrealized foreign exchange results</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdoptionOfIFRS16Member" xlink:label="mrus_AdoptionOfIFRS16Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AdoptionOfIFRS16Member_lbl" xml:lang="en-US" id="id_14264487_3553416_3_1">Adoption Of IFRS 16.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AdoptionOfIFRS16Member_lbl" xml:lang="en-US" id="id_14264487_3553416_1_1">Adoption Of IFRS 16 [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AdoptionOfIFRS16Member_lbl" xml:lang="en-US" id="id_14264487_3553416_2_1">Adoption Of IFRS 16 [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AdoptionOfIFRS16Member" xlink:to="mrus_AdoptionOfIFRS16Member_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AgencyBondMember" xlink:label="mrus_AgencyBondMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AgencyBondMember_lbl" xml:lang="en-US" id="id_14264487_3530660_3_1">Agency bond.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AgencyBondMember_lbl" xml:lang="en-US" id="id_14264487_3530660_1_1">Agency bond [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AgencyBondMember_lbl" xml:lang="en-US" id="id_14264487_3530660_2_1">Agency bond [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AgencyBondMember" xlink:to="mrus_AgencyBondMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xml:lang="en-US" id="id_14264487_3417242_1_1">Aggregated time bands [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xml:lang="en-US" id="id_14264487_3417242_2_1">Aggregated time bands [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_AggregatedTimeBandsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AggregateValueOfCommonSharesIssued" xlink:label="mrus_AggregateValueOfCommonSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AggregateValueOfCommonSharesIssued_lbl" xml:lang="en-US" id="id_14264487_3558217_3_1">Aggregate value of common shares issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AggregateValueOfCommonSharesIssued_lbl" xml:lang="en-US" id="id_14264487_3558217_1_1">Aggregate value of common shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AggregateValueOfCommonSharesIssued_lbl" xml:lang="en-US" id="id_14264487_3558217_2_1">Aggregate value of common shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AggregateValueOfCommonSharesIssued" xlink:to="mrus_AggregateValueOfCommonSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US" id="id_14264487_3417028_1_1">All Currencies [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US" id="id_14264487_3417028_2_1">All Currencies [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AllOtherEmployeesMember" xlink:label="mrus_AllOtherEmployeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AllOtherEmployeesMember_lbl" xml:lang="en-US" id="id_14264487_3514206_3_1">All other employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AllOtherEmployeesMember_lbl" xml:lang="en-US" id="id_14264487_3514206_1_1">All other employees [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AllOtherEmployeesMember_lbl" xml:lang="en-US" id="id_14264487_3514206_2_1">All other employees [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AllOtherEmployeesMember" xlink:to="mrus_AllOtherEmployeesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AllowanceForImpairment" xlink:label="mrus_AllowanceForImpairment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AllowanceForImpairment_lbl" xml:lang="en-US" id="id_14264487_3444079_3_1">Allowance for Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AllowanceForImpairment_lbl" xml:lang="en-US" id="id_14264487_3444079_1_1">Allowance for Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AllowanceForImpairment_lbl" xml:lang="en-US" id="id_14264487_3444079_2_1">Allowance for impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AllowanceForImpairment" xlink:to="mrus_AllowanceForImpairment_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_14264487_3416806_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_14264487_3416806_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" id="id_14264487_3417258_1_1">Amortisation, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" id="id_14264487_3417258_14_1">Amortization for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AmountPaidForFullTimeEquivalentFunding" xlink:label="mrus_AmountPaidForFullTimeEquivalentFunding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AmountPaidForFullTimeEquivalentFunding_lbl" xml:lang="en-US" id="id_14264487_3448891_3_1">Amount paid for full time equivalent funding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AmountPaidForFullTimeEquivalentFunding_lbl" xml:lang="en-US" id="id_14264487_3448891_1_1">Amount Paid For Full Time Equivalent Funding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AmountPaidForFullTimeEquivalentFunding_lbl" xml:lang="en-US" id="id_14264487_3448891_2_1">Paid for full time equivalent funding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AmountPaidForFullTimeEquivalentFunding" xlink:to="mrus_AmountPaidForFullTimeEquivalentFunding_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AmountPaidToCompensateForResearchServices" xlink:label="mrus_AmountPaidToCompensateForResearchServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AmountPaidToCompensateForResearchServices_lbl" xml:lang="en-US" id="id_14264487_3448892_3_1">Amount paid to compensate for research services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AmountPaidToCompensateForResearchServices_lbl" xml:lang="en-US" id="id_14264487_3448892_1_1">Amount Paid To Compensate For Research Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AmountPaidToCompensateForResearchServices_lbl" xml:lang="en-US" id="id_14264487_3448892_2_1">Compensate for research service</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AmountPaidToCompensateForResearchServices" xlink:to="mrus_AmountPaidToCompensateForResearchServices_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AmountRemittedToOtherBeneficiaries" xlink:label="mrus_AmountRemittedToOtherBeneficiaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AmountRemittedToOtherBeneficiaries_lbl" xml:lang="en-US" id="id_14264487_3464163_3_1">Amount remitted to other beneficiaries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AmountRemittedToOtherBeneficiaries_lbl" xml:lang="en-US" id="id_14264487_3464163_1_1">Amount remitted to other beneficiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AmountRemittedToOtherBeneficiaries_lbl" xml:lang="en-US" id="id_14264487_3464163_2_1">Amount remitted to other beneficiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AmountRemittedToOtherBeneficiaries" xlink:to="mrus_AmountRemittedToOtherBeneficiaries_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AnandMehraMember" xlink:label="mrus_AnandMehraMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AnandMehraMember_lbl" xml:lang="en-US" id="id_14264487_3498639_3_1">Anand Mehra.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AnandMehraMember_lbl" xml:lang="en-US" id="id_14264487_3498639_1_1">Anand Mehra [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AnandMehraMember_lbl" xml:lang="en-US" id="id_14264487_3498639_2_1">Anand Mehra [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AnandMehraMember" xlink:to="mrus_AnandMehraMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AndresSirulnikChiefMedicalOfficerMember" xlink:label="mrus_AndresSirulnikChiefMedicalOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AndresSirulnikChiefMedicalOfficerMember_lbl" xml:lang="en-US" id="id_14264487_3498640_3_1">Andres Sirulnik Chief Medical Officer (CMO).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AndresSirulnikChiefMedicalOfficerMember_lbl" xml:lang="en-US" id="id_14264487_3498640_1_1">Andres Sirulnik Chief Medical Officer [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AndresSirulnikChiefMedicalOfficerMember_lbl" xml:lang="en-US" id="id_14264487_3498640_2_1">Andres Sirulnik Chief Medical Officer [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AndresSirulnikChiefMedicalOfficerMember" xlink:to="mrus_AndresSirulnikChiefMedicalOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US" id="id_14264487_3417268_1_1">Applicable tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US" id="id_14264487_3417268_2_1">Estimated effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" id="id_14264487_3417056_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" id="id_14264487_3417056_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers" xlink:label="mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers_lbl" xml:lang="en-US" id="id_14264487_3522423_3_1">Average exercise price per share held by the chief executive officers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers_lbl" xml:lang="en-US" id="id_14264487_3522423_1_1">Average exercise price per share held by the chief executive officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers_lbl" xml:lang="en-US" id="id_14264487_3522423_2_1">Average exercise price per share held by the chief executive officers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers" xlink:to="mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AverageQualifyingProfitsEffectiveTaxRate" xlink:label="mrus_AverageQualifyingProfitsEffectiveTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AverageQualifyingProfitsEffectiveTaxRate_lbl" xml:lang="en-US" id="id_14264487_3523342_3_1">Average qualifying profits effective tax rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AverageQualifyingProfitsEffectiveTaxRate_lbl" xml:lang="en-US" id="id_14264487_3523342_1_1">Average Qualifying Profits Effective Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AverageQualifyingProfitsEffectiveTaxRate_lbl" xml:lang="en-US" id="id_14264487_3523342_2_1">Percentage of income tax rate effectively owed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AverageQualifyingProfitsEffectiveTaxRate" xlink:to="mrus_AverageQualifyingProfitsEffectiveTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare_lbl" xml:lang="en-US" id="id_14264487_3416664_1_1">Basic and diluted earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare_lbl" xml:lang="en-US" id="id_14264487_3416664_2_1">Basic (and diluted) loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare_lbl" xml:lang="en-US" id="id_14264487_3416664_12_1">Loss per share-basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_BettaPharmaceuticalsCoLtdMember" xlink:label="mrus_BettaPharmaceuticalsCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_BettaPharmaceuticalsCoLtdMember_lbl" xml:lang="en-US" id="id_14264487_3554523_3_1">Betta Pharmaceuticals Co Ltd [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_BettaPharmaceuticalsCoLtdMember_lbl" xml:lang="en-US" id="id_14264487_3554523_1_1">Betta Pharmaceuticals Co Ltd [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_BettaPharmaceuticalsCoLtdMember_lbl" xml:lang="en-US" id="id_14264487_3554523_2_1">Betta Pharmaceuticals Co Ltd [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_BettaPharmaceuticalsCoLtdMember" xlink:to="mrus_BettaPharmaceuticalsCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_BiophraseBVMember" xlink:label="mrus_BiophraseBVMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_BiophraseBVMember_lbl" xml:lang="en-US" id="id_14264487_3493439_3_1">Biophrase BV.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_BiophraseBVMember_lbl" xml:lang="en-US" id="id_14264487_3493439_1_1">Biophrase BV [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_BiophraseBVMember_lbl" xml:lang="en-US" id="id_14264487_3493439_2_1">Biophrase BV [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_BiophraseBVMember" xlink:to="mrus_BiophraseBVMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_BonusMember" xlink:label="mrus_BonusMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_BonusMember_lbl" xml:lang="en-US" id="id_14264487_3498764_3_1">Bonus.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_BonusMember_lbl" xml:lang="en-US" id="id_14264487_3498764_1_1">Bonus [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_BonusMember_lbl" xml:lang="en-US" id="id_14264487_3498764_2_1">Bonus [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_BonusMember" xlink:to="mrus_BonusMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" id="id_14264487_3416700_1_1">Bottom of range [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" id="id_14264487_3416700_2_1">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CapitalisedDevelopmentExpenditureMember" xlink:label="ifrs-full_CapitalisedDevelopmentExpenditureMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalisedDevelopmentExpenditureMember_lbl" xml:lang="en-US" id="id_14264487_3416901_1_1">Capitalised development expenditure [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalisedDevelopmentExpenditureMember_lbl" xml:lang="en-US" id="id_14264487_3416901_2_1">Capitalised development expenditure [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalisedDevelopmentExpenditureMember" xlink:to="ifrs-full_CapitalisedDevelopmentExpenditureMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xml:lang="en-US" id="id_14264487_3416904_1_1">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xml:lang="en-US" id="id_14264487_3416904_2_1">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CarryingAmountAndValueMember" xlink:label="mrus_CarryingAmountAndValueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CarryingAmountAndValueMember_lbl" xml:lang="en-US" id="id_14264487_3509593_3_1">Carrying amount and value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CarryingAmountAndValueMember_lbl" xml:lang="en-US" id="id_14264487_3509593_1_1">Carrying Amount and value [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CarryingAmountAndValueMember_lbl" xml:lang="en-US" id="id_14264487_3509593_2_1">Carrying amount and value [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CarryingAmountAndValueMember" xlink:to="mrus_CarryingAmountAndValueMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CarryingAmountMember_lbl" xml:lang="en-US" id="id_14264487_3417348_1_1">Carrying amount [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CarryingAmountMember_lbl" xml:lang="en-US" id="id_14264487_3417348_2_1">Carrying amount [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_CarryingAmountMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" id="id_14264487_3416724_1_1">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" id="id_14264487_3416724_4_1">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" id="id_14264487_3416724_5_1">Cash and cash equivalents, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" id="id_14264487_3416724_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CashAndCashEquivalents1Member" xlink:label="mrus_CashAndCashEquivalents1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CashAndCashEquivalents1Member_lbl" xml:lang="en-US" id="id_14264487_3499174_3_1">Cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CashAndCashEquivalents1Member_lbl" xml:lang="en-US" id="id_14264487_3499174_1_1">Cash and cash equivalents [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CashAndCashEquivalents1Member_lbl" xml:lang="en-US" id="id_14264487_3499174_2_1">Cash and cash equivalents [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CashAndCashEquivalents1Member" xlink:to="mrus_CashAndCashEquivalents1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CashAndCashEquivalentsMaximumMaturityPeriod" xlink:label="mrus_CashAndCashEquivalentsMaximumMaturityPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CashAndCashEquivalentsMaximumMaturityPeriod_lbl" xml:lang="en-US" id="id_14264487_3472572_3_1">Cash And Cash Equivalents Maximum Maturity Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CashAndCashEquivalentsMaximumMaturityPeriod_lbl" xml:lang="en-US" id="id_14264487_3472572_1_1">Cash And Cash Equivalents Maximum Maturity Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CashAndCashEquivalentsMaximumMaturityPeriod_lbl" xml:lang="en-US" id="id_14264487_3472572_2_1">Cash and cash equivalents, maximum original maturities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CashAndCashEquivalentsMaximumMaturityPeriod" xlink:to="mrus_CashAndCashEquivalentsMaximumMaturityPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CashCompensationMember" xlink:label="mrus_CashCompensationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CashCompensationMember_lbl" xml:lang="en-US" id="id_14264487_3499176_3_1">Cash compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CashCompensationMember_lbl" xml:lang="en-US" id="id_14264487_3499176_1_1">Cash compensation [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CashCompensationMember_lbl" xml:lang="en-US" id="id_14264487_3499176_2_1">Cash compensation [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CashCompensationMember" xlink:to="mrus_CashCompensationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_14264487_3416913_1_1">Cash flows from (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_14264487_3416913_6_1">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3416914_1_1">Cash flows from (used in) financing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3416914_2_1">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_14264487_3416731_1_1">Cash flows from (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_14264487_3416731_6_1">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3416732_1_1">Cash flows from (used in) investing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3416732_2_1">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_14264487_3416918_1_1">Cash flows from (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_14264487_3416918_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3417363_1_1">Cash flows from (used in) operating activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3417363_2_1">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xml:lang="en-US" id="id_14264487_3416734_1_1">Cash flows from (used in) operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xml:lang="en-US" id="id_14264487_3416734_6_1">Cash used in operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_lbl" xml:lang="en-US" id="id_14264487_3417139_1_1">Cash flows from (used in) operations before changes in working capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_lbl" xml:lang="en-US" id="id_14264487_3417139_6_1">Cash flows from (used in) operations before changes in working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US" id="id_14264487_3416740_1_1">Categories of related parties [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US" id="id_14264487_3416740_2_1">Categories of related parties [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ChangeInWorkingCapitalAbstract" xlink:label="mrus_ChangeInWorkingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ChangeInWorkingCapitalAbstract_lbl" xml:lang="en-US" id="id_14264487_3431003_3_1">Change in working capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ChangeInWorkingCapitalAbstract_lbl" xml:lang="en-US" id="id_14264487_3431003_1_1">Change in Working Capital [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ChangeInWorkingCapitalAbstract_lbl" xml:lang="en-US" id="id_14264487_3431003_2_1">Changes in working capital:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="mrus_ChangeInWorkingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ChangesInAccruedCapitalExpenditures" xlink:label="mrus_ChangesInAccruedCapitalExpenditures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ChangesInAccruedCapitalExpenditures_lbl" xml:lang="en-US" id="id_14264487_3464218_3_1">Changes in accrued capital expenditures.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ChangesInAccruedCapitalExpenditures_lbl" xml:lang="en-US" id="id_14264487_3464218_1_1">Changes in accrued capital expenditures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ChangesInAccruedCapitalExpenditures_lbl" xml:lang="en-US" id="id_14264487_3464218_2_1">Changes in accrued capital expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ChangesInAccruedCapitalExpenditures" xlink:to="mrus_ChangesInAccruedCapitalExpenditures_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements" xlink:label="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements_lbl" xml:lang="en-US" id="id_14264487_3449816_3_1">Changes in fair value of financial assets and liabilities and exchange movements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements_lbl" xml:lang="en-US" id="id_14264487_3449816_1_1">Changes in fair value of financial assets and liabilities and exchange movements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements_lbl" xml:lang="en-US" id="id_14264487_3449816_2_1">Change in fair value asset and discount on share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements" xlink:to="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:label="ifrs-full_ChangesInPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ChangesInPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3416946_1_1">Increase (decrease) in property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ChangesInPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3416946_6_1">Change in book value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:to="ifrs-full_ChangesInPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_14264487_3417169_1_1">Changes in property, plant and equipment [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_14264487_3417169_2_1">Changes in book value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ChangesInRestrictedCash" xlink:label="mrus_ChangesInRestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ChangesInRestrictedCash_lbl" xml:lang="en-US" id="id_14264487_3449782_3_1">Changes in restricted cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ChangesInRestrictedCash_lbl" xml:lang="en-US" id="id_14264487_3449782_1_1">Changes in Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ChangesInRestrictedCash_lbl" xml:lang="en-US" id="id_14264487_3449782_2_1">Changes in restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ChangesInRestrictedCash" xlink:to="mrus_ChangesInRestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassAPreferenceShareCapitalMember" xlink:label="mrus_ClassAPreferenceShareCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ClassAPreferenceShareCapitalMember_lbl" xml:lang="en-US" id="id_14264487_3495215_3_1">Class A preference share capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ClassAPreferenceShareCapitalMember_lbl" xml:lang="en-US" id="id_14264487_3495215_1_1">Class A preference share capital [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ClassAPreferenceShareCapitalMember_lbl" xml:lang="en-US" id="id_14264487_3495215_2_1">Class A preference share capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ClassAPreferenceShareCapitalMember" xlink:to="mrus_ClassAPreferenceShareCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassAPreferenceSharePremiumMember" xlink:label="mrus_ClassAPreferenceSharePremiumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ClassAPreferenceSharePremiumMember_lbl" xml:lang="en-US" id="id_14264487_3495218_3_1">Class A preference share premium.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ClassAPreferenceSharePremiumMember_lbl" xml:lang="en-US" id="id_14264487_3495218_1_1">Class A preference share premium [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ClassAPreferenceSharePremiumMember_lbl" xml:lang="en-US" id="id_14264487_3495218_2_1">Class A preference share premium [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ClassAPreferenceSharePremiumMember" xlink:to="mrus_ClassAPreferenceSharePremiumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassBPreferenceShareCapitalMember" xlink:label="mrus_ClassBPreferenceShareCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ClassBPreferenceShareCapitalMember_lbl" xml:lang="en-US" id="id_14264487_3495216_3_1">Class B preference share capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ClassBPreferenceShareCapitalMember_lbl" xml:lang="en-US" id="id_14264487_3495216_1_1">Class B preference share capital [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ClassBPreferenceShareCapitalMember_lbl" xml:lang="en-US" id="id_14264487_3495216_2_1">Class B preference share capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ClassBPreferenceShareCapitalMember" xlink:to="mrus_ClassBPreferenceShareCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassBPreferenceSharePremiumMember" xlink:label="mrus_ClassBPreferenceSharePremiumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ClassBPreferenceSharePremiumMember_lbl" xml:lang="en-US" id="id_14264487_3495219_3_1">Class B preference share premium.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ClassBPreferenceSharePremiumMember_lbl" xml:lang="en-US" id="id_14264487_3495219_1_1">Class B preference share premium [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ClassBPreferenceSharePremiumMember_lbl" xml:lang="en-US" id="id_14264487_3495219_2_1">Class B preference share premium [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ClassBPreferenceSharePremiumMember" xlink:to="mrus_ClassBPreferenceSharePremiumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassCPreferenceShareCapitalMember" xlink:label="mrus_ClassCPreferenceShareCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ClassCPreferenceShareCapitalMember_lbl" xml:lang="en-US" id="id_14264487_3495217_3_1">Class C preference share capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ClassCPreferenceShareCapitalMember_lbl" xml:lang="en-US" id="id_14264487_3495217_1_1">Class C preference share capital [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ClassCPreferenceShareCapitalMember_lbl" xml:lang="en-US" id="id_14264487_3495217_2_1">Class C preference share capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ClassCPreferenceShareCapitalMember" xlink:to="mrus_ClassCPreferenceShareCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassCPreferenceSharePremiumMember" xlink:label="mrus_ClassCPreferenceSharePremiumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ClassCPreferenceSharePremiumMember_lbl" xml:lang="en-US" id="id_14264487_3495220_3_1">Class C preference share premium.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ClassCPreferenceSharePremiumMember_lbl" xml:lang="en-US" id="id_14264487_3495220_1_1">Class C preference share premium [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ClassCPreferenceSharePremiumMember_lbl" xml:lang="en-US" id="id_14264487_3495220_2_1">Class C preference share premium [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ClassCPreferenceSharePremiumMember" xlink:to="mrus_ClassCPreferenceSharePremiumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US" id="id_14264487_3417430_1_1">Classes of assets [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US" id="id_14264487_3417430_2_1">Classes of assets [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xml:lang="en-US" id="id_14264487_3417431_1_1">Assets [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xml:lang="en-US" id="id_14264487_3417431_2_1">Assets [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_ClassesOfAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" xml:lang="en-US" id="id_14264487_3417434_1_1">Classes of financial assets [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" xml:lang="en-US" id="id_14264487_3417434_2_1">Classes of financial assets [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl" xml:lang="en-US" id="id_14264487_3417436_1_1">Classes of intangible assets other than goodwill [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl" xml:lang="en-US" id="id_14264487_3417436_2_1">Classes of intangible assets other than goodwill [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_lbl" xml:lang="en-US" id="id_14264487_3416963_1_1">Classes of liabilities [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_lbl" xml:lang="en-US" id="id_14264487_3416963_2_1">Classes of liabilities [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US" id="id_14264487_3417395_1_1">Classes of property, plant and equipment [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US" id="id_14264487_3417395_2_1">Classes of property, plant and equipment [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US" id="id_14264487_3417439_1_1">Classes of share capital [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US" id="id_14264487_3417439_2_1">Classes of share capital [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US" id="id_14264487_3417180_1_1">Share capital [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US" id="id_14264487_3417180_2_1">Share capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClinicalCosts" xlink:label="mrus_ClinicalCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ClinicalCosts_lbl" xml:lang="en-US" id="id_14264487_3449704_3_1">Clinical costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ClinicalCosts_lbl" xml:lang="en-US" id="id_14264487_3449704_1_1">Clinical costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ClinicalCosts_lbl" xml:lang="en-US" id="id_14264487_3449704_2_1">Clinical costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ClinicalCosts" xlink:to="mrus_ClinicalCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CommercialPaper1Member" xlink:label="mrus_CommercialPaper1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CommercialPaper1Member_lbl" xml:lang="en-US" id="id_14264487_3479596_3_1">Commercial paper 1.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CommercialPaper1Member_lbl" xml:lang="en-US" id="id_14264487_3479596_1_1">Commercial Paper 1 [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CommercialPaper1Member_lbl" xml:lang="en-US" id="id_14264487_3479596_2_1">Commercial paper [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CommercialPaper1Member" xlink:to="mrus_CommercialPaper1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CommonShareCapitalMember" xlink:label="mrus_CommonShareCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CommonShareCapitalMember_lbl" xml:lang="en-US" id="id_14264487_3495214_3_1">Common share capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CommonShareCapitalMember_lbl" xml:lang="en-US" id="id_14264487_3495214_1_1">Common share capital [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CommonShareCapitalMember_lbl" xml:lang="en-US" id="id_14264487_3495214_2_1">Common share capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CommonShareCapitalMember" xlink:to="mrus_CommonShareCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CommonSharePremiumMember" xlink:label="mrus_CommonSharePremiumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CommonSharePremiumMember_lbl" xml:lang="en-US" id="id_14264487_3495221_3_1">Common share premium.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CommonSharePremiumMember_lbl" xml:lang="en-US" id="id_14264487_3495221_1_1">Common share premium [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CommonSharePremiumMember_lbl" xml:lang="en-US" id="id_14264487_3495221_2_1">Common share premium [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CommonSharePremiumMember" xlink:to="mrus_CommonSharePremiumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" id="id_14264487_3417632_1_1">Components of equity [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" id="id_14264487_3417632_2_1">Components of equity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" id="id_14264487_3417449_1_1">Comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" id="id_14264487_3417449_32_1">Total comprehensive loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" id="id_14264487_3417449_2_1">Net loss attributable to equity holders of the Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" id="id_14264487_3417449_6_1">Total comprehensive loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" id="id_14264487_3417449_12_1">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl" xml:lang="en-US" id="id_14264487_3417454_1_1">Condensed Balance Sheet Statements, Captions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl" xml:lang="en-US" id="id_14264487_3417454_2_1">Condensed Balance Sheet Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedBalanceSheetStatementTable" xlink:label="srt_CondensedBalanceSheetStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementTable_lbl" xml:lang="en-US" id="id_14264487_3417851_1_1">Condensed Balance Sheet Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedBalanceSheetStatementTable_lbl" xml:lang="en-US" id="id_14264487_3417851_2_1">Condensed Balance Sheet Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems_lbl" xml:lang="en-US" id="id_14264487_3417455_1_1">Condensed Cash Flow Statements, Captions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems_lbl" xml:lang="en-US" id="id_14264487_3417455_2_1">Condensed Cash Flow Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="srt_CondensedCashFlowStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedCashFlowStatementTable" xlink:label="srt_CondensedCashFlowStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedCashFlowStatementTable_lbl" xml:lang="en-US" id="id_14264487_3417456_1_1">Condensed Cash Flow Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedCashFlowStatementTable_lbl" xml:lang="en-US" id="id_14264487_3417456_2_1">Condensed Cash Flow Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_CondensedCashFlowStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems_lbl" xml:lang="en-US" id="id_14264487_3417640_1_1">Condensed Income Statements, Captions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems_lbl" xml:lang="en-US" id="id_14264487_3417640_2_1">Condensed Income Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedIncomeStatementTable_lbl" xml:lang="en-US" id="id_14264487_3417457_1_1">Condensed Income Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedIncomeStatementTable_lbl" xml:lang="en-US" id="id_14264487_3417457_2_1">Condensed Income Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="ifrs-full_ConsiderationPaidReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ConsiderationPaidReceived_lbl" xml:lang="en-US" id="id_14264487_3417643_1_1">Consideration paid (received)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ConsiderationPaidReceived_lbl" xml:lang="en-US" id="id_14264487_3417643_2_1">Consideration from the issuance and sale of common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConsiderationPaidReceived" xlink:to="ifrs-full_ConsiderationPaidReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ContractAssets" xlink:label="ifrs-full_ContractAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContractAssets_lbl" xml:lang="en-US" id="id_14264487_3418083_1_1">Contract assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_ContractAssets_lbl" xml:lang="en-US" id="id_14264487_3418083_4_1">Contract assets, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_ContractAssets_lbl" xml:lang="en-US" id="id_14264487_3418083_5_1">Contract assets, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContractAssets" xlink:to="ifrs-full_ContractAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContractLiabilities_lbl" xml:lang="en-US" id="id_14264487_3417870_1_1">Contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_ContractLiabilities_lbl" xml:lang="en-US" id="id_14264487_3417870_4_1">Contract liabilities, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_ContractLiabilities_lbl" xml:lang="en-US" id="id_14264487_3417870_5_1">Contract liabilities, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContractLiabilities" xlink:to="ifrs-full_ContractLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ContractManufacturingExpenses" xlink:label="mrus_ContractManufacturingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ContractManufacturingExpenses_lbl" xml:lang="en-US" id="id_14264487_3464169_3_1">Contract manufacturing expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ContractManufacturingExpenses_lbl" xml:lang="en-US" id="id_14264487_3464169_1_1">Contract manufacturing expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ContractManufacturingExpenses_lbl" xml:lang="en-US" id="id_14264487_3464169_2_1">Contract manufacturing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ContractManufacturingExpenses" xlink:to="mrus_ContractManufacturingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CooperatiefLspFourUitgeslotenAansprakelijkheidMember" xlink:label="mrus_CooperatiefLspFourUitgeslotenAansprakelijkheidMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CooperatiefLspFourUitgeslotenAansprakelijkheidMember_lbl" xml:lang="en-US" id="id_14264487_3486460_3_1">Cooperatief LSP Four Uitgesloten Aansprakelijkheid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CooperatiefLspFourUitgeslotenAansprakelijkheidMember_lbl" xml:lang="en-US" id="id_14264487_3486460_1_1">Cooperatief LSP Four Uitgesloten Aansprakelijkheid[member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CooperatiefLspFourUitgeslotenAansprakelijkheidMember_lbl" xml:lang="en-US" id="id_14264487_3486460_2_1">Cooperatief LSP Four Uitgesloten Aansprakelijkheid [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CooperatiefLspFourUitgeslotenAansprakelijkheidMember" xlink:to="mrus_CooperatiefLspFourUitgeslotenAansprakelijkheidMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights" xlink:label="ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights_lbl" xml:lang="en-US" id="id_14264487_3418088_1_1">Copyrights, patents and other industrial property rights, service and operating rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights_lbl" xml:lang="en-US" id="id_14264487_3418088_2_1">Intellectual property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights" xlink:to="ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CorporateFixedIncomeBondsMember" xlink:label="mrus_CorporateFixedIncomeBondsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CorporateFixedIncomeBondsMember_lbl" xml:lang="en-US" id="id_14264487_3514284_3_1">Corporate fixed income bonds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CorporateFixedIncomeBondsMember_lbl" xml:lang="en-US" id="id_14264487_3514284_1_1">Corporate fixed income bonds [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CorporateFixedIncomeBondsMember_lbl" xml:lang="en-US" id="id_14264487_3514284_2_1">Corporate fixed income bonds [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CorporateFixedIncomeBondsMember" xlink:to="mrus_CorporateFixedIncomeBondsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xml:lang="en-US" id="id_14264487_3417666_1_1">Counterparties [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xml:lang="en-US" id="id_14264487_3417666_2_1">Counterparties [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CounterpartiesMember_lbl" xml:lang="en-US" id="id_14264487_3417482_1_1">Counterparties [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CounterpartiesMember_lbl" xml:lang="en-US" id="id_14264487_3417482_2_1">Counterparties [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="ifrs-full_CounterpartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CowenAndCoLlcMember" xlink:label="mrus_CowenAndCoLlcMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CowenAndCoLlcMember_lbl" xml:lang="en-US" id="id_14264487_3513899_3_1">Cowen And Co LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CowenAndCoLlcMember_lbl" xml:lang="en-US" id="id_14264487_3513899_1_1">Cowen And Co LLC [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CowenAndCoLlcMember_lbl" xml:lang="en-US" id="id_14264487_3513899_2_1">Cowen and Company LLC [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CowenAndCoLlcMember" xlink:to="mrus_CowenAndCoLlcMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US" id="id_14264487_3418104_1_1">Currency [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US" id="id_14264487_3418104_2_1">Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrencyRiskMember_lbl" xml:lang="en-US" id="id_14264487_3417893_1_1">Currency risk [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrencyRiskMember_lbl" xml:lang="en-US" id="id_14264487_3417893_2_1">Currency risk [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrencyRiskMember" xlink:to="ifrs-full_CurrencyRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" id="id_14264487_3417497_1_1">Current accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" id="id_14264487_3417497_2_1">Other liabilities and accruals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" id="id_14264487_3417497_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAdvances" xlink:label="ifrs-full_CurrentAdvances"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAdvances_lbl" xml:lang="en-US" id="id_14264487_3417686_1_1">Current advances received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAdvances_lbl" xml:lang="en-US" id="id_14264487_3417686_2_1">Subsidy advance received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAdvances" xlink:to="ifrs-full_CurrentAdvances_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" id="id_14264487_3418106_1_1">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" id="id_14264487_3418106_6_1">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" id="id_14264487_3417498_1_1">Current assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" id="id_14264487_3417498_2_1">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_14264487_3417510_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_14264487_3417510_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentHeldtomaturityInvestments" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments_lbl" xml:lang="en-US" id="id_14264487_3417907_1_1">Current held-to-maturity investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments_lbl" xml:lang="en-US" id="id_14264487_3417907_2_1">Current investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments_lbl" xml:lang="en-US" id="id_14264487_3417907_12_1">Investments, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentHeldtomaturityInvestments" xlink:to="ifrs-full_CurrentHeldtomaturityInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentInterestReceivable" xlink:label="ifrs-full_CurrentInterestReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInterestReceivable_lbl" xml:lang="en-US" id="id_14264487_3417704_1_1">Current interest receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentInterestReceivable_lbl" xml:lang="en-US" id="id_14264487_3417704_2_1">Interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInterestReceivable" xlink:to="ifrs-full_CurrentInterestReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" id="id_14264487_3417514_1_1">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" id="id_14264487_3417514_6_1">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3417909_1_1">Current liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3417909_2_1">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" id="id_14264487_3418120_1_1">Current payables on social security and taxes other than income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" id="id_14264487_3418120_2_1">Taxes and social security liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CurrentPrepaidGeneralExpenses" xlink:label="mrus_CurrentPrepaidGeneralExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CurrentPrepaidGeneralExpenses_lbl" xml:lang="en-US" id="id_14264487_3449796_3_1">Current prepaid general expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CurrentPrepaidGeneralExpenses_lbl" xml:lang="en-US" id="id_14264487_3449796_1_1">Current prepaid general expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CurrentPrepaidGeneralExpenses_lbl" xml:lang="en-US" id="id_14264487_3449796_2_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CurrentPrepaidGeneralExpenses" xlink:to="mrus_CurrentPrepaidGeneralExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CurrentPrepaidPensionCosts" xlink:label="mrus_CurrentPrepaidPensionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CurrentPrepaidPensionCosts_lbl" xml:lang="en-US" id="id_14264487_3449790_3_1">Current prepaid pension costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CurrentPrepaidPensionCosts_lbl" xml:lang="en-US" id="id_14264487_3449790_1_1">Current prepaid pension costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CurrentPrepaidPensionCosts_lbl" xml:lang="en-US" id="id_14264487_3449790_2_1">Prepaid pension costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CurrentPrepaidPensionCosts" xlink:to="mrus_CurrentPrepaidPensionCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US" id="id_14264487_3417919_1_1">Current trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US" id="id_14264487_3417919_2_1">Trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CurrentUnbilledReceivables" xlink:label="mrus_CurrentUnbilledReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CurrentUnbilledReceivables_lbl" xml:lang="en-US" id="id_14264487_3464205_3_1">Current unbilled Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CurrentUnbilledReceivables_lbl" xml:lang="en-US" id="id_14264487_3464205_1_1">Current unbilled Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CurrentUnbilledReceivables_lbl" xml:lang="en-US" id="id_14264487_3464205_2_1">Unbilled receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CurrentUnbilledReceivables" xlink:to="mrus_CurrentUnbilledReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables_lbl" xml:lang="en-US" id="id_14264487_3418132_1_1">Current value added tax receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables_lbl" xml:lang="en-US" id="id_14264487_3418132_2_1">VAT receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentValueAddedTaxReceivables" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_lbl" xml:lang="en-US" id="id_14264487_3417755_1_1">Deductible temporary differences for which no deferred tax asset is recognised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_lbl" xml:lang="en-US" id="id_14264487_3417755_2_1">Deductible temporary difference, deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:to="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DeductionsInContractAssets" xlink:label="mrus_DeductionsInContractAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DeductionsInContractAssets_lbl" xml:lang="en-US" id="id_14264487_3448899_3_1">Deductions in contract assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DeductionsInContractAssets_lbl" xml:lang="en-US" id="id_14264487_3448899_1_1">Deductions in contract assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrus_DeductionsInContractAssets_lbl" xml:lang="en-US" id="id_14264487_3448899_14_1">Contract assets, deductions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DeductionsInContractAssets" xlink:to="mrus_DeductionsInContractAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DeductionsInContractLiabilities" xlink:label="mrus_DeductionsInContractLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DeductionsInContractLiabilities_lbl" xml:lang="en-US" id="id_14264487_3448901_3_1">Deductions in contract liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DeductionsInContractLiabilities_lbl" xml:lang="en-US" id="id_14264487_3448901_1_1">Deductions in contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrus_DeductionsInContractLiabilities_lbl" xml:lang="en-US" id="id_14264487_3448901_14_1">Contract liabilities, deductions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DeductionsInContractLiabilities" xlink:to="mrus_DeductionsInContractLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DeductionsInTradeReceivables" xlink:label="mrus_DeductionsInTradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DeductionsInTradeReceivables_lbl" xml:lang="en-US" id="id_14264487_3554547_3_1">Deductions in trade receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DeductionsInTradeReceivables_lbl" xml:lang="en-US" id="id_14264487_3554547_1_1">Deductions in trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrus_DeductionsInTradeReceivables_lbl" xml:lang="en-US" id="id_14264487_3554547_14_1">Trade receivables, deductions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DeductionsInTradeReceivables" xlink:to="mrus_DeductionsInTradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncome" xlink:label="ifrs-full_DeferredIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredIncome_lbl" xml:lang="en-US" id="id_14264487_3417554_1_1">Deferred income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredIncome_lbl" xml:lang="en-US" id="id_14264487_3417554_2_1">Total deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_DeferredIncome_lbl" xml:lang="en-US" id="id_14264487_3417554_6_1">Total deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredIncome" xlink:to="ifrs-full_DeferredIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent_lbl" xml:lang="en-US" id="id_14264487_3417757_1_1">Deferred income classified as current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent_lbl" xml:lang="en-US" id="id_14264487_3417757_2_1">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent_lbl" xml:lang="en-US" id="id_14264487_3417757_12_1">Deferred revenue-current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:to="ifrs-full_DeferredIncomeClassifiedAsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent_lbl" xml:lang="en-US" id="id_14264487_3417758_1_1">Deferred income classified as non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent_lbl" xml:lang="en-US" id="id_14264487_3417758_2_1">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent_lbl" xml:lang="en-US" id="id_14264487_3417758_12_1">Deferred revenue, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredIncomeClassifiedAsNoncurrent" xlink:to="ifrs-full_DeferredIncomeClassifiedAsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DeferredRevenueMember" xlink:label="mrus_DeferredRevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DeferredRevenueMember_lbl" xml:lang="en-US" id="id_14264487_3508994_3_1">Deferred revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DeferredRevenueMember_lbl" xml:lang="en-US" id="id_14264487_3508994_1_1">Deferred revenue [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DeferredRevenueMember_lbl" xml:lang="en-US" id="id_14264487_3508994_2_1">Deferred revenue [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DeferredRevenueMember" xlink:to="mrus_DeferredRevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xml:lang="en-US" id="id_14264487_3417555_1_1">Deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xml:lang="en-US" id="id_14264487_3417555_2_1">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssets" xlink:to="ifrs-full_DeferredTaxAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates" xlink:label="ifrs-full_DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates_lbl" xml:lang="en-US" id="id_14264487_3418157_1_1">Deferred tax asset when utilisation is dependent on future taxable profits in excess of profits from reversal of taxable temporary differences and entity has suffered loss in jurisdiction to which deferred tax asset relates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates_lbl" xml:lang="en-US" id="id_14264487_3418157_2_1">Tax losses carried forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates" xlink:to="ifrs-full_DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:label="mrus_DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_14264487_3429556_3_1">Denominator Computation Of Basic And Diluted Earnings Per Share [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_14264487_3429556_1_1">Denominator Computation Of Basic And Diluted Earnings Per Share [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_14264487_3429556_2_1">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="mrus_DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US" id="id_14264487_3417764_1_1">Depreciation and amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US" id="id_14264487_3417764_2_1">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3417768_1_1">Depreciation, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3417768_14_1">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DerivativeFinancialAssets" xlink:label="ifrs-full_DerivativeFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DerivativeFinancialAssets_lbl" xml:lang="en-US" id="id_14264487_3417770_1_1">Derivative financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DerivativeFinancialAssets_lbl" xml:lang="en-US" id="id_14264487_3417770_2_1">Total derivative asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DerivativeFinancialAssets" xlink:to="ifrs-full_DerivativeFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" xlink:label="mrus_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_lbl" xml:lang="en-US" id="id_14264487_3521310_3_1">The description of the entity's accounting policy for basis of consolidation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_lbl" xml:lang="en-US" id="id_14264487_3521310_1_1">Description of accounting policy for basis of consolidation [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_lbl" xml:lang="en-US" id="id_14264487_3521310_2_1">Basis of consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" xlink:to="mrus_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xlink:label="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3518096_3_1">The description of the entity's accounting policy for cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3518096_1_1">Description of accounting policy for cash and cash equivalents explanatory [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3518096_2_1">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xlink:to="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418181_1_1">Description of accounting policy for employee benefits [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418181_2_1">Employee Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory" xlink:label="mrus_DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522344_3_1">The description of the entity's accounting policy for finance income and finance expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522344_1_1">Description of accounting policy for finance income and finance expenses explanatory [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522344_2_1">Finance Income and Finance Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory" xlink:to="mrus_DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3417583_1_1">Description of accounting policy for financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3417583_2_1">Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US" id="id_14264487_3417953_1_1">Description of accounting policy for foreign currency translation [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US" id="id_14264487_3417953_2_1">Foreign Currency Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3417959_1_1">Description of accounting policy for impairment of assets [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3417959_2_1">Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US" id="id_14264487_3417790_1_1">Description of accounting policy for income tax [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US" id="id_14264487_3417790_2_1">Income Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl" xml:lang="en-US" id="id_14264487_3417962_1_1">Description of accounting policy for intangible assets and goodwill [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl" xml:lang="en-US" id="id_14264487_3417962_2_1">Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfAccountingPolicyForInvestmentsExplanatory" xlink:label="mrus_DescriptionOfAccountingPolicyForInvestmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfAccountingPolicyForInvestmentsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3521140_3_1">The description of the entity's accounting policy for investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfAccountingPolicyForInvestmentsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3521140_1_1">Description of accounting policy for investments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfAccountingPolicyForInvestmentsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3521140_2_1">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfAccountingPolicyForInvestmentsExplanatory" xlink:to="mrus_DescriptionOfAccountingPolicyForInvestmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418190_1_1">Description of accounting policy for leases [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418190_2_1">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418193_1_1">Description of accounting policy for property, plant and equipment [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418193_2_1">Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3417590_1_1">Description of accounting policy for provisions [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3417590_2_1">Provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xml:lang="en-US" id="id_14264487_3417965_1_1">Description of accounting policy for recognition of revenue [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xml:lang="en-US" id="id_14264487_3417965_2_1">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice" xlink:label="mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice_lbl" xml:lang="en-US" id="id_14264487_3470863_3_1">Description of depository receipts based exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice_lbl" xml:lang="en-US" id="id_14264487_3470863_1_1">Description of depository receipts based exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice_lbl" xml:lang="en-US" id="id_14264487_3470863_2_1">Description of depository based exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice" xlink:to="mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US" id="id_14264487_3418231_1_1">Expected volatility, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US" id="id_14264487_3418231_2_1">Expected volatility (weighted-average)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfGrantAward" xlink:label="mrus_DescriptionOfGrantAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfGrantAward_lbl" xml:lang="en-US" id="id_14264487_3470882_3_1">Description of grant award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfGrantAward_lbl" xml:lang="en-US" id="id_14264487_3470882_1_1">Description of grant award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfGrantAward_lbl" xml:lang="en-US" id="id_14264487_3470882_2_1">Description of grant award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfGrantAward" xlink:to="mrus_DescriptionOfGrantAward_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfNonVestingCondition" xlink:label="mrus_DescriptionOfNonVestingCondition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfNonVestingCondition_lbl" xml:lang="en-US" id="id_14264487_3470864_3_1">Description of non vesting condition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfNonVestingCondition_lbl" xml:lang="en-US" id="id_14264487_3470864_1_1">Description of non vesting condition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfNonVestingCondition_lbl" xml:lang="en-US" id="id_14264487_3470864_2_1">Description of non-vesting condition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfNonVestingCondition" xlink:to="mrus_DescriptionOfNonVestingCondition_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfOptionLapse" xlink:label="mrus_DescriptionOfOptionLapse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfOptionLapse_lbl" xml:lang="en-US" id="id_14264487_3470861_3_1">Description of option lapse.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfOptionLapse_lbl" xml:lang="en-US" id="id_14264487_3470861_1_1">Description of option lapse</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfOptionLapse_lbl" xml:lang="en-US" id="id_14264487_3470861_2_1">Description of option lapse</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfOptionLapse" xlink:to="mrus_DescriptionOfOptionLapse_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xml:lang="en-US" id="id_14264487_3418967_1_1">Option life, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xml:lang="en-US" id="id_14264487_3418967_2_1">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfOptionsGranted" xlink:label="mrus_DescriptionOfOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfOptionsGranted_lbl" xml:lang="en-US" id="id_14264487_3470862_3_1">Description of options granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfOptionsGranted_lbl" xml:lang="en-US" id="id_14264487_3470862_1_1">Description of options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfOptionsGranted_lbl" xml:lang="en-US" id="id_14264487_3470862_2_1">Description of options vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfOptionsGranted" xlink:to="mrus_DescriptionOfOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US" id="id_14264487_3418349_1_1">Risk free interest rate, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US" id="id_14264487_3418349_2_1">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DirectorsRemunerationExpense" xlink:label="ifrs-full_DirectorsRemunerationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DirectorsRemunerationExpense_lbl" xml:lang="en-US" id="id_14264487_3418789_1_1">Directors' remuneration expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DirectorsRemunerationExpense_lbl" xml:lang="en-US" id="id_14264487_3418789_2_1">Directors remuneration expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DirectorsRemunerationExpense" xlink:to="ifrs-full_DirectorsRemunerationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementAbstract" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementAbstract_lbl" xml:lang="en-US" id="id_14264487_3429109_3_1">Disclosure charged to the profit and loss statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementAbstract_lbl" xml:lang="en-US" id="id_14264487_3429109_1_1">Disclosure charged to the profit and loss statement [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementAbstract_lbl" xml:lang="en-US" id="id_14264487_3429109_2_1">Disclosure charged to the profit and loss statement [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementAbstract" xlink:to="mrus_DisclosureChargedToTheProfitAndLossStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementExplanatory" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementExplanatory_lbl" xml:lang="en-US" id="id_14264487_3519080_3_1">The disclosure charged to the profit and loss statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementExplanatory_lbl" xml:lang="en-US" id="id_14264487_3519080_1_1">Disclosure charged to the profit and loss statement [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementExplanatory_lbl" xml:lang="en-US" id="id_14264487_3519080_2_1">Summary of Profit and Loss Statement for the Remuneration of the Statutory Directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementExplanatory" xlink:to="mrus_DisclosureChargedToTheProfitAndLossStatementExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems_lbl" xml:lang="en-US" id="id_14264487_3429113_3_1">Line items represent concepts included in a table. Disclosure charged to the profit and loss statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems_lbl" xml:lang="en-US" id="id_14264487_3429113_1_1">Disclosure charged to the profit and loss statement [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems_lbl" xml:lang="en-US" id="id_14264487_3429113_2_1">Disclosure charged to the profit and loss statement [line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementTable_lbl" xml:lang="en-US" id="id_14264487_3473592_3_1">Schedule disclosing of charged to the profit and loss statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementTable_lbl" xml:lang="en-US" id="id_14264487_3473592_1_1">Disclosure charged to the profit and loss statement [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementTable_lbl" xml:lang="en-US" id="id_14264487_3473592_2_1">Disclosure charged to the profit and loss statement [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:to="mrus_DisclosureChargedToTheProfitAndLossStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:label="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract_lbl" xml:lang="en-US" id="id_14264487_3429262_3_1">Disclosure of accruals and other payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract_lbl" xml:lang="en-US" id="id_14264487_3429262_1_1">Disclosure of accruals and other payables [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract_lbl" xml:lang="en-US" id="id_14264487_3429262_2_1">Disclosure of accruals and other payables [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock" xlink:label="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock_lbl" xml:lang="en-US" id="id_14264487_3522345_3_1">Disclosure of accruals other liabilities explanatory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock_lbl" xml:lang="en-US" id="id_14264487_3522345_1_1">Disclosure of accruals other liabilities explanatory [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock_lbl" xml:lang="en-US" id="id_14264487_3522345_2_1">Summary of Short-term and Payable Within 1 Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock" xlink:to="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418585_1_1">Disclosure of accrued expenses and other liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418585_2_1">Other Liabilities and Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory" xlink:label="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3521685_3_1">Disclosure of adoption of new international financial information regulations amendments and interpretations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3521685_1_1">Disclosure of adoption of new international financial information regulations amendments and interpretations explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3521685_2_1">Condensed Consolidated Statements of Financial Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory" xlink:to="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418806_1_1">Disclosure of basis of preparation of financial statements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418806_2_1">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory" xlink:label="mrus_DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522305_3_1">The disclosure of information about board compensation and key management personnel.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522305_1_1">Disclosure of board compensation and key management personnel [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522305_2_1">Board Compensation and Key Management Personnel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory" xlink:to="mrus_DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl" xml:lang="en-US" id="id_14264487_3418392_1_1">Disclosure of changes in accounting estimates [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl" xml:lang="en-US" id="id_14264487_3418392_2_1">Disclosure of changes in accounting estimates [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_lbl" xml:lang="en-US" id="id_14264487_3418811_1_1">Disclosure of changes in accounting estimates [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_lbl" xml:lang="en-US" id="id_14264487_3418811_2_1">Disclosure of changes in accounting estimates [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418607_1_1">Disclosure of changes in accounting policies, accounting estimates and errors [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418607_2_1">Recently Issued or Adopted International Financial Reporting Standards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3431956_3_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3431956_1_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3431956_2_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract" xlink:to="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_14264487_3431957_3_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_14264487_3431957_1_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_14264487_3431957_2_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable_lbl" xml:lang="en-US" id="id_14264487_3473222_3_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable_lbl" xml:lang="en-US" id="id_14264487_3473222_1_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable_lbl" xml:lang="en-US" id="id_14264487_3473222_2_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:to="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xml:lang="en-US" id="id_14264487_3419037_1_1">Disclosure of classes of share capital [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xml:lang="en-US" id="id_14264487_3419037_2_1">Disclosure of classes of share capital [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418394_1_1">Disclosure of classes of share capital [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418394_2_1">Summary of Reconciliation of Common Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" id="id_14264487_3418395_1_1">Disclosure of classes of share capital [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" id="id_14264487_3418395_2_1">Disclosure of classes of share capital [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xml:lang="en-US" id="id_14264487_3418609_1_1">Disclosure of classes of share capital [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xml:lang="en-US" id="id_14264487_3418609_2_1">Disclosure of classes of share capital [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfCommitmentsAndContingenciesAbstract" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesAbstract_lbl" xml:lang="en-US" id="id_14264487_3429726_3_1">Disclosure of commitments and contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesAbstract_lbl" xml:lang="en-US" id="id_14264487_3429726_1_1">Disclosure of commitments and contingencies [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesAbstract_lbl" xml:lang="en-US" id="id_14264487_3429726_2_1">Disclosure of commitments and contingencies [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesAbstract" xlink:to="mrus_DisclosureOfCommitmentsAndContingenciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfCommitmentsAndContingenciesExplanatory" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3516335_3_1">The entire disclosure for commitment and contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3516335_1_1">Disclosure of commitments and contingencies [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3516335_2_1">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesExplanatory" xlink:to="mrus_DisclosureOfCommitmentsAndContingenciesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_14264487_3431392_3_1">Disclosure of commitments and contingencies [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_14264487_3431392_1_1">Disclosure of commitments and contingencies [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_14264487_3431392_2_1">Disclosure of commitments and contingencies [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_DisclosureOfCommitmentsAndContingenciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfCommitmentsAndContingenciesTable" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesTable_lbl" xml:lang="en-US" id="id_14264487_3474462_3_1">Disclosure Of Commitments And Contingencies [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesTable_lbl" xml:lang="en-US" id="id_14264487_3474462_1_1">Disclosure Of Commitments And Contingencies [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesTable_lbl" xml:lang="en-US" id="id_14264487_3474462_2_1">Disclosure Of Commitments And Contingencies [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesTable" xlink:to="mrus_DisclosureOfCommitmentsAndContingenciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDeferredIncomeAbstract" xlink:label="mrus_DisclosureOfDeferredIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDeferredIncomeAbstract_lbl" xml:lang="en-US" id="id_14264487_3426261_3_1">Disclosure of deferred income [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDeferredIncomeAbstract_lbl" xml:lang="en-US" id="id_14264487_3426261_1_1">Disclosure of deferred income [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDeferredIncomeAbstract_lbl" xml:lang="en-US" id="id_14264487_3426261_2_1">Disclosure of deferred income [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDeferredIncomeAbstract" xlink:to="mrus_DisclosureOfDeferredIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfDeferredIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfDeferredIncomeExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDeferredIncomeExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418404_1_1">Disclosure of deferred income [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDeferredIncomeExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418404_2_1">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDeferredIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfDeferredIncomeExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDeferredIncomeLineItems" xlink:label="mrus_DisclosureOfDeferredIncomeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDeferredIncomeLineItems_lbl" xml:lang="en-US" id="id_14264487_3426262_3_1">Disclosure of deferred income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDeferredIncomeLineItems_lbl" xml:lang="en-US" id="id_14264487_3426262_1_1">Disclosure of deferred income [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDeferredIncomeLineItems_lbl" xml:lang="en-US" id="id_14264487_3426262_2_1">Disclosure of deferred income [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_DisclosureOfDeferredIncomeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDeferredIncomeTable" xlink:label="mrus_DisclosureOfDeferredIncomeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDeferredIncomeTable_lbl" xml:lang="en-US" id="id_14264487_3474543_3_1">Disclosure of deferred income [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDeferredIncomeTable_lbl" xml:lang="en-US" id="id_14264487_3474543_1_1">Disclosure of deferred income [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDeferredIncomeTable_lbl" xml:lang="en-US" id="id_14264487_3474543_2_1">Disclosure of deferred income [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="mrus_DisclosureOfDeferredIncomeTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDeferredRevenueExplanatory" xlink:label="mrus_DisclosureOfDeferredRevenueExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDeferredRevenueExplanatory_lbl" xml:lang="en-US" id="id_14264487_3520728_3_1">The disclosure of deferred revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDeferredRevenueExplanatory_lbl" xml:lang="en-US" id="id_14264487_3520728_1_1">Disclosure of deferred revenue [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDeferredRevenueExplanatory_lbl" xml:lang="en-US" id="id_14264487_3520728_2_1">Summary of Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDeferredRevenueExplanatory" xlink:to="mrus_DisclosureOfDeferredRevenueExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:label="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems_lbl" xml:lang="en-US" id="id_14264487_3429636_3_1">Rental expenses on real estate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems_lbl" xml:lang="en-US" id="id_14264487_3429636_1_1">Disclosure Of Deferred Tax Assets Notional Interest [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems_lbl" xml:lang="en-US" id="id_14264487_3429636_2_1">Disclosure of deferred tax assets notional interest [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:to="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3519231_3_1">The disclosure of detailed information about employee benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3519231_1_1">Disclosure of detailed information about employee benefits [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3519231_2_1">Disclosure of Detailed Information About Employee Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory" xlink:to="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419052_1_1">Disclosure of detailed information about intangible assets [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419052_2_1">Summary of Movements of Intellectual Property Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3516016_3_1">Disclosure of detailed information about other income and expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3516016_1_1">Disclosure of detailed information about other income and expenses [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3516016_2_1">Summary of Other Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory" xlink:to="mrus_DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418416_1_1">Disclosure of detailed information about property, plant and equipment [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418416_2_1">Schedule of Changes in Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3516801_3_1">Share based payment arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3516801_1_1">Disclosure of Detailed Information about Share Based Payment Arrangements Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3516801_2_1">Schedule of Share-based Compensation Expenses Recognized as Employee Benefit Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" xlink:to="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDetailedInformationOfRelatedPartyExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationOfRelatedPartyExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDetailedInformationOfRelatedPartyExplanatory_lbl" xml:lang="en-US" id="id_14264487_3516943_3_1">The disclosure of detailed information related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDetailedInformationOfRelatedPartyExplanatory_lbl" xml:lang="en-US" id="id_14264487_3516943_1_1">Disclosure of detailed information of related party [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDetailedInformationOfRelatedPartyExplanatory_lbl" xml:lang="en-US" id="id_14264487_3516943_2_1">Summary of the Remuneration Received for Key Management Personnel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDetailedInformationOfRelatedPartyExplanatory" xlink:to="mrus_DisclosureOfDetailedInformationOfRelatedPartyExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" id="id_14264487_3521052_3_1">Disclosure of detailed information of research and development expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" id="id_14264487_3521052_1_1">Disclosure of detailed information of research and development expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" id="id_14264487_3521052_2_1">Breakdown of Other Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory" xlink:to="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522346_3_1">Disclosure of detailed information related to operating expenses explanatory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522346_1_1">Disclosure of detailed information related to operating expenses explanatory [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522346_2_1">Summary of Total Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory" xlink:to="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDetailsOfEarningsPerShareExplanatory" xlink:label="mrus_DisclosureOfDetailsOfEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDetailsOfEarningsPerShareExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522347_3_1">Disclosure of details of earnings per share explanatory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDetailsOfEarningsPerShareExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522347_1_1">Disclosure of details of earnings per share explanatory [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDetailsOfEarningsPerShareExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522347_2_1">Summary of Basic and Diluted Loss per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDetailsOfEarningsPerShareExplanatory" xlink:to="mrus_DisclosureOfDetailsOfEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418633_1_1">Disclosure of earnings per share [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418633_2_1">Loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfEmployeeBenefitsAbstract" xlink:label="mrus_DisclosureOfEmployeeBenefitsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfEmployeeBenefitsAbstract_lbl" xml:lang="en-US" id="id_14264487_3430319_3_1">Disclosure of employee benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfEmployeeBenefitsAbstract_lbl" xml:lang="en-US" id="id_14264487_3430319_1_1">Disclosure of employee benefits [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfEmployeeBenefitsAbstract_lbl" xml:lang="en-US" id="id_14264487_3430319_2_1">Disclosure of employee benefits [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfEmployeeBenefitsAbstract" xlink:to="mrus_DisclosureOfEmployeeBenefitsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418423_1_1">Disclosure of employee benefits [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418423_2_1">Employee Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfEmployeeBenefitsLineItems" xlink:label="mrus_DisclosureOfEmployeeBenefitsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfEmployeeBenefitsLineItems_lbl" xml:lang="en-US" id="id_14264487_3429102_3_1">Line items represent concepts included in a table. Disclosure of employee benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfEmployeeBenefitsLineItems_lbl" xml:lang="en-US" id="id_14264487_3429102_1_1">Disclosure of employee benefits [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfEmployeeBenefitsLineItems_lbl" xml:lang="en-US" id="id_14264487_3429102_2_1">Disclosure of employee benefits [line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfEmployeeBenefitsLineItems" xlink:to="mrus_DisclosureOfEmployeeBenefitsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfEmployeeBenefitsTable" xlink:label="mrus_DisclosureOfEmployeeBenefitsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfEmployeeBenefitsTable_lbl" xml:lang="en-US" id="id_14264487_3474064_3_1">Schedule disclosing of employee benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfEmployeeBenefitsTable_lbl" xml:lang="en-US" id="id_14264487_3474064_1_1">Disclosure of employee benefits [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfEmployeeBenefitsTable_lbl" xml:lang="en-US" id="id_14264487_3474064_2_1">Disclosure of employee benefits [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="mrus_DisclosureOfEmployeeBenefitsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418842_1_1">Disclosure of events after reporting period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418842_2_1">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:label="mrus_DisclosureOfEventsAfterReportingPeriodLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfEventsAfterReportingPeriodLineItems_lbl" xml:lang="en-US" id="id_14264487_3427285_3_1">Disclosure of events after reporting period line items.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfEventsAfterReportingPeriodLineItems_lbl" xml:lang="en-US" id="id_14264487_3427285_1_1">Disclosure of Events After Reporting Period [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfEventsAfterReportingPeriodLineItems_lbl" xml:lang="en-US" id="id_14264487_3427285_2_1">Disclosure of Events After Reporting Period [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="mrus_DisclosureOfEventsAfterReportingPeriodLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfEventsAfterReportingPeriodTable" xlink:label="mrus_DisclosureOfEventsAfterReportingPeriodTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfEventsAfterReportingPeriodTable_lbl" xml:lang="en-US" id="id_14264487_3474984_3_1">Disclosure of events after reporting period table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfEventsAfterReportingPeriodTable_lbl" xml:lang="en-US" id="id_14264487_3474984_1_1">Disclosure of Events After Reporting Period [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfEventsAfterReportingPeriodTable_lbl" xml:lang="en-US" id="id_14264487_3474984_2_1">Disclosure of Events After Reporting Period [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfEventsAfterReportingPeriodTable" xlink:to="mrus_DisclosureOfEventsAfterReportingPeriodTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeAbstract" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeAbstract_lbl" xml:lang="en-US" id="id_14264487_3418848_1_1">Disclosure of finance lease and operating lease by lessee [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeAbstract_lbl" xml:lang="en-US" id="id_14264487_3418848_2_1">Disclosure of finance lease and operating lease by lessee [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeAbstract" xlink:to="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419076_1_1">Disclosure of finance lease and operating lease by lessee [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419076_2_1">Schedule of Future Minimum Lease Payments Under Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems_lbl" xml:lang="en-US" id="id_14264487_3418646_1_1">Disclosure of finance lease and operating lease by lessee [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems_lbl" xml:lang="en-US" id="id_14264487_3418646_2_1">Disclosure of finance lease and operating lease by lessee [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems" xlink:to="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable_lbl" xml:lang="en-US" id="id_14264487_3418647_1_1">Disclosure of finance lease and operating lease by lessee [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable_lbl" xml:lang="en-US" id="id_14264487_3418647_2_1">Disclosure of finance lease and operating lease by lessee [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable" xlink:to="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl" xml:lang="en-US" id="id_14264487_3419080_1_1">Disclosure of financial assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl" xml:lang="en-US" id="id_14264487_3419080_2_1">Disclosure of financial assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl" xml:lang="en-US" id="id_14264487_3418649_1_1">Disclosure of financial assets [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl" xml:lang="en-US" id="id_14264487_3418649_2_1">Disclosure of financial assets [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable_lbl" xml:lang="en-US" id="id_14264487_3418851_1_1">Disclosure of financial assets [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable_lbl" xml:lang="en-US" id="id_14264487_3418851_2_1">Disclosure of financial assets [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="ifrs-full_DisclosureOfFinancialAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419087_1_1">Disclosure of financial assets that are either past due or impaired [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419087_2_1">Summary of Aging of Trade and Unbilled Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:label="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_lbl" xml:lang="en-US" id="id_14264487_3418852_1_1">Disclosure of financial assets that are either past due or impaired [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_lbl" xml:lang="en-US" id="id_14264487_3418852_2_1">Disclosure of financial assets that are either past due or impaired [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:to="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:label="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_lbl" xml:lang="en-US" id="id_14264487_3418651_1_1">Disclosure of financial assets that are either past due or impaired [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_lbl" xml:lang="en-US" id="id_14264487_3418651_2_1">Disclosure of financial assets that are either past due or impaired [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:to="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureoffinancialinformationAbstract" xlink:label="mrus_DisclosureoffinancialinformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureoffinancialinformationAbstract_lbl" xml:lang="en-US" id="id_14264487_3431928_3_1">Disclosure of financial information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureoffinancialinformationAbstract_lbl" xml:lang="en-US" id="id_14264487_3431928_1_1">DisclosureOfFinancialInformation [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureoffinancialinformationAbstract_lbl" xml:lang="en-US" id="id_14264487_3431928_2_1">DisclosureOfFinancialInformation [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureoffinancialinformationAbstract" xlink:to="mrus_DisclosureoffinancialinformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xml:lang="en-US" id="id_14264487_3418657_1_1">Disclosure of detailed information about financial instruments [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xml:lang="en-US" id="id_14264487_3418657_2_1">Disclosure of detailed information about financial instruments [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418859_1_1">Disclosure of financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418859_2_1">Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418445_1_1">Disclosure of general information about financial statements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418445_2_1">General Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfGeneralInformationAbstract" xlink:label="mrus_DisclosureOfGeneralInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfGeneralInformationAbstract_lbl" xml:lang="en-US" id="id_14264487_3426958_3_1">Disclosure of general information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfGeneralInformationAbstract_lbl" xml:lang="en-US" id="id_14264487_3426958_1_1">Disclosure of general information [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfGeneralInformationAbstract_lbl" xml:lang="en-US" id="id_14264487_3426958_2_1">Disclosure of general information [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfGeneralInformationAbstract" xlink:to="mrus_DisclosureOfGeneralInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfGeneralInformationLineItems" xlink:label="mrus_DisclosureOfGeneralInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfGeneralInformationLineItems_lbl" xml:lang="en-US" id="id_14264487_3426959_3_1">Line item represents disclosure of general information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfGeneralInformationLineItems_lbl" xml:lang="en-US" id="id_14264487_3426959_1_1">Disclosure of general information [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfGeneralInformationLineItems_lbl" xml:lang="en-US" id="id_14264487_3426959_2_1">Disclosure of general information [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="mrus_DisclosureOfGeneralInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfGeneralInformationTable" xlink:label="mrus_DisclosureOfGeneralInformationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfGeneralInformationTable_lbl" xml:lang="en-US" id="id_14264487_3475207_3_1">Disclosure of General Information [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfGeneralInformationTable_lbl" xml:lang="en-US" id="id_14264487_3475207_1_1">Disclosure of General Information [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfGeneralInformationTable_lbl" xml:lang="en-US" id="id_14264487_3475207_2_1">Disclosure of General Information [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfGeneralInformationTable" xlink:to="mrus_DisclosureOfGeneralInformationTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfHeldToMaturityInvestmentExplanatory" xlink:label="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory_lbl" xml:lang="en-US" id="id_14264487_3515435_3_1">Disclosure of held to maturity investment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory_lbl" xml:lang="en-US" id="id_14264487_3515435_1_1">Disclosure of Held to Maturity Investment [Text Bock]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory_lbl" xml:lang="en-US" id="id_14264487_3515435_2_1">Summary of Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory" xlink:to="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418677_1_1">Disclosure of income tax [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418677_2_1">Taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418679_1_1">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418679_2_1">Summary of Inputs Used in the Measurement of the Fair Values and the Related Fair Values at the Grant Dates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfInformationAboutRevenueExplanatory" xlink:label="mrus_DisclosureOfInformationAboutRevenueExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfInformationAboutRevenueExplanatory_lbl" xml:lang="en-US" id="id_14264487_3519386_3_1">The disclosure of information about revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfInformationAboutRevenueExplanatory_lbl" xml:lang="en-US" id="id_14264487_3519386_1_1">Disclosure of detailed information about revenue [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfInformationAboutRevenueExplanatory_lbl" xml:lang="en-US" id="id_14264487_3519386_2_1">Summary of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfInformationAboutRevenueExplanatory" xlink:to="mrus_DisclosureOfInformationAboutRevenueExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract_lbl" xml:lang="en-US" id="id_14264487_3418467_1_1">Disclosure of detailed information about intangible assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract_lbl" xml:lang="en-US" id="id_14264487_3418467_2_1">Disclosure of detailed information about intangible assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419130_1_1">Disclosure of intangible assets [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419130_2_1">Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="id_14264487_3418886_1_1">Disclosure of detailed information about intangible assets [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="id_14264487_3418886_2_1">Disclosure of detailed information about intangible assets [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xml:lang="en-US" id="id_14264487_3418716_1_1">Disclosure of detailed information about intangible assets [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xml:lang="en-US" id="id_14264487_3418716_2_1">Disclosure of detailed information about intangible assets [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfInterestBearingFinancialInstrumentsAbstract" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsAbstract_lbl" xml:lang="en-US" id="id_14264487_3430375_3_1">Disclosure of interest bearing financial instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsAbstract_lbl" xml:lang="en-US" id="id_14264487_3430375_1_1">Disclosure of interest bearing financial instruments [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsAbstract_lbl" xml:lang="en-US" id="id_14264487_3430375_2_1">Disclosure of interest bearing financial instruments [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfInterestBearingFinancialInstrumentsAbstract" xlink:to="mrus_DisclosureOfInterestBearingFinancialInstrumentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfInterestBearingFinancialInstrumentsExplanatory" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3519957_3_1">The disclosure of interest bearing financial instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3519957_1_1">Disclosure of interest bearing financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3519957_2_1">Summary of Interest Rate Profile of the Company's Interest-bearing Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfInterestBearingFinancialInstrumentsExplanatory" xlink:to="mrus_DisclosureOfInterestBearingFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems_lbl" xml:lang="en-US" id="id_14264487_3430376_3_1">Line items represents information about interest bearing financial instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems_lbl" xml:lang="en-US" id="id_14264487_3430376_1_1">Disclosure of interest bearing financial instruments [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems_lbl" xml:lang="en-US" id="id_14264487_3430376_2_1">Disclosure of interest bearing financial instruments [line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems" xlink:to="mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfInterestBearingFinancialInstrumentsTable" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsTable_lbl" xml:lang="en-US" id="id_14264487_3474084_3_1">Schedule disclosing information related to interest bearing financial instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsTable_lbl" xml:lang="en-US" id="id_14264487_3474084_1_1">Disclosure of interest bearing financial instruments [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsTable_lbl" xml:lang="en-US" id="id_14264487_3474084_2_1">Disclosure of interest bearing financial instruments [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfInterestBearingFinancialInstrumentsTable" xlink:to="mrus_DisclosureOfInterestBearingFinancialInstrumentsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418476_1_1">Disclosure of investments other than investments accounted for using equity method [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418476_2_1">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3419150_1_1">Disclosure of maturity analysis for non-derivative financial liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3419150_2_1">Disclosure of maturity analysis for non-derivative financial liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_14264487_3419151_1_1">Disclosure of maturity analysis for non-derivative financial liabilities [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_14264487_3419151_2_1">Disclosure of maturity analysis for non-derivative financial liabilities [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_lbl" xml:lang="en-US" id="id_14264487_3419407_1_1">Disclosure of maturity analysis for non-derivative financial liabilities [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_lbl" xml:lang="en-US" id="id_14264487_3419407_2_1">Disclosure of maturity analysis for non-derivative financial liabilities [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfMaximumExposureToCreditRiskExplanatory" xlink:label="mrus_DisclosureOfMaximumExposureToCreditRiskExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfMaximumExposureToCreditRiskExplanatory_lbl" xml:lang="en-US" id="id_14264487_3530813_3_1">The disclosure of maximum exposure to credit risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfMaximumExposureToCreditRiskExplanatory_lbl" xml:lang="en-US" id="id_14264487_3530813_1_1">Disclosure Of Maximum Exposure To Credit Risk Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfMaximumExposureToCreditRiskExplanatory_lbl" xml:lang="en-US" id="id_14264487_3530813_2_1">Summary of Carrying Amount of Financial Assets Represents the Maximum Credit Exposure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfMaximumExposureToCreditRiskExplanatory" xlink:to="mrus_DisclosureOfMaximumExposureToCreditRiskExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_lbl" xml:lang="en-US" id="id_14264487_3418487_1_1">Disclosure of nature and extent of risks arising from financial instruments [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_lbl" xml:lang="en-US" id="id_14264487_3418487_2_1">Disclosure of nature and extent of risks arising from financial instruments [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xml:lang="en-US" id="id_14264487_3418910_1_1">Disclosure of nature and extent of risks arising from financial instruments [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xml:lang="en-US" id="id_14264487_3418910_2_1">Disclosure of nature and extent of risks arising from financial instruments [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl" xml:lang="en-US" id="id_14264487_3418911_1_1">Disclosure of nature and extent of risks arising from financial instruments [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl" xml:lang="en-US" id="id_14264487_3418911_2_1">Disclosure of nature and extent of risks arising from financial instruments [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418918_1_1">Disclosure of number and weighted average exercise prices of share options [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418918_2_1">Summary of Reconciliation of Outstanding Share Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory" xlink:label="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3520275_3_1">The disclosure of the number and weighted average exercise prices of share other than options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3520275_1_1">Disclosure of number and weighted average exercise prices of share other than options [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3520275_2_1">Summary of Reconciliation of RSU's</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory" xlink:to="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOperatingExpensesAbstract" xlink:label="mrus_DisclosureOfOperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfOperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_14264487_3431344_3_1">Disclosure Of Operating Expenses [abstract].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfOperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_14264487_3431344_1_1">Disclosure Of Operating Expenses [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfOperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_14264487_3431344_2_1">Disclosure of operating expenses [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_DisclosureOfOperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOperatingExpensesByNatureExplanatory" xlink:label="mrus_DisclosureOfOperatingExpensesByNatureExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfOperatingExpensesByNatureExplanatory_lbl" xml:lang="en-US" id="id_14264487_3516215_3_1">Disclosure of operating expenses by nature explanatory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfOperatingExpensesByNatureExplanatory_lbl" xml:lang="en-US" id="id_14264487_3516215_1_1">Disclosure Of Operating Expenses By Nature Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfOperatingExpensesByNatureExplanatory_lbl" xml:lang="en-US" id="id_14264487_3516215_2_1">Operating Expenses by Nature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfOperatingExpensesByNatureExplanatory" xlink:to="mrus_DisclosureOfOperatingExpensesByNatureExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOperatingExpensesExplanatory" xlink:label="mrus_DisclosureOfOperatingExpensesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfOperatingExpensesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3515484_3_1">The disclosure of information about operating expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfOperatingExpensesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3515484_1_1">Disclosure of Operating Expenses Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfOperatingExpensesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3515484_2_1">Total Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfOperatingExpensesExplanatory" xlink:to="mrus_DisclosureOfOperatingExpensesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardAbstract" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardAbstract_lbl" xml:lang="en-US" id="id_14264487_3429163_3_1">Disclosure of options held by the members of Supervisory board.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardAbstract_lbl" xml:lang="en-US" id="id_14264487_3429163_1_1">Disclosure of options held by the members of Supervisory board [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardAbstract_lbl" xml:lang="en-US" id="id_14264487_3429163_2_1">Disclosure of options held by the members of Supervisory board [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardAbstract" xlink:to="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522375_3_1">The disclosure of options held by the members of super visory board.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522375_1_1">Disclosure of options held by the members of super visory board [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522375_2_1">Summary of Average Exercise Price Per Share Held by the Members of the Supervisory Board</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory" xlink:to="mrus_DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems_lbl" xml:lang="en-US" id="id_14264487_3429167_3_1">Line items represent concepts included in a table. Disclosure of options held by the members of supervisory board.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems_lbl" xml:lang="en-US" id="id_14264487_3429167_1_1">Disclosure of options held by the members of supervisory board [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems_lbl" xml:lang="en-US" id="id_14264487_3429167_2_1">Disclosure of options held by the members of supervisory board [line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" xlink:to="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable_lbl" xml:lang="en-US" id="id_14264487_3473581_3_1">Schedule disclosing information related to options held by the members of supervisory board.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable_lbl" xml:lang="en-US" id="id_14264487_3473581_1_1">Disclosure of options held by the members of supervisory board [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable_lbl" xml:lang="en-US" id="id_14264487_3473581_2_1">Disclosure of options held by the members of supervisory board [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" xlink:to="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOtherIncomeExpenseExplanatory" xlink:label="mrus_DisclosureOfOtherIncomeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfOtherIncomeExpenseExplanatory_lbl" xml:lang="en-US" id="id_14264487_3519540_3_1">Disclosure of other income expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfOtherIncomeExpenseExplanatory_lbl" xml:lang="en-US" id="id_14264487_3519540_1_1">Disclosure Of Other Income Expense Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfOtherIncomeExpenseExplanatory_lbl" xml:lang="en-US" id="id_14264487_3519540_2_1">Other Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfOtherIncomeExpenseExplanatory" xlink:to="mrus_DisclosureOfOtherIncomeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_14264487_3419184_1_1">Disclosure of detailed information about property, plant and equipment [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_14264487_3419184_2_1">Disclosure of detailed information about property, plant and equipment [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418935_1_1">Disclosure of property, plant and equipment [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" id="id_14264487_3418935_2_1">Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_14264487_3419170_1_1">Disclosure of detailed information about property, plant and equipment [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_14264487_3419170_2_1">Disclosure of detailed information about property, plant and equipment [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_14264487_3419185_1_1">Disclosure of detailed information about property, plant and equipment [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_14264487_3419185_2_1">Disclosure of detailed information about property, plant and equipment [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfRecentlyIssuedIfrsAbstract" xlink:label="mrus_DisclosureOfRecentlyIssuedIfrsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfRecentlyIssuedIfrsAbstract_lbl" xml:lang="en-US" id="id_14264487_3431953_3_1">Disclosure of recently issued ifrs [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfRecentlyIssuedIfrsAbstract_lbl" xml:lang="en-US" id="id_14264487_3431953_1_1">Disclosure of recently issued ifrs [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfRecentlyIssuedIfrsAbstract_lbl" xml:lang="en-US" id="id_14264487_3431953_2_1">Disclosure of recently issued ifrs [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfRecentlyIssuedIfrsAbstract" xlink:to="mrus_DisclosureOfRecentlyIssuedIfrsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfRelatedPartyAbstract" xlink:label="mrus_DisclosureOfRelatedPartyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfRelatedPartyAbstract_lbl" xml:lang="en-US" id="id_14264487_3429139_3_1">Disclosure of related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfRelatedPartyAbstract_lbl" xml:lang="en-US" id="id_14264487_3429139_1_1">Disclosure of related party [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfRelatedPartyAbstract_lbl" xml:lang="en-US" id="id_14264487_3429139_2_1">Disclosure of related party [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfRelatedPartyAbstract" xlink:to="mrus_DisclosureOfRelatedPartyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419856_1_1">Disclosure of related party [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419856_2_1">Related party disclosures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419207_1_1">Disclosure of revenue [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419207_2_1">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419857_1_1">Disclosure of revenue from contracts with customers [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419857_2_1">Summary of Changes in Tarde Receivables, Contract Assets and Contract Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419461_1_1">Disclosure of share-based payment arrangements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419461_2_1">Shareholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfShareOfEquityInvestmentLineItems" xlink:label="mrus_DisclosureOfShareOfEquityInvestmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfShareOfEquityInvestmentLineItems_lbl" xml:lang="en-US" id="id_14264487_3429482_3_1">Disclosure Of Share Of Equity Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfShareOfEquityInvestmentLineItems_lbl" xml:lang="en-US" id="id_14264487_3429482_1_1">Disclosure Of Share Of Equity Investment [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfShareOfEquityInvestmentLineItems_lbl" xml:lang="en-US" id="id_14264487_3429482_2_1">Disclosure Of Share Of Equity Investment [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfShareOfEquityInvestmentLineItems" xlink:to="mrus_DisclosureOfShareOfEquityInvestmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_14264487_3427823_3_1">Disclosure of significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_14264487_3427823_1_1">Disclosure of significant accounting policies [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_14264487_3427823_2_1">Disclosure of significant accounting policies [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="mrus_DisclosureOfSignificantAccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_14264487_3427826_3_1">Disclosure of significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_14264487_3427826_1_1">Disclosure of significant accounting policies [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_14264487_3427826_2_1">Disclosure of significant accounting policies [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:to="mrus_DisclosureOfSignificantAccountingPoliciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfSignificantAccountingPoliciesTable" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_14264487_3475215_3_1">Disclosure of significant accounting policies [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_14264487_3475215_1_1">Disclosure of significant accounting policies [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_14264487_3475215_2_1">Disclosure of significant accounting policies [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesTable" xlink:to="mrus_DisclosureOfSignificantAccountingPoliciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory" xlink:label="mrus_DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522374_3_1">The disclosure of statement of profit or loss and comprehensive loss for the remuneration of the former member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522374_1_1">Disclosure of statement of profit or loss and comprehensive loss for the remuneration of the former members [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory_lbl" xml:lang="en-US" id="id_14264487_3522374_2_1">Summary of Statement of Profit and Loss for the Remuneration of the(Former) Members of the Supervisory Board</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory" xlink:to="mrus_DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419471_1_1">Disclosure of significant accounting policies [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419471_2_1">Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_lbl" xml:lang="en-US" id="id_14264487_3419638_1_1">Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_lbl" xml:lang="en-US" id="id_14264487_3419638_2_1">Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" xml:lang="en-US" id="id_14264487_3419639_1_1">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" xml:lang="en-US" id="id_14264487_3419639_2_1">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl" xml:lang="en-US" id="id_14264487_3419871_1_1">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl" xml:lang="en-US" id="id_14264487_3419871_2_1">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US" id="id_14264487_3419472_1_1">Disclosure of terms and conditions of share-based payment arrangement [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US" id="id_14264487_3419472_2_1">Disclosure of terms and conditions of share-based payment arrangement [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419640_1_1">Disclosure of terms and conditions of share-based payment arrangement [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419640_2_1">Summary of Number of Share Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" id="id_14264487_3419219_1_1">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" id="id_14264487_3419219_2_1">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xml:lang="en-US" id="id_14264487_3419473_1_1">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xml:lang="en-US" id="id_14264487_3419473_2_1">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory" xlink:label="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory_lbl" xml:lang="en-US" id="id_14264487_3518387_3_1">Disclosure of trade and other current receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory_lbl" xml:lang="en-US" id="id_14264487_3518387_1_1">Disclosure of trade and other current receivable [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory_lbl" xml:lang="en-US" id="id_14264487_3518387_2_1">Summary of Trade and Other Receivables Due Within 1 Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory" xlink:to="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419641_1_1">Disclosure of trade and other receivables [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US" id="id_14264487_3419641_2_1">Trade and Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3419874_1_1">Disclosure of transactions between related parties [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3419874_2_1">Disclosure of transactions between related parties [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US" id="id_14264487_3419475_1_1">Disclosure of transactions between related parties [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US" id="id_14264487_3419475_2_1">Disclosure of transactions between related parties [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xml:lang="en-US" id="id_14264487_3419644_1_1">Disclosure of transactions between related parties [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xml:lang="en-US" id="id_14264487_3419644_2_1">Disclosure of transactions between related parties [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DiscoveryAndPreclinicalCosts" xlink:label="mrus_DiscoveryAndPreclinicalCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DiscoveryAndPreclinicalCosts_lbl" xml:lang="en-US" id="id_14264487_3449706_3_1">Discovery and pre-clinical costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DiscoveryAndPreclinicalCosts_lbl" xml:lang="en-US" id="id_14264487_3449706_1_1">Discovery and pre-clinical costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DiscoveryAndPreclinicalCosts_lbl" xml:lang="en-US" id="id_14264487_3449706_2_1">Discovery and preclinical costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DiscoveryAndPreclinicalCosts" xlink:to="mrus_DiscoveryAndPreclinicalCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3419658_1_1">Disposals, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3419658_14_1">Disposals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DividendDeclared" xlink:label="mrus_DividendDeclared"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DividendDeclared_lbl" xml:lang="en-US" id="id_14264487_3452957_3_1">Dividend declared.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DividendDeclared_lbl" xml:lang="en-US" id="id_14264487_3452957_1_1">Dividend Declared</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DividendDeclared_lbl" xml:lang="en-US" id="id_14264487_3452957_2_1">Dividend declared</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DividendDeclared" xlink:to="mrus_DividendDeclared_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DocumentAndEntityInformationAbstract" xlink:label="mrus_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_14264487_3548748_3_1">Document and entity information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_14264487_3548748_1_1">Document and entity information [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_14264487_3548748_2_1">Document and entity information [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="mrus_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_14264487_3419904_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_14264487_3419904_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_14264487_3419905_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_14264487_3419905_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_14264487_3419242_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_14264487_3419242_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_14264487_3419909_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_14264487_3419909_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DutchMember" xlink:label="mrus_DutchMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DutchMember_lbl" xml:lang="en-US" id="id_14264487_3503788_3_1">Dutch [member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DutchMember_lbl" xml:lang="en-US" id="id_14264487_3503788_1_1">Dutch [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DutchMember_lbl" xml:lang="en-US" id="id_14264487_3503788_2_1">Dutch [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DutchMember" xlink:to="mrus_DutchMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="ifrs-full_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_14264487_3419251_1_1">Earnings per share [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_14264487_3419251_2_1">Earnings per share [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_14264487_3419690_1_1">Effect of exchange rate changes on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_14264487_3419690_2_1">Effects of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EffectOfOverlayApproachReclassificationAxis" xlink:label="ifrs-full_EffectOfOverlayApproachReclassificationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfOverlayApproachReclassificationAxis_lbl" xml:lang="en-US" id="id_14264487_3419692_1_1">Effect of overlay approach reclassification [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfOverlayApproachReclassificationAxis_lbl" xml:lang="en-US" id="id_14264487_3419692_2_1">Effect of overlay approach reclassification [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfOverlayApproachReclassificationAxis" xlink:to="ifrs-full_EffectOfOverlayApproachReclassificationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_EmployeeBenefitSchemeAxis" xlink:label="mrus_EmployeeBenefitSchemeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_EmployeeBenefitSchemeAxis_lbl" xml:lang="en-US" id="id_14264487_3475782_3_1">Employee Benefit Scheme [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_EmployeeBenefitSchemeAxis_lbl" xml:lang="en-US" id="id_14264487_3475782_1_1">Employee Benefit Scheme [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_EmployeeBenefitSchemeAxis_lbl" xml:lang="en-US" id="id_14264487_3475782_2_1">Employee Benefit Scheme [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_EmployeeBenefitSchemeAxis" xlink:to="mrus_EmployeeBenefitSchemeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_EmployeeBenefitSchemeDomain" xlink:label="mrus_EmployeeBenefitSchemeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_EmployeeBenefitSchemeDomain_lbl" xml:lang="en-US" id="id_14264487_3513250_3_1">Employee Benefit Scheme [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_EmployeeBenefitSchemeDomain_lbl" xml:lang="en-US" id="id_14264487_3513250_1_1">Employee Benefit Scheme [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_EmployeeBenefitSchemeDomain_lbl" xml:lang="en-US" id="id_14264487_3513250_2_1">Employee Benefit Scheme [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_EmployeeBenefitSchemeDomain" xlink:to="mrus_EmployeeBenefitSchemeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US" id="id_14264487_3419930_1_1">Employee benefits expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US" id="id_14264487_3419930_2_1">Employee costs and related benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_EmployeeOptionExercisedPricePerShare" xlink:label="mrus_EmployeeOptionExercisedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_EmployeeOptionExercisedPricePerShare_lbl" xml:lang="en-US" id="id_14264487_3522464_3_1">Employee option exercised price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_EmployeeOptionExercisedPricePerShare_lbl" xml:lang="en-US" id="id_14264487_3522464_1_1">Employee option exercised price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_EmployeeOptionExercisedPricePerShare_lbl" xml:lang="en-US" id="id_14264487_3522464_2_1">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_EmployeeOptionExercisedPricePerShare" xlink:to="mrus_EmployeeOptionExercisedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_14264487_3419937_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_14264487_3419937_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_14264487_3419274_1_1">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_14264487_3419274_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_14264487_3419277_1_1">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_14264487_3419277_2_1">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="id_14264487_3419279_1_1">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="id_14264487_3419279_2_1">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" id="id_14264487_3419280_1_1">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" id="id_14264487_3419280_2_1">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_14264487_3419281_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_14264487_3419281_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_14264487_3419722_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_14264487_3419722_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" id="id_14264487_3419724_1_1">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" id="id_14264487_3419724_2_1">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="ifrs-full_EntitysTotalForAssociatesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForAssociatesMember_lbl" xml:lang="en-US" id="id_14264487_3419727_1_1">Entity's total for associates [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EntitysTotalForAssociatesMember_lbl" xml:lang="en-US" id="id_14264487_3419727_2_1">Entity's total for associates [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForAssociatesMember" xlink:to="ifrs-full_EntitysTotalForAssociatesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember" xlink:label="ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember_lbl" xml:lang="en-US" id="id_14264487_3419294_1_1">Entity's total for impairment of financial assets [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember_lbl" xml:lang="en-US" id="id_14264487_3419294_2_1">Entity's total for impairment of financial assets [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember" xlink:to="ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" id="id_14264487_3419733_1_1">Entity's total for related parties [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" id="id_14264487_3419733_2_1">Entity's total for related parties [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_14264487_3419736_1_1">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_14264487_3419736_2_1">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_14264487_3419954_1_1">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_14264487_3419954_2_1">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" id="id_14264487_3419957_1_1">Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" id="id_14264487_3419957_4_1">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" id="id_14264487_3419957_5_1">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" id="id_14264487_3419957_6_1">Total shareholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" id="id_14264487_3419541_1_1">Equity [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" id="id_14264487_3419541_2_1">Shareholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" id="id_14264487_3419542_1_1">Equity and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" id="id_14264487_3419542_6_1">Total shareholders' equity and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" id="id_14264487_3419740_1_1">Equity [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" id="id_14264487_3419740_2_1">Equity [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_EstimatedContractualTerm" xlink:label="mrus_EstimatedContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_EstimatedContractualTerm_lbl" xml:lang="en-US" id="id_14264487_3471983_3_1">Estimated contractual term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_EstimatedContractualTerm_lbl" xml:lang="en-US" id="id_14264487_3471983_1_1">Estimated contractual term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_EstimatedContractualTerm_lbl" xml:lang="en-US" id="id_14264487_3471983_2_1">Estimated contractual term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_EstimatedContractualTerm" xlink:to="mrus_EstimatedContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ExercisePricePerShare" xlink:label="mrus_ExercisePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ExercisePricePerShare_lbl" xml:lang="en-US" id="id_14264487_3522638_3_1">Exercise price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ExercisePricePerShare_lbl" xml:lang="en-US" id="id_14264487_3522638_1_1">Exercise price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ExercisePricePerShare_lbl" xml:lang="en-US" id="id_14264487_3522638_2_1">Exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ExercisePricePerShare" xlink:to="mrus_ExercisePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US" id="id_14264487_3419755_1_1">Expected dividend as percentage, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US" id="id_14264487_3419755_2_1">Expected dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" id="id_14264487_3419569_1_1">Expense from share-based payment transactions with employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" id="id_14264487_3419569_2_1">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_FairValueAssumptionsGrantDateSharePrice" xlink:label="mrus_FairValueAssumptionsGrantDateSharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_FairValueAssumptionsGrantDateSharePrice_lbl" xml:lang="en-US" id="id_14264487_3522564_3_1">Fair value assumptions grant date share price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_FairValueAssumptionsGrantDateSharePrice_lbl" xml:lang="en-US" id="id_14264487_3522564_1_1">Fair Value Assumptions Grant Date Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_FairValueAssumptionsGrantDateSharePrice_lbl" xml:lang="en-US" id="id_14264487_3522564_2_1">Fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_FairValueAssumptionsGrantDateSharePrice" xlink:to="mrus_FairValueAssumptionsGrantDateSharePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" id="id_14264487_3419392_1_1">Finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" id="id_14264487_3419392_2_1">Finance cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" id="id_14264487_3419392_14_1">Finance cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" id="id_14264487_3419392_19_1">Finance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" id="id_14264487_3419831_1_1">Finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" id="id_14264487_3419831_2_1">Finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" id="id_14264487_3419831_6_1">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsMember_lbl" xml:lang="en-US" id="id_14264487_3420713_1_1">Financial assets, class [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssetsMember_lbl" xml:lang="en-US" id="id_14264487_3420713_2_1">Financial assets, class [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="ifrs-full_FinancialAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinancialAssetsNeitherPastDueNorImpairedMember" xlink:label="ifrs-full_FinancialAssetsNeitherPastDueNorImpairedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsNeitherPastDueNorImpairedMember_lbl" xml:lang="en-US" id="id_14264487_3420078_1_1">Financial assets neither past due nor impaired [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssetsNeitherPastDueNorImpairedMember_lbl" xml:lang="en-US" id="id_14264487_3420078_2_1">Neither past due nor impaired [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsNeitherPastDueNorImpairedMember" xlink:to="ifrs-full_FinancialAssetsNeitherPastDueNorImpairedMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinancialAssetsTypeMember" xlink:label="ifrs-full_FinancialAssetsTypeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsTypeMember_lbl" xml:lang="en-US" id="id_14264487_3420716_1_1">Financial assets, type [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssetsTypeMember_lbl" xml:lang="en-US" id="id_14264487_3420716_2_1">Financial assets, type [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="ifrs-full_FinancialAssetsTypeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_FivePercentageDecreaseInFunctionalRateMember" xlink:label="mrus_FivePercentageDecreaseInFunctionalRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_FivePercentageDecreaseInFunctionalRateMember_lbl" xml:lang="en-US" id="id_14264487_3514297_3_1">Five percentage decrease in functional rate [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_FivePercentageDecreaseInFunctionalRateMember_lbl" xml:lang="en-US" id="id_14264487_3514297_1_1">Five percentage decrease in functional rate [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_FivePercentageDecreaseInFunctionalRateMember_lbl" xml:lang="en-US" id="id_14264487_3514297_2_1">5% decrease in functional rate [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_FivePercentageDecreaseInFunctionalRateMember" xlink:to="mrus_FivePercentageDecreaseInFunctionalRateMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_FivePercentageIncreaseInFunctionalRateMember" xlink:label="mrus_FivePercentageIncreaseInFunctionalRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_FivePercentageIncreaseInFunctionalRateMember_lbl" xml:lang="en-US" id="id_14264487_3514296_3_1">Five percentage increase in functional rate [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_FivePercentageIncreaseInFunctionalRateMember_lbl" xml:lang="en-US" id="id_14264487_3514296_1_1">Five percentage increase in functional rate [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_FivePercentageIncreaseInFunctionalRateMember_lbl" xml:lang="en-US" id="id_14264487_3514296_2_1">5% increase in functional rate [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_FivePercentageIncreaseInFunctionalRateMember" xlink:to="mrus_FivePercentageIncreaseInFunctionalRateMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_FixedRateOfInstrumentsAbstract" xlink:label="mrus_FixedRateOfInstrumentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_FixedRateOfInstrumentsAbstract_lbl" xml:lang="en-US" id="id_14264487_3426673_3_1">Fixed rate of instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_FixedRateOfInstrumentsAbstract_lbl" xml:lang="en-US" id="id_14264487_3426673_1_1">Fixed Rate of Instruments [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_FixedRateOfInstrumentsAbstract_lbl" xml:lang="en-US" id="id_14264487_3426673_2_1">Fixed rate of instruments [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_FixedRateOfInstrumentsAbstract" xlink:to="mrus_FixedRateOfInstrumentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="ifrs-full_FloatingInterestRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FloatingInterestRateMember_lbl" xml:lang="en-US" id="id_14264487_3420520_1_1">Floating interest rate [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FloatingInterestRateMember_lbl" xml:lang="en-US" id="id_14264487_3420520_2_1">Variable rate instruments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FloatingInterestRateMember" xlink:to="ifrs-full_FloatingInterestRateMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax" xlink:label="mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax_lbl" xml:lang="en-US" id="id_14264487_3449030_3_1">Foreign exchange sensitivity effect on profit before tax.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax_lbl" xml:lang="en-US" id="id_14264487_3449030_1_1">Foreign exchange sensitivity effect on profit before tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax_lbl" xml:lang="en-US" id="id_14264487_3449030_2_1">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax" xlink:to="mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_GabrieleDallmannMember" xlink:label="mrus_GabrieleDallmannMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_GabrieleDallmannMember_lbl" xml:lang="en-US" id="id_14264487_3505387_3_1">Gabriele Dallmann.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_GabrieleDallmannMember_lbl" xml:lang="en-US" id="id_14264487_3505387_1_1">Gabriele Dallmann [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_GabrieleDallmannMember_lbl" xml:lang="en-US" id="id_14264487_3505387_2_1">Gabriele Dallmann [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_GabrieleDallmannMember" xlink:to="mrus_GabrieleDallmannMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US" id="id_14264487_3420553_1_1">Foreign exchange gain (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US" id="id_14264487_3420553_2_1">Foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GainsOnLitigationSettlements" xlink:label="ifrs-full_GainsOnLitigationSettlements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsOnLitigationSettlements_lbl" xml:lang="en-US" id="id_14264487_3420151_1_1">Gains on litigation settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsOnLitigationSettlements_lbl" xml:lang="en-US" id="id_14264487_3420151_2_1">Gain on litigation settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsOnLitigationSettlements" xlink:to="ifrs-full_GainsOnLitigationSettlements_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_14264487_3420155_1_1">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_14264487_3420155_2_1">Management and administration costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_14264487_3420155_14_1">Management and administration costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_GeneralLegalInsuranceAndFacilityRelatedExpenses" xlink:label="mrus_GeneralLegalInsuranceAndFacilityRelatedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_GeneralLegalInsuranceAndFacilityRelatedExpenses_lbl" xml:lang="en-US" id="id_14264487_3439004_3_1">General, legal, insurance and facility related expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_GeneralLegalInsuranceAndFacilityRelatedExpenses_lbl" xml:lang="en-US" id="id_14264487_3439004_1_1">General, legal, insurance and facility related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_GeneralLegalInsuranceAndFacilityRelatedExpenses_lbl" xml:lang="en-US" id="id_14264487_3439004_2_1">General legal, insurance and facility related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_GeneralLegalInsuranceAndFacilityRelatedExpenses" xlink:to="mrus_GeneralLegalInsuranceAndFacilityRelatedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US" id="id_14264487_3420782_1_1">Geographical areas [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US" id="id_14264487_3420782_2_1">Geographical areas [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xml:lang="en-US" id="id_14264487_3420376_1_1">Geographical areas [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xml:lang="en-US" id="id_14264487_3420376_2_1">Geographical areas [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="ifrs-full_GeographicalAreasMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_GrantIncome" xlink:label="mrus_GrantIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_GrantIncome_lbl" xml:lang="en-US" id="id_14264487_3453221_3_1">Grant income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_GrantIncome_lbl" xml:lang="en-US" id="id_14264487_3453221_1_1">Grant income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_GrantIncome_lbl" xml:lang="en-US" id="id_14264487_3453221_2_1">Grant income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_GrantIncome" xlink:to="mrus_GrantIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_GregoryPerryMember" xlink:label="mrus_GregoryPerryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_GregoryPerryMember_lbl" xml:lang="en-US" id="id_14264487_3505535_3_1">Gregory Perry.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_GregoryPerryMember_lbl" xml:lang="en-US" id="id_14264487_3505535_1_1">Gregory Perry [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_GregoryPerryMember_lbl" xml:lang="en-US" id="id_14264487_3505535_2_1">Gregory Perry [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_GregoryPerryMember" xlink:to="mrus_GregoryPerryMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossCarryingAmountMember_lbl" xml:lang="en-US" id="id_14264487_3420576_1_1">Gross carrying amount [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GrossCarryingAmountMember_lbl" xml:lang="en-US" id="id_14264487_3420576_2_1">Cost [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossCarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_GrossSalaryMember" xlink:label="mrus_GrossSalaryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_GrossSalaryMember_lbl" xml:lang="en-US" id="id_14264487_3505512_3_1">Gross salary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_GrossSalaryMember_lbl" xml:lang="en-US" id="id_14264487_3505512_1_1">Gross salary [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_GrossSalaryMember_lbl" xml:lang="en-US" id="id_14264487_3505512_2_1">Gross salary [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_GrossSalaryMember" xlink:to="mrus_GrossSalaryMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_HealthInsurance" xlink:label="mrus_HealthInsurance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_HealthInsurance_lbl" xml:lang="en-US" id="id_14264487_3457644_3_1">Health insurance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_HealthInsurance_lbl" xml:lang="en-US" id="id_14264487_3457644_1_1">Health insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_HealthInsurance_lbl" xml:lang="en-US" id="id_14264487_3457644_2_1">Health insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_HealthInsurance" xlink:to="mrus_HealthInsurance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_HeldtomaturityInvestments" xlink:label="ifrs-full_HeldtomaturityInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_HeldtomaturityInvestments_lbl" xml:lang="en-US" id="id_14264487_3420816_1_1">Held-to-maturity investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_HeldtomaturityInvestments_lbl" xml:lang="en-US" id="id_14264487_3420816_2_1">Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_HeldtomaturityInvestments_lbl" xml:lang="en-US" id="id_14264487_3420816_6_1">Total investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_HeldtomaturityInvestments" xlink:to="ifrs-full_HeldtomaturityInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IAS39Member" xlink:label="mrus_IAS39Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IAS39Member_lbl" xml:lang="en-US" id="id_14264487_3495181_3_1">IAS 39.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IAS39Member_lbl" xml:lang="en-US" id="id_14264487_3495181_1_1">IAS 39 [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IAS39Member_lbl" xml:lang="en-US" id="id_14264487_3495181_2_1">IAS 39 [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IAS39Member" xlink:to="mrus_IAS39Member_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IFRS15RevenueFromContractsWithCustomersMember" xlink:label="mrus_IFRS15RevenueFromContractsWithCustomersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IFRS15RevenueFromContractsWithCustomersMember_lbl" xml:lang="en-US" id="id_14264487_3508886_3_1">IFRS 15 revenue from contracts with customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IFRS15RevenueFromContractsWithCustomersMember_lbl" xml:lang="en-US" id="id_14264487_3508886_1_1">IFRS 15 revenue from contracts with customers [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IFRS15RevenueFromContractsWithCustomersMember_lbl" xml:lang="en-US" id="id_14264487_3508886_2_1">IFRS 15 revenue from contracts with customers [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IFRS15RevenueFromContractsWithCustomersMember" xlink:to="mrus_IFRS15RevenueFromContractsWithCustomersMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ImpairmentOfFinancialAssetsAxis" xlink:label="ifrs-full_ImpairmentOfFinancialAssetsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentOfFinancialAssetsAxis_lbl" xml:lang="en-US" id="id_14264487_3420436_1_1">Impairment of financial assets [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ImpairmentOfFinancialAssetsAxis_lbl" xml:lang="en-US" id="id_14264487_3420436_2_1">Impairment of financial assets [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentOfFinancialAssetsAxis" xlink:to="ifrs-full_ImpairmentOfFinancialAssetsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InAccordanceWithIFRS9Member" xlink:label="ifrs-full_InAccordanceWithIFRS9Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InAccordanceWithIFRS9Member_lbl" xml:lang="en-US" id="id_14264487_3420440_1_1">In accordance with IFRS 9 [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InAccordanceWithIFRS9Member_lbl" xml:lang="en-US" id="id_14264487_3420440_2_1">In accordance with IFRS 9 [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InAccordanceWithIFRS9Member" xlink:to="ifrs-full_InAccordanceWithIFRS9Member_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeMember" xlink:label="mrus_IncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncomeMember_lbl" xml:lang="en-US" id="id_14264487_3509602_3_1">Income [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncomeMember_lbl" xml:lang="en-US" id="id_14264487_3509602_1_1">Income [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncomeMember_lbl" xml:lang="en-US" id="id_14264487_3509602_2_1">Income from grants on research projects [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncomeMember" xlink:to="mrus_IncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeStatementLineItemLocationAxis" xlink:label="mrus_IncomeStatementLineItemLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncomeStatementLineItemLocationAxis_lbl" xml:lang="en-US" id="id_14264487_3475752_3_1">Income statement line item location.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncomeStatementLineItemLocationAxis_lbl" xml:lang="en-US" id="id_14264487_3475752_1_1">Income statement line item location [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncomeStatementLineItemLocationAxis_lbl" xml:lang="en-US" id="id_14264487_3475752_2_1">Income statement line item location [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncomeStatementLineItemLocationAxis" xlink:to="mrus_IncomeStatementLineItemLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeStatementLineItemLocationMember" xlink:label="mrus_IncomeStatementLineItemLocationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncomeStatementLineItemLocationMember_lbl" xml:lang="en-US" id="id_14264487_3512505_3_1">Income statement line item location [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncomeStatementLineItemLocationMember_lbl" xml:lang="en-US" id="id_14264487_3512505_1_1">Income statement line item location [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncomeStatementLineItemLocationMember_lbl" xml:lang="en-US" id="id_14264487_3512505_2_1">Income statement line item location [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_IncomeStatementLineItemLocationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeTaxAuthority1Axis" xlink:label="mrus_IncomeTaxAuthority1Axis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncomeTaxAuthority1Axis_lbl" xml:lang="en-US" id="id_14264487_3475724_3_1">Income tax authority 1 [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncomeTaxAuthority1Axis_lbl" xml:lang="en-US" id="id_14264487_3475724_1_1">Income tax authority 1 [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncomeTaxAuthority1Axis_lbl" xml:lang="en-US" id="id_14264487_3475724_2_1">Income tax authority 1 [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncomeTaxAuthority1Axis" xlink:to="mrus_IncomeTaxAuthority1Axis_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeTaxAuthority1Domain" xlink:label="mrus_IncomeTaxAuthority1Domain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncomeTaxAuthority1Domain_lbl" xml:lang="en-US" id="id_14264487_3476346_3_1">Income Tax Authority domain.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncomeTaxAuthority1Domain_lbl" xml:lang="en-US" id="id_14264487_3476346_1_1">Income Tax Authority 1 [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncomeTaxAuthority1Domain_lbl" xml:lang="en-US" id="id_14264487_3476346_2_1">Income Tax Authority 1 [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncomeTaxAuthority1Domain" xlink:to="mrus_IncomeTaxAuthority1Domain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xml:lang="en-US" id="id_14264487_3420215_1_1">Income taxes paid (refund), classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xml:lang="en-US" id="id_14264487_3420215_14_1">Taxes paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" id="id_14264487_3420859_1_1">Tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" id="id_14264487_3420859_2_1">Income tax expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" id="id_14264487_3420859_14_1">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl" xml:lang="en-US" id="id_14264487_3420637_1_1">Increase (decrease) due to application of IFRS 15 [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl" xml:lang="en-US" id="id_14264487_3420637_2_1">Increase (decrease) due to application of IFRS 15 [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncreaseDecreaseInCapital" xlink:label="mrus_IncreaseDecreaseInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncreaseDecreaseInCapital_lbl" xml:lang="en-US" id="id_14264487_3433500_3_1">Increase decrease in capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncreaseDecreaseInCapital_lbl" xml:lang="en-US" id="id_14264487_3433500_1_1">Increase Decrease In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncreaseDecreaseInCapital_lbl" xml:lang="en-US" id="id_14264487_3433500_2_1">Increased capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncreaseDecreaseInCapital" xlink:to="mrus_IncreaseDecreaseInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" id="id_14264487_3420461_1_1">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" id="id_14264487_3420461_6_1">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncreaseDecreaseInDeferredRevenue1" xlink:label="mrus_IncreaseDecreaseInDeferredRevenue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncreaseDecreaseInDeferredRevenue1_lbl" xml:lang="en-US" id="id_14264487_3439577_3_1">Increase decrease in deferred revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncreaseDecreaseInDeferredRevenue1_lbl" xml:lang="en-US" id="id_14264487_3439577_1_1">Increase Decrease In Deferred Revenue1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrus_IncreaseDecreaseInDeferredRevenue1_lbl" xml:lang="en-US" id="id_14264487_3439577_14_1">Decrease in Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncreaseDecreaseInDeferredRevenue1" xlink:to="mrus_IncreaseDecreaseInDeferredRevenue1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xml:lang="en-US" id="id_14264487_3420475_1_1">Increase (decrease) in number of ordinary shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xml:lang="en-US" id="id_14264487_3420475_2_1">Common shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xml:lang="en-US" id="id_14264487_3420475_12_1">Number of common shares purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncreaseDecreaseInSharePremium" xlink:label="mrus_IncreaseDecreaseInSharePremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncreaseDecreaseInSharePremium_lbl" xml:lang="en-US" id="id_14264487_3459093_3_1">Increase decrease in share premium.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncreaseDecreaseInSharePremium_lbl" xml:lang="en-US" id="id_14264487_3459093_1_1">Increase Decrease In Share Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncreaseDecreaseInSharePremium_lbl" xml:lang="en-US" id="id_14264487_3459093_2_1">Increased premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncreaseDecreaseInSharePremium" xlink:to="mrus_IncreaseDecreaseInSharePremium_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" xml:lang="en-US" id="id_14264487_3420487_1_1">Increase (decrease) through conversion of convertible instruments, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" xml:lang="en-US" id="id_14264487_3420487_2_1">Conversion of preference shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" id="id_14264487_3420273_1_1">Increase (decrease) through share-based payment transactions, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" id="id_14264487_3420273_2_1">Equity settled shared-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" xlink:label="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity_lbl" xml:lang="en-US" id="id_14264487_3447314_3_1">Increase through contributions by and distributions to owners, equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity_lbl" xml:lang="en-US" id="id_14264487_3447314_1_1">Increase through contributions by and distributions to owners, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity_lbl" xml:lang="en-US" id="id_14264487_3447314_6_1">Total contributions by and distributions to owners of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" xlink:to="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteCollaborationAgreementMember" xlink:label="mrus_IncyteCollaborationAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncyteCollaborationAgreementMember_lbl" xml:lang="en-US" id="id_14264487_3486516_3_1">Incyte collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncyteCollaborationAgreementMember_lbl" xml:lang="en-US" id="id_14264487_3486516_1_1">Incyte collaboration agreement [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncyteCollaborationAgreementMember_lbl" xml:lang="en-US" id="id_14264487_3486516_2_1">Incyte collaboration agreement [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncyteCollaborationAgreementMember" xlink:to="mrus_IncyteCollaborationAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteCorporationMember" xlink:label="mrus_IncyteCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncyteCorporationMember_lbl" xml:lang="en-US" id="id_14264487_3486468_3_1">Incyte Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncyteCorporationMember_lbl" xml:lang="en-US" id="id_14264487_3486468_1_1">Incyte Corporation [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncyteCorporationMember_lbl" xml:lang="en-US" id="id_14264487_3486468_2_1">Incyte Corporation [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncyteCorporationMember" xlink:to="mrus_IncyteCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteMember" xlink:label="mrus_IncyteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncyteMember_lbl" xml:lang="en-US" id="id_14264487_3496066_3_1">Incyte [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncyteMember_lbl" xml:lang="en-US" id="id_14264487_3496066_1_1">Incyte [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncyteMember_lbl" xml:lang="en-US" id="id_14264487_3496066_2_1">Incyte [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncyteMember" xlink:to="mrus_IncyteMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteProprietaryTechnologyMember" xlink:label="mrus_IncyteProprietaryTechnologyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncyteProprietaryTechnologyMember_lbl" xml:lang="en-US" id="id_14264487_3496065_3_1">Incyte proprietary technology [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncyteProprietaryTechnologyMember_lbl" xml:lang="en-US" id="id_14264487_3496065_1_1">Incyte proprietary technology [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncyteProprietaryTechnologyMember_lbl" xml:lang="en-US" id="id_14264487_3496065_2_1">Incyte proprietary technology [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncyteProprietaryTechnologyMember" xlink:to="mrus_IncyteProprietaryTechnologyMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteShareSubscriptionAgreementMember" xlink:label="mrus_IncyteShareSubscriptionAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncyteShareSubscriptionAgreementMember_lbl" xml:lang="en-US" id="id_14264487_3554473_3_1">Incyte share subscription agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncyteShareSubscriptionAgreementMember_lbl" xml:lang="en-US" id="id_14264487_3554473_1_1">Incyte share subscription agreement [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncyteShareSubscriptionAgreementMember_lbl" xml:lang="en-US" id="id_14264487_3554473_2_1">Incyte share subscription agreement [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncyteShareSubscriptionAgreementMember" xlink:to="mrus_IncyteShareSubscriptionAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InitialPublicOfferingCosts" xlink:label="mrus_InitialPublicOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_InitialPublicOfferingCosts_lbl" xml:lang="en-US" id="id_14264487_3466170_3_1">Initial Public Offering costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_InitialPublicOfferingCosts_lbl" xml:lang="en-US" id="id_14264487_3466170_1_1">Initial Public Offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrus_InitialPublicOfferingCosts_lbl" xml:lang="en-US" id="id_14264487_3466170_14_1">IPO expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_InitialPublicOfferingCosts" xlink:to="mrus_InitialPublicOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InitialPublicOfferingMember" xlink:label="mrus_InitialPublicOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_InitialPublicOfferingMember_lbl" xml:lang="en-US" id="id_14264487_3509221_3_1">Initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_InitialPublicOfferingMember_lbl" xml:lang="en-US" id="id_14264487_3509221_1_1">Initial Public Offering [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_InitialPublicOfferingMember_lbl" xml:lang="en-US" id="id_14264487_3509221_2_1">Initial public offering [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_InitialPublicOfferingMember" xlink:to="mrus_InitialPublicOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InnovationsBoxRate" xlink:label="mrus_InnovationsBoxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_InnovationsBoxRate_lbl" xml:lang="en-US" id="id_14264487_3558071_3_1">Innovations box rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_InnovationsBoxRate_lbl" xml:lang="en-US" id="id_14264487_3558071_1_1">Innovations Box rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_InnovationsBoxRate_lbl" xml:lang="en-US" id="id_14264487_3558071_2_1">Tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_InnovationsBoxRate" xlink:to="mrus_InnovationsBoxRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xml:lang="en-US" id="id_14264487_3421839_1_1">Intangible assets and goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xml:lang="en-US" id="id_14264487_3421839_2_1">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" id="id_14264487_3421841_1_1">Intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" id="id_14264487_3421841_4_1">Intangible assets, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" id="id_14264487_3421841_5_1">Intangible assets, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_lbl" xml:lang="en-US" id="id_14264487_3421843_1_1">Intangible assets other than goodwill [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_lbl" xml:lang="en-US" id="id_14264487_3421843_2_1">Intangible assets other than goodwill [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IntellectualPropertyCosts" xlink:label="mrus_IntellectualPropertyCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IntellectualPropertyCosts_lbl" xml:lang="en-US" id="id_14264487_3449734_3_1">Intellectual property costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IntellectualPropertyCosts_lbl" xml:lang="en-US" id="id_14264487_3449734_1_1">Intellectual property costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IntellectualPropertyCosts_lbl" xml:lang="en-US" id="id_14264487_3449734_2_1">IP costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IntellectualPropertyCosts" xlink:to="mrus_IntellectualPropertyCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InterestAndOtherExpense" xlink:label="mrus_InterestAndOtherExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_InterestAndOtherExpense_lbl" xml:lang="en-US" id="id_14264487_3465348_3_1">Interest and other expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_InterestAndOtherExpense_lbl" xml:lang="en-US" id="id_14264487_3465348_1_1">Interest and other expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrus_InterestAndOtherExpense_lbl" xml:lang="en-US" id="id_14264487_3465348_14_1">Interest and other expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_InterestAndOtherExpense" xlink:to="mrus_InterestAndOtherExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InterestAndRelatedIncome" xlink:label="mrus_InterestAndRelatedIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_InterestAndRelatedIncome_lbl" xml:lang="en-US" id="id_14264487_3464165_3_1">Interest and related income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_InterestAndRelatedIncome_lbl" xml:lang="en-US" id="id_14264487_3464165_1_1">Interest and related income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_InterestAndRelatedIncome_lbl" xml:lang="en-US" id="id_14264487_3464165_2_1">Interest income and similar related income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_InterestAndRelatedIncome" xlink:to="mrus_InterestAndRelatedIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" id="id_14264487_3421854_1_1">Interest paid, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" id="id_14264487_3421854_14_1">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestRateTypesMember_lbl" xml:lang="en-US" id="id_14264487_3421207_1_1">Interest rate types [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestRateTypesMember_lbl" xml:lang="en-US" id="id_14264487_3421207_2_1">Interest rate types [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="ifrs-full_InterestRateTypesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_14264487_3421388_1_1">Interest received, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_14264487_3421388_2_1">Interest received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InvestmentMember" xlink:label="mrus_InvestmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_InvestmentMember_lbl" xml:lang="en-US" id="id_14264487_3479569_3_1">Investment [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_InvestmentMember_lbl" xml:lang="en-US" id="id_14264487_3479569_1_1">Investment [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_InvestmentMember_lbl" xml:lang="en-US" id="id_14264487_3479569_2_1">Investment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_InvestmentMember" xlink:to="mrus_InvestmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InvestorsMember" xlink:label="mrus_InvestorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_InvestorsMember_lbl" xml:lang="en-US" id="id_14264487_3507527_3_1">Investors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_InvestorsMember_lbl" xml:lang="en-US" id="id_14264487_3507527_1_1">Investors [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_InvestorsMember_lbl" xml:lang="en-US" id="id_14264487_3507527_2_1">Investors [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_InvestorsMember" xlink:to="mrus_InvestorsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IPAndLicenseCosts" xlink:label="mrus_IPAndLicenseCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IPAndLicenseCosts_lbl" xml:lang="en-US" id="id_14264487_3530329_3_1">I p and license costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IPAndLicenseCosts_lbl" xml:lang="en-US" id="id_14264487_3530329_1_1">I p and license costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IPAndLicenseCosts_lbl" xml:lang="en-US" id="id_14264487_3530329_2_1">IP and license costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IPAndLicenseCosts" xlink:to="mrus_IPAndLicenseCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" id="id_14264487_3421012_1_1">Issued capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" id="id_14264487_3421012_2_1">Issued and paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" id="id_14264487_3421013_1_1">Issued capital [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" id="id_14264487_3421013_2_1">Issued capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" id="id_14264487_3421895_1_1">Issue of equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" id="id_14264487_3421895_2_1">Issuance of shares (net)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_JohnCrowleyChiefFinancialOfficerMember" xlink:label="mrus_JohnCrowleyChiefFinancialOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_JohnCrowleyChiefFinancialOfficerMember_lbl" xml:lang="en-US" id="id_14264487_3504974_3_1">John Crowley Chief Financial Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_JohnCrowleyChiefFinancialOfficerMember_lbl" xml:lang="en-US" id="id_14264487_3504974_1_1">John Crowley Chief Financial Officer [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_JohnCrowleyChiefFinancialOfficerMember_lbl" xml:lang="en-US" id="id_14264487_3504974_2_1">John Crowley Chief Financial Officer [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_JohnCrowleyChiefFinancialOfficerMember" xlink:to="mrus_JohnCrowleyChiefFinancialOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_JohnDeKoningMember" xlink:label="mrus_JohnDeKoningMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_JohnDeKoningMember_lbl" xml:lang="en-US" id="id_14264487_3504975_3_1">John de Koning.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_JohnDeKoningMember_lbl" xml:lang="en-US" id="id_14264487_3504975_1_1">John de Koning [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_JohnDeKoningMember_lbl" xml:lang="en-US" id="id_14264487_3504975_2_1">John de Koning [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_JohnDeKoningMember" xlink:to="mrus_JohnDeKoningMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xml:lang="en-US" id="id_14264487_3421270_1_1">Key management personnel compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xml:lang="en-US" id="id_14264487_3421270_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_lbl" xml:lang="en-US" id="id_14264487_3421271_1_1">Key management personnel compensation, other long-term employee benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_lbl" xml:lang="en-US" id="id_14264487_3421271_2_1">Other long-term benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl" xml:lang="en-US" id="id_14264487_3421272_1_1">Key management personnel compensation, post-employment benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl" xml:lang="en-US" id="id_14264487_3421272_2_1">Post-employment benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US" id="id_14264487_3421908_1_1">Key management personnel compensation, share-based payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US" id="id_14264487_3421908_2_1">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US" id="id_14264487_3421022_1_1">Key management personnel compensation, short-term employee benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US" id="id_14264487_3421022_2_1">Short-term employment benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_lbl" xml:lang="en-US" id="id_14264487_3421909_1_1">Key management personnel compensation, termination benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_lbl" xml:lang="en-US" id="id_14264487_3421909_2_1">Termination benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xml:lang="en-US" id="id_14264487_3421023_1_1">Key management personnel of entity or parent [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xml:lang="en-US" id="id_14264487_3421023_2_1">Key management personnel [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xml:lang="en-US" id="id_14264487_3421286_1_1">Later than one year and not later than five years [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xml:lang="en-US" id="id_14264487_3421286_2_1">Between one and five years [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl" xml:lang="en-US" id="id_14264487_3421288_1_1">Later than one year and not later than two years [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl" xml:lang="en-US" id="id_14264487_3421288_2_1">1-2 years [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl" xml:lang="en-US" id="id_14264487_3421294_1_1">Later than two years and not later than three years [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl" xml:lang="en-US" id="id_14264487_3421294_2_1">2-5 years [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:to="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="ifrs-full_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_14264487_3421037_1_1">Leasehold improvements [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_14264487_3421037_2_1">Leasehold improvements [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US" id="id_14264487_3421455_1_1">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US" id="id_14264487_3421455_2_1">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LeasesAgreementForCorporateHeadquartersMember" xlink:label="mrus_LeasesAgreementForCorporateHeadquartersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_LeasesAgreementForCorporateHeadquartersMember_lbl" xml:lang="en-US" id="id_14264487_3556804_3_1">Leases agreement for corporate headquarters [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_LeasesAgreementForCorporateHeadquartersMember_lbl" xml:lang="en-US" id="id_14264487_3556804_1_1">Leases agreement for corporate headquarters [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_LeasesAgreementForCorporateHeadquartersMember_lbl" xml:lang="en-US" id="id_14264487_3556804_2_1">Leases agreement for corporate headquarters [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LeasesAgreementForCorporateHeadquartersMember" xlink:to="mrus_LeasesAgreementForCorporateHeadquartersMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LeasesExpirationPeriod" xlink:label="mrus_LeasesExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_LeasesExpirationPeriod_lbl" xml:lang="en-US" id="id_14264487_3472053_3_1">Leases expiration period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_LeasesExpirationPeriod_lbl" xml:lang="en-US" id="id_14264487_3472053_1_1">Leases Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_LeasesExpirationPeriod_lbl" xml:lang="en-US" id="id_14264487_3472053_2_1">Leases expiration period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LeasesExpirationPeriod" xlink:to="mrus_LeasesExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LeaseTermExpirationDate" xlink:label="mrus_LeaseTermExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_LeaseTermExpirationDate_lbl" xml:lang="en-US" id="id_14264487_3471177_3_1">Lease term expiration date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_LeaseTermExpirationDate_lbl" xml:lang="en-US" id="id_14264487_3471177_1_1">Lease term expiration date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_LeaseTermExpirationDate_lbl" xml:lang="en-US" id="id_14264487_3471177_2_1">Operating lease expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LeaseTermExpirationDate" xlink:to="mrus_LeaseTermExpirationDate_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LenKanavyMember" xlink:label="mrus_LenKanavyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_LenKanavyMember_lbl" xml:lang="en-US" id="id_14264487_3556564_3_1">Len Kanavy [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_LenKanavyMember_lbl" xml:lang="en-US" id="id_14264487_3556564_1_1">Len Kanavy [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_LenKanavyMember_lbl" xml:lang="en-US" id="id_14264487_3556564_2_1">Len Kanavy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LenKanavyMember" xlink:to="mrus_LenKanavyMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" id="id_14264487_3421936_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" id="id_14264487_3421936_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesMember_lbl" xml:lang="en-US" id="id_14264487_3421050_1_1">Liabilities [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LiabilitiesMember_lbl" xml:lang="en-US" id="id_14264487_3421050_2_1">Liabilities [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="ifrs-full_LiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LicenceFeeIncome" xlink:label="ifrs-full_LicenceFeeIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LicenceFeeIncome_lbl" xml:lang="en-US" id="id_14264487_3421468_1_1">Licence fee income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LicenceFeeIncome_lbl" xml:lang="en-US" id="id_14264487_3421468_2_1">Licence fee income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LicenceFeeIncome" xlink:to="ifrs-full_LicenceFeeIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LionelCarnotMember" xlink:label="mrus_LionelCarnotMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_LionelCarnotMember_lbl" xml:lang="en-US" id="id_14264487_3504768_3_1">Lionel Carnot.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_LionelCarnotMember_lbl" xml:lang="en-US" id="id_14264487_3504768_1_1">Lionel Carnot [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_LionelCarnotMember_lbl" xml:lang="en-US" id="id_14264487_3504768_2_1">Lionel Carnot [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LionelCarnotMember" xlink:to="mrus_LionelCarnotMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LitigationCosts" xlink:label="mrus_LitigationCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_LitigationCosts_lbl" xml:lang="en-US" id="id_14264487_3463229_3_1">Litigation costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_LitigationCosts_lbl" xml:lang="en-US" id="id_14264487_3463229_1_1">Litigation costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_LitigationCosts_lbl" xml:lang="en-US" id="id_14264487_3463229_2_1">Litigation and opposition cost incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrus_LitigationCosts_lbl" xml:lang="en-US" id="id_14264487_3463229_12_1">Litigation costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LitigationCosts" xlink:to="mrus_LitigationCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LitigationSettlementsGrantedForAttorneysFees" xlink:label="mrus_LitigationSettlementsGrantedForAttorneysFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_LitigationSettlementsGrantedForAttorneysFees_lbl" xml:lang="en-US" id="id_14264487_3556808_3_1">Litigation settlements granted for attorneys fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_LitigationSettlementsGrantedForAttorneysFees_lbl" xml:lang="en-US" id="id_14264487_3556808_1_1">Litigation settlements granted for attorneys fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_LitigationSettlementsGrantedForAttorneysFees_lbl" xml:lang="en-US" id="id_14264487_3556808_2_1">Attorneys fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LitigationSettlementsGrantedForAttorneysFees" xlink:to="mrus_LitigationSettlementsGrantedForAttorneysFees_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LitigationSettlementsGrantedForExpertFees" xlink:label="mrus_LitigationSettlementsGrantedForExpertFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_LitigationSettlementsGrantedForExpertFees_lbl" xml:lang="en-US" id="id_14264487_3556809_3_1">Litigation settlements granted for expert fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_LitigationSettlementsGrantedForExpertFees_lbl" xml:lang="en-US" id="id_14264487_3556809_1_1">Litigation settlements granted for expert fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_LitigationSettlementsGrantedForExpertFees_lbl" xml:lang="en-US" id="id_14264487_3556809_2_1">Expert fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LitigationSettlementsGrantedForExpertFees" xlink:to="mrus_LitigationSettlementsGrantedForExpertFees_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts" xlink:label="mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts_lbl" xml:lang="en-US" id="id_14264487_3556810_3_1">Litigation settlements granted for litigation expenses and costs .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts_lbl" xml:lang="en-US" id="id_14264487_3556810_1_1">Litigation settlements granted for litigation expenses and costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts_lbl" xml:lang="en-US" id="id_14264487_3556810_2_1">Litigation expenses and costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts" xlink:to="mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ManagementAndAdministrationCostsMember" xlink:label="mrus_ManagementAndAdministrationCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ManagementAndAdministrationCostsMember_lbl" xml:lang="en-US" id="id_14264487_3514214_3_1">Management and administration costs [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ManagementAndAdministrationCostsMember_lbl" xml:lang="en-US" id="id_14264487_3514214_1_1">Management and administration costs [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ManagementAndAdministrationCostsMember_lbl" xml:lang="en-US" id="id_14264487_3514214_2_1">Management and administration costs [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ManagementAndAdministrationCostsMember" xlink:to="mrus_ManagementAndAdministrationCostsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ManufacturingCost" xlink:label="mrus_ManufacturingCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ManufacturingCost_lbl" xml:lang="en-US" id="id_14264487_3463230_3_1">Manufacturing cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ManufacturingCost_lbl" xml:lang="en-US" id="id_14264487_3463230_1_1">Manufacturing cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ManufacturingCost_lbl" xml:lang="en-US" id="id_14264487_3463230_2_1">Manufacturing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ManufacturingCost" xlink:to="mrus_ManufacturingCost_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MarkIwickiMember" xlink:label="mrus_MarkIwickiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_MarkIwickiMember_lbl" xml:lang="en-US" id="id_14264487_3505029_3_1">Mark Iwicki.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_MarkIwickiMember_lbl" xml:lang="en-US" id="id_14264487_3505029_1_1">Mark Iwicki [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_MarkIwickiMember_lbl" xml:lang="en-US" id="id_14264487_3505029_2_1">Mark Iwicki [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_MarkIwickiMember" xlink:to="mrus_MarkIwickiMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_lbl" xml:lang="en-US" id="id_14264487_3421967_1_1">Disclosure of maturity analysis for non-derivative financial liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_lbl" xml:lang="en-US" id="id_14264487_3421967_2_1">Summary of Contractual Maturities of Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:to="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAxis_lbl" xml:lang="en-US" id="id_14264487_3421968_1_1">Maturity [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MaturityAxis_lbl" xml:lang="en-US" id="id_14264487_3421968_2_1">Maturity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="ifrs-full_MaximumExposureToCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaximumExposureToCreditRisk_lbl" xml:lang="en-US" id="id_14264487_3421343_1_1">Maximum exposure to credit risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_MaximumExposureToCreditRisk_lbl" xml:lang="en-US" id="id_14264487_3421343_6_1">Maximum exposure to credit risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaximumExposureToCreditRisk" xlink:to="ifrs-full_MaximumExposureToCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MilestonePaymentReceived" xlink:label="mrus_MilestonePaymentReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_MilestonePaymentReceived_lbl" xml:lang="en-US" id="id_14264487_3442998_3_1">Milestone Payment Received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_MilestonePaymentReceived_lbl" xml:lang="en-US" id="id_14264487_3442998_1_1">Milestone Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_MilestonePaymentReceived_lbl" xml:lang="en-US" id="id_14264487_3442998_2_1">Milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_MilestonePaymentReceived" xlink:to="mrus_MilestonePaymentReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MilestoneRevenues" xlink:label="mrus_MilestoneRevenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_MilestoneRevenues_lbl" xml:lang="en-US" id="id_14264487_3433995_3_1">Milestone revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_MilestoneRevenues_lbl" xml:lang="en-US" id="id_14264487_3433995_1_1">Milestone revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_MilestoneRevenues_lbl" xml:lang="en-US" id="id_14264487_3433995_2_1">Milestone revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_MilestoneRevenues" xlink:to="mrus_MilestoneRevenues_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MilestoneRevenuesAndCostsReimbursements" xlink:label="mrus_MilestoneRevenuesAndCostsReimbursements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_MilestoneRevenuesAndCostsReimbursements_lbl" xml:lang="en-US" id="id_14264487_3434018_3_1">Milestone revenues and costs reimbursements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_MilestoneRevenuesAndCostsReimbursements_lbl" xml:lang="en-US" id="id_14264487_3434018_1_1">Milestone Revenues And Costs Reimbursements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_MilestoneRevenuesAndCostsReimbursements_lbl" xml:lang="en-US" id="id_14264487_3434018_2_1">Cost reimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_MilestoneRevenuesAndCostsReimbursements" xlink:to="mrus_MilestoneRevenuesAndCostsReimbursements_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease" xlink:label="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease_lbl" xml:lang="en-US" id="id_14264487_3421108_1_1">Minimum lease payments payable under non-cancellable operating lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease_lbl" xml:lang="en-US" id="id_14264487_3421108_2_1">Minimum lease payments payable under non cancellable operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease" xlink:to="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MitCambridgeRealEstateLlcMember" xlink:label="mrus_MitCambridgeRealEstateLlcMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_MitCambridgeRealEstateLlcMember_lbl" xml:lang="en-US" id="id_14264487_3556647_3_1">MIT Cambridge Real Estate LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_MitCambridgeRealEstateLlcMember_lbl" xml:lang="en-US" id="id_14264487_3556647_1_1">MIT Cambridge Real Estate LLC [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_MitCambridgeRealEstateLlcMember_lbl" xml:lang="en-US" id="id_14264487_3556647_2_1">MIT Cambridge Real Estate LLC [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_MitCambridgeRealEstateLlcMember" xlink:to="mrus_MitCambridgeRealEstateLlcMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NetFinanceIncomeExpenseMember" xlink:label="mrus_NetFinanceIncomeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NetFinanceIncomeExpenseMember_lbl" xml:lang="en-US" id="id_14264487_3486700_3_1">Net finance income expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NetFinanceIncomeExpenseMember_lbl" xml:lang="en-US" id="id_14264487_3486700_1_1">Net Finance Income Expense [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NetFinanceIncomeExpenseMember_lbl" xml:lang="en-US" id="id_14264487_3486700_2_1">Finance Income Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NetFinanceIncomeExpenseMember" xlink:to="mrus_NetFinanceIncomeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetForeignExchangeGain_lbl" xml:lang="en-US" id="id_14264487_3422463_1_1">Net foreign exchange gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NetForeignExchangeGain_lbl" xml:lang="en-US" id="id_14264487_3422463_2_1">Foreign currency exchange gains</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NetForeignExchangeGain_lbl" xml:lang="en-US" id="id_14264487_3422463_12_1">Net gain on foreign exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetForeignExchangeGain" xlink:to="ifrs-full_NetForeignExchangeGain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="ifrs-full_NetForeignExchangeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetForeignExchangeLoss_lbl" xml:lang="en-US" id="id_14264487_3422464_1_1">Net foreign exchange loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NetForeignExchangeLoss_lbl" xml:lang="en-US" id="id_14264487_3422464_14_1">Net loss on foreign exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetForeignExchangeLoss" xlink:to="ifrs-full_NetForeignExchangeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NetInterestIncomeAndExpenseTable" xlink:label="mrus_NetInterestIncomeAndExpenseTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NetInterestIncomeAndExpenseTable_lbl" xml:lang="en-US" id="id_14264487_3473899_3_1">Net Interest Income And Expense [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NetInterestIncomeAndExpenseTable_lbl" xml:lang="en-US" id="id_14264487_3473899_1_1">Net Interest Income And Expense [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NetInterestIncomeAndExpenseTable_lbl" xml:lang="en-US" id="id_14264487_3473899_2_1">Net Interest Income And Expense [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NetInterestIncomeAndExpenseTable" xlink:to="mrus_NetInterestIncomeAndExpenseTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NetProceedsFromIssuingShares" xlink:label="mrus_NetProceedsFromIssuingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NetProceedsFromIssuingShares_lbl" xml:lang="en-US" id="id_14264487_3464160_3_1">Net proceeds from issuing shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NetProceedsFromIssuingShares_lbl" xml:lang="en-US" id="id_14264487_3464160_1_1">Net Proceeds from issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NetProceedsFromIssuingShares_lbl" xml:lang="en-US" id="id_14264487_3464160_2_1">Proceeds from net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NetProceedsFromIssuingShares" xlink:to="mrus_NetProceedsFromIssuingShares_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember" xlink:label="mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember_lbl" xml:lang="en-US" id="id_14264487_3556805_3_1">New leases agreement for additional corporate headquarters space member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember_lbl" xml:lang="en-US" id="id_14264487_3556805_1_1">New leases agreement for additional corporate headquarters space member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember_lbl" xml:lang="en-US" id="id_14264487_3556805_2_1">New leases agreement for additional corporate headquarters space member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember" xlink:to="mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_NL" xlink:label="country_NL"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_NL_lbl" xml:lang="en-US" id="id_14264487_3421581_1_1">NETHERLANDS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_NL_lbl" xml:lang="en-US" id="id_14264487_3421581_2_1">Netherlands [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="country_NL_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NonAdjustingEventMember" xlink:label="mrus_NonAdjustingEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NonAdjustingEventMember_lbl" xml:lang="en-US" id="id_14264487_3537338_3_1">Non adjusting event.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NonAdjustingEventMember_lbl" xml:lang="en-US" id="id_14264487_3537338_1_1">Non adjusting event [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NonAdjustingEventMember_lbl" xml:lang="en-US" id="id_14264487_3537338_2_1">Non adjusting event [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NonAdjustingEventMember" xlink:to="mrus_NonAdjustingEventMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US" id="id_14264487_3421584_1_1">Non-adjusting events after reporting period [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US" id="id_14264487_3421584_2_1">Non-adjusting events after reporting period [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xml:lang="en-US" id="id_14264487_3421585_1_1">Non-adjusting events after reporting period [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xml:lang="en-US" id="id_14264487_3421585_2_1">Non-adjusting events after reporting period [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_NonadjustingEventsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" id="id_14264487_3421635_1_1">Non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" id="id_14264487_3421635_6_1">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" id="id_14264487_3422476_1_1">Non-current assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" id="id_14264487_3422476_2_1">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:label="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3426637_3_1">Non current assets finance liabilities abstract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3426637_1_1">Non Current Assets Finance Liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3426637_2_1">Non Current Assets Finance Liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:to="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentHeldtomaturityInvestments" xlink:label="ifrs-full_NoncurrentHeldtomaturityInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentHeldtomaturityInvestments_lbl" xml:lang="en-US" id="id_14264487_3422491_1_1">Non-current held-to-maturity investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentHeldtomaturityInvestments_lbl" xml:lang="en-US" id="id_14264487_3422491_2_1">Non-current investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentHeldtomaturityInvestments" xlink:to="ifrs-full_NoncurrentHeldtomaturityInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3422334_1_1">Non-current liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3422334_2_1">Non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_lbl" xml:lang="en-US" id="id_14264487_3422049_1_1">Non-derivative financial liabilities, undiscounted cash flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_lbl" xml:lang="en-US" id="id_14264487_3422049_6_1">Non-derivative financial liabilities undiscounted cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NonexecutiveCompensationProgramMember" xlink:label="mrus_NonexecutiveCompensationProgramMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NonexecutiveCompensationProgramMember_lbl" xml:lang="en-US" id="id_14264487_3514208_3_1">Non-Executive Compensation Program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NonexecutiveCompensationProgramMember_lbl" xml:lang="en-US" id="id_14264487_3514208_1_1">Non-Executive Compensation Program [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NonexecutiveCompensationProgramMember_lbl" xml:lang="en-US" id="id_14264487_3514208_2_1">Non-Executive Compensation Program [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NonexecutiveCompensationProgramMember" xlink:to="mrus_NonexecutiveCompensationProgramMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NonRefundableUpfrontPaymentsReceivable" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable_lbl" xml:lang="en-US" id="id_14264487_3463395_3_1">Non-refundable upfront payments receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable_lbl" xml:lang="en-US" id="id_14264487_3463395_1_1">Non Refundable Upfront Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable_lbl" xml:lang="en-US" id="id_14264487_3463395_2_1">Non-refundable upfront payment receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NonRefundableUpfrontPaymentsReceivable" xlink:to="mrus_NonRefundableUpfrontPaymentsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US" id="id_14264487_3422054_1_1">Not later than one year [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US" id="id_14264487_3422054_2_1">Less than one year [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfCommonShareEntitledToReceive" xlink:label="mrus_NumberOfCommonShareEntitledToReceive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NumberOfCommonShareEntitledToReceive_lbl" xml:lang="en-US" id="id_14264487_3471855_3_1">Number of common share entitled to receive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NumberOfCommonShareEntitledToReceive_lbl" xml:lang="en-US" id="id_14264487_3471855_1_1">Number of common share entitled to receive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NumberOfCommonShareEntitledToReceive_lbl" xml:lang="en-US" id="id_14264487_3471855_2_1">Number of common share entitled to receive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NumberOfCommonShareEntitledToReceive" xlink:to="mrus_NumberOfCommonShareEntitledToReceive_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfEmployees" xlink:label="ifrs-full_NumberOfEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfEmployees_lbl" xml:lang="en-US" id="id_14264487_3422055_1_1">Number of employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfEmployees_lbl" xml:lang="en-US" id="id_14264487_3422055_2_1">Number of employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfEmployees" xlink:to="ifrs-full_NumberOfEmployees_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" id="id_14264487_3422508_1_1">Number of other equity instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" id="id_14264487_3422508_2_1">Granted during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod" xlink:label="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod_lbl" xml:lang="en-US" id="id_14264487_3472932_3_1">Number of instruments other equity instruments vesting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod_lbl" xml:lang="en-US" id="id_14264487_3472932_1_1">Number Of Instruments Other Equity Instruments vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod_lbl" xml:lang="en-US" id="id_14264487_3472932_2_1">Vesting period of Restricted Stock Units vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod" xlink:to="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers" xlink:label="mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers_lbl" xml:lang="en-US" id="id_14264487_3432949_3_1">Number of options held by the chief executive officers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers_lbl" xml:lang="en-US" id="id_14264487_3432949_1_1">Number of options held by the chief executive officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers_lbl" xml:lang="en-US" id="id_14264487_3432949_2_1">Number of options held by the chief executive officers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers" xlink:to="mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard" xlink:label="mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard_lbl" xml:lang="en-US" id="id_14264487_3432950_3_1">Number of options held by the members of supervisory board.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard_lbl" xml:lang="en-US" id="id_14264487_3432950_1_1">Number of options held by the members of supervisory board</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard_lbl" xml:lang="en-US" id="id_14264487_3432950_2_1">Number of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard" xlink:to="mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers" xlink:label="mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers_lbl" xml:lang="en-US" id="id_14264487_3433180_3_1">Number of options of other equity instruments held by the chief executive officers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers_lbl" xml:lang="en-US" id="id_14264487_3433180_1_1">Number of options of other equity instruments held by the chief executive officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers_lbl" xml:lang="en-US" id="id_14264487_3433180_2_1">Number of RSU held</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers" xlink:to="mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3421677_1_1">Number of other equity instruments exercised or vested in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3421677_2_1">Vesting of RSUs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3421677_14_1">Vested during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3422352_1_1">Number of other equity instruments expired in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3422352_14_1">Expired during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3421678_1_1">Number of other equity instruments forfeited in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3421678_14_1">Forfeited during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3422353_1_1">Number of other equity instruments outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3422353_4_1">Unvested ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3422353_5_1">Unvested beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US" id="id_14264487_3421679_1_1">Number of share options outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US" id="id_14264487_3421679_4_1">Outstanding at December 31</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US" id="id_14264487_3421679_5_1">Outstanding at January 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US" id="id_14264487_3421679_2_1">Number of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfReportableSegments1" xlink:label="mrus_NumberOfReportableSegments1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NumberOfReportableSegments1_lbl" xml:lang="en-US" id="id_14264487_3471616_3_1">Number of reportable segments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NumberOfReportableSegments1_lbl" xml:lang="en-US" id="id_14264487_3471616_1_1">Number of Reportable Segments1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NumberOfReportableSegments1_lbl" xml:lang="en-US" id="id_14264487_3471616_2_1">Number of reportable segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NumberOfReportableSegments1" xlink:to="mrus_NumberOfReportableSegments1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3422355_1_1">Number of share options exercisable in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3422355_2_1">Exercisable at December 31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3422356_1_1">Number of share options exercised in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3422356_2_1">Exercise of common share options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3422356_14_1">Exercised during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3421681_1_1">Number of share options expired in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3421681_14_1">Expired during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3421682_1_1">Number of share options forfeited in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3421682_14_1">Forfeited during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3422057_1_1">Number of share options granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3422057_2_1">Granted during the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3422057_12_1">Number of options allocated to Chief Medical Officer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfSharesIssuable" xlink:label="mrus_NumberOfSharesIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NumberOfSharesIssuable_lbl" xml:lang="en-US" id="id_14264487_3468895_3_1">The number of shares which may be issued by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NumberOfSharesIssuable_lbl" xml:lang="en-US" id="id_14264487_3468895_1_1">Number Of Shares Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NumberOfSharesIssuable_lbl" xml:lang="en-US" id="id_14264487_3468895_2_1">Common shares issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NumberOfSharesIssuable" xlink:to="mrus_NumberOfSharesIssuable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" id="id_14264487_3422510_1_1">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" id="id_14264487_3422510_2_1">Common shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" xml:lang="en-US" id="id_14264487_3421685_1_1">Number of shares issued and fully paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" xml:lang="en-US" id="id_14264487_3421685_2_1">Number of shares fully issued and paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfSharesIssuedForCash" xlink:label="mrus_NumberOfSharesIssuedForCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NumberOfSharesIssuedForCash_lbl" xml:lang="en-US" id="id_14264487_3468194_3_1">Number of shares issued for cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NumberOfSharesIssuedForCash_lbl" xml:lang="en-US" id="id_14264487_3468194_1_1">Number of shares issued for cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NumberOfSharesIssuedForCash_lbl" xml:lang="en-US" id="id_14264487_3468194_2_1">Issued for cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NumberOfSharesIssuedForCash" xlink:to="mrus_NumberOfSharesIssuedForCash_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" id="id_14264487_3422357_1_1">Number of shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" id="id_14264487_3422357_4_1">Common shares outstanding, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" id="id_14264487_3422357_5_1">Common Shares outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumeratorComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:label="mrus_NumeratorComputationOfBasicAndDilutedEarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NumeratorComputationOfBasicAndDilutedEarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_14264487_3429558_3_1">Numerator Computation Of Basic And Diluted Earnings Per Share [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NumeratorComputationOfBasicAndDilutedEarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_14264487_3429558_1_1">Numerator Computation Of Basic And Diluted Earnings Per Share [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NumeratorComputationOfBasicAndDilutedEarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_14264487_3429558_2_1">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NumeratorComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="mrus_NumeratorComputationOfBasicAndDilutedEarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OnoResearchAndLicenseAgreementMember" xlink:label="mrus_OnoResearchAndLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OnoResearchAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_14264487_3513897_3_1">ONO Research And License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OnoResearchAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_14264487_3513897_1_1">ONO Research And License Agreement [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OnoResearchAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_14264487_3513897_2_1">ONO Research and License Agreement [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OnoResearchAndLicenseAgreementMember" xlink:to="mrus_OnoResearchAndLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OperatingExpense_lbl" xml:lang="en-US" id="id_14264487_3422069_1_1">Operating expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OperatingExpense_lbl" xml:lang="en-US" id="id_14264487_3422069_2_1">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OperatingExpense_lbl" xml:lang="en-US" id="id_14264487_3422069_6_1">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_OperatingExpense_lbl" xml:lang="en-US" id="id_14264487_3422069_19_1">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_OperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:label="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract_lbl" xml:lang="en-US" id="id_14264487_3429119_3_1">Disclosure of operating expenses from railroad and related business.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract_lbl" xml:lang="en-US" id="id_14264487_3429119_1_1">Operating expenses from railroad and related business [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract_lbl" xml:lang="en-US" id="id_14264487_3429119_2_1">Operating expenses from railroad and related business [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OperatingLeaseTermOfLeaseAgreement" xlink:label="mrus_OperatingLeaseTermOfLeaseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OperatingLeaseTermOfLeaseAgreement_lbl" xml:lang="en-US" id="id_14264487_3472898_3_1">Operating lease term of lease agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OperatingLeaseTermOfLeaseAgreement_lbl" xml:lang="en-US" id="id_14264487_3472898_1_1">Operating lease term of lease agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OperatingLeaseTermOfLeaseAgreement_lbl" xml:lang="en-US" id="id_14264487_3472898_2_1">Operating lease term of lease agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OperatingLeaseTermOfLeaseAgreement" xlink:to="mrus_OperatingLeaseTermOfLeaseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OptionCostMember" xlink:label="mrus_OptionCostMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OptionCostMember_lbl" xml:lang="en-US" id="id_14264487_3506232_3_1">Option cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OptionCostMember_lbl" xml:lang="en-US" id="id_14264487_3506232_1_1">Option cost [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OptionCostMember_lbl" xml:lang="en-US" id="id_14264487_3506232_2_1">Option cost [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OptionCostMember" xlink:to="mrus_OptionCostMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" id="id_14264487_3422519_1_1">Ordinary shares [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" id="id_14264487_3422519_2_1">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherAccruals" xlink:label="mrus_OtherAccruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OtherAccruals_lbl" xml:lang="en-US" id="id_14264487_3436382_3_1">Other accruals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OtherAccruals_lbl" xml:lang="en-US" id="id_14264487_3436382_1_1">Other Accruals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OtherAccruals_lbl" xml:lang="en-US" id="id_14264487_3436382_2_1">Other accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OtherAccruals" xlink:to="mrus_OtherAccruals_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherAssetsMember" xlink:label="ifrs-full_OtherAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAssetsMember_lbl" xml:lang="en-US" id="id_14264487_3422077_1_1">Other assets [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherAssetsMember_lbl" xml:lang="en-US" id="id_14264487_3422077_2_1">Other assets [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssetsMember" xlink:to="ifrs-full_OtherAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" id="id_14264487_3422081_1_1">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" id="id_14264487_3422081_2_1">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" id="id_14264487_3422081_12_1">Total other comprehensive income for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="id_14264487_3422082_1_1">Other comprehensive income [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="id_14264487_3422082_2_1">Other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" id="id_14264487_3422537_1_1">Other comprehensive income, net of tax, exchange differences on translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" id="id_14264487_3422537_2_1">Exchange differences from translation of foreign operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US" id="id_14264487_3422548_1_1">Other current receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US" id="id_14264487_3422548_2_1">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherExpenseByNature" xlink:label="ifrs-full_OtherExpenseByNature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherExpenseByNature_lbl" xml:lang="en-US" id="id_14264487_3422558_1_1">Other expenses, by nature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherExpenseByNature_lbl" xml:lang="en-US" id="id_14264487_3422558_6_1">Total other expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherExpenseByNature_lbl" xml:lang="en-US" id="id_14264487_3422558_14_1">Other expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherExpensesMember" xlink:label="mrus_OtherExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OtherExpensesMember_lbl" xml:lang="en-US" id="id_14264487_3491841_3_1">Other expenses [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OtherExpensesMember_lbl" xml:lang="en-US" id="id_14264487_3491841_1_1">Other expenses [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OtherExpensesMember_lbl" xml:lang="en-US" id="id_14264487_3491841_2_1">Other expenses [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OtherExpensesMember" xlink:to="mrus_OtherExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherExternalAndOutsourcedCosts" xlink:label="mrus_OtherExternalAndOutsourcedCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OtherExternalAndOutsourcedCosts_lbl" xml:lang="en-US" id="id_14264487_3464168_3_1">Other external and outsourced costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OtherExternalAndOutsourcedCosts_lbl" xml:lang="en-US" id="id_14264487_3464168_1_1">Other external and outsourced costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OtherExternalAndOutsourcedCosts_lbl" xml:lang="en-US" id="id_14264487_3464168_2_1">Other external and outsourced costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OtherExternalAndOutsourcedCosts" xlink:to="mrus_OtherExternalAndOutsourcedCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherFinanceIncome" xlink:label="ifrs-full_OtherFinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFinanceIncome_lbl" xml:lang="en-US" id="id_14264487_3421725_1_1">Other finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherFinanceIncome_lbl" xml:lang="en-US" id="id_14264487_3421725_2_1">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncome" xlink:to="ifrs-full_OtherFinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="ifrs-full_OtherFinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFinanceIncomeCost_lbl" xml:lang="en-US" id="id_14264487_3422560_1_1">Other finance income (cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherFinanceIncomeCost_lbl" xml:lang="en-US" id="id_14264487_3422560_6_1">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncomeCost" xlink:to="ifrs-full_OtherFinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherFundingCommitmentsMember" xlink:label="mrus_OtherFundingCommitmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OtherFundingCommitmentsMember_lbl" xml:lang="en-US" id="id_14264487_3558220_3_1">Other funding commitments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OtherFundingCommitmentsMember_lbl" xml:lang="en-US" id="id_14264487_3558220_1_1">Other Funding Commitments [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OtherFundingCommitmentsMember_lbl" xml:lang="en-US" id="id_14264487_3558220_2_1">Other funding commitments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OtherFundingCommitmentsMember" xlink:to="mrus_OtherFundingCommitmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherIncome" xlink:label="ifrs-full_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US" id="id_14264487_3421727_1_1">Other income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US" id="id_14264487_3421727_2_1">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherIncomeExpense" xlink:label="mrus_OtherIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OtherIncomeExpense_lbl" xml:lang="en-US" id="id_14264487_3441308_3_1">Other income (expense).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OtherIncomeExpense_lbl" xml:lang="en-US" id="id_14264487_3441308_1_1">Other Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OtherIncomeExpense_lbl" xml:lang="en-US" id="id_14264487_3441308_2_1">Total other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OtherIncomeExpense" xlink:to="mrus_OtherIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows" xlink:label="mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows_lbl" xml:lang="en-US" id="id_14264487_3464207_3_1">Other liabilities and accruals, undiscounted cash flows.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows_lbl" xml:lang="en-US" id="id_14264487_3464207_1_1">Other liabilities and accruals, undiscounted cash flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows_lbl" xml:lang="en-US" id="id_14264487_3464207_2_1">Other liabilities and accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows" xlink:to="mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US" id="id_14264487_3421733_1_1">Other non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US" id="id_14264487_3421733_2_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherOperatingExpenses" xlink:label="mrus_OtherOperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OtherOperatingExpenses_lbl" xml:lang="en-US" id="id_14264487_3459137_3_1">Other operating expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OtherOperatingExpenses_lbl" xml:lang="en-US" id="id_14264487_3459137_1_1">Other Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OtherOperatingExpenses_lbl" xml:lang="en-US" id="id_14264487_3459137_2_1">Other operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OtherOperatingExpenses" xlink:to="mrus_OtherOperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" id="id_14264487_3421738_1_1">Other property, plant and equipment [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" id="id_14264487_3421738_2_1">Other fixed assets [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherResearchAndDevelopmentExpenseOther" xlink:label="mrus_OtherResearchAndDevelopmentExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OtherResearchAndDevelopmentExpenseOther_lbl" xml:lang="en-US" id="id_14264487_3449705_3_1">Other research and development expense other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OtherResearchAndDevelopmentExpenseOther_lbl" xml:lang="en-US" id="id_14264487_3449705_1_1">Other research and development expense other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OtherResearchAndDevelopmentExpenseOther_lbl" xml:lang="en-US" id="id_14264487_3449705_2_1">Other R&amp;D costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OtherResearchAndDevelopmentExpenseOther" xlink:to="mrus_OtherResearchAndDevelopmentExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherResearchAndDevelopmentExpenses" xlink:label="mrus_OtherResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OtherResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" id="id_14264487_3463232_3_1">Other research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OtherResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" id="id_14264487_3463232_1_1">Other research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OtherResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" id="id_14264487_3463232_2_1">Other R&amp;D costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="mrus_OtherResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" id="id_14264487_3463232_6_1">Total other R&amp;D costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OtherResearchAndDevelopmentExpenses" xlink:to="mrus_OtherResearchAndDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherShorttermEmployeeBenefits" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits_lbl" xml:lang="en-US" id="id_14264487_3422113_1_1">Other short-term employee benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits_lbl" xml:lang="en-US" id="id_14264487_3422113_2_1">Other personnel expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherShorttermEmployeeBenefits" xlink:to="ifrs-full_OtherShorttermEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OverAllotmentOption1Member" xlink:label="mrus_OverAllotmentOption1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OverAllotmentOption1Member_lbl" xml:lang="en-US" id="id_14264487_3486453_3_1">Over-allotment option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OverAllotmentOption1Member_lbl" xml:lang="en-US" id="id_14264487_3486453_1_1">Over Allotment Option 1 [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OverAllotmentOption1Member_lbl" xml:lang="en-US" id="id_14264487_3486453_2_1">Over allotment option [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OverAllotmentOption1Member" xlink:to="mrus_OverAllotmentOption1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" id="id_14264487_3422421_1_1">Par value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" id="id_14264487_3422421_2_1">Issue price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PatentsAndIntellectualPropertyMember" xlink:label="mrus_PatentsAndIntellectualPropertyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PatentsAndIntellectualPropertyMember_lbl" xml:lang="en-US" id="id_14264487_3508720_3_1">Patents and intellectual property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PatentsAndIntellectualPropertyMember_lbl" xml:lang="en-US" id="id_14264487_3508720_1_1">Patents and intellectual property [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PatentsAndIntellectualPropertyMember_lbl" xml:lang="en-US" id="id_14264487_3508720_2_1">Patents and intellectual property [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PatentsAndIntellectualPropertyMember" xlink:to="mrus_PatentsAndIntellectualPropertyMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PaymentOfPropertyPlantAndEquipment" xlink:label="mrus_PaymentOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PaymentOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3449645_3_1">Payment of Property Plant and Equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PaymentOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3449645_1_1">Payment of property plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PaymentOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3449645_2_1">Purchase property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PaymentOfPropertyPlantAndEquipment" xlink:to="mrus_PaymentOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PaymentsForDebtIssueCosts" xlink:label="ifrs-full_PaymentsForDebtIssueCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsForDebtIssueCosts_lbl" xml:lang="en-US" id="id_14264487_3422577_1_1">Payments for debt issue costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsForDebtIssueCosts_lbl" xml:lang="en-US" id="id_14264487_3422577_14_1">Financing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForDebtIssueCosts" xlink:to="ifrs-full_PaymentsForDebtIssueCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US" id="id_14264487_3422581_1_1">Payments for share issue costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US" id="id_14264487_3422581_14_1">Prepaid share issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PensionCosts" xlink:label="mrus_PensionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PensionCosts_lbl" xml:lang="en-US" id="id_14264487_3457490_3_1">Pension costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PensionCosts_lbl" xml:lang="en-US" id="id_14264487_3457490_1_1">Pension costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PensionCosts_lbl" xml:lang="en-US" id="id_14264487_3457490_2_1">Pension costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PensionCosts" xlink:to="mrus_PensionCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PensionMember" xlink:label="mrus_PensionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PensionMember_lbl" xml:lang="en-US" id="id_14264487_3556606_3_1">Pension [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PensionMember_lbl" xml:lang="en-US" id="id_14264487_3556606_1_1">Pension [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PensionMember_lbl" xml:lang="en-US" id="id_14264487_3556606_2_1">Pension [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PensionMember" xlink:to="mrus_PensionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfAggregateCompensationPayable" xlink:label="mrus_PercentageOfAggregateCompensationPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PercentageOfAggregateCompensationPayable_lbl" xml:lang="en-US" id="id_14264487_3528631_3_1">Percentage of aggregate compensation payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PercentageOfAggregateCompensationPayable_lbl" xml:lang="en-US" id="id_14264487_3528631_1_1">Percentage Of Aggregate Compensation Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PercentageOfAggregateCompensationPayable_lbl" xml:lang="en-US" id="id_14264487_3528631_2_1">Aggregate compensation payable, percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PercentageOfAggregateCompensationPayable" xlink:to="mrus_PercentageOfAggregateCompensationPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfInitialVestingOptions" xlink:label="mrus_PercentageOfInitialVestingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PercentageOfInitialVestingOptions_lbl" xml:lang="en-US" id="id_14264487_3528547_3_1">Percentage of initial vesting options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PercentageOfInitialVestingOptions_lbl" xml:lang="en-US" id="id_14264487_3528547_1_1">Percentage of initial vesting options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PercentageOfInitialVestingOptions_lbl" xml:lang="en-US" id="id_14264487_3528547_2_1">Percentage of initial vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PercentageOfInitialVestingOptions" xlink:to="mrus_PercentageOfInitialVestingOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfOwnershipInterestByShareholders" xlink:label="mrus_PercentageOfOwnershipInterestByShareholders"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PercentageOfOwnershipInterestByShareholders_lbl" xml:lang="en-US" id="id_14264487_3524219_3_1">Percentage of ownership interest by shareholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PercentageOfOwnershipInterestByShareholders_lbl" xml:lang="en-US" id="id_14264487_3524219_1_1">Percentage of ownership interest by shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PercentageOfOwnershipInterestByShareholders_lbl" xml:lang="en-US" id="id_14264487_3524219_2_1">Ownership interest held by shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PercentageOfOwnershipInterestByShareholders" xlink:to="mrus_PercentageOfOwnershipInterestByShareholders_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfRemainingVestingOptions" xlink:label="mrus_PercentageOfRemainingVestingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PercentageOfRemainingVestingOptions_lbl" xml:lang="en-US" id="id_14264487_3528546_3_1">Percentage of remaining vesting options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PercentageOfRemainingVestingOptions_lbl" xml:lang="en-US" id="id_14264487_3528546_1_1">Percentage of remaining vesting options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PercentageOfRemainingVestingOptions_lbl" xml:lang="en-US" id="id_14264487_3528546_2_1">Percentage of remaining vesting options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PercentageOfRemainingVestingOptions" xlink:to="mrus_PercentageOfRemainingVestingOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod" xlink:label="mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod_lbl" xml:lang="en-US" id="id_14264487_3528759_3_1">Percentage of severance payment being paid in form of salary continuation over the six-month period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod_lbl" xml:lang="en-US" id="id_14264487_3528759_1_1">Percentage of severance payment being paid in form of salary continuation over six-month period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod_lbl" xml:lang="en-US" id="id_14264487_3528759_2_1">Percentage of severance payment being paid in form of salary continuation over six-month period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod" xlink:to="mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfSeverancePaymentPaid" xlink:label="mrus_PercentageOfSeverancePaymentPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PercentageOfSeverancePaymentPaid_lbl" xml:lang="en-US" id="id_14264487_3528760_3_1">Percentage of severance payment paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PercentageOfSeverancePaymentPaid_lbl" xml:lang="en-US" id="id_14264487_3528760_1_1">Percentage of severance payment paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PercentageOfSeverancePaymentPaid_lbl" xml:lang="en-US" id="id_14264487_3528760_2_1">Percentage of severance payment paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PercentageOfSeverancePaymentPaid" xlink:to="mrus_PercentageOfSeverancePaymentPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfVestingOptions" xlink:label="mrus_PercentageOfVestingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PercentageOfVestingOptions_lbl" xml:lang="en-US" id="id_14264487_3528548_3_1">Percentage of vesting options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PercentageOfVestingOptions_lbl" xml:lang="en-US" id="id_14264487_3528548_1_1">Percentage of vesting options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PercentageOfVestingOptions_lbl" xml:lang="en-US" id="id_14264487_3528548_2_1">Percentage of vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PercentageOfVestingOptions" xlink:to="mrus_PercentageOfVestingOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PeriodOfAwardsWillBeVestedAndExercised" xlink:label="mrus_PeriodOfAwardsWillBeVestedAndExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PeriodOfAwardsWillBeVestedAndExercised_lbl" xml:lang="en-US" id="id_14264487_3470883_3_1">Period of awards will be vested and exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PeriodOfAwardsWillBeVestedAndExercised_lbl" xml:lang="en-US" id="id_14264487_3470883_1_1">Period of awards will be vested and exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PeriodOfAwardsWillBeVestedAndExercised_lbl" xml:lang="en-US" id="id_14264487_3470883_2_1">Period of option will be vested and exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PeriodOfAwardsWillBeVestedAndExercised" xlink:to="mrus_PeriodOfAwardsWillBeVestedAndExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions" xlink:label="mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions_lbl" xml:lang="en-US" id="id_14264487_3470857_3_1">Period of option to exercise treated as non vesting conditions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions_lbl" xml:lang="en-US" id="id_14264487_3470857_1_1">Period of option to exercise treated as non vesting conditions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions_lbl" xml:lang="en-US" id="id_14264487_3470857_2_1">Period of option to exercise treated as non-vesting condition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions" xlink:to="mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PeriodOfRemainingOptionsVestingPeriod" xlink:label="mrus_PeriodOfRemainingOptionsVestingPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PeriodOfRemainingOptionsVestingPeriod_lbl" xml:lang="en-US" id="id_14264487_3470860_3_1">Period of remaining options vesting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PeriodOfRemainingOptionsVestingPeriod_lbl" xml:lang="en-US" id="id_14264487_3470860_1_1">Period of remaining options vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PeriodOfRemainingOptionsVestingPeriod_lbl" xml:lang="en-US" id="id_14264487_3470860_2_1">Period of remaining option vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PeriodOfRemainingOptionsVestingPeriod" xlink:to="mrus_PeriodOfRemainingOptionsVestingPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards" xlink:label="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards_lbl" xml:lang="en-US" id="id_14264487_3470858_3_1">Period of vesting installments of initial vesting awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards_lbl" xml:lang="en-US" id="id_14264487_3470858_1_1">Period of vesting installments of initial vesting awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards_lbl" xml:lang="en-US" id="id_14264487_3470858_2_1">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards" xlink:to="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PersonnelRelatedResearchAndDevelopmentExpense" xlink:label="mrus_PersonnelRelatedResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PersonnelRelatedResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_14264487_3463231_3_1">Personnel related research and development expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PersonnelRelatedResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_14264487_3463231_1_1">Personnel related research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PersonnelRelatedResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_14264487_3463231_2_1">Personnel related R&amp;D</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PersonnelRelatedResearchAndDevelopmentExpense" xlink:to="mrus_PersonnelRelatedResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PeterSilvermanSeniorVicePresidentMember" xlink:label="mrus_PeterSilvermanSeniorVicePresidentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PeterSilvermanSeniorVicePresidentMember_lbl" xml:lang="en-US" id="id_14264487_3494322_3_1">Peter Silverman Senior Vice President.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PeterSilvermanSeniorVicePresidentMember_lbl" xml:lang="en-US" id="id_14264487_3494322_1_1">Peter Silverman Senior Vice President [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PeterSilvermanSeniorVicePresidentMember_lbl" xml:lang="en-US" id="id_14264487_3494322_2_1">Peter Silverman Senior Vice President [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PeterSilvermanSeniorVicePresidentMember" xlink:to="mrus_PeterSilvermanSeniorVicePresidentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PlantAndEquipmentMember" xlink:label="mrus_PlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PlantAndEquipmentMember_lbl" xml:lang="en-US" id="id_14264487_3509419_3_1">Plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PlantAndEquipmentMember_lbl" xml:lang="en-US" id="id_14264487_3509419_1_1">Plant and equipment [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PlantAndEquipmentMember_lbl" xml:lang="en-US" id="id_14264487_3509419_2_1">Plant and equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PlantAndEquipmentMember" xlink:to="mrus_PlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PreclinicalCosts" xlink:label="mrus_PreclinicalCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PreclinicalCosts_lbl" xml:lang="en-US" id="id_14264487_3449733_3_1">Preclinical costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PreclinicalCosts_lbl" xml:lang="en-US" id="id_14264487_3449733_1_1">Preclinical costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PreclinicalCosts_lbl" xml:lang="en-US" id="id_14264487_3449733_2_1">Preclinical costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PreclinicalCosts" xlink:to="mrus_PreclinicalCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PrepaidShareIssueRelatedCost" xlink:label="mrus_PrepaidShareIssueRelatedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PrepaidShareIssueRelatedCost_lbl" xml:lang="en-US" id="id_14264487_3463226_3_1">Prepaid share issue related cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PrepaidShareIssueRelatedCost_lbl" xml:lang="en-US" id="id_14264487_3463226_1_1">Prepaid share issue related cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PrepaidShareIssueRelatedCost_lbl" xml:lang="en-US" id="id_14264487_3463226_2_1">Issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PrepaidShareIssueRelatedCost" xlink:to="mrus_PrepaidShareIssueRelatedCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PreviouslyStatedMember_lbl" xml:lang="en-US" id="id_14264487_3422609_1_1">Previously stated [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PreviouslyStatedMember_lbl" xml:lang="en-US" id="id_14264487_3422609_2_1">Previously stated [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreviouslyStatedMember" xlink:to="ifrs-full_PreviouslyStatedMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ProceedsFromCollaborationAgreement" xlink:label="mrus_ProceedsFromCollaborationAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ProceedsFromCollaborationAgreement_lbl" xml:lang="en-US" id="id_14264487_3447310_3_1">Proceeds from collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ProceedsFromCollaborationAgreement_lbl" xml:lang="en-US" id="id_14264487_3447310_1_1">Proceeds from collaboration agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ProceedsFromCollaborationAgreement_lbl" xml:lang="en-US" id="id_14264487_3447310_2_1">Proceeds from collaboration and license agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ProceedsFromCollaborationAgreement" xlink:to="mrus_ProceedsFromCollaborationAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xml:lang="en-US" id="id_14264487_3421781_1_1">Proceeds from exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xml:lang="en-US" id="id_14264487_3421781_2_1">Proceeds from stock option exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US" id="id_14264487_3422155_1_1">Proceeds from issue of ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US" id="id_14264487_3422155_32_1">Total proceeds received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US" id="id_14264487_3422155_2_1">Aggregate purchase price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US" id="id_14264487_3422155_12_1">Proceeds from issue of common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" id="id_14264487_3422452_1_1">Proceeds from issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" id="id_14264487_3422452_2_1">Aggregate purchase price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" id="id_14264487_3422452_12_1">Proceeds from issuing shares, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_14264487_3423106_1_1">Proceeds from sales or maturity of financial instruments, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_14264487_3423106_2_1">Proceeds from investment maturities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" id="id_14264487_3422158_1_1">Product and Service [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" id="id_14264487_3422158_2_1">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" id="id_14264487_3422159_1_1">Product and Service [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" id="id_14264487_3422159_2_1">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US" id="id_14264487_3423109_1_1">Professional fees expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US" id="id_14264487_3423109_2_1">Expenses related to professional fees for consulting, audit, and tax services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" id="id_14264487_3423110_1_1">Profit (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" id="id_14264487_3423110_2_1">Restated result after taxation for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" id="id_14264487_3423110_6_1">Result after taxation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" id="id_14264487_3423110_12_1">Result after taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" id="id_14264487_3422161_1_1">Profit (loss) before tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" id="id_14264487_3422161_6_1">Result before taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" id="id_14264487_3422167_1_1">Profit (loss) from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" id="id_14264487_3422167_2_1">Operating result</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" id="id_14264487_3422167_6_1">Operating result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3423123_1_1">Property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3423123_4_1">Property, plant and equipment, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3423123_5_1">Property, plant and equipment, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3423123_2_1">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" id="id_14264487_3422628_1_1">Property, plant and equipment [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" id="id_14264487_3422628_2_1">Property, plant and equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_14264487_3422686_1_1">Purchase of financial instruments, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_14264487_3422686_2_1">Purchases of investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_14264487_3422686_14_1">Purchases of investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_14264487_3423149_1_1">Purchase of intangible assets, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_14264487_3423149_2_1">Purchase of intellectual property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_14264487_3423149_14_1">Purchase of intellectual property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_14264487_3422688_1_1">Purchase of property, plant and equipment, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_14264487_3422688_14_1">Acquisition of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PurchasePricePerCommonShare" xlink:label="mrus_PurchasePricePerCommonShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PurchasePricePerCommonShare_lbl" xml:lang="en-US" id="id_14264487_3522436_3_1">Purchase price per common share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PurchasePricePerCommonShare_lbl" xml:lang="en-US" id="id_14264487_3522436_1_1">Purchase Price Per Common Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PurchasePricePerCommonShare_lbl" xml:lang="en-US" id="id_14264487_3522436_2_1">Purchase price per common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PurchasePricePerCommonShare" xlink:to="mrus_PurchasePricePerCommonShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US" id="id_14264487_3422662_1_1">Range [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US" id="id_14264487_3422662_2_1">Range [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" id="id_14264487_3422700_1_1">Ranges [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" id="id_14264487_3422700_2_1">Ranges [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RegeneronPharmaceuticalsIncMember" xlink:label="mrus_RegeneronPharmaceuticalsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RegeneronPharmaceuticalsIncMember_lbl" xml:lang="en-US" id="id_14264487_3481669_3_1">Regeneron pharmaceuticals, INC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RegeneronPharmaceuticalsIncMember_lbl" xml:lang="en-US" id="id_14264487_3481669_1_1">Regeneron Pharmaceuticals, INC [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RegeneronPharmaceuticalsIncMember_lbl" xml:lang="en-US" id="id_14264487_3481669_2_1">Regeneron Pharmaceuticals, INC [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RegeneronPharmaceuticalsIncMember" xlink:to="mrus_RegeneronPharmaceuticalsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RegeneronSubscriptionAgreementMember" xlink:label="mrus_RegeneronSubscriptionAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RegeneronSubscriptionAgreementMember_lbl" xml:lang="en-US" id="id_14264487_3556559_3_1">Regeneron Subscription Agreement [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RegeneronSubscriptionAgreementMember_lbl" xml:lang="en-US" id="id_14264487_3556559_1_1">Regeneron Subscription Agreement [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RegeneronSubscriptionAgreementMember_lbl" xml:lang="en-US" id="id_14264487_3556559_2_1">Regeneron Subscription Agreement [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RegeneronSubscriptionAgreementMember" xlink:to="mrus_RegeneronSubscriptionAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ReimbursementOfExpenses" xlink:label="mrus_ReimbursementOfExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ReimbursementOfExpenses_lbl" xml:lang="en-US" id="id_14264487_3438751_3_1">Reimbursement of expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ReimbursementOfExpenses_lbl" xml:lang="en-US" id="id_14264487_3438751_1_1">Reimbursement Of Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ReimbursementOfExpenses_lbl" xml:lang="en-US" id="id_14264487_3438751_2_1">Reimbursement of expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ReimbursementOfExpenses" xlink:to="mrus_ReimbursementOfExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ReimbursementOfGrant" xlink:label="mrus_ReimbursementOfGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ReimbursementOfGrant_lbl" xml:lang="en-US" id="id_14264487_3464192_3_1">Reimbursement of grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ReimbursementOfGrant_lbl" xml:lang="en-US" id="id_14264487_3464192_1_1">Reimbursement of grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ReimbursementOfGrant_lbl" xml:lang="en-US" id="id_14264487_3464192_2_1">Reimbursement of grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ReimbursementOfGrant" xlink:to="mrus_ReimbursementOfGrant_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RemunerationForFormerEmployees" xlink:label="mrus_RemunerationForFormerEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RemunerationForFormerEmployees_lbl" xml:lang="en-US" id="id_14264487_3458001_3_1">Remuneration for former employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RemunerationForFormerEmployees_lbl" xml:lang="en-US" id="id_14264487_3458001_1_1">Remuneration for former employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RemunerationForFormerEmployees_lbl" xml:lang="en-US" id="id_14264487_3458001_2_1">Remuneration for former employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RemunerationForFormerEmployees" xlink:to="mrus_RemunerationForFormerEmployees_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RentalExpense" xlink:label="ifrs-full_RentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RentalExpense_lbl" xml:lang="en-US" id="id_14264487_3423194_1_1">Rental expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RentalExpense_lbl" xml:lang="en-US" id="id_14264487_3423194_2_1">Rental expense Per year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentalExpense" xlink:to="ifrs-full_RentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RentalExpensesOnRealEstateAbstract" xlink:label="mrus_RentalExpensesOnRealEstateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RentalExpensesOnRealEstateAbstract_lbl" xml:lang="en-US" id="id_14264487_3429062_3_1">Rental expenses on real estate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RentalExpensesOnRealEstateAbstract_lbl" xml:lang="en-US" id="id_14264487_3429062_1_1">Rental expenses on real estate [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RentalExpensesOnRealEstateAbstract_lbl" xml:lang="en-US" id="id_14264487_3429062_2_1">Rental expenses on real estate [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="mrus_RentalExpensesOnRealEstateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RentAndServiceChargesExpense" xlink:label="mrus_RentAndServiceChargesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RentAndServiceChargesExpense_lbl" xml:lang="en-US" id="id_14264487_3463381_3_1">Rent and service charges expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RentAndServiceChargesExpense_lbl" xml:lang="en-US" id="id_14264487_3463381_1_1">Rent and service charges expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RentAndServiceChargesExpense_lbl" xml:lang="en-US" id="id_14264487_3463381_2_1">Rent and service charges expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RentAndServiceChargesExpense" xlink:to="mrus_RentAndServiceChargesExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" id="id_14264487_3423198_1_1">Repayments of borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" id="id_14264487_3423198_14_1">Repayment of borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember" xlink:label="mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember_lbl" xml:lang="en-US" id="id_14264487_3554539_3_1">Research and development cost reimbursement and milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember_lbl" xml:lang="en-US" id="id_14264487_3554539_1_1">Research and development cost reimbursement and milestone [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember_lbl" xml:lang="en-US" id="id_14264487_3554539_2_1">R&amp;D cost reimbursement and milestone [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember" xlink:to="mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ResearchAndDevelopmentCostsMember" xlink:label="mrus_ResearchAndDevelopmentCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ResearchAndDevelopmentCostsMember_lbl" xml:lang="en-US" id="id_14264487_3481637_3_1">Research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ResearchAndDevelopmentCostsMember_lbl" xml:lang="en-US" id="id_14264487_3481637_1_1">Research and Development Costs [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ResearchAndDevelopmentCostsMember_lbl" xml:lang="en-US" id="id_14264487_3481637_2_1">R&amp;D costs [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ResearchAndDevelopmentCostsMember" xlink:to="mrus_ResearchAndDevelopmentCostsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_14264487_3422758_1_1">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_14264487_3422758_6_1">Total R&amp;D costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_14264487_3422758_14_1">Research and development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestatedMember_lbl" xml:lang="en-US" id="id_14264487_3423218_1_1">Currently stated [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RestatedMember_lbl" xml:lang="en-US" id="id_14264487_3423218_2_1">Currently stated [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_RestatedMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" id="id_14264487_3422771_1_1">Retained earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" id="id_14264487_3422771_2_1">Accumulated loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_14264487_3422911_1_1">Retained earnings [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_14264487_3422911_2_1">Accumulated loss [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xml:lang="en-US" id="id_14264487_3422913_1_1">Retrospective application and retrospective restatement [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xml:lang="en-US" id="id_14264487_3422913_2_1">Retrospective application and retrospective restatement [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" id="id_14264487_3422778_1_1">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" id="id_14264487_3422778_2_1">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" id="id_14264487_3422778_12_1">Total Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US" id="id_14264487_3422914_1_1">Revenue [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US" id="id_14264487_3422914_2_1">Revenue [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueFromContractsWithCustomersMember" xlink:label="mrus_RevenueFromContractsWithCustomersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RevenueFromContractsWithCustomersMember_lbl" xml:lang="en-US" id="id_14264487_3496102_3_1">Revenue from contracts with customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RevenueFromContractsWithCustomersMember_lbl" xml:lang="en-US" id="id_14264487_3496102_1_1">Revenue from contracts with customers [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RevenueFromContractsWithCustomersMember_lbl" xml:lang="en-US" id="id_14264487_3496102_2_1">Revenue from contracts with customers [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RevenueFromContractsWithCustomersMember" xlink:to="mrus_RevenueFromContractsWithCustomersMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueLineItems" xlink:label="mrus_RevenueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RevenueLineItems_lbl" xml:lang="en-US" id="id_14264487_3429589_3_1">Revenue [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RevenueLineItems_lbl" xml:lang="en-US" id="id_14264487_3429589_1_1">Revenue [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RevenueLineItems_lbl" xml:lang="en-US" id="id_14264487_3429589_2_1">Revenue [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_RevenueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueRecognized" xlink:label="mrus_RevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RevenueRecognized_lbl" xml:lang="en-US" id="id_14264487_3530760_3_1">Revenue recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RevenueRecognized_lbl" xml:lang="en-US" id="id_14264487_3530760_1_1">Revenue recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RevenueRecognized_lbl" xml:lang="en-US" id="id_14264487_3530760_2_1">Revenue recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RevenueRecognized" xlink:to="mrus_RevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueRecognizedIncludedInDeferredRevenue" xlink:label="mrus_RevenueRecognizedIncludedInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RevenueRecognizedIncludedInDeferredRevenue_lbl" xml:lang="en-US" id="id_14264487_3448881_3_1">Revenue recognized included in deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RevenueRecognizedIncludedInDeferredRevenue_lbl" xml:lang="en-US" id="id_14264487_3448881_1_1">Revenue recognized included in deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RevenueRecognizedIncludedInDeferredRevenue_lbl" xml:lang="en-US" id="id_14264487_3448881_2_1">Revenue recognized included in deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RevenueRecognizedIncludedInDeferredRevenue" xlink:to="mrus_RevenueRecognizedIncludedInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueRecognizedNotIncludedInDeferredRevenue" xlink:label="mrus_RevenueRecognizedNotIncludedInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RevenueRecognizedNotIncludedInDeferredRevenue_lbl" xml:lang="en-US" id="id_14264487_3448882_3_1">Revenue recognized not included in deferred revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RevenueRecognizedNotIncludedInDeferredRevenue_lbl" xml:lang="en-US" id="id_14264487_3448882_1_1">Revenue recognized not included in deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RevenueRecognizedNotIncludedInDeferredRevenue_lbl" xml:lang="en-US" id="id_14264487_3448882_2_1">Revenue recognized not included in deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RevenueRecognizedNotIncludedInDeferredRevenue" xlink:to="mrus_RevenueRecognizedNotIncludedInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueRemainingPerformanceObligations" xlink:label="mrus_RevenueRemainingPerformanceObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RevenueRemainingPerformanceObligations_lbl" xml:lang="en-US" id="id_14264487_3448890_3_1">Revenue remaining performance obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RevenueRemainingPerformanceObligations_lbl" xml:lang="en-US" id="id_14264487_3448890_1_1">Revenue Remaining Performance Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RevenueRemainingPerformanceObligations_lbl" xml:lang="en-US" id="id_14264487_3448890_2_1">Performance obligation recognized as revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RevenueRemainingPerformanceObligations" xlink:to="mrus_RevenueRemainingPerformanceObligations_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueTable" xlink:label="mrus_RevenueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RevenueTable_lbl" xml:lang="en-US" id="id_14264487_3473742_3_1">Revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RevenueTable_lbl" xml:lang="en-US" id="id_14264487_3473742_1_1">Revenue [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RevenueTable_lbl" xml:lang="en-US" id="id_14264487_3473742_2_1">Revenue [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RevenueTable" xlink:to="mrus_RevenueTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ReverseStockSplitConversionRatio" xlink:label="mrus_ReverseStockSplitConversionRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ReverseStockSplitConversionRatio_lbl" xml:lang="en-US" id="id_14264487_3473054_3_1">Reverse Stock Split Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ReverseStockSplitConversionRatio_lbl" xml:lang="en-US" id="id_14264487_3473054_1_1">Reverse Stock Split Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ReverseStockSplitConversionRatio_lbl" xml:lang="en-US" id="id_14264487_3473054_2_1">Reverse share split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ReverseStockSplitConversionRatio" xlink:to="mrus_ReverseStockSplitConversionRatio_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" id="id_14264487_3423634_1_1">Right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" id="id_14264487_3423634_2_1">Right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RussellGreigMember" xlink:label="mrus_RussellGreigMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RussellGreigMember_lbl" xml:lang="en-US" id="id_14264487_3556563_3_1">Russell Greig [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RussellGreigMember_lbl" xml:lang="en-US" id="id_14264487_3556563_1_1">Russell Greig [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RussellGreigMember_lbl" xml:lang="en-US" id="id_14264487_3556563_2_1">Russell Greig [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RussellGreigMember" xlink:to="mrus_RussellGreigMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SecuritiesPledgedAsCollateralForRegistration" xlink:label="mrus_SecuritiesPledgedAsCollateralForRegistration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SecuritiesPledgedAsCollateralForRegistration_lbl" xml:lang="en-US" id="id_14264487_3463396_3_1">Securities pledged as collateral for registration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SecuritiesPledgedAsCollateralForRegistration_lbl" xml:lang="en-US" id="id_14264487_3463396_1_1">Securities Pledged As Collateral For Registration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SecuritiesPledgedAsCollateralForRegistration_lbl" xml:lang="en-US" id="id_14264487_3463396_2_1">Securities registered</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SecuritiesPledgedAsCollateralForRegistration" xlink:to="mrus_SecuritiesPledgedAsCollateralForRegistration_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SecurityDeposits" xlink:label="mrus_SecurityDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SecurityDeposits_lbl" xml:lang="en-US" id="id_14264487_3439623_3_1">Security deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SecurityDeposits_lbl" xml:lang="en-US" id="id_14264487_3439623_1_1">Security Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SecurityDeposits_lbl" xml:lang="en-US" id="id_14264487_3439623_2_1">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SecurityDeposits" xlink:to="mrus_SecurityDeposits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:label="ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_lbl" xml:lang="en-US" id="id_14264487_3423258_1_1">Sensitivity analysis for types of market risk [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_lbl" xml:lang="en-US" id="id_14264487_3423258_2_1">Summary of Sensitivity Analysis for Change in Primary Currency Exposures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:to="ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SeveranceCostsMember" xlink:label="mrus_SeveranceCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SeveranceCostsMember_lbl" xml:lang="en-US" id="id_14264487_3513422_3_1">Severance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SeveranceCostsMember_lbl" xml:lang="en-US" id="id_14264487_3513422_1_1">Severance Costs [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SeveranceCostsMember_lbl" xml:lang="en-US" id="id_14264487_3513422_2_1">Severance costs [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SeveranceCostsMember" xlink:to="mrus_SeveranceCostsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_14264487_3467974_3_1">Share Based Compensation Arrangements by Share Based Payment Award Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_14264487_3467974_1_1">Share Based Compensation Arrangements by Share Based Payment Award Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_14264487_3467974_2_1">Increase in authorized share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SharebasedCompensationAwardVestingPeriod" xlink:label="mrus_SharebasedCompensationAwardVestingPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SharebasedCompensationAwardVestingPeriod_lbl" xml:lang="en-US" id="id_14264487_3472168_3_1">Sharebased Compensation Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SharebasedCompensationAwardVestingPeriod_lbl" xml:lang="en-US" id="id_14264487_3472168_1_1">Sharebased Compensation Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SharebasedCompensationAwardVestingPeriod_lbl" xml:lang="en-US" id="id_14264487_3472168_2_1">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SharebasedCompensationAwardVestingPeriod" xlink:to="mrus_SharebasedCompensationAwardVestingPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SharebasedCompensationWeightedAverageRemainingContractualLife" xlink:label="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" id="id_14264487_3472021_3_1">Share-based Compensation, Weighted Average Remaining Contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" id="id_14264487_3472021_1_1">Share-based Compensation, Weighted Average Remaining Contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" id="id_14264487_3472021_2_1">Weighted-average remaining contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife" xlink:to="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US" id="id_14264487_3422970_1_1">Share-based payment arrangements [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US" id="id_14264487_3422970_2_1">Share-based payment arrangements [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US" id="id_14264487_3423692_1_1">Share premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US" id="id_14264487_3423692_2_1">Share premium account</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US" id="id_14264487_3422849_1_1">Share premium [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US" id="id_14264487_3422849_2_1">Share premium [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SharePurchasedPricePerShare_lbl" xml:lang="en-US" id="id_14264487_3522559_3_1">Share purchased price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SharePurchasedPricePerShare_lbl" xml:lang="en-US" id="id_14264487_3522559_1_1">Share Purchased Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="mrus_SharePurchasedPricePerShare_lbl" xml:lang="en-US" id="id_14264487_3522559_32_1">Share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SharePurchasedPricePerShare_lbl" xml:lang="en-US" id="id_14264487_3522559_2_1">Purchase price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrus_SharePurchasedPricePerShare_lbl" xml:lang="en-US" id="id_14264487_3522559_12_1">Purchase price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SharePurchasedPricePerShare" xlink:to="mrus_SharePurchasedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ShelleyMargetsonFormerCOOMember" xlink:label="mrus_ShelleyMargetsonFormerCOOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ShelleyMargetsonFormerCOOMember_lbl" xml:lang="en-US" id="id_14264487_3556605_3_1">Shelley Margetson former Chief Operating Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ShelleyMargetsonFormerCOOMember_lbl" xml:lang="en-US" id="id_14264487_3556605_1_1">Shelley Margetson former COO [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ShelleyMargetsonFormerCOOMember_lbl" xml:lang="en-US" id="id_14264487_3556605_2_1">Shelley Margetson, Former COO [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ShelleyMargetsonFormerCOOMember" xlink:to="mrus_ShelleyMargetsonFormerCOOMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl" xml:lang="en-US" id="id_14264487_3423695_1_1">Short-term employee benefits accruals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl" xml:lang="en-US" id="id_14264487_3423695_2_1">Accrued bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xml:lang="en-US" id="id_14264487_3423696_1_1">Short-term employee benefits expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xml:lang="en-US" id="id_14264487_3423696_6_1">Total employee benefits expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_lbl" xml:lang="en-US" id="id_14264487_3423697_1_1">Short-term employee benefits expense [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_lbl" xml:lang="en-US" id="id_14264487_3423697_2_1">Short-term employee benefits expense [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_lbl" xml:lang="en-US" id="id_14264487_3423280_1_1">Short-term investments, classified as cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_lbl" xml:lang="en-US" id="id_14264487_3423280_2_1">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl" xml:lang="en-US" id="id_14264487_3422992_1_1">Associates [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl" xml:lang="en-US" id="id_14264487_3422992_2_1">Associates [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SimcereCollaborationAndLicenseAgreementMember" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_14264487_3496111_3_1">Simcere collaboration and license agreement [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_14264487_3496111_1_1">Simcere collaboration and license agreement [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_14264487_3496111_2_1">Simcere collaboration and license agreement [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SimcereCollaborationAndLicenseAgreementMember" xlink:to="mrus_SimcereCollaborationAndLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SimcerePharmaceuticalCoLtdMember" xlink:label="mrus_SimcerePharmaceuticalCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SimcerePharmaceuticalCoLtdMember_lbl" xml:lang="en-US" id="id_14264487_3554542_3_1">Simcere Pharmaceutical Co Ltd [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SimcerePharmaceuticalCoLtdMember_lbl" xml:lang="en-US" id="id_14264487_3554542_1_1">Simcere Pharmaceutical Co Ltd [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SimcerePharmaceuticalCoLtdMember_lbl" xml:lang="en-US" id="id_14264487_3554542_2_1">Simcere Pharmaceutical Co Ltd [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SimcerePharmaceuticalCoLtdMember" xlink:to="mrus_SimcerePharmaceuticalCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SocialSecurityContributions" xlink:label="ifrs-full_SocialSecurityContributions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SocialSecurityContributions_lbl" xml:lang="en-US" id="id_14264487_3422859_1_1">Social security contributions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SocialSecurityContributions_lbl" xml:lang="en-US" id="id_14264487_3422859_2_1">Social security premiums</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SocialSecurityContributions" xlink:to="ifrs-full_SocialSecurityContributions_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SofinnovaVenturePartnersNineLimitedPartnershipMember" xlink:label="mrus_SofinnovaVenturePartnersNineLimitedPartnershipMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SofinnovaVenturePartnersNineLimitedPartnershipMember_lbl" xml:lang="en-US" id="id_14264487_3486462_3_1">Sofinnova Venture Partners Nine Limited Partnership.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SofinnovaVenturePartnersNineLimitedPartnershipMember_lbl" xml:lang="en-US" id="id_14264487_3486462_1_1">Sofinnova Venture Partners Nine Limited Partnership [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SofinnovaVenturePartnersNineLimitedPartnershipMember_lbl" xml:lang="en-US" id="id_14264487_3486462_2_1">Sofinnova Venture Partners Nine Limited Partnership [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SofinnovaVenturePartnersNineLimitedPartnershipMember" xlink:to="mrus_SofinnovaVenturePartnersNineLimitedPartnershipMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement" xlink:label="mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement_lbl" xml:lang="en-US" id="id_14264487_3556571_3_1">Lease agreement for square feet of office space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement_lbl" xml:lang="en-US" id="id_14264487_3556571_1_1">Square feet of office space under lease agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement_lbl" xml:lang="en-US" id="id_14264487_3556571_2_1">Lease agreement square feet of office space</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement_lbl" xml:lang="en-US" id="id_14264487_3556571_12_1">Square feet of office space under lease agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement" xlink:to="mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_14264487_3423004_1_1">Statement of cash flows [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_14264487_3423004_2_1">Statement of cash flows [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US" id="id_14264487_3422872_1_1">Statement of changes in equity [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US" id="id_14264487_3422872_2_1">Statement of changes in equity [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" id="id_14264487_3423719_1_1">Statement of changes in equity [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" id="id_14264487_3423719_2_1">Statement of changes in equity [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" id="id_14264487_3423720_1_1">Statement of changes in equity [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" id="id_14264487_3423720_2_1">Statement of changes in equity [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_StockAwardExpense" xlink:label="mrus_StockAwardExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_StockAwardExpense_lbl" xml:lang="en-US" id="id_14264487_3458121_3_1">Stock award expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_StockAwardExpense_lbl" xml:lang="en-US" id="id_14264487_3458121_1_1">Stock award expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_StockAwardExpense_lbl" xml:lang="en-US" id="id_14264487_3458121_2_1">Stock award expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_StockAwardExpense" xlink:to="mrus_StockAwardExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:label="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3423012_1_1">Subclassifications of assets, liabilities and equities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_lbl" xml:lang="en-US" id="id_14264487_3423012_2_1">Sub classifications of assets, liabilities and equities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SubsequentsEventsAbstract" xlink:label="mrus_SubsequentsEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SubsequentsEventsAbstract_lbl" xml:lang="en-US" id="id_14264487_3432238_3_1">Subsequents events.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SubsequentsEventsAbstract_lbl" xml:lang="en-US" id="id_14264487_3432238_1_1">Subsequents events [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SubsequentsEventsAbstract_lbl" xml:lang="en-US" id="id_14264487_3432238_2_1">Subsequents events [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SubsequentsEventsAbstract" xlink:to="mrus_SubsequentsEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SubsidiarySaleOfStock1Axis" xlink:label="mrus_SubsidiarySaleOfStock1Axis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SubsidiarySaleOfStock1Axis_lbl" xml:lang="en-US" id="id_14264487_3475672_3_1">Subsidiary sale of stock 1 [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SubsidiarySaleOfStock1Axis_lbl" xml:lang="en-US" id="id_14264487_3475672_1_1">Subsidiary sale of stock 1 [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SubsidiarySaleOfStock1Axis_lbl" xml:lang="en-US" id="id_14264487_3475672_2_1">Subsidiary sale of stock 1 [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SubsidiarySaleOfStock1Axis" xlink:to="mrus_SubsidiarySaleOfStock1Axis_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SubsidiarySaleOfStockDomain" xlink:label="mrus_SubsidiarySaleOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SubsidiarySaleOfStockDomain_lbl" xml:lang="en-US" id="id_14264487_3486452_3_1">Subsidiary sale of stock [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SubsidiarySaleOfStockDomain_lbl" xml:lang="en-US" id="id_14264487_3486452_1_1">Subsidiary sale of stock [domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SubsidiarySaleOfStockDomain_lbl" xml:lang="en-US" id="id_14264487_3486452_2_1">Subsidiary sale of stock [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SubsidiarySaleOfStockDomain" xlink:to="mrus_SubsidiarySaleOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:label="mrus_SupplementalDisclosureOfCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SupplementalDisclosureOfCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_14264487_3431513_3_1">Supplemental disclosure of cash flow information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SupplementalDisclosureOfCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_14264487_3431513_1_1">Supplemental Disclosure Of Cash Flow Information [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SupplementalDisclosureOfCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_14264487_3431513_2_1">Supplemental disclosure of non-cash activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:to="mrus_SupplementalDisclosureOfCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TaxesAndSocialSecurityLiabilitiesMember" xlink:label="mrus_TaxesAndSocialSecurityLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_TaxesAndSocialSecurityLiabilitiesMember_lbl" xml:lang="en-US" id="id_14264487_3558218_3_1">Taxes and social security liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_TaxesAndSocialSecurityLiabilitiesMember_lbl" xml:lang="en-US" id="id_14264487_3558218_1_1">Taxes and social security liabilities [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_TaxesAndSocialSecurityLiabilitiesMember_lbl" xml:lang="en-US" id="id_14264487_3558218_2_1">Taxes and social security liabilities [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TaxesAndSocialSecurityLiabilitiesMember" xlink:to="mrus_TaxesAndSocialSecurityLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" xml:lang="en-US" id="id_14264487_3423034_1_1">Temporary difference, unused tax losses and unused tax credits [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" xml:lang="en-US" id="id_14264487_3423034_2_1">Temporary difference, unused tax losses and unused tax credits [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" xml:lang="en-US" id="id_14264487_3423035_1_1">Temporary difference, unused tax losses and unused tax credits [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" xml:lang="en-US" id="id_14264487_3423035_2_1">Temporary difference, unused tax losses and unused tax credits [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TermsOfPaymentOfTradeReceivables" xlink:label="mrus_TermsOfPaymentOfTradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_TermsOfPaymentOfTradeReceivables_lbl" xml:lang="en-US" id="id_14264487_3470294_3_1">Terms of payment of trade receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_TermsOfPaymentOfTradeReceivables_lbl" xml:lang="en-US" id="id_14264487_3470294_1_1">Terms of payment of trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_TermsOfPaymentOfTradeReceivables_lbl" xml:lang="en-US" id="id_14264487_3470294_2_1">Payment terms related to receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TermsOfPaymentOfTradeReceivables" xlink:to="mrus_TermsOfPaymentOfTradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_TextBlockAbstract_lbl" xml:lang="en-US" id="id_14264487_3426207_3_1">Text Block [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_TextBlockAbstract_lbl" xml:lang="en-US" id="id_14264487_3426207_1_1">Text block [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_TextBlockAbstract_lbl" xml:lang="en-US" id="id_14264487_3426207_2_1">Text Block [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_TextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TonLogtenbergCEOMember" xlink:label="mrus_TonLogtenbergCEOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_TonLogtenbergCEOMember_lbl" xml:lang="en-US" id="id_14264487_3492855_3_1">Ton logtenberg chief executive officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_TonLogtenbergCEOMember_lbl" xml:lang="en-US" id="id_14264487_3492855_1_1">Ton Logtenberg CEO [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_TonLogtenbergCEOMember_lbl" xml:lang="en-US" id="id_14264487_3492855_2_1">Ton Logtenberg, CEO [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TonLogtenbergCEOMember" xlink:to="mrus_TonLogtenbergCEOMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" id="id_14264487_3423353_1_1">Top of range [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" id="id_14264487_3423353_2_1">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US" id="id_14264487_3423356_1_1">Current trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US" id="id_14264487_3423356_2_1">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" id="id_14264487_3423049_1_1">Trade and other current receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" id="id_14264487_3423049_2_1">Trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" id="id_14264487_3423049_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_lbl" xml:lang="en-US" id="id_14264487_3424015_1_1">Trade and other payables, undiscounted cash flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_lbl" xml:lang="en-US" id="id_14264487_3424015_2_1">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:to="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TradeAndOtherReceivableMember" xlink:label="mrus_TradeAndOtherReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_TradeAndOtherReceivableMember_lbl" xml:lang="en-US" id="id_14264487_3476336_3_1">Trade and other receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_TradeAndOtherReceivableMember_lbl" xml:lang="en-US" id="id_14264487_3476336_1_1">Trade And Other Receivable [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_TradeAndOtherReceivableMember_lbl" xml:lang="en-US" id="id_14264487_3476336_2_1">Trade and other receivables [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TradeAndOtherReceivableMember" xlink:to="mrus_TradeAndOtherReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TradeAndUnbilledReceivables" xlink:label="mrus_TradeAndUnbilledReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_TradeAndUnbilledReceivables_lbl" xml:lang="en-US" id="id_14264487_3464206_3_1">Trade and unbilled receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_TradeAndUnbilledReceivables_lbl" xml:lang="en-US" id="id_14264487_3464206_1_1">Trade and unbilled receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_TradeAndUnbilledReceivables_lbl" xml:lang="en-US" id="id_14264487_3464206_2_1">Trade and unbilled receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TradeAndUnbilledReceivables" xlink:to="mrus_TradeAndUnbilledReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TradePayablesOtherLiabilitiesAndAccrualsMember" xlink:label="mrus_TradePayablesOtherLiabilitiesAndAccrualsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_TradePayablesOtherLiabilitiesAndAccrualsMember_lbl" xml:lang="en-US" id="id_14264487_3529562_3_1">Trade payables, other liabilities and accruals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_TradePayablesOtherLiabilitiesAndAccrualsMember_lbl" xml:lang="en-US" id="id_14264487_3529562_1_1">Trade payables, other liabilities and accruals [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_TradePayablesOtherLiabilitiesAndAccrualsMember_lbl" xml:lang="en-US" id="id_14264487_3529562_2_1">Trade payables, other liabilities and accruals [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TradePayablesOtherLiabilitiesAndAccrualsMember" xlink:to="mrus_TradePayablesOtherLiabilitiesAndAccrualsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeReceivables_lbl" xml:lang="en-US" id="id_14264487_3423360_1_1">Trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_TradeReceivables_lbl" xml:lang="en-US" id="id_14264487_3423360_4_1">Trade receivables, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_TradeReceivables_lbl" xml:lang="en-US" id="id_14264487_3423360_5_1">Trade receivables, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivables" xlink:to="ifrs-full_TradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeReceivablesMember" xlink:label="ifrs-full_TradeReceivablesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeReceivablesMember_lbl" xml:lang="en-US" id="id_14264487_3424016_1_1">Trade receivables [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeReceivablesMember_lbl" xml:lang="en-US" id="id_14264487_3424016_2_1">Trade receivables [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivablesMember" xlink:to="ifrs-full_TradeReceivablesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradingIncomeExpenseOnDerivativeFinancialInstruments" xlink:label="ifrs-full_TradingIncomeExpenseOnDerivativeFinancialInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradingIncomeExpenseOnDerivativeFinancialInstruments_lbl" xml:lang="en-US" id="id_14264487_3424439_1_1">Trading income (expense) on derivative financial instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradingIncomeExpenseOnDerivativeFinancialInstruments_lbl" xml:lang="en-US" id="id_14264487_3424439_2_1">Derivative financial instrument expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradingIncomeExpenseOnDerivativeFinancialInstruments" xlink:to="ifrs-full_TradingIncomeExpenseOnDerivativeFinancialInstruments_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_14264487_3423057_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_14264487_3423057_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TransactionsWithOwnersAbstract" xlink:label="mrus_TransactionsWithOwnersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_TransactionsWithOwnersAbstract_lbl" xml:lang="en-US" id="id_14264487_3430978_3_1">Transactions with owners.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_TransactionsWithOwnersAbstract_lbl" xml:lang="en-US" id="id_14264487_3430978_1_1">Transactions With Owners [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_TransactionsWithOwnersAbstract_lbl" xml:lang="en-US" id="id_14264487_3430978_2_1">Transactions with owners of the Company:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="mrus_TransactionsWithOwnersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TwoThousandSixteenOptionPlanMember" xlink:label="mrus_TwoThousandSixteenOptionPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_TwoThousandSixteenOptionPlanMember_lbl" xml:lang="en-US" id="id_14264487_3514207_3_1">Two thousand sixteen option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_TwoThousandSixteenOptionPlanMember_lbl" xml:lang="en-US" id="id_14264487_3514207_1_1">Two Thousand Sixteen Option Plan[member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_TwoThousandSixteenOptionPlanMember_lbl" xml:lang="en-US" id="id_14264487_3514207_2_1">2016 Plan [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TwoThousandSixteenOptionPlanMember" xlink:to="mrus_TwoThousandSixteenOptionPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TwoThousandTenOptionPlanMember" xlink:label="mrus_TwoThousandTenOptionPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_TwoThousandTenOptionPlanMember_lbl" xml:lang="en-US" id="id_14264487_3514087_3_1">2010 Option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_TwoThousandTenOptionPlanMember_lbl" xml:lang="en-US" id="id_14264487_3514087_1_1">Two Thousand Ten Option Plan[member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_TwoThousandTenOptionPlanMember_lbl" xml:lang="en-US" id="id_14264487_3514087_2_1">2010 Option plan [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TwoThousandTenOptionPlanMember" xlink:to="mrus_TwoThousandTenOptionPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfContractsAxis_lbl" xml:lang="en-US" id="id_14264487_3423078_1_1">Types of contracts [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TypesOfContractsAxis_lbl" xml:lang="en-US" id="id_14264487_3423078_2_1">Types of contracts [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfContractsMember_lbl" xml:lang="en-US" id="id_14264487_3423383_1_1">Types of contracts [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TypesOfContractsMember_lbl" xml:lang="en-US" id="id_14264487_3423383_2_1">Types of contracts [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="ifrs-full_TypesOfContractsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfFinancialAssetsAxis" xlink:label="ifrs-full_TypesOfFinancialAssetsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfFinancialAssetsAxis_lbl" xml:lang="en-US" id="id_14264487_3424453_1_1">Types of financial assets [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TypesOfFinancialAssetsAxis_lbl" xml:lang="en-US" id="id_14264487_3424453_2_1">Types of financial assets [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfFinancialAssetsAxis" xlink:to="ifrs-full_TypesOfFinancialAssetsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfInterestRatesAxis_lbl" xml:lang="en-US" id="id_14264487_3424455_1_1">Types of interest rates [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TypesOfInterestRatesAxis_lbl" xml:lang="en-US" id="id_14264487_3424455_2_1">Types of interest rates [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xml:lang="en-US" id="id_14264487_3424456_1_1">Types of risks [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xml:lang="en-US" id="id_14264487_3424456_2_1">Types of risks [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xml:lang="en-US" id="id_14264487_3423384_1_1">Risks [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xml:lang="en-US" id="id_14264487_3423384_2_1">Risks [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_TypesOfRisksMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US" id="id_14264487_3424457_1_1">Types of share-based payment arrangements [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US" id="id_14264487_3424457_2_1">Types of share-based payment arrangements [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_UnbilledReceivablesMember" xlink:label="mrus_UnbilledReceivablesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_UnbilledReceivablesMember_lbl" xml:lang="en-US" id="id_14264487_3496068_3_1">Unbilled receivables [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_UnbilledReceivablesMember_lbl" xml:lang="en-US" id="id_14264487_3496068_1_1">Unbilled receivables [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_UnbilledReceivablesMember_lbl" xml:lang="en-US" id="id_14264487_3496068_2_1">Unbilled receivables [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_UnbilledReceivablesMember" xlink:to="mrus_UnbilledReceivablesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="ifrs-full_UnusedTaxLossesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UnusedTaxLossesMember_lbl" xml:lang="en-US" id="id_14264487_3424053_1_1">Unused tax losses [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_UnusedTaxLossesMember_lbl" xml:lang="en-US" id="id_14264487_3424053_2_1">Unused tax losses [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnusedTaxLossesMember" xlink:to="ifrs-full_UnusedTaxLossesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_UpfrontAndMilestonePaymentsMember" xlink:label="mrus_UpfrontAndMilestonePaymentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_UpfrontAndMilestonePaymentsMember_lbl" xml:lang="en-US" id="id_14264487_3496110_3_1">Upfront and milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_UpfrontAndMilestonePaymentsMember_lbl" xml:lang="en-US" id="id_14264487_3496110_1_1">Upfront and Milestone Payments [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_UpfrontAndMilestonePaymentsMember_lbl" xml:lang="en-US" id="id_14264487_3496110_2_1">Upfront and Milestone Payments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_UpfrontAndMilestonePaymentsMember" xlink:to="mrus_UpfrontAndMilestonePaymentsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_UpfrontPayment" xlink:label="mrus_UpfrontPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_UpfrontPayment_lbl" xml:lang="en-US" id="id_14264487_3433983_3_1">Upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_UpfrontPayment_lbl" xml:lang="en-US" id="id_14264487_3433983_1_1">Upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_UpfrontPayment_lbl" xml:lang="en-US" id="id_14264487_3433983_2_1">Non-refundable upfront payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_UpfrontPayment" xlink:to="mrus_UpfrontPayment_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_UpfrontPaymentAmortization" xlink:label="mrus_UpfrontPaymentAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_UpfrontPaymentAmortization_lbl" xml:lang="en-US" id="id_14264487_3464161_3_1">Up-front payment amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_UpfrontPaymentAmortization_lbl" xml:lang="en-US" id="id_14264487_3464161_1_1">Up-front payment amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_UpfrontPaymentAmortization_lbl" xml:lang="en-US" id="id_14264487_3464161_2_1">Up-front payment amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_UpfrontPaymentAmortization" xlink:to="mrus_UpfrontPaymentAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_UpfrontPaymentAmortizationMember" xlink:label="mrus_UpfrontPaymentAmortizationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_UpfrontPaymentAmortizationMember_lbl" xml:lang="en-US" id="id_14264487_3514219_3_1">Up-front payment amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_UpfrontPaymentAmortizationMember_lbl" xml:lang="en-US" id="id_14264487_3514219_1_1">Up-front payment amortization [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_UpfrontPaymentAmortizationMember_lbl" xml:lang="en-US" id="id_14264487_3514219_2_1">Up-front payment amortization [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_UpfrontPaymentAmortizationMember" xlink:to="mrus_UpfrontPaymentAmortizationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" id="id_14264487_3424474_1_1">UNITED STATES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" id="id_14264487_3424474_2_1">United States [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_USD" xlink:label="currency_USD"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl" xml:lang="en-US" id="id_14264487_3423397_1_1">United States of America, Dollars</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_USD_lbl" xml:lang="en-US" id="id_14264487_3423397_2_1">USD [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:label="ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3424475_1_1">Useful lives or depreciation rates, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_14264487_3424475_2_1">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:to="ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_USTreasurySecuritiesMember" xlink:label="mrus_USTreasurySecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_USTreasurySecuritiesMember_lbl" xml:lang="en-US" id="id_14264487_3535979_3_1">U.S. Treasury securities [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_USTreasurySecuritiesMember_lbl" xml:lang="en-US" id="id_14264487_3535979_1_1">U.S. Treasury securities [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_USTreasurySecuritiesMember_lbl" xml:lang="en-US" id="id_14264487_3535979_2_1">U.S. Treasury securities [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_USTreasurySecuritiesMember" xlink:to="mrus_USTreasurySecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ValueOfCommonSharesIssued" xlink:label="mrus_ValueOfCommonSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ValueOfCommonSharesIssued_lbl" xml:lang="en-US" id="id_14264487_3556600_3_1">value of common shares issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ValueOfCommonSharesIssued_lbl" xml:lang="en-US" id="id_14264487_3556600_1_1">value of common shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ValueOfCommonSharesIssued_lbl" xml:lang="en-US" id="id_14264487_3556600_2_1">Aggregate value of common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ValueOfCommonSharesIssued" xlink:to="mrus_ValueOfCommonSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WagesAndSalaries_lbl" xml:lang="en-US" id="id_14264487_3423771_1_1">Wages and salaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WagesAndSalaries_lbl" xml:lang="en-US" id="id_14264487_3423771_2_1">Gross salary includes severance payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WagesAndSalaries_lbl" xml:lang="en-US" id="id_14264487_3423771_12_1">Salaries and wages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_WBSOSubsidy" xlink:label="mrus_WBSOSubsidy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_WBSOSubsidy_lbl" xml:lang="en-US" id="id_14264487_3458295_3_1">WBSO subsidy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_WBSOSubsidy_lbl" xml:lang="en-US" id="id_14264487_3458295_1_1">WBSO subsidy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrus_WBSOSubsidy_lbl" xml:lang="en-US" id="id_14264487_3458295_14_1">WBSO subsidy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_WBSOSubsidy" xlink:to="mrus_WBSOSubsidy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3424493_1_1">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3424493_2_1">Vested during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3423416_1_1">Weighted average exercise price of other equity instruments expired in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3423416_2_1">Expired during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3423779_1_1">Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3423779_2_1">Forfeited during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3424071_1_1">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3424071_2_1">Granted during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3423417_1_1">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3423417_4_1">Unvested ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3423417_5_1">Unvested beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3423780_1_1">Weighted average exercise price of share options exercisable in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3423780_2_1">Exercisable at December 31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3423781_1_1">Weighted average exercise price of share options exercised in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3423781_2_1">Exercised during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3424494_1_1">Weighted average exercise price of share options expired in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3424494_2_1">Expired during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3424495_1_1">Weighted average exercise price of share options forfeited in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3424495_2_1">Forfeited during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3424073_1_1">Weighted average exercise price of share options granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3424073_2_1">Granted during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3424496_1_1">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3424496_4_1">Outstanding at December 31</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3424496_5_1">Outstanding at January 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_14264487_3424496_2_1">Weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard" xlink:label="mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard_lbl" xml:lang="en-US" id="id_14264487_3522424_3_1">Weighted average exercise price per share held by the members of the supervisory board.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard_lbl" xml:lang="en-US" id="id_14264487_3522424_1_1">Weighted average exercise price per share held by the members of the supervisory board</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard_lbl" xml:lang="en-US" id="id_14264487_3522424_2_1">Weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard" xlink:to="mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_WeightedAverageNumberOfShares" xlink:label="mrus_WeightedAverageNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_WeightedAverageNumberOfShares_lbl" xml:lang="en-US" id="id_14264487_3468902_3_1">Weighted average number of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_WeightedAverageNumberOfShares_lbl" xml:lang="en-US" id="id_14264487_3468902_1_1">Weighted average number of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_WeightedAverageNumberOfShares_lbl" xml:lang="en-US" id="id_14264487_3468902_2_1">Weighted average shares outstanding-basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_WeightedAverageNumberOfShares" xlink:to="mrus_WeightedAverageNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio" xlink:label="mrus_WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio_lbl" xml:lang="en-US" id="id_14264487_3558219_3_1">Weighted average remaining maturity period for investment portfolio.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio_lbl" xml:lang="en-US" id="id_14264487_3558219_1_1">Weighted average remaining maturity period for investment portfolio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio_lbl" xml:lang="en-US" id="id_14264487_3558219_2_1">Weighted average remaining days to maturity for investment portfolio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio" xlink:to="mrus_WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageSharePrice" xlink:label="ifrs-full_WeightedAverageSharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePrice_lbl" xml:lang="en-US" id="id_14264487_3423784_1_1">Weighted average share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharePrice_lbl" xml:lang="en-US" id="id_14264487_3423784_2_1">Weighted-average share price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePrice" xlink:to="ifrs-full_WeightedAverageSharePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_WolfgangBertholdMember" xlink:label="mrus_WolfgangBertholdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_WolfgangBertholdMember_lbl" xml:lang="en-US" id="id_14264487_3492745_3_1">Wolfgang Berthold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_WolfgangBertholdMember_lbl" xml:lang="en-US" id="id_14264487_3492745_1_1">Wolfgang Berthold [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_WolfgangBertholdMember_lbl" xml:lang="en-US" id="id_14264487_3492745_2_1">Wolfgang Berthold [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_WolfgangBertholdMember" xlink:to="mrus_WolfgangBertholdMember_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>mrus-20181231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN Xcelerate Taxonomy Presentation Linkbase - https://www.dfinsolutions.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 6 -->
<!-- Creation date: 2019-04-03T15:11:08Z -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DocumentandEntityInformation" roleURI="http://www.merus.nl/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#ias_1_2018-03-16_role-210000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#ias_1_2018-03-16_role-320000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#ias_1_2018-03-16_role-610000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfChangesInEquity-610000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#ias_7_2018-03-16_role-520000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureGeneralInformationAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureGeneralInformationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBasisOfPresentationAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfFinancialPositions" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfFinancialPositions"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfCashFlows" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosurePropertyPlantAndEquipmentScheduleOfChangesInPropertyPlantAndEquipment" roleURI="http://www.merus.nl/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfChangesInPropertyPlantAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureIntangibleAssetsSummaryOfMovementsOfIntellectualPropertyRight" roleURI="http://www.merus.nl/taxonomy/role/DisclosureIntangibleAssetsSummaryOfMovementsOfIntellectualPropertyRight"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureIntangibleAssetsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTaxationAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTaxationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureInvestmentsSummaryOfInvestments" roleURI="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureInvestmentsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureOtherLiabilitiesAndAccrualsSummaryOfShorttermAndPayableWithin1Year" roleURI="http://www.merus.nl/taxonomy/role/DisclosureOtherLiabilitiesAndAccrualsSummaryOfShorttermAndPayableWithin1Year"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureDeferredRevenueSummaryOfDeferredRevenue" roleURI="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureDeferredRevenueAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquityAdditionalInformationEquity" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationEquity"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquitySummaryOfReconciliationOfCommonSharesOutstanding" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfCommonSharesOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquityAdditionalInformationShareBasedPaymentArrangements" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationShareBasedPaymentArrangements"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRevenueSummaryOfRevenue" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueSummaryOfRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRevenueAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTotalOperatingExpensesAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureTotalOperatingExpensesOperatingExpensesByNature" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesOperatingExpensesByNature"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureEmployeeBenefitsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureOtherIncomeExpenseSummaryOfOtherIncomeExpense" roleURI="http://www.merus.nl/taxonomy/role/DisclosureOtherIncomeExpenseSummaryOfOtherIncomeExpense"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureOtherIncomeExpenseAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureOtherIncomeExpenseAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShare" roleURI="http://www.merus.nl/taxonomy/role/DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureLossPerShareAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureLossPerShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentSummaryOfMaximumCreditExposure" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfMaximumCreditExposure"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentSummaryOfAgingOfTradeAndUnbilledReceivables" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfAgingOfTradeAndUnbilledReceivables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentsSummaryOfMaturityAnalysisForNonderivativeFinancialLiabilities" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfMaturityAnalysisForNonderivativeFinancialLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentsSummaryOfSensitivityAnalysisForChangeInPrimaryCurrencyExposure" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfSensitivityAnalysisForChangeInPrimaryCurrencyExposure"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureFinancialInstrumentSummaryOfInterestBearingFinancialInstruments" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfInterestBearingFinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatement" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatement"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatementParenthetical" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatementParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfRelatedParty" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfConsolidatedStatementOfProfitAndLossForTheRemunerationOfTheFormerMembersOfTheSupervisoryBoard" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfConsolidatedStatementOfProfitAndLossForTheRemunerationOfTheFormerMembersOfTheSupervisoryBoard"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard" roleURI="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureRelatedPartyDisclosuresAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRelatedPartyDisclosuresAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderLease" roleURI="http://www.merus.nl/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderLease"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfIncomeTaxExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIncomeTaxExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfRevenueExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfRelatedPartyExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRelatedPartyExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20181231.xsd#Role_NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DocumentAndEntityInformationAbstract" xlink:label="mrus_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityShellCompany" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityExTransitionPeriod" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000" xlink:title="[210000] Statement of financial position, current/non-current">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentHeldtomaturityInvestments" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:label="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentHeldtomaturityInvestments" xlink:label="ifrs-full_NoncurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentHeldtomaturityInvestments" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Assets" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_DeferredIncomeClassifiedAsCurrent" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_SharePremium" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentHeldtomaturityInvestments" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentAssets" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:to="ifrs-full_EquityAbstract" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:to="ifrs-full_Liabilities" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_DeferredIncomeClassifiedAsNoncurrent" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000" xlink:title="[320000] Statement of comprehensive income, profit or loss, by nature of expense">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:label="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherExpenseByNature" xlink:label="ifrs-full_OtherExpenseByNature"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherFinanceIncome" xlink:label="ifrs-full_OtherFinanceIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="ifrs-full_OtherFinanceIncomeCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_Revenue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_OtherExpenseByNature" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_OperatingExpense" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_FinanceIncome" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_FinanceCosts" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_OtherFinanceIncome" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_OtherFinanceIncomeCost" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="1.1500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_ProfitLoss" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncome" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfChangesInEquity-610000" xlink:title="[610000] Statement of changes in equity">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassAPreferenceShareCapitalMember" xlink:label="mrus_ClassAPreferenceShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassAPreferenceSharePremiumMember" xlink:label="mrus_ClassAPreferenceSharePremiumMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassBPreferenceShareCapitalMember" xlink:label="mrus_ClassBPreferenceShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassBPreferenceSharePremiumMember" xlink:label="mrus_ClassBPreferenceSharePremiumMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassCPreferenceShareCapitalMember" xlink:label="mrus_ClassCPreferenceShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClassCPreferenceSharePremiumMember" xlink:label="mrus_ClassCPreferenceSharePremiumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CommonShareCapitalMember" xlink:label="mrus_CommonShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CommonSharePremiumMember" xlink:label="mrus_CommonSharePremiumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" xlink:label="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InitialPublicOfferingCosts" xlink:label="mrus_InitialPublicOfferingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TransactionsWithOwnersAbstract" xlink:label="mrus_TransactionsWithOwnersAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_CommonShareCapitalMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_ClassAPreferenceShareCapitalMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_ClassBPreferenceShareCapitalMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_ClassCPreferenceShareCapitalMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_CommonSharePremiumMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_ClassAPreferenceSharePremiumMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_ClassBPreferenceSharePremiumMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_ClassCPreferenceSharePremiumMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_SharePremiumMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="mrus_TransactionsWithOwnersAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="ifrs-full_IssueOfEquity" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="mrus_InitialPublicOfferingCosts" order="1.2000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="ifrs-full_Equity" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000" xlink:title="[520000] Statement of cash flows, indirect method">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ChangeInWorkingCapitalAbstract" xlink:label="mrus_ChangeInWorkingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ChangesInAccruedCapitalExpenditures" xlink:label="mrus_ChangesInAccruedCapitalExpenditures"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ChangesInRestrictedCash" xlink:label="mrus_ChangesInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PaymentsForDebtIssueCosts" xlink:label="ifrs-full_PaymentsForDebtIssueCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ProceedsFromCollaborationAgreement" xlink:label="mrus_ProceedsFromCollaborationAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:label="mrus_SupplementalDisclosureOfCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" order="1.2700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="1.3100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsForDebtIssueCosts" order="1.1500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsForShareIssueCosts" order="1.1700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="mrus_ProceedsFromCollaborationAgreement" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="1.1900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="mrus_ChangesInRestrictedCash" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_2" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="mrus_SupplementalDisclosureOfCashFlowInformationAbstract" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperations" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities" order="1.4000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" order="1.4100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="mrus_ChangeInWorkingCapitalAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="mrus_ChangesInAccruedCapitalExpenditures" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureGeneralInformationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CowenAndCoLlcMember" xlink:label="mrus_CowenAndCoLlcMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfGeneralInformationAbstract" xlink:label="mrus_DisclosureOfGeneralInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfGeneralInformationLineItems" xlink:label="mrus_DisclosureOfGeneralInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfGeneralInformationTable" xlink:label="mrus_DisclosureOfGeneralInformationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_HeldtomaturityInvestments" xlink:label="ifrs-full_HeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteCorporationMember" xlink:label="mrus_IncyteCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InitialPublicOfferingMember" xlink:label="mrus_InitialPublicOfferingMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InvestorsMember" xlink:label="mrus_InvestorsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfSharesIssuable" xlink:label="mrus_NumberOfSharesIssuable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OverAllotmentOption1Member" xlink:label="mrus_OverAllotmentOption1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfAggregateCompensationPayable" xlink:label="mrus_PercentageOfAggregateCompensationPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ReverseStockSplitConversionRatio" xlink:label="mrus_ReverseStockSplitConversionRatio"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SecuritiesPledgedAsCollateralForRegistration" xlink:label="mrus_SecuritiesPledgedAsCollateralForRegistration"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SubsidiarySaleOfStock1Axis" xlink:label="mrus_SubsidiarySaleOfStock1Axis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SubsidiarySaleOfStockDomain" xlink:label="mrus_SubsidiarySaleOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationAbstract" xlink:to="mrus_DisclosureOfGeneralInformationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="ifrs-full_HeldtomaturityInvestments" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="mrus_ReverseStockSplitConversionRatio" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="mrus_SecuritiesPledgedAsCollateralForRegistration" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="mrus_NumberOfSharesIssuable" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="mrus_PercentageOfAggregateCompensationPayable" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationLineItems" xlink:to="mrus_SharePurchasedPricePerShare" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationTable" xlink:to="mrus_SubsidiarySaleOfStock1Axis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationTable" xlink:to="mrus_DisclosureOfGeneralInformationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_InvestorsMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncyteCorporationMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_CowenAndCoLlcMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_SubsidiarySaleOfStock1Axis" xlink:to="mrus_SubsidiarySaleOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_SubsidiarySaleOfStockDomain" xlink:to="mrus_InitialPublicOfferingMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_SubsidiarySaleOfStockDomain" xlink:to="mrus_OverAllotmentOption1Member" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfSignificantAccountingPoliciesTable" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfReportableSegments1" xlink:label="mrus_NumberOfReportableSegments1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="mrus_DisclosureOfSignificantAccountingPoliciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:to="mrus_NumberOfReportableSegments1" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesTable" xlink:to="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ActuarialAssumptionOfRetirementAge" xlink:label="ifrs-full_ActuarialAssumptionOfRetirementAge"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CashAndCashEquivalentsMaximumMaturityPeriod" xlink:label="mrus_CashAndCashEquivalentsMaximumMaturityPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfSignificantAccountingPoliciesTable" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LeaseholdImprovementsMember" xlink:label="ifrs-full_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PlantAndEquipmentMember" xlink:label="mrus_PlantAndEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" xlink:label="ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="mrus_DisclosureOfSignificantAccountingPoliciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:to="mrus_CashAndCashEquivalentsMaximumMaturityPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_ActuarialAssumptionOfRetirementAge" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesTable" xlink:to="mrus_DisclosureOfSignificantAccountingPoliciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="mrus_PlantAndEquipmentMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdoptionOfIFRS16Member" xlink:label="mrus_AdoptionOfIFRS16Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfRecentlyIssuedIfrsAbstract" xlink:label="mrus_DisclosureOfRecentlyIssuedIfrsAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_EstimatedContractualTerm" xlink:label="mrus_EstimatedContractualTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncreaseDecreaseInDeferredRevenue1" xlink:label="mrus_IncreaseDecreaseInDeferredRevenue1"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteCollaborationAgreementMember" xlink:label="mrus_IncyteCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteProprietaryTechnologyMember" xlink:label="mrus_IncyteProprietaryTechnologyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OnoResearchAndLicenseAgreementMember" xlink:label="mrus_OnoResearchAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="mrus_EstimatedContractualTerm" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="mrus_IncreaseDecreaseInDeferredRevenue1" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_LeaseLiabilities" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_RightofuseAssets" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_TypesOfContractsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfRecentlyIssuedIfrsAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="mrus_AdoptionOfIFRS16Member" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteCollaborationAgreementMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_OnoResearchAndLicenseAgreementMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteProprietaryTechnologyMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureoffinancialinformationAbstract" xlink:label="mrus_DisclosureoffinancialinformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_Revenue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureoffinancialinformationAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfFinancialPositions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedBalanceSheetStatementTable" xlink:label="srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureoffinancialinformationAbstract" xlink:label="mrus_DisclosureoffinancialinformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="ifrs-full_RetainedEarnings" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="ifrs-full_DeferredIncomeClassifiedAsNoncurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="ifrs-full_DeferredIncomeClassifiedAsCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureoffinancialinformationAbstract" xlink:to="srt_CondensedBalanceSheetStatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ChangeInWorkingCapitalAbstract" xlink:label="mrus_ChangeInWorkingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedCashFlowStatementTable" xlink:label="srt_CondensedCashFlowStatementTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureoffinancialinformationAbstract" xlink:label="mrus_DisclosureoffinancialinformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="ifrs-full_ProfitLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="mrus_ChangeInWorkingCapitalAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_CondensedCashFlowStatementsCaptionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureoffinancialinformationAbstract" xlink:to="srt_CondensedCashFlowStatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfChangesInPropertyPlantAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:label="ifrs-full_ChangesInPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PlantAndEquipmentMember" xlink:label="mrus_PlantAndEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_ChangesInPropertyPlantAndEquipment" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment_2" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="mrus_PlantAndEquipmentMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureIntangibleAssetsSummaryOfMovementsOfIntellectualPropertyRight">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_2" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CapitalisedDevelopmentExpenditureMember" xlink:label="ifrs-full_CapitalisedDevelopmentExpenditureMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights" xlink:label="ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PatentsAndIntellectualPropertyMember" xlink:label="mrus_PatentsAndIntellectualPropertyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="mrus_PatentsAndIntellectualPropertyMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="ifrs-full_CapitalisedDevelopmentExpenditureMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTaxationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AverageQualifyingProfitsEffectiveTaxRate" xlink:label="mrus_AverageQualifyingProfitsEffectiveTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates" xlink:label="ifrs-full_DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DutchMember" xlink:label="mrus_DutchMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeTaxAuthority1Axis" xlink:label="mrus_IncomeTaxAuthority1Axis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeTaxAuthority1Domain" xlink:label="mrus_IncomeTaxAuthority1Domain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteMember" xlink:label="mrus_IncyteMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InnovationsBoxRate" xlink:label="mrus_InnovationsBoxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LicenceFeeIncome" xlink:label="ifrs-full_LicenceFeeIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_NL" xlink:label="country_NL"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="ifrs-full_UnusedTaxLossesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeferredTaxAssets" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_LicenceFeeIncome" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="mrus_AverageQualifyingProfitsEffectiveTaxRate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="mrus_InnovationsBoxRate" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_ApplicableTaxRate" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_MaturityAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="mrus_IncomeTaxAuthority1Axis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncyteMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_NL" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeTaxAuthority1Axis" xlink:to="mrus_IncomeTaxAuthority1Domain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeTaxAuthority1Domain" xlink:to="mrus_DutchMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_UnusedTaxLossesMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AgencyBondMember" xlink:label="mrus_AgencyBondMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CommercialPaper1Member" xlink:label="mrus_CommercialPaper1Member"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CorporateFixedIncomeBondsMember" xlink:label="mrus_CorporateFixedIncomeBondsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentHeldtomaturityInvestments" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinancialAssetsTypeMember" xlink:label="ifrs-full_FinancialAssetsTypeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_HeldtomaturityInvestments" xlink:label="ifrs-full_HeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentHeldtomaturityInvestments" xlink:label="ifrs-full_NoncurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfFinancialAssetsAxis" xlink:label="ifrs-full_TypesOfFinancialAssetsAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_USTreasurySecuritiesMember" xlink:label="mrus_USTreasurySecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_CurrentHeldtomaturityInvestments" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NoncurrentHeldtomaturityInvestments" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_HeldtomaturityInvestments" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="ifrs-full_TypesOfFinancialAssetsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="mrus_CommercialPaper1Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="mrus_USTreasurySecuritiesMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="mrus_CorporateFixedIncomeBondsMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="mrus_AgencyBondMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsTypeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeStatementLineItemLocationAxis" xlink:label="mrus_IncomeStatementLineItemLocationAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeStatementLineItemLocationMember" xlink:label="mrus_IncomeStatementLineItemLocationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NetFinanceIncomeExpenseMember" xlink:label="mrus_NetFinanceIncomeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NetForeignExchangeGain" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="mrus_IncomeStatementLineItemLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeStatementLineItemLocationAxis" xlink:to="mrus_IncomeStatementLineItemLocationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_NetFinanceIncomeExpenseMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentInterestReceivable" xlink:label="ifrs-full_CurrentInterestReceivable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CurrentPrepaidGeneralExpenses" xlink:label="mrus_CurrentPrepaidGeneralExpenses"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CurrentPrepaidPensionCosts" xlink:label="mrus_CurrentPrepaidPensionCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CurrentUnbilledReceivables" xlink:label="mrus_CurrentUnbilledReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:label="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="ifrs-full_CurrentTradeReceivables" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="mrus_CurrentUnbilledReceivables" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="mrus_CurrentPrepaidGeneralExpenses" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="mrus_CurrentPrepaidPensionCosts" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="ifrs-full_CurrentInterestReceivable" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureOtherLiabilitiesAndAccrualsSummaryOfShorttermAndPayableWithin1Year">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AccruedAuditorsFee" xlink:label="mrus_AccruedAuditorsFee"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AccruedIntellectualPropertyLegalFee" xlink:label="mrus_AccruedIntellectualPropertyLegalFee"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AccruedPersonnel" xlink:label="mrus_AccruedPersonnel"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AccruedResearchAndDevelopmentStudies" xlink:label="mrus_AccruedResearchAndDevelopmentStudies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAdvances" xlink:label="ifrs-full_CurrentAdvances"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:label="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherAccruals" xlink:label="mrus_OtherAccruals"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="mrus_AccruedAuditorsFee" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="mrus_AccruedPersonnel" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="mrus_AccruedResearchAndDevelopmentStudies" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="mrus_AccruedIntellectualPropertyLegalFee" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="ifrs-full_CurrentAdvances" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="mrus_OtherAccruals" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenue">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncome" xlink:label="ifrs-full_DeferredIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDeferredIncomeAbstract" xlink:label="mrus_DisclosureOfDeferredIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeAbstract" xlink:to="ifrs-full_DeferredIncomeClassifiedAsCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeAbstract" xlink:to="ifrs-full_DeferredIncomeClassifiedAsNoncurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeAbstract" xlink:to="ifrs-full_DeferredIncome" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AmountPaidForFullTimeEquivalentFunding" xlink:label="mrus_AmountPaidForFullTimeEquivalentFunding"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AmountPaidToCompensateForResearchServices" xlink:label="mrus_AmountPaidToCompensateForResearchServices"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_BettaPharmaceuticalsCoLtdMember" xlink:label="mrus_BettaPharmaceuticalsCoLtdMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="ifrs-full_ConsiderationPaidReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncome" xlink:label="ifrs-full_DeferredIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DeferredRevenueMember" xlink:label="mrus_DeferredRevenueMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDeferredIncomeAbstract" xlink:label="mrus_DisclosureOfDeferredIncomeAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDeferredIncomeLineItems" xlink:label="mrus_DisclosureOfDeferredIncomeLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDeferredIncomeTable" xlink:label="mrus_DisclosureOfDeferredIncomeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteCollaborationAgreementMember" xlink:label="mrus_IncyteCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteCorporationMember" xlink:label="mrus_IncyteCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteShareSubscriptionAgreementMember" xlink:label="mrus_IncyteShareSubscriptionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MilestonePaymentReceived" xlink:label="mrus_MilestonePaymentReceived"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NonRefundableUpfrontPaymentsReceivable" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OnoResearchAndLicenseAgreementMember" xlink:label="mrus_OnoResearchAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PurchasePricePerCommonShare" xlink:label="mrus_PurchasePricePerCommonShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueRecognized" xlink:label="mrus_RevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueRemainingPerformanceObligations" xlink:label="mrus_RevenueRemainingPerformanceObligations"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SimcereCollaborationAndLicenseAgreementMember" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_UpfrontAndMilestonePaymentsMember" xlink:label="mrus_UpfrontAndMilestonePaymentsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_UpfrontPayment" xlink:label="mrus_UpfrontPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeAbstract" xlink:to="mrus_DisclosureOfDeferredIncomeTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="ifrs-full_DeferredIncome" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_NonRefundableUpfrontPaymentsReceivable" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_SharePurchasedPricePerShare" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_UpfrontPayment" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_PurchasePricePerCommonShare" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="ifrs-full_ConsiderationPaidReceived" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_MilestonePaymentReceived" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_RevenueRecognized" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_RevenueRemainingPerformanceObligations" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_AmountPaidForFullTimeEquivalentFunding" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_AmountPaidToCompensateForResearchServices" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="ifrs-full_TypesOfContractsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="srt_ProductOrServiceAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="ifrs-full_RangeAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="mrus_DisclosureOfDeferredIncomeLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncyteCorporationMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrus_UpfrontAndMilestonePaymentsMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="mrus_DeferredRevenueMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteCollaborationAgreementMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_SimcereCollaborationAndLicenseAgreementMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_OnoResearchAndLicenseAgreementMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteShareSubscriptionAgreementMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_BettaPharmaceuticalsCoLtdMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationEquity">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AggregateValueOfCommonSharesIssued" xlink:label="mrus_AggregateValueOfCommonSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements" xlink:label="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="ifrs-full_EntitysTotalForAssociatesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GainsOnLitigationSettlements" xlink:label="ifrs-full_GainsOnLitigationSettlements"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncreaseDecreaseInCapital" xlink:label="mrus_IncreaseDecreaseInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncreaseDecreaseInSharePremium" xlink:label="mrus_IncreaseDecreaseInSharePremium"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteCorporationMember" xlink:label="mrus_IncyteCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InitialPublicOfferingMember" xlink:label="mrus_InitialPublicOfferingMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InvestorsMember" xlink:label="mrus_InvestorsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NetProceedsFromIssuingShares" xlink:label="mrus_NetProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OverAllotmentOption1Member" xlink:label="mrus_OverAllotmentOption1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PrepaidShareIssueRelatedCost" xlink:label="mrus_PrepaidShareIssueRelatedCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RegeneronPharmaceuticalsIncMember" xlink:label="mrus_RegeneronPharmaceuticalsIncMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ReverseStockSplitConversionRatio" xlink:label="mrus_ReverseStockSplitConversionRatio"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SubsidiarySaleOfStock1Axis" xlink:label="mrus_SubsidiarySaleOfStock1Axis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SubsidiarySaleOfStockDomain" xlink:label="mrus_SubsidiarySaleOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ReverseStockSplitConversionRatio" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_NetProceedsFromIssuingShares" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PrepaidShareIssueRelatedCost" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_IncreaseDecreaseInCapital" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_IncreaseDecreaseInSharePremium" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharePurchasedPricePerShare" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_AggregateValueOfCommonSharesIssued" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_GainsOnLitigationSettlements" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="mrus_SubsidiarySaleOfStock1Axis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForAssociatesMember" xlink:to="mrus_RegeneronPharmaceuticalsIncMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncyteCorporationMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_InvestorsMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_EntitysTotalForAssociatesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_SubsidiarySaleOfStock1Axis" xlink:to="mrus_SubsidiarySaleOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_SubsidiarySaleOfStockDomain" xlink:to="mrus_InitialPublicOfferingMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_SubsidiarySaleOfStockDomain" xlink:to="mrus_OverAllotmentOption1Member" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfCommonSharesOutstanding">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfSharesIssuedForCash" xlink:label="mrus_NumberOfSharesIssuedForCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="mrus_NumberOfSharesIssuedForCash" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationShareBasedPaymentArrangements">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice" xlink:label="mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfGrantAward" xlink:label="mrus_DescriptionOfGrantAward"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfNonVestingCondition" xlink:label="mrus_DescriptionOfNonVestingCondition"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfOptionLapse" xlink:label="mrus_DescriptionOfOptionLapse"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfOptionsGranted" xlink:label="mrus_DescriptionOfOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NonexecutiveCompensationProgramMember" xlink:label="mrus_NonexecutiveCompensationProgramMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfCommonShareEntitledToReceive" xlink:label="mrus_NumberOfCommonShareEntitledToReceive"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod" xlink:label="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfInitialVestingOptions" xlink:label="mrus_PercentageOfInitialVestingOptions"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfRemainingVestingOptions" xlink:label="mrus_PercentageOfRemainingVestingOptions"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfVestingOptions" xlink:label="mrus_PercentageOfVestingOptions"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PeriodOfAwardsWillBeVestedAndExercised" xlink:label="mrus_PeriodOfAwardsWillBeVestedAndExercised"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions" xlink:label="mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PeriodOfRemainingOptionsVestingPeriod" xlink:label="mrus_PeriodOfRemainingOptionsVestingPeriod"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards" xlink:label="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SharebasedCompensationAwardVestingPeriod" xlink:label="mrus_SharebasedCompensationAwardVestingPeriod"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SharebasedCompensationWeightedAverageRemainingContractualLife" xlink:label="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TwoThousandSixteenOptionPlanMember" xlink:label="mrus_TwoThousandSixteenOptionPlanMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TwoThousandTenOptionPlanMember" xlink:label="mrus_TwoThousandTenOptionPlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageSharePrice" xlink:label="ifrs-full_WeightedAverageSharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_DescriptionOfOptionsGranted" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharebasedCompensationAwardVestingPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PercentageOfInitialVestingOptions" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PercentageOfRemainingVestingOptions" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PeriodOfRemainingOptionsVestingPeriod" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PercentageOfVestingOptions" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_DescriptionOfOptionLapse" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_DescriptionOfNonVestingCondition" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_NumberOfCommonShareEntitledToReceive" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PeriodOfAwardsWillBeVestedAndExercised" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_DescriptionOfGrantAward" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="mrus_TwoThousandTenOptionPlanMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="mrus_TwoThousandSixteenOptionPlanMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="mrus_NonexecutiveCompensationProgramMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AllOtherEmployeesMember" xlink:label="mrus_AllOtherEmployeesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_EmployeeOptionExercisedPricePerShare" xlink:label="mrus_EmployeeOptionExercisedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_FairValueAssumptionsGrantDateSharePrice" xlink:label="mrus_FairValueAssumptionsGrantDateSharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_FairValueAssumptionsGrantDateSharePrice" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharePurchasedPricePerShare" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_EmployeeOptionExercisedPricePerShare" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_AllOtherEmployeesMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_2" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AllOtherEmployeesMember" xlink:label="mrus_AllOtherEmployeesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_AllOtherEmployeesMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" order="1.0900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueSummaryOfRevenue">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeMember" xlink:label="mrus_IncomeMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember" xlink:label="mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueFromContractsWithCustomersMember" xlink:label="mrus_RevenueFromContractsWithCustomersMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueLineItems" xlink:label="mrus_RevenueLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueTable" xlink:label="mrus_RevenueTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_UpfrontPaymentAmortizationMember" xlink:label="mrus_UpfrontPaymentAmortizationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_UpfrontPaymentAmortizationMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_RevenueFromContractsWithCustomersMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncomeMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="mrus_RevenueTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="ifrs-full_Revenue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueTable" xlink:to="mrus_RevenueLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AmountRemittedToOtherBeneficiaries" xlink:label="mrus_AmountRemittedToOtherBeneficiaries"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_BettaPharmaceuticalsCoLtdMember" xlink:label="mrus_BettaPharmaceuticalsCoLtdMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_GrantIncome" xlink:label="mrus_GrantIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IFRS15RevenueFromContractsWithCustomersMember" xlink:label="mrus_IFRS15RevenueFromContractsWithCustomersMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncreaseDecreaseInDeferredRevenue1" xlink:label="mrus_IncreaseDecreaseInDeferredRevenue1"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteCollaborationAgreementMember" xlink:label="mrus_IncyteCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MilestoneRevenues" xlink:label="mrus_MilestoneRevenues"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MilestoneRevenuesAndCostsReimbursements" xlink:label="mrus_MilestoneRevenuesAndCostsReimbursements"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OnoResearchAndLicenseAgreementMember" xlink:label="mrus_OnoResearchAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ReimbursementOfGrant" xlink:label="mrus_ReimbursementOfGrant"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember" xlink:label="mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueLineItems" xlink:label="mrus_RevenueLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueRecognizedIncludedInDeferredRevenue" xlink:label="mrus_RevenueRecognizedIncludedInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueRecognizedNotIncludedInDeferredRevenue" xlink:label="mrus_RevenueRecognizedNotIncludedInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RevenueTable" xlink:label="mrus_RevenueTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SimcereCollaborationAndLicenseAgreementMember" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SimcerePharmaceuticalCoLtdMember" xlink:label="mrus_SimcerePharmaceuticalCoLtdMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TermsOfPaymentOfTradeReceivables" xlink:label="mrus_TermsOfPaymentOfTradeReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_UpfrontPaymentAmortization" xlink:label="mrus_UpfrontPaymentAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_OnoResearchAndLicenseAgreementMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_SimcerePharmaceuticalCoLtdMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_BettaPharmaceuticalsCoLtdMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncyteCollaborationAgreementMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="mrus_IFRS15RevenueFromContractsWithCustomersMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="mrus_RevenueTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_UpfrontPaymentAmortization" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="ifrs-full_Revenue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_MilestoneRevenuesAndCostsReimbursements" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_MilestoneRevenues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_GrantIncome" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_ReimbursementOfGrant" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_AmountRemittedToOtherBeneficiaries" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_TermsOfPaymentOfTradeReceivables" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_IncreaseDecreaseInDeferredRevenue1" order="1.0900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_RevenueRecognizedIncludedInDeferredRevenue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_RevenueRecognizedNotIncludedInDeferredRevenue" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueTable" xlink:to="ifrs-full_TypesOfContractsAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueTable" xlink:to="mrus_RevenueLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteCollaborationAgreementMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_OnoResearchAndLicenseAgreementMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_SimcereCollaborationAndLicenseAgreementMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_BettaPharmaceuticalsCoLtdMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdditionsInContractAssets" xlink:label="mrus_AdditionsInContractAssets"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdditionsInContractLiabilities" xlink:label="mrus_AdditionsInContractLiabilities"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AdditionsToTradeReceivables" xlink:label="mrus_AdditionsToTradeReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ContractAssets" xlink:label="ifrs-full_ContractAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ContractAssets" xlink:label="ifrs-full_ContractAssets_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DeductionsInContractAssets" xlink:label="mrus_DeductionsInContractAssets"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DeductionsInContractLiabilities" xlink:label="mrus_DeductionsInContractLiabilities"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DeductionsInTradeReceivables" xlink:label="mrus_DeductionsInTradeReceivables"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DeferredRevenueMember" xlink:label="mrus_DeferredRevenueMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeReceivablesMember" xlink:label="ifrs-full_TradeReceivablesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_UnbilledReceivablesMember" xlink:label="mrus_UnbilledReceivablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_TradeReceivablesMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="mrus_UnbilledReceivablesMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract" xlink:to="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_TradeReceivables" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_AdditionsToTradeReceivables" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_DeductionsInTradeReceivables" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_TradeReceivables_2" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_ContractAssets" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_AdditionsInContractAssets" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_DeductionsInContractAssets" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_ContractAssets_2" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_ContractLiabilities" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_AdditionsInContractLiabilities" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_DeductionsInContractLiabilities" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_ContractLiabilities_2" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:to="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="mrus_DeferredRevenueMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOperatingExpensesAbstract" xlink:label="mrus_DisclosureOfOperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IPAndLicenseCosts" xlink:label="mrus_IPAndLicenseCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LitigationCosts" xlink:label="mrus_LitigationCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ManufacturingCost" xlink:label="mrus_ManufacturingCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherExpenseByNature" xlink:label="ifrs-full_OtherExpenseByNature"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherOperatingExpenses" xlink:label="mrus_OtherOperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherResearchAndDevelopmentExpenses" xlink:label="mrus_OtherResearchAndDevelopmentExpenses"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PersonnelRelatedResearchAndDevelopmentExpense" xlink:label="mrus_PersonnelRelatedResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_ManufacturingCost" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_IPAndLicenseCosts" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_PersonnelRelatedResearchAndDevelopmentExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_OtherResearchAndDevelopmentExpenses" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_LitigationCosts" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_OtherOperatingExpenses" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="ifrs-full_OtherExpenseByNature" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="ifrs-full_OperatingExpense" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClinicalCosts" xlink:label="mrus_ClinicalCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOperatingExpensesAbstract" xlink:label="mrus_DisclosureOfOperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DiscoveryAndPreclinicalCosts" xlink:label="mrus_DiscoveryAndPreclinicalCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherResearchAndDevelopmentExpenseOther" xlink:label="mrus_OtherResearchAndDevelopmentExpenseOther"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherResearchAndDevelopmentExpenses" xlink:label="mrus_OtherResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_DiscoveryAndPreclinicalCosts" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_ClinicalCosts" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_OtherResearchAndDevelopmentExpenseOther" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_OtherResearchAndDevelopmentExpenses" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ClinicalCosts" xlink:label="mrus_ClinicalCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOperatingExpensesAbstract" xlink:label="mrus_DisclosureOfOperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_GeneralLegalInsuranceAndFacilityRelatedExpenses" xlink:label="mrus_GeneralLegalInsuranceAndFacilityRelatedExpenses"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IntellectualPropertyCosts" xlink:label="mrus_IntellectualPropertyCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PreclinicalCosts" xlink:label="mrus_PreclinicalCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="ifrs-full_ProfessionalFeesExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_GeneralLegalInsuranceAndFacilityRelatedExpenses" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_PreclinicalCosts" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_ClinicalCosts" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_IntellectualPropertyCosts" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesOperatingExpensesByNature">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ContractManufacturingExpenses" xlink:label="mrus_ContractManufacturingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOperatingExpensesAbstract" xlink:label="mrus_DisclosureOfOperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherExternalAndOutsourcedCosts" xlink:label="mrus_OtherExternalAndOutsourcedCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_ContractManufacturingExpenses" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_OtherExternalAndOutsourcedCosts" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="ifrs-full_OperatingExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_HealthInsurance" xlink:label="mrus_HealthInsurance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherShorttermEmployeeBenefits" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PensionCosts" xlink:label="mrus_PensionCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SocialSecurityContributions" xlink:label="ifrs-full_SocialSecurityContributions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_WBSOSubsidy" xlink:label="mrus_WBSOSubsidy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_WagesAndSalaries" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="mrus_WBSOSubsidy" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_SocialSecurityContributions" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="mrus_HealthInsurance" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="mrus_PensionCosts" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_OtherShorttermEmployeeBenefits" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfEmployeeBenefitsAbstract" xlink:label="mrus_DisclosureOfEmployeeBenefitsAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfEmployeeBenefitsTable" xlink:label="mrus_DisclosureOfEmployeeBenefitsTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfShareOfEquityInvestmentLineItems" xlink:label="mrus_DisclosureOfShareOfEquityInvestmentLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeStatementLineItemLocationAxis" xlink:label="mrus_IncomeStatementLineItemLocationAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeStatementLineItemLocationMember" xlink:label="mrus_IncomeStatementLineItemLocationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ManagementAndAdministrationCostsMember" xlink:label="mrus_ManagementAndAdministrationCostsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherExpensesMember" xlink:label="mrus_OtherExpensesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ResearchAndDevelopmentCostsMember" xlink:label="mrus_ResearchAndDevelopmentCostsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_StockAwardExpense" xlink:label="mrus_StockAwardExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEmployeeBenefitsAbstract" xlink:to="mrus_DisclosureOfEmployeeBenefitsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="mrus_IncomeStatementLineItemLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="mrus_DisclosureOfShareOfEquityInvestmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfShareOfEquityInvestmentLineItems" xlink:to="mrus_StockAwardExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeStatementLineItemLocationAxis" xlink:to="mrus_IncomeStatementLineItemLocationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_ResearchAndDevelopmentCostsMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_ManagementAndAdministrationCostsMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_OtherExpensesMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfEmployeeBenefitsLineItems" xlink:label="mrus_DisclosureOfEmployeeBenefitsLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfEmployeeBenefitsTable" xlink:label="mrus_DisclosureOfEmployeeBenefitsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeStatementLineItemLocationAxis" xlink:label="mrus_IncomeStatementLineItemLocationAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncomeStatementLineItemLocationMember" xlink:label="mrus_IncomeStatementLineItemLocationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ManagementAndAdministrationCostsMember" xlink:label="mrus_ManagementAndAdministrationCostsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_NL" xlink:label="country_NL"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfEmployees" xlink:label="ifrs-full_NumberOfEmployees"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEmployeeBenefitsLineItems" xlink:to="ifrs-full_NumberOfEmployees" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="mrus_IncomeStatementLineItemLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="mrus_DisclosureOfEmployeeBenefitsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_NL" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeStatementLineItemLocationAxis" xlink:to="mrus_IncomeStatementLineItemLocationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_ManagementAndAdministrationCostsMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="mrus_DisclosureOfEmployeeBenefitsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureOtherIncomeExpenseSummaryOfOtherIncomeExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InterestAndOtherExpense" xlink:label="mrus_InterestAndOtherExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InterestAndRelatedIncome" xlink:label="mrus_InterestAndRelatedIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="ifrs-full_NetForeignExchangeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherIncome" xlink:label="ifrs-full_OtherIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherIncomeExpense" xlink:label="mrus_OtherIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RentalExpensesOnRealEstateAbstract" xlink:label="mrus_RentalExpensesOnRealEstateAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradingIncomeExpenseOnDerivativeFinancialInstruments" xlink:label="ifrs-full_TradingIncomeExpenseOnDerivativeFinancialInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="mrus_InterestAndRelatedIncome" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="ifrs-full_NetForeignExchangeGain" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="ifrs-full_FinanceIncome" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="ifrs-full_OtherIncome" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="mrus_InterestAndOtherExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="ifrs-full_NetForeignExchangeLoss" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="ifrs-full_TradingIncomeExpenseOnDerivativeFinancialInstruments" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="ifrs-full_FinanceCosts" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="mrus_OtherIncomeExpense" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureOtherIncomeExpenseAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DerivativeFinancialAssets" xlink:label="ifrs-full_DerivativeFinancialAssets"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:label="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EffectOfOverlayApproachReclassificationAxis" xlink:label="ifrs-full_EffectOfOverlayApproachReclassificationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GainsOnLitigationSettlements" xlink:label="ifrs-full_GainsOnLitigationSettlements"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IAS39Member" xlink:label="mrus_IAS39Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InAccordanceWithIFRS9Member" xlink:label="ifrs-full_InAccordanceWithIFRS9Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_IncyteShareSubscriptionAgreementMember" xlink:label="mrus_IncyteShareSubscriptionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NetInterestIncomeAndExpenseTable" xlink:label="mrus_NetInterestIncomeAndExpenseTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PurchasePricePerCommonShare" xlink:label="mrus_PurchasePricePerCommonShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RegeneronSubscriptionAgreementMember" xlink:label="mrus_RegeneronSubscriptionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RentalExpensesOnRealEstateAbstract" xlink:label="mrus_RentalExpensesOnRealEstateAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ValueOfCommonSharesIssued" xlink:label="mrus_ValueOfCommonSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:to="mrus_PurchasePricePerCommonShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:to="mrus_ValueOfCommonSharesIssued" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:to="ifrs-full_GainsOnLitigationSettlements" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:to="ifrs-full_DerivativeFinancialAssets" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" xlink:to="ifrs-full_FinanceCosts" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EffectOfOverlayApproachReclassificationAxis" xlink:to="ifrs-full_InAccordanceWithIFRS9Member" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InAccordanceWithIFRS9Member" xlink:to="mrus_IAS39Member" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NetInterestIncomeAndExpenseTable" xlink:to="ifrs-full_EffectOfOverlayApproachReclassificationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NetInterestIncomeAndExpenseTable" xlink:to="ifrs-full_TypesOfContractsAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NetInterestIncomeAndExpenseTable" xlink:to="mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="mrus_NetInterestIncomeAndExpenseTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteShareSubscriptionAgreementMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_RegeneronSubscriptionAgreementMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:label="mrus_DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumeratorComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:label="mrus_NumeratorComputationOfBasicAndDilutedEarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_WeightedAverageNumberOfShares" xlink:label="mrus_WeightedAverageNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="mrus_WeightedAverageNumberOfShares" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="mrus_NumeratorComputationOfBasicAndDilutedEarningsPerShareAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="mrus_DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NumeratorComputationOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureLossPerShareAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DividendDeclared" xlink:label="mrus_DividendDeclared"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="ifrs-full_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="mrus_DividendDeclared" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfMaximumCreditExposure">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_FixedRateOfInstrumentsAbstract" xlink:label="mrus_FixedRateOfInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_HeldtomaturityInvestments" xlink:label="ifrs-full_HeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="ifrs-full_MaximumExposureToCreditRisk"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TradeAndUnbilledReceivables" xlink:label="mrus_TradeAndUnbilledReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_FixedRateOfInstrumentsAbstract" xlink:to="mrus_TradeAndUnbilledReceivables" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_FixedRateOfInstrumentsAbstract" xlink:to="ifrs-full_HeldtomaturityInvestments" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_FixedRateOfInstrumentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_FixedRateOfInstrumentsAbstract" xlink:to="ifrs-full_MaximumExposureToCreditRisk" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfAgingOfTradeAndUnbilledReceivables">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:label="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:label="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember" xlink:label="ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinancialAssetsNeitherPastDueNorImpairedMember" xlink:label="ifrs-full_FinancialAssetsNeitherPastDueNorImpairedMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_FixedRateOfInstrumentsAbstract" xlink:label="mrus_FixedRateOfInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ImpairmentOfFinancialAssetsAxis" xlink:label="ifrs-full_ImpairmentOfFinancialAssetsAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TradeAndUnbilledReceivables" xlink:label="mrus_TradeAndUnbilledReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:to="mrus_TradeAndUnbilledReceivables" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:to="ifrs-full_ImpairmentOfFinancialAssetsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:to="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember" xlink:to="ifrs-full_FinancialAssetsNeitherPastDueNorImpairedMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_FixedRateOfInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ImpairmentOfFinancialAssetsAxis" xlink:to="ifrs-full_EntitysTotalForImpairmentOfFinancialAssetsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AllowanceForImpairment" xlink:label="mrus_AllowanceForImpairment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio" xlink:label="mrus_WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="mrus_AllowanceForImpairment" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="mrus_WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfMaturityAnalysisForNonderivativeFinancialLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CarryingAmountAndValueMember" xlink:label="mrus_CarryingAmountAndValueMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows" xlink:label="mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="mrus_CarryingAmountAndValueMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_MaturityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfSensitivityAnalysisForChangeInPrimaryCurrencyExposure">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CashAndCashEquivalents1Member" xlink:label="mrus_CashAndCashEquivalents1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_FivePercentageDecreaseInFunctionalRateMember" xlink:label="mrus_FivePercentageDecreaseInFunctionalRateMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_FivePercentageIncreaseInFunctionalRateMember" xlink:label="mrus_FivePercentageIncreaseInFunctionalRateMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax" xlink:label="mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_InvestmentMember" xlink:label="mrus_InvestmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherAssetsMember" xlink:label="ifrs-full_OtherAssetsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TaxesAndSocialSecurityLiabilitiesMember" xlink:label="mrus_TaxesAndSocialSecurityLiabilitiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TradeAndOtherReceivableMember" xlink:label="mrus_TradeAndOtherReceivableMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TradePayablesOtherLiabilitiesAndAccrualsMember" xlink:label="mrus_TradePayablesOtherLiabilitiesAndAccrualsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_USD" xlink:label="currency_USD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="srt_CurrencyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="mrus_CashAndCashEquivalents1Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="mrus_InvestmentMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="mrus_TradeAndOtherReceivableMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="ifrs-full_OtherAssetsMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="mrus_TaxesAndSocialSecurityLiabilitiesMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="mrus_TradePayablesOtherLiabilitiesAndAccrualsMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="mrus_FivePercentageIncreaseInFunctionalRateMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="mrus_FivePercentageDecreaseInFunctionalRateMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_InterestRateTypesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CurrencyRiskMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfInterestBearingFinancialInstruments">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfInterestBearingFinancialInstrumentsAbstract" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfInterestBearingFinancialInstrumentsTable" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="ifrs-full_FloatingInterestRateMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_HeldtomaturityInvestments" xlink:label="ifrs-full_HeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfInterestBearingFinancialInstrumentsAbstract" xlink:to="mrus_DisclosureOfInterestBearingFinancialInstrumentsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems" xlink:to="ifrs-full_HeldtomaturityInvestments" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfInterestBearingFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfInterestBearingFinancialInstrumentsTable" xlink:to="mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="ifrs-full_FloatingInterestRateMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_InterestRateTypesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatement">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_BonusMember" xlink:label="mrus_BonusMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DirectorsRemunerationExpense" xlink:label="ifrs-full_DirectorsRemunerationExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementAbstract" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_GrossSalaryMember" xlink:label="mrus_GrossSalaryMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OptionCostMember" xlink:label="mrus_OptionCostMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PensionMember" xlink:label="mrus_PensionMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ShelleyMargetsonFormerCOOMember" xlink:label="mrus_ShelleyMargetsonFormerCOOMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TonLogtenbergCEOMember" xlink:label="mrus_TonLogtenbergCEOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="mrus_GrossSalaryMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="mrus_BonusMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="mrus_PensionMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="mrus_OptionCostMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementAbstract" xlink:to="mrus_DisclosureChargedToTheProfitAndLossStatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="ifrs-full_DirectorsRemunerationExpense" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:to="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_TonLogtenbergCEOMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_ShelleyMargetsonFormerCOOMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatementParenthetical">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementAbstract" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_EmployeeBenefitSchemeAxis" xlink:label="mrus_EmployeeBenefitSchemeAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_EmployeeBenefitSchemeDomain" xlink:label="mrus_EmployeeBenefitSchemeDomain"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SeveranceCostsMember" xlink:label="mrus_SeveranceCostsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementAbstract" xlink:to="mrus_DisclosureChargedToTheProfitAndLossStatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="ifrs-full_WagesAndSalaries" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:to="mrus_EmployeeBenefitSchemeAxis" order="3.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:to="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_EmployeeBenefitSchemeAxis" xlink:to="mrus_EmployeeBenefitSchemeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_EmployeeBenefitSchemeDomain" xlink:to="mrus_SeveranceCostsMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AndresSirulnikChiefMedicalOfficerMember" xlink:label="mrus_AndresSirulnikChiefMedicalOfficerMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers" xlink:label="mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementAbstract" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ExercisePricePerShare" xlink:label="mrus_ExercisePricePerShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_JohnCrowleyChiefFinancialOfficerMember" xlink:label="mrus_JohnCrowleyChiefFinancialOfficerMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers" xlink:label="mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers" xlink:label="mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PeterSilvermanSeniorVicePresidentMember" xlink:label="mrus_PeterSilvermanSeniorVicePresidentMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TonLogtenbergCEOMember" xlink:label="mrus_TonLogtenbergCEOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementAbstract" xlink:to="mrus_DisclosureChargedToTheProfitAndLossStatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" xlink:to="mrus_ExercisePricePerShare" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureChargedToTheProfitAndLossStatementTable" xlink:to="mrus_DisclosureChargedToTheProfitAndLossStatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_TonLogtenbergCEOMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_AndresSirulnikChiefMedicalOfficerMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_JohnCrowleyChiefFinancialOfficerMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_PeterSilvermanSeniorVicePresidentMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfRelatedParty">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfRelatedPartyAbstract" xlink:label="mrus_DisclosureOfRelatedPartyAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfRelatedPartyAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfRelatedPartyAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfRelatedPartyAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfRelatedPartyAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfRelatedPartyAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfRelatedPartyAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensation" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfConsolidatedStatementOfProfitAndLossForTheRemunerationOfTheFormerMembersOfTheSupervisoryBoard">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AnandMehraMember" xlink:label="mrus_AnandMehraMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CashCompensationMember" xlink:label="mrus_CashCompensationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardAbstract" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_GregoryPerryMember" xlink:label="mrus_GregoryPerryMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_JohnDeKoningMember" xlink:label="mrus_JohnDeKoningMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LenKanavyMember" xlink:label="mrus_LenKanavyMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LionelCarnotMember" xlink:label="mrus_LionelCarnotMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MarkIwickiMember" xlink:label="mrus_MarkIwickiMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OptionCostMember" xlink:label="mrus_OptionCostMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RemunerationForFormerEmployees" xlink:label="mrus_RemunerationForFormerEmployees"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RussellGreigMember" xlink:label="mrus_RussellGreigMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_WolfgangBertholdMember" xlink:label="mrus_WolfgangBertholdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="mrus_CashCompensationMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="mrus_OptionCostMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardAbstract" xlink:to="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" xlink:to="mrus_RemunerationForFormerEmployees" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" xlink:to="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_RussellGreigMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_MarkIwickiMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_LenKanavyMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_WolfgangBertholdMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_LionelCarnotMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_JohnDeKoningMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_AnandMehraMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_GregoryPerryMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AnandMehraMember" xlink:label="mrus_AnandMehraMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardAbstract" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_GabrieleDallmannMember" xlink:label="mrus_GabrieleDallmannMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_GregoryPerryMember" xlink:label="mrus_GregoryPerryMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_JohnDeKoningMember" xlink:label="mrus_JohnDeKoningMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LenKanavyMember" xlink:label="mrus_LenKanavyMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LionelCarnotMember" xlink:label="mrus_LionelCarnotMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MarkIwickiMember" xlink:label="mrus_MarkIwickiMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard" xlink:label="mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RussellGreigMember" xlink:label="mrus_RussellGreigMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard" xlink:label="mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_WolfgangBertholdMember" xlink:label="mrus_WolfgangBertholdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardAbstract" xlink:to="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" xlink:to="mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" xlink:to="mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardTable" xlink:to="mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_RussellGreigMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_MarkIwickiMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_LenKanavyMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_WolfgangBertholdMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_LionelCarnotMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_JohnDeKoningMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_AnandMehraMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_GregoryPerryMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_GabrieleDallmannMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRelatedPartyDisclosuresAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_AccrualsToEmployeeSeveranceIndemnities" xlink:label="mrus_AccrualsToEmployeeSeveranceIndemnities"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_BiophraseBVMember" xlink:label="mrus_BiophraseBVMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_CooperatiefLspFourUitgeslotenAansprakelijkheidMember" xlink:label="mrus_CooperatiefLspFourUitgeslotenAansprakelijkheidMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfOwnershipInterestByShareholders" xlink:label="mrus_PercentageOfOwnershipInterestByShareholders"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod" xlink:label="mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PercentageOfSeverancePaymentPaid" xlink:label="mrus_PercentageOfSeverancePaymentPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SofinnovaVenturePartnersNineLimitedPartnershipMember" xlink:label="mrus_SofinnovaVenturePartnersNineLimitedPartnershipMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="mrus_PercentageOfSeverancePaymentPaid" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="mrus_AccrualsToEmployeeSeveranceIndemnities" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="mrus_PercentageOfOwnershipInterestByShareholders" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_CooperatiefLspFourUitgeslotenAansprakelijkheidMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_SofinnovaVenturePartnersNineLimitedPartnershipMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_BiophraseBVMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfCommitmentsAndContingenciesAbstract" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfCommitmentsAndContingenciesTable" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LeasesAgreementForCorporateHeadquartersMember" xlink:label="mrus_LeasesAgreementForCorporateHeadquartersMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LeasesExpirationPeriod" xlink:label="mrus_LeasesExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LitigationCosts" xlink:label="mrus_LitigationCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LitigationSettlementsGrantedForAttorneysFees" xlink:label="mrus_LitigationSettlementsGrantedForAttorneysFees"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LitigationSettlementsGrantedForExpertFees" xlink:label="mrus_LitigationSettlementsGrantedForExpertFees"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts" xlink:label="mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_MitCambridgeRealEstateLlcMember" xlink:label="mrus_MitCambridgeRealEstateLlcMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember" xlink:label="mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NonAdjustingEventMember" xlink:label="mrus_NonAdjustingEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OperatingLeaseTermOfLeaseAgreement" xlink:label="mrus_OperatingLeaseTermOfLeaseAgreement"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OtherFundingCommitmentsMember" xlink:label="mrus_OtherFundingCommitmentsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PaymentOfPropertyPlantAndEquipment" xlink:label="mrus_PaymentOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_PurchasePricePerCommonShare" xlink:label="mrus_PurchasePricePerCommonShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RegeneronSubscriptionAgreementMember" xlink:label="mrus_RegeneronSubscriptionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_ReimbursementOfExpenses" xlink:label="mrus_ReimbursementOfExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RentalExpense" xlink:label="ifrs-full_RentalExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_RentAndServiceChargesExpense" xlink:label="mrus_RentAndServiceChargesExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SecurityDeposits" xlink:label="mrus_SecurityDeposits"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement" xlink:label="mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="mrus_MitCambridgeRealEstateLlcMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesAbstract" xlink:to="mrus_DisclosureOfCommitmentsAndContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="ifrs-full_RentalExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_OperatingLeaseTermOfLeaseAgreement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_LeasesExpirationPeriod" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_RentAndServiceChargesExpense" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_SecurityDeposits" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_PaymentOfPropertyPlantAndEquipment" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_LitigationSettlementsGrantedForAttorneysFees" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_LitigationSettlementsGrantedForExpertFees" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_LitigationCosts" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_PurchasePricePerCommonShare" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" xlink:to="mrus_ReimbursementOfExpenses" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesTable" xlink:to="ifrs-full_TypesOfContractsAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesTable" xlink:to="ifrs-full_CounterpartiesAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfCommitmentsAndContingenciesTable" xlink:to="mrus_DisclosureOfCommitmentsAndContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="mrus_OtherFundingCommitmentsMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="mrus_NonAdjustingEventMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_LeasesAgreementForCorporateHeadquartersMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_RegeneronSubscriptionAgreementMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderLease">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeAbstract" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease" xlink:label="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeAbstract" xlink:to="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems" xlink:to="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable" xlink:to="ifrs-full_MaturityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable" xlink:to="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:label="mrus_DisclosureOfEventsAfterReportingPeriodLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfEventsAfterReportingPeriodTable" xlink:label="mrus_DisclosureOfEventsAfterReportingPeriodTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_LeaseTermExpirationDate" xlink:label="mrus_LeaseTermExpirationDate"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_NonAdjustingEventMember" xlink:label="mrus_NonAdjustingEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_OperatingLeaseTermOfLeaseAgreement" xlink:label="mrus_OperatingLeaseTermOfLeaseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RentalExpense" xlink:label="ifrs-full_RentalExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement" xlink:label="mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_SubsequentsEventsAbstract" xlink:label="mrus_SubsequentsEventsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="mrus_OperatingLeaseTermOfLeaseAgreement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="mrus_LeaseTermExpirationDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_RentalExpense" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEventsAfterReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEventsAfterReportingPeriodTable" xlink:to="mrus_DisclosureOfEventsAfterReportingPeriodLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="mrus_NonAdjustingEventMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_SubsequentsEventsAbstract" xlink:to="mrus_DisclosureOfEventsAfterReportingPeriodTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" xlink:label="mrus_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xlink:label="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory" xlink:label="mrus_DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DescriptionOfAccountingPolicyForInvestmentsExplanatory" xlink:label="mrus_DescriptionOfAccountingPolicyForInvestmentsExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DescriptionOfAccountingPolicyForInvestmentsExplanatory" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory" xlink:label="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatoryTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatoryTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIncomeTaxExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfHeldToMaturityInvestmentExplanatory" xlink:label="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory" xlink:label="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock" xlink:label="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfDeferredIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfDeferredIncomeExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfDeferredIncomeExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDeferredRevenueExplanatory" xlink:label="mrus_DisclosureOfDeferredRevenueExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfDeferredRevenueExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory" xlink:label="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfInformationAboutRevenueExplanatory" xlink:label="mrus_DisclosureOfInformationAboutRevenueExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfInformationAboutRevenueExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOperatingExpensesExplanatory" xlink:label="mrus_DisclosureOfOperatingExpensesExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfOperatingExpensesExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOperatingExpensesByNatureExplanatory" xlink:label="mrus_DisclosureOfOperatingExpensesByNatureExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfOperatingExpensesByNatureExplanatory" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatory">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOtherIncomeExpenseExplanatory" xlink:label="mrus_DisclosureOfOtherIncomeExpenseExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfOtherIncomeExpenseExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDetailsOfEarningsPerShareExplanatory" xlink:label="mrus_DisclosureOfDetailsOfEarningsPerShareExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfDetailsOfEarningsPerShareExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatoryTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfInterestBearingFinancialInstrumentsExplanatory" xlink:label="mrus_DisclosureOfInterestBearingFinancialInstrumentsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfMaximumExposureToCreditRiskExplanatory" xlink:label="mrus_DisclosureOfMaximumExposureToCreditRiskExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" xlink:label="ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfMaximumExposureToCreditRiskExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfInterestBearingFinancialInstrumentsExplanatory" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory" xlink:label="mrus_DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureChargedToTheProfitAndLossStatementExplanatory" xlink:label="mrus_DisclosureChargedToTheProfitAndLossStatementExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfDetailedInformationOfRelatedPartyExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationOfRelatedPartyExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory" xlink:label="mrus_DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory" xlink:label="mrus_DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureChargedToTheProfitAndLossStatementExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfDetailedInformationOfRelatedPartyExplanatory" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRelatedPartyExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatory">
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_DisclosureOfCommitmentsAndContingenciesExplanatory" xlink:label="mrus_DisclosureOfCommitmentsAndContingenciesExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfCommitmentsAndContingenciesExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatoryTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20181231.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g696632g05g03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g696632g05g03.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2%L4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $ < 5H  QLE1QP"   "0.@< E  "')R,CDS-S0Y' (% !]-:6-R;W-O
M9G0@5V]R9" M(#(P,3<@,C M1BYD;V-X.$))300E       0EJA>J03\.L="
MP[F+@+UOW3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]       $@ U     0 M    !@       3A"24T#]P
M'   _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             30   %<          $                          0
M           !7    30                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   30     4F=H=&QO;F<   %<    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   $T
M     %)G:'1L;VYG   !7     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     CA"24T$#      7B     $   "@    C@   >
M 0I    7;  8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ C@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M]&Z.[G$L/TC$/@[OI[O=[F_R'?G_ *1GZ12?TOI=@(?C6.!%@((=Q<7NR/\
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T
M*@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    )
ML(=I  0    !    O    .@ #II(   G$  .FD@  "<0061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP-#HR,R R,#HT-3HT. !R<C(Y,S<T
M.0       Z !  ,    !__\  * "  0    !   !7* #  0    !   !-
M       & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@
M P    $  @   @$ !     $   %& @( !     $              $@    !
M    2     $X0DE- _T       @          /_A 4A-30 J    "  ( 1(
M P    $      1H !0    $   !N 1L !0    $   !V 2@  P    $  @
M 3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $
M  "\    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*0 R,#$X.C T.C(S(#(P.C0U.C0X ')R,CDS-S0Y       #H $
M P    '__P  H ( !     $   %<H , !     $   $T          8! P #
M     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "   "
M 0 $     0   48" @ $     0             #P     $   /      ?_A
M/_IH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I
M;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^/'@Z>&UP
M;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@
M6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R+S V+3$T.C4V
M.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W
M=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@(" @(" @
M(" \>&UP.D-R96%T941A=&4^,C Q."TP-"TR,U0R,#HQ.3HR-RLP-3HS,#PO
M>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^4%-C
M<FEP=#4N9&QL(%9E<G-I;VX@-2XR+C(\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,3@M,#0M,C-4,C Z-#4Z-#@K,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#$X+3 T+3(S5#(P.C0U.C0X*S U.C,P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D
M=6-E<CY!8W)O8F%T($1I<W1I;&QE<B Q,"XQ+C0@*%=I;F1O=W,I/"]P9&8Z
M4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @
M(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @
M(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7
M;W)D("T@,C Q-R R,"U&+F1O8W@\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z8W)E
M871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D^<G(R.3,W-#D\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QD8SIF;W)M870^
M:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @
M(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O4F5S;W5R8V52968C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E
M240^>&UP+FEI9#HW0C,S0D,S,S Y-#=%.#$Q.3<W-$4R,T0S.45%,#A%,3PO
M>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^
M>&UP+F1I9#I&.$8T-S8S1# X-#=%.#$Q.3<W-$4R,T0S.45%,#A%,3PO>&UP
M34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE
M;G1)1#YX;7 N9&ED.D8X1C0W-C-$,#@T-T4X,3$Y-S<T13(S1#,Y144P.$4Q
M/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(
M:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I&.$8T
M-S8S1# X-#=%.#$Q.3<W-$4R,T0S.45%,#A%,3PO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q."TP-"TR,U0R
M,#HT-3HS.2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C=!,S-"0S,S,#DT-T4X,3$Y-S<T
M13(S1#,Y144P.$4Q/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#$X+3 T+3(S5#(P.C0U.C0X*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE
M=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@
M:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD
M+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T
M97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HW0C,S
M0D,S,S Y-#=%.#$Q.3<W-$4R,T0S.45%,#A%,3PO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q."TP-"TR,U0R
M,#HT-3HT."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F
M.FEN<W1A;F-E240^>&UP+FEI9#HW03,S0D,S,S Y-#=%.#$Q.3<W-$4R,T0S
M.45%,#A%,3PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F
M.F1O8W5M96YT240^>&UP+F1I9#I&.$8T-S8S1# X-#=%.#$Q.3<W-$4R,T0S
M.45%,#A%,3PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.D8X1C0W-C-$,#@T-T4X,3$Y
M-S<T13(S1#,Y144P.$4Q/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @
M(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R
M36]D93XQ/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_;
M $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_  !$( 34!70,!$0 "$0$#$0'_Q  >  $  @(# 0$!            !P@&
M"0,%"@0" ?_$ %@0   & @$" 08+!@(%!P<-  $" P0%!@ '"!$2$PD4%2&7
MUQ87&#$V559WF+?6(C=!5%>V(U$*,F%X\"1"@96QX?$9&C58EM'4)C,T4V-Q
M<G:1H<'2T__$ !4! 0$                    !_\0 '1$!  $#!0
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M_NRP'RA]<_R&V_P];_\ =E@/E#ZY_D-M_AZW_P"[+ ?*'US_ "&V_P /6_\
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MP)/P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P&!&\7^]Z\_=OJK^Y]R8'!J+Z*2WWG[N_.>_8$GX# 8# 8# 8# 8# 8#
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MQ8^SR%ECI/7&TM43.P6#)BYD*VS<LYZ.5:>:OW*":1%EF*)VRB#=XN@F&W;
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MZ!/-[!9(FJQ\'-/;RWK+AQ68QTC9GCA2P4\MA<DL[8[0B*"E<G 9+O"HMS.
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M!R&VIR9T+O=!M.VB<8Q!+[3'UVLEXM1%^K\]?9I&9.Y&"?INUEX2(9-UHH?
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M"R$S6ZW./IA\C-2BKVMSEV7>**P3]G&"[61?(-&2IG; 'B)B,VY4TQ %B@4
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M;A8;Y97%>/0I9K*2]E22;MRNEYGPX2VP)HE@W243(49)LJ5\N<R:"Z0ICU#
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MKK/';E10/0K@,!@,"JO'7Z?\KO\ > 4_+:A8%JL!@,!@,!@,!@5H9\NM&/\
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M13<QBZ*2K!%$5/"(1XJJFH!?#_9'Q#=HB8,#8*!2@4" 4H$ H% @  % H!T
MH%#U 4 ]0!TZ=/5\V!P),F:)P41:-DC@ @!TD$DS@ ^H0 Q" /00]0^OUX'T
MX# 8# 8# 8# 8# 8# 8$;Q?[WKS]V^JO[GW)@<&HOHI+?>?N[\Y[]@2?@>1/
MAFWTQ=O*7&V9&17'"A6 _(C<E;;:8<;6VM8KM7IJE67;L,6R5^E)LU=9,[5)
M.)JX6EJ9J_4C(YK>+ O'E0=/#!@>NS 8# 8%5>.OT_Y7?[>0"@#[-J$.!:K
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M0>_NZA_JE]0>H>@=0P,CP& P& P& P& P& P& P& P(WB_WO7G[M]5?W/N3
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MO;VI2>T?$/K-:J;'S.]:5<]IJV2V1,C$KN["S(<UCLWG2<BLFRC"H>G5W[Y
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MX"0BH<)%=D,E)&7.@KYDNF9T*1TD%!0%/JJIU#T*@ % "@       >H  /4
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MKR*A"$3%NV H/GZ(&$._PRG*/S %P?#3[2E\,G:0  I>TO:4 #H %#IT
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M3;.Y>5=2C=F0Z*IV[53_  T_%41,8HG5$IC]AC"9,/V1 /5@6NP& P& P&!
M>W.15%TQ)Q<5;$Y4[F79KO6HL&@N">$@J1(X', _LF[CEZ!_$,"(_EXZ9_\
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ME$ _C@$G+=<ZJ:*Z*QT# 1<B2I%#HG'U@54I#"*9A .H%. #_LP.; 8# 8#
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M5N'K['2@=,".H/=M=E7=HK>H2L;9>)BU2A(P&K8Q(J+8*^&!I^3?E2*D$2V
M#'+X1S"Y5 J*8")AZ!,==HP:]KLL^!O(72Z6 IE+)-$!OZ3EGJZ9R@5$7:Z*
M;2)9";PVC(BH$22Z&[3J"8<#*M?'DBUMBQE(20A'4<D5N=)\9H;QA$QU!40,
MT<N"B0O<!1[Q(;NZ_L]/7@9Q@,!@,!@,#53S_BI.0NE&.PCWKPB<!)%4,U;+
M+E(87C;H!A2(8"B(!Z@'IU !$,"@/P8L?U#,?]7._P#_ !P-C7D_(J3CI78
MR$>\9%4CXT$Q=-E4.\0<]1 HJ$+W= _@'_3@5IYD7J[:&YVAR3@6MNEZW0-"
MUNF6ZNP2,I(MY>)VA:9>J1;I.); JV66K5T=U:SR#DC=5PA%1+H#&31.<P!5
MK0-1@];V2L5SG#(%>:"8[FY'O;NYV6\?/-5NN2=EJNE;&P2MYI=4\*[KHFE]
MI$I4?/ M")2Y8I)@@$B@S[ M+KC>W&C2_)31]H:W-]IWCC+:(Y/Q&NI/;MF]
M$5&==&W%I1VT5H#B8>F*%/=E1GUZ.R7.50L.W?*1"2<$+,,#"-J[=VW8N7$7
MS8HE+MUGXW:&O%.U,UV!"7&ODHTIK"W073==I)3C3J=@M;$YKG3)2OSL=7G;
M-K(4EUX3[P3.>P+B<Y@W'>>)6V9*Q1MNTW,4RX1K^JM-<7R-EE=@UME-M&[,
M;$M&12[]I$2J2_G#^OM'$>_$R2:+A\=J*[=8*[[WMVHK5S>>42O;6)2=P4[:
M.F9^QW&[[:<0$VQ9PB$)8FN@-!:N:/6_PH+LZ-4\PN3^:C"P!RW1P(R\Y*1+
M&!9!A7DPYRUNN1C1>0M$99/A7H3;4QL&&K=GN<U8Z9=0WC5WT*RY)QMH>.8N
M+VTQA)!_68(E<29MT4XZ[,F[=6%1BP8AZ ,!@,!@,!@1O%_O>O/W;ZJ_N?<F
M!P:B^BDM]Y^[OSGOV!)^ P& P& P*J\=?I]RN_W@%/RVH.!:K 8# 8# 8# 8
M&-EIM0(_"5)5:V24!87 218.+*_!P/417!X#4' +"(B(J^)WCU']KUX'93$6
MUG(J2AGR95&<HQ=,')3$(</"=(F1.(%.!BB8I3B8@B ]#@4?X8%7^/O&0ND;
M+;+ K8B3/ILOF<8V0;*-BM(\KE1P7SKO,('<]#@GVI]R8 7N*;J/3 ME@,!@
M,!@,!@,!@,!@,#C511<)F272362.'0R:I"J)F#J ]#$. E$.H /K ?6 8'[
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M:U9ZNC)"9EIY\%M>7R9MSZ0UG$T1"9@ZGL#4$E=-4WAZM%()6F9I_(M2K3T
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4XM;%R&,1=FD@DS2 $E3*G.4/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g696632g19c23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g696632g19c23.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2@<4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $ < 5H  QLE1QP"   "0.@< E  "')R,CDS-S0Y' (% !]-:6-R;W-O
M9G0@5V]R9" M(#(P,3<@,C M1BYD;V-X.$))300E       0EJA>J03\.L="
MP[F+@+UOW3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]       $@ U     0 M    !@       3A"24T#]P
M'   _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             30   %<          $                          0
M           !7    30                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   30     4F=H=&QO;F<   %<    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   $T
M     %)G:'1L;VYG   !7     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     CA"24T$#      >-P    $   "@    C@   >
M 0I    >&P 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN
M=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M              #VU@ !     -,M2% @(
M                                    $6-P<G0   %0    ,V1E<V,
M  &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=8
M65H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
MB'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,
M  0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M            $G-21T(@245#-C$Y-C8M,BXQ
M                                          !865H@        \U$
M 0    $6S%A96B                      6%E:(        &^B   X]0
M Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S
M8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#
M(&AT=' Z+R]W=W<N:65C+F-H
M                         &1E<V,         +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%
M0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                          !D97-C         "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,
M  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                       "CP    )S:6<@     $-25"!C=7)V
M!      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &,
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M&!8R2RP?I/I-<Y)2OVW]7VG"%GIU#J&._+I=8UK6BIC&WO=>YW\S^A?ZGO\
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M:^KKW>FYU5=S8#Z7L <UQ+Z_2=H6^IZM%U7L=].M7,)_3,[&9EXC:[:+9++
MP &"6'Z31^<U4OV+T@6-L;@V,<Q]=DM<YLNH!9C;]MOO]'=^CW*W@TXO3\9N
M)AXCZ:&%Q;6T" 7.-CSJ[\Y[W.24V?LN-_H6?YH_N2^RXW^A9_FC^Y-]H/\
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MCF.]E5;F[5M+G<ZKJPZUTYK^HXS+G,M^SUC"M<"X5U_:G/M^W[:V[_TE+/\
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MQZFT,!#3NC5YBQM?_7'_ *:[Z"O?8G?]R;O\X?\ D$E-E)5OL3O^Y-W^</\
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M=^X?P_\ ));G?N'\/_))*84XV/1N]"IE6Z-VQH;,#8WZ/[K6HJCN=^X?P_\
M));G?N'\/_))*9)*.YW[A_#_ ,DEN=^X?P_\DDIC=CT7@"ZMM@:9:'@.@\?G
M*5;&5L;76T,8P!K6M$  :!K0EN=^X?P_\DEN=^X?P_\ ))*<Z[ZM]$N;8'8K
M ZWU2;!(<#>'LO<QWYF[UK?[=CU;QNGX6(^VS&I;4^_9ZKFB"[TVBJK=_P 7
M6W8U&W._</X?^22W._</X?\ DDE/_]D .$))300A      !5     0$    /
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-
M30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D
M  "PAVD !     $   "\    Z  .GC   "<0  Z>,   )Q!!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C T.C(S(#(P.C0R.C(S ')R,CDS
M-S0Y       #H $  P    '__P  H ( !     $   %<H , !     $   $T
M          8! P #     0 &   !&@ %     0   38!&P %     0   3X!
M*  #     0 "   " 0 $     0   48" @ $     0              2
M  $   !(     3A"24T#_0      "           _^$!2$U- "H    (  @!
M$@ #     0     !&@ %     0   &X!&P %     0   '8!*  #     0 "
M   !,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $
M 0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I #(P,3@Z,#0Z,C,@,C Z-#(Z,C, <G(R.3,W-#D       .@
M 0 #     ?__  "@ @ $     0   5R@ P $     0   30         !@$#
M  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (
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M_&?S;YP]4<O^"H';\9_-OG#U1R_X*@=OQG\V^</5'+_@J!V_&?S;YP]4<O\
M@J!V_&?S;YP]4<O^"H';\9_-OG#U1R_X*@=OQG\V^</5'+_@J!V_&?S;YP]4
M<O\ @J!V_&?S;YP]4<O^"H';\9_-OG#U1R_X*@=OQG\V^</5'+_@J!V_&?S;
MYP]4<O\ @J!V_&?S;YP]4<O^"H';\9_-OG#U1R_X*@=OQG\V^</5'+_@J!V_
M&?S;YP]4<O\ @J!V_&?S;YP]4<O^"H';\9_-OG#U1R_X*@=OQG\V^</5'+_@
MJ!V_&?S;YP]4<O\ @J!V_&?S;YP]4<O^"H';\9_-OG#U1R_X*@=OQG\V^</5
M'+_@J"+XY/$DSSMDM2ECDV8@HL282(&5+8F[1E0?<R8Z@#+&(R',DD:HD-K;
MIAI5K@ /8 5[7O06%QG\W'+I!RU]:LSH)!H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H%!7);X?Y]T/86]],_T$F8S^;C
MET@Y:^M69T$@T"@4"@KQ&);(UNJ'+T)5.IYT6C^(L+O[.S""59,@>)'(\NHW
MM<2()=CKG."=@9RCK&&C+L%"5Q807N.X@L/0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!05R6^'^?=#V%O?3/]!)F,_FXY=(.6OK
M5F=!(- H% H*JPWZ96=^@G3W[V9TH+54"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4%<EOA_GW0]A;WTS_029C/YN.72#EKZU9G0
M2#01KF.1S2'XLGTJQVQL$DFL>B[J\1]EE+RL8(^M5MZ<2D?91U;VMX6D)TZ8
ML]5Q*9 ,Q<806@LH0V4W7I@S36ZWLY*H=$)NR(L=HT,.TK:7-2V76IT8GI:L
MFX=04YE<2=(M"%::1( 18<>;H&_N#2L6HY#=S>W5F0GD@2(%I;@$D:>]7>5)
M[*X$Y3QKBZN YVPWF[-^.X_#(Z]%S>",^&9E V2\4D9RE^<R9<_2-AR7'C06
M0M;$,B3LT@2$)Q(U:%(WA0_*?#+:?--FMS.#5-\#ZSWQ6?B/!3'8$)T^*WNY
M2EO4Y&DYJD\M9)FE04A.0S-M3I5(R;64+T;LG #=16-.#G"K[H5TG)(^U20S
M3=P@ T;NL<$2=*5IC$-P),;1$6.,5IOEQ8)))O'ANG,L:/C+!'M"&]K;0-7W
M0MI-=VY_<T^F[7^23'4:=<K*5Z8Q$J5):E4!( M 5:<#LH."8989@!#*L$JP
MA6%>]MV@_&/?=#FDR2/3<Q(]-G"!IE3DHLG)/<-,(DR(L=PB'O*#[3@VY9=K
M!V7%8L5[7O;FV7VT'RU'W1CI$3'G)QZ9N$,$,DP90A%Z7+C!<18A!O< OEY;
M>#>]K[HMEMMME_X ^S(ONA;2;&EQ*!;INX0!2:<A1. 3&[3&)40$I<G I*+&
M.\X*N$\L!E@G%[M]PRP@V$+9:]P\'_="^DU/'D,D%INX0 :-P7JV\I*7IB&)
MQ+-1A+$8:>FO-PA+3CL:&Q1G&BN.]A6N"VSG#RS_ '0MI->DCVL3Z;N$ (+8
M4 7!4!9IB$2:H*&>!/8M$ ,W,LH4;X["N7<1=K L(6]S7M0>LQ_=$&DI_=V]
MF2Z:^$$3J7)2%,2<NTP"3I"ABM>]A*#K3DRY9>RU]H[ %L_+:@])9]T6Z142
MQ0C-TS\(6,Q*>:G&,G2[<9(QE#$ 0BQ_+L.^"]P[0BN&VVU[7V6Y]@?7D'W0
MKI.CAR,A7IMU_J1+FY*Y%";],8E( $JR[&%E'7O."MQ0"U]AI6R^X+FWKVYZ
M#P9]T+:3BXZ1)KZ;N$ NB4.)K8!*'3&*[B$XDJQHC3$ORXV!3W"*U@F<;>]Q
M<VY;9MH#)]T+:3GTIW.2Z;>$ ("S-QCFILMTQ"(&<06, !%I AG!G'*+W':X
M2[[EKVM>^]S4'IL_W1'I)>G- U)M-7"#$'N"DM*4:LTOB(3%C-%NA&>;:=#N
M67:_X0[ %LMS[+T'XN/W15I';5ZQO.TT<(2::B4&IC3$^EZYI QE#$6(1)EY
MT&XRQ7#>X1;H=H=E]EN]0?2?ONA;2;'AMY:O3=P@"D3BW)G,FZ#3$)2$HE4'
M>+*47O."N+4!V;#"OOMV_-O7M0>LL^Z(M(3=$E$T<-/&O="RI%@TBL2O32%,
M<FL40)0:L4!.G0""4)9017,5&* A!LOOVM:VV@Y]!.'CTF9)B+%.8CAW6&Z1
MN2(^7M*]/@Q(J)4IN--)XPL]#-E:0RW&%##O$*30;;;-[;:]K!)$.X933-,I
MNP8]38TU-L4DDW*+,J:58F0L1:WDH-\^Y-U,O$>=8NWX5R"#MV][6%LVT%J.
M[4QUY"YB]"DOV]0?9C>KS'4FDC#%B8UDAJ<9&XE-;::^1E&WHQJC;7O;C#NS
M1P[ #:U[CN64:*UN>P+T%J:!0*!0*!0*!0*!0*!0*!0*!0*"N2WP_P ^Z'L+
M>^F?Z"3,9_-QRZ0<M?6K,Z"0:#TG%O1NS>O:W @"I YHE3>N3&;;EJ$:T@:=
M20.UMGWAQ)@RQ[-E[A%05]>-)6G]^,QR-QQXW"!BQDC$:B*5.J<$:(N.0IS2
MOD.C[TB2JB4TD98J_(DS['FU^*<$C0]EW=4)1*X8SA!]_'VG/#F+9E(Y[!H:
ME99-)K.1:Q6!4N4IVY,]/2F2O:&.-ZM2<@C+>^2)6H?7E Q)T"5T>#;N*THY
M58)M@CF*-Z!3K,SP-0A1GC[1.GN^\<F)-%M^56<P[=X8!7_! $/?_!"&W>M;
M8%I>P[3LL'L6W;MMNP/(DVRVWO[+<5LMM_+LH%FAIM:]K-;=:PN85K(DUK7V
M<]MMN*Y]E^?GH%F=I#>UPM;<&]N]>R)-:]OX+V*VT'CL,S]_L4V[;]_]XI?^
ME0>;M#2*^T36W"OLM;;=$FO?9;O6YRN];\E [$-.RP>Q;=NVO>]@\B3;+7OW
M[VMQ6RU[_EH%FAIM:]K-;=:PK;+VLB36M>WYK_N7/;^&@69VD-[7"UMUKVY[
M7LB36O;^"]BMMJ#QV&:/%3;_ .A2_P#2H/-V=IOLVM;=?9;9;:B37V6MWK6V
ME=ZWYJ!V':=F[V+;MW;MV<B3;-OY]G%;-OZZ!9G:;;=C6W6VVV7V(DUMMOS7
M_<N>WZJ!9G:+7M>S6W6O;GM>R%-:]OX+\50>+L[1?GNU-M[WY[WNA2\__P!J
M@\W9VF^S:UMU]EMEMJ)-?9:W>M;:5WK?FH(?U!0B(RS!>78M('-FA;"_X[ES
M4[RQ6VISDD:;U[(L3*WQ01;B.-*;"#!JC <:5<02KVXP/?L%=N#-PYC+"^A/
M3?C#&>3(YGB"0Z"=BXUEUD:"F]JG*#LTZJ>RZ)&)0X"(*X\\U+N76'WWTXK[
M_/LL%<]6Z-(5PF'!Y@*2IRP&-V3-\!9!0 CV%$[-\(0VL+9^3;:^S\E!K]R1
M+_HR?_@E_P#+055U $DE9%TXW+*++O?)MMNX6$&W_-JB_/NVMMH+94"@4"@4
M"@4"@4"@4"@4"@4"@4%<EOA_GW0]A;WTS_029C/YN.72#EKZU9G02#0*!0*"
MJL-^F5G?H)T]^]F=*"U5 H% H% H% H% H% H% H%!6O63]$[4??_P"2N1_=
M9RH*4\!1^*5T1=$M]GI1(/\ R_@_GH/F:N_QF?!X?[.R;_1$T&OM!5+4'X1=
M.'2;;^S%-!:V@4"@4"@4"@4"@4"@4"@4"@4"@KDM\/\ /NA["WOIG^@DS&?S
M<<ND'+7UJS.@D&@4"@4%58;],K._03I[][,Z4%JJ!0*!0*!0*!0*!0*!0*!0
M*"'M0DS58YP7EZ?(6QK>ED-QS+I*E:'LDQ2SN1[,R+%Q2%S3DFD&G(5(R;%*
M2BSBAC)$((3 7O85@KCP9&?GG5)H0TVY^D$1AT#>,FP2[^OB./T"IKAS$=9Z
M=4/(V%O6K'!4E1[B,)O%G+% ^.,-%O[+VM8*XZN_QF7!X?[.R;_1$T&OM!!F
M:,0.&4AP]6TRY3#W2'/)CT@<4J("PZRD:8:<%P6&:58L1>_<5A7W[?\ PT'!
M.TCFS])"3?L9+\10.TCFS])"3?L9+\10.TCFS])"3?L9+\10.TCFS])"3?L9
M+\10.TCFS])"3?L9+\10.TCFS])"3?L9+\10.TCFS])"3?L9+\10.TCFS])"
M3?L9+\10>CA9=D!IS1D7'DPGKG.$<?B[,XHU"\H"?<4."DBXA@)+$*P1!+$(
MN]]^^];\E!;R@4"@4"@4"@4%<EOA_GW0]A;WTS_029C/YN.72#EKZU9G02#0
M*!0*"JL-^F5G?H)T]^]F=*"U5 H% H% H% H% H% H% H%!#>H>'*LA8(S!!
M43BVM"R7XXE\<2NCRH"D:6\]W9%B$I8XJ17"$A$G&=8Q0:(5@EEA$*][;*"M
M_!AX&=],6@S35@=^E,4FKQC6!785TH@[F4\Q-X.N]NR[E3(YDC,*6)=Q6 KC
M0#%;C"S [?O:"NVKO\9GP>'^SLF_T1-!K[0*!0*!0*!0*!0*"J,$^E=F/^(\
M5_ID]!:Z@4"@4"@4"@4%<EOA_GW0]A;WTS_029C/YN.72#EKZU9G02#0*!0*
M"JL-^F5G?H)T]^]F=*"U5 H% H% H% H% H% H% H%!6O60;<G2?J.."(0!E
MX7R*( P7%8816B[ENW!<.P5A6OLV7#>U[7[U!AEP8'"@Z.M*G!':(7;4#EHZ
M*A5,<EQMRE0Q2!W.-F43>G)P?&P8DB14:*Z-&XHC.4BVDF6-L$LP5PWM8([R
M_P +?H/SEKPT?92QIF.\@A6'VN;F3]VM&9$CNR@>KE$MVU,J;RCU7*#+;O[W
M 9N_^+9MH-7/\LQP>GGMOZ*2;[-H.:XXX5?0]EB>17&L&R[V7F,U>$S%'&J\
M<?TMU[FKWN(3V/4H2R2M_=%]^8,(;;.>]!HI0*!0*!0*!0*"AQV4H3B_5'E-
M=-7?L0E<HC&D2,P28\^QR@ODQX@VX@L=P[I>]>]Q;+?D_)02W?5W@2UK[9J&
MVS\O8UP_GY/L_NH+!LKPWR!H;'UJ.Y2V.Z%*Y(%&Z(''HUI(%"<W=':P@\84
M8$6P5K7MMV7MMM0?3H% H% H%!7);X?Y]T/86]],_P!!)F,_FXY=(.6OK5F=
M!(- H% H*JPWZ96=^@G3W[V9TH+54"@4"@4"@4"@4"@4"@4"@4'XJ4R=8G.2
M*R"52526,E0F4% /(/),#<)A1Q)@1%FEC#>X1@&$01!O>U[7M>@X6;B[&9[<
ME9SL=P8UH0G'*436;$V$;<C4*;6LH/2HA(+IDYQ]K6L<:44 9MK6L,0ME!A_
MK0Y/!^%BX,O',/;&.-03(37E0<XB;*P,B!CE0FVR>[?=\0IT "E_([BO=/Q]
MA<5>][AV7H-Q.UICCR A/HJQ? 4&3/"%Q6,1[4UP9QK!'&%C-4ZHP%J#&AH;
MVTP\L,<6B" X:-.2(P 1??!".]PVOSVMMH-G*!0*!0*!0*!0?-4,S.L-N>K:
MFU4>*UK".4(4IYHK6MLM:YAI0AWM:W-:U[\UN]00OJ"86,C">4#B&9J).*A;
M^84:4W)"S"QA;S[A& P!(1 $&]K7L(-[7M?O7H.789\$>,/XAQ3^PD=!)E H
M% H% H*Y+?#_ #[H>PM[Z9_H),QG\W'+I!RU]:LSH)!H% H%!56&_3*SOT$Z
M>_>S.E!:J@4"@4"@4"@4"@4"@4"@4"@4"@ROU2H])AW"&Z$U66'*?)M1Z=!D
M&V 4+"FL9#EB<02OE%>6'W4E\2(&P'([63G[U^;[V@U0H,@>$C^DMP9'^],'
MW;74&OU H% H% H% H%!#6H;P'Y3_B1(?[./H/LX9\$>,/XAQ3^PD=!)E H%
M H% H*Y+?#_/NA["WOIG^@DS&?S<<ND'+7UJS/\ Q_B^P,B)_P *=GK%,Y^0
MF3-)^)X$\V4)1B;)7K2Q6R2(+,N4W+1._P FE\?(=+@6)@W5(R+%<8JM]X1<
M>\$0@VWM?;:U_P ]K7_/W_UT'F@4%58;],K._03I[][,Z4%JJ!0*!0*!0*!0
M*!0*!0*!0*!0*#&?A&M!.J?4=J7TGZF-+&:,>XCF6F]-)T]S9Y$#)@0XADJU
M*-1R9 (\M%_W$H\C:H+,N P83 7M<-J#^<]X5X:V09)<G/3]K/TZ0#&9K8QE
M-L:E6 FJ3/"9S(:DQ3ZJ.=CAV,-)7.P5*I*5>VQ,0: FW,"@HGK",UFXOSUP
M+\<U.9<@&4)N^:O71HFS_"H(AB38[&G-*A2SFH&\K?LW@2-9:A*H"5>USCS
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M5%P/LSEKJE88K&=98W:0/J\0BV]H;4\1<..6K30A'Q2<NU_OAWMLMMH-4_\
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M"P+V/.:UQI!.WC3+7"J$-X.7,F.')GR@P3*$O^8HE,,893*4O13B0QSZ>M4
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M6';<O>@D$(@C"$016$$5K""(-[7"(-[;;"#>VVU[7M?;:]N:]N>U!YH% H%
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MFP^9BMODITR1P84.;>P2>5*4XD:A_+3V+L.SH<D%R4U5<RY@TP"B!7N424
M8^:S\)X^T;ZX."89](T :\"L>8]0N5F;,R/%+>;'4.06./XZ:U,?:IP%OO8#
MTU-2ES=5;:A<[FI$RI2H5$E!4?NE@TXURY"<-.2S#^K(UU?B\>8H=);%LRL#
M>K7#:5\#GK!QC8_*V<HRZ18[LDXC<99&50),)65>8+"BA[AEPT&?KKJ7U=Z>
M&>$0-K D=I2?A5+JER6[3T;.YI9+*<I9(E(W'&[4]S/($0*A\;8DR$EN;5;0
M3(;M-W1 F[!)$B8@*D/Q5ZB-2N/,9YSECG*F.40.<Y7X0=G9X(XM4A'(XF=
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M6R PMNG+BA+;'":(8LQI)8N;20@"2WK)&G0EO"I"4$HL):0]8-. )8+!+M8
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M8 '!F'0P18]ADJN%!QE"@Q)5(PB+$%_4QRS)9G/>PB))$%U-1B76$47>Q^T
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)GW"Q#,-%0?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g696632g23o72.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g696632g23o72.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2:J4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $@< 5H  QLE1QP!6@ #&R5'' (   ) Z!P"4  (<G(R.3,W-#D< @4
M'TUI8W)O<V]F="!7;W)D("T@,C Q-R R,"U&+F1O8W@X0DE-!"4      !
M*'%((=/4,:1KT:E%J?JK.$))300Z      #E    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0%?S,P
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M_P  .$))300-       $    >#A"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          CA"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              28
M  (6          $                          0             "%@
M 28                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M 28     4F=H=&QO;F<   (6    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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MU@ !     -,M2% @(
M                    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0
M  'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)8
M65H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
MAG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M    0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY
M  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-2
M1T(@245#-C$Y-C8M,BXQ
M                          !865H@        \U$  0    $6S%A96B
M                    6%E:(        &^B   X]0   Y!865H@
M8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#
M(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N
M:65C+F-H
M         &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M          !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !
M6%E:(       3 E6 %    !7'^=M96%S          $
M       "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4
M !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($
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M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 6 "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M/]:WOW-RL:IIW@M92Z!+=E3P;:;7/V/_ $KZ_P!'_P ;L^AT:22GG#C_ %I
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M+PK:\7!]6M]_V[%#\8/&\M]1N]NV1MW,<B#13$U*)/[P_-Y*OZ;?BS_J[$3
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MQ%O_ %#E:1$(V1Y(.:?#&5]9#_!]$J8U@BMH.A  /W*-_P#,O^!1$._^9?\
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M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU- "H    (  @!
M$@ #     0 !   !&@ %     0   &X!&P %     0   '8!*  #     0 "
M   !,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $
M 0   +P   #H  Z>,   )Q  #IXP   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I #(P,3@Z,#0Z,C,@,C$Z,S,Z,3D <G(R.3,W-#D       .@
M 0 #     ?__  "@ @ $     0   A:@ P $     0   28         !@$#
M  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (
M  (!  0    !   !1@("  0    !              !(     0   $@    !
M.$))30/]       (          #_X0%(34T *@    @ " $2  ,    !
M  $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M    ?@$R  (    4    G $[  (    )    L(=I  0    !    O    .@
M  /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD
M,C Q.#HP-#HR,R R,3HS,SHQ.0!R<C(Y,S<T.0       Z !  ,    !__\
M * "  0    !   "%J #  0    !   !)@         & 0,  P    $ !@
M 1H !0    $   $V 1L !0    $   $^ 2@  P    $  @   @$ !     $
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MP=8I0T28I^'Q149(25)B969HAI.FLL959W.$A\?5_\0 '0$!  $% 0$!
M          8!! 4'" ,""?_$ '(1  $# P$$! 0-#P8(!PT&!P$  @,$!1$&
M!Q(A,0@3%$$5(E%A%B,V-W%U=X&1H;'1\!<D,C,U.'1VLK.TM;;!X1@E-$)R
M<R8G*$-28H+Q"4A796:$ID1%1E-59&=XDI66I*495&.#DZ*%H\72T]35_]H
M# ,!  (1 Q$ /P#^[@\=.3<Q8S(W>RP+6-E&L<UCX=E3%6I4S5^#D3K'4G*C
M-/SKJ.9%<3B+WP2D!,J:*8%,)B+[>U*?_&A>OWOUG]'>$3VHS_XT+U^]^L_H
M[PB>U&?_ !H7K][]9_1WA$]J,_\ C0O7[WZS^CO")[49_P#&A>OWOUG]'>$3
MVHS_ .-"]?O?K/Z.\(GM1G_QH7K][]9_1WA$]J,_^-"]?O?K/Z.\(GM1G_QH
M7K][]9_1WA$]J,_^-"]?O?K/Z.\(M.6[;FGM?V%>I7SF)5J3:6Q&AW-9MU^X
M_5NPMROT4G+$R\+,U9E(I$>MED7#4RC<H.$5DU4>^10AA(/A^F?D^);A3J\V
MJ0BJ6TKLJDJ4JB2J;'6:B:B9R@<BA#EUX)3$.4>I3%$2F*(" CU#*>3C\G'X
MOD5<CR#X_G7[]J4_^,^\_O?K3Z/,K[_R?,F?,/C^===Q7)9J"1G.V;DV*LLF
MW2%PUU@B"JZO4$D$A4UZ7Q%E! 032*(G/T'N@(ATPJ+QX C:V)/UZMO2;LJ$
M5*/H.47@'&HYE*-FHQ8S>2AWZD=0W)&<I'N"&0?,'!DW;18IDG"*9P$H$7O^
MU*?_ !H7K][]:?1WA$&ISQ0$3;1O(  "(B+#68  !ZB(C[G@=.@>^/O=,)[W
MR_.L8CG,7+UI6Z16_I*4IR+9Z]6M<>_T^]K2+.-\7V1=J3K:C*1:;9AX"WG5
MSNP2:^"KXYR>&?H3ES'O'/SKP=<W.B;ACGTOJ/E"SVE$QCPT;)2FN;-HZ[QT
M?(D*!SL7SVLTZ3;-'I"F*8S5=5-8I3 (I@ @.%7EW=WG[^(/P<NY;&]J4_\
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M:>@?)V.$3VI3_P"-"]?O?K/Z._\ CWA]>H81/:C/_C0O7[WZS^CO")[49_\
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M%4QSQN\F\R!S&2<DCCYN[CP\F,O=@=IS?]776VW7;/++6-TU9P9J6WJ7#TF
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M_P!U_A^'[^$_V3Y/ZOSK&[?H3A)>ZU,5&S<&XQW!3K0S*119<9&D(]%$QBG
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M(L39)P@WGJCQM9UR900=)'0=(HR</ LWJ:3E YT5TR+E(LD<R:@&(80$F?\
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MN+!O$+0Y7+Y!RQ.Z3>-C D4"=V.Y9P-%Y-\?.BNJ;.KR/U@U]1U7MB<,UVI
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MC!HNEWUT5CHI**%\QJ"WN; X-K\5+RR/-KN0.\UP:>L!I<PMRX8=*&-(R02
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M8.7#AJW>,4/<W[[ANNY:N$$5D0,155)1,AA,40RV+FBCI[B2.PU=0:2EK/\
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MQP[PJ6YH]$?3RP&G=I:'=& <?X47?.!CD1Y/)["AO5T$3<&]RG\)+O%Y%:!
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M6:"Z#39&%CNV7X/:YI:[U?6?[(. .2.YP[_(I0235J'%_LG1\LAU/R'U*!C
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M#V=>V*XW: T<W#QZ69UP9-+%R=-04+CQA&8U>UM93A?KNQA89]-%QR0KD,$
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MDC^)T8G%HB'0_0<)'M0CK:K9':9='Z59!%7RF%QH<QT!J1#*^:@C<\,I9/\
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M$/18'X8.?_.5$%I'3?#89TS/-J;2'G_[\2>5112$?J!]8?M\JJV;_&&IC?\
M'_M'+1@ N?2R&,^)JOG^& ?'CBI[4<-1_P#!^?BMH/GQ_P XX_3S<%,2+ /Y
MH%JS\VG18?XOJ9\C]?QV>]',=PU!?L>]V$CXU2W'_"3IY_@M!^U-W"AK5/M&
M=R_M<C- ?P*;PZ9L-O#;1MY]SNL/L'T-Q#]RA5TX;&^A+C_E'K1_VUM8^GG4
MK(K[<7L[0_\ Y7Z"_2@M_JS4U0/\0.@#Y-IM%\=+*MOT_'I'=*_/_)#K,?\
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MS[ESU=/O/-E?NLZG_6Y6U)S]F.S7_)BR_P#65MV:)H/O=JKW4J'\[7+I^O\
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M79"> XGML?-<<4F#&0Y2\ZTG[)H]3)M*&.1-VW1<D*<(1KT.4BQ#E*8/@,
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M,,@DQQ_TB,$^^M2[+=?/V:ZMAU1';VW-T-ON=!V5TIA!%QI'TIDWP"?2P_>
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MYW$S (B(&(!1 1$>N4W&8#=UN!Q W1@>P,8'O+Z[14;[Y.OFZR0%LDG6OWY
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MCG&.%SH^/'R8SE1'>-U6O9S\=D%T%&RA.6E%ZHJIF2.4H[#EA+]8<I1*42B
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MCX,WC6:EI]0>%.N^PZA@9V?J-WCO8SO[W#R*2.9M:N3"*N'@K]E/F]\?3?\
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MG,>TAS7#N(((1NW;M$4FS5!%LW1(":+=ND1%%(A?>(DDF4I$R!\!2E  ^ ,
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M6JE"#F(BLK7]/BBDJIW>1?)'O>$F=3N_J\*(";N@(!UZ#W>OOB _>R'Z6/\
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M:_D>NF-6?>L;)OQYUS^?B7:[3 ASZ:U8!"F.(<E]*&$"E$P@4L^X$3"  /0
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M?RNY5:OF[/&VQZXUNE< E(MHY8M2M[<]?S2#,478BJ*K--T5!53KW%#D$Q
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M JL=)DD')E&D:1 3N'8E$#+=.\90PG4$P]<P=\LXNEKEMU.Z*EZR6*7>$>&
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MQ&X<EO Y70TFW"UOU1L1OXL=>(ME6FK;8[A3]HI^LNTU"^L>^>B=C=@CD%2
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M$]8^0$LFJ2 -YH!%GQ2E*4"E "E* %*4 Z 4H!T   /0  /0 #W@R5+H #'
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MKA5[C[(^0K-8/]D[E^4C7YH57"HLDPB81,(F$51?:.\;TI.S\?=Y:<>M*)R
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M%VA>LRJ%2,Z;%44*4Z:9ET@.H4R:BI3$*)^\<HIHJJ )0$!(DH<![I#"!%^
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M1EQ8M\DM ['6T=9* [EX.=6%Q$V620F"QTA&S\:X(J"S1=VU61>-W "FH0!
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M:VVFT4YEXY&5@HZ?H\S1BQJT@R.^LC8&GF4DU/$+DE"L<B>&?+PY'!'O<SY
MM..^U/Y@KSR4- :JK\XQC-V<!J/"^64K\=9]B1')&J1%ALD$Z1>VY2$@)ZT%
M<N5X61.Z1AZL4IF<DX>'\)P9],*H X<>8/EYC..[EP&<9^%2B9=KL\L;(*S2
MN+E]L^[JJCR0EMQZO3NE C$-=5OBW=XR@;&E6]NE)MO!VQ:1L$U&-JDP@U5U
M94%'"C@S%%$JJA,><<P,\<<?>[L<5FT;VMNKK+5K3<ZEKVV2L!#VK@_7(5=R
MZBX]W.(<X6%8D:=(&:+.>\Q&HH6= +$T6.*IU&CHK(5@*!A+YXY(Y$<_>Y_-
M[.5A-8YY\B[;V6/*SE]8*35=?[@U&3E>UI#!DHWG:\Y/I.UW*LU]V\9(S#LR
MB[1]75(:735D4$Y5]%NI9B1O%R3(I2^MWQ@W.,EN3Y,XS]/]ZUC>>U\JD#5'
M] W[Q<=I[C87S2U0CM<W*RZO>4^=-MG5=GVU7;K(6I_+R%7K:+*O4FQ^R4>X
M5<R,=+J1<8S%XH[.JB0 ]W^CG([NXCXP/?Y865,>VLHJU9D[K%\<MG$UEK_C
M"QY([/L1Y&F1WM A7$UMR@1U)2A7$VBYG)^2V3JLM3A309',.M&S:5E6?-82
M/<N IGGPY?[^'O<DW>.,CG@<_-YN'/D>//@NY0>V30V@[J^N:'QKMUHY"6W9
MRM#A=:15_P!>'J\E#,M726W96Y1^U7$ZA2G#&+K$/)QCN.\^223M#;V),W!$
MY7@U5 />X9X^3..[///P<5]X3MJ-=S.EMA[E'2]XCV6ON(D7RV>0#R5KY91U
M"2G(3;/'XM.*9-ZHV3G4)C5+V867%4S'RLJU;$6,X34*!5+2#CRNW1CB"<@?
MO"P![VFVRM?;(VHXOZOLS3]5[O[46-)4:U6(Q)S9]<\,-!Z]VQ5X5Y8Y"PME
M(:>*M,S"9)!M%2+>:<.T6[XD.W: Y6?+]/X*@&<COR,>_P#Q/T'%3[X=<W7G
M*2Y;3U_9-,6C3%KUW0=#[:8QUBL%7L:=CUIR*A+?,Z_ER.ZM)R;>-F4PH\\W
MGH%V<'$8?R?ZHL958B!5(P <YR2._NQQX]W'Z<0)03GV;]:_%IN+YQZ5PJ=Q
M]D?(5FL'^R=R_*1K\T*KA46281,(F$3"*&W,CU9\:_VN6^F^O_X5G_U_\#A%
M,G")A$PB81,(F$3"*M7?^K[SQFV7-<S.-M=>V**FO <<LM P21C#L^O,4B)*
M;?U_%I=$DMS4^.3$\HS;IE]T>O-C,7 &L3&-7=E4<>'+SGN^GR]ZG5JW:-%W
M10:QLW6UA8VBEV^*;2\',1ZH*(N&SD@&\-4O_*-W;<_>;NVBY4W#5RFJ@LF1
M0AB@5%L#")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3"+P[-6H*Y5Z;J=GC4)BNV.+>PLW%.14!O(
MQ<B@=J]9KBB=)4$G""ATC^&H0_=,/=, ^N>4\$53#+3SL$D,\;HI8W9P^-X+
M7-."#@@D<"#Y"LA:KI<+)<Z"\6JJDHKG:ZN"NH*R(-,M-5TLC9H)XP]KV;\4
MC6O;O-<W(&00HK?S/WAK^(&F?_B3G_\ U\C_ *#M,_\ DBF^&;__ "K;W\I#
M;A_RC7S_ -FW_P#^DI(PVO*57Z,AK6&KS%A16T.Y@$*VF"JL>G#O"+D<L !P
MJLJ9!4KA8# =4QNB@@!@  Z9ZFIH*.".FIHVPP0MW8HVYW6-R3@9).,D\R5J
M6]7JZ:BNM;>[U6RW"ZW&8U%=6SA@EJ9BUK#))U;6,WBUK1XK6CAR40:;V9O"
MC7\>UC*EI6-B6K+2-EXZM?#G[0NLAJ.W3\M9I^L$<.9E9?Q'LO.S"Q9D5!FF
MR$D[9MGZ3-4R&>ZQA)/,YR<^_P"5>\T[/?BBQNL3?F>NWS>PPLCIF98@G=KM
M[#EG./Z+-KJ:<7@#6 T,YEZHRCVK%%\LR.L^9$4;2)G2;AP"I,GY?)W\"L?O
M'9H<.]@)N?9G7$S'/7USVK=Y.9J6QMB4N=EW^\99O-[:A9>:JUGBI&2I][DF
MC5>:J+MPK =6Z7DF+00$1*H<1R/#GCF,^P5^[!V:7#6R7N%V$[U6ZCY:OHZA
M)'0U>O-\K=)%SH5=D?4$D_HL'9&-3EI.A-(]O$P+V4B7BC:( [#ZY(XCA4R1
MPSSY\ 2??()^ A;,B>&7'J$TYN#0#"G/PU%O6<V)8=B4QU;;8_CWK[:ZR[N^
MHPBSV9</*M&SS]V^DU8JNN8V/:R4A(/F;=NX>+J')D\#Y,>3NY+$[[V?G%G8
M\A89R?H<LRM%CE-93BMQJ]ZO%2N$1-Z@K$]3*#+5FR5RP1TI77T15;/8(%PI
M$N&Q9>.EG:$N1\!RB4@)!SW]^>.<\\YSGWU[$;P5XMQL-=*^&L$)*'V+IN T
M'=F<]8K78#6/5U:?6J4BH.2>S,V]D57R<G=K-(KV,'A;&X?29G2LJ9=!L=%^
M_G\B9.<Y[R??)R3Y?F[E%;>W9:TBTZVIM1TG+I5^Q5+9R>RCVS<-OWQL.W2#
MLM1?4@&<9LZ$W#5-FU))M7G248FTB+$M"/(I!>->PQE7QY)$F3Q\XQY!Y?(<
M\0.[/G7GZ^[&3B-':+U)J+;D-.;1E-=:=?:8L=GC+9>];1VPZC*7ZQ[36@K-
M5:A;VS"5KL'?[;/3U1B9QQ,G@W+E-?S;EVDFN0F?)PXY'>0>[CYL?.I36'L_
MN*%I=VI].:P*]<W66Y$3=D.-DM*(2,GRKH\5KC>K@2H3"94/;I3X6.B13; D
MG#^!YJ$+'NU%%S%0<.7E!]\+<6NN/6I-47&Q7VB58(2U6K7VJ=6SLF$G*O/.
MT?2;2RL=;0WEGSUPU1]KS6W3Z0/$$4WK_P ]WI%PZ,@@*9/I^[]R]&<^S?K7
MXM-Q?./2N%7N/LCY"LU@_P!D[E^4C7YH57"HLDPB81,(F$6)VNCU6\%KQ+5#
MHS!:K:(FZ5\%EW:'L;9X,')8J63\HX;BJJS!VY B+GQFI_%'QD%.A>Z199A$
MPB^*SA!L4#N%T4""/= ZRA$BB80$0*!CF* CT 1Z=>O0!PB_1%DE.YX:J9^^
M7OD[ARF[Y/\ Y9.@CWB^H?7!U#U_;PB_7?+WA)WB]\"@<2=0[P%,)@*82]>H
M%,)3  ].@B4P /4!PB_6$7Y*8IPZD,4P )B]2B!@ Q1[I@Z@/OE, @8/? 0Z
M#T$,(OUA%"K7?&:SZ)Y$6*Y:6G8.(X\[<3F[)M73,H+Y!M4]L**MUDK_ *C(
MS:.&48VNHJ/3WVINC1T3[+HIV.(72=OY%DL5<Y^131\5,0(8#D[J@@5,>^7H
M<1 3 !!Z]#"(%$0 O41 !'IT >A47TPB81,(N!$  1$0  #J(CZ   '41'K[
MW0/4>N$0! P 8H@8!]0$! 0$/O@(>@X1<X1,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$6IIS[-^M?BTW%\X]*X5>X^R/D*S6#_ &3N7Y2-?FA5<*BR3")A
M$PB81,(F$3"*JOM0)&/8GX?I3\U0X2J/^1$^VLZVT[M9-?ZV<LD^/VY';!O;
MK'5P-(H(!-(1R\0W,11%Q/)1:9@ PE.4J^7V.'PCGY!YU '5/(W:NK("*C:S
M-P:E=)8=HP+?="<E;]D:PI^O;-R=KD02W:]G;3*MG=BUQ2JQ85*_ O;,84V$
M@P0<*O#UZ/4:."IGB1CD /)QQY./L^?CR[MR+<D]DQ6Z'LG$\@8.R4FRTW1>
MMK%R33J#J/I-.IA=U<WT%=@$@)%\G45IV1?4VC:W<7!JX5J4I)V"+G&2;F+]
MC(XQ?7]7W_?[OBY^_A>ZQY8<KK5&;#L4#L2KIUO2FJV6P8J8::W*[9[^8MN2
M^[M90EH075G#EA*WL'6FN(.Q$2A!>'!W.-)2)DAC2> _?3Z=R^<'WSQX$=W'
MRY]GEGS+]Z^Y8;,4N+^KSFTZAH6&B;O8)6H1DQ29:TN=[3EBY:[3U[,5"*3<
M2[F;4&*KD! ( A5$7#^,F+6VGWK=&N)-(Y<./'Y/X\4Q@=YY]_?@>SPSQP!_
M"0'!/E'LS=.Q]A4S8UPC+4\;5&+M[,U1B:PK3H4SVQ6&)5;1DI%V5U=*X846
M;1#VD;;IE9N+%VP?N?,R*2BS:-?3"8/P^QY!C'LY[U'2G<V^6\_M*'U!.0T(
MBO-7%30RD^G49%)HELOC^FPN?(NV**"\%NG6+K5Y0]2I:(*]&$W%N':#M\)B
MD$> )\BK@8P?/\!'#X/C''EA:*UQ<]\7^[Z4AFFZYBH25EVWQ:D(:M$C'LG%
M4J"F^,.XGMBD(R"E)TZSZ,DI1DJT[LNX7CO;$R0D7Y'[MN=L=\:KS#OA^/NY
M?%\"L.G^1>Z([A"QV4M:JI$;-0NY:+*6Z:8LZW&OFD;;WD"\DVA9IR:JUR?F
MV##^AKBT23.IMY1TFBZ>$*LV15+Y/T]CXE'&"[1:]-J;*&G;C#(6)]4M(CK9
M*SUJ$B)V\V&P[_?:VOJ\,RK5LM5?MS=*N,5%TY2ESDK F3*,^R<!&JID*3!/
M+G@_$,Y]Y:[-V@O(MG2'UTINP*3N>TOH?9H7+6<!4(YDOHEK4MH4:F0]OEW*
MEG;#X:%=LEDFI5"V/HB*EUZRJ^9/XF(:29T2J/IQXYQ^\^99U7.47*#8T8SJ
MS&_5U2NG:\C)%W=PKU.M4I=*YK/7^M[(T@5'NN;S,TF)D1L%JG:TZE8.;D5O
M8UH/?CXZ; Y6;Z?3V?\ <J'AW=V?)\9\O/R!=6O\S]YQS&).UM]5C;7%RU;I
M\)QK4JZKFP6.AO=3NK6YVNA*.YE6QG20DD"3"#XJ"T VA2'@7P+S"A) ">3W
ML^;XL^;D?85J?$Z=V1;M$T:[;5M#*T6^Z1OME>*QM;)5XZ)0D55%&L(SC?9"
M37,C'H@1'S;IV=PY, JJ$3Z@0"*1^$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3"+4TY]F_6OQ:;B^<>E<*O<?9'R%9K!_LG<ORD:_-"JX5%DF$3")A$PB81,
M(F$6JMF[3I.LCULU]>0T1!39[2N]L-@GZI!P];C:=3IR[3LY)!9)B-=NV$?!
MP,@Y?&@6DLYC&::\K)H,X5F_D6I ,\!Q/<!Q6A+/SRXF0:%0=AMG7]CJ-MN4
MCKA_<(2U560J-1F6E1>7 K*W2)Y5-)@C)Q+9)./;IINEGBL@P$C86SCQP(NK
M=N</&^@2M0A;%8*NA0[RM Q4-L)O:=>.=?\ L98J1-W>&>R'A64TC'P4C&1"
MK.*7>PZ3>7=OFOL01ZS.LY2)C.,?P][XO?7IV7F[QVJ-BI%;?VZL*MMES%8K
M.N)J,ME$?PUM<V:C66_0QVA6MC.]BX9:-K9V325G&49%/9.7AD8URZ2?%7*5
M<?QSP^G<LVA>3?'B<D*/"R>QM:0E\M-=8W" I$I<Z2_L[=E,0JLV5PS&&F95
M@[\6(1=O ?PD@]8OF+=P[:/'3,AEL*G,9[O*LKU7O+0VWGMD;Z;V9K?8#^%.
MQ>6I.B6*#G7#,93S"4>]EO8=PN<"OA8NDFSMQWBKF9N$B*&,W4*0F,'EQ^A6
MGML<Z.,6JZ3LVXCLVCW)_JA1BWL]0JEPIRUF;RTQ8VU191JI)2;C(Z.65GW(
M1[MW+2#!BR.V>>>=(@T6[A%MBU;ZTGKBNTVV[0OM$UDUNS1F:N'N5EKD29\=
M5N@Y\DP>F?F9OS,RR"?C'CG3EJGY@%"+"FL4YR+#-@\M>.E.8;%BUM@4JW6?
M7M/F;A9-85V?KDI<EX:(9(OWY$J\O((@HH#9TV44(Z,BD0KIN=P=,BQ#"3Z?
M3X"O:UWOK5=^UU:-JN$6]'IVM[7L&E3$O=@@XAK"#KRQ.ZU.R8/DWKEE'P;A
MW&"LU44<ME#-O %TW;JAX12J1CWQE:]U7N_A)1*O"5_6FZ--(P4_8)*%A4FN
MP8"1<S=C<FCYF2AD7"\FN]D)!%.S1;U6.,=15FTEV)_"2;N4.\5/W_*5LFI\
ME.,MF3,SIFY=1RJ3&27@@;0=OK2J;>33C'TTO')(M7G<*O[$1<E*&13+U.P8
M.W?04&ZIRD_<L V3S6XLZS'7KV4V32)J1V<S.-!2KDU7I60GX9>NV"SL'T>J
MF^*!H&91K;UG&/RK>QSR55:-2J"=8! BS[07)S2W(^!+)ZKNU=FY!K&L9&?J
M;*;A7]EJ)9 RI&[:QQL2_?!&N!5151$#*&2\9-1,JACD, $4@0_X_P#7T].N
M$7.$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6IIS[-^M?BTW%\X]*X5>X^R/D
M*S6#_9.Y?E(U^:%5PJ+),(F$3")A$PB81,(H5\U^*DKRMH[*HQ5IC:LHUJ>^
M*X=S)L7+Y%4^X-![$TVS7\-L8#>%$/+NC,.R#U,X:,EFZ7150@X0<#]"L8'A
M@Y#DA2=Y$L< 2,ITK39-.NDAE"N14JNG;#JX1:KE_G=NLL,VF[0.4@&28HG:
M=0[Y2X3/+Z9]E1[JO9W;9UA.:FNU!V!K27M.I5=?K1\7<(:?0@9?VHZKN&M'
MR7LA&)/'\(J[):QDF+]M'2!VZ;11@JU,5X=9%_'X>[^*'..'[\?3Y@NW5.S=
MN=)7ITI$;+J\A+5^]T>[2B;V%E(^*>+1^I]S:SN3.*;ME7BL6S5/N)Y,55F8
MSE-HC"M8MXJ4JYG215SS\_F\X/[OX+B![.C8T#4$-2(['H[G6LU8]0[$MTXM
M"30;$:W346O*I2F4/65BG&-&M3CREPS]:4?.F\G%03J7JJ,4_;NDI! J?3V/
M84L>/W%UWI.PTJ8-/1+]M5.,.J^/QV<;'*L?,.]<V"[32DVAUZ$2CWI;85%J
MS']5;G;K',( J&4QQSY/WHHLM^SRV.\KE$HD[L6C)U;1M"6UGJ62AH*92LMG
MK\GM74FPI&9V@9PH5J2=;QNH8B);(0RTDUD)B6FK"[<M?,I1S>J=V/I\O[C[
MV%)O>_'O9-SNM2V%K"?UXA.1VK;AIR?B-HP+^PU@U;NAXY1W8(V-9D73D))D
M+-9-]6I5%&(M3-1JQD)..19B+@BAR][+ZR.Y"_1JEXK+BN3\MN.X5N>>3FVS
M2\;9]OH/BNF9=<-[<AJF#C(0\J_2-*Q\5)/)MH5D"L5&NVYG2A,GZ=_L\/G\
MO?A;]M?%^?IG$+<NLD'[^W3LSMF?W;!IU.!/*O5GI]VQ>XH2#/ .9".6FVS9
MS&-F,\Q8NP?R<6601AFSR159LG JI/+AR&/W9_?].,=]%\4=I;TN^TMV[IC6
M6MD+ZKOVMQL,RIUAJ<Y[$;;U1I_6:=KBH2XLHNRP4C$GUY,K$<6&(A927+(H
M/BL6B*QR"0' /O8R/)Y>*RRY]G=L[:M<DRW;95!K=U@]?ZVU1K68H%=F4(V.
MJ]+D+DUF[-/-GZS=R2SV6F;'NM>9Q4>=>-KBCQNY2E)'ON>I4X=W+X/BY+ZP
M79K3U+@5XNK;"KKA1ENIS;JDWEHB0;L:OJ)+4ULU17]<,E&9UU@6K[.S'FT5
MBI$8NI#SA?#;%<@H5CCGWE7//'>,?/\ P&.'E[U+#1'&-WIRX5:R'GHI\TKG
M'&H:,]CX^/69^*\K-XM%M4FTNO1))DY2L)&J;3IXI%4%%#")3EPJ*7^$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3"+4TY]F_6OQ:;B^<>E<*O<?9'R%9K!_L
MG<ORD:_-"JX5%DF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3I_Q_
MV81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+4TY]F_6OQ:;B^<>E<*O
M<?9'R%9K!_LG<ORD:_-"JX5%DF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81:FG/LWZU^+3<7S
MCTKA5[C[(^0K(7,-<49.8=P-@K3!G*O4'PM9:IRDVZ(LE$1D6?H[9W.O(@D<
M(XARHBS.8@F,(N#]\")%1?/R.S?PKH_R=SOTIX1/([-_"NC_ "=SOTIX1/([
M-_"NC_)W._2GA$\CLW\*Z/\ )W._2GA$\CLW\*Z/\G<[]*>$3R.S?PKH_P G
M<[]*>$3R.S?PKH_R=SOTIX1/([-_"NC_ "=SOTIX1/([-_"NC_)W._2GA$\C
MLW\*Z/\ )W._2GA$\CLW\*Z/\GD[]*6$7/D=F?A52/D]G/I1RG'RCX/XJO#R
M'X1\R>1V9^%5(^3R<^E+''S>?A_'YTX>0_#_  7'D=F_A71_D[G?I3RJHGD=
MF_A71_D[G?I3PB>1V;^%='^3N=^E/")Y'9GX54?Y/)WZ4L)P^A_@GD=F?A51
M_D\G?I2PG#Z'^">1V9^%5'^3R=]_Y4OX/X<)]/IP^GE7/D=F?A52/D\G/I2R
MG'NQ\'\0J\/(?A_@GD=F?A52/D]G/I1QQ\WP?Q3AY#\(^9/([,_"JD?)[.?2
MCE>/T'\4X>0_#_!/([,_"JD?)[.?2CE./F^#^*</(?A'S)Y'9GX54CY/9SZ4
M<<?*/@_BG#R'X1\R>1V9^%5(^3V<^E'''S?!_%.'D/PCYD\CLS\*J1\GLY]*
M.5^GTXIP\A^$?,N/([-_"NC_ "=SOTIX5$\CLS\*J/U^+R=_Z/=2_P"W'R?3
MS_N5>'D/P_P3R.S/@M='^3R=^E(,*BY\CLSX;52/D\G/I2'"KP\A^'^"X\CL
MW\*Z/\GD[]*6%1/([-_"NC_)Y._2EA$\CLS\*Z/\GD[]*6$^GTX)Y'9GX5T?
MY/)WZ4L)]/IP3R.S/PJH_P GD[]*6$X?0_P7Z]C]F?A;1?D[G_I0PB>Q^R_P
MMHOR=S_TH81/8_9?X6T8?_\ '<__ (_?V@'_ !]_"</H?A[OIYT\ALS\+*/\
MGD]]*.%7AY_A_@GD-E_A71_D\G?I1Q['T^,)P\A^'^"X\CLS\*Z/\GD[]*6$
MX>?X?X?3R+CR.S/@M='^3R=^E(,*BY\CLS\*J1\GDY]*6%7AY#\/\$\CLS\*
MJ1\GDY]*6$X>?X?X)Y'9GX54CY/)SZ4L<?H/XIP\A^'^"X\CLS\*Z/\ )Y._
M2EA4^GTX)Y'9OX5T?Y/)WZ4L(GD=F?#:J/\ )Y._2D.$^GTX+GR.S/AM5(^3
MR<^E(<?3Z<?IY57AWY^'^!7'D=F?A51_D\G?I2PJ</H?X+GR.S/PJI'R>3GT
MI85>'D/P_P $\CLS\*J1T^+R<^E+_LPG#SX]G^'[EQY'9OX5T?Y.YWZ4\*B>
M1V;^%='^3N=^E/"+CR.S?PJI'R>3GTJ81/([-_"FD?)Y-_2IA$\CLW\*:1\G
MDW]*F$3R.S?PII'R>3?TJ81/([-_"FD?)Y-_2IA$\CLW\*:1\GDW]*F$3R.S
M?PII'R>3?TJ81/([-_"FD?)Y-_2IA$\CLW\*:1\GDW]*F$3R.S?PII'R>3?T
MJ81/([-_"FD?)Y-_2IA%T6-3M:EYA+A8;! R!(2K6VM(,(>M/X$3!:92ERBS
AM91Y:K,#@R!Z<W11(F+($R.G J Y$Z0MR9X8\X^(%?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g696632g28d86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g696632g28d86.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[3#L4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $ < 5H  QLE1QP"   "0.@< E  "')R,CDS-S0Y' (% !]-:6-R;W-O
M9G0@5V]R9" M(#(P,3<@,C M1BYD;V-X.$))300E       0EJA>J03\.L="
MP[F+@+UOW3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              1\   %/          $
M 0             !3P   1\                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   1\     4F=H=&QO;F<   %/    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      F?@    $   "@    B0
M >   0#@   F8@ 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M               !  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 "_^X
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MVEE#ZYKK(+!Q&U"ZGTZO/8P.L-3ZY+7  \\AS4")=VO/'E()$S?8>EQ^D49
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M+?6?C_S>!_4'_4M24TZ/K';9TRO(-$93'U59C"+&5L>Z_P"PW^G997[K&/\
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M_P#/=J6'_1*/^+;^0)(3))))*4DDDDI22222G__9.$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M     49-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0
M  $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L
M @    D   "PAVD !     $   "\    Z  .I@   "<0  ZF    )Q!!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C T.C(S(#(P.C0P.C$U
M ')R,CDS-S0Y       #H $  P    '__P  H ( !     $   %/H , !
M  $   $?          8! P #     0 &   !&@ %     0   38!&P %
M 0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M    2     $   !(     3A"24T#_0      "           _^$!2$U- "H
M   (  @!$@ #     0     !&@ %     0   &X!&P %     0   '8!*  #
M     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"'
M:0 $     0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#0Z,C,@,C Z-# Z,34 <G(R.3,W-#D
M      .@ 0 #     ?__  "@ @ $     0   4^@ P $     0   1\
M    !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,
M   !  (   (!  0    !   !1@("  0    !              /      0
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M%2)!419A"B,R<1>!D1@S0K'P)%*AP1DE0U5BF-'7)C1$<G-XX__$ !X! 0
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MUKA_5+73]*6WBC:S2\>XGA$YG+RRQB-.9@@A41^<H#*7;9T4>;UA^R#^RO\
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MVFQD9F(!3!7X->6EB-#*F @ ;X1P5N*A@+Y)U&XY'7H*S@FN9+6V/+\Q</!
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M(:K]H_9O)'\O]I&8N+SQ#SBW^8)EY/#YO&Y?W7.(P/.)*]$?MR_]@OSG!?\
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M!4(^F2\7+5\D2W?.;*S71,UG)%VDFI)S"KCK "&<.A, )KF!5JBFDS,4HH@
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MV]_\W2M\UN!)RGP3@#"0/N(B/D!#R/(_OT\<^?(_>2XFY1UR3U.0>FYV'KG
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M+/CQX\)(R[)(0!B5!_"LHP_)_P"&Q:/?ER9)ZQ=5Z:4II2FE*:4II2FE*"(
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MHPB/@>1$.0+[\@'/ ?Y\A]/'!O'4&H>%_P"4>HWQWVQCUV';89.,YJPDO?\
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M28YC@8)_$;C?)[G!/\6-\?3 (?(P&_1<8P<CUQU.YSZ]:D]4FI>D"@4.0Z0
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M;UW$XY?E^9(X[:]FN&A@2-YM9,MT<,XK-<EX^MV65G[/-259B:*V08(V$T_
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MNGR.[4DWE;TI9UWD&XGY)=1HC1;;R@G ]??&>G4 [CTST.:G4Y(8YP4Y3LN
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M.KB%B+'V4TE&)3DG&,'@L%&@O2+N&Y3U&M[AN1EB8A6#GL6 )!QG S@D@$[
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M??V\CR'^0>_L'XBQPH]L@^GX?6I/U_[_ /6O803$HF,/@"^>>!X'Z?'CP(@
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MO927%B_3RE)FE0=>\,T1_P#-N*WGC&V,&MRN,\MRD-R,9)_W9A/4''[R$GL
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MSM^/;(IR=!]?Y8/]\5)=,O0L'(\\%-QX^W)/[_D?[?;WU.Y\A_YE_O\ Z5(
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MQF*L+])),O2FTG&[T2E*1)%ZS3YUI6M\!:=J1>>T'V?=NQ8M$O-;R$Y)+P9
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MY%&PC9$#A6BO() 8[JS<"16'.@='&+"I]P<%%$PY^D.DOGR  !/J'CD/'(<
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M45JICIY'7+.#Z.7,;YCD,J3PE>HSE1%;LJ-*E'._G$LT4*H V"18)J DZ@1
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MQP 3JIEZAZAYX$1\^/\ (? \>/%SS(K-S,HV3!Y@!D\OOOU]]LUK%^Z9!YD
MYFR25'3F_P!/7'3\-'STE'HI*KK/V:2"?68ZJKE%-(@!T^3J'4 @  !Y$3%
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M#S$\S>& S<X<D^9D!S][<FHLVFQ2-@DQ</#@F1'K*W;)B;LH%$./'5R)E#>
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M,4T)25-F#KR,ASL"K*""<$8P.F03WR&/MBQ0#^:8!XY$/I\CT_5Y  Y ./
M(AQ^=4O .X"C8A1C(Z[ ;L?QS[8VZVY1SGE.X._E&Q]0,'MN,$@?EC*FUR.4
M ZE?Z?O[#Y,(B(!R7C^P>/8>0'5.2 \OIG YNNQ[;GWZ=>V,=:D)D5R6&_*=
MSG.<*1T]/X=\ \W3S9_=^M0'_P!J/^O_ /KJU\/MG'MC_K5[XC^B_BKY_&OH
M7N9S '0J')?R(^W _P#Q<>.1\_OQU!JO##D,>O< #N3@],$=-\Y_/ JVN2[!
M2%R<G/WE&,=CZ X^IWVP#6/N;<L8JG*P@4>>>/( /'/''/'/CQ]A$0^_O7\
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MX&?NIG)"CZG)WKOFA:!::';^'%F6X=0+BY<8:0]>5%R1'$#DA-SW9F;>NST
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M/IFL6W W*Q,.H[=0)+8'?W*R]_7E_#?;4B_\,MNR(41;[A<#+' W %5;7UN
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M >*X,LNVX(DE+LI_Y2M6)E*4A2D(4I"$*!2$* %*4I0X*4I0X I2@
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M<B1NLQLKJ<_VAPQIVDV:R->6>HW-W<6RJ2;I9X^6*2'E)\62!1RO'RB3E;*
MA6(]9?L3\9\(\"?%KB6YXPO[#2$XHX7M=&T/6M0FCM[6TO+748[JXTZYN9N2
M*S74E5)(KB2186EM4@=T>6,-108IB&$ARF(<!X$AP$I@'\"4P (#^PASKGA1
MPQ0JP<;%"I##KG*G<8QZ>OI7V6BN[2>W6[ANK>:U=0Z7,4T<D#(>CK,K&,J?
M\P;'O5UGIZ5U!C0IZ7%N4CQR>-;=TQ0*H4%1>OE2\\ (=TJS(3<C[()<^"\:
M]7\ VHL^$=&7DY6GBENI!@KS-/.[@D$C?DY!GV\O;'YU?VPN)7XI_:0^)=U\
MPMS;Z9JEKH%E(K"6..UT73[2S9(&4LGA_-+=2>3*%W9R,NQ-B0>P?V_'[!K;
MZ\T#&Q']L_R_"O1PTFNZWH[3VS P@[3LMY>K 0ACG".:TUZ=\8>@0$J?9 Y3
M*'ZB )P Y1*/ ZUQDRKPQJQ?H8H5&_\ $;F()UZ^8 #'K[5F>'0QUW3PO9IF
M; SMX#DYP-O*20?7Z;=)&O.E=@II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4J&V]//.0<+4_$M9PZRJSG,VX_/-(V[8MDKTSDI
M*DU"<M4+;+I8KW:H:'DH>5L,;2\<X]O%B:UIA,PBUCFF$5"'F(QN]7>HJ?K^
MP_,X'XUH[(%@WW;8,:[C;Q=LGXPW#4:F[4<XY:J.0CXP9XJM^/\ -.,ZHM/5
MJJV"FPMNF(2_8XN34K^0;/H_Y)8:N\K*\3,.YUM9&,C%/U]/U^-.B^I&>W7^
M?X8QT[YK!6>=-X^"(3:=F'->4\/9QPYN,R%@;$]WKU=PA+X@O6+[!N/4BJYC
MFV5FQHY:OD-;H2-R+8Z[7+; 2]8B7JL)*#88F;9JQ+F*D%1 SGL<9'IMU'KT
MW'7?;H=OF!W@[F:WNVP)@_+TOML+.;@[QE%B\VG4J-EG&X/ .'*Q4LG6VAYN
MNF4VF8+91[O$3:='K<-:HQOC.AMD9S(,=&U*6F75:E$Y5^OU_I_K3;'?/Y@G
M;88&V.N2>@)VZ"W/2H4TI47]YF&5\];;,HX[CD@5L3N$+.U'^D%"VNKND)Z#
M32.)1[9GKM@$<<X>>R]5+R &UG.&]3^R-:L+UF*Q),([C_\ IY@8I2?4(K>)
M]4%8S6+(ZAIMW:J 9'C+0Y&?WL9#QX_YF7D/LQJ@_'UE-::K&OUR*-I=JF,3
M86"Y>TZC+#&<M9AB\;F'K;KHNTCF[*I2J%243$Q0YZ=>E 5<*Z,&210Z%2"K
M*V"K C8A@05P3D'OUKC YAE6'*RL58-D.KKGF0Y!WVP<]#OCH*]&W3;:MU:P
M3KU0J:$7$/7@F./!1,F@;L)>WDRZYDT4BAY.J<A ^H>!F'4#&,M@@;G\\]1C
MZ[[;'(-]UB>RC?IODXZ8&[9 ]!@D9%34VL>EYMBR%MRQ'<<U8N-*Y%M592M<
MU(#.ST>Y5;V)RYEX9!TT;/DFR*B$(\CTE")-T5"&+TJ\JD,;7%M>XXUJVUG4
M8-.OE6S@G:")3#!(H,2B.4JQC+$&57()9L]1VQT?2.&-,ETRSEN[9FN98%EE
M;Q9D)\7+JI57"@!&48 !SU[U^**V_82QUN"N<'BBA156K&-(N"B"(I*OI%S(
MV=ZW^/<23Y[*.7KI51BFJ=JU1%4B38R1%$42'ZC:TK5-;U36I(Y-2NWN3$&$
M2L$1(^8CFY(T55\V!EL$G &<8K8K33;'349+&W2 /RAV',7;&<<SL6<@;X&<
M>FX(J0C]@SE&3F/D&Z+QD\2.@Y;."%42514+TG(8H^! 0YX'W*/D!\!K%U=@
MXS^6_?ZC<;=#OT/:MB;1;H^K\U:\"3SU5TE7FQ+7CETZ5%18],>N!;.885#F
MZC_(7W05N4 $0076 !*D@F4'Z_I54'(]NVYS[YSZ&I;Y+O,;C2AVJ]RWEE6H
M=U("EU 47+D *BQ9$Y$ [KY\JV:)?_&L <ASI4:K'H,3)//F&1+@?X^^7U8T
M[,O5P,92.:OA!=A LNZ)CM6$<U,BB5L4P%*8@)CU%23X?K]?SJDQZC\SZ_7;
MKL/R_+Z,P4J,O5!L,5(,47BR,:\>1PJIE4$CMNW44*F'(<]MT4IVKE,/"J"Q
MR^3" !/'(\4B2QN8Y(W61'4X*.A#*P/8J0"/I4I"NAC8!D=61E(R&5@05(]&
M!(/L>V,UZF'/3CV293QM0LCN\2*)/;'7V#V59,K?;F\7\Y0*=G-%1;$F1,BV
M&5;/.TD58I4T^A,O2  76R_XRUX^9KBW>3&/&DL;-I\=/]X8>8^Q.^"?6K-=
M)M401QR7T4 &%MHM1OH[=0>J+"LX0+VY0.4=@*KKMV+H;;_N>SQAZ#ARU^LJ
M/*]><?QH*.%D#U*6C2('!JL[45<N",)%)9@HJHLN<54%04.8Y3AKM7"^I/JV
MA6-W+-XMP ]O=.0H/CQDJ<A0JAF4HP4!1RMV&&/+-<M%L-6O($01PMR31+YC
MF)U'\3%B<OS DEB63)S7O![>_MP'D/\ KW\>/?C\".L_^'T_77 W'X>U8SVV
M&-NYWQCKGZ$?SZC$@O3JH3O)6Y:[YO%'N4G#]9>XVK;\Y>I"1O5@60<6%:..
M8HD4+$0Y3LGBR)@X,_9!U&*;7-OB3J4<.GVVDJV9[J9;F90=D@AY@G-O_P")
M*5Y<C!,3^BUN/!EB\EY/J+#]U!&UO$=_--+RE\9_R1['&!B0=<X%[&N+UTBH
M,[M,U9?@,E;;MLVW^0J%3RKN5E,F2*^3[U77=T@L78LPO6XF<R#9HZD,YNMC
M;KH_DK72:K4(J0FV$$T>6%U/S8/V4(,/)J>O\OU]-_PQMG(T#F[+&^7:1A?+
M]BR!<,69DCH*Z;3V.),SMZ&E19R02R_N1H^),L4+(N,8VSR,0I*5JM6-O,4R
M]UIW#Q<D%B*TDZZA(595Q.JF #$#!Z';/<#(W(.,GKG.!6YO4BW%W3;%@"L9
M I-YI6,'=@W!;?,66#)&0ZT-OJF/Z5E'*$#3KC<Y.OEGZP60+68&4>3!4E)Z
M.1$6?"CE(@F4*J P3OGH>G78$[9SZ>AQUQ43VF_"=HF"MP69ZUO*V\[[YN@Q
MF,JC3,=XNQ23$K>)RQG#)D#B?$BEWLC'+&2G)JO.76QL64FDWBV;IO&-91ZU
M='<-R("^GMU_]OY5$XVP"/7)SV'L/K^/IBIAXZJ._P!Q_D;&[S).9L0[B,;6
MY:6C,Q0T-B%/"LQB5V-;E):!MN+)$E]M:MQJ9+2R94^:I]R(^M8QLZSM3"SB
M>%DX:15#;Z>G_4Y_H/RK#,2;L=QEWROOSHEKV\QL'*;9*/BFR8<QA#7J$F[G
ME5]>JCE*PMVLS<4'A:= N;E*4Z%AJ[&F1*E62.5G4_+/A=F2C%0_T_([]=_Z
M5Y6#=QFY:.W2P>VW<98-O=YEK/MKL.X"VI8-J%NI4EMDFH"S8]A&F/<J+6?*
MV4&-H@[TWN\XICR]\8[DYUQC"YNPI)HA0KB&?K]=O7IG^=1VQD=C@_B"0<=1
MTW!&V1O6,;"=[V4]Q>6LG53+,-6(*IY'HS/='LO7@X]ZQDK7M2E\F7K%\8]M
MBKMZY3?6Q-K7,<9)D5F*#5JW@<XU1@0BIF9UE%"-@<$=B#UR,9SMMU(QOTSG
M>K6M*A32E-*4TI32E-*4TI32E-*4TI32E-*4TI48-U^W1SN.HE2C:Y>%,891
MQ/E"G9OPOD<(%&V,Z=DZC_,VD<YGJBXD(=.U52P5R>M%+MT 2:A'<C6+-+)1
MLS$R7PDBV4_OU_,'^1 /X;@U&VQ[0MS.=XG,3G<SN"H:DU<]LF:-MF-J1@V@
MW6H8@I)\VPK:*M.7+I"6[)EJGLFWM/Y5",ZXT<R=>B*;7$9^,ARN92U2D_I^
MOT:CGVW]]QM^ V/<?H_35-F6XZV.-N=?W.;@\0W/$.V.RX_OM0QQA/ =NQ<^
MO=_Q-% RQA-Y.N5XSSEY5]#TJ82971I6ZG 54DI<(N&D).3/&1@0SE3(P?+N
M>^<[>VPW]_RK^8_9IN-LEQP'$YOW#4K)>']LF:U\X8\G_P##BRM]R-UEHQA=
MHRAUG(^193(,Q5D6%:C;H>/MD_6*@TE,ELH&/:.6E50DYI)Z_G_;V^G]P/K3
M/7J/H=NQZ8S_ #]ZLYTJ%-*4TI51>Z78!=Y'(,WFC:^_KC*=M[A21R)BVU.E
MHRM6B94.8R]EK\B@F=.&GG@FZI%-R5%D[6$78N"**KHK=,X6XZ33[:/3=766
M2VAPMM=1*))8HQTBE0LI=$Z1NN75<(5957&DZ[PJUW.][IS11SR;S0R>6.1]
M\R(54A9&VYN;"L<L3DG-=SO;?G[(61U<:Y29U6AP=-5BIJUQ$-+HVH7RZADW
MT2PD'S3O1RY3B!7!HLBI>HJ)S.3%.1,29C7/B)8K:R0:*)Y;J9"HN98C%#;J
M=BRJQ$CS*#^[RJH&\Y+8Y3C--X0NO'275#%';Q,K&")Q)),?,55F7RK'S??W
M)8948)YA9&A"Y.03;]O/>4&ZK5%-%!)@_8,HINFB3H11;1*33X=!NB4"D20*
M;ME3(5/C@.=<<))))))))).Y)/4DG<D]R:Z('P ,=!C; _(8P,=JP?%AI5*Z
MY>9V&9<3\_\ J&(?O9EZFDD]E".XPW9=N$T"E2 XD(4#= ='4(B'U".H?K'Z
M]:BV<=/KZC(&Q[]1U/M]*WEI5//?O6+P;M:#W)8'EVWCYNYME1D2E$.IPSD(
M8R[=,P<AR1!T4%^#<AR// #QR_7Z^GZ[U44]-N^,_4_],>V/I4A=\3L_^$U<
M@0$W:MF4*1!/0*/2"C,'+N443,'/U%,K'(CTB(^0YX'C2IST_$#]?T]LYK4!
M2@0I2%#@I"@4H?@"AP ?Y &E4,[Y_&O-FEDD(>5<+#PBA&OE51^P$3;*G/R
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M( \D+(]M 3>!4+P(@H$ ._;US^7Z_$#K4OL-;=*?B(SB;,X>6^_RA"A,WF?
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M\":7_P"_LR__ #$Y_P#_ +EZQWV[??\  T;_ /#G#W_[75[]FV__ !+_ /\
MO75/_P!97U*X!QZZ*",@\RA,,Q404<14[G3-T["R":*Q%@:2\)+Y">Q,Q&KG
M3 CR*E6;R-D&XJM'S1RU661/$:_J"GFC32X7P>66#0M#@FC)4KSPSPZ<DT,B
MYRDL3I)&^'C97 82G2[1MG:]D4D%HY=3U*6)P/X7BDNVCDC/1XW5HW'E=6&U
M;JUA:R--*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI
M32E-*4TI32E-*4TI32E-*4TI32E:PS;?7F+,,Y<R?',&\J_QQC&^WQE%.U%4
M6LD[J%5EK U8.E40%=%N\7CB-UE4@$Y$E#G( F H@I55C[U5K"U]+LF]I/%<
M"?/0OU\?GP,>>?A"DRS&6AVPFF S@(?,AJ3+'D9*9L3D"HF=N,:MB22 *JK)
ME.J.-\9'??<#89)P=^W3KG;WK;D+NVW.;A[NYQQM6I>#X-WC;$&$<@9QR'G-
M_>I&M,+[G6BH9%K&(\?U&BFBYF4<Q=/7862TW.;L;%G#LK)6V3"OS[U:1,Q5
M [$CT_Z_]/7OTV)V!2-V.:5LP;4<)Y?P?%XNO&;:ONW=Y$CTK2M9H^#F=L\]
MC*$A)W'4VDRC@L>/\J,;V>W0#V>B86PL()Q$,96)8S",FW*J.-B1OC&>VQSO
MW[X&,G<[$C>LHW[;HKWM<P]$S.&L;,,S9ZR'<$:5A[$TA*.XAM<96)K=DR7>
M#NGT<V>/VK6O8JH-ZGDW"+11$\NRAXYRH@G) J"BC)WV P6/H,@?WQW]<5)C
M$&4JGF_%&-,RT1Z#^EY6H=3R)57?403K0%Q@V$_%BL"9C%(Y(TD$4W2//4@Y
M*H@< .0Q05#IL>HV/L1L1MZ5'&G;N)2W[U[EM(5PQ>Z;&4["4CEA#)MU+%QL
M??%V628Z@@E0(J.DI9U(U0".U'QK),C!NUW/::-851$JKS2F.^WY[^VWOO\
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4:4II2FE*:4II2FE*:4II2FE*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g696632g41l33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g696632g41l33.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2J.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $ < 5H  QLE1QP"   "0.@< E  "')R,CDS-S0Y' (% !]-:6-R;W-O
M9G0@5V]R9" M(#(P,3<@,C M1BYD;V-X.$))300E       0EJA>J03\.L="
MP[F+@+UOW3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              2X   &$          $
M 0             !A    2X                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   2X     4F=H=&QO;F<   &$    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      @(     $   "@    ?0
M >   .I@   @!  8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M               !  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 "_^X
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M*4DDDDI22222E))))*4DDDDI22222E(.9_1+_P#BW_\ 4E&0<S^B7_\ %O\
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M:2F^<?.^W"X9/ZKI^K[!^ZYO\Y_7.]57@_\ .>HD@S@VQ^C(( MQ^<CZ-O\
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M &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU- "H
M   (  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!*  #
M     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"'
M:0 $     0   +P   #H  ZF    )Q  #J8    G$$%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#0Z,C,@,C Z-#0Z,#D <G(R.3,W-#D
M      .@ 0 #     ?__  "@ @ $     0   82@ P $     0   2X
M    !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,
M   !  (   (!  0    !   !1@("  0    !              !(     0
M $@    !.$))30/]       (          #_X0%(34T *@    @ " $2  ,
M   !      $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q
M  (    >    ?@$R  (    4    G $[  (    )    L(=I  0    !
MO    .@   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD ,C Q.#HP-#HR,R R,#HT-#HP.0!R<C(Y,S<T.0       Z !  ,
M   !__\  * "  0    !   !A* #  0    !   !+@         & 0,  P
M  $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @   @$
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M-%HVH('V![+'W,XI"(L6@C (&^R+?9,"+6_9UO6B7/$]Z]PJPK  1#,KR!
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M428CN@"S"^[*-(]E%=T+-*&#MC#V@&EB#[ P[VNESQ/>LEY+:R]'4$^:,?\
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ML!>]'<W5(8WR;ADEGE+*@M%1UX\",E4<B3RP/2M4F WC51PQ.ZI@)9"0VJU
M3TY!I(RR:;!V=M-" 3GS'CU<UU!UL6_;G$*W8AQ05<D(+T?$/JSCG4$PH:O.
M-G%I'9=1<GKWLBZ9<FMR)PVLY2VR*RY,P-(S$#?NL*]G<4G:%5-%-AKY#M*E
M+,"3(YV+KZW=H  !Z5K<^5];  "QO:#E3+N=C)=\NXVH[<(>ZZMJ"VOR972I
MNK6OT>JHXXU,W6M'ISQ]3F*V-:H?E=A.4LXKL2:8NHE4Z0+'RYGI@?D;<@C2
M%D*,@+\XX\]]X@Z_8Z'(#)M[W*U1=&SQ^D-.7GT(%A/M3<>JC9;PIFZ%#58/
M'A+-F>W+7<4G&,,B(8^5YTA1M49<DCHC.42$@IB\.J3;!;40DQR),#:DYX/6
MI-SOZ^B><Z9VTZ\AT*YO2(<X>;-5<\I+4=96TP4XP12,\;'?CS7LH31P$>Y0
M/,^EBU':B!8Q&TC:ELVP,LQ/JO2V*EI-!G>NCN]9FY!6%'J59;ITMXS4 97L
M3\K3FLW(Y6Y];WTOT#KBSI .3R?E7S9K8GE ^'4/4%9\Z);Q2GQU,5ZW)KSN
MFKZCB,BD%&>.RF(FL<C;>'#VX/SBPK8^V-KO9QA2D<R?9<TQ=<A<%[ ]&>GT
M<#XO>RG=%AD;FP.HW;DY@7S)%L^8<PW@JZ)NDHYEAI2VY53O,UTY#KBN"?&"
M[IS.G&D:M0).+?*ZP^1U-0!XIQ,VL%?1]I4(976\KFZQ3!IL2_2IN3QC<E0/
MB$3D%:)S^S+U>->I" TF[;6-K;Q (&\"03=UP1KI?*VMIIY&\M.D'X_<S3..
M .5!2MQKKS7":<365&JVB:?F3JT) );<;@XUW$: G$]GYI*M6XU8U)*'DT"(
MJ0$<;9))"UFUKB\9'CO[_ Y@EA:]KWWKY&S<LL[Y\1KVK'QSI&.6Q'+#D[6Z
MKDD9)S4\;YZ&09KC]>1^>UQ2IE/Q>0O]+N=L\?6>@X7S2I8$$&V)6IYD#N5R
M"CM]O2DE#!TKF0Y-#N.?!'./'#K0 '=RR.Z==0ZV0N=TZY:.&=]"5%]-<V[W
MOF!0./6-9:V^5L+Z2'HL$I4X?63C7=U=)2[/L%;X]$5[:M:U37C6FD!2]H\-
M BDCJJ(7'Q] L:46Y>N<E^E36\>/'5=+9Y"WHN.>\TVW;FXN;:D#.QROSJ>*
M@Y@](4F%QJM45W2>\G3D8IZ5^'HN/CU5=7-D43/'$=MNUYX^%1U="(/')R?)
M7J10%FC[PI7212D?V-R2-I;84Z)QO3BU\>.SVA0 +.O?(-<+Y.L=V_1SWT[;
M#.6.BKYI71>/+&&5=)N8TFY00]\Z/,J_+089+3D K<^J>4"RVJWC4WKQ&OBM
M=0AQ/0P!*].C.GC"Q4Z*F+PH:!Z7NAHV/;863FC=)W=TAP'/8@@V.?\ 9-NW
M7FXY/-OD>JY9<C8UKD\_-MZ5WR%Y$5S3W1OE<=VB:,5G417-,.$JJ2Q5LB9&
M-HM6(;LA]*0RL%T.-@+H$(U63 DL7/$J3D$.?GX6\>.&>N!&EL\@;YG/*XZ\
MSD!<FQO866LM?R^Y6\FN$?)ALMN]6:](NJJGA38<W8]$Q5?,*8O]SYLT0E?8
M0(-9T95\>KQB5LYKVG-IVQ9)-+2B:Z&>$M.*YF=%SD)X\<ZRR'-;Y0ZQ;T3\
MHFQXV'1<J8[7Y.WKQF8^11U3WFCH]FEO2O\ 22+IJ 3G!*YD\W%&&"KU\(11
M&W[RI&W:!8S&IX5K'-QKJ9N$#E]Q$]ZQVNY"$Q%(#D)0!<GT;Y#4DW-@+BUC
M:_"]N!6T[F!;TOMSHON(S](QRQ(Q<J;-X UYR.=Y7$TM=R0%2W9:-;-%M'RJ
M*-;BZ-4/33A,O%&7]E1N:QG S2]8TI%!J%45O \7]V1]2@:GB 2+&V8!L0>N
MQ6H#F1&>3AG'+I^%-=2NG67CXFY:*"K @LBK":/-KR%>"'<=@D'5]-FBQ&.)
MQQI 1MB)"E=(!)1A&@=MA4]E6G*01;7AS\=.CUYK(6NS>'"WX1MH+GTNG/17
M"8N=/-]SZ2265&KMU@B[='N64TJ9'Q9D":,=T=N*S)7RERCUN1V$L]'/%Q;?
M70CO6T$ET/EQHJ@4?XQ!%[8VE )(-$V!XV)\<R@MR! RM\KI^US(&6F0).NF
MD>1_F!S%9>,?1W65R4Z0.84U .8L7N2Q[EY-)Z.I1$"GI!7E9L1M-4DR)%-;
MO<03 M%_#(I4]*'N/"E$W>F!?%(4HC:)>4T$3S9FU\NKFOJ?HTZRI(%W6;?=
MY@<SF;\YTTMD<P3HZ^/LWI">?#?R,@4,:.0K2PZ(@/"5ZI%AFU6-M+-_,PBV
M4K8JN&5.=#/=.VU>CLZ2%8>Y1(,6J>?0D5).*$AZ?TA:10H.31G;B>[WI9N[
MO:_*O:YMEEH0#I<$ ^Q9FIN<?*>V;ZB%:Q_FQ+YS9-B<P>;/'*P>,4?J&GDJ
MNFN,D'.NINA/(MDD :L4.@9'6;I'XB0R2>5K)'")@XB20]XCCV[,DN+>Y\>.
MJZ$"VELFD&^9N!E;IS(L+Z9V!O3>E>2EQU)Q.I6QJGMM1)+1KOH<N6LJ2SI]
M@U4R^?5A:<5Y(TLU^3T$C<*]-?PM\3"J4%*H9*E;QMR5C(72P#XXH&Q8BCM\
M>H=W;DIM<Z7^,M:YL;\]^\BVHR',OHGX%V-R('RDYK\?+MNZ0WQ'ZIA?$"S8
M'*I9"J^ASRT.5_PNS'FP8PB!747BC8JB;:\PUM,BJ-T2N;VR(%!J!P?7@X0E
MIDK#[%IM;,@]) !YSTCO6M*K.872"HI%QYL[RUR:[S;WM+I5JK1\<GFKJN:(
MCOS4XI?\KX_)F1VAD*C\_'*':45PP1QR<U<H-3/T>7I&T+:!U(4OCJZ_;QZ/
M=?K6>Z#<?)LUKKZFQMK>P^RX#3K5=E'26\PFGC[<<VI[F)(N2,A;^CX27_<C
MXZ4K5K)YFO+<RT*Q8 5$W)V>LV-I))=6J1SYA%55C(YA+FXJ$^-I#H6F-6#4
MN/BRQRYP6C>%LR;C.^9',0WTK $&X &8VK5'>/2 5O>O..@HVA+Z0-VH^;\7
MU\446Q.*RXMNK!%[RIN8S:>#)DD%IMVCC\SL4UCS0VQ6,'1?PVWM#^?W]*W'
M33K2HEAD2;7OD!>UK<3?.YXCT;:JDUV<M^D BE8<K;S;>1SVB@\<Z429\, -
MY<!J*,L?&_C>PV$H/<+<.L=VK.8)DSUH!D=JTB?V/&)7$H<QOQ<D<V5RD!9K
MV(@ O8Y9$C(YFV0.8.>N1N;Y$7N*\VQTD/..(T!1\O<^7L93MI_G5KF69P4=
M;0V:WPR5_+8^BI^1M5AW=Q23\9;Y>8NE/?HQ(J<IU94$DNU42W26!O"YL4*5
M3>X<P]?#._'+]JD ;QRRLW6]FFP^5GE>]\[[NA'"3KJZ2'E$AO&_$L-Y7R^)
MV9 YGT=8N,/"!YH:MTCER!%R&I>@Y7=L!E:13$9)8:1R0#FTH?G1FC=C =*L
M7+56UKZN;=1;P9'OX=7?KJ-.]0VWV0RL;NS-C8\UP.%KG52S"^>/*URY6QF,
M'<@WQYNI]YQ7;1]J='F;4\)2L-,<0X>W6(=$[^2R=/!T]D[.;6MAA$X)LIYG
MKE"K$%,@L;.SZ1(0I0"<NFQYNWQ?J2UAIJ 0;_V;C6V0N;6#M+ZV4%PKG/TE
M<*H*M[>(N^5<AK Y!=%IR!Y+)('(:?JEN:ZXMRI)C7#&QR2#-E?P&..[H<BB
M<M?7]]C4G5R1NDCTV#-3MB5N.0,C8SMQ-OI\="RW0-?M[',Y#47O:W7T',VN
MH)7\M+@KFQ>65U<;.8#OR>2R6 ]&? ;#YCND)KF)JJXJZ63Z^@6?(-*T-7JZ
MI9 PYT5IXJ9-'ZM)*@K4J3#13%$\26%.:\<J-0/1^R<+-OG9K3SDF^?R;W.0
M%BZYO7QDY-\\.0%H\(ZJ4\N24D"L&1\X'I^M: 0&O)TX734_'R34 YUFC73%
MWIV"0Y<_&;D\XKE^LBGXFWPN7,85[RP%'R,:1V8"BP .68.[8WR^5SCGR!%S
M:U[W.L+\>N7UP<I%/-#COR>O1=>$*DG#OE7+)*.*-=:&UC7#E"9 >BCKV?&@
M5'1G);B3)(PQJ$:6/5Y?[1.)#)7QH-F[9+$"YN(V8\:>/'2I( L1S'.XU%\C
M?,$<2&@#+T<POHMX)3N>V?PFXD61:&U0[&G7&VE9=-E"X @+G"2O]=QYS=G1
M86/6AD*WA6H-<U2<>MF)CU@R1]0B^K"Q(L2.!([BK884)A%1TSW5^0'QF1OZ
MB:9RI^O9[2K6:=OL"L"S7%4;>T-2!?:=<(ER)M0I%J)7.(RF5I%:9*42H2JD
MYSH Y.H3G &4<2: !A1@!%F!"(.]:L&@Z@JG$7.8U(62\MU,>EVL/G]%/O;)
M47'$=X3RW4QZ7:P^?T4^]L)<<1WA0B_L'#.4/+E(7R75FM=W=48M<%>KC&DT
MH4F]7=#-)D4T3)">UU:_8((*+U_0#61;K[S[TN.([PL+Y/\ @WVMC\8JS[6P
M]G8_+4L[79UU[ZNUX]=>@ZWO>]:Z^K6][W^_>]XMUY=)]Z7'$=X7EX@\'O?'
M6GKK6?CK%AT]Y]Z7'$=X7CN <'-]G>Y#68A!WL0?^VI7O81;"(.]AWN=:ZM[
M"(0.O75O>A;UOV-[Q;K[S[TN.([UY>(/![WQUIZZUGXZQ8=/>?>EQQ'>$\0>
M#WOCK3UUK/QUBPZ>\^]+CB.\)X@\'O?'6GKK6?CK%AT]Y]Z7'$=X44K.+O1T
MN5PLMX.D@A[I-HQ$'*&10IPY%2!7%XH@>U1:B0.D;BAUA"9&>42(DA(U/DD1
MI .SBR($C2>J[R+V2.;>+E3O"UMX6.N8S4K>(/![WQUIZZUGXZR+#I[S[U%Q
MQ'>%X[K_ (."V$0I#66Q Z]AWNZE>]@WL.P[V'>YSUZZP[V'>]=76'>];]C?
M5BPZ>\^]+CB.\**=\8>C\%>8;^'.8R.6%5..GB&,5\AW#T\=/F!<U5.I#9XS
MZ<@218Y)T:14NV\B0F-:%(GTV!4%B5C6Z^\^]3O"UMX6O?4:J6/$'@][XZT]
M=:S\=8L.GO/O47'$=X7CNO\ @X+81"D-9;$#8M@%NZ5F]@Z];#UAWN==8=[!
MO81;UU=>M[U^[>+#I[S[TN.([PNORZFN \XBDGA<@?:Z4,,NCKU&'M,1>3@F
M./:) VJFER(*4E3S0R#3$2Q0 !Q8M#)&+1@-Z%K6\FWBY3>'$=Z\(;2O .!1
M*,0F-OE<)6"(1UCBS(0=>+@I/)9XZU)&5J)/5'3P1RDXEN0IB3%!HA&';+[8
M]]>]Y%NOO(]27'$>/\/H79-P#@YL6A;D59[$'K[(MW4KV(/:UU;ZM^/77KM:
M]C?5^_7L;Q8=/>?>EQK<?0OS5?\ !O0MCU(:RT,6@Z&/5TJ]"%H/7V=;WX]=
M>]![0NSK>]]GM;ZOW[Q8=/>?>EQQ'>$U7_!P&NH$AK(.MBV+>@W2KUK>QB[0
MQ;UJ=:UVA;WL0M_OWO>][Z]_O6'3WGWI<<1WA>I37/!A8E4(U,BK4:=60:F4
M #=S@3L9)Y8BC0A,*GH#2MB ,6M#+, 8#K[0!A%K0M+=?>?>EQQ'>% -2<)N
MC4IR4/<V89BFE4P>F8B+ D]H\M;!L]\886E<!NR:$1ERFEI.ZEBBI3F9X0,;
M$1@-K5A292XG+#4:01"V5L^_/OU4E]Q8N%M>89\<M3T]BL'Y/N#?:V/QBK+M
M[#H&QZNE9H6PZWO>@]KQZ[79UL6]ZUU^QO>]Z]G>]XL.GO/O47'$=X0, X-A
M[79D59:[0M[%V;J5ZZQ;UK6]BZIU[(MZUK6][]GJUK7[M8L.GO/O2XXC/-!U
M_P '!Z[(I#60]=8=]0KI5BUUA%H6M]6YUU=8=ZT+6_WZWK6]>SK6+#I[S[TN
M.([PNGV#0G1Z6C"I)7TV<*Q=XO*6XQL=$6[O<"#M!$(!Z5>@6$3PM4V/#4N*
M3.K([H327%G=T:%U;E"=<D3G%K=?>?>I#@,P1WKM22NN#J1*F2ZE->*-)DY*
M?1ZN\%QZH_1)82^[*3Q3K0CE!G9[9QHM=9A@A#W[.\6Z^\CU*+CB.\+W^3_@
MYVNWXQ5GV^SV>UY:E?:[/7U]GM>/77V>OV>KKZNOV<6'3WGWI=O$=X7X*O\
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MN^2]N]&-YCK>BX7:>8JH3P&]IHC8D&TC#8C4'/(CG',O$RX*D*&,HVTJY+,
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M#L6]:S%^%XG&USWX=7,8P%SW/I*AK6M:+N<YQC :  222 !F4$\!( FB).0
MD82;Z6%[FZD#-%6JN?,+^:1RE_LYW=]6<GSH=D?Y5[,?[0X+_P!2IEI8E_DZ
MO_T*J_X$B_FMY_0]?!%L\J?HP)[;(>(BIKL^*-C9RK8YP];<5;,[G%5:&+*U
M#6PII. HW7A$<\?"!,<;&WB)UW^ \"G6@$;$9\WQ3RDT.%G:MLN&U4DFR\U%
M#R;98FG$S5,9).ZFWA\6*&%XFJ!)<\F0YMR;+H:79Z:J^#"VHC:W$63/WBUQ
M\VY(EK1(!F[EGC<818;Q]*PS,12/AW&X/7[0[V#R'K^$VO+:P>+D@U3/+%)
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M!YMR J"/));3<$MMID[8=(9DDD!EC2\$*C$&@++%FMPD-AR@;F>!<OW&V\Y
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M2J*CD"B3[6:1''6<#0\>+^#JIRL+=O#HRMS#+GY^;7?%A0F$3")A%JJLR/6
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MSN\S2H7R&UB1-;PYAW*_5*J:)Y'DIM)3)!<;6&GR9A*FQA32<Z;4ZVQB'@#
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M9#Y]J?[K3]8,X!?U=X^KAM_%V/K@8!_7?Q$?Z=/W%/EF^WV0^?:G^ZT_6#.
M7]7>/JX;?Q=CZX& ?UW\1'^G3]Q3Y9OM]D/GVI_NM/U@S@%_5WCZN&W\78^N
M!@']=_$1_IT_<4^6;[?9#Y]J?[K6Z*'RALF\3B\T9>^/ TOCC+*&C2PG2=9X
M+?VQ*ZH.^B-&&Z)4:2JRN[E:,,T6;O8-#%V>T+LX963PQ3QWW)HXY67%CN2-
M#VW%S8V(N+G/G7Y4Q/#ZC",2Q#"JO<\[PRNJ\/J>2=OQ^<451)33<F\AI>SE
M(W;CBUN\VQL+V78\L6BJ.F>ZOR ^,R-_433.5/U[/:5:S3M]@5R(W[76#X%:
M_H)&6#0=0]2K.IZSZUFLE0F$3")A$PB81,(M3UCP.H6+I?N*,ZB<9@[;;,\X
MV<R2;<DK(C:B9M)4\5WQ";:^+FZM)K3JM)96-6O21G3KUA3-QRH"#J(V;A3G
MNG6UQU:._;]/2ML.%"81=7ELVAL!:3I!.Y=&(4PI]"VH>Y;(&J.-!.@!V(7=
MG%Y5(T16@A[0A;$>'J"'6][ZNOJV:6CJZZ4045+4UD[ODPTL$M1*[FRCB:]Y
MSRR"Q>]D;2^1[8VC5SW!K1UEQ '>J?K>D-X\.JI0STB.P.5LB3&#),:^,$$>
M+594YH/V.PY6>F\&TVQ:$;V2^U(+';>H0];WOL?M:ZMFP6/Q-;+C(H=F('"X
MEVDKHL,E<+__ "\.=RN+S\Y/F^'RY \^1T#BE([*F,E:ZQ-J.,SMRXS"U.VY
MR&_,WNS6C/A:GZ1FTN>_(6*+Z@B/#N*)S'Q:YSP'%2K53S3#5W;O:+1NJ)H!
M(1&7R4S=C5@(<'Q4[65'7E!IWE06=S) 2=K[/M?)L!AVQ& U3,5JMK*EW(LC
MH7;3XF(L7EW=ZIJ,5I-\U$--1S-+F0LBPV>&3DJ4RQ$EBYK#OAB;%*N-]/'A
M\0WB9/,H"Z!N\-QD$K28W2RM=Z3MZ=K@'/W' !P^A2F>(=/4Q(5%@IDTCLJY
MG)%M ^7M<<A6V+;;HE'VN[($4D>>M+#6$[M;UN(U\UQ*(%A"6$EB+T4'/A&+
M[58MB\#:!SJ?#L(B?OP8)A%.S#\*B?E:1]/#Z57."+^=5\M75DDWG-UU5/04
M].\RM#Y:@@AU54/,U0X'4;[LHVG3DX6QQ<&!6@SFUN)A$PB81,(F$3"*+;GM
MEAHZNI!:$J1*547BI 5LA4D/\ C)32U]>PFNBYXLJ9P.,)TA1NR4_<S'\*]2
MJ5)DR!$K.-[&M>JJ64D#ZB0$QQC>>0^%FZW[8NGEAC O86W[DD  DKVMG\#J
MMH\6I<&HI&,K:UW)4K'4V)U;IYM1#'!A&'XE6.>YN\^XIC&QC'OED8UMUYT_
M:**Y((U6 UQN01AH?-=V:DDD70A>X*T6R"#-+=C@4QF[2ET$\T]O4MRUU3/;
M>XH%R1R:T8RB]FS35 J86S-8]C7YM#W1.+A8>E\3+*T9W:6EP>US7!S1;/''
M<&DP'$I\+FJZ6LGIO1GDI(L1BBCDN[XNV)T&'3O]$-E9+' ^FEBECDAGD:XV
MD_+UXZZ=8<M2U_7\YG:X: M%"8=)I:K,=%2Y$V 2QME7/!XW):V-3XYI$(24
M0A+%3>R/"Y.1HPU(UN*@!:4ZN:00PRS&UHHY)#<D"S&EQN6M>X#+,ACB!HUQ
MR._A="_%,3P[#(A(9,1KZ.AC$+(Y)B^KJ(Z=@BCFGIH7R%T@W&2U-/&YUFOG
MB:3(VG' WF=(^:E:,MO+*G:JO@\V12USK@>K!53!^D[9"["?:Z?5BYK\18TE
M8N\G1E+/4)ANBY0 AY9ME@/"H4&)/+PC%'XK RI\W;3PRB1T'QQE?(V*9\#G
M%O(QAEG,N1=Q <S6YW>]\I>P%)Y/<9J<!CQR;&<2PZ2BBQ8?!3,/IJ.7$,+I
M<5I61S?"=:^IY2"I+6N$,;-ZGGN1NL#[\9["^9IA$PB81,(N(:N0IU*1$<L2
MDJUVCN\4IJ@DM0LTG!HP_O0@8PFJ.X%[T8;W$ ]% ZA#[(=ZWN+@$ D7-["^
M9MK8<]N=9B-[FO>UCW,CW>4>&DM9OG=;ON LW>.3=XBYR%RN7DK!,(NIRZ>P
M:OT:!QGDSB<);W5W0Q]K72Z1,\;1N3\YB$!M9$"IY6(B%CNX" (*%M3C,6*Q
M!%H@DS>MZU7)-%" Z:6.)KG!C3(]K Y[ODM!<0"X\S1F>8+>H,,Q+%))(<,P
M^NQ&:&"2JFBH*2>LDBIH0#-42,IXY'1P1 @R2N C8""YPNNTE&EG%EG$F -)
M-  THTH83"S"S Z$ PL8=[", P[T( P[V$0=ZWK>];RQ:1!:2UP(()!!%B",
MB"#F"#D0=%73F+_-%Y3_ -G&\/JRD^>;C/\ D?%?]6UW_*RKNO);_P!YODZ_
MV[V1_P#4&'K^9[GYI7][5L_XE\&*]Y#UE0DYD%BML-6SWFYOCY,&Q^G#)%E+
M]79;%3#L,BK&]PC3J>Z6@>=/W].D J4+&PT?@ GP1V^^!J^JPK!(,0IZ*>2J
M; ZHQKX/F8^>.(OI^3H7_O4.B>7U(-3(!=Q;?DOB\S?\]^4KRNXSL/C^V6$4
M6!5&+0X+Y)?JUPRIH\'K,1CI,<-;M93!^T<L-?3LI\ :S!**25T<<,[6^>O\
M[L8FQ]IUT3U@.XH<<TVK7K,98L\A[3&(I)#GOP^C@UCV^HJ&&2-4YI68EFD#
MX0NVW/TCB\?V8XMT76[>= [:1R;F^P;+5+Q"654#'5,\,<44I?R@@J:PTD,I
M>&<G))O;LDL,8+A$>4O<.8-$_P#:.P2F^%(ZK9W'*IF!X/BM57XCA[*3S*7&
M,!V69M-BE"R!]6ZKHJ-T(GH:'$:T-@GQ"/S7-KX)YH45\$0:CC2[M'(>J'=U
MGSY*&*EF(#/9;9Y7#H(\1N+3(;,[.L-2H8UI/+GY9'HT5,-,ITE''G-QUIM;
MSVLU?I'!/BXWMQ"DD?4/D911[E4WSMT)CBFW2^!K8K3O,<7+;G*\G(^S&;A=
MU4?E@)KZNDJ=B=I*2FP6CPZLVKK358!/]3#,8IL0Q#"VU5-38K++7[^&4<5;
M7.POSL8>*VFA)J9F5+(94G/1</-;GRU=,^1U1M4.KZ)RB13J4%LUA+U,?60N
MSJZJV0-08@BC*B6+B%SS9K$LA3V!K):I4D*<0B,9S&]=WKMS;,24SI3-B%(R
M&"&26>8MJ'&,P55+22LY!D7*EI?4QN@E#0V9K77W+.MSN$?]H.DQYF'187L/
MM-4XIC.(X?0X-ASJG X&5L>+;/8]M%15)Q.;$6X;"^"EP"MBQ:C-1)48;))3
MV;4B:+E>TN'1JQV!1P94QL($JLA"Z<T&EVC4<<'"/QD3;QTXZ-MUQ"8,<C70
M5Y.5%K4K]''ATCK@C1*'MNDK3'"'&+.+=(W9MLDV=CIXP9IQ)4-=C;'QQES(
MP,-PUM=#,R5T#]X/#V/<Q[&N>V5C 8GME>WSZ7R\5N,UH?AF"/P_ )Z;R4U5
M+7UT4%97"?;C;JHV1Q/#*N@AQBD;$Z&2CKZ6FKH)IF4<V'U-<^'$:>?#Z:IK
M/R1X2/'':#KIF=:\'GQD:LB(U=.6".-<O;W"*R:>UJ=:T2 )9(61N;'Q.LBZ
M-P\)GM"M26U.:<E"(:GO@9A'FXA@LF'PNE-53U')U$5-.R)LS70RSTIJHOX2
M-@D!B#@XL-FOR]*]UWVPWE:I-M\6APMFSN,8,VOP/$=H,'K*^?#)HL3H,&Q]
MNS>)GDZ.MJ*BDDBQ&6!T#*N)AJJ=[Y;1;@9)1W/!7UQ?TZ>.'\WBAOB8J[_@
M=CS]-X;_ ).H/]"I?^!&OX!;>?RXVS_VKVB_ZO6*9\W5RBHZ9[J_(#XS(W]1
M-,Y4_7L]I5K-.WV!7(C?M=8/@5K^@D98-!U#U*LZGK/K6:R5"81,(F$3")A$
MPBU.V,RTNCZ7_BF\0UIK!+<;SQLYD!N=UC*"*DV8ZIF[?$1/6X;/7M9092N(
M0,!KB1!PRLPTM*SF+2F#N:(1X1%.>[SVN+:V^R[-;_3TK939SS+H[6MAR"OX
M^5+)XQ0>6O,)BJ@P11$EES8PN"V-Q\XT)I(RB7EY(1MQA@3BM@+4[$$TOJT/
M6[AL-)48C005\[J6AFK:6&LJF@%U-223QLJ)V@AP+H87/D +2"6Y@Z*J9SV0
MROB9RDC8WNC9]N]K26,U'RG #4:ZKYX>B_2\T^=KGR%DO.^6<LX)&XW((XF@
MK3%II87&".*W%U/E)LRAJ=C@Q<)D#H@BQ26/$Z/\,C/;@+M('12O5J-&$?>?
M*0[9#8N+ J;8JEV6K:BHIZAU;+4T=!M)4LCC;2BCJS-6^>4\3ZDFH-N1W9"P
MR1-8UOI<E@GPEB?G;L5=7PM8]G)!CYJ%A+M_E(PV,12$1V9GO7;?=<2Y;DHE
MT?O#2'NQ,A3\?8+*I0GWH1,NM0ESN68%':%VA*BI7;3C-)"4K,,ZQFJRW$"@
MT6^L1N]:#K7R6JVZVMJHC3NQVMIJ8@ TN&&+"*4M L&FFPJ.C@+ -&&,M',%
MT3,+P^-P>*6)\@TDF!J)!QM).9'@GG.]<\ZMXB1(VY(G0H$B9"B2E!)3(T1!
M25(F)!KJ 4G3DA 424#7L!++"$(=>QK6<J][GN<][G/>XESGO)<YQ.I<XDDD
M\Y)N5O      #( 9 =04:1FC*2A4AW+8;3M5Q*5BTHT*31FOHDPR$6E10TZK
MK>6IH2.6]*"#3"%'6I_PQ1@RS.T 8@[]&IQK&:RG\UJ\6Q.JI1NVIJFOJIZ<
M;I#F_$RRNC]%P#F^CD0",PJF4U/&[?C@AC?GZ;(F-=GD?2:T',:YYJ5,\Q7)
MA$PB81,(N"O<VUK) H<W!"W)S%!"0L]>K(2$F*E)FB4R8!J@PL U"@W>BB"0
MBV8:9O0"PB%OJS%SFM%W.:T9"[B +G("YX\RLCBEF<60Q22O#7/+8V.>X,8"
MY[BUH)W6-!<YUK- )) "@2Z>5] <?U"%ILRQ6M!,'D._%NM(\G<9M;$L-[F,
MPHF+5=#D;Y.GW9^P@+ >@8CD99AI7?2E. >AYJ56(T='9L\[6RN_@X&!TM3+
M_P"%31!\TG EK"T7&\1==-L]L3M/M0V6;!\*FEH*?^.8O5/BP_!*%H(#G5N,
MU\E-AM-NWWBV6I;(X!VXQY!"@\-P\V[FZM4OQVC''J(J>K9%C\NGLQ?,CDH_
MV-K&?CM4KLL<@CU^T:2EG]MUXY@UW/OQC+%L9&:GG.*U7\5HHZ*,Z3XD_>EZ
M',HJ9Q/3::I@=Q9QZ,X#Y.\ _E!M56[4US =["=A:9L6'MD&?)U&U6.PQQ6T
M#GX7@6+0G/DZDBSU5_F;T>U^\G./DP@-M\M;NMQU>#&Q8Q0*H:PXYUC6R&2-
MRW3HVNSU&)>[,LLD<>;%28D 6MQY >$4XS"ER?P@I)%V?/Q3!:S$*.2&IQ*K
MJ'.W2V"F@H8(!(T[S7.9(6221M</DNK-[0YD+LM@/*ELQL?M308I@6P^SF!0
MT[9HZC$\>QG:S&<7EI)8S#+!!64$%10TE7.Q[B9X=EQ"X QN$+'9R'0?1^MB
MBNVXVW+!YR,,V.[R+DK(NYC6K&FQ2L;V)F;"%30UTY>\C8@LZ5,B3-J$Y<]%
MO)VVH8S&II:=-#6FNHL&;R#?.)L69+D'L.*5,;26L:T%K::LD9N@ -:2X.);
M<L:-UH\G:?RH2MQ648%A7DXJ,/;RAI*B/8' ZR=D<M342NCJ)L?V:I:CEWND
M=-*V*G, Y8?'U%1R\SYJ_1VT&;^TOF/+)S,U[ #7#G!S ,-)+_?W$O9-V$!T
M7V]['U;"+?;WO?:ZNK6MOX$I.>;$G=>+8G^M!<]]=/:8?P=!L1".<1>3C8$
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ML-\RIJ2DJ"7LIC7T^&U50ZA+F;[';S9;V?HZ..O^ON47^^YS&_\ CW<O_O\
M\\];X$H_YW$OG;$^_P#C7[.A?-/KK;5_T;8W_=UL!W?R;_;TK]_1T\=O]?<H
M_P#?=YC_ )YX^ Z/^>Q+YVQ+]:3ZZNU/]$V+_P!W.P'_ +;5:;TZ(^!S:P>,
M]GU7:%K1U]X]W5&;35Q^UKIOFYX[-6UD>&5U-:$:F?6;(G&!/18V8O2*01@
M>^B%*M \HEQ6T"AMTJO9N&6>@J(*BJ8^BJXZ@LJ*NLJF2M8]CBT&:=[H7^AE
M)'J"6O#ANEO7;-^7'$\.PG;#!<9P;!*NFVJV=K,%958+L_LUL]58?-405,+:
MB1N%X/2PXG3D5+N4I:R^XYD<E/)$>5;-M=A\>#$XK'8R%2%;X!9D#5WV!-I$
M2=M&G*)$-,@"<H W(]B!OO)N*/.);TH2411HRR "WT4;.3C8R]]UH;>UKV',
M+FPX-O9HL!D%\4KZKSVMJJS<,?G-1+-N%_*.;RCRX!\I:PRR9_&3.:UTK]Z1
MP#G%0KS%_FB\I_[.-X?5E)\T,9_R/BO^K:[_ )65=AY+?^\WR=?[=[(_^H,/
M7\SW/S2O[VJ4XK=EIPEL@S-%IFY,S96EH@NN#(TQ+>,$=M,!$:3 F2(1Z,TP
MQRT1#XT7HI6,]!U-"?M(^L1PC=Z*MJH&P,BF<QL%7Y[3BS?BZJT;>6&\#Z5H
M8A8W;9HLW,KG<0V3V=Q:HQ>JQ'"X:JHQ[9T[*8Q)(Z:]=L\7XA(<+EW)&-;3
ME^*X@0Z(13$U,@,E@PMDYOYJ\HVIMC;4@M]^(3Q&2M<MCJC3='3'5 [,DN5S
MYF)\.G,QCVKC[1-%JF4M<27N"J*H'L[;@E9"E.@"#M-QG$V-C8VKD AF9-&?
MB]]KXY?.&-Y0L+RQLY=*V$NY%LERU@7.S^2KR?5%17U,^S%%))BF'SX;7-Y6
MN;33TU9AD>"U;Q1MJA2Q5E5@\,6'5&)PP1XE/1-$$M4]AW#UN/<I>0$2KQVJ
MF-VE(F:"/2QW7+&E#X.*6)AR%8UN$B3LT@[RW)(ZVR)<R-"N0M$?=VQI?3T"
M8UU1K!E^S1'B6(14SJ6.IE9 [?NP?*!DW'2-9)N\K&R0Q,,K&/#)'-O(#>Z]
M&N\GVQ6)8[3;25^SU!5XQ214T4=3-RKHWMHHZF&A?5T1E%!75%#%65,=%5UU
M+45-''.]M++&+-$ZQGI&>2C/NRU[]*2)C))[71\ ;7QV98H4GC W.RX)9,FD
MYT<)C&XW+W^7JX*G:9:OE;8XKY&F7"4O:YP-1)09Z$>T.(M-0Z27E)9Z<P![
MV1 1[U5354LIC##%*^;S?<E=*QSI XF1Q+0#QV(>0S8.J;@5/1X>[#*#",=9
MC<])2U>(N?7BGP#&<!P_#V8@^N&(891X4W&)*G#(,.G@AP]\.Y1PP-F>Y1"I
MY@<E5:61I5]M2!P!+9+8TP?SW).S."];(+<A"FN+*5EN:QL/<4">80E6./.S
M:VJDC68E3MQA*$E8U-BA'IG%L1<V5KJN5XEDJ9'[VZYQ?60.IJEV\YI<WEH'
M;CVM<UF[ND-#FL(ZAGDRV#A?0RP[-4,!PW#\"PRC9#)5PP14.S&+18[@,+J>
M*I93S.PS%HA6TM1/%+4B5\['2OCJ:B.3H\VOJWK(;)"S3:<.DA;)5+8Y.I C
M5DMP"W26Q&)*H)''L_:5&F,"K:8DM4LJ<!)A1 DQVS#RC5.@G!IGKJNH9(VH
MG=*V66.>4.MZ4L,1@BD-FZB)Q8+ #=)N'.S7JX3L?LU@<]%4X1A-/15&'8;7
MX/120OG<ZGPW%,2CQ?$*1C9)G MJ,3BBK'EX,@E8T,>UEV&(\T%TZ_IT\</Y
MO%#?$Q5W_ ['GZ;PW_)U!_H5+_P(U_ +;S^7&V?^U>T7_5ZQ3/FZN45'3/=7
MY ?&9&_J)IG*GZ]GM*M9IV^P*Y$;]KK!\"M?T$C+!H.H>I5G4]9]:S62H3")
MA$PB81,(F$6IVQE=,F]+_P 4TD-55@;<:3C9S)W<R:,G14=EI4ZCS01UONT"
M&H>Y242>P!<!PC<K" LQFTLVP]I%HX6%.=N>U^R_O6U\8P% &88,(  "(8QC
M%H( A!K8A"$(6]!#H(=;$(6]ZUK6NL6^K7L%"C6L;JIR[6YW>*9MFM+;:(^\
M'QY^=*RG47GC<ROZ4(1J61V6Q9T=4S<[$ $$9S<L-)5E@$$8B=!%K>RD@C46
M4FX4)A%%42O2EI].9E64'MBNI?8E=FB(G<'C4RC[W*H@>6:6G/(D3$W."AR:
M3DBDXA*M*6IR1HE9Y*55HE0: K=+*B"1[XXYHWOC):]K7M<YI;;>! .K20'#
M5I(#K$A>C581BM#34U968=6TM+5LCEI:BHIIH8IXYFN?!)&][&AS)XV/D@>/
M1GC8]\1>QKB)5RY><NJ/L[A$6T,4GF44C@2_9'M^D+0T: 'JZ^L>W!81H.MZ
MUL77OJ]C]_[MY6^:&/\ A)8V6UWWM;_YB%NTN&XC6D"CH*VK)T%+2SU!/4(H
MWW6MFP^F#X:UQR7,XXO-DPW0FBO"K!E%GJ;#@S; D>E3PS-::&Q96H>AJ)W.
MR43P&3N<:8@]^$QY Y::MODA2&1[7D28]1QU<E/FZ"" 35-<',\TB+G-:V'E
M 2'SD/$AC!#N3#MS?D')GZ31^2#:BJP"AQ=[6TV*8QBDF&X'LK-!4-VAQ%L%
M/43S8D:!S&34V%B2F=1LK7QOB%4^+SDTM(_SL3)OI'N+;KK15;O%I7DX#]A(
MAHB@KPM4A:+?L:[C(HK 5D-(*%U]??+A)4:,(-"-&H"66,P-GPWA[K"!]15N
M.8%'1U=3<<=^*%T8'2YX%L[VS6G]:7;2 @XO3X+LW%GOR;2[4;.8(Z*QL=^D
MK<4CQ N_S(Z.20Y ,)+0?5ODGRIL#_!4OP;FC(E4"T4FF7*:SH)2D>)%[/:5
MCB$&475:AQ!6MZ$!,OA3 >J%U![HEZMC \^Q";^*X3,P'(2XA/#2,Z^2B-54
M$9Z.BCOF+C5/J1V+PO/:'RCX?4O9F^@V+P?$MHJIVEF"NQ)NSV"!QSN^+$:I
MC +@27 .M#I#^.=LSQRXOV]S:YS\6Z2AU<W2D4)ZP12B5<:(0X)G@M)MW(BE
MUR*3RZ6R.U"6MJ-3L[YN(1E.Q-*Q]<6Y/'0&N)ZKRL1P7%,3EH9:JMIPVFGY
M1U+3"HI6<F[=#RRIWYI73V&ZV3DH@T.=NAA))^A;$^5/R?[!T.UF&X#LKCCY
M<?P=U%#M#CLF#X]5FJCY4TT51@(@PO#Z?"722\M4TK,0K9)GQ0B=]4V.(1[B
M>-7&&C..T-:2*IA4/1O3NQ-0Y19#:0-WEEB*AHD8SWQ]GSTL>Y?*$Z\PLM6A
M$]R1W"2EVE*3G;*++%GO4.'TM#&!!#&R1S6B68 NEE< +F29Y=+)F,M]YL++
MX_M7MIM!M?6R3XMBE944;)I78?AKI&18?AL#GO,4-'AU(RGPZEW&.W7FEI81
M(XN>X7<59C-Y<FND6-9=>U!"9#9-J36+UU7\31:<9-,YF]M\=C3&C$>2E+.<
MGAT/3(4W=UBE,B2@&=HQ6N4)T24!RH\HH9%Z:QM.MKJ@S!9M13N*677LI3&J
MX[,X2^MTCCCP2G4G(E7>3JUJ%"0TU&N3*4"Y/W72A"O3*42PHA4G.* 0@C(B
MQX')=]PB]1QQ1!1IYQI1))!8S3CCAA+*)++#VQFFF#$$!998-;&,0]Z"$.NU
ML0=:WO"*%:4Y+\>N2*23K^/]V5?<R.%/.H_+%-:S5@F),>=QZ.$0D=1L:Y9I
M)WZ!.H-;5!G4E<R4YYS>>I*),&$EB-01U@CUJ;\(F$5'H%TD7">S^4<UX8P:
M^HV^<CX -^322 %MDF2%EN<4[?C:Q-,K<&-+#)%(8KHH_<B86%_<G5J[R=-*
MD@!,KR%O*2" "18'(%78[\1_Z6F_VY7_ #84)WXC_P!+3?[<K_FPBKO8?,+B
MU4UM5]1%EWY5T(N&U.]?)_7DBEC8W262^$%YK4TZ2(CCM=PV^.R=0T1[2X:7
M<A=TZAJ9>_W @U. EB>;37H5B._$?^EIO]N5_P V$3OQ'_I:;_;E?\V$5&^<
M720<4.CQBL(E?)B<.3"18[\NC\-9HO'G*72)Z-9R$:F0N1+8T@%LAGCB9R;3
M7=>I/)T6-R;TJ0M6N6IDIA2 7:"]E;NO+ AUK0*%6?7K^CE,$L2*L$WADD0:
M."B?HO*6I,]L+LE+4E$*BB5[8L3J0$JB"%1.A]R4DE'@,+"4+QLB>QBJZ\GM
MGS=8:WPNN(7*)[+EY")4XGHHQ#V-?(9 L);T19ZQ>:F:6Y6<6B2$&JE(P:)(
M+,-, #92+W%M;Y6X\RTB?K)'1 ^FZ5^H>V/P?D7'3W'W*WX_C)^$?>GZR1T0
M/INE?J'MC\'XN.GN/N3X_C)^$?>GZR1T0/INE?J'MC\'XN.GN/N3X_C)^$?>
MGZR1T0/INE?J'MC\'XN.GN/N3X_C)^$?>GZR1T0/INE?J'MC\'XN.GN/N3X_
MC)^$?>GZR1T0/INE?J'MC\'XN.GN/N3X_C)^$?>GZR1T0/INE?J'MC\'XN.G
MN/N3X_C)^$?>GZR1T0/INE?J'MC\'XN.GN/N3X_C)^$?>MX\*E[#/X=$IW%U
M)BR,S:,,4NCJPY,H1&*F&1-21Y:%)B-662I2&'MZY.:-,H*+/($+9)P &%B#
MJ52NT814=,]U?D!\9D;^HFF<J?KV>TJUFG;[ KD1OVNL'P*U_02,L&@ZAZE6
M=3UGUK-9*A,(F$3")A$PB81:9U5\<8;GZ6;BTCHNS*BL2?0:A^=3#= *\>XX
M]2B.NZ5^XJL[$TS\QF&8XIEB4U@DK:U)7H?=$^VIU3)@@TF4!T65B&Y@BY!'
M3D<UM3M^N4-P5-:-2NCJYL;9:5=36N7!Z9# DO+,AFT:=(TL=6DX7[)3FWIW
M,:M 8+]DM424/?L:WF+@7-<T&Q+2 ;7L2+7MSVULLX)&PSPRN8)&Q2QR.C)W
M1(UCPXL)LZP<!NWW3:]['1:".C:_D^[7PC;K>U.>6MXR=VLAYCFD'F_6!9O&
MAH3Q^)!D(6LZ4)X1.MJY6_+!2)28'3DI-01PL!R9H$H$Y."LW1GHC6;GG$M1
M$(][<;15E53[V]N[SI71/B+[[HW&.!Y+TK/<7Y=;A6U8V<$[<(P[!\1\[,;Y
MW[4[-X#CW(<B)!%#0PXI2XBREW>5D-34POB=7_$"2GA;2L#]D9O1F5&<682;
M?7.8PHP(@#+,YK<@C ;"+_*"(!DS$ 8=]77L(PB#O?[];U[&:_P)1Y_'8D;Z
MCX6Q*QZ[56?#J*]?ZZFT@^3AFPK'?8N;Y.-A YAYBV^SQ%QS7!'0L"KZ*6A5
M^@:67'S35:*WL1>E',.\#^QL75VM@[K*!]G8NK7:[/5U]6NOV=:ZI.!X>?E>
M?._M8KBA_P#[% \J^V#?X,;*0\>1\GVP,>]T.W=FA>V=N%S;5:@N-/\ )F&>
MKN6UR7!;/):7S2F9-J8!KZ-0-]FD"MM=J7/Q#N4*S[ 0.A9JW;"D <C6A:CE
MFIJZF$2!?MA G&RJMN6@I)X(Z:2*\,1:6,$DK"W=:6-^,8]LA]$D'>>=X?*W
MCFN?P[;+:'"<6K,=H*_D<5Q#E_/:A])0U$<_G,S:B8>:U---2L!FCC?&(X6>
M;EC1!N!K;;$7;H%. K\ 9;V7R&=BQB"(8''D99JP Q%ZT$ A!/=S [V$.M:#
MO?LZUK6O8ZNK-3X!P@_*H8W_ /B.ED_\\CN"Z+Z\/E*;;DMK*^FM8 T<5%1&
MPYKTE+ 0WBUI#3J1O$E=;1_R>/HVFY5W\AC-W)%G:V(*DB_+% < ?7L7:+,"
MY]HH77[/:!L.^O\ IZ\L9@N$1_(PR@'2:6%[OPGL<[Z5IU/E4\I57<3[>[7$
M'[!FT.*PQVM;=Y&&JCBMP]#)5#MS^3&TQ,^5E27G77):WZ[K>%*XBYRV"N+A
M(IG9:YRA;QX50J*^NM=,4#]!!.!9:-,4HVU/"R*K$QKTPJ!*%)"1NWXX8H6[
MD,<<3+D[D;&L9<Y$[K0&W-A<VOD!>RY.MQC$\2G%7B-?6XA5AK8Q5UU94550
M(VES@SE9Y))-T/>][6AP:USW$#,WVV_HS:@_IY =(-O?L=>]](ES)Z][U_3O
MJN/6NO?]/5K6O_++%Y^\?\W\%O/V?X<R?HS:?]/_ $@W_P"Q/F5^<GL?^V$W
MC_F_@M]V?:M?_/K^3WU7S1CE<M[-RLY/0M_KY^=5I+M=-KVYRY9U#%(26LI]
M;6:/W#; 38>[*1LK8<![C;TC)5Z3!3O[0]@(:QM;QX\9:J6O+;Y#/6UF^H6T
MOJ.Y75@7104C7\&AD$:K^Y]:;(5%([$6[3=SWY61EOT@CC0C9DFD,;B]IL\8
MCZ/2=$7WLR1QH:V-J)["!H;D2 A.E*+&_-9O8UOKM?Z5VO\ 1D4F;^RNNWGP
MZ$:]D*9PZ1#F@-/HSV.R=H*>ZTQG= :V( >LSL]D8_V-[WH6H(!R*;QZ/P6^
MY5TY6=")QWY,T7,J>*NKEQ%7&0A:U3)))ERLY)WS'&-Y9G-(YMZYTJFW+@?(
M3*4VAI!)S$ZU,A<""SS%+.\M#H4F<"%K=JR:\M-[-_!''B #T+A<1.@PXP\8
M:-C53/=E<E['?VM2[.3],8UR;Y,\?X^\NCNN,4G'--5TQ=T>AL<2%$]P3@#V
M7=X5B*$J=7QP4#!LF?'/QOS$*'/+K_)%];-;?O()^E68%T5_$(_>M+P<GW8
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MY*!D+#(?X^\K8DF3$(TY"1*26G2IB2DZ8@D.@%$$$%A**)*+#K02RBBP
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+[=&E[YZ]G#H7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g696632g42u11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g696632g42u11.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[24\4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $ < 5H  QLE1QP"   "0.@< E  "')R,CDS-S0Y' (% !]-:6-R;W-O
M9G0@5V]R9" M(#(P,3<@,C M1BYD;V-X.$))300E       0EJA>J03\.L="
MP[F+@+UOW3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              -8   );          $
M 0             "6P   -8                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   -8     4F=H=&QO;F<   );    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      :S0    $   "@    .0
M >   &K@   :L0 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M               !  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 "_^X
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M  P# 0 "$0,1 #\ [[)ZSU"JV^NKI.1<VI^VNQI8&O;M:?5$G>W]+ZM?T/\
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M@!P=Q9M9^[[_ &)H!-D=-U\H2C&,B*C.^#^OP?-P_P!U_]'T7[2[&Z7C6-+
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MZ49G&:9!!.LP1'BG=T7I;W;G8[29W:SR &^/\E74E&EA33514VFINVM@AK?
M?-<A_C,('U>RR> [$_\ /SUV2Y/Z_P"(<[I;\%IAV7?@T ^=F0ZO^*?C^>/F
M%'8MGZE8)P.@=)J<(?9C67O\=U[Z\GW?U?5V+HU7V-9DTL8 UK:GAK1P #3
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M$7%E))#T^#B4MMLS(_36 TN/\FNW(L:/\Z]Z/1_.9'_&#_SW4@]'_P"3<?\
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M &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P "  0P!3 #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #
M 0 !   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P
M  #H  Z>,   )Q  #IXP   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3@Z,#0Z,C,@,C Z-30Z,#  <G(R.3,W-#D       .@ 0 #
M ?__  "@ @ $     0   EN@ P $     0   -8         !@$#  ,    !
M  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0
M   !   !1@("  0    !              !(     0   $@    !.$))30/]
M       (          #_X0%(34T *@    @ " $2  ,    !      $:  4
M   !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R
M  (    4    G $[  (    )    L(=I  0    !    O    .@   /
M 0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP
M-#HR,R R,#HU-#HP, !R<C(Y,S<T.0       Z !  ,    !__\  * "  0
M   !   "6Z #  0    !    U@         & 0,  P    $ !@   1H !0
M  $   $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @(
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MU4*!)"4SD9:AU/ FP=$G-#524W2&I>'_Q  = 0$  04! 0$
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M",/CS \]LISCN-J6((',<3<$\GM*_,UPE/>W6>'&#"7H-L8L)!8KF-AT[-"
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MAE^+1LTD^RS0&UMHM)BJ0O441+*OI5\UB9"7/-K0T>P(ZDU5>^(C'K2D>9=
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MC1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1%PI+HKE,=)5)4I3"0YDE"*%*8O\
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ML_G:#EY"YTY6S2-DCI>OU"1+'N7S)<&LA9VR)X--G*, )*>/( "0(D9B)!U
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M@!R80*4.1AO6)A  #\(B !YCHD#@/(+7X/V!?R)8B_RVIO\ LNB0. \@M#8
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M' >06W[ . ^KH^PIB#K'G@OV.*9U#P "/Q?0W/D @(^7D @/X=$@<!Y!:_8
MP(!@*.$\0@80$0+]C>F=0@'K$ ]#<B ?A_%HD#@/(+C5P+M_1Z>^PQAU+K'@
MO>XZI2?4/XB]4.'(_P!0<Z) X#R"WC@' 11* X4Q  G\B ..*6 GX#D>D!AN
M3<!Y^7/EHD#@/(+=\'[ OY$L1?Y;4W_9=$@<!Y!'P?L"_D2Q%_EM3?\ 9=$@
M<!Y!:?!_P*(B'V$L0\AZP^QM3.0Y]7/_ %-Y:) X#R"U^#]@7\B6(O\ +:F_
M[+HD#@/((^#]@7\B6(O\MJ;_ ++HD#@/(*"9''>/Z-NLPBK2J)3:>J_HV44W
MJE6K$)7E'B236,,F1V>)9-3.")F$3$*J)P*8>2@ CHIW_/NT"=/1$:(C1$NN
M[-)%QMSRP@NDFNBO6016153*JBLBI),"*I*D.4Q#IG()BG3/R4Y1$#%$!'1%
M4ZW@# YZ[ G-A/$9C&A8LQC&QO33&,8S% 1,)AAA$1$1Y$1'D1\QT40. \E6
MO@_8%_(EB+_+:F_[+HD#@/(+@+@?;Z=04289PV=4O("D7'=),H''KY($.)@X
M_#R'EHD#@/(+G^#]@7\B6(O\MJ;_ ++HD#@/(+9]@' 7 #]A7#_!C=)1^QQ2
M^#&]72 ^AO,WD/D'GY:) X#R"W?!_P "\B'V$L0\AQR'V-J9R'/JY_ZF\N?P
M:) X#R"!V_X% !$<)8A  \Q$<;4P   ]8B/H71(' >007 &!#!R7">(3!^,N
M-Z8(>KGUA#?B$!_L'1(' >06AL X#)T]>%,0%ZC 4O5CBF%ZC#ZBEYA@Y,/X
M #S'1(' >06[X/V!?R)8B_RVIO\ LNB0. \@M!P!@0H<FPGB$H?C'&], /\
MO&&T2!P'D$!M_P "& #%PGB$0$ $!#&],$! ?,! 0AN! 0\P$/7HD#@/(+7X
M/V!?R)8B_P MJ;_LNB0. \@M P!@0P 8N$\0F*/F AC>F" _V"$-P.B0. \@
MM?@_8%_(EB+_ "VIO^RZ) X#R"AC$=/J-*W29]C:;5:W4XY?'.%W*S"M0D9
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M=!8G42&$.M)9-1)0O/)%"'(8 ,40 D#@/(+E';_@4/,<)8B  \Q$<;4SR_\
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M]-8[A<^:ZTGC/L_@K$U!RT'MF2J>.9M&,LK)W(41O$TF980+R*+7[ 8[Y-*
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MHBP_^Z:_O="'MJQ__K):Z+Z,?WC=]@Q7P8L-MS]C'\UGS2F^Y5\W^F,1[AL
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MRM0M)^Y [Q!))V9,Z).M;;MU]>4>Y7;$[-[7#5R=P]&9L]%;<Y=S<%TZ'%4
M$,BILKC#R$6O67^4'MRDH>0J\8K)*OV+8F-6<VHNUCB/)]P1NN+L@MN'7X[U
M->&L79;HCE$,BYEB[_"PE4B:=4JY6<<*8]C&3&(,<J4[8S/;U?7=AMCIF#9B
MY?,7-=A"MVQ#-Z\BX456.3KJPZWIAM$1HB-$1HB5V]?.KP-]!\K?58G1%A_]
MTU_>Z$/;5C__ %DM=%]&/[QN^P8KX,6&VY^QC^:SYKSE^YQLW#BOM$Z_3'CS
MP\-FNEV"CJH=?3XN=:IA+U\GQAZ#=VHB^/T](F'SZ>.!YZ7Z2L!]+[.5*[6Y
MGX&M2Q&:#[%,^Q5[IEHX>*Q&QZWJ\8&$P*K2R)_BU!M TFP'DOHK:^;UN"7K
M==\W?*GT>3_6D?HBN^PQ=UF<9Q3#'\VSKUE4BH$[:4?]7ADD2-$!<$-TQ\G\
M90G %#PA_/\ XB>O101(UCN5^5UM+LX**:SSQ*0FD&2"4F]0_P"Q=/"D %ED
MN4&P]!S>9>6Z/E_P%]6BE8>,C;,-R<R>SQD0H5^RL5MF)^HNF66YZJUS';YU
M=&4^>>L=,8*MXJ]J24:V I&S^/EE$ET0C52M&2@NM$M<1KS/CYZ\OCNI.SC=
ML]%ZQR'D:]!$*.K,ZE4F>X#(+,MEL2E>EV\#8V7HBRNI6-B#33F/7-$^FXAF
M/<D47J37P+90Y+:Q?PZTZW+J#L4S_(MK%#R\H[78V&PPUKL#A7,5T5;6>;;-
MZIP]<MBRA5DW;!>%?B[%1-%&4773=*@\.<ZA2'E\K><S\5O>[2=\02]K66RK
M;Y.N/J=/1,/&5[.]AK\B@F[MUQD6D2FG,,IB.<RQ6$K77*,L5W6'SA"./$N[
MG'-6R+1P4V\?=\">7XJ=<@X8W53NT[&>-8I5L3),>\DB7%Q$9)OL7+M&)E9E
M6M+LK&\R7X^0=LE7$2>>:S5VM44Q31<IPT?8&S6/CQ*+;Q/R/%<^9,*[H[9C
M3;-'UB3F37W'\-7F>03FRU.Q$')V6/B8Z,D)BW&KDQ3+';H]==L]D$)AA;0E
MFSMPBZ<U&9.JY;IDW]:=<O"%&\?LYW(PSYA;8_(=R<W-&7+//0E=PN7WU<=R
M)\E627<I'@E[.I#I1:E%?Q4&6/:1;9JBV1%HW;(K()N-$ZZZ^:BEILRW>VF.
MD&=V<-5$1,M(1<?/Y-EK0VC)B7H4G 6<T2><GKI*,6$K8%6;I$CB=>*KL$DG
MCL&CL5(YN[D3E9TV\9ION3Y^]TJ\62#[MYBUO3F[3*EXKL#&1$:C8D<C&<U&
M'E$J\NZE0>Q1?$.HIX\>)H"!%411)R1+T^VP;OLE)PS>]66V56.KM I%3!C!
M;A[Q'.K!::5B+(E3?7EZ]I<M#N#!9K[-5>R&;O7CAX[".:2<^D:19 T0)[MW
M'QC3NO/=JJ).[,MR;2QJOH.1LLPY2A;O7*!;E=Q60F,SCAY: PI*1]BF73N9
M5F;?7V5DI]YDG=8?.IENFYDT'S2%<+. (B3D1;C:WS\E7Z9M+W:+6F9)D/)-
MQ>U^0RG79JS/HW-EYA$+C56F9&]N5&$81%C<RL"W9XW1&I/(V.>T1NZ ZL*>
M G6*B<Z@ZFU^O!-_#7N[OGX:\<OQ"%3(1,H#TIE*4O48QQ "@!2\F.)C&'@/
M,QA$PCYB(B(CHB6&D?.QSS[,\*_6;]HB\@?NJ_YQ^VCV4VW]H8G7=/13?9FT
M1QQE+_B*U;;_ .OP_P#*=]]-1[E-S=XZC[F=O+]YRI S=9RI6F GY$&<JBM7
M+6X[L?Z/_2T:L3D@<#SP8?BEYQOI9P.6OLO:+6P'TZN$J.C4L/K*0G4F/6DS
MX;U<[!J>Q7HD_5<VHT'4!TAW#>!N\3*]>FN.K8$L>ZG[D\5_XG-LG[ZZ;HB9
MS1%29V99UV$E9Y^"@L8:.=R3L$"D,J+=D@=PJ"13G33$XD3$"]:B9.1 3G(3
MDP$6/>#[3#$]KBP=T_&>5KE+IR,XS>UNIO\ "T^[CV=>J:-TD9=U8HW,"]#,
MU3@U5# P;6YS/E?ME8M:&1D#-FZY.NN/@NC?.TJQE'.+96J'"24S;X>H(W&O
M&E9*F>B[&P%I395PB: A[H]R175@BKDT79.+C2ZQ&22S-ZC'2#OH0%PZZ[DN
M8@:Z<.5]T[N2NVS=HUA.MPZ4P:O7Q\F52&8S!538_JS&K3\M-Y*KJE9M=HOU
M^J5+@9V+F<2W6,?-GUD306E6D5#Q;F2F+% ,)(G6[KYJWJ7O:P96;ZQQO$41
M>">Y1RP_:,7->@\?4&,=S<Y&8U?.IN=;SMU@Y6^V]\:^QSF<&C1%KM/H]@X>
M24*BVCTWCLD'A;J_Q62#1%3H^(B8DT@>+BXZ-/+2"DM*GCV39F:3E%6[9HK)
M2!FZ28O9!1JS9ME'CD5'!V[1LB904T$BE(JCHB-$7&=--4AT54R*(J$%,Z:A
M2G34(<!*=,Z9@$IB"7R,4P"4P"("''.B*D5RM5RG0<96*C 0E6K4(U(PAJ]7
M(IC!P<0Q2$PI,XR)C$&K!@U3$QA(W:MTD2"8PE('(Z(JWHB-$1HB@C$7R@;I
M?;O7OX9-N>BDZ#N^944; ?FS1/MBW4?Q4YIT4)SM$41VS!N-+O/S%FLL$I(2
MT\3#"<JJ,E(H(ND\ 9%L.5<7$,U0<IMR%@KM:9J4<@FF4)E%R6/EO&,$$6Y'
M7OE%",#L*VWU^/D8Q&NVJ3;25+?8Y5&?R%=)M9M17M+D\=IUB/5D)I8T?&Q]
M+E74''^%[IRB7IDE7"\R=>26(N[?-C6WC(MFE[A/U^R-[#/JF6G)""N]J@E)
M,P1./XAL58(Z31!%%FEB^D.4F[+PJ#ES#B623?,W\DT=DZZZYZW4NT?!6-,=
M/FLA4X1Q'/6=5=4UNJI*RCWIKSRRRMM<LQ(\=+IG.>>FI%WXDQ1<D*N5N54J
M":2920--RC-]LKV\R%79TY>H2!8%A"1-=:MD+59FRZ4/"X;N. F#4KY"53>E
M,GBV^VBOBY*N#DRT@28%;TNS:/$2===;SQ6RR[*=O<_/MK3&U62QY8&?O<,T
MD\366<Q@HW<5>%R-6XQ\1M3'L0P&2-7,K7>#?2*C0[U]'R$<5PN=>N5Q>*(J
M_C[:AA/%M^CLC4VO2D=.0-,<X^JK5U9K!*P5.J#XE7"2@ZM$2<@[;P\:_P#>
M76CJ,DA%DS6C5%HMNP5DY<\@3KR3(:(C1$:(C1$:(C1$L&X'Y0-J'M]6_=%E
M'1%B@]TJ?>T93VV8U^I6S70/1I^\S?L.*^]16(VW^Q?[K?NO7SZ\97F4Q?DC
M'^2X03!,X]NM7NL5TG%,PR%6G&4XT+WA0ZB@==BF01\^2&$!*("//T3B:+,7
MA<3A:GZO$T*E!\ &6UF.IGV9T <3=:FUSFN94;<L+' &UVN!$ #2UID>*^NI
MBN\1>2\:T'($*Z*]BKI3Z_9F#L@ATN&TQ%M7I%2B41#@_?<@("(?B'7Q]BZ#
ML-BL1AWC*ZA6JTG#@6/+8]RZ!3=G8QXT<T'S'C\5T\S_ "/97]FMZ_9>4U;J
MM='!'R,8M^@M:_5;?1%+&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1*[>OG
M5X&^@^5OJL3HBP_^Z:_O="'MJQ__ *R6NB^C']XW?8,5\&+#;<_8Q_-9\UX7
M=IF57N$-S6"<KL7'A%:1E"HS"[GO!3[J.]+-VDN;K#CI_P"JG+P.1$ \_/RY
MUWG:V%&T-EX[".;(Q&%K,#>+LA+/-X:9]RUC#U32K4JDQEJ!Q-IRS!%R-TVD
M#E"^M? S#2PP<-/QYNMA.14=,,C\@/6TDV:+UL;D!$!ZD5R#R B \\@.OD2H
MQU.H^FZSJ;W,<.#F$M/O"W\$$ C0@$=QNH/W7?-WRI]'D_UI'ZH4J:JU]SE?
M_N2*^H(:(JWHBPTW/=KG7(=DAZ!4[/2:H[E<F5QE9XJJU^9DK]A^$99%6KSB
MH9-.K;42)REWB&A)6-D6\?5'+5D_1!",DV8G?')8&\'QCQ&\C6^EH[J-N<SM
MERF;KLB1%8RY'PS6INL *5C& 94BXR[V6,LS%^:Y(4+!#W'<V;+BCQ4$CR3D
MEZJCB&*@J=LN4R/"I3:W'?<Z3:U^>Z?<NHOO;S#/4.VQK6ST>GV>%3.VBZ$Y
M96%]G*>9M;>B0<@PSX'*\,2INV@*1B:4M56S,Z(JF3LY7A"LQ(1>!?S]W&_/
M<I:4WD9RG6Z*E-GL#NIA2;R8I9J8-9M4U9L4QN.F=E>,ZC=VS#(K%R:UW1""
M;O8^5>QM6;1K%^+AM7+"W30<.RC03Y<^Y6K1]^&2I:7>LG[G&=&[ITWD(6IY
M)+;W]KRDC/(>)<-<<OX95 S%E0NE-.?<N:M.QA!>-C2TI560J2)21OFT=2=!
M8$_DI6QYO1R+9]IV0<^J052M5DQE-F-/Q=3;(+P<O!-&L:]DV%9?U/(&3X*8
MF4$WJB#9S&7.2.)RHC,04$^,K$I$@Z;^C\$M=LWS[E;7C=*SQ<+#X?L$0XL,
M-*OEX*5F(^,LL-3G=LG(]Y&3;Q@UD48R'?U04'C@P-D'TB^5%)<6R1"D_KIU
M":C:MG3-\TU")R5+5*[,I/&.6<GU6PQL),0LB5.H9?EZ?&Q4\]"8GF,LWD8Y
M1LY8KP\5'*,(UHV2!.<56,[ A\/BH&K?:7V="-?.;P7%J )J6)JUEFCE@U@'
M%@0KKR<K]+BI>"R5D&#GK HLS%F[C2SL3=@$P)SV/*7)&)&'*+QQCKGU94!Q
MVE.7TXJ<E8J,Q#;WB+E]%2U5K9'",W@YJU>UIJCD7+CZR9$@H+WGJA.+F5;2
MC_'+)#PR*AK@*!WBC%IKW<+J1I/=/GNXVWQX<;NC=ZNX:UPT38#U:G)PT'.X
M:+((50%9%_?E+ODVS5?Q->FZU=[C5&5=<1==1>NF;*9NA3*N7$:A-ND.ZD]$
M_#KPYJ_\,;Q<RY7ON+:3&.,.ST5;YFON[3?JQ"6=U!P360QA<L@V;%3=D6X/
M2%R50Y"KLJM8Y23FVHM%YUJ\DJ+$NB$B'"_5^[AY)XCCW]WFLI>B)7Z1\['/
M/LSPK]9OVB+R!^ZK_G'[:/93;?VAB==U]%/]V;1^VTO^(K5MO_K\/_*=]])+
M[G9S:.).TEQ]7W3L6L+F>KVC%\G\;H!=X^8&F*RV$HB!5!7M$5$$Z>>0$>HG
M)@*4<_Z1\!]+[,XBH&YGX.K2Q;(W!KLE5Q[J)J?#?>WV14%/&TVF!ZQKF&U]
M"6\8)($\IE?1VU\UK<4L>ZG[D\5_XG-LG[ZZ;HB9S1%0K/6H.Y5V:J=FCTI:
MO6*-=P\S&K'622?1SY$R#IL=5LJBX2!5(YB]X@LDL01 R:A#@!@(E^J.SC;Q
M27[V5A*9-+RDDR5CWTG9<E92ND@X:+P*M762,[N-TG5R"I7U1BC*)G(KX9)L
M ' [1J=$BM]ML0VMLW:+MKCR4(5HE)(QT4IDW+2]9C"S+!C'2P1U25O8UI@$
MJC&QZ\F+.+0._D6B,NY.>6*#W1.M+>6G@N*K;+L7Q]?NT7;324S*Y S%:<U3
M\S1IV]X?.E9K+%&K0M8A2D7E"P,(DM7,JQEHM2SNXR>EI>SSKE@@I/KLD"*M
MMME.VE@>$]&8\=1+* D(239P4/?,CQ-6>.:TA5VU=)8*E'6YM6K2R@TJ96BQ
M4;9(J5CF(QHBW:D%_)>,)'777F4U&B(T1&B(T1&B(T1&B(T1&B*",1?*!NE]
MN]>_ADVYZ*3H.[YE11L!^;-$^V+=1_%3FG10G.T1&B(T1&B(T1&B(T1&B(T1
M&B(T1&B(T1&B)8-P/R@;4/;ZM^Z+*.B+%![I4^]HRGMLQK]2MFN@>C3]YF_8
M<5]ZBL1MO]B_W6_=>OG:Z^B)6G2OI:=@KG3[-_9I8,!V[\3-XK;RN(I9(5 4
M4:HTB06C:\54W(F$SBM%B7GQOC<.  >>.H?FOM_@/H/:?'PTBGBRS&,)_B-=
MH=5.FZKG'@MVV34%3 TKWIYJ1Y!AAO\ ^F4K*5F?Y'LK^S6]?LO*:TM9)6%1
M3V]/;51CT))HO;2X_J?H9)\*!6IUNXC@< L+I1)#CP8N!+WARAU@7@1-T@)%
M+U,/:3U>&/=$FJ-H,S3&:3:&1%L1YQ]L!$6YE$.CGU=V<Q?Q".G=?OU^ ZXZ
MJ!,7U2MMMRDU 8VSWD"RQD;,JXTS5;L<UB$9"_BC2[9E=&M3KC)=6/C;/+NY
M%4[U%1P$'7IJ8?\ =J(Q%?D7ZC=@L4J%H7M#Y:SEBD*_@I521>0T.$@$_?92
MIQT?<K!DFPXUBZ_Q.8R;VA"&"0JTQ*2-@L50K4LQ9#&,R5%W+OSQ[5UUUS3J
M]M=//BN:@=HJ:\Y(@<>DP5;6I@LS2F7Z<BW=IM454+%)&E@CACYR QHXI$U!
M]W&)*2$A/72D2B OT2QT#+%;O#H$-NMW&_\ 7?$*2+WO,?4^>OB#/%[&9J=/
MM2&-F,ZZR=!UZPS62G4[4*VWCCTJ1A#O&E+"7N+(CJX1DG89)JT9N7IJ@=)W
M#A)DZW]?+?HEFO\ VC=RI5\*64I3&.K=3%S"Y"J,*+FZRJ]MK=@S?6+$QIUI
M090JLM$R$QCN")#2+FIQS\C1=VX>PC==0S1 D6GKEXGAJI;I&_JS7]^6NQ&
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MZ<R$D1(A6B29!43ZG#4JY)ZZ[BK=KN_C%\W-3T<\J]UAQC9)W 0L0XJ=P<9
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MO2U@>)) 8RJC:(8KR*J:12\B*ATVXD)P B)AX HCKTH43B,30H@@&M492DZ
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M9/(-91M/3[-S.&=5==K57ZZ$18I1%0[* =)NXALO#.VS(BZEDO>RVB8/^RQ
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M]I5MSR#+4S/D?0LJC6Y(8^<KUHJJ-8E2>'5Z5%&$[62L5EBN$P%5FNX;N$1
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MIX[U/&><&U_<!3FE,LLM+0[!G,+S*;F%!GXHZ[BKV6JF24\<W=(BB#.SNW
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MV7)'+6.HL@6\2ZJ:Q/\ L3>C*X[(500$"'4+R4PB!1Q7:?%LP?9[:^(J06C
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M)NCJ=ZDD8"@43 (E 1#CRZ%U:)Z[TNJ:92%(FF4"E(4"$*' %*4H !2E#R
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M&G[S-^PXK[U%8C;?[%_NM^Z]?.V* G,!2 )CF,!2E+R8QC&'@  H<B)A'R
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MKF3[TYJC)HX .D6#@(@$@  W' <+*VGN;+WN NB^)< XUE[S9"+HMY%S$,U
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M]1]%[&-_\B8G6)6 VA2]=M'!,UFY$6@$$D]T<%ZL0 "@         !P  'J
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M&T1'PK=RGYNN#OTIK[_*-HB/A6[E/S=<'?I37W^4;1$?"MW*?FZX._2FOO\
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L_B.B(E7L4U1,=.EWSMU3GK]5NG6R-VK=VU2*]=* J)''E^ /S4G0=WS*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g696632g51n81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g696632g51n81.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1R$4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $ < 5H  QLE1QP"   "0.@< E  "')R,CDS-S0Y' (% !]-:6-R;W-O
M9G0@5V]R9" M(#(P,3<@,C M1BYD;V-X.$))300E       0EJA>J03\.L="
MP[F+@+UOW3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D
M("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U
M8D!OX            $)R9%15;G1&(U)L=                $)L9"!5;G1&
M(U)L=                %)S;'15;G1&(U!X;$!7^9F         "G9E8W1O
M<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F
M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              .<   &_          $
M 0             !OP   .<                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   .<     4F=H=&QO;F<   &_    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      2%@    $   "@    4P
M >   )N@   1^@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 4P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
M]522224I)9N3]8^B8SS6_+99:#!JIFZP'^55C"VQO^:A#ZU]#+VL-MC'.(:T
M/Q[V22=K0W?2W\Y*P@D T2'723 @B1XD?=HG22I874>A]4R<VZ_'SG44V$/;
M6'6"',J.,UOL>UK*K?5M];9^?Z%_\]4MU#<+'/(#BUH @@#4F9^D"DIPW=&Z
MP_'NQ&9#,2G(V$/JLN>Z@-+G>CC;_3W-=^C_ $OJT?X3]61\WIO5+Z]YR&^J
MZK9:T6655@^HV[U*O3W[;*JO4JKM>S])^C^T,LK_ $2U?3?_ *5WW-_\BF=2
MY[2UUCBUP@B&\'^RC]56X5G0>L/PW4#,EYRG7->;'R&&JRAOOV.^A<]F2RK;
M^9_2?5_3(G[*^L$[OMP+FR 0XM#@[;M_1^F_T?1<S=_VH^U?S?ZOZUBVO3?_
M *5WW-_\BEZ;_P#2N^YO_D4OJJW&'2_K UX=^T/4T]Q,,.\CW6?S5C?2;:;/
M3Q=O^$_G?U?])JX%>55A4U9;Q;D,:!98V8)'?W(C0]KR"XN;$R0.?[*(@I22
M2BY[6-+GD-:.7$P DIDDJ1ZST=IAV=C ^!M9_P"25BC*Q<D3CW5W <FMP</^
M@2E87&$@+,2!XA*DDDDM?__0],S^H8_3Z!=?)W/;776P;GO>\[65U,_.=_WS
M])_-H6>RC/P'4.H^TUY#-PK?HPP6N8+3(_.51F,[/ZI;FY7NQ\0NQ\&KM.C<
MS)?^\]]GZJS]RFJS_N3>M0"4D:F^@<0?5WT]M56T8[6F0R&&8X8P#TVM<LZW
M%SNF7LR306^F[<UY_2,\/?L/_D%U3[0T:*L_*(.AA-.,'P8)X<?0\)!MYOJO
M6\G-Z?527[7>X97IRT. +'T6UN:?4K]S?\'9[%5Z?]:.H=.!9D7/R\(M<"Y_
MZ2^DGZ-U=GTLJICOYVF[U+]G\U;9Z?V:RYUO"J8#F8X#!(]:L<:Z"UC?S?\
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M .<9Z?L7)E^6'UG&DC:]K@(C<_8RJQV[_0./K?\ %^HM'I_4NLU!M>QVUK&
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MM_F=[?SEZ!3]3/JMUKI^'GX]%F'5?C,=6VA^P[7CU&NL_G/4O9O_ )Y%P/\
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M224_522^54DE/U4DOE5))3]5)+Y5224__]DX0DE-!"$      %4    ! 0
M  \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !
M1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0
M '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M"0   +"':0 $     0   +P   #H  ZB&   )Q  #J(8   G$$%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#0Z,C,@,C Z-3 Z,S( <G(R
M.3,W-#D       .@ 0 #     ?__  "@ @ $     0   ;^@ P $     0
M .<         !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !
M/@$H  ,    !  (   (!  0    !   !1@("  0    !              !(
M     0   $@    !.$))30/]       (          #_X0%(34T *@    @
M" $2  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,    !
M  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0
M   !    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q.#HP-#HR,R R,#HU,#HS,@!R<C(Y,S<T.0
M Z !  ,    !__\  * "  0    !   !OZ #  0    !    YP         &
M 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $
M @   @$ !     $   %& @( !     $              \     !   #P
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MN2J3@9^]'7M^ZIRSKNB0KV];*V'\N_$TR)M*QO2L.X7G\?(P<1MN:NKO+V2
M%S9IV57R?@7(#Q=V[4(D^69Q/X.R:K.3I-F+=+TT$U$@Y\G,._F_@1[U(6VC
M.>]/<M@=LMC+-D'.X]'<+D6II;WIFF8ZB[/*;>:8588J_,,9/VT#2G-JG)(H
MQ!9,*D$$@S9+S*M:%)RB!5# ^@QG?\=NH)!JVGP^,X9*R_$9XB+QD6+SG5<4
M9AD:%C3<)$5F'J['+M<:1S9R_D#-ZN"5-D7M:F%75=?S%2;,X1^Z9G40:HG
MY05X8Z8[C./K-; EY>*:G!-U),&YS?PD7=H)&-_]I5%"B/\ 0!U6&UJDI0L@
M;PDF/>!BJ>9/[0SZBN8FLDJ &2534*(<@*9RG 0'P("41 0'[ZHB-Z]FOII2
MFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2N!*2D;"1SR7F'[.+BXYN
MJ[?R,@X2:,F;5 @J+.'+E<Y$444B%$QU%#E*4H"(CJE2DH25K4$I2)4I1 2
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M;$^F.I&*V-RZMV 1(4KZ[3)/2.^X.]9"VB.H"AT_]/X>>P#SV#V_P^\HU9
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M/A=@\3 0;R<6[Y^882;0YNMJ^:*).$3#R4_ F <ZQN+K3GT7-H^MAYLCS),
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MHMDDS'645$ 3(F4!$XGZNP@ >0_F\<#VY\QZ0,GMC/[]]J\QZ&3M^_TF=_\
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MHJ2E)JB4:Q$3%$2CR(![<_EX_P!W/'']!#6=9VN$I"8 /2<SO/?N>_IM7;T
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MIR\RP?,];SREM0! *FRKG2I6R0H9P!3X[LOU"=4PF]_J'D!$>_\ I"(=_''
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M@@SUZSZUS[6M=19-K)4"HR&T$\I4<SW\HR2HSC836S&AU&(K4:WB8ELBV1(
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M#%]0  PE 0$W0// B =P*(_S#V[<?EI5U)B>PD_G^'J:Z]<!Z!XY[>0#R//
M<?\ ?]PZH4F00!G)^H_G[8'0":SF59$_QCW^7IU([UCLHP92K%U&R3-N^8/F
MZK5ZR>()N&KMJLF)%F[A%8ITU454SF(<ARB4Q1$# (#J->:)21',((@C! D1
M&V^X@XF"28,K;/NV[K;S#JV7F5I<:>:6I"VG$*E#B5((4E:5 $$00K[I!%:$
M-\NS,,4JN,HXU9K*8[>N0_'(9/U'"E.>N3\$.D8>I0T Z5,5-!18QS1[DZ;8
MYS)+(&+J6HVG+SD"4*D9SR$]XW3D1,1M,Q/UY\+/B:>(D-Z'KCB!K339%M<J
MY4#4VFTDJ"P(2+MM.5I2 'D!3@ 4%S &R#='-;2\]UK(**SI:FR2R-<R5"-P
M%3\6ID@Y2^=51;")2JRL&H1*9B3 9,YGC/Y,RQ&KYT52"L+Q>EWZ'AS%OFY'
MD R%L+(YL')4G[[<?K)3B"H'9/BU\/;3XD\&ZAH:DMIU5A*KW0+MS!MM48;5
MX"5N %2;>[23:7>X#+I>"%.M-U[AHF5CIV*C9N'>MY*)F(]G*1<@U4*LU?Q\
M@W3=LGC=4GT*(.6RJ:R2A?I.F<I@[#KJJ%I<0EQ"@I"TI6A0V4E0"DJ'H001
M7Y'W-N_9W#]I=-+8N;5YVWN&'!RN,OL+4TZTXD_=6VXE2%#HH$5K7WYP3G,&
M6=J& FR[=U'%M=MS_:JXN0J[:91Q0RAZ_1"RR8]12,(B^Y#C;VS%8ABGE* B
MNFF91AR6L J( !))@1W]S@>OIUK5^)7+@V";&S_^\ZF\FS09("6RE3MPI1&S
M?@MK0LP3RK, [&Y5.J\?4("/@V!"^FU1*"RX)E34>NS!RY>+B C^\75Y,/)C
M DF!$2#Z:9 +E0&TA()P))ZGW/2>_2([5G:5IS.G6;-JTD0T@<ZX@N.&"XXL
M"94I4P#@ \H4  *R\I>_ <\ '//GL <?5XXX\#SV /'/8-45,C82,@@3@2>L
M>Y$XQ,3!!Y>8B3J^H0#@!#I\B B';J_P 0Y'[A_-JTH[C;KOZ_S@QN,]ZI [
M@P,1WDDP!C:1@8$1&\=DDGU=Q[%\^>_;N''GOV]_8?S !HKPJDGU@?S _I^^
M*.7!6Y.W'4/8 Y_A_7O]O/?D.W?GD0 28'Y]:H4H)R<#/]!W/IVS6%OY41,(
M=0B;^X>WN8>?U'W^XCK)0S!GN,F!MW],=3M-1-S>?JC'R[]]SZ_2L&D9D$Q/
M]7)^>_\ ,'M_3V'N/C@..-9*4=L=)C!&<3&W4G>=O6'=?W*E'O$Q.8D=O;I4
M?24R8PF'U!\"/(B !^7C]?/G^_5]*(QU($XG;KZ",G;J,FH6YO-P# GO$_O'
M3'S.U8<[F1Y'Z_OYX_4.WY>.P<!J\$>D#<B8'>9,$]#.(QTJ(<NR9\T3@',]
M=AF/K_(8PZF##U<GY_\ [" ?T#[^../^'.KJ6\;>N/\ \N0"#MGK\ZP'+J"9
M/MS'U\T GI(B#G(KHE9?S]9NW<._V[_IQ_OXXY]M5\@!,^^(QZ;_ (?A@5A*
MO1T7!QB=_P"(GV.?K732#MM(-'3)\BDZ9O$%FKMLX*4Z+ALX(=-9)9,>HJB:
MB9C%.4P !BF, Z+80ZVMI:$NMN)*%MJ2.5:% I4A23@A0408.1OTK#>N6W$+
M;=0E;;B5MK0L!2%H4.4I4#(4DC!"DQZ;SHISU2O\F>2I^OMR&2B#K_B4$8YA
M.4\2]'UFQ 4$>3_+")VRA@\*HF#@!#G7S9Q)P^='UJZM4(4+=2R[;&#EATR@
M?LGPY+9/4I(%?+/&+/\ 8>L75H)0PI7CVA4H0JW7YD@'"CR&4$[<R3L9J$EG
M**R:J*W2HFL0R2A.>2'34*)3D, !P)3%$2C^HA]]0@M%?LB1$G VW.#UV,Q'
MX5I[FI(5S))YTJ!2I,E0(4(()@ @B>^"<UKJR <*U:YJ'("@H-G9S-04$>?E
M53>JW,)AX*8!2,'CR//'/O,,V?,A*B #$=3)]L?N C$]N:7I^SW3[38E(68)
M2!Y"2H85$G;8S/;:H^6G5S'^CZ0\AY\#W\@(!W]^H1[@ #WUEILT  F) Z0/
M3??OWW.]8G_4.*4$A6.PG"B8,1Z>FWZN:Z60<?B3-Y'N^E5L\;+LW)!*4P*H
M.4C(JD, ]8"!R',4>2B/L&LA#"$*"T@\R2%),F01D1$'$3,^YS6?9-WUG=6=
MZQS)=M+EF[96%<I#MLZE]M?-S2A06A)! )21(].7LI^&AN\W<4>[R&!*-"75
MABVZ/*3.I.+W3:X_:+F2)*192LK+-Q2JB#B+<MU45TNI$>>CK P"&MQ:MW[M
MM%PRGG0ZD$^9 (4-P><@^4R)([0*_H8^"WQMX4U3X;<*/ZE?W#-T=*MTN%=K
M<W)E" D\RV&G,@@A22>8'?O6_P ^#[\)G>MMNWHU_,6?<4L:#1JA5;*DG)+7
MBBV-:1F)9)NU8-H]E4[%..A,4A5U%UG2;9%(@E#K,<W2$A96=PT^%NH"$I2J
M3S)5),1'*2>_H,#M$U\1_B%PQK?#+NFZ1?KN[NXN&%% M+ME*&FRHK4M=PPR
MG.(2))["!/L'$H"'2(=11 0, \" @(<" @;GD/R[]NW?4W7SE7C2^,G\.RP8
M7R1,[B,80+A[B2]R"LC84(UOZI*98W9C*NTG22)>4(U\J)UV:YB GU&.D94Z
MA3!KS5;)6IM'4+9/->,M@:@PD2MY"! OD"962!%PE()2KSX2H"OT8_0V_2&L
M-)8MOA%QMJ";-DO%/!&KWCH1;?WZRH\./NJ 0PI"R5:8IQ:4.(5]F3+B05:%
MM:A7Z<5Z)/@(QS2E73+>6["G(?(&@&-7@6D>Q6>O)1\NY.X> D0A0201;I%3
M$SMVJW: )^D7!3<EUMNELJ8TAQU?E-[=)#8(W:MTY<'IXBE(^1(K\H?T]N+[
M#5.-^%.$K-U#[_#6EW-[J?AJ2K[-=ZJM(9MEP<.?96D.D$@CG (FO1C>\Q/[
MA6YFO,:*Y;(2;<$4W4O/Q[95(4UDW"*PM8Y&7(/"B)!,3Y@H\<AU?:L9.XC$
MGM[QM7P65 "<G?$9,;Q,?G:H33EIQN0H/ZTZ.!2%!1:,?Q[TO)0#J/Z*RK%R
M;GN($105/[ 4=6E023SR>Y!&WUJH;;1Z5V,;.QDHH=NV<"5VD'4LP=)*,I!$
MO/'4LR=II.2)B(" *"GZ9_)#F\ZI((Z?/I^'X4J8,+2)X[(#R.]0P-[%"F4,
MB!N""^B3E-\P(!VZQ:*D1Y#@>DO'<.VKR<I!B (3[QUV'\2.IJD0#'4Y^4^Y
M_@*M]KVJJ:4II2FE*:4II2FE*:4II2L0O]QB\?4JTW>;73;Q56@I*;>**&Z2
M DP:J+](CS_.8A2!VYY-VU:?>2PRZ\O[K2%+/_Q$U):-I=QK>K:=I%HDKN-1
MO&+-I(WYGW$HG/[()5\J\%&9\FS>9\KWK)T^X6<2-RLDE+B*Q^3(,E%S%C60
M#W ",8Y-JU+QY]+J\B(CR-Q:[NY<?<RX\XI:CV"C@9C9,)](K]D.%>'[3A;A
MS1^'[) 0QI=BQ:CDB%N(2%7#N",NO*6Z=_O0-JQV);@(E'CSP/@>./R[^??M
MQ[ZV:Q:DI[XZ").-AC;'SS-; F(4KH 3U&V?Y[^E2C#M.3%  []NW^B(^_!>
M_/?[?X:V^V: 2#,=HW_D?;88FM/U:Z"E*DP),&1,#ITF1^9WEJ&:<B4O0'
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M567(U\YC\S^,=(GWV'XS%Y&H*(;2AD^.Z5#PEJY @-D!:E*A7E!^Z4I)4"(
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MB<]P:QAQ8! QN#   /8.1[>0[^0[_;D/\=7DMSLDP8[1W!C$#K(W'7K4>N[
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M%L\P\$I);>9<:<Y5@*0I3;H"TA22% D0H'F$@BND,^X'^/CD/ ?]1_KJC)R
M3)R8ZX]/EMMU$5=38",-R![@?SW& =\QOGT/_P!F@OK:.SQO&Q<J[](9^L8T
MR-&LC*\ Z<)?/UZ4<(H_S'3(R; L8/!!3 0XX'6_\-NE=@4$&6W5C/K!'4_U
MF:^]_P!'VZ#WP_M[4GSV%]>LJ3)(0E;OB-B.@Y".4=IQ&:]A^MAKN5-*5T\_
M 0=JAI*NV6(C9Z"EVJK*4AY9FWD(Y^T6+TJ-W;-R11!9(X?RJ$$.0 P<" "%
M;;CC*TNM+4VX@\R%H)2I)[@C(_B,'%>%(4(4 0>A]#(/N" 0=P1(S6IN\_!
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MO!Y/W[#W 1]O80#I\\\#X[AQYY#G5\B$CT^F>\_SZQ$$BINV$\H^0W]1$D[
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M2[A+#4_B#(VY^WRDO"R$=F_+Q,A5QG%&?"[AXLE3KU?!A,?--&Z!7X+PZRP
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MM#IU <GD),<(P$T^M.3GZ#$[*-1F%[E6(]&E0J2JGXJY:0CV:?KO42-PDP;
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MPZ?7^=5ZO*]J_;>/2N![(!C5XXPQ;,E3FYC* \,#_P"0)3'+EB?@.CK^:/\
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MB8?!2B//COP AR/;P'GS_0 $=>5;^?S]^YKAIF]= INPB F*(^?JZNW/'<!
M.Y0XX#K 1X#MKTB#!VW,>T_CMB.\XJWS<R92=CB<^FTGL.QP=LBL)O"9TH!^
MH0IA GHF/V !Z!<)@;L/?L/'<.X!^7.LBW_Q$I]3'KY3!P-X[1O,9)$1JP4F
MR>4GIR*5N" 7$A0[P-XF8$S54)AZ/U![@(AV 1[]^_ #V$.>.?<?TU+-IV&=
MO<1N#WSZ]]NE<WNG>8J/J0".JB8.!VS@=NF:C&5>=S=^.![_ &[?GY$0#GV_
M/WYUEM@9.X.>V.FV(]"?PK6KUZ?3J1N9WQ&=Y/:<S,BHLF9/DPE$>>P\=P$"
M^W(]AY$>..!$ #N//;62A$B>@($9GV$="*URZ?Y1\B?7'7Y'&"1L-MHXDGX
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MD] GF5F(@;E0Z#,#O.-FMUVHM/M@N6?LOA\YN2\WX ;D_P!X7I\+E&1S<W+
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MH@3L ! 'X $5Z^_[,[DD^4VN9MNUW>2CEK4H^.MU$DV;]5M)P2+M91K),$'
MBH1>/$Q2+)1KY!W'$5,=0K8#F$P\=^*VG-)18:HVA(=*U6SRH'G2 %-SW4DB
M)WC&!@S>A.J1<OVY,-NH#R4?LN)40LIR8YDP2!R@*DY)$>H6\X<DZ;7)JQ,L
M@*.FT8W]9-K-5=D[<*F463012.\BI.!1[J*DZC@P$>.1Z!'7%01),$DG,*(G
M\#&];1RXW&-O*('\3]9]:A%.(L#HJ9I"T.$RB0HG1AHIA'%$1* B0RSP)AP
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M \8 %2H/GUCUNA0OCCGCCL(]O?\ 7[=P#\OO%Z>Z8 _9,1T&.FVXZ3WZ5]M
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M6M)ENER#8/A5[CJZSW 6"TYOVSWUYA*=SG3+XHO<K/%C;8U:IY!1NU=D%_\
MQ2R5"732/(QLB<P/(]WP<JA!#3\*JC*>Q@B1TF-JL9FBI7O8<ZV^YSQWN*W(
M9%J-KS!C7%>6\29RRS-9G@[37,F/484LO45;F1_8:K;*[(+I235S"S*#!XW3
M5:2,:Y2/UD R)[P?S_6@@S@;2.D1V'K_ $KJ]O&&;GOYI62-RF4MS.YZA6&=
MRAE&J8<JV$<Z7K$5"P_6<>V>1J5=6/2:9)1<#>;$]>Q*\Q9'&265N;O2.21J
M;1LS(*8J$QB!TF1D]>^-\\L5V,A&9SSKN,Q7L@R5N3O;&LXIVXKY?S?D/ E@
MD\-7//=@4N+>E5./"XU%XWL],AVC58).XMZ=+Q3J6FDCI(/X]DK\J"@@">L@
M &.TDQF1TS5Q,2;5)3'O^6#$EMS7=,Y[>[[ L"5G'N;K1-Y/R705G23IE9F(
MY.M4E(VFS4Z63.T7B6EI7E92%?-E ;RZC9<4"VWF6WVELNI"VW$E*DGJ#^<=
MJSM+U2^T;4;/5M-N%VM_87#=U:OM'E4V\TH+0H1'401L02*\N6^C9E;MGV5'
M,:9!W)XPLSIT^Q_;.@QD5V(G%0T%(*E$01F8DA@25(H("];D(\0$>5R(\SO[
M%[2+LI(46'"?"<_54CFPE1,CG1@$')^\(Z?JM\(/BGIOQ.X=;N0I#&OV#:&M
M<T[F 6V]'*+QA."JUN".=)'^&LEI40DJJ'&/1+P43#R''D1[^._]?MV_+OQQ
M*65S@$*$&)DR/F1/]:ZX"(Y%9!QF1C]YG?I\JD2+?](%$3_8?XO//;SYY[AW
M[!VY[=^-IM;D$!)5(Z8SZ#WQ'],Z[J=ADD)\JONF!_3&W?<14B1LN'!0ZO @
M'D1#[^WN/^/;IY[ ,RT\0!D<L2#U&-AOZSN.W0'1K[39*O+(S(ZX'ZN)(,B9
M]S-2#%3(IB!NOCCW^PCW#G[\>??D!#W$!U(MOR!)[9]@)F!(C?('>#&-,OM,
M^]"1V@COB9[^A^G42#&V8Z8D$JHE,'?J*?@P>>P=O'(=P'L !QVUFH?V).#&
M!!WV$=)SF?>36KW.EC(*(.1,"3V!$ =-\5(T?>NDA"JGZ?')R&$1_(>GN(^W
M<OD/!??60EY)B#'3? ^9B-L_QZP+VBF3">;_ $P0<=3MC$R2>@P<5FS2Y^H3
M]VX _8.P'[^WD.0$// AV[?IVN!\G 7@?QG:-OR*BW=)Y3"D00>T=9P2(,^_
M;;8\X;<<! 05[^WU"(CY#\^XA["/CL >=4%]7<]>8QB2,=8(!]XWHG2TD&$)
M^FYP(VQ]*X:UI-SP*@\^0X\\_EVY#COX$/?VY#6,MZ3,Y@Q)F!V@3F<;3^\9
MK.FG'EC80, '$SV]<'?L*ZQ>S^IX./\ 4P_80-R <>>QN.^L-UX &9VS$P?4
M^8G;$'I[U)L:<9'E 221, S[1!(!V^F":Z9Y:6[0HJNW:*"1>>55E2)D* =A
M#DX]O/?\N_;44Z\220"0.TGI.3,8S$3'JJ*G+71W'>1*&UN*,1R)429Q@)^I
M!(B?0U$EHSK"Q!%4XDIYEX &*!B',@Q2-QV]1<Y?46#N')4$S%. <>J4=1;Z
ME$$G8]\JP>O2=]XZX[[SH_!EW=*1]H*;=N4B(YW2,SRI2H!$B!*R(VY<9J#>
M\AV&X.17F7QE$TC"+9BD)DF#3@..$$>LP <2AP98XG6,'("<2@4-05W<)3('
M69G,QM$8WZ=L9@$]?TO1K#16/"M60%J #CRH+SADX+A&T@@(3"=ZP*JU2TY(
MMD'2:9"OK!:;-)-8F%AXY$SAV]?/%2IHI$*7L0 $1,JL<Q4DDBF57.FDF<VM
M8N'5W#@8:!<<6OD" ))5L$B<DG?:)*C,[5:GJEAHFGWNK:I<LV.G6##EQ=W;
MY*6V66D*4LDF9,82D!2E*(" 5*Q[+?A_;*H+9WB<K%^#25RU=DV4IDJQH=*J
M1'*1#F8U2%7$A5 @J^5=5,%!$32<FJ^DS^FBLS9LM[T324Z9;^?E5=O *N%C
M($3RM(/[*)R?UERK">4)_+7XU?%>\^*/$A>9\2VX:TE3MOH%@J4*+:RD/:C=
M(YE#[9>E"3R[6]NEJW$K2ZX[??4U7&::4II2O/Q\0KX5V9[)FZV;Q]B\O16>
M2KK#12N:,#W=9Y6*]EFPU! R4#=J1<HA(Z=.RDYC"EA7CJ::C7YU5"/D)5\Q
M>).7BVN<0<-VFOM->(Z[:W5LHJM[IF.=!/*84#',F4I(A25)(E*AF=+XRX(T
M[C%BV^TOOV-_8E:K'4+7E\1E2^4E+B#'BM<Z&W D+;<0M/,VZDJ5S5 VX?%/
MR,M^,T3+E:F%[?C>34JF3\<7MO\ L_F;&M@9"HU7BIHQP!*9;];<ZT9+O6JQ
M9]N K)30F]5-'3VN+>).$[I.G:^P-4M,>!>"6WWF@("FWX"'E(\OB(?27B?*
MMZ"E9X3JW%?&' %Z-*XJMTZQ8'F-GJ: 4/7;""/[QJY(\-]QL*'CLW+:;H.J
M\[Y2IMQR]4%OCP5<E?2>2DK2W!S !0M;!)NS,<_;@9&-<R;-$A?YEGJK5(H>
M#  :W73?B3PU?*2RZ_<:>LPD?;&8:/6"\PIY* ,RIWPP!LHUY;?%'A2_R]=.
M::HF1_:+:64 SRF7FUN- #]MQ2$;RH14I*3T+/1_XA!3$;,L5B>HD]BG[21:
M*IG[E.1=JJLD<I@[E,4Q@X[@/;MT6UNK:Z0EZUN&+E@\I0ZR\AULIW!"T*4D
MS/,#,216<[=VUTCQ[:X9N&G 5)=9=0\VM.1*%H4M!&(E/R)WJ,)E3J,IP;D>
M_;L'@.!^W/''MX[<\]]2;4<H$ @CI&9/UV$Q\^PK6]0(DB<SMZ$>G<[[=!B)
M$23YP #!V_T1$?[_ '[#_$ <?F(??64U]Y.#B3WZ'>=O^!BM0O#(629B?J5&
M)F>^WI]<9QW09G-5[_R<49Y#.+,#!S+/$'<@5).*C&IB)J2$D5LD]=MVQW"R
M+9(WRBAE5UB)D(/U')Y<:G86B2''VRZE7^ VI"WN@GPPL$ ;RKE'3K6N:!P_
M>\9\0KT#1G;-=^+=R[>#S_(BVM4*Y2_<>&AYYMM;I#2%>"KF<5RI&"1VFZW:
M%E7;;@RU9KEI6F6-O55XHKZ$B'<T*Q&TM(MXLKSYEU#-$C)MG;IN"B7203$/
MR4X<<:P?_4[0(2Q;N*4HGS.E* (!,^3Q"< X,1.2:D/B3\(>).!>#-4XNN[W
M2;]&EFU\:RLW+PJ\.ZNFK7Q?&?M6$D-K>0I0Y 2)"2))KS@9@SR[LC@%;1)M
M63)L)C-(*,]4R9#<<>L= 5%5UUS%$ !PX,1,O(@B"0")1P=2XEMFDC[=<-M%
M,%-JT2M9)!R4 J49@^9<#H" ,?)FG6NO<5727D6A6PE:O.$*:M&YB#XKIY5J
M(.R5*5^PD U4FQ90"2151@D'+<%!$IGKD$P6 O !P@DF93H,(<AUJ&$Q0^HI
M .(&#2]4XZ/@JMM);<8<<!2JZ>" IM)ZLH2I8YCF%+/EZ)!@CLO"OPZE]#^L
MN-.LME*A:L%12XK]E]Q2$$MIF5)0/-Y97',DQD'4;ZC&$QS"(F$1$3&.81$P
MB(CR/)N>1'O_ '\ZYBZI3KI6LJ4I2BI2E94HF943!))WDYD[]_H_2[5"$H2V
MA*4)0$(0D !(  2 !A("8  'KL*E;"N;\G[=<DUS+6'K2O3L@591TI#3B#*,
MD@1!ZU68NV[B.F&<C%OF[IHNJBJ@]9+I?454H%6334)GVSCK#B765<BTG"H)
M(D $%)$%)B,_\UONEO/V3[5Q;.^$\UE*X2H#F$*$*!2008R"#[Y'O,^#KO+R
M[O8VR3>1,U+UM[<ZQD*4I:LA6H7\"1D&;.*BI%LZ?L$WCAH204+(_OCLD6+4
MQ>@4VB?<1WO3+IRZM_$=Y>=*R@\HY=HB1)SZX]J[3H&H7&HV1>N?#+J75-DM
MI* 0 ""I))A1G,!([ 5MFU(U.4TI753,'#6)@M%ST5'S,:N'"S&3:(/6JG'@
M3(."*)B8ODINGJ*/<H@/?7A2%8(!'J)K(M;NZLGDW%G</6KZ)Y'K=U;+B9W
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M:UK^H6^G:=:)*W'[E80.:/*VTF%+>?69#3+*''75'D;0I1 KUH[ /AV4_:-
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MA-6#IWPJM\-N51!UC2-I;)?I 7]ON589D1*/?K5CXJ1EYDG2'\10C1/R'3T
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MHM,>PF362[$GE0K[YLM$R$1C)1PQ=%BWJGKOUU>Q$9YNY(Z[D 8,1^>E7O\
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0*4TI32E-*4TI32E-*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g696632g64b25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g696632g64b25.jpg
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MR55-0Y$58J8V^%EA 4CAF<07"3'OHENX[*TFOL.?/-"DKR3K$#TP7*K$"%)
MQEON4(0WBRW%S;1M>V4UH#HN9,-GQ;$K;",>ATZ9!+;PP6CW! T7EA))<D%U
M0ML)O*5S$* \5,@BSL[-9&O=/GM4,[/NHF6ALT6'/<WR=&U+''*[@0JC(->
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M*JV@*?B^]W()8(WFCNK>SA*SP/K"744LIW(->VVZS0MFK9+#=XCC:221[C2
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M7YR^*/,O'"4^3G8*9\[G=T.?V.CY.3D_AY>7WO?:H>J?TH]G5K+<J,]^,_\
M\!]M4:[I9=WP9/(17KVFJ'JG]*/9U;^$]='Z ^UIW2R[O@R>0BO7M-4/5/Z4
M>SI^$]='Z ^UIW2R[O@R>0BO7M-4/5/Z4>SI^$]='Z ^UIW2R[O@R>0BO7M-
M4/5/Z4>SI^$]='Z ^UIW2R[O@R>0BO7M-4/5/Z4>SI^$]='Z ^UIW2R[O@R>
M0BO7M-4/5/Z4>SI^$]='Z ^UIW2R[O@R>0BO7M-4/5/Z4>SI^$]='Z ^UIW2
MR[O@R>0BO7M-4/5/Z4>SI^$]='Z ^UJT6Q5==O"6)R3S(5%047S23NBEDKFG
MCEGDFEDHMDGA?*][XX754OC;DM?/+DY;QG+,Y#(?,"<R!_+D,_V"LI<]*ZB"
MV0S(&0)RZ2!F<OY,S7.JE74I2E*4I2OY(DS_ 'X2S^DK[_U0JOH2'\E%^K3^
MR*^/)_R\WZV3^V:C525%2E*4I2E*4I2E*4I2E*4I2E*4I7WI^P'?Z.'7O_$'
M:_\ ; RO'^6'^W)_U-M_=+7T/\'7^[%M_P S>?W[5W.UR]=S2E*4I2E*4I2E
M*4I2E*4I2E*4I4QAW[9,_D$_RE*O3P_S?XBIF>X-[4(L>Z'!MH _,NN:>2B&
M(ATBF"*?3$D9IHI](JHFEAS\\><IGAACRY98VO<J,[!45G8^!5!9CD,SD "3
MD 3T?-5TDD<2-)+(D4:Y:GD941<R -3,0HS) &9\) K@C22.F,Q$C$?V4J/"
MX.:A3Z.Z KLPR;(04*\YKNB:^02.#24":,YY*+XX@+AE(E724'5QPN,4JR")
MHY%E.C*,HPD.X%:/)"-1UJRE,AWP92N8(JQ;FW>%KE+B%[=-TO.LL;0J(&=)
MBTH8HNR\;K+FPVV1U?(J0,5[8,"[*>7[NWB'8<<3"6D+SW2LW93$BY-;>^-R
MKRX]=ZFUIGLKLU/ 69JR&)36YM[@A?,0T992_FMSKCCYO/N2EA%'M2:Y"CM&
MXC73J<K(CQL%!TNC*<F4@0_&&'[,UQSZSV+8(UQ-SF'9MQ)%'/&9I->B(203
M13(790T4L<BYHZDRRZF%L\4KYX64SPS4P3OE:V>6"=T\5,\<.7G98)Y*I8YY
M6M>V-U$[97M?/'E@R^?YO!G_ "YY?MR/[#67F,\LQF02!\Y RS.7B&8S\68\
M=?NE5I2E*4KTH$#DXYYC+HD8)K+#J9(*X*XX$#*YH$(9Y)Y96Q6'6PS162RO
M;-)7#-//''/&]K5((\((S /2,N@C,'I^8@@@_.#F*M5E8$JRL S*2I! 9259
M3EX&5@58>$$$'I%>ZJ5=2E*Q0CZQGN1[,"\M1KPU"MQSHU".(9#DVA.^1N+2
M6>"BMF4&*Z9-KCBW$$))I&Y &V&S5N*OT=[1R*BR-&ZHY=4=E8([1Z=:JQ&3
M%-::P"2NI<\M0SB2>"222&.:)YH5C>6))$:2))M>R\D8)9%EVI-MF #[;Z2=
M#996K*EI2E>E0D=%1%)8A%)4FZF(Z2BJ::B^22>2RMD<,LK9*W21PS54MA;*
M^">.6>7)CC>]J@$@D D#+,@$@9G(9^+,D ?IZ*M+*I 9E!;/2"0"V0S.0/AR
M ).7@'2>BN,W.K6\(*%-+D Z#(EF@*D-Q@YR"1[:4L"XA**C**IX%@&CKAFC
M9966%*06'7P363SPQJR.A =60E58!E*DJZAD8 @'2RD,I\#*01F#5L<L4REH
MI(Y5#O&6C=7421N8Y$)4D!XW5D=3THZE6 ((KGU;4E*4I2E*4K63B'W:Q:F5
MB83NS/;LJ_IO)0UVCL[FH)M638DO8BYYP?ZY3)Q1Z*R72<ML%.=S>3'G>:?"
M#\*&#?!T^%)BUCB5Y\;+>- </6V81\S-L'$O.+B YOSE2F@,.];41T9]5R;Y
M'WO*E+R2TN[.U%BUNDG.M_-S<B8IHV89?Q1 VK5I\*Y9].6MGNQH9X'3+_E[
MUW7G/WS?([S)RC]%AW^85TW<DQ?SMA/[+[W2GNQH9X'3+_E[UW3[YOD=YDY1
M^BP[_,*=R3%_.V$_LOO=*>[&AG@=,O\ E[UW3[YOD=YDY1^BP[_,*=R3%_.V
M$_LOO=*>[&AG@=,O^7O7=/OF^1WF3E'Z+#O\PIW),7\[83^R^]TI[L:&>!TR
M_P"7O7=/OF^1WF3E'Z+#O\PIW),7\[83^R^]TI[L:&>!TR_Y>]=T^^;Y'>9.
M4?HL._S"G<DQ?SMA/[+[W2GNQH9X'3+_ )>]=T^^;Y'>9.4?HL._S"G<DQ?S
MMA/[+[W2GNQH9X'3+_E[UW3[YOD=YDY1^BPW_,*=R3%_.V$_LOO=*GHW'MKV
MXZ%[06>7M=%*]KVM&;6O;F8\E[<L@M?W[>_[]K7_ ([6O5#_ *3?) =!P/E%
MF.@]YAWA^O5(?@FQA>].*X3FO>G_ %[PCH^AU[O=ZZ^\!)[_ .$8^L%/OF^1
M_F3E%Z/#O?J=R?%_.N$_^N]SI[O77W@)/?\ PC'U@I]\WR/\R<HO1X=[]3N3
MXOYUPG_UWN=/=ZZ^\!)[_P"$8^L%/OF^1_F3E%Z/#O?J=R?%_.N$_P#KO<Z>
M[UU]X"3W_P (Q]8*??-\C_,G*+T>'>_4[D^+^=<)_P#7>YT]WKK[P$GO_A&/
MK!3[YOD?YDY1>CP[WZG<GQ?SKA/_ *[W.GN]=?> D]_\(Q]8*??-\C_,G*+T
M>'>_4[D^+^=<)_\ 7>YT]WKK[P$GO_A&/K!3[YOD?YDY1>CP[WZG<GQ?SKA/
M_KO<ZS\6XJHCMI]#AK1&)4TG+X%..!;O9EZGT;>,IFJG>X#L8O93.RENC_8>
M9[U^=EC[W+UW(GX:^3W+G'(\!PW#,8M;F2WN+D37BV8@"VZ:V4F&ZEDU,.A<
MD(S\)%:/E#R!Q' ,,DQ.XOK"XBBFAB:.WYSN9S,44C=MXTR!\/?9^(&K<KV2
MO/Z4I2E*4I2E*4I2E*4I5P-/[F-_\S'_ "6-*G'@'\@_JK(4JM*4I2E*4K^2
M),_WX2S^DK[_ -4*KZ$A_)1?JT_LBOCR?\O-^MD_MFHU4E14I2E*4I2E*4I2
ME*4I2E*4I2E*5]Z?L!W^CAU[_P 0=K_VP,KQ_EA_MR?]3;?W2U]#_!U_NQ;?
M\S>?W[5W.UR]=S2E*4I2E*4I2E*4I2E*4I2E*4I4QAW[9,_D$_RE*O3P_P W
M^(K';FA-MBZZ>H?D"4?B['1A3/%MD1<4>04VN6,;PH^QV0!<BS=*8Y@WY2"+
M9J9)!KR)L;!7%=!O7)6PS+"XYK=1SZE70LP[^)9HV+P21B*6)NAH9M6U-EFP
MB=V0%@!6!C-E\8X=-9[;2;LEJ3MW#VDT8BNX)C<6UPG3'=6PCYQ:YY(US%$D
MC+&S,-03=!\4:S+9CSVQVP%FU+M@^;@X8-)"S7>2[D,>$9RV1]N#CDHED[A\
MLUNR/D@3 S'$DD>>Y AE<I(9S?MVN)8.'W.9:&U!CI4N ^S8+&;9Y7::&&VG
MANY(XM>;121Q$:24BY!\ Y4- ;<XMO(86B4R2")FB-SC3S"^BMXH[:ZN[ZSO
M,-AGN!&52YMY[A27"R7%<2CA4XEGJ"2B"#RAMO&W^#*Q4:+J[!DH+0@[WX>=
M1ZW;'(VX;<K9>/,TUAVP7'*-W0(;ST)<U/2C?V@*J,WY<.,X3'<PW)A?=BN-
MXS"UB9RGQI>W3HNIQE+);SVR[N893 \>O2P+:ZZY*\I9[&ZL1=1\VN+!K1;0
MXC=1P+-]SV$8;%)(8XCJMX;ZSQ"7FVEHY%O(IFCW%*Q[([QU#MR73U6;:Z><
M68FVIP(J$JC.9%&B@7YOVG&)JX(()-0V8JHTCCK8>PD%J71Q6Y4D7)/(/!'&
MVJPZ^LH+86]U&77GK3,#;Q3!HVLYK=2=; YQ2NL@49Y=)3OB:Z/','Q>\OVO
ML.GV&^*8[2-EOKFV>.XCQ6VO9 JQ*4*W%O%) SG+5WJR IEE5X.BN**[U&RW
MK8;XLV /3.N[A-VY]@8V(9+[RVI+'\'];DV=<)4U%*X=#!%B+8*8%1Y 4<D(
M9G:G*LQL2P?;F6.UC#O'(L;/86ITR?%UG#$W\/(<^AGG8#YI2Q#&1TK5I@/*
M@S6SS8C.8HYH6F2/&L1R:#X\Q6[N(_#%N,<(N[.R1FR.NV"JT:PPRUAU=#\9
MRT"['4W*1:7>UEA'^UD9Y)AL+/B6DL(2DC9P''2,[5]N!.VT5IYU3MY=LOFU
MK**+**-^5XQ' 1<;@L!L\[W-!MHC\F<0YP6TDE=',?P,6VK;#]^   U1' >6
M9L-@XRW._BT6^\N(7*C>&!BR UJH?=^.1\:&_P!'.6BSA8G,Q':*":YV%$MK
MN;O>5R!TU>=%C1T([+Y?(9<Y-$E*)C)Z9+,>Y.Y&:@*ZV,H&/"?QG<IF3&9\
MHM(D&IZ=H\VZ>YNK:>R1-F)+M9E)E@@B@22("92)%1  P&R5:,H),Y-Z(O''
M*_46.'8A:8M)-SJXEPN2U=5M[N\N;R6&Y9K:0-#)+,Q,;-SI72=9F@"0\UN%
MBGEMXJ 'T;Q!=+J9$>8R -HAL)T?%)J&#LF71G"1/\*DLHQW'(DFQF+&!,SV
M!'7$!0!S743/.)Z%0S-K+;QC,-F<1PS*^)@C:2XN,1FMV:T@FVHKB*$V$1:0
M,PYM*C!D&:H,PNM6*USZX%R@SPD+>W"0V=C@=I>HF)7EL+F>RN;H8Q<"*%UC
M<XA;21F.5B))'R+F)XT<1F^AN-!6 *,R^YB>["^N;,6+NA/I,,GVQAIR.PX<
M>QR Z1>+JGMAN=MF$3KJEWTEM.[,5464,+;4I1B6 "Y$G,%V.=;F@VT1.WSZ
M6<G225VS9.EH+;/;#KKR 57K&^(>69P\PG&6YW\7<WW5O[I1O#!K:S0"15#B
M5<7CFQ-K[3SAXGVB6+O&)\#ICB9PD^2F6SG :)VV"8XM )4XDKJ4T0A7<1<O
M<FQV6(45*D"T@U:4EK]L'/+/O#S0[*M)@XJF#@ECM?X080!:*9^;*LC"VA0/
M<"P$".@ RB$5X#<N5"[ZMWZLW>5G1X+RG%R3\9NMI\8/)!&]]=3/#8G&7O)8
MYBY+7#7&%.,/C61Y.9NF<3A2)!4\-X6>)*(BP]9@EC?%).SZST=KUT?&^?21
MQ#*5U]&]]MDG<'1M7 0'DK:L^['ACZP-;P&3B#V2XIAXMF8 '7\RXQC"IVG$
ML+30O=8C<I&UM"C#G,N&O"J.&)A81VMQ'*Z$:M:ZM>IM.JL^2O*2T6S:WNX[
M2Z@PS \.DGCO[F1'.'VV/174DL31JMS$T^(V4]O%,C;>U((]HQQ[EI!:0X@,
MA 5W&<S4@T'2\U"0;2-ZRU >VZSB&!>+F+N<>9F+,Z)BYA2/!,M\;I"Y B/8
MF"XQUAT1&;#;$,,U,$MK=5;$+=BRX="3\7J)1,H2620+.=46:QM$C&-LBN9:
M3:)@?* K&TE]>L\>"7J+&V.W83X[D:W:U<R6\$)>SCV[D!YXKB5$G1620*$A
MK1;7O%CE.&&'%2^6"GN+)LN1@21NG,^6@D9OGNK34AC*+T;@-=N=W=LAUMB,
MS/#7S(_%P9,S&FQ2S-A=0?,%U@@MI)U@A94DM(FB>WM1<S96%_'*8USU1QO/
MS5WGB"%9 KZ0YZ=:<.Y5\^M[-[R[262'$[F.YCO\0:PML\:P6XM5F<+MS2QV
M7QE##93Z]R#<AUF %EO&(:\GCS$F](J235X&<-W-\FBKA-5)H#(F+4#=+7.8
M+L\F F6:3^!(EVE[D&L+JKBAN#E&^Y=(E%0,!<ZM;/=6T<[%8H$*X>T,RV_-
MVBDOFA2 20M;YQ/$'CBNP,V5)=XJ0S!:WEGA]_-9QAKF]F63&X[JTDO>>QW-
MO@\=Y+>-#<QWI%Q'<-#/<X7J*))+;<U5U,<;25L?K?6,5U4S'L421.2"<7DM
M[)NX'K."]R"$1@AATU%N2V K8T@-K0'C;'K"HK>D4YD.+N0X.9FKN[R:]D62
M<J62-8QH4*,@2S'(?PGD9Y&^8,Q5 D81%Z/#<+M,*AD@M%D"23/.VY(TC:F"
MHJ@MX$BB2.)!EJ*1AI&DE:21["K%K8TI2E*4I2NM#V0!1-)YU1DIG@GC=LF]
MK99Y6PM>_6HG?DY<KVMR\EKWY/L\EKW_ (+U\A_Z4:LT_(S2I/R6.^ $_P /
M"O%7MGP1J6ML?"@D[^%G( G_ +O$/%77MUL7X2/\LG\ZOD[;DZM^%NRO7]N3
MJWX6[*=;%^$C_+)_.IMR=6_"W93;DZM^%NRG6Q?A(_RR?SJ;<G5OPMV4VY.K
M?A;LIUL7X2/\LG\ZFW)U;\+=E-N3JWX6[*=;%^$C_+)_.IMR=6_"W93;DZM^
M%NRG6Q?A(_RR?SJ;<G5OPMV4VY.K?A;LIUL7X2/\LG\ZFW)U;\+=E-N3JWX6
M[*\7+%Y+_P"4C_8O_P#G)_Q?_P JJ(Y,QWC^$?P6[*;<G5OPMV5Z!"AL11L<
MB$,<L1T;98W53M>U[)XVO:]KY<MKVO[U[7]^UZJT;EF(1R"Q((4]/3_)5\D;
MEW(1R"[$$*>GI/Z*Y'6Q?A(_RR?SJMVY.K?A;LJS;DZM^%NRG6Q?A(_RR?SJ
M;<G5OPMV4VY.K?A;LIUL7X2/\LG\ZFW)U;\+=E-N3JWX6[*=;%^$C_+)_.IM
MR=6_"W93;DZM^%NRG6Q?A(_RR?SJ;<G5OPMV4VY.K?A;LIUL7X2/\LG\ZFW)
MU;\+=E-N3JWX6[*=;%^$C_+)_.IMR=6_"W93;DZM^%NRMA.%U9%7<3/9)5-2
M]F607O;!3'.]K=2Q]^]L;WY*]S_T>59?A&M=2L/^R\4\*D?]Q^D?IK@OA+5E
MY)7>I67.\L/""/\ OCXZ[1*^^J^::4I2E*4I2E*4I2E*4I5P-/[F-_\ ,Q_R
M6-*G'@'\@_JK(4JM*4I2E*4K^2),_P!^$L_I*^_]4*KZ$A_)1?JT_LBOCR?\
MO-^MD_MFHU4E14I2KJX>M#S'B8VU%]*:\/BX4YFMW$:*H2YW486IY=P&PMT0
M8$7;J1@HKN\)AJALV#A<,,USS&;[FI$EC8*XMY=QV-O)=3+(T461?:76RJ2
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MR9RH61)"F?8-V0^2DZ_1:1I L/LC.3C,+CFU62 '=(A9X[=:77+(GK(A0N;
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M)8<@4T5=!=5-44I&^5TU[+()8EU:R6CHCM$XEACGC>%]:-')GD0<@<P596!
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M9 #++H'1X*R-5JM*4I2E*4K^2),_WX2S^DK[_P!4*KZ$A_)1?JT_LBOCR?\
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MX$DC:8 JZUE9 6'%,XLM0W$;"HVY.$PR<WW4#*F,Q-I-B1\-UD0K*%N9HY^
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M+$A!<=!Q-S9TFP4M='.PN!9"PV2+CB"MA]$?Z,O(/DY\(/PB2X?RJ'.\.PG
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MVM PETU6_9#8L.@Z/[>&N-MUU1?=BYK@M[L*&N=)7@81R6<UD,W( L(!5I+
MR!#Z'.CQ;$(OQ+EADUJX)2)F!LD,=J S(6"Q1ED" Z&5F#JVIL]1/R:P2YSW
MK!&!CQ*(JLMQ&C+B\PN,1+)',B,]S,J2M*RF6-T1HGC*)E^WOAUU+)#D'1]8
MWUS<T&Z(-=W(F?[#R<"Q('(W:6Q&[F9C*L2'4MD?WUX-&<7)0MPSP<" ERE0
M,L1<:1XI>PJ4CDC5"T[Z!;6ND-<0I!-I79R19(HT4H@"9J&"AN^I/R<PFYD6
M6>">658[.+=;$,1W'2PN9;NTW'%T&E>"XGFD620M)\HR,QCR4<!/A?T>D)'@
M\(8M;")M4/9(R3>5S.[FQ-,!<XH\Q(!K>+R&[L(.S.L(C)Z.")N-EB6]54KI
M\G)UN=<<8Q$M*QG'R\D\LJ[-OHD>Y69)V>/:T,9$N)5.:] 8 9:4TV#DO@:I
M;H+-LK2*S@MFYW>[L$-A+:S6D<4W.-U%AELK:10KC-XRSZC++N?EFX7=(1]<
M<IHB;D&4(_L4G%*QG$_5)%?(W>7=C'#D+RA59#JN$\EB"@R6> AHKPL(<@2,
M@(D/63&,1E!$DZL&BDA8<WM@#'+L;BD"$ Y\V@()&:F,,I!+$T@Y+8';,KPV
MDB.MQ!=*W/K]F2>VYYLNK-=$KH%_=J5!".DQ1U950+)M>Z-UCJE?!?7T?*C5
ML8_'XQF*-)I64VE-,6 NU1[$]K<7LQN<7!J:N8V#/9XI+UV<.&$HX9C!")(P
MW6(W=Z,KF59?E)9@3#"K*\S:Y=+I&KHKOWYC5A'K+,%!9B<K#L#PO"F#8?;M
M;96]O:E5N;MXWAM8]JW$D4D[Q221191+/(C3[:HAD*H@$77X6=$%!O0!<%N8
M-($YNDY=<E$S+7YNR9 )*)Y=O+(D2I;*K*GT$,UY79EP%BL1TA,E+!8]6J88
MQB2M&ZW.EHC;E-,,"C\%B,-MK41!9!#&S*@D# 9ELM736*W); 72>-[$NMP+
MY9-=W>N<L2N$NK_;9KDM ;N=$>8P-&7TA,]'>U(GW0VKY(?)G)U8W/(J9.$/
M=Y-U&831G&=WJ!$LI,3?2 6B0@A8OK3E'&)"STB.DZ& -0;:X%EMZ5AKQ1XC
M>1+"B2(! LZ0ZH+=RD=R)!/&&>)FVWW93MDE%9V955CG61/@.%W,EU++!*7O
M9+.:YT7E["LLU@T#VDY2&X1!<1&V@7?55F>.)(Y':,::CMN%G178[<Q90E51
MN9VA!A9\595,UC&=I%>XU)!@VET5D.3HVX(/L/CKHEF$8@JF6W=)BI;K9UB9
M?CC$=QY!<9/)(99,H;<*[F.:(LZ"+0^<<\J$,I&ELLN]7+'^Y; MF.#F1,4,
M*P0 W5XSPQ+-;7"I#*UP98PL]G;2C0X(>//^&^J;R_4L-G&;K=^'=;I2",@Q
M"0V:9%((Z8\,+2[+/;,(N^1QT:9 ADUN)CKDEF&ZCXE"O;P&Y)G(F860QX+V
M>W";93.*9IXB\44H21T$<A$<J/$0Z*F89#DT<;(5*G/-O,(LKXRFX6;*XM8[
M.X$-S<6SS00RM/"C3VTL5PNU(\V125=:SS)*'5@!Z%-,:[4:8.SY-3K9'6[H
MN\PMPPE\R3DC.Y&".0#B3>6X2#&4N7:P3PYB/*3L\'HO"!BF#FF5;%/F5Y_=
M![A]:9W:!+A-B Q2*K(R#8,6RNAD1HRD:F,J"A6K3@N'&*QAVI<L-E::RDYY
M><YAD=9$D;G?..=2[J32I,)II%F5R) V0RC2_#-H\@A(K.#(X+CGIN(B@S[)
MP[@K(FSEQ2' L&](8@MB9^RIP8FS"V2:<") NIB%:XK=U.88OB &0N#D5*G.
M.%M0*VR$MJC.IRMI;J9&S<B/+5WSZL9N3.!LP8V(#+()$*SW2&-E>^D"QZ)U
MT1B3$KYQ"F40:X8A.]CT<)3A5T$JS$Q[/7P_8Q<>6BZX&+_*D\,FDF*1>#%<
MU5-]Q(2=#(?"XQ'#'Y);!]+:6K 4AR4P)-ZS7XYQ+<$O.CN"43!C%"?E%FFN
M%Z#'D46>XFE6(C:5W)"#)<K#R4P PM;_ !>NR]N;4H+B['R+6EK8ODPGU"5[
M.RM;9[@,)WBB"M(0SZI+)]#:JF9TE<)-&EW5:9-C*SRM%:1RE)ND+?'@GEN9
MT79I'>D6LS,$1_=,$RE@\B\E51RE%\RV]O7%BBQ*]@6)(I@@@>1X2(H2T32M
M&\A1S&74,T2$J&TY @ *[ALFZP'"KU[J2YM3*;V*&&[5KBZ$=S';QSQ0K-$L
MPB<QI<2@.4UYE7+%XXV2>QV,-L:Q><@<,LBY$_'R9\,4Y+*N#NX8#CY+9VQM
M;'%(1N!;F@%/]=FDVMH22RI"^"I"N-+,\NWJ_%BC6&-1X%1<SE_*SL[L?G=V
M( &0&PM[6.V$VWF7N)Y+F=SEG)-)I7,Y #)(TCA0>$11H&+,"S2*HJR*4I2E
M*4I4,F/_ & /\JM_]&%*CD^;^?\ PJ!4J.E*4I2E*4I2E*4I2E*5=0_[70_D
M4O\ Z,:5./ /Y!_57NI5:4I2E*4I2E*4I2E*H#B!U&R;88F 1Z='EKQ9'=4L
M91FS;\%%<RPE1U,%NT #T[X6PPM?'F8896RO?ERO;WJX+E]\'N$?"'96%CB]
MWB%I%A]S)=1-ATEO&[O)%M%9#<6UR"H7I 55.?A)'171<G>5%YR7FN9[.WM+
MAKN)(9%NQ,554?<!38F@8-F,CFQ&7S5JI[CJ#>%\X^5C7U<KR[[V7D5YXY3?
M6,,_RNNK[K>-^:\&X,0]_I[CJ#>%\X^5C7U<I][+R*\\<IOK&&?Y73NMXWYK
MP;@Q#W^GN.H-X7SCY6-?5RGWLO(KSQRF^L89_E=.ZWC?FO!N#$/?Z>XZ@WA?
M./E8U]7*?>R\BO/'*;ZQAG^5T[K>-^:\&X,0]_I[CJ#>%\X^5C7U<I][+R*\
M\<IOK&&?Y73NMXWYKP;@Q#W^GN.H-X7SCY6-?5RGWLO(KSQRF^L89_E=.ZWC
M?FO!N#$/?Z>XZ@WA?./E8U]7*?>R\BO/'*;ZQAG^5T[K>-^:\&X,0]_J+S/@
M%TUL2-.D.G)TDE,8>D;#N;*\)18L(K#!3!9'.^&<;YR1 RZ:9 A2&210A*21
M(JR2Z2:F.UP3X <!Y-XI:8U@/*KECA.*V,ADM;ZROL.AGB9E*. RX7D\<D;-
M'-%(&BFB=XI4>-F4Z[%OA$N,=P^YPK&.3O)W$<.NT"7%I=07TL,@5@Z'(W^:
MO&ZK)%(A62*15DC9756&R/"%P0\,W!G$26K0&L66''2<<-662F]R7272BZ&:
MQ :#Q(G1<MR5;P,RENH-""Z#2'DHJN.$F0NNLK[XMUBLMK:V^*XO>XS-;(4Y
M[?)9Q3S$L6W)(L/M;*S63(A"T-K%J5%U9G,GS2TPG!<-EN)<'PBTPE+DJS0V
MK74P4 #*,3WUQ=W;1@YN$DN'"LS%0 <AMPH$&MGDHL(,JIGC;#/-1!+///&W
M)>V.666%[Y8VYN/):][VMR6][WK5:&8> D?R$BLTHC',HI)&1)4$D>+,CP5X
ML"%;!1.P8MDUKXW53L.ES%;X7Y<+J8\SFYWQO[^-\K7OC?W[<EZ:FZ.^/1X.
MD]'\GBIH3(C0N1RS&D9'+P9C+(Y?-G7FX0>6.6&0@U\<TT4<L;H)7QR1'RRR
M02RM?#DNFAEGGDCA>U\4\L\KX6QOE?E:CXSX2?"?"?"?Y3\_CH40C(HI&07(
MJ,LE_%'@\ S.0\ SZ*]R:2:.-L$D\$L+7O>V">&.&-KWORWO;'&UK<M[^_?W
MO?O0DGI))/Z>FJ@ =   \0&5?RWY=I;2RDLD^>?&%J)#/.0O6>:*FNN)'+-'
M+)R)ODEGDEI=1++-.][X973443O>U[X9Y8\F5_=XKBY$<>6'SD:$R.]:#,:1
MTY<X^>ODZ>SM-Z;_ +5M/RLG_<8AY9_X.H][2FE/OQM/_BYXE/S*5?SFY\WS
M^FM/>*BYG:>=K3T&(^YT]I32GWXVG_Q<\2GYE*<YN?-\_IK3WBG,[3SM:>@Q
M'W.GM*:4^_&T_P#BYXE/S*4YS<^;Y_36GO%.9VGG:T]!B/N=/:4TI]^-I_\
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M)'10ZK.;F6V)>,LBL2PE*(SC1';_ !)S"<\+.B](2"?X2[N=D;S)EV$=M;!
M-?QF'L8.L-51!!9O:P.E=D@0Y_)GHNY3K=W;99$S##,G1 W)3:VUE'%?W5TD
M1CUQJ@=F8F:25VGGE[YCDN;11J,ETF.0 !<JT-YB<UQA.'V,ESO;4CRF/0JK
M;Q0QK:V<(*HOR@5;B60YOK2:$L=8;/2^MI6EI2E*4K[T_8#O]'#KW_B#M?\
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M\4^'KRG,_P#BKST__P :?&7_  &&_5?^I3W3-_O?N&/\4^'KRG,_^*O/3_\
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MC_=3LG\).WCGZ.FZ.JBX3ZU-G^-FX_W4[)_"3MXY^CINCJHN$^M39_C9N/\
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MQZSDNFFH#C@D2K@@HBWN! C<X*"EEC)JVRV$T,*W#-$8W,H0JY.LPR[3A>]
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M;Y+=MX941'$ADV+K5UT=*4I2E*4I2E*4I2E*4I2E*4I2E*4K2'B^U%,]F'0
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M<6$\6R"YN*:6:XIS?@7@HYH.)*UK#H!RR/@(\7S@C/IR(_J/S$"A_DR/S_\
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M#>FZ?M*^5[Y='S.BM:W.Y_ZWQSX5OA4F^#:3!$BP:+%ABZ7[,9+U[38YDUH
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M1@R"KD] B60JN@D@.IGBLLHLE@GAEDIA:^RV9BP7:EU,I95VWU%0"2P&694
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ME*4I2E*4I2E*N!I_<QO_ )F/^2QI4X\ _D']59"E5I2E*4I2E?!C)/WQ/_\
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MPLK2ZM8D@DCFL#=6CF3%+8N87AN;U([F/9(*G=?+76MG7.4I2E*5].7L8?\
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M66T*R3O&L\,E9QD1:5I(H7CYQ;<Q-OL?A6K5SG1'GM[@;F_E9>&3G.>]GE;
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M7IR=1UUVMTZ*W3O9CD$4Z(HQ_.,XI+*$E(.KDUCM13NA@4^*EJ.JKZ>JG;J
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MD5&UBBTP\5%L0!5B<E<@V_%=?$ 3H \5UK(65STU[<\\N[BZT"/?E>01@ZM
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MM;+&]KXWO:O'^6/RF.3,G?KL6XU)WPZ(QGTC,5]0_!<K0\D+1)E:)Q=7Q*2
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M@#XV/Z2FA_);A/93<CZQ.)>VG:;;WP!\;'])30_DMPGLIN1]8G$O;3M-M[X
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M)#9%C98DMYX!SBSN2/2]0<B5!2TQ^2Q_ L:Y,WQP_%XVAE*"2&6.5I+:YBZ
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MQ]*4I2E?3E[&'_W2(G_2B<?VA*KQKEI_MV;]1;?W0KZI^"G_ '.L_P#F[_\
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MP[#W4%6D);.^(([\V<BQZ%'1'+(DKY:8\\&^D=$"KF _XS#PY9@:?_NS.?\
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MXV:-V0E)%*NA*D$HZDJZGH92000:S:<YFR(6+:C,)2DW8/ DBP 3D#M@%C(
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M9TVT*YQW+![F,Y(.\N' >=?Q96 :0,>FLBX1J..P)[8ZL#*YMKJ4B:YM[@U
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M;(:EUH=+9#,9'(>"L]6=6-2E*4I2E*4I2E*4I46EW[F)?SU+\B12K'\'\_\
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M MFCNT663*9"XA;=9$M;&.W$<NG-,YH;AES*E5<!\@Q6M-?6'*4WRRX;,]O
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MRI\-3LIL8\MC#S_"%PG*:F15Y@N3L/#([BIC"T>(!IB^8E@^H+"I=69,\VG
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M.-NRYO;ERO:W_M<2_CKY#_THP3/R,R!/R6.^ 9_P\*KVSX) 3;8_D"?E\+\
MS_[O$*Z^>F2^ZI_U\?[Z^3=#^2W">RO7M#^2W">RG3)?=4_Z^/\ ?30_DMPG
MLIH?R6X3V4Z9+[JG_7Q_OIH?R6X3V4T/Y+<)[*=,E]U3_KX_WTT/Y+<)[*:'
M\EN$]E.F2^ZI_P!?'^^FA_);A/930_DMPGLITR7W5/\ KX_WTT/Y+<)[*:'\
MEN$]E.F2^ZI_U\?[Z:'\EN$]E-#^2W">RG3)?=4_Z^/]]-#>2W[#V4T/Y+<)
M[*[YM)__ ',ZC_X8P+^RK37ZA\@_]Q^1G_\ 2G)W_P#Q%G7RCRG_ -Y>4/\
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M*=&G]SP_JX_W4I3HT_N>']7'^ZE*=&G]SP_JX_W4I7FV../^;CCC_LM:W_\
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MDEDBAD/<&5.1$RH"(176%3VD32S20J S*B%P'FT"U+&(9D2=%TC*49U:-))
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M2]L;7SSRRO>]X68NS.QS9F+,?&6.9/\ .364B+&BQH-*(JHJCYE4 *.GIZ
M.FH!EI'2^;',HQGJ+6&<:V+(5)=L&/90&*9,<ZE:I0)RLGF33=IN!)Y"J:V-
MI:CT]CG.693>"1D3=40?-.7G5SKCDYQ/KA3;A?=DUQ1Y$;<;:LT3)F&E2%R8
MC+I-8W,+$QSQ&RM-JZEWKF+FT.W<3$JQEG31IEE+(C;D@9\U4YYJ,HFOPJ\,
M)+C9W7X=-&*NME2U[..6J()UVRY[K*7T]?K-F*RO3GO<YFCR:MSND+=9;)7
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M&Q,\D?FY?*^/I3/+.T*OKODODCD?6L$B7$-QIA)3<C#&-D;0ZJR2=^CLB,,
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I4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g696632g78q41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g696632g78q41.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2N:4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $ < 5H  QLE1QP"   "0.@< E  "')R,CDS-S0Y' (% !]-:6-R;W-O
M9G0@5V]R9" M(#(P,3<@,C M1BYD;V-X.$))300E       0EJA>J03\.L="
MP[F+@+UOW3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              2\   &$          $
M 0             !A    2\                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   2\     4F=H=&QO;F<   &$    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      A+     $   "@    ?0
M >   .I@   A$  8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M               !  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 "_^X
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M>@__ $]G_1_\@DIY_-^L;*+K*:.F&^"&UV"-IW4_:0YT,^AO_0_HWV?S=_\
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M/;<QS@]KO;G6UMNN9_A,?[+7_.5(I(ZO:^OGIM+BRSPR+&G:^K_PG2[VW?\
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M^W'?^D4MV9_HJ_\ MQW_ *124YC:/K4VF/M&*^W>\ESVNC:17Z0;Z;*]OO\
MM'^D_P !^FO_ $F]S5]:]P R,+;W<:[)^3/4_P"__P#J32W9G^BK_P"W'?\
MI%+=F?Z*O_MQW_I%)3E''^M_L R\,[1+B:W2XR[VN_D;-GT/\)_X(1]'UH=6
MT#)Q6VG?N<*W;0"*O1#6N+G;FO\ 7]__ (&M'=F?Z*O_ +<=_P"D4MV9_HJ_
M^W'?^D4E-7I%76*JWMZK?7D62-CZV[?ZV@:SV_16@@[LS_15_P#;CO\ TBEN
MS/\ 15_]N._](I*3)(.[,_T5?_;CO_2*6[,_T5?_ &X[_P!(I*3)(.[,_P!%
M7_VX[_TBENS/]%7_ -N._P#2*2DR#E_T6[_BW?D*6[,_T5?_ &X[_P!(H64[
M+^S6S76!L=)%A)B/^*"2G__9.$))300A      !5     0$    / $$ 9 !O
M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J
M"  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P
M  $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD
M!     $   "\    Z  .I@   "<0  ZF    )Q!!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$X.C T.C(S(#(P.C0Y.C V ')R,CDS-S0Y
M   #H $  P    '__P  H ( !     $   &$H , !     $   $O
M  8! P #     0 &   !&@ %     0   38!&P %     0   3X!*  #
M 0 "   " 0 $     0   48" @ $     0              2     $   !(
M     3A"24T#_0      "           _^$!2$U- "H    (  @!$@ #
M 0     !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P
M  #H   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3@Z,#0Z,C,@,C Z-#DZ,#8 <G(R.3,W-#D       .@ 0 #
M ?__  "@ @ $     0   82@ P $     0   2\         !@$#  ,    !
M  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M1!I4?<L)K9K@S\NFO)]0MM^/K668& ;I.-)1BEYMUI358!&VKY:R&IJKNBY
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M%RCS772&,(D+\O<E@!Q]K:4;&D;A%-Q"+1(1;-*DWX#@./#MX_X67X-W1?\
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MM7'7C(>@3+62BJ).:W(@AP1JVJL:_&@7IE9)9R9<F4(V3:=40I3B*-(5%#&
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MM;R@;!HA$00G#K990- QL?Y;3[M5'#,(JW%'1A]/#YKI<0J'2$6C'OB >86
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MV-K6L#!KN[K?-;:^8&5[K<\ZBR*//+63QN'<7^0#[+)"R1=E(IVQ$9KS(W9
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M=N8-A^(FP>Z*\IZZKZ(U1 X=6<!9DT?A<#CC/$XNRI-=1#<R,: AO0$;%O\
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MF*;01Q/>X0Q[,X-54<.''<W?;.OPUT5FX<\-N2  !0 EE@"66 (0   .@
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M$10C[T0Z)-[4PMH1:2GJE?7V@QV7'*N-[864.&T4(H\'PJ%Q-/AM PDQPL)
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MEO9754J5,,G41F.MTF<WADBJV:S5 RJX; D\M?(\^,<1,FS\P:E3VU+FB/\
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M\X!]/?RNY:<E>0]-//1Y3:6-M:D/3HR1JCE\9:K.KE.S3%/%3&"Z%E[6A 8
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M02+CKS7#+G'8'$=GFK,;YA\M-ZWH'14\J]CWY@:,NO@B67V6_,#MAFN51FP
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M+);)][4A9&__ !D2)1KK+U,^CO\ W*9<Y[A]9>;9=X]*O6M<SVQ-\-^($Y#
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M&T3Z[I6XJ4-TG1I9+"'^(.25,,DGCQ^Y85+T2W%1#.+&GB0$V)<[*L%EL]R
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..$Y91I S"R,< ,SQ7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g696632g79t36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g696632g79t36.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1TJ4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $ < 5H  QLE1QP"   "0.@< E  "')R,CDS-S0Y' (% !]-:6-R;W-O
M9G0@5V]R9" M(#(P,3<@,C M1BYD;V-X.$))300E       0EJA>J03\.L="
MP[F+@+UOW3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              0,   &9          $
M 0             !F0   0,                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   0,     4F=H=&QO;F<   &9    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      2NP    $   "@    90
M >   +U@   2GP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 90"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M'2G-,M=0"(@C';V^C^<DER1]8_JWZAK.'JW\YE5=C7'LVHU%_J[G?1=_-?\
M">FBNZ]]5QBNRA0'5-M-(BC4O#/M VM<UOTZW-V+1'2W 0'40.WV=O\ Y)19
MT9M9<:QCL+W^H\MQF#<_CU7^[W6?RTD.5D_63ZMXKBR["(L;73;8P55DM]=I
ML],^[:ZRAOH>OL_[E4?SGZ3T[#.J]&MP:<S'P&VBV\8SZ@VGU*G$N9^F9O\
MY'T&?I=G^#6A^S'Q&^F!J!]G;R?[7DF'2G DAU ),DC';J?'Z22G,/UC^J4G
M94VQL$ML;C^QQ_<;86!FYW^8GOZ]]7*F8]WV5IQ\D7/%QJ8P!F.17:]M=WIW
M7.WN_1T45V9#V?I/26E^R3MVS1MB-OV=L1X?23GI;R9+J"1)!^SMY(VN_._.
M:Y)3FXG7?JSE9+<=N.*W6%PK=92UK7!C'9#W<>S;4S_#>F]#J^LGU5N]'T<?
M><A]==?ZOMDV.;4?=8UC?T'J-];_ ,"]5:O[*<(AU&F@_5VZ?])+]E.@#=1
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M4\KJN#AW-IR;/3<YH<"08U):T;OY6URM>I7^\/O"RQA=1%KGGJ#+FS+&/K:
M&[MQJ=M=[][?;O\ ^"]B2FVSJ>%9?50RS<^]H?7 ,%I:;&N:^-ON8URMK,9A
M93<=E3NH2YE?I[VUL;)]P%GM^@[:YG\W_HEH-<QK0W>'0(DD2?BDIF@9O]#O
M_P"+?_U)10]A,!P)\)0LW^AW_P#%O_ZDI*?_T?2^E_\ )F)_Q%?_ %#519U3
M*SL>ZS$:,<T9HQPYX+M[&NK#G;"VOTO6<_T_^#K_ $G\XKW2_P#DS$_XBO\
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M_J2@/;E--7K.#VE[#YAW=K8:-S/ZR/F_T.__ (M__4E$&^E>:G__TO2^E_\
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MT!UMCFP[G>U[W>I_)W_05M("E*4+:Q:S8>"03\ =RFDBI22222GGA;:_)^L
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M-?>S_"?S=GZ+V)&S1,B5&1D=233*QUUKJQZ#V!KPXN<60 /ZMCG*>;_0[_\
MBW_]24= S?Z'?_Q;_P#J2DA__]3TOI?_ "9B?\17_P!0U6E5Z7_R9B?\17_U
M#5:24I))))2D.UKR6%@!+7203'9S?!W[R(DDI'-_[C?\X_\ D$IO_<;_ )Q_
M\@B++RNF=3?;8_&Z@ZH/M-C6N:7A@])M3&-][-S&7M?D>G]"SU-GYB2J\70F
M_P#<;_G'_P @E-_[C?\ ./\ Y!874!U'IE%63F=:])@>]MCW8P<'&S:^MNVL
MN]+T&TV^G_QW_%JC?UE^/>,2WZP 65/V61B!TN+:KO?:U^UM>V[W._KU_P"
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M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J    "  ( 1(
M P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @
M 3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $
M  "\    Z  .GC   "<0  Z>,   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*0 R,#$X.C T.C(S(#(P.C4U.C0V ')R,CDS-S0Y       #H $
M P    '__P  H ( !     $   &9H , !     $   $#          8! P #
M     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "   "
M 0 $     0   48" @ $     0              2     $   !(     3A"
M24T#_0      "           _^$!2$U- "H    (  @!$@ #     0     !
M&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@
M 'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H   #
MP     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P
M,3@Z,#0Z,C,@,C Z-34Z-#8 <G(R.3,W-#D       .@ 0 #     ?__  "@
M @ $     0   9F@ P $     0   0,         !@$#  ,    !  8   $:
M  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !   !
M1@("  0    !              /      0   \     !_^$_^FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED
M/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX\>#IX;7!M971A('AM;&YS
M.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U
M+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @
M("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O
M,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E
M871E1&%T93XR,#$X+3 T+3(S5#(P.C$Y.C(W*S U.C,P/"]X;7 Z0W)E871E
M1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y04V-R:7!T-2YD;&P@
M5F5R<VEO;B U+C(N,CPO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP
M.DUO9&EF>41A=&4^,C Q."TP-"TR,U0R,#HU-3HT-BLP-3HS,#PO>&UP.DUO
M9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,3@M,#0M
M,C-4,C Z-34Z-#8K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B
M92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%C<F]B
M870@1&ES=&EL;&5R(#$P+C$N-" H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O
M<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2 R,#$W
M(#(P+48N9&]C>#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @
M(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR<C(Y
M,S<T.3PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F
M/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @
M(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z
M<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED
M.C=#-C1$-3(S,$$T-T4X,3$Y-S<T13(S1#,Y144P.$4Q/"]X;7!-33I);G-T
M86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C=!
M-C1$-3(S,$$T-T4X,3$Y-S<T13(S1#,Y144P.$4Q/"]X;7!-33I$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD
M:60Z-T$V-$0U,C,P030W13@Q,3DW-S1%,C-$,SE%13 X13$\+WAM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C=!-C1$-3(S,$$T-T4X
M,3$Y-S<T13(S1#,Y144P.$4Q/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$X+3 T+3(S5#(P.C4U.C,W*S U
M.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z-T(V-$0U,C,P030W13@Q,3DW-S1%,C-$,SE%13 X
M13$\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,3@M,#0M,C-4,C Z-34Z-#8K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@
M87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F
M/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE
M=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO
M=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C=#-C1$-3(S,$$T-T4X
M,3$Y-S<T13(S1#,Y144P.$4Q/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$X+3 T+3(S5#(P.C4U.C0V*S U
M.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C="-C1$-3(S,$$T-T4X,3$Y-S<T13(S1#,Y144P.$4Q/"]S
M=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)
M1#YX;7 N9&ED.C=!-C1$-3(S,$$T-T4X,3$Y-S<T13(S1#,Y144P.$4Q/"]S
M=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$
M;V-U;65N=$E$/GAM<"YD:60Z-T$V-$0U,C,P030W13@Q,3DW-S1%,C-$,SE%
M13 X13$\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X
M;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H
M;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H
M;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!! &:
M P$1  (1 0,1 ?_$ !X  0 " @(# 0             '" 8)! 4" PH!_\0
M9Q    8! @(""@L,!@8## L  0(#! 4&!P ($1(3(0D4%187(EB6F-@8,34X
M5E=T=[.WUR,R-T%1579XE[:XU"0T876TUD)Q@9&R\#.QP1DE)B<H-D-BE:'1
MTDA28V1R<X*$J+7A_\0 '0$!  (# 0$! 0            $& P0% @<("?_$
M %L1  $# @,#!@<)"@H'"0$!  $  @,$$04A,1)!408387&Q\!05(E2!D:$'
M%C*4E<'1TM,C,S1"4E5SM.'Q"#4V4W)T=9*3LB0E0T1B=L)%5H.BHZ2SM=1&
MA?_:  P# 0 "$0,1 #\ ^L+:-A6 S#A8F0<A9"W*S5KF,M;D&#U\TW?;K*XS
M*PJVXW*U3KS!C UC,T- 13"(KL)%1#)G%1C-LDU9(!T(GYCB[Z][^E2=2,M3
MN';;H[>)5F?8CXK^%FYWTV-Y?V\Z*$]B/BOX6;G?38WE_;SHB>Q'Q7\+-SOI
ML;R_MYT1/8CXK^%FYWTV-Y?V\Z(GL1\5_"S<[Z;&\O[>=$3V(^*_A9N=]-C>
M7]O.B)[$?%?PLW.^FQO+^WG1$]B/BOX6;G?38WE_;SHB>Q'Q7\+-SOIL;R_M
MYT1/8CXK^%FYWTV-Y?V\Z(GL1\5_"S<[Z;&\O[>=$3V(^*_A9N=]-C>7]O.B
M)[$?%?PLW.^FQO+^WG1$]B/BOX6;G?38WE_;SHB>Q'Q7\+-SOIL;R_MYT1/8
MCXK^%FYWTV-Y?V\Z(GL1\5_"S<[Z;&\O[>=$3V(^*_A9N=]-C>7]O.B)[$?%
M?PLW.^FQO+^WG1$]B/BOX6;G?38WE_;SHB>Q'Q7\+-SOIL;R_MYT1/8CXK^%
MFYWTV-Y?V\Z(GL1\5_"S<[Z;&\O[>=$3V(^*_A9N=]-C>7]O.B)[$?%?PLW.
M^FQO+^WG1$]B/BOX6;G?38WE_;SHB>Q'Q7\+-SOIL;R_MYT1/8CXK^%FYWTV
M-Y?V\Z(GL1\5_"S<[Z;&\O[>=$3V(^*_A9N=]-C>7]O.B)[$?%?PLW.^FQO+
M^WG1$]B/BOX6;G?38WE_;SHB>Q'Q7\+-SOIL;R_MYT1/8CXK^%FYWTV-Y?V\
MZ(GL1\5_"S<[Z;&\O[>=$3V(^*_A9N=]-C>7]O.B)[$?%?PLW.^FQO+^WG1$
M]B/BOX6;G?38WE_;SHB>Q'Q7\+-SOIL;R_MYT1/8CXK^%FYWTV-Y?V\Z(GL1
M\5_"S<[Z;&\O[>=$3V(^*_A9N=]-C>7]O.B)[$?%?PLW.^FQO+^WG1$]B/BO
MX6;G?38WE_;SHB>Q'Q7\+-SOIL;R_MYT1/8CXK^%FYWTV-Y?V\Z(GL1\5_"S
M<[Z;&\O[>=$3V(^*_A9N=]-C>7]O.B)[$?%?PLW.^FQO+^WG1%QGNTS%R+)V
MJG;MSA5$FJZA#>S6WDFY3II'.4>!L\" \#  \! 0$.H0$.K1.^BS/;!)R<UM
MIV\3$U)R<W,RV#,2R<M,S<B]F)F7DW]!K[I_)R\M(KN9"4DW[I55V_D7[EP]
M?.E57+I=5=4ZAB*'>Q\^]AB/GEW7?Q7YLT4G4]9[5=710FB)HB:(FB+5E9^R
MN89J.?\ >-M[G*'?FUEV>X@>9>EY<IX,T5DUG'UFGV-Y6*(GW1(\-8TU[]3(
M,B$JBU;J25@8EZ<J*H',7K9-@=Q-NKK6 5;LOD'ENE[>W&W;:UF?.69-P>,[
M3FF.PA"6'&=3E*%BBH6Y[1I&W7R\7.T0],C2R5G8N(BM1K)^_=S+U!R@/:8I
M)F7)LV-B0!Q-_8 #>V\Y 9"]R%8G"79"*/FW+F',-M,3Y@Q[;<O8"OF>.YF4
M:XE3INCH8XR-$XQLE*M=>=NE) D\2P20K,)",[>KTK%-PDXZ2=LGK1=8HMKT
M&W;IZE^[S>R+8>V37O -!R) VZQ2>>+46$!W4V[)RRQQ7!L%8JALA7X[IR@>
M+IY+);X6)-(D*<.V55BAXR0$.0 GT=77\RN-D3)%7Q?0I_)5H&>7JU<C4Y60
M&I5&V7^?7:+KMVZ 0]1HT+8;5.N%E72 %;0T,^6(D8[I8B;1!PND4+7O,]EC
MV^0&R6N[YI.G9F\'MP&43K51B\<SE@N+A>+GQKZA+ I -Y.L41LHMP<A)7JP
M5V-(0>TQ=C*B5@8I N; C6U[BWH.A]"[[<KV1@^V:<K+:=VA[GK[3KE+8ZK=
M5R7C]+"3NK6*V9*;LE86JP<58LR5R]RLVS6=+MI-LSJ"I40C)-^B=>*9+/RD
MMTCO[%E6[GL@N.]G=]VIT3(-&NTNINKO+BBPTQ"C#$84!ZB^I42G(7,CY^@J
M5@K,7R$C3'C.VS(KF5$X"3HQ.2Q()%LK7_9D>O=DL&QCV5?;5>K]NYJUMD2X
M9I^T"X1U.N&6\HV*L5^@6MY)34] -WE6?J273':K2=>>H,RO$TG$@!DCLT52
MB(@4[)RWEPN .NV:SO<KV3#9UMCQBED6V9OQG..I_'[O)&-:5!9 J9[+E:N-
MTQ40=48JTF5G)MY#E53CWHKD9NUD5D&ZRJZ1TRE :3H-#8]'7ZB?0O.#[(GM
M^;0N1K9EVUT_!E,Q_.4ROA9+YDO'RY9N2NU/C;C',"0L#/R4_!2Z3.0,B,%/
MQS"8=$:K231FK&&(Y$EC>UB>H'C;@A>R9[,E\T5#";#,]2DY.[X??YO@[W'V
M2J.,8#2(\ZQU3N[:-A)VO(GCFZTVFEW/48EATS.UY! Q11 EC:_3;T]6JS>.
M[(#LDEL66/-L;NFP@\Q14)M"M6:](Y @304+87?C,H5^N9V55*3D$N+F.9"B
M*\@T 7C(B[4!6T46/ ]5C?U+'\'[[\5[@<(YSS[CQB^EZ'A&;RG$JR+"4A)5
MI>6N+6+^0>352DHQZXCW$;.MV)AB57"Z8ATI.V03X&X%)%LM]K]5^*A?#G93
M<:[A4&SK"N,;O=XZ$PBXS1EVREF*C#4C#)SUYU88?&=ON<I+(0:^2)1JVYW<
M/'+JL:RS4+(6>3B4BB311WW^OA98T_[+GBN) J<CBVYF=%@=OLZN6$M%!M$8
M">X6SJ5> 096&NS\C!2Y8)TF+B6>Q;]TQ<(" 1ZZZ@"4"FQN!;6_LW=:GMGV
M1G:_ UZ=L.;<I8SP(C&7R_4>,;WG*^.Y ]C''LBG'RTG&+5FP2R!%>95-5Q7
M7)T[)% 84I2,;*E,4" $Z"_5<_,L[O6_;97C%"B.<@[IL%U%MDVOC:\?N9S(
M]:9H6VL@03A/0JQWP)NXD_*9-)\4P-UER';I'.N0R8.^B!I.@)Z@2I5R=N$P
M=A;'"&7LLY7HF/,9.D8Q=E=K;8XZ&@) DTB1Q$$CGKM8A9%>304(LP:L2N'+
MI,>=%(Y0$0)8G( D\ "3ZAFJC7+LGVVB)RYM:Q#CNSP>9I/=8\DSTZR4.[TE
M6J0U<BD#F<6&0DWTV@:3,L[(,>S@H1%],N'15BBV3Z%3@2QSRTUZ/0N_WR=D
M.Q+L/'$*>2*Y<+8YRY<"UQLUI;=@[6J<&@XCFTQ?;25X[;"QJ,&I*- D'Y>8
M"B8Q"\5  IB 7ONL";GH[Y+I,A]DIP]C?=UC[:7,UNTN7^1<4O\ +,3D]BM#
MGHS:(;L59"/CG72O4Y47TTBB;N<HDU.V.82\ZA0$1 ELKY:@:YY_-Q/[;1#M
M[[+_ (AW#RN)XJO8IR77SY>SU?L#0*TZO6N1E*T2$//GLT@1E)KG"#FXX$E8
MU-#I'Q073%= @=>BDM(&HTN1WR]JV-9OR%<L6XYF[K1,06K.=AB>@42QW3+!
M2:U/2;03&%Z[:RV0K#5ZPB2/0*9PLFZET5EB!R-DEE1 FB\^SIS^8$^Q4JVF
M=DCAMR552R%>L'W3;)CB<LI:)0+MEZ_X@=Q^1,@EGEZZXI%>C*9=9Z>1FT9!
MJX(EW5BV+1^")NY[ET(DYBDC@0>J_"^\!3]>=]^S3&;-R_R!N:PU3VC2<L-8
M77G[S"QX%L=3*B>R01"KN"G6EX4KA TA'HE4=(%5*)DN Z)8\#ZER*;OFV;Y
M"B\@3=(W/X.M$-BF&;6+(\O$9(J[N,IL [2(LVFYZ03D>U&42J51-,) RPM"
MN3E9F5*['H-%%CP[]]1NWKJ8SL@6R*9QP;+T9NJP8ZQDE8T*BXNH9"KZ<"SL
M[I(Z[2"?NUGB7<^3>H)G79-GI4%'B!16:@JGP-I=38WM8WX6-UUNY?>U0]ON
M/<36ZNU6T9XL^X6P5VJ[?L=8P6@RS.5)JU103L0K'S=FDX:MPM?[A<9M_89F
M1;,V<845@(X5$B!RBW[>CK6&4GLB>*F>/+A<]U=<G]CTOCZZM*!;*UN)DZU&
M,7-ADV7=&)-C^\0$I*U#)T7),ND53?4Z1?JM#MW*4BT9BD!CE-L[#RKZ6![-
M5A.:.RHX)Q)+6%M$Q$OE6NP^"ZUGR-N^/)RKRU6M%3M&0(?'K%M R/=/HG3Q
M.2F$WBRO-VJ5NV<H=)VV3H=$L?;;J-B<^ RMU[E:N$W?[8;#ELV XK.V,'F;
M$D^9QBUO;XA:XH.2QZ4HO&&BTW)CGF&D<LF^=Q*1CR3=D<KM9H1L8JHAGFHL
M;7L;<;&WK]!7LR9N[VO89R#5\4Y7SWBS'N1[F#0U:IEKN,1#SLDG(.@8QZ_:
M3MRF9HWD'H@SCW+\6J#YUQ;M%%EBB0"D G,"_4NGB-[FT*>RP&"H;<EAN1S%
MW1G(<V-FU[@CVY.7K8'&<BUHCML'*,E'E27,HQ5*1TH5LZ,@DJ5LX%,EC:]C
M;C;)114>R2[7<G;GJ/M<PYD*KYCMMJA\I2,]/8ZME<L4)CY_BQ*+4D82V)LG
MZC]![,C(K)0ZS9%9DNK%22?; G:K 0IV38FU@+:@B]]+<>M15E[LC64L5[FZ
MOM?;;!\]7:TY$);Y+%E@@\E[=(^#R%5J"VB75QM,<G.Y3CGL&RA$9AJ8T=:T
MH.:?^,6,CGA_%",^'JM;YC[%%ND#UY>SLOZU9+=GN^@=JM9QVHICN[99REF6
M\1>-,088H*M>1M=VO$JS<R'<\\O8Y>(K->AHI@R>/YVR3$FE%QK-L=3F75.@
M@M* 7^GATY7/L4<TOLB>*&6.;A==UM>GMCDSCV],\=6RK[BI*N1C-S9)2.++
MPQL>WB!DY6H91B9:-%5=!]39!^LU.RD$Y-BQ!KTBA+</*WY ]EKK <Z=E8P1
MAB1LZ<;"S65ZY ;?:IN,CKKCF:JTM5K73;?DZ$Q?&M:[)C* B[>EE)M&157$
MX,NTD%TBKB\+T.B 7-K@9VSXY_05;EANWVQR>:5MN;#/&+G>=6YEDEL5H7"'
M5N*;UM%DG'42$61R*BDVTA3EFG4&0QYAM$&[IK,DV/W?1+&U[9?3WU5B=%":
M(FB)HBX4E[G/_D3KZ!31%!FTWWK&VC]7_#7U=5S1%%78^?>PQ'SR[KOXK\V:
M*3J>L]JNKHH31$T1-$7YQ_)U\.KJ]KV^ _V#PX=?XP_V]9%\SVXOL>N>LE;S
M,AYWAJ3>4ZI;]SN-+;9$(YKCX[BV[?:M5\),LAT5)9WDIBH5U=[=@6I/8X'2
M+=N>N+KA(&8OQ[6*4[1R%C8 C=:^=CQ&IX9VSR"QS"NSK?5M#;[;\E[;<4M[
M%FW&&WRZ;9\F5?+[.M(8IM5&F,NV'+M2LE9GJAE@+;%66L3%@>M';)[#'CYM
M@Z5;=L,%&Z#S127;5[@C,6&7ITZ-^NE@0+*39?%'92:]F[;UN;J]8C,R9SH&
MV[(6$<I36;:A1*;5YU_D/*$;D95Q3JYB#*L:5G#U5"'BZM JR;D)-]%LQ?SH
M/I=RL\$@V<P<KD&^_*^6AXWW#AT1]N)V&[KM[]XRMD_<FWSYC*R63;=4L(T:
MH;;2X)&AI/F1>_&V%N9\KV6U692GR67$(ZP1C>JRD)9DHF.;E=3AWZ+,S)W[
M]_2@=;(-XDW)S%K!N1'IOD>C0[&-MV/\@XS?53+&4\7[Q;=GL^)*YCO(C6/R
MW RN!I"5B8:!C)"Q5/$4]GIO3X%^_6@$'82C6M,I4AW<CS+G,_>'6*+]0ZP+
MZZ$@7ZMW5HJPQ>V#.K#L4]IV$J8<R4ID:=@)V);7 J6,>\U%>5R02YHJ*B.5
M0F0238%[54$D:8X.^'*4R7CZ(#9]]P=>^[CUZY:*RUQIV7+YN?VK94LF",OO
M,2[:<9W0D;2Q3Q.,P\SA9VT%7&%W32'+G<M>+A::QFHUB9VZ+(-'4V[.U;E*
MNNH9W[]_G4<<N%COROD.O(FY%["^BA+LD6W7,.]F>PA,5##.5ZEX(:WG0J2E
MC;8M47-=+M$T5UC278%CLMN2=IUNY4=C)3)E5$7!68$/'D<N %,"D.L#EO&^
MQW@YC=8YZ=&]:WGO8H-RZV/[ Q"EY >7YPYVHWI)T9_ UR&N>3\*U2XPF3%;
M3.4S-4!<*Y$727NTG-P,Y6'J\_'JMT0<-DC+K"! [,D M%C8&Q]&^_I&E]ZR
M.Q=C<W:U2BWRCX0PA!$CL[;7:Y@/*33(T<$VQQW+5F7DII&9PZZL6XK(=ID8
MN57D!3?-[I9P<MWB*,N@*ATBL!+T#F"2/A$V^FS2,\M+_P!$*1K?L;WDEF[%
M-4.@WAJVL68Z+?)2&"<@,?RLC7:WA6(QBY:M,FX^RJAD2F23668.I<B-*E(=
M2RQ2X0\C8(@IS*$(79M( ^#GP!VB=[<_5F-ZCAIV,S=4.*Z)BYYCZV-VK?:S
ME+;I>)ILK5GLBV<VK)KG)E:LM97=Y;2D9= SLC&&L;2=E&4D#)1\Y1EI-V8I
MCE&UJ;'X5[9<=0-/:-R[:O=CSW;Q#*+RAX"UB;@Z1E7$-YK;"Q7Z]9?H5]AL
M55E_6&\;DFU9;W*V6:C7!F\B=S5D*;1&36H%:-6'2SB)$5FQ-H'46U;:S00#
MOR!'7OUMJK_;8,0[AL4;9-T^)\C8'MRV0-Q-ISU:FSC&\9C2-Q]7'67XZ7;L
M&:+&6R[W6;LXES)$[9*D1X8R*9CI"H<P$ O).M@,K 6WVWW/S@'H50MO'8_L
M_P"T>KMZK@'$U^A*OF#;+8\/[L<?RB]%4J5FRTO392OU_...E?"J^=,YQ9P^
M3:6ED_9199:-3!T915R@V9$=^_T+T3?(F_ W-@.%B+]/HZ@L79=CKW,-X*)B
MCXSN1EH^D;0:RHJ">/N0[O;Q=E[/9UR@.3"F!O--%2MX,1 %!< /;Q&J? ^H
MMF3QM[%%\VG?GORS.I&M^D7RU4L4/9!G>MY5B[W.8<O$M%QUHWBV$K &>,EW
M1!W&($0JAT2N\H @1W %Z0)M0% X$4$L>=R B&I4$W]  &F=M^OKTW <5KNW
M [;=TN ,9AAZC8!RE?+?FK:-6MM-Q9R.VFU96KS-[5+>^EH>1QO?\6W"?J].
M6?E?)$F$\HC ,&9$1EDA623 VB]!V=[6\JY=M;C<G*]R=-/2MT>X;&NXK)F,
MME\YBW %\89FVDR=/ML75LKLL:.<76^3:4%I49N(L+NMYB5L$89H)%',-+,H
MMZNV<E'I&?*H8 =]?FU0$9W/PM=;CIMH>J_1>UU"&V/9_N PQEG &7;AB:]R
MLM3+7N,R!DV!J,5C2,KC6Q9V=,G:$)C9D_R^H?N! J-3$7?3"D:]D#'%UVBD
MH<R8%Y+N@[AJ-W1M6S7,WI;*<Q[WMP5WR/=H[==B_'3/ +K#V*ZQBI/;::8<
MNK*LI)753(_?[8[A'GKTI)H1O0(5)6.GNU6Q@&80,")$REKB+#9MG<D[[;AL
MG?TW%U5F_P#8[MZN18>BRLO6[DURMCW >+\/0E[;HT-159]CVZK.7,JLF?):
M2B#*;Q\J$$X;EZ94)$H\P"V$%2E)<,Q;*Y(((WC07&[B1N7>PNQ#>CA=YB:S
M8 Q$BYLN'=R%JS'78S)K:LDJKZM3>,X>A,8F13JF5D94)=!:.4>N>UG238Q%
M ,#Q94QR@4[0L <\K$BU\L\\A[+K=_B[,^YN1Q:#'<#MHMR65'K679RIL/I4
M$,?D3<IJ(QYX\+EFM6P](5,_%WVR)B\X?<0X=6B\>SOT76K9SM/W/PFRG%6#
MZ9B*W+9EPWN0+G^NR%E1H(8VGNU[_)VQ"O33J,RN6S,068/P:K/&<:Y%%VF(
ME371$#Z*;YZ$Y6O<#=:^A/5E?0%1IC+8SNJC+FSOV3L33$M-/+'NZM4^QJ\=
M0RPZ<CN,HZ5;KS>&1G,KN7((5F0**D@X=N.G6:D*Y:%Z=06J127:V_X3D;:9
M6(L,Q?.U@+976(N>QI9]?8^BJF&.+O#R=?VHXIPY&N6<-C-[#2>1<69+;Y":
MN;'&CEN,5?T"9%OW-D$DW"<N)5E#D:!PZR;1U.I<3K>PSS]M^/$%9LILEW59
M2RFEG;.^"FK2XSFX/;SD2WXPQC!457$P4#!:,BB=JV&TY4!_8;E8^Z(E*>5B
M8Z,C&+5O&BZ>D '!2BY!%KFUP#IJ+7U^;CQ5\M\-&SKG$-O^2-OV#\CT_-NV
M#*#3)>.F62(G%SG&=H1-$/*_+TZV!6,U!/1,2_B7RI6\E"-UWC!RD@=-NHF!
MDQ*#<9#?J1;3T_O5'<^[:>R/[F(;'N2LO05GE\UX\R]*7FK8II<G&8@PG3Z5
M+4][475/KF6L9YA@<\.)=0SY2==6F=,_5=+ :%0CXZ+74X%ZO:]@- .-]+D7
MMU6/J*C-_P!C4SZ2ER58KF';+70EMM$1B%6.CUV$A!QUR#.\7EZ9D(]Y?-P&
M0K>YKRC=J[9D=2UF>R;V76._&/C&KD6K41<=>2;6F_RKW/0+9Y>T#T*8:%M"
MW:4G?+'9_A<7WFF8A2RS(90M-=I]@8/4L@%>UI&#,PEL'7?.-GQ;5;NL*147
MN5Z/8(.5<L2_<ZVW<*J\RW?+OT:?,@.5C;06RS!OQMH!>XOOWZ#K=_VS[>-N
MSSI:KC4<=W^+QI88'$C>+AYNSQ%-D(&2QO;E+))H3=5QUEQO6<IM)T@I)1#W
M(\A,MJ@Z [J*K:BQA5$H:1<7!&N=QPTL-_2L@'9-G!TV@$G.&\@,7+;LC62-
MXTS)1B&,2R)L?WFE/*NUK#%YX3VZRUNCUG8JG%P9O$F0*/1OP,;HP?/WZQT>
ML*;BVZX%AKQ.=K6TR&Y<+9EM1W@X$S)M0G\F8/:/\:[0<4YJPW37>-8*D1V1
M;_!9(=MG4-9+H$QEE.$8RZ':J9I6(BW;AFF]5?R"4E(*O@3;$)RN+DNU&66\
M\!KI8G(V5\\K57*E^WM[6-S3# N9&=0P5CG/U+LD$Y)B@EDEGF6XJMQ\.Z@S
M-LNJ,2MXT\,X/(F=O&JQ2JH&:E6,!@*7BYX'V?2JP9VVB9/1?X[RYM7H&Z<N
M><39W3SG6&VZ/),?F'&DRH]B;% V.@'[J[AYN=Q[4Y>+LKOH0H[<G:*S*-(F
MQ,BV3!,O0<<QNM;*POH;9 G=PZSK>%<];:>R/[DXW&^4\MP=JELX8WS!.W>K
MXII$M&X;PE3J'/45[1W5.K.7,7YB@<]N)_I'RME<VZ=,_%XX4<5U&)CH-RH4
M27L"0.&1S)L;W%_) Z"1U744S?8S,_JX]DZ56,.V.MDE-I\)A (]BM'/(**N
MY=RK#/,_(Q[J];@LB7%S65&Y)".0=R]ID99[,+"^[G1$>Y"/8+7'LX]^Q>MK
MIL-L.L=38$9V;;?<YYD'R=+S_2]GFZ^*[(7&[@8#'UNQAAF5W"2&8;DQ@[$F
M[871K-4_O45;6[!%FS1=L70%Z 101F,VX]DH>Q.H9H=5G3$Y)PL51;O?OWZ%
MXONSR&6F\[CKQR)MJ=2+_1YHB:(FB)HBX4E[G/\ Y$Z^@4T109M-]ZQMH_5_
MPU]75<T14TV/V3<JTV^H-J?A["T_6TLT;I^YDO8MPUTJDT\(.Z;,QUS/J_';
M;+>SCC)/#.&Z1$+))@NV22='.@HN=F@4GX1ZRK;]]N[OXAMO?I3Y!]4;10G?
M;N[^(;;WZ4^0?5&T1.^W=W\0VWOTI\@^J-HB=]N[OXAMO?I3Y!]4;1$[[=W?
MQ#;>_2GR#ZHVB)WV[N_B&V]^E/D'U1M$3OMW=_$-M[]*?(/JC:(G?;N[^(;;
MWZ4^0?5&T1.^W=W\0VWOTI\@^J-HB=]N[OXAMO?I3Y!]4;1$[[=W?Q#;>_2G
MR#ZHVB)WV[N_B&V]^E/D'U1M$3OMW=_$-M[]*?(/JC:(G?;N[^(;;WZ4^0?5
M&T1.^W=W\0VWOTI\@^J-HB=]N[OXAMO?I3Y!]4;1$[[=W?Q#;>_2GR#ZHVB)
MWV[N_B&V]^E/D'U1M$7YWV;NO:\ NWK@'M?^5-D'J_\ XC:(OWOMW=_$-M[]
M*?(/JC:(G?;N[^(;;WZ4^0?5&T1.^W=W\0VWOTI\@^J-HB=]F[OXA=O?I3Y!
M]4;1$[[=W?Q#;>_2GR#ZHVB)WV[N_B&V]^E/D'U1M$3OMW=_$-M[]*?(/JC:
M(G?;N[^(;;WZ4^0?5&T1.^W=W\0VWOTI\@^J-HB=]N[OXAMO?I3Y!]4;1$[[
M=W?Q#;>_2GR#ZHVB)WV[N_B&V]^E/D'U1M$3OMW=_$-M[]*?(/JC:(G?;N[^
M(;;WZ4^0?5&T1.^W=W\0VWOTI\@^J-HB=]N[OXAMO?I3Y!]4;1$[[=W?Q#;>
M_2GR#ZHVB)WV[N_B&V]^E/D'U1M$3OMW=_$-M[]*?(/JC:(G?;N[^(;;WZ4^
M0?5&T1.^W=W\0VWOTI\@^J-HB=]N[OXAMO?I3Y!]4;1$[[=W?Q#;>_2GR#ZH
MVB)WV[N_B&V]^E/D'U1M$3OMW=_$-M[]*?(/JC:(G?;N[^(;;WZ4^0?5&T1.
M^W=W\0VWOTI\@^J-HB=]N[OXAMO?I3Y!]4;1$[[=W?Q#;>_2GR#ZHVB)WV[N
M_B&V]^E/D'U1M$7#D+;NZ%@^ V!]OA2BS<\QB[I<@F,!>A/Q$"CM(*!A .(@
M F+Q'JXAQX@1=YM'%8VU+;&9PFFDN;;WA<5DDE3+I)K#C>M"HFDL=)N99,A^
M8I%3((F4* '%),1$@$47=CY][#$?/+NN_BOS9HI.IZSVJZNBA-$31$T1-$31
M$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1<*2]SG_ ,B=?0*:(H,V
MF^]8VT?J_P"&OJZKFB**NQ\^]AB/GEW7?Q7YLT4G4]9[5=710FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(N%)>YS_ .1.OH%-$4&;
M3?>L;:/U?\-?5U7-$45=CY][#$?/+NN_BOS9HI.IZSVJZNBA-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$31$T1-$7I7<MVQ2F<.$6Y3FY"&75(D4QQ 1 I1.8H&,( (\H#Q$ '
M1%[M$31$T1-$31$T1-$31$T1-$7"DO<Y_P#(G7T"FB*#-IOO6-M'ZO\ AKZN
MJYHBBKL?/O88CYY=UW\5^;-%)U/6>U75T4)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MBI%O#Q^[ND_MOE76&)O.E*I.3KA-7NEP2-1>.!C)7"V2JM"2"T?<[+5XEZ@U
MM<Y!\P%?JN6ICD>)-E.@$2E(T/'+U9W5+X6F[WJ))8WKS1"\TW&T(S?EE'C2
MR5Y]6Z52;;=,JRR$4]4<W:-10DL7TV4QW".S+5*X%:H0*9:=,,TF[I-^3+O?
M/I^;OE<K R>5LW[5YV=RY(SC.V96C9AU'1M:G'M;<P,<U@&-69$K4]#.8]ZW
MC;5+P4E>HM^BY15/&V]LB=0$42%*4>WV=^'M5;*A@?-L;?< .IBA6!2S5FB;
M/8]ODL9B"5BL<0^-X^1)N#HTHIW>[L"_N<>J$&8\-$RT?9%WK7ND^;MXI%QH
MHL-0.GIW;^KAJMNVBE-$31$T1-$31$T1<*2]SG_R)U] IHB@S:;[UC;1^K_A
MKZNJYHBBKL?/O88CYY=UW\5^;-%)U/6>U75T4)HB:(FB)HB:(FB)HB:(J0[J
M,IS-)R7@BGESW';>:C>8K+S^R7.00QIRNG]0;4(]=C4WN4(:9A6O-WP2[A1%
MJDD\> B' QDT3 4BJ;5NR09(3\'U7E<?U^UW*:I;8T@Q:2):_8)BY*8BD\NQ
MPMZ^^<M)%@G:86+(VC(F-@)EF@YEV"CRQ,715H)(G9N[[^^7&QD_NFG;M@>I
M95J,FQQC4\AYE9T6-RB[+%R3.O8X,^G&R&2A"S,5JZFWL[J$91T(M,LW$:D2
MSQRJR9U^CT16+VR9 L64<&X]O-J5;/)N=A2K.I9FV29,I\J2JJ#>Q,FB!2H-
MVDZ@DG)MT4"@BFDY*"0=&!0T13SHB:(FB)HB:(FB)HB:(FB)HB\3&*4IC&$"
ME*43&,(\ *4 XB(C^( #KX_BT1?I1 Q2F*/,40 2F#KX@(<0'C^/B'7HB_=$
M31$T1-$31$T1-$31$T1-$31$T14^WNY)RIBS#438,-R+",N\EEK$]506DHUC
M+M%X:R72-C; R.UD&[A(#O(A1VW272(5TW5.11LJFJ4IP)[._2M?]9WOY7R[
MEB;1)DYMAO;O?[/B$]%R!(U^G1\GCVE3- SR\F>Z\M;(EW$M)BZY3Q2WI*"]
MI(Z39HJMDH$K23DDE#E/[_9\VO;P5F\-[MJXVO\ >:=DW<30;A5HK&50FZ)8
M)\E0Q^_R"^=7K,$!./H9@H,6%F.JSJE?BNV8)NI!2CAL67A&B#2:3Z8H_;V]
M"Z7:%NZRG?E[Y!Y/QW?'TG)3,+D#$<='4^K5ETUP=?'TC'ULPQ[F>A22431V
M4=!N[/-'6<3G;5R:- CSE1;HI._#M3CWX#T^S)=];,X[AX/$^Z:Q)6>@#:L.
M;A5J?#O$Z4][F)XZ&D8GLZ,6RCUK J<;*0MS?E--S+F7:'>&45"*!D5JQ;$Z
M^_:ILIDKDN7W0WZ":98G+#C"B5I@ZLU3E*Q0&\?'VZYF65K-=@)V%JT=9U"P
M$1%2$O.A,3;YP8TK72 91!PN!2=[_-WX=*MMHB:(FB)HB:(FB+A27N<_^1.O
MH%-$4&;3?>L;:/U?\-?5U7-$45=CY][#$?/+NN_BOS9HI.IZSVJZNBA-$31$
MT1-$31$T1-$31%UTA#Q$N5(LM%QTF5 3BB608MGI414 H*"D#E)4$Q.!2@<2
M<.8"E W'@&B+I9BDUF;;OD7,4W;.7\<O&#+Q90BYYDW69+1Y58J;8@C)1;QJ
MU74(Q>L7*#ED(@=LHF8I>!%ZJ_0:?6*7#8\AX".;TV!B&4'%U]5NFY8-XR/2
M(DT;"BX*H50$BID'F4 QA4#I!,)^O1%E3=NW:((M6B"+9LW3(B@W;ID10123
M "D3223 I$TR% "E(0H%* <   T1>[1$T1-$31$T1-$31$T1-$31%U\M[ER8
M_C[GO.O_ /;J:@Z'J*+$,;6,+)5VJYS\SMB8\<\#B G!9L/(4QOR <G*8O$/
M:_+K'%() >+26G=U&W2$6?ZRHFB)HB:(FB)HB:(FB)HB:(FB)HB]*[=NY*4C
ME!%P0BA%2D72(J4JJ1N9-4I5"F %$S !B'  ,0P<2B Z(NJ<5FN.V:L>Z@(9
MPP7*D19FM&,E&JI$%%54"G0,B*9@157752 2_<U%E3DY3*'$2+P-5JP<6YCU
MV".9FBFW:&/$1YS-D$C&,DBW,9N(HI)F.8Q$TQ*0IC&,4 $PB)%VQ&C1)0BJ
M35NFJDW!JFJ1%,BB;4!((-B'*4#$;@*:8@B403 2$'EXE#@1>)F#$Y'"9V;4
MZ;M3IG29FZ)B.5N1-/I7!1()5E.C11)TB@&-R))EX\I"@!%[4T$$CK*I(I)J
M.#%.NHFF0AUSE*!"F6.4 ,H8I  I3'$P@4 * \ X:(O;HB:(FB)HB:(FB+A2
M7N<_^1.OH%-$4&;3?>L;:/U?\-?5U7-$45=CY][#$?/+NN_BOS9HI.IZSVJZ
MNBA-$31%XB<H&*43!S&YN4O$.(@7AS" >V(%X@ B'4 B #[8:(HKS58IVKX]
M?2E;D.Y,PM8J!!-I+M1F^.Q2M.0:O5WSE)I((.62RZ4?,.CMP=(*HE7!(YTS
M 40T1>DM$R&)2CX<+;UE ?\ S1QG^3]#]%&?$>K]JXDA4[K%,'LI)Y\LD?'1
MK-S(2#]Y5\7MV;%BS1.X=O';A6HD20;-D$SK+K*'(FFD0QSF*4HB'IC'2.:Q
MC2][W!C&M!+G.<0&M:!F220 !F2;*'.#&N>]S6L:"YSCD&M:+N))-@  23N5
M6:]NMP?:JA=KY!;W%WE5QT2%5MTDK1:HP4CT+([[GUMTSC)'&S26G6=C? +.
MO/(!C*-9QT MXI9VJ E#M2\FL=@J*:EEPZ9L]7S@@8'1.#S"W:F:Y[)'1QNA
M;Y4K97,=&W-X:%R8L>PF:&>HBKX70TVP9G;$H+1*[9B(:YH?()7#9C,;7"0Y
M,N5Y#NIPF6EU[(1M[#LM2M$[*UJ(D34&KE==VH%5%&?:2T,;&@3E>) G<M1G
M'M@C8MC#INFRTDY;).$5%'O;QSPF6D\7R\_#%'-(P/A(YN4$Q.9)SG-R\Z&N
MYIL3WNDL0QKB"I\>85S$=1X;$(I7OC:XLE!VX[<X'1[/.1\W<<X9&M#+C:(N
M%8J :SEI=3K.O;B++++UI\VC)KM2GXZ,@S?NXQE,(M@=&I16KI3N?(-%E>TU
MG!6YU1;.!2=)+()\F6":$1NEC+!,TOCVK N:U[HR[9OM-&TQP&T!<#:%VD$]
M&.9DID;'(UYB<&OL#9KG,:\"]['R7-)L3:]C8@@9-WAY#^/"V^:.,_\ )^L*
MRY\1ZOVIWAY#^/"V^:.,_P#)^B9\1ZC]*=X>0_CPMOFCC/\ R?HF?$>H_2G>
M)D/X\+;YHXS_ ,H?\_[M%/?OFOSO#R)\>%L\TL9_Y._[=%&?$>K]J=X>0^(?
M^/"V^:6,_P#=P[S^O_GVM$SXCU?M7[WB9#Z__'A;?-'&?_N_\$/^O1,^/L[<
M_7IZ$[P\A_'A;?-'&7^3]$SXCU'Z5@V04LE8^AF%D1RW/3A4[158US%2=5H*
M+-ZSF9YA%NTE%XVL,WJ0@@Z.8BC9RD<BA2CS<.("4Y[^RWSE64T1-$31$T1=
M?+>Y4G_=[W_#*:@Z'J/8BIU@JY$B\@R]2=*@5O/HF=,0,;@4'[/[X@<1 .=9
M >4I0#B(D'7(IZG8K7T[_P#:W+;G\9NZW$CLSZ/9'DW&ZWMUZ['O:RNKKL+P
MFB)HB:(FB)HB=?'^S\O_ /FB+\*8I@XE$#!UAQ*("'$!$!#B'5U" @/Y! 0]
MO1%7(J61;MD3(D;%Y6G*5#5-:O,X^+AJS191-0T@Q=.G+EP[LE<EWQE3G3(4
M"%<%1(4OBI@(F$2+(?!QE#RAKKYD8D_R/HHL>)]GT*$\XY#B=M]9;VS,F\*8
MI<8_?M8J(0D:GA\)6=DWCA-L@P@X@M*[H2SD5%B"HFR05Z!/BLL*:13&UT<-
MPK$,6F,&'TTE0]C7/D+&GFXF-!)?+);9C;ED7$7.0N5HU^(T6&1"6MJ6P,>X
M,9M$;;W$@!K& ;3SF+[(-@;G+,=!,YEKE?RLTPO+[MKRSO3MBU>BB;%E!-!L
MSOV#V3C8R1M">-CU^/FI*.CG[QA$N9%-ZY1:J"1+F%,I\L>"8E+0G$(Z?:I@
M\LN)(^==LN:QSV0[?.NC8][6OD:TM:7"YMFO#\4HHZMM$^=S:AP!MS;]@;37
M.:UTHCYMKW-8\M8YP<0TFVEYJJM?O=RKT3:('<5?'$--M2OHMRM0<3MS.V*A
MSE;/4TU:.!^UWJ12NFBA@#IVJR*Y0Y5 USIX9*>62"4 21.V7M!!V7#X321E
MM-/DN&YP(W+>CD;-&R6-Q+)!M,-K7:=" 1>Q&8OJ""LA\'&4/*&NOF1B3_(^
ML2]V/$^SZ$\'&4/*&NOF1B3_ "/HECQ/L^A/!QE#RAKKYD8D_P CZ)8\3[/H
M3P<90\H:Z^9&)/\ (^B6/$^SZ$\'&4/*&NOF1B3_ "/HECQ/L^A/!QE#RAKK
MYD8D_P CZ)8\3[/H3P<90\H:Z^9&)/\ (^B6/$^SZ$\'&4/*&NOF1B3_ "/H
MECQ/L^A>ESCW**#9=8-PMT,9%%14 -2,3<#"0AC !N%( > B  / 0'A[0A[>
MB'+.Y]GT++\0V.3N&)\86Z;435F;3CNE6.7512(@BK)S=:C)-^HD@D!4T4SN
MG2IB))E*1,H@0@ 4 #12,\U(FB+A27N<_P#D3KZ!31%!FTWWK&VC]7_#7U=5
MS1%%78^?>PQ'SR[KOXK\V:*3J>L]JNKHH74STW&5J#F;'-.BLH:OQ,C-RSPY
M3&(TC(IHL_?NC%(!CF*W:MUE3%(4QA H@4!'@&B*IVV'?1@K=Q/W>N8C6MBC
MZA0]4G)96QU\L.R>L+9W6;HC#N"/WH/5H69@)NN6!(Y4!CYZ*>LDQ<D2Z<2*
MKFXV&W"SV[K%>2:H\L$&CBZ*RL3$^,4),C6,RNPKC3'#[([FQLDUA9N%\@,I
MJ2J5)[JG,E7WM;KMI(DU6>ODCDONX]6@]N_=Z5L0RTU";QVDFY:J(BO:,7/E
M&BY@3505:9(I\B"2HIB< 405;@!BE,8ICDY>80'CKTUKG&S07',V )-F@N<;
M#/)H)/  G<EB<AK8V] OW&_07*E<.H"AQ#CPZ@'\? /]_5U<>'^W7E%@65JL
MRO>,<BT*09.I1E=:#<JJ\C&3T(QY),I^O/X=VQ:29DU"1SIVB_%L@],0_:JJ
MQ7'1G!(2ZVJ&=U-6T=2US6.IZJGG:]S=MK'12LD#G,RVVM+;EM_* MO6"JB$
M]+4P.:7-F@FB<UKMDN$D;F%H=GLD@V#K&QS7SX8$P5N2HDW=\NV;".2\B5;'
MF"<#8+K&-<FQF-:_?%V5"R#,SDI-4AK52,(&RR^)(AXREJ[9YXR4A8K +YT4
M[=$&J)/J>*8G@]3%34,>)45)-5XEBN)RUE')62TH=54K&,CJC.72PQUSPZ.6
M&,;$,.P-=HGYYAU!B=.^HJWT%54Q4]#AU!%353*6*H+:>H=(^2 0;,<DE(PA
M\4DGERREQN-%-6#]F2EMV_9A?9MQ9D-]87F<\Q7K",%:+%WLY8ME7RJY@6KM
MKE]S3Y1LC(PEEEVS,]JBW#MTW/4XMF1RFJJU32'G8ERB%/BN',PZOI&QMPO#
MZ;$9(8N>HH)J%LKFNH!4,)9+"QSA ]K6D3O<00'76]08*9L.K7UM)4/D=7UL
M]$R63FJJ6*K?&"VL,#VM<R9S&F5A)!B:T$$BRL=M;CMW>,,_3.)[=7Q\ T>Q
MN#XUG>PE<:0TM-.EJZ\K-DBK4U7"SSMHML@^MBMOB)1N2,AS-&*405)(P%-R
M,;DP&LPN.N@E'C1[J=HA$DQD8P"9LT,D#AS$<,#6P"!\9+Y-IVV25TL*;C%-
MB#J.6,^+V-F<9#'&&N<3&8Y62@\[)+*YTQF8X;++-V,EM046Y"AP%(5!,4H%
M,H4@#XQ04X"/'B) $P\H!Q$0 .KCJE*U+W_\A_;HB]*G.7G5+Q,8J74B)@*0
MQB\PAQ,(#RB81 !-U@ %#J]OB1=;&+J.D'7;2R+@@KK F*9>"?:O$2D*8P@!
M3CR@/.<!$IAXF+P*( !%S&L>Q9E(5HV10(F94Z8)%  *9P(&6,7_ /-$ $WY
M1#CHB]I6K<IB'*BF!DPY2& H<2EXB/ !_$'$QA_VCHB]ATR*<H'*!N4P'+Q_
M$8./ P?VAQ'_ 'Z(O/1%!^X/\'[?]-L?_OA#Z(IPT1-$31$T1=?+>Y4G_=[W
M_#*:@Z'J/8BU$6^T.J9<8FSLSG(K"2S=]XOWQD4UR@X3 /\ [1 RA> CPXF#
MVAU3L1F=3U;)FY&-X=<<!<N WYB^?SK:B&TP@G(Y:7M;Z,CGNW+;A S+.PPD
M5.L%"JLY9@V?MSD'F(*;A$JO#F#B'B"82#U^V40U;HI&S1QRL-VR-:X'H(NM
M8BQ(X$A=OK(H31$T1-$5/=SV^+!FTE[68G*KBTKS=N1*Y@X6I019V2=-S22<
M4"_0J/H\H)@\4Y3<%#&(0AU#% I>(D4IY$L]KL^'VLQAEJK*3.1(ROI5:5-R
MMTH.)N+=!4MN?@JJ15-O$13L7XD2YW";CH *D?E,71%4_L<L!DS'^,7-&M4U
M9;_23S>19^G9 LD@$G+H/VV6+E 6.K3+E50'!C*KLVMAA^C1,D!7<V0ZQ")M
M$"D5LL=_A-S9Q_.E1]KVO<A[_P _[]$4VZ(J0]D(PG8L\[9;E2*56&%FO"[Z
MMNZX@Z(T(X;G96".=O%FCQV']$5*S16$QTSD,<H"3B(&X:L7);$(<-QB"HJ)
MG0TX9,V4M+K':B<UH<UOPAM$:[UP^45#+B&%ST\$39)RZ,QAP%QLR-<2TG0V
M!]'398EN6VAUS)5AKUSJ5#9AE26:(1L[>UGKA%A%QM<@I$[,SN/3<D;KSD@9
M=:MQ,T5L=]%(RKA1-8B0G*;9P?'IJ.&:GGJG&B8XOBI=D%TCYI6;6R\MVA&V
MPFDCV@UY8VXO98L2P>.IECGA@;X6]H8^H<?)8R.-^R2VX!>ZYB:\ N8'DZ76
M0[%FNZIA3K8PW.$7169/J\TIC:01JJ$@UZ"*52MK=DG48Z,CDZ8C*$:)TE-R
M@>33BRJ$?*F.!>&'E*[!'5$#L&L0YLKJAS3.6NN\&!S^?>]WA!9M&H+2&&3X
M(MFLF!#%6PRMQ3(M=&(0X0AS;,(E#>98QG,AP', C;#,G$D*]6JTNZG_ #_U
M_P#P_P#>&B)HB:(FB)HB:(FB+B/_ .HO?DCGZ$^B@Z'J/8HIV\?@ P;\SV,_
MW+A-$&@ZAV*8=%*X4E[G/_D3KZ!31%!FTWWK&VC]7_#7U=5S1%%78^?>PQ'S
MR[KOXK\V:*3J>L]JNKHH5>=URF3T]OF238;[;\(O<Z))!]HMZH[7%JI9(9.Q
M +>\,Y"J*-QK!ID'O=EFL@5F*YTN1T5!0A%JX[#@HBNYS0LU3K)6!(>F-8LT
M!$XCB^=FVN&4RR/)X-(*%=.V'?4-DZ-U*"[8+28RIXQ45#/C&*3:]Q?/>3T<
M/9Z%LSR3[YG;5^BN>OH,7Z+P3FT<;W]2@WLG,F]C]L\6T:V&9K#2Q;@MM%4G
MY6 E'<+*IUFR9PI,98$FLHQ,1XQ.K&.%P!RV.19$0!1(Q3D*.K/R2V6XI/*8
MXI74^$8U4QMF8V2/G8,,J9(RYC@6O&T!=I%B"0N)RA+_  "*-DTL'/XCAE.]
M\+S')S4]=!%*UKVY@N8YPRSSR5:I? >V>(8R#EYFS<<H\9QG;**#'<-DE4Q5
M>B0.L1N"SK^E/$S+I K'@H0Y2@4 ,!@5-J??;7^98+\DTO5^3ZUC][E$!^%8
MII^<JG.V^VW]*PH,?;48PYV<]G+<FE+%*HDBV0W#7]-FZE$2BB[ADW2LF<>V
MFSOGZBF'G1124562Z0XE>^RO\QP7Y)I.C_A]/<)[W*&X_P!*Q2_]I5.Z_P#Q
M][66 OT-H3=R_$<S;ES-VR;H$C.MP]_1367*G%'"/(F#LRW3II/%S/ !98@&
M0<B50R;44%7OMK_,L%^2:7HS'D]>Y/>[1>=XKO'\95.NA'PM3>]M_4L#4)MO
M[FIR+S-&?F,HB20*HR+N+N\B[0; 4KEGW/7)+(MWKV4:B4A"*"V9HN&P]*F(
M (*R.5F('(4."DG=XII3V-W>I2.3E&76%3BUQG_&5423G?+:SO8WL-W!8ODE
MKAR3Q/E:WXVS!N-83U)QQ<)N /)Y_N<VW>3L3 2SI!\! >$*DR1?MFQD$E4#
M]MG;=&N":2P\V]A7*6JJ<3PVEEH,&,-37T<$S6X52M+HY:B.-XN&^22QQ <-
M#8C-:.(8%34^'UT\57B@D@HZF>,NQ&H($D4#GL)876(N!<'+(C?GNBVTY,<7
M_"N*WDA*/7\F\I=6>33E/M9T\DWBD)&NC I*$446-(+.2+KK&Z-$ZHJ%(J)"
MF,(5C%F-CQ2OCC:&1LJYVM8T6:UHD(: -P %@%8<.>Z2@HY'DN<^FA<YQ-R7
M.C:23QN223K?.QNK?-#F,GV^L9NJ8_2I]*V,J5-./3464;F,10R@J.2$,4C@
M4^!3*"8Q  A2EUSUNKG"/3I\Q3"F(F4*7@<OW3@50A> ]8<#<>< X"(<.(AU
M:(O6V1*V:-FRPF.84RMS"?QS*&Z,>;I#)E*7QBE-Q-RE*(_D$P )%S@    #
MJ .H _L#1$T1>/ W.)N<>3E  3X!P P"(B?FX<W$0$ X<> <.(!Q$=$7EHB@
M_<'^#]O^FV/_ -\(?1%.&B)HB:(FB+KY;W*D_P"[WO\ AE-0=#U'L1:7,T??
M//\ 4?\ X@U1\:^_N&ZQR_O+:@)L[/?VZ^M7-V)9.[\,9O*>]<]++4)^9B5,
MQ@Z0T,[^[QYBEX<131$QD.<1#B<!#KX=?2Y+UWA-&^G<?+I'[ XF-Q):?1F.
MM14Q[+PX:. /IM]"O-JSK631$T1-$7SN]DZ=9&)N+IR-F3BSTUR5E'8M[XH'
M L@!G;H &QI0KBZUB3M*2)S%3[<6<O",TS@'0*)'XZ*<K:'T?/D?F6_>AE M
M&IA0! H%JE=*!6H,P;  1#, !N$<4D>" !U) Q(1F"?+VL4J'( %"A/:'^ >
M _3/,OUTY"T14<IFW>N[B=T^])_>;]FB)"G9!H,# L*%E2STF*;1SBD$?*)J
M1\*X1;KJ]L"=0JRA1.7G.4!X&X:O<^)OP?!N3_@E'AKG5=+4RSR5-#!422/;
M4; )?(TFP&5M%4(:!F*8IC)J:JN:VFJ8(XHX*R:"-C70!SALL(&9SO\ /FI_
M_P"YTX?^-'=#Z1&0/Y[7,]]E?YE@OR32?56_[W*/SO%OE*I^LG_<Z</_ !H[
MH?2(R!_/:>^RO\RP7Y)I/JJ/>W1^=XK\I5/UEZQ['5B HF.;*>Z'HP((\!W#
MW\ *(=8CSB^ >L/Q"( 'XO['OLK_ #+!?DFE^JI][='?\*Q7Y2J?KWU7XGV.
MW#JA"*AE#=$4#EXEYMQ%_P"/*/6 ]4@(<!#@8! 1XAP'3WV5_F6"_)-)]5/>
MW1^=XK;AXRJ?K+"]M-,-A?>IGW#D)>LD62@,,"X:O+&.R+>9B[+1]CG[9D2+
ME';1_-K++MDW#*'8)"@0Q4@%(3 ',<VMG&*@8AR=PO$):>CAJGXIB-,]U)31
MTS70PP4;V-<V( $M=(XW.>? "VOA</@6.XA0QSU,M.W#Z*H#:FH?4%LLLU2Q
MQ:Z0EP!;&T6Z+[\]F BH)S%Y"]%R=1^?QA,(\!+R\.H.7VC<?;_%JG*T+\$#
M)) 5$G.)"E(0@GY>HH 4.)A ?: /R"(Z(O;HB:(FB)HB:(N(_P#ZB]^2.?H3
MZ*#H>H]BBG;Q^ #!OS/8S_<N$T0:#J'8IAT4KA27N<_^1.OH%-$4&;3?>L;:
M/U?\-?5U7-$45=CY][#$?/+NN_BOS9HI.IZSVJZNBA51WO9?#!FV')=^-7(V
MTE4&G4$\9/2+B'J[9/+E]J^*%+!<9AH4SJ'I-5)=#6>Y2J'*K'5B(E795412
MZ8A/VGU"_P"[B<E0CL:^-<+X3W'[F\58BLXY/B(G'&$['7LCQV16V0H2-J%K
MFLIRIL9NUHT58R(GZ_>U;O8 33<K/).N6B!>/2(+!Q7)P]-N.[V9<=RV%Y(]
M\QMI_17/7T&+]%Y/PF^GL53^S#S/>[LP=6#H>V.X6<MN4SVN(\H+]S,S4]Z*
M',(#PZ4$>3CPZN;C^+5FY*"]?6_V#R@_^HJ['ISM^W1<3E!^"4G1C&"G6W_:
M=,OFZ?Y;M#Q55SW7E(U1B[D%45'+Q=9PE'RA#H%:F.J85'7:X*CTRAP%50IP
M4X\Q0X<B/#YY70M9S<AJ [FPQX.@=8NR 8W::6W=87!&Y7&FP>KJI:6.$1R/
MJQ)S#6R"_DL?9SMJS8V<XS8+W$-N'#KB.9R#8)-V9\X?/G+D3NE XK&#E5=B
M<7*A.L (=85%2&-P PD#K'[WA=J+D0)1:HJ6C4MDCOY0<7-:"VY%V@!YV3:[
MF@W -_KO)_W'I<4#FU%4P6VW">(FQ:XO8PNC+C]Z:&2.<PZO:P@@.+L86LDP
M[3Z%)1TX5 _(F!#+& #K'+PY.(@'.?G$O'J$2B?KZN&K90>YS1S2Q!D$TX<Y
MK=DNVPY^S(/*(%FM+O*(O8[#1IM+LXWR.]S#D5!/58[C<<3J" ULC:^9K(IX
MXX)W/(C=]V+&-D9.]L8S,+6"VT0[CJRLH@DB+E%R51=,P%)T8F P)F$H=0&X
ME,3@/'@41Y0$>L '73F]S*(%S&TSF6>9 0\!T7DM#PX6NYNR07--[;66BJ5!
MCWN#XQ!514>/<W64U2"UL6<39YXHGPQ,F?L">.=CFA@>6M;(\-R=8'G3N092
M-QW=XA!5<J3VE6=L %76;@GV]#.BNA633$".A5Z-(@D6 2I]"F)2]9A&ILY%
MR4F+T50QP88,6HWF, ECFLKH[M;<W9L, =F3?RAJW/3Y=>YFV#DIC>.X=5QS
M4[L&K<1@YGRX)*::"HDB;&^X,)%.&3 2$[0) )LW:WK=C3R58+;6\;55F@Y0
M8EJ;-M N$7JB,=#.J_VN]E>D(94KER1S%.8YGVX\,JHJOT2"1@:%73'YWC7\
M<8G_ %ZI_P#E=Z/5DOC^%_Q;0[_]$@]/W-JWR1AG[MP@DA),8^/5:E/VHRYC
M+.UC*"+U<78G$2KDZ!)$J0)$Z(JKGI .H!1+RUOKJ32#FP%:L44E(\6RR;D@
M"KQ:(OF:A'+,C9Z0Q55FKLS91!XJ!4TC(+<" 8[CJ(I"@7 O&C=R)")<ZSD3
MG!0 3<+*&YQ.@!#"0P',50PD'QB<!#AQ PZ6MHB[\5><!*@8AE X#P'F$O+S
M\AAXAU<0X&X!QZA#K#AHBABY9I9U6\1E$:5][/2;U@QDG"K20C&B;1K(/5V+
M< *_<H'<K<[=14R38%3]%P'E 1#C4\5Y5PX;C$&"LH9ZRJF@AJ'&*:GB;$R>
M9T,8(GD8Z1Q+'.+8PYP;8VS"UY*@,D$8:7.(!R(&1)  N1<Y7L+Y=*ZUGN&J
M[RQV"M%BY1-[#*.VK03&;&-+2#*1)$KL4VR9S.6:@OSE(@=TF4KA %'28"DD
M?AKQ<ML.EKZ[#_!ZALM(Z2.,GFR:J:&<4TD38PXR1.YX@,,C0'LVI&^2TJ!5
M,+W,V77;< _E%KMDBVHSXCI&A4^)F,=),YR"D<Z93'3$0,*9C% 3$$P=0B01
M$O$.H1#B&KFTDM!(V20"6G4$C,'JT6R,P-W1P4)[@_P?M_TVQ_\ OA#ZE%.&
MB)HB:(FB+KY;W*D_[O>_X934'0]1[$6ES-'WSS_4?_B#5'QK\(=U'_J6S!H[
MK'8HDV@Y;+C'<?"QS]T"$#?BGJTCTAN5$CM8QEHE=4P]0=&Z R90]LQERE]O
MVJY@&("AQR*,DB*KVX7W/XQ(,9M<#(W&0X<0MN>+;A<0/*9Y7HL+C+K7T':^
MN+EIHB:(FB+Y\>R,/\5YJR7EPE\F87'MCVC5VF2-08O<HDHULS,WLCLT_+P$
M;#.!*H^AA(V,TB7D0@[?.)I8C4XE2-T8D[]G?]ZWHXJ4C%L7XW5A(IY PRM"
MIZD1!R)CGD(:,/7HXS"*?'4 %#/(YJ*3-T8X <RZ)Q, "(Z(HEVA_@'@/TSS
M+]=.0M$4.;4_?+;^_G:QU]7J6K5CHM@_);IP^J/_ +I5_"?XSY0_URF_56E7
MZU558%US]Z1J")!6*BHLNDF0QR@<@F.(B5)0H&Z0.GY13()"B;F$.'#VP(L6
M=W>)6;N21;@CERB=1%4ADU2BB8@&$YS)&2'I2%(4QA\8I2\/'$!ZM$7-:RCQ
MPV,IS1KHCL50BR-@4Y0;D 3)*NC%54 "'2*!RBD <1,4I0+QX:(J1T%8B_9(
M=P*W/S$':K@$#D!(2 N<;UE@O*F1<"J%\<0$@=0B/ HB.K35?R/PG^V\5_5:
M'OZ%7:?^5&(\/%&'>OPFL^9; >D(W0(8YE1*4"AQ4YE%1$P\  _ !,)N(\!'
M\7XQX!QU5E8E[%#% @F.(%()1 1,8"!P,'5Q$>  (CP /R<=$7H(<4TTDBH]
M&)003*F*A0*!>4.8J1QXBJ") 'CXH"8"]7#K$"+R.N "D)!Y@,MT1B@7QS<0
M$HB4#"7Q4AX**&#FX)$.( .B+S<KE;-UW!P,8B"*JYP+[8E2()S '_K" #P#
M\8Z\O>(V/><PQKGD#6S02;>I"; GAFJ:L-X$62/>3L_6B1T&^J-ON-1%I,MW
MTG),Z?)IQCIA,LBIE&%D'ZBR2S,JHF*"8*D. G3-KY5%[J-,V":LK</YBDEP
MO%,5PLQ5<<U14Q854-IY(*J #:HYYG/:Z)K[@#::[RFD#0%<VQ>YEF%CWQV<
M"X\V[9<US?Q7$D$"^E[YA=L3<Q)A35K$>IQ*[PEH:UX31EC"1@FR;F$>3G;4
MB];,E'3(Y 9&BB)J-03<2;IH"*ID50,.R/= J!A3JYV&TSI1B4=">8K_  BC
MC;)22UG.5$T<)DA($)I6@QELE3+#L.+'Y2*L\WMEC2=L,\E]VB[2^[B ;6 +
M<]7V&ANIIJ%_2OD5(/F[!2-:#!QRZ:+U4I9'ND\B@?S# [7J,!8,[QG&.EP*
M =U"2#0P$.S, W+!<:9C+#,R%U/&8*1[63. GY^6 354)CUM1NEBIY'@6\);
M/$0#$0MADG.-) V1L--CDX.+;N:1_P -P#;\:XW+K]O'X ,&_,]C/]RX37<6
M4:#J'8IAT4KA27N<_P#D3KZ!31%!FTWWK&VC]7_#7U=5S1%%78^?>PQ'SR[K
MOXK\V:*3J>L]JNKHH6*7IDA(TNV,G->86U%>NS(#5Y1FA(1]@4*P740B';)S
M]P<H/UB$;'25$I3=('C%^^ FF?8J&]COS9B[*]0M$3CS;@3;S*U8L ?(L/%H
MT U=<7>31?)R\7&R-)L4XN_4A%V"I14FDV2P,W;(R!#=(L5(AZ3<_3G?CZU8
M/)/OF=M7Z*YZ^@Q?HO)^$WT]BJ1V9%H=_LGDF1$ =*.\V;>&J;7CR]LJ.,QU
M%%-OS"( 7IA."8F$0X<WMAJS<E+^'UMOS#R@UOE_JBKX9CK"XO*#\$I/[9P7
M_P"TI=^[K^=?,O;:PX3276;(K*)-&@G=],4XNFIRJ%251<<J92+'%P=10JI"
MBF1L#8QE?&*0='":QM+4Q;;6R 5$5AI=NTX&SLCLAQ:XC1S#(TVV[J_<G<3&
M&U].YX9*&UE/:X.R1MO#B'Y.,>T6%S!DZ(RLU?=08JBN +D.) $#''[X>(FY
MAZC<HAU&\8!#C[8]?7K[E05--*R&6 .YI[8]@.C  :6 @LU]!X-N+C-?M'!*
MJ@Q;"A/AQE@CDI8'4\-O!X"Z*D+A$TL?<Q3,-RT_#L"2=FZD;'3([M H."%'
MF?=(DL @?@*"?1FX!P\4Q#$*("'5UE'@(:V_=*Y2S\AO<\QOE5ALS(I,.BCE
MI*<%L9KJO*&6!S9 1*PLJ&3.C%G!L4I!! 7\=?X77*/'Z[E[@?)]V,U<=?/1
M5>%8S3RS2;=+A=;4LKJ26%[2(IPV*/P2.5K#M,?(9'-&PU2U)UUF9HHH(% 4
MFZAQ$Y2"0!*43@8XF 1*4#<.80$!X<W6(<=?B?W-/X47+!F/X7ATL,>)1XWC
MT5(SPN9\CJ>GK:R.*6FAH6OC8V>2-CY&R7MMR0L!+6[*_-51R;Q/!3!B.$XU
MBL%3AK'5,E+3RR2QXA(1&0Q^WSCGASMF)H8"]MB66<T$5;O$&^?1UAA(5)>0
MD'D++M635$"G7=.',4[2!!(I1X&,<XAR]?4!P 1ZNK]T<IJS"<)J'8EB$[*/
M#H705E7--(1#2L;4QRB1T@'XHV2YELB7-&B_L)[E?*7&N5W\&#$\3Y5P4]+5
M3<GJYM((R89ZV!N'N@HN?BF^Z1R";8:TFQGYL$?"(&UK84 5-A61L$>O$2I8
M2#AW;J3FEF39@T,V6;SAFY"$= 14[0HINTTR=&9-WU&**20E_(F,<N.24N*8
MA+%CE&^*2LJ'1O:)K/:9'%K@.;OF,U\4H:B".CI6%[6EE-"TBQ!NV-HS&8!O
M>^=O65OVJ>8L<MXUDPDL@Q2+Q./>G5.W;B+,[XYQ!9$RR38H%Z5$XHH'3)S@
M*BBP"4PE .;[].2VOCJEW[IN@Y_<N^:VO"J?^>9QRN.-CZLM]]R[=EF/&LD@
MQ825[BV?%FDBN^52<I.%$4VJG3LP4;H%42Z,78"B<A3&,HFN B4A2#I[\^2_
MYYI-+_[:][_HOV]&:GPJG.7/,TX[CV%9BUS/@I!O&LDKO&NF\:Z'M)ZX/(*&
M:F(L(KB9;H YBF,@4A!$H@*8^W[8"]^G);\\TOJF^R_?N0U4'\\SUZ6UZ.J_
M7GHLC;[@,7BX/T]XKZ;8#E(ET /%!. =(8ZJG%L HE,'(  /-UAQ#[[3WZ<E
MOSS2^J;[)/"J?7G6Y=?T=BBJ\X]7SD\&Q49]C]_79<D/'&M96;D;/7%J[,$=
M.S0T@B9$55E.A,V(DX(4&AU%1#F*/ :KC6".Y8S&NP>HP6HH*IM) <3,,GC*
M@DH*L22^"S,+2YSMDL#9 .;<XY%N2PR1"I.W$Z,M=L@R6.VS8=<[)Z1E8Z7)
MO:P4FY Q"ZLI')J\M&P4B2'1,WF44.AD)*P$72(9Q).FX$<=%W,27:)K)GZ4
MBDD[6X\Y4Q#OXWR8DQ!LIH9(**H%*W8JF,V:B>M#V@R5$K U^SX.U\3'M.VU
MU1*_(@+/)"7 [)#7;.3L[E^6;K9Z7 (-QM$ZV6;XJK%BJ%-90EGE@EY-%T^7
MZ4JSARFS:.7)UFD:DZ=F.Z<I,$3%;D77,*BA2<QAZ]=;DYAU=A>%0TF(57A5
M0R29^V'22-BCDD+HJ=DDI=(]L#+1M>\ES@+E>H6.9&&O=M.N3OR!-PT$W) T
MN5BNX/\ !^W_ $VQ_P#OA#Z[JRJ<-$31$T1-$77RWN5)_P!WO?\ #*:@Z'J/
M8BTN9H^^>?ZC_P#$&J/C7X0[J/\ U+9@T=UCL6KS)$F\AI1K,,%3(/XI^VD&
M2Q!$IDG3)<CANH AP'B15(A@Z_Q<-?,L0D?%,)6&TD<A>TB]PYK@X9Z6N+D#
M+T%=>-NTUP=H;#ISL!Z#O7T_;9LL,\UX.Q]D)JL55S*P35O,%*<#G0FXXA6<
MFDM[?*L*Z0KF*/M L77W'!,09BF&4E8TW,D31(+@D2-&R\'@21M=17#F9S<K
MV;FN('4IXUU5C31$T1:R]Z>5,58<S!AF8R?M?ALPQUB;2#2-R DQQ\K:*Q:F
M;YN$'$-0NL]!#((NRJG6329"[6:G)TI"%X\HD&_UZZ]]RV21+PLA%1C\K1=@
M5]'LGA6#DJ9'+(KELFL#1P1$ZB)%VP'Z%4J2ATRJ$,!#F* &$BKQM#_ / ?I
MGF7ZZ<A:(H<VI^^6W]_.UCKZO4O^?]FK3CE_$_):_F%7;J\+/?J5>PC^,^4/
M]=IOU9O<*];]844OOEPZ0!3*5NGSJ@8>OI -U 0$R\3&$QBAP ?;'JU5E85!
M5_N3A1@]CX9BY8%8'66<RZXB1!!L*:ABODT2"<[Q %^D$2<Q3%'E$@% 2*%(
MJDOLP/EK>$1")!)DD"-H0LDHW=G7$\@0AQ.T*B=5$\>5!1(';LZJ+IF)G1E0
M%1P!16O?33?IIWTZ^E&M)OI< FY-K@7.6N9X9>H*YM&8HM89 >"[<RK=6/22
M,4 3,Z67<?T],JBRCANU3$5$TCB($% 2 8@="!M$50(6Q0V/NR#9CE[O)!%0
MTSM?P;%L)V6%86\C*Q-VR<L_;H+$(J91=+MMLL!>!>"2I# /'@&MC&.57)W#
M.3N%X978M2TV(,Q/$*M](\O,[*::"DCBF<UK'6CD?%(UKB<W,<-RKS/N7*.N
MFD\B.3"Z&-CCHY[*BJ+@"+_!#FG,9;72K;FSOAI#M9N2\,$D2N3]%VF=\*0%
M HJB+KBW W1J'$Q.3QP$PE]H!ZJ?[].2WYYI?5-]DNSX53_SK?;]"X1L]XA1
M;/N6Y1R:W4AP,=\\**!5%C)KH\K<H\W(H90P ',F?E(83<@<7OTY+?GFE]4W
MV5O2GA5.?]JWUGOO[V7BTSYBGM))-_?8YRHD9NHF86CCI1(@1,!YN*'6NN8A
MCJ&X@)!5Y2CQ#3WZ<EOSU2^J;[+OU)X73_SK>^GKW+N&V></ 5+A?(=))$BA
M"(J Z.8/&#D4%06@G)RD Q (!A 2J  \1*&GOTY+?GFE]4WV2>%4_P#.M]OT
M+FESKB!V8C1*_P 'TKLY6J)3"Y+S*KB"29 %5L4G$YS 4.<0*(B ".I'+'DQ
M(6Q-QJDVY2(V7YP7>_R6@%T8;<DV )S.2D55.382MN>L=H4)&VB14J]MKFQ3
M;%8LS7[7 0YX:#;13AGWUOT7SB6E!3$R3^19@U;MVX%(FW,3ISJ)BHL8VJB[
MW,*6JEQ.2OJXGBKH<3H:4TE)'2OB\9SLF?55&SY,U1#S4;(P&B.VVXMVWDK7
M\!#C)MN!#VR-:6M#2#(;EQXN%A8Y;[J4<?8?D:<A?Y*1FHF6M-Z)#E46;P:#
M"OL#5R*6BX51&'2#DZ3BN=R^4^^64Y *(%3)PL6!\EY\*;C51/5T]5B&,BD#
MG,HV04,)H*9U/2%E(RS2[RS),[(N(:!DQH&:& Q"1Q<'/DV;^39@V&[++-&G
M3Q70L\ )P%Y979C9G8L(F/,H>/43$7SQZ2NRL.Z37? < &-DW,DM8)!J*?%>
M<#MGB &$-8*7D6*/'J/%X<0EYBE:'&!S?NTLO@=12RM?,#8T]3)4.KIXRV[J
MP<YM6-AY\&V9.<#SDW,;W.V7--S^2XN+R-[\UG&WC\ &#?F>QG^Y<)J]+:&@
MZAV*8=%*X4E[G/\ Y$Z^@4T109M-]ZQMH_5_PU]75<T115V/GWL,1\\NZ[^*
M_-FBDZGK/:KJZ*%A>1BQIL>WPLR:4)#C3+265-"',G,EC30;[MXT0H0Z9R29
M6HJBP.10ABN^B$IRB & BTF=AB;0TJ^RI<8YVQ60'&6%*96BQCK%S-1:AUYS
MD%]69"Y5W'*AG(9$>=W'@66P6A,DC(@DS9$,88Q<I2D]5MPUSZ[]^P;3<D^^
M9VU?HKGKZ#%^B\'X3?3V*J79A'";39DY=*\_1-LZ;<7"G1$!13D0S/3U3]&F
M/4<_*0>0@]1C< 'V]6;DH+XA6_V#R@OU>)ZQ<7E!^"4G]L8*?5B=-ZO:M$61
MBQ+T'DI 1$P6.90D; NB W!T;ND98S9_(2@)(I'>$=*O$630W,!3&=LSF#[D
MW*6M VS!L001QZP=UEV@XBQ!((-@ZY!N+9]!.=KZ'K5)[4R24>+O$R]&)Q Y
MTT$P2Y15*"I^5N7Q42 *ARE2-XR8<$S")B\1^@\CL7?3O\63.&S(2^,RN:&-
M<W9 C:\FX)NW9L2&W.ZX7W3W).5DN'5;,#JY&<Q/,)V&J?&V!KX]AC8F3.)+
M7;+X^;M<,S;LV+@N9CQTFQ=G3.\'H3&!8K<X\  3\I3<YPX\.4#I'!/@'W@F
M'[TPZMWNF<E,4Y=>YWC.'X2'18I2-;+3211<[*^&';?504K'NYOPBH8]T;7.
M:3L23$9L"_*_\.[DGAF#<H>37*>EP^GJ9ZEE0[&JR:1KIH:.-IGH&,:P-=&8
MIHIS*]K@^.GC8'-+*B-IF*Q3Z<;#*.N)3@HF82IB8@&43XE(?[_B4!X''@'
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MK JIY,,VL;9KW"6@W!(PSI-^@^563[49$.+DS61226 KAX_6 O0)\ACI )1
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MEIF.;-0EKFP1M<TFM@%VEK00>D%:U6UH@=9K0=IF=@/QV[U9'5Z6VFB+B/\
M^HO?DCGZ$^B@Z'J/8HIV\?@ P;\SV,_W+A-$&@ZAV*8=%*X4E[G/_D3KZ!31
M%!FTWWK&VC]7_#7U=5S1%%78^?>PQ'SR[KOXK\V:*3J>L]JNKHH6&Y#9(2E
MO48Z!/M:0I]G8N 7<%:(B@[A'K=;I71P$C9(4U3<ZYP$J).*I@$"B&B+2AV'
M=T:N73.>* =0<JSIU PX\B9:KSE&M<.,6[E,E0C>,=V.F5F!.M/L0KW3R+*9
M7?.B-7L>]3,3MY4QRDBV^XW9'KWWX[M.A;1\D^^9VU?HKGKZ#%^B\'X3?3V*
ML79;>7V)+43\.C]D'MDYP,052\OAPI?-S)@4XJ!P]LA2F,;[T"CQX:LW)7\/
MKO[!Q_\ ^IJEP^43BVBIG#48O@O#\YTO'O?H6INX)L':+=%1HSE&I>*Y;# .
MBL59:/91,<=PT1AA*>.3>ID7(Z:J.C*'.X8BL4I!:JG+65V^/'HTS.F[.XUU
MOQM94'N]9;*N[$\AE!4;@1<$^4Z!DE&S$C(CETV-Q!11+MD3"D?Q>8"&* <3
M\-;5'((ZJFD<01'40O+7$AKFM>'.NX7M>UL@3Y5]RW\-F;!B%%,ZSFP5M+,8
MGEPCD9'*U[P7 $M#M@,) =<.T(;95W,5S".@,@B<5.9,%PZ,$S (#S '*?JX
M]1B /$"G >OAQXA^DN2W**(QR SMD@FA,,K0\O=L2,V7N839P<-HG.Q#;[R5
M]O\ =)]S?D_[O_(MV%N,#L4BAGBBE;5OO,Z6C$>Q-(XMJ&<\TS1;;1SD;F4]
M@ %VZLF[M0,(Y-LIRJ+)D(EP454%10PEXE A3&#DZ3AR%*;FY0$ 'CPU[QC%
ML/P2BKF8?'3PF=IJ)W#9C?53,#W EK3D)"T;6R22;DDN<5\:]PW^#7R3]P%U
M1RNQBMFQ'E)AE'6-PC#JLQNI[30>27AYYPR1NBF9(]H%WO);M;+"KCT'#$Q7
M:^[G'L(HY(C#2RZAU %N:'*#!9)1PX:N 17(L=4444S)B?B00!5(@J !?R-[
MHE;)B&!XY5S$E\K&.+;DM:#5P[+&$Y[(%O;9:'*K%JC&I,3Q*K+C)4B>0M+B
M]D37.+F1,OGLL!L+C7356?V]-@K]9K5B7>HR[Q"+C8]V*J+9D5Z6*B5'J)R
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MNX9B@Q2L$))*NECG.V6K4:5)BO'$=1X'3?\ ;S4I7#5$J\L+=15,_.*J8LP
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MU=UMKB#"5!A*CBJP7.>K3"1A;AFVPREM65L\5%,TY6PMK7%Q"XQJ:RIVE89
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MU>-JI7F[ML[!8';9TC$,TUT'0.%%EP<(JE.FL"ZJJW2%-TBAS\QA*%">T/\
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M0$@\Q'!ENE.)P S=4%4BB<I"F'<Y'1,/NI\H72QF8/Y)\G71EQ+A#M8CBMP
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M-:KPLEI%RR&#B1:.)CG[KKM18-^UUI3I2)*=T54N0[[I$TS]LF5YR$-Q*!%
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M H\ -Q(8@E.'^D7Q^;AU>,4H\>K@)%PEW*3)N/,4A%4DES-T!$RASI-N'$2
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M=^_!62C6ZZ9U'"P$!-1!L1O_ -*1<$RI =0KA$P B0Y5C*<!2#B8O#GX" %
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MK87/K*DLB9$^;D(4G,83FY2@7F./#B8> !Q,/ .(CUCPZ]<VY.IO;(=7!=T
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M+Q*%P(O*6-YNIS%\B+W4I.E5X98)VUL)Z-=5^'&!3%6:"2ED7!F3,8I,!4D
M76)VH0.9;D#KT1=M5KG4;Q6X.XTZS05HJEF9)25=LD#*,I2$G&"X"9%Y%23-
M95H_;*E 136;*J$, "("/#1%U4)E'&]EF2UVO7NIS<\:,5F2P\5/1KZ1-$H2
M2T,O) T;.%%A9)2S=>-4< 3HB/D5&QC L0Q (LFDIV%AV+V3EI:-C8Z.9KR#
M]\]>MVS5FP:D,HY>.5U5"IHM4"$,=9=0Q4TRE,)C  #HBZ6NY HUN/*)U:WU
MRPGA'#-I,%AYAA(#&.I!HF_8-WW:RZG:RSQBJD[;)J\IEFZA%4P,0P")%E15
MT3G,D19(RI0$3)E4(90H / 1$@")@X#U#Q#J'J'1%XBY; *@"X0 4A %0%5,
M!3$?:!0.;Q!'\0&X<?Q:(L?LEUI]/9LI&U6>!KK&2DF$/'O)J591S9]*RJP-
MHV.:+.EDDUWK]P((-&Z9C*KJB!$RF-U:(HRLNYS;M3<CLL/6S-V+JWE:1",,
MQQU-7>O1US=!,](,2*%=<OB2:@28)*BQ$C8P.03.*0F HB!-U]RFPSMJ4.8S
MEN4O !XF63 . ^T/$3<. \!X?EX>WHB_1<MP$Q171 Y2 H8@JI@8J8]0','-
MU$'\1A\4?RZ(OSMIMP3-VRWY53"5,>F3X*&#VRICS\#&+P'B!>(AHBZ*M7*I
M7*,2FJG98.QQ*[V5CD9*%DVDBR5?P<BZB)EFFX:JJ)G<Q<HR=Q[]$IA.U>-E
MVZQ2*)F*!%V[F3CF;-[(.G[1NQC6ZSN0=K.$B-F35LD==PX=+&.!$$444SJJ
M**&*4B9#',(% 1T1=;7[76;77X>V5FP0\_6+"Q:R<%8(F1:OX>8CGR956;Z-
MD&ZJC5XU=)F*=NN@J=-4I@,0P@.B+N1<( *A170 Z1>=4HJDXI$'VCJ!S )"
MB'^D;@']NB*/ZWF'%-QFWM:JF1J58[!&HR;A_"PMDBI&29H0TDUAY95RS:NE
M5T4XV5?,XYZ90A0;/72#942JJD*)%(';+?BF';"'W4.*0=*GQ5 >  *?C>.'
M$0ZR\0ZPT1>_1$T1-$31$T1-$31$T1-$31$T1<*2]SG_ ,B=?0*:(H,VF^]8
MVT?J_P"&OJZKFB**NQ\^]AB/GEW7?Q7YLT4G4]9[5=710FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB*I&Z? ,]G*5VX/X M7 N(]PU5RG9QLAEDU7E3A
M:K=H9]'0XMXN2[:DE7UB8+(LGAF+%1))PHH]343235*0;7Z1;VA59SAM*W.H
M9<I^;\967&NY><BZ7E+&;BB[GEV=&JU8KF1U&*S)] J8]QC8D)ME#&:J,)V$
MEHEI)6&$Z)GWQ%. @4@MON-=,^K4C?;?IQ50;AV+S>#:,C93F5LGT)&KW&I-
MXROQ-:R)=*ACN(0$]+52QZVPH&.;!%Q=0K;B DU*^_9707#<JK5P6.*ZD9)-
MN4#( =-^YO??[-5:4FQS<*SV-WS:U7[IC>O7#)N7I:8L%M54GIV"BL96&QQ\
MO,D;1XQ4.[F)YPQCBQRL&JI%1[QN[=-SSS8IP5 O1(R(OD!KEF.HFW7FJZT[
ML:F[K'S+$6.E;GBO)V*,0SMLAJ:S1R?FG!J-:J4Q<6=D@K@SJ-$93P.[#!0X
M2%71IKVY/(DK0Z(A8%&Z[I$I"1F0#G;7.QW^CA<=.NO'K?8PMV%.J=OCZ)D6
MA4&SP]8GEL2OX?)&274*IDD^:YF_0UBMS(]7;J-8B0J<PK$S;1J274(_*1N5
M!ZS2(Y$EQ8 W.8ON]69Z=V_H6/9)[%AN\N%T2;-,HU-QC[P1KT&2=2>9LN)R
M-C=3>/9&-GFUAJZU8F8]XS&_O2R2#YA-PZ:\,DDL^A'<DF*8E!/#*U[:<;WO
MK>V7HZ<N9(]C3WG)55C&1=GQRZ8I-4XQEC8-P.:ZG6JG)>#&%ID-D6,M-<HX
MS,Q+4.Q1KFR0U6?1K:)D.V"@=TS7,H %(V<[WZ!8:WOK?HUUZ%:G;-L6W X<
MW 5K,-XRLE<0"=S$%^='R+D255M-8L]>JK'';8E2F&I:HV<PDW%S,D^3;HLQ
M:&?%<(/)%PLL4A><MW :V[^GADJU*=C9WG6/-.4;9;LFU9ICC(]XK\I+U^NY
MTS00TK7X;)J%C5,C&C6VK^MO7=)3- K-FMQD4EW!U6;=6(B# D8O0(M:V>E[
M#2W?/4:A=:7L86[@;9BD9VXT*^U>BV6H245(6;.F9RO<:05,RA/6D(FN54]3
MDH6]N+%5G\5'+O;4_8N(MW&D:)N7+0A'!BB^HR]0[=?:K.Y)V?[DE-_%OW,4
MF%H-IQK<(#%<4I&2>XR_XJDV:U'C9IA+$G*' 8+OT%=6;T9)(6(.;G G!,JA
M%>B\4PDOY-MX)(]-M_[#T65&K?L(WRU1I7*;(I169#9!SE;;(B:+SUN A:S1
M*/)U&S)05*N-N8UQW,0U5H\I(,G%>?(,E6]A?G4;2+-IVG'B+I4ZYG<-UAGU
M;_0L@4[&%V05W:)Q[)9UJCEG(8GD\<*S;3.69FSV<([K$(PASR,0XJ;Q=F\@
MI9G(\)Z.L;,5$#-)!K (RB[Q<A0T@:@'AEWW_3J,\\N'8T=X;2ST)3&F3Z^E
M4Z1FNU7" B+-GC,IHJ#HLZ\J+QLQ?1*-9=6&=E&QHNQ"B#6_Q LE9--$SB0C
MW3U A,O9PW^OV^Q>V3['!O:5L,$X:98J:X!-SKZ.N1LV9@B)7#B+O-5SR X<
MU2GQU54K]^6N5,GXFLS+.S/8MO$K181[=1[$B*YBDF]SU96!OEGF<QIE[5:;
M:SL@S1@YAE5A:+U'SZ&3,#A3I%%?(F0[B@ZRP>6N9U[2L2WLU2Q\>I!3D1&B
MZC"I+BFS.W[E DV0.H4 V(X7!54+?L9[(?D3:_MQP!+K88QXEMX)#P:Y<6;G
M,H1Q<IQ+.FR-;:SDQ+K;<HY6LR%9F58ZR1L'W.M+)XLV,'=!DY105.4W%R=;
MYYC3VY\/:%B4]V,WL@$G=<BV%/,M4.PL-1:UE5J;<%F=OX26L0RHA6D?:SI4
M(7]65FS5N;93MBKT@L"1I@\G#5:-.[?MSDN,O:=EOJ&>?_EZUW5*[%ANBCFC
M2)D;?0ZA3Y.U$F;%2*;FO,;M)G OL^4#)$M L;4>KU^PRC@:/7)FNFDG*[!R
M[<N4(\RZ<8X6<H$VLC<7OO-MU['37TW41V_:CO'QGG';I1T6V0LHMXVT8Z28
M7&O6S<@^K.+:5"[A+?;9EB6PM:DIBN9:R>,)BNPML3RU<:S+,6]>195A"U<J
M93DNVQRL=V7&U\[WRL;6%M+V7T]:+RFB)HB:(FB)HB:(FB)HB:(FB+A27N<_
M^1.OH%-$4&;3?>L;:/U?\-?5U7-$45=CY][#$?/+NN_BOS9HI.IZSVJZNBA-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3AU\=$31$T1-$6C'<-N;WI87
MW'[AX6NRCP^+%+#B4M3LLOMJR;E>N8PJLI0'LA*RD3&8^GXF0NHS=O:HUF54
M;R1204DJ+UX@U(Y:M +UD;99YWSMZ;VMV'K63[OLT;U;ULUV]P^(<:9AK6YO
M/!VTG;6V&HJ(@[)CV*J\2\FY5P8^3[348.JI3SX(!+N7:;@PD^YKN3BFHR4D
MCVNJ4"UQ<Y=(/J-KD=?SY+7-F_<1V1>YR,Y+8ZC=SU/;Y?VP5.BJQ,97;BV#
M#F8:_2G%CG;C&IMF"S6(L4Q8(-_!/9%@JNDL9^V1(NOVPV4.3+B/A#=<$'I-
ML@.H\<Q9;1M@VXNY!?LEXDS]*YI<7Z=FZ([QVWN>-\LO8'N*;&L&XFQ;7@]1
M5H\00T]V\=ZA(6)BL:2%8ADNF'E$4/H]&?T^WTJ.LAL,_8'SGO/RK0K1N2R#
M%8OI.);/BVBW&W94R'C!\[N<G%AD\L31V;U-&R'@(=62>L(J(.NM7SMPZ!N)
M2F;J% %S;OIZ._2H\L>^_L@-R?2LEAK'\'#4UK.6U6$?W;;)F9[(6.N,+U1Z
MO7!".?76B244LYB;!-SJSES'B>2:QA%V;5DT36<BRX]*]6:+7O?> 1D?;?OI
MH/8XWV]D+B9NJ0$KBZ'4F6K]S$-8YAMHS0];9^D&F0'5<E305@C[D_A,*(PE
M632L8C:G=H1?AS.4'1HX>HHRTTR)O=O#( :DZ=F2GF^Y+WGVCL?4AE&QNYF"
MR/:KTW4L,;@_%ULK&2,;83;9"?P5D-!PLC.7>TSET;U./++DFX6,C7QD79G,
M-!)'326,4'HS_<JTV/=EN2PVQQO"[2&>?,MX:N%_LA&>3=W6(<SW^=D3,G$,
MW:46JR,:TB\M$JDFFX?O8BZY"K\S+'<-W35@W<L&XJ)%.1N>P@>K:!&?6IDV
M5W?=A/Y SR&6768"1K?$629"J,;6WM!8MA:$LA2*4*E7E)5@S(M(MH@$D(L4
M$BNE(XJ1TD2I"  4=^_[+JH6'<L[^([&\H;/2.>WV8Y,V+7F)&\(.4@QZ[Q$
MZOK]A:'4V,"A6Y<^98\Q6ZMN1M;UVW+ '9&B&8Q!'G2%)M;+IRW[LMPXV[@>
M^HYNW\U:6CIAQ'YOMYVKVMKHQUMB<I.8CI$<E;BP<"[8P[V&(_07A(ND-GS.
M3.[8+1)8(%6PIJ,5!*2!E8C/IZ!KPW_2I&NN_P"[(3C6C-7-]@*1!+K-*I:7
MV4&NU3-=BA(E.QX(F\E$QXXQG7,E25C.X2O46RHTE>AL"3"![H*+3,2Q< DF
MD'?U)Y-O38Y@#6V^YMP-L^S>-MYO<YE+ >$LEV9%BWL>0\28YO$^A&-UVD8C
M,VNH0\[)I1S5RX>.&[%-Z_6*T07=NEDD 3(HX6.45#%!R)'2IAT4)HB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HBX4E[G/_D3KZ!31%!FTWWK&VC]7_#7U=5S1%%7
M8^?>PQ'SR[KOXK\V:*3J>L]JNKHH31$T1-$31$T1-$31$T1-$31$T1-$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T11GD["^'\UQ<="9CQ7
MCK*T-#R1)B)BLC4NN76.C)9-,Z)))@RL<=(MVCXJ*BB/;3=--845#I"<4SF*
M)/9T@V/K&:D)BQ91C)G&QK-K'QT>U;L6#!BW2:,F+)HD1NU9LVK<B:#9JV03
M31;MT4R)(I$(FF0I"@ $7*T1-$31$T1-$31$T1-$31$T1-$31$T1-$7"DO<Y
M_P#(G7T"FB*#-IOO6-M'ZO\ AKZNJYHBCVC[3)K&4$O5<?;J]QM5JI[1>;8S
MKS:)VNRS2*D,A7>PY!L+=D_LFVB;G56/?%9Y91BG)R\BY;-%$6HNE2HE-HI)
MO<V&?7]/I])Z+9?X"\G>67N3\V-H7JJ:*$\!>3O++W)^;&T+U5-$3P%Y.\LO
M<GYL;0O54T1/ 7D[RR]R?FQM"]531$\!>3O++W)^;&T+U5-$3P%Y.\LO<GYL
M;0O54T1/ 7D[RR]R?FQM"]531$\!>3O++W)^;&T+U5-$3P%Y.\LO<GYL;0O5
M4T1/ 7D[RR]R?FQM"]531$\!>3O++W)^;&T+U5-$3P%Y.\LO<GYL;0O54T1/
M 7D[RR]R?FQM"]531$\!>3O++W)^;&T+U5-$3P%Y.\LO<GYL;0O54T1/ 7D[
MRR]R?FQM"]531$\!>3O++W)^;&T+U5-$3P%Y.\LO<GYL;0O54T1/ 7D[RR]R
M?FQM"]531$\!>3O++W)^;&T+U5-$3P%Y.\LO<GYL;0O54T1/ 7D[RR]R?FQM
M"]531$\!>3O++W)^;&T+U5-$3P%Y.\LO<GYL;0O54T1/ 7D[RR]R?FQM"]53
M1$\!>3O++W)^;&T+U5-$3P%Y.\LO<GYL;0O54T1/ 7D[RR]R?FQM"]531$\!
M>3O++W)^;&T+U5-$3P%Y.\LO<GYL;0O54T1/ 7D[RR]R?FQM"]531$\!>3O+
M+W)^;&T+U5-$3P%Y.\LO<GYL;0O54T1/ 7D[RR]R?FQM"]531$\!>3O++W)^
M;&T+U5-$3P%Y.\LO<GYL;0O54T1/ 7D[RR]R?FQM"]531$\!>3O++W)^;&T+
MU5-$3P%Y.\LO<GYL;0O54T1/ 7D[RR]R?FQM"]531$\!>3O++W)^;&T+U5-$
M3P%Y.\LO<GYL;0O54T1/ 7D[RR]R?FQM"]531$\!>3O++W)^;&T+U5-$3P%Y
M.\LO<GYL;0O54T1/ 7D[RR]R?FQM"]531$\!>3O++W)^;&T+U5-$3P%Y.\LO
M<GYL;0O54T1/ 7D[RR]R?FQM"]531%X*8'R8LFHDIO)W)F35(9,Y>]G:&',0
MY1*8.(;50$.)1$.(" A^(0'13?H'MX=?IZ^C)3'CFCQF,L>T/&T(\DY"&Q[3
M*O1XA_-*,UIA]&5.$8P+!Y++1S&,CU9-RT8)+/U&,;'LSNCJF:L6B D;IE"_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g696632g97j68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g696632g97j68.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1P.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $ < 5H  QLE1QP"   "0.@< E  "')R,CDS-S0Y' (% !]-:6-R;W-O
M9G0@5V]R9" M(#(P,3<@,C M1BYD;V-X.$))300E       0EJA>J03\.L="
MP[F+@+UOW3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D
M("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U
M8D!OX            $)R9%15;G1&(U)L=                $)L9"!5;G1&
M(U)L=                %)S;'15;G1&(U!X;$!7\S,         "G9E8W1O
M<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F
M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              3H   (&          $
M 0             "!@   3H                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   3H     4F=H=&QO;F<   (&    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     CA"24T$#      1GP    $   "@    80
M >   +7@   1@P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 80"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M'^2DI:CZ+OZ[_P#JBBH+/68'#TYESB#N'!)A)]SV-+WL#&-$ESG  ?%)29)
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M &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %,
M-@    $ .$))300B      %&34T *@    @ " $2  ,    !  $   $:  4
M   !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R
M  (    4    G $[  (    )    L(=I  0    !    O    .@ #IXP   G
M$  .GC   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP
M-#HR,R R,#HT-SHP. !R<C(Y,S<T.0       Z !  ,    !__\  * "  0
M   !   "!J #  0    !   !.@         & 0,  P    $ !@   1H !0
M  $   $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @(
M!     $              $@    !    2     $X0DE- _T       @
M     /_A 4A-30 J    "  ( 1(  P    $      1H !0    $   !N 1L
M!0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "<
M 3L  @    D   "PAVD !     $   "\    Z    \     !   #P     %!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C T.C(S(#(P.C0W
M.C X ')R,CDS-S0Y       #H $  P    '__P  H ( !     $   (&H ,
M!     $   $Z          8! P #     0 &   !&@ %     0   38!&P %
M     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
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MP3-"L=$*)28G0U)R@Y+A&2@T-TATAJ6FI\3'\?_$ !P! 0 !!0$!
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M1Y#U.Z7R%W*:R2-O4O36JZ'\ZKV26:NF4C+N /IT[5R[=-GKI)0ZZ"@=%C=
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M++Y*9FLFNVF%SE %GGS_ +JLQ@-WMX$<,CF>7S\++N-9=L!PX0-W+\._-.G
M>B@;6XU;LKJ21O@$%';&FS+("@/PJ%<F2_3XG3UX5%CV>(_-2G4^U"[/6ZN
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M'TOC]8B&*;^EW2(@@N?]/3O$*8<':+<S=LC4-X93QS@\M*ACOAW#-/\ $W2
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MO*SK*+KTN68:^4E)"R[]5NU>J,C 9!^4#E\G6#NB)BB Y2*JG)<.M;ZMLR0
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M3")A$PB81,(F$3")A$PB81,(JW7K\Z/CQ^[3D7_':0PJA[+N[YJ:8#\K7?\
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M5#VD<BU[G M[#DHT>]FQQ#77%S':\DZNL/40/4+G;:P*?ZO""(EVP)]/T=P
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MZJB"Z0%( *)K>(0QP(4JO=\4H=TX9JZR6.>JFFA9U<<CRYK+ ;H(%Q86&M]
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M&^]$,-I137;<D%IWQ<',W-^TS6W'O1VH&*,?K+5-%IC9#NBD,)78YNX*)0Z
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MCM-TO;72=%6(830MP^FBV V:PYC=H999.NEQ'$X9H9(8Y(@!$SJ0W>N<@ K
MZ5T]Q^UXPIFJ.0+3D7Q&VRWAXF)96)+<-K::QM\FBT20%U V=D[4K;1TZ6*8
MP0TF1D*)Q,1,3% N6I-N<3J)WFLI<-/62.<(YZ&"5GK.WMQLI:'FU[7)WG:W
M)6LQ+^$; H,.=BO13M7BVVV!T$9;*_!L7K*':.BC@;NF;$=GS)ON;NM#W343
M):?0!C1DNQ!OPXVNQ12>4#G=R)9LE$R+1R4Z]K-\BU$#% R/=5F&"QUFQRB
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M]C$QMU#SIAM8\YFEF.4,CB>H>0#ZJY+$:6HP:K=C6&1NDII<\7P^,7ZQH_\
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M)^X>SE^]EZ)7Q1;;86_&:1C6[389"#C5)&T XI2L%ABD#&YF>,"U4QHNX?S
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MY[,K5=ME%UF7<-MAY-X5!>#UTI-%KJ-E>"8.Z1HO-')'($ZBLLX,5-),QC%
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M/0"87^'<O'NU;"Q'K8^(/*V"3+_TCA/6XV!NE^L3+5UY)$$H?^L41 ?T9/\
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ML??K;7.VMAKWVMR6LI=KOHM927(75V[BE,91KKM4\+3@3V[+(WCT?*Q%,_\
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M=\E=QLHR+%+L'#%O)IE/.F<RZY"2=3R^&0T\VRT5HZ3P_P"->NZ+?]:U/4T
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4XV37*BY,U;"L0XH)"4ESS/BO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g696632g97x19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g696632g97x19.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[20(4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $ < 5H  QLE1QP"   "0.@< E  "')R,CDS-S0Y' (% !]-:6-R;W-O
M9G0@5V]R9" M(#(P,3<@,C M1BYD;V-X.$))300E       0EJA>J03\.L="
MP[F+@+UOW3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              .,   &P          $
M 0             !L    .,                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   .,     4F=H=&QO;F<   &P    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      9F@    $   "@    5
M >   )V    9?@ 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M               !  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 "_^X
M#D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3
M&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0
M#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,_\  $0@ 5 "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $%
M 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 "
M P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&
M%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B
M9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>G
MM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"
M(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$
MP]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:
M  P# 0 "$0,1 #\ ]525,=7Z9!<<FMH'.X[3PTP&OV[G-]1FYJ9W6NDL>6.R
MZ@6F''<(!A[O<_Z#?YMZ2E^HX5V4*W47&BVDO+7#=!+JWU,WL:]C7[+75W>_
M?_-+/?TSZP%P;^TR*]GZ6T,&XNXVUTM;^C:QOZ3U/4WO?^C6KC-!#K))+G/$
MDDB-[ML"=OT5S7UKZ]U&C;3@O]"DV.K?>T2\N8!N8W<-M;-SG?\ "?HD_'C,
MY"(_%;.8A&RV.D?:^LX-75,#J5U6)E-#J6V5^^6,;C2]MK[-K?M&/Z^S_#>I
M_+]1'LZ3UYE#S1U(ON<26L<(:-[GN_G'>K9^BW5;?;]"GT/\*N6POK9US$L!
M?=]KJGW57 :C^3<QHL8[_MS^HNZZ3U3&ZKA-R\>0"2U['?28\?2K>G9<$\>I
MU'<+<>:,]!H>Q;BQ7])ZM566XN>[TV,.RITRY^Y[_?DVF^UC=MGI^W_@UM(6
M5E8^)CV9.2\5TU#<]Y[#_OW]51;LEN5^SNL5XMC[^I.?=%;][6&&^F766[*:
MH]3U-WT=GZ3TV,5;IM'4.JX.'U'%ZK<W&R&MN8'U!CP'3[/3#MGN86?3]5C/
M2]6OU/567E?7/JN;DMQ^E4LQQ8X-K-@WV'^4[7TJO;]+^=6UT[/SZ;*ZLV]N
M4RPAAL%8K+7.T9MV':^ES_T?T?44LL$XBY4/ZOZ3''-&1H:^/1O=,QNI469
MS;_M%9<W[.?SH .XO;M;L_,9^?\ S?J_X57TD#-R?LN+9?MW%H]K>)<3LK;_
M &GN40%Z,A3I+#JZGETV!^1:+:20+1M#=H)_G*MONV5_GLL]3]%_A/\ 2;B=
M*)CNB,@=E))+@^I_6_K3>HY%>.]E%-%KZFUE@<3L<6;K7/\ SG[?S$[%BED)
M$:T[K<F2, ">O9[Q)<OT/ZYMR[F8G4F-INL(;5=7/IN<?HL>UVYU3W?F>Y['
MKJ$)XY0-2%)A.,A<3:DDDDQ<_P#_T.TZB,;$RGO/2!936;'G*)(9-@%F198Q
MM=GTW7>[^<L_G?29_@T/$Q<:][*K.AFJJT@V/>3[-W#VM</YWZ.Y];_YG\_U
M:_LRZ5))2+& %1 T >\ >0>Y<YEXU5XR,7);N8;;-PX()>ZVNQI_-?LL8]JZ
M.EEK"X.+2PESA$S[G%^O^<JF=TT76')J?Z=D18TMW->&_1.T.K=ZK?H[]_\
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MDE\JI)*?JI)?*J22G__9.$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J    "  (
M 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !
M  $   "\    Z  .GC   "<0  Z>,   )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$X.C T.C(S(#(P.C,X.C0P ')R,CDS-S0Y       #
MH $  P    '__P  H ( !     $   &PH , !     $   #C          8!
M P #     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "
M   " 0 $     0   48" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!2$U- "H    (  @!$@ #     0
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H
M   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,3@Z,#0Z,C,@,C Z,S@Z-#  <G(R.3,W-#D       .@ 0 #     ?__
M  "@ @ $     0   ;"@ P $     0   .,         !@$#  ,    !  8
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
MY &Q P$1  (1 0,1 ?_$ !X  0 " @(# 0             '" 8)! 4! @,*
M_\0 3Q    8" 0($! $&"0@&"P   0(#! 4&  <1"!(3%"$Q"14B018C,E%A
M<? 7-#="0U*!H;,D,W1V=Y&UT25B@K'!X0H8)C535&.#DZ+Q_\0 '0$!  (#
M 0$! 0            $" P8'!0@$"?_$ #L1  (! @,%!@0%! (" P$    !
M @,1!"$Q!1)!46$&<8&1H? 3(K'!!S)"T>$4(U+Q8G(5)#."DD/_V@ , P$
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M#F$>\O?OB3=@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & 4CMG0OKFSZ7V;I@+;=&$9LGJ GNI1><.6H3#R(V%,[D)O C$D
M+.U22J,]3&=M238_ANUUZ>3>0)?+OG3B2*C*HB;\5D[6R[K?0Q[4_P /^GZP
MV&PV4XVQM"[SS#;TKNTB$^TUA#Q(W2>TLPT;+H)1E&UQ4FK&MGJT9'N8Z#CB
M,TXN09H^46*P%9BJ(OZ9>K?CKQZ<D4H9= VU]C[6K^LMA1=^KG2=1I;J%'\#
M2FP-93U#-7MO04[56,;K![6Z%!;<45!C8WTBQ-L>;,.O4VZ$1!K6 RII1,%E
MKF\K:6RUOHGPX+J6;E.@/7=1U3L5'8745L=M%(L-:3#78;]CHRC--70^A[M'
M[0K4ZG%UK4]=H$G)$F(1NO;[->JW8GLU&($8*K-&31FBVBW/AH3?I;S\M? R
MTD1J3K]B]']4'3/U7VR,5UC';+K=.V5J FO)1G*EOHU&.N<9<ZSL?7=J9"[:
MK4>.7:1JL-"G8R @[5;.$"MD2R--5YZ^_N<FK_#CTK49&E24-8]BD5I*.H0;
M ZEX%T:9?:?D-ARL;+SJZM:%R[E+-)[+GWMJ7;K-".ETF(QB,4";@'(CW]CF
M3O01637B;VAKO<>VM3[)L=IV9-3-NJAM>2+IU ;;>1#^VTTL?;Z#98E*+;/8
M5D_J\H1C^)Z\^%VJA.+(OGK=</?O[G4ZO^&[I_50Z>/#77:$JMIAQIYS +3<
MI55E)=72^M+QJZO'G_(U&/*N:5AK]+2,_P#+RQP.)=LP5CPC6:;ABZ$WS;RS
M6?I^R(8ZAND#8=(L"M[Z96^UW5VNUAWS,VNW4N\:AAK#&#NF61L+NJNH3:.N
MIZLO**E,J.5H^>C527RG]JB[#\1J/5$R W>W3+C^_P!+%\^E354YH_IPTQJ.
MS2"4K8=?T&"KDU(HK>83>23)O_E:P./+,P7$RQS]ZQ6C8BIP,H1NB0P)E$%@
M< 8!4.T=&NO+54>IJH/+%<V[3JCL36TW%VV=0(N8"58,(1FR)6TG-><,3QI3
M0#%9Y&61G8FLD0[QE($<1[I1I@$/TKX<=.K%E-:YK<>T;=)*VW5EW69KQ&GZ
MI HSNI(B7K];0BX.@ZMJ<?&0R\+*%9R+!NF"SE1BW>^=(\5>+N7AH,[O-VUM
M>]F]=>Y<2M=_Z,MWWW?J%1:1]XJW36KU*NM[6N"5O6LI34MCCY.&FF5@6C(]
M"ALMVQMHL;B7,JK45;4-)A7(NG3.3=I*(,T!/OW[>7(L/6OAH:_@JM;*0YVY
MM23J<K27^OZA%)1VHZZ:CP3V30EDG97E3U?!.[O/1R[5HVCY38ZEM%%@U(B9
MN==1PY7$$\[9Z6?X4:OIB,2W)LZD7'1<PPL5.V-54-=FG7TW'PPP95[)"V"A
MSE+E&;MF8XO8U&LLF:BI@.DF@9-(2!ZOW[_DHY)=/70Y'[GANEZS]2\\XZE[
M=4W=ME:S(V2FHWR^N76RX_9TU<Y5HTI2$"TL,S/1C=,L+&M8A,]>*8T7 @!/
MF("R<OS6\;?+?DL^7"_H6XO_ $0U2V[&LVY:SLS8^MMMS-QKUSAKM6/P/(J5
M1Y"4U*BO(N,A+?2[+ OX2Q0:*/SIG/QTNL9XW07CW; A#H*/Y]<RO3WP_8C.
MK?#&U'6P9+N=E[CLLJW;,DGLS/R]+5D)9TTVDYVVH_?#'T:.:E7=61VLT529
MMFK5*'\-JV;H+I@ZP0[N^>O3^<SJ>I3I/LL5<?X==$-=G26VY/97XO=S=)MV
MJX:TTQ!U35Z;(MZG#[1H=@HUCA)V-5!K88FU+$>-TP+(0TD5REY5463:NLK-
M<?MEKURT+!]#>F+SH;IPIM V5)JRUY+)6JR65TYD&<N["0M-EDYT47LI'1D)
M&/9!%%XD5^M%P\;%E>>.E&,T6";<N"'KEETY="W6 , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & /_']O[A^_P!\ 8 P!@# *6?$
M/Z?''5%T8]0>EHN!5L]FMFM[,E2H$DZXKZ$E>&\4Z4J23UXF_CVBC5*;\HY\
M"56/%BX1;N'*1O (8HE.S3-<G_H_70!MKH/Z6+=7>H&B?@/<EOV'+2$RR:6]
MO8X]_7&R:*=?="A#2S^OHNR)G<)&7123D#HE22=*&(DD4D)6Z]29.[=KVX7-
M]V25& , 8 P!@# & , 8 P!@'Y0-O_!_W):_CK4WJMA]3'>])H.ZE:K7<5=D
MD3F/QHS@')YB2*T7LA;D"A+ #82%:$!N)  B) :@8H1;._2S]V^_\W4K0<7G
MF[=+OZY=4KY=/U>)D!-,B8"<0(0I %0YE#B!0 H"=0YC'.8>.3&,8QC#ZF$1
M$<DH>^ , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M%>4.8)&5@*@]K<=9I5HF!.T[6%>V^LMGIA.4Q%)ED %,!S"4#!>H#^179?\
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MMC[0>S,;!MVPF)FJ>(CG:,I90K6T3B\I.V<7:ZMGNH*8IBE,40,4P 8I@$#
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M='_#+@DY& :Q^N*1-+;FZ?J@)O\ )(*O;,V$Y2$>2GD!-6*E#+"3G\]LVE;
M4AA#T!R?@0$!SI'8.DHX?:^*M>4I83#1YJ+^-6J+3]3C3TY9K0TCM=4;K;.H
M7R4<17:XW7PZ<>/*52SYW*5[ZU&PW/KB6J#@4T9$0"0@'RG %9S+9,W@"<P
M)@07*8[5?T, $5\0"&.B0!Z+LS'U=FXVEC*3M*E)-I7NXW>37&ZO=<5?A++2
ML?A(8["U<-42:J1:5^#X/HUSX:H_.W<:?/T2Q2=8LD>O&RL4Z4;.$%R&*/)#
M#VG((AVJ)*%X425()DU4S%.0QB&*8?H39>T\-M;"T\51DLXK?A=.4)OA)*S:
MZZM/A9I<7VA@*^SL3/#UHO*3<9.Z4X\&GXYZ65\KF+Y^\_&, 8N#<]\&#?\
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M"I.E4C_C.G)PDO"29]8TJL*U*G6IN\*M.%2#YQG%2B_%-'>9B,@P!@# & ,
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M49(T%I=JZXMIGT'YGYQ'A (R!Y(LA&%9/5'L>+<'C9%D\650*DU7.F!Z;_
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MB@H/J'/J F$!_0(" ^H9VRHMV<X\I27DV<NIM2A!IW3C%WYY'?Y0N>?L/O\
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MH]]$B?%IIY>GTLK:<2%IAE*U_?\ 2.FZ(JE6V'/-/BGUS>;W98RC\^RXRLN
M5V#-HS-7D:Z67*UJ$.X=5IO>%+ O4WU+CXEBQ<+33M-BB(OP_;O7U[UH]3,*
M_P!!/4W2]$V_2A:'KV[2F]^DO3.@WM^?W$C9?I\M-&J$Q3)R;AT7$"Z=3\5"
MGE?X1*>,0YA71KF1T1P9,'*+E!_/K]_N2VF[];Z>*5DUE?7/3AP+35[HJO\
M!&K,BE%U,;''_$6MG4M+V$'I"R[[6<M&;&AFCE5^# '*LXO&V*%:.8<R@(>
M"Z0N3E1#O$>_?OTR+_=0'\BNR_\ 5.3_ ,,, EAI_%6W^CH_X9< Y& :^/B
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MBS&"Q&.WMA):TI$E8BIE<RJADHNNQX\",C/2 BC'H"7W%(A^YPY$..&Z"OJ
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M)U:^W6#; /\ 1M%989]ND'_522G"ID#[$*4 X   !F6:Z\<[^^99D.> Y]^
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M*<\]X&$#<\C@K'7>;OER[[I<[6X=22RE*0I2$ "E(4"E*'H!2E#@  /L
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M#_+YK+_9YM#_ (KK_ )KP!@$6[EO2FO->3]@: 0\R9-&)KJ!Q_C$_,*E8Q@
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MU+NBOI9RS9MVR\H](W1:$>2*R*9%'KHK1NW:E<.3*JE;H(H <$DB%*!V& ,
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MP8@B40'!2>OO/NZ6M_NYW6"IPXYLM,;+U3 M $ZY[>6=<]GJ+>-A(]X9PX4
M/4$_&=-TNX> [C\<X,L$M=?#2]LK^]?/9I@N, 8 P!@# & , 8 P!@# & ,
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M+@LDEI[]^^)L.;MT&B"+5JBDW;-TR(H((D*FDBDF4"D333( %(0I0 "E*
M!Z8)*T[UUCK5T@K>IBR(ZVL+=/L_%+4Z*99+MY\-I*QIQ*G, /H4G!?-$[Q[
M5/4 R'[RO]"+)^_MX% W=ZO35V9K#P1+;$%4["6MO#ST8@=+G@7'RM9J+E8"
M%^L0:>*4X?F&$!#)*?+=>+]ZIW\+6X,O%TSU2G+MWU_;VEO<K@]2+%R"Q&JD
M<2L-RG\4T(VBG/#QGRI]3A5T4BSHP%$P=I2@ NDDE;^?$MM@D8 P!@# & ,
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M+M%D"*B'>*:X%,(E(4,&2,KZYO\ CR_GO-D."XP!@# & , 8 P!@# & , 8
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M5, <H$6 "JD^E0 [^.\/0W'."IV& , 8 P!@# & , 8 P!@# & , 8 P!@#
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M$8P[:VKMGGRH:K:KBX:';C\Z:1:2J1S"6DLN/'+Z?RD7J_OP0, 8 P!@# &
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MO^)KKJ_2AX1_4E&3R)W-JC3MOFJ??]9[1H]4?[QC[&36<K(7.A6Z:B3DD[A
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M7_<& , 8 P!@# ''_/\ 3[__ -_W>GM@# & , 8 P!@# & , 8 P!@# & ,
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6746062432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DocumentAndEntityInformationAbstract', window );"><strong>Document and entity information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRUS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Merus N.V.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001651311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">23,358,977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6737814768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Financial Position - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, net</a></td>
<td class="nump">&#8364; 2,420<span></span>
</td>
<td colspan="2" class="nump">&#8364; 1,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,445<span></span>
</td>
<td colspan="2" class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentHeldtomaturityInvestments', window );">Non-current investments</a></td>
<td class="nump">16,945<span></span>
</td>
<td colspan="2" class="nump">7,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">1,075<span></span>
</td>
<td colspan="2" class="nump">129<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">22,885<span></span>
</td>
<td colspan="2" class="nump">8,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">7,032<span></span>
</td>
<td colspan="2" class="nump">4,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentHeldtomaturityInvestments', window );">Current investments</a></td>
<td class="nump">44,855<span></span>
</td>
<td colspan="2" class="nump">34,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">143,747<span></span>
</td>
<td colspan="2" class="nump">149,678<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="nump">195,634<span></span>
</td>
<td colspan="2" class="nump">188,134<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">218,519<span></span>
</td>
<td colspan="2" class="nump">196,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued and paid-in capital</a></td>
<td class="nump">2,102<span></span>
</td>
<td colspan="2" class="nump">1,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium account</a></td>
<td class="nump">264,854<span></span>
</td>
<td colspan="2" class="nump">213,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated loss</a></td>
<td class="num">(175,085)<span></span>
</td>
<td colspan="2" class="num">(158,775)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders' equity</a></td>
<td class="nump">91,871<span></span>
</td>
<td colspan="2" class="nump">56,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">97,675<span></span>
</td>
<td colspan="2" class="nump">112,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">3,819<span></span>
</td>
<td colspan="2" class="nump">2,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Taxes and social security liabilities</a></td>
<td class="nump">256<span></span>
</td>
<td colspan="2" class="nump">243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsCurrent', window );">Deferred revenue</a></td>
<td class="nump">16,934<span></span>
</td>
<td colspan="2" class="nump">15,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Other liabilities and accruals</a></td>
<td class="nump">7,964<span></span>
</td>
<td colspan="2" class="nump">8,627<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">28,973<span></span>
</td>
<td colspan="2" class="nump">27,660<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">126,648<span></span>
</td>
<td colspan="2" class="nump">140,211<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total shareholders' equity and liabilities</a></td>
<td class="nump">&#8364; 218,519<span></span>
</td>
<td colspan="2" class="nump">&#8364; 196,803<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of resources: (a) controlled by the entity as a result of past events; and (b) from which future economic benefits are expected to flow to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentHeldtomaturityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current held-to-maturity investments. [Refer: Held-to-maturity investments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 8<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_8_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentHeldtomaturityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred income classified as current. [Refer: Deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeClassifiedAsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred income classified as non-current. [Refer: Deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeClassifiedAsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of present obligations of the entity arising from past events, the settlement of which is expected to result in an outflow from the entity of resources embodying economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentHeldtomaturityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current held-to-maturity investments. [Refer: Held-to-maturity investments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 8<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_8_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentHeldtomaturityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2018-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2018-03-01&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 70<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6746516736">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Profit or Loss and Comprehensive Loss - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract', window );"><strong>Operating expenses from railroad and related business [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 31,448<span></span>
</td>
<td colspan="2" class="nump">&#8364; 21,915<span></span>
</td>
<td colspan="2" class="nump">&#8364; 2,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(46,740)<span></span>
</td>
<td colspan="2" class="num">(34,125)<span></span>
</td>
<td colspan="2" class="num">(18,424)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">Management and administration costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,395)<span></span>
</td>
<td colspan="2" class="num">(13,697)<span></span>
</td>
<td colspan="2" class="num">(4,258)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Other expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,160)<span></span>
</td>
<td colspan="2" class="num">(9,395)<span></span>
</td>
<td colspan="2" class="num">(7,709)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(70,295)<span></span>
</td>
<td colspan="2" class="num">(57,217)<span></span>
</td>
<td colspan="2" class="num">(30,391)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating result</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(38,847)<span></span>
</td>
<td colspan="2" class="num">(35,302)<span></span>
</td>
<td colspan="2" class="num">(27,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,843<span></span>
</td>
<td colspan="2" class="nump">1,112<span></span>
</td>
<td colspan="2" class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4)<span></span>
</td>
<td colspan="2" class="num">(30,335)<span></span>
</td>
<td colspan="2" class="num">(19,644)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncome', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,095<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other income (expense)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,934<span></span>
</td>
<td colspan="2" class="num">(29,223)<span></span>
</td>
<td colspan="2" class="num">(19,556)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Result before taxation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23,913)<span></span>
</td>
<td colspan="2" class="num">(64,525)<span></span>
</td>
<td colspan="2" class="num">(47,437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(356)<span></span>
</td>
<td colspan="2" class="num">(249)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result after taxation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,269)<span></span>
</td>
<td colspan="2" class="num">(64,774)<span></span>
</td>
<td colspan="2" class="num">(47,437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences from translation of foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34<span></span>
</td>
<td colspan="2" class="nump">89<span></span>
</td>
<td colspan="2" class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Total other comprehensive income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34<span></span>
</td>
<td colspan="2" class="nump">89<span></span>
</td>
<td colspan="2" class="nump">8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (24,235)<span></span>
</td>
<td colspan="2" class="num">&#8364; (64,685)<span></span>
</td>
<td colspan="2" class="num">&#8364; (47,429)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Basic (and diluted) loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">&#8364; (1.09)<span></span>
</td>
<td colspan="2" class="num">&#8364; (3.37)<span></span>
</td>
<td colspan="2" class="num">&#8364; (3.58)<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">For the periods included in these financial statements, share options and restricted stock units were excluded from the diluted loss per share calculation as the Company was in a loss position in each period presented above. As a result, basic and diluted loss per share are equal.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2018-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=26&amp;date=2018-03-01&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2018-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=4&amp;date=2018-03-02&amp;anchor=para_39L_e&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2018-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=17&amp;date=2018-03-01&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=5&amp;date=2018-03-01&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2018-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=32&amp;date=2018-03-01&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2018-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2018-03-01&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=5&amp;date=2018-03-01&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of operating expenses from railroad and related business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759406400">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Shareholders' Equity - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th">
<div>Issued capital [member] </div>
<div>Common share capital [member]</div>
</th>
<th class="th">
<div>Issued capital [member] </div>
<div>Class A preference share capital [member]</div>
</th>
<th class="th">
<div>Issued capital [member] </div>
<div>Class B preference share capital [member]</div>
</th>
<th class="th">
<div>Issued capital [member] </div>
<div>Class C preference share capital [member]</div>
</th>
<th class="th">
<div>Share premium [member] </div>
<div>Common share premium [member]</div>
</th>
<th class="th">
<div>Share premium [member] </div>
<div>Class A preference share premium [member]</div>
</th>
<th class="th">
<div>Share premium [member] </div>
<div>Class B preference share premium [member]</div>
</th>
<th class="th">
<div>Share premium [member] </div>
<div>Class C preference share premium [member]</div>
</th>
<th class="th"><div>Accumulated loss [member]</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance (Previously stated [member]) at Dec. 31, 2015</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 28,302<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 30<span></span>
</td>
<td class="nump">&#8364; 21<span></span>
</td>
<td class="nump">&#8364; 351<span></span>
</td>
<td class="nump">&#8364; 373<span></span>
</td>
<td class="nump">&#8364; 1,564<span></span>
</td>
<td class="nump">&#8364; 1,334<span></span>
</td>
<td class="nump">&#8364; 38,906<span></span>
</td>
<td class="nump">&#8364; 49,105<span></span>
</td>
<td class="num">&#8364; (63,382)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance (Increase (decrease) due to application of IFRS 15 [member]) at Dec. 31, 2015</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">599<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Dec. 31, 2015</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">28,901<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="nump">1,564<span></span>
</td>
<td class="nump">1,334<span></span>
</td>
<td class="nump">38,906<span></span>
</td>
<td class="nump">49,105<span></span>
</td>
<td class="num">(62,783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Restated result after taxation for the period | Previously stated [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(47,228)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Restated result after taxation for the period | Increase (decrease) due to application of IFRS 15 [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(209)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Restated result after taxation for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(47,437)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss | Previously stated [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(47,220)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss | Increase (decrease) due to application of IFRS 15 [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(209)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(47,429)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,429)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TransactionsWithOwnersAbstract', window );"><strong>Transactions with owners of the Company:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of shares (net)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,151<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_InitialPublicOfferingCosts', window );">IPO expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,509)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Conversion of preference shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">745<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(351)<span></span>
</td>
<td class="num">(373)<span></span>
</td>
<td class="nump">89,345<span></span>
</td>
<td class="num">(1,334)<span></span>
</td>
<td class="num">(38,906)<span></span>
</td>
<td class="num">(49,105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity settled shared-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,307<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,307<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity', window );">Total contributions by and distributions to owners of the Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52,949<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,418<span></span>
</td>
<td class="num">&#8364; (21)<span></span>
</td>
<td class="num">&#8364; (351)<span></span>
</td>
<td class="num">&#8364; (373)<span></span>
</td>
<td class="nump">138,314<span></span>
</td>
<td class="num">&#8364; (1,334)<span></span>
</td>
<td class="num">&#8364; (38,906)<span></span>
</td>
<td class="num">&#8364; (49,105)<span></span>
</td>
<td class="nump">3,307<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Dec. 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">34,421<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106,905)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Restated result after taxation for the period | Previously stated [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(73,089)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Restated result after taxation for the period | Increase (decrease) due to application of IFRS 15 [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,315<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Restated result after taxation for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(64,774)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,774)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss | Previously stated [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(73,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss | Increase (decrease) due to application of IFRS 15 [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,315<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(64,685)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,685)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TransactionsWithOwnersAbstract', window );"><strong>Transactions with owners of the Company:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of shares (net)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">74,041<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity settled shared-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,815<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,815<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity', window );">Total contributions by and distributions to owners of the Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86,856<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,815<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">56,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(158,775)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Restated result after taxation for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,269)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,235)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TransactionsWithOwnersAbstract', window );"><strong>Transactions with owners of the Company:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of shares (net)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,589<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity settled shared-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,925<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,925<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity', window );">Total contributions by and distributions to owners of the Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59,514<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,925<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 91,871<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 2,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 264,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (175,085)<span></span>
</td>
</tr>
<tr><td colspan="13"></td></tr>
<tr><td colspan="13"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2018-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=4&amp;date=2018-03-02&amp;anchor=para_39L_e&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2018-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=17&amp;date=2018-03-01&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase through contributions by and distributions to owners, equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_InitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Public Offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_InitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TransactionsWithOwnersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transactions with owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TransactionsWithOwnersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760095136">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash flows - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result after taxation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (24,269)<span></span>
</td>
<td class="num">&#8364; (64,774)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">&#8364; (47,437)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value derivative</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,667<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19,213<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Unrealized foreign exchange results</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,553)<span></span>
</td>
<td class="nump">15,767<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">365<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">638<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">234<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payment expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,925<span></span>
</td>
<td class="nump">12,815<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,307<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Net finance (income) expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,181)<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(33)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Cash flows from (used in) operations before changes in working capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(22,440)<span></span>
</td>
<td class="num">(26,247)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(24,351)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ChangeInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,576)<span></span>
</td>
<td class="num">(1,837)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,256)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(946)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(109)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Trade payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">618<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(121)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals', window );">Other liabilities and accruals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(663)<span></span>
</td>
<td class="nump">4,977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">286<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,877)<span></span>
</td>
<td class="num">(14,933)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities', window );">Tax and social security liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(113)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash used in operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(39,871)<span></span>
</td>
<td class="num">(37,341)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(25,678)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(55)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Taxes paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(624)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(40,499)<span></span>
</td>
<td class="num">(37,413)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(25,733)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Purchases of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(75,930)<span></span>
</td>
<td class="num">(41,830)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Proceeds from investment maturities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58,912<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intellectual property</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,552)<span></span>
</td>
<td class="num">(724)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(496)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities', window );">Interest received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,279<span></span>
</td>
<td class="nump">929<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">88<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(19,416)<span></span>
</td>
<td class="num">(41,625)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(408)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuing shares, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,713<span></span>
</td>
<td class="nump">74,738<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">50,547<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsForDebtIssueCosts', window );">Financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from stock option exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Prepaid share issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(230)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ProceedsFromCollaborationAgreement', window );">Proceeds from collaboration and license agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,993<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayment of borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(486)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(167)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ChangesInRestrictedCash', window );">Changes in restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">51<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,589<span></span>
</td>
<td class="nump">186,222<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">50,201<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,326)<span></span>
</td>
<td class="nump">107,184<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">24,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effects of exchange rate changes on cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,395<span></span>
</td>
<td class="num">(14,423)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">149,678<span></span>
</td>
<td class="nump">56,917<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">32,851<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">143,747<span></span>
</td>
<td class="nump">149,678<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 56,917<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SupplementalDisclosureOfCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ChangesInAccruedCapitalExpenditures', window );">Changes in accrued capital expenditures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 346<span></span>
</td>
<td class="nump">&#8364; 52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gains (losses) on changes in the fair value of derivatives to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: At fair value [member]; Derivatives [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in deferred income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=sect_AStatementofcashflowsforanentityotherthanafinancialinstitution&amp;doctype=Illustrative%20Examples<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=sect_AStatementofcashflowsforanentityotherthanafinancialinstitution&amp;doctype=Illustrative%20Examples<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForDebtIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForDebtIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2018-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=4&amp;date=2018-03-02&amp;anchor=para_39L_e&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2018-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=17&amp;date=2018-03-01&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other liabilities and accurals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in Tax and social security liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ChangeInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ChangeInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ChangesInAccruedCapitalExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in accrued capital expenditures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ChangesInAccruedCapitalExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ChangesInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ChangesInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ProceedsFromCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ProceedsFromCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SupplementalDisclosureOfCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental disclosure of cash flow information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SupplementalDisclosureOfCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735492016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">General Information</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 </p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>1.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>General Information</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b>Nature of Business</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Merus N.V. is a clinical-stage immuno-oncology company developing
 innovative bispecific antibody therapeutics, headquartered in
 Utrecht, the Netherlands. Merus US, Inc. is a wholly-owned
 subsidiary of Merus N.V. located at One Broadway, Cambridge,
 Massachusetts, United States (&#x201C;U.S.&#x201D;). These
 consolidated financial statements as at and for year ended
 December&#xA0;31, 2018 comprise Merus N.V. and Merus US, Inc.
 (collectively, the &#x201C;Company&#x201D;).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Merus N.V. was incorporated in the Netherlands, with its statutory
 seat in Utrecht. In connection with becoming a listed company on
 the Nasdaq Global Market (&#x201C;Nasdaq&#x201D;), on May&#xA0;19,
 2016, Merus N.V.&#x2019;s legal structure under Dutch law was
 changed from a private company with limited liability (in Dutch:
 <i>besloten vennootschap met beperkte aansprakelijkheid</i>) to a
 public company with limited liability (in Dutch: naamloze
 vennootschap) and Merus N.V.&#x2019;s name changed from &#x201C;Merus
 B.V.&#x201D; to &#x201C;Merus N.V.&#x201D; The address of the
 Company&#x2019;s registered office is Yalelaan 62, 3584 CM Utrecht,
 The Netherlands.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Since inception, the Company has generated an accumulated loss of
 &#x20AC;175.1&#xA0;million as of December&#xA0;31, 2018. The Company
 expects to continue to incur significant expenses and operating
 losses for the foreseeable future as its bispecific antibody
 candidates advance through discovery, preclinical development and
 clinical trials and as it seeks regulatory approval and pursues
 commercialization of any approved bispecific antibody
 candidate.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 As a result, the Company may need additional financing to support
 its continuing operations. Until the Company can generate
 significant revenue from product sales, if ever, the Company
 expects to finance its operations through public equity offerings,
 debt financings, or other sources, which may include collaborations
 with third parties and business development opportunities. Adequate
 additional financing may not be available to the Company on
 acceptable terms, or at all. The Company&#x2019;s inability to raise
 capital as and when needed would have a negative impact on its
 financial condition and ability to pursue its business strategy.
 The Company will need to generate significant revenues to achieve
 profitability and may never do so.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Based on the Company&#x2019;s current operating plan, Merus expects
 that its existing cash and cash equivalents of
 &#x20AC;143.7&#xA0;million and investments of
 &#x20AC;61.8&#xA0;million as of December&#xA0;31, 2018 will be
 sufficient to fund its operations into the second quarter of
 2021.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Reverse Share Split</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On May&#xA0;6, 2016, the general meeting of the Company&#x2019;s
 shareholders resolved to approve and effect a capital
 reorganization, based on a reverse share split. The effect of the
 reverse share split was a <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">1-for-1.8</font></font> reverse share split
 of the outstanding common and preferred shares held by the
 Company&#x2019;s shareholders. This reverse share split became
 effective on May&#xA0;6, 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Initial Public Offering</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On May&#xA0;24, 2016, the Company closed the initial public
 offering of 5,500,000 of its common shares and, on May&#xA0;26,
 2016, of an additional 639,926 of its common shares, at a price to
 the public of $10.0 per share (the &#x201C;IPO&#x201D;). Net proceeds
 to the Company after deducting underwriting discounts and
 commissions and offering expenses were $53.3&#xA0;million. On
 May&#xA0;19, 2016, the Company&#x2019;s common shares were listed on
 the Nasdaq and all of the Company&#x2019;s preferred shares
 converted into common shares.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><font style="WHITE-SPACE: nowrap">Follow-on</font> Public
 Offering</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On June&#xA0;1, 2017, the Company filed with the U.S. Securities
 and Exchange Commission a registration statement on Form
 <font style="WHITE-SPACE: nowrap">F-3</font> (Registration Number
 <font style="WHITE-SPACE: nowrap">333-218432)</font> (the
 <font style="WHITE-SPACE: nowrap">&#x201C;F-3</font> Registration
 Statement&#x201D;), under which it registered up to
 $250.0&#xA0;million of its securities and 3,200,000 shares sold to
 Incyte Corporation (&#x201C;Incyte&#x201D;). The <font style="WHITE-SPACE: nowrap">F-3</font> Registration Statement became
 effective on June&#xA0;16, 2017. On June&#xA0;1, 2017, the Company
 also entered into a sales agreement with Cowen and Company, LLC
 (&#x201C;Cowen&#x201D;), under which the Company may issue and sell
 from time to time up to $50.0&#xA0;million of its common shares
 registered under the <font style="WHITE-SPACE: nowrap">F-3</font>
 Registration Statement through Cowen as its sales agent. Sales of
 common shares, if any, will be made at market prices by any method
 that is deemed to be an &#x201C;at the market&#x201D; offering. The
 aggregate compensation payable to Cowen as sales agent equals 3.0%
 of the gross sales price of the shares sold through it pursuant to
 the sales agreement. No sales have been made by the Company under
 the sales agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Private Placement of Common Shares</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On February&#xA0;13, 2018, the Company entered into a Securities
 Purchase Agreement (the &#x201C;Purchase Agreement&#x201D;) with the
 purchasers named therein (the &#x201C;Investors&#x201D;). Pursuant to
 the Purchase Agreement, the Company agreed to sell an aggregate of
 3,099,997 of its common shares, nominal value &#x20AC;0.09 per
 share, to the Investors at a purchase price equal to $18.0 per
 share (the &#x201C;Private Placement&#x201D;). The Purchase Agreement
 contained customary representations and warranties from the Company
 and the Investors and customary closing conditions. On
 February&#xA0;15, 2018, the Company completed the sale under the
 Private Placement and received aggregate gross proceeds of
 approximately $55.8&#xA0;million, or &#x20AC;44.8&#xA0;million.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 51<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735503776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Presentation</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>2.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left"><b>Basis of Presentation</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 These consolidated financial statements have been prepared in
 accordance with International Financial Reporting Standards
 (&#x201C;IFRS&#x201D;) as issued by the International Accounting
 Standards Board (&#x201C;IASB&#x201D;). Certain amounts were
 reclassified in the prior period financial statements to conform to
 the current period presentation. These changes in classification do
 not materially affect the previously reported consolidated
 financial statements for any period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The financial statements have been prepared under the historical
 cost convention unless otherwise stated in the below accounting
 policies.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 These consolidated financial statements have been authorized for
 issuance on April 3, 2019.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Functional and Presentation Currency</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Items recorded in each of the Company&#x2019;s entities are measured
 using the currency of the primary economic environment in which the
 entity operates (the &#x201C;functional currency&#x201D;). The
 consolidated financial statements are presented in euros, which is
 Merus N.V.&#x2019;s functional currency. The functional currency of
 Merus US, Inc. is the U.S. dollar.&#xA0;All amounts are rounded to
 the nearest thousand euros, except where otherwise indicated.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Segment Reporting</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company operates in one reportable segment, which comprises the
 discovery and development of innovative bispecific
 therapeutics.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Use of Estimates, Judgements and Assumptions</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 In the application of the Company&#x2019;s accounting policies,
 management is required to make judgments, estimates and assumptions
 that affect the reported amounts of assets, liabilities, income and
 expenses that are not readily apparent from other sources. The
 estimates and associated assumptions are based on historical
 experience and other factors that are considered to be relevant.
 Actual results may differ from these estimates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Estimates and underlying assumptions are reviewed on an ongoing
 basis. Revisions to accounting estimates are recognized
 prospectively.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The following are the critical judgments and assumptions that
 management has made in the process of applying the Company&#x2019;s
 accounting policies and that have the most significant effect on
 the amounts recognized in the consolidated financial
 statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Equity Settled Share-Based Payments</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Share options granted to employees, consultants and directors are
 measured at the grant date fair value of the equity instruments
 granted. The grant date fair value is determined through the use of
 an option-pricing model considering the following variables:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="4%">&#xA0;</td>
 <td valign="top" width="4%" align="left">(a)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">the exercise price of the option;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="4%">&#xA0;</td>
 <td valign="top" width="4%" align="left">(b)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">the expected life of the option;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="4%">&#xA0;</td>
 <td valign="top" width="4%" align="left">(c)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">the current value of the underlying shares;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="4%">&#xA0;</td>
 <td valign="top" width="4%" align="left">(d)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">the expected volatility of the share price;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="4%">&#xA0;</td>
 <td valign="top" width="4%" align="left">(e)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">the dividends expected on the shares; and</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="4%">&#xA0;</td>
 <td valign="top" width="4%" align="left">(f)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">the risk-free interest rate for the life of the
 option.</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Prior to the Company&#x2019;s IPO, the estimated fair value of each
 share option granted was determined utilizing the Black-Scholes
 option pricing model. Subsequent to the IPO, the Company&#x2019;s
 judgment was that the Hull&#xA0;&amp; White option pricing model is
 the most appropriate method for determining the fair value of its
 share options since it considers the terms and conditions attached
 to the grants made and is reflective of expected exercise
 behavior.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Since the Company was not listed on a national securities exchange
 until May&#xA0;19, 2016, there was no published share price
 information available until May&#xA0;19, 2016. Consequently, the
 Company estimated the fair value of its common shares and the
 expected volatility for the period up to May&#xA0;19, 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 As the Company&#x2019;s shares have not been publicly traded for a
 sufficient amount of time, the expected volatility is set by
 considering the historic share price volatility of a set of peer
 companies.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 For&#xA0;<font style="WHITE-SPACE: nowrap">pre-IPO</font>&#xA0;valuations,
 the continuous yield on euro government bonds with a term to
 maturity comparable to the expected life of the share options, as
 published by the European Central Bank, was applied.
 For&#xA0;<font style="WHITE-SPACE: nowrap">post-IPO</font>&#xA0;valuations,
 the continuous yield on U.S. Treasury Bills with a term to maturity
 comparable to the expected life of the share options, as published
 by the U.S. Department of Treasury, is applied.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The result of the share option valuations and the related
 compensation expense that is recognized for the respective vesting
 periods during which services are received, is dependent on the
 model and input parameters used. Even though management considers
 the fair values reasonable and defensible based on the
 methodologies applied and the information available, others might
 derive a different fair value for the Company&#x2019;s share
 options. These assumptions and estimates are further discussed in
 Note 12 to the consolidated financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Capitalization of Development Costs</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The criteria for capitalization of development costs have been
 considered by management and determined not to have been met
 through December&#xA0;31, 2018. Therefore, all development
 expenditures relating to internally generated intangible assets in
 the year ended December&#xA0;31, 2018 were expensed as
 incurred.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Income Taxes</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The criteria for the recognition of unused tax losses and
 deductible temporary differences are disclosed in Note 3. As of
 December&#xA0;31, 2018, deferred tax assets have not been
 recognized in respect of tax losses and deductible temporary
 differences as the Company has no history of generating taxable
 profits. Therefore, at the balance sheet date, there is no
 convincing evidence that sufficient taxable profit will be
 available against which the tax losses and deductible temporary
 differences can be utilized. The amount of the unrecognized tax
 losses and deductible temporary differences is disclosed in Note
 7.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Merus US, Inc., which is incorporated in the U.S. in the State of
 Delaware, is subject to statutory U.S. Federal corporate income
 taxes and state income taxes for Massachusetts. Current year income
 tax expense was attributable entirely to Merus US, Inc. which
 provides general management services and strategic advisory
 services to the Company. Corporate income tax expenses were
 &#x20AC;0.4&#xA0;million, &#x20AC;0.2&#xA0;million and
 &#x20AC;0.0&#xA0;million for the years ended December&#xA0;31, 2018,
 2017 and 2016, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Revenue Recognition</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Pursuant to the Company&#x2019;s research, collaboration and license
 agreements with ONO Pharmaceutical Co., Ltd. (&#x201C;ONO&#x201D;),
 Incyte, Jiangsu Simcere Pharmaceutical Co. Ltd.
 (&#x201C;Simcere&#x201D;) and Betta Pharmaceuticals Co. Ltd.
 (&#x201C;Betta&#x201D;), the Company has received or will receive
 upfront&#xA0;nonrefundable&#xA0;payments and milestones for certain
 rights granted under the respective agreements. The applicable
 period over which to recognize these upfront or milestone payments
 requires significant judgment and was impacted by the adoption of
 IFRS 15. See Note 4 and Note 11.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Accrual of R&amp;D expenses</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Research and Development (&#x201C;R&amp;D&#x201D;) expenses are
 recognized in the consolidated statement of profit or loss and
 comprehensive loss as incurred and have no alternative future
 uses.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 As part of the process of preparing its consolidated financial
 statements, the Company is required to estimate certain of its
 R&amp;D expenses, including estimates of third-party contract costs
 relating to preclinical studies and clinical trial activities and
 related contract manufacturing expenses. This process involves
 reviewing open contracts and purchase orders, communicating with
 R&amp;D personnel to identify services that have been performed for
 the Company and estimating the level of service performed and the
 associated cost incurred for the service when the Company has not
 yet been invoiced or otherwise notified of the actual cost. See
 Note 14.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The majority of the Company&#x2019;s service providers invoice
 monthly in arrears for services performed or when contractual
 milestones are met. The Company makes estimates of its R&amp;D
 expenses as of each reporting date in its consolidated financial
 statements based on facts and circumstances known to it at that
 time. The Company periodically confirms the accuracy of its
 estimates with the service providers to gauge the reasonableness of
 its estimates. Differences between actual and estimated expenses
 recorded have not been material and are adjusted for in the period
 in which they become known.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735553840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Significant Accounting Policies</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>3.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Significant Accounting Policies</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The accounting policies set out below have been consistently
 applied to all periods presented in the consolidated financial
 statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Income and expenses are accounted for on an accrual basis. Profit
 is only included when realized at the statement of financial
 position date. Losses originating before the end of the financial
 year are taken into account if they have become known before
 preparation of the financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Basis of consolidation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <i>(i) Subsidiaries</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Subsidiaries are entities controlled by the Company, consisting of
 Merus N.V.&#x2019;s wholly owned subsidiary Merus US, Inc. The
 Company controls an entity when it is exposed to, or has rights to,
 variable returns from its involvement with the entity and has the
 ability to affect those returns through its power over the entity.
 The financial statements of subsidiaries are included in the
 consolidated financial statements from the date on which control
 commences until the date on which control ceases.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>(ii) Loss of control</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 When the Company loses control over a subsidiary, it derecognizes
 the assets and liabilities of the subsidiary, and any <font style="WHITE-SPACE: nowrap">non-controlling</font> interests and other
 components of equity. Any resulting gain or loss is recognized in
 profit or loss. Any interest retained in the former subsidiary is
 measured at fair value when control is lost.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>(iii) Transactions eliminated on consolidation</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Intercompany balances and transactions, and any unrealized income
 and expenses arising from intercompany transactions, are eliminated
 in consolidation. Unrealized gains arising from transactions with
 equity-accounted investees are eliminated against the investment to
 the extent of the Company&#x2019;s interest in the investee.
 Unrealized losses are eliminated in the same way as unrealized
 gains, but only to the extent that there is no evidence of
 impairment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Foreign Currency Transactions</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Foreign currency transactions are translated using the exchange
 rates at the dates of the transactions. Foreign exchange gains and
 losses resulting from the settlement of such transactions and from
 the translation of monetary assets and liabilities denominated in
 foreign currencies at the exchange rate at the reporting date are
 generally recognized in the statement of profit or loss and
 comprehensive loss as a component of finance costs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The results and financial position of foreign operations that have
 a functional currency different from the presentation currency are
 translated into the presentation currency as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">assets and liabilities for each balance sheet
 presented are translated at the closing rate at the date of that
 balance sheet;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">income and expenses for each statement of profit or
 loss and comprehensive income or loss are translated at average
 exchange rates (unless this is not a reasonable approximation of
 the cumulative effect of the rates prevailing on the transaction
 dates, in which case income and expenses are translated at the
 exchange rates at the dates of the transactions); and</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">all resulting exchange differences are recognized in
 other comprehensive income.</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Property, Plant and Equipment</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Property, plant and equipment are measured at cost less accumulated
 depreciation and accumulated impairment losses (if any). Cost
 includes expenditures that are directly attributable to the
 acquisition of the items. Depreciation of property, plant and
 equipment is recognized in the consolidated statement of profit and
 loss and comprehensive loss on a straight-line basis over estimated
 useful lives of generally five years, taking residual value into
 account. If significant parts of an item of property, plant and
 equipment have different useful lives, they are accounted for as
 separate items (major components) of property, plant and
 equipment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Subsequent expenditures are capitalized only when the expenditure
 will increase the future economic benefit of the asset. All other
 expenditures are expensed in the consolidated statement of profit
 or loss and comprehensive loss.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Depreciation rates are based on the following estimated economic
 useful lives of the tangible fixed assets concerned:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Plant and
 equipment&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;5
 years</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Leasehold improvements
 &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Shorter of useful
 life or term of lease</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Other fixed
 assets:&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;5
 years</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Intangible Assets</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Intangible assets are identifiable <font style="WHITE-SPACE: nowrap">non-monetary</font> assets without physical
 substance. An asset is a resource that is controlled by the
 enterprise as a result of past events (for example, purchase or
 self-creation) and from which future economic benefits (inflows of
 cash or other assets) are expected.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The useful lives of intangible assets are assessed to be finite and
 amortized over the useful economic life and assessed for impairment
 whenever there is an indication that the intangible asset may be
 impaired. Amortization begins when the asset is available for
 use.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Patents</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Patents acquired separately by the Company are reported at cost
 less accumulated amortization and accumulated impairment losses.
 Amortization is recognized in the consolidated statement of profit
 and loss and comprehensive loss on a straight-line basis over the
 shorter of the estimated economic or legal lives. The estimated
 useful life and amortization method are reviewed at the end of each
 reporting period, with the effect of any changes in estimates being
 accounted for on a prospective basis.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>R&amp;D</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company incurs R&amp;D expenses related to its clinical trials
 and preclinical drug development programs. Development expenses are
 defined as expenses incurred to achieve technical and commercial
 feasibility. Expenditures on research activities are recognized as
 an expense in the period in which it is incurred.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Development is capitalized if, and only if, all of the following
 have been demonstrated:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the technical feasibility of completing the intangible
 asset so that it will be available for use or sale;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the intention to complete the intangible asset and use
 or sell it;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the ability to use or sell the intangible asset;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">how the intangible asset will generate probable future
 economic benefits;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the availability of adequate technical, financial and
 other resources to complete the development and to use or sell the
 intangible asset; and</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the ability to measure reliably the expenditure.</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Financial Instruments</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company classifies <font style="WHITE-SPACE: nowrap">non-derivative</font> financial assets as
 either financial assets at fair value through profit or loss,
 financial assets at amortized cost or financial assets at fair
 value through other comprehensive income or loss. The Company
 classifies <font style="WHITE-SPACE: nowrap">non-derivative</font>
 financial liabilities into either financial liabilities at fair
 value through profit or loss or the other financial liabilities
 category.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i><font style="WHITE-SPACE: nowrap">Non-Derivative</font>
 Financial Assets and Financial Liabilities</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company initially recognizes receivables and investments at
 fair value on the date when they are originated. Subsequent to
 initial recognition, they are measured at amortized cost using the
 effective interest rate method. All other financial assets and
 financial liabilities are initially recognized on the trade
 date.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The Company derecognizes a financial asset when the contractual
 rights to the cash flows from the asset expire, or it transfers the
 rights to receive the contractual cash flows in a transaction in
 which substantially all the risks and rewards of ownership of the
 financial asset are transferred, or it neither transfers nor
 retains substantially all of the risks and rewards of ownership and
 does not retain control over the transferred asset. Any interest in
 such derecognized financial assets that is created or retained by
 the Company is recognized as a separate asset or liability.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company initially recognizes <font style="WHITE-SPACE: nowrap">non-derivate</font> financial liabilities at
 fair value less any directly attributable transaction costs.
 Subsequent to initial recognition, these liabilities are measured
 at amortized cost using the effective interest method.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company derecognizes a financial liability when its contractual
 obligations are settled or cancelled, or expire.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Financial assets and financial liabilities are offset and the net
 amount presented in the statement of financial position when, and
 only when, the Company has a legal right to offset the amounts and
 intends either to settle them on a net basis or to realize the
 asset and settle the liability simultaneously.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Investments</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Investments are classified and accounted for at amortized cost and
 initially measured at fair value. Subsequent to initial
 recognition, they are measured at amortized cost using the
 effective interest rate method. Investments are classified as
 amortized cost as the Company has the positive intent and ability
 to hold them until maturity. Interest income from these securities
 is included in finance income.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Receivables</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 These assets are initially recognized at fair value plus any
 directly attributable transaction costs, if any.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Derivative Financial Assets and Liabilities</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Derivative financial instruments are initially recognized at fair
 value on the date on which a derivative contract is entered into
 and are subsequently remeasured at fair value with net changes in
 fair value presented as finance expenses (negative net changes in
 fair value) or finance income (positive net changes in fair value)
 in the consolidated statement of profit or loss and comprehensive
 loss. Derivatives are carried as financial assets when the fair
 value is positive and as financial liabilities when the fair value
 is negative. Derivatives embedded in host contracts are accounted
 for as separate derivatives and recorded at fair value if their
 economic characteristics and risks are not closely related to those
 of the host contracts and the host contracts are not held for
 trading or designated at fair value through profit or loss. These
 embedded derivatives are measured at fair value with changes in
 fair value recognized in profit or loss. Reassessment only occurs
 if there is either a change in the terms of the contract that
 significantly modifies the cash flows that would otherwise be
 required or a reclassification of a financial asset out of the fair
 value through profit or loss category.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Cash and Cash Equivalents</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 For the purpose of presentation in the statement of cash flows as
 well as the statement of financial position, cash and cash
 equivalents include deposits held with financial institutions with
 original maturities of less than three months from the date of
 acquisition. Cash and cash equivalents include
 &#x20AC;49.1&#xA0;million of investments with a three month or less
 maturity, callable on demand. The carrying values of cash
 equivalents approximate fair value due to their short-term
 maturities.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>Treatment of equity issuance costs</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Costs related to the issuance of new shares have been accounted for
 as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Incremental costs, if any, that are directly
 attributable to issuing new shares are included as prepaid expenses
 and are deducted from equity on the date the Company closes its new
 share transactions (net of any income tax benefit). Such as, for
 example, the date of the closing of its IPO, <font style="WHITE-SPACE: nowrap">follow-on</font> public offerings or the
 share subscription agreements with Incyte or Regeneron
 Pharmaceuticals Inc. (&#x201C;Regeneron&#x201D;);</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Incremental costs directly associated with a probable,
 successful future offering of equity instruments are also deferred
 and deducted from equity when the new shares are issued;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Costs that relate to listing on Nasdaq, or other new
 share transaction costs that are otherwise not incremental and
 directly attributable to issuing new shares, are recorded as an
 expense in the consolidated statement of profit or loss and
 comprehensive loss; and</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Costs that relate to both share issuance and listing
 are allocated between those functions on a rational and consistent
 basis.</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Provisions</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 A provision is recognized if the following applies:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the company has a legal or constructive obligation,
 arising from a past event;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the amount can be estimated reliably; and</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">it is probable that an outflow of resources embodying
 economic benefits will be required to settle the obligation.</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 If all or part of the payments that are necessary to settle a
 provision are virtually certain to be fully or partially
 compensated by a third party upon settlement of the provision, then
 the compensation amount is presented separately as an asset.
 Provisions are determined by discounting the expected future cash
 flows at a <font style="WHITE-SPACE: nowrap">pre-tax</font> rate
 that reflects current market assessments of the time value of money
 and the risks specific to the liability. The unwinding of the
 discount is recognized as finance cost.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Impairment</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <i>Financial Assets Measured at Amortized Cost</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 At each reporting date, the Company considers evidence of
 impairment for these assets at both an individual asset and a
 collective level. All individually significant assets are
 individually assessed for impairment. Those found not to be
 impaired are then collectively assessed for any impairment that has
 been incurred but not yet individually identified. Assets that are
 not individually significant are collectively assessed for
 impairment. Collective assessment is carried out by grouping
 together assets with similar risk characteristics.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 To assess impairment for its financial assets, the Company uses the
 general expected credit loss model over the next twelve months of
 the expected life of its financial assets. Under this model, the
 Company calculates the allowance for credit losses by considering
 on a discounted basis, the cash shortfalls it would incur in
 various default scenarios for prescribed future periods and
 multiplying the shortfalls by the probability of each scenario
 occurring. The allowance on the financial asset is the sum of these
 probability-weighted outcomes.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 For the Company&#x2019;s investments, the Company applies the low
 credit risk simplification as it does not believe there to be any
 credit risk related to these assets given the credit quality
 ratings required by the Company&#x2019;s investment policy. At every
 reporting date, the Company evaluates whether a particular debt
 instrument is considered to have low credit risk using all
 supportable information.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Impairment losses are recognized in the consolidated statement of
 profit or loss and comprehensive loss and is the amount required to
 adjust the loss allowance at the reporting date to the amount that
 is required to be recognized based on the aforementioned policy. If
 the amount of impairment loss subsequently decreases and the
 decrease can be related objectively to an event occurring after the
 impairment was recognized, then the previously recognized
 impairment loss is reversed through profit or loss.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i><font style="WHITE-SPACE: nowrap">Non-Financial</font>
 Assets</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 At each reporting date, the Company reviews the carrying amounts of
 its <font style="WHITE-SPACE: nowrap">non-financial</font> assets
 to determine whether there is any indication of impairment. If any
 such indication exists, then the asset&#x2019;s recoverable amount
 is estimated.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 For impairment testing, assets are grouped together into the
 smallest group of assets that generates cash inflows from
 continuing use that are largely independent of the cash inflows of
 other assets or cash generating units (&#x201C;CGU&#x201D;).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The recoverable amount of an asset or CGU is the greater of its
 value in use and its fair value less costs to sell. Value in use is
 based on the estimated future cash flows, discounted to their
 present value using a <font style="WHITE-SPACE: nowrap">pre-tax</font> discount rate that reflects
 current market assessments of the time value of money and the risks
 specific to the asset or CGU.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 An impairment loss is recognized if the carrying amount of an asset
 or CGU exceeds its recoverable amount.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Impairment losses are recognized in profit or loss. They are
 allocated first to reduce the carrying amount of any goodwill
 allocated to the CGU, and then to reduce the carrying amounts of
 the other assets in the CGU on a pro rata basis.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 An impairment loss is reversed only to the extent that the
 asset&#x2019;s carrying amount does not exceed the carrying amount
 that would have been determined, net of depreciation or
 amortization, if no impairment loss had been&#xA0;recognized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Revenue Recognition</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Effective January&#xA0;1, 2018, the Company adopted IFRS 15,
 <i>Revenue from Contracts with Customers</i> (&#x201C;IFRS
 15&#x201D;). This standard applies to all contracts with customers,
 except for contracts that are within the scope of other standards,
 such as leases, insurance, collaboration arrangements and financial
 instruments.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The terms of the contracts within the scope of IFRS 15&#xA0;may
 contain multiple promised goods and services, which often include
 license rights to certain of the Company&#x2019;s product candidates
 and R&amp;D activities. Payments under such agreements include:
 (i)&#xA0;upfront nonrefundable license fees; (ii)&#xA0;payments for
 R&amp;D services performed by the Company, including reimbursement
 for certain external costs; (iii)&#xA0;payments based upon the
 achievement of certain development, regulatory and commercial
 milestones; and (iv)&#xA0;royalties on net product sales, if
 any.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Under IFRS 15, the Company recognizes revenue when its customer
 obtains control of promised goods or services, in an amount that
 reflects the consideration that the Company expects to receive in
 exchange for those goods or services. The Company recognizes
 revenue following the five-step model prescribed under IFRS 15: (i)
 identification of the contract(s) with the customer;
 (ii)&#xA0;identification of the performance obligations;
 (iii)&#xA0;determination of the transaction price, including the
 constraint on variable consideration; (iv)&#xA0;allocation of the
 transaction price to the performance obligations in the contract;
 and (v)&#xA0;recognition of revenue when (or as) the Company
 satisfies each performance obligation.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In order to account for contracts with customers, the Company
 identifies the promised goods or services in the contract and
 evaluates whether such promised goods or services represent
 performance obligations. The Company accounts for those components
 as separate performance obligations when the following criteria are
 met: (i)&#xA0;the customer can benefit from the good or service
 either on its own or together with other resources that are readily
 available to the customer, and (ii)&#xA0;the Company&#x2019;s
 promise to transfer the good or service to the customer is
 separately identifiable from other promises in the contract. This
 evaluation requires subjective determinations and requires the
 Company to make judgments about the promised goods and services and
 whether such goods and services are separable from the other
 aspects of the contractual relationship. In determining the
 performance obligations, the Company evaluates certain criteria,
 including whether the promised good or service is capable of being
 distinct and whether such good or service is distinct within the
 context of the contract, based on consideration of the relevant
 facts and circumstances for each arrangement. Factors considered in
 this determination include the research, manufacturing and
 commercialization capabilities of the partner; the availability of
 research and manufacturing expertise in the general marketplace;
 and the level of integration, interrelation, and interdependence
 among the promises to transfer goods or services.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The transaction price is allocated among the performance
 obligations using the relative selling price method and the
 applicable revenue recognition criteria are applied to each of the
 separate performance obligations. At contract inception, the
 Company determines the standalone selling price for each
 performance obligation identified in the contract. If an observable
 price of the promised good or service sold separately is not
 readily available, the Company utilizes assumptions that require
 judgment to estimate the standalone selling price, which may
 include development timelines, probabilities of technical and
 regulatory success, reimbursement rates for personnel costs,
 forecasted revenues, potential limitations to the selling price of
 the product, expected technological life of the product and
 discount rates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i><font style="WHITE-SPACE: nowrap">Up-front</font> License
 Payments</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 If the license to the Company&#x2019;s intellectual property is
 determined to be distinct from the other performance obligations
 identified in the arrangement, the Company recognizes revenue
 allocated to the license when the license is transferred to the
 customer and the customer is able to use and benefit from the
 license. For licenses that are not distinct and bundled with other
 performance obligations, the Company utilizes judgment to assess
 the nature of the combined performance obligation to determine
 whether the combined performance obligation is satisfied over time
 or at a point in time and, if over time, the appropriate method of
 measuring progress for purposes of recognizing revenue from the
 combined performance obligation. The Company evaluates the measure
 of progress each reporting period and, if necessary, adjusts the
 measure of performance and related revenue recognition.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Milestones</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 At the inception of each arrangement that includes <font style="WHITE-SPACE: nowrap">pre-commercial</font> milestone payments, the
 Company evaluates whether the milestones are considered probable of
 being reached and estimates the amount to be included in the
 transaction price using the most likely amount method. If it is
 probable that a significant cumulative revenue reversal would not
 occur, the associated milestone value is included in the
 transaction price. Milestone payments that are not within the
 Company&#x2019;s control, such as regulatory approvals, are not
 considered probable of being achieved until the uncertainty related
 to the milestone is resolved. The transaction price is then
 allocated to each performance obligation on a relative selling
 price basis, for which the Company recognizes revenue as or when
 the performance obligations under the contract are satisfied. Any
 such adjustments are recorded on a cumulative <font style="WHITE-SPACE: nowrap">catch-up</font> basis, which affects revenue
 in the period of adjustment. At the end of each subsequent
 reporting period, the Company reevaluates the probability of
 achievement of such development milestones and any related
 constraint, and if necessary, adjusts its estimate of the overall
 transaction price.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Royalties</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 For arrangements that include sales-based royalties, including
 milestone payments based on the level of sales, and where the
 license is deemed to be the predominant item to which the royalties
 relate, the Company recognizes revenue at the later of:
 (i)&#xA0;when the related sales occur, or (ii)&#xA0;when the
 performance obligation to which some or all of the royalty has been
 allocated has been satisfied (or partially satisfied). To date, the
 Company has not recognized any royalty revenue.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>R&amp;D Cost Reimbursement</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 R&amp;D cost reimbursement revenue, which is typically related to
 reimbursements from customers for the Company&#x2019;s performance
 of R&amp;D services under the respective agreements, is recognized
 on the basis of labor hours valued at a contractually agreed rate.
 R&amp;D cost reimbursement revenue also includes reimbursements for
 related <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">out-of-pocket</font></font> expenses and
 third-party costs. R&amp;D cost reimbursement revenue is recognized
 in the same period as the costs for which they are intended to
 compensate.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company typically acts as the principal under such arrangements
 and, therefore, records these reimbursements on a gross basis. The
 impact of the new revenue standard IFRS 15 was also assessed for
 the instances under the ONO research and license agreement (defined
 below) where the Company acts as an agent. The Company concluded
 that no control was obtained for these pass-through arrangements to
 reimburse costs under the ONO research and license agreement and as
 such the costs were netted in R&amp;D instead of being recognised
 as expense.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Costs of Obtaining a Contract with a Customer</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company capitalizes the incremental costs of obtaining a
 contract with a customer if it expects to recover those costs. To
 date, the Company has not capitalized any incremental costs for
 obtaining a contract.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Government Grants</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company receives certain government and regional grants, which
 support its research efforts in defined projects, and include
 contributions towards the R&amp;D cost. When there is reasonable
 assurance that the Company will comply with the conditions attached
 to a received grant, and when there is reasonable assurance that
 the grant will be received, government grants are recognized as
 revenue on a gross basis in the consolidated statement of profit or
 loss and comprehensive loss on a systematic basis over the periods
 in which the Company recognizes expenses for the related costs for
 which the grants are intended to compensate. In the case of grants
 related to assets, the received grant will be deducted from the
 carrying amount of the asset.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>WBSO</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The WBSO (<i>afdrachtvermindering speur- en ontwikkelingswerk</i>)
 is a Dutch fiscal facility that provides subsidies to companies,
 knowledge centers and self-employed people who perform R&amp;D
 activities (as defined in the WBSO Act). Under this act, a
 contribution is paid towards the labor costs of employees directly
 involved in R&amp;D and other related expenditures. The
 contribution is in the form of a reduction of payroll taxes.
 Subsidies relating to labor costs are deferred and recognized in
 the consolidated statement of profit or loss and comprehensive loss
 as negative labor costs over the period necessary to match them
 with the labor costs that they are intended to compensate (see Note
 15).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Employee Benefits</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <i>Short-term Employee Benefits</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Short-term employee benefits are expensed as the related service is
 provided. A liability is recognized for the amount expected to be
 paid if the Company has a present legal or constructive obligation
 to pay this amount as a result of past service provided by the
 employee and the obligation can be estimated reliably.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <i>Share-Based Payment Transactions</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The grant-date fair value of equity-settled share-based payment
 awards granted to employees including grants of employee options,
 restricted share units, and modifications to existing instruments,
 is recognized as an expense, net of an estimated forfeiture rate,
 with a corresponding increase in equity (accumulated loss), over
 the vesting period of the awards. Service conditions and
 <font style="WHITE-SPACE: nowrap">non-market</font> related
 conditions are not taken into account in determining the fair
 value. The amount recognized as an expense is adjusted to reflect
 the number of awards for which the related service and <font style="WHITE-SPACE: nowrap">non-market</font> performance conditions are
 expected to be met, such that the amount ultimately recognized is
 based on the number of awards that meet the related service and
 <font style="WHITE-SPACE: nowrap">non-market</font> performance
 conditions at the vesting date. For any share-based payment awards
 with market conditions or <font style="WHITE-SPACE: nowrap">non-vesting</font> conditions, the grant-date
 fair value of the share-based payment is measured to reflect such
 conditions and there is no <font style="WHITE-SPACE: nowrap">true-up</font> for differences between
 expected and actual outcomes.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Post-Employment Benefit Plans</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company contributes to a post-employment benefit plan that
 entitles executive officers and other staff members to retire at
 the age of 67 and receive annual payments based upon the average
 salary earned during the service period. The Company has insured
 the liabilities from the post-employment benefit plan with an
 insurance company and has no other obligation than to pay the
 annual insurance premiums to the insurance company. The annual
 pension payments are conditional; the Company will have no further
 obligation (legal or constructive) to pay further amounts if the
 insurance fund has insufficient assets to pay all employee benefits
 relating to current and prior service. Based on its
 characteristics, the Company&#x2019;s post-employment benefit plan
 is classified as a defined contribution plan.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Obligations for contributions to defined contribution plans are
 expensed as the related service is provided. Prepaid contributions
 are recognized as an asset.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Leases</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <i>Determining whether an Arrangement Contains a Lease</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 At inception of an arrangement, the Company determines whether such
 an arrangement is or contains a lease.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 At inception or on reassessment of the arrangement, the Company
 separates payments and other consideration required by such an
 arrangement into those for the lease and those for other elements
 on the basis of their relative fair values. If the Company
 concludes for a finance lease that it is impracticable to separate
 the payments reliably, then an asset and a liability are recognized
 at an amount equal to the fair value of the underlying asset.
 Subsequently, the liability is reduced as payments are made and an
 imputed finance cost on the liability is recognized using the
 Company&#x2019;s incremental borrowing rate.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Leased Assets</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Assets held by the Company under leases that transfer to the
 Company substantially all of the risks and rewards of ownership are
 classified as finance leases. The leased assets are measured
 initially at an amount equal to the lower of their fair value and
 the present value of the minimum lease payments. Subsequent to
 initial recognition, the assets are accounted for in accordance
 with the accounting policy applicable to that asset.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Assets held under other leases are classified as operating leases
 and are not recognized in the Company&#x2019;s statement of
 financial position.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Lease Payments</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Payments made under operating leases are recognized in the
 consolidated statement of profit or loss and comprehensive loss on
 a straight-line basis over the term of the lease. Lease incentives
 received are recognized as an integral part of the total lease
 expense, over the term of the lease.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Minimum lease payments made under finance leases are apportioned
 between the finance expense and the reduction of the outstanding
 liability. The finance expense is allocated to each period during
 the lease term so as to produce a constant periodic rate of
 interest on the remaining balance of the&#xA0;liability.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Finance Income and Finance Expenses</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company&#x2019;s finance income and finance expenses
 include:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">interest and related income;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">interest expense and changes in fair value of the
 forward contract (derivative);</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">financing costs; and</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the foreign currency gain or loss on financial assets
 and financial liabilities.</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Interest income or expense is recognized using the effective
 interest method.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Income Tax</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Income tax expense comprises current and deferred tax. It is
 recognized in the consolidated statement of profit or loss and
 comprehensive loss except to the extent that it relates to a
 business combination, or items recognized directly in equity or in
 other comprehensive income or loss. Current tax comprises the
 expected tax payable or receivable on the taxable income or loss
 for the year and any adjustment to tax payable or receivable in
 respect of previous years. It is measured using tax rates enacted
 or substantively enacted at the reporting date. Current tax also
 includes any tax arising from dividends. Current tax assets and
 liabilities are offset only if certain criteria are met.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Deferred tax is recognized in respect of temporary differences
 between the carrying amounts of assets and liabilities for
 financial reporting purposes and the amounts used for taxation
 purposes. Deferred tax is not recognized for:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">temporary differences on the initial recognition of
 assets or liabilities in a transaction that is not a business
 combination and that affects neither accounting nor taxable profit
 or loss;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">temporary differences related to investments in
 subsidiaries, associates and joint arrangements to the extent that
 the group is able to control the timing of the reversal of the
 temporary differences and it is probable that they will not reverse
 in the foreseeable future; and</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">taxable temporary differences arising on the initial
 recognition of goodwill.</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Deferred tax assets are recognized for unused tax losses, unused
 tax credits and deductible temporary differences to the extent that
 it is probable that future taxable profits will be available
 against which they can be used. Deferred tax assets are reviewed at
 each reporting date and are reduced to the extent that it is no
 longer probable that the related tax benefit will be realized; such
 reductions are reversed when the probability of future taxable
 profits improves.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Unrecognized deferred tax assets are reassessed at each reporting
 date and recognized to the extent that it has become probable that
 future taxable profits will be available against which they can be
 utilized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Deferred tax is measured at the tax rates that are expected to be
 applied to temporary differences when they reverse, using tax rates
 enacted or substantively enacted at the reporting date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The measurement of deferred tax reflects the tax consequences that
 would follow from the manner in which the Company expects, at the
 reporting date, to recover or settle the carrying amount of its
 assets and liabilities.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Deferred tax assets and liabilities are offset only if certain
 criteria are met.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735576256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued or Adopted International Financial Reporting Standards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory', window );">Recently Issued or Adopted International Financial Reporting Standards</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 </p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>4.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Recently Issued or Adopted International Financial
 Reporting Standards</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b>Newly Adopted International Financial Reporting
 Standards</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>IFRS 15, Revenue from Contracts with Customers</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In May 2014, the IASB issued IFRS 15, which supersedes existing
 revenue recognition guidance. Prior to the adoption of IFRS 15,
 revenue was recognized to the extent that it was probable that the
 economic benefits would flow to the Company and the revenue could
 be reliably measured. The standard requires an entity to recognize
 the amount of revenue to which it expects to be entitled for the
 transfer of promised goods or services to customers. To achieve
 that core principle, an entity must identify the contract(s) with a
 customer, identify the performance obligations in the contract,
 determine the transaction price, allocate the transaction price to
 the performance obligations in the contract, and recognize revenue
 when (or as) the entity satisfies the performance obligation. IFRS
 15 was effective for annual and interim reporting periods beginning
 on or after January&#xA0;1, 2018 and should be applied
 retrospectively to each prior reporting period presented or
 retrospectively with the cumulative effect of initially applying
 this update recognized at the date of initial application.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company adopted the new standard effective January&#xA0;1,
 2018, using the retrospective method, with the effect of initially
 applying this standard recognized at the beginning of the earliest
 period presented. The Company had two open contracts on the
 adoption date and has assessed these contracts under the new
 revenue standard. In addition, the Company elected to apply the
 practical expedient to not apply this guidance to contracts that
 were completed before the beginning of the earliest period
 presented, or January&#xA0;1, 2016, and the practical expedients
 for contract modifications (assessing the contracts in combination
 with any modifications before January&#xA0;1, 2016). Under the
 practical expedient, the Company excluded certain option and
 exclusivity agreements that expired in 2015 and 2014,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The adoption of IFRS 15 impacted the amortization of the
 Company&#x2019;s upfront license payments under the collaboration
 and license agreement entered into with Incyte on December&#xA0;20,
 2016 (the &#x201C;Incyte collaboration and license agreement&#x201D;)
 and under the research and license agreement entered into with ONO
 on April&#xA0;8, 2014 (the &#x201C;ONO research and license
 agreement&#x201D;). The Company previously recognized revenue from
 upfront license payments on a straight-line basis over the
 contractual term or the period of continuing managerial
 involvement, which was previously estimated to be 21 years for the
 Incyte collaboration and license agreement and 4.5 years for the
 ONO research and license agreement. Upon adoption of IFRS 15, the
 Company assessed the goods and services promised under the Incyte
 collaboration and license agreement and identified only one
 performance obligation to which the transaction price was
 allocated&#x2014;a license to the Company&#x2019;s proprietary
 technology combined with the joint steering committee
 (&#x201C;JSC&#x201D;) services during the research term. The transfer
 of the license and the JSC participation represented one combined
 performance obligation since they were not deemed distinct. As a
 result, under IFRS 15, revenue from upfront license payments under
 the Incyte collaboration and license agreement will be recognized
 as the Company satisfies the combined performance obligation, or
 over the nine-year research term, which is a period during which
 the Company has a present enforceable obligation to provide JSC
 services.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 As a result of the adoption of IFRS 15, prior year financial
 statements have been restated. The impact of adopting IFRS 15
 resulted in a decrease of approximately &#x20AC;8.7&#xA0;million to
 deferred revenue with an offset to accumulated deficit, effective
 January&#xA0;1, 2018.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The following financial statement line items have been shown to
 reflect the adjustments recognized for each individual line item in
 the Company&#x2019;s respective consolidated financial statements
 for the period noted:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Consolidated Statement of Profit or Loss and Comprehensive
 Loss</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 </p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="50%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,&#xA0;2017<br />
 (As originally<br />
 presented)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS&#xA0;15<br />
 Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,&#xA0;2017<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,600</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,315</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,915</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Operating result</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,617</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,315</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(35,302</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total comprehensive loss for the period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(73,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,315</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(64,685</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Loss per share&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3.80</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.43</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3.37</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 </p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="48%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,&#xA0;2016<br />
 (As originally<br />
 presented)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS&#xA0;15<br />
 Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,&#xA0;2016<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,719</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(209</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,510</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Operating result</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(27,672</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(209</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(27,881</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total comprehensive loss for the period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(47,220</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(209</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(47,429</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Loss per share&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3.57</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.01</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3.58</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Consolidated Statement of Financial Position</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 </p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="49%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2017<br />
 (As originally<br />
 presented)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS 15<br />
 Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2017<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(167,480</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,705</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(158,775</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue, <font style="WHITE-SPACE: nowrap">non-current</font></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">130,195</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17,644</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">112,551</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,996</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,939</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,935</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 </p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="48%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2016<br />
 (As originally<br />
 presented)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS 15<br />
 Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2016<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(107,295</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">390</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(106,905</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue, <font style="WHITE-SPACE: nowrap">non-current</font></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30,206</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,272</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,610</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,882</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,492</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <i>Consolidated Statement of Cash Flows</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 </p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="50%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2017<br />
 (As originally<br />
 presented)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS 15<br />
 Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2017<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Result after taxation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(73,089</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,315</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(64,774</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Changes in working capital:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,618</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,315</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14,933</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 </p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="49%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2016<br />
 (As originally<br />
 presented)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS 15<br />
 Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2016<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Result after taxation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(47,228</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(209</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(47,437</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Changes in working capital:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(223</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">209</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>IFRS 9 Financial Instruments</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 IFRS 9, <i>Financial Instruments</i> (&#x201C;IFRS 9&#x201D;)
 replaces the provisions of IAS 39 that relate to the recognition,
 classification and measurement of financial assets and financial
 liabilities; derecognition of financial instruments; impairment of
 financial assets and hedge accounting. IFRS 9 also significantly
 amends other standards dealing with financial instruments such as
 IFRS 7, <i>Financial Instruments: Disclosures</i>. The Company
 assessed the classification and measurement of the financial
 instruments it held at the date of initial application of IFRS 9,
 or January&#xA0;1, 2018, and has classified its financial
 instruments into the appropriate IFRS 9 categories. There were no
 changes to the carrying value of the Company&#x2019;s financial
 instruments resulting from this reclassification and, accordingly,
 there was no impact to the Company&#x2019;s opening accumulated
 deficit at January&#xA0;1, 2018, as a result of the adoption of
 IFRS&#xA0;9.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 IFRS 9 replaces the &#x2018;incurred loss&#x2019; model in IAS 39
 with an &#x2018;expected credit loss&#x2019; (&#x201C;ECL&#x201D;)
 model. The new impairment model applies to financial assets
 measured at amortized cost, contract assets and debt investments at
 fair value recorded through other comprehensive loss, but not to
 investments in equity instruments. Under IFRS&#xA0;9, credit losses
 are recognized earlier than under IAS 39. Under IFRS 9, loss
 allowances are measured on either <font style="WHITE-SPACE: nowrap">12-month</font> ECLs, which result from
 possible default events within the 12 months after the reporting
 date, or lifetime ECLs, which result from all possible default
 events over the expected life of a financial</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 instrument.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company&#x2019;s financial assets recorded at amortized cost
 consist of cash and cash equivalents, investments and trade and
 other receivables. These financial assets are considered to have a
 low credit risk and, as such, there was no impact to the
 Company&#x2019;s opening accumulated deficit as a result of the
 change in impairment methodology.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Newly Issued International Financial Reporting Standards</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>IFRS 16 Leases</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In January 2016, the IASB issued IFRS 16, <i>Leases</i>.
 IFRS&#xA0;16 established a <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">right-of-use</font></font> model that
 requires all lessees to recognize a <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">right-of-use</font></font> asset and a lease
 liability in their statement of financial position that arise from
 leases with a term that is greater than twelve months. The standard
 is effective for periods beginning on or after January&#xA0;1,
 2019.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company adopted IFRS 16 on January&#xA0;1, 2019, using a
 modified retrospective transition approach applied to leases
 existing as of, or entered into after, January&#xA0;1, 2019. The
 Company elected the practical expedients available under the
 transition guidance including, but not limited to, the recognition
 exemption for short-term and <font style="WHITE-SPACE: nowrap">low-value</font> leases.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The Company has reviewed its existing lease contracts and the
 impact of the new leasing standard on its consolidated statement of
 profit or loss and comprehensive loss, financial position and
 related disclosures. Although the Company is in the process of
 evaluating the full impact of IFRS 16 on its consolidated financial
 statements, it expects to recognize a lease liability and related
 <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">right-of-use</font></font> asset of
 approximately &#x20AC;3.0&#xA0;million in its consolidated statement
 of financial position for its real estate leases existing as of
 January&#xA0;1, 2019. This amount does not include the Cambridge,
 Massachusetts office lease, which was executed in March 2019 (see
 Note&#xA0;22). The Company is still evaluating the impact of its
 <font style="WHITE-SPACE: nowrap">non-real</font> estate leases,
 but it is not expected to be material to the Company&#x2019;s
 financial statements. The Company&#x2019;s consolidated statement of
 profit or loss and comprehensive loss will reflect additional
 depreciation expense due to the <font style="WHITE-SPACE: nowrap">right-of</font> use assets, an increase in
 finance costs for effective interest expense on its lease
 liabilities and a decrease in rent expense. The Company also
 expects to expand its disclosures regarding the amounts, timing and
 uncertainties of cash flows related to its lease portfolio.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>IFRIC 23 Uncertainty over Income Tax Treatments</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 IFRIC 23 <i>Uncertainty over Income Tax Treatments</i>
 (&#x201C;IFRIC 23&#x201D;) clarifies how the recognition and
 measurement requirements of IAS 12, <i>Income taxes</i>, are
 applied where there is uncertainty over income tax treatments. An
 uncertain tax treatment is any tax treatment applied by an entity
 where there is uncertainty over whether that treatment will be
 accepted by the tax authority.&#xA0;Under IFRIC 23, the key test is
 whether it&#x2019;s probable that the tax authority will accept the
 company&#x2019;s chosen tax treatment allowing for the assumption
 that the tax authorities will have full knowledge of all relevant
 information in assessing a proposed tax treatment. IFRIC 23 applies
 for annual periods beginning on or after January&#xA0;1, 2019, with
 early adoption permitted. The Company does not expect IFRIC 23 will
 have a material impact on the Company&#x2019;s financial
 statements.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for changes in accounting policies, accounting estimates and errors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Section Accounting policies<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=8&amp;date=2018-03-01&amp;anchor=sect_Accountingpolicies&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735575248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, Plant and Equipment</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>5.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Property, Plant and Equipment</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Movements in property, plant and equipment, net were as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Plant and</b><br />
 <b>equipment</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Other&#xA0;fixed</b><br />
 <b>assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as at January&#xA0;1, 2017</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">649</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,386</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,035</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(221</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,166</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,387</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Book value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">428</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">220</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">648</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Changes in book value</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Additions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">663</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">113</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">776</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(186</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(70</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(256</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Disposals (Cost)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(51</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,086</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,137</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Disposals (Accumulated depreciation)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,086</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,137</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">477</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">43</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">520</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as at December&#xA0;31, 2017</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,261</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">413</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,674</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(356</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(150</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(506</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Book value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">905</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">263</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,168</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Changes in book value</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Additions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,498</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">300</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,798</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(448</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(98</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(546</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Disposals (Cost)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Disposals (Accumulated depreciation)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,050</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">202</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,252</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as at December&#xA0;31, 2018</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,759</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">713</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,472</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(804</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(248</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,052</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Book value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,955</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">465</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,420</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2018-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2018-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735475984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">Intangible Assets</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 </p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>6.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Intangible Assets</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The intangible assets, net are related to acquired intellectual
 property rights were as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(euros&#xA0;in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as at January&#xA0;1</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Historical cost</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>860</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">860</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(548</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(486</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Book value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>312</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">374</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Additions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,225</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Amortization for the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(92</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(62</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Book value as at December&#xA0;31</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,445</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">312</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as at December&#xA0;31</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Historical cost</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>3,085</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">860</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(640</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(548</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Book value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,445</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">312</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 During the year ended December&#xA0;31, 2018, the Company acquired
 or licensed certain intellectual property and, under the terms of
 the related agreements, paid &#x20AC;2.2&#xA0;million in fees. The
 transactions were accounted for as an asset acquisition. As a
 result, the Company capitalized &#x20AC;2.2&#xA0;million as
 intangible assets in its consolidated statements of financial
 position. The Company amortizes the cost of the acquired or
 licensed intellectual property over its estimated economic life
 based on the remaining legal life of the related patents from the
 date of acquisition or license.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2018-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2018-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735478624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Taxation</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>7.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Taxation</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Deferred tax assets have not been recognized in respect of tax
 losses and deductible temporary differences, because the Company
 has no history of generating taxable profits and at the balance
 sheet date, there is no convincing evidence that sufficient taxable
 profit will be available against which the tax losses can be
 utilized. As of December&#xA0;31, 2018, the tax losses carried
 forward amounted to &#x20AC;75.9&#xA0;million as compared to
 &#x20AC;140.5&#xA0;million at December&#xA0;31, 2017 (as restated
 for the adoption of IFRS 15. See Note 4 for details). The
 deductible temporary difference, which completely relates to
 deferred revenue, amounted to &#x20AC;114.6&#xA0;million at
 December&#xA0;31, 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In November 2018, the Dutch tax authorities confirmed that the
 $120.0&#xA0;million upfront license fee received from Incyte can be
 fully recognized in 2017 for Dutch corporate income tax purposes,
 which resulted in a significant reduction of the Company&#x2019;s
 tax loss carry-forwards. The treatment of upfront license fees
 received is consistently applied by the Company for Dutch corporate
 income tax purposes. There will be no impact on the Company&#x2019;s
 consolidated statements of financial position or consolidated
 statement of profit or loss and comprehensive loss as no deferred
 tax asset was recognized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In order to promote innovative technology development activities
 and investments in new technologies, a corporate income tax
 incentive has been introduced in Dutch tax law called the
 Innovations Box. Based on the Innovations Box ruling, the Company
 would owe on the first 75% of qualifying profits under the Dutch
 jurisdiction effectively 7% for Dutch income taxes. The remaining
 profit would be taxed at the headline Dutch statutory tax rate of
 25%. The headline Dutch statutory tax rate is 25% for fiscal years
 2018 and 2019. Legislation has been enacted amending the headline
 Dutch statutory tax rate to 22.55% for fiscal year 2020 and 20.5%
 for fiscal year 2021. Taxable profits will only qualify for the
 Innovations Box once the tax losses carried forward are completely
 utilized. The agreement with the tax authorities was originally
 signed for the tax years beginning in 2011 through 2015 and was
 subsequently extended up to and including year 2019. Since the
 Company is loss-making, no Dutch income tax is recognized in the
 consolidated statement of profit or loss and comprehensive
 loss.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Merus US, Inc., which is incorporated in the U.S. in the State of
 Delaware, is subject to statutory U.S. Federal corporate income
 taxes and state income taxes for Massachusetts at a blended rate of
 28% and 40% for the years ended December&#xA0;31, 2018 and 2017,
 respectively. Current year income tax expense was attributable
 entirely to Merus US, Inc. which was established on
 February&#xA0;17, 2016 and provided general management services and
 strategic advisory services to the Company. Corporate income tax
 expenses were &#x20AC;0.4&#xA0;million and &#x20AC;0.2&#xA0;million
 for the years ended December&#xA0;31, 2018 and 2017,
 respectively.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6742413904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory', window );">Investments</a></td>
<td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr style="page-break-inside:avoid">
 <td width="4%" valign="top" align="left"><b>8.</b></td>
 <td align="left" valign="top">
 <p style="margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;" align="left"><b>Investments</b></p>
 </td>
 </tr>
 </table>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 On January&#xA0;1, 2018, the Company adopted IFRS 9 and classifies
 and accounts for its investments at amortized cost. The
 Company&#x2019;s investments as of December&#xA0;31, 2017 were
 classified and accounted for as <font style="white-space:nowrap"><font style="white-space:nowrap">held-to-maturity</font></font> under IAS 39.
 The initial adoption of IFRS 9 had no impact on previously reported
 amounts (See Note 4).</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company&#x2019;s investments include investments in commercial
 paper, debt securities issued by several public corporations and
 the U.S. Treasury. Current investments include investments with a
 maturity date of greater than three months at the date of
 settlement. Investments with a maturity of 12 months or more from
 the original investment date are classified <font style="white-space:nowrap">as&#xA0;non-current.</font></p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Investments as of December&#xA0;31, 2018 and 2017 consisted of the
 following:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b><i>(euros in
 thousands)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>22,208</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,527</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 U.S. Treasury securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>6,733</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,177</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Corporate fixed income bonds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>14,185</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,886</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Agency bonds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,729</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,453</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Current investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>44,855</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34,043</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Corporate fixed income bonds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>16,945</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,060</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <font style="white-space:nowrap">Non-current</font> investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>16,945</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,060</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>61,800</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">41,103</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company first began its investment program during the fourth
 quarter of 2017. During the years ended December&#xA0;31, 2018 and
 2017, the Company purchased investments totaling
 &#x20AC;75.9&#xA0;million and &#x20AC;41.8&#xA0;million,
 respectively, which are held and denominated in U.S. dollars.
 During the years ended December&#xA0;31, 2018 and 2017, the Company
 received proceeds of &#x20AC;58.9&#xA0;million and &#x20AC;0,
 respectively, relating to investment maturities. As a result of the
 fluctuation in foreign currency between the euro and U.S. dollar,
 the Company recorded foreign currency exchange net gains of
 &#x20AC;3.2&#xA0;million as a component of finance income for the
 year ended December&#xA0;31, 2018. For the year ended
 December&#xA0;31, 2017, the Company recorded foreign currency
 exchange net losses of &#x20AC;0.8&#xA0;million as a component of
 finance expense.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments other than investments accounted for using the equity method. [Refer: Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735536608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">Trade and Other Receivables</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>9.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Trade and Other Receivables</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 All trade and other receivables are short-term and due within 1
 year.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b><i>(euros&#xA0;in&#xA0;thousands)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,690</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,594</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unbilled receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>236</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 VAT receivable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>891</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">582</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Prepaid expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,783</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">427</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Prepaid pension costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">838</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Interest receivable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>213</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>219</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">92</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>7,032</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,413</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Trade and unbilled receivables relate primarily to invoicing for
 cost reimbursements relating to the Incyte collaboration and
 license agreement, ONO research and license agreement and Simcere
 research and license agreement. VAT receivable relates to a value
 added tax receivable from the Dutch tax authorities based on the
 tax application for the fourth quarter of 2018. The Company is
 evaluating if the benefits of claiming foreign VAT are favorable
 compared to the related costs and expects to finalize the
 assessment and conclude in the course of 2019.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Prepaid expenses consist of expenses that were paid but are related
 to activities taking place in subsequent periods and prepaid taxes.
 The increase in prepaid expenses at December&#xA0;31, 2018 relates
 primarily to advance payments made to contract research and
 contract manufacturing organizations in support of the
 Company&#x2019;s preclinical, clinical trial, and contract
 manufacturing activities.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735588800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities and Accruals<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory', window );">Other Liabilities and Accruals</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>10.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left"><b>Other Liabilities and Accruals</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 All amounts are short-term and payable within 1 year.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b><i>(euros&#xA0;in&#xA0;thousands)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Audit fees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>167</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">96</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Personnel-related</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>560</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">446</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accrued bonus</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,523</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,545</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 R&amp;D costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,409</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,272</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 IP legal fees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>212</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">509</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Subsidy advance received</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>42</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">224</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other accruals</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,051</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">535</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>7,964</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,627</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Accrued R&amp;D costs relate to third-party contract costs for
 preclinical studies and clinical trial activities and related
 contract manufacturing expenses. The decrease in R&amp;D costs is
 due to the timing of invoices received.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Accrued bonuses relate to employee bonuses for the financial year
 2018, which were paid out in February 2019.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Subsidy advances received relate to active grants where the Company
 has received cash in excess of allowances, which is required to be
 repaid or recognized as grant revenue when the relevant
 reimbursable costs are incurred as services are performed.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accrued expenses and other liabilities. [Refer: Accruals; Other liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735572752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDeferredIncomeExplanatory', window );">Deferred Revenue</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>11.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left"><b>Deferred Revenue</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Deferred revenue consisted of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017<br />
 Restated*</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b><i>(euros&#xA0;in&#xA0;thousands)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue&#x2014;current portion</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>16,934</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,935</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>97,675</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">112,551</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>114,609</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,486</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left">*</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left"><i>See Note 4 for details regarding the restatement as
 a result of a change in accounting policy.</i></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Of the total deferred revenue balance at December&#xA0;31, 2018,
 &#x20AC;112.6&#xA0;million related to the Incyte collaboration and
 license agreement and a share subscription agreement (the
 &#x201C;Incyte share subscription agreement&#x201D;) entered into by
 the Company with Incyte on December&#xA0;20, 2016 (together, the
 &#x201C;Incyte Agreements&#x201D;) and &#x20AC;2.1
 million&#xA0;related to the collaboration and license agreement
 entered into by the Company with Simcere on January&#xA0;8, 2018
 (the &#x201C;Simcere collaboration and license agreement&#x201D;).
 The total deferred revenue balance at December&#xA0;31, 2017,
 related solely to the Incyte Agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Under the Incyte collaboration and license agreement, Incyte agreed
 to pay the Company a $120.0&#xA0;million,
 or&#xA0;<font style="WHITE-SPACE: nowrap">&#x20AC;112.0&#xA0;million,&#xA0;non-refundable&#xA0;upfront</font>&#xA0;payment,
 and under the Incyte share subscription agreement, Incyte agreed to
 purchase 3.2&#xA0;million common shares at a price per share of
 $25.0, for an aggregate purchase price of $80.0&#xA0;million. In
 January 2017, the Company completed the sale of its common shares
 under the Incyte share subscription agreement and received the
 $80.0&#xA0;million in aggregate purchase price. In February 2017,
 the Company received the $120.0&#xA0;million, or
 &#x20AC;112.0&#xA0;million,&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;upfront
 payment and recorded it as deferred revenue.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company combined the Incyte collaboration and license agreement
 and Incyte share subscription agreement and accounted for them as a
 single contract based on the following criteria: (i)&#xA0;they were
 entered into at the same time with the same customer; (ii)&#xA0;the
 arrangements&#x2019; mutual existence is acknowledged in the
 separate agreements; and (iii)&#xA0;they were negotiated as a
 package with a single commercial objective.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 As the Incyte share subscription agreement was denominated in a
 foreign currency (U.S. dollars) other than the Company&#x2019;s
 functional currency (euro), the Company determined that the
 freestanding forward contract to sell its own shares at a future
 date, to which the Company became committed on December&#xA0;20,
 2016, did not qualify as equity and thus a freestanding forward
 contract (derivative asset) was recognized in the Company&#x2019;s
 consolidated statement of financial position. The difference
 between the purchase price of $25.0 per common share in the Incyte
 share subscription agreement and the market price of the
 Company&#x2019;s common shares on December&#xA0;20, 2016 was
 considered to be part of the consideration received under the
 Incyte Agreements. As a result, on December&#xA0;20, 2016, the
 Company recorded a liability (deferred revenue) of
 $32.6&#xA0;million, or &#x20AC;31.4&#xA0;million, in its
 consolidated statement of financial position for the same amount as
 the fair value of the freestanding forward contract (derivative
 asset). The deferred revenue liability is not remeasured subsequent
 to the initial recognition and is accounted for in the same manner
 as the&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;upfront
 payment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company&#x2019;s fixed consideration under the Incyte Agreements
 is $152.6&#xA0;million, consisting of the $120.0&#xA0;million, or
 &#x20AC;112.0&#xA0;million,&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;upfront
 payment from the Incyte collaboration and license agreement and
 $32.6&#xA0;million, or &#x20AC;31.4&#xA0;million, in consideration
 from the issuance and sale of common shares pursuant to the Incyte
 share subscription agreement. The transaction price was allocated
 to a single combined performance obligation that includes a license
 to the Company&#x2019;s technology combined with the JSC services
 during the research term. Revenue from upfront license payments
 under the Incyte collaboration and license agreement will be
 recognized as the Company satisfies the combined performance
 obligation, or over the nine-year research term, which is a period
 during which the Company has present enforceable obligation to
 provide JSC services.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Under the Simcere collaboration and license agreement, the Company
 agreed to grant Simcere an exclusive license to develop and
 commercialize in China three bispecific antibodies to be produced
 by Merus utilizing the Company&#x2019;s Biclonics<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;technology
 platform in the area of immuno-oncology. The Company will retain
 all rights outside of China. As part of the agreement, the Company
 has agreed to lead research and discovery activities, while Simcere
 has agreed to be responsible for the Investigational New Drug
 (&#x201C;IND&#x201D;) enabling studies, clinical development,
 regulatory filings and commercialization of these product
 candidates in China. The Company received an
 upfront,&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;payment
 of $2.75&#xA0;million, or &#x20AC;2.3&#xA0;million, relating to
 three separate research programs. Each research program was
 determined to be a separate performance obligation and
 consideration was allocated to each separate obligation. In
 addition, the Company received a payment of $0.8&#xA0;million, or
 &#x20AC;0.6&#xA0;million, relating to one of the programs, which was
 also recorded as deferred revenue.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company amortizes the upfront and milestone payment to revenue
 over time based on the estimated duration of each research program.
 As of December&#xA0;31, 2018, the first and second research
 programs had commenced. For the year ended December&#xA0;31, 2018,
 the Company recognized revenue of &#x20AC;0.9&#xA0;million, relating
 to these two programs for the amortization of upfront and milestone
 payments. The remaining research program had not commenced as of
 December&#xA0;31,&#xA0;2018. Accordingly, no revenue has been
 recognized related to the remaining research program.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 On March&#xA0;14, 2018, the Company entered into a second contract
 research and license agreement with ONO (the &#x201C;second ONO
 research and license agreement&#x201D;). Pursuant to an exclusive
 option granted to ONO in the ONO research and license agreement,
 ONO exercised its option to enter into the second ONO research and
 license agreement. The Company granted ONO an exclusive, worldwide,
 royalty-bearing license, with the right to sublicense, research,
 test, make, use and market bispecific antibody candidates based on
 the Company&#x2019;s Biclonics<b><sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup></b><b><sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xA0;</sup></b>technology
 platform against two undisclosed targets directed to a particular
 undisclosed target combination.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Under the terms of the agreement, ONO identifies and selects the
 licensed bispecific antibodies for which it is responsible for
 conducting&#xA0;<font style="WHITE-SPACE: nowrap">further&#xA0;non-clinical&#xA0;and</font>&#xA0;clinical
 development activities for such licensed bispecific antibodies and
 pharmaceutical products containing such antibodies, including
 manufacture and process development. Additionally, ONO controls and
 has exclusive rights over the worldwide commercialization of any
 approved products, including worldwide supply, and is solely
 responsible for all costs and expenses related to
 commercialization. ONO has also agreed to fund the Company&#x2019;s
 R&amp;D activities and be responsible for the payment of all costs
 and expenses for its own R&amp;D activities, which are set out in a
 mutually agreed upon research plan. The Company retains all rights
 to use and commercialize any antibodies that are generated under
 the collaborative research program, excluding the up to five lead
 and/or selected antibodies against the targets ONO is pursuing,
 provided that the use and commercialization is not with respect to
 the particular target combination.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 ONO agreed to pay the Company an&#xA0;<font style="WHITE-SPACE: nowrap">upfront,&#xA0;non-refundable&#xA0;payment</font>&#xA0;of
 &#x20AC;0.7&#xA0;million, &#x20AC;0.3&#xA0;million intended to
 compensate the Company for research services already completed upon
 entering into the agreement, and &#x20AC;0.2&#xA0;million to be paid
 to the Company over time for full time equivalent funding. The
 Company identified a single performance obligation of providing
 research services to ONO, which were fully completed in 2018, and
 recognized all deferred payments received of approximately
 &#x20AC;1.2&#xA0;million as revenue during the year ended
 December&#xA0;31, 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 On December&#xA0;10, 2018, the Company entered into a collaboration
 and license agreement with Betta (the &#x201C;Betta collaboration
 and license agreement&#x201D;), where the Company granted Betta an
 exclusive license to develop and commercialize in
 China&#xA0;<font style="WHITE-SPACE: nowrap">MCLA-129,</font>&#xA0;a
 proprietary Biclonics<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;produced
 by its Biclonics<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;technology
 platform. The Company retains all rights outside of China. Under
 the terms of the Betta collaboration and license agreement, Betta
 has agreed to retain a contract manufacturing organization with
 experience in filing IND applications with U.S. regulatory
 authorities and CTAs with European regulatory authorities in order
 to produce clinical trial materials for the Chinese market and rest
 of the world. As a key strategic component of the collaboration,
 Betta will be responsible for IND enabling studies and
 manufacturing of clinical trial materials in China, which the
 Company intends to use to assist regulatory filing and early stage
 clinical development in the rest of the world.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 In addition to a&#xA0;<font style="WHITE-SPACE: nowrap">non-refundable</font>&#xA0;upfront
 payment of $1.0&#xA0;million, or &#x20AC;0.9&#xA0;million, Betta and
 the Company will share equally the cost of the transfer of the
 manufacturing technology to a contract manufacturing organization.
 The Company is also eligible to receive an aggregate of
 $12.0&#xA0;million, or &#x20AC;10.5&#xA0;million, in milestone
 payments contingent upon Betta achieving certain specified
 development and commercial goals as well as tiered royalty payments
 of net sales of any products resulting from the collaboration in
 China.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company identified a single combined performance obligation,
 which includes a license to&#xA0;<font style="WHITE-SPACE: nowrap">MCLA-129</font>&#xA0;and other
 promised goods and services, and will recognize revenue over time
 based on the estimated duration of
 the&#xA0;<font style="WHITE-SPACE: nowrap">IND-enabling</font>&#xA0;studies.
 For the year ended December&#xA0;31, 2018, the Company recognized
 revenue of less than &#x20AC;0.1&#xA0;million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Betta is eligible to receive from the Company an aggregate of
 $12.0&#xA0;million, or &#x20AC;10.5&#xA0;million, in milestone
 payments contingent upon the Company achieving certain specified
 development and commercial goals, and is eligible to receive tiered
 royalty payments of net sales outside of China.&#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"></td>
 </tr>
 </table>
 <p>&#xA0;</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDeferredIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of deferred income. [Refer: Deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDeferredIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6747353920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Shareholders' Equity</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>12.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Shareholders&#x2019; Equity</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b>Reverse Share Split</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On May&#xA0;6, 2016, the general meeting of the Company&#x2019;s
 shareholders resolved to approve and effect a capital
 reorganization, based on a reverse share split. The effect of the
 reverse share split was a <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">1-for-1.8</font></font> reverse share split
 of the outstanding common and preferred shares held by the
 Company&#x2019;s shareholders. This reverse share split became
 effective on May&#xA0;6, 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Initial Public Offering</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On May&#xA0;24, 2016, the Company closed the initial public
 offering of 5,500,000 of its common shares and, on May&#xA0;26,
 2016, of an additional 639,926 of its common shares, at a price to
 the public of $10.0 per share. Net proceeds to the Company after
 deducting underwriting discounts and commissions and offering
 expenses were $53.3&#xA0;million. On May&#xA0;19, 2016, the
 Company&#x2019;s common shares were listed on the Nasdaq and all of
 the Company&#x2019;s preferred shares converted into common
 shares.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Share Subscription Agreement with Incyte</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Concurrent with the Incyte collaboration and license agreement
 discussed above under Note 11, the Company entered into the Incyte
 share subscription agreement on December&#xA0;20, 2016. On
 January&#xA0;23, 2017, under the terms of the Incyte share
 subscription agreement, the Company issued 3,200,000 of its common
 shares to Incyte at the agreed price per share of $25.0, for an
 aggregate purchase price of $80.0&#xA0;million, or
 &#x20AC;74.7&#xA0;million. The Company received proceeds of
 &#x20AC;74.4&#xA0;million, net of issuance costs of
 &#x20AC;0.2&#xA0;million. A &#x20AC;1.1&#xA0;million discount on the
 subscription share price, combined with a &#x20AC;0.4&#xA0;million
 foreign currency translation accompanying the issuance of these
 shares, increased share capital by &#x20AC;0.3&#xA0;million and
 share premium by &#x20AC;73.4&#xA0;million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Private Placement of Common Shares</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On February&#xA0;13, 2018, the Company entered into the Purchase
 Agreement. Pursuant to the Purchase Agreement, the Company agreed
 to sell an aggregate of 3,099,997 of its common shares to the
 Investors at a purchase price equal to $18.0 per share. The
 Purchase Agreement contains customary representations and
 warranties from the Company and the Investors and customary closing
 conditions. On February&#xA0;15, 2018, the Company completed the
 sale under the Private Placement and received gross proceeds of
 approximately $55.8&#xA0;million, or &#x20AC;44.8&#xA0;million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Share Subscription Agreement with Regeneron</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On December&#xA0;20, 2018, the Company entered into a share
 subscription agreement with Regeneron (the &#x201C;Regeneron
 Subscription Agreement&#x201D;). See Note 21 for details. Pursuant
 to the Regeneron Subscription Agreement, the Company agreed to sell
 an aggregate of 600,000 of its common shares to Regeneron at a
 purchase price equal to $25.0 per share. The Regeneron Subscription
 Agreement contains customary representations and warranties from
 the Company and Regeneron and customary closing conditions. On
 December&#xA0;21, 2018, the Company completed the sale under the
 Regeneron Subscription Agreement and received gross proceeds of
 $15.0&#xA0;million, or &#x20AC;13.1&#xA0;million. Accordingly, the
 Company recorded the common shares issued at the fair value of the
 underlying securities on the date of issuance. The difference
 between the total proceeds received of $15.0&#xA0;million, or
 &#x20AC;13.1&#xA0;million, and the aggregate value of common shares
 issued of $6.9&#xA0;million, or &#x20AC;6.0&#xA0;million, was
 recorded as a gain on litigation settlement of $8.1&#xA0;million,
 or &#x20AC;7.1&#xA0;million, during the year-ended December&#xA0;31,
 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Issued and <font style="WHITE-SPACE: nowrap">Paid-in</font>
 Share Capital</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 All issued shares have been fully paid in cash.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Common Shares</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 At December&#xA0;31, 2018, 2017 and 2016, a total of 23,358,977,
 19,429,848, and 16,085,851 common shares, respectively, were issued
 and fully paid in cash. The following is a tabular reconciliation
 of common shares outstanding for the years ended December&#xA0;31,
 2018 and 2017, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Common Shares outstanding at January&#xA0;1,</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>19,429,848</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,085,851</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Issued for cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>3,699,997</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,200,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercise of common share options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>135,888</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">136,666</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vesting of RSUs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>93,244</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,331</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Common shares outstanding at December&#xA0;31,</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>23,358,977</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,429,848</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Share Premium Reserve</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The share premium reserve relates to amounts contributed by
 shareholders at the issue of shares in excess of the par value of
 the shares issued.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 All share premium can be considered as free share premium as
 referred to in the Netherlands Income tax act.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Share-Based Payment Arrangements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In 2010, the Company established the Merus B.V. 2010 Employee
 Option Plan (the &#x201C;2010 Plan&#x201D;) that entitled key
 management personnel, staff and consultants providing similar
 services to purchase shares in the Company. Under the 2010 Plan,
 holders of vested options were entitled to purchase depositary
 receipts for common shares at the exercise price determined at the
 date of grant. Upon exercise of the option, common shares were
 issued to a foundation established to facilitate administration of
 share-based compensation awards and pool the voting interests of
 the underlying shares, and depositary receipts were issued by the
 foundation to the individual holders. In connection with the IPO,
 the 2010 Plan was amended to cancel the depositary receipts and
 allow individual holders to directly hold the common shares
 obtained upon exercise of their options.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Options granted under the 2010 Plan are exercisable once vested.
 The options granted under the 2010 Plan vest in installments over a
 four-year period from the grant date. Twenty-five percent of the
 options vest on the first anniversary of the vesting commencement
 date, and the remaining seventy-five percent of the options vest in
 36 monthly installments for each full month of continuous service
 provided by the option holder thereafter, such that 100% of the
 options become vested on the fourth anniversary of the vesting
 commencement date. Options lapse on the eighth anniversary of the
 date of grant.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Prior to the IPO, participants that voluntarily left the Company,
 except for members of the former Supervisory Board, were required
 to offer to the foundation the depositary receipts acquired from
 exercising options against payment of the exercise price or the
 lower fair market value of the underlying shares. This obligation
 for a participant to offer depositary receipts to the foundation
 upon resignation within four years from exercising the options was
 treated as a <font style="WHITE-SPACE: nowrap">non-market</font>
 vesting condition. In connection with the IPO, the foundation was
 dissolved and the common shares underlying depositary receipts
 distributed. In addition, the 2010 Option Plan was amended such
 that a participant is no longer required to offer depositary
 receipts to the foundation upon resignation.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The reduction of the vesting period has been accounted for, taking
 into consideration the modified vesting conditions, to reflect the
 best estimate available of the options that are expected to vest.
 At the modification date in 2016, the cumulative expense for the
 options has been <font style="WHITE-SPACE: nowrap">trued-up</font>
 to reflect the reduced vesting period. This amendment of a
 <font style="WHITE-SPACE: nowrap">non-market</font> vesting
 (service) condition did not impact the fair value of the options
 granted.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In connection with the IPO, the Company established the 2016
 Incentive Award Plan (the &#x201C;2016 Plan&#x201D;). Following the
 IPO, the Company is no longer making grants under the 2010 Plan;
 however, the terms of the 2010 Plan will continue to govern grants
 made under the 2010 Plan. All new incentive award grants since the
 IPO are being made under the 2016 Plan.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Options granted under the 2016 Plan are exercisable once vested.
 The options granted under the 2016 Plan vest in installments over a
 four-year period from the grant date. Twenty-five percent of the
 options vest on the first anniversary of the vesting commencement
 date, and the remaining seventy-five percent of the options vest in
 36 monthly installments for each full month of continuous service
 provided by the option holder thereafter, such that 100% of the
 options shall become vested on the fourth anniversary of the
 vesting commencement date. Options will lapse on the tenth
 anniversary of the date of grant.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The RSUs granted under the 2016 Plan also vest in installments over
 a four-year period from the grant date. Each RSU represents the
 right to receive one common share.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company also established the Supervisory Board Compensation
 Program, which was subsequently replaced by the <font style="WHITE-SPACE: nowrap">Non-Executive</font> Director Compensation
 Program to reflect the change in governance structure of the
 Company (see Note 1). As part of this program, <font style="WHITE-SPACE: nowrap">non-executive</font> directors are entitled
 to cash compensation as well as equity compensation. The equity
 compensation consists of an initial option grant as well as annual
 awards.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The initial awards granted under the <font style="WHITE-SPACE: nowrap">Non-Executive</font> Compensation Program
 vest in installments over a three-year period. Thirty-three percent
 of the options vest on the first anniversary of the vesting
 commencement date, and the remaining sixty seven percent of the
 options in 24 substantially equal monthly installments thereafter,
 such that the award shall be fully vested on the third anniversary
 of the vesting commencement date. Each subsequent award shall vest
 and become exercisable in 12 substantially equal monthly
 installments following the vesting commencement date, such that the
 subsequent award shall be fully vested on the first anniversary of
 the date of grant.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Share-based payment expenses are recognized as from the IPO date
 for each subsequent award that a <font style="WHITE-SPACE: nowrap">non-executive</font> director is entitled to
 over their remaining term. Since subsequent awards are not subject
 to shareholder approval, the grant date is established and expenses
 are based on grant date fair value. The grant date fair value is
 not updated in each future reporting period and therefore the
 estimated fair value is not revised and expense recognized is based
 on the actual grant date fair value of the awards granted.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Pursuant to the &#x201C;evergreen&#x201D; provisions of the 2016
 Plan, the number of common shares authorized for issuance under the
 plan automatically increased by 934,359 common shares to 1,469,785
 common shares effective January&#xA0;1, 2019.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Measurement of Fair Value of the Equity-Settled Share-Based
 Payment Arrangements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The fair value of the share options granted to the employee and the
 Board of Directors has been measured using a binomial option
 pricing model. Service and <font style="WHITE-SPACE: nowrap">non-market</font> performance conditions
 attached to the transactions were not taken into account in
 measuring fair value. Key management personnel include the
 Company&#x2019;s executive management and the Board of
 Directors.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The inputs used in the measurement of the fair values and the
 related fair values at the grant dates for the options granted
 during the respective years were as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="29%"></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="11" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"><b>2016</b></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>Key</b><br />
 <b>Management</b><br />
 <b>Personnel</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>All Other</b><br />
 <b>Employees</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>Key</b><br />
 <b>Management</b><br />
 <b>Personnel</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>All Other</b><br />
 <b>Employees</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>Key</b><br />
 <b>Management</b><br />
 <b>Personnel</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>All Other</b><br />
 <b>Employees</b></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Fair value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 <b>&#x20AC;6.82&#xA0;&#x2013;&#xA0;&#x20AC;12.27</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 <b>&#x20AC;7.74&#xA0;&#x2013;&#xA0;&#x20AC;13.32</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;9.04&#xA0;&#x2013;&#xA0;&#x20AC;16.10</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;8.94&#xA0;&#x2013;&#xA0;&#x20AC;18.02</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;9.97&#xA0;&#x2013;&#xA0;&#x20AC;11.03</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;5.74&#xA0;&#x2013;&#xA0;&#x20AC;5.79</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Share price</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 <b>&#x20AC;13.01&#xA0;&#x2013;&#xA0;&#x20AC;19.90</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 <b>&#x20AC;12.29&#xA0;&#x2013;&#xA0;&#x20AC;21.02</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;17.08&#xA0;&#x2013;&#xA0;&#x20AC;24.54</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;13.71&#xA0;&#x2013;&#xA0;&#x20AC;27.47</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;15.24&#xA0;&#x2013;&#xA0;&#x20AC;16.85</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;8.46&#xA0;&#x2013;&#xA0;&#x20AC;8.87</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercise price</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 <b>&#x20AC;13.01&#xA0;&#x2013;&#xA0;&#x20AC;19.90</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 <b>&#x20AC;12.29&#xA0;&#x2013;&#xA0;&#x20AC;21.02</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;17.08&#xA0;&#x2013;&#xA0;&#x20AC;24.54</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;13.71&#xA0;&#x2013;&#xA0;&#x20AC;27.47</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;15.24&#xA0;&#x2013;&#xA0;&#x20AC;16.85</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;8.46&#xA0;&#x2013;&#xA0;&#x20AC;8.87</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility (weighted-average)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>94.71%</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>92.16%</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">95.05%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">94.88%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">95.30%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">97.15%</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected life</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>10 years</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>10 years</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">10 years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">10&#xA0;years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">10 years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">8&#xA0;&#x2013;&#xA0;10
 years</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividends</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>0%</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>0%</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 <b>2.79%&#xA0;&#x2013;&#xA0;3.20%</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 <b>2.83%&#xA0;&#x2013;&#xA0;3.10%</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 2.29%&#xA0;&#x2013;&#xA0;2.51%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 2.24%&#xA0;&#x2013;&#xA0;2.62%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 1.84%&#xA0;&#x2013;&#xA0;1.86%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 0.10%&#xA0;&#x2013;&#xA0;1.87%</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Reconciliation of outstanding share options</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The number of share options and the weighted average exercise
 prices of share options granted were as follows for the respective
 years:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="49%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>average</b><br />
 <b>exercise</b><br />
 <b>price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of</b><br />
 <b>options</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>average</b><br />
 <b>exercise</b><br />
 <b>price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of</b><br />
 <b>options</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>average</b><br />
 <b>exercise</b><br />
 <b>price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of</b><br />
 <b>options</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(&#x20AC;)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(&#x20AC;)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(&#x20AC;)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at January&#xA0;1</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>13.99</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,213,985</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.69</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,394,844</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.35</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">953,689</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Forfeited during the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>14.48</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(38,874</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.27</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(58,164</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.07</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(31,351</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expired during the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>11.00</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(31,629</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.67</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(762</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.95</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5,454</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercised during the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>6.80</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(135,888</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.24</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(136,666</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.93</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(18,283</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted during the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>14.96</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>625,445</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19.88</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,014,733</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14.74</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">496,243</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>14.62</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,633,039</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13.99</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,213,985</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.69</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,394,844</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercisable at December&#xA0;31</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,275,669</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">687,070</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">418,453</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The options outstanding at December&#xA0;31, 2018 had an exercise
 price in the range of &#x20AC;1.93 to &#x20AC;27.47 (2017:
 &#x20AC;1.93 to &#x20AC;27.47; 2016: &#x20AC;1.93 to &#x20AC;16.85) and
 a weighted-average remaining contractual life of 7.0 years (2017:
 8.25 years; 2016: 6.68 years).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The weighted-average share price at the date of exercise for share
 options exercised in 2018 was &#x20AC;17.03.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The number of share options outstanding, by group of employees, was
 as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 <b>Group of employees entitled</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Key management personnel</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,148,744</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,777,437</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,302,417</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 All other employees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">484,295</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">436,548</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">92,427</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,633,039</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,213,985</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,394,844</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 During 2017, the Company granted RSUs to Key Management Personnel.
 The following table summarizes the Company&#x2019;s RSU&#x2019;s
 activity:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>average</b><br />
 <b>grant&#xA0;date<br />
 fair value</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br />
 average<br />
 grant&#xA0;date<br />
 fair value</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested at January&#xA0;1</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">20.03</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">194,546</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#x20AC;</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Forfeited during the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#x20AC;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(12,219</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expired during the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vested during the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#x20AC;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(93,244</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#x20AC;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(7,331</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted during the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#x20AC;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>214,096</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested at December&#xA0;31</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#x20AC;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>101,302</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#x20AC;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>194,546</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735510208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Revenue</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>13.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Revenue</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Revenue is recognized at the amount to which the Company expects to
 be entitled for the transfer of promised goods or services to
 customers.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Disaggregation of Revenue</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company&#x2019;s revenues are generated entirely in the
 Netherlands. In the following table, revenue is disaggregated by
 primary source of revenue as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017<br />
 Restated*</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016<br />
 Restated*</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b><i>(euros in
 thousands)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Upfront payment amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>17,686</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,933</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 R&amp;D cost reimbursement and milestone</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>13,566</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,787</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,109</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Revenue from contracts with customers</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>31,252</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,720</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,123</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Income from grants on research projects</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>196</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,195</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,387</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>31,448</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,915</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,510</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left">*</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><i>See Note 4 for details regarding the restatement as
 a result of a change in accounting policy.</i></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 For the year ended December&#xA0;31, 2018, the Company recognized
 amortization of &#x20AC;15.9&#xA0;million on upfront payments
 related to the Incyte collaboration and license agreement,
 amortization of &#x20AC;1.2&#xA0;million on upfront payments related
 to the second ONO research and license agreement,
 &#x20AC;0.5&#xA0;million on upfront payments related to the Simcere
 collaboration and license agreement and less than
 &#x20AC;0.1&#xA0;million on the upfront payment related to the Betta
 collaboration and license agreement. For the year ended
 December&#xA0;31, 2017, the Company recognized
 &#x20AC;14.9&#xA0;million of amortization of the upfront payment
 related to the Incyte collaboration and license agreement. For the
 year ended December&#xA0;31, 2016, the Company recognized
 approximately &#x20AC;14,000 of amortization of the <font style="WHITE-SPACE: nowrap">up-front</font> payment related to the ONO
 research and license agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 R&amp;D cost reimbursement and milestone revenue for the year ended
 December&#xA0;31, 2018, was &#x20AC;13.6&#xA0;million and consisted
 of cost reimbursements, milestone payment amortization and research
 milestones achieved in support of the Company&#x2019;s research and
 license agreements with Incyte, ONO and Simcere. During the year
 ended December, 2018, the Company recognized
 &#x20AC;8.8&#xA0;million of cost reimbursements in support of the
 Company&#x2019;s research and license agreements with Incyte and
 &#x20AC;0.4&#xA0;million of cost reimbursements in support of the
 Company&#x2019;s research and license agreements with ONO. The
 Company recognized an aggregate of &#x20AC;4.0&#xA0;million in
 research milestones under its ONO agreements and
 &#x20AC;0.4&#xA0;million in research milestone payment amortization
 under its Simcere agreements for the year ended December&#xA0;31,
 2018. The Company did not recognize any revenue relating to
 research milestones under its Betta collaboration and license
 agreement for the year ended December&#xA0;31, 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 R&amp;D cost reimbursement and milestone revenue for the year ended
 December&#xA0;31, 2017 was &#x20AC;5.8&#xA0;million and consisted of
 cost reimbursements in support of the Company&#x2019;s agreements
 with Incyte and ONO. The Company did not recognize any research
 milestones during 2017. During 2016, the Company recognized one
 research milestone reached under the ONO agreement, which amounted
 to &#x20AC;0.7&#xA0;million. Additionally, the Company recorded
 revenue of &#x20AC;0.4&#xA0;million from an agreement that was
 signed with ONO on March&#xA0;7, 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company has been awarded grants consisting of cash allowances
 for specific R&amp;D projects. The unconditional receipt of the
 grant allowances is dependent on the final review of the reporting
 provided by the Company at the end of the contract term. For the
 years ended December&#xA0;31, 2018, 2017, and 2016, the Company
 recognized &#x20AC;0.2&#xA0;million, &#x20AC;1.2&#xA0;million, and
 &#x20AC;1.4&#xA0;million in grant income, respectively. As of August
 2018, all grants awarded were completed. On June&#xA0;12, 2017, the
 European Commission approved for reimbursement the final
 installment of the <font style="WHITE-SPACE: nowrap">FP-7</font>
 grant and the Company subsequently recognized the remaining
 &#x20AC;0.7&#xA0;million to grant revenue. On October&#xA0;16, 2017,
 the Company received notification from the European Commission
 requesting the Company to revise its final report and indicated
 that the remaining &#x20AC;0.4&#xA0;million of funds were to remain
 with the Company and distributed to the other beneficiaries to the
 program. In November 2017, the Company remitted
 &#x20AC;0.2&#xA0;million to the other beneficiaries and recognized
 an additional &#x20AC;0.2&#xA0;million of grant revenue.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Contract Balances</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 A trade receivable is recorded when the Company satisfies a
 performance obligation by transferring a promised good or service
 and has earned the unconditional right to consideration from its
 customer. Trade receivables relate to invoicing for cost
 reimbursements, upfront payments and research milestones achieved
 in support of the Company&#x2019;s research and license agreements
 with Incyte, ONO, Simcere and Betta. Payment terms relating to
 receivables with Incyte, ONO and Simcere are 30 days and payment
 terms relating to receivables with Betta are 60 days.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 A contract asset is recorded when the Company satisfies a
 performance obligation by transferring a promised good or service
 and has earned the right to consideration from its customer. These
 assets represent a conditional right to consideration. Contract
 assets relate to unbilled amounts for cost reimbursements and
 research milestones achieved in support of the Company&#x2019;s
 research and license agreements with Incyte and ONO.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 A contract liability is recorded when consideration is received, or
 such consideration is unconditionally due, from a customer prior to
 transferring goods or services under the terms of the contract.
 Contract liabilities are recognized as revenue as control of the
 products or services is transferred to the customer and all revenue
 recognition criteria have been met. Contract liabilities relate to
 upfront payments received related to the Incyte collaboration and
 license agreement, ONO research and license agreement and the
 Simcere research and license agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table presents changes in the Company&#x2019;s trade
 receivables, contract assets and contract liabilities during the
 year ended December&#xA0;31, 2018:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="50%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2017<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Additions</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Deductions</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade&#xA0;receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,594</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,951</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(18,855</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,690</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total trade&#xA0;receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,594</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,951</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(18,855</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,690</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contract assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unbilled receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,045</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,519</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">236</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total contract assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,045</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,519</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">236</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contract liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,486</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,137</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(18,014</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">114,609</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total contract liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,486</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,137</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(18,014</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">114,609</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table presents changes in the Company&#x2019;s trade
 receivables, contract assets and contract liabilities during the
 year ended December&#xA0;31, 2017:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="49%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2016<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Additions</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Deductions</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2017<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade&#xA0;receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">205</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">122,781</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(121,392</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,594</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total trade&#xA0;receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">205</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">122,781</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(121,392</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,594</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contract assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unbilled receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">121,240</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(120,530</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total contract assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">121,240</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(120,530</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contract liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">31,426</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">111,993</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14,933</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,486</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total contract liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">31,426</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">111,993</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14,933</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,486</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 As a result of the adoption of IFRS 15, total deferred revenue was
 reduced by &#x20AC;8.7&#xA0;million as of December&#xA0;31, 2017.
 See Note 4 for details.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 For the year ended December&#xA0;31, 2018, deductions from deferred
 revenue are comprised of revenue recognized that was included in
 deferred revenue at the beginning of the period totaling
 &#x20AC;15.9&#xA0;million and revenue recognized that was not
 included in deferred revenue at the beginning of the period
 totaling &#x20AC;2.1&#xA0;million. For the year ended
 December&#xA0;31, 2017, deductions from deferred revenue are
 comprised of revenue recognized that was included in deferred
 revenue at the beginning of the period totaling
 &#x20AC;3.2&#xA0;million and revenue recognized that was not
 included in deferred revenue at the beginning of the period
 totaling &#x20AC;11.7&#xA0;million.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735491584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Total Operating Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOperatingExpensesExplanatory', window );">Total Operating Expenses</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>14.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Total Operating Expenses</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The following table presents a breakdown of operating expenses:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Manufacturing costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>18,914</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,567</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,162</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 IP and license costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,852</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,858</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,167</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Personnel related R&amp;D</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>7,036</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,673</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,285</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other R&amp;D costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>18,938</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,027</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,810</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <i>Total R&amp;D costs</i></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>46,740</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34,125</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,424</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <i>Management and administration costs</i></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>10,395</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,258</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Litigation costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,425</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,039</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,490</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other operating expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>11,735</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,356</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,219</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <i>Total other expenses</i></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>13,160</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,395</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,709</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Total operating expenses</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>70,295</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">57,217</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30,391</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 R&amp;D costs primarily include: (i)&#xA0;payroll and related costs
 (including share-based payment expenses) associated with R&amp;D
 personnel; (ii)&#xA0;costs related to clinical trials and
 preclinical testing of the Company&#x2019;s technologies under
 development; (iii)&#xA0;costs to develop product candidates,
 including raw materials and supplies, product testing,
 depreciation, and facility related expenses; (iv)&#xA0;expenses for
 research services provided by universities and contract
 laboratories; (v)&#xA0;costs associated with obtaining and
 maintaining patents and other intellectual property; and
 (vi)&#xA0;other R&amp;D expenses.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Other R&amp;D costs consist mainly of laboratory supplies and
 depreciation expense related to R&amp;D activities, which cannot be
 specifically allocated to a research project.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table presents a breakdown of other R&amp;D
 costs:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Discovery and preclinical costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>5,506</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,473</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,185</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Clinical costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>9,169</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,919</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,409</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other R&amp;D costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,263</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,635</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,216</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Total other R&amp;D costs</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>18,938</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,027</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,810</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Management and administrative costs consist of salaries and related
 expenses for employees in finance, legal, human resources, investor
 relations and business development functions. These costs include
 all salary, salary related expenses and share-based compensation
 expenses.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Other operating expenses consist primarily of expenses related to
 professional fees for consulting, audit, and tax services of
 &#x20AC;6.3&#xA0;million (2017: &#x20AC;4.0&#xA0;million, 2016:
 &#x20AC;1.7 million), which support the finance function in
 maintaining and establishing public company status and general
 legal, insurance and facility related expenses amounting to
 &#x20AC;4.2&#xA0;million (2017: &#x20AC;3.2&#xA0;million, 2016:
 &#x20AC;3.9&#xA0;million).</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Operating expenses presented by nature are outlined below:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contract manufacturing</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>18,914</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,567</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,162</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other external and outsourced costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>32,459</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22,333</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,885</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Employee costs&#xA0;and related benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>18,284</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,999</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,110</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Depreciation and amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>638</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">318</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">234</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total operating expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>70,295</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">57,217</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30,391</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The other external and outsourced costs consist mainly of
 preclinical costs of &#x20AC;5.5&#xA0;million (2017:
 &#x20AC;2.5&#xA0;million, 2016: &#x20AC;5.2 million), clinical costs
 of &#x20AC;9.2&#xA0;million (2017: &#x20AC;5.9&#xA0;million, 2016:
 &#x20AC;3.4 million) and IP costs of &#x20AC;3.3&#xA0;million (2017:
 &#x20AC;2.9&#xA0;million, 2016: &#x20AC;2.7 million).</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfOperatingExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfOperatingExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6758528288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">Employee Benefits</a></td>
<td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr style="page-break-inside:avoid">
 <td width="4%" valign="top" align="left"><b>15.</b></td>
 <td align="left" valign="top">
 <p style="margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;" align="left"><b>Employee Benefits</b></p>
 </td>
 </tr>
 </table>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Details of the employee benefits are as follows:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Salaries and wages</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>10,783</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,556</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,166</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 WBSO subsidy</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(4,257</b></td>
 <td nowrap="nowrap" valign="bottom"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,523</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,721</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Social security premiums</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>919</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">621</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">382</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Health insurance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>330</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">222</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Pension costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>749</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">652</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">507</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Share-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>7,925</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,815</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,307</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Other personnel expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,835</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">656</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">442</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total employee benefits expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>18,284</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,999</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,110</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Share-based compensation expense recognized as employee benefit
 expenses during the years ended December&#xA0;31, 2018, 2017 and
 2016 was as follows:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b><i>(euros in
 thousands)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 R&amp;D costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,710</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,245</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">703</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Management and administration costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,742</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,942</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,037</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Other expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>473</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">628</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">567</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>7,925</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,815</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,307</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Subsidies earned under the WBSO relating to eligible R&amp;D costs
 are deferred and recognized in the Company&#x2019;s income statement
 as a reduction to labor costs over the period labor costs are
 expected to be incurred.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company&#x2019;s headcount at&#xA0;December 31, 2018 was
 approximately 98&#xA0;full-time equivalents and consisted of 81
 employees in the Netherlands and&#xA0;17 employees in the U.S. A
 total of 21&#xA0;employees who are devoted to activities other than
 R&amp;D and overall management of the Company were included under
 management and administration costs for the year ended
 December&#xA0;31, 2018.</p>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company&#x2019;s headcount at&#xA0;December 31, 2017 was
 approximately 83&#xA0;full-time equivalents and consisted of 70
 employees in the Netherlands and&#xA0;13 employees in the U.S. A
 total of 21&#xA0;employees who are devoted to activities other than
 R&amp;D and overall management of the Company were included under
 management and administration costs for the year ended
 December&#xA0;31, 2017.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2018-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=19&amp;date=2018-03-01&amp;anchor=sect_Scope&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735478624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Expense)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOtherIncomeExpenseExplanatory', window );">Other Income (Expense)</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>16.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Other Income (Expense)</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The following table presents a breakdown of other income
 (expense):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="67%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Finance income</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Interest income and similar related income</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,809</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,112</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">88</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net gain on foreign exchange</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>6,034</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="right"><b>7,843</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="right"><b>1,112</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="right"><b>88</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other income</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>7,095</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Finance costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Interest and other expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(4</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(190</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss on foreign exchange</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(19,449</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(409</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Derivative financial instrument expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,696</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(19,235</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(4</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(30,335</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(19,644</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total other income (expense)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>14,934</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(29,223</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(19,556</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Interest income primarily results from interest earned on cash held
 on account and accretion of investment earnings.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company presents foreign currency gains and losses on a net
 basis as either finance income or finance expense depending on
 whether foreign currency movements are in a net gain or net loss
 position.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Other income consists of a gain recorded in connection with the
 Regeneron Subscription Agreement. See Note 12 and Note 21 for
 details. Pursuant to the Regeneron Subscription Agreement, the
 Company agreed to sell an aggregate of 600,000 of its common shares
 to Regeneron at a purchase price equal to $25.0 per share. On
 December&#xA0;21, 2018, the Company completed the sale under the
 Regeneron Subscription Agreement and received gross proceeds of
 $15.0&#xA0;million, or &#x20AC;13.1&#xA0;million. Accordingly, the
 Company recorded the common shares issued at the fair value of the
 underlying securities on the date of issuance. The difference
 between the total proceeds received of $15.0&#xA0;million, or
 &#x20AC;13.1&#xA0;million, and the aggregate value of common shares
 issued of $6.9&#xA0;million, or &#x20AC;6.0&#xA0;million, was
 recorded as a gain on litigation settlement of $8.1&#xA0;million,
 or &#x20AC;7.1&#xA0;million, during the year-ended December&#xA0;31,
 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On December&#xA0;20, 2016, the Company entered into the share
 subscription agreement with Incyte and recognized a freestanding
 forward contract (derivative asset) of $32.6&#xA0;million, or
 &#x20AC;31.4&#xA0;million, in its statement of financial position.
 In accordance with IAS 39, the finance costs for the year ended
 December&#xA0;31, 2017 and 2016, include an amount of
 &#x20AC;10.7&#xA0;million and &#x20AC;19.2&#xA0;million,
 respectively, related to a fair value remeasurement of the forward
 contract through December&#xA0;31, 2016 and through
 January&#xA0;23, 2017, the date the shares were issued to
 Incyte.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfOtherIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other income expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfOtherIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6742350880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Loss per share</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>17.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Loss per share</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company calculates basic net income (loss) per share
 attributable to equity holders of the Company and diluted net loss
 per share attributable to equity holders of the Company by dividing
 the net income (loss) attributable to equity holders of the Company
 by the weighted average number of common shares outstanding during
 the period. Diluted net income per share attributable to common
 stockholders is computed by dividing net income attributable to
 equity holders of the Company by the diluted number of shares
 outstanding during the period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Except where the result would be antidilutive to net income,
 diluted net income per share attributable to equity holders of the
 Company is computed assuming the exercise of share options and the
 vesting of RSUs (using the treasury stock method), as well as their
 related income tax effects.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Basic and diluted net loss per share attributable to equity holders
 of the Company was calculated as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="57%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017<br />
 Restated*</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016<br />
 Restated*</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(e</b><b><i>uros
 in thousands, except per share data</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Numerator:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss attributable to equity holders of the Company</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(24,235</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(64,685</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(47,429</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Denominator:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average shares outstanding&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>22,286,720</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,196,440</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,236,649</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Loss per share&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(1.09</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3.37</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3.58</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left">*</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">See Note 4 for details regarding the restatement as a
 result of a change in accounting policy</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 During the years ended December&#xA0;31, 2018, 2017 and 2016, share
 options and unvested RSUs were excluded from the calculation of net
 loss per attributable to equity holders of the Company due to their
 antidilutive effect.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company did not declare dividends for any of the years
 presented in these financial statements.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2018-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=33&amp;date=2018-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735475984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial Instruments</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>18.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Financial Instruments</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 As discussed in Note 4, the Company&#x2019;s initial adoption of
 IFRS 9 had no impact on previously reported amounts.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Financial Risk Management</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company is exposed to a variety of financial risks: credit
 risk, liquidity risk and market risk. The Company&#x2019;s overall
 risk management program seeks to minimize potential adverse effects
 of these financial risk factors on the Company&#x2019;s financial
 performance. Management is primarily responsible for the overall
 risk management approach and for the approval of risk strategies
 and principles of the Company. The Company&#x2019;s Audit Committee
 oversees these risk management activities. The Company&#x2019;s
 management reviews and approves policies for managing each of these
 risks which are summarized below.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Credit Risk</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Credit risk is the risk of financial loss to the Company if a
 customer or counterparty to a financial instrument fails to meet
 its contractual obligations and arises principally from the
 Company&#x2019;s receivables from its collaborators and investments
 in debt securities and financial institutions. The Company&#x2019;s
 principal financial assets are held to maturity investments, trade
 receivables, unbilled receivables and cash and cash equivalents
 that are derived primarily from financing activities and, to a
 lesser extent, from its operations. The main purpose of these
 financial assets is to support the Company&#x2019;s operations which
 consist primarily of research and development, preclinical and
 clinical development and related manufacturing in support of the
 Company&#x2019;s preclinical and clinical development programs for
 <font style="WHITE-SPACE: nowrap">MCLA-128,</font> <font style="WHITE-SPACE: nowrap">MCLA-117,</font> <font style="WHITE-SPACE: nowrap">MCLA-158</font> and <font style="WHITE-SPACE: nowrap">MCLA-145.</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The carrying amount of financial assets represents the maximum
 credit exposure.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade and unbilled receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,926</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,283</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>61,800</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">41,103</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>143,747</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">149,678</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>208,473</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">193,064</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Cash and cash equivalents include deposits and investments held
 with financial institutions with original maturities of less than
 three months. Investments include commercial paper, securities
 issued by several public corporations and the U.S. Treasury with a
 maturity date of greater than three months at the date of
 settlement. Cash and cash equivalents are held at banks and
 financial institutions with credit ratings varying between A and
 AA, while investments are in highly rated vehicles with identical
 credit ratings.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The aging of trade and unbilled receivables was as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(</b><b><i>euros&#xA0;in&#xA0;thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Neither past due nor impaired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,926</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,283</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Past due</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,926</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,283</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 There is no allowance for impairment relating to trade and unbilled
 receivables, investments and cash and cash equivalents.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Liquidity Risk</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Liquidity risk is the risk that the Company will not be able to
 meet its financial obligations as they become due. The
 Company&#x2019;s core objective is to maintain a balance between
 continuity of funding and flexibility through the monitoring of
 cash flows at varying levels to ensure that it has sufficient cash
 on demand to meet expected operational expenses.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following are the remaining contractual maturities of financial
 liabilities as at December&#xA0;31, 2018 and 2017. The amounts are
 gross and undiscounted.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="22" align="center"><b>December&#xA0;31, 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Carrying</b><br />
 <b>amount</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>&lt; 12</b><br />
 <b>months</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>1&#xA0;-&#xA0;2</b><br />
 <b>years</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2&#xA0;-&#xA0;5</b><br />
 <b>years</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>&gt;&#xA0;5&#xA0;years</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="22" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade payables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,819</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,819</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,819</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other liabilities and accruals</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,964</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,964</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,964</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,783</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,783</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,783</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="22" align="center"><b>December&#xA0;31, 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Carrying</b><br />
 <b>amount</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>&lt; 12</b><br />
 <b>months</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>1&#xA0;-&#xA0;2</b><br />
 <b>years</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2&#xA0;-&#xA0;5</b><br />
 <b>years</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>&gt; 5&#xA0;years</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="22" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade payables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,855</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,855</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,855</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other liabilities and accruals</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,176</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,176</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,176</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,031</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,031</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,031</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>Market Risk</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Market risk is the risk that changes in market prices&#x2014;such as
 foreign exchange rates and interest rates&#x2014;will affect the
 Company&#x2019;s income or the value of its holdings of financial
 instruments. The objective of market risk management is to manage
 and control market risk exposures within acceptable parameters,
 while optimizing the return. The Company&#x2019;s market risk
 relates to foreign exchange and to a lesser extent, interest
 risks.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Foreign currency risk</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Foreign exchange risk arises from future commercial transactions
 and recognized assets and liabilities in foreign currencies. With
 respect to monetary assets and liabilities denominated in foreign
 currencies, the Company&#x2019;s primary currency exposure is
 impacted by monetary assets and liabilities denominated in U.S.
 dollars. Changes in sensitivity rates reflect various changes in
 the economy year-over-year.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table provides a sensitivity analysis for a change in
 the primary currency exposure for the Company relating to monetary
 assets and liabilities denominated in U.S. dollars as of
 December&#xA0;31, 2018. The analysis shows the impact that a change
 in the exchange rate at that date would have on the Company&#x2019;s
 total comprehensive loss:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="52%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 <b>Financial Statement Line Item Exposure</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Balance</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Effect&#xA0;on&#xA0;profit</b><br />
 <b>before&#xA0;tax&#xA0;if&#xA0;USD</b><br />
 <b>strengthens 5%</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Effect&#xA0;on&#xA0;profit</b><br />
 <b>before&#xA0;tax&#xA0;if&#xA0;USD</b><br />
 <b>weakens 5%</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">43,074</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,154</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,154</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">61,800</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,090</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,090</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade and other receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,886</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">144</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(144</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">123</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Taxes and social security liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(88</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade payables, other liabilities and accruals</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,795</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(240</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">240</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>103,000</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>5,150</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(5,150</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The closing exchange rate per the European Central Bank utilized
 above for converting the U.S. dollar to euro at December&#xA0;31,
 2018 was 0.8734.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Exposure to interest rate risk</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The interest rate profile of the Company&#x2019;s interest-bearing
 financial instruments is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Fixed-rate instruments</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>61,800</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">41,103</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Variable rate instruments</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>143,747</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">149,678</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The weighted average remaining days to maturity for the
 Company&#x2019;s investment portfolio is 135 days as of
 December&#xA0;31, 2018. Due to the short remaining hold period for
 the Company&#x2019;s investments and resulting limited impact of
 changes in interest rates on the Company, no sensitivity data is
 provided.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Accounting Classifications and Fair Values</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The classifications of the Company&#x2019;s financial assets and
 financial liabilities, all of which are not measure at fair value,
 are disclosed in the tables above. The fair value of the financial
 assets and financial liabilities not measured at fair value is not
 disclosed, as the carrying amount of the financial assets and
 financial liabilities is a reasonable approximation of the fair
 value. Accordingly, information on the fair value hierarchy is
 omitted.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2018-03-01&amp;anchor=sect_Scope&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735518032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Board Compensation and Key Management Personnel<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory', window );">Board Compensation and Key Management Personnel</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>19.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Board Compensation and Key Management
 Personnel</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On May&#xA0;29, 2017, the Company changed its governance structure
 from a <font style="WHITE-SPACE: nowrap">two-tier</font> model
 consisting of a Management Board acting under the supervision of a
 separate Supervisory Board to a <font style="WHITE-SPACE: nowrap">one-tier</font> board model with a unitary
 Board of Directors consisting of an executive director and
 <font style="WHITE-SPACE: nowrap">non-executive</font> directors.
 In the <font style="WHITE-SPACE: nowrap">one-tier</font> board
 model, the Board of Directors as a collective (i.e., the executive
 director and the <font style="WHITE-SPACE: nowrap">non-executive</font> directors) are charged
 with both the management and monitoring functions of the
 Company&#x2019;s general course of affairs inclusive of the
 Company&#x2019;s overall business strategy and financial policies.
 The executive director manages the day <font style="WHITE-SPACE: nowrap">to-day</font> business and operations of the
 Company and implements the Company&#x2019;s strategy. The
 <font style="WHITE-SPACE: nowrap">non-executive</font> directors
 focus on the supervision of policy and the performance of the
 duties of all directors, as well as the Company&#x2019;s general
 state of affairs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Prior to May&#xA0;29, 2017, the Company&#x2019;s Management Board
 was in charge of managing the Company and consisted of Ton
 Logtenberg, Chief Executive Officer (&#x201C;CEO&#x201D;) and Shelly
 Margetson, the former Chief Operating Officer (&#x201C;COO&#x201D;).
 Ms.&#xA0;Margetson resigned as a statutory director of the Company
 effective as of May&#xA0;24, 2017 and ended her employment with the
 Company effective as of August&#xA0;1, 2017. The Supervisory Board
 was responsible for the supervision of the Management Board and the
 general course of affairs of the Company. Subsequent to
 May&#xA0;29, 2017, the members of the Supervisory Board are now
 <font style="WHITE-SPACE: nowrap">non-executive</font> directors,
 while Mr.&#xA0;Logtenberg remains as the lone executive director on
 the unitary Board of Directors.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In addition to Board of Directors, the Company employs certain key
 management personnel responsible for executing the <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">day-to-day</font></font> business and
 operations of the Company. Key management personnel are those
 persons having authority and responsibility for planning, directing
 and controlling the activities of the Company. The Company includes
 the following employees in this classification: Alexander Berthold
 Hendrik Bakker, Ph.D., Chief Development Officer, John de Kruif,
 Chief Technology Officer, Hui Liu, Ph.D., Chief Business Officer
 and Head of Merus U.S., Peter Silverman, General Counsel and Chief
 Intellectual Property Officer, L. Andres Sirulnik, M.D., Ph.D.,
 Chief Medical Officer (&#x201C;CMO&#x201D;), and Mark Throsby, Ph.D.,
 Chief Scientific Officer. On January&#xA0;2, 2019, Mr.&#xA0;Crowley
 resigned as the Executive Vice President and CFO to pursue other
 opportunities.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Executive Directors</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In 2018, 2017 and 2016, the following amounts were charged to the
 consolidated statement of profit or loss and comprehensive loss for
 the remuneration of the statutory directors:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 <b>Name</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross&#xA0;salary</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Bonus</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Pension</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Option&#xA0;cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="18" align="center"><b>(</b><b><i>in
 euros</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Ton Logtenberg, President, CEO and Principal Financial Officer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">445,606</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">155,962</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">31,881</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,696,918</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,330,367</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">432,782</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">337,945</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51,528</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,675,590</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,497,845</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">369,204</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">147,820</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,717</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">907,236</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,441,977</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Shelley Margetson(*), Former COO</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(**)&#xA0;420,782</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,595</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">451,752</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">892,129</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">198,987</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">84,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,152</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">164,547</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">453,686</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left">(*)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Resigned as a statutory director of the Company
 effective as of May&#xA0;24, 2017.</p>
 </td>
 </tr>
 </table>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left">(**)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Gross salary includes severance payments totaling
 &#x20AC;257,260.</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 During the year ended December&#xA0;31, 2018, Mr.&#xA0;Logtenberg
 was granted 129,000 share options. As of December&#xA0;31, 2018,
 2017 and 2016, Mr.&#xA0;Logtenberg held 758,925, 661,629 and
 376,912 share options, respectively, with a weighted average
 exercise price of &#x20AC;17.07, &#x20AC;14.20, &#x20AC;2.98,
 respectively. As of December&#xA0;31, 2018 and 2017,
 Mr.&#xA0;Logtenberg held 64,450 and 123,745 unvested RSUs,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Upon Ms.&#xA0;Margetson&#x2019;s separation date, she was entitled
 to an accelerated vesting of any unvested share options and RSUs
 held that would have vested during the <font style="WHITE-SPACE: nowrap">12-month</font> period following her
 separation date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Key Management Personnel</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The remainder of the key management personnel has received the
 following remuneration:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 <b>Remuneration</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>in
 euros</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Short-term employment benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,705,438</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,808,998</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,139,763</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Post-employment benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">40,882</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">108,416</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,720</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other long-term benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Termination benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Share-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,688,978</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,171,233</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,195,876</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,435,298</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,088,647</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,354,359</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Some of the key management personnel have long-term benefits in the
 form of life and long-term disability insurance policies, which
 have been affected in their name as well as severance conditions in
 case of termination without cause or leave for a good reason.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 A number of key management personnel, or their related parties,
 hold positions in other companies that result in them having
 control or significant influence over these companies. These
 companies did not enter into transactions with the Company during
 the year.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On October&#xA0;27, 2016, the Company appointed Andres Sirulnik as
 its CMO. A total 219,890 share options were granted to
 Dr.&#xA0;Sirulnik with an exercise price of &#x20AC;16.85&#xA0;per
 share.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On February&#xA0;15, 2017, the Company appointed Peter Silverman as
 its Senior Vice President, Legal. A total 50,000 share options were
 granted to Mr.&#xA0;Silverman with an exercise price of
 &#x20AC;24.54&#xA0;per share.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On November&#xA0;1, 2016, the Company appointed John Crowley as its
 CFO. A total of 183,241 share options were granted to
 Mr.&#xA0;Crowley with an exercise price of &#x20AC;15.24&#xA0;per
 share. On January&#xA0;2, 2019, Mr.&#xA0;Crowley resigned as the
 Executive Vice President and CFO. In connection with his departure,
 Mr.&#xA0;Crowley entered into a separation and release agreement
 with the Company, pursuant to which Mr.&#xA0;Crowley will be
 entitled to receive a severance payment equal to 6 months of his
 annual salary.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><font style="WHITE-SPACE: nowrap">Non-Executive</font>
 Directors</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In May 2016, the Company established the Supervisory Board
 Remuneration Program, which was subsequently replaced by the
 <font style="WHITE-SPACE: nowrap">Non-Executive</font> Compensation
 Program to reflect the change in governance structure of the
 Company. As part of this program, <font style="WHITE-SPACE: nowrap">non-executive</font> directors are entitled
 to cash compensation as well as equity compensation. The equity
 compensation consists of an initial option grant as well as
 subsequent annual share-based awards.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The following amounts were charged to the consolidated statement of
 profit or loss and comprehensive loss for the remuneration of the
 members of the Board:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="28%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31, 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31, 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31, 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 <b>Name</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Cash</b><br />
 <b>compensation</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Option</b><br />
 <b>cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Cash</b><br />
 <b>compensation</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Option</b><br />
 <b>cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Cash</b><br />
 <b>compensation</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Option</b><br />
 <b>cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b><i>(in
 euros)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b><i>(in
 euros)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b><i>(in
 euros)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Russell Greig</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">38,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">79,333</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">117,936</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Mark Iwicki</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">55,066</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">68,666</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">123,732</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">59,840</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">120,596</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,436</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">50,394</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">183,367</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">233,761</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Len Kanavy</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">32,859</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">152,485</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">185,344</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Wolfgang Berthold</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,315</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">65,776</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">85,091</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">37,530</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">90,944</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,474</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">50,928</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">70,778</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Lionel Carnot*</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,401</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">&#x2014;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,401</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">35,445</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">61,870</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">97,315</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24,852</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">66,959</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">91,811</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 John de Koning</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">40,768</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51,044</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">91,812</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">38,573</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">113,613</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">152,186</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,230</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">37,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">63,230</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Anand Mehra</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">39,863</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34,449</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">74,312</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">39,615</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">83,683</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">123,298</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,938</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">84,703</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">111,641</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Gregory Perry</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">45,356</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,797</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">100,153</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">41,700</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">103,169</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">144,869</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,356</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">97,365</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">125,721</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>292,231</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>506,550</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>798,781</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>252,703</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>573,875</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>826,578</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>176,620</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>520,322</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>696,942</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left">(*)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">former board member</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 As at December&#xA0;31, members of the Board held the following
 number of options:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="50%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31, 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31, 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December, 31 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 <b>Name</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>average</b><br />
 <b>exercise</b><br />
 <b>price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>average</b><br />
 <b>exercise</b><br />
 <b>price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>average</b><br />
 <b>exercise</b><br />
 <b>price</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Russell Greig</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,966</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">19.97</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#x20AC;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#x20AC;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Mark Iwicki</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">84,209</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">10.07</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">79,226</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">7.32</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">73,576</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">6.57</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Len Kanavy</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,818</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">16.33</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#x20AC;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#x20AC;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Wolfgang Berthold</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36,540</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">15.22</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24,040</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">8.90</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,724</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">3.02</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Lionel Carnot*</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#x20AC;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">11.80</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">8.87</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 John de Koning</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,633</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">14.34</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">11.80</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">8.87</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Anand Mehra</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,633</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">14.34</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">11.80</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">8.87</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Gregory Perry</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,633</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">14.34</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">11.80</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">8.87</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Gabriele Dallmann*</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#x20AC;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#x20AC;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,828</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">3.24</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">235,432</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">11.52</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">193,866</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">9.61</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">185,128</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">7.21</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left">(*)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">former board member</p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about board compensation and key management personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6742331152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related party disclosures</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>20.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left"><b>Related party disclosures</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 For the years ended December&#xA0;31, 2018, 2017 and 2016, certain
 Key Management Personnel and other senior management received
 regular salaries, bonuses and contributions to post-employment
 schemes as well as&#xA0;<font style="WHITE-SPACE: nowrap">non-cash</font>&#xA0;compensation
 as disclosed in Note 19. Additionally, members of the Board of
 Directors received compensation for their services in the form of
 cash compensation as well as&#xA0;<font style="WHITE-SPACE: nowrap">non-cash</font>&#xA0;compensation,
 as disclosed in Note 19.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 On May&#xA0;24, 2017, the Company entered into a settlement
 agreement with Shelley Margetson, the Company&#x2019;s former Chief
 Operating Officer pursuant to which Ms.&#xA0;Margetson resigned as
 a statutory director of the Company effective as of May&#xA0;24,
 2017 and ended her employment with the Company effective as of
 August&#xA0;1, 2017. As part of the terms of the settlement
 agreement, Ms.&#xA0;Margetson is entitled to a severance payment
 equal to 12 months of her annual base salary, 50% of which was paid
 in a lump sum in August 2017 and the remaining 50% is being paid in
 the form of salary continuation over
 the&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;period
 following August&#xA0;1, 2017. In addition, Ms.&#xA0;Margetson was
 entitled to an accelerated vesting of any unvested Company options
 and restricted stock units held by Ms.&#xA0;Margetson that would
 have vested during the&#xA0;<font style="WHITE-SPACE: nowrap">12-month</font>&#xA0;period
 following her separation date. As of December&#xA0;31, 2018 and
 2017, the Company had an accrual of &#x20AC;0 and less than
 &#x20AC;0.1&#xA0;million, respectively, related to this agreement
 included in accrued personnel.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 On January&#xA0;2, 2019, John Crowley resigned as the Executive
 Vice President and Chief Financial Officer of the &#x201C;Company.
 In connection with his departure, Mr.&#xA0;Crowley entered into a
 Separation and Release Agreement with the Company, pursuant to
 which Mr.&#xA0;Crowley is entitled to receive a severance payment
 equal to 6 months of his annual salary. The transaction will be
 recorded in the Company&#x2019;s consolidated financial statements
 during the three months ending March&#xA0;31, 2019.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 As disclosed in Note 11 and Note 13, the Company entered into the
 Incyte collaboration and license agreement and the Incyte share
 subscription agreement in which the terms and transactional amounts
 incurred between Incyte and the Company are more fully
 described.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 As of March 31, 2019, the following shareholders currently hold a
 position in the Board of Directors and have filed a
 form&#xA0;<font style="WHITE-SPACE: nowrap">13-D</font>&#xA0;to reflect
 ownership in the Company of greater than 5%:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">Co&#xF6;peratief LSP IV U.A.</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">Sofinnova Venture Partners IX, L.P.</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Additionally, Ton Logtenberg, the Company&#x2019;s President, CEO
 and Principal Financial Officer and Executive Director, is the sole
 the Director and owner of Biophrase BV (&#x201C;Biophrase&#x201D;).
 As of March&#xA0;31, 2019, Biophrase is a less than 1% shareholder.
 There were no transactions between the Company and Biophrase BV in
 2018.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2018-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2018-03-01&amp;anchor=sect_Disclosures&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735583808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfCommitmentsAndContingenciesExplanatory', window );">Commitments and Contingencies</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 </p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>21.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Commitments and contingencies</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Lease Commitments</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company leases its corporate headquarters under an agreement,
 which expires in the fourth quarter of 2021. If the lease is not
 terminated by Merus N.V., it will be automatically renewed for a
 period of two years. The agreed rental price is
 &#x20AC;0.4&#xA0;million per year. On May&#xA0;1, 2018, the Company
 leased additional space to expand its corporate headquarters under
 a separate agreement. Under the terms of the new agreement, the
 term began on May&#xA0;1, 2018 and expires in the fourth quarter of
 2021. The agreed upon rental price is &#x20AC;0.6&#xA0;million per
 year.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 For leases that contain fixed increases in the minimum annual lease
 payment during the original term of the lease, the Company
 recognizes rental expense on a straight-line basis over the lease
 term and records the difference between rent expense and the amount
 currently payable as deferred rent, as a component of other
 liabilities and accruals. For the years ended December&#xA0;31,
 2018, 2017 and 2016 the Company recognized &#x20AC;1.3&#xA0;million,
 &#x20AC;0.6&#xA0;million and &#x20AC;0.3&#xA0;million, respectively,
 for rent and service charges related to the leased office space. In
 addition, the Company has provided deposits totaling
 &#x20AC;0.3&#xA0;million and &#x20AC;0.1&#xA0;million included in
 other assets as of December&#xA0;31, 2018, and December&#xA0;31,
 2017, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Future minimum lease payments under these leases as of
 December&#xA0;31, 2018 are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 </p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="88%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Less than one year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,579</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Between one and five years</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,106</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 More than five years</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,685</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The Company is contractually obligated to return leased space in
 good order, repair and condition excluding ordinary wear and tear
 upon termination of the lease agreement. The Company&#x2019;s asset
 retirement obligations were not significant as of December&#xA0;31,
 2018 and 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company&#x2019;s contractual obligations associated with
 <font style="WHITE-SPACE: nowrap">non-real</font> estate leases
 were not significant as of December&#xA0;31, 2018 and 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In March 2019, the Company entered in a lease agreement for
 approximately 7,583 square feet of office space in Cambridge,
 Massachusetts. Refer to Note 22 for further details.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Commitments Related to the Collaboration and License
 Agreements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Under the Incyte collaboration and license agreement, the Company
 and Incyte have agreed to collaborate with respect to the research,
 discovery and development of bispecific antibodies utilizing the
 Company&#x2019;s proprietary bispecific technology platform. The
 collaboration encompasses up to 11 independent programs, including
 some of the Company&#x2019;s current preclinical immuno-oncology
 discovery programs. For one of the current programs, concerning
 <font style="WHITE-SPACE: nowrap">MCLA-145,</font> the Company
 retains the exclusive right to develop and commercialize products
 and product candidates in the U.S., while Incyte has the exclusive
 right to develop and commercialize products and product candidates
 arising from such program outside the U.S. For <font style="WHITE-SPACE: nowrap">MCLA-145,</font> the Company and Incyte will
 conduct and share equally the costs of mutually agreed global
 development activities and will be solely responsible for
 independent development activities in the respective territories.
 The actual amounts that the Company may pay to Incyte or that
 Incyte may pay to the Company will depend on numerous factors
 outside of the Company&#x2019;s control, including the success of
 certain clinical development efforts with respect to <font style="WHITE-SPACE: nowrap">MCLA-145,</font> the content and timing of
 decisions made by the regulators, the reimbursement and competitive
 landscape around <font style="WHITE-SPACE: nowrap">MCLA-145</font>
 and other factors.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In addition, the Company has commitments to make potential future
 milestone payments to third parties under certain of its license
 arrangements. These milestones primarily relate to the initiation
 and results of clinical trials, obtaining regulatory approval in
 various jurisdictions and the future commercial success of
 development programs, the outcome and timing of which are difficult
 to predict and subject to significant uncertainty. In addition to
 the milestones discussed above, the Company is obligated to pay
 royalties on future sales, which are contingent on generating
 levels of sales of future products that have not been achieved and
 may never be achieved.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Other Funding Commitments</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 As of December&#xA0;31, 2018, the Company had several ongoing
 clinical and nonclinical studies for its various pipeline programs.
 The Company enters into contracts in the normal course of business
 with contract research organizations and clinical sites for the
 conduct of clinical trials, professional consultants for expert
 advice and other vendors for clinical supply manufacturing or other
 services. These contracts are generally cancellable, with notice,
 at the Company&#x2019;s option and do not have significant
 cancellation penalties.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 During 2018, the Company entered into certain contracts to purchase
 property, plant and equipment in 2019 for
 &#x20AC;0.6&#xA0;million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Guarantees</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company indemnifies its officers and directors for certain
 events or occurrences while the officer or director is, or was,
 serving at the Company&#x2019;s request in such capacity. The
 maximum potential amount of future payments the Company could be
 required to make is unlimited; however, the Company has
 directors&#x2019; and officers&#x2019; insurance coverage that is
 intended to limit its exposure and enable it to recover a portion
 of any future amounts paid.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The Company enters into certain agreements with other parties in
 the ordinary course of business that contain indemnification
 provisions. These typically include agreements with directors and
 officers, business partners, contractors, landlords, clinical sites
 and customers. Under these provisions, the Company may indemnifies
 and holds harmless the indemnified party for losses suffered or
 incurred by the indemnified party as a result of the
 Company&#x2019;s activities, such as gross negligence, willful
 misconduct or at times, other activities. These indemnification
 provisions may survive termination of the underlying agreements.
 The maximum potential amount of future payments the Company could
 be required to make under these indemnification provisions may be
 unlimited. However, to date the Company has not incurred material
 costs to defend lawsuits or settle claims related to these
 indemnification provisions. As a result, the estimated fair value
 of these obligations is minimal. Accordingly, the Company did not
 have any liabilities recorded for these obligations as of
 December&#xA0;31, 2018 and 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Litigation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On March&#xA0;11, 2014, Regeneron Pharmaceuticals, Inc.
 (&#x201C;Regeneron&#x201D;) filed a complaint in the U.S. District
 Court for the Southern District of New York, alleging that the
 Company was infringing one or more claims in Regeneron&#x2019;s U.S.
 Patent No.&#xA0;8,502,018, entitled &#x201C;Methods of Modifying
 Eukaryotic Cells.&#x201D; In 2015, the trial court entered judgments
 finding that the Company does not infringe the claims of the Patent
 No.&#xA0;8,502,018, that the patent is invalid, and that the patent
 was procured through inequitable conduct and is unenforceable. On
 July&#xA0;27, 2017 the U.S. Court of Appeals for the Federal
 Circuit affirmed the trial court&#x2019;s conclusion that Regeneron
 engaged in inequitable conduct before the U.S. Patent and Trademark
 Office while prosecuting the Patent No.&#xA0;8,502,018 and affirmed
 that the Patent No.&#xA0;8,502,018 is unenforceable. On
 December&#xA0;26, 2017, the Federal Circuit denied
 Regeneron&#x2019;s petition for rehearing and rehearing en banc
 seeking a review of that decision and on October&#xA0;1, 2018, the
 Supreme Court of the U.S. denied Regeneron&#x2019;s petition for
 certiorari, rendering the case finally resolved in the
 Company&#x2019;s favor.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On March&#xA0;26, 2018, the trial court granted the Company&#x2019;s
 motion for attorneys&#x2019; fees, expert fees, and costs associated
 with the Company&#x2019;s defense of the above litigation, and
 ordered the parties to address the amount of the award. The Company
 provided a detailed explanation of its attorneys&#x2019; fees,
 expert fees, and costs of such award, which Regeneron responded to,
 seeking a reduction of the amount. The matter was fully briefed as
 of May&#xA0;18, 2018, and the court issued an Order on
 June&#xA0;25, 2018, which published on July&#xA0;10, 2018, granting
 the Company&#x2019;s motion for $8,332,453.46 in attorneys&#x2019;
 fees, $465,390.34 in expert fees, and $1,717,100.69 in litigation
 expenses and costs, along with <font style="WHITE-SPACE: nowrap">pre-</font> and post-judgment interest.
 Regeneron appealed the decision awarding attorneys&#x2019; fees to
 the Company to the Federal Circuit, filing its opening brief on
 November&#xA0;7, 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On March&#xA0;11, 2014, Regeneron served a writ in the Netherlands
 alleging that the Company was infringing one or more claims in
 their European patent EP 1 360 287 B1. The Company had opposed that
 patent in June 2014. On September&#xA0;17, 2014, Regeneron&#x2019;s
 patent EP 1 360 287 B1 was revoked in its entirety by the European
 Opposition Division of the European Patent Office (the
 &#x201C;EPO&#x201D;). In Europe, an appeal hearing occurred in
 October and November 2015 at the Technical Board of Appeal for the
 EPO at which time the patent was reinstated to Regeneron with
 amended claims. On October&#xA0;2, 2017, the Company filed an
 appeal with the Technical Board of Appeal for the EPO to address
 whether the patent having claims amended during the course of
 opposition complies with Art. 84 EPC, Art. 123(2) EPC and Rule 80
 EPC. On May&#xA0;25, 2018, at Regeneron&#x2019;s request, a hearing
 before the Technical Board of Appeals for the EPO was scheduled for
 September&#xA0;13, 2018, to address whether the description of EP 1
 360 287 B1 patent having claims amended during the course of
 opposition complies with Art. 84 EPC, Art. 123(2) EPC and Rule 80
 EPC. The Technical Board of Appeals provided preliminary views on
 the matter on August&#xA0;23, 2018, after which the Company&#x2019;s
 appeal filed on October&#xA0;2, 2017 was withdrawn on
 September&#xA0;5, 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The costs incurred in the above litigation and opposition were
 &#x20AC;1.4&#xA0;million, &#x20AC;1.0&#xA0;million and
 &#x20AC;1.5&#xA0;million for the years ended December&#xA0;31, 2018,
 2017 and 2016, respectively.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Regeneron also previously raised opposition proceedings against
 certain of the Company&#x2019;s patents in jurisdictions including
 Europe, Japan and Australia.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On December&#xA0;20, 2018, the Company signed a global settlement
 and cross-license agreement with Regeneron, where the parties have
 agreed to end all pending litigation and opposition proceedings
 pertaining to the Company&#x2019;s and Regeneron&#x2019;s respective
 antibody generation technologies. Regeneron also purchased 600,000
 of the Company&#x2019;s common shares at a price of $25 per share
 for total aggregate proceeds of $15.0&#xA0;million. The
 cross-license and stock purchase were made in conjunction with the
 agreement to withdraw Regeneron&#x2019;s appeal of the fee award,
 and agreement to dismissal of all claims to approximately
 $10.5&#xA0;million for the reimbursement of attorneys&#x2019; fees
 and other expenses, plus interest, awarded to Merus by the trial
 court. Under the terms of the settlement, Regeneron has withdrawn
 its appeal of the decision awarding attorneys&#x2019; fees to the
 Company as a result of the U.S. District Court litigation described
 above. In addition, Regeneron has dismissed its stayed case in the
 Netherlands asserting the EP 1 360 287 B1 patent, and both parties
 have withdrawn all pending oppositions as of December&#xA0;20,
 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On April&#xA0;5, 2018, an unnamed third party and Regeneron filed
 notices of opposition against the Company&#x2019;s EP 2604625
 patent, entitled &#x201C;Generation of Binding Molecules,&#x201D; in
 the EPO. The notices asserted, as applicable, added subject matter,
 lack of novelty, lack of inventive step, and insufficiency.
 Regeneron will no longer be pursuing this opposition pursuant to
 December&#xA0;20, 2018 settlement. On August&#xA0;20, 2018, the
 Company timely responded to these submissions, with proceedings to
 be ongoing with respect to the unnamed third party. An opposition
 hearing is scheduled for June 2019. As this opposition proceeding
 continues, the Company cannot be certain that the Company will
 ultimately prevail.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 From time to time, the Company may be involved in various other
 claims and legal proceedings relating to claims arising out of the
 Company&#x2019;s operations. The Company is not currently a party to
 any other material legal proceedings.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfCommitmentsAndContingenciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitment and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfCommitmentsAndContingenciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759425824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent Events</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>22.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Subsequent events</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On February&#xA0;15, 2019, the Company entered in a lease agreement
 for approximately 7,583 square feet of office space in Cambridge,
 Massachusetts. The lease has a term of seven years and expires on
 April&#xA0;1, 2026. The lease provides for escalating rent each
 year, with total cash payments of approximately $4.9&#xA0;million,
 or &#x20AC;4.2&#xA0;million, payable over the lease term.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center">&#xA0;</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2018-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=10&amp;date=2018-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6747027264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory', window );">Basis of consolidation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Basis of consolidation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <i>(i) Subsidiaries</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Subsidiaries are entities controlled by the Company, consisting of
 Merus N.V.&#x2019;s wholly owned subsidiary Merus US, Inc. The
 Company controls an entity when it is exposed to, or has rights to,
 variable returns from its involvement with the entity and has the
 ability to affect those returns through its power over the entity.
 The financial statements of subsidiaries are included in the
 consolidated financial statements from the date on which control
 commences until the date on which control ceases.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>(ii) Loss of control</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 When the Company loses control over a subsidiary, it derecognizes
 the assets and liabilities of the subsidiary, and any <font style="WHITE-SPACE: nowrap">non-controlling</font> interests and other
 components of equity. Any resulting gain or loss is recognized in
 profit or loss. Any interest retained in the former subsidiary is
 measured at fair value when control is lost.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>(iii) Transactions eliminated on consolidation</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Intercompany balances and transactions, and any unrealized income
 and expenses arising from intercompany transactions, are eliminated
 in consolidation. Unrealized gains arising from transactions with
 equity-accounted investees are eliminated against the investment to
 the extent of the Company&#x2019;s interest in the investee.
 Unrealized losses are eliminated in the same way as unrealized
 gains, but only to the extent that there is no evidence of
 impairment.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign Currency Transactions</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Foreign Currency Transactions</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Foreign currency transactions are translated using the exchange
 rates at the dates of the transactions. Foreign exchange gains and
 losses resulting from the settlement of such transactions and from
 the translation of monetary assets and liabilities denominated in
 foreign currencies at the exchange rate at the reporting date are
 generally recognized in the statement of profit or loss and
 comprehensive loss as a component of finance costs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The results and financial position of foreign operations that have
 a functional currency different from the presentation currency are
 translated into the presentation currency as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">assets and liabilities for each balance sheet
 presented are translated at the closing rate at the date of that
 balance sheet;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">income and expenses for each statement of profit or
 loss and comprehensive income or loss are translated at average
 exchange rates (unless this is not a reasonable approximation of
 the cumulative effect of the rates prevailing on the transaction
 dates, in which case income and expenses are translated at the
 exchange rates at the dates of the transactions); and</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">all resulting exchange differences are recognized in
 other comprehensive income.</p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, Plant and Equipment</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Property, Plant and Equipment</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Property, plant and equipment are measured at cost less accumulated
 depreciation and accumulated impairment losses (if any). Cost
 includes expenditures that are directly attributable to the
 acquisition of the items. Depreciation of property, plant and
 equipment is recognized in the consolidated statement of profit and
 loss and comprehensive loss on a straight-line basis over estimated
 useful lives of generally five years, taking residual value into
 account. If significant parts of an item of property, plant and
 equipment have different useful lives, they are accounted for as
 separate items (major components) of property, plant and
 equipment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Subsequent expenditures are capitalized only when the expenditure
 will increase the future economic benefit of the asset. All other
 expenditures are expensed in the consolidated statement of profit
 or loss and comprehensive loss.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Depreciation rates are based on the following estimated economic
 useful lives of the tangible fixed assets concerned:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Plant and
 equipment&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;5
 years</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Leasehold improvements
 &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Shorter of useful
 life or term of lease</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Other fixed
 assets:&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;5
 years</p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory', window );">Intangible Assets</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Intangible Assets</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Intangible assets are identifiable <font style="WHITE-SPACE: nowrap">non-monetary</font> assets without physical
 substance. An asset is a resource that is controlled by the
 enterprise as a result of past events (for example, purchase or
 self-creation) and from which future economic benefits (inflows of
 cash or other assets) are expected.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The useful lives of intangible assets are assessed to be finite and
 amortized over the useful economic life and assessed for impairment
 whenever there is an indication that the intangible asset may be
 impaired. Amortization begins when the asset is available for
 use.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Patents</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Patents acquired separately by the Company are reported at cost
 less accumulated amortization and accumulated impairment losses.
 Amortization is recognized in the consolidated statement of profit
 and loss and comprehensive loss on a straight-line basis over the
 shorter of the estimated economic or legal lives. The estimated
 useful life and amortization method are reviewed at the end of each
 reporting period, with the effect of any changes in estimates being
 accounted for on a prospective basis.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>R&amp;D</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company incurs R&amp;D expenses related to its clinical trials
 and preclinical drug development programs. Development expenses are
 defined as expenses incurred to achieve technical and commercial
 feasibility. Expenditures on research activities are recognized as
 an expense in the period in which it is incurred.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Development is capitalized if, and only if, all of the following
 have been demonstrated:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the technical feasibility of completing the intangible
 asset so that it will be available for use or sale;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the intention to complete the intangible asset and use
 or sell it;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the ability to use or sell the intangible asset;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">how the intangible asset will generate probable future
 economic benefits;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the availability of adequate technical, financial and
 other resources to complete the development and to use or sell the
 intangible asset; and</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the ability to measure reliably the expenditure.</p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial Instruments</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Financial Instruments</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company classifies <font style="WHITE-SPACE: nowrap">non-derivative</font> financial assets as
 either financial assets at fair value through profit or loss,
 financial assets at amortized cost or financial assets at fair
 value through other comprehensive income or loss. The Company
 classifies <font style="WHITE-SPACE: nowrap">non-derivative</font>
 financial liabilities into either financial liabilities at fair
 value through profit or loss or the other financial liabilities
 category.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i><font style="WHITE-SPACE: nowrap">Non-Derivative</font>
 Financial Assets and Financial Liabilities</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company initially recognizes receivables and investments at
 fair value on the date when they are originated. Subsequent to
 initial recognition, they are measured at amortized cost using the
 effective interest rate method. All other financial assets and
 financial liabilities are initially recognized on the trade
 date.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The Company derecognizes a financial asset when the contractual
 rights to the cash flows from the asset expire, or it transfers the
 rights to receive the contractual cash flows in a transaction in
 which substantially all the risks and rewards of ownership of the
 financial asset are transferred, or it neither transfers nor
 retains substantially all of the risks and rewards of ownership and
 does not retain control over the transferred asset. Any interest in
 such derecognized financial assets that is created or retained by
 the Company is recognized as a separate asset or liability.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company initially recognizes <font style="WHITE-SPACE: nowrap">non-derivate</font> financial liabilities at
 fair value less any directly attributable transaction costs.
 Subsequent to initial recognition, these liabilities are measured
 at amortized cost using the effective interest method.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company derecognizes a financial liability when its contractual
 obligations are settled or cancelled, or expire.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Financial assets and financial liabilities are offset and the net
 amount presented in the statement of financial position when, and
 only when, the Company has a legal right to offset the amounts and
 intends either to settle them on a net basis or to realize the
 asset and settle the liability simultaneously.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Receivables</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 These assets are initially recognized at fair value plus any
 directly attributable transaction costs, if any.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Derivative Financial Assets and Liabilities</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Derivative financial instruments are initially recognized at fair
 value on the date on which a derivative contract is entered into
 and are subsequently remeasured at fair value with net changes in
 fair value presented as finance expenses (negative net changes in
 fair value) or finance income (positive net changes in fair value)
 in the consolidated statement of profit or loss and comprehensive
 loss. Derivatives are carried as financial assets when the fair
 value is positive and as financial liabilities when the fair value
 is negative. Derivatives embedded in host contracts are accounted
 for as separate derivatives and recorded at fair value if their
 economic characteristics and risks are not closely related to those
 of the host contracts and the host contracts are not held for
 trading or designated at fair value through profit or loss. These
 embedded derivatives are measured at fair value with changes in
 fair value recognized in profit or loss. Reassessment only occurs
 if there is either a change in the terms of the contract that
 significantly modifies the cash flows that would otherwise be
 required or a reclassification of a financial asset out of the fair
 value through profit or loss category.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfAccountingPolicyForInvestmentsExplanatory', window );">Investments</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Investments</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Investments are classified and accounted for at amortized cost and
 initially measured at fair value. Subsequent to initial
 recognition, they are measured at amortized cost using the
 effective interest rate method. Investments are classified as
 amortized cost as the Company has the positive intent and ability
 to hold them until maturity. Interest income from these securities
 is included in finance income.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Cash and Cash Equivalents</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 For the purpose of presentation in the statement of cash flows as
 well as the statement of financial position, cash and cash
 equivalents include deposits held with financial institutions with
 original maturities of less than three months from the date of
 acquisition. Cash and cash equivalents include
 &#x20AC;49.1&#xA0;million of investments with a three month or less
 maturity, callable on demand. The carrying values of cash
 equivalents approximate fair value due to their short-term
 maturities.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Provisions</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 A provision is recognized if the following applies:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the company has a legal or constructive obligation,
 arising from a past event;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the amount can be estimated reliably; and</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">it is probable that an outflow of resources embodying
 economic benefits will be required to settle the obligation.</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 If all or part of the payments that are necessary to settle a
 provision are virtually certain to be fully or partially
 compensated by a third party upon settlement of the provision, then
 the compensation amount is presented separately as an asset.
 Provisions are determined by discounting the expected future cash
 flows at a <font style="WHITE-SPACE: nowrap">pre-tax</font> rate
 that reflects current market assessments of the time value of money
 and the risks specific to the liability. The unwinding of the
 discount is recognized as finance cost.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory', window );">Impairment</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Impairment</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <i>Financial Assets Measured at Amortized Cost</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 At each reporting date, the Company considers evidence of
 impairment for these assets at both an individual asset and a
 collective level. All individually significant assets are
 individually assessed for impairment. Those found not to be
 impaired are then collectively assessed for any impairment that has
 been incurred but not yet individually identified. Assets that are
 not individually significant are collectively assessed for
 impairment. Collective assessment is carried out by grouping
 together assets with similar risk characteristics.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 To assess impairment for its financial assets, the Company uses the
 general expected credit loss model over the next twelve months of
 the expected life of its financial assets. Under this model, the
 Company calculates the allowance for credit losses by considering
 on a discounted basis, the cash shortfalls it would incur in
 various default scenarios for prescribed future periods and
 multiplying the shortfalls by the probability of each scenario
 occurring. The allowance on the financial asset is the sum of these
 probability-weighted outcomes.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 For the Company&#x2019;s investments, the Company applies the low
 credit risk simplification as it does not believe there to be any
 credit risk related to these assets given the credit quality
 ratings required by the Company&#x2019;s investment policy. At every
 reporting date, the Company evaluates whether a particular debt
 instrument is considered to have low credit risk using all
 supportable information.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Impairment losses are recognized in the consolidated statement of
 profit or loss and comprehensive loss and is the amount required to
 adjust the loss allowance at the reporting date to the amount that
 is required to be recognized based on the aforementioned policy. If
 the amount of impairment loss subsequently decreases and the
 decrease can be related objectively to an event occurring after the
 impairment was recognized, then the previously recognized
 impairment loss is reversed through profit or loss.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i><font style="WHITE-SPACE: nowrap">Non-Financial</font>
 Assets</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 At each reporting date, the Company reviews the carrying amounts of
 its <font style="WHITE-SPACE: nowrap">non-financial</font> assets
 to determine whether there is any indication of impairment. If any
 such indication exists, then the asset&#x2019;s recoverable amount
 is estimated.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 For impairment testing, assets are grouped together into the
 smallest group of assets that generates cash inflows from
 continuing use that are largely independent of the cash inflows of
 other assets or cash generating units (&#x201C;CGU&#x201D;).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The recoverable amount of an asset or CGU is the greater of its
 value in use and its fair value less costs to sell. Value in use is
 based on the estimated future cash flows, discounted to their
 present value using a <font style="WHITE-SPACE: nowrap">pre-tax</font> discount rate that reflects
 current market assessments of the time value of money and the risks
 specific to the asset or CGU.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 An impairment loss is recognized if the carrying amount of an asset
 or CGU exceeds its recoverable amount.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Impairment losses are recognized in profit or loss. They are
 allocated first to reduce the carrying amount of any goodwill
 allocated to the CGU, and then to reduce the carrying amounts of
 the other assets in the CGU on a pro rata basis.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 An impairment loss is reversed only to the extent that the
 asset&#x2019;s carrying amount does not exceed the carrying amount
 that would have been determined, net of depreciation or
 amortization, if no impairment loss had been&#xA0;recognized.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue Recognition</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Revenue Recognition</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Effective January&#xA0;1, 2018, the Company adopted IFRS 15,
 <i>Revenue from Contracts with Customers</i> (&#x201C;IFRS
 15&#x201D;). This standard applies to all contracts with customers,
 except for contracts that are within the scope of other standards,
 such as leases, insurance, collaboration arrangements and financial
 instruments.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The terms of the contracts within the scope of IFRS 15&#xA0;may
 contain multiple promised goods and services, which often include
 license rights to certain of the Company&#x2019;s product candidates
 and R&amp;D activities. Payments under such agreements include:
 (i)&#xA0;upfront nonrefundable license fees; (ii)&#xA0;payments for
 R&amp;D services performed by the Company, including reimbursement
 for certain external costs; (iii)&#xA0;payments based upon the
 achievement of certain development, regulatory and commercial
 milestones; and (iv)&#xA0;royalties on net product sales, if
 any.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Under IFRS 15, the Company recognizes revenue when its customer
 obtains control of promised goods or services, in an amount that
 reflects the consideration that the Company expects to receive in
 exchange for those goods or services. The Company recognizes
 revenue following the five-step model prescribed under IFRS 15: (i)
 identification of the contract(s) with the customer;
 (ii)&#xA0;identification of the performance obligations;
 (iii)&#xA0;determination of the transaction price, including the
 constraint on variable consideration; (iv)&#xA0;allocation of the
 transaction price to the performance obligations in the contract;
 and (v)&#xA0;recognition of revenue when (or as) the Company
 satisfies each performance obligation.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In order to account for contracts with customers, the Company
 identifies the promised goods or services in the contract and
 evaluates whether such promised goods or services represent
 performance obligations. The Company accounts for those components
 as separate performance obligations when the following criteria are
 met: (i)&#xA0;the customer can benefit from the good or service
 either on its own or together with other resources that are readily
 available to the customer, and (ii)&#xA0;the Company&#x2019;s
 promise to transfer the good or service to the customer is
 separately identifiable from other promises in the contract. This
 evaluation requires subjective determinations and requires the
 Company to make judgments about the promised goods and services and
 whether such goods and services are separable from the other
 aspects of the contractual relationship. In determining the
 performance obligations, the Company evaluates certain criteria,
 including whether the promised good or service is capable of being
 distinct and whether such good or service is distinct within the
 context of the contract, based on consideration of the relevant
 facts and circumstances for each arrangement. Factors considered in
 this determination include the research, manufacturing and
 commercialization capabilities of the partner; the availability of
 research and manufacturing expertise in the general marketplace;
 and the level of integration, interrelation, and interdependence
 among the promises to transfer goods or services.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The transaction price is allocated among the performance
 obligations using the relative selling price method and the
 applicable revenue recognition criteria are applied to each of the
 separate performance obligations. At contract inception, the
 Company determines the standalone selling price for each
 performance obligation identified in the contract. If an observable
 price of the promised good or service sold separately is not
 readily available, the Company utilizes assumptions that require
 judgment to estimate the standalone selling price, which may
 include development timelines, probabilities of technical and
 regulatory success, reimbursement rates for personnel costs,
 forecasted revenues, potential limitations to the selling price of
 the product, expected technological life of the product and
 discount rates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i><font style="WHITE-SPACE: nowrap">Up-front</font> License
 Payments</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 If the license to the Company&#x2019;s intellectual property is
 determined to be distinct from the other performance obligations
 identified in the arrangement, the Company recognizes revenue
 allocated to the license when the license is transferred to the
 customer and the customer is able to use and benefit from the
 license. For licenses that are not distinct and bundled with other
 performance obligations, the Company utilizes judgment to assess
 the nature of the combined performance obligation to determine
 whether the combined performance obligation is satisfied over time
 or at a point in time and, if over time, the appropriate method of
 measuring progress for purposes of recognizing revenue from the
 combined performance obligation. The Company evaluates the measure
 of progress each reporting period and, if necessary, adjusts the
 measure of performance and related revenue recognition.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Milestones</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 At the inception of each arrangement that includes <font style="WHITE-SPACE: nowrap">pre-commercial</font> milestone payments, the
 Company evaluates whether the milestones are considered probable of
 being reached and estimates the amount to be included in the
 transaction price using the most likely amount method. If it is
 probable that a significant cumulative revenue reversal would not
 occur, the associated milestone value is included in the
 transaction price. Milestone payments that are not within the
 Company&#x2019;s control, such as regulatory approvals, are not
 considered probable of being achieved until the uncertainty related
 to the milestone is resolved. The transaction price is then
 allocated to each performance obligation on a relative selling
 price basis, for which the Company recognizes revenue as or when
 the performance obligations under the contract are satisfied. Any
 such adjustments are recorded on a cumulative <font style="WHITE-SPACE: nowrap">catch-up</font> basis, which affects revenue
 in the period of adjustment. At the end of each subsequent
 reporting period, the Company reevaluates the probability of
 achievement of such development milestones and any related
 constraint, and if necessary, adjusts its estimate of the overall
 transaction price.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Royalties</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 For arrangements that include sales-based royalties, including
 milestone payments based on the level of sales, and where the
 license is deemed to be the predominant item to which the royalties
 relate, the Company recognizes revenue at the later of:
 (i)&#xA0;when the related sales occur, or (ii)&#xA0;when the
 performance obligation to which some or all of the royalty has been
 allocated has been satisfied (or partially satisfied). To date, the
 Company has not recognized any royalty revenue.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>R&amp;D Cost Reimbursement</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 R&amp;D cost reimbursement revenue, which is typically related to
 reimbursements from customers for the Company&#x2019;s performance
 of R&amp;D services under the respective agreements, is recognized
 on the basis of labor hours valued at a contractually agreed rate.
 R&amp;D cost reimbursement revenue also includes reimbursements for
 related <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">out-of-pocket</font></font> expenses and
 third-party costs. R&amp;D cost reimbursement revenue is recognized
 in the same period as the costs for which they are intended to
 compensate.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company typically acts as the principal under such arrangements
 and, therefore, records these reimbursements on a gross basis. The
 impact of the new revenue standard IFRS 15 was also assessed for
 the instances under the ONO research and license agreement (defined
 below) where the Company acts as an agent. The Company concluded
 that no control was obtained for these pass-through arrangements to
 reimburse costs under the ONO research and license agreement and as
 such the costs were netted in R&amp;D instead of being recognised
 as expense.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Costs of Obtaining a Contract with a Customer</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company capitalizes the incremental costs of obtaining a
 contract with a customer if it expects to recover those costs. To
 date, the Company has not capitalized any incremental costs for
 obtaining a contract.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Government Grants</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company receives certain government and regional grants, which
 support its research efforts in defined projects, and include
 contributions towards the R&amp;D cost. When there is reasonable
 assurance that the Company will comply with the conditions attached
 to a received grant, and when there is reasonable assurance that
 the grant will be received, government grants are recognized as
 revenue on a gross basis in the consolidated statement of profit or
 loss and comprehensive loss on a systematic basis over the periods
 in which the Company recognizes expenses for the related costs for
 which the grants are intended to compensate. In the case of grants
 related to assets, the received grant will be deducted from the
 carrying amount of the asset.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>WBSO</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The WBSO (<i>afdrachtvermindering speur- en ontwikkelingswerk</i>)
 is a Dutch fiscal facility that provides subsidies to companies,
 knowledge centers and self-employed people who perform R&amp;D
 activities (as defined in the WBSO Act). Under this act, a
 contribution is paid towards the labor costs of employees directly
 involved in R&amp;D and other related expenditures. The
 contribution is in the form of a reduction of payroll taxes.
 Subsidies relating to labor costs are deferred and recognized in
 the consolidated statement of profit or loss and comprehensive loss
 as negative labor costs over the period necessary to match them
 with the labor costs that they are intended to compensate (see Note
 15).</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee Benefits</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Employee Benefits</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <i>Short-term Employee Benefits</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Short-term employee benefits are expensed as the related service is
 provided. A liability is recognized for the amount expected to be
 paid if the Company has a present legal or constructive obligation
 to pay this amount as a result of past service provided by the
 employee and the obligation can be estimated reliably.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <i>Share-Based Payment Transactions</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The grant-date fair value of equity-settled share-based payment
 awards granted to employees including grants of employee options,
 restricted share units, and modifications to existing instruments,
 is recognized as an expense, net of an estimated forfeiture rate,
 with a corresponding increase in equity (accumulated loss), over
 the vesting period of the awards. Service conditions and
 <font style="WHITE-SPACE: nowrap">non-market</font> related
 conditions are not taken into account in determining the fair
 value. The amount recognized as an expense is adjusted to reflect
 the number of awards for which the related service and <font style="WHITE-SPACE: nowrap">non-market</font> performance conditions are
 expected to be met, such that the amount ultimately recognized is
 based on the number of awards that meet the related service and
 <font style="WHITE-SPACE: nowrap">non-market</font> performance
 conditions at the vesting date. For any share-based payment awards
 with market conditions or <font style="WHITE-SPACE: nowrap">non-vesting</font> conditions, the grant-date
 fair value of the share-based payment is measured to reflect such
 conditions and there is no <font style="WHITE-SPACE: nowrap">true-up</font> for differences between
 expected and actual outcomes.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Post-Employment Benefit Plans</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company contributes to a post-employment benefit plan that
 entitles executive officers and other staff members to retire at
 the age of 67 and receive annual payments based upon the average
 salary earned during the service period. The Company has insured
 the liabilities from the post-employment benefit plan with an
 insurance company and has no other obligation than to pay the
 annual insurance premiums to the insurance company. The annual
 pension payments are conditional; the Company will have no further
 obligation (legal or constructive) to pay further amounts if the
 insurance fund has insufficient assets to pay all employee benefits
 relating to current and prior service. Based on its
 characteristics, the Company&#x2019;s post-employment benefit plan
 is classified as a defined contribution plan.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Obligations for contributions to defined contribution plans are
 expensed as the related service is provided. Prepaid contributions
 are recognized as an asset.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Leases</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <i>Determining whether an Arrangement Contains a Lease</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 At inception of an arrangement, the Company determines whether such
 an arrangement is or contains a lease.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 At inception or on reassessment of the arrangement, the Company
 separates payments and other consideration required by such an
 arrangement into those for the lease and those for other elements
 on the basis of their relative fair values. If the Company
 concludes for a finance lease that it is impracticable to separate
 the payments reliably, then an asset and a liability are recognized
 at an amount equal to the fair value of the underlying asset.
 Subsequently, the liability is reduced as payments are made and an
 imputed finance cost on the liability is recognized using the
 Company&#x2019;s incremental borrowing rate.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Leased Assets</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Assets held by the Company under leases that transfer to the
 Company substantially all of the risks and rewards of ownership are
 classified as finance leases. The leased assets are measured
 initially at an amount equal to the lower of their fair value and
 the present value of the minimum lease payments. Subsequent to
 initial recognition, the assets are accounted for in accordance
 with the accounting policy applicable to that asset.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Assets held under other leases are classified as operating leases
 and are not recognized in the Company&#x2019;s statement of
 financial position.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Lease Payments</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Payments made under operating leases are recognized in the
 consolidated statement of profit or loss and comprehensive loss on
 a straight-line basis over the term of the lease. Lease incentives
 received are recognized as an integral part of the total lease
 expense, over the term of the lease.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Minimum lease payments made under finance leases are apportioned
 between the finance expense and the reduction of the outstanding
 liability. The finance expense is allocated to each period during
 the lease term so as to produce a constant periodic rate of
 interest on the remaining balance of the&#xA0;liability.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory', window );">Finance Income and Finance Expenses</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Finance Income and Finance Expenses</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company&#x2019;s finance income and finance expenses
 include:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">interest and related income;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">interest expense and changes in fair value of the
 forward contract (derivative);</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">financing costs; and</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the foreign currency gain or loss on financial assets
 and financial liabilities.</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Interest income or expense is recognized using the effective
 interest method.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income Tax</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Income Tax</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Income tax expense comprises current and deferred tax. It is
 recognized in the consolidated statement of profit or loss and
 comprehensive loss except to the extent that it relates to a
 business combination, or items recognized directly in equity or in
 other comprehensive income or loss. Current tax comprises the
 expected tax payable or receivable on the taxable income or loss
 for the year and any adjustment to tax payable or receivable in
 respect of previous years. It is measured using tax rates enacted
 or substantively enacted at the reporting date. Current tax also
 includes any tax arising from dividends. Current tax assets and
 liabilities are offset only if certain criteria are met.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Deferred tax is recognized in respect of temporary differences
 between the carrying amounts of assets and liabilities for
 financial reporting purposes and the amounts used for taxation
 purposes. Deferred tax is not recognized for:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">temporary differences on the initial recognition of
 assets or liabilities in a transaction that is not a business
 combination and that affects neither accounting nor taxable profit
 or loss;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">temporary differences related to investments in
 subsidiaries, associates and joint arrangements to the extent that
 the group is able to control the timing of the reversal of the
 temporary differences and it is probable that they will not reverse
 in the foreseeable future; and</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">taxable temporary differences arising on the initial
 recognition of goodwill.</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Deferred tax assets are recognized for unused tax losses, unused
 tax credits and deductible temporary differences to the extent that
 it is probable that future taxable profits will be available
 against which they can be used. Deferred tax assets are reviewed at
 each reporting date and are reduced to the extent that it is no
 longer probable that the related tax benefit will be realized; such
 reductions are reversed when the probability of future taxable
 profits improves.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Unrecognized deferred tax assets are reassessed at each reporting
 date and recognized to the extent that it has become probable that
 future taxable profits will be available against which they can be
 utilized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Deferred tax is measured at the tax rates that are expected to be
 applied to temporary differences when they reverse, using tax rates
 enacted or substantively enacted at the reporting date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The measurement of deferred tax reflects the tax consequences that
 would follow from the manner in which the Company expects, at the
 reporting date, to recover or settle the carrying amount of its
 assets and liabilities.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Deferred tax assets and liabilities are offset only if certain
 criteria are met.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for the impairment of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for basis of consolidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for finance income and finance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfAccountingPolicyForFinanceIncomeAndFinanceExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfAccountingPolicyForInvestmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfAccountingPolicyForInvestmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735422688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued or Adopted International Financial Reporting Standards (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory', window );">Condensed Consolidated Statements of Financial Information</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The following financial statement line items have been shown to
 reflect the adjustments recognized for each individual line item in
 the Company&#x2019;s respective consolidated financial statements
 for the period noted:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Consolidated Statement of Profit or Loss and Comprehensive
 Loss</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="50%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,&#xA0;2017<br />
 (As originally<br />
 presented)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS&#xA0;15<br />
 Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,&#xA0;2017<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,600</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,315</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,915</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Operating result</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,617</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,315</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(35,302</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total comprehensive loss for the period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(73,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,315</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(64,685</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Loss per share&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3.80</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.43</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3.37</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="48%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,&#xA0;2016<br />
 (As originally<br />
 presented)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS&#xA0;15<br />
 Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,&#xA0;2016<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,719</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(209</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,510</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Operating result</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(27,672</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(209</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(27,881</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total comprehensive loss for the period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(47,220</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(209</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(47,429</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Loss per share&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3.57</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.01</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3.58</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Consolidated Statement of Financial Position</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="49%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2017<br />
 (As originally<br />
 presented)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS 15<br />
 Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2017<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(167,480</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,705</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(158,775</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue, <font style="WHITE-SPACE: nowrap">non-current</font></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">130,195</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17,644</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">112,551</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,996</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,939</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,935</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="48%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2016<br />
 (As originally<br />
 presented)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS 15<br />
 Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2016<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(107,295</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">390</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(106,905</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue, <font style="WHITE-SPACE: nowrap">non-current</font></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30,206</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,272</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,934</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,610</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,882</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,492</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <i>Consolidated Statement of Cash Flows</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="50%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2017<br />
 (As originally<br />
 presented)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS 15<br />
 Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2017<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Result after taxation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(73,089</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,315</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(64,774</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Changes in working capital:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,618</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,315</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14,933</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="49%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2016<br />
 (As originally<br />
 presented)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS 15<br />
 Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2016<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Result after taxation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(47,228</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(209</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(47,437</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Changes in working capital:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(223</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">209</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of adoption of new international financial information regulations amendments and interpretations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735396144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of Changes in Property, Plant and Equipment</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Movements in property, plant and equipment, net were as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Plant and</b><br />
 <b>equipment</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Other&#xA0;fixed</b><br />
 <b>assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as at January&#xA0;1, 2017</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">649</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,386</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,035</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(221</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,166</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,387</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Book value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">428</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">220</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">648</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Changes in book value</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Additions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">663</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">113</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">776</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(186</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(70</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(256</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Disposals (Cost)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(51</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,086</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,137</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Disposals (Accumulated depreciation)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,086</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,137</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">477</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">43</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">520</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as at December&#xA0;31, 2017</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,261</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">413</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,674</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(356</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(150</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(506</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Book value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">905</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">263</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,168</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Changes in book value</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Additions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,498</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">300</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,798</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(448</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(98</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(546</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Disposals (Cost)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Disposals (Accumulated depreciation)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,050</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">202</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,252</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as at December&#xA0;31, 2018</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,759</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">713</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,472</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(804</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(248</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,052</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Book value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,955</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">465</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,420</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2018-01-01<br> -Paragraph 73<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2018-03-01&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6593215168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Summary of Movements of Intellectual Property Right</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The intangible assets, net are related to acquired intellectual
 property rights were as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(euros&#xA0;in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as at January&#xA0;1</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Historical cost</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>860</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">860</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(548</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(486</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Book value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>312</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">374</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Additions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,225</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Amortization for the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(92</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(62</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Book value as at December&#xA0;31</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,445</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">312</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as at December&#xA0;31</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Historical cost</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>3,085</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">860</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(640</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(548</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Book value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,445</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">312</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2018-01-01<br> -Paragraph 118<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2018-03-01&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735519040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfHeldToMaturityInvestmentExplanatory', window );">Summary of Investments</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Investments as of December&#xA0;31, 2018 and 2017 consisted of the
 following:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b><i>(euros in
 thousands)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>22,208</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,527</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 U.S. Treasury securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>6,733</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,177</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Corporate fixed income bonds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>14,185</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,886</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Agency bonds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,729</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,453</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Current investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>44,855</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34,043</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Corporate fixed income bonds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>16,945</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,060</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <font style="white-space:nowrap">Non-current</font> investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>16,945</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,060</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>61,800</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">41,103</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfHeldToMaturityInvestmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of held to maturity investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfHeldToMaturityInvestmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6638716496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory', window );">Summary of Trade and Other Receivables Due Within 1 Year</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 All trade and other receivables are short-term and due within 1
 year.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b><i>(euros&#xA0;in&#xA0;thousands)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,690</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,594</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unbilled receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>236</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 VAT receivable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>891</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">582</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Prepaid expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,783</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">427</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Prepaid pension costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">838</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Interest receivable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>213</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>219</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">92</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>7,032</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,413</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of trade and other current receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6742306624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities and Accruals (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock', window );">Summary of Short-term and Payable Within 1 Year</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 All amounts are short-term and payable within 1 year.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b><i>(euros&#xA0;in&#xA0;thousands)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Audit fees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>167</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">96</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Personnel-related</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>560</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">446</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accrued bonus</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,523</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,545</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 R&amp;D costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,409</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,272</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 IP legal fees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>212</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">509</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Subsidy advance received</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>42</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">224</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other accruals</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,051</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">535</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>7,964</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,627</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accruals other liabilities explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6593215168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredRevenueExplanatory', window );">Summary of Deferred Revenue</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Deferred revenue consisted of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017<br />
 Restated*</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b><i>(euros&#xA0;in&#xA0;thousands)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue&#x2014;current portion</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>16,934</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,935</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>97,675</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">112,551</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>114,609</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,486</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left">*</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><i>See Note 4 for details regarding the restatement as
 a result of a change in accounting policy.</i></p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDeferredRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDeferredRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6730801616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Summary of Reconciliation of Common Shares Outstanding</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The following is a tabular reconciliation of common shares
 outstanding for the years ended December&#xA0;31, 2018 and 2017,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Common Shares outstanding at January&#xA0;1,</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>19,429,848</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,085,851</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Issued for cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>3,699,997</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,200,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercise of common share options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>135,888</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">136,666</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vesting of RSUs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>93,244</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,331</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Common shares outstanding at December&#xA0;31,</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>23,358,977</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,429,848</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Summary of Inputs Used in the Measurement of the Fair Values and the Related Fair Values at the Grant Dates</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The inputs used in the measurement of the fair values and the
 related fair values at the grant dates for the options granted
 during the respective years were as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="29%"></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="11" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"><b>2016</b></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>Key</b><br />
 <b>Management</b><br />
 <b>Personnel</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>All Other</b><br />
 <b>Employees</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>Key</b><br />
 <b>Management</b><br />
 <b>Personnel</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>All Other</b><br />
 <b>Employees</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>Key</b><br />
 <b>Management</b><br />
 <b>Personnel</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>All Other</b><br />
 <b>Employees</b></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Fair value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 <b>&#x20AC;6.82&#xA0;&#x2013;&#xA0;&#x20AC;12.27</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 <b>&#x20AC;7.74&#xA0;&#x2013;&#xA0;&#x20AC;13.32</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;9.04&#xA0;&#x2013;&#xA0;&#x20AC;16.10</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;8.94&#xA0;&#x2013;&#xA0;&#x20AC;18.02</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;9.97&#xA0;&#x2013;&#xA0;&#x20AC;11.03</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;5.74&#xA0;&#x2013;&#xA0;&#x20AC;5.79</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Share price</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 <b>&#x20AC;13.01&#xA0;&#x2013;&#xA0;&#x20AC;19.90</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 <b>&#x20AC;12.29&#xA0;&#x2013;&#xA0;&#x20AC;21.02</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;17.08&#xA0;&#x2013;&#xA0;&#x20AC;24.54</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;13.71&#xA0;&#x2013;&#xA0;&#x20AC;27.47</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;15.24&#xA0;&#x2013;&#xA0;&#x20AC;16.85</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;8.46&#xA0;&#x2013;&#xA0;&#x20AC;8.87</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercise price</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 <b>&#x20AC;13.01&#xA0;&#x2013;&#xA0;&#x20AC;19.90</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 <b>&#x20AC;12.29&#xA0;&#x2013;&#xA0;&#x20AC;21.02</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;17.08&#xA0;&#x2013;&#xA0;&#x20AC;24.54</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;13.71&#xA0;&#x2013;&#xA0;&#x20AC;27.47</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;15.24&#xA0;&#x2013;&#xA0;&#x20AC;16.85</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 &#x20AC;8.46&#xA0;&#x2013;&#xA0;&#x20AC;8.87</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility (weighted-average)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>94.71%</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>92.16%</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">95.05%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">94.88%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">95.30%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">97.15%</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected life</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>10 years</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>10 years</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">10 years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">10&#xA0;years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">10 years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">8&#xA0;&#x2013;&#xA0;10
 years</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividends</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>0%</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>0%</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 <b>2.79%&#xA0;&#x2013;&#xA0;3.20%</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 <b>2.83%&#xA0;&#x2013;&#xA0;3.10%</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 2.29%&#xA0;&#x2013;&#xA0;2.51%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 2.24%&#xA0;&#x2013;&#xA0;2.62%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 1.84%&#xA0;&#x2013;&#xA0;1.86%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 0.10%&#xA0;&#x2013;&#xA0;1.87%</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Summary of Reconciliation of Outstanding Share Options</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The number of share options and the weighted average exercise
 prices of share options granted were as follows for the respective
 years:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="49%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>average</b><br />
 <b>exercise</b><br />
 <b>price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of</b><br />
 <b>options</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>average</b><br />
 <b>exercise</b><br />
 <b>price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of</b><br />
 <b>options</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>average</b><br />
 <b>exercise</b><br />
 <b>price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of</b><br />
 <b>options</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(&#x20AC;)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(&#x20AC;)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(&#x20AC;)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at January&#xA0;1</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>13.99</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,213,985</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.69</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,394,844</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.35</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">953,689</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Forfeited during the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>14.48</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(38,874</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.27</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(58,164</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.07</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(31,351</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expired during the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>11.00</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(31,629</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.67</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(762</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.95</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5,454</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercised during the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>6.80</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(135,888</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.24</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(136,666</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.93</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(18,283</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted during the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>14.96</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>625,445</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19.88</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,014,733</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14.74</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">496,243</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>14.62</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,633,039</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13.99</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,213,985</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.69</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,394,844</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercisable at December&#xA0;31</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,275,669</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">687,070</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">418,453</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory', window );">Summary of Number of Share Options Outstanding</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The number of share options outstanding, by group of employees, was
 as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 <b>Group of employees entitled</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Key management personnel</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,148,744</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,777,437</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,302,417</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 All other employees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">484,295</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">436,548</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">92,427</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,633,039</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,213,985</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,394,844</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory', window );">Summary of Reconciliation of RSU's</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 During 2017, the Company granted RSUs to Key Management Personnel.
 The following table summarizes the Company&#x2019;s RSU&#x2019;s
 activity:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>average</b><br />
 <b>grant&#xA0;date<br />
 fair value</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br />
 average<br />
 grant&#xA0;date<br />
 fair value</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested at January&#xA0;1</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">20.03</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">194,546</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#x20AC;</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Forfeited during the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#x20AC;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(12,219</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expired during the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vested during the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#x20AC;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(93,244</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#x20AC;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(7,331</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted during the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#x20AC;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>214,096</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested at December&#xA0;31</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#x20AC;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>101,302</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#x20AC;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>194,546</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the general terms and conditions of share-based payment arrangements. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share other than options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6731244656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfInformationAboutRevenueExplanatory', window );">Summary of Revenue</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company&#x2019;s revenues are generated entirely in the
 Netherlands. In the following table, revenue is disaggregated by
 primary source of revenue as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017<br />
 Restated*</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016<br />
 Restated*</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b><i>(euros in
 thousands)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Upfront payment amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>17,686</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,933</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 R&amp;D cost reimbursement and milestone</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>13,566</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,787</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,109</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Revenue from contracts with customers</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>31,252</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,720</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,123</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Income from grants on research projects</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>196</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,195</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,387</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>31,448</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,915</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,510</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left">*</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><i>See Note 4 for details regarding the restatement as
 a result of a change in accounting policy.</i></p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Summary of Changes in Tarde Receivables, Contract Assets and Contract Liabilities</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table presents changes in the Company&#x2019;s trade
 receivables, contract assets and contract liabilities during the
 year ended December&#xA0;31, 2018:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="50%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2017<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Additions</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Deductions</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade&#xA0;receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,594</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,951</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(18,855</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,690</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total trade&#xA0;receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,594</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,951</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(18,855</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,690</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contract assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unbilled receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,045</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,519</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">236</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total contract assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,045</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,519</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">236</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contract liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,486</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,137</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(18,014</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">114,609</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total contract liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,486</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,137</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(18,014</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">114,609</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table presents changes in the Company&#x2019;s trade
 receivables, contract assets and contract liabilities during the
 year ended December&#xA0;31, 2017:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="49%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2016<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Additions</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Deductions</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2017<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade&#xA0;receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">205</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">122,781</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(121,392</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,594</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total trade&#xA0;receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">205</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">122,781</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(121,392</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,594</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contract assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unbilled receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">121,240</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(120,530</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total contract assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">121,240</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(120,530</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contract liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">31,426</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">111,993</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14,933</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,486</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total contract liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">31,426</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">111,993</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14,933</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,486</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2018-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2018-03-01&amp;anchor=sect_Presentation&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2018-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2018-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfInformationAboutRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfInformationAboutRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6730829392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Total Operating Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory', window );">Summary of Total Operating Expenses</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The following table presents a breakdown of operating expenses:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Manufacturing costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>18,914</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,567</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,162</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 IP and license costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,852</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,858</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,167</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Personnel related R&amp;D</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>7,036</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,673</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,285</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other R&amp;D costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>18,938</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,027</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,810</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <i>Total R&amp;D costs</i></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>46,740</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34,125</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,424</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <i>Management and administration costs</i></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>10,395</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,258</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Litigation costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,425</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,039</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,490</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other operating expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>11,735</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,356</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,219</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <i>Total other expenses</i></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>13,160</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,395</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,709</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Total operating expenses</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>70,295</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">57,217</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30,391</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory', window );">Breakdown of Other Research and Development Costs</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table presents a breakdown of other R&amp;D
 costs:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Discovery and preclinical costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>5,506</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,473</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,185</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Clinical costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>9,169</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,919</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,409</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other R&amp;D costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,263</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,635</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,216</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Total other R&amp;D costs</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>18,938</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,027</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,810</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOperatingExpensesByNatureExplanatory', window );">Operating Expenses by Nature</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Operating expenses presented by nature are outlined below:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contract manufacturing</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>18,914</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,567</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,162</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other external and outsourced costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>32,459</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22,333</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,885</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Employee costs&#xA0;and related benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>18,284</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,999</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,110</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Depreciation and amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>638</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">318</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">234</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total operating expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>70,295</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">57,217</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30,391</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information of research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information related to operating expenses explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfOperatingExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of operating expenses by nature explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfOperatingExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735404448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory', window );">Disclosure of Detailed Information About Employee Benefits</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Details of the employee benefits are as follows:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Salaries and wages</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>10,783</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,556</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,166</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 WBSO subsidy</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(4,257</b></td>
 <td nowrap="nowrap" valign="bottom"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,523</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,721</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Social security premiums</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>919</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">621</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">382</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Health insurance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>330</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">222</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Pension costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>749</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">652</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">507</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Share-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>7,925</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,815</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,307</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Other personnel expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,835</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">656</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">442</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total employee benefits expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>18,284</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,999</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,110</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory', window );">Schedule of Share-based Compensation Expenses Recognized as Employee Benefit Expenses</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Share-based compensation expense recognized as employee benefit
 expenses during the years ended December&#xA0;31, 2018, 2017 and
 2016 was as follows:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b><i>(euros in
 thousands)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 R&amp;D costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,710</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,245</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">703</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Management and administration costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,742</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,942</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,037</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Other expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>473</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">628</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">567</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>7,925</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,815</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,307</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6656189872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Expense) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory', window );">Summary of Other Income (Expense)</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The following table presents a breakdown of other income
 (expense):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="67%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Finance income</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Interest income and similar related income</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,809</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,112</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">88</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net gain on foreign exchange</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>6,034</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="right"><b>7,843</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="right"><b>1,112</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="right"><b>88</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other income</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>7,095</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Finance costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Interest and other expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(4</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(190</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss on foreign exchange</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(19,449</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(409</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Derivative financial instrument expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,696</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(19,235</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(4</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(30,335</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(19,644</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total other income (expense)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>14,934</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(29,223</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(19,556</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about other income and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6742362736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDetailsOfEarningsPerShareExplanatory', window );">Summary of Basic and Diluted Loss per Share</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Basic and diluted net loss per share attributable to equity holders
 of the Company was calculated as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="57%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017<br />
 Restated*</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016<br />
 Restated*</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(e</b><b><i>uros
 in thousands, except per share data</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Numerator:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss attributable to equity holders of the Company</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(24,235</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(64,685</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(47,429</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Denominator:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average shares outstanding&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>22,286,720</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,196,440</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,236,649</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Loss per share&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(1.09</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3.37</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3.58</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left">*</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">See Note 4 for details regarding the restatement as a
 result of a change in accounting policy</p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDetailsOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of details of earnings per share explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDetailsOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6738232000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfMaximumExposureToCreditRiskExplanatory', window );">Summary of Carrying Amount of Financial Assets Represents the Maximum Credit Exposure</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The carrying amount of financial assets represents the maximum
 credit exposure.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade and unbilled receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,926</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,283</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>61,800</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">41,103</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>143,747</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">149,678</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>208,473</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">193,064</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory', window );">Summary of Aging of Trade and Unbilled Receivables</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The aging of trade and unbilled receivables was as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(</b><b><i>euros&#xA0;in&#xA0;thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Neither past due nor impaired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,926</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,283</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Past due</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,926</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,283</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities', window );">Summary of Contractual Maturities of Financial Liabilities</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following are the remaining contractual maturities of financial
 liabilities as at December&#xA0;31, 2018 and 2017. The amounts are
 gross and undiscounted.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="22" align="center"><b>December&#xA0;31, 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Carrying</b><br />
 <b>amount</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>&lt; 12</b><br />
 <b>months</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>1&#xA0;-&#xA0;2</b><br />
 <b>years</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2&#xA0;-&#xA0;5</b><br />
 <b>years</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>&gt;&#xA0;5&#xA0;years</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="22" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade payables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,819</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,819</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,819</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other liabilities and accruals</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,964</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,964</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,964</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,783</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,783</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,783</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="22" align="center"><b>December&#xA0;31, 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Carrying</b><br />
 <b>amount</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>&lt; 12</b><br />
 <b>months</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>1&#xA0;-&#xA0;2</b><br />
 <b>years</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2&#xA0;-&#xA0;5</b><br />
 <b>years</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>&gt; 5&#xA0;years</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="22" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade payables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,855</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,855</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,855</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other liabilities and accruals</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,176</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,176</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,176</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,031</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,031</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,031</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk', window );">Summary of Sensitivity Analysis for Change in Primary Currency Exposures</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table provides a sensitivity analysis for a change in
 the primary currency exposure for the Company relating to monetary
 assets and liabilities denominated in U.S. dollars as of
 December&#xA0;31, 2018. The analysis shows the impact that a change
 in the exchange rate at that date would have on the Company&#x2019;s
 total comprehensive loss:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="52%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 <b>Financial Statement Line Item Exposure</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Balance</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Effect&#xA0;on&#xA0;profit</b><br />
 <b>before&#xA0;tax&#xA0;if&#xA0;USD</b><br />
 <b>strengthens 5%</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Effect&#xA0;on&#xA0;profit</b><br />
 <b>before&#xA0;tax&#xA0;if&#xA0;USD</b><br />
 <b>weakens 5%</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">43,074</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,154</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,154</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">61,800</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,090</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,090</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade and other receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,886</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">144</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(144</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">123</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Taxes and social security liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(88</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade payables, other liabilities and accruals</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,795</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(240</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">240</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>103,000</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>5,150</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(5,150</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfInterestBearingFinancialInstrumentsExplanatory', window );">Summary of Interest Rate Profile of the Company's Interest-bearing Financial Instruments</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The interest rate profile of the Company&#x2019;s interest-bearing
 financial instruments is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(</b><b><i>euros
 in thousands</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Fixed-rate instruments</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>61,800</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">41,103</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Variable rate instruments</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>143,747</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">149,678</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets that are either past due or impaired. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 37<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_37&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 40<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfInterestBearingFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of interest bearing financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfInterestBearingFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfMaximumExposureToCreditRiskExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of maximum exposure to credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfMaximumExposureToCreditRiskExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6606530992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Board Compensation and Key Management Personnel (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementExplanatory', window );">Summary of Profit and Loss Statement for the Remuneration of the Statutory Directors</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In 2018, 2017 and 2016, the following amounts were charged to the
 consolidated statement of profit or loss and comprehensive loss for
 the remuneration of the statutory directors:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 <b>Name</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross&#xA0;salary</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Bonus</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Pension</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Option&#xA0;cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="18" align="center"><b>(</b><b><i>in
 euros</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Ton Logtenberg, President, CEO and Principal Financial Officer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">445,606</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">155,962</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">31,881</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,696,918</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,330,367</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">432,782</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">337,945</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51,528</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,675,590</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,497,845</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">369,204</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">147,820</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,717</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">907,236</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,441,977</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Shelley Margetson(*), Former COO</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(**)&#xA0;420,782</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,595</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">451,752</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">892,129</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">198,987</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">84,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,152</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">164,547</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">453,686</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left">(*)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Resigned as a statutory director of the Company
 effective as of May&#xA0;24, 2017.</p>
 </td>
 </tr>
 </table>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left">(**)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Gross salary includes severance payments totaling
 &#x20AC;257,260.</p>
 </td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDetailedInformationOfRelatedPartyExplanatory', window );">Summary of the Remuneration Received for Key Management Personnel</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The remainder of the key management personnel has received the
 following remuneration:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 <b>Remuneration</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(</b><b><i>in
 euros</i></b><b>)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Short-term employment benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,705,438</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,808,998</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,139,763</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Post-employment benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">40,882</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">108,416</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,720</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other long-term benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Termination benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Share-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,688,978</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,171,233</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,195,876</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,435,298</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,088,647</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,354,359</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory', window );">Summary of Statement of Profit and Loss for the Remuneration of the(Former) Members of the Supervisory Board</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The following amounts were charged to the consolidated statement of
 profit or loss and comprehensive loss for the remuneration of the
 members of the Board:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="28%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31, 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31, 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended</b><br />
 <b>December&#xA0;31, 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 <b>Name</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Cash</b><br />
 <b>compensation</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Option</b><br />
 <b>cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Cash</b><br />
 <b>compensation</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Option</b><br />
 <b>cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Cash</b><br />
 <b>compensation</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Option</b><br />
 <b>cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b><i>(in
 euros)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b><i>(in
 euros)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b><i>(in
 euros)</i></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Russell Greig</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">38,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">79,333</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">117,936</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Mark Iwicki</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">55,066</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">68,666</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">123,732</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">59,840</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">120,596</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,436</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">50,394</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">183,367</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">233,761</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Len Kanavy</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">32,859</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">152,485</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">185,344</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Wolfgang Berthold</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,315</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">65,776</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">85,091</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">37,530</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">90,944</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,474</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">50,928</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">70,778</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Lionel Carnot*</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,401</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">&#x2014;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,401</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">35,445</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">61,870</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">97,315</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24,852</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">66,959</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">91,811</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 John de Koning</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">40,768</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51,044</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">91,812</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">38,573</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">113,613</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">152,186</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,230</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">37,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">63,230</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Anand Mehra</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">39,863</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34,449</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">74,312</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">39,615</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">83,683</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">123,298</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,938</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">84,703</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">111,641</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Gregory Perry</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">45,356</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,797</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">100,153</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">41,700</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">103,169</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">144,869</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,356</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">97,365</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">125,721</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8.5pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>292,231</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>506,550</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>798,781</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>252,703</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>573,875</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>826,578</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>176,620</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>520,322</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>696,942</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left">(*)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">former board member</p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory', window );">Summary of Average Exercise Price Per Share Held by the Members of the Supervisory Board</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 As at December&#xA0;31, members of the Board held the following
 number of options:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="50%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31, 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31, 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December, 31 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 <b>Name</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>average</b><br />
 <b>exercise</b><br />
 <b>price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>average</b><br />
 <b>exercise</b><br />
 <b>price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted</b><br />
 <b>average</b><br />
 <b>exercise</b><br />
 <b>price</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Russell Greig</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,966</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">19.97</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#x20AC;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#x20AC;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Mark Iwicki</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">84,209</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">10.07</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">79,226</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">7.32</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">73,576</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">6.57</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Len Kanavy</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,818</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">16.33</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#x20AC;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#x20AC;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Wolfgang Berthold</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36,540</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">15.22</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24,040</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">8.90</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,724</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">3.02</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Lionel Carnot*</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#x20AC;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">11.80</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">8.87</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 John de Koning</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,633</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">14.34</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">11.80</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">8.87</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Anand Mehra</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,633</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">14.34</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">11.80</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">8.87</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Gregory Perry</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,633</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">14.34</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">11.80</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">8.87</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Gabriele Dallmann*</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#x20AC;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#x20AC;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,828</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">3.24</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">235,432</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">11.52</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">193,866</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">9.61</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">185,128</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#x20AC;</td>
 <td valign="bottom" align="right">7.21</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left">(*)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">former board member</p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureChargedToTheProfitAndLossStatementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure charged to the profit and loss statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureChargedToTheProfitAndLossStatementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDetailedInformationOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDetailedInformationOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of options held by the members of super visory board.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfOptionsHeldByTheMembersOfSuperVisoryBoardExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of statement of profit or loss and comprehensive loss for the remuneration of the former member.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfstatementOfProfitOrLossAndComprehensiveLossForTheRemunerationOfTheFformerMembersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6742382000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory', window );">Schedule of Future Minimum Lease Payments Under Lease</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Future minimum lease payments under these leases as of
 December&#xA0;31, 2018 are as follows:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="88%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Less than one year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,579</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Between one and five years</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,106</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 More than five years</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,685</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance leases and operating leases by the lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2019-01-01<br> -Name IAS<br> -Number 17<br> -IssueDate 2018-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=17&amp;date=2018-03-02&amp;anchor=para_31&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2019-01-01<br> -Name IAS<br> -Number 17<br> -IssueDate 2018-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=17&amp;date=2018-03-02&amp;anchor=para_35&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760313856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General Information - Additional Information (Detail)<br> &#8364; / shares in Units, $ / shares in Units, &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 15, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 15, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 13, 2018 </div>
<div>$ / shares </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 23, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 23, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 26, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>May 06, 2016</div></th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th">
<div>Jun. 01, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 24, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfGeneralInformationLineItems', window );"><strong>Disclosure of general information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated loss | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 175,100<span></span>
</td>
<td class="nump">&#8364; 175,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,747<span></span>
</td>
<td class="nump">143,747<span></span>
</td>
<td class="nump">&#8364; 149,678<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">&#8364; 56,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">&#8364; 32,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_HeldtomaturityInvestments', window );">Investments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 61,800<span></span>
</td>
<td class="nump">61,800<span></span>
</td>
<td class="nump">41,103<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ReverseStockSplitConversionRatio', window );">Reverse share split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50,713<span></span>
</td>
<td class="nump">&#8364; 74,738<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">&#8364; 50,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SubsidiarySaleOfStock1Axis=mrus_InitialPublicOfferingMember', window );">Initial public offering [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfGeneralInformationLineItems', window );"><strong>Disclosure of general information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SubsidiarySaleOfStock1Axis=mrus_OverAllotmentOption1Member', window );">Over allotment option [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfGeneralInformationLineItems', window );"><strong>Disclosure of general information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">639,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_InvestorsMember', window );">Investors [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfGeneralInformationLineItems', window );"><strong>Disclosure of general information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Issue price per share | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price</a></td>
<td class="nump">&#8364; 44,800<span></span>
</td>
<td class="nump">$ 55.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,099,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Purchase price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember', window );">Incyte Corporation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfGeneralInformationLineItems', window );"><strong>Disclosure of general information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 74,700<span></span>
</td>
<td class="nump">$ 80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SecuritiesPledgedAsCollateralForRegistration', window );">Securities registered | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Purchase price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_CowenAndCoLlcMember', window );">Cowen and Company LLC [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfGeneralInformationLineItems', window );"><strong>Disclosure of general information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfSharesIssuable', window );">Common shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfAggregateCompensationPayable', window );">Aggregate compensation payable, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="19"></td></tr>
<tr><td colspan="19"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HeldtomaturityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-derivative financial assets with fixed or determinable payments and fixed maturity that an entity has the positive intention and ability to hold to maturity other than: (a) those that the entity upon initial recognition designates as at fair value through profit or loss; (b) those that the entity designates as available for sale; and (c) those that meet the definition of loans and receivables. An entity shall not classify any financial assets as held to maturity if the entity has, during the current financial year or during the two preceding financial years, sold or reclassified more than an insignificant amount of held-to-maturity investments before maturity (more than insignificant in relation to the total amount of held-to-maturity investments) other than sales or reclassifications that: (i) are so close to maturity or the financial asset&#8217;s call date (for example, less than three months before maturity) that changes in the market rate of interest would not have a significant effect on the financial asset&#8217;s fair value; (ii) occur after the entity has collected substantially all of the financial asset&#8217;s original principal through scheduled payments or prepayments; or (iii) are attributable to an isolated event that is beyond the entity&#8217;s control, is non-recurring and could not have been reasonably anticipated by the entity. [Refer: Derivative financial assets; Held-to-maturity investments; Prepayments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 8<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_8_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HeldtomaturityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfGeneralInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line item represents disclosure of general information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfGeneralInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NumberOfSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares which may be issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NumberOfSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PercentageOfAggregateCompensationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate compensation payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PercentageOfAggregateCompensationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ReverseStockSplitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse Stock Split Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ReverseStockSplitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SecuritiesPledgedAsCollateralForRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities pledged as collateral for registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SecuritiesPledgedAsCollateralForRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SharePurchasedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share purchased price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SharePurchasedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SubsidiarySaleOfStock1Axis=mrus_InitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SubsidiarySaleOfStock1Axis=mrus_InitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SubsidiarySaleOfStock1Axis=mrus_OverAllotmentOption1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SubsidiarySaleOfStock1Axis=mrus_OverAllotmentOption1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_InvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_InvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_CowenAndCoLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_CowenAndCoLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6738523600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation - Additional Information (Detail)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>Segment</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfReportableSegments1', window );">Number of reportable segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expenses</a></td>
<td class="nump">&#8364; 356<span></span>
</td>
<td class="nump">&#8364; 249<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expenses</a></td>
<td class="nump">&#8364; 400<span></span>
</td>
<td class="nump">&#8364; 200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2018-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=26&amp;date=2018-03-01&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NumberOfReportableSegments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reportable segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NumberOfReportableSegments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6746229168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Detail)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>yr</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Estimated useful lives</a></td>
<td class="text">Five years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_CashAndCashEquivalentsMaximumMaturityPeriod', window );">Cash and cash equivalents, maximum original maturities</a></td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents', window );">Short-term investments | &#8364;</a></td>
<td class="nump">&#8364; 49.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfRetirementAge', window );">Retirement age | yr</a></td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=mrus_PlantAndEquipmentMember', window );">Plant and equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Other fixed assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment', window );">Estimated useful lives</a></td>
<td class="text">Shorter of useful life or term of lease<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfRetirementAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The retirement age used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2018-01-01<br> -Paragraph 144<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=19&amp;date=2018-03-01&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfRetirementAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The useful lives or depreciation rates used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2018-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2018-03-01&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_CashAndCashEquivalentsMaximumMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents Maximum Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_CashAndCashEquivalentsMaximumMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=mrus_PlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=mrus_PlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760810112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued International Financial Reporting Standards - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 08, 2014</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_AdoptionOfIFRS16Member', window );">Adoption Of IFRS 16 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member', window );">Increase (decrease) due to application of IFRS 15 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncreaseDecreaseInDeferredRevenue1', window );">Decrease in Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember', window );">Incyte collaboration agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_EstimatedContractualTerm', window );">Estimated contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember', window );">ONO Research and License Agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_EstimatedContractualTerm', window );">Estimated contractual term</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteProprietaryTechnologyMember', window );">Incyte proprietary technology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_EstimatedContractualTerm', window );">Estimated contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2019-01-01<br> -Name IFRS<br> -Number 16<br> -IssueDate 2018-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=16&amp;date=2018-03-01&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2019-01-01<br> -Name IFRS<br> -Number 16<br> -IssueDate 2018-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=16&amp;date=2018-03-01&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_EstimatedContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated contractual term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_EstimatedContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncreaseDecreaseInDeferredRevenue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncreaseDecreaseInDeferredRevenue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_AdoptionOfIFRS16Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_AdoptionOfIFRS16Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteProprietaryTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_IncyteProprietaryTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6746219344">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Recently Issued International Financial Reporting Standards - Consolidated Statements of Profit or Loss and Comprehensive Loss (Detail) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 31,448<span></span>
</td>
<td class="nump">&#8364; 21,915<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 2,510<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating result</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(38,847)<span></span>
</td>
<td class="num">(35,302)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(27,881)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (24,235)<span></span>
</td>
<td class="num">&#8364; (64,685)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">&#8364; (47,429)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Loss per share-basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">&#8364; (1.09)<span></span>
</td>
<td class="num">&#8364; (3.37)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">&#8364; (3.58)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Previously stated [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 2,719<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating result</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,617)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(27,672)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (73,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">&#8364; (47,220)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Loss per share-basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (3.80)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">&#8364; (3.57)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member', window );">Increase (decrease) due to application of IFRS 15 [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,315<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">&#8364; (209)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating result</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,315<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(209)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,315<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">&#8364; (209)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Loss per share-basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.43<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">&#8364; (0.01)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">For the periods included in these financial statements, share options and restricted stock units were excluded from the diluted loss per share calculation as the Company was in a loss position in each period presented above. As a result, basic and diluted loss per share are equal.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2018-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=32&amp;date=2018-03-01&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=5&amp;date=2018-03-01&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedIncomeStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedIncomeStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6738591200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Recently Issued International Financial Reporting Standards - Consolidated Statements of Financial Positions (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated loss</a></td>
<td class="num">&#8364; (175,085)<span></span>
</td>
<td class="num">&#8364; (158,775)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">&#8364; (106,905)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">97,675<span></span>
</td>
<td class="nump">112,551<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsCurrent', window );">Deferred revenue</a></td>
<td class="nump">&#8364; 16,934<span></span>
</td>
<td class="nump">15,935<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Previously stated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(167,480)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(107,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,195<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,996<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member', window );">Increase (decrease) due to application of IFRS 15 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,705<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,644)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,939<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 1,882<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred income classified as current. [Refer: Deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeClassifiedAsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred income classified as non-current. [Refer: Deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeClassifiedAsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedBalanceSheetStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6746563040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued International Financial Reporting Standards - Consolidated Statements of Cash Flows (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedCashFlowStatementsCaptionsLineItems', window );"><strong>Condensed Cash Flow Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result after taxation</a></td>
<td class="num">&#8364; (24,269)<span></span>
</td>
<td class="num">&#8364; (64,774)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">&#8364; (47,437)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ChangeInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome', window );">Deferred revenue</a></td>
<td class="num">&#8364; (13,877)<span></span>
</td>
<td class="num">(14,933)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Previously stated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedCashFlowStatementsCaptionsLineItems', window );"><strong>Condensed Cash Flow Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result after taxation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,089)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(47,228)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ChangeInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,618)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(223)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member', window );">Increase (decrease) due to application of IFRS 15 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedCashFlowStatementsCaptionsLineItems', window );"><strong>Condensed Cash Flow Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result after taxation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,315<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(209)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ChangeInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (8,315)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in deferred income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2018-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=4&amp;date=2018-03-02&amp;anchor=para_39L_e&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2018-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=17&amp;date=2018-03-01&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ChangeInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ChangeInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedCashFlowStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedCashFlowStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759019360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Schedule of Changes in Property, Plant and Equipment (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">&#8364; 1,168<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 648<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Changes in book value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">1,798<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">776<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(546)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(256)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInPropertyPlantAndEquipment', window );">Change in book value</a></td>
<td class="nump">1,252<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">520<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">2,420<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,168<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">1,674<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,035<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Changes in book value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,137)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">3,472<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,674<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation and amortisation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="num">(506)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,387)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Changes in book value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,137<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="num">(1,052)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(506)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=mrus_PlantAndEquipmentMember', window );">Plant and equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">905<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">428<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Changes in book value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">1,498<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">663<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(448)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(186)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInPropertyPlantAndEquipment', window );">Change in book value</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">477<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">1,955<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">905<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=mrus_PlantAndEquipmentMember', window );">Plant and equipment [member] | Cost [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">1,261<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">649<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Changes in book value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(51)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">2,759<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,261<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=mrus_PlantAndEquipmentMember', window );">Plant and equipment [member] | Accumulated depreciation and amortisation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="num">(356)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(221)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Changes in book value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">51<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="num">(804)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(356)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Other fixed assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">220<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Changes in book value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">113<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(98)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(70)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInPropertyPlantAndEquipment', window );">Change in book value</a></td>
<td class="nump">202<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">43<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">465<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Other fixed assets [member] | Cost [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">413<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,386<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Changes in book value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,086)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">713<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">413<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Other fixed assets [member] | Accumulated depreciation and amortisation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="num">(150)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,166)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Changes in book value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,086<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="num">&#8364; (248)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">&#8364; (150)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2018-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2018-03-01&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2018-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2018-03-01&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2018-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2018-03-01&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2018-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2018-03-01&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2018-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2018-03-01&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2018-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2018-03-01&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=mrus_PlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=mrus_PlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759281248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Summary of Movements of Intellectual Property Right (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets, beginning balance</a></td>
<td class="nump">&#8364; 312<span></span>
</td>
<td class="nump">&#8364; 374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">2,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization for the year</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets, ending balance</a></td>
<td class="nump">2,445<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets, beginning balance</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets, ending balance</a></td>
<td class="nump">3,085<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets, beginning balance</a></td>
<td class="num">(548)<span></span>
</td>
<td class="num">(486)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets, ending balance</a></td>
<td class="num">&#8364; (640)<span></span>
</td>
<td class="num">&#8364; (548)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2018-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2018-03-01&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2018-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2018-03-01&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2018-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2018-03-01&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6656628320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Additional Information (Detail)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intellectual property</a></td>
<td class="nump">&#8364; 2,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CapitalisedDevelopmentExpenditureMember', window );">Capitalised development expenditure [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights', window );">Intellectual property</a></td>
<td class="nump">2,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=mrus_PatentsAndIntellectualPropertyMember', window );">Patents and intellectual property [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intellectual property</a></td>
<td class="nump">&#8364; 2,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2018-01-01<br> -Paragraph 119<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2018-03-01&amp;anchor=para_119_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CapitalisedDevelopmentExpenditureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CapitalisedDevelopmentExpenditureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=mrus_PatentsAndIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=mrus_PatentsAndIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6758955040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expenses</a></td>
<td class="nump">&#8364; 356,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 249,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteMember', window );">Incyte [member] | Dutch [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LicenceFeeIncome', window );">Licence fee income | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_NL', window );">Netherlands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AverageQualifyingProfitsEffectiveTaxRate', window );">Percentage of income tax rate effectively owed</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_InnovationsBoxRate', window );">Tax rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Estimated effective tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expenses</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_NL', window );">Netherlands [member] | Less than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Estimated effective tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_NL', window );">Netherlands [member] | 1-2 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Estimated effective tax rate</a></td>
<td class="nump">22.55%<span></span>
</td>
<td class="nump">22.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_NL', window );">Netherlands [member] | 2-5 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Estimated effective tax rate</a></td>
<td class="nump">20.50%<span></span>
</td>
<td class="nump">20.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Estimated effective tax rate</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expenses</a></td>
<td class="nump">&#8364; 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">Unused tax losses [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates', window );">Tax losses carried forward</a></td>
<td class="nump">75,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 140,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Deductible temporary difference, deferred revenue</a></td>
<td class="nump">&#8364; 114,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax asset when: (a) the utilisation of the deferred tax asset is dependent on future taxable profits in excess of the profits arising from the reversal of existing taxable temporary differences; and (b) the entity has suffered a loss in either the current or preceding period in the tax jurisdiction to which the deferred tax asset relates. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_82&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssetWhenUtilisationIsDependentOnFutureTaxableProfitsInExcessOfProfitsFromReversalOfTaxableTemporaryDifferencesAndEntityHasSufferedLossInJurisdictionToWhichDeferredTaxAssetRelates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2018-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=26&amp;date=2018-03-01&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LicenceFeeIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from licence fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LicenceFeeIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AverageQualifyingProfitsEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average qualifying profits effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AverageQualifyingProfitsEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_InnovationsBoxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Innovations box rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_InnovationsBoxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncomeTaxAuthority1Axis=mrus_DutchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncomeTaxAuthority1Axis=mrus_DutchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6746960208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Investments (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentHeldtomaturityInvestments', window );">Investments, current portion</a></td>
<td class="nump">&#8364; 44,855<span></span>
</td>
<td class="nump">&#8364; 34,043<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentHeldtomaturityInvestments', window );">Non-current investments</a></td>
<td class="nump">16,945<span></span>
</td>
<td class="nump">7,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_HeldtomaturityInvestments', window );">Total investments</a></td>
<td class="nump">61,800<span></span>
</td>
<td class="nump">41,103<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialAssetsAxis=mrus_CommercialPaper1Member', window );">Commercial paper [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentHeldtomaturityInvestments', window );">Investments, current portion</a></td>
<td class="nump">22,208<span></span>
</td>
<td class="nump">15,527<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialAssetsAxis=mrus_USTreasurySecuritiesMember', window );">U.S. Treasury securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentHeldtomaturityInvestments', window );">Investments, current portion</a></td>
<td class="nump">6,733<span></span>
</td>
<td class="nump">9,177<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialAssetsAxis=mrus_CorporateFixedIncomeBondsMember', window );">Corporate fixed income bonds [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentHeldtomaturityInvestments', window );">Investments, current portion</a></td>
<td class="nump">14,185<span></span>
</td>
<td class="nump">7,886<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentHeldtomaturityInvestments', window );">Non-current investments</a></td>
<td class="nump">16,945<span></span>
</td>
<td class="nump">7,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialAssetsAxis=mrus_AgencyBondMember', window );">Agency bond [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentHeldtomaturityInvestments', window );">Investments, current portion</a></td>
<td class="nump">&#8364; 1,729<span></span>
</td>
<td class="nump">&#8364; 1,453<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentHeldtomaturityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current held-to-maturity investments. [Refer: Held-to-maturity investments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 8<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_8_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentHeldtomaturityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HeldtomaturityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-derivative financial assets with fixed or determinable payments and fixed maturity that an entity has the positive intention and ability to hold to maturity other than: (a) those that the entity upon initial recognition designates as at fair value through profit or loss; (b) those that the entity designates as available for sale; and (c) those that meet the definition of loans and receivables. An entity shall not classify any financial assets as held to maturity if the entity has, during the current financial year or during the two preceding financial years, sold or reclassified more than an insignificant amount of held-to-maturity investments before maturity (more than insignificant in relation to the total amount of held-to-maturity investments) other than sales or reclassifications that: (i) are so close to maturity or the financial asset&#8217;s call date (for example, less than three months before maturity) that changes in the market rate of interest would not have a significant effect on the financial asset&#8217;s fair value; (ii) occur after the entity has collected substantially all of the financial asset&#8217;s original principal through scheduled payments or prepayments; or (iii) are attributable to an isolated event that is beyond the entity&#8217;s control, is non-recurring and could not have been reasonably anticipated by the entity. [Refer: Derivative financial assets; Held-to-maturity investments; Prepayments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 8<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_8_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HeldtomaturityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentHeldtomaturityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current held-to-maturity investments. [Refer: Held-to-maturity investments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 8<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_8_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentHeldtomaturityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialAssetsAxis=mrus_CommercialPaper1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialAssetsAxis=mrus_CommercialPaper1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialAssetsAxis=mrus_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialAssetsAxis=mrus_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialAssetsAxis=mrus_CorporateFixedIncomeBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialAssetsAxis=mrus_CorporateFixedIncomeBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialAssetsAxis=mrus_AgencyBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialAssetsAxis=mrus_AgencyBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760381696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Purchases of investments</a></td>
<td class="nump">&#8364; 75,930<span></span>
</td>
<td class="nump">&#8364; 41,830<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Proceeds from investment maturities</a></td>
<td class="nump">58,912<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign currency exchange gains</a></td>
<td class="nump">6,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncomeStatementLineItemLocationAxis=mrus_NetFinanceIncomeExpenseMember', window );">Finance Income Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign currency exchange gains</a></td>
<td class="nump">&#8364; 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2018-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=21&amp;date=2018-03-01&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncomeStatementLineItemLocationAxis=mrus_NetFinanceIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncomeStatementLineItemLocationAxis=mrus_NetFinanceIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735530176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and Other Receivables - Summary of Trade and Other Receivables Due Within 1 Year (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 2,690<span></span>
</td>
<td class="nump">&#8364; 1,594<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_CurrentUnbilledReceivables', window );">Unbilled receivables</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxReceivables', window );">VAT receivable</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_CurrentPrepaidGeneralExpenses', window );">Prepaid expenses</a></td>
<td class="nump">2,783<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_CurrentPrepaidPensionCosts', window );">Prepaid pension costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentInterestReceivable', window );">Interest receivable</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Total</a></td>
<td class="nump">&#8364; 7,032<span></span>
</td>
<td class="nump">&#8364; 4,413<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current interest receivable. [Refer: Interest receivable]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax receivables. [Refer: Value added tax receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_CurrentPrepaidGeneralExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current prepaid general expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_CurrentPrepaidGeneralExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_CurrentPrepaidPensionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current prepaid pension costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_CurrentPrepaidPensionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_CurrentUnbilledReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current unbilled Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_CurrentUnbilledReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735933744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Liabilities and Accruals - Summary of Short-term and Payable Within 1 Year (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfAccrualsAndOtherPayablesAbstract', window );"><strong>Disclosure of accruals and other payables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AccruedAuditorsFee', window );">Audit fees</a></td>
<td class="nump">&#8364; 167<span></span>
</td>
<td class="nump">&#8364; 96<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AccruedPersonnel', window );">Personnel-related</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsAccruals', window );">Accrued bonus</a></td>
<td class="nump">1,523<span></span>
</td>
<td class="nump">1,545<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AccruedResearchAndDevelopmentStudies', window );">R&amp;D costs</a></td>
<td class="nump">4,409<span></span>
</td>
<td class="nump">5,272<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AccruedIntellectualPropertyLegalFee', window );">IP legal fees</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAdvances', window );">Subsidy advance received</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OtherAccruals', window );">Other accruals</a></td>
<td class="nump">1,051<span></span>
</td>
<td class="nump">535<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Total</a></td>
<td class="nump">&#8364; 7,964<span></span>
</td>
<td class="nump">&#8364; 8,627<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current payments received for goods or services to be provided in the future. [Refer: Advances received]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AccruedAuditorsFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>accrued auditors fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AccruedAuditorsFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AccruedIntellectualPropertyLegalFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued intellectual property legal fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AccruedIntellectualPropertyLegalFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AccruedPersonnel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AccruedPersonnel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AccruedResearchAndDevelopmentStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development studies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AccruedResearchAndDevelopmentStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfAccrualsAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accruals and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfAccrualsAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OtherAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OtherAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735497536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred Revenue - Summary of Deferred Revenue (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeAbstract', window );"><strong>Disclosure of deferred income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsCurrent', window );">Deferred revenue-current portion</a></td>
<td class="nump">&#8364; 16,934<span></span>
</td>
<td class="nump">&#8364; 15,935<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 3,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">97,675<span></span>
</td>
<td class="nump">112,551<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 27,934<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncome', window );">Total deferred revenue</a></td>
<td class="nump">&#8364; 114,609<span></span>
</td>
<td class="nump">&#8364; 128,486<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liability representing income that has been received but is not yet earned. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred income classified as current. [Refer: Deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeClassifiedAsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred income classified as non-current. [Refer: Deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeClassifiedAsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDeferredIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of deferred income [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDeferredIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6762070400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 10, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 10, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 23, 2017 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 23, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 20, 2016 </div>
<div>EUR (&#8364;) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 01, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 20, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncome', window );">Total deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 114,609,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 128,486,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,713,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 74,738,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">&#8364; 50,547,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrus_UpfrontAndMilestonePaymentsMember', window );">Upfront and Milestone Payments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember', window );">Incyte Corporation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NonRefundableUpfrontPaymentsReceivable', window );">Non-refundable upfront payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 112,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Common shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 74,700,000<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPayment', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 112,000,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember', window );">Incyte collaboration agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncome', window );">Total deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 112,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPayment', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,000,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration from the issuance and sale of common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_SimcereCollaborationAndLicenseAgreementMember', window );">Simcere collaboration and license agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncome', window );">Total deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPayment', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember', window );">ONO Research and License Agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueRemainingPerformanceObligations', window );">Performance obligation recognized as revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AmountPaidForFullTimeEquivalentFunding', window );">Paid for full time equivalent funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AmountPaidToCompensateForResearchServices', window );">Compensate for research service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember', window );">ONO Research and License Agreement [member] | Deferred revenue [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPayment', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteShareSubscriptionAgreementMember', window );">Incyte share subscription agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncome', window );">Total deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 31,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PurchasePricePerCommonShare', window );">Purchase price per common share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration from the issuance and sale of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,400,000<span></span>
</td>
<td class="nump">32,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_BettaPharmaceuticalsCoLtdMember', window );">Betta Pharmaceuticals Co Ltd [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPayment', window );">Non-refundable upfront payment</a></td>
<td class="nump">&#8364; 900,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="nump">&#8364; 10,500,000<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,500,000<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="18"></td></tr>
<tr><td colspan="18"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsiderationPaidReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 40<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsiderationPaidReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liability representing income that has been received but is not yet earned. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AmountPaidForFullTimeEquivalentFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid for full time equivalent funding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AmountPaidForFullTimeEquivalentFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AmountPaidToCompensateForResearchServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid to compensate for research services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AmountPaidToCompensateForResearchServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDeferredIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDeferredIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NonRefundableUpfrontPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable upfront payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NonRefundableUpfrontPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PurchasePricePerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price per common share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PurchasePricePerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RevenueRemainingPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue remaining performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RevenueRemainingPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SharePurchasedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share purchased price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SharePurchasedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrus_UpfrontAndMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrus_UpfrontAndMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_SimcereCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_SimcereCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=mrus_DeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=mrus_DeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteShareSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_IncyteShareSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_BettaPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_BettaPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763727104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Additional Information - Equity (Detail)<br> &#8364; / shares in Units, $ / shares in Units, &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 21, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 21, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 20, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 15, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 15, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 13, 2018 </div>
<div>$ / shares </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 23, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 23, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 26, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>May 06, 2016</div></th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 01, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 23, 2017 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 24, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ReverseStockSplitConversionRatio', window );">Reverse share split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 74,738<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 50,547<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SubsidiarySaleOfStock1Axis=mrus_InitialPublicOfferingMember', window );">Initial public offering [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Common shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SubsidiarySaleOfStock1Axis=mrus_OverAllotmentOption1Member', window );">Over allotment option [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Common shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">639,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember', window );">Incyte Corporation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Common shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 74,700<span></span>
</td>
<td class="nump">$ 80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NetProceedsFromIssuingShares', window );">Proceeds from net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PrepaidShareIssueRelatedCost', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements', window );">Change in fair value asset and discount on share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncreaseDecreaseInCapital', window );">Increased capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncreaseDecreaseInSharePremium', window );">Increased premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 73,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Purchase price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_InvestorsMember', window );">Investors [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Issue price per share | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 44,800<span></span>
</td>
<td class="nump">$ 55.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Common shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,099,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Purchase price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=mrus_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price</a></td>
<td class="nump">&#8364; 13,100<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Common shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Purchase price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Total proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,100<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AggregateValueOfCommonSharesIssued', window );">Aggregate value of common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsOnLitigationSettlements', window );">Gain on litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7,100<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of shares fully issued and paid | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,358,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,429,848<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,085,851<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">23,358,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="22"></td></tr>
<tr><td colspan="22"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=sect_AStatementofcashflowsforanentityotherthanafinancialinstitution&amp;doctype=Illustrative%20Examples<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2018-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=21&amp;date=2018-03-01&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsOnLitigationSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gain on settlements of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 98<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_98_f&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsOnLitigationSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AggregateValueOfCommonSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of common shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AggregateValueOfCommonSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in fair value of financial assets and liabilities and exchange movements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncreaseDecreaseInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncreaseDecreaseInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncreaseDecreaseInSharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in share premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncreaseDecreaseInSharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NetProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NetProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PrepaidShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid share issue related cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PrepaidShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ReverseStockSplitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse Stock Split Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ReverseStockSplitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SharePurchasedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share purchased price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SharePurchasedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SubsidiarySaleOfStock1Axis=mrus_InitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SubsidiarySaleOfStock1Axis=mrus_InitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SubsidiarySaleOfStock1Axis=mrus_OverAllotmentOption1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SubsidiarySaleOfStock1Axis=mrus_OverAllotmentOption1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_InvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_InvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=mrus_RegeneronPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=mrus_RegeneronPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6758989104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Summary of Reconciliation of Common Shares Outstanding (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercise of common share options</a></td>
<td class="nump">135,888<span></span>
</td>
<td class="nump">136,666<span></span>
</td>
<td class="nump">18,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vesting of RSUs</a></td>
<td class="nump">93,244<span></span>
</td>
<td class="nump">7,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Common Shares outstanding, Beginning balance</a></td>
<td class="nump">19,429,848<span></span>
</td>
<td class="nump">16,085,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfSharesIssuedForCash', window );">Issued for cash</a></td>
<td class="nump">3,699,997<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercise of common share options</a></td>
<td class="nump">135,888<span></span>
</td>
<td class="nump">136,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vesting of RSUs</a></td>
<td class="nump">93,244<span></span>
</td>
<td class="nump">7,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Common shares outstanding, Ending balance</a></td>
<td class="nump">23,358,977<span></span>
</td>
<td class="nump">19,429,848<span></span>
</td>
<td class="nump">16,085,851<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NumberOfSharesIssuedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NumberOfSharesIssuedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6738931920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Additional Information - Share Based Payment Arrangements (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 01, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice', window );">Description of depository based exercise price</a></td>
<td class="text">Prior to the IPO, participants that voluntarily left the Company, except for  members of the former Supervisory Board, were required to offer to the foundation the depositary receipts acquired from exercising options against  payment of the exercise price or the lower fair market value of the underlying shares.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfNonVestingCondition', window );">Description of non-vesting condition</a></td>
<td class="text">This obligation for a participant to offer depositary receipts to the foundation upon resignation within four years from exercising the options was treated as a non-marketvesting condition.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions', window );">Period of option to exercise treated as non-vesting condition</a></td>
<td class="text">Within four years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Weighted average exercise price</a></td>
<td class="nump">&#8364; 14.62<span></span>
</td>
<td class="nump">&#8364; 13.99<span></span>
</td>
<td class="nump">&#8364; 8.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharebasedCompensationWeightedAverageRemainingContractualLife', window );">Weighted-average remaining contractual life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">8 years 3 months<span></span>
</td>
<td class="text">6 years 8 months 5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice', window );">Weighted-average share price</a></td>
<td class="nump">&#8364; 17.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Weighted average exercise price</a></td>
<td class="nump">1.93<span></span>
</td>
<td class="nump">&#8364; 1.93<span></span>
</td>
<td class="nump">&#8364; 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Weighted average exercise price</a></td>
<td class="nump">&#8364; 27.47<span></span>
</td>
<td class="nump">&#8364; 27.47<span></span>
</td>
<td class="nump">&#8364; 16.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=mrus_TwoThousandTenOptionPlanMember', window );">2010 Option plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfOptionsGranted', window );">Description of options vested</a></td>
<td class="text">Options granted under the 2010 Plan are exercisable once vested.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharebasedCompensationAwardVestingPeriod', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfInitialVestingOptions', window );">Percentage of initial vesting period</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfRemainingVestingOptions', window );">Percentage of remaining vesting options</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PeriodOfRemainingOptionsVestingPeriod', window );">Period of remaining option vesting period</a></td>
<td class="text">36 monthly installments<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfVestingOptions', window );">Percentage of vesting period</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfOptionLapse', window );">Description of option lapse</a></td>
<td class="text">Options lapse on the eighth anniversary of the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice', window );">Description of depository based exercise price</a></td>
<td class="text">The 2010 Option Plan was amended such that a participant is no longer required to offer depositary receipts to the foundation  upon resignation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=mrus_TwoThousandSixteenOptionPlanMember', window );">2016 Plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfOptionsGranted', window );">Description of options vested</a></td>
<td class="text">Options granted under the 2016 Plan are exercisable once vested.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharebasedCompensationAwardVestingPeriod', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfInitialVestingOptions', window );">Percentage of initial vesting period</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfRemainingVestingOptions', window );">Percentage of remaining vesting options</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PeriodOfRemainingOptionsVestingPeriod', window );">Period of remaining option vesting period</a></td>
<td class="text">36 monthly installments<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfVestingOptions', window );">Percentage of vesting period</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfOptionLapse', window );">Description of option lapse</a></td>
<td class="text">Options will lapse on the tenth anniversary of the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod', window );">Vesting period of Restricted Stock Units vested</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfCommonShareEntitledToReceive', window );">Number of common share entitled to receive | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Increase in authorized share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">934,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,469,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=mrus_NonexecutiveCompensationProgramMember', window );">Non-Executive Compensation Program [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfInitialVestingOptions', window );">Percentage of initial vesting period</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfRemainingVestingOptions', window );">Percentage of remaining vesting options</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PeriodOfRemainingOptionsVestingPeriod', window );">Period of remaining option vesting period</a></td>
<td class="text">24 substantially equal monthly  installments<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards', window );">Vesting period</a></td>
<td class="text">Three-year period<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PeriodOfAwardsWillBeVestedAndExercised', window );">Period of option will be vested and exercised</a></td>
<td class="text">12 substantially equal monthly installments<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfGrantAward', window );">Description of grant award</a></td>
<td class="text">Following  the vesting commencement date, such that the subsequent award shall be fully  vested on the first anniversary of the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of depository receipts based exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfDepositoryReceiptsBasedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfGrantAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of grant award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfGrantAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfNonVestingCondition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of non vesting condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfNonVestingCondition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfOptionLapse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of option lapse.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfOptionLapse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NumberOfCommonShareEntitledToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common share entitled to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NumberOfCommonShareEntitledToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of instruments other equity instruments vesting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PercentageOfInitialVestingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of initial vesting options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PercentageOfInitialVestingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PercentageOfRemainingVestingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining vesting options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PercentageOfRemainingVestingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PercentageOfVestingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PercentageOfVestingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PeriodOfAwardsWillBeVestedAndExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of awards will be vested and exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PeriodOfAwardsWillBeVestedAndExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of option to exercise treated as non vesting conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PeriodOfOptionToExerciseTreatedAsNonVestingConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PeriodOfRemainingOptionsVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of remaining options vesting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PeriodOfRemainingOptionsVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of vesting installments of initial vesting awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangements by Share Based Payment Award Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SharebasedCompensationAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebased Compensation Award Vesting Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SharebasedCompensationAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SharebasedCompensationWeightedAverageRemainingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Weighted Average Remaining Contractual Life</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SharebasedCompensationWeightedAverageRemainingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=mrus_TwoThousandTenOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=mrus_TwoThousandTenOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=mrus_TwoThousandSixteenOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=mrus_TwoThousandSixteenOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=mrus_NonexecutiveCompensationProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=mrus_NonexecutiveCompensationProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6739551840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Summary of Inputs Used in the Measurement of the Fair Values and the Related Fair Values at the Grant Dates (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (weighted-average)</a></td>
<td class="nump">94.71%<span></span>
</td>
<td class="nump">95.05%<span></span>
</td>
<td class="nump">95.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life | yr</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_FairValueAssumptionsGrantDateSharePrice', window );">Fair value</a></td>
<td class="nump">&#8364; 6.82<span></span>
</td>
<td class="nump">&#8364; 9.04<span></span>
</td>
<td class="nump">&#8364; 9.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Share price</a></td>
<td class="nump">13.01<span></span>
</td>
<td class="nump">17.08<span></span>
</td>
<td class="nump">15.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_EmployeeOptionExercisedPricePerShare', window );">Exercise price</a></td>
<td class="nump">&#8364; 13.01<span></span>
</td>
<td class="nump">&#8364; 17.08<span></span>
</td>
<td class="nump">&#8364; 15.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">2.79%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">1.84%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_FairValueAssumptionsGrantDateSharePrice', window );">Fair value</a></td>
<td class="nump">&#8364; 12.27<span></span>
</td>
<td class="nump">&#8364; 16.10<span></span>
</td>
<td class="nump">&#8364; 11.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Share price</a></td>
<td class="nump">19.90<span></span>
</td>
<td class="nump">24.54<span></span>
</td>
<td class="nump">16.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_EmployeeOptionExercisedPricePerShare', window );">Exercise price</a></td>
<td class="nump">&#8364; 19.90<span></span>
</td>
<td class="nump">&#8364; 24.54<span></span>
</td>
<td class="nump">&#8364; 16.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">2.51%<span></span>
</td>
<td class="nump">1.86%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AllOtherEmployeesMember', window );">All other employees [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (weighted-average)</a></td>
<td class="nump">92.16%<span></span>
</td>
<td class="nump">94.88%<span></span>
</td>
<td class="nump">97.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life | yr</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AllOtherEmployeesMember', window );">All other employees [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_FairValueAssumptionsGrantDateSharePrice', window );">Fair value</a></td>
<td class="nump">&#8364; 7.74<span></span>
</td>
<td class="nump">&#8364; 8.94<span></span>
</td>
<td class="nump">&#8364; 5.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Share price</a></td>
<td class="nump">12.29<span></span>
</td>
<td class="nump">13.71<span></span>
</td>
<td class="nump">8.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_EmployeeOptionExercisedPricePerShare', window );">Exercise price</a></td>
<td class="nump">&#8364; 12.29<span></span>
</td>
<td class="nump">&#8364; 13.71<span></span>
</td>
<td class="nump">&#8364; 8.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">2.83%<span></span>
</td>
<td class="nump">2.24%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AllOtherEmployeesMember', window );">All other employees [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_FairValueAssumptionsGrantDateSharePrice', window );">Fair value</a></td>
<td class="nump">&#8364; 13.32<span></span>
</td>
<td class="nump">&#8364; 18.02<span></span>
</td>
<td class="nump">&#8364; 5.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Share price</a></td>
<td class="nump">21.02<span></span>
</td>
<td class="nump">27.47<span></span>
</td>
<td class="nump">8.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_EmployeeOptionExercisedPricePerShare', window );">Exercise price</a></td>
<td class="nump">&#8364; 21.02<span></span>
</td>
<td class="nump">&#8364; 27.47<span></span>
</td>
<td class="nump">&#8364; 8.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">2.62%<span></span>
</td>
<td class="nump">1.87%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_EmployeeOptionExercisedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee option exercised price per share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_EmployeeOptionExercisedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_FairValueAssumptionsGrantDateSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assumptions grant date share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_FairValueAssumptionsGrantDateSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SharePurchasedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share purchased price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SharePurchasedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AllOtherEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AllOtherEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735952352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Summary of Reconciliation of Outstanding Share Options (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at January 1 | shares</a></td>
<td class="nump">2,213,985<span></span>
</td>
<td class="nump">1,394,844<span></span>
</td>
<td class="nump">953,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year | shares</a></td>
<td class="num">(38,874)<span></span>
</td>
<td class="num">(58,164)<span></span>
</td>
<td class="num">(31,351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired during the year | shares</a></td>
<td class="num">(31,629)<span></span>
</td>
<td class="num">(762)<span></span>
</td>
<td class="num">(5,454)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the year | shares</a></td>
<td class="num">(135,888)<span></span>
</td>
<td class="num">(136,666)<span></span>
</td>
<td class="num">(18,283)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted during the year | shares</a></td>
<td class="nump">625,445<span></span>
</td>
<td class="nump">1,014,733<span></span>
</td>
<td class="nump">496,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at December 31 | shares</a></td>
<td class="nump">2,633,039<span></span>
</td>
<td class="nump">2,213,985<span></span>
</td>
<td class="nump">1,394,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable at December 31 | shares</a></td>
<td class="nump">1,275,669<span></span>
</td>
<td class="nump">687,070<span></span>
</td>
<td class="nump">418,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Outstanding at January 1 | &#8364;</a></td>
<td class="nump">&#8364; 13.99<span></span>
</td>
<td class="nump">&#8364; 8.69<span></span>
</td>
<td class="nump">&#8364; 5.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year | &#8364;</a></td>
<td class="nump">14.48<span></span>
</td>
<td class="nump">17.27<span></span>
</td>
<td class="nump">6.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired during the year | &#8364;</a></td>
<td class="nump">11.00<span></span>
</td>
<td class="nump">8.67<span></span>
</td>
<td class="nump">11.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the year | &#8364;</a></td>
<td class="nump">6.80<span></span>
</td>
<td class="nump">2.24<span></span>
</td>
<td class="nump">1.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted during the year | &#8364;</a></td>
<td class="nump">14.96<span></span>
</td>
<td class="nump">19.88<span></span>
</td>
<td class="nump">14.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Outstanding at December 31 | &#8364;</a></td>
<td class="nump">14.62<span></span>
</td>
<td class="nump">13.99<span></span>
</td>
<td class="nump">8.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable at December 31 | &#8364;</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759400592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity - Summary of Number of Share Options Outstanding (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of outstanding share options</a></td>
<td class="nump">2,633,039<span></span>
</td>
<td class="nump">2,213,985<span></span>
</td>
<td class="nump">1,394,844<span></span>
</td>
<td class="nump">953,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of outstanding share options</a></td>
<td class="nump">2,148,744<span></span>
</td>
<td class="nump">1,777,437<span></span>
</td>
<td class="nump">1,302,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AllOtherEmployeesMember', window );">All other employees [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of outstanding share options</a></td>
<td class="nump">484,295<span></span>
</td>
<td class="nump">436,548<span></span>
</td>
<td class="nump">92,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AllOtherEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AllOtherEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6740118464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Summary of Reconciliation of RSU's (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Unvested beginning balance | &#8364;</a></td>
<td class="nump">&#8364; 20.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Expired during the year | &#8364;</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested during the year | &#8364;</a></td>
<td class="nump">20.03<span></span>
</td>
<td class="nump">20.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement', window );">Granted during the year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Unvested ending balance | &#8364;</a></td>
<td class="nump">&#8364; 20.03<span></span>
</td>
<td class="nump">&#8364; 20.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Unvested beginning balance | shares</a></td>
<td class="nump">194,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,219)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Expired during the year | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested during the year | shares</a></td>
<td class="num">(93,244)<span></span>
</td>
<td class="num">(7,331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Unvested ending balance | shares</a></td>
<td class="nump">101,302<span></span>
</td>
<td class="nump">194,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6740083872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of Revenue (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">&#8364; 31,448<span></span>
</td>
<td class="nump">&#8364; 21,915<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 2,510<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_UpfrontPaymentAmortizationMember', window );">Up-front payment amortization [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">17,686<span></span>
</td>
<td class="nump">14,933<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember', window );">R&amp;D cost reimbursement and milestone [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">13,566<span></span>
</td>
<td class="nump">5,787<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,109<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_RevenueFromContractsWithCustomersMember', window );">Revenue from contracts with customers [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">31,252<span></span>
</td>
<td class="nump">20,720<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,123<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncomeMember', window );">Income from grants on research projects [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">&#8364; 196<span></span>
</td>
<td class="nump">&#8364; 1,195<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 1,387<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=5&amp;date=2018-03-01&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue [line items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_UpfrontPaymentAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_UpfrontPaymentAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_RevenueFromContractsWithCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_RevenueFromContractsWithCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760695792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Detail) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 16, 2017</div></th>
<th class="th"><div>Jun. 12, 2017</div></th>
<th class="th"><div>Mar. 07, 2016</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 31,448,000<span></span>
</td>
<td class="nump">&#8364; 21,915,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 2,510,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_GrantIncome', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ReimbursementOfGrant', window );">Reimbursement of grant</a></td>
<td class="nump">&#8364; 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AmountRemittedToOtherBeneficiaries', window );">Amount remitted to other beneficiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueRecognizedIncludedInDeferredRevenue', window );">Revenue recognized included in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,900,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueRecognizedNotIncludedInDeferredRevenue', window );">Revenue recognized not included in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_OnoResearchAndLicenseAgreementMember', window );">ONO Research and License Agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_MilestoneRevenuesAndCostsReimbursements', window );">Cost reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_MilestoneRevenues', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TermsOfPaymentOfTradeReceivables', window );">Payment terms related to receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_SimcerePharmaceuticalCoLtdMember', window );">Simcere Pharmaceutical Co Ltd [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_MilestoneRevenues', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TermsOfPaymentOfTradeReceivables', window );">Payment terms related to receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_BettaPharmaceuticalsCoLtdMember', window );">Betta Pharmaceuticals Co Ltd [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TermsOfPaymentOfTradeReceivables', window );">Payment terms related to receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember', window );">R&amp;D cost reimbursement and milestone [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,566,000<span></span>
</td>
<td class="nump">5,787,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,109,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCollaborationAgreementMember', window );">Incyte collaboration agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_MilestoneRevenuesAndCostsReimbursements', window );">Cost reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember', window );">Incyte collaboration agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPaymentAmortization', window );">Up-front payment amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,900,000<span></span>
</td>
<td class="nump">14,900,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember', window );">ONO Research and License Agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPaymentAmortization', window );">Up-front payment amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 14,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_SimcereCollaborationAndLicenseAgreementMember', window );">Simcere collaboration and license agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPaymentAmortization', window );">Up-front payment amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_BettaPharmaceuticalsCoLtdMember', window );">Betta Pharmaceuticals Co Ltd [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPaymentAmortization', window );">Up-front payment amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=mrus_IFRS15RevenueFromContractsWithCustomersMember', window );">IFRS 15 revenue from contracts with customers [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncreaseDecreaseInDeferredRevenue1', window );">Decrease in Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=5&amp;date=2018-03-01&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AmountRemittedToOtherBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remitted to other beneficiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AmountRemittedToOtherBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncreaseDecreaseInDeferredRevenue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncreaseDecreaseInDeferredRevenue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_MilestoneRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_MilestoneRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_MilestoneRevenuesAndCostsReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone revenues and costs reimbursements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_MilestoneRevenuesAndCostsReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ReimbursementOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ReimbursementOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue [line items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RevenueRecognizedIncludedInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized included in deferred revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RevenueRecognizedIncludedInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RevenueRecognizedNotIncludedInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized not included in deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RevenueRecognizedNotIncludedInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TermsOfPaymentOfTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Terms of payment of trade receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TermsOfPaymentOfTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_UpfrontPaymentAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Up-front payment amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_UpfrontPaymentAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_OnoResearchAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_OnoResearchAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_SimcerePharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_SimcerePharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_BettaPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_BettaPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_ResearchAndDevelopmentCostReimbursementAndMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_SimcereCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_SimcereCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_BettaPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_BettaPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=mrus_IFRS15RevenueFromContractsWithCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=mrus_IFRS15RevenueFromContractsWithCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759382592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Disclosure Of Changes In Trade Receivables Contract Assets And Contract Liabilities Explanatory (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems', window );"><strong>Disclosure of changes in trade receivables, contract assets and contract liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables, beginning balance</a></td>
<td class="nump">&#8364; 1,594<span></span>
</td>
<td class="nump">&#8364; 205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdditionsToTradeReceivables', window );">Trade receivables, additions</a></td>
<td class="nump">19,951<span></span>
</td>
<td class="nump">122,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DeductionsInTradeReceivables', window );">Trade receivables, deductions</a></td>
<td class="num">(18,855)<span></span>
</td>
<td class="num">(121,392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables, ending balance</a></td>
<td class="nump">2,690<span></span>
</td>
<td class="nump">1,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractAssets', window );">Contract assets, beginning balance</a></td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdditionsInContractAssets', window );">Contract assets, additions</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">121,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DeductionsInContractAssets', window );">Contract assets, deductions</a></td>
<td class="num">(1,519)<span></span>
</td>
<td class="num">(120,530)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractAssets', window );">Contract assets, ending balance</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities, beginning balance</a></td>
<td class="nump">128,486<span></span>
</td>
<td class="nump">31,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdditionsInContractLiabilities', window );">Contract liabilities, additions</a></td>
<td class="nump">4,137<span></span>
</td>
<td class="nump">111,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DeductionsInContractLiabilities', window );">Contract liabilities, deductions</a></td>
<td class="num">(18,014)<span></span>
</td>
<td class="num">(14,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities, ending balance</a></td>
<td class="nump">114,609<span></span>
</td>
<td class="nump">128,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=mrus_DeferredRevenueMember', window );">Deferred revenue [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems', window );"><strong>Disclosure of changes in trade receivables, contract assets and contract liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities, beginning balance</a></td>
<td class="nump">128,486<span></span>
</td>
<td class="nump">31,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdditionsInContractLiabilities', window );">Contract liabilities, additions</a></td>
<td class="nump">4,137<span></span>
</td>
<td class="nump">111,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DeductionsInContractLiabilities', window );">Contract liabilities, deductions</a></td>
<td class="num">(18,014)<span></span>
</td>
<td class="num">(14,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities, ending balance</a></td>
<td class="nump">114,609<span></span>
</td>
<td class="nump">128,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems', window );"><strong>Disclosure of changes in trade receivables, contract assets and contract liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables, beginning balance</a></td>
<td class="nump">1,594<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdditionsToTradeReceivables', window );">Trade receivables, additions</a></td>
<td class="nump">19,951<span></span>
</td>
<td class="nump">122,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DeductionsInTradeReceivables', window );">Trade receivables, deductions</a></td>
<td class="num">(18,855)<span></span>
</td>
<td class="num">(121,392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables, ending balance</a></td>
<td class="nump">2,690<span></span>
</td>
<td class="nump">1,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=mrus_UnbilledReceivablesMember', window );">Unbilled receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems', window );"><strong>Disclosure of changes in trade receivables, contract assets and contract liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractAssets', window );">Contract assets, beginning balance</a></td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdditionsInContractAssets', window );">Contract assets, additions</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">121,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DeductionsInContractAssets', window );">Contract assets, deductions</a></td>
<td class="num">(1,519)<span></span>
</td>
<td class="num">(120,530)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractAssets', window );">Contract assets, ending balance</a></td>
<td class="nump">&#8364; 236<span></span>
</td>
<td class="nump">&#8364; 710<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s right to consideration in exchange for goods or services that the entity has transferred to a customer, when that right is conditioned on something other than the passage of time (for example, the entity&#8217;s future performance).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2018-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2018-03-01&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2018-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2018-03-01&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2018-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2018-03-01&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2018-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2018-03-01&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AdditionsInContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions in contract assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AdditionsInContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AdditionsInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions in contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AdditionsInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AdditionsToTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions to trade receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AdditionsToTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DeductionsInContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deductions in contract assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DeductionsInContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DeductionsInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deductions in contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DeductionsInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DeductionsInTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deductions in trade receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DeductionsInTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of changes in trade receivables, contract assets and contract liabilities [line items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=mrus_DeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=mrus_DeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=mrus_UnbilledReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=mrus_UnbilledReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735859328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Total Operating Expenses - Summary of Total Operating Expenses (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOperatingExpensesAbstract', window );"><strong>Disclosure Of Operating Expenses [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ManufacturingCost', window );">Manufacturing costs</a></td>
<td class="nump">&#8364; 18,914<span></span>
</td>
<td class="nump">&#8364; 13,567<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 3,162<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IPAndLicenseCosts', window );">IP and license costs</a></td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">1,858<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PersonnelRelatedResearchAndDevelopmentExpense', window );">Personnel related R&amp;D</a></td>
<td class="nump">7,036<span></span>
</td>
<td class="nump">6,673<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,285<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OtherResearchAndDevelopmentExpenses', window );">Other R&amp;D costs</a></td>
<td class="nump">18,938<span></span>
</td>
<td class="nump">12,027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,810<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Total R&amp;D costs</a></td>
<td class="nump">46,740<span></span>
</td>
<td class="nump">34,125<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">18,424<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">Management and administration costs</a></td>
<td class="nump">10,395<span></span>
</td>
<td class="nump">13,697<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,258<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_LitigationCosts', window );">Litigation costs</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,490<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OtherOperatingExpenses', window );">Other operating expenses</a></td>
<td class="nump">11,735<span></span>
</td>
<td class="nump">8,356<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,219<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Total other expenses</a></td>
<td class="nump">13,160<span></span>
</td>
<td class="nump">9,395<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,709<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Total operating expenses</a></td>
<td class="nump">&#8364; 70,295<span></span>
</td>
<td class="nump">&#8364; 57,217<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 30,391<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2018-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2018-03-01&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Operating Expenses [abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IPAndLicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>I p and license costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IPAndLicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_LitigationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_LitigationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ManufacturingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ManufacturingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OtherOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OtherOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OtherResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other research and development expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OtherResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PersonnelRelatedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Personnel related research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PersonnelRelatedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735516016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Total Operating Expenses - Breakdown of Other Research and Development Costs (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOperatingExpensesAbstract', window );"><strong>Disclosure Of Operating Expenses [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DiscoveryAndPreclinicalCosts', window );">Discovery and preclinical costs</a></td>
<td class="nump">&#8364; 5,506<span></span>
</td>
<td class="nump">&#8364; 2,473<span></span>
</td>
<td class="nump">&#8364; 5,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ClinicalCosts', window );">Clinical costs</a></td>
<td class="nump">9,169<span></span>
</td>
<td class="nump">5,919<span></span>
</td>
<td class="nump">3,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OtherResearchAndDevelopmentExpenseOther', window );">Other R&amp;D costs</a></td>
<td class="nump">4,263<span></span>
</td>
<td class="nump">3,635<span></span>
</td>
<td class="nump">2,216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OtherResearchAndDevelopmentExpenses', window );">Total other R&amp;D costs</a></td>
<td class="nump">&#8364; 18,938<span></span>
</td>
<td class="nump">&#8364; 12,027<span></span>
</td>
<td class="nump">&#8364; 10,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ClinicalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ClinicalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Operating Expenses [abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DiscoveryAndPreclinicalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discovery and pre-clinical costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DiscoveryAndPreclinicalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OtherResearchAndDevelopmentExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other research and development expense other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OtherResearchAndDevelopmentExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OtherResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other research and development expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OtherResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6733763296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Total Operating Expenses - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOperatingExpensesAbstract', window );"><strong>Disclosure Of Operating Expenses [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Expenses related to professional fees for consulting, audit, and tax services</a></td>
<td class="nump">&#8364; 6,300<span></span>
</td>
<td class="nump">&#8364; 4,000<span></span>
</td>
<td class="nump">&#8364; 1,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_GeneralLegalInsuranceAndFacilityRelatedExpenses', window );">General legal, insurance and facility related expenses</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PreclinicalCosts', window );">Preclinical costs</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ClinicalCosts', window );">Clinical costs</a></td>
<td class="nump">9,169<span></span>
</td>
<td class="nump">5,919<span></span>
</td>
<td class="nump">3,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IntellectualPropertyCosts', window );">IP costs</a></td>
<td class="nump">&#8364; 3,300<span></span>
</td>
<td class="nump">&#8364; 2,900<span></span>
</td>
<td class="nump">&#8364; 2,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ClinicalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ClinicalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Operating Expenses [abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_GeneralLegalInsuranceAndFacilityRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General, legal, insurance and facility related expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_GeneralLegalInsuranceAndFacilityRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IntellectualPropertyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intellectual property costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IntellectualPropertyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PreclinicalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preclinical costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PreclinicalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6661727728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Total Operating Expenses - Operating Expenses by Nature (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOperatingExpensesAbstract', window );"><strong>Disclosure Of Operating Expenses [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ContractManufacturingExpenses', window );">Contract manufacturing</a></td>
<td class="nump">&#8364; 18,914<span></span>
</td>
<td class="nump">&#8364; 13,567<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 3,162<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OtherExternalAndOutsourcedCosts', window );">Other external and outsourced costs</a></td>
<td class="nump">32,459<span></span>
</td>
<td class="nump">22,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,885<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employee costs and related benefits</a></td>
<td class="nump">18,284<span></span>
</td>
<td class="nump">20,999<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,110<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">638<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">234<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Total operating expenses</a></td>
<td class="nump">&#8364; 70,295<span></span>
</td>
<td class="nump">&#8364; 57,217<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 30,391<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ContractManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract manufacturing expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ContractManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Operating Expenses [abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OtherExternalAndOutsourcedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other external and outsourced costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OtherExternalAndOutsourcedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6730591408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Disclosure of Detailed Information About Employee Benefits (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract', window );"><strong>Short-term employee benefits expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Salaries and wages</a></td>
<td class="nump">&#8364; 10,783<span></span>
</td>
<td class="nump">&#8364; 9,556<span></span>
</td>
<td class="nump">&#8364; 5,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WBSOSubsidy', window );">WBSO subsidy</a></td>
<td class="num">(4,257)<span></span>
</td>
<td class="num">(3,523)<span></span>
</td>
<td class="num">(1,721)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SocialSecurityContributions', window );">Social security premiums</a></td>
<td class="nump">919<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_HealthInsurance', window );">Health insurance</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PensionCosts', window );">Pension costs</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">652<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation</a></td>
<td class="nump">7,925<span></span>
</td>
<td class="nump">12,815<span></span>
</td>
<td class="nump">3,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherShorttermEmployeeBenefits', window );">Other personnel expense</a></td>
<td class="nump">1,835<span></span>
</td>
<td class="nump">656<span></span>
</td>
<td class="nump">442<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Total employee benefits expense</a></td>
<td class="nump">&#8364; 18,284<span></span>
</td>
<td class="nump">&#8364; 20,999<span></span>
</td>
<td class="nump">&#8364; 8,110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits), which are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services, that the entity does not separately disclose in the same statement or note. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2018-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=19&amp;date=2018-03-01&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SocialSecurityContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2018-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=19&amp;date=2018-03-01&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SocialSecurityContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2018-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=19&amp;date=2018-03-01&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_HealthInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health insurance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_HealthInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PensionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pension costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PensionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_WBSOSubsidy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>WBSO subsidy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_WBSOSubsidy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6739203968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Schedule of Share-based Compensation Expenses Recognized as Employee Benefit Expenses (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfShareOfEquityInvestmentLineItems', window );"><strong>Disclosure Of Share Of Equity Investment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_StockAwardExpense', window );">Stock award expense</a></td>
<td class="nump">&#8364; 7,925<span></span>
</td>
<td class="nump">&#8364; 12,815<span></span>
</td>
<td class="nump">&#8364; 3,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncomeStatementLineItemLocationAxis=mrus_ResearchAndDevelopmentCostsMember', window );">R&amp;D costs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfShareOfEquityInvestmentLineItems', window );"><strong>Disclosure Of Share Of Equity Investment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_StockAwardExpense', window );">Stock award expense</a></td>
<td class="nump">2,710<span></span>
</td>
<td class="nump">3,245<span></span>
</td>
<td class="nump">703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncomeStatementLineItemLocationAxis=mrus_ManagementAndAdministrationCostsMember', window );">Management and administration costs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfShareOfEquityInvestmentLineItems', window );"><strong>Disclosure Of Share Of Equity Investment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_StockAwardExpense', window );">Stock award expense</a></td>
<td class="nump">4,742<span></span>
</td>
<td class="nump">8,942<span></span>
</td>
<td class="nump">2,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncomeStatementLineItemLocationAxis=mrus_OtherExpensesMember', window );">Other expenses [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfShareOfEquityInvestmentLineItems', window );"><strong>Disclosure Of Share Of Equity Investment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_StockAwardExpense', window );">Stock award expense</a></td>
<td class="nump">&#8364; 473<span></span>
</td>
<td class="nump">&#8364; 628<span></span>
</td>
<td class="nump">&#8364; 567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfShareOfEquityInvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share Of Equity Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfShareOfEquityInvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_StockAwardExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock award expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_StockAwardExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncomeStatementLineItemLocationAxis=mrus_ResearchAndDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncomeStatementLineItemLocationAxis=mrus_ResearchAndDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncomeStatementLineItemLocationAxis=mrus_ManagementAndAdministrationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncomeStatementLineItemLocationAxis=mrus_ManagementAndAdministrationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncomeStatementLineItemLocationAxis=mrus_OtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncomeStatementLineItemLocationAxis=mrus_OtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6735780400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Benefits - Additional Information (Detail) - Employees<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfEmployeeBenefitsLineItems', window );"><strong>Disclosure of employee benefits [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_NL', window );">Netherlands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfEmployeeBenefitsLineItems', window );"><strong>Disclosure of employee benefits [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfEmployeeBenefitsLineItems', window );"><strong>Disclosure of employee benefits [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncomeStatementLineItemLocationAxis=mrus_ManagementAndAdministrationCostsMember', window );">Management and administration costs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfEmployeeBenefitsLineItems', window );"><strong>Disclosure of employee benefits [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of personnel employed by the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfEmployeeBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. Disclosure of employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfEmployeeBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncomeStatementLineItemLocationAxis=mrus_ManagementAndAdministrationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncomeStatementLineItemLocationAxis=mrus_ManagementAndAdministrationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6740498800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Expense) - Summary of Other Income (Expense) (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RentalExpensesOnRealEstateAbstract', window );"><strong>Rental expenses on real estate [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_InterestAndRelatedIncome', window );">Interest income and similar related income</a></td>
<td class="nump">&#8364; 1,809<span></span>
</td>
<td class="nump">&#8364; 1,112<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 88<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Net gain on foreign exchange</a></td>
<td class="nump">6,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">7,843<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">88<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">7,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_InterestAndOtherExpense', window );">Interest and other expenses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeLoss', window );">Net loss on foreign exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,449)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(409)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradingIncomeExpenseOnDerivativeFinancialInstruments', window );">Derivative financial instrument expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,696)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(19,235)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance cost</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(30,335)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(19,644)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OtherIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">&#8364; 14,934<span></span>
</td>
<td class="num">&#8364; (29,223)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">&#8364; (19,556)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2018-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=21&amp;date=2018-03-01&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net loss arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2018-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=21&amp;date=2018-03-01&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2018-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=26&amp;date=2018-03-01&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradingIncomeExpenseOnDerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of trading income (expense) relating to derivative financial instruments. [Refer: Derivatives [member]; Trading income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradingIncomeExpenseOnDerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_InterestAndOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and other expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_InterestAndOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_InterestAndRelatedIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and related income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_InterestAndRelatedIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RentalExpensesOnRealEstateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expenses on real estate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RentalExpensesOnRealEstateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6761078064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Expense) - Additional Information (Detail)<br> $ / shares in Units, &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 21, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 21, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 20, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 20, 2016 </div>
<div>EUR (&#8364;) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 20, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems', window );"><strong>Disclosure of deferred tax assets notional interest [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance cost | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 30,335<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 19,644<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteShareSubscriptionAgreementMember', window );">Incyte share subscription agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems', window );"><strong>Disclosure of deferred tax assets notional interest [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PurchasePricePerCommonShare', window );">Purchase price per common share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Total derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 32.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_RegeneronSubscriptionAgreementMember', window );">Regeneron Subscription Agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems', window );"><strong>Disclosure of deferred tax assets notional interest [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Common shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PurchasePricePerCommonShare', window );">Purchase price per common share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Aggregate purchase price</a></td>
<td class="nump">&#8364; 13,100<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,100<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ValueOfCommonSharesIssued', window );">Aggregate value of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsOnLitigationSettlements', window );">Gain on litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7,100<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfOverlayApproachReclassificationAxis=mrus_IAS39Member', window );">IAS 39 [member] | Incyte share subscription agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems', window );"><strong>Disclosure of deferred tax assets notional interest [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance cost | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 19,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsOnLitigationSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gain on settlements of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 98<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_98_f&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsOnLitigationSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expenses on real estate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDeferredTaxAssetsNotionalInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PurchasePricePerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price per common share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PurchasePricePerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ValueOfCommonSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>value of common shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ValueOfCommonSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteShareSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_IncyteShareSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_RegeneronSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_RegeneronSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfOverlayApproachReclassificationAxis=mrus_IAS39Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfOverlayApproachReclassificationAxis=mrus_IAS39Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6730861744">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Loss per Share - Summary of Basic and Diluted Loss per Share (Detail) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumeratorComputationOfBasicAndDilutedEarningsPerShareAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss attributable to equity holders of the Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (24,235)<span></span>
</td>
<td class="num">&#8364; (64,685)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">&#8364; (47,429)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageNumberOfShares', window );">Weighted average shares outstanding-basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,286,720<span></span>
</td>
<td class="nump">19,196,440<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,236,649<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Loss per share-basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">&#8364; (1.09)<span></span>
</td>
<td class="num">&#8364; (3.37)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">&#8364; (3.58)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">For the periods included in these financial statements, share options and restricted stock units were excluded from the diluted loss per share calculation as the Company was in a loss position in each period presented above. As a result, basic and diluted loss per share are equal.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator Computation Of Basic And Diluted Earnings Per Share [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DenominatorComputationOfBasicAndDilutedEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NumeratorComputationOfBasicAndDilutedEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator Computation Of Basic And Diluted Earnings Per Share [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NumeratorComputationOfBasicAndDilutedEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_WeightedAverageNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_WeightedAverageNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6638454736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loss per Share - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DividendDeclared', window );">Dividend declared</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DividendDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend declared.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DividendDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6740163712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instrument - Summary of Maximum Credit Exposure (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_FixedRateOfInstrumentsAbstract', window );"><strong>Fixed Rate of Instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TradeAndUnbilledReceivables', window );">Trade and unbilled receivables</a></td>
<td class="nump">&#8364; 2,926<span></span>
</td>
<td class="nump">&#8364; 2,283<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_HeldtomaturityInvestments', window );">Investments</a></td>
<td class="nump">61,800<span></span>
</td>
<td class="nump">41,103<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">143,747<span></span>
</td>
<td class="nump">149,678<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">&#8364; 56,917<span></span>
</td>
<td colspan="2" class="nump">&#8364; 32,851<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaximumExposureToCreditRisk', window );">Maximum exposure to credit risk</a></td>
<td class="nump">&#8364; 208,473<span></span>
</td>
<td class="nump">&#8364; 193,064<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HeldtomaturityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-derivative financial assets with fixed or determinable payments and fixed maturity that an entity has the positive intention and ability to hold to maturity other than: (a) those that the entity upon initial recognition designates as at fair value through profit or loss; (b) those that the entity designates as available for sale; and (c) those that meet the definition of loans and receivables. An entity shall not classify any financial assets as held to maturity if the entity has, during the current financial year or during the two preceding financial years, sold or reclassified more than an insignificant amount of held-to-maturity investments before maturity (more than insignificant in relation to the total amount of held-to-maturity investments) other than sales or reclassifications that: (i) are so close to maturity or the financial asset&#8217;s call date (for example, less than three months before maturity) that changes in the market rate of interest would not have a significant effect on the financial asset&#8217;s fair value; (ii) occur after the entity has collected substantially all of the financial asset&#8217;s original principal through scheduled payments or prepayments; or (iii) are attributable to an isolated event that is beyond the entity&#8217;s control, is non-recurring and could not have been reasonably anticipated by the entity. [Refer: Derivative financial assets; Held-to-maturity investments; Prepayments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 8<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_8_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HeldtomaturityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaximumExposureToCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 35K<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_35K_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_36_a&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaximumExposureToCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_FixedRateOfInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fixed rate of instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_FixedRateOfInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TradeAndUnbilledReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trade and unbilled receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TradeAndUnbilledReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6738936368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instrument - Summary of Aging of Trade and Unbilled Receivables (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of financial assets that are either past due or impaired [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TradeAndUnbilledReceivables', window );">Trade and unbilled receivables</a></td>
<td class="nump">&#8364; 2,926<span></span>
</td>
<td class="nump">&#8364; 2,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentOfFinancialAssetsAxis=ifrs-full_FinancialAssetsNeitherPastDueNorImpairedMember', window );">Neither past due nor impaired [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of financial assets that are either past due or impaired [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TradeAndUnbilledReceivables', window );">Trade and unbilled receivables</a></td>
<td class="nump">&#8364; 2,926<span></span>
</td>
<td class="nump">&#8364; 2,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TradeAndUnbilledReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trade and unbilled receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TradeAndUnbilledReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentOfFinancialAssetsAxis=ifrs-full_FinancialAssetsNeitherPastDueNorImpairedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentOfFinancialAssetsAxis=ifrs-full_FinancialAssetsNeitherPastDueNorImpairedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6661208464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instrument - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AllowanceForImpairment', window );">Allowance for impairment</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio', window );">Weighted average remaining days to maturity for investment portfolio</a></td>
<td class="text">135 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AllowanceForImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for Impairment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AllowanceForImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining maturity period for investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_WeightedAverageRemainingMaturityPeriodForInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763863584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Maturity Analysis For Nonderivative Financial Liabilities (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Trade payables</a></td>
<td class="nump">&#8364; 3,819<span></span>
</td>
<td class="nump">&#8364; 2,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows', window );">Other liabilities and accruals</a></td>
<td class="nump">7,964<span></span>
</td>
<td class="nump">6,176<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Non-derivative financial liabilities undiscounted cash flows</a></td>
<td class="nump">11,783<span></span>
</td>
<td class="nump">9,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_CarryingAmountAndValueMember', window );">Carrying amount and value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Trade payables</a></td>
<td class="nump">3,819<span></span>
</td>
<td class="nump">2,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows', window );">Other liabilities and accruals</a></td>
<td class="nump">7,964<span></span>
</td>
<td class="nump">6,176<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Non-derivative financial liabilities undiscounted cash flows</a></td>
<td class="nump">11,783<span></span>
</td>
<td class="nump">9,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Trade payables</a></td>
<td class="nump">3,819<span></span>
</td>
<td class="nump">2,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows', window );">Other liabilities and accruals</a></td>
<td class="nump">7,964<span></span>
</td>
<td class="nump">6,176<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Non-derivative financial liabilities undiscounted cash flows</a></td>
<td class="nump">&#8364; 11,783<span></span>
</td>
<td class="nump">&#8364; 9,031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2019-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph IG31A<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_IG31A&amp;doctype=Implementation%20Guidance<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph B11D<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_B11D&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other liabilities and accruals, undiscounted cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OtherLiabilitiesAndAccrualsUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_CarryingAmountAndValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_CarryingAmountAndValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6740875408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Summary of Sensitivity Analysis for Change in Primary Currency Exposure (Detail) - Currency risk [member]<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="nump">&#8364; 103,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="nump">43,074<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Investment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="nump">61,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Trade and other receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="nump">2,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Other assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Taxes and social security liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Trade payables, other liabilities and accruals [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="num">(4,795)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [member] | 5% increase in functional rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="nump">5,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [member] | 5% increase in functional rate [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="nump">2,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [member] | 5% increase in functional rate [member] | Investment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="nump">3,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [member] | 5% increase in functional rate [member] | Trade and other receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [member] | 5% increase in functional rate [member] | Other assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [member] | 5% increase in functional rate [member] | Taxes and social security liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [member] | 5% increase in functional rate [member] | Trade payables, other liabilities and accruals [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [member] | 5% decrease in functional rate [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="num">(5,150)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [member] | 5% decrease in functional rate [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="num">(2,154)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [member] | 5% decrease in functional rate [member] | Investment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="num">(3,090)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [member] | 5% decrease in functional rate [member] | Trade and other receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [member] | 5% decrease in functional rate [member] | Other assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [member] | 5% decrease in functional rate [member] | Taxes and social security liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [member] | 5% decrease in functional rate [member] | Trade payables, other liabilities and accruals [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax', window );">Balance</a></td>
<td class="nump">&#8364; 240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange sensitivity effect on profit before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ForeignExchangeSensitivityEffectOnProfitBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=mrus_CashAndCashEquivalents1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=mrus_CashAndCashEquivalents1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=mrus_InvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=mrus_InvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=mrus_TradeAndOtherReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=mrus_TradeAndOtherReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=mrus_TaxesAndSocialSecurityLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=mrus_TaxesAndSocialSecurityLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=mrus_TradePayablesOtherLiabilitiesAndAccrualsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=mrus_TradePayablesOtherLiabilitiesAndAccrualsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=mrus_FivePercentageIncreaseInFunctionalRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=mrus_FivePercentageIncreaseInFunctionalRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=mrus_FivePercentageDecreaseInFunctionalRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=mrus_FivePercentageDecreaseInFunctionalRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760078656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instrument - Summary of Interest Bearing Financial Instruments (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems', window );"><strong>Disclosure of interest bearing financial instruments [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_HeldtomaturityInvestments', window );">Investments</a></td>
<td class="nump">&#8364; 61,800<span></span>
</td>
<td class="nump">&#8364; 41,103<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">143,747<span></span>
</td>
<td class="nump">149,678<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">&#8364; 56,917<span></span>
</td>
<td colspan="2" class="nump">&#8364; 32,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember', window );">Variable rate instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems', window );"><strong>Disclosure of interest bearing financial instruments [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 143,747<span></span>
</td>
<td class="nump">&#8364; 149,678<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 4 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HeldtomaturityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-derivative financial assets with fixed or determinable payments and fixed maturity that an entity has the positive intention and ability to hold to maturity other than: (a) those that the entity upon initial recognition designates as at fair value through profit or loss; (b) those that the entity designates as available for sale; and (c) those that meet the definition of loans and receivables. An entity shall not classify any financial assets as held to maturity if the entity has, during the current financial year or during the two preceding financial years, sold or reclassified more than an insignificant amount of held-to-maturity investments before maturity (more than insignificant in relation to the total amount of held-to-maturity investments) other than sales or reclassifications that: (i) are so close to maturity or the financial asset&#8217;s call date (for example, less than three months before maturity) that changes in the market rate of interest would not have a significant effect on the financial asset&#8217;s fair value; (ii) occur after the entity has collected substantially all of the financial asset&#8217;s original principal through scheduled payments or prepayments; or (iii) are attributable to an isolated event that is beyond the entity&#8217;s control, is non-recurring and could not have been reasonably anticipated by the entity. [Refer: Derivative financial assets; Held-to-maturity investments; Prepayments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 8<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_8_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HeldtomaturityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represents information about interest bearing financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfInterestBearingFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6747385840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Board Compensation and Key Management Personnel - Summary on Charge to the Profit and Loss Statement (Detail) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_TonLogtenbergCEOMember', window );">Ton Logtenberg, CEO [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors remuneration expense</a></td>
<td class="nump">&#8364; 3,330,367<span></span>
</td>
<td class="nump">&#8364; 5,497,845<span></span>
</td>
<td class="nump">&#8364; 1,441,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_TonLogtenbergCEOMember', window );">Ton Logtenberg, CEO [member] | Gross salary [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors remuneration expense</a></td>
<td class="nump">445,606<span></span>
</td>
<td class="nump">432,782<span></span>
</td>
<td class="nump">369,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_TonLogtenbergCEOMember', window );">Ton Logtenberg, CEO [member] | Bonus [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors remuneration expense</a></td>
<td class="nump">155,962<span></span>
</td>
<td class="nump">337,945<span></span>
</td>
<td class="nump">147,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_TonLogtenbergCEOMember', window );">Ton Logtenberg, CEO [member] | Pension [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors remuneration expense</a></td>
<td class="nump">31,881<span></span>
</td>
<td class="nump">51,528<span></span>
</td>
<td class="nump">17,717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_TonLogtenbergCEOMember', window );">Ton Logtenberg, CEO [member] | Option cost [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors remuneration expense</a></td>
<td class="nump">&#8364; 2,696,918<span></span>
</td>
<td class="nump">4,675,590<span></span>
</td>
<td class="nump">907,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_ShelleyMargetsonFormerCOOMember', window );">Shelley Margetson, Former COO [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors remuneration expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">892,129<span></span>
</td>
<td class="nump">453,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_ShelleyMargetsonFormerCOOMember', window );">Shelley Margetson, Former COO [member] | Gross salary [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors remuneration expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,782<span></span>
</td>
<td class="nump">198,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_ShelleyMargetsonFormerCOOMember', window );">Shelley Margetson, Former COO [member] | Bonus [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors remuneration expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_ShelleyMargetsonFormerCOOMember', window );">Shelley Margetson, Former COO [member] | Pension [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors remuneration expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,595<span></span>
</td>
<td class="nump">6,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_ShelleyMargetsonFormerCOOMember', window );">Shelley Margetson, Former COO [member] | Option cost [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors remuneration expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 451,752<span></span>
</td>
<td class="nump">&#8364; 164,547<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DirectorsRemunerationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of remuneration paid or payable to the entity's directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DirectorsRemunerationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. Disclosure charged to the profit and loss statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureChargedToTheProfitAndLossStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_TonLogtenbergCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_TonLogtenbergCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_GrossSalaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_GrossSalaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_BonusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_BonusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_PensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_PensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_OptionCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_OptionCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_ShelleyMargetsonFormerCOOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_ShelleyMargetsonFormerCOOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760277776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Board Compensation and Key Management Personnel - Summary on Charge to the Profit and Loss Statement (Parenthetical) (Detail) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Gross salary includes severance payments</a></td>
<td class="nump">&#8364; 10,783,000<span></span>
</td>
<td class="nump">&#8364; 9,556,000<span></span>
</td>
<td class="nump">&#8364; 5,166,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_EmployeeBenefitSchemeAxis=mrus_SeveranceCostsMember', window );">Severance costs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Gross salary includes severance payments</a></td>
<td class="nump">&#8364; 257,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2018-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=19&amp;date=2018-03-01&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. Disclosure charged to the profit and loss statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureChargedToTheProfitAndLossStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_EmployeeBenefitSchemeAxis=mrus_SeveranceCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_EmployeeBenefitSchemeAxis=mrus_SeveranceCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6746928880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Board Compensation and Key Management Personnel - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 15, 2017 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 01, 2016 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 27, 2016 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options allocated to Chief Medical Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,445<span></span>
</td>
<td class="nump">1,014,733<span></span>
</td>
<td class="nump">496,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_TonLogtenbergCEOMember', window );">Ton Logtenberg, CEO [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options allocated to Chief Medical Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers', window );">Number of options held by the chief executive officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">758,925<span></span>
</td>
<td class="nump">661,629<span></span>
</td>
<td class="nump">376,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers', window );">Average exercise price per share held by the chief executive officers | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17.07<span></span>
</td>
<td class="nump">&#8364; 14.20<span></span>
</td>
<td class="nump">&#8364; 2.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers', window );">Number of RSU held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,450<span></span>
</td>
<td class="nump">123,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AndresSirulnikChiefMedicalOfficerMember', window );">Andres Sirulnik Chief Medical Officer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options allocated to Chief Medical Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ExercisePricePerShare', window );">Exercise price per share | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_JohnCrowleyChiefFinancialOfficerMember', window );">John Crowley Chief Financial Officer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options allocated to Chief Medical Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ExercisePricePerShare', window );">Exercise price per share | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_PeterSilvermanSeniorVicePresidentMember', window );">Peter Silverman Senior Vice President [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems', window );"><strong>Disclosure charged to the profit and loss statement [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options allocated to Chief Medical Officer</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ExercisePricePerShare', window );">Exercise price per share | &#8364; / shares</a></td>
<td class="nump">&#8364; 24.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average exercise price per share held by the chief executive officers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AverageExercisePricePerShareHeldByTheChiefExecutiveOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureChargedToTheProfitAndLossStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. Disclosure charged to the profit and loss statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureChargedToTheProfitAndLossStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options held by the chief executive officers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NumberOfOptionsHeldByTheChiefExecutiveOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options of other equity instruments held by the chief executive officers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NumberOfOptionsOfOtherEquityInstrumentsHeldByTheChiefExecutiveOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_TonLogtenbergCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_TonLogtenbergCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AndresSirulnikChiefMedicalOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AndresSirulnikChiefMedicalOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_JohnCrowleyChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_JohnCrowleyChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_PeterSilvermanSeniorVicePresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_PeterSilvermanSeniorVicePresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6730768560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Board Compensation and Key Management Personnel - Summary of Related Party (Detail) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfRelatedPartyAbstract', window );"><strong>Disclosure of related party [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employment benefits</a></td>
<td class="nump">&#8364; 2,705,438<span></span>
</td>
<td class="nump">&#8364; 2,808,998<span></span>
</td>
<td class="nump">&#8364; 1,139,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Post-employment benefits</a></td>
<td class="nump">40,882<span></span>
</td>
<td class="nump">108,416<span></span>
</td>
<td class="nump">18,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other long-term benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based compensation</a></td>
<td class="nump">3,688,978<span></span>
</td>
<td class="nump">5,171,233<span></span>
</td>
<td class="nump">1,195,876<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">&#8364; 6,435,298<span></span>
</td>
<td class="nump">&#8364; 8,088,647<span></span>
</td>
<td class="nump">&#8364; 2,354,359<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2018-03-01&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2018-03-01&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2018-03-01&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2018-03-01&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2018-03-01&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2018-03-01&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6740221120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Board Compensation and Key Management Personnel - Summary of Consolidated Statement of Profit and Loss for the Remuneration of the (Former) Members of the Supervisory Board (Detail) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">&#8364; 798,781<span></span>
</td>
<td class="nump">&#8364; 826,578<span></span>
</td>
<td class="nump">&#8364; 696,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_RussellGreigMember', window );">Russell Greig [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">117,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_MarkIwickiMember', window );">Mark Iwicki [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">123,732<span></span>
</td>
<td class="nump">180,436<span></span>
</td>
<td class="nump">233,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_LenKanavyMember', window );">Len Kanavy [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">185,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_WolfgangBertholdMember', window );">Wolfgang Berthold [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">85,091<span></span>
</td>
<td class="nump">128,474<span></span>
</td>
<td class="nump">70,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_LionelCarnotMember', window );">Lionel Carnot [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">20,401<span></span>
</td>
<td class="nump">97,315<span></span>
</td>
<td class="nump">91,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_JohnDeKoningMember', window );">John de Koning [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">91,812<span></span>
</td>
<td class="nump">152,186<span></span>
</td>
<td class="nump">63,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AnandMehraMember', window );">Anand Mehra [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">74,312<span></span>
</td>
<td class="nump">123,298<span></span>
</td>
<td class="nump">111,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_GregoryPerryMember', window );">Gregory Perry [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">100,153<span></span>
</td>
<td class="nump">144,869<span></span>
</td>
<td class="nump">125,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_CashCompensationMember', window );">Cash compensation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">292,231<span></span>
</td>
<td class="nump">252,703<span></span>
</td>
<td class="nump">176,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_CashCompensationMember', window );">Cash compensation [member] | Russell Greig [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">38,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_CashCompensationMember', window );">Cash compensation [member] | Mark Iwicki [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">55,066<span></span>
</td>
<td class="nump">59,840<span></span>
</td>
<td class="nump">50,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_CashCompensationMember', window );">Cash compensation [member] | Len Kanavy [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">32,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_CashCompensationMember', window );">Cash compensation [member] | Wolfgang Berthold [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">19,315<span></span>
</td>
<td class="nump">37,530<span></span>
</td>
<td class="nump">19,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_CashCompensationMember', window );">Cash compensation [member] | Lionel Carnot [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">20,401<span></span>
</td>
<td class="nump">35,445<span></span>
</td>
<td class="nump">24,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_CashCompensationMember', window );">Cash compensation [member] | John de Koning [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">40,768<span></span>
</td>
<td class="nump">38,573<span></span>
</td>
<td class="nump">26,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_CashCompensationMember', window );">Cash compensation [member] | Anand Mehra [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">39,863<span></span>
</td>
<td class="nump">39,615<span></span>
</td>
<td class="nump">26,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_CashCompensationMember', window );">Cash compensation [member] | Gregory Perry [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">45,356<span></span>
</td>
<td class="nump">41,700<span></span>
</td>
<td class="nump">28,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_OptionCostMember', window );">Option cost [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">506,550<span></span>
</td>
<td class="nump">573,875<span></span>
</td>
<td class="nump">520,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_OptionCostMember', window );">Option cost [member] | Russell Greig [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">79,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_OptionCostMember', window );">Option cost [member] | Mark Iwicki [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">68,666<span></span>
</td>
<td class="nump">120,596<span></span>
</td>
<td class="nump">183,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_OptionCostMember', window );">Option cost [member] | Len Kanavy [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">152,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_OptionCostMember', window );">Option cost [member] | Wolfgang Berthold [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">65,776<span></span>
</td>
<td class="nump">90,944<span></span>
</td>
<td class="nump">50,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_OptionCostMember', window );">Option cost [member] | Lionel Carnot [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,870<span></span>
</td>
<td class="nump">66,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_OptionCostMember', window );">Option cost [member] | John de Koning [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">51,044<span></span>
</td>
<td class="nump">113,613<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_OptionCostMember', window );">Option cost [member] | Anand Mehra [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">34,449<span></span>
</td>
<td class="nump">83,683<span></span>
</td>
<td class="nump">84,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_OptionCostMember', window );">Option cost [member] | Gregory Perry [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemunerationForFormerEmployees', window );">Remuneration for former employees</a></td>
<td class="nump">&#8364; 54,797<span></span>
</td>
<td class="nump">&#8364; 103,169<span></span>
</td>
<td class="nump">&#8364; 97,365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. Disclosure of options held by the members of supervisory board.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RemunerationForFormerEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remuneration for former employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RemunerationForFormerEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_RussellGreigMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_RussellGreigMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_MarkIwickiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_MarkIwickiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_LenKanavyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_LenKanavyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_WolfgangBertholdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_WolfgangBertholdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_LionelCarnotMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_LionelCarnotMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_JohnDeKoningMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_JohnDeKoningMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AnandMehraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AnandMehraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_GregoryPerryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_GregoryPerryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_CashCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_CashCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_OptionCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=mrus_OptionCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6739090576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Board Compensation and Key Management Personnel - Summary of Average Exercise Price Per Share Held by the Members of the Supervisory Board (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard', window );">Number of options | shares</a></td>
<td class="nump">235,432<span></span>
</td>
<td class="nump">193,866<span></span>
</td>
<td class="nump">185,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard', window );">Weighted average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 11.52<span></span>
</td>
<td class="nump">&#8364; 9.61<span></span>
</td>
<td class="nump">&#8364; 7.21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_RussellGreigMember', window );">Russell Greig [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard', window );">Number of options | shares</a></td>
<td class="nump">9,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard', window );">Weighted average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 19.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_MarkIwickiMember', window );">Mark Iwicki [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard', window );">Number of options | shares</a></td>
<td class="nump">84,209<span></span>
</td>
<td class="nump">79,226<span></span>
</td>
<td class="nump">73,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard', window );">Weighted average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 10.07<span></span>
</td>
<td class="nump">&#8364; 7.32<span></span>
</td>
<td class="nump">&#8364; 6.57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_LenKanavyMember', window );">Len Kanavy [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard', window );">Number of options | shares</a></td>
<td class="nump">21,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard', window );">Weighted average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 16.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_WolfgangBertholdMember', window );">Wolfgang Berthold [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard', window );">Number of options | shares</a></td>
<td class="nump">36,540<span></span>
</td>
<td class="nump">24,040<span></span>
</td>
<td class="nump">26,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard', window );">Weighted average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 15.22<span></span>
</td>
<td class="nump">&#8364; 8.90<span></span>
</td>
<td class="nump">&#8364; 3.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_LionelCarnotMember', window );">Lionel Carnot [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard', window );">Number of options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,650<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard', window );">Weighted average exercise price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.80<span></span>
</td>
<td class="nump">&#8364; 8.87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_JohnDeKoningMember', window );">John de Koning [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard', window );">Number of options | shares</a></td>
<td class="nump">27,633<span></span>
</td>
<td class="nump">22,650<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard', window );">Weighted average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 14.34<span></span>
</td>
<td class="nump">&#8364; 11.80<span></span>
</td>
<td class="nump">&#8364; 8.87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AnandMehraMember', window );">Anand Mehra [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard', window );">Number of options | shares</a></td>
<td class="nump">27,633<span></span>
</td>
<td class="nump">22,650<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard', window );">Weighted average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 14.34<span></span>
</td>
<td class="nump">&#8364; 11.80<span></span>
</td>
<td class="nump">&#8364; 8.87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_GregoryPerryMember', window );">Gregory Perry [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard', window );">Number of options | shares</a></td>
<td class="nump">27,633<span></span>
</td>
<td class="nump">22,650<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard', window );">Weighted average exercise price | &#8364; / shares</a></td>
<td class="nump">&#8364; 14.34<span></span>
</td>
<td class="nump">&#8364; 11.80<span></span>
</td>
<td class="nump">&#8364; 8.87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_GabrieleDallmannMember', window );">Gabriele Dallmann [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems', window );"><strong>Disclosure of options held by the members of supervisory board [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard', window );">Number of options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard', window );">Weighted average exercise price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. Disclosure of options held by the members of supervisory board.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfOptionsHeldByTheMembersOfSupervisoryBoardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options held by the members of supervisory board.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NumberOfOptionsHeldByTheMembersOfSupervisoryBoard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share held by the members of the supervisory board.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_WeightedAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_RussellGreigMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_RussellGreigMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_MarkIwickiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_MarkIwickiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_LenKanavyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_LenKanavyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_WolfgangBertholdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_WolfgangBertholdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_LionelCarnotMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_LionelCarnotMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_JohnDeKoningMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_JohnDeKoningMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AnandMehraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AnandMehraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_GregoryPerryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_GregoryPerryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_GabrieleDallmannMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_GabrieleDallmannMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6740757088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures - Additional Information (Detail) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 24, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfSeverancePaymentPaid', window );">Percentage of severance payment paid</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod', window );">Percentage of severance payment being paid in form of salary continuation over six-month period</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AccrualsToEmployeeSeveranceIndemnities', window );">Accrued severance payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member] | Cooperatief LSP Four Uitgesloten Aansprakelijkheid [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfOwnershipInterestByShareholders', window );">Ownership interest held by shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member] | Sofinnova Venture Partners Nine Limited Partnership [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfOwnershipInterestByShareholders', window );">Ownership interest held by shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AccrualsToEmployeeSeveranceIndemnities', window );">Accrued severance payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100,000<span></span>
</td>
<td class="nump">&#8364; 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Biophrase BV [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfOwnershipInterestByShareholders', window );">Ownership interest held by shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AccrualsToEmployeeSeveranceIndemnities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accruals To Employee Severance Indemnities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AccrualsToEmployeeSeveranceIndemnities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PercentageOfOwnershipInterestByShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership interest by shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PercentageOfOwnershipInterestByShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of severance payment being paid in form of salary continuation over the six-month period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PercentageOfSeverancePaymentBeingPaidInFormOfSalaryContinuationOverSixmonthPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PercentageOfSeverancePaymentPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of severance payment paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PercentageOfSeverancePaymentPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_CooperatiefLspFourUitgeslotenAansprakelijkheidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_CooperatiefLspFourUitgeslotenAansprakelijkheidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_SofinnovaVenturePartnersNineLimitedPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_SofinnovaVenturePartnersNineLimitedPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_BiophraseBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_BiophraseBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763839632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 21, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 21, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 20, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 01, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 26, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfCommitmentsAndContingenciesLineItems', window );"><strong>Disclosure of commitments and contingencies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RentAndServiceChargesExpense', window );">Rent and service charges expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SecurityDeposits', window );">Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_LitigationSettlementsGrantedForAttorneysFees', window );">Attorneys fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,332,453.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_LitigationSettlementsGrantedForExpertFees', window );">Expert fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">465,390.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts', window );">Litigation expenses and costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,717,100.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_LitigationCosts', window );">Litigation and opposition cost incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,039<span></span>
</td>
<td class="nump">&#8364; 1,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_LeasesAgreementForCorporateHeadquartersMember', window );">Leases agreement for corporate headquarters [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfCommitmentsAndContingenciesLineItems', window );"><strong>Disclosure of commitments and contingencies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RentalExpense', window );">Rental expense Per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OperatingLeaseTermOfLeaseAgreement', window );">Operating lease term of lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_LeasesExpirationPeriod', window );">Leases expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Fourth quarter of 2021<span></span>
</td>
<td class="text">Fourth quarter of 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember', window );">New leases agreement for additional corporate headquarters space member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfCommitmentsAndContingenciesLineItems', window );"><strong>Disclosure of commitments and contingencies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RentalExpense', window );">Rental expense Per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_LeasesExpirationPeriod', window );">Leases expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Fourth quarter of 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_RegeneronSubscriptionAgreementMember', window );">Regeneron Subscription Agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfCommitmentsAndContingenciesLineItems', window );"><strong>Disclosure of commitments and contingencies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Number of common shares purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PurchasePricePerCommonShare', window );">Purchase price per common share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of common share</a></td>
<td class="nump">&#8364; 13,100<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,100<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ReimbursementOfExpenses', window );">Reimbursement of expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_OtherFundingCommitmentsMember', window );">Other funding commitments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfCommitmentsAndContingenciesLineItems', window );"><strong>Disclosure of commitments and contingencies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PaymentOfPropertyPlantAndEquipment', window );">Purchase property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_NonAdjustingEventMember', window );">Non adjusting event [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfCommitmentsAndContingenciesLineItems', window );"><strong>Disclosure of commitments and contingencies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RentalExpense', window );">Rental expense Per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,200<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OperatingLeaseTermOfLeaseAgreement', window );">Operating lease term of lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement', window );">Lease agreement square feet of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,583<span></span>
</td>
<td class="nump">7,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_NonAdjustingEventMember', window );">Non adjusting event [member] | MIT Cambridge Real Estate LLC [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfCommitmentsAndContingenciesLineItems', window );"><strong>Disclosure of commitments and contingencies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement', window );">Lease agreement square feet of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,583<span></span>
</td>
<td class="nump">7,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised on rental activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfCommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of commitments and contingencies [line items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfCommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_LeasesExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_LeasesExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_LitigationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_LitigationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_LitigationSettlementsGrantedForAttorneysFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation settlements granted for attorneys fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_LitigationSettlementsGrantedForAttorneysFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_LitigationSettlementsGrantedForExpertFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation settlements granted for expert fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_LitigationSettlementsGrantedForExpertFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation settlements granted for litigation expenses and costs .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_LitigationSettlementsGrantedForLitigationExpensesAndCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OperatingLeaseTermOfLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease term of lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OperatingLeaseTermOfLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PaymentOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of Property Plant and Equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PaymentOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PurchasePricePerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price per common share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PurchasePricePerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ReimbursementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ReimbursementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RentAndServiceChargesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent and service charges expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RentAndServiceChargesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement for square feet of office space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_LeasesAgreementForCorporateHeadquartersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_LeasesAgreementForCorporateHeadquartersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_NewLeasesAgreementForAdditionalCorporateHeadquartersSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_RegeneronSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_RegeneronSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_OtherFundingCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_OtherFundingCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_NonAdjustingEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_NonAdjustingEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=mrus_MitCambridgeRealEstateLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=mrus_MitCambridgeRealEstateLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759514336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Lease (Detail)<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems', window );"><strong>Disclosure of finance lease and operating lease by lessee [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease', window );">Minimum lease payments payable under non cancellable operating lease</a></td>
<td class="nump">&#8364; 4,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems', window );"><strong>Disclosure of finance lease and operating lease by lessee [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease', window );">Minimum lease payments payable under non cancellable operating lease</a></td>
<td class="nump">1,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Between one and five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems', window );"><strong>Disclosure of finance lease and operating lease by lessee [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease', window );">Minimum lease payments payable under non cancellable operating lease</a></td>
<td class="nump">&#8364; 3,106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of future minimum lease payments payable under non-cancellable operating leases. Minimum lease payments are payments over the lease term that the lessee is or can be required to make, excluding contingent rent, costs for services and taxes to be paid by, and reimbursed to, the lessor, together with: (a) for a lessee, any amounts guaranteed by the lessee or by a party related to the lessee; or (b) for a lessor, any residual value guaranteed to the lessor by: (i) the lessee; (ii) a party related to the lessee; or (iii) a third party unrelated to the lessor that is financially capable of discharging the obligations under the guarantee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2019-01-01<br> -Name IAS<br> -Number 17<br> -IssueDate 2018-01-01<br> -Paragraph 35<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=17&amp;date=2018-03-02&amp;anchor=para_35_a&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6746057360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) - 1 months ended Mar. 31, 2019 - Non adjusting event [member]<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>EUR (&#8364;) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of Events After Reporting Period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement', window );">Square feet of office space under lease agreement</a></td>
<td class="nump">7,583<span></span>
</td>
<td class="nump">7,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OperatingLeaseTermOfLeaseAgreement', window );">Operating lease term of lease agreement</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_LeaseTermExpirationDate', window );">Operating lease expiration date</a></td>
<td class="text">Apr.  01,  2026<span></span>
</td>
<td class="text">Apr.  01,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RentalExpense', window );">Rental expense Per year</a></td>
<td class="nump">&#8364; 4.2<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised on rental activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of events after reporting period line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_LeaseTermExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease term expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_LeaseTermExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OperatingLeaseTermOfLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease term of lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OperatingLeaseTermOfLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement for square feet of office space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SquareFeetOfOfficeSpaceUnderLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_NonAdjustingEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_NonAdjustingEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>121
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MZP^_F[#MM3F8?VQ\%6P;^'47[1=02P,$%     @  8B#3IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M^7(1LF':3.4U49WD[.Q(39W0-%TE#:O:>%>XM:/<%>*NZZKE1QFI>],P^??
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M0FAN$DJ?3"HWTZI-DYI?M!VNS5@._<HPT:(;>[%D:@AW_P!02P,$%     @
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M>^F'R]1?MY<#L,M-WYRFP[WH>L*X_@]02P,$%     @  8B#3IX#/,W.!
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MDA.SK*%H[8IF:V6EP3!^$/.%B6"!COG* S EPPAK-E"S<36SG*\,$B,TGV@
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MM&,6[?CMF17(PRLDB85X)YH2H TBWD3G !:)+HIT!2;V5"%Y6(@DQU# 289
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MPI\\ -2-'TW$]R@@I'R@*+EXO39-,]2.'=< Q^7&M@0@X<I&>J3R!2;?_Z<
M9UW"GT"N 4Q3/#:U#;93 ^S4\.VGD5;IUZN()R&%."DP T'EK3UAW'02-M-4
MPPQ@#S=@]VE&=I]FY%D[L&?+=Y]&/OW6XF@=@/B.)P/11B5S!Q_^B@W5_+]7
M+@'&\8$77+S4L2^JE^X-GGKV6+X=FE;BQ=7S6T)+:E\*8==7:K%1X'I*BPSA
MU[38H.N?C5VL?4KD+UZ/_Z5[I2;XV=73ZTV_Y]7+]E#/'LJF*??=RR?/9=D4
M/@WA)Y_?UR)_.G_9%<]-^S'RGZO3:T6G+TUY[%^9"L[O;=W_!U!+ P04
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MK%*V"K1M41,#54;OMH?C+N CX$<+@UWL2>CDC/@:@B]E1C?!$$@H7% 0?KG
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M%S8'$BH7MC=^;\8Y&P.'W?2$V/R.\P]02P,$%     @  8B#3LO>&Y"V 0
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M4/NPO<6]'>=L#+SIIB?$YG=<_ )02P,$%     @  8B#3BWWF!6T 0  TP,
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M_-E,<S89#OOY"['E'Y>_ 5!+ P04    "  !B(-."!#D5;0!  #3 P  &0
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M11^>-CU @^@AI+*["S/4A1^V& H:'X_WX6RG.9L,C_W\A=CRC\O?4$L#!!0
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M"V@0/00KN[LP0UUX84N@H/%Q>Q_V=IJS*?#8ST^(+>^X_ U02P,$%     @
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M_&&+H:#VX?@1SW::L\GPII^_$%O^<?$;4$L#!!0    (  &(@TZG+V6PM0$
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MGNTT9Y/A33]_(;;\X_(W4$L#!!0    (  &(@TZ2S'3!MP$  -,#   9
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MSZ#,F-,=?74\RJ;UP<&*K!<-? ?_H[]8M-BB4DD-G9.F(Q;JG-[O3N=]P$?
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M.8,R8T[W]-7Q))O6!P<KLEXT\!W\C_YBT6*+2B4U=$Z:CEBH<_JP/YW3@(^
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M>S7V_F@8V4]CC<ZSM?@-4$L#!!0    (  &(@TX^R,<"P $  #@$   9
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MXS40T+JP?>_W9G[,<^#TL,PI6?\LJK]02P,$%     @  8B#3NB&NE?2 0
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M/YMISB;#Z7[^0F3YQ^4?4$L#!!0    (  &(@TXX5+_'MP$  -,#   9
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M'"[&;5.[5V/OCX:1W336Z#Q;B]]02P,$%     @  8B#3NJ<(^[? 0   @4
M !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL=53;CILP$/T5Y ]8$Q-"
M-@*DS595*[52M%7;9P>&B];&U#9A^_>U#:&4=5^P9WSFG!GCF704\E4U #IX
MXZQ3&6JT[D\8JZ(!3M6#Z*$S)Y60G&ICRAJK7@(M71!GF(3A 7/:=BA/G>\B
M\U0,FK4=7&2@!LZI_'T&)L8,[=#=\=+6C;8.G*<]K>$;Z._]11H++RQERZ%3
MK>@""56&GG:G<V+Q#O"CA5&M]H&MY"K$JS4^EQD*;4+ H-"6@9KE!L_ F"4R
M:?R:.=$B:0/7^SO[1U>[J>5*%3P+]K,M=9.A(PI*J.C ](L8/\%<3XR"N?@O
M< -FX#83HU$(IMPW* :E!9]93"J<ODUKV[EUG/GO8?X ,@>030">A%SF'ZBF
M>2K%&,CI[GMJ?_'N1,S=%-;IKL*=F>25\=YR<HQ3?+-$,^8\8<@*LUL0V+ O
M$L0G<2;OPJ/8'Q]Y4XQ<?+26CXF?8.\EV#N"_3\U'C8U^C")7R3VBL0>@N-&
MQ(=Y](L<O"*']P2/X4;$A_G/_TJ\(HF'@&Q$?)AH(X)7;Y"#K%WWJ: 00^<Z
M?^5=&OR)N#?\%SY-AZ]4UFVG@JO0IA/<>ZV$T&!2"1_,K39F("T&@TK;;6+V
M<FK+R="BGR<.7L9>_@=02P,$%     @  8B#3GOK9P"X 0  TP,  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL;5/;;MP@$/T5Q >$7=9.TY5M*9NH
M:J566J5J^\S:8QL%/"[@=?KW!>RX;N(78(9SSEP8LA'-LVT!''G1JK,Y;9WK
MCXS9L@4M[ WVT/F;&HT6SINF8;8W(*I(THKQW>Z6:2$[6F31=S9%AH-3LH.S
M(7;06I@_)U XYG1/7QU/LFE=<+ BZT4#W\']Z,_&6VQ1J:2&SDKLB($ZI_?[
MXRD)^ CX*6&TJS,)E5P0GX/QI<KI+B0$"DH7%(3?KO  2@4AG\;O69,N(0-Q
M?7Y5_Q1K][5<A(4'5+]DY=J<WE%202T&Y9YP_ QS/2DE<_%?X0K*PT,F/D:)
MRL:5E(-UJ&<5GXH6+],NN[B/TTV:S+1M I\)?"'<Q3AL"A0S?Q1.%)G!D9BI
M][T(3[P_<M^;,CAC*^*=3]YZ[[7@'Y.,78/0C#E-&+["[!<$\^I+"+X5XL3?
MT0_I-O^PF>(A\@_K\"G?%D@V!9(HD/Q78_JFQBW,[9L@;-54#::)XV1)B4,7
M1WGE72;VGL='^0>?QOV;,(WL++F@\T\;'Z!&=.!3V=WX&6K]#UL,!;4+QP_^
M;*8YFPR'_?R%V/*/B[]02P,$%     @  8B#3@D#!PS7!0  (!T  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#4N>&ULE5G;4MM($/T5ES\ JWMT+Z J0,@%
M,F:9VMUG!02X8ENL)"#Y^VW)LK%&9QR%!VS-.=T],WVZ1Y:.WXKR1_64Y_7D
MYVJYKDZF3W7]G,YFU=U3OLJJH^(Y7POR4)2KK);+\G%6/9=Y=M\:K98S]KQP
MMLH6Z^GI<3MV4YX>%R_U<K'.;\I)];):9>6OLWQ9O)U,:;H=N%T\/M7-P.ST
M^#E[S$U>__U\4\K5;.?E?K'*U]6B6$_*_.%D^H%2H_S&H&7\L\C?JKWODV8I
MWXOB1W/QY?YDZC4SRI?Y7=VXR.3C-3_/E\O&D\SCO\[I=!>S,=S_OO5^V2Y>
M%O,]J_+S8OGOXKY^.IG&T\E]_I"]+.O;XNUSWBTHF$ZZU5_GK_E2Z,U,),9=
ML:S:_Y.[EZHN5IT7F<HJ^[GY7*S;S[?._]8,&W!GP&,-5&>@=@9,!PW\SL#?
M&?B'(P2=03 V0M@9A#L#%1TTB#J#Z-T@/&@0=P;QSH#408.D,TC&KH&\;>:\
ML:N@7;+?L\V_,=FFFWCTQ+8)I_>,^X<MMADG?W20;<XI&!MDFW0*1R]^FW9Z
MSSLEATVVB:=X]%*VJ:>DOY39IG3;7G"1U=GI<5F\3<I-.WO.FJY)J1B)[V:T
M[2XM*/V@DM'74TZBX]EKXZGCG&TXW./$?<XYXB1]SL60HSROS_F(.-3G7"(.
M]SF?$$?U.9\1Q^]SOB!.T.=\19RPS[E"'&N?KQ''VF>-.-8^SP''"G4#*&2E
MXB_$L5)QBSA6*LS!Z<Q$GCN-,M8HMPY4+XC"'A3VH%H/?L^#E>FO&T[8<M8M
MAZ* ;(%>_9;6FX^/Y^.#^=BJVG""_4"^BGPKDU?C:-?^<-I^$D:6O+Z!B5F>
M]-!3$"9DL6Z'+,5Q0'B7 KQ+ =@EJZZ^!H,X(<6#I 6#30*LZR'+)_(<2@OQ
MG$,P9VMO/F\X\5X<[R@(@A 'BG"@" 2RLGD5#5/E162UP>LA2^2C;&6 >+8R
M4+C =]1ZC)<5@V4EV$."/23CNT5S%P0/16\X"QZT1V\@ER#PFC]',-<)3""8
MU6<_=:1DOWY=<1Q=E!C$&1R;&U*SMO=5J2/7_CG:+8%^RRX?CA9)_A_DT=%
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M2?U!TP:.QU?VS\Z\,;-G"IX%_U4>=+'RY[YW@",[<_TBVB_0&TI\KW?_#2[
M#=QF8C1RP95[>OE9:5'U+":5BKUW[[)V[[;GOX;A 6$?$ X!L0L@G9#+_!/3
M;)U)T7JRV_R&V7],EZ'9F]PNNJUPWTSRRJQ>UE$<9.1BB7K,ML.$(PP=$,2P
M#Q(A)K$-[\*C>((@0G.,'$$T)HA2G"!&"6)'$/^707AC$L-$N$B"BB0(07PC
M@F$27"1%15*$(+T1Z3"T^Z>U \6+IXD=GZ$R,T1F=B/389*12CK#->:HQAS1
MF.,$"Y1@\?BQH %^^(,'#@8*6DSH3!09O:=(@@D*M(@V-/R 6[R,:/2(6PPT
MY1:O-HJ44C)Q_"A>2S3Y@%N\4BA6*G=N$5 2WNB0T5U:@3RY+J*\7)QKU\)&
MJT.GVH3N+OX'[]K<=R9/9:V\O=#F1G?W[E$(#2:7X,EX+DQG'28<CMH.9V8L
MN_;23;1H^M9)AOZ]_@M02P,$%     @  8B#3ON-T)!' @  8P@  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#@N>&ULE5;MKIHP&+X5P@58RJ<:()F:94NV
MQ)QEV^^J5<@IE+55SNY^;4$F[&7Q^$/:^GR\;^&AIBT7K[*@5#EO%:MEYA9*
M-6N$Y+&@%9$+WM!:_W+FHB)*3\4%R490<K*DBB'?\V)4D;)V\]2N[46>\JMB
M94WWPI'7JB+B]X8RWF8N=N\++^6E4&8!Y6E#+O0;5=^;O= S-*B<RHK6LN2U
M(^@Y<S_@]0XGAF 1/TK:RH>Q8UHY</YJ)I]/F>N9BBBC1V4DB+[<Z)8R9I1T
M';]Z47?P-,3'\5W]HVU>-W,@DFXY^UF>5)&Y2]<YT3.Y,O7"VT^T;RARG;[[
M+_1&F8:;2K3'D3-IOYWC52I>]2JZE(J\==>RMM>VU[_38(+?$_R!T&W.+"'H
M"<%?0OA?0M@3P@D!=:W8O=D11?)4\-81W>UMB'F*\#K4NW\TBW:S[6]Z>Z1>
MO>5!%*3H9H1ZS*;#^"-,.,9L(<P8L@,@\0!!NLJA5!\LU;?\<&01P0(!*!!8
M@6 D,%-!" J$0 7)9",Z3&PQ=8>!+2+0(@(LEA.+Z%F+&+2( 8L5+)"  LGS
M^[@$!9;_5A![DZ>EPV#\T.5R$:]&']AS!7JN $\,"V /CHKW?-]X)FT8J,*?
M1@D"S=QA#$<% UF)PQD)."SX'6G!<%PPD)=IMQL0-!-K#&<& Z&)YTJ%,X'C
M=W0+IP(GS]Q;")1,?-##R]L<OU^)N)2U= Y<Z7/ OJW/G"NJ!;V%[KW0)_XP
M8?2LS##18]$=>]U$\:8_TM'POR+_ U!+ P04    "  !B(-.0&->C)T#  "V
M#P  &0   'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6R55UMOFS 4_BN(]P9?
M ),HB=2&IINT2=6F;<\T<1(TP!DXS?;O9\!E8!]H]A+ _LYWKC[.65Y%^;,Z
M<2Z=WWE65"OW).5YX7G5[L3SI)J),R_4SD&4>2+59WGTJG/)DWTCE&<>02CT
M\B0MW/6R67LNUTMQD5E:\.?2J2YYGI1_'G@FKBL7NV\+7]+C2=8+WGIY3H[\
M*Y??SL^E^O(ZEGV:\Z)*1>&4_+!R[_'BB9!:H$%\3_FUZKT[M2LO0ORL/S[N
M5RZJ+>(9W\F:(E&/5[[A658S*3M^:5*WTUD+]M_?V+>-\\J9EZ3B&Y']2/?R
MM'(CU]GS0W+)Y!=Q_<"U0X'K:.\_\5>>*7AMB=*Q$UG5_#J[2R5%KEF4*7GR
MNWVF1?.\:OXW,5B : %RJP#5 K03P.&D@*\%_'\"_J1 H 6"3F :'VI\>*L"
MI@784('7QK9)5IS(9+TLQ=4IVWH[)W59XP53Y;"K%YOL-WLJ7Y5:?5W3,%IZ
MKS61QFQ:#.EA<(?P%'NG@D J-L02I\%00PQ PB%D:T-""EM!04=I(T\'*N8P
M@0\2^ V!WS? <&/30L(&4K0ZL.\;X8QM%,%S;' ]VNHH,T("$ 48#4%/DSP#
MMP/0[<"29X:*30L)>G;<T2CR#7-C"!901 S';866XP 385&$#=<GF0:NAZ#K
MH25OJMB$5@KNB$^L^@9@H1]&9LYMA9;K )//?#(W7)]D&KC.0-<9(&^D_<'&
M1-0(3PMA?6OQ#!G&Q@"*SDS/'R&3C." 1(%Q_IXFB0:QB<#81(#\2$.<@P3S
MVUL11G#71N\VHUAC^J6":8B,+&X!&&%XS)R12P2_VR1BC1D<6I^&V,PAA",L
M9&3$(O#.N<?DW;,;:\S@+#&*[ @!.)\1@D8L@N\?3-\_4K$&&14<F0:!J&"D
MB#%\G6'@8@C&T@Y?#3CXCT*&6RRV&Y5=R';/BZAY7VX!U!U!8]; 70_;K<%.
M$;/J$[+&1DU8 _<9;#<:NX:CFV)CHR:L@9L6GM]2OW.K,M',IZ8Y-NH.S=#8
MGTJS!0YWX8Y$[(YDWA8/ "8<LP'N,@3H,M34 F!\0XO7^[>>\_+8C&:5LQ.7
M0M9QZJUVX]]#,_T9ZQLU%F)@/2:+1PB_)6J,!-;O"5IL"0)V5-34#J1#>:IV
M&C;OGQ/M1/LY*8]I43DO0JI!IIDW#D)(K@*$9NJ0G-00W7UD_"#K5Z;>RW:2
M;#^D..LIV>M&]?5?4$L#!!0    (  &(@TXT^MT4!P,  *<+   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;)5686^;,!#]*XCO+39@&T=)I)9TVJ1-
MJCIM^TP3)T$%G('3=/]^QA!&[*/IOB38O'MW[VR>;GZ2]4NS%T)Y;V51-0M_
MK]1A%@3->B_*K+F5!U'I-UM9EYG2RWH7-(=:9!L35!9!B! -RBRO_.7<[#W6
MR[D\JB*OQ&/M-<>RS.H_]Z*0IX6/_?/&4[[;JW8C6,X/V4Y\%^K'X;'6JV!@
MV>2EJ)I<5EXMM@O_#L\>,&L##.)G+D[-Z-EKI3Q+^=(NOFP6/FHK$H58JY8B
MTW^O(A5%T3+I.G[WI/Z0LPT</Y_9/QGQ6LQSUHA4%K_RC=HO_,3W-F*;'0OU
M)$^?12^(^%ZO_JMX%86&MY7H'&M9-.;76Q\;)<N>19=29F_=?UZ9_U//?PZ#
M \(^(/QH0-0'1$, CM\-B/N > AX'T]Z/+$2!)UTT\M5IK+EO)8GK^ZNPR%K
M;QV>$7U:ZW;3'(YYI]O9Z-W79<3">?#:$O68^PX3CC'D$I("$'H)>7 A-!H@
M@2YRJ#0$*PU-?'11Z01!!!)$AB >$1!L*>T@U$ J [G!C*#$E@OA2,*8A5NY
M*2-FM06B0I0C DN+06DQD">VM'48,DK$&;4K3ET4QB&Q&[6"$EK"7*:0\2B&
M91%0%G%/S%9%G/9A.L[2J2*N*L+M2[QRTSFB7*(HYB&LB8*:*) $PP0,)& ?
M_PX2D""Y^AVDB2/S!E,6)\AJ!X1#+.03EY>#]?#KES?E[@%&"'/K!!]<6(1"
M1.%J,((=$5V]=6F/&2>BG#N.YZ(PQ6BBF@E_QFYW")^@@(T3_X=S8M@Z\77O
M3'O,6&W"D'U" "KB4RV!S0Y_P.U2[-J/MG(:QW8] "X,V<0GC6&?PM>-*L6N
M4R4\XG8Y@)\ER50UML-<OH7M [.K+G</8*CM4<%HPBA%O3/37N.MY;%2[64;
M[78398IG*S/_6?MWF.I1DP)O=!WG(33XEZ(;8;]E]2ZO&N]9*CT;F0EF*Z42
MNGQTJYNXUU/SL"C$5K6/3#_7W>C8+90\]&-Q,,SFR[]02P,$%     @  8B#
M3NES#ZGK @  <@L  !D   !X;"]W;W)K<VAE971S+W-H965T-3$N>&ULE591
MCZ(P$/XKA/==:(&"1DV4U=PE=\EF+W?WC%J5+% /JN[]^VM+Y: ,ZKX(';[Y
M9KYA&&=R8>5[=:"46Q]Y5E13^\#Y<>PXU>9 \Z1Z9D=:B"<[5N8)%\=R[U3'
MDB9;Y91G#G9=XN1)6MBSB;*]EK,)._$L+>AK:56G/$_*OPN:L<O41O;5\);N
M#UP:G-GDF.SI#\I_'E]+<7(:EFV:TZ)*66&5=#>UYVB\0I%T4(A?*;U4K7M+
M2EDS]BX/7[=3VY49T8QNN*1(Q.5,8YIEDDGD\4>3VDU,Z=B^O[*OE'@A9IU4
M-&;9[W3+#U,[LJTMW26GC+^QRQ>J!06VI=5_HV>:";C,1,38L*Q2O];F5'&6
M:Q:12IY\U->T4->+YK^ZP0Y8.^!''3SMX#4.R+_IX&L'OW&XC0\T/G@T -$.
MI!O J4NE:O^2\&0V*=G%*NOV.2:R2]&8B+>[D4;U,M4S4?Y*6,\S+PPFSED2
M:<RBQN 6!C4(1[ W(3 48H%[[IX1(08@I M9]B'$@[/P0*&>\O<Z0@E,X(,$
MOB+P6P1A:!2JAA %*13D"?N8C RU (SX8>AW82_]@)X1< DP^:%OPE8WF3K2
M U!ZT*L=P@/%)R !Z240&&H7I"\%>9%9XKB&!1V8/_(\HW;]@+W:@4Q&X6[2
M='2'H.X0\!_X=B*0('J\:T<@P>ANU\:C?B%"SXV,KET",#_$.(*S02X\;MS'
M6PD-3"QTMYEBC>DD2PB*#$D0# ^F TZW.<+]=QR,!BC@T80^,9L0/)S0_>D4
M:TQ;;>2AP*Q)'_6$W2%!\+Q GQ@8")X8Z/[(B!$P,R!%?=BP(/,[[CZ%/U(4
MW9TV"P!#S$G@M/ZT<UKNU<)561MV*KC,OV5MEKHYEG_ZAGTAESW 'N/Q"X1?
MXO$*LL]1*(A",$)TW2>=_ZG6V^CWI-RG166M&1=;BUHN=HQQ*LK@/HO..(@%
MN#ED=,?E;2CNRWH+K ^<'?6&ZS1K]NP?4$L#!!0    (  &(@TZBPF]P' 4
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M@"5;$"AR90;SAO#1"<)F! I-H0Q PI483!K"1R4(^_XOE"D2 (A<>DYB^I&
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MK9LTA%^:JCCJ]'"[R/1KW?Z,FM]E?\[77]3%93C##&X'J=O_ %!+ P04
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M%C3X*:(P'><$0(7IG:*'X%J!@&(QW:)H4I*>XG!R8 !47W0KQ^MUE9+RDVG
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M?"^+TY$ZSZJM=74AQ:G^V\!I_KN8_P-02P,$%     @  8B#3MYHC57B @
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M3HQ)4.5Z3^I8%>K"&R843E(/$S7F7=?O)I(U_8V&AFMU_0]02P,$%     @
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M22=/,'O2Z1/,GS0!!!D@30%!#EASP) #UAPPKGM3>,@!:PX8<L": X8<L.:
M(0>L.6#( 6L.&'+ F@.&'+#F@"$'HCD0R(%H#@1R()H#P:N_6?Z0 ]$<".1
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M#A-QFX@:B[]H,%Z'2+@^,;;>C8WRN<^,)-T"?$9<=Q"=X ;JOM>1%KF (Q?
M$H>P!P_VX U/LP][\*TY<-]8_:<&([K+(=SJ#V8*8*8 R+,A0E<-)NPP$80D
MA$E"@,10YZL&4[4LAWC8A,$\%0R\G;@ $^8#NR61X>DC2*$3^GD"KQ2HFT&/
MA2%%"I4@DD  3: !X@.I=L*_$#-2-\0N'"OFA0)U8V94W[5*V <"?PT%/@X
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MZ,-*!W&C4A]+>G!*!4^4<0_ZJ(X!V.-"#L C;14@0 ^V]:")(Q2J'&6IO6\
M$JZY+82$B\Z[ZP 5Y6?3785S8)=:ZG/T;G7HX"O3P*WUM>[LIK/\H^FN!=\(
M/Q>U</9,JOYDNLB),4F54/]%2<S53628E/0D]3!58]ZUXVXB6=-?-;SAOK/\
M"U!+ P04    "  !B(-.)'U]K2($  #L%0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970V-"YX;6R5F&MOHS@4AO\*X@< OD&HDDA-LM6NM"-5LYJ9SS1Q$C2
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MD$Y$T]%.Q\>S3#BC6^F$$!<Y7DRS0%S@\)FYP* W/C,.I%-'T%#TF7* (>$
M>Z ;6RD#7AHE5#> 8FH/$&)4,X+XC&+LW<P'(<1,".S>+/B%SL.>RI"I&IT7
MFD^(.SRBE0-8Z!BE Q13'3HC&QLL0ZYG=%@$.D)U-I4-,.X[ 35:&$XYT(Q7
M,NRV#-FMT6"Q62,@W*2@;A#L@6SL\2Q9TE\ BNF:!B&ZM8+0S-Z*XS6%@S4E
MGFD.CGV<L^7]Q;&?<N"GQ@X+03&!MA"B2QF"DIFM"\=.RI&3TFV6AA[NLQXS
M4RG8(CFP2&,?!2%C.[\ VGT"315C1^9@DYO,_3C!CLS#7YATV!TY<D=JZAH:
MVT+DF(4SJ=A)C,J95.#,E@X;(T?&2"U=0U,/5DL1M4;("2>BBQ'B8L</%^S]
M.#9*CHS2:/@$+JA&%@!#29C8PAP$MDZ!MN/$ G8:&K=W/',7[*X"[9+IDH*@
MA.[Y(22H7@3-3%&!S5P@=YU91\7,3WZQO+L%=D6!;(IVMX;(U!%&Y0 6.Y[Q
MK$U,]7<R(QM;HT"__VE_:VBZ%V.&H"WD(L>/J'# Q4X<XI^#TS2P/0NT8:;]
M+<P]+LP"8"@)$UN: UX?!%H?C&<>+5Z^!79T@1S=:'  )2$M%(*,,B&(6I([
M.H<L9'WJSW@;:U]=R[8[RQM=O9\C/_/N')-<?V%/N^$T^/\PP^'TGVE]RLK&
M>JO:MBKZL\QC5;52:?0<5<ZS3 _W+[D\MMW'2'VNAT/AX4M;7?2!MWL_==_\
M!U!+ P04    "  !B(-.6%,(+'\#   U#@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970V-BYX;6R-EVV/FS@0Q[\*XOT!?L VJR32)JAJI3MIU=/=O683)T$%
MG(*S:;]]S</FR'AHNR\6</XS\_,P9NS5S;1?NK/6-OA65TVW#L_67I[BN-N?
M=5UTD;GHQOUR-&U=6/?8GN+NTNKB,!C554R31,1U43;A9C6,O;2;E;G:JFST
M2QMTU[HNVN];79G;.B3A^\#G\G2V_4"\65V*D_Y;VW\N+ZU[BN]>#F6MFZXT
M3=#JXSI\)D\YD;W!H/BWU+=N=A_T4WDUYDO_\.FP#I.>2%=Z;WL7A;N\Z9VN
MJMZ3X_@Z.0WO,7O#^?V[]P_#Y-UD7HM.[TSU7WFPYW6HPN"@C\6ULI_-[:.>
M)I2&P33[/_6;KIR\)W$Q]J;JAO_!_MI94T]>'$I=?!NO93-<;Y/_=S/<@$X&
M]&Y Y4\-V&3 ?M> 3P8<&,3C5(;<Y(4M-JO6W()V?+V7HJ\B\L1=]O?]X)#L
MX3>7GLZ-OFW2+%O%;[VC2;,=-72F(7=%[+S?0U LQ)9ZYBR1CR%VOH9GZ:,F
MQS0"!V'H7-G@@,T<B"3!'7#4 1\<\ <'!"1KU*2#IADTE!*6*3";G:]S*JXX
M![/V=5G*A,IP[A3E3A%N"KA3+\X?3"D)<':(+%5$0&K,&V'I0MT(E%H@U Q0
M"RR.H*""=XA,"I"!'!&E/.4XLD21)8(,4K.5?AB7&:448$9UPOT!;$RGJ&(X
MMT*Y%<(-"G:KO#B"IIS#NO9E)"%<,O#F<E_G5C/E"]@9BITAV" ]V\Q?CX*Q
MA,$20738NLU]'5RW#^ DP3^["8(NX7<W\6-1F0H!V1&A4#*1"6!'=)PHGBXD
MG2RT#(*P*\@^BN1#GB+86G:(3$5P?CFB2B.6+E"C7>B94(3:ZW2CB- Y-H\X
M7)NH3D940G!$)Z+9BWXDQ]L683XY22 Y\VN%0&KFT[AL>]"(C) H6\HWWBL)
MTBPAT782@?QXV494-**PYV RA[U4W'BK)$BO)+!73B)8)IF X)@NB^"G/E_P
M)Y>^*7B_)$C#)+!A3B(8"C;#':KS%W".Z1Y6\",YWC8)TC<)[)N32,P")1#Z
MEY+\IY*1-9[MG6O=GH9S21?LS;6Q_?YS-GH_^SS3?N\-QK?]F6C8D__O9CQ0
M_56TI[+I@E=CW<Y^V'\?C;':$2:1*X:S.\/='RI]M/VM=/?M>) 9'ZRY3(>T
M^'Y2W/P 4$L#!!0    (  &(@TXK67?T00(  $,'   9    >&PO=V]R:W-H
M965T<R]S:&5E=#8W+GAM;(U5;:^;(!C]*\8?<%' M\::[+9WV9(M:>YRM\^T
MI=5<% >TWOW[ 5K7*EWZI<#C.<?G'"GD'1?OLJ14>1\U:^32+Y5J%P#(74EK
M(I]X2QO]Y,!%391>BB.0K:!D;TDU S (8E"3JO&+W-8VHLCY2;&JH1OAR5-=
M$_'GF3+>+?W0OQ1>JV.I3 $4>4N.] =5;^U&Z!485?9531M9\<83]+#T/X6+
ME\S@+>!G13MY-?>,DRWG[V;Q=;_T ],0972GC +1PYFN*&-&2+?Q>]#TQU<:
MXO7\HO[9>M=>MD32%6>_JKTJEW[J>WMZ(">F7GGWA0Y^(M\;S'^C9\HTW'2B
MW['C3-I?;W>2BM>#BFZE)A_]6#5V[ ;]"\U-@ ,!CH00_Y> !@)ZE( ' GZ4
M$ V$:$( O7<;YIHH4N2"=Y[HMT-+S*X+%Y'^7#M3M%_'/M-Y2ET]%W$8Y>!L
MA ;,<X^!5Q@T@:P<D/@6LIY#8G0+>7% PG\R0!L9W4"G&V@%T)4 SA*W '(*
M("N ;SI()G'TF,AB&HN!,4(!RB:9.' P1%DZR6X]QVD43C&>I#/'91&*T\SM
M#SO]X9F_*+X34.04B!Y/.'8*Q \D',^3"W&:3!-9S7%ADB083?36#AP*( [O
M-)XX&T_FT:5W!%*G0/IX=)E3('L@NFQF5>\DF$W_KPX8BB.<3H*;PS*(X;1I
M<'78F.OE.Q''JI'>EBM];MG3Y<"YHEHQ>-)BI;[1Q@6C!V6FB9Z+_ESO%XJW
MPY4%QGNS^ M02P,$%     @  8B#3K^F(RJK @  HPD  !D   !X;"]W;W)K
M<VAE971S+W-H965T-C@N>&ULE59=C]HP$/PK4=Y[\4="R F0@*IJI59"5UW[
M[ ,#T25Q:ANX_OO:3D@39SET+\0VLSLSCK/>V47(5W7D7 =O95&I>7C4NGZ,
M(K4]\I*I!U'SRORS%[)DVDSE(5*UY&SG@LHB(@A-HI+E5;B8N;6-7,S$21=Y
MQ3<R4*>R9/+OBA?B,@]Q>%UXR@]';1>BQ:QF!_Z3Z^=Z(\TLZK+L\I)7*A=5
M(/E^'B[QXQHG-L A?N7\HGKCP%IY$>+53K[MYB&RBGC!M]JF8.9QYFM>%#:3
MT?&G31IVG#:P/[YF_^+,&S,O3/&U*'[G.WV<A],PV/$].Q7Z25R^\M90$@:M
M^^_\S L#MTH,QU84ROT&VY/2HFRS&"DE>VN>>>6>ES;_-0P.(&T Z0)(^FX
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M;&:\9J%$V<ZO7C=$+_X!4$L#!!0    (  &(@TYCAM]T1P0  &,6   9
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MS%2+$&QTS'*#$(3IWPIW47+H%P.4<I,2LUN")R8A&^3<+ :5[IF132:QU)3
M5F119O&Q<9Q%Y-!%AH61<<"(F8RXE2EB/#7YV"C&M.YP!R$LM PH;6(J[00R
M)"5DIMA"7)1S%R6LN Q(;F)*+@-JRJ(DM-H:J>[=[MY3PK++@.XF#G5B6"E9
M.O\_D6&%8T#B[':V-0ZWLXU[U,Y8#AG00[N=;:U#[0P4\4$[$U9$ HIHM3,A
MJ0/M#''N=B:LB 04T6IGLL4.MC/"/6AGPKI(2!<=KHBPD-'_L'B$I8?FF#RR
M)06X/(!RVCS"JD-SC![-<WH(]L#J$18=FF/V:*;;@[@'=H^PBM$<PT>S'!]
MN2T?844DI(BNWP*6,,KG-S+'HL.1#3.M)[?%Q&EG.%82CKR5Z3XY4 C;?B+4
M __)L8YPH".6_^2V;T+^$\(>^$_N>/,$!LORGQ/H[JW0\I\ 9&]8</->7XOV
M,!R!=-Y6GAO5OT#?C%Z/69ZI/Q<PQM?L:3,>EOP.,Y[=?"[:0]ETWJM42M;#
MV<!>2B4TQ_"#7JZC*';7ATKL57^;ZOMV/#,9'Y0\3>=!P?50:O4+4$L#!!0
M   (  &(@TZ4+Q1B50,  )0-   9    >&PO=V]R:W-H965T<R]S:&5E=#<R
M+GAM;(U786^;,!#]*X@?4+ -!J(D4B"--FF3JD[;/M/$25 !9^ TW;^?#82%
M\S7JEP#.NW?O'6=LSR^R>6V/0BCGO2KK=N$>E3K-/*_='D65MP_R)&K]SUXV
M5:[T8W/PVE,C\ET75)4>]7WN57E1N\MY-_;4+.?RK,JB%D^-TYZK*F_^IJ*4
MEX5+W.O <W$X*C/@+>>G_"!^"/7S]-3H)V]DV165J-M"UDXC]@MW168;$IJ
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MY"SU,E5K/D[A<2-9/QTP8#[EBO]02P,$%     @  8B#3O=JA%9< @  G@<
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M%F,?,4X4'Z8>*9H;M=5_4$L#!!0    (  &(@TZYY/].=@(  ( (   9
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M!:[35?^=7FFAX#H3=4;*"F%^G?0B)"L[%95*2=[;:UZ9:]/IWVAV NP(L">
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M&1?V0DBNRA ^JV-V5"-MM\CY7NK'D7JNFKFN64AQ:F?6H!N<9_\ 4$L#!!0
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M5\J>^8D0X;Q49<T7[DF()O,\OCN1"O,9;4@MWQPHJ["04W;T>,,(WFM257K
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M\)DO@8(^1/<6?9<O.P?!CO,[9LO/U/P'4$L#!!0    (  &(@T[(V48TO0(
M $<)   9    >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;(V6;6^;,!#'OPKB
M Y0'/T"L)%)#H4S:I*K5MM<T<1)4P,QVDN[;SQB7!?"ZO GV\;N[O\]'[.6%
M\3=QI%0Z[W75B)5[E+(EGB>V1UH7XHZUM%%O]HS7A513?O!$RVFQTTYUY86^
MC[VZ*!MWO=2V)[Y>LI.LRH8^<4><ZKK@OS>T8I>5&[@?AN?R<)2=P5LOV^)
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M[\_V?B)9:ZXMWG!W6O\!4$L#!!0    (  &(@T[!]C9BT@$  . $   9
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M7T.J "1;(-@X6&R0H WB^,F5C:>P0!(42)Q >B60W>28,9G## Y#GL@-J J
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MGWY1L(-LIT3-17<#Z!:2U^9RX_0WK/4_4$L#!!0    (  *(@T[]T!D'A@,
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M 9\,B1(4>%Z"**X;-\],[L#SC%TDJ1LX<$=<*,7\WQ8(ZS:N[]X2+W5929U
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MP4 I*.-7&#.69[A[P8R5*>Y>4C?.Y$W&20LFM@!B4RX$)IC,,..""293S+@
M,QX2UW0'8.P,Q[,%1NN\;F;<F0=UP.J<P1!,5YGA[ 735:8X>TFM.+*F ,9&
M)+:F*)IXD_&5@C5"@$9P9G443%>98>P%TU6F&'M)K;@H9WU<O13&WKAX80,P
MLEEG:K!&&* 1G-NPP>0W,XR]P>0W4XR]29TX!V]C8P5A-GDL C"R@3,B;;#B
M&* XG%EH#2:_F>'K36;+;(JO-ZD1%\,F7B413#L5ZQZ D3^-=CYNK#@&* YG
M%EJ#R6]FN'J#R6^FN'J3NO#.8ABCXO(!G&/ODMD'<*0X]TAML.@8(#J<R=YB
M_ML9KMYB_MLIKMZF+MP%SG'%8IFP0"9R>ZX6,];.,.$6,]9.,>$V->'6V\24
M I@F94*\"X%PG=+8W,XX%@H+A()S(3*[ZS-,O<6<M5-,O04[[*8W!YFN,+<M
MX'9.XBWFF)WAPQWFF)OBPUWJPZUQ+IXP !94D'C+%,","KE'$(>)[0"Q.>/J
M'6:LF^'J'6:LF^#J[USJPZWV+EZV$,R&W,..P_QW@/^2<5T.$]'-L.L.$]%-
ML>LN-=A&JWBVW &8UFQU[#@!CCMOD,L]\WH-T#^W'>@PK=T,O^XPK=T4O^Z
M$1>1$)<OA77+DD^J!V#B<OLR'FN)!UJ2>\'J,:W]#+_N,:W]%+\^@DY?!QMQ
MP475 S"M6"<;H0 7'-MXX*N3@P3;LGX9#FDTB\?J;=?VK^-/[AX/@MP,YT"B
M^[?ZXOYPG.-'F,/IDC^*^F6]:Q9?JK:MML-AA.>J:LMNE.I3]^]]+8NGX\6F
M?&[[KSWEZ\.ICL-%6^W'$RNKX[&9Z_\!4$L#!!0    (  *(@TX&ILMO' 0
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M!$D&IF?,5?R Z&','&PC>EB7*:@!$ PT (!]T0!L^-]D(WH8B![0  BF-P!
MV38 IDL&=&EZ63$F.'Y  3'F(;910 P4$&H  $,-H,.^:@!,?FRCIQCH*=0
M  8:0$?9-@ F7T;D:]#^C'F0'Q!J$O.0M!!J&ZE+*Q$EIO_\$M.5M)!6&XGD
MD+8M_,E94J'JPW!.USC;ZKUL^_.8R>CM+/"9^K.HV?B+>-I<3_3^=W,]8/PC
MJP^GLG'>JK:MBN$\:E]5K>J"#+PN$4>5[6X/N=JW_6W<W=?7@[WK0UN=QT-+
M_W9RNOH/4$L#!!0    (  *(@TZ/\@XG80(  !P)   9    >&PO=V]R:W-H
M965T<R]S:&5E=#DU+GAM;)56[6[;(!1]%<L/4(R_4SF6UK33)FU2U&G;;Y*0
MV"HV'I"D>_L!)E[LWJ1I?L2 SSGW'N :BB,7+[*B5'FO#6OEW*^4ZNX1DNN*
M-D3>\8ZV^LV6BX8HW14[)#M!R<:2&H;"($A10^K6+PL[MA1EP?>*U2U="D_N
MFX:(OP^4\>/<Q_YIX+G>5<H,H++HR([^H.IGMQ2ZAP:53=W05M:\]03=SOU/
M^/X)9X9@$;]J>I1G;<]867'^8CI?-W,_,!E11M?*2!#].- %9<PHZ3S^.%%_
MB&F(Y^V3^F=K7IM9$4D7G/VN-ZJ:^[GO;>B6[)EZYL<OU!E*?,^Y_T8/E&FX
MR43'6',F[;^WWDO%&Z>B4VG(:_^L6_L\.OT3#2:$CA .!!Q=)42.$/TGQ%<)
ML2/$MQ(21T@F!-1[MY/Y2!0I"\&/GNCW0T?,ML/WB5ZNM1FTJV/?Z?F4>O10
MYG%6H(,1<IB''A..,/D8LWB+B9(QY!& I&/($Q1I-F"0=C+8"4$[H16(S@62
M !:(0('("L0C 3R9#P@3PD%B,$@,"$23(!#F0I $#)(  O%DU7I,:C&MQ023
M1;N&&"61@DFD0!()+)"! MGM"YJ# CF0P73;09@,#C(#@\P @1P6P %<A\'M
M1O&%4L8W6 5!%[QBN,9P^$8BB:(+$G"5X>@#;N$:PE"!3/>W YUO7QR8W_33
M]"YNG!)<<1@JN0N?+PS7"TX_,#%PQ>#L_6VP@$#I- XZ.T3,O>$[$;NZE=Z*
M*WT>V5-CR[FB6C"XT]XK?549.HQNE6EFNBWZ\[KO*-ZYNP@:+D3E/U!+ P04
M    "  "B(-.'!$VA"L$  #/%   &0   'AL+W=O<FMS:&5E=',O<VAE970Y
M-BYX;6R5F'MOFSP4A[]*Q <(V.9BJB32VBYMND:J]NK=_J:-TT3CD@%MMF\_
M P[%]CDI4:5RR7-N/O;/P.Q8E+^JG1#UY$^6YM7<V=7UX<IUJY>=R))J6AQ$
M+G_9%F66U/*R?'6K0RF236N4I2[UO-#-DGWN+&;MO:=R,2O>ZG2?BZ=R4KUE
M65+^O19I<9P[Q#G=^+Y_W=7-#7<Q.R2OXC]1_W]X*N65VWO9[#.15_LBGY1B
M.W>^D*LU\QN#EOBQ%\=J<#YI2GDNBE_-Q6HS=[PF(Y&*E[IQD<C#N[@1:=IX
MDGG\5DZ=/F9C.#P_>5^VQ<MBGI-*W!3IS_VFWLT=[DPV8IN\I?7WXG@O5$&!
M,U'5/XIWD4J\R43&>"G2JOT_>7FKZB)37F0J6?*G.^[S]GA4_D]FL %5!K0W
MH.2L 5,&;*R!KPS\WH!%9PT"91!\1&!G#4)E$'X8^&<-(F40C37@RH"/+3I6
M!O&'P?FBB7?JG#=VG$C?;#(V+7)J-QG=;W)J.#$[[G9SL9W<MTF=+&9E<9R4
MW?H\)(T,D"MI)9TW=]OETOXH)W@E[[XO>$AF[GOC23'7'4,'C!\;S W$4)VY
MM9F(<)WY:C,\-/PL(8;IS!W$^#IS#S&!SJQLAGF1SCQ =<4Z\PWR8]3^"#&&
MGS64<]@SKFQVWW$*=YRV'ICF(8(],-@#:SWXF@>CEE7'A"V3MPQAGF<,B@V%
M)O-H,T,_6KH^G*X/I&L,ZZIC B1*EZW-$"R3 ,XDL#.)C"CKCB'^( QGC/H!
MF_I(HT,X6@A$,Y;MNF,('43SPX#%WI3Y<+ (#A8!P8QUNX[LTD@D_SQO.FB(
M%HW#T3@0S5" %;?;Y5-C>7_C]C3UF#$Y'@'(CY'.QW#",9 P,L#-7@,JM3=^
MX1),[0F0AR5YQ*K7QR8Z042&4"!0: :"($M<ST-Z-HA@$4"Q(E.Q0"@VLSD/
MZ=D@>D0 0>+8^")*0H(+)@.B#P02"&,R?%40IM%Z($0;""0.UL8/0=C((K)
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M6Q2UD!Z]J?2U$\FFOTC%MFY.(WE>=I_8NHNZ.*C/AV[_#7/Q#U!+ P04
M"  "B(-.Z<NV:]\!   K!0  &0   'AL+W=O<FMS:&5E=',O<VAE970Y-RYX
M;6R-5.V.G" 4?17# RQ^C%\3->ELT[1)FTRV:?N;T>MH%L0",V[?OH".M;ML
M,G^$>SGWG'M *"8NGF4'H+P71@=9HDZI<8^QK#M@1#[P$0:]TG+!B-*A.&,Y
M"B"-+6(4A[Z?8$;Z 56%S1U%5?"+HOT 1^')"V-$_#D Y5.) G1+//7G3ID$
MKHJ1G.$[J!_C4>@(KRQ-SV"0/1\\ 6V)/@3[0V[P%O"SATENYIYQ<N+\V01?
MFA+YIB&@4"O#0/1PA4>@U!#I-GXOG&B5-(7;^8W]D_6NO9R(A$=.?_6-ZDJ4
M(:^!EERH>N+39UC\Q,A;S'^%*U --YUHC9I3:;]>?9&*LX5%M\+(RSSV@QVG
MA?]6YBX(EX)P+0AG+[.0[?PC4:0J!)\\,>_]2,P1!_M0[TUMDG8K[)IN7NKL
MM<JRO,!70[1@#C,FW&"B_!\&:_Y5)'2*A)8@VHKDOIL@<A)$EF#W'T'PJLL9
MDUC,8#&[)(O=*CNGRNZ-2AJ_TV;L)(CO]YDX"9([?,Z8>.,SB--WCB-UJJ0.
ME=!-D#D)LOM]YDZ"_ Z?^9OSC (_>:6"-_^Y>4:^$7'N!^F=N-)7QO[8+><*
M-*'_H/>LTR_7&E!HE9FF>B[F^SL'BH_+TX37]['Z"U!+ P04    "  "B(-.
M2B#^".\!  !R!0  &0   'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6R%E-N.
MFS 0AE\%\0 QX91L!$A=JJJ56BG:JMMK!X: UF!J.V'[]K6-@X+72F_P@7]^
M?S.8R2;*WG@+(+SWG@P\]ULAQ@-"O&JAQWQ#1QCDFX:R'@NY9&?$1P:XUD$]
M06$0I*C'W> 7F=X[LB*C%T&Z 8[,XY>^Q^SO,Q ZY?[6OVV\=.=6J U49",^
MPT\0O\8CDRNTN-1=#P/OZ. Q:'+_T_90IDJO!:\=3/QN[JE,3I2^J<6W.O<#
M!00$*J$<L!RN4 (ARDAB_#&>_G*D"KR?W]R_Z-QE+B?,H:3D=U>+-O?WOE=#
M@R]$O-#I*YA\$M\SR7^'*Q I5R3RC(H2KI]>=>&"]L9%HO3X?1Z[08^3\;^%
MN0-"$Q N ?+L1P&1"8BL #23Z50_8X&+C-')8_/'&K&Z$]M#)(M9J4U=._U.
M9LOE[K78/T49NBHCHWF>->%*$Z\UI4N3+!HD&1:0T D2:H-H99"Z#2*G0:0-
MXI7!SLIDUB1:,VC-+ME;Z9;_$:U08B=*_!%EEUHH'S5)^&21/-:L0!(G2.*H
MR=X"<6ELD,>:%4CJ!$D=%4DLD%FSW=X5/MZ$%HD1!2N1C8+N;K_J1C\P.W<#
M]TY4R!])7_>&4@'2,-C(W%K9 )<%@4:HZ4[.V=P&YH6@H^EP:&FSQ3]02P,$
M%     @  HB#3G=)>!F$VP  'CH# !0   !X;"]S:&%R9613=')I;F=S+GAM
M;.R]>V\D1W8G^O?&ITAX)2^Y2-;4^Z'V&F"WNL<]*ZD;:FD&AK%_)*N29$Y7
M598SJ\BF<3_\/<^($_DHLJ49WXN% 7O$)C,CXW'BO,_O_%-='Y/3OOCW4_ZF
M/.V/_^L?5L/A/R1?=MM]_;_^X?YX/'SWAS_4Z_M\E]6#\I#OX2^W9;7+CO#/
MZNX/]:'*LTU]G^?'W?8/X^%P_H==5NS_X9__J2[^^9^.__Q]N3[M\OTQR?:;
MY.W^6!R?DO=['J$H]__TA^,__],?\%%^?#1.?BSWQ_L:GMWDF^:?O\_7@V0R
M2I/Q<+2L[[,JKUN/V _F_,$B?##YM^RF/E;9^OA_>M_\Y>F0-_\X'EZ]:_[N
M&I[>T!OOMME=\Z^WV;9N#>._\3&OBA)W9)-\GQW;S\E"W7_[;[C4WF'>%?4Z
MVR;_FF=5\@Y^V=J.E[PM<^E\_]V_-G_S2Y5MBOU=\NEI=U-NFW_]\>=?/S5_
M)\?^<WY7X-;#AW_*=JTE_YA7ISKY:?#G0<_[;V#*%4SW/5#&E^1_YT_-YX;#
MX6@^&TU&H^9?WIRJJKE=?5M_=34:7TU:0\@D_I)OMU>?]^7C/OF49W6YSS?)
M^[H^Y57SA9_*OG7(9'[.#V5UI*T\9L?VUO]KF[AEA#^76[BJ6?4$"]KF5=]C
M],?D#:SQKJQ:NW6]7N?P=_CKAI_L&>73/2PY>5/N#MF^-8@\\W:75W>XDC]6
MY>/QON_I8W5J;;>.\"4!PMK7!5U2ILB^_2MW.WCFT[%<?TYA>L@%D@^G8WV$
M*P^3:!U^N:_+;;&AE>)6YT3\Y2TL>Y_MUP5>@5*^?)6\_?7GY.(?__MR,I^^
MNDSD!V AR2_WY:F&3[19CN5*Y_ZX:/[QWT8M+O13N;]:"X5D=9T?6Y_[6 $?
MKHY/:7+89LKH_OU4''!9:;+/C\TWW@.Q[.^*FVTN0W8^9;]<[!_R^H@#MC[_
MX7@/5-4]M3=G)XZ<(Z?IEC1&E:_SXB&#:?4.=&8>;[+ZG@9;XP^X 0_9MNO!
M7\HCG'#WE(AZ[LOM!F[1_Z!!CBVJI>N]H4\=LF)S!:2PS@X%#-HY6@(2<5><
M=DFV7J-$[;AWI]UI2]2X+>N>Z=8OF)@]L&V1W11;H.$.B9C?YO#0!O;[(=^W
M;^";YX?@DSMD3YV']4OV!6X@[D]=TFVJ<Y@67M4S0S(9F0=H -BSZ@2"LWM3
MSLVP=]=HW#-O?LKSY*?RF"?3!+2$9),?LV);PV;=914).I@H_*OVC".#J>(O
M3EMB(EFROH?;E2.+D"/'MP[ <M9/+5G6SXS@6M\6\%.5_ !40;-&-@KKR8$M
M/N3\Z]_+G^:M<SB@#, 9YU] O:OA(&ZK<I=4L M5F3'=5SG3Z\VI+O8Y3*-?
MB_JYF\A^SFL0NFN^L1MX9EL2OTK69=V^EC]F^^PN]VI<MMD5>](=B$=WOL+T
MI&OH)H^RM=;^W> #;JE#)#'PK-=E6X71O^($N^?7_9[]6W(A<[OLV$(DN9L<
MR#1/CMF73@WZ/8\"?]9%]HR3W1[AHWW#\)36$0%V3_[M%Z'_37$+C":'#1 2
M0EVOWO*9 8'CM(N[O9X"7(2>4^K]-%U0O(Z'3OV 7X]?1 [[S&NOL[I8)Q=$
MF,7V!'1^R:_!X\Q16F)[W"+[=]$G:ISP]@06#%Y,^'T-<_?*AF<E((=I?-@2
MV@^Y:T#HQ1JO6XTJ#EIGQSIYA*V%$Y51>7_O<YUQ8\(@H+;KDVP]\"M\4G2R
MY#&KB57)*ZKXP*_R#.XG+P"%6 TS1+EW4S[D@^0Z<+TTN:$M,SO6_#[^/[#?
M;/L5#/ -D1%-+A;+;YF/_Q;61R31(]!%B"?_MLMW-WGU?T2OU V,__C2,;:@
M9R37N'UR%_X6X[W^&X_WYNO'BU6;SBUK_O&%0_3MV.\9KF/#?L]P'?OUW'!-
M+:_WP==@%>_W*'%NLBU)CXN/H*@50-#;)V85&__R99(=$RO.9R\8#B1"!:8J
M_+3)^:?+9',"$5$FV>$ 6HKGT._?_?PI&<U^U^>>>^/G7-94=8FA!JM._I^D
M?S-^[\B_?5]^UY=?++6^9NUG!OG;+;/O(QW6PKX&W9!$VF-QO$_*QSUP<OR&
MD43?=?$LHB%XCIU[R078J2U%Z/W'#[T*'(B7!_B4K*AY;=N>$A8M8!H>MRAP
M\:'-%8BW'(V]IT[#4[=A#V+ZYL2KO'D2:5B;7\(.=RZ\[=?8G+E!+8W]_.,M
M'\/YQUO^BC/R&>WLVVWY^-NL$/,Z:2]!&4=2>>BTS:XW?SV)^8^WJ$4Q;[SE
M=9L55?*0;8&P06DH'F#DAY;>]NL>Z'];_ <J4**,YJJ]\M7ML)V AD!K8TT*
M;9$=.NW^HU-I)AD24T\OH?Z4'T4EA)O)ZNUE/U4W]N[B5)-J>6F4:34,UD&-
M>BRKS[C!/>Z*-[U/MC8:3/RO-?!ISC+/,SK_>U R4>4EWTJW9Z'K+[A]ZXXO
MG"6GYC:R=^G\.Q]/8+5F:!;#%3CCC@+S?9WGFVAD(H!==L2].C,TCWS,M]M\
M?02=&=@6>_C:2@6P*]'7B;N=<03V[C-[W=JQE=:.OF1WFCLJ1L[Y'8UW"I@^
M/L_\F1R3M!\J"SJ-_7?^,YU_CK_ 5A2;6'##\FI==%PQD+5(9Z+>G?]\//ZZ
MW&[!2*H"CP"ABM<XR>ZJ/.\ZC)]S90^P5'BU*A]A,>W=#1?46(5X2+V'!S3Q
M4*"%"!+I)8>!+Q8=&@(Y.5_H8'T+=O_Z2!<DL%,0')X5E5\Q6*];%ZQ.KVPB
M\7<J4V?>SM'OW/?>IQ.H0G14</U BJ]!KSE5=#/WZ&6E8?TF]LBA6ER E;6\
MB*5O"N ![<W_8P[: 46T>@.BO^1?CLG-%BFXW^<V&KB.H=Q/R'EH#:_%;^="
MD U('%V7VV(/&N#V"O1+%*2[W6E?7I4@CK;EW1/I>N@S$(<=;+V#$RA9NB8W
M17T V7A+KH!C<5-NGE#-J;)##AK0&O;\/L\V_W[**F0]R%/<KT=@/_?'E-0A
MH#UX>HO*PB#AF?WZ*46%56;W> ]7Z^D*E:B-JT\W=;$I,.H%*S(+@<TA904T
MFP_[/'F-7LO'#+CBFVQW4Q6;NSQU/X(9EZWO3ZCHP;Q^W1=>O:E)CQF/AZ]^
M'7P:T(^C5Y<#4&3R.G=KJPYUN7#('<R\%_7\)PPMYAB[=J!FD1[M52U6G8'Y
MV-GCB_':W05RE!RI+=\^\5;)#$6!]).TY\E^G759'4H.ZK'GR>YRRMHXNI-P
M :=C63VY.L^0!21R- .8 RJW^YP4>'[C)H>I$R,!WE83$Q+* #*CCV3U)OOW
MY(_;$O3,Y,>L^@Q\1?>5_ZB33I$=_)@]):-5ZE"_3<UVX$.CQ:LZV>9WM,W5
M:4U$?((MK9+O3\?U?;+-'G&UCMF+.,,R8'VH]N5^:C3S;;&CHU9%Y0F5+1[G
M.W>3U]ORF.^3AQRHNCS6,.(AV>7H9 4^\1D&R\"4.539YWQ;_/7S?5YLW*="
M', Y290T<JZ!.$_NZ"H211([B/T Y:T3;7FTF U&R:[8;L5+!V3=HAFB0QW>
M(3-!3@N6!=H?Q9[M.)C,J4IJT&?Q,F9&Z^1HFZI&#F>0!W\HZHMUGF-0)[D]
MT3XC$<$'.JZV6V-X=4,W)ML\D'0\WE?EZ>Z>.&8)=A>J(D!%PE0B/S^\[/P?
M0)1E6XGXX =!H<P_4\P%MPJH$DU3D&08M\.PVZFJ3SD<>+G;H?A&'=Y;K;CM
M_#1*O7/S'KC(B6G/;0?TN,_QR#8;TJ_@RT%\PA;7("! \7>X.;+U)(B\7CL
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M#H8FS'1A=*/W'S\$Y0W-FH-8::[!1]@["_<=F"ZNBU2+1S31X1\DR4ZDUZ'
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M_/A(T3P^>&O:;0)+]6&YV!>AL5'V9F,N*E5_"7VJYYJ6ZFR0[8G3DW/>K%;
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M*26QDDJ^F4UCC'_/>ECB+YVV;+O/K;Q\S*R6R"J%W&0#V.C1NYJ3I>T@O.8
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MKI_"7DQ6UXV4W^1B-(>E+/GD%T,X^=$,?EC@T7_?8"4IY>]JK'@T&::C%;X
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M.QXL)_9W(_K=V#PW'LQ&]+NI_=U\_*T;#9;F=_"O^;=NB"/8WRV^Q>[K)H:
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MG2^6,)\E)5.-5I-T.)^>>5,M>(&Q;]U3]N22UZ#[:DK2757<41VN7+:"F7B
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MB(Z#447W9/'T79*WB+<XX?BVDH!2FU]RB'WE9#9M\N!?XE!'0A<X0B@8EE,
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MDJWAB2_)N#SR-9O#:!9(PZ,5@U8"M+!D[Q9":,EX<NV#.&I/.BQE>>9IKY1
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M]^+M]FOZ:S0."0"3@_:2!\/5B.W#NVEUA0=OYV^Q1'B=O3?#I<]N@XF">R8
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MG,I;^L.Q@$W1LJY(X\,@K)V'T$3(4;S#*/*5O,P'@J#&$!*AA8^0Q)=MH\6
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M(*ZWBLO[G QL*K"PU0[%4Z)7B)J, \ELG$NP*0V?]BU7H?0J?T#0)LU1^+I
MDP=D%I,GYN5XC->9P61"<')%(Z'X,]1WE% ^I, ^9<%-,3O3?-ARZ0/G[CPX
M$"7<7Q-X9#BKS+_5B_7^U@-4&L+A755P T+5[V5I%-,1O#7&1("I8*(Q]%1
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M!&MZ"NG'C]0LMN#$5<38\K3\ZCD6D,3I&[*!),Q+1PH2^1I\7(AH*7QJD(2
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M_?WS;;WJ4"M?P11J;E?WSG.H1E;C5<!&4YGDR\WW^ /8DIO-]LNB^ .&BD*
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M2<?6X#4[HE7;RMC3H\L$(A8QBP]*\]_^&VA/#P[A?S;-_E__7U!+ P04
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M'F) UHO@DVH$A0P!9+@O2-=)%XI S@'D?%^0QTO1W!+("$!&>X,4=AD0R!A
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MX2U21Q;*7FOUV@;35SO%1!;*]K"<;;P6RI"%,F8+04ROR,B0A3)F"^W '"F
M,V2AC-E"XU.6VZ=.,9&%,F8+04S_H2,+9<P6PGV35I89_-D,LX7P#+"'B2R4
M,5L(8](".$<6RIDMA#%I 9PC"^7,%L*8"<5$%LKWNCHAI9C(0OD^EU=_RR@F
MLE#^2LNK+X;EU4_EQ6-Z3#&1A?)]+K+VYBQS9*&<V4(0T[-0CBR4<X_(/5\-
MOK,6RI&%\L%"T^%D^^%]Z<JJ1I;_NEM8M[\057%A@OY/?Z59&,7]+VL6754=
MNWWGS1<M^OW#-3:_\?_P'U!+ P04    "  "B(-.WL!BHN$"   M.@  &@
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MF0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @  8B#3IE<G",0!@
MG"<  !,              ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    "  !B(-.14>% (\"   <"@  &               @ 'X"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @  8B#3FPY4]9]!
M;10  !@              ( !O0L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    (  &(@TZ> SS-S@0  / 5   8              "  7 0
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  !B(-.@E3A
M*R8&  "@(0  &               @ %T%0  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @  8B#3B]P0%C !@  PR4  !@
M ( !T!L  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (  &(
M@TZ>C ^VM $  -,#   8              "  <8B  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    "  !B(-.$I=\!K0!  #3 P  &
M        @ &P)   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @  8B#3E]6OWNU 0  TP,  !@              ( !FB8  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (  &(@T[+WAN0M@$  -,#   8
M              "  84H  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    "  !B(-.+?>8%;0!  #3 P  &0              @ %Q*@  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (  &(@TX($.15M $
M -,#   9              "  5PL  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @  8B#3K4N7K&T 0  TP,  !D              ( !
M1RX  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  !B(-.
MWL0W[;4!  #3 P  &0              @ $R,   >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    (  &(@TY&ZAAHM0$  -,#   9
M      "  1XR  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @  8B#3H0,66:T 0  TP,  !D              ( !"C0  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  !B(-.E7CZ.+0!  #3 P
M&0              @ 'U-0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    (  &(@TXH1D#<M $  -,#   9              "  > W  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @  8B#3DOTI2>V
M 0  T0,  !D              ( !RSD  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    "  !B(-.[ALC#+4!  #3 P  &0
M@ &X.P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (  &(
M@TXWN9*=M@$  -,#   9              "  :0]  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @  8B#3JWS,S*T 0  TP,  !D
M         ( !D3\  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    "  !B(-.IR]EL+4!  #3 P  &0              @ %\00  >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (  &(@TY/M#^4M0$  -,#
M   9              "  6A#  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @  8B#3H;RN5RU 0  TP,  !D              ( !5$4
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  !B(-.DLQT
MP;<!  #3 P  &0              @ % 1P  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    (  &(@TY*!>==M $  -,#   9
M  "  2Y)  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
M 8B#3CI'>]VU 0  TP,  !D              ( !&4L  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    "  !B(-._)2Z'',"   -"0  &0
M            @ $%30  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    (  &(@T[6(=^TLP$  -,#   9              "  :]/  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @  8B#3M)X$!6W 0
MTP,  !D              ( !F5$  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    "  !B(-.V T1&K@!  #3 P  &0              @ &'
M4P  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (  &(@T[%
M!BG[N0$  -,#   9              "  795  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @  8B#3G=N?:JW 0  TP,  !D
M     ( !9E<  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  &(@T[HAKI7T@$  )T$   9              "
M 4QA  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @  8B#
M3KPG1-/" 0  . 0  !D              ( !56,  'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    "  !B(-.6G"5[;D!  #3 P  &0
M        @ %.90  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   (  &(@TXX5+_'MP$  -,#   9              "  3YG  !X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @  8B#3EH;YWSK 0  9P4
M !D              ( !+&D  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    "  !B(-.ZIPC[M\!   "!0  &0              @ %.:P
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (  &(@TY[ZV<
MN $  -,#   9              "  61M  !X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @  8B#3@D#!PS7!0  (!T  !D
M ( !4V\  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  !
MB(-.*QQ(H54"  !K!P  &0              @ %A=0  >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (  &(@TYFO#8]0@(  ,L'   9
M          "  >UW  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#
M%     @  8B#3ON-T)!' @  8P@  !D              ( !9GH  'AL+W=O
M<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  !B(-.0&->C)T#  "V
M#P  &0              @ 'D?   >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM
M;%!+ 0(4 Q0    (  &(@TXT^MT4!P,  *<+   9              "  ;B
M  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @  8B#3NES
M#ZGK @  <@L  !D              ( !]H,  'AL+W=O<FMS:&5E=',O<VAE
M970U,2YX;6Q02P$"% ,4    "  !B(-.HL)O<!P%  !4'0  &0
M    @ $8AP  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (
M  &(@TXX2BGSD@(  !X)   9              "  6N,  !X;"]W;W)K<VAE
M971S+W-H965T-3,N>&UL4$L! A0#%     @  8B#3N]5"N,  @  J04  !D
M             ( !-(\  'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"
M% ,4    "  !B(-.WJE=PX4#  #'$   &0              @ %KD0  >&PO
M=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (  &(@T[>:(U5X@(
M #,+   9              "  2>5  !X;"]W;W)K<VAE971S+W-H965T-38N
M>&UL4$L! A0#%     @  8B#3F3</3=< @  8@<  !D              ( !
M0)@  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  !B(-.
MTD7D,9("  "["   &0              @ '3F@  >&PO=V]R:W-H965T<R]S
M:&5E=#4X+GAM;%!+ 0(4 Q0    (  &(@T[CJ,SDF0(  . (   9
M      "  9R=  !X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%
M  @  8B#3N+:^4U1 @  \08  !D              ( !;*   'AL+W=O<FMS
M:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    "  !B(-.S0N7'.$%  "C'P
M&0              @ 'TH@  >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+
M 0(4 Q0    (  &(@TZDR*VZ504  & ;   9              "  0RI  !X
M;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @  8B#3IQ]I4*/
M @  ^P@  !D              ( !F*X  'AL+W=O<FMS:&5E=',O<VAE970V
M,RYX;6Q02P$"% ,4    "  !B(-.)'U]K2($  #L%0  &0
M@ %>L0  >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (  &(
M@TX@BGT[9P0  ($7   9              "  ;>U  !X;"]W;W)K<VAE971S
M+W-H965T-C4N>&UL4$L! A0#%     @  8B#3EA3""Q_ P  -0X  !D
M         ( !5;H  'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4
M    "  !B(-.*UEW]$$"  !#!P  &0              @ $+O@  >&PO=V]R
M:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (  &(@TZ_IB,JJP(  *,)
M   9              "  8/   !X;"]W;W)K<VAE971S+W-H965T-C@N>&UL
M4$L! A0#%     @  8B#3A]C&>[H @  4 L  !D              ( !9<,
M 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    "  !B(-.8X;?
M=$<$  !C%@  &0              @ &$Q@  >&PO=V]R:W-H965T<R]S:&5E
M=#<P+GAM;%!+ 0(4 Q0    (  &(@TY]S_,KTP,  * 2   9
M  "  0++  !X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @
M 8B#3I0O%&)5 P  E T  !D              ( !#,\  'AL+W=O<FMS:&5E
M=',O<VAE970W,BYX;6Q02P$"% ,4    "  !B(-.R+M"Y5$"  #Q!@  &0
M            @ &8T@  >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4
M Q0    (  &(@T[W:H167 (  )X'   9              "  2#5  !X;"]W
M;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @  8B#3B=PJGFN @
M, D  !D              ( !L]<  'AL+W=O<FMS:&5E=',O<VAE970W-2YX
M;6Q02P$"% ,4    "  !B(-..\CR6[P"  "T"0  &0              @ &8
MV@  >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    (  &(@TZY
MY/].=@(  ( (   9              "  8O=  !X;"]W;W)K<VAE971S+W-H
M965T-S<N>&UL4$L! A0#%     @  8B#3L?BKY8: @  \P8  !D
M     ( !..   'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  &(@T[(V48TO0(  $<)   9              "
M 1KN  !X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @  8B#
M3L'V-F+2 0  X 0  !D              ( !#O$  'AL+W=O<FMS:&5E=',O
M<VAE970X-"YX;6Q02P$"% ,4    "  !B(-.$\*+#,H!   W!   &0
M        @ $7\P  >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0
M   (  &(@TX"EP6]9 (  $$)   9              "  1CU  !X;"]W;W)K
M<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @  8B#3F)=>4KY P  <18
M !D              ( !L_<  'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q0
M2P$"% ,4    "  "B(-.RV44LK,"  !M"0  &0              @ 'C^P
M>&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    (  *(@T[]T!D'
MA@,  '(/   9              "  <W^  !X;"]W;W)K<VAE971S+W-H965T
M.#DN>&UL4$L! A0#%     @  HB#3M9/[E$7 @  T@4  !D
M ( !B@(! 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6Q02P$"% ,4    "  "
MB(-."OK#*@,#  !%#   &0              @ '8! $ >&PO=V]R:W-H965T
M<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    (  *(@T[Y"X@+D0(  %H(   9
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M970Y-BYX;6Q02P$"% ,4    "  "B(-.Z<NV:]\!   K!0  &0
M    @ %B' $ >&PO=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4 Q0    (
M  *(@TY*(/X([P$  '(%   9              "  7@> 0!X;"]W;W)K<VAE
M971S+W-H965T.3@N>&UL4$L! A0#%     @  HB#3G=)>!F$VP  'CH# !0
M             ( !GB ! 'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%
M  @  HB#3@6VIJ&* @  0@\   T              ( !5/P! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    "  "B(-.&DH1@;0&  !G0   #P
M@ $)_P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @  HB#3M[ 8J+A @
M+3H  !H              ( !Z@4" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @  HB#3E&CJR59 @  .#@  !,              ( !
M PD" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     &L :P!?'0  C0L"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>389</ContextCount>
  <ElementCount>372</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>116</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Consolidated Statement of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000</Role>
      <ShortName>Consolidated Statement of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Consolidated Statement of Profit or Loss and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000</Role>
      <ShortName>Consolidated Statement of Profit or Loss and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Consolidated Statement of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/StatementOfChangesInEquity-610000</Role>
      <ShortName>Consolidated Statement of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Consolidated Statement of Cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000</Role>
      <ShortName>Consolidated Statement of Cash flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Disclosure - General Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</Role>
      <ShortName>General Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Recently Issued or Adopted International Financial Reporting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory</Role>
      <ShortName>Recently Issued or Adopted International Financial Reporting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatory</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatory</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Taxation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIncomeTaxExplanatory</Role>
      <ShortName>Taxation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Trade and Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory</Role>
      <ShortName>Trade and Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Other Liabilities and Accruals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory</Role>
      <ShortName>Other Liabilities and Accruals</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Deferred Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory</Role>
      <ShortName>Deferred Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Total Operating Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory</Role>
      <ShortName>Total Operating Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Other Income (Expense)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatory</Role>
      <ShortName>Other Income (Expense)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatory</Role>
      <ShortName>Loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatory</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Board Compensation and Key Management Personnel</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory</Role>
      <ShortName>Board Compensation and Key Management Personnel</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Related party disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRelatedPartyExplanatory</Role>
      <ShortName>Related party disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatory</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Recently Issued or Adopted International Financial Reporting Standards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables</Role>
      <ShortName>Recently Issued or Adopted International Financial Reporting Standards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatoryTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatory</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatoryTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatory</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Trade and Other Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables</Role>
      <ShortName>Trade and Other Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Other Liabilities and Accruals (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables</Role>
      <ShortName>Other Liabilities and Accruals (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Deferred Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables</Role>
      <ShortName>Deferred Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>139 - Disclosure - Total Operating Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables</Role>
      <ShortName>Total Operating Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140 - Disclosure - Employee Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables</Role>
      <ShortName>Employee Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>141 - Disclosure - Other Income (Expense) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatoryTables</Role>
      <ShortName>Other Income (Expense) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatory</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>142 - Disclosure - Loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatoryTables</Role>
      <ShortName>Loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatory</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>143 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatoryTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatory</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>144 - Disclosure - Board Compensation and Key Management Personnel (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatoryTables</Role>
      <ShortName>Board Compensation and Key Management Personnel (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfBoardCompensationAndKeyManagementPersonnelExplanatory</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>145 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatoryTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingenciesExplanatory</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>146 - Disclosure - General Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureGeneralInformationAdditionalInformation</Role>
      <ShortName>General Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>147 - Disclosure - Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation</Role>
      <ShortName>Basis of Presentation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>148 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>149 - Disclosure - Recently Issued International Financial Reporting Standards - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation</Role>
      <ShortName>Recently Issued International Financial Reporting Standards - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>150 - Disclosure - Recently Issued International Financial Reporting Standards - Consolidated Statements of Profit or Loss and Comprehensive Loss (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss</Role>
      <ShortName>Recently Issued International Financial Reporting Standards - Consolidated Statements of Profit or Loss and Comprehensive Loss (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>151 - Disclosure - Recently Issued International Financial Reporting Standards - Consolidated Statements of Financial Positions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfFinancialPositions</Role>
      <ShortName>Recently Issued International Financial Reporting Standards - Consolidated Statements of Financial Positions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>152 - Disclosure - Recently Issued International Financial Reporting Standards - Consolidated Statements of Cash Flows (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Recently Issued International Financial Reporting Standards - Consolidated Statements of Cash Flows (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>153 - Disclosure - Property, Plant and Equipment - Schedule of Changes in Property, Plant and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfChangesInPropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment - Schedule of Changes in Property, Plant and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>154 - Disclosure - Intangible Assets - Summary of Movements of Intellectual Property Right (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureIntangibleAssetsSummaryOfMovementsOfIntellectualPropertyRight</Role>
      <ShortName>Intangible Assets - Summary of Movements of Intellectual Property Right (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>155 - Disclosure - Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation</Role>
      <ShortName>Intangible Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>156 - Disclosure - Taxation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureTaxationAdditionalInformation</Role>
      <ShortName>Taxation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>157 - Disclosure - Investments - Summary of Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments</Role>
      <ShortName>Investments - Summary of Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>158 - Disclosure - Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureInvestmentsAdditionalInformation</Role>
      <ShortName>Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>159 - Disclosure - Trade and Other Receivables - Summary of Trade and Other Receivables Due Within 1 Year (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year</Role>
      <ShortName>Trade and Other Receivables - Summary of Trade and Other Receivables Due Within 1 Year (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>160 - Disclosure - Other Liabilities and Accruals - Summary of Short-term and Payable Within 1 Year (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureOtherLiabilitiesAndAccrualsSummaryOfShorttermAndPayableWithin1Year</Role>
      <ShortName>Other Liabilities and Accruals - Summary of Short-term and Payable Within 1 Year (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>161 - Disclosure - Deferred Revenue - Summary of Deferred Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenue</Role>
      <ShortName>Deferred Revenue - Summary of Deferred Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>162 - Disclosure - Deferred Revenue - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation</Role>
      <ShortName>Deferred Revenue - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>163 - Disclosure - Shareholders' Equity - Additional Information - Equity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationEquity</Role>
      <ShortName>Shareholders' Equity - Additional Information - Equity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>164 - Disclosure - Shareholders' Equity - Summary of Reconciliation of Common Shares Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfCommonSharesOutstanding</Role>
      <ShortName>Shareholders' Equity - Summary of Reconciliation of Common Shares Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>165 - Disclosure - Shareholders' Equity - Additional Information - Share Based Payment Arrangements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationShareBasedPaymentArrangements</Role>
      <ShortName>Shareholders' Equity - Additional Information - Share Based Payment Arrangements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>166 - Disclosure - Shareholders' Equity - Summary of Inputs Used in the Measurement of the Fair Values and the Related Fair Values at the Grant Dates (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates</Role>
      <ShortName>Shareholders' Equity - Summary of Inputs Used in the Measurement of the Fair Values and the Related Fair Values at the Grant Dates (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>167 - Disclosure - Shareholders' Equity - Summary of Reconciliation of Outstanding Share Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions</Role>
      <ShortName>Shareholders' Equity - Summary of Reconciliation of Outstanding Share Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>168 - Disclosure - Shareholders' Equity - Summary of Number of Share Options Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding</Role>
      <ShortName>Shareholders' Equity - Summary of Number of Share Options Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>169 - Disclosure - Shareholders' Equity - Summary of Reconciliation of RSU's (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs</Role>
      <ShortName>Shareholders' Equity - Summary of Reconciliation of RSU's (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>170 - Disclosure - Revenue - Summary of Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureRevenueSummaryOfRevenue</Role>
      <ShortName>Revenue - Summary of Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>171 - Disclosure - Revenue - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureRevenueAdditionalInformation</Role>
      <ShortName>Revenue - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>172 - Disclosure - Revenue - Disclosure Of Changes In Trade Receivables Contract Assets And Contract Liabilities Explanatory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory</Role>
      <ShortName>Revenue - Disclosure Of Changes In Trade Receivables Contract Assets And Contract Liabilities Explanatory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>173 - Disclosure - Total Operating Expenses - Summary of Total Operating Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses</Role>
      <ShortName>Total Operating Expenses - Summary of Total Operating Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>174 - Disclosure - Total Operating Expenses - Breakdown of Other Research and Development Costs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts</Role>
      <ShortName>Total Operating Expenses - Breakdown of Other Research and Development Costs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>175 - Disclosure - Total Operating Expenses - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesAdditionalInformation</Role>
      <ShortName>Total Operating Expenses - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>176 - Disclosure - Total Operating Expenses - Operating Expenses by Nature (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesOperatingExpensesByNature</Role>
      <ShortName>Total Operating Expenses - Operating Expenses by Nature (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>177 - Disclosure - Employee Benefits - Disclosure of Detailed Information About Employee Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits</Role>
      <ShortName>Employee Benefits - Disclosure of Detailed Information About Employee Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>178 - Disclosure - Employee Benefits - Schedule of Share-based Compensation Expenses Recognized as Employee Benefit Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses</Role>
      <ShortName>Employee Benefits - Schedule of Share-based Compensation Expenses Recognized as Employee Benefit Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>179 - Disclosure - Employee Benefits - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation</Role>
      <ShortName>Employee Benefits - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>180 - Disclosure - Other Income (Expense) - Summary of Other Income (Expense) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureOtherIncomeExpenseSummaryOfOtherIncomeExpense</Role>
      <ShortName>Other Income (Expense) - Summary of Other Income (Expense) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatoryTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>181 - Disclosure - Other Income (Expense) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureOtherIncomeExpenseAdditionalInformation</Role>
      <ShortName>Other Income (Expense) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherIncomeExpenseExplanatoryTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>182 - Disclosure - Loss per Share - Summary of Basic and Diluted Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureLossPerShareSummaryOfBasicAndDilutedLossPerShare</Role>
      <ShortName>Loss per Share - Summary of Basic and Diluted Loss per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>183 - Disclosure - Loss per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureLossPerShareAdditionalInformation</Role>
      <ShortName>Loss per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>184 - Disclosure - Financial Instrument - Summary of Maximum Credit Exposure (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfMaximumCreditExposure</Role>
      <ShortName>Financial Instrument - Summary of Maximum Credit Exposure (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>185 - Disclosure - Financial Instrument - Summary of Aging of Trade and Unbilled Receivables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfAgingOfTradeAndUnbilledReceivables</Role>
      <ShortName>Financial Instrument - Summary of Aging of Trade and Unbilled Receivables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>186 - Disclosure - Financial Instrument - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentAdditionalInformation</Role>
      <ShortName>Financial Instrument - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>187 - Disclosure - Financial Instruments - Summary of Maturity Analysis For Nonderivative Financial Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfMaturityAnalysisForNonderivativeFinancialLiabilities</Role>
      <ShortName>Financial Instruments - Summary of Maturity Analysis For Nonderivative Financial Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>188 - Disclosure - Financial Instruments - Summary of Sensitivity Analysis for Change in Primary Currency Exposure (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfSensitivityAnalysisForChangeInPrimaryCurrencyExposure</Role>
      <ShortName>Financial Instruments - Summary of Sensitivity Analysis for Change in Primary Currency Exposure (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>189 - Disclosure - Financial Instrument - Summary of Interest Bearing Financial Instruments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureFinancialInstrumentSummaryOfInterestBearingFinancialInstruments</Role>
      <ShortName>Financial Instrument - Summary of Interest Bearing Financial Instruments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>190 - Disclosure - Board Compensation and Key Management Personnel - Summary on Charge to the Profit and Loss Statement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatement</Role>
      <ShortName>Board Compensation and Key Management Personnel - Summary on Charge to the Profit and Loss Statement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>191 - Disclosure - Board Compensation and Key Management Personnel - Summary on Charge to the Profit and Loss Statement (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOnChargeToTheProfitAndLossStatementParenthetical</Role>
      <ShortName>Board Compensation and Key Management Personnel - Summary on Charge to the Profit and Loss Statement (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>192 - Disclosure - Board Compensation and Key Management Personnel - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelAdditionalInformation</Role>
      <ShortName>Board Compensation and Key Management Personnel - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>193 - Disclosure - Board Compensation and Key Management Personnel - Summary of Related Party (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfRelatedParty</Role>
      <ShortName>Board Compensation and Key Management Personnel - Summary of Related Party (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>194 - Disclosure - Board Compensation and Key Management Personnel - Summary of Consolidated Statement of Profit and Loss for the Remuneration of the (Former) Members of the Supervisory Board (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfConsolidatedStatementOfProfitAndLossForTheRemunerationOfTheFormerMembersOfTheSupervisoryBoard</Role>
      <ShortName>Board Compensation and Key Management Personnel - Summary of Consolidated Statement of Profit and Loss for the Remuneration of the (Former) Members of the Supervisory Board (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>195 - Disclosure - Board Compensation and Key Management Personnel - Summary of Average Exercise Price Per Share Held by the Members of the Supervisory Board (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureBoardCompensationAndKeyManagementPersonnelSummaryOfAverageExercisePricePerShareHeldByTheMembersOfTheSupervisoryBoard</Role>
      <ShortName>Board Compensation and Key Management Personnel - Summary of Average Exercise Price Per Share Held by the Members of the Supervisory Board (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>196 - Disclosure - Related Party Disclosures - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureRelatedPartyDisclosuresAdditionalInformation</Role>
      <ShortName>Related Party Disclosures - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>197 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>198 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Lease (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderLease</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Lease (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="mrus-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>199 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mrus-20181231.xml</File>
    <File>mrus-20181231.xsd</File>
    <File>mrus-20181231_cal.xml</File>
    <File>mrus-20181231_def.xml</File>
    <File>mrus-20181231_lab.xml</File>
    <File>mrus-20181231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.ifrs.org/taxonomy/2018-03-16/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>126
<FILENAME>0001193125-19-096700-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-19-096700-xbrl.zip
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M^-;!<"2ZY?2<V.[9>T6E>8:5=D]OES'@8+5 *?%XDHO> TC?CE@0$D=SN8%
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M@L,+VD8!+D>26&3W3*JK88*S8T/T4])>X?]U,,'9H9<5!9PZ>U<4'#>FBNL
M[-BI&?N,J0(KSO7LD&B<8/S%"CGX9HZNF:[NNZ;M!3J)JC%5U-QOUMY))J8\
M!_C) =4/F9CR-D\>P1T5[XHWWR4X243,(3K;78^80S<6;/J18=2A,1YD%T1G
MJ>'E4]3PTH^&@\ZF8_5\L'%%O ?-UCL*--/TN4TCIOG,Q=2)'VF.H8/=2P+F
MD##T?3- ZP3]"L>R]6[?P_#</*6EW/D\!TIN3,X2J17U[N%!XJ,@]FV?19[M
M:C3PX49!^&J>8X(P9B$'N@U\SP';]"/'3!'MU6+O"=@6Q%P(])&739%;N=7+
MDST/WE%C08\"S3;TT'4-6[,Y =!L -+U'4LS#"MR/6ZYD1LJGX/:_5J!W4-
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MNL ?!N$VX1T^/"ZSI_V7I_114#WI68FM,SWPB(%D37R-!9:E.<RWM%"WJ,[
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M]YTZ/:!W0=&'V05<K+.\N$X0<5UDGW(;9^Y+G-]7GU( ?W'=(9Q&D=HSAV]
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M>F_MRLZ55^D*-T7]DL1%HN+'A1+6OV,5-UK+Z!0NE_C2F\<DC]? N.+SDZ(
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MI#(7>OTJ<<'$9-%GS)(QT(V0'BIF>_5RU, (M&U1VIT5/PZF\7+TZC&!&[U
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MB>&ZLVY&ZUEH]O5HK\J=&.F!=<-')X!QG.^EO.%K0==()6B(5!K\YWD';!2
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MFE]\XBJ!A-LS+#56:Q]@FDR:%O,,_"#4X6_S9'[U%XN#&AAO<N<."%H6ZF3
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M#X!P.VJV]=Y/C[*N"W$DPD3<V.!(/B>$NQE+'R/.)\/>01IM/#;1K6<WM(K
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M,!2.HEY>)K?KYF.H3NGX!Y']C]#]W0G"7+W?E!*Y[_B@PY@)^21]Y-JQQ(Q
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MM505=V(X:5Z7A*@!5RN!/5FP6_1F;XK\I^QM7H*/^/?F=T0G6DL5U*,0&IW
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M0YQWRK,7V2.&BU]'[][/B/FJ%?M6P(D4HU^MS!.1?G]3K+.')&]DA]HU7/A
M>!@QVY5<LP_8,H!)U$6<+^KJ\$S$/>?M'YF7/X+'4L.S;^7Z(_6QJB0-/U_.
MIYAGCZ*N2&JG\K?$0T1=8%S,EJ(.%CM3@5TQH?M*RF&0JBHMU)SKV)H-\5VS
M8ON"@RL&-_<5@XA0EUN3PD,LUV"LQ,!IU?(@3-J'%/.A6)13J,6W^>=TCJB2
MT?3L=BV[@G 6-B;7X$T,OM=;T<LQUNID@R7U\$,X0 V+CA<B9U8F)IHIC3KR
M?S-[6ZX%V8B^$WF-=WF2E-,ZQ7E^@J?\D/ZYAG/S"+2[PL:E59[<PG>%XB[/
M?)LD!5!MVOQ&M7]$)F&;YRE1@1D&++3OM0V\4N<0@PR2].'3)B\2E5 69*LP
M@T4]N9@6@J5_X@2#1Y"%?V(?B:K]D4F5,K-8/J]A9;V"'[[#3"96J_0R+@\I
M5H)F*P0;W_PA_=SXW3Q[BI<BT0(_B,4_Y2UA!%8LW!67=*&%Z;+AJ!13G1KE
M:B-WKD16O8-;B1 T5C_)E??5DOK;+L$+N[2D=YRFO.J4[+?&D96=&IV*@,Z,
M,35)+)%=NM\U6MIE4R%V\/5^_::5[JOA$T=00KE:52B;BCXG6K%.'E6K5Z/+
M:=-$W$_('RC!5,5,74;=E"(_%'^N\[DE!G\6S-4DU.&'*.Z0+4_USG/U]>;W
MRV*SUM>;\ZL?\Q0E<\U5D@WD]KLX%?M.1;N78.O6??S<(6Y56UC_T'=_ZO]4
M676W!81&KE^@Z6<EM'YH<5%[U&B+('\0&W+_W"03U$GP]$(L5A75^,,_?J&"
M4*SX6\C=Z2I9WU' '3W= :WJ#2W*SKDM[-9%K?(O^PU40O+O>$Z>J')G^/:6
M:VPSEP*K:+!C-:9*CO6K-QIOHXMZIW+%E,T)=RAYD_5/;=749"W5?".'CE;S
MHA"X!FR(#CF8/9.B+?NRDEOK5=&_N(J>1UX:2'D2+U*Q_:K.LBER+X_Q2BF%
M[C&'5/AW?RIO03P%.>E6E5MUSMW]%5G4WJCB:57O">@E$.KY/=J0-F1-':DH
M%Q#50:+A234NS5KBI5Q!K3[6;E9%QRW^(YG]QV9QIRR^3UCY-T"S39M($6F+
M-(<^A?O.!;@5@%69LB PJ2<Z,G@CYO[+40K%??IX@\Q8@E3+PBTDN:T/L;MC
MY-5W?VJ(UT:W31ONYG7*^@6YK.6V*N598 ?U2C)N'R.=[U<?KHU598YB8W('
M$:_J!HBVQJT&IB\!/FED59N^YVD^WSS(6LW&P)V&57\SB^#36=[JN$SE7C<\
M8DLW*?M2_9ZL3'F%$T8W^),;V0]7CKY3]E994R6050[(JK;<Y>L5J-390.!-
MZ/BR^ 5 :?\*6A6XL:LJ=RG[OF6S!?CS\Z342Z(]$6U#54F9W.5ES396HI;4
M)=E>O%2V\PAI Z:/LBXJ3FRR>M]HN9PKU%/D:='H)F@ 4G.+, AK$5[/A91H
M^9R($*6H<!-/+$OCJLY)X;K.!1^42KZI^ULC3AN#?04=5B;(<ZI%M!I72A'(
M,'E<ESL(&P*L*MM7O>3"Y5V"#NL 43+"5L'1F.;0%[NBNPX^C!=>S;%.YTEC
M1>*PR"BR9:MN4PZ@$H0NE%*MDCKC#>1$9YP>66P>'ANS%Y4@AT>4,EO@5E48
M[D1"Z<E*'[CD[&:D&KN3L/P2I&C=AE]R;[.>34!0N5L@[7!3Y:NV[Z<F5XG1
M V A9:M5HAR_5](M3.9Q(5?;"B+"'\U$ 8&HX7Q(U^7,2:E&VQ=:-;TH7^U5
M8Z@TGC1;9G?BM.4TA\9G%02M7JY+EUOB/\84[__^J G/7IRV*MS_13KVW_VI
MBA=<MF;SM<1W&6\HNYJ&APP 9Z!OB7K_4:TDE*928S.HK'>OU&?;EM@F0YIV
M>,75#4WXG#/]W4!G5@E29?F6+V KI-(0>?5QU(NE]5<JIH8Y6&U%*=LDNZ9P
M'6<2,WC+/YI+8K-UVP3Y!&XO-E_41O%88ZD2.DW)(CL%%*^!4;#)D]I.P5U*
MV)8_+%&;_<P-:W',5S%2JIS#LIT!*.\[42TDEKX^BATT>*6IG*@GVK&J3TK
MQ&@_$!<H&)46$V)#YBJD+,GN<JR2%U*J7+,FO%=)##*BU8@&EQ;;SO.W':W:
M",5#J40)PG);_WZG'5V5\I9P59N 7ZD!#*4=7V9=\%&-DTB+?QDWI&M315]8
MU/U:!>,N*Z3<LI%%V1;53)N&B%"5FN4&Q+%2&GN':X.X+:NK6&2U\KEKU/2=
M?T$X%=K4^*C*>*\*,@1U"\<$#8SY?2+-MKK_8-V8Q2$DJH*LE(Z#L:':0GP
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M(C8K#BEW"L6M>+EP>LLUI$&W#(O[HE I+$EB7!?ANA>I!CY*4&Z@B;B#0@M
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MQ&%X' E\[[@B3C>. ;P46RMV3Z 5P73X,$7/CSS1]AO/0ZI!\C(4(WK9O?T
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M$Y8^CA+CUIT,46^;'9$&/,JUFQ&/9X:E]9Z">+%SHT1SAZ&GLVN;T5"EE]D
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M:@?;??E<5S2.Q28+7",O@"7WQN)WQ4X$SDDR^$N-_@,\ K@2WFW\/ -[0$K
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MUR:LX&!-= @[.\_81L3\"-ZYIS'%1,0AFWBXWWLXZ2")%!X#2R#P<)ZP^MS
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MQ.P^SKP6J%M( /M?VT_L<)Z=O55 G$[\JAKF'=/^J[@8*B;V?[D1&.WNV/:
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M+H6NVZT\?JIIPS.:+JSJX7#E^NBJ_8W9$3OSG<\SAGOV;^F'C_/?&"S&MM/
MH3/H7W;/+QHMRSIK=%O=46/4M=J-\TYWV+*NSD:C_OF3#1RF=GCK^HTXF+WG
M1")^X-?_/=T$PD;D_I>]M[*_3^RIZ\W?%ZZ#Q,]5@A@UIH#Q:3(U/#P,8V;/
ML3E&9"2^PRC; GZD?XK0TQU,3MZL: 1._0C6ZBN@P(M;4K;8ROZ:;7 -FN+5
M[&N69_>'/ZGUV(4"U+1<7?YAY7D6#W]%3>2R8N]A#8N]%U2F!7-"GMK,OF6-
MG 5"!HBQV:F5[WI99"A/,$;IG1 _>6P2O[>:K18:&L3U7*!M/W[?D#\^X_(@
MSX#;8?L&"(:*$I)>J&I;9F]0WJV[F#^WX<>7*=M5T(E1-:%\9/$#8YQ,;-\Q
M)NX]IY?]:^_>,:U6>?W.:Q-,K5A-Y23T>P!2E7C-KHCGA?A\>H772\G=$J]2
MT 3*=#T= VL1)E=RN/(()"C]G;*9VY;,SXI TY)I [;R+8AM;^^$4-?L#\M;
MS&I.L/9UZ_#KQKT^-6,%KP7;"QU13[DH-O4I/.V?<&V/>S6^W=GQ6<@N7;"^
MPVL[BB\2]CG\-)W9V-MO*WZ*UGG_\N*J?];HG_>N&MW6U:#QL0=_M0:#RU;_
MJG,QZFVCT>2R!N&I0RSE57>@/0/1W!K!Q(A#V^'*=.+?N)[''"-D8^;>(PHC
MX\&.7K&WX>8>T65M]1:;02UL?VF[O%KWG=MZ\[<*/_VL)E\O[<#_;'&YD5PI
M;[J6#3IXNN-::?LO7)W"C:5N0H+DN=%(C9U-L',0/0!?=<-U: "X']2WV947
M[_%<OOP9IW]P\0_K= .D]]T41_F5:M$J\/5GT+UJ"LZK3EWY@Y$6:LQ #36<
MA&&,SW"%*KI[X]';9@;.J-W?<+5#S,!IF^WA5F9;ZFE&RKVZ%O=IIU?H@%LK
MZ(/2F7!Z>IS&1XWQ41=E4TI$K;!IA>WH147],G/UW#.-D<7;]\SXU.8QI55Q
MJIW,/&NWN\-A9W39N!SU+AK=\\%E8WC>L1J#_FATT;/..A?GE[L.1?7ST?WG
M3E':0KS':K5^6AKAD5 ]PV16 BQ2XF 20EYB]IMK2DI:L;C,EG&F9N(N@IZ1
MLL%IN;"3Y3=W>P4,ZY)@[>?!O5[,=#>72 _K>MU/'W!@1$_G.N3I7/M!@R\(
MSNW-.*[MN3UJ%@A(<:-G;>T9S-7$L^H;*C[DQF!ZD)9Z"GL6&-[_+(SCZ *F
MIV31^WI*UIH74/>;JKM/7V-%JXU'VM!+C\"B4ZC3"*RCTACU?*N:7JLCSRT\
M)M&FAU<=D]FFAU?51@>O,VS::JLC;%6+MOW7./5DJGW41E_%R*O39*H#K1=+
MB42/G=H[F+7L..;0L9XIM=?!XWV[2L<1*M8#H[C/00^,JH\)66?8-B<VC97J
ML:(5QR,-'FO/0N6>A0.0;O6KI-73H#1>5MS$G153JJUE+Y(0^\K*T*S!? =,
MI^4S;DQZ]#R8SFQ_GE98PD)!:'CNF/D1O#YF86R[?J[N,JNZM'W'S ;L&#$+
MIV*T#OY5UF_:MR%C-(S'-&:VZV0A_;/S#^UF.P-MZGH>AICA@Q/&HB96B.)B
MH>U']IC20$2)YW@<)#XNCM%H="'ZO'R4[R.BE)&F<0;_ .^'+$J\.+_?L3US
M8R"X_[(UX+$C6&6A4A7!=.%_Q@ 6:E*TV2B&_^&3AX*),9'%Z_#^+)!@?5//
MG9NV+"+HT&E$G8&Q3;"L>0U">#O%2#DF@GO  0+#HMB=$B0,X JF[AA>G> I
MWMCX.NR&XV8*:$5Z\=@M+(3/R ]+O,W@OW$?DS"8XC_ &KA'?$PY985<FKEK
MQ/]#/SU1XO_,:5A?V#WSD^W,N^I=##^V.IU>XVS4_=CH#EO#QJAGM1KML\''
M]M ZLWIG'Y<5[Q]Q(;W5V=]*>D%.!?CK7#\O(#;<"/N&![<^<3,[YNQCBAP2
MB^<?[MSQ78[YL<<9,!!@.0'R!0:B(G9C3W!3XN3(<2? 4N"N X^9NL@Z;H/
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MUXO, QD,_X+@#W0VG\=QD",2) <ZGI,W1?["7#P2X*5X6<2P'-$[I^P4B9(
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M46.2>-[["S<:>T&4A.SSY L'XO)QYMF^'0?A_%=XT_B'P]SW%\$XF3(_OB9
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M"S1,8/-H32V\W2IQ!C6-L[R+IL0YEK(MP2&*J.$G1V>"4R^G-Z[/'$ZZ=@&
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M2[(\R\E]Y#FYSRDTW1O =L9K-.5HRM&4HREG#<K1'MB56;)E(_N>10QUM9-
MK^QOV /YZ&S)MMGO=,Q6IX;YQ+NR/M)LZH.W/O))T0=J3>J\YU?9KC8GZZG:
M=4"#<H+DQF-UT^U>%S)M%M0=0_6%3--.W3%47\A>0RX>=YA2)/I0B[PZF9G[
M=E.W:?999GO0,_O]/3;[]A&C+U3X^\.!V1JL-7^T,NOM"-'2M89FM[>#H-X&
MG6D?\RP?_YYK/=M6;+?EPG%;;61;^3:RLO5K\+2#TC2P"Z%Q9SN&[2^TDS5<
MG_>(M?U;AJUEQ:M\P%5SU#'B(/<;#>LR3K'EW_OL*%8__@%!Z+]_\F$:J/4.
M>^'"RK91G+=DA&QJNS[N=1SX<6B/X\3V:((*0CYHBED5&73#9KO'?Y,@])O]
M(?_E77-GR,.FN2KV%C869;-=$8V($,>.:5<28=3-EYZ#123Z69HA#&@D-#_8
MT<(0N4YU.UW6[EBA6].XF1NW89#,:+MRH+N)6T$R2/L9'UO3XF'W93V+^];F
M/8L[U?6Q/>1/'W!KKI>W5[-:*_NKE<JTU]67JT1/F7ZS(7M; [:GT%-BK5Y\
M^GK]VQDL1ERP@4Q*!8X._Y\+;-L #+JQ5^P^N#W3==OM_2IHX5SYAG?=S+GR
M#>^^K?-./%YQ\"Q^LFUWU_]C<P,6 <5W"N@P9BR, M]GWG89Q5:BPU9W: XJ
M:J-40?1T,!B8W<Z15"U;9J?5-KO65K9;3:9531G"F><9 1B]8:9'[!TOZ Z[
M9OM8BL"[G;[9ZQY)1<D(F,!V&AWM4\;(.BQ#)];NCJIKL>W: J;Q42_ JE:'
M-K68]D$NY1.1#UX,5YN*JU-5]TWQT.E7&B,:(QHCFZL?NQMGK$3++WB+$O2^
MFY0 <!Y,9[8_3Z?[?OGZ9X0)$^@]_3WSGEY+[VGSA(?<>;2<VIWP\'4RG=JA
M^U\ 0UDVS1&P1A\B7#OW RQEX\!@-YX?6]1]U'Y9U+WWC$G!W>I"WQ5^NL*
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M('<CQ0.D;"2[+2?Y=I%99TQ^+/>,?*@T'I-6E',UTV@7F:YCN@=2R*NR7Q4
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MKPAJVFA#?,2 U% SDGQ@5 4?BP%%*N'CT3';R6P!0>L1;YT8R7M4L4CAS;(
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M*Q(*C2/;MAIE; /\YDE%Q73@AUXX),SD:J6-",Z:)2_XKHO -Z)W"+Q,JZ.
M%SZ09&=@H(NE2QW+[DD6J(NN:SGPJ\,TR#*\FA'Z$D=#0D8)ADD+90+*9GH
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MSP_WBZMI=138[ >2[ P,W!=UJ6/9/<E2=;WK6@[\ZJ#>!/-'7M@4FQ%8U0"
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M+ZXOA!'V+(SAVD2(QG#KTLY@]@7%L 0]N8^^)Q08'V 9IO#12TMD7N7-.0C
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M%Z3W972DE:AHA?+*49F#><:IFV0A[>,?A2"F\)\)B8NSVQWRJ>F87M55K6^
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M8*!DQ,[L$<OJ$;P[SP_!1\$*:YJ^D<.47TJ[O@/)\P;O0000"6//CX4)K8O
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M%.X%U)>^?.ZZ*H5[,4WYYY'_@'_^X^=)G"7OL#=6$"593*[&9?IO/S=1X=_
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M%TKYL0*X>V@D5#^)\!,:HL6ZZHP&^Z-;ZGVS<%M,P T/BX@;B[#3\-9=A <
MZ,YB9&KJ^7%QC,0B<#CI*,C0*<:K_-"+'X7OV(^$QDCA SR#!KB+XPB\IQ[4
MK0?D:_!6YH#S/F'A-1KQ3?V87ER #X]+X(5@(X51*B0@C/[8'WH88%P>B\NC
MI46<U#I,F&TIMC4^S: )5(BP.H1@\""]ST'%@$D![5P4JE1\811*,<G5/=Z
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MT AA>07*&>+SGRC^0Q1 >9,[%A!CADFEG]!P@7>,T<JEOD!(XW833*W*5P)
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M.E^T/C>AU<@<AYQX%6H>?A5ZP4;,;7YUBZ]4SM #VE0]H%NRE>K.=IW@,_>
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MFBGGFG[B#[.)_%?BP:)'4EV!ERJ_^"S$PWJ;R?.9J([7ZSF>QPR&!P.#>/8
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M0MIBH:-*O:YOXNBG2S5%/#6EP])MLY24COK1ZN@6NI9T:*2[Y="J1J;EBRG
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M;A9Y6V7(I<LP'[5*=-.<9KEI:V"<630YPB1P  ],&6ZX2; 3J/,?/:<5?II
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M;ODG'<Z>)/?HUGCWU^V#D!A*V\=DI0=DVK2W]]#O'_<:__UCAF5)P&:3L<W
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M,^8%V?/PHL42A>1;!%-:9#M>'ZMSLHX[9&OMC1Q,DT)TS=J6#158B990%/D
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MH%1[$OF?>0G*[6-506G*BB(?0*GIFL9L*/L9*!_A#(80HW"R>HY<["?'WG5
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MZ*,!BB+Z\JQ!UPG<59"4IZ1C39^D-7"=<'WSTXF28<Z^@B(_>8K\"3KN/.O
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M _/\LY%/5VF"P/;92,GOF6CG+JER*!M5E&Y<<P>O7WLY22&7'CP3T(J7E+X
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M;-FX)?A-WX1JF2?5$/:)T<*[O0S?<+;F5)C]'?&6(0O80MZ"&<#:)YH8$F>
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M@K8@D%<Z]PRO2+Q24E\I9 OE%=_5+35Y1N6OTWB]#@AFZG'IU(C-R"LAQ3J
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M:HHFY41LA1']JG5M9=7Q@5-V\?ZYUW*PZ=0VL'_N-=^0ON^CPNTQ.,4EX5Y
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M!D" N+K+B*9,7KAGTB&7I#T%UED$YTS269Y.TSC*BU$<XU*\V7*/V79A+/%
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M2K[A'_A;Q_R)9T*C[&Y:-Y8M-L\UR MV@_TUHI-2?$YXN=N;_+]*DM(DC3D
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MDP,N/;U *8[E^L0FZR.K/-NZYG[@21<Q(GM"M\ME[S8 E!-RKO5]KO4]4+H
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ML\_L[#,;E,],%:JOY"HRT-P'.07_%AMOSMA0=^E$YA+S-OAK\>6=S?5G<_V
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M".U:G"V#!![\A<.IJ&(9YZ?<7'^Y?W"6S',3>4_JKR^RS!#?E(.;6%$VI)+
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M.R_ :PJ^($-P_18?UOKJA9A1#I$?1.WN2.9-[;FFD%D25QRLUL5F(B(9H+S
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MR71:#0;CZ,#9PU[_9^VXJW1+S/Q>H 2.(@Z_KAMJ@TUV2I.-HFNP_:Z8_7H
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M-[#6@H*.*%B*E+X;RIA/FT2+]%U>\^(\P,N\-9F^FDR!/ZZ@/\;PP;V3K#,
MUF&DO1A7J%MAO60&,0Q+I!K:_*BC.5K3;DF7,][3=M\CX:D!E'$:9@?8NB)D
M'>:NT;@L>@Z>0D@MO<U>8/+XXD4_Q;'_-0A#,12*B3&#2R';I-KO\@BI0:FC
M:, QU@(RI 8\YWIL@>\4 6D#>FQ #*!<"@H=N!</K75,4-_X(H3Y]@MFT-VR
M0F:/1'E67M5LZQO&+$'K. ?;N!1ST #Z.II?!\Y80;$.4=V+W(7PQ7_=#-JX
M-LD<RKA>'&&O;[>'%6A4&8 V-H<&P !:A9IV!W;[0V@=DNO3.&+@/7K##%[;
M9DAE=>LCB+8FZ.R Y$@?VR@4]=$ ZKJ:80?0F(&Q&ENB]='IUSH,P)=T;=%9
MY7,+#Q;,]$_AG"OGG&%$"551IYW0#Z)@XX57<=IQQDKC ?W3]#7M,OO;SHOK
MR',!8(,E:)]_'VZ]<VR]D?GTX1ZX8AYHFA]G-//:5'C;2S78BG<[F."*[)V'
MLD^'LT"&_:1VM#'-$+_;>;U8%ZOU2TE@CT4!1S?T5+CBM%RYHZX87>"BPB^7
M^8G,+V+AXJ5":W<(E,$VC@07Q'8]:P*Z+$.D5DG.*_ 6YS&96O"JQAVGRQW3
M$%;@FSO(-VU YB&H >7.4*@&<_\RU:YG#8)Y^-I%AP%F0\M0U;AS#&8;%IRJ
M\>T8S/8L+>U!$ O,%B\CC7?[.,*GZMUN<1$X>^?75MF/ZRW\,&V0*(LLRXLU
M2TFXZ B)+-,5517.N0.<TUCXX3:Y5LVG.QPV(2B!+S!*@U=X'6WB'>1^W?:S
MVK'3,D"F5#]?5\ IQ8" R)D$,?LX#3*DHQ\TX[R:$<@\XA,BP:;A7!BG*=C&
M>-4,ZH1@$L2^26X8YZ9;W+9)O/*R+ F>#IF'5PAE<<$1+W'H(V,P:V"?L58O
M>C=V).=HIY>F/^TK3)[BZ3^NPVW#YCF_@R2/"9\5AN%LO_72)V)UFF2$Z'^
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M'@AG6"",[BZ9/"CNL*#8L"]E.$W4*&U@@.T9 >W?D^#Y)4OOO Q/*%Q&/CD
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M*OH;'I#A#&AX [B6Z! :?#CL=E[RCFLB=U4XL 90JB"+TW' ZHE0<;X ?NI
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MDX9 2'7OAHM"8YJ\)-;'E',,(EUBD5SWZW8A7'8AV))Q&CJ_0[=G/9PJ_Z5
M;=T*N-Z&+8GE"0]GP\E0D!6[*G$9 "5",-K(K.H0$&&TL-IOG\0Q71<N>T5&
MI:0L/95J#!9"E?O.8B:>[Q8MB5 >"Q9+C8B%_O*C./C9]47!B.ID+8EMDH)2
M+.6N04?I+V>SVD9()#9(&OLA\=GY51,^;L$&]SI.$@IY-K-G*^,D <F/MVB&
MX*JO,[.)N42W)DJ$3R=_=94ZALFPE+N&+!>9K=E3UGRX3EWY&$M=0R,A3US&
M:D ZPB&?B1FN!(VB!%D^&U,+&L=F8@MW^MZWE,4DUS7,YXP#OF_I?$314"_;
MO:T%:VG4!J!-7$8#H(2SAD2AS5=CHF 350FL21$)I'**^@2W,$F@?QVA;@&*
M5K8ZWC))1VR3Q.L62W?IL-(H/Y>+KY5"@JW8&J3$5T:BI-E7<9)1XC C%9)S
M6#N?\,')9!%.I&R<ZFJ:*[N,I?MM8Q-=G29)S//,SYD+5XX:JV7K552Y3G%:
M.'L/7V%T,'[KN$23[9[#XD=HXKY=N'[2]9H]O;O\8!CW ,PJ20M4!LNX:EP4
MX0U["AYJ?!;IV&VK:O1@4Z!OG[AVT50F5*Y@O6(/:<B.1A?SF=!XP'098KR7
M0KF&#;6&\:Z*4(5%!04." 480D/9(,_.).:6.6_:P!7'9HF?<7I^X:ZZ#M,M
M6UE"%5B0:(QVE<<;N9LV30LK\[N]DMZ&L<H A'(9I"-(DQ')H_=&]]S]$M.S
ML<A!63 ]OJRZ[_,*2+*!:/K-E%ASM9SE:^_NL1EA=0\6N=L$_T".\K> =)2[
MS9@V*?&(E &J#13J0*'/QF&0\N#PTIT,!2??$AP5P0E$@V.,SL1Y@DMO@I&>
M@.XR+PAQ@E:>K7^)C];_O-N'\3N$'V$$MP'OKA,E(LT2H+2]XDNUUBCRW2D8
M5<RXV #FNL%3KMPH4TX='V;>)AX;NW*ZJ8/%H-!":?WZ*D#4@D(O*!1;0IZ#
M6:>#18=%W<X9*+8OJ$- S2- (VC:4<C/3<G+-3AK)6VLS%D#BXZZ="?G!*7>
M(D6Q;[)KZHBU1YD_QZ_5%7HX70E#N,D.*&N[2^(]3+)W<!\\OV0VS90-AA9O
M#FU8X+6E<N2JV7SZ/2KOH%60T/4+MC&MZ[5:8AW^N</<8L8A$GH'=%[9)>>4
MYP98F."ICI0<Y79&ZA32/=6A:W,OO4>;*@#?YO*_LSJW$Z8AJ0Q/+-"GE.<5
MG><=\B##/OWS$.PQZZE*^(046)?YB5@MLZY'FH_VN0$? -9'=]S!PHB320<G
M""/EILT+] \A">)5=?S?71FTNS)HI4K[$T,9+,IGB,+?0ENJ2(XR^.BET+_S
MWK$EETF"OV7/=<?JY=N8.(H:+]&UK\[SXB"1C2] 1M2SI]*!5Q-O878X43@8
MI,PL;U%2IG$C5H#<#%"W ]0,L315G"B.1ZQ,])S1)M:X[+1(FL@!;,]1\%_H
M 2\]JAR6SUF=9<HRF%2R*?6I=)#V[?8>AEZ&[4']R#B"[I9E&1EW&BJ!D'6Q
MEDYP5B:A&A$W(Y5VD;&J<(AFP^CW1C0L'XZK"D][!([&G8@P=X<(TDOI 3VT
M&44%G\QA]>710XA$E"?YX=;%B2E$<7E!*?4G^ K#N$BJ<?<UGB0%A5O(FF*6
MBR\^<_"T@&C]D_ &M8 , _W*AJ*T9Q^Q3A(Q*:;E1^P$R'>2$!(V_IA [P\_
M_AI5%='[>KQJ"E'&F]H[]RU/63)T+/$!=/!SWC\\QK=[TG5&SVJFI,3D6L;*
M0D:+8\.=S<4GI(HL+HM!7&BO)EE@I=\N6IXB9**,+!PRRWEYBABV$^3'&"_\
M+1587SZ0XB51_A4/]$34F]YN/WM)A!2G:!!""AC2--LCPSRE\@V4:L?,>QDI
M%Y!U+C#7 ]#WS$\WMHDIE4:BDQ4%(F$? 2H-39OL/GIIL*%)9Q ><!=Q$Z<T
M-$231:0GQ@@<@A,(I(WS[>(T*/^^L=ER!2T:G^,^8Y;_& BW;9I;G?\$T25H
M4U.@'=QVNZ>?U8)5(/-HK[H6/<2K\SV3&4:74>+'7I[/G#4KJ[!ICX<B+UDD
M<KQ;PY9#O!0YS=B0(>NT]E2@#Z+,[I\;+RN[?.%-;/+OF^ORQ^\DP@NW7':7
M;]'>JJG=)[BU8G_4X-;+Z?25[GP:T.G?B&Z3[W[1IF[_9L"&9^<\GQV[*?<N
M@P3N\9Q.E(&\/>!EDIOPX)-*(_  .>SE>W ZJ<+0R(BQ3VC-GGA5?HNE"\3O
M:WNVN_?"6RACN)EV,WM;G= A8>R7;.(>V7.ESI?S?%5IL?PO7^&$R_"6L\D0
M7P7S&!L.#%/AKAB!6'1H&!>60KQA]PWWGU_)&>E;U SNX3Y.\#3/'4R"V)<>
M< A),C?T$#%/(@M':3@3O*_T*A"L!R=,5!&NRR%-]@U()@A*/KWPE,)_'G"N
M2'58-#21:?&<08IPZ-2G"IVJQ0<N B*,IA']]HFGKA?N:L$L8G*Q6F7O)E,,
MY7%@<!95 H@64*H!=SEG632,41X-1CXR+AKZ$Q1Q,F"G*X(QU<AB8D.?GM?M
M9"_9G'F]FLLS%RW#V$A:0]R7)RP[1DM*@R#/4S:-H<20+DE/=H^KO@21AR)T
M [T4'^Y0+J$C/WQ\OX%I"KMNB%(AT=@X2\I,J:$%\XSD+54'0BR>+&*J%K?2
MWY[>T1]8J;')6_V!8M"%ND"9&;8- E3W\$T^^B?+,K*%'&FA=G/-P$/C+I@K
MZZ509%FQ9^)H'6W:_W+(<-1^#J)@=]@!HJ8XZ" %OT8^REO(CR=&,E)EHD%!
M/UFJZ:H_*1%I-\W(5R"<U9*]?4>*9(Q59PS$:FQ:8[AVHQ)8(QEG3&W'(KYA
M58I&B[.;9^2J!Q@WS,TP<HF,@8**YA"-I19SY195\!G)**=0C@F\D)YG/*#P
M<ORN89XX,D@F7U^==Y,"$EP>%&YAQ62LWYU(%_;;)*([FW ??-EA.P&L#AE3
M,%ZV!:W#<E_F]I3C9FOE8&"TZT*(M3BW[V[*PJ ]E7R]-%@V,V^]: M:95/)
MU8)Y"NAQ<[4MI1[EL1! [<R0V0U6&)<GE?4^OGC990(_!_BXJ3LOS3X=X&UR
MO=M[00*EUWL.%FX-MD4MEDHP.:/M&AHRI!N08R>(=K!'ZH%_0 \G(,@ML'0"
M8?+XM<^GN'S.U_X_)IY/!^*_1D]!&))+8O'!E1B$%JTP'0L[<?:1^@(GSU"C
M1@*BHD^#G8:DTBOV\8T#N<GNH<8TT1/)<Y1$[P1X:_A81N;;G#QG#1\'"8@]
M#:Z2+L<+CJ$$<RAK!UK*@Z:.GFP?JXE#3A$K#1WG]:Z#C[?E)PKJ-S:(G#K4
M\ZZY%?!\P\2/J''6[HJU_+UJU37QQA:\*_6V17RU9EJ_0,:28XB4>NXJ\%SS
MTG8Q\#+6M0L$SNK,YSI"EA(V&#B5RA)@/IMA6"75!7..'65>RU?GL5*SK9.N
MXX/#R$\4!\=P=L*!A4 >TA7@4V&"P07D#AE6\<' _?"+GHG;1M.VM=RK) P$
M_*5(4)-I-Y"'U6<Y(;,1SC]!?!54/=$B=\:5[CR@K+_O(DV5DHU!?Y"Y,F?W
MS9D[\)^I6FXOF):JK6,*'5$C_)$KJE^F:0][C )1-Z<,#Z[R+?LL4\2.1^:\
M:7*C?K=9XN=(+-<+9I&"@6F#>_*5>2K(7I94*!0ZSAB]R#NN?>]]/V29V^Y[
MHJ:!6;HF>Z5>M8M;Y*<=<<M;M\YAK8YA35NWO]K..$/]%Z4<8U/2$_HNRCJ&
M)Y2' %J0>,9," ]B'J'CA[I>LXMQ)(^:6;CGS#ND&&GWI!.K _EEB+<,;M'M
M[1A:&>(R@U(D7;: 3?I/#N(%2SF+_!6&_F/\LY<=DB![OXY>89KE=Y6*WE<G
M(L(DNPC8)WXM^6(^8Q[)^(*4X!LJ=[D:U,D5>@RF,NI=9]#.7W/7"S6@T@-^
M?\0%GX\6W$>G/A3MY;Z53#NNVY2 -I.'1"-F8UWX.MK$._CHO<F6?9DO&JOJ
MLJR1F;N\8.8) 9$*4-"M*\@J<)C $DFPK,C*:Y'=-=3.>-@).C](X";[&7KX
M!\P5M]LO7I#\YH4'G-C$L9_>)@\P>0TV,*5;(*!/[L>[W>//E?Z4>%$&_4^(
M<H8>YSZ]%0;I8&+7I*#&K&\$N8E@5]E(9HZ1E> 5FTDJ =A0O'(SS4T%26[K
MA_S.RYB:"YZIO< G!MMZ'+UM'^8X-=D?\-%E*;WP*'N!X.?F]\$_88,!L3@E
MFY7P;_E=VLU_R\@_$8O!)_3/%LV$:^,@'F?K: S*1X+M>;I[?%;S0>;B<@$)
M)L>!_>:)#P#6L]62#@,?7V"KFGT\%YY0308'@LI]EULOF ? IOO)E4>DS;FY
M0"N&@N+89HX$!6-E9TZ:H8\7/(5PP %*G2\;S #9%LFL25G*KO8-2J5V'J^D
M*"ARJWQE@V(J'>(W?UX6PPGJ*2!=?MS8_;XU>!]V.($S8YZ:QFC"UHVK5+E/
MP%V) U2>O4"5'''PPW0*<.U:-B/[MC50E5\XX:Q6TIDU \/&5I-,&Y?1W;/A
ME28#82".^C'K3<Q@7OR, ?:;UF!==M/[A:, Y_8<$* B'*/A;=O6?VYC%T?U
MA&L_D"J(6D?V$7JXSBBQ27:4*+,U0&$[Q7>!G\\NF&M"@EP9>*+:V-OGC%8%
MIXH&>[0A$ U[UM]/%QP&U2D)CH&RHC2!=-07Y4)M@@FEYD&DI%G.A\,JXNO%
M1??\R.G3XO"@C&!&FR9/)HS0\>1U'IY[+X/@+HFW ;VG"T]"7\6[O1>]_R4M
M'SLKHFC-GFU%=#.4.C7,'/?:T%7=&2?+<N:4KW3@_&#9VC:5UO=-,4=")\^F
M0P,U@DN-%<ETQF=$HDGB<VW/MJPA'#.4,,<4TM30I=!.+F$YEM.D[+7BY\75
M\N6=G7E^B9MSG2"3?.U:%O\I6')(G,9DFS9L')LH+".(T:+-9;)$,I0/[;XK
MHK;MYA8?@?KXXD6UWRXWF_B %U-^B9-?,45\_N<AR-Y_AMG+D+7E:G09G+A0
MXH#,RIJN/*U4"F)RH&^&3&G\[!7& $3IX$#H'1)[P(X89.%R!1/1S9<V&-U\
MI@6:O$D3=8&WD>.*37B7D1>^IT&*_/@EQO>0!Z\HU7F%)6O?!-Y3$ 99 .56
M.HY28(S-QE@MLWYHP5P^56[U]7+UA*>B.#JK+*AE$6%E@V7K)S6&D9%X319&
M,YRG JK=1#?Z4_U9V*VKH#B%AI/B-_E:$48F\^**,<@T5E\S'TG%'-<3R=-A
M.69];JK/]6?A.?$E<L.EGQ2_2:XM6\_99R6-0:0]"^]T!5 QI=FV5&\T,-4R
MV81+_G[VWH+=88?&O.2'Q_@J@7Z0W0?I'Q(+7 2EF)QW$#-1>&7"['SES+H6
MM.RH+@!S97C"84/4@03I,SBK,$D4VFQZNP6Y'E H H\QH*H U@5JR@Q/*$P2
MD?:*E2LO2=YQN?)RA^M.^*=J,0I=U@ONJTE]<AQ#'L$\:H5]5LPSR)$&<Y9!
M(NPV9FZ_8!:'EY'_^2TCQSE@P]-+A&X\98*B-OJ"H7$:C&5PH\R6J7.SKZ>.
MB'IR6 DD!N ?,>>FP*,V -RF+5MJ;#Z4C'QNRE":R>J4@+8[LQO_O?XT3"=7
MC!NIXK2X;D 1:;5VF/,-(Q%J645.:S35\YV553DUX%5,>?;7Y0:Y)5Z8&R'^
MM+A.=MOGVF%..XQ$ICW5.6U!5$]OME7HQD-4,:O9O2;NE\/N"2;(I;_#X/DE
M@_[E*TR\9_CY#2:;((5W"3YY\'9;/W-0=BW<6!WFN&V<X5+89%X[%1$#"#:_
MYB8 C]J P$J- 'MB!7Z\>2"J;6O>]$;S^) ]3"5!&- 5W^B7VT.69BBTF.&(
M3I KM8C,U*"3PV@*OHGRJ0<YHXI5?+WD-)T>D],7JIP0+F2[YVYQB,'Q! <N
M4 \CK6IE;\Y?!B=##,5460=P%$N;=@0;"FY_?W#_\.M?[-CUJYH F1,M2K^#
M\C[@=H^,R? "[+<]C-+.1<H2+YIDZ4ZKQ/=I.K/Y_.CLF%N4QA2B02&[5F,W
M2**J7&9,(G-=-DQOJMQFC-3CTFTHYK9VXNI%+9.)^"&;GEH^OM.!O43J*"3#
M*L)A&"A^VL;2=9CG5C%:Y--[45&"E2:;:&A\(,08Z>,[H(HL6M,R03 (3S'<
M?RK<MY.8.)@7XZBNR$U/5V-HREIZ&GBY7K'!7^1NC6.RLHF6A@> ,6QDX-%B
M$AKN.KW!+<Z\D.&RG<0SF' T$ T9VN'+'#^^(T#]#/$ $8\ #WM\ U&*-'^,
MO<07'XK)"C1+29+6BE]SOG:6,W;Z1*LSY$I8U&'BZMF.JL7_7%,,GK!FHWPU
M;708)"8;'9O&@-,&BSDV5!HL SPYD'PZR'/(!]#,J+]59DBE= -DVLNK;(/%
M:[ONK'LRH@<3*=8/3H)?E41)GF*/(V331(*&D+4G#?(2.2AJY( 4R<$=BA*=
M0?YK+9 _5X'$_UFG8&+6"? NGZ(&4"_GJYC+9X_6-8[NUV^L.'A4WERI/.2B
M^_A1D#=!? SI)CSX]#)9#Y#%8M\#>1(Z"996$-&!'-VDZ-":$TLGCY=\)MP5
M+XM.,!U.7..2X9MI3S,5MD/H3%-):2?!PY('5,X6*T?Z?-,_(]L.B9L2IK7B
MY--)PZ2$8"TZ"748"8WCU0E/:2#K<JZC3;R#>9U8II3 ?=DH8_(LD[@D8C$_
M9]9=R0*Y@,@O)H,,TIQ"9UE3T\19*K^8&[%I-DBA]W0NNN[OM[G,[^P@'Q&T
MLKFF-THV;BZY2_"<:_9^ARS-\+:9?QZ"/28!J0,/^J48VR#2:YK,@7#LJ5S.
MU8;[7/L'@)M"1K=P%198=F:!ZDC)70(Y)E)F=GX(0Z=[;X=8R$^*-V1WG@D)
MLH\]!NYZFC%K_#UMW[)-8A/$A%#%71F%NS(*I>P3@+W4KB[A()X4^+O*](/%
MV =\^3(HZ@TOF&> #.\-C96/-05+:>K0$RS+6(19,!X5]I-B$/&3.'I$V,<<
MLF>U.BMFLC <"/8<IJ$T1DK)PK:S,L2 ,H C)JQXWL,-4A"^7Z?I ?K7R"[1
MY:B<-TW6.KO-DM@QMEXP%Y@FN6P0$.$ ?\:I"P-"-4]E3C,XS(33XO5.99XS
MF&F Y]IKH/WX919 >\(V <V0&=,[#]&;.,$PWC%++<<&R2RPF*W9I$(GD_=8
MK,'I807>,=FCYIU-M#':629AB#MK@"FZ(=C!$1TQLG&04C=6MJS9]:ZQ84F'
M01*Y]FK!O/RQU4 M*U:J<9O@\K[A:+6.W:+#J'I:;/<P@1<F.Z'Y"J,#9R6%
M\&L& =FV1:)1NNR+<!(JTT(4CO0U!R"18A/<NEHA#VG,4%@,,GQJYE4<D;XZ
M_7N0O5P=TBS>H18P$'YB DT#4\A*J7Z$"UER@.NFT >^(H5@4VBT%=!3Q.CH
M_I47]!;$VQ3 HY?X$!\+!H-77+Y*/X!">W$3"R[GE;_5KF&RCC2D4-5+)^(?
MPD:B(1NSGKP4)R#O9/E#DN"/3@[GE24986'&"$;40IE[W9;,Y=+DL,$SH@JE
MK407\&K*K..5B4)#.07+?HE#'YGT%T!O#;>'%F0QT$T)4C%47I6C9Q%N:7BK
M:]N[5@;(OV^R6M=GG$2Y9[YR64<%YJ<<;_/V"2HEYJIXBKUF+(#N]MJFK7**
MX] N]HV+@_;:GRC0F75 H5"JYZ;@.0JVP09/A6XV^#:_('J^B\-@P[BWO;,5
M" DQRE(B%HHWUHN5RYRY3"LUP"OU@'VNR."TPQ0!8&57_ #8,S,Q13P84Q7C
MXJ&?P&38@,UBPG'52V7BR9:8%&O);$#7BQKO\D_$9D,C,(3.+,K$I@C)$$:S
M+BF3H@5Y4C.9H F=.2 @P5HVD]S\O>@X\;FWT4ZX#G0\H0T)PA RL^)< .61
M&,)A%FW]%\>_/'5-N. U1> GY36RWG8;9+?)39RFEY%_%>_V"7R!41J\0OS;
MESAY?('W<'>(R.&Q<72[13]\P<N489*?3R!Q0,"4JDT2Y81^21TPUWEX=6E@
MOH$/F0CB!* 'Z"34IFXF_1D91$[B2&JF%D?/46/S0SH,)IOVQ)U%ZA/&W*H+
MF.SY"NW9V(?Z)Z"VD=#?U(-]?QSL;[\0>[X[C2,7-1 ZLP.;^KM;.?E+&U=/
M[RT]"RPMU=QTL*RI,I.?%^QYX=Z<T+)IX8E#1%FN%I1*."BD6S15/!0QG#GC
M00&VD4X>X6X?)\B73\%V"Q.(8OMK=$BA_^B]8=Z$F$W+7ZX2Z =9U]S/%!J,
MT<PHLR7PM)PQ[TG."O4HCR[T?P 'H@^@5D#2-4CSN-JO&VJ'94?EZ(PE8T@_
M:2S-<)H2V';SV_@/]J?ANJ[)H4E4G!;;R<\<8(@R]ZB-A:BQN18+PCD!XQF>
MIYD2OHI);\P,C\6L)WZNR CQI\5VLF=MK-ACR;'0M.=4$FU1G(#@;#NW9#Q(
M%?/:T.D?79R6[&B9+T+&XC.K^>NX)0>L X4;Y+-A%DN5?8Y7(A,<(LWY9$*A
M6V GA77C4RWQ8_+8%/$SQ6'C0,ECL!'?Y\_ 7[+E_#'R3X;%AM6OEXPSY<<
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MQ8[T?/CL8MF-'L,3_FJ\ZT20%=/\/<VN!T6J)_C)<1W,#>E'_ZP]]ZUT"S>
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MBG-2RZQXQKMJ3C0K<;IB1:/(6CO#:?4D3K(#AM'6J7GLI0'Q# ZM7*'=OU
M+&6^Q+#(DAW5>402QN(T=V<VY^AV_ @R%>Q/FKE#?3-GF'06S.8.S0;!; N(
MLQ"HB6348E+[4[48M-*HZ %D.IXK>$B?K<*FSLR"JPB6ACPI='5_EO=XQ]WA
MO_'Y5*6O^_-\(OE[#>98]K,B=]9E\]_B?%U*MJ+X2$F/-T["*M-7GEB71*K
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M7=HLTZ8(A'08*S[7LF_2DZ9>CP[OOC L4) P@P&[##?(?)Z"5_S-!<2'2;(
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M2F'MV<=^#%87RP-]9HAHUAS)3BY&+!,0:7$%R/>I.TWUE>K,9Q$L[V2=MD=
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M*/1LX><[F2A?U5.<4@<O'M[9WRE0B0:3Q"\CQ57MM3/%+75P@C+11D[12[8
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M6:FE Q&=XIQR9O8)+W8.HNL"'>KCZ%OC^Z;"1>R_%*3TTBR-?@/Q:HV)G[T
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M,C Q.#$R,S$N>&UL4$L! A0#%     @  HB#3A?7D.1F)P  Y.T! !$
M         ( !^30" &UR=7,M,C Q.#$R,S$N>'-D4$L! A0#%     @  HB#
M3C*/U]$]'   G*4! !4              ( !CEP" &UR=7,M,C Q.#$R,S%?
M8V%L+GAM;%!+ 0(4 Q0    (  *(@TYF38ZS;$<  /'5!  5
M  "  ?YX @!M<G5S+3(P,3@Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  "B(-.
M-4XW\BJR  ",<@H %0              @ &=P ( ;7)U<RTR,#$X,3(S,5]L
M86(N>&UL4$L! A0#%     @  HB#3AE9.&&'90  3><' !4
M ( !^G(# &UR=7,M,C Q.#$R,S%?<')E+GAM;%!+!08     !@ & (H!  "T
%V ,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
